

EAU 26 | LONDON, GB

13-16 March 2026

Cutting-edge Science at Europe's largest Urology Congress

Join us
in London!



www.eau26.org

eau European
Association
of Urology

Management of oligometastatic prostate cancer: Not as easy as it seems

Plenary Session

Friday 13 March
08:00 - 10:00

Location Orange Area, eURO Auditorium 1
Chairs A. Briganti, Milan (IT)
C. Gratzke, Freiburg (DE)

08:00 - 08:03

Welcome and introduction
A. Briganti, Milan (IT)

08:03 - 08:12

State-of-the-art lecture **The biology of oligometastatic disease**
To be confirmed

08:12 - 08:50

Debate **Optimal management of de-novo oligometastatic disease**

08:12 - 08:15

Case presentation **ISUP 5, young patient, five bone mets on CT and bone scan**
R. Nicoletti, Florence (IT)

08:15 - 08:20

Can't say we always need PSMA PET/CT imaging in this setting!
R. Eapen, Melbourne (AU)

08:20 - 08:25

Surgery is still an option in 2025
M. Graefen, Hamburg (DE)

08:25 - 08:30

Radiotherapy: Treat all you can see
A. Kishan, Los Angeles (US)

08:30 - 08:35

Intensified systemic therapy is still mandatory
J. Casuscelli, München (DE)

08:35 - 08:40

Live interview **Optimal trial design in oligometastatic disease at diagnosis**

Interviewer V. Parry, London (GB)

Speaker B.F. Chapin, Houston (US)

08:40 - 08:50

Panel discussion and voting

08:50 - 09:46

Debate **Optimal management of oligorecurrent disease**

08:50 - 08:59

State-of-the-art lecture **The road to cure: Does intensification matter?**
B. Tombal, Brussels (BE)

08:59 - 09:08

State-of-the-art lecture **Who can really benefit from metastasis directed therapies?**
B.A. Jereczek-Fossa, Milan (IT)

09:08 - 09:11

Case presentation **Node only recurrence - 3 lymph nodes in the pelvis at PSMA PET**
I. Heidegger, Innsbruck (AT)

09:11 - 09:16

Take them out! Radioguided surgery
H.G. Van Der Poel, Amsterdam (NL)

09:16 - 09:21

Irradiate them!
G. Marvaso, Milan (IT)

09:21 - 09:26

Too late! Systemic treatment

U. Vogl, Bellinzona (CH)

09:26 - 09:31

Is there a role for Lutetium PSMA?

K. Herrmann, Essen (DE)

09:31 - 09:36

Live interview What if the patient had two bone mets in addition?

Interviewer

V. Parry, London (GB)

Speaker

A. Bossi, La Garenne Colombes (FR)

09:36 - 09:46

Panel discussion and voting

09:46 - 09:55

State-of-the-art lecture Ongoing practice changing trials in the oligorecurrent setting

A. Kishan, Los Angeles (US)

09:55 - 10:00

Closing remarks

C. Gratzke, Freiburg (DE)

Cutting-edge developments in functional and neurourology: Shaping the future

Plenary Session

Friday 13 March

08:00 - 10:00

Location

Orange Area, eURO Auditorium 2

Chairs

T.M. Kessler, Zurich (CH)

B. Peyronnet, Rennes (FR)

Learning objectives

The aim of this session will be to provide the audience with a comprehensive overview of the latest developments in functional urology and neurology with emphasis on the new technology that have arrived on the market within the past three years.

08:00 - 08:02

Welcome and introduction

08:02 - 08:10

State-of-the-art lecture To know where you're going, know where you come from: Insights in functional and neurourology

P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

08:10 - 08:18

State-of-the-art lecture Ketamine cystitis: What all urologists should know

L. De Kort, Utrecht (NL)

08:18 - 08:52

Round-table discussion Bladder dysfunction: Who will win the battle of neuromodulation?

08:18 - 08:22

Transcutaneous tibial

J-N.L. Cornu, Rouen (FR)

08:22 - 08:26

Peroneal

J. Krhut, Ostrava (CZ)

08:26 - 08:30

Implantable tibial with anklet

J. Heesakkers, Maastricht (NL)

08:30 - 08:34	Implantable tibiale without anklet U. Lee, Seattle, WA (US)
08:34 - 08:38	Pudendal S. De Wachter, Edegem (BE)
08:38 - 08:42	Newer sacral S. Musco, Florence (IT)
08:42 - 08:52	Case based discussion A. Nic An Riogh, Dublin (IE)
08:52 - 09:02	State-of-the-art lecture Single use vs, reusable catheters for self catheterisation B. Blok, Rotterdam (NL)
09:02 - 09:12	State-of-the-art lecture Wireless urodynamic: Are we there yet? M. Damaser, Cleveland (US)
09:12 - 09:17	Discussion and Q&A
09:17 - 09:37	Debate What is the best way to approach OAB in 2026? <i>Moderator</i> B. Peyronnet, Rennes (FR)
09:17 - 09:19	Case presentation B. Peyronnet, Rennes (FR)
09:19 - 09:24	The stepwise approach is still the way to go: Defending the EAU guidelines C. Harding, Newcastle upon Tyne (GB)
09:24 - 09:29	It is time for a nonstep approach: Defending the AUA guidelines A. Pelletier Cameron, Ann Arbor (US)
09:29 - 09:37	Rebuttal
09:37 - 09:47	Spotlight talk Latest advancement in robotic functional and reconstructive urology A. Sahai, London (GB)
09:47 - 09:57	State-of-the-art lecture Update on electromechanical sphincter: From bench to bedside? E. Chartier-Kastler, Paris (FR)
09:57 - 10:00	Summary and conclusion

Patient Advocacy Poster Session with Top 3 Awards

Patient Advocacy Focused - Poster Session



Friday 13 March
08:30 - 09:30

Location Red Area, Room 14
Chairs J. Daly, Galway (IE)
To be confirmed

08:30 - 08:31

Introduction

J. Daly, Galway (IE)

To be confirmed

PA1

Bladder health and lived experience in multiple sclerosis outcome measurement

L. Makaroff, London (GB)

PA2

Education materials on bladder cancer: A scoping review and recommendations for future initiatives

R.C.A. Leenen, Rotterdam (NL)

PA5

Supporting men on androgen deprivation therapy (ADT) for prostate cancer: a patient centred innovation

L. Fleure, London (GB)

PA4

What prostate cancer patients find important when making treatment decisions

P. Nasser, Rotterdam (NL)

PA3

Key determinants influencing treatment decision-making for and adherence to active surveillance for prostate cancer: A qualitative study

P. Nasser, Rotterdam (NL)

PA6

Impact of behavioural factors on care seeking for urinary symptoms linked to bladder cancer

A. Filicevas, Brussels (BE)

08:31 - 08:36

Top 3 award winners

To be confirmed

08:36 - 08:38

Closing

To be confirmed

Advanced endourology in non-standard patients with urolithiasis

ESU Course 03

Friday 13 March
08:30 - 11:30

Location

Red Area, Room 10

Chair

S. Doizi, Paris (FR)

Voting will be available via the EAU26 App or via www.qna.at/eau

Learning objectives

The course will discuss available literature and practical management options and examples treatment of urolithiasis in 'non-index' patients. The course will cover:

- Horseshoe kidney, caliceal diverticula duplicate urinary system
- Pregnancy and complex metabolic patients
- After bladder substitution/ileal conduit/reimplanation
- Transplanted kidneys and spinal malformation

Introduction

S. Doizi, Paris (FR)

Urolithiasis in urinary system anomalies: Horseshoe kidneys

A. Tsaturyan, Yerevan (AM)

Urolithiasis in urinary system anomalies: Calyceal diverticula stones

S. Doizi, Paris (FR)

Urolithiasis in pregnancy

O. Angerri Feu, Barcelona (ES)

Urolithiasis in urinary system anomalies: After bladder substitution/ ileal conduit/ ureteral reimplantation

A. Tsaturyan, Yerevan (AM)

Medullary sponge kidneys

S. Doizi, Paris (FR)

Urolithiasis in transplant kidneys

O. Angerri Feu, Barcelona (ES)

Urolithiasis in urinary system anomalies: Duplicate urinary system and ectopic kidney

S. Doizi, Paris (FR)

Bilateral stone treatment; Do's and don'ts

A. Tsaturyan, Yerevan (AM)

Patients with relative contraindications: Spinal and skeletal malformations

O. Angerri Feu, Barcelona (ES)

Advanced course on upper tract laparoscopy

ESU Course 01

Friday 13 March
08:30 - 11:30

Location Red Area, Room 8

Chair P.J. Zondervan, Amsterdam (NL)

Learning objectives

This ESU course is designed for experienced urologists looking to develop their skills in laparoscopic surgery of the upper urinary tract. The course covers transperitoneal and retroperitoneal approaches in depth, including laparoscopic management of renal tumours, UPJ obstruction, ureteral pathology and stone disease. The course also covers intraoperative complications, complex case management and special scenarios, combining expert-led discussions with practical insights to improve surgical decision-making and technique.

Introduction

P.J. Zondervan, Amsterdam (NL)

Transperitoneal versus retroperitoneal upper tract laparoscopic surgery

J. Gómez Rivas, Madrid (ES)

P.J. Zondervan, Amsterdam (NL)

Laparoscopic advanced renal oncology (radical, partial and nephroureterectomy), tips & tricks

A. Celia, Bassano Del Grappa (IT)

J. Gómez Rivas, Madrid (ES)

P.J. Zondervan, Amsterdam (NL)

Laparoscopic complex UPJ, ureter and stones

A. Celia, Bassano Del Grappa (IT)

J. Gómez Rivas, Madrid (ES)

P.J. Zondervan, Amsterdam (NL)

Complications, interactive be prepared

A. Celia, Bassano Del Grappa (IT)

J. Gómez Rivas, Madrid (ES)

P.J. Zondervan, Amsterdam (NL)

Complex cases tips & tricks

A. Celia, Bassano Del Grappa (IT)

J. Gómez Rivas, Madrid (ES)

Special case: What can we learn from this?

P.J. Zondervan, Amsterdam (NL)

Complications in BPO managment. A guide on how to mess up BPO management (fast)

ESU Course 04

Friday 13 March
08:30 - 11:30

Location

Red Area, Room 11

Chair

C. Netsch, Hamburg (DE)

Introduction: A guide to messing up BPO surgery (from informed hand)

C. Netsch, Hamburg (DE)

EAU BPO surgery: The current pathway

K.A.O. Tikkinen, Helsinki (FI)

Critical appraisal of energy sources (lasers, HF, water yet and steam)

C. Netsch, Hamburg (DE)

The role of preoperative assessment (patient self-reported questionnaires, uroflowmetry, DRE and urodynamics)

K.A.O. Tikkinen, Helsinki (FI)

Perioperative safety considerations in BPO surgery

K.A.O. Tikkinen, Helsinki (FI)

MIST, new ultra minimal invasive, minimal invasive, endoscopic and open surgery. Coining and reality

I. Kartalas Goumas, Vigevano (IT)

Complications and how to avoid them in TURP

K.A.O. Tikkinen, Helsinki (FI)

Complications and how to avoid them in vaporisation

C. Netsch, Hamburg (DE)

Clinical cases

K.A.O. Tikkinen, Helsinki (FI)

Complications and how to avoid them in enucleation and morcellation. Training, setup and safety measures

C. Netsch, Hamburg (DE)

Clinical case

C. Netsch, Hamburg (DE)

Complications and how to avoid them in laparoscopic and robotic enucleation. A reference to open prostatectomy

I. Kartalas Goumas, Vigevano (IT)

Clinical case

I. Kartalas Goumas, Vigevano (IT)

Case discussion Interactive case discussions on salvage manoeuvres after failed 1st treatment

I. Kartalas Goumas, Vigevano (IT)

C. Netsch, Hamburg (DE)

K.A.O. Tikkinen, Helsinki (FI)

Closing remarks

C. Netsch, Hamburg (DE)

Oligometastatic prostate cancer

ESU Course 05

Friday 13 March
08:30 - 10:30

Location Red Area, Room 12

Chair T. Maurer, Hamburg (DE)

Voting will be available via the EAU26 App or via www.qna.at/eau

Learning objectives

- Provide an introduction to working definition(s), background, and biology of oligometastatic prostate cancer.
- Update the current molecular imaging to provide such a diagnosis.
- Review the potential roles of surgery and/or radiation as metastasis-directed therapy.
- Understand opportunities and challenges in individualising care of the oligometastatic prostate cancer patient.

Introduction: Oligometastatic prostate cancer as a diagnosis

T. Maurer, Hamburg (DE)

Surgery of primary oligometastatic prostate cancer (N1/M1)

G. Gandaglia, Milan (IT)

Surgery for recurrent nodal metastasis with updates on molecular/PET imaging

T. Maurer, Hamburg (DE)

Radiation in oligometastatic prostate cancer (primary and recurrent) and clinical trial updates

T. Zilli, Bellinzona (CH)

Further cases (case illustrations throughout)

G. Gandaglia, Milan (IT)

T. Maurer, Hamburg (DE)

T. Zilli, Bellinzona (CH)

Discussion and conclusion

T. Maurer, Hamburg (DE)

How we manage upper tract tumours

ESU Course 06

Friday 13 March
08:30 - 10:30

Location Red Area, Room 13

Chair A. Masson-Lecomte, Paris (FR)

Learning objectives

This course will address contemporary concepts and controversies in UTUC such as:

- Accurate staging and its role in clinical decision-making/risk stratification.
- Risks, benefits, and side effects of current and novel therapeutic approaches including endoscopic and minimal-invasive surgery.
- Optimal management of the bladder cuff as well as indication and extent of lymphadenectomy.
- Systemic therapy for high-risk and metastatic patients.

Epidemiology, pathology and risk stratification

A. Masson-Lecomte, Paris (FR)

Diagnosis and evaluation

J. Baard, Amsterdam (NL)

Kidney sparing treatments of low-risk and selected high risk cancers

J. Baard, Amsterdam (NL)

Treatment of localised high-risk (invasive) and metastatic cancer

A. Masson-Lecomte, Paris (FR)

Chronic pelvic pain in men and women

ESU Course 02

Friday 13 March
08:30 - 11:30

Location Red Area, Room 9

Chair To be confirmed

Learning objectives

The urologist is often dealing with patients having Chronic Pelvic Pain. This course will offer the urologist practical guidance in treating these patients. In the case discussion the participants will have the opportunity to help outlining the problem. In the lectures, theoretical knowledge will be translated into daily guidelines for diagnostics and treatment of patients with pelvic pain.

At the end of this course the participant will:

- Know the basic principles of treating patients with chronic pelvic pain.
- Know how to rule out well-known causes.
- Have knowledge of the myofascial and psychological aspects.
- Be able to refer patients at the right time to the right team.

Chronic pelvic pain, the basics: Mechanisms and terminology

P. Abreu-Mendes, Porto (PT)

Chronic pelvic pain in men: Case presentation and discussion

To be confirmed

Chronic pelvic pain in men: Practical guidelines on diagnostics and treatment

To be confirmed

Chronic pelvic pain in women: Case presentation and discussion

P. Abreu-Mendes, Porto (PT)

Chronic pelvic pain in women: Practical guidelines on diagnostics and treatment

P. Abreu-Mendes, Porto (PT)

The interdisciplinary approach: Team members and organisation

To be confirmed

Innovations and insights in andrological research: From erectile dysfunction to sexual well-being

EGPT 02

Friday 13 March
08:30 - 10:00

Location Orange Area, EGPT 2

Chairs J.I. Martínez Salamanca, Majadahonda (ES)
R. Sandher, London (GB)
H.C. Son, Seoul (KR)

08:30 - 08:55

Translational biomedicine

P0019

Innovative Noninvasive Assessment of Erectile Function in Mice: A Methodological Study Integrating Optogenetics and Chemogenetics

Authors

Hu P., Liu J.

Institutions

Institute of Urology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Dept. of Urology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China

P0020

A novel mechanism underlying the emission phase of ejaculation: Purinergic stimulation potentiates oscillatory and tonic contraction during α 1-receptor activation by phenylephrine in Human seminal vesicle smooth muscle.

Authors

Kajioaka S.¹, Okada T.², Saito H.¹, Shiota M.², Eto M.²

Institutions

¹International University of Health and Welfare, Dept. of Pharmaceutical Sciences, Okawa Fukuoka, Japan, ²Kyushu University, Dept. of Urology, Fukuoka, Japan

P0021

Extracellular matrix remodeling mediates cavernosal fibroblast senescence and erectile dysfunction under diabetic conditions

Authors

Han Z., Xu J.R., Liu B., Zhao L.Y., Tang Y.X.

Institutions

The Fifth Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Zhuhai, China

P0022

Exosomes delivering CRISPRi technology ameliorate erectile dysfunction by targeting PDE5 and JAK2 in diabetic ED rats

Authors

Sun T.¹, Yuan P.¹, Deng W.¹, Liu Y.², Jia Z.¹, Yang J.¹, Liu J.³

Institutions

¹The First Affiliated Hospital of Zhengzhou University, Dept. of Urology, Zhengzhou, China, ²The Third People's Hospital of Zhengzhou, Dept. of Plastic Surgery, Zhengzhou, China, ³Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China

P0023

Urinary microbiome dysbiosis in erectile dysfunction: Enrichment of stress-tolerant genera in a 16S rRNA-based analysis

Authors

Hwang W.K.¹, Lee T.H.¹, Kim H.J.¹, Jo S.B.¹, Yoo E.S.², Kim J.W.¹, Oh M.M.¹, Park H.S.¹, Ahn S.T.¹, Moon D.G.¹

Institutions

¹Korea University Guro Hospital, Dept. of Urology, Seoul, South Korea, ²Kyungpook National University Hospital, Dept. of Urology, School of Medicine, Daegu, South Korea

08:55 - 09:10

Ejaculation disorders

P0024

Exploring the impact of sexual positions on ejaculation: Insights from a survey study by the Andrology Working Group of the Society of Urological Surgery in Turkey

Authors

Gül M.¹, Sahin A.¹, Dogan C.², Ceker G.³, Altintas E.¹, Deliktas H.⁴, Demir M.⁵, Yavuz A.⁶, Altunkol A.⁷, Deger D.⁸, Kaynar M.¹, Duran B.⁹, Toprak T.¹⁰, Bahceci T.¹¹, Gul U.¹²

Institutions

¹Selçuk University, Dept. of Urology, Konya, Turkey, ²Namik Kemal University, Dept. of Urology, Tekirdağ, Turkey, ³Basaksehir Cam and Sakura City Hospital, Dept. of Urology, İstanbul, Turkey, ⁴Mugla Sitki Kocman University, Dept. of Urology, Mugla, Turkey, ⁵Van Yüzüncü Yil University, Dept. of Urology, Van, Turkey, ⁶MedicalPark Hospital, Dept. of Urology, Mersin, Turkey, ⁷Adana City Teaching and Research Hospital, University of Health Sciences, Dept. of Urology, Adana, Turkey, ⁸Hospital Edirne Sultan 1st Murat, Dept. of Urology, Edirne, Turkey, ⁹Pamukkale University, Dept. of Urology, Denizli, Turkey, ¹⁰University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Dept. of Urology, İstanbul, Turkey, ¹¹Adnan Menderes University School of Medicine, Dept. of Urology, Aydın, Turkey, ¹²EPC Hospital, Dept. of Urology, Adana, Turkey

P0025

Effect of a silicone patch applied to the penile frenulum for premature ejaculation: a prospective, randomised controlled trial assessing functional outcomes, safety, and satisfaction

Authors

Sezgin V.¹, Culha M.G.K.², Dogan T.², Canat H.L.¹, Ötünçtemur A.²

Institutions

¹Basaksehir Cam And Sakura City Hospital, Dept. of Urology, Istanbul, Turkey, ²Prof.dr. Cemil Tascioglu City Hospital, Dept. of Urology, Istanbul, Turkey

P0026

Ejaculatory Dysfunction after Post-Chemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND): Prognostic Factors and Clinical Impact of Nerve-Sparing Technique

Authors

Tsubotani K., Kin C., Yamashita Y., Kawamura S., Sato K., Okada K., Chiba K., Miyake H.

Institutions

Kobe University, Dept. of Urology, Kobe, Japan

09:10 - 09:45

Sexual dysfunction

P0027

Lack of association between oxidative stress and erectile dysfunction in diverse male populations

Authors

Fujita N.¹, Momota M.¹, Ishida M.², Iwane T.², Hatakeyama S.¹

Institutions

¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Hirosaki University Graduate School of Medicine, Innovation Center for Health Promotion, Hirosaki, Japan

P0028

Validation of optimal peak systolic velocity thresholds for the diagnosis of arteriogenic erectile dysfunction via penile Color Doppler Duplex Ultrasound: insights from a single-center comparative cohort study

Authors

Pozzi E.¹, Oddo M.¹, Bertini A.¹, Corsini C.¹, Piccolo C.¹, Raffo M.¹, Negri F.¹, Birolini G.², De Luca S.², Boeri L.³, Sucapuca R.¹, d'Arma A.¹, Montorsi F.¹, Salonia A.¹

Institutions

¹IRCCS San Raffaele Scientific Institute, Division of Experimental Oncology - Unit of Urology - Urological Research Institute, Milan, Italy, ²Vita-Salute San Raffaele University, Faculty of Medicine and Surgery, Milan, Italy, ³IRCCS Fondazione Ca' Granda, Dept. of Urology, Milan, Italy

P0029

AI-Powered Chatbot for Personalized Sexual Health Education in Adolescent Males: A Randomized Controlled Trial in a Resource-Limited Urban Setting

Authors

Patil A., Kamble A., Sharma S.

Institutions

Grant Government Medical College and Sir J.J. Group of Hospitals, Dept. of Urology, Mumbai, India

P0030

From Erectile Dysfunction Treatment to Heart Outcomes: Risk Ratios Linking Phosphodiesterase Type 5 Inhibitors to 1-Year Major Adverse Cardiac Events in Routine Care

Authors

Wang P.H., Lin Y.S., Hsu C.Y., Ou Y.C., Tung M.C.

Institutions

Tungs' Taichung Metroharbor Hospital, Dept. of Urology, Taichung, Taiwan

P0031

Asymptomatic hyperuricemia signals higher erectile-dysfunction risk: A multicenter propensity-matched cohort with a parallel treatment comparison

Authors

Liu P.C., Lin Y.S., Hsu C.Y., Ou Y.C., Tung M.C.

Institutions

Tungs' Taichung Metroharbor Hospital, Dept. of Urology, Taichung City, Taiwan

P0032

Minimally invasive; Functionally Preserved: Sexual health after focal brachytherapy in prostate cancer patients

Authors

Boesen L.¹, Nørgaard N.², Løgager V.³, Bisbjerg R.², Lindberg H.⁴, Wilken E.⁴, Andersen K.⁴, Fode M.M.¹

Institutions

¹Herlev Gentofte University Hospital, Dept. of Urology and Urological Research, Herlev, Denmark, ²Herlev Gentofte University Hospital, Dept. of Urology, Herlev, Denmark, ³Herlev Gentofte University Hospital, Dept. of Radiology, Herlev, Denmark, ⁴Herlev Gentofte University Hospital, Dept. of Oncology, Herlev, Denmark

P0033

A 20-year interval study to compare the prevalence and risk factors of female sexual dysfunction in Korea: the Korean Internet Sexuality Survey (KISS) 2024

Authors

Choi CWS¹, Son H.², Lee J.H.², Cho M.C.², Park J.³

Institutions

¹Konkuk University Hospital, Dept. of Urology, Seoul, South Korea, ²Seoul National University Boramae Hospital, Seoul National University College of Medicine, Dept. of Urology, Seoul, South Korea, ³Asan Medical Center, Dept. of Urology, Seoul, South Korea

09:45 - 10:00

Penile implant

P0034

Determinants of Decision Regret and Quality of Life After Penile Prosthesis Implantation: Insights From a Prospective Single-Center Study

Authors

Gravina C.¹, Stira J.¹, Polito C.¹, Paradiso M.¹, Zarrelli G.¹, Lombardo R.², Santioni M.², Pastore A.³, Al Salhi Y.³, Fuschi A.³, Nacchia A.², Cicione A.², Tema G.², Franco A.², Tubaro A.², De Nunzio C.²

Institutions

¹Asti Hospital, Dept. of Urology, Asti, Italy, ²Sant'Andrea Hospital Sapienza University of Rome, Dept. of Urology, Rome, Italy, ³ICOT Latina Università La Sapienza, Dept. of Urology, Latina, Italy

P0035

Does extending postoperative antibiotic prophylaxis reduce penile prosthesis infection? A retrospective institutional analysis

Authors

Henriques A., Ramos P., Silva J., Morgado A.

Institutions

Unidade Local Saúde Sao Joao, Dept. of Urology, Porto, Portugal

P0036

A 15-year analysis of the economic burden of postoperative infection following inflatable penile prosthesis implantation

Authors

Nguyen V.¹, Shin Y.E.², Rojanasart S.², Telang S.², Loh-Doyle J.³, Brant W.⁴, Patel D.P.⁵, Hsieh T.C.⁵

Institutions

¹University of Washington, Dept. of Urology, Seattle, United States of America, ²Boston Scientific, Dept. of Health Economics, Marlborough, United States of America, ³University of Southern California, Dept. of Urology, Los Angeles, United States of America, ⁴Veterans Affairs, Dept. of Urology, Salt Lake City, United States of America, ⁵UC San Diego Health, Dept. of Urology, San Diego, United States of America

Friday 13 March
08:30 - 10:00

Location Orange Area, EGPT 1
Chairs To be confirmed
A. Sierra Del Rio, Barcelona (ES)
K. Thomas, London (GB)

08:30 - 08:45

Infections and stones: Clinical

P0001

Predictive value of perinephric fat stranding for obstructive pyelonephritis and septic shock

Authors

Kottooran C.¹, Villanueva-Congote J.¹, Lee J.¹, Eisner B.²

Institutions

¹Massachusetts General Hospital, Dept. of Urology, Boston, United States of America, ²Tulane University School of Medicine, Dept. of Urology, New Orleans, United States of America

P0002

Percutaneous nephrostomy or ureteral stenting in septic obstructive urolithiasis: a propensity-matched comparative study

Authors

Menozi M.¹, Perri D.², Hoxha S.¹, Ferrari I.¹, Carelli C.¹, Livio V.², Maltagliati M.², Calcagnile T.², Maruccia S.², Gastaldi C.², Orlandi F.³, Sene N.³, Demirkiran E.D.⁴, Micali S.³, Bozzini G.²

Institutions

¹Università di Modena e Reggio Emilia, Dept. of Urology, Como, Italy, ²ASST Lariana, Sant'Anna Hospital Como, Dept. of Urology, Como, Italy, ³Università di Modena e Reggio Emilia, Dept. of Urology, Modena, Italy, ⁴Zonguldak Bulent Ecevit University, Dept. of Urology, Zonguldak, Turkey

P0003

Are SGLT2 inhibitors a new risk factor for urinary tract infections after ureteroscopy in diabetic patients?

Authors

Fazaa N.¹, Eigner E.¹, Shashar R.¹, Nsair A.¹, Atallah M.¹, Soloveichik Y.², Mullerad M.¹, Goldin O.¹, Amiel G.¹, Stabholz Y.³, Sadeh O.¹

Institutions

¹Rambam Health Care Campus, Dept. of Urology, Haifa, Israel, ²The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Dept. of Medicine, Haifa, Israel, ³Rambam Health Care Campus, Dept. of Infectious Diseases, Haifa, Israel

08:45 - 09:00

Infections and stones: Research

P0004

Multimodal integration of CT-derived 3D morphology, radiomics, and deep learning features for predicting urine culture positivity and clinical stratification in ureteral stone patients

Authors

[Ikuma S.](#), Akatsuka J., Kaneko G., Mikami H., Obayashi K., Endo Y., Takeda H., Kimura G., Kondo Y.

Institutions

Nippon Medical School Hospital, Dept. of Urology, Tokyo, Japan

P0005

Evaluation of new-generation systemic immune markers for predicting positive urine culture in urolithiasis patients

Authors

[Li C.](#), Xie L., Luo D., Liu C.

Institutions

The Second Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China

P0006

Species-Level Profiling Reveals Two Distinct Urobiome Clusters in Unilateral Stone Formers

Authors

[Hong S-Y.](#), Yang Y.Y., Wang S.G.

Institutions

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China

09:00 - 09:40

Genetics and stones

P0007

Exome-wide association of kidney stone disease in the UK Biobank

Authors

[Lovegrove C.](#)¹, Holmes M.V.², Furniss D.³, Howles S.A.⁴

Institutions

¹University of Glasgow, School of Cardiovascular and Metabolic Health, Glasgow, United Kingdom, ²University of Bristol, MRC Integrative Epidemiology Unit, Bristol, United Kingdom, ³University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ⁴University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom

P0008

Bidirectional Association Between Nephrolithiasis and Osteoporosis: Evidence From a Large Prospective Cohort Study in the UK Biobank

Authors

[Huang C-Y.](#)¹, Wu C.H.²

Institutions

¹National Taiwan University Hospital. University of Alabama at Birmingham. Case Western Reserve University, Dept. of Urology, Taipei, Taiwan, ²University of Alabama at Birmingham, Case Western Reserve University, Dept. of Urology, Dept. of Genetics and Genome Sciences, Birmingham, United States of America

P0009

Mendelian disorders are an uncommon cause of kidney stone disease

Authors

[Lovegrove C.](#)¹, Bull K.², Holmes M.V.³, Furniss D.⁴, Howles S.⁵

Institutions

¹University of Glasgow, School of Cardiovascular and Metabolic Health, Glasgow, United Kingdom, ²University of Oxford, Nuffield Department of Medicine, Oxford, United Kingdom, ³University of Bristol, MRC Integrative Epidemiology Unit, Bristol, United Kingdom, ⁴University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ⁵University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom

P0010

Bidirectional Association Between Kidney Stones and Atherosclerosis: A Study on Mediation, Genetics, and Risk Prediction

Authors

Tang Z.¹, [He Z.](#)¹, Wang J.¹, Zhang J.¹, Qian Y.¹, Ling K.¹, Wu H.¹, Tianwang G.², Fucai T.¹

Institutions

¹The Eighth Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Shenzhen, China, ²Dongguan People's Hospital, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, dongguan, China

P0011

Kidney stone disease-associated genetic variant may regulate CYP24A1 expression

Authors

[Lovegrove C.](#)¹, Goldsworthy M.², Haley J.³, Smesler D.³, Carey D.³, Hannan F.⁴, Mahajan A.⁵, Holmes M.⁶, Thakker R.⁷, Furniss D.⁸, Howles S.A.²

Institutions

¹University of Glasgow, School of Cardiovascular and Metabolic Health, Glasgow, United Kingdom, ²University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom, ³Geisinger Medical Center, Division of Molecular and Functional Genomics, Danville, United States of America, ⁴University of Oxford, Nuffield Department of Women's and Reproductive Health, Oxford, United Kingdom, ⁵University of Oxford, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom, ⁶University of Bristol, MRC Integrative Epidemiology Unit, Bristol, United Kingdom, ⁷University of Oxford, Academic Endocrine Unit, Oxford, United Kingdom, ⁸University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

P0012

Polygenic Risk scores Perform poorly in Prediction of Kidney Stone Disease: Cross-over validation in All of Us and UK Biobank

Authors

[Geraghty R.](#)¹, Lovegrove C.², Cordell H.³, Howles S.⁴, Sayer J.⁵

Institutions

¹Freeman Hospital, Dept. of Urology, Newcastle upon Tyne, United Kingdom, ²Glasgow University, Dept. of Urology, Glasgow, United Kingdom, ³Newcastle University, Dept. of Biosciences, Newcastle upon Tyne, United Kingdom, ⁴Oxford University Hospitals, Dept. of Urology, Oxford, United Kingdom, ⁵Freeman Hospital, Dept. of Nephrology, Newcastle upon Tyne, United Kingdom

P0013

A Mouse Model Study on Gene Therapy for Primary Hyperoxaluria Type 3 Using Base Editing Technology

Authors

Ge Y., He L., Qi S., Deng H., Tian Y., Wang W.

Institutions

Beijing Friendship Hospital Capital Medical University, Dept. of Urology, Beijing, China

P0014

Prevalence and biochemical associations of pathogenic genetic variants in a targeted population of high-risk kidney stone formers

Authors

Croghan S.¹, Asaad W.¹, Geraghty R.¹, Luk A.¹, Fitzpatrick J.¹, Shaw M.¹, Rix D.¹, Mabillard H.², Rogers A.¹, Sayer J.²

Institutions

¹Freeman Royal Hospital, Dept. of Urology, Newcastle Upon Tyne, United Kingdom,

²Freeman Royal Hospital, Dept. of Nephrology, Newcastle upon Tyne, United Kingdom

09:40 - 10:00

The microbiome

P0015

Multi-Omics Analysis of the Urinary Microbiome and Metabolome in Recurrent and Type-Specific Urinary Stones

Authors

Min K.¹, Park J.², Lee M.², Lee D.¹, Wee C.B.¹, Tae J.H.¹, Choi S.Y.¹, Chang I.H.¹, Kim T.H.¹, Myung S.C.¹, Lee C.U.³, Choi J.³, Kim J.H.³, Kim J.W.³, Lee Y.S.³, Park H.², Kim B.S.⁴

Institutions

¹Chung-Ang University Hospital, Dept. of Urology, Seoul, South Korea, ²Gwangju Institute of Science and Technology, Dept. of Biomedical Science and Engineering, Gwangju, South Korea, ³Chung-Ang University Gwangmyung Hospital, Dept. of Urology, Gwangmyung, South Korea, ⁴Kyungpook National University Hospital, Dept. of Urology, Daegu, South Korea

P0016

Distinct urinary microbial profiles in calcium oxalate urolithiasis: A 16S rRNA-based comparative study

Authors

Hwang W.K.¹, Lee T.H.¹, Kim H.J.¹, Jo S.B.¹, Yoo E.S.², Kim J.W.¹, Oh M.M.¹, Park H.S.¹, Ahn S.T.¹, Moon D.G.¹

Institutions

¹Korea University Guro Hospital, Dept. of Urology, Seoul, South Korea, ²Kyungpook National University Hospital, Dept. of Urology, School of Medicine, Daegu, South Korea

P0017

A novel synbiotic formulation prevents calcium oxalate stones by educating gut microbiota

Authors

Xun Y., Li X.M., Yu X.

Institutions

Tongji Hospital, Dept. of Urology, Wuhan, China

AuthorsCui T., Yang Y., Wang X., Dang K., Zhou Y., Liu J., Xiao J.**Institutions**

Beijing Friendship Hospital, Capital Medical University, Dept. of Urology, Beijing, China

BALANCE: Diversity in prostate cancer – Our journey so far

Patient Advocacy Roundtable



Friday 13 March
09:45 - 10:45

Location Red Area, Room 14

Chair D. James, London (GB)

Learning objectives

Share experiences and key learnings from the BALANCE study, including study design, stakeholder engagement, questionnaire rollout, and regional insights from participating countries.

Highlight the importance of honesty and transparency, including discussing challenges, delays, and obstacles encountered so far.

Emphasize community involvement and co-creation, exploring lessons from both researchers' and stakeholders' perspectives and best practices for engagement.

Discuss future aspirations and collaboration, including implications for education, policy, and subsequent studies.

09:45 - 09:53**Welcome & introduction**

D. James, London (GB)

09:53 - 10:01**The Suriname experience: local perspectives from Prostate Cancer Suriname**

C. Warning, Paramaribo (SR)

10:01 - 10:09**LACOG's contribution: lessons and perspectives from Latin America**

M. Caitano Maia, Belém (BR)

10:09 - 10:17**Community engagement and challenges: the Sierra Leone perspective**

T. Davies OBE, Waltham Cross (GB)

10:17 - 10:25**UK insights: patient and community reflections from the Rose Thompson Foundation**

L. Thompson, (GB)

10:25 - 10:33**Health equity insights and the future impact of the BALANCE study**

N Natalia, London (GB)

10:33 - 10:45**Q&A and closing**

D. James, London (GB)

Beyond the stone: Metabolic management of urolithiasis

Thematic Session

Friday 13 March
10:45 - 12:15

Location Orange Area, eURO Auditorium 1

Chairs S. Proietti, Milan (IT)
A. Skolarikos, Athens (GR)

Learning objectives

By the end of this session, delegates will: Recognize how climate change and environmental factors are shifting the epidemiology of kidney stones. Know how, who and when to undertake metabolic screening, and when genetic testing is warranted. Weigh prevention strategies - 24-hour urine-guided medical therapy versus treatment of residual fragments -through debate. Apply practical recurrence-reduction measures: Optimal drinking water choices, OTC supplements, and the potential role of SGLT-2 inhibitors. Tailor metabolic evaluation and therapy to paediatric, infection/struvite, and hypercalciuric calcium stones, including indications for thiazides.

10:45 - 10:46

Introduction

10:46 - 10:54

State-of-the-art lecture **Climate change, the environment and incidence of urolithiasis**

G. Tasian, Philadelphia (US)

10:54 - 11:02

State-of-the-art lecture **How, who and when to undertake metabolic screening in stone formers?**

H.U. Jung, Vejle (DK)

11:02 - 11:10

State-of-the-art lecture **Who should have genetic testing in kidney stone disease?**

S. Howles, High Wycombe (GB)

11:10 - 11:25

Debate **To prevent stone recurrence, it is more important to:**

Moderator B. Ballesta Martinez, Alicante (ES)

11:10 - 11:12

Introduction

B. Ballesta Martinez, Alicante (ES)

11:12 - 11:17

Obtain a 24-hour urine and optimise medical management

M.A. Corrales Acosta, Clermont Ferrand (FR)

11:17 - 11:22

Treat the residual stone fragments

S. Tonyali, Istanbul (TR)

11:22 - 11:25

Summary

11:25 - 11:50

Panel discussion **Reducing the risk of stone recurrence**

Moderator E. Ventimiglia, Uppsala (SE)

11:25 - 11:27

Introduction

E. Ventimiglia, Uppsala (SE)

11:27 - 11:32

What water should our patients drink?

To be confirmed

11:32 - 11:37	Over-the-counter supplements to reduce stone formation G. Kamphuis, Amsterdam (NL)
11:37 - 11:42	Should we offer SGLT-2 inhibitors to reduce kidney stone risk? D. Fuster, Bern (CH)
11:42 - 11:50	Discussion
<hr/>	
11:50 - 12:14	Management of stones in specific situations
11:50 - 11:58	State-of-the-art lecture Paediatric stones: Specifications in metabolic evaluation and management T.M. Oktar, Istanbul (TR)
11:58 - 12:06	State-of-the-art lecture Infection stones: Metabolic evaluation, medical management and prevention To be confirmed
12:06 - 12:14	State-of-the-art lecture Calcium stones: When to use thiazides in hypercalciuria? J. Sayer, Newcastle upon Tyne (GB)
<hr/>	
12:14 - 12:15	Conclusion

Common problems and controversies in bladder cancer: Rapid-fire debates

Thematic Session

Friday 13 March
10:45 - 12:15

Location Orange Area, eURO Auditorium 2
Chairs A.M. Kamat, Houston (US)
A. Stenzl, Stuttgart (DE)

10:45 - 10:48	Introduction A.M. Kamat, Houston (US)
<hr/>	
10:48 - 11:05	Urinary markers vs. cystoscopy: Is it time to ditch the scope? <i>Moderator</i> P. Gontero, Turin (IT)
10:48 - 10:50	Case presentation P. Gontero, Turin (IT)
10:50 - 10:54	Debater 1: Yes, urinary markers are ready to replace cystoscopy J.Y.C. Teoh, Hong Kong (HK)
10:54 - 10:58	Debater 2: Not yet, cystoscopy remains the gold standard for a reason L.S. Mertens, Amsterdam (NL)
10:58 - 11:05	Discussion and Q&A <i>Speakers</i> P. Gontero, Turin (IT) M.C. Mir Maresma, Valencia (ES)
<hr/>	
11:05 - 11:22	High-risk BCG naïve NMIBC: BCG + IO – Bold new standard or overreach? <i>Moderator</i> A.M. Kamat, Houston (US)

11:05 - 11:07	Case presentation A.M. Kamat, Houston (US)
11:07 - 11:11	Debater 1: BCG + IO: The next logical step for high-risk NMIBC N. Shore, Myrtle Beach (US)
11:11 - 11:15	Debater 2: Not so fast: BCG + IO is overkill E. Laukhtina, Vienna (AT)
11:15 - 11:22	Discussion and Q&A <i>Speakers</i> A.M. Kamat, Houston (US) M. Moschini, Milan (IT)
11:22 - 11:39	TMT for MIBC: Radiation, responsibility, and recurrences – who manages the fallout, and how? <i>Moderator</i> P. Mariappan, Edinburgh (GB)
11:22 - 11:24	Case presentation P. Mariappan, Edinburgh (GB)
11:24 - 11:28	Debater 1: Radiation toxicity is real and it's urologists who manage the consequences A. Van Der Heijden, Nijmegen (NL)
11:28 - 11:32	Debater 2: Toxicity happens but is manageable - radiation oncologists can and should take responsibility N. Vapiwala, Philadelphia (US)
11:32 - 11:39	Discussion and Q&A <i>Speakers</i> A.J Birtle, Preston (GB) P. Mariappan, Edinburgh (GB)
11:39 - 11:56	Bladder preservation post-NAC: Smart strategy or risky business? <i>Moderator</i> B. Pradère, Toulouse (FR)
11:39 - 11:41	Case presentation B. Pradère, Toulouse (FR)
11:41 - 11:45	Debater 1: Bladder preservation in cCR patients: A smart, data-driven strategy F.C. Maluf, São Paulo (BR)
11:45 - 11:49	Debater 2: Bladder preservation post-NAC: Risky business B. Schmidt, Salt Lake City (US)
11:49 - 11:56	Discussion and Q&A <i>Speakers</i> B. Pradère, Toulouse (FR) A. Stenzl, Stuttgart (DE)
11:56 - 12:13	MIBC systemic therapy: Maximise early or strategise post-op? <i>Moderator</i> M. Galsky, New York (US)
11:56 - 11:58	Case presentation M. Galsky, New York (US)
11:58 - 12:02	Debater 1: Peri-operative IO based therapy for all T. Powles, London (GB)

12:02 - 12:06

Debater 2: NAC + Risk-adapted adjuvant IO

P. Giannatempo, Milan (IT)

12:06 - 12:13

Discussion and Q&A

Speakers

M. Galsky, New York (US)

F. Guerrero-Ramos, Madrid (ES)

12:13 - 12:15

Closure

5 top tips for genital surgery

Thematic Session

Friday 13 March

10:45 - 12:15

Location

Orange Area, Room 3

Chairs

S.C. Morgenstern, Frankfurt am Main (DE)

H. Veiby Holm, Oslo (NO)

10:45 - 10:47

Introduction

10:47 - 11:28

Andrology

10:47 - 10:57

History lecture What can we learn from past mistakes in genital surgery?

J.C. Goddard, Leicester (GB)

10:57 - 11:04

Peyronie's disease: Straight to the point

M.Y. Ortega González, San Cristóbal de La Laguna (ES)

11:04 - 11:11

Erectile prosthesis: Avoiding disaster

J. Torremade Barreda, Barcelona (ES)

11:11 - 11:18

Managing complications after penile surgery: When things don't go as planned...

D.J. Ralph, London (GB)

11:18 - 11:28

Panel discussion and Q&A

11:28 - 12:13

Reconstruction

11:28 - 11:35

Grafting in penile cancer patients

S. Yan, London (GB)

11:35 - 11:42

Distal urethral stricture: The final frontier

M.W. Vetterlein, Hamburg (DE)

11:42 - 11:49

When there's not enough skin

M. Skrodzka, London (GB)

11:49 - 11:56

FTM gender affirming surgery

R. Djinovic, Belgrade (RS)

11:56 - 12:03

Fournier's gangrene

M. Falcone, Turin (IT)

12:03 - 12:13

Panel discussion and Q&A

12:13 - 12:15

Closing remarks

Friday 13 March
10:45 - 12:15

Location	Red Area, Room 17
Chairs	To be confirmed
	To be confirmed
	To be confirmed

10:45 - 11:05

ARPi and chemotherapy

A0001

(ARTO trial-NCT03449719): Long-term overall survival analysis from a randomized phase II trial testing the benefit of stereotactic body radiotherapy addition to abiraterone acetate in oligometastatic castrate resistant prostate cancer patients

Authors

Fracoloni G.¹, Bertini N.², Caini S.³, Di Cataldo V.², Garlatti P.², Aquilano M.², Bruni A.⁴, Ingrosso G.⁵, D'Angelillo R.M.⁶, Tagliaferri L.⁷, Augugliaro M.⁸, Triggiani L.⁹, Parisi S.¹⁰, Masieri L.¹¹, Campi R.¹², Simontacchi G.², Valincenti R.K.¹³, Tang C.¹⁴, Livi L.¹⁵

Institutions

¹Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, Dept. of Biomedical Experimental and Clinical Sciences Mario Serio, Florence, Italy, ²Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, ³Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Cancer Risk Factors and Lifestyle Epidemiology Unit, Florence, Italy, ⁴University Hospital of Modena, Radiation Oncology Unit, Dept. of Oncology and Hematology, Modena, Italy, ⁵University of Perugia, Radiation Oncology Section, Dept. of Medicine and Surgery, Perugia, Italy, ⁶University of Rome Tor Vergata, Radiation Oncology, Dept. of Biomedicine and Prevention, Rome, Italy, ⁷Fondazione Policlinico Universitario "A.Gemelli" IRCCS, UOC of Oncological Radiotherapy, Dept. of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Rome, Italy, ⁸Azienda USL-IRCCS di Reggio Emilia, Unit of Radiotherapy, Reggio Emilia, Italy, ⁹Università degli Studi di Brescia, Brescia University, Dept. of Radiation Oncology, Brescia, Italy, ¹⁰University of Messina, Radiation Oncology Unit, Dept. of Biomedical, Dental Sciences and Morphological and Functional Imaging, Messina, Italy, ¹¹Careggi University Hospital, Unit of Urology and Renal Transplantation, Oncology Department, Florence, Italy, ¹²University of Florence, Careggi Hospital, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ¹³University of California, Davis Comprehensive Cancer Center, Sacramento, United States of America, ¹⁴The University of Texas MD Anderson Cancer Center, Houston, United States of America, ¹⁵Experimental and Clinical sciences "Mario Serio", University of Florence, Dept. of Biomedical, Florence, Italy

A0002

Long-term effects of enzalutamide and abiraterone acetate in men with metastatic castration-resistant prostate cancer: Results from a randomised clinical trial (HEAT)

Authors

Kvorning Ternov K.¹, Fode M.¹, Sønksen J.¹, Bisbjerg R.¹, Lindberg H.², Palapattu G.³, Bratt O.⁴, Østergren P.B.¹

Institutions

¹Copenhagen University Hospital - Herlev and Gentofte Hospital, Dept. of Urology, Herlev, Denmark, ²Copenhagen University Hospital - Herlev and Gentofte Hospital, Dept. of Oncology, Herlev, Denmark, ³Michigan Medicine, Dept. of Urology, Ann Arbor, United States of America, ⁴Sahlgrenska Academy, University of Gothenburg, Institute of Clinical Sciences, Gothenburg, Sweden

A0003

CABPOSTAAT: A randomized phase II study of Docetaxel versus Cabazitaxel post Androgen Receptor Pathway Inhibitor (ARPI) progression

Authors

De vries-brilland M.¹, Hamilou Z.², Nadiri A.³, Sperlich C.⁴, Paradis J.B.⁵, Lattouf J.B.⁶, Tian Z.⁷, Saad F.⁷

Institutions

¹Institut de cancérologie de l'ouest, Dept. of Medical Oncology, Angers, France, ²Centre Hospitalier de l'Université de Montréal, Dept. of Hemato-Oncology, Montréal, Canada, ³Centre de Recherche du Centre Hospitalier de l'Université de Montréal, CRCHUM, Montréal, Canada, ⁴CSSS Charles-Le Moyne, Clinique Intégrée de Cancérologie de la Montérégie (CICM), Greenfield Park, Canada, ⁵Saguenay-Lac-Saint-Jean Integrated Health and Social Services Centre, Dept. of Urology, Chicoutimi, Canada, ⁶Centre Hospitalier de l'Université de Montréal, Division of Urology, Dept. of Surgery, Montréal, Canada, ⁷University of Montréal Health Center, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montréal, Canada

A0004

Clinical efficacy of combining novel hormonal therapy with docetaxel and carboplatin in neuroendocrine prostate cancer

Authors

Yuan S.¹, Wu B.¹, Wang Y.², Niu Y.², Cao X.¹

Institutions

¹First hospital of Shanxi Medical University, Dept. of Urology, Taiyuan, China, ²The Second Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China

11:05 - 11:30

Radium-223

A0005

Time-dependent survival benefit of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: reconstructed analysis of the PEACE-3 trial

Authors

Chen W.¹, Yoshida S.¹, Yajima S.², Tanabe K.¹, Fujiwara M.³, Fukushima H.¹, Tanaka H.¹, Hirakawa A.⁴, Masuda H.², Fujii Y.¹

Institutions

¹Institute of Science Tokyo, Dept. of Urology, Tokyo, Japan, ²National Cancer Center Hospital East, Dept. of Urology, Chiba, Japan, ³Teikyo University Hospital, Dept. of Urology, Tokyo, Japan, ⁴Institute of Science Tokyo, Dept. of Clinical Biostatistics, Tokyo, Japan

External validation of a prognostic risk model for overall survival after Radium-223 treatment in metastatic castration-resistant prostate cancer

Authors

Fujita N.¹, Kato T.², Hashimoto K.³, Mizokami A.⁴, Kurokawa S.⁵, Sugaya S.⁶, Kawahara T.⁷, Tsuchiya N.⁸, Makino S.⁹, Sato H.¹⁰, Takahashi S.¹¹, Hoshi S.¹², Kato M.¹³, Naya Y.¹⁴, Hatakeyama S.¹

Institutions

¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Kagawa University, Dept. of Urology, Kagawa, Japan, ³Sapporo Medical University School of Medicine, Dept. of Urology, Sapporo, Japan, ⁴Kanazawa University Hospital, Dept. of Urology, Kanazawa, Japan, ⁵Sano Kosei General Hospital, Dept. of Urology, Sano, Japan, ⁶Machida Municipal Hospital, Dept. of Urology, Tokyo, Japan, ⁷Yokohama City University Medical Center, Dept. of Urology, Yokohama, Japan, ⁸Yamagata University Faculty of Medicine, Dept. of Urology, Yamagata, Japan, ⁹Shinkuki General Hospital, Dept. of Radiology, Saitama, Japan, ¹⁰Akita University School of Medicine, Dept. of Urology, Akita, Japan, ¹¹The University of Tokyo, Institute of Medical Science, Dept. of Urology, Tokyo, Japan, ¹²Fukushima Medical University Hospital, Dept. of Urology, Fukushima, Japan, ¹³Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Dept. of Urology, Nagoya, Japan, ¹⁴Teikyo University Chiba Medical Center, Dept. of Urology, Chiba, Japan

Study Group

FRONTIER study group(Kagawa, Japan)

A Clinically Accessible Risk Calculator for Radium-223 Non-Completion and Overall Survival Stratification in Bone-metastatic Castration-resistant Prostate Cancer

Authors

Yaegashi H.¹, Kato T.², Fujita K.³, Harabayashi T.⁴, Hasegawa Y.⁵, Kawamura N.⁶, Yokoyama M.⁷, Tsukuda F.⁸, Saika T.⁹, Kohjimoto Y.¹⁰, Shiraishi K.¹¹, Nonomura N.¹², Haga N.¹³, Kokura K.¹⁴, Mizokami A.¹

Institutions

¹Kanazawa University Hospital, Dept. of Integrative Cancer Therapy and Urology, Kanazawa, Japan, ²Kagawa University Hospital, Dept. of Urology, Miki-Cho, Japan, ³Kindai University Hospital, Dept. of Urology, Sayama, Japan, ⁴NHO Hokkaido Cancer Center, Dept. of Urology, Sapporo, Japan, ⁵NHO Mie Chuo Medical Center, Dept. of Urology, Tsu, Japan, ⁶Osaka International Cancer Institute, Dept. of Urology, Osaka, Japan, ⁷Teikyo University School of medicine University Hospital, Mizonokuchi, Dept. of Urology, Kawasaki, Japan, ⁸Edogawa Hospital, Dept. of Urology, Edogawa Ward, Japan, ⁹Ehime University Hospital, Dept. of Urology, Toon, Japan, ¹⁰Wakayama Medical University Hospital, Dept. of Urology, Wakayama, Japan, ¹¹Yamaguchi University Hospital, Dept. of Urology, Ube, Japan, ¹²Osaka University Hospital, Dept. of Urology, Suita, Japan, ¹³Fukuoka University Hospital, Dept. of Urology, Fukuoka, Japan, ¹⁴Hyogo Medical University Hospital, Dept. of Urology, Nishinomiya, Japan

Study Group

FRONTIER study group(Miki-Cho, Japan)

Safety and Skeletal Event Profile of Radium-223 Combined with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis in Japan

Authors

Kato T.¹, Eto M.², Sato M.³, Negishi T.⁴, Wada A.⁵, Tsukino H.⁶, Matsunaga Y.⁷, Kohguchi D.⁸, Hagiwara M.⁹, Fujita N.¹⁰, Tatarano S.¹¹, Izaki H.¹², Kamikawa S.¹³, Taniguchi H.¹⁴, Nagata Y.¹⁵, Mochizuki T.¹⁶, Tohi Y.¹, Sugimoto M.¹

Institutions

¹Kagawa university, Dept. of Urology, Miki-cho, Japan, ²Kyushu University Graduate School of Medical Sciences, Dept. of Urology, Fukuoka, Japan, ³Toyonaka Municipal Hospital, Dept. of Urology, Toyonaka, Japan, ⁴NHO Kyushu Cancer Center, Dept. of Urology, Fukuoka, Japan, ⁵Shiga University of Medical Science Hospital, Dept. of Urology, Otsu, Japan, ⁶Junwakai Memorial Hospital, Dept. of Urology, Miyazaki, Japan, ⁷Kurume University Hospital, Dept. of Urology, Kurume, Japan, ⁸Kitasato University Kitasato Institute Hospital, Dept. of Urology, Sagami-hara, Japan, ⁹Saitama Medical University International Medical Center, Dept. of Urology, Hidaka, Japan, ¹⁰Hirosaki University Hospital, Dept. of Urology, Hirosaki, Japan, ¹¹Kagoshima University Hospital, Dept. of Urology, Kagoshima, Japan, ¹²Tokushima Prefectural Central Hospital, Dept. of Urology, Tokushima, Japan, ¹³Osaka City General Hospital, Dept. of Urology, Osaka, Japan, ¹⁴Kansai Medical University Hospital, Dept. of Urology, Hirakata, Japan, ¹⁵University Hospital of Occupational and Environmental Health, Dept. of Urology, Kitakyushu, Japan, ¹⁶University of Yamanashi Hospital, Dept. of Urology, Chuo, Japan

Study Group

FRONTIER study group(Miki-cho, Japan)

Impact of Germline Mutations in Homologous Recombination Genes on Efficacy of Radium-223 in mCRPC: Results from PRORADIUM study

Authors

González Ginel I.¹, de Velasco G.², Romero-Laorden N.³, Lozano R.⁴, Tello D.⁵, Conteduca V.⁶, Ovejero M.⁵, Villa-Guzman J.C.⁷, Villatoro R.⁸, Puente J.⁹, Esteban J.², Almagro E.¹⁰, Gómez A.¹¹, Sanz S.¹², Herrera B.¹³, Rodríguez-Antolín A.¹, Castellanos D.², Lorente D.¹⁴, Olmos D.², Castro E.²

Institutions

¹Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ²Hospital Universitario 12 de Octubre, Dept. of Medical Oncology, Madrid, Spain, ³Hospital Universitario de La Princesa, Dept. of Medical Oncology, Madrid, Spain, ⁴Hospital Clínico Universitario de Salamanca, Dept. of Medical Oncology, Salamanca, Spain, ⁵Hospital Universitario 12 de Octubre, I+12 Biomedical Research Institute, Madrid, Spain, ⁶Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl – IRCCS, Dept. of Medical Oncology, Meldola, Italy, ⁷Hospital General Universitario de Ciudad Real, Dept. of Medical Oncology, Ciudad Real, Spain, ⁸Hospital Universitario Costa del Sol, Dept. of Medical Oncology, Marbella, Spain, ⁹Hospital Clínico San Carlos, Dept. of Medical Oncology, Madrid, Spain, ¹⁰Hospital Universitario Quirónsalud, Dept. of Medical Oncology, Pozuelo de Alarcón, Spain, ¹¹Hospital Universitario 12 de Octubre, Dept. of Nuclear Medicine, Madrid, Spain, ¹²Hospital Universitario Virgen de la Victoria, Dept. of Nuclear Medicine, Málaga, Spain, ¹³Hospital Universitario Virgen de la Victoria, Dept. of Urology, Málaga, Spain, ¹⁴Instituto Valenciano de Oncología, Dept. of Medical Oncology, Valencia, Spain

A0010

Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics

Authors

Wenzel M.¹, [Le D.Q.C.](#)¹, Siech C.¹, Hoeh B.², Klimek K.³, Happel C.³, Saad F.⁴, Preisser F.⁵, Tilki D.⁵, Graefen M.⁵, Steuber T.⁵, Maurer T.⁵, Kriegmair M.C.⁶, Karakiewicz P.I.⁴, Chun F.K.H.¹, Groener D.³, Mandel P.⁵

Institutions

¹Goethe University Frankfurt, Dept. of Urology, Frankfurt, Germany, ²Carl Gustav Carus University Dresden, Dept. of Urology, Dresden, Germany, ³Goethe University Frankfurt, Dept. of Nuclear Medicine, Frankfurt, Germany, ⁴Centre de Hospitalier de l'University de Montreal, Dept. of Urology, Montréal, Canada, ⁵Martini Klinik Hamburg, Dept. of Urology, Hamburg, Germany, ⁶Urological Hospital Munich-Planegg, Dept. of Urology, Munich, Germany

A0011

PSMA-RLT vs. Cabazitaxel for Japanese metastatic castration resistance prostate cancer : Comparison of oncological outcomes using propensity score matching

Authors

[Enei Y.](#)¹, Yanagisawa T.¹, Kuruma H.², Okazaki C.², Okada A.³, Watanabe K.⁴, Lenzo N.⁵, Kimura T.¹, Miki K.¹

Institutions

¹The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ²Theranostics Yokohama, Dept. of Urology, Kanagawa, Japan, ³Jinsenkaï MI Clinic, Dept. of Radiology, Osaka, Japan, ⁴The Jikei University School of Medicine, Dept. of Radiology, Tokyo, Japan, ⁵ICON Cancer Centre Theranostics, Dept. of Radiology, Perth, Australia

A0012

Prognostic role of site specific volumetric response in mCRPC treated with Lu-177-PSMA radioligand therapy

Authors

[Pikul M.](#)¹, Ufton D.², Drzezga A.², Schmidt M.², Heidenreich A.¹

Institutions

¹University Hospital Cologne, Dept. of Urology, Cologne, Germany, ²University Hospital Cologne, Dept. of Nuclear Medicine, Cologne, Germany

11:45 - 12:15

Biomarkers in mCRPC

A0013

Nationwide genomic data analysis of Japanese advanced prostate cancer ~analyzing C-CAT database~

Authors

[Tsukahara S.](#), Shiota M., Tanegashima T., Mutaguchi J., Goto S., Kobayashi S., Matsumoto T., Eto M.

Institutions

Kyushu University, Dept. of Urology, Fukuoka, Japan

A0014

Concordance between tissue and ctDNA of homologous recombination repair gene alterations (HRRm) in a prospective molecular characterization initiative for metastatic castration resistant prostate cancer (mCRPC)

Authors

Pillay S.¹, te Paske I.¹, Tolmeijer S.², Kloots I.¹, Ligtenberg M.³, Mehra N.¹

Institutions

¹Radboudumc, Dept. of Medical Oncology, Nijmegen, The Netherlands, ²University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, ³Radboudumc, Dept. of Medical Oncology and Human Genetics, Nijmegen, The Netherlands

A0015

Heterogeneity and Synergistic Inhibition of the Poly(ADP-ribose) Polymerase and Androgen Receptor Signaling Pathway in Patients with Metastatic Castration-resistant Prostate Cancer

Authors

Yang B.¹, Li D.¹, Zhang Y.², Chen W.³, Dong B.⁴, Hanxu G.HX¹, Jin C.¹, Xu J.¹, Luo W.¹, Mao S.¹, Guo C.¹, Peng B.¹, Yao X.¹, Shen B.¹

Institutions

¹Shanghai Tenth People's Hospital Tongji University School of Medicine, Dept. of Urology, Shanghai, China, ²School of Life Sciences and Technology, Tongji University, Frontier Science Center for Stem Cell Research, Shanghai, China, ³The First Affiliated hospital of Wenzhou Medical University, Dept. of Urology, Wenzhou, China, ⁴Renji Hospital, Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China

A0016

Quantitative Functional RAD51 Foci Outperform Genomic Alterations in Predicting PARPi Response in mCRPC: A Multicenter Real-world Study

Authors

Yang B.¹, Hanxu G.HX¹, Ding L.¹, Jin C.¹, Liu W.², Dong B.³, Chen W.⁴, Xie J.⁵, Xu J.¹, Luo W.¹, Xu Q.⁵, Zhao T.⁶, Mao S.¹, Guo C.¹, Peng B.¹, Yao X.¹, Shen B.¹

Institutions

¹Shanghai Tenth People's Hospital Tongji University School of Medicine, Dept. of Urology, Shanghai, China, ²Shanghai Tenth People's Hospital, Dept. of Pathology, Shanghai, China, ³Renji Hospital, Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China, ⁴The First Affiliated Hospital of Wenzhou Medical University, Dept. of Urology, Shanghai, China, ⁵Urologic Cancer Institute, Tongji University School of Medicine, Dept. of Urology, Shanghai, China, ⁶Tongji University, School of Life Sciences and Technology, Shanghai, China

A0017

Artificial intelligence-driven molecular subtyping for precision treatment of metastatic castration-resistant prostate cancer

Authors

Yuan S.¹, Wu B.¹, Wang Y.², Niu Y.², Cao X.¹

Institutions

¹First hospital of Shanxi Medical University, Dept. of Urology, Taiyuan, China, ²The Second Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China

A0018

Assessment of Neuroendocrine Differentiation at Prostate Cancer Diagnosis: An Investigation of Histological Neuroendocrine Tumor Markers

Authors

Shimomura T., Murakami M., Kasai K., Imai Y., Inaba Y., Miki J., Yamada H., Kimura T.

Institutions

The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan

The new era of robotic prostate surgery: Guidance, precision and global connectivity

Video Session 01

Friday 13 March
10:45 - 12:15

Location Blue Area, George 3
Chairs To be confirmed
J. Stranne, Göteborg (SE)
To be confirmed

V001 (□ 8 min.)

Augmented Reality PSMA-3D guided robotic pelvic lymph node dissection (PLND) in prostate cancer patients
L. Bianchi, Bologna (IT)

V002 (□ 8 min.)

Sentinel lymph node biopsy in prostate cancer
L. Viver Colet, Barcelona (ES)

V003 (□ 8 min.)

Dual Sphincter Preservation Technique – The Victory Technique: An Extraperitoneal, Single-Site Robot Assisted Radical Prostatectomy
V. Stankov, Skopje (MK)

V004 (□ 7 min.)

Single-port extraperitoneal versus multiport transperitoneal robot-assisted radical prostatectomy: a pair-matched analysis of perioperative, pathological and early functional outcomes
M. Oderda, Turin (IT)

V005 (□ 6 min.)

Simultaneous Step-by-Step Comparison of Four Robotic Platforms in Radical Prostatectomy: Da Vinci Xi, Da Vinci SP, Hugo™ RAS, and TOUMAI®
R. Brime Menéndez, Madrid (ES)

V006 (□ 6 min.)

Kuwait–Shanghai–Strasbourg: Multi Continental Experience in Human Telesurgery
S. Alhelal, Kuwait City (KW)

V007 (□ 5 min.)

First Experience with the Edge MP1000/OMNIBOT Robotic System in Urological Surgery
S. Orellana, Santiago (CL)

Minimally invasive surgery in urology - Urethral strictures

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Maghreb Union countries

Friday 13 March
10:45 - 12:45

Location Blue Area, Victoria 6

Chairs A. Belkacem Nacer, Algiers (DZ)
K. Benakila, Alger (DZ)
P.E.V. Van Kerrebroeck, Berchem- Antwerp (BE)

Learning objectives

This session will deal with two distinct topics relevant in clinical urologic practice in 2026. In the first part speakers from Maghreb countries as well as the EAU will discuss key techniques and benefits minimal invasive urologic surgery such as laparoscopic partial nephrectomy and review current management strategies for benign prostatic hyperplasia. Furthermore an update will be given on the diagnosis and treatment of upper urinary tract urothelial carcinoma and innovations in the treatment of urethral strictures will be presented. In a second session clinical guidelines and perspectives shaping contemporary urologic practice will be discussed.

10:45 - 11:45

Minimally invasive surgery in urology

Moderators A. Belkacem Nacer, Algiers (DZ)
S. Ben Rhouma, Tunis (TN)

10:45 - 10:55

Laparoscopic partial nephrectomy: Key techniques and outcomes

S. Rezkallah, Alger (DZ)

10:55 - 11:05

Benign prostatic hyperplasia: Current advances in minimally invasive therapies for BPH

To be confirmed

11:05 - 11:15

Upper urinary tract urothelial carcinoma: Endoscopic management

To be confirmed

11:15 - 11:25

Minimal invasive urologic surgery and the lower urinary tract

V. Phé, Paris (FR)

11:25 - 11:45

Discussion

11:45 - 12:45

Urethral strictures

Chairs To be confirmed
To be confirmed

11:45 - 11:55

Emerging therapies for urethral strictures

To be confirmed

11:55 - 12:05

Complex urethral reconstruction: Current standards

To be confirmed

12:05 - 12:15

Urethral stricture guidelines: 2025 Update

To be confirmed

12:15 - 12:25

Tips, tricks and pitfalls in urethral surgery

To be confirmed

12:25 - 12:45

Discussion and conclusion

Prostate cancer 2036: A global outlook

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Urological Society of Australia and New Zealand (USANZ)

Friday 13 March
10:45 - 12:45

Location Blue Area, Victoria 2
Chairs M. Albersen, Leuven (BE)
D. Bolton, Heidelberg (AU)

10:45 - 10:55

Screening & early detection in 2036

Moderators M. Roberts, Brisbane (AU)
R. Van Den Bergh, Rotterdam (NL)

10:45 - 10:55

State of the art: Modern early detection: How will we do it in 2036?

T. Nordström, Stockholm (SE)

10:55 - 11:25

Current implementation: A global perspective:

Moderators M. Roberts, Brisbane (AU)
R. Van Den Bergh, Rotterdam (NL)

10:55 - 11:05

USANZ perspective

P.S. Heathcote, Brisbane (AU)

11:05 - 11:15

EAU perspective: PRAISE-U and more

M.J. Roobol, Rotterdam (NL)

11:15 - 11:25

Panel Discussion

P.S. Heathcote, Brisbane (AU)
T. Nordström, Stockholm (SE)
M.J. Roobol, Rotterdam (NL)

11:25 - 11:35

Local therapy in 2036: What innovations can we expect?

Moderators D. Murphy, Melbourne (AU)
H.G. Van Der Poel, Amsterdam (NL)

11:25 - 11:35

State of the art: Localised prostate cancer in 2036: Innovation outlook

N. Sathianathen, Melbourne (AU)

11:35 - 12:05

Case-based DEBATE: Is radical prostatectomy still a relevant surgery in 2036?

Moderators D. Murphy, Melbourne (AU)
H.G. Van Der Poel, Amsterdam (NL)

11:35 - 11:40

Decision support RT vs. Surgery

Case presenter E. Dinneen, London (GB)

11:40 - 11:50

PRO

W. Everaerts, Leuven (BE)

11:50 - 12:00

CON

S. Siva, Melbourne (AU)

12:00 - 12:05

Discussion

12:05 - 12:45

Tracers and theranostics 2036

Moderators

K. Goffin, Leuven (BE)

To be confirmed

12:05 - 12:15

State of the art: Standardizing PSMA PET/CT for better outcomes in 2036: The SPARC initiative

A.S. Bjartell, Malmö (SE)

12:15 - 12:25

State of the art: Diagnostic PSMA trials: Where are we coming from and where are we going?

R. Eapen, Melbourne (AU)

12:25 - 12:35

State of the art: Theranostic PSMA trials: Where are we coming from and where are we going?

K. Herrmann, Essen (DE)

12:35 - 12:45

Discussion

From MRI to Post-treatment care: A Global perspective on prostate cancer in 2026

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Société Internationale d'Urologie (SIU)

Friday 13 March

10:45 - 12:45

Location

Blue Area, Victoria 4

Chairs

W. Lynch, Montreal, Quebec (CA)

H. Van Poppel, Leuven (BE)

Learning objectives

The optimal imaging techniques and markers for prostate cancer diagnosis and staging including MRI, PET and biomarkers will be discussed. There will be an ample overview of the status of prostate cancer screening all over the globe. Active surveillance and functional disturbances after treatment are discussed.

10:45 - 11:15

Imaging and biomarkers in 2026

Moderator

To be confirmed

10:45 - 10:55

The current role of MRI

C. Moore, London (GB)

10:55 - 11:05

The current role of PSMA PET imaging

D. Murphy, Melbourne (AU)

11:05 - 11:15

The evolving role of biomarkers

K.J. Tay, Singapore (SG)

11:15 - 11:55

Where does screening and early detection sit today?

Moderator

To be confirmed

11:15 - 11:20

Europe

H. Van Poppel, Leuven (BE)

11:20 - 11:25

North America

To be confirmed

11:25 - 11:30	Middle East / Africa To be confirmed
11:30 - 11:35	Asia To be confirmed
11:35 - 11:40	South America G. Vitagliano, Buenos Aires (AR)
11:40 - 11:55	Panel discussion <i>Moderators</i> W. Lynch, Montreal, Quebec (CA) H. Van Poppel, Leuven (BE) <i>Panel</i> To be confirmed
11:55 - 12:45	Managing localized prostate cancer and functional outcomes <i>Moderator</i> To be confirmed
11:55 - 12:05	Active Surveillance in 2025 A.S. Rannikko, Espoo (FI)
12:05 - 12:15	Post-prostatectomy incontinence: Advances and challenges To be confirmed
12:15 - 12:25	Post-radiation incontinence: Current approaches To be confirmed
12:25 - 12:35	Bladder emptying disorders / dysfunction after treatment W. Lynch, Montreal, Quebec (CA)
12:35 - 12:45	Discussion

Reconstructive urology in developing world

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Urological Society of India (USI)

Friday 13 March
10:45 - 12:45

Location Blue Area, Victoria 1
Chairs P. Albers, Düsseldorf (DE)
R. Keshavamurthy, Bangalore (IN)

Learning objectives

This session will update the audience in special topics of reconstructive urology in complex urethral strictures and hot topics in GU oncology (penile cancer, prostate cancer, renal cancer).

10:45 - 11:45	Reconstructive urology Redo hypospadias - Managing the unmanageable
10:45 - 10:50	Novel flaps and graft techniques A. Bhatt, Jaipur (IN)
10:50 - 10:55	Dealing with fibrosis and complications M. Fisch, Hamburg (DE)

10:55 - 11:05

Complex urethral stricture - Lessons learnt

G. Gopalakrishnan, Coimbatore (IN)

11:05 - 11:15

Pelvic fracture urethral distraction injuries - Optimising timing and approach

S. Kulkarni, Pune (IN)

11:15 - 11:45

Panel discussion

Discussant

R. Nayyar, New Delhi (IN)

Panel

A.K. Chawla, Manipal (IN)

B.V. Sistla, Coimbatore (IN)

M. Waterloos, Ghent (BE)

11:45 - 12:35

Uro-oncology

11:45 - 11:55

Penile cancer - Lessons from indian subcontinent

K. Patel, Ahmedabad (IN)

Debate Should Sentinel lymph node biopsy be the new standard for CNO groin in carcinoma penis?

11:55 - 12:00

Yes

A. Tamhankar, Delhi (IN)

12:00 - 12:05

No

O. Brouwer, Amsterdam (NL)

12:05 - 12:15

Role of radical prostatectomy as part of multimodal treatment in locally advanced and oligometastatic prostate cancer

U. Mete, Chandigarh (IN)

Debate Can PSMA PET/CT spare extended pelvic lymph node dissection in high risk prostate cancer

12:15 - 12:20

Yes

G.K. Pooleri, Kochi (IN)

12:20 - 12:25

No

J.P. Radtke, Düsseldorf (DE)

12:25 - 12:35

Role of artificial intelligence in renal tumour detection and prognostication - Leapfrogging the gap

A. Bex, London (GB)

12:35 - 12:45

Management of advanced renal cell cancer

Moderator

A. Volpe, Novara (IT)

12:35 - 12:40

Latest systemic therapy strategies

To be confirmed

12:40 - 12:45

Sequencing and evidence

N. Ragavan, Chennai (IN)

Open vs. minimally invasive diagnosis and treatment

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Caucasus/Central Asian countries

Friday 13 March
10:45 - 12:45

Location Red Area, Room 7

Chairs
A. Amanov, Almaty (KZ)
D. Nikoleishvili, Tbilisi (GE)
J.O.R. Sønksen, Herlev (DK)

Learning objectives

The best techniques in a given situation, both open and minimally invasive

10:45 - 11:34

Laparoscopy and oncology

Moderators
To be confirmed
J.O.R. Sønksen, Herlev (DK)
A. Tsaturyan, Yerevan (AM)

10:45 - 10:52

Comparative analysis of open and laparoscopic partial nephrectomy

S. Kussymzhanov, Almaty (KZ)
R. Nurzhan, Almaty (KZ)

10:52 - 10:59

Advantages of 3D laparoscopy in partial nephrectomy

To be confirmed

10:59 - 11:06

Female urethral diverticulectomy: Tips and tricks with surgical video demonstration

G. Shadyan, Yerevan (AM)

11:06 - 11:13

Robotic partial nephrectomies

D. Yunusov, Tashkent (UZ)

11:13 - 11:20

Open vs. robotic assisted partial nephrectomy in IR/HR renal cell cancer: A prospective randomized study

M-O. Grimm, Jena (DE)

11:20 - 11:27

Laparoscopic radical cystectomy the experiences of National Center of Urology

A. Pertia, Tbilisi (GE)

11:27 - 11:34

Discussion

11:34 - 12:16

Andrology

Moderators
A. Chkhotua, Tbilisi (GE)
Z Khakhazov, Almaty (KZ)
To be confirmed

11:34 - 11:41

Penile implantation in patients with spinal cord injury

To be confirmed

11:41 - 11:48

Comparative efficacy and safety of intracavernosal PRP therapy and autologous bone marrow mesenchymal stem cells in patients with moderate to severe erectile dysfunction

Y. Iskakov, Astana (KZ)
R. Nugumanov, Astana (KZ)
R. Omarbayev, Astana (KZ)

11:48 - 11:55	Prostate enucleation J-N.L. Cornu, Rouen (FR)
11:55 - 12:02	Effectiveness of endovascular treatment of recurrent varicocele B. Abishev, Almaty (KZ) Z Khakhazov, Almaty (KZ)
12:02 - 12:09	Beyond the gold standard, the critical role of malleable prostheses in Central Asia: Experience of a high-volume center To be confirmed
12:09 - 12:16	Discussion
<hr/>	
12:16 - 12:44	Stones <i>Moderators</i> A. Amanov, Almaty (KZ) J. Rassweiler, Tübingen (DE) A. Tursunkulov, Tashkent (UZ)
12:16 - 12:23	Do you follow ALARA principles? A. Tursunkulov, Tashkent (UZ)
12:23 - 12:30	Management of kidney complex stones To be confirmed
12:30 - 12:37	Lower calyceal stone management J. Rassweiler, Tübingen (DE)
12:37 - 12:44	Discussion
<hr/>	
12:44 - 12:45	Closing remarks

Foundation skills in urologic excellence

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Federation of ASEAN Urological Associations (FAUA)

Friday 13 March
10:45 - 12:45

Location Blue Area, Victoria 5
Chairs To be confirmed
To be confirmed

10:45 - 10:50	Introduction
<hr/>	
10:50 - 11:05	Foundation skills in the past 40 years: A narrative from the FAUA experience To be confirmed
<hr/>	
11:05 - 11:35	Radical prostatectomy beside robotics <i>Moderators</i> A. Martini, Cincinnati (US) To be confirmed
11:05 - 11:20	Open surgery – a lost art? F. Safriadi, Bandung (ID)
11:20 - 11:35	3D-Laparoscopy – the best of two worlds? To be confirmed

11:35 - 12:15

Challenges in renal & ureteric surgery

Moderators

To be confirmed

To be confirmed

11:35 - 11:50

Staghorn calculi – any alternatives to PCNL & RIRS?

To be confirmed

Debate ablation vs surgery in complex renal tumor: FAUA experience

11:50 - 12:00

Partial nephrectomy when there is no robot

To be confirmed

12:00 - 12:15

Ablation

To be confirmed

12:15 - 12:35

Reconstruction for ureteral injuries

Moderators

P. Gontero, Turin (IT)

To be confirmed

12:15 - 12:25

Upper ureter

To be confirmed

12:25 - 12:35

Middle to lower third ureter

To be confirmed

12:35 - 12:40

Conclusion

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the World Chinese Urologists

Friday 13 March

10:45 - 12:45

Location

Blue Area, George 1

Chairs

P.K-F. Chiu, Hong Kong (HK)

J. Chueh, Taipei (TW)

To be confirmed

E. Liatsikos, Patras (GR)

To be confirmed

10:45 - 11:10

Artificial intelligence & precision diagnostics

10:45 - 10:51

An AI-agent decision support system for precision treatment recommendation of urological cancer management

C-Y. Tsai, New Taipei City (TW)

10:51 - 10:57

Development and application of non-invasive precision subtyping technologies for primary aldosteronism

To be confirmed

10:57 - 11:03

Intraoperative navigation systems facilitate precise management of urological tumors: Current applications and single-center experience

M. Zhang, Shenyang (CN)

11:03 - 11:10

Discussion

11:10 - 11:47	Robotic and Surgical Innovation
11:10 - 11:16	Robotic transurethral en-bloc resection of bladder tumour P.K-F. Chiu, Hong Kong (HK)
11:16 - 11:22	Robotic autonomous suturing in renal surgery: How far are we? To be confirmed
11:22 - 11:28	The long-term follow-up for 700 cases of RNRS-RARP (retrograde release of neurovascular bundle technique in Retzius-sparing RARP) To be confirmed
11:28 - 11:34	Robotic Telesurgery: A tool or a tale? To be confirmed
11:34 - 11:40	Experience of urology single port robotic (Da Vinci) surgery in Macau SAR S.F. Ho, Macau (MO)
11:40 - 11:47	Discussion
<hr/>	
11:47 - 12:24	Urooncology
11:47 - 11:53	Research on the efficacy and mechanisms of irreversible electroporation in the treatment of prostate cancer To be confirmed
11:53 - 11:59	Kidney tumour with level III–IV IVC thrombus: What options do we have? C.H. Yee, Hong Kong (HK)
11:59 - 12:05	Bipolar androgen therapy for mCRPC: initial experience from Beijing Hospital To be confirmed
12:05 - 12:11	14:24 – 14:31 Mechanisms of immunoresistance and reversal therapy in bladder cancer: From bedside to bench and back to bedside To be confirmed
12:11 - 12:17	Update on bladder sparing treatments E.N. Xylinas, Paris (FR)
12:17 - 12:24	Discussion
<hr/>	
12:24 - 12:45	Functional and reconstructive urology
12:24 - 12:30	An alternative approach for treating female underactive bladders with chronic urine retention: A pilot study on combined transvaginal ultrasound-guided botulinum Toxin A external sphincter injection and transurethral incision of the bladder neck E. Chou, Taichung (TW)
12:30 - 12:36	Innovations and practices in ureteral stricture reconstruction Y. Fan, Beijing (CN)
12:36 - 12:45	Discussions and closing remarks

Meeting of the Young Academic Urologists (YAU): Spotlight on innovation, evidence, and education in modern medicine

Special Session

Friday 13 March
10:45 - 14:45

Location Blue Area, George 4

Chair G.I. Russo, Catania (IT)

Learning objectives

This session will explore how young academic urologists are shaping the future of urology through cutting-edge research, innovative clinical practices, and educational initiatives. Delegates will learn about emerging technologies, collaborative research opportunities, and strategies for integrating evidence-based medicine into daily practice. The session will also emphasize the importance of mentorship, global networking, and academic leadership in advancing modern urological care.

10:45 - 10:50

Introduction

G.I. Russo, Catania (IT)

10:50 - 11:14

YAU awards

10:50 - 10:58

YAU reviewer of the year: How to perform the perfect peer-review

To be confirmed

10:58 - 11:06

YAU best paper published in 2025

To be confirmed

11:06 - 11:14

Best abstract at EAU 2026 by a YAU Group

To be confirmed

11:14 - 12:09

Digital disruption in urology and oncology

Moderators

I. Andras, Cluj (RO)

M. Frankiewicz, Gdańsk (PL)

A. Morgado, Porto (PT)

11:14 - 11:24

Multidisciplinary tumour boards: From cancer profiling to virtual oncology networks

E. Grobet-Jeandin, Geneva (CH)

11:24 - 11:34

Cutting-edge technologies in robotic surgery: From digital twins to the next-gen platforms

D. Amparore, Orbassano (Turin) (IT)

11:34 - 11:44

Digital health solutions: Enhancing functional recovery after surgery

S.T. De Cillis, Turin (IT)

11:44 - 11:54

Digital training in urology: Building the next-generation endourologist

A. Pietropaolo, Southampton (GB)

11:54 - 12:04

Data-driven conception: The AI era in fertility and ART

E. García Rojo, Madrid (ES)

12:04 - 12:09

Questions and answers

12:09 - 12:54

Precision, progress, and partnership: YAU and oncology

Moderators

L.A. 't Hoen, Rotterdam (NL)

S. Albisinni, Rome (IT)

M. Przydacz, Krakow (PL)

12:09 - 12:19

How to design a clinical study: From hypothesis to protocol

K-F. Kowalewski, Mannheim (DE)

12:19 - 12:29

How to present a paper for publication: "to AI or not to AI"

N.R. Bhatt, Cambridge (GB)

12:29 - 12:39

Basic biostatistics: Power, p-values, and pitfalls

A.J. Vickers, New York (US)

12:39 - 12:49

How to design an appropriate meta-analysis (and get it published)

G. Cacciamani, Los Angeles (US)

12:49 - 12:54

Questions and Answers

12:54 - 13:09

Non oncology From rejection to revision: Turning abstract setbacks into success

Moderators

B. Ballesta Martinez, Alicante (ES)

E. García Rojo, Madrid (ES)

M. Vallée, Poitiers (FR)

M.G. Çulha, Istanbul (TR)

12:54 - 12:57

Endourology: Flexible ureteroscopy with integrated suction, a useful innovation: A systematic review by the YAU and EAU endourology sections

E. Ventimiglia, Uppsala (SE)

12:57 - 12:59

Questions and Answers

12:59 - 13:02

Endourology: Evaluation of safety and efficacy of PCNL in elderly patients (≥ 70 Years) - A multicentre LASSO-based analysis from the YAU and EAU endourology sections

To be confirmed

13:02 - 13:04

Questions and Answers

13:04 - 13:07

Endourology: Impact of lithotomy position on ureteral course and psoas muscle: A combined survey and radiological evaluation by the EAU endourology & YAU endourology working groups

To be confirmed

13:07 - 13:09

Questions and Answers

13:09 - 13:24

Oncology: Part one From rejection to revision: Turning abstract setbacks into success

Moderators

S. Rodler, Kiel (DE)

A. Territo, Barcelona (ES)

W. Verla, Ghent (BE)

13:09 - 13:12

Urothelial cancer: Bladder tumor location matters: Trigone and bladder neck involvement predict worse outcomes in high-grade non-muscle-invasive bladder cancer

A. Ślusarczyk, Warsaw (PL)

13:12 - 13:14

Questions and Answers

13:14 - 13:17	<p>Urotechnology: "Artificial intelligence in the diagnosis of urinary stone disease: A systematic review from EAU & YAU endourology" R.B. Ergül, Istanbul (TR)</p>
13:17 - 13:19	<p>Questions and Answers</p>
13:19 - 13:22	<p>Urothelial: Patient's selection to endoscopic kidney-sparing surgery vs upfront radical nephroureterectomy according to diagnostic ureteroscopy: insight from large multicenter EAU-YAU urothelial working group To be confirmed</p>
13:22 - 13:24	<p>Questions and Answers</p>
13:24 - 13:39	<p>Oncology: Part two From rejection to revision: Turning abstract setbacks into success</p> <p><i>Moderators</i></p> <p>M. Christodoulidou, Leicester (GB) A. Cimadamore, Udine (IT) E. Roussel, Leuven (BE) To be confirmed C. Würnschimmel, Lucerne (CH)</p>
13:24 - 13:27	<p>Renal cancer: Histopathological outcomes after renal surgery: insights from the EAU-YAU RCC and US-KIDNET collaborative To be confirmed</p>
13:27 - 13:29	<p>Questions and Answers</p>
13:29 - 13:32	<p>Robotic: Comprehensive intraoperative checklist—pharmacologic and non-pharmacologic factors to reduce postoperative pain in robotic urologic surgery: a 3-round Delphi from the YAU/J-ERUS To be confirmed</p>
13:32 - 13:34	<p>Questions and Answers</p>
13:34 - 13:37	<p>Robotic: Performance metrics and error-analysis in patient-side assistance during robotic surgery: A J-ERUS/YAU construct validation study C. Würnschimmel, Lucerne (CH)</p>
13:37 - 13:39	<p>Questions and Answers</p>
13:39 - 14:45	<p>Joint session by ESUR and YAU "From Bench to Bedside: Translational Research and Imaging in Urology"</p> <p><i>Moderators</i></p> <p>G. Marra, Turin (IT) B. Pradère, Toulouse (FR)</p>
13:39 - 13:51	<p>Beyond mCRPC: PARP inhibition in earlier stages of prostate cancer J. Gómez Rivas, Madrid (ES)</p>
13:51 - 14:03	<p>Redefining intravesical therapy: From BCG to novel agents in NMIBC E. Compérat, Vienna (AT)</p>
14:03 - 14:15	<p>Radiogenomics and AI: Integrating imaging with molecular data V. Kasivisvanathan, London (GB)</p>
14:15 - 14:27	<p>NGS in urologic tumours: What every clinician should know C. Jerónimo, Porto (PT)</p>
14:27 - 14:39	<p>MicroRNA signatures in prostate and bladder cancer: Biomarkers in action E.S. Martens-Uzunova, Rotterdam (NL)</p>

Renal cell carcinoma: Advancements in diagnosis, prognosis, and personalized treatment

EGPT 05

Friday 13 March
10:45 - 12:15

Location Orange Area, EGPT 3

Chairs S. Fernández-Pello Montes, Gijón (ES)
A. Govorov, Moscow (RU)

10:45 - 11:30

VHL and other genetic disorders - diagnosis and treatment

P0073

Construction of an Early Diagnostic Model for Von Hippel-Lindau Syndrome Renal Cell Carcinoma (VHL-RCC) Lipid Biomarkers Using Machine Learning and AI Algorithms to Analyze Blood and Tissue Metabolomics

Authors

[Chen X.L.C.](#), Kan G., Yizhou W., Jingcheng Z., Jianhui Q.

Institutions

Peking University First Hospital, Dept. of Urology, Peking, China

P0074

Overtaking Intra and Inter Tumoral Heterogeneity in von Hippel-Lindau related Renal Cancer: a Multi Modal Data Integration Approach

Authors

[Rowe I.](#)¹, Colombo A.², Corea F.¹, Pisu F.², Genova F.³, Uggé M.⁴, Ciaparrone C.⁵, Giangrasso A.⁵, Pipitone G.B.⁶, Larcher A.⁷, Colciago G.¹, Morelli M.³, Lucianò R.⁸, Carrera P.⁶, Zeppa P.⁹, Caputo A.⁹, Bertini R.⁷, Montorsi F.⁷, Salonia A.⁷, Verze P.⁹, Palmisano A.¹⁰, Esposito A.¹⁰, Bernardi R.⁴, Capitanio U.⁷

Institutions

¹IRCCS San Raffaele, VHL Program, Milan, Italy, ²Vita-Salute San Raffaele University, Dept. of Engineering, Milan, Italy, ³IRCCS San Raffaele, Center for Omics Sciences, Milan, Italy, ⁴IRCCS San Raffaele, Comprehensive Cancer Center, Milan, Italy, ⁵A.O.U. San Giovanni di Dio e Ruggi d'Aragona "Scuola Medica Salernitana", Pathology Unit, Salerno, Italy, ⁶IRCCS San Raffaele, Laboratory of Clinical Molecular Genetics, Milan, Italy, ⁷IRCCS San Raffaele Scientific Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ⁸IRCCS San Raffaele, Dept. of Pathology, Milan, Italy, ⁹A.O.U. San Giovanni di Dio e Ruggi d'Aragona "Scuola Medica Salernitana", Dept. of Urology, Salerno, Italy, ¹⁰IRCCS San Raffaele, Clinical and Experimental Radiology Unit, Milan, Italy

P0075

Natural history of Von Hippel–Lindau Disease receiving local treatment before systemic therapy with HIF-2a inhibitors: updated data reporting system from a large VHL Care Center

Authors

Barretta A.¹, Belladelli F.², Cei F.², Re C.², Salerno L.², Musso G.², Piccolo C.², Disabato N.², Rowe I.³, Corea F.³, Brembilla G.⁴, Imperiale G.⁴, Guazzarotti G.⁴, De Cobelli F.⁴, Cigliola A.⁵, Necchi A.⁵, Bianchi L.¹, Schiavina R.¹, Rosiello G.², Montorsi F.², Capitanio U.², Salonia A.², Larcher A.²

Institutions

¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, Italy, ²IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ³IRCCS San Raffaele, VHL Program, Milan, Italy, ⁴IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy, ⁵IRCCS San Raffaele Scientific Institute, Dept. of Medical Oncology, Milan, Italy

P0076

Clinicopathologic and prognosis of 30 patients with FH-deficient Renal Cell carcinoma: a single-center retrospective study

Authors

Bai J.¹, Huang J.², Ye Y.², Wen Y.³, Zhu S.², Chen J.², Li X.⁴

Institutions

¹The Shengli Clinical Medical College of Fujian Medical University, Dept. of Urology, Fuzhou, China, ²Fujian Medical University Union Hospital, Dept. of Urology, Fuzhou, China, ³The First Affiliated Hospital of Fujian Medical University, Dept. of Thyroid and Breast Surgery, Fuzhou, China, ⁴Fujian Medical University Union Hospital, Dept. of Pathology, Fuzhou, China

P0077

Differential Belzutifan response driven by distinct VHL exon deletions: From molecular mechanisms to translational validation in renal cell carcinoma

Authors

Bao Y., Song Z., Zhou J., Wang Y., Gong K.

Institutions

Peking University First Hospital, Dept. of Urology, Peking, China

P0078

Multidisciplinary Management of Von Hippel–Lindau Disease Throughout the Patient’s Lifetime: Observational Analysis from a Large Comprehensive Care Center

Authors

Cei F.¹, Barretta A.², Salerno L.¹, Capitanio J.F.³, Bailo M.³, Lattanzio R.⁴, Bandello F.⁴, Guarneri G.⁵, Partelli S.⁵, Cigliola A.⁶, Necchi A.⁶, Brembilla G.⁷, De Cobelli F.⁷, Calloni S.⁷, Falini A.⁸, Castellino L.⁹, Sciarrone Alibrandi M.T.¹⁰, Pipitone G.B.¹¹, Corea F.¹², Capitanio U.¹, Schiavina R.², Montorsi F.¹, Larcher A.¹, Salonia A.¹

Institutions

¹IRCCS San Raffaele Scientific Institute, Dept. of Urology and Division of Experimental Oncology, URI-Urological Research Institute, Milan, Italy, ²IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, Italy, ³IRCCS San Raffaele Scientific Institute, Dept. of Neurosurgery, Milan, Italy, ⁴IRCCS San Raffaele Scientific Institute, Dept. of Ophthalmology, Milan, Italy, ⁵IRCCS San Raffaele Scientific Institute, Pancreas Translational & Clinical Research Center, OSR ENETS Center of Excellence, Unit of Pancreatic Surgery, Milan, Italy, ⁶IRCCS San Raffaele Scientific Institute, Dept. of Medical Oncology, Milan, Italy, ⁷IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy, ⁸IRCCS San Raffaele Scientific Institute, Dept. of Neuroradiology, Milan, Italy, ⁹IRCCS San Raffaele Scientific Institute, Dept. of Endocrinology, Milan, Italy, ¹⁰IRCCS San Raffaele Scientific Institute, Dept. of Nephrology, Milan, Italy, ¹¹IRCCS San Raffaele Scientific Institute, Service of Laboratory Medicine, Molecular Genetics Service and Clinical Genomics, Milan, Italy, ¹²IRCCS San Raffaele, VHL Program, Milan, Italy

P0079

Hotspot Mutations and Tumor Risk in VHL Syndrome: Genotype-Phenotype Analysis of a Large Patient Cohort

Authors

Wang C., Gong K.

Institutions

Peking University First Hospital, Dept. of Urology, Peking, China

P0080

Long-term outcomes of repeated renal interventions in von Hippel–Lindau–associated renal cell carcinoma

Authors

Astheimer S.C.¹, Himmelsbach R.¹, Sigle A.¹, Grabbert M.¹, Kotsis F.², Bechtel-Walz W.², Ganner A.², Spohn S.³, Gratzke C.¹, Jilg C.A.¹

Institutions

¹Medical Center University of Freiburg, Dept. of Urology, Freiburg, Germany, ²Medical Center University of Freiburg, Dept. of Nephrology, Freiburg, Germany, ³Medical Center University of Freiburg, Dept. of Radiation Oncology, Freiburg, Germany

P0081

Androgen–Receptor Axis Drives Tumor Initiation in VHL-Associated Early-Onset Renal Cell Carcinoma: Mechanistic Basis and Preventive Implications

Authors

Song Z., Bao Y., Zhou J., Wang Y., Gong K.

Institutions

Peking University First Hospital, Institute of Urology, Beijing, China

11:30 - 11:40

Improvng imaging RCC Diagnosis

P0082

Development of a Novel ⁶⁸Ga-Labeled Radiotracer Targeting Carbonic Anhydrase IX for Diagnosis of Clear Cell Renal Cell Carcinoma

Authors

Liu T.¹, Xu H.C.², Chen X.Q.², Wang Y.Z.³, Zhang J.H.², Yang X.⁴, Gong K.¹

Institutions

¹Peking University First Hospital, Dept. of Urology, Beijing, China, ²Peking University First Hospital, Dept. of Nuclear Medicine, Beijing, China, ³Peking University First Hospital, Dept. of Central Laboratory, Beijing, China, ⁴Peking University People's Hospital, Dept. of Nuclear Medicine, Beijing, China

P0083

Impact of girentuximab based radionuclide imaging in patients with renal cell carcinoma on virtual tumor board decision making - an interim analysis

Authors

van der Werff T.J.¹, Fütterer J.J.², Mulder S.F.³, Langenhuijsen J.F.¹, Wegelin O.¹, Oprea-Lager D.E.², Mulders P.F.A.¹, Muselaers C.H.J.¹

Institutions

¹Radboud university medical center, Dept. of Urology, Nijmegen, The Netherlands, ²Radboud University Medical Center, Dept. of Imaging, Nijmegen, The Netherlands, ³Radboud University Medical Center, Dept. of Medical oncology, Nijmegen, The Netherlands

11:40 - 11:50

Molecular Characterization of RCC

P0084

Pre-Diagnostic Plasma Proteomics Profile Uncovers New Biomarkers and Mechanistic Insights for Incident Kidney Cancer

Authors

Wen L.¹, Guiming Z.², Nianzeng X.¹

Institutions

¹National Cancer Center, Dept. of Urology, Beijing, China, ²The Affiliated Hospital of Qingdao University, Dept. of Urology, Qingdao, China

P0085

Decoding Metabolic Causality Across Kidney Cancer Subtypes: An Integrative Mendelian Randomization and Metabolomic Validation Study

Authors

Wang Z., Xu B.

Institutions

The Ninth People's Hospital, Dept. of Urology, Shanghai, China

11:50 - 12:15

Prognosis and other therapies

P0086

Machine Learning–Derived CART Reclassification Improves Prognostic Accuracy in Stage III Renal Cell Carcinoma

Authors

Saitta C.¹, Garofano G.¹, Musso G.², Karamcheti S.³, Meagher M.⁴, Baker B.⁴, Liss M.⁴, Vourganti S.³, Cherullo E.³, Casale P.¹, Lughezzani G.¹, Buffi N.M.¹, Derweesh I.³

Institutions

¹IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy, ²IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ³Rush University, Dept. of Urology, Chicago, United States of America, ⁴UC San Diego Health System, Dept. of Urology, San Diego, United States of America

Comparative Prognostic Performance of KEYNOTE-564 and AUA Risk Stratification in Non-Metastatic Clear Cell Renal Cell Carcinoma

Authors

Garofano G.¹, Saitta C.¹, Musso G.², Saita A.¹, Lazzeri M.¹, Capitanio U.², Dabbas M.³, Larcher A.², Autorino R.⁴, Pandolfo S.D.⁵, Patil D.⁶, Tanaka H.⁷, Fontana G.¹, Montorsi F.², Lughezzani G.¹, Casale P.¹, Buffi N.M.¹, Campbell S.C.⁴, Derweesh I.H.⁸

Institutions

¹Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Urological Research Institute, Milan, Italy, ³UC San Diego Health System, Dept. of Urology, San Diego, United States of America, ⁴Glickman Urological and Kidney Institute, Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ⁵University of L'Aquila, Dept. of Urology, L'Aquila, Italy, ⁶Emory Medical Center, Dept. of Urology, Atlanta, United States of America, ⁷University of Science Tokyo, Dept. of Urology, Tokyo, Japan, ⁸RUSH University Medical Center, Dept. of Urology, Chicago, United States of America

The accuracy of KEYNOTE-564 study eligibility criteria on recurrence prediction in papillary renal cell carcinoma: A multi-institutional comparative analysis with prognostic scores

Authors

Erdem S.¹, Campi R.², Klatte T.³, Amparore D.⁴, Mir M.C.⁵, Capitanio U.⁶, Roussel E.⁷, Bertolo R.⁸, Pavan N.⁹, Kara O.¹⁰, Wu Z.¹¹, Anceschi U.¹², Carbonara U.¹³, Ates Y.¹⁴, Erden M.E.¹⁴, Serni S.², Sanli O.¹, Ozcan F.¹, Bex A.¹⁵, Stewart G.D.¹⁶

Institutions

¹Istanbul University Istanbul Faculty of Medicine, Division of Urologic Oncology, Dept. of Urology, Istanbul, Turkey, ²University of Florence, Unit of Urological Robotic Surgery and Renal Transplantation, Dept. of Experimental and Clinical Medicine, Florence, Italy, ³Helios Klinikum Bad Saarow, Dept. of Urology, Bad Saarow, Germany, ⁴University of Turin School of Medicine San Luigi Gonzaga Hospital, Division of Urology, Dept. of Oncology, Orbassano, Italy, ⁵Mount Sinai Icahn School of Medicine Elmhurst/Queens Hospital, Dept. of Urology, New York, United States of America, ⁶IRCCS San Raffaele Scientific Institute, Dept. of Urology and Division of Experimental Oncology, Urological Research Institute, Milan, Italy, ⁷University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁸Azienda Ospedaliera Universitaria Integrata of Verona, Dept. of Urology, Verona, Italy, ⁹University of Palermo, Urology Clinic, Dept. of Precision Medicine in Medical Surgical and Critical Care, Palermo, Italy, ¹⁰Kocaeli University, Dept. of Urology, Kocaeli, Turkey, ¹¹Changhai Hospital Naval Medical University, Dept. of Urology, Shanghai, China, ¹²IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹³University of Bari, Unit of Andrology and Kidney Transplantation, Dept. of Emergency and Organ Transplantation-Urology, Bari, Italy, ¹⁴Istanbul University Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ¹⁵Royal Free London NHS Foundation Trust University College London, Division of Surgery and Interventional Science, London, United Kingdom, ¹⁶University of Cambridge, Dept. of Surgery, Cambridge, United Kingdom

P0089

Predicting disease-free survival (DFS) after surgery for non-metastatic clear cell renal cell carcinoma (ccRCC): KEYNOTE-564 criteria vs Leibovich, ASSURE, and UroPredict prognostic models

Authors

Granata S.¹, Pecoraro A.², Bocu G.³, Crescente A.¹, Sessa F.², Serni S.², Masieri L.², Campi R.²

Institutions

¹AOU Careggi, Urological Robotic Surgery and Renal Transplantation Unit and Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy, ²AOU Careggi, Dept. of Urology and Renal Transplantation, Florence, Italy, ³University of Florence, Dept. of Experimental and Clinical Medicine, Florence, Italy

P0090

Identification of a novel pyroptosis gene signature for prognosis prediction in patients with clear cell renal cell carcinoma

Authors

Yang J., Xu H., Yang L.

Institutions

West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China

From translational research to Functional Repair: A Comprehensive analysis of Urethral Reconstruction

EGPT 04

**Friday 13 March
10:45 - 12:15**

Location

Orange Area, EGPT 2

Chairs

To be confirmed

W. Verla, Ghent (BE)

B.R. Viers, Rochester (US)

10:45 - 11:00

Deeper insights Urethral stricture pathogenesis

P0055

BULBOSPONGIOSUS MUSCLE STRUCTURE DURING THE HUMAN FETAL PERIOD: A TRANSLATIONAL RESEARCH

Authors

Favorito L.A., Lannes W., Farias Alves E., Silva Costa W., Sampaio F.

Institutions

State University from Rio de Janeiro, Dept. of Anatomy, Rio de Janeiro, Brazil

P0056

A Missing Link in Urethral Stricture Pathogenesis? The Role of Serum Testosterone

Authors

Chawla A.K., Choudhari A.

Institutions

KMC Manipal, Dept. of Urology and Transplant, Manipal, India

P0057

Lichen sclerosus as an etiological factor of phimosis. Prevalence and results of combined treatment.

Authors

Kotov S.V., Alekberov E., Pulbere S., Iritsyan M., Korochkin N., Badakva G.

Institutions

Pirogov Russian National Research Medical University, Dept. of Urology and Andrology, Moscow, Russia

11:00 - 11:30

Translating basic research in clinical practice

P0058

Two-year results from a completed First-in-Human study of an engineered collagen-based mesh for urethral reconstruction

Authors

Vythilingam G.¹, Larsson H.², Mardiana M.³, Yeoh W.³, Zainuddin S.⁴, Engelhardt E.², Sanmugam A.³, Ch'ng L.³, Xuan J.³, Pinnagoda K.², Sothilingam S.³, Hubbell J.⁵, Frey P.⁶, Joshi P.⁷, Kulkarni S.⁷, Aik O.³

Institutions

¹Great Ormond Street Hospital, Dept. of Paediatric Urology, London, United Kingdom, ²Regenosca S.A Lausanne, Regenosca, Laussane, Switzerland, ³Universiti Malaya, Dept. of Surgery, Kuala Lumpur, Malaysia, ⁴Hospital Serdang, Dept. of Urology, Kuala Lumpur, Malaysia, ⁵NYU Tandon School of Engineering, Dept. of Engineering, New York, United States of America, ⁶Swiss Federal Institute of Technology Lausanne, Institute of Bioengineering, Laussane, Switzerland, ⁷Urokul Hospital, Dept. of Urology, Pune, India

P0059

Mesenchymal stem cells-derived biomimetic hydrogels integrate the repair of the urethra

Authors

Liu Q., Li X.

Institutions

Zhejiang Provincial People's Hospital, Dept. of Urology, Hangzhou, China

P0060

Integrative multi-omics analysis reveals THBS1-positive fibroblasts as therapeutic targets to inhibit ureteral fibrosis progression after thermal injury

Authors

Fangzhou Z., Honggang Y., Xinfei L., Liqing X., Kunlin Y., Ruili G., Xuesong L.

Institutions

Peking University First Hospital, Dept. of Urology, Beijing, China

P0061

A Multilayered Urethral Construct with Functional Tissue Engineered Vasculature and Epithelial Barrier

Authors

Xing Z., Liu X., Qin J., de Kort L., de Graaf P.

Institutions

University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands

P0062

Autologous Live-Cultured Buccal Epithelial Cells for Bulbar Urethral Strictures: 24-Months Follow-Up Results

Authors

Mandal S., [Huzaifa M.](#), Nayak P., Tripathy S., Chowdhury P., Yadav M., Rathod V., Kumar A., Dharap S.S., R S., Ambade S., Das M.K.

Institutions

All India Institute of Medical Sciences, Dept. of Urology and Renal Transplant, Bhubaneswar, India

P0063

Low-dose ionizing radiation and low-intensity shock wave therapy as adjunctive promoters of buccal mucosa urethral graft take in a rat model.

Authors

[Simoes De Oliveira P.M.](#)¹, Vala I.S.², Rocha F.², Oliveira P.², Ministro A.³, Constantino S.²

Institutions

¹ULSSM-Hospital de Santa Maria, Dept. of Urology, Lisbon, Portugal, ²Centro Cardiovascular da Universidade de Lisboa, Faculty of Medicine, Lisbon, Portugal, ³ULSSM-Hospital de Santa Maria, Dept. of Vascular Surgery, Lisbon, Portugal

11:30 - 12:15

Urethral reconstruction: special situations and uncommon scenarios

P0064

Treatment Outcomes of Pelvic fracture urethral injury: a 10-Year Experience at Binh Dan Hospital

Authors

[Do L.H.](#), Chung T.T., Le T.T., Nguyen H.N., Le N.H.D.

Institutions

Binh Dan Hospital, Dept. of Reconstructive Urology, Ho Chi Minh, Vietnam

P0065

Orandi and Asopa Techniques for Anterior Urethral Stricture Repair: Comparative Analysis From a Single-Center Experience

Authors

[Talavera Cobo V.](#)¹, Rodríguez Canton D.², Puerto Jiménez C.², Avetisyan Akopyan D.², Puche Sanz I.²

Institutions

¹Clínica Universidad de Navarra, Dept. of Urology, Pamplona, Spain, ²Hospital Universitario Virgen de las Nieves, Dept. of Urology, Granada, Spain

P0066

Resection urethroplasty for extended bulbar urethral strictures: Complications and factors of their development

Authors

Bugaenko V.A., [Glukhov V.P.](#), Ilyash A.V., Kogan M.I.

Institutions

Rostov State Medical University, Dept. of Urology and Paediatric Urology-andrology, Rostov-on-Don, Russia

P0067

Urethroplasty After Kidney Transplantation: A reconstructive Challenge in a high risk population

Authors

Martinez Garcia C., Costa M., Alfambra H., Pagès R., Villalba E., Payet G., Maicas E., Musquera M., Alcaraz A., Peri Ll.

Institutions

H. Clínic of Barcelona, Dept. of Urology, Barcelona, Spain

P0068

Comparative outcomes of dorsal, ventral buccal mucosal graft, and non-transecting anastomotic urethroplasties in bulbar urethral strictures: A multicenter retrospective analysis

Authors

Deger M.¹, Eldemir A.¹, Zumrutbas A.E.², Gulpinar O.³, Ergun K.E.⁴, Dogan C.⁵, Koparal Y.⁶, Aybek Z.⁷

Institutions

¹Cukurova Univestiy School of Medicine, Dept. of Urology, Adana, Turkey, ²Pamukkale UniversitySchool of Medicine, Dept. of Urology, Denizli, Turkey, ³Ankara University School of Medicine, Dept. of Urology, Ankara, Turkey, ⁴Ege University School of Medicine, Dept. of Urology, İzmir, Turkey, ⁵Tekirdağ Namık Kemal University School of Medicine, Dept. of Urology, Tekirdag, Turkey, ⁶Gazi University, Dept. of Urology, Ankara, Turkey, ⁷Pamukkale University School of Medicine, Dept. of Urology, Denizli, Turkey

P0069

The injectable gelatin-sodium alginate drug delivery systems for urethral stricture disease through the enhancement of tissue repair and prevention of fibroblast-driven extracellular matrix remodeling

Authors

Zhu Z.¹, Ji X.¹, Zhao J.², Zheng Y.², Li X.¹, Lin J.¹

Institutions

¹Peking University First Hospital, Dept. of Urology, Beijing, China, ²University of Science and Technology Beijing, School of Materials Science and Engineering, Beijing, China

P0070

Does preoperative urinary diversion by way of a suprapubic catheter affect the outcomes of urethroplasty?

Authors

Noyman Y.¹, Chertin B.¹, Rapoport Y.², Kovalniuk A.², Shenfeld O.²

Institutions

¹Shaarei Zedek Medical Center, Dept. of urology, Jerusalem, Israel, ²Shaarei Zedek Medical Center, Dept. of Urology and Center for Reconstructive and Functional Urology, Jerusalem, Israel

P0071

Environmental impact of digitizing post-operative monitoring: development of a model applied to urethroplasty.

Authors

Tokarski E., Uko A., Stivale N., Hermieu J.F.O., Xylinas E., Ouzaid I.

Institutions

Hospital Bichat Claude Bernard, Dept. of Urology, Paris, France

Authors

Koparal M.Y.¹, Huseynli A.², Gulpinar O.³, Ergun K.E.⁴, Zumrutbas A.E.⁵, Deger M.⁶, Dogan C.⁷, Aybek Z.⁵

Institutions

¹Gazi University School of Medicine, Dept. of Urology, Ankara, Turkey, ²Ministry of Health Etlik City Hospital, Dept. of Urology, Ankara, Turkey, ³Ankara University School of Medicine, Dept. of Urology, Ankara, Turkey, ⁴Ege University School of Medicine, Dept. of Urology, İzmir, Turkey, ⁵Pamukkale University School of Medicine, Dept. of Urology, Denizli, Turkey, ⁶Cukurova University School of Medicine, Dept. of Urology, Adana, Turkey, ⁷Tekirdag Namik Kemal University School of Medicine, Dept. of Urology, Tekirdag, Turkey

Study Group

Reconstructive Urology, Minimally Invasive and "Hands-On Training" Working Group of Turkish Continence Society(Ankara, Turkey)

Prostate cancer - Basic and translational research

EGPT 07

Friday 13 March
10:45 - 12:15

Location Orange Area, EGPT 5

Chairs
I. Heidegger, Innsbruck (AT)
J. Linxweiler, Homburg/saar (DE)
To be confirmed

- | | |
|-------|--|
| P0109 | <p>A Transformer-Enabled Multimodal Framework Integrating MRI Radiomics and Clinical Features for Predicting Biochemical Recurrence After Radical Prostatectomy: Development and Multi-Institutional Validation</p> <p>R. Chen, shanghai (CN)</p> |
| P0110 | <p>A single-cell spatial atlas of the PCa immune microenvironment identifies CCL18⁺ macrophages as a favorable subset</p> <p>J-H. Pan, Shanghai (CN)</p> |
| P0111 | <p>Hypoxia-Induced CAF-Derived CALR⁺ Extracellular Vesicles Drive Endothelial-Mesenchymal Transition and Aggressive Progression in Non-Metastatic Hormone-Sensitive Prostate Cancer via ITGA3/β1 Integrin Signaling</p> <p>L. Dong, Shanghai (CN)</p> |
| P0112 | <p>ACOT8 Drives Senescent Cell Carcinogenesis by Promoting Histone Glutarylation in Prostate Epithelial Cells</p> <p>C.Z Chao, Wuhan (CN)</p> |
| P0113 | <p>Targeted GPX4 Degradation Using a Peptide-based PROTAC with SIAH1 as E3 Ligase Induces Ferroptosis in Prostate Cancer</p> <p>To be confirmed</p> |
| P0114 | <p>Prostatic Fluid DNA Methylation Biomarkers Enable High-Accuracy Prostate Cancer Diagnosis: A Prospective Pilot Study</p> <p>y. Peng, Chongqing (CN)</p> |

P0115	Luminal stem-like cells in high-risk/locally advanced prostate cancer promote resistance to hormonal therapy Y. Cai, Changsha (CN)
P0116	Chromatin conformational reprogramming by an enhancer RNA reveals a novel therapeutic in prostate cancer To be confirmed
P0117	PSMA-Targeted Silicasome Co-delivery of Rucaparib and Tazemetostat Enhances Synergistic Treatment of Metastatic Castration-Resistant Prostate Cancer Q. Huang, Shenyang (CN)
P0118	Co-targeting β-catenin and CTHRC1 disrupts the stromal-epithelial crosstalk to overcome enzalutamide resistance in CRPC To be confirmed
P0119	Bipolar androgen therapy reverses neuroendocrine lineage differentiation of prostate cancer through inhibition EZH2 H. Hou, Beijing (CN)
P0120	De Novo Design Delivers ACP3-Specific Macrocyclic Peptide for ^{68}Ga-Based PET Imaging of Metastatic Castration-Resistant Prostate Cancer To be confirmed
P0121	Blood-Based Epigenetic Profiling Predicts Recurrence and Survival in Prostate Cancer Patients via ctDNA Methylation J.H. Choi, Busan (KR)
P0122	Circulating Tumor Cell Micronuclei as a Potential Surrogate Marker of DNA Repair Gene Deficiency in Prostate Cancer R. Wenta, Gdańsk (PL)
P0123	Prospective comparison of AR-V7 transcripts from whole blood and circulating tumor cells in castration-resistant prostate cancer patients undergoing treatment with androgen-receptor signaling inhibitors (PEARL Trial) M. Heck, Augsburg (DE)
P0124	CAF-derived epigenetic reprogramming drives prostate cancer metastasis via an EZH2-dependent enhancer activation program To be confirmed
P0125	Bone metastasis enrichment factor SHMT2 mediates immunosuppressive microenvironment and drives prostate cancer progression via the PI3K/AKT/mTOR pathway Y. Lai, Guangzhou (CN)

Friday 13 March
10:45 - 12:15

Location Orange Area, EGPT 1
Chairs L. Pacheco-Figueiredo, Braga (PT)
D. Penson, Nashville (US)
To be confirmed

10:45 - 11:05

Estimating prognosis in advanced prostate cancer

P0037

Bone scan index as a better prognostic imaging biomarker for disease progression among patients with CHARTED high-volume metastatic castration sensitive prostate cancer

Authors

Horiguchi Y., Hagiwara K., Tsukuda F., Kawano Y., Koga S.

Institutions

Edogawa Hospital, Dept. of Urology, Tokyo, Japan

P0038

Clinical significance of the De Ritis ratio in patients with metastatic hormone-sensitive prostate cancer treated with upfront therapy

Authors

Ichiyama T.¹, Fujita N.¹, Noro D.¹, Yoneyama F.¹, Tazawa S.¹, Murasawa H.¹, Horiguchi H.¹, Ishimoto K.¹, Narita J.¹, Fukuokaya W.², Yanagisawa T.², Narita S.³, Kimura T.², Habuchi T.³, Hatakeyama S.¹

Institutions

¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²The Jikei University, School of Medicine, Dept. of Urology, Tokyo, Japan, ³Akita University School of Medicine, Dept. of Urology, Akita, Japan

P0039

Beyond First Progression: PFS2 as a Strong Surrogate of Overall Survival in Real-World Apalutamide-Treated mHSPC patients

Authors

Sanchis-Bonet A.¹, Gomez-Rivas J.¹, Sopena Sutil R.², Linares Espinos E.³, Garcia Lopez J.C.⁴, Martinez Breijo S.⁵, Dominguez Esteban M.⁶, de Pablos Rodriguez P.⁷, Munoz Rodriguez J.⁸, Gujarro Cascales A.⁹, Beamud Cortes M.¹⁰, de la Morena Gallego J.M.¹¹, Rios Gonzalez E.³

Institutions

¹Hospital Univ. Clinico San Carlos, Dept. of Urology, Madrid, Spain, ²Hospital Univ 12 de Octubre, Dept. of Urology, Madrid, Spain, ³Hospital Univ La Paz, Dept. of Urology, Madrid, Spain, ⁴Hospital Clinic, Dept. of Urology, Barcelona, Spain, ⁵CH Univ A Coruña, Dept. of Urology, A Coruña, Spain, ⁶Hospital Univ Marques de Valdecilla, Dept. of Urology, Santander, Spain, ⁷Instituto Val Oncologia (IVO), Dept. of Urology, Valencia, Spain, ⁸Hospital Parc Tauli, Dept. of Urology, Sabadell, Spain, ⁹Fundacion Alcorcon, Dept. of Urology, Madrid, Spain, ¹⁰Hospital Univ Dr Peset, Dept. of Urology, Valencia, Spain, ¹¹Hospital Univ Infanta Sofia, Dept. of Urology, Madrid, Spain

Study Group

Spanish multicentre registry of real-world use of Apalutamide(Madrid, Spain)

P0040

Prognostic Impact of TP53 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy

Authors

Ofner H.¹, Weiss J.¹, Kreschan A.¹, Haimberger V.¹, Hübner N.¹, Korn S.¹, Rasul S.², Einspieler H.², Wasinger G.³, Compérat E.³, Cussenot O.¹, Kramer G.¹, Shariat S.F.¹, Hassler-Di Fratta M.¹

Institutions

¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²Medical University of Vienna, Dept. of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Vienna, Austria, ³Medical University of Vienna, Dept. of Pathology, Vienna, Austria

11:05 - 11:40

Optimizing therapies for advanced prostate cancer

P0041

Opportunistic CT as a tool for evaluation and monitoring bone mineral density in patients undergoing androgen deprivation therapy and androgen receptor pathway inhibitor for metastatic hormonosensitive prostate cancer

Authors

Monllor Méndez A., Carrión Valencia A., Amador Robayna A., Clemente Graffigna R., Sotillo A.J., Díaz Mesa C., Jiménez García P., Ledesma Reyes J., Gomez De Segura Melcon C., García García A.L., Torres León L., Rodríguez Talavera J., Monllor Gisbert J.

Institutions

Hospital Universitario Nuestra Señora de Candelaria, Dept. of Urology, Santa Cruz de Tenerife, Spain

P0042

Real-world access to genotype-matched therapy through comprehensive cancer genomic profiling test in patients with metastatic prostate cancer: Analysis of the nationwide genomic database in Japan

Authors

Tsumura H.¹, Koguchi D.¹, Shiba I.¹, Shimura S.¹, Hirano S.¹, Ikeda M.¹, Takahashi K.², Araki N.², Takada F.², Matsumoto K.¹

Institutions

¹Kitasato University School of Medicine, Dept. of Urology, Sagamihara, Japan, ²Kitasato University Hospital, Genetics Division, Dept. of Genetics, Sagamihara, Japan

P0043

[¹⁸F]PARPi PET/CT for Precision Guidance of PARP-Inhibitor Therapy in HRR-Mutated and Non-Mutated Metastatic Castration-Resistant Prostate Cancer

Authors

Einspieler H.¹, Ofner H.², Ozenil M.¹, Spielvogel C.P.¹, Langrate I.K.¹, Bamminger K.¹, Hassler M.R.², Baltzer P.A.T.¹, Shariat S.F.², Hacker M.¹, Kramer G.², Rasul S.¹

Institutions

¹Medical University of Vienna, Dept. of Biomedical Imaging and Image-Guided Therapy, Vienna, Austria, ²Medical University of Vienna, Dept. of Urology, Vienna, Austria

P0044

Early Prediction of Response to ADT Plus ARPI in mHSPC Using Interpretable Machine Learning on PSMA PET/CT: A Real-World Study

Authors

Wang Y., Yang Y., Chen M., [Cai Y.](#)

Institutions

Xiangya Hospital Central South University, Dept. of Urology, Changsha, China

P0045

Analysis of PSA Superresponders in a Single-Center Study of ¹⁷⁷Lu-PSMA-617 Therapy

Authors

[Lin T.H.](#)¹, Lin K.H.², Huang E.Y.H.¹, Chang Y.H.¹, Huang T.H.¹, Wei T.C.¹, Chung H.J.¹

Institutions

¹Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ²Taipei Veterans General Hospital, Dept. of Nuclear Medicine, Taipei, Taiwan

P0046

Optimizing the timing of Docetaxel after AR pathway inhibitor therapy: Development and validation of a novel prognostic model in metastatic castration-resistant prostate cancer

Authors

[España Navarro R.](#)¹, Nogueira L.R.², Ruiz-Vico M.², Esteban J.², Llacer C.³, Lozano R.⁴, Romero-Laorden N.⁵, De Velasco G.², Villatoro R.⁶, Garcia L.⁷, Saez F.⁸, Alvarez P.², Hernández D.¹, Rodríguez-Antolín A.⁷, González-Billalabeitia E.², Herrera-Imbroda B.⁸, Castellanos D.², Castro E.², Lorente D.⁹, Olmos D.²

Institutions

¹Regional University Hospital. Málaga University, Dept. of Urology, Malaga, Spain, ²Hospital Universitario 12 de Octubre, Dept. of Oncology, Madrid, Spain, ³Instituto de Investigación Biomédica de Málaga, Genito-Urinary Research Group, Málaga, Spain, ⁴Hospital Universitario de Salamanca, Dept. of Oncology, Salamanca, Spain, ⁵Hospital Universitario de la Princesa, Dept. of Oncology, Madrid, Spain, ⁶Regional University Hospital, Dept. of Oncology, Málaga, Spain, ⁷Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ⁸Virgen de la Victoria University Hospital, Dept. of Urology, Malaga, Spain, ⁹Instituto Valenciano de Oncología, Dept. of Oncology, Valencia, Spain

P0047

Clinical Investigation of Docetaxel Therapy for Castration-Resistant Prostate Cancer in Patients Aged 75 Years or Older

Authors

[Kyono M.](#), Suzuki K., Ueki H., Okamura Y., Bando Y., Hara T., Terakawa T., Chiba K., Yao A., Teishima J., Miyake H.

Institutions

Kobe University Graduate School of Medicine, Dept. of Urology, Kobe, Japan

11:40 - 11:55

Prevention and management of treatment-related side effects in advanced prostate cancer

P0048

Clinical features of medication-related osteonecrosis of the jaw in prostate cancer management: Results From a multicenter cohort study

Authors

[Nakata M.](#), Urabe F., Kasuya E., Ogihara Y., Koike Y., Takahashi H., Uchida N., Taneda Y., Iwamoto Y., Iwatani K., Atsuta M., Yanagisawa T., Miki J., Kimura T.

Institutions

Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan

P0049

SPoRT-MU Study: Velocity-Based Resistance Training Improves Multiple Quality-of-Life Domains in Prostate Cancer Patients on Androgen Deprivation Therapy

Authors

Herrero Vidal L.¹, Cao Avellaneda E.¹, Soler López A.², Toledo Pozuelo R.², López González P.Á.¹, Moreno Alarcón C.¹, Aznar Martínez L.¹, Yago Giménez P.¹, Rull Hernández J.¹, Rosino Sanchez A.³, Guzmán Martínez-Vals P.L.¹

Institutions

¹Arrixaca Clinical and University Hospital, Dept. of Urology, Murcia, Spain, ²Never Surrender Foundation, Oncological Strength Training, Never Surrender Foundation, Oncological Strength Training, Murcia, Spain, ³Morales Meseguer University Hospital, Dept. of Urology, Murcia, Spain

P0050

Cardiologic and Oncologic Outcomes with GLP-1 Receptor Agonists in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Authors

Fazekas T.¹, Lénárt D.M.¹, Ruppert M.L.², Blasszauer C.L.³, Reibl D.N.³, Komka I.³, Szalontai J.N.¹, Mischczyk M.⁴, Rajwa P.⁴, Hegyi P.T.⁵, Szarvas T.¹, Shariat S.⁴, Leapman M.⁶, Nyirády P.T.¹

Institutions

¹Semmelweis University, Dept. of Urology, Budapest, Hungary, ²Semmelweis University, Dept. of Experimental Cardiology and Surgical Techniques, and Dept. of Cardiology, Budapest, Hungary, ³Medicalscan, LTD, Budapest, Hungary, ⁴Medical University of Vienna, Dept. of Urology, Comprehensive Cancer Center, Vienna, Austria, ⁵Semmelweis University, Centre for Translational Medicine, Budapest, Hungary, ⁶Yale School of Medicine, Dept. of Urology, New Haven, United States of America

11:55 - 12:15

New treatment strategies in mCRPC

P0051

First-in-human study of PSMA-targeted chimeric antigen receptor engineered natural killer cells for metastatic castration resistant prostate cancer

Authors

Kehao P.¹, Xutao Y.¹, Yunhao G.¹, Feiya Y.¹, Dong C.¹, Lu Y.¹, Yong Z.¹, Xiongjun Y.¹, Shuai L.², Yun Z.¹, Nianzeng X.¹

Institutions

¹Chinese Academy of Medical Sciences and Peking Union Medical College, Dept. of Urology, Beijing, China, ²BOE Regenerative Medicine Technology Co, Beijing, China

P0052

Bipolar androgen therapy sequential novel ARSI combined with PD-1 Inhibitor for patients with mCRPC: A single-arm prospective clinical study

Authors

Liu M., Hou H., Li L., Liu S., Wang M., Chen Y., Chen Z.

Institutions

Beijing Hospital, Dept. of urology, Beijing, China

P0053

A Phase II Single-Arm, Open-Label Trial of Pamiparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with Deleterious Germline or Somatic BRCA1/2 Alterations or Homologous Recombination Deficiency (HRD)

Authors

Zhao D.¹, Cai X.¹, Zhao J.¹, Li Y.¹, Yang Z.¹, Chen D.¹, Long X.¹, Yang L.², Zhou F.¹, Li Y.¹, Wang J.¹

Institutions

¹Sun Yat-sen University Cancer Center, Dept. of Urology, Guangzhou, China, ²Sun Yat-sen University Cancer Center, Dept. of Radiation Oncology, Guangzhou, China

P0054

Long-term Clinical Outcomes and Genomic Predictors of PSMA-PET/CT-Guided Cytoreductive Progression-Directed Therapy in Patients with Oligoprogressive Castration-Resistant Prostate Cancer

Authors

Yang B.¹, Ding L.¹, Yang G.¹, Xu J.¹, Zou L.¹, Xu Q.², Jia Z.³, Zhang X.⁴, Xu G.⁵, Zhu K.⁶, Zhao B.⁷, Zhao T.⁸, Hanxu G.HX¹, Jin C.¹, Mao S.¹, Guo C.¹, Fu H.⁹, Yao X.¹, Shen B.¹

Institutions

¹Shanghai Tenth People's Hospital Tongji University School of Medicine, Dept. of Urology, Shanghai, China, ²Tongji University School of Medicine, Urologic Cancer Institute, Shanghai, China, ³Shanghai Tenth People's Hospital, Tongji University School of Medicine, Dept. of Radiation Oncology, Shanghai, China, ⁴Shanghai Tenth People's Hospital, Tongji University School of Medicine, Dept. of Nuclear Medicine, Shanghai, China, ⁵Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Dept. of Medical Ultrasound, Shanghai, China, ⁶Shanghai Tenth People's Hospital, Tongji University School of Medicine, Dept. of Pathology, Shanghai, China, ⁷Shanghai Tenth People's Hospital, Tongji University School of Medicine, Dept. of Radiology, Shanghai, China, ⁸Tongji University, School of Life Sciences and Technology, Shanghai, China, ⁹Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Dept. of Nuclear Medicine, Shanghai, China

Innovations in urology: Advancements and outcomes in lower urinary tract dysfunction

EGPT 06

**Friday 13 March
10:45 - 12:15**

Location Orange Area, EGPT 4

Chairs To be confirmed

To be confirmed

S. Musco, Florence (IT)

10:45 - 11:20

Neuromodulation from basic science to clinical practice

P0091

3D bioprinting of tissue engineered bladder patches containing a neural-vascular network using conductive microgels

Authors

An Z., Wang Z., Bi KP., Chen GQ., Ye Z.J., Shao JP., Wang PC., Zhao J., Xiao SW., Fu WJ.

Institutions

PLA General Hospital, Dept. of Urology, Beijing, China

P0092

Predicting treatment success at time of referral for sacral neuromodulation for overactive bladder: a retrospective audit of a tertiary UK referral centre

Authors

Mazhar E., Fletcher N., Ahmed H., Phillips A., Telford N., Gray S., Foster E.

Institutions

Salford Royal Hospital Northern Care Alliance, Dept. of Urology, Manchester, United Kingdom

P0093

Get Ready™ for Better Care: Enhancing Patient Engagement in Sacral Neuromodulation via Digital Tools – Two-Year Experience from an University Hospital

Authors

Thuillier C.

Institutions

Grenoble Alpes University Hospital, Dept. of Urology, Grenoble, France

P0094

Identifying positive predictive factors for the outcome of therapy with Botulinumtoxin for iOAB and NDO in a real world study

Authors

Nestler S.¹, Alloussi S.¹, Neisius A.², Grüne B.³

Institutions

¹UroGATE, Dept. of Urology, Bad Vilbel, Germany, ²Krankenhaus der Barmherzigen Brüder, Dept. of Urology, Trier, Germany, ³Universitätsklinikum Mannheim, Dept. of Urology, Mannheim, Germany

P0095

Advancing Sacral Neuromodulation: Clinical Efficacy of a Next-Generation System in Lower Urinary Tract Dysfunction

Authors

ciavarella G.¹, Martino L.¹, Martino B.¹, Nasuto M.C.¹, Mancini V.², Liuzzi G.¹, Cinelli F.P.¹, Ricapito A.¹, Finati M.¹, Cormio A.¹, Busetto G.¹, Bettocchi C.¹, Cormio L.¹, Falagarò U.G.¹, Carrieri G.¹

Institutions

¹Policlinico Riuniti di Foggia - University of Foggia, Dept. of Urology, Foggia, Italy, ²Molfetta Hospital, Dept. of Urology, Molfetta, Italy

P0096

Wireless on-demand electrostimulation implants enable sphincter neuromuscular restoration from mixed urinary incontinence

Authors

Shao Y.¹, Tao L.¹, Zheng T.X.², Shao L.²

Institutions

¹Ruijin Hospital School of Medicine Shanghai Jiaotong University, Dept. of Urology, Shanghai, China, ²School of Mechanical Engineering Shanghai Jiao Tong University, Dept. of Mechanical Engineering, Shanghai, China

P0097

The Impact of Right or Left Handedness on Sacral Neuromodulation Outcomes for Lower Urinary Tract Dysfunction: Does Ipsilateral or Contralateral Lead Placement Matter?

Authors

Kendall H.J., van Renterghem A.R.P.K.M., Smits M.A.C., Heesakkers J.P.F.A.

Institutions

Maastricht University Medical Center, Dept. of Urology, Maastricht, The Netherlands

11:20 - 11:40

OAB and SUI

P0098

The Negative Feedback of the Glutamine/Prostatitis Loop Identified among 1,400 Metabolites and Prostatitis via Mendelian Randomization

Authors

Wang Y., Li Z.

Institutions

The Second People's Hospital of Changzhou, Dept. of Urology, Changzhou, China

P0099

SATURN Registry for mSUI – 3 years outcome

Authors

Hamid R.^{1,2}, Martens F.^{3,2}, Van der Aa F.^{4,2}, Thiruchelvam N.^{5,2}, Witjes W.⁶, Caris C.⁶, Heesakkers J.^{7,2}, Hervé F.², Van Renterghem K.², Van Bruwaene S.², De Wachter S.², Zchoval R.², Hüscher T.², Queissert F.², Fisch M.², Martinez-Salamanca J.², Medina-Polo J.², Hernández Hernández D.², Puche-Sanz I.², Gago J.², Lledó E.², Arlandis S.², Fraile Poblador A.², Romero Hoyuela A.², Lopez E.², Tikkinen K.A.O.², Nobrega R.², Sahai A.², Bientinesi R.², De Kort L.², Nilsen O.J.², Pedersen J.M.²

Institutions

¹Royal National Orthopaedic Hospital, Dept. of Urology, London, United Kingdom, ²EAU Research Foundation SATURN Registry Study Group, Arnhem, The Netherlands, ³Radboud UMC, Dept. of Urology, Nijmegen, The Netherlands, ⁴University Hospital Leuven, Dept. of Urology, Leuven, Belgium, ⁵Addenbrooke's Hospital, Cambridge University Hospitals Trust, Dept. of Urology, Cambridge, United Kingdom, ⁶EAU Research Foundation, Clinical Research, Arnhem, The Netherlands, ⁷Maastricht UMC+, Dept. of Urology, Maastricht, The Netherlands

Study Group

EAU Research Foundation SATURN Registry Study Group(Arnhem, The Netherlands)

P0101

Contemporary surgical management and trends of male stress urinary incontinence - Results from the GRAND study

Authors

Volz Y.¹, Kidess M.¹, Hermans J.¹, Georgieva T.¹, Bauer R.², Gozzi C.³, Stief C.¹, Schulz G.¹, Pyrgidis N.¹

Institutions

¹LMU University Hospital, Dept. of Urology, Munich, Germany, ²Urologische Klinik Planegg, Dept. of Urology, Munich, Germany, ³Cityklinik Bozen, Dept. of Urology, Bozen, Italy

11:40 - 12:15

Chronic pelvic pain

P0107

Radiofrequency Therapy at 448 kHz as a Novel Treatment for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS): Results from a Prospective Multicentre Pilot Study

Authors

García Rojo E.¹, Alonso Isa M.¹, Fraile Poblador A.², Fiorillo A.², Celada Luis G.¹, Paesano N.¹, Brime Menendez R.¹, Barrientos F.¹, Lista Mateos F.³, Espinales G.M.³, Saenz Calzada D.⁴, Justo Quintas J.¹, Hevia Palacios V.¹, Romero Otero J.¹

Institutions

¹Hm Sanchinarro, Dept. of Urology, Madrid, Spain, ²Hm Rivas, Dept. of Urology, Madrid, Spain, ³Hm Montepríncipe, Dept. of Urology, Madrid, Spain, ⁴Hm Puerta Del Sur, Dept. of Urology, Madrid, Spain

P0102

Urine proteomic study for identifying promising biomarkers in Asian male with urologic chronic pelvic pain syndrome

Authors

Lin Y-H.¹, Wang Y.Y.², Chen M.H.¹, Ku W.C.³, Lin Y.H.²

Institutions

¹Cardinal Tien Hospital, Dept. of Surgery, Division of Urology, New Taipei City, Taiwan, ²Fu Jen Catholic University, Graduate Institute of Biomedical and Pharmaceutical Science, New Taipei City, Taiwan, ³Fu Jen Catholic University, School of Medicine, New Taipei City, Taiwan

P0103

In situ urethroplasty during artificial urinary sphincter explantation for erosion: early findings from the Systematic assessment of Artificial urinary sphincter Failure and Erosion Recovery (SAFER) collaborative

Authors

Frankiewicz M.¹, Neuville P.², Ruffion A.², Kałużny A.³, Kaftan A.⁴, Karapanos L.⁵, Abbasi B.⁶, Breyer B.N.⁶, Mantica G.⁷, Thiruchelvam N.⁸, Cocci A.⁹, Lo Re M.⁹, Erbetta M.², Roessler N.¹⁰, Fisch M.¹⁰, Dahlem R.¹⁰, Vetterlein M.W.¹⁰

Institutions

¹Medical University of Gdańsk, Dept. of Urology, Gdańsk, Poland, ²Hospital Lyon Sud, Hospices Civils de Lyon, Dept. of Urology, Lyon, France, ³Regional Specialist Hospital Olsztyn, Dept. of Urology, Olsztyn, Poland, ⁴Medical University of Gdańsk, Faculty of Medicine, Gdańsk, Poland, ⁵Leverkusen General Hospital, Dept. of Urology, Leverkusen, Germany, ⁶University of California, Dept. of Urology, San Francisco, United States of America, ⁷University of Genoa, Dept. of Surgical and Diagnostic Integrated Sciences (DISC), Genoa, Italy, ⁸Cambridge University Hospitals NHS Foundation Trust, Dept. of Urology, Cambridge, United Kingdom, ⁹University of Florence, Careggi Hospital, Unit of Urology and Andrology, Florence, Italy, ¹⁰University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

Study Group

Trauma and Reconstructive Urology Working Party of the European Association of Urology Young Academic Urologists(Amsterdam, The Netherlands)

P0104

Post-massage PSA kinetics predict therapeutic response in chronic prostatitis/chronic pelvic pain syndrome

Authors

Shih Y.C., Chung S.D., Au C.F.

Institutions

Far Eastern Memorial Hospital, Dept. of Surgery - Division of Urology, New Taipei City, Taiwan

P0105

Cases of Pudendal Neuropathy (PN) after robot-assisted radical prostatectomy (RARP).

Authors

Maltagliati M.¹, Ferrari I.¹, Perri D.¹, Calcagnile T.¹, Menozzi M.¹, Hoxha S.¹, Carelli C.¹, Livio V.¹, Micali S.², Pini G.¹, Bozzini G.¹

Institutions

¹ASST Lariana, Dept. of Urology, Como, Italy, ²Università degli Studi di Modena e Reggio Emilia, Dept. of Urology, Modena, Italy

P0106

Efficacy of Combined Inferior Hypogastric Plexus and Pudendal Nerve Elongated Needle Electrical Stimulation for Chronic Refractory Pelvic and Perineal Pain: A Pilot Study

Authors

Lyu R., Lv T., Lv J., Fang W., Ji X., Li Z.

Institutions

Shanghai Pudong New Area Gongli Hospital, Dept. of urology, Shanghai, China

P0108

Interstitial cystitis/bladder pain syndrome Increases Alzheimer's Disease Risk: Mendelian Randomization-Based Causal Evidence and Comorbidity Gene-Driven Machine Learning Diagnostic Model

Authors

Huang J., Wang Z., Li W., Zhou X., Liu B.

Institutions

The Third Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Guangzhou, China

Friday 13 March
11:00 - 12:00

Location Red Area, Room 14

Chair M.R. Van Balken, Arnhem (NL)

Learning objectives

Present the BCLEAR project.

Share insights from the Needs Assessment survey and differences across member states.

Discuss how findings can inform the development of the HCP Educational Toolbox and improve SDM in bladder cancer care.

11:00 - 11:05

Welcome & introduction

M.R. Van Balken, Arnhem (NL)

11:05 - 11:15

Patient coalition insights: WBCPC perspectives on strengthening SDM in Bladder Cancer

A. Filicevas, Brussels (BE)

11:15 - 11:25

The GP perspective: Primary care insights from WONCA Europe

J. Vilaseca, Barcelona (ES)

11:30 - 11:35

The Hungarian perspective on clinician needs and SDM gaps

B. Der, Budapest (HU)

11:35 - 11:40

The Greek perspective on barriers and opportunities in SDM

C. Zabaftis, Athens (GR)

11:40 - 11:45

The Polish perspective in improving SDM

R. Sosnowski, Olsztyn (PL)

11:45 - 12:00

Q&A and closing

M.R. Van Balken, Arnhem (NL)

Medical writing for urologists: An interactive workshop on how to write, publish and promote the “perfect” manuscript

ESU Course 07

Friday 13 March
11:00 - 13:00

Location Red Area, Room 12

Chair A. Briganti, Milan (IT)

Learning objectives

This ESU course is a collaboration between *European Urology* and the *The Lancet*

This course will offer an expansive and interactive overview of the entire scholarly publishing procedure, specifically focusing on the writing process and what it means to be an outstanding author. The Faculty will offer instruction on how to construct a well-written introduction and methods section for your manuscript, learn how to present statistical analyses, understand key points when writing and how to use Social Media to best promote important work. Participants will obtain insight directly from editors on what they expect to see. The course will be structured into two modules including lectures and breakout sessions.

- To learn how to write a full length article from the Author and Editor perspective
- To understand systematic reviews and meta-analysis.
- Using Social Media platforms in a responsible and successful manner.
- To learn from experienced editors.

Welcome and introduction

A. Briganti, Milan (IT)

How to capture the Editor's attention

To be confirmed

How to report statistical analyses for publication

M. Assel, New York (US)

Beyond the scientific manuscript: The role of social media in 2026

To be confirmed

What did I do wrong? Practical examples on "How to improve the methodological approach to your research question"

R. L. Dunn, Ann Arbor (US)

Captivating the reader: Unlocking the power of abstracts and introductions

L. Bukavina, Cleveland (US)

Contextualising results and crafting impactful discussions

B.F. Chapin, Houston (US)

Conclusion

A. Briganti, Milan (IT)

Ultrasound in Urology: From basics to proficiency

ESU Course 08

Friday 13 March
11:00 - 13:00

Location Red Area, Room 13

Chair K.F. Stock, Munich (DE)

Learning objectives

- To understand principles of US imaging acquisition and interpretations, avoiding pitfalls
- To learn how and in which clinical scenarios of urological emergency care US scan plays a role for patients' management
- To learn how US should be used in the outpatients setting to implement patients' diagnostic pathway
- To understand how US imaging can support imaging-guided interventions

Intro of probes

K.F. Stock, Munich (DE)

Point-of-care ultrasound (POCUS) in emergency care

K.F. Stock, Munich (DE)

Ultrasound at outpatient office

G. Fojecki, Odense (DK)

Ultrasound to guide interventions

G. Fojecki, Odense (DK)

Tips and tricks of ultrasound exploration

K.F. Stock, Munich (DE)

Closure

K.F. Stock, Munich (DE)

Focal therapy for beginners: How to start with focal therapy

ESU Course 09

Friday 13 March
12:00 - 15:00

Location Red Area, Room 8

Chair R. Sanchez-Salas, Montreal (CA)

Learning objectives

- Explain focal therapy as a disruptive treatment option for localized prostate cancer
- Interpret MRI for lesion targeting and prepare patients for focal treatment
- Perform practical steps for transperineal and transrectal focal therapy procedures
- Advocate for focal therapy in tumor boards and multidisciplinary care pathways.

Welcome and introduction

R. Sanchez-Salas, Montreal (CA)

Imaging and index lesion concept

L. Rodriguez-Sanchez, Paris (FR)

Technologies, approaches and practical Steps

H.U. Ahmed, London (GB)

Building a programme and facing your peers

R. Sanchez-Salas, Montreal (CA)

Interactive case-based discussion

H.U. Ahmed, London (GB)

L. Rodriguez-Sanchez, Paris (FR)

R. Sanchez-Salas, Montreal (CA)

Wrap-up and take-home messages

R. Sanchez-Salas, Montreal (CA)

Male prosthetic urology

ESU Course 10

Friday 13 March
12:00 - 15:00

Location

Red Area, Room 9

Chair

S. Malde, London (GB)

Learning objectives

This is a state of the art course on the use of prosthetics in the management of erectile dysfunction and urinary incontinence. The main learning objectives are:

- Step-by-step preparation and insertion of a penile prosthesis
- Complications and difficult situations for IPP
- Step-by-step options and techniques in the surgical management of incontinence
- Complications and difficult situations for GSI management

Introduction to the course

S. Malde, London (GB)

Penile prosthesis**Development of different types of penile prosthesis**

A. Fraile Poblador, Madrid (ES)

Selection of patients for penile prosthesis surgery

J. Romero-Otero, Madrid (ES)

Theatre set-up and preparation of patients

J. Romero-Otero, Madrid (ES)

Surgical techniques and intraoperative complications

P. Świniarski, Warsaw (PL)

Penile prosthesis training - role of modular training and training tools

P. Świniarski, Warsaw (PL)

The difficult implant: Peyronie's, priapism, fibrotic penis

A. Fraile Poblador, Madrid (ES)

Revision surgery and managing post operative complications

J. Romero-Otero, Madrid (ES)

Prosthetic surgery for male urinary incontinence

AUS: Indications, types, techniques and complications

S. Malde, London (GB)

Slings: Indications, types, techniques and complications

S. Malde, London (GB)

Future of prosthetic urology

P. Świniarski, Warsaw (PL)

Male genital diseases

ESU Course 11

Friday 13 March
12:30 - 15:30

Location Red Area, Room 10

Chair M. Skrodzka, London (GB)

Voting will be available via the EAU26 App or via www.qna.at/eau

Learning objectives

This novel and revised course will give a state-of-the-art update on the variety of genital diseases that urologists will encounter in daily clinical practice. The faculty consists of a group of internationally renowned experts in this field.

A spectrum of pathologies can affect the male genitals, from benign disorders to cancers. There will be particular focus and emphasis on interactive case-based discussions and surgical videos of the latest surgical techniques used in this evolving field. The course will also deal with the surgical management of these diseases including the surgical indications and techniques used in genital reconstructive surgery. Particular focus will be on:

- The aetiology, diagnosis and medical management of the common genital skin diseases including inflammatory conditions.
- The medical and surgical management of HPV, BXO and pre-malignant conditions of the penis, including the techniques of circumcision, skin grafting, glans resurfacing, surgery for buried penis and the correction of genital lymphoedema.
- The surgical management of Peyronie's disease including plication procedures and grafting
- The management of penile carcinoma including the aetiopathogenesis, techniques/outcome of organ-sparing surgery and ilioinguinal lymphadenectomy will be discussed and illustrated.

Surgical management of Peyronie's disease

K. Van Renterghem, Hasselt (BE)

Penile and scrotal dermatology for the urologist

M. Skrodzka, London (GB)

Circumcision, frenuloplasty and preputioplasty

K. Van Renterghem, Hasselt (BE)

The buried penis

K. Van Renterghem, Hasselt (BE)

Management of genital lymphoedema

M. Skrodzka, London (GB)

Premalignant lesions of the penis and scrotum

A. Parnham, Manchester (GB)

Penile cancer: Penile preserving surgery

M. Skrodzka, London (GB)

Penile cancer: Management of lymph nodes

A. Parnham, Manchester (GB)

Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 1.1

Friday 13 March
12:45 - 13:35

Location

Red Area, Room 1

Tutors

M. Elmussareh, Dubai (AE)

V. Novak, Praha (CZ)

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 1.1

Friday 13 March
12:45 - 13:35

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 1.1

Friday 13 March
12:45 - 13:35

Location Red Area, Room 1

Tutor To be confirmed

Learning objectives

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 1.1

Friday 13 March
12:45 - 13:35

Location Red Area, Room 1

Tutors M. Goossens, Aalst (BE)
M.C. Klitsch, Vienna (AT)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 1.1

Friday 13 March
12:45 - 13:35

Location Red Area, Room 1

Tutors A.C. Bouma - Houwert, Amsterdam (NL)
I.M. Tjiam, Poortugaal (NL)
To be confirmed

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 1.1

Friday 13 March
12:45 - 13:35

Location Red Area, Room 1

Tutors I. Kartalas Goumas, Vigevano (IT)
To be confirmed
To be confirmed

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 1.1

Friday 13 March
12:45 - 13:35

Location Red Area, Room 1

Tutors To be confirmed
M. Paciotti, Rozzano, Milan (IT)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

HOT debates: Blades vs. Beams in urological cancers

Thematic Session

Friday 13 March
13:00 - 14:30

Location Orange Area, eURO Auditorium 2

Chairs M. Albersen, Leuven (BE)
J. Walz, Marseille (FR)

13:00 - 13:02

Introduction and concept

13:02 - 13:22

Debate **Kidney**

13:02 - 13:05

Case presentation by chairs

13:05 - 13:06

Voting

13:06 - 13:16

Blades vs. Beams

Speakers B.J. Challacombe, London (GB)
S. Siva, Melbourne (AU)

13:16 - 13:21

Rebuttal

13:21 - 13:22

Voting

13:22 - 13:42

Debate **Bladder**

13:22 - 13:25

Case presentation by chairs

13:25 - 13:26

Voting

13:26 - 13:36

Blades vs. Beams

Speakers V. Fonteyne, Ghent (BE)
S. Psutka, Seattle (US)

13:36 - 13:41

Rebuttal

13:41 - 13:42

Voting

13:42 - 14:02

Debate **Prostate**

13:42 - 13:45

Case presentation by chairs

13:45 - 13:46

Voting

13:46 - 13:56

Blades vs. Beams

Speakers O. Akre, Stockholm (SE)
B.A. Jereczek-Fossa, Milan (IT)

13:56 - 14:01

Rebuttal

14:01 - 14:02

Voting

14:02 - 14:22

Debate **Testis**

14:02 - 14:05

Case presentation by chairs

14:05 - 14:06

Voting

14:06 - 14:16

Blades vs. Beams

Speakers

A. Heidenreich, Cologne (DE)

A. Papachristofilou, Basel (CH)

14:16 - 14:21

Rebuttal

14:21 - 14:22

Voting

14:22 - 14:30

Conclusions

Emerging Europe: Organising top-notch prostate cancer care in resource-limited environments

Thematic Session

Friday 13 March
13:00 - 14:30

Location

Blue Area, Victoria 4

Chairs

M. Hora, Plzen (CZ)

P. Rajwa, Warsaw (PL)

Learning objectives

The EAU guidelines provide clear instructions on how to proceed in the diagnosis and treatment of prostate cancer based on evidence-based medicine. In real practice, however, these procedures cannot be implemented for a number of reasons. Among other things, financial and human resources are limiting factors. The thematic session will address this issue.

13:00 - 13:02

Introduction

13:02 - 13:43

Multidisciplinary management of prostate cancer: Building teams without borders

13:02 - 13:09

Setting the scene: Why MDTs are central to modern prostate cancer care

B.W. Lamb, London (GB)

13:09 - 13:16

Establishing MDTs in resource limited environments

M. Miszczyk, Vienna (AT)

13:16 - 13:23

Integrating radiologists into prostate cancer MDTs

I.G. Schoots, Rotterdam (NL)

13:23 - 13:30

Delivering value-based prostate cancer care in resource-limited settings

D. Penson, Nashville (US)

13:30 - 13:33

Case presentation Unfavorable prostate cancer

T. Fazekas, Budapest (HU)

13:33 - 13:43

Case-based panel discussion MDT decision-making with conventional imaging only

B.W. Lamb, London (GB)

M. Miszczyk, Vienna (AT)

D. Penson, Nashville (US)

I.G. Schoots, Rotterdam (NL)

13:43 - 14:04	Centralisation in cancer care: Who benefits, who gets left behind?
13:43 - 13:50	Setting the scene: Centralise or decentralise care in genitourinary malignancies? J. Oldenburg, Oslo (NO)
13:50 - 13:57	Challenges of centralisation in middle-income regions P. Nyirády, Budapest (HU)
13:57 - 14:04	Quality measures in urologic oncological care: Why should we follow up on patients and treatment outcomes? J. Walz, Marseille (FR)
14:04 - 14:17	Case-based panel discussion Referral dilemmas and oncology patient pathways: How do we do it in our countries?
14:04 - 14:07	Case presentation mHSPC T. Ložar, Ljubljana (SI)
14:07 - 14:17	Panel discussion Country perspectives M. Hora, Plzen (CZ) P. Nyirády, Budapest (HU) J. Oldenburg, Oslo (NO) I. Tomašković, Zagreb (HR) J. Walz, Marseille (FR)
14:17 - 14:22	How EAU mobility programmes and fellowships can transform your clinical practice and research P. Rajwa, Warsaw (PL)
14:22 - 14:30	Baltic25 Young urologist competition winner When PSMA doesn't light up: Challenges in prostate cancer diagnosis and treatment A. Rautio, Tallinn (EE)

Friday 13 March
13:00 - 14:00

Location Red Area, Room 14

Chair To be confirmed

Learning objectives

Explore shared decision-making (SDM) in kidney cancer using global patient survey data, clinical perspectives, and real patient experience.

Highlight disparities across Europe and identify practical approaches to improve patient involvement.

Compare patient-reported and clinician-reported barriers in SDM.

Identify practical tools to advance SDM in kidney cancer care.

13:00 - 13:10

Welcome & introduction

To be confirmed

13:10 - 13:20

Key findings from the kidney cancer SDM study

K. Beyer, Rotterdam (NL)

13:20 - 13:25

Clinician's role in improving SDM in kidney cancer

R. Campi, Florence (IT)

13:25 - 13:30

Aligning patient and clinician perspectives in kidney cancer care

M. Tran, London (GB)

13:30 - 13:40

Patient advocacy insights on what patients need for better decision-making

K. Kastrati, (DE)

13:40 - 13:50

Lived experience in practice: A patient's view on SDM in kidney cancer

S. Pointon, (GB)

13:50 - 14:00

Q&A and closing

To be confirmed

Female urology: Changing landscapes

Abstract Session 02

Friday 13 March
13:00 - 14:30

Location Red Area, Room 17

Chairs
R. Barratt, London (GB)
E. Costantini, Perugia (IT)
To be confirmed

13:00 - 13:35

Periurethral injection, artificial sphincter and more in the mesh controversy era

A0019

Transurethral Injection of Autologous Muscle Precursor Cells in Collagen Solution for the Treatment of Female Stress Urinary Incontinence – Results from a Blinded, Prospective and Randomised Phase II Clinical Trial (SUISSE MPC2 Study)

Authors

Schmid F.A.¹, Schmidli T.S.¹, Prange J.A.², Leitner L.¹, Kozomara M.¹, Hunziker M.¹, Kranzbuehler B.¹, Karrer M.¹, Steinke N.², Veit M.², Pettinello R.², Rauch B.², Hoetker A.³, Betschart C.⁴, Eberli D.¹, Mohr-Haralampieva D.²

Institutions

¹University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, ²University of Zurich, Wyss Zurich Translational Centre, Zurich, Switzerland, ³University Hospital Zurich, Institute for Diagnostic and Interventional Radiology, Zurich, Switzerland, ⁴University Hospital Zurich, Dept. of Gynecology, Zurich, Switzerland

A0020

Ultrasound-Based Predictors of Polyacrylamide Hydrogel Injection Success in Stress Urinary Incontinence: Longitudinal Study by a Single Experienced Surgeon

Authors

Illiano E.¹, Polisini G.¹, Trama F.², Balsamo R.³, Costantini E.¹

Institutions

¹Andrology and Urogynecological Clinic, Santa Maria Terni Hospital University of Perugia, Terni, Italy, ²Urology Clinic, Santa Maria delle Grazie Hospital, Naples, Italy, ³Urology Clinic, Monaldi Hospital, Naples, Italy

A0021

Efficacy of Periurethral Platelet-Rich Plasma Therapy in Women with Stress Urinary Incontinence: A Prospective Evaluation Using VAS, Stamey Scale, and King's Health Questionnaire

Authors

Borislavski A.¹, Petca R.C.², Petca A.¹

Institutions

¹Carol Davila University of Medicine and Pharmacy, Dept. of Obstetrics and Gynecology, Bucharest, Romania, ²Carol Davila University of Medicine and Pharmacy, Dept. of Urology, Bucharest, Romania

A0022

10-year evolution of the number of surgeries for female urinary incontinence in France (2015-2024)

Authors

Dequirez P.L.D.¹, Biardeau X.¹, Demeestere A.¹, Lallemand M.²

Institutions

¹CHU de Lille, Dept. of Urology, Lille, France, ²CHU de Lille, Dept. of Gynaecology, Lille, France

A0023

1-year outcomes of female artificial urinary sphincter implantation in Europe: the VENUS registry[CC1]

Authors

Peyronnet B.¹, Chartier-Kastler E.², Lopez-Fando L.³, perrouin-verbe M.A.⁴, Herve F.⁵, Wagner L.⁶, Sievert K.D.⁷, Calleja Hermosa P.⁸, Capon G.⁹, Descazeaud A.¹⁰, Game X.¹¹, Ruffion A.¹², Mazeaud C.¹³, Zachoal R.¹⁴, Karsenty G.¹⁵, Witjes W.¹⁶, Biardeau X.¹⁷, Van Goeveringe G.¹⁸, Thiruchelvam N.¹⁹, Van Der Aa F.²⁰

Institutions

¹CHU Rennes, Dept. of Urology, Rennes, France, ²hopital Pitié salpêtrière, Dept. of Urology, Paris, France, ³Hopital La Princesa, Dept. of Urology, madrid, Spain, ⁴CHU Nantes, Dept. of Urology, Nantes, France, ⁵UZ Ghent, Dept. of Urology, Ghent, Belgium, ⁶CHU Nimes, Dept. of Urology, Nimes, France, ⁷linikum lippe, Dept. of Urology, Detmold, Germany, ⁸University Hospital Santander, Dept. of Urology, santander, Spain, ⁹CHU Bordeaux, Dept. of Urology, Bordeaux, France, ¹⁰CHU Limoges, Dept. of Urology, Limoges, France, ¹¹CHU Toulouse, Dept. of Urology, toulouse, France, ¹²CHU Lyon, Dept. of Urology, Lyon, France, ¹³CHU Nancy, Dept. of Urology, Nancy, France, ¹⁴University of Prague, Dept. of Urology, Prague, Czech Republic, ¹⁵Hopital la Conception, Dept. of Urology, Marseille, France, ¹⁶EAU Research Foundation, Dept. of Research, nijmegen, The Netherlands, ¹⁷CHU Lille, Dept. of Urology, Lille, France, ¹⁸University of Maastricht, Dept. of Urology, Maastricht, The Netherlands, ¹⁹university of cambridge, Dept. of Urology, cambridge, United Kingdom, ²⁰UZ Leuven, Dept. of Urology, leuven, Belgium

A0024

Implantation of an AMS-800 artificial urinary sphincter in women with severe stress urinary incontinence: comparison between open and robot-assisted approaches in a single-center retrospective study

Authors

Dubois Fresney S.¹, Bento L.², de Normandie A.C.², Chen K.², Vaessen C.², Mozer P.², Chartier-Kastler E.², Lenfant L.²

Institutions

¹University Hospital of Angers, Dept. of Urology, Angers, France, ²Pitié-Salpêtrière University Hospital, Dept. of Urology, Paris, France

13:35 - 13:50

Mesh removal: What then?

A0026

Sexual morbidity pre and post mesh removal in a New Zealand population

Authors

Stewart H., Fong E.

Institutions

Te Whatu Ora Health New Zealand, Female Pelvic Mesh Service, Auckland, New Zealand

A0027

The Natural History of Continence and Patient Satisfaction after Mesh Removal: a Tertiary-Centre Experience

Authors

Loufopoulos I.¹, Pace K.¹, Alqahtani L.¹, Kapriniotis K.², Gresty H.¹, Greenwell T.¹, Ockrim J.¹

Institutions

¹University College London Hospitals, Dept. of Urology, London, United Kingdom, ²Whipps Cross Hospital Barts Health, Dept. of Urology, London, United Kingdom

A0028

SUSTeR study : Sub-Urethral Sling Treatment Removal, a retrospective multicentric cohort about mid and long term mid-urethral sling complications between 2010-2024 : Symptomatic recovery is it possible ?

Authors

Boileau A.¹, Saunière C.², Angeloz T.³, Lefief M.⁴, Poussot B.⁵, Lecourt A.⁶, Erhard H.⁷, Aoun R.⁸, Chapuis M.⁹, Lasri S.¹⁰, Biardeau X.¹⁰, Peyronnet B.⁹, Manceau C.¹¹, Chartier Kastler E.⁷, Cornu N.⁶, Saussine C.⁵, Descazard A.L.⁴, Neuville P.², Perrouin Verbe M.A.E.³, Gamé X.¹

Institutions

¹CHU Toulouse, Dept. of Urology and Kidney Transplantation, Toulouse, France, ²Hospices Civils Lyon, Dept. of Urology, Lyon, France, ³CHU Nantes, Dept. of Urology, Nantes, France, ⁴CHU Limoges, Dept. of Urology, Limoges, France, ⁵CHU Strasbourg, Dept. of Urology, Strasbourg, France, ⁶CHU Rouen, Dept. of Urology, Rouen, France, ⁷La Pitié Salpêtrière, Dept. of Urology, Paris, France, ⁸Bichat, Dept. of Urology, Paris, France, ⁹CHU Rennes, Dept. of Urology, Rennes, France, ¹⁰CHU Lille, Dept. of Urology, Lille, France, ¹¹CHU Montpellier, Dept. of Urology, Montpellier, France

13:50 - 14:05

Pelvic organ prolapse: Is robotic sacrocolpopexy evidence based?

A0029

Extended Follow-Up of a Randomized Study Comparing Robotic and Laparoscopic Sacrocolpopexy: Results at 9 Years

Authors

Illiano E., Costantini E.

Institutions

Andrology and Urogynecological Clinic, Santa Maria Terni Hospital University of Perugia, Terni, Italy

A0030

Biomechanical modeling and finite element analysis of pelvic floor reconstruction for pelvic organ prolapse

Authors

Tian D., Jihong J.

Institutions

The First Affiliated Hospital of Kunming Medical University, Dept. of Urology, Kunming, China

A0031

Laparoscopic versus Robot-Assisted Laparoscopic Sacrocolpopexy: A Randomized Controlled Trial (ROBOLAPS Study)

Authors

Kutchukian S.¹, Wagner L.¹, Douvier S.², Ruffion A.³, Saussine C.⁴, Rigaud J.⁵, Meurette G.⁵, Chartier-Kastler E.⁶, Vidart A.⁷, Manunta A.⁸, Vincens E.⁹, Dorez M.¹⁰, Hoepffner J.L.¹¹, Bouvier S.¹, Droupy S.¹

Institutions

¹CHU de Nimes, Dept. of Urology, Nimes, France, ²CHU de Dijon, Dept. of Gynaecology, Dijon, France, ³CHU de Lyon, Dept. of Urology, Lyon, France, ⁴CHU de Strasbourg, Dept. of Urology, Strasbourg, France, ⁵CHU de Nantes, Dept. of Urology, Nantes, France, ⁶CHU Pitié-Salpêtrière, Dept. of Urology, Paris, France, ⁷Hopital Foch, Dept. of Urology, Suresnes, France, ⁸CHU de Rennes, Dept. of Urology, Rennes, France, ⁹Hopital des Diaconesses, Dept. of Gynaecology, Paris, France, ¹⁰CHU de Nice, Dept. of Gynaecology, Nice, France, ¹¹Clinique Saint Augustin, Dept. of Urology, Bordeaux, France

14:05 - 14:20

Overactive bladder

A0032

A double-blind randomized controlled trial of low intensity extracorporeal shock wave therapy for overactive bladder in women with metabolic syndrome

Authors

Leong M.¹, Goi S.H.², Lee M.R.³, Tang T.Y.³, Jhan J.H.³, Wang H.S.³, Shen J.T.³, Geng J.H.³, Lee Y.C.³

Institutions

¹Kaohsiung Medical University Hospital, Dept. of Urology, Kaohsiung, Taiwan, ²Kaohsiung Medical University Hospital, Dept. of Internal Medicine, Kaohsiung, Taiwan, ³Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Dept. of Urology, Kaohsiung, Taiwan

A0033

Treatment of Refractory Idiopathic Overactive Bladder With IncobotulinumtoxinA and Vibe Delivery System (XAVIER): Pilot Study

Authors

Schwarzschuh Gildor O.¹, Geva A.², Eftel A.³, Frederico B.⁴, Xambre L.⁵, Dmochowski R.⁶, Vainrib M.¹

Institutions

¹Meir Medical Center, Dept. of Urology, Kfar Saba, Israel, ²Vensica Medical LTD, New York, United States of America, ³Vensica Medical LTD, CTO, New York, United States of America, ⁴Hospital da Prelada, Dept. of Urology, Porto, Portugal, ⁵Centro Hospitalar, Dept. of Urology, Vila Nova de Gaia, Portugal, ⁶Vanderbilt University Medical Center, Dept. of Urology, Nashville, United States of America

A0034

Ambulatory Posterior Tibial Nerve Stimulation Using the TENSI+ Device: A Prospective Clinical Study in Detrusor Overactivity

Authors

Batista Miranda J.E., Monzon Falconi J.F., Gonzalez Munoz A., Herrero Elorza P., Lekue Mantzizidor I., Bassas Pargas A.S.

Institutions

Teknon Medical Center And Uroclinica Barcelona, Dept. of Functional Urology and Urodynamics, Barcelona, Spain

14:20 - 14:30

Pelvic pain

A0035

Multi-omics profiling reveals divergent pathogenic mechanisms between Hunner-type and non-Hunner-type interstitial cystitis

Authors

Ke H.¹, Lin Z.², Xu K.³, Wang K.¹

Institutions

¹West China Hospital, Dept. of Urology, Chengdu, China, ²Beijing Chaoyang Hospital Capital Medical University, Dept. of Plastic Surgery, Beijing, China, ³Peking University People's Hospital, Dept. of Urology, Beijing, China

A0036

Validation of a new Symptom Index to Assess Female Genitourinary Pain

Authors

Galkin D.¹, Galkina N.²

Institutions

¹I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Dept. of urology, Moscow, Russia, ²Penza State University, Dept. of surgery, Penza, Russia

Guided precision: AR, novel imaging and advanced robotics in partial nephrectomy

Video Session 02

Friday 13 March
13:00 - 14:30

Location Blue Area, George 3

Chairs R. Barod, London (GB)
O. Tayara, Otwock (PL)
To be confirmed

V008 (□: 7 min.)

Single-Port Robot-assisted Partial Nephrectomy: Early Spanish Experience
V. Hevia Palacios, Madrid (ES)

V009 (□: 7 min.)

Robot-Assisted Partial Nephrectomy Using Four Different Robotic Platforms: Institutional Experience and Feasibility
C. Cámara Martínez, Ourense (ES)

V010 (□: 8 min.)

Hyperspectral Imaging Enables Selective Clamping During Robot-Assisted Partial Nephrectomy
A. Studier-Fischer, Mannheim (DE)

V011 (□: 8 min.)

3D-Image Guided Robot Assisted Partial Nephrectomy for non-oncological reasons
G.L. Margue, Bordeaux (FR)

V012 (□: 8 min.)

Exploring the Feasibility of 3D Augmented Reality in Image-Guided Robot-Assisted Partial Nephrectomy: Initial prospective Clinical Experience and Outcomes of 3D AR-IGRAPN (UroCCR 112)
To be confirmed

V013 (□: 7 min.)

Minimally invasive partial nephrectomy under the guidance of augmented reality dynamic real-time navigation based on the deep-learning multi-structural tridimensional kidney model
S. Zhang, Nanjing (CN)

V014 (□: 7 min.)

Prone position "Three-Port" retroperitoneal laparoscopic partial nephrectomy for complete dorsal T1a renal tumors
Q. Cao, Nanjing (CN)

Challenges in African urology

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Pan-African Urological Surgeons Association (PAUSA)

Friday 13 March
13:00 - 15:00

Location Blue Area, Victoria 6

Chairs J. N'Dow, Aberdeen (GB)
A.S. Zribi, Tunis (TN)

Learning objectives

Master the Transition to Minimally Invasive Surgery (MIS)

Compare and contrast the current roles of traditional open surgery versus laparoscopic surgery in various African settings. Analyze and manage the risks associated with conversion from laparoscopy to open surgery (laparotomy). Understand the continuing necessity for African urologists to maintain and teach open surgical skills.

Initiate and Develop Robotic Surgery Programs

Outline the essential steps for launching a robotic surgery program, including logistical, technical, and training requirements. Evaluate initial feedback and lessons learned from recent robotic surgery experiences in African countries.

Manage Complex Reconstructive Challenges

Review alternative management strategies for complex vesico-vaginal fistulas, including the presentation of a novel continent cystoplasty technique from a major reference center. Discuss prevention and treatment strategies for high-risk complications, such as buccal mucosa graft contracture in urethroplasty. Detail the specific surgical techniques required for redo repairs of pelvic fracture urethral injuries.

13:00 - 13:05

Introduction

13:05 - 13:50

Open surgery in the era of minimally invasive surgery

Moderators Z. Aslam, Aberdeen (GB)
To be confirmed

13:05 - 13:15

Open surgery, initial choice: When and why

To be confirmed

13:15 - 13:30

Laparoscopy to laparotomy: The decision and management of conversion

M. Benatta, Oran (DZ)
To be confirmed

The enduring relevance of laparoscopy in the robotic era

13:30 - 13:37

In Africa

To be confirmed

13:37 - 13:44

In Europe

I. Minčík, Presov (SK)

13:44 - 13:50

Discussion

13:50 - 14:25

Robotic surgery

Moderators

A. Mottrie, Aalst (BE)

P. Ngwu, Umuahia (NG)

To be confirmed

13:50 - 14:05

Building a robotic surgery program: Step-by-step roadmap

A. Mottrie, Aalst (BE)

14:05 - 14:15

The recent experience of robotic surgery in Africa

Speakers

A. Ouzzane, Casablanca (MA)

To be confirmed

14:15 - 14:25

Discussion

14:25 - 15:00

Reconstructive surgery

Moderators

A.D. Dangi, Aberdeen (GB)

H. Kibansha, Kampala (UG)

A.A. Mbassi, Yaounde (CM)

14:25 - 14:35

Complex pelvic fracture urethral injuries re-do

E. Moshokoa, Midrand (ZA)

14:35 - 14:45

Buccal mucosa graft contracture in African countries

To be confirmed

14:45 - 14:55

The new continent augmentation cystoplasty

I. Vaz, Maputo (MZ)

14:55 - 15:00

Discussion

Controversies in uro-oncology: Case based discussions

Urology Beyond Europe: Joint session between the European Association of Urology (EAU), the SAARC Association of Urological Surgeons (SAUS) and Pakistan Association of Urological Surgeons (PAUS)

Friday 13 March

13:00 - 15:30

Location

Red Area, Room 7

Chairs

M.S. Agrawal, Agra (IN)

H. Ather, Karachi (PK)

M. Babjuk, Prague (CZ)

Rajeev Thekumpadam Puthenveetil, Guwahati (IN)

Learning objectives

"This UBE session is divided into two sections. The first section, case-based learning, enhances clinical reasoning, problem-solving, and decision-making skills by having urologists analyse real scenarios in general urology, thereby integrating theory with practice and developing critical thinking abilities. Section 2 addresses some contemporary issues in uro-oncology, focusing on three primary urological cancers: bladder, prostate, and kidney. There is ample opportunity for interactive discussion during the session.

13:00 - 13:05

Opening by president of SAUS and PAUS

H. Ather, Karachi (PK)

13:05 - 14:10	Case based discussions: Benign urological conditions
13:05 - 13:08	Case presentation Moderate burden staghorn stone in a 30-year-old male, first-time stone former
	<i>Case presenter</i> S.K. Chandrasekera, Sri Jayewardenepura (LK)
13:08 - 13:14	PCNL is still the treatment of choice
	B. Somani, Southampton (GB)
13:14 - 13:20	RIRS with FANS is the new gold standard
	<i>Case presenter</i> To be confirmed
13:20 - 13:25	Discussion and voting
13:25 - 13:28	Case discussion: 57-year-old male with medical treatment-refractory BPH
	H. Mithani, Karachi (PK)
13:28 - 13:34	MIST is the standard of care now
	M. Rieken, Zürich (CH)
13:34 - 13:40	TURP/laser enucleation is still the gold standard
	P. Maheshwari, Mumbai (IN)
13:40 - 13:45	Discussion and voting
13:45 - 13:48	Case presentation 2 cm bulbar urethral stricture in a 32-year-old male
	<i>Case presenter</i> I. Memon, Hyderabad (PK)
13:48 - 13:54	Dorsal onlay urethroplasty
	<i>Case presenter</i> A. Abdullah, Karachi (PK)
13:54 - 14:00	Ventral onlay urethroplasty
	K. Dimitropoulos, Larissa (GR)
14:00 - 14:05	Discussion and voting
14:05 - 14:10	Session wrap-up
	A.P. Malalasekera, Colombo (LK)
<hr/>	
14:10 - 15:30	Uro oncology
	<i>Moderators</i> M. Babjuk, Prague (CZ)
	N. Bin Nusrat, Galway (IE)
	Rajeev Thekumpadam Puthenveetil, Guwahati (IN)
14:10 - 14:20	Evolving role of PSMA PET CT in diagnosis and staging
	To be confirmed
14:20 - 14:30	Balancing toxicity and cancer control in metastatic prostate cancer
	M.J. Kabir, Dhaka (BD)
14:30 - 14:35	Discussion
14:35 - 14:45	Management of complex renal masses in a solitary kidney
	T. Klatte, Bad Saarow (DE)
14:45 - 14:55	Modern imaging modalities in staging and diagnosis of RCC
	Z. Aslam, Aberdeen (GB)
14:55 - 15:00	Discussion

15:00 - 15:10

Management dilemma in pT0 bladder cancer following NAC

H. Ather, Karachi (PK)

15:10 - 15:20

De-escalations in the follow-up of NMI bladder cancer - pros and cons

A.H. Qureshi, Karachi (PK)

15:20 - 15:25

Discussion

15:25 - 15:30

Session wrap-up

F. Mumtaz, London (GB)

Hidden challenges: Diagnosis and management of rare GU Tumors

Urology Beyond Europe: Joint session of the European Association of Urology (EAU) and the Canadian Urological Association (CUA)

Friday 13 March
13:00 - 15:00

Location

Blue Area, George 1

Chairs

W. Kassouf, Montreal (CA)

J.L. Vásquez, Copenhagen (DK)

Learning objectives

1. Recognize the burden of rare genitourinary cancers and understand their impact on patients and healthcare systems. 2. Review advances in penile cancer, including HPV-related disease and management of node-positive disease. 3. Identify clinical and pathological precursors of penile, bladder and testicular cancer and their implications for diagnosis, surveillance, and intervention. 5. Discuss complex management challenges in postchemotherapy germ cell tumors.

13:00 - 13:05

Introduction

13:05 - 13:15

State-of-the-art lecture The burden of rare genitourinary cancers

A. Necchi, Milan (IT)

13:15 - 13:20

Discussion

13:20 - 13:35

Penile cancer

13:20 - 13:30

State-of-the-art lecture Penile intraepithelial neoplasia and HPV

A. Thomas, Mainz (DE)

13:30 - 13:35

Discussion

13:35 - 14:10

Node-positive penile carcinoma - a case-based discussion

Moderator

M. Lodde, Québec (CA)

Panel

B.E. Ayres, London (GB)

J.M. Crook, Kelowna (CA)

L. Elst, Leuven (BE)

S. Sridhar, Toronto (CA)

14:10 - 14:25

Bladder cancer

14:10 - 14:20

State-of-the-art lecture Premalignant bladder cancer lesions

M.P. St-Laurent, Vancouver (CA)

14:20 - 14:25

Discussion

14:25 - 14:55

Testicular cancer

14:25 - 14:35

State-of-the-art lecture Clinical and pathologic precursors of testicular cancer

C. Tholomier, Montréal (CA)

14:35 - 14:40

Discussion

14:40 - 14:50

State-of-the-art lecture Challenging postchemotherapy germ cell tumors: growing teratoma and malignant transformation

R. Hamilton, Toronto (CA)

14:50 - 14:55

Discussion

14:55 - 15:00

Wrap up

Current topics of urology: Prostate cancer and urolithiasis

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Japanese Urological Association (JUA)

Friday 13 March

13:00 - 15:30

Location

Blue Area, Victoria 1

Chairs

A.S. Merseburger, Lübeck (DE)

M. Sugimoto, Kagawa (JP)

Learning objectives

The topic of this session is prostate cancer and urolithiasis, two of the most common conditions in urology. The objective is to enhance participants' basic and clinical knowledge of both diseases. A wide range of treatment options is available for prostate cancer, and pharmacotherapy is becoming increasingly complex. In addition to hormonal therapy, personalized treatments based on genetic testing are being developed. Theranostics using PSMA is also becoming more widespread, while significant advancements are being made in both particle beam radiation therapy and surgical techniques. In the field of urolithiasis, progress is being made not only in molecular-level understanding but also in the rapid evolution of endoscopic surgery. Moreover, preventive strategies are gaining more attention alongside therapeutic approaches. This session offers participants an opportunity to refresh their current knowledge and stay updated on the latest developments in the management of these two important urological diseases.

13:00 - 13:05

Opening

13:05 - 13:50

Prostate cancer

Moderator

H. Miyake, Kobe (JP)

Chair

G. Kramer, Vienna (AT)

13:05 - 13:15

Comprehensive genomic profiling tests in prostate cancer: How to translate basic research knowledge into real-world clinical practice?

T. Sasaki, Tsu (JP)

13:15 - 13:25

From mHSPC to mCRPC

A.S. Bjartell, Malmö (SE)

13:25 - 13:50

Case presentation: Prostate cancer

Case presenter N. Gunge, Fukuoka (JP)

Panel discussion

Panel G. Gandaglia, Milan (IT)
N. Gunge, Fukuoka (JP)
To be confirmed
K.M. Morozumi, Sendai (JP)

13:50 - 14:35

JUA abstract presentations

Moderators A.S. Merseburger, Lübeck (DE)
M. Sugimoto, Kagawa (JP)

14:35 - 14:40

Break

14:40 - 15:25

Stones

Moderators T.R.W. Herrmann, Frauenfeld (CH)
T. Yasui, Nagoya (JP)

14:40 - 14:50

Discovery of a novel biomarker for urolithiasis using crystal engineering techniques

Y. Tanaka, Nagoya (JP)

14:50 - 15:00

How to crack the stones?

T.R.W. Herrmann, Frauenfeld (CH)

15:00 - 15:25

Case presentation: Stones

Case presenter S. Kayano, Oshima-cho, Ota-shi, Gunma (JP)

Panel discussion

Panel S. Kayano, Oshima-cho, Ota-shi, Gunma (JP)
Y. Nagata, Kitakyushu (JP)
T. Tailly, Ghent (BE)
L. Tzelves, Athens (GR)

15:25 - 15:30

Closing

H. Kume, Tokyo (JP)

Facing the grey zones: Urological debates

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Arab Association of Urology (AAU)

Friday 13 March
13:00 - 15:00

Location Blue Area, Victoria 5

Chairs
H. Abol-Enein, Mansoura (EG)
W. Kamal, Jeddah (SA)
T. Knoll, Sindelfingen (DE)

Learning objectives

Participants should learn to make evidence-based decisions in challenging urological grey zones. They should understand how to balance early cystectomy versus intravesical escalation in high-risk NMIBC, how to choose between urethroplasty and endoscopic approaches for a recurrent 2-cm stricture, and how to manage refractory storage dysfunction in high-risk neuro-urological patients. In addition, they should be able to compare multi-tract PCNL with ECIRS for multi-calyceal stones, evaluate treatment options after BCG failure, and determine when residual fragments ≥ 4 mm should be observed or actively treated.

Welcome and introduction

W. Kamal, Jeddah (SA)

13:00 - 13:20

Debate High-risk NMIBC

13:00 - 13:10

Early cystectomy

H. Abol-Enein, Mansoura (EG)

13:10 - 13:20

Intravesical therapy escalation

M. Moschini, Milan (IT)

13:20 - 13:40

Debate Recurrent 2 cm urethral stricture

13:20 - 13:30

Urethroplasty

S.C. Morgenstern, Frankfurt am Main (DE)

13:30 - 13:40

Endoscopic management

K. Hosny, Blackburn (GB)

13:40 - 14:00

Debate Refractory storage dysfunction in the high risk neurology patient

13:40 - 13:50

Botulinium toxin injection

M. Bulbul, Riad El Solh - Beirut (LB)

13:50 - 14:00

Augmented cystoplasty

T. Antunes Lopes, Porto (PT)

14:00 - 14:20

Debate Multiple stones in different calyces

14:00 - 14:10

PCNL with multiple tracks

T. Knoll, Sindelfingen (DE)

14:10 - 14:20

ECIRS

W. Kamal, Jeddah (SA)

14:20 - 14:40

Debate High risk NMIBC post BCG failure

14:20 - 14:30

Radical cystectomy

P. Sountoulides, Panorama - Thessaloniki (GR)

14:30 - 14:40

Newer agents

W.A. Hassen, Abu Dhabi (AE)

14:40 - 15:00

Debate Residual fragments 4 mm or more after some stone surgery

14:40 - 14:50

Leave it

M. Moussa, Beirut (LB)

14:50 - 15:00

Chase it

A. Pietropaolo, Southampton (GB)

Closing remarks

H. Abol-Enein, Mansoura (EG)

Transforming urologic practice through innovation and technology

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Korean Urological Association (KUA)

Friday 13 March

13:00 - 15:00

Location

Blue Area, Victoria 2

Chairs

F.K-H. Chun, (DE)

S.I. Jung, Gwangju (KR)

Learning objectives

This joint session will bring together specialists and key opinion leaders from South Korea and Europe to address cutting-edge topics in uro-oncology, robotic surgery, and andrology/LUTS. Delegates can expect detailed and up-to-date coverage of specific topics including the treatment of urothelial carcinoma, new platforms in robotic surgery, and the management of post-prostatectomy urinary symptoms. The session will feature lectures from both European and Korean speakers, followed by discussion panels composed of members from both associations.

13:00 - 13:05

Welcome and introduction

F.K-H. Chun, (DE)

S.I. Seo, Seoul (KR)

13:05 - 13:45

Advances in the management of urothelial carcinoma

Moderators

A. Masson-Lecomte, Paris (FR)

S.I. Seo, Seoul (KR)

13:05 - 13:15

En-bloc TURB: A new standard for NMIBC?

J.H. Kim, Seoul (KR)

13:15 - 13:25

Updates on the treatment of BCG-refractory NMIBC

H.K. Seo, Goyang-si, (KR)

13:25 - 13:35

Cytoreductive cystectomy: Where are we now?

To be confirmed

13:35 - 13:45

Panel discussion

Panel

J.S. Chung, Busan (KR)

Y.H. Ko, Daegu (KR)

J.Y. Ku, Busan (KR)

To be confirmed

13:45 - 14:22

Revolutionizing urologic surgery through emerging technologies

Moderators

S.K. Hong, Seongnam (KR)

S. Secco, Milan (IT)

13:45 - 13:55

Urological applications of a robotic surgical system

B.M.C. Rocco, Rome (IT)

13:55 - 14:05

Urologic surgery with a robotic assisted system

C.W. Jeong, Seoul (KR)

14:05 - 14:15

Telesurgery: Technical challenges and prospects

B. Somani, Southampton (GB)

14:15 - 14:22

Panel discussion

Panel

B.M.C. Rocco, Rome (IT)

B. Somani, Southampton (GB)

S.H. Song, Seoul (KR)

14:22 - 14:59

Emerging therapeutic paradigms in andrology and LUTS

Moderators

S.I. Jung, Gwangju (KR)

V. Phé, Paris (FR)

14:22 - 14:32

Androgen replacement therapy for prostate cancer survivors with hypogonadism

H. Han, Seoul (KR)

14:32 - 14:42

Changes and management of urinary symptom after radical prostatectomy

S. Bang, Seoul (KR)

14:42 - 14:52

Current status of neuromodulation for urinary disease

M. Tutolo, Milan (IT)

14:52 - 14:59

Panel discussion

Panel

K.J. Oh, Gwangju (KR)

H.J. Park, Busan (KR)

M. Tutolo, Milan (IT)

14:59 - 15:00

Wrap-up and closing

Speaker

S.I. Jung, Gwangju (KR)

Hands-on Training in PSMA/PET image reading for urologists

HOT PSMA/PET

Friday 13 March
13:00 - 16:30

Location	Red Area, Room 2
Chairs	V. Kasivisvanathan, London (GB) F. Sanguedolce, Barcelona (ES)
Tutors	To be confirmed R. Mei, Bologna (IT)

Learning objectives

The Hands-on Training in PSMA/PET image reading for urologists provides training in PET imaging for prostate cancer with an emphasis on PSMA. The course aims to help urologists understand the role PET imaging plays in the management of patients with prostate cancer and how to interpret the images. The training addresses how prostate PET imaging works, what different tracers might be used for prostate cancer, and how to use the information generated by PET (i.e. in clinical decision making or modifying management of patients). The course will cover initial staging, staging at recurrence, and the use of PET imaging for radioligand treatment. The current limitations and pitfalls of PET imaging will be critically assessed and discussed.

Navigating the future of urologic care: Trials in progress

EGPT 08

Friday 13 March
13:00 - 14:30

Location	Orange Area, EGPT 1
Chairs	To be confirmed A. Røder, Gentofte (DK) To be confirmed

13:00 - 13:25

Benign urological disease

P0127

A Multicenter Randomized Controlled Trial Protocol: Evaluating Transpelvic Magnetic Stimulation Combined with Biofeedback for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Authors

Chao Q.¹, Tao X.², Chengliang X.³

Institutions

¹The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Dept. of Urology, Nanjing, China, ²Xi'an Jiaotong University, Dept. of Global Health, Xi'an, China, ³Huazhong University of Science and Technology, Tongji Medical College, Wuhan, China

P0128

Cord blood platelet-rich plasma (CB-PRP) plus penile traction therapy versus penile traction alone in patients with Peyronie's disease: a randomized clinical trial (CB-PRP-TRAC1)

Authors

Gadda F.¹, Boeri L.¹, Basadonna L.M.¹, Graps G.¹, Passarelli F.¹, Turetti M.¹, Villa S.², Montemurro T.², Coluccio E.², Myhailova L.², Sequi M.³, Cortesi L.³, Montanari E.⁴

Institutions

¹IRCCS Ca Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ²IRCCS Ca Granda Ospedale Maggiore Policlinico, Transfusion Center, Milan, Italy, ³IRCCS Ca Granda Ospedale Maggiore Policlinico, Scientific Direction, Milan, Italy, ⁴IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dept. of Clinical Sciences and Community Health, University of Milan, Milan, Italy

P0129

Epidural spinal cord stimulation to restore bladder and bowel function after spinal cord injury: the ImPRESS Project

Authors

Knight S.L.¹, Houlston H.K.¹, Duffell L.², Baxter D.³, Afolayan J.¹, Martinez E.¹, Nobrega R.¹, Vasquez L.N.¹, Desai M.¹, Doherty S.P.², Emmanuel A.¹

Institutions

¹Royal National Orthopaedic Hospital, London Spinal Cord Injury Centre, Stanmore, United Kingdom, ²University College London, Dept. of Medical Physics and Biomedical Engineering, London, United Kingdom, ³Whittington Hospital, Dept. of Neurosurgery, London, United Kingdom

P0130

A multicenter, randomized, placebo-controlled trial to compare sacral neuromodulation versus placebo in patients with multiple sclerosis with neurogenic lower urinary tract, bowel and sexual dysfunction

Authors

Kobberø H.¹, Krhut J.², Zvara P.¹, Fode M.³, Mejlidal A.⁴, Nielsen H.H.⁵, Blaaberg M.⁵, Poulsen M.H.⁶

Institutions

¹Odense University Hospital, Dept. of Urology, Odense, Denmark, ²University Hospital Ostrava, Dept. of Urology, Ostrava, Czech Republic, ³Copenhagen University Hospital - Herlev and Gentofte Hospital, Dept. of Urology, Copenhagen, Denmark, ⁴Odense Patient Explorative Network, Odense, Denmark, ⁵Odense University Hospital, Dept. of Neurology, Odense, Denmark, ⁶Esbjerg and Grindsted Hospital, University Hospital of Southern Denmark, Dept. of Urology, Esbjerg, Denmark

P0131

PRescription exercise for Older men with Urinary Disease (PROUD) trial

Authors

Bauer S.¹, Huang A.², Boscardin J.³, Luke A.⁴, McVary K.T.⁵, Breyer B.⁶, Van Blarigan E.L.³, Molina A.⁷, Evans W.⁸, Kenfield S.A.⁶

Institutions

¹University of California San Francisco - UCSF, Dept. of Medicine and Urology, San Francisco, United States of America, ²University of California San Francisco - UCSF, Dept. of Medicine and Urology, San Francisco, United States of America, ³University of California San Francisco - UCSF, Dept. of Epidemiology and Biostatistics, San Francisco, United States of America, ⁴University of California San Francisco - UCSF, Dept. of Orthopaedic Surgery, San Francisco, United States of America, ⁵Loyola University Medical Center, Dept. of Urology, Chicago, United States of America, ⁶University of California San Francisco - UCSF, Dept. of Urology, San Francisco, United States of America, ⁷University of California San Diego - UCSD, Dept. of Medicine, San Diego, United States of America, ⁸University of California Berkeley, Dept. of Nutritional Sciences, Berkeley, United States of America

13:25 - 13:30

Prostate cancer

P0132

Penile vibratory stimulation in the prevention of sexual dysfunction and urinary incontinence after radical prostatectomy (ProVibrate)

Authors

Andersen H.R.¹, Juul-Haslund M.¹, Østergren P.B.¹, Jensen C.F.S.¹, Nielsen T.K.², Lindeborg L.³, Timmermann A.M.¹, Fode M.¹

Institutions

¹Copenhagen University Hospital - Herlev and Gentofte Hospital, Dept. of Urology, Herlev, Denmark, ²Rigshospitalet, Dept. of Urology, Copenhagen, Denmark, ³Zealand University Hospital, Dept. of Urology, Roskilde, Denmark

13:30 - 13:40

Penile cancer

DEPECA-1 (DEfeating PEtile CAncer 1) – A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for advanced and metastatic penile carcinoma

Authors

Tsaur I.¹, Barcena M.L.¹, Feng Y.S.², Eismann L.³, Thomas C.⁴, Gäbel C.⁵, Müller D.W.⁵, Al-Batran S.E.⁵, Thomas A.⁶, Borkowetz A.⁷, Meister B.⁸, Schnabel M.⁹, Retz M.¹⁰, Reimann M.¹¹, Niegisch G.¹², Erne E.¹, Rausch S.¹

Institutions

¹University Hospital Tübingen, Dept. of Urology, Tübingen, Germany, ²University Hospital Tübingen, Institute for Clinical Epidemiology and Applied Biostatistics (IKEAB), Tübingen, Germany, ³University Hospital Munich, LMU, Dept. of Urology, Munich, Germany, ⁴University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dept. of Urology, Dresden, Germany, ⁵The Frankfurt Institute of Clinical Cancer Research IKF GmbH, University Cancer Center Frankfurt, Frankfurt am Main, Germany, ⁶University Medical Center of Johannes Gutenberg-University, Dept. of Urology and Pediatric Urology, Mainz, Germany, ⁷Rostock University Medical Center, Dept. of Urology, Rostock, Germany, ⁸Medical Faculty Mannheim of Heidelberg University, Dept. of Urology and Uro-Surgery, Mannheim, Germany, ⁹Caritas Hospital St. Josef, Dept. of Urology, Regensburg, Germany, ¹⁰Technical University of Munich, School of Medicine and Health, TUM University Hospital Munich, Dept. of Urology, Munich, Germany, ¹¹Charité – Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ¹²University Hospital and Medical Faculty, Heinrich-Heine-University; Centre for Integrated Oncology (CIO) Düsseldorf, Dept. of Urology; CIO Aachen-Bonn-Cologne-Düsseldorf (ABCD), Düsseldorf, Germany

DEPECA-2 (DEfeating PEtile CAncer 2) – Robot-assisted vs. open inguinal lymphadenectomy for penile cancer – a prospective randomized trial with a supporting translational program

Authors

Tsaur I.¹, Barcena M.L.¹, Feng Y.S.², Eismann L.³, Thomas C.⁴, Thomas A.⁵, Borkowetz A.⁶, Michel M.S.⁷, Bolenz C.⁸, Wullich B.⁹, Apel H.⁹, Schlomm T.¹⁰, Reimann M.¹⁰, Gäbel C.¹¹, Müller D.W.¹¹, Al-Batran S.E.¹¹, Erne E.¹, Rausch S.¹

Institutions

¹University Hospital Tübingen, Dept. of Urology, Tübingen, Germany, ²University Hospital Tübingen, Institute for Clinical Epidemiology and Applied Biostatistics (IKEAB), Tübingen, Germany, ³University Hospital Munich, LMU, Dept. of Urology, Munich, Germany, ⁴University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dept. of Urology, Dresden, Germany, ⁵University Medical Center of Johannes Gutenberg-University, Dept. of Urology and Pediatric Urology, Mainz, Germany, ⁶Rostock University Medical Center, Dept. of Urology, Rostock, Germany, ⁷Mannheim University Medical Center, Dept. of Urology and Uro-Surgery, Mannheim, Germany, ⁸University Hospital Ulm, Dept. of Urology and Pediatric Urology, Ulm, Germany, ⁹Universitätsklinikum Erlangen, Dept. of Urology and Pediatric Urology, Erlangen, Germany, ¹⁰Charité – Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ¹¹The Frankfurt Institute of Clinical Cancer Research IKF GmbH, University Cancer Center Frankfurt, Frankfurt am Main, Germany

P0135

Prospective multicenter real-time Lund Taxonomy bladder cancer classification

Authors

Liedberg F.¹, Eriksson P.², Aramendia Cotillas E.², Mattsson A.², Zadoroznyj A.², Bernardo C.², Sjö Dahl G.¹, Edsjö A.³, Heidenblad M.⁴, Höglund M.²

Institutions

¹Institution of Translational Medicine, Lund University, Skåne University Hospital, Dept. of Urology, Malmö, Sweden, ²Lund University, Division of Oncology, Dept. of Clinical Sciences, Lund, Sweden, ³Skåne University Hospital, Dept. of Clinical Genetics Pathology and Molecular Diagnostics, Office for Medical Services, Lund, Sweden, ⁴Center for Translational Genomics, Lund University, Clinical Genomics Lund, Lund, Sweden

P0136

COOKER-Bladder Trial- modificatiOn of fOod intaKe to influence the Equilibrium of the uRinary BLADDER – a trial in progress

Authors

Manser S., Abt D., Seiler R., Blarer J.

Institutions

Spitalzentrum Biel - Centre hospitalier Bienne, Dept. of Urology, Biel, Switzerland

P0137

Artificial Intelligence (AI) CystoSmart™ Software for Papillary and Flat Lesions during Bladder Endoscopy: A Pilot, Non-interventional, Prospective Observational Protocol Proposal for Video Analysis and AI Generating Models

Authors

Corvino R.¹, Del Giudice F.¹, Santarelli V.¹, Asero V.¹, Razeto E.¹, Rocco B.², De Berardinis E.¹, Laszkiewicz J.³, Chung B.I.⁴, Basile G.⁵, Khan A.⁶, Abu-Ghanem Y.⁷, Mensah E.⁷, Thurairaja R.⁷, Khan M.S.⁷, Nair R.⁷

Institutions

¹Sapienza University of Rome, Dept. of Gynecological-Obstetrics Sciences and Urological Sciences, Rome, Italy, ²IRCCS A. Gemelli University Polyclinic Foundation, Sacred Heart Catholic University, Dept. of Urology, Rome, Italy, ³University Center of Excellence in Urology, Wroclaw Medical University, Dept. of Minimally Invasive and Robotic Urology, Wroclaw, Poland, ⁴Stanford University School of Medicine, Dept. of Urology, Stanford, United States of America, ⁵IRCCS Ospedale San Raffaele, Division of Experimental Oncology, Unit of Urology, Milan, Italy, ⁶University of Maryland School of Medicine, Division of Urology, Dept. of Surgery, Baltimore, United States of America, ⁷Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, Dept. of Urology, London, United Kingdom

P0138

A Phase II randomized trial of bicalutamide in patients receiving intravesical BCG for non-muscle invasive bladder cancer (BicaBCa)

Authors

Toren P.¹, Kassouf W.², Kulkarni G.³, Richard P.⁴, Gratton M.⁵, Lattouf J.B.⁶, Huynh M.J.⁷, Besançon M.¹, Girard C.¹, Gris T.¹, Lacombe L.¹, Fradet Y.¹

Institutions

¹CHU de Québec-Université Laval, Dept. of Surgery, Quebec City, Canada, ²McGill University, Dept. of Surgery, Montréal, Canada, ³University Health Network, University of Toronto, Dept. of Surgery, Toronto, Canada, ⁴Sherbrooke University, Dept. of Surgery, Sherbrooke, Canada, ⁵Hotel-Dieu de Lévis, Dept. of Surgery, Lévis, Canada, ⁶CHU de Montréal, Dept. of Surgery, Montréal, Canada, ⁷Western University, Dept. of Urology, London, Canada

P0139

A classic test, a new concept: Development of a prognostic model based on dynamic urine cytology and Decision Support System (DSS) in NMIBC patients treated with BCG- Study Design

Authors

Papavasileiou G.¹, Angelidis P.², Gklinos K.¹, Kontolatis N.¹, Kakkos I.², Matsopoulos G.², Fragkoulis C.¹, Politi A.³, Dellis A.⁴, Ntoumas K.¹

Institutions

¹G. Gennimatas General Hospital, Dept. of Urology, Athens, Greece, ²NTUA, Biomedical Engineering Lab, School of Electrical & Computer Engineering, Athens, Greece, ³Medical School, National & Kapodistrian University, Cytopathology, Athens, Greece, ⁴Medical School, National & Kapodistrian University, Dept. of Urology, Athens, Greece

P0140

SPICE: Supporting Sexual Health in Bladder Cancer Patients - A Sequential Mixed-Methods Intervention Study

Authors

Krieger J.¹, Giraldi A.², Jensen J.B.³, Graugaard-Jensen C.¹

Institutions

¹Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ²Mental Health Center Copenhagen, Sexological Clinic, Copenhagen, Denmark, ³Aarhus University, Dept. of Clinical Medicine, Aarhus, Denmark

14:10 - 14:20

UTUC

P0141

A Phase 2A/B, Multi center, Open Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)

Authors

Matin S.¹, Jayram G.², Bukavina L.³, Huang X.⁴, Degaonkar V.⁵, Ganapathy D.⁶, Goluboff E.⁵, Roupret M.⁷

Institutions

¹MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ²Urology Associates P.C., Dept. of Urology, Nashville, United States of America, ³Cleveland Clinic Glickman Urologic Institute, Dept. of Urologic Oncology, Cleveland, United States of America, ⁴Tyra Biosciences, Dept. of Biostatistics, Carlsbad, United States of America, ⁵Tyra Biosciences, Dept. of Clinical Development, Carlsbad, United States of America, ⁶Tyra Biosciences, Dept. of Medical Affairs and Clinical Development, Carlsbad, United States of America, ⁷Sorbonne University, Dept. of Urology, Paris, France

P0142

Single bladder instillation with chemotherapy following endoscopic management for upper tract urothelial carcinoma to reduce bladder recurrence

Authors

Pilosov Solomon I.¹, Dekel Y.¹, Benzekry I.¹, Klein I.¹, Feigin P.², Lifshitz D.³, Freifeld Y.¹

Institutions

¹Carmel Medical Center, Dept. of Urology, Haifa, Israel, ²Technion, Institute of Technology, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel, ³HaSharon Medical Center, Dept. of Urology, Petah Tikva, Israel

14:20 - 14:30

Kidney cancer

Real-Time Image-Guided Robot-Assisted Partial Nephrectomy: Design and Methodology of the BISTOURY-CLINICAL Prospective Trial

Authors

Prata F.¹, Lauretti C.², Morfino R.², Manni G.³, Capillo A.⁴, Di Noto D.⁴, Chessari M.⁴, Massenzi M.⁴, Soda P.³, Zollo L.², Papalia R.¹

Institutions

¹Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy, ²Campus Bio-Medico University of Rome, Unit of Advanced Robotics and Human-Centered Technologies, Departmental faculty of Engineering, Rome, Italy, ³Campus Bio-Medico University of Rome, Unit of Artificial Intelligence and Computer Systems, Dept. of Engineering, Rome, Italy, ⁴Teleconsys S.p.A., Business Unit Strategy & Innovation, Rome, Italy

Clinical outcomes for Caval Thrombus involved Renal Cancer (IR1 – CAVALThromb): a prospective, multicentre, international registry

Authors

Connor M.J.¹, Berry B.², Cazzaniga W.³, Gulamhusein A.G.⁴, Mahrous A.⁵, Hoskings-Jervis F.¹, Hatim E.⁶, Gopalakrishnan A.¹, Morris S.¹, Thanigasalam R.⁷, Hill P.⁸, Laird A.⁹, Bex A.², Manson-Bahr D.¹⁰, Mumtaz F.², Hughes-Hallett A.⁶, Nicol D.³

Institutions

¹Imperial College London, Division of Surgery, London, United Kingdom, ²The Royal Free Hospital, Dept. of Urology, London, United Kingdom, ³The Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, ⁴The Christie NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom, ⁵North Bristol NHS Trust, Dept. of Urology, London, United Kingdom, ⁶Imperial College Healthcare NHS Trust, Dept. of Urology, London, United Kingdom, ⁷The Royal Prince Alfred Hospital, Dept. of Urology, Sydney, Australia, ⁸Imperial College Healthcare NHS Trust, Dept. of Renal Medicine, London, United Kingdom, ⁹The Western General Hospital, Dept. of Urology, Edinburgh, United Kingdom, ¹⁰Norfolk and Norwich University Trust, Dept. of Urology, Norwich, United Kingdom

Study Group

IR1-CAVALThromb Study Investigators(London, United Kingdom)

Navigating the complexities of penile health: Innovations, challenges, and insights

EGPT 11

Friday 13 March
13:00 - 14:30

Location Orange Area, EGPT 4

Chairs To be confirmed
W.G. Lee, London (GB)
To be confirmed

13:00 - 13:35

Erectile dysfunction

P0181

Bridging the Knowledge Gap: Impact of Education on Healthcare Provider Understanding of Erectile Dysfunction Comorbidities and Orodispersible Therapy

Authors

Voorn S.¹, Lucifero D.¹, Scot-Smith C.¹, Jannini A.², Kirby G.³, Nappi E.⁴

Institutions

¹Medscape Global, Dept. of Medical Education, London, United Kingdom, ²University of Rome Tor Vergata, Dept. of Systems Medicine, Rome, Italy, ³The Prostate Center, London, United Kingdom, ⁴IRCCS San Matteo Hospital, Research Center for Reproductive Medicine, Pavia, Italy

P0182

A contemporary series of treatment outcomes and satisfaction following insertion of penile prosthesis for psychogenic erectile dysfunction in men aged \leq 40 years

Authors

Lindsay J.S.L., Ralph D., Muneer A., Alnajjar H.

Institutions

University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom

P0183

Clinical implications of systematic ASCVD score assessment in men with suspected vasculogenic erectile dysfunction: Results from a tertiary referral center

Authors

Bertini A.¹, Pozzi E.¹, Oddo M.¹, Negri F.¹, Raffo M.¹, Piccolo C.¹, Birolini G.², De Luca S.², Sucapuca R.¹, d'Arma A.¹, Montorsi F.¹, Salonia A.¹

Institutions

¹IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ²Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy

P0184

A more accurate evaluation of erectile function using the IIEF in men who do not engage in sexual intercourse after radical prostatectomy

Authors

Kirchhoff E., Blaha F., Schiele S., Schulwitz H., Peter C., Meissner V.H., Jahnen M., Gschwend J.E., Herkommer K.

Institutions

TUM University Hospital Rechts der Isar Technical University of Munich, Dept. of Urology, Munich, Germany

P0185

Beyond testosterone: the role of dehydroepiandrosterone sulfate and estradiol in erectile dysfunction in men without hypoandrogenism

Authors

Fujita N.¹, Okamoto T.¹, Mikami T.², Itoh K.³, Hatakeyama S.¹

Institutions

¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Hirosaki University Graduate School of Medicine, Innovation Center for Health Promotion, Hirosaki, Japan, ³Hirosaki University Graduate School of Medicine, Stress Response Science, Center for Advanced Medical Science, Hirosaki, Japan

P0186

Corporal Flow Reserve Assessed via Dynamic Penile Color Doppler Duplex Ultrasound: Translating a Cardiological Paradigm to Evaluate Arteriogenic Erectile Dysfunction

Authors

Pozzi E.¹, Oddo M.¹, Bertini A.¹, Piccolo C.¹, Raffo M.¹, Negri F.¹, Birolini G.², De Luca S.², Boeri L.³, Sucapuca R.¹, d'Arma A.¹, Montorsi F.¹, Salonia A.¹

Institutions

¹IRCCS San Raffaele Scientific Institute, Division of Experimental Oncology - Unit of Urology - Urological Research Institute, Milan, Italy, ²Vita-Salute San Raffaele University, Faculty of Medicine and Surgery, Milan, Italy, ³IRCCS Fondazione Ca' Granda, Dept. of Urology, Milan, Italy

P0187

Association Between Erectile Dysfunction and Frailty in Elderly Male Patients With Urological Diseases

Authors

Soma O., Ishimoto K., Miura Y.

Institutions

Hirosaki General Medical Center, Dept. of Urology, Hirosaki, Japan

13:35 - 14:05

Peyronie's disease

P0188

Validated Simulator for Training Penile Reconstructive Procedures in Peyronie's Disease and Congenital Curvature

Authors

Wang Z.¹, Nunez Rubio A.², Raison N.³, Cakir O.O.³, Satchi M.³, Yap T.⁴, Rhode K.¹, Pontiki A.¹, Castiglione F.³

Institutions

¹King's College London, Dept. of Surgical and Interventional Engineering, London, United Kingdom, ²King's College London, Dept. of Biomedical Engineering, London, United Kingdom, ³King's College Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁴Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom

P0189

Quality and Reliability of TikTok Videos on Peyronie's Disease: A Cross-Sectional Study

Authors

Ibrahim M.H., Özer C., Bay M.K., Çevik G.K., Akdere H., Aktoz T.

Institutions

Trakya university faculty of medicine, Dept. of Urology, Edirne, Turkey

P0190

Operation for penile deviation and risk of depression. A nationwide 25-year cohort study

Authors

Lund L.¹, Kristensen C.¹, Andersen I.², Noergaard M.²

Institutions

¹Odense University Hospital, Dept. of Urology, Odense, Denmark, ²Aarhus University Hospital, Dept. of Clinical Epidemiology, Aarhus, Denmark

P0191

Exploring depression among men with Peyronie's Disease: A binational cohort from Australia and Denmark

Authors

Juul-Haslund M.¹, Durukan E.¹, Thy S.A.¹, Jensen C.F.S.¹, Giraldi A.², Jacobsen A.³, Chung E.⁴, Fode M.¹

Institutions

¹Copenhagen University Hospital - Herlev and Gentofte, Dept. of Urology, Herlev, Denmark, ²Copenhagen University Hospital - Mental Health Services CPH, Sexological Clinic, Mental Health Center, Copenhagen, Denmark, ³Zealand University Hospital, Dept. of Urology, Roskilde, Denmark, ⁴Princess Alexandra Hospital, University of Queensland, Dept. of Urology, Brisbane, Australia

P0192

Global tunical thickness: a new ultrasonographic signature of Peyronie's disease

Authors

Maiolino G., Fernández-Pascual E., Lledó García E., Martínez-Salamanca J.I.

Institutions

Lyx Institute of Urology, Universidad Francisco de Vitoria, Dept. of Andrology and Sexual Medicine, Madrid, Spain

P0193

3D DOCUMENTATION OF COMPLEX PENILE DEFORMITIES IN PEYRONIE'S DISEASE – AN EXPERIMENTAL ANALYSIS OF 2 DEVICES.

Authors

Sanvido L.¹, Coimbra I.V.¹, Horta M.¹, Ruggeri M.T.¹, Nahas W.C.¹, Hallak J.¹, Pato E.Z.S.¹, Torres J.¹, Fraga L.¹, Filho N.M.¹, Rosseti C.A.², Moraes C.A.³, Aragao B.⁴, Gomes C.M.¹, Mulhall J.P.⁵, Nascimento B.C.G.¹

Institutions

¹Hospital das Clinicas University of Sao Paulo Medical School, Division of Urology, São Paulo, Brazil, ²Albert Einstein Israeli School of Health Sciences, School, São Paulo, Brazil, ³Arc Team Italy, Dept. of Reconstruction, Trentino, Italy, ⁴Hospital das Clinicas University of Sao Paulo Medical School, Dept. of Radiology, São Paulo, Brazil, ⁵Memorial Sloan Kettering Cancer Center, Dept. of Sexual Medicine, New York, United States of America

14:05 - 14:20

Transgender

P0194

Impact of Gender-Affirming Surgery on Sexual Quality of Life and Sexual Satisfaction in Transgender Women

Authors

Vural A.¹, Gultekin M.H.¹, Kuzucu F.¹, Turan S.², Akkus E.¹, Ozkara H.¹

Institutions

¹Istanbul University Cerrahpasa-Cerrahpasa Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ²Istanbul University Cerrahpasa-Cerrahpasa Faculty of Medicine, Dept. of Psychiatry, Istanbul, Turkey

P0195

First of its kind: A Multicentre Retrospective Cohort Analysis of ZSI 475 FTM Penile Implants Following Phalloplasty

Authors

[Levy M.](#)¹, Neuville P.², Morel-Journal N.², Falcone M.³, Peretti F.³, Guadagni L.³, van Abbema E.¹, Belinkey J.⁴, Bencic M.⁵, Djordevic M.⁵, Pigot G.¹

Institutions

¹Amsterdam University Medical Center, Dept. of Urology, Amsterdam, The Netherlands, ²Hôpital Lyon Sud, Dept. of Urology, Lyon, France, ³Molinette Hospital, Dept. of Urology, Turin, Italy, ⁴Guemes Hospital, Dept. of Urology, Buenos Aires, Argentina, ⁵Belgrade Center for Genital Reconstructive Surgery, Dept. of Urology, Belgrade, Serbia

P0196

A long learning curve demonstrates the complexity of Gender-affirming inflatable penile prosthesis insertion

Authors

[Gobbo A.](#), di Giovanni A., Tinajero J., Ralph D.J., Christopher A.N., Lee W.G.

Institutions

New Victoria Hospital, Gender Dysphoria Service, London, United Kingdom

14:20 - 14:30

Vasectomy

P0197

Feasibility Study: Use of the Symani™ microsurgical robot with a 4K 3D Video-Exoscope to perform vaso-vasostomy using fresh human tissues

Authors

[Garcia M.](#), Talamas A., Kim H., Dadashian E.

Institutions

Cedars Sinai Medical Center, Dept. of Urology, Los Angeles, United States of America

P0198

Post-vasectomy pain syndrome and vasectomy complications: real-life data from a single tertiary referral center

Authors

[Raffo M.](#)¹, De Rocco Ponce M.², Izquierdo P.², Haddad Baldassari J.³, Murillo Pinto J.C.⁴, Vantman Luft D.², Montorsi F.¹, Salonia A.¹, Ruiz-Castane E.²

Institutions

¹IRCCS Ospedale San Raffaele, Unit of Urology, Milan, Italy, ²Fundació Puigvert, Dept. of Andrology, Barcelona, Spain, ³Hospital Metropolitano de Santiago, Unit of Urology, Santiago de Compostela, Dominican Republic, ⁴Clinica de Marly Jorge Cavalier Gaviria, Unit of Urology, Bogotá, Colombia

Navigating Prognostic Terrain: Prediction Models and Surgical Outcomes in Renal Tumour Management

EGPT 10

Friday 13 March
13:00 - 14:30

Location

Orange Area, EGPT 3

Chairs

P. Nyirády, Budapest (HU)
H. Tanaka, Tokyo (JP)
To be confirmed

P0163

Barriers to Care and Individual Expenditures Among Patients with Von Hippel–Lindau Syndrome: Insights from a Patient-Reported Outcomes Study in a Large Comprehensive Care Center

Authors

Barretta A.¹, Cei F.², Salerno L.², Re C.², Capitanio J.F.³, Bailo M.³, Lattanzio R.⁴, Bandello F.⁴, Guarneri G.⁵, Partelli S.⁵, Cigliola A.⁶, Necchi A.⁶, Brembilla G.⁷, De Cobelli F.⁷, Calloni S.⁷, Falini A.⁸, Castellino L.⁹, Sciarrone Alibrandi M.T.¹⁰, Capitanio U.², Bianchi L.¹, Schiavina R.¹, Montorsi F.², Salonia A.², Larcher A.²

Institutions

¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, Italy, ²IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ³IRCCS San Raffaele Scientific Institute, Dept. of Neurosurgery, Milan, Italy, ⁴IRCCS San Raffaele Scientific Institute, Dept. of Ophthalmology, Milan, Italy, ⁵IRCCS San Raffaele Scientific Institute, Pancreas Translational & Clinical Research Center, OSR ENETS Center of Excellence, Unit of Pancreatic Surgery, Milan, Italy, ⁶IRCCS San Raffaele Scientific Institute, Dept. of Medical Oncology, Milan, Italy, ⁷IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy, ⁸IRCCS San Raffaele Scientific Institute, Dept. of Neuroradiology, Milan, Italy, ⁹IRCCS San Raffaele Scientific Institute, Dept. of Endocrinology, Milan, Italy, ¹⁰IRCCS San Raffaele Scientific Institute, Dept. of Nephrology, Milan, Italy

P0164

Positive Surgical Margins After Partial Nephrectomy: Still a Real Concern or a Fading Threat?

Authors

Bertini A.¹, Re C.¹, Salerno L.¹, Musso G.¹, Cei F.¹, Rosiello G.¹, Barretta A.¹, Belladelli F.¹, Piccolo C.¹, Disabato N.¹, Campugiani A.¹, Montesano M.¹, Ficarra G.¹, Tenace N.², Colecchia M.², Ponzoni M.², Cigliola A.³, Necchi A.³, Briganti A.¹, Bertini R.¹, Salonia A.¹, Montorsi F.¹, Larcher A.¹, Capitanio U.¹

Institutions

¹IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Dept. of Pathology, Milan, Italy, ³IRCCS San Raffaele Scientific Institute, Dept. of Medical Oncology, Milan, Italy

P0165

Prognostic Impact and Predictors of Indeterminate Surgical Margins after Nephrectomy for Renal Cell Carcinoma: Analysis from the NCDB

Authors

Musso G.¹, Vourganti S.², Salonia A.¹, Meagher M.F.³, Baker B.³, Puri D.³, Karamcheti S.³, Agrawal L.⁴, Sabir W.², Liss M.³, Cherullo E.², Capitanio U.¹, Larcher A.¹, Montorsi F.¹, Derweesh I.²

Institutions

¹IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²RUSH-MD Anderson Cancer Center, Dept. of Urology, Chicago, United States of America, ³University of California San Diego School of Medicine, Dept. of Urology, La Jolla, United States of America, ⁴UT Health Houston, Dept. of Urology, Houston, United States of America

P0166

Predictors of Recurrence Following Robot-Assisted Partial Nephrectomy for Primary Renal Cancer

Authors

Kyono M., Teishima J., Ueki H., Okamura Y., Bando Y., Suzuki K., Hara T., Terakawa T., Chiba K., Yao A., Miyake H.

Institutions

Kobe University Graduate School of Medicine, Dept. of Urology, Kobe, Japan

P0167

Surgery- and patient-specific determinants of renal function decline after partial nephrectomy in solitary-kidney patients

Authors

Salerno L.¹, Cei F.¹, Rha K.H.², Wagner C.³, Kutikov A.⁴, Porter J.⁵, Chalamcombe B.⁶, Badani K.⁷, Roussel E.⁸, Bertolo R.⁹, Antonelli A.⁹, Schiavina R.¹⁰, Bensalah K.¹¹, Zhang X.¹², Derweesh I.¹³, Mottrie A.¹⁴, Breda A.¹⁵, Minervini A.¹⁶, Campi R.¹⁷, Salonia A.¹, Briganti A.¹, Montorsi F.¹, Capitanio U.¹, Larcher A.¹

Institutions

¹IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²Urological Science Institute, Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ³St. Antonius Hospital, Dept. of Urology, Gronau, Germany, ⁴Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ⁵Swedish Medical Center, Swedish Urology Group, Seattle, United States of America, ⁶Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁷Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ⁸KU Leuven, Dept. of Urology, Leuven, Belgium, ⁹Azienda Ospedaliera Universitaria Integrata, University of Verona, Dept. of Urology, Verona, Italy, ¹⁰S. Orsola-Malpighi Hospital, University of Bologna, Dept. of Urology, Bologna, Italy, ¹¹University of Rennes, Dept. of Urology, Rennes, France, ¹²The Third Medical Centre, Chinese People's Liberation Army General Hospital, Dept. of Urology, Beijing, China, ¹³RUSH-MD Anderson Cancer Center, Dept. of Urology, Chicago, United States of America, ¹⁴Onze Lieve Vrouw Hospital, Dept. of Urology, Aalst, Belgium, ¹⁵Fundació Puigvert, Autònoma University of Barcelona, Dept. of Urology, Barcelona, Spain, ¹⁶Careggi Hospital, University of Florence, Dept. of Urology, Florence, Italy, ¹⁷Careggi University Hospital, Dept. of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Unit of Urology and Renal Transplantation, Oncology Department, Florence, Italy

P0168

Proton pump inhibitors and renal vulnerability: hidden risks in patients undergoing unilateral nephrectomy or nephroureterectomy

Authors

Hsu T.W.

Institutions

National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan

13:30 - 13:55

Subsequent systemic therapies

P0169

BRCA2 Expression Predicts Immune Infiltration and Tumor Progression in Kidney Chromophobe and Renal Papillary Cell Carcinoma

Authors

Wu Y., Xue K., Luo X., Liu C.

Institutions

The Third Affiliated Hospital of Southern Medical University, Dept. of Urology, Guangzhou, China

P0170

Development and Internal Validation of a Novel Prognostic Score for Real-World Renal Cell Carcinoma Patients Eligible for Adjuvant therapy

Authors

[Flammia R.S.](#), Brassetti A., Tuderti G., Anceschi U., Ferriero M.C., Bove A.M., Proietti F., Misuraca L., Bologna E., D'Annunzio S., Mastroianni R., Licari L.C., Chiacchio G., Pula M., Leonardo C., Guaglianone S., Simone G.

Institutions

IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy

P0171

Real-World Data of Patients Eligible for Adjuvant Pembrolizumab Prior to its National Reimbursement in Italy: Results from an Italian National Cancer Institute Registry

Authors

[Flammia R.S.](#), Brassetti A., Tuderti G., Anceschi U., Ferriero M.C., Bove A.M., Proietti F., Misuraca L., Bologna E., D'Annunzio S., Mastroianni R., Licari L.C., Chiacchio G., Pula M., Leonardo C., Guaglianone S., Simone G.

Institutions

IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy

P0172

Dynamic and Reversible Drug Tolerance to Cabozantinib in Renal Cell Carcinoma

Authors

[Zaccagnino A.](#), Ayoubian H., Junker K.

Institutions

Saarland University, Dept. of Urology and Pediatric Urology, Homburg, Germany

P0173

An International Multidisciplinary Delphi Consensus Statement on Definition, Classification, and Characterization of Oligometastatic Renal Cell Carcinoma to Guide Treatment Decisions

Authors

Leung D.K.W.¹, Leow J.², Campi R.³, Powles T.⁴, Volpe A.⁵, Shariat S.⁶, Fazekas T.S.⁶, Poon D.⁷, Wong K.⁸, Maclennan S.⁹, [Wu Z.](#)¹⁰, Bex A.¹¹

Institutions

¹The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ²Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore, ³Careggi Hospital, Dept. of Urology, Florence, Italy, ⁴St. Bartholomew's Hospital, Dept. of Oncology, London, United Kingdom, ⁵University of Eastern Piedmont, Dept. of Urology, Novara, Italy, ⁶Medical University of Vienna, Dept. of Surgery, Vienna, Austria, ⁷Hong Kong Sanatorium & Hospital, Dept. of Oncology, Hong Kong, Hong Kong, ⁸The Chinese University of Hong Kong, Dept. of Oncology, Hong Kong, Hong Kong, ⁹University of Aberdeen, Academic Urology Unit, Scotland, United Kingdom, ¹⁰Shanghai Changhai Hospital Naval Medical University, Dept. of Urology, Shanghai, China, ¹¹University College London, Dept. of Surgical Biotechnology, London, United Kingdom

Study Group

International Oligometastatic Renal Cell Carcinoma Collaborative Group(Multi-centre, Hong Kong)

13:55 - 14:30

Models to predict survival

P0174

Prospective Validation of a 10-Point Prognostic Model in RCC With IVC Tumor Thrombus: Thrombus Level Does Not Predict Survival

Authors

Meyyappan V., Sharma R., Mohan A., Balagangatharan P., Janaki K.L., Krishna G.

Institutions

Basavatarakam Indo-American Cancer Hospital, Dept. of Uro-Oncology, Hyderabad, India

P0175

Prognostic Indicators in pT3a Renal Cell Carcinoma

Authors

Rosmaninho L.¹, Lopes T.¹, Seixas L.¹, Lopes-Fernandes P.², Barroca A.³, Ramos M.S.³, Silva J.¹

Institutions

¹Centro Hospitalar Universitario de Sao Joao, Dept. of Urology, Porto, Portugal,

²Unidade Local de Saude do Alto Ave, Dept. of Urology, Guimarães, Portugal,

³Unidade Local de Saúde de Santo António, Dept. of Urology, Porto, Portugal

P0176

Development and Validation of a Prognostic Nomogram Based on Clinicopathological Characteristics of Renal Cell Carcinoma in Patients Under 30 Years old : A 12-Year Single-Center Study

Authors

Li Z.¹, Changwei S.¹, Junnan X.¹, Manwei H.¹, Xu B.¹, Chun Khoo H.², Xu Z.¹, Xin M.¹, Qingbo H.¹

Institutions

¹Chinese PLA General Hospital, Dept. of Urology, Beijing, China, ²Universiti Kebangsaan Malaysia, Dept. of Surgery, Kuala Lumpur, Malaysia

Authors

Pecoraro A.¹, Amparore D.², Bertolo R.³, Branger N.⁴, Caliò A.⁵, Carbonara U.⁶, Diana P.⁷, Distante A.⁸, Erdem S.⁹, Marchioni M.¹⁰, Margue G.¹¹, Martignoni G.¹², Muselaers C.H.J.¹³, Pavan N.¹⁴, Warren H.¹⁵, Wu Z.¹⁶, Albersen A.¹⁷, Raspolini M.R.¹⁸, Campi R.¹⁹, Roussel E.¹⁷

Institutions

¹Pederzoli Hospital, Dept. of Urology, Peschiera del Garda, Italy, ²San Luigi Hospital, Dept. of Urology, Turin, Italy, ³Azienda Ospedaliera Universitaria Integrata, Borgo Trento Hospital, Dept. of Urology, Verona, Italy, ⁴Institut Paoli-Calmette, Dept. of Urology, Marseille, France, ⁵Azienda Ospedaliera Universitaria Integrata, Borgo Trento Hospital, Diagnostic and Public Health, Section of Pathology, Verona, Italy, ⁶University of Bari, Dept. of Andrology and Kidney Transplantation, Dept. of Emergency and Organ Transplantation-Urology, Bari, Italy, ⁷Fundació Puigvert, Autonomous University of Barcelona, Dept. of Urology, Barcelona, Spain, ⁸Hôpital Cochin, Dept. of Urology, Paris, France, ⁹Istanbul University Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ¹⁰Università degli Studi "G. d'Annunzio" of Chieti, Dept. of Medical Oral and Biotechnological Science, Chieti, Italy, ¹¹Oncology Committee of the French Urology Association, Kidney Group, Maison de l'Urologie, Hôpital Pellegrin, Dept. of Urology, Bordeaux, France, ¹²Pederzoli Hospital, Dept. of Pathology, Peschiera del Garda, Italy, ¹³Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ¹⁴University of Palermo, Precision Medicine in Medical, Surgical and Critical Care, Palermo, Italy, ¹⁵Royal Free Hospital-University College London, Dept. of Urology, Specialist Centre for Kidney Cancer, London, United Kingdom, ¹⁶Changhai Hospital, Naval Medical University, Dept. of Urology, Shanghai, China, ¹⁷University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹⁸University Hospital Careggi, Dept. of Histopathology and Molecular Diagnostics, Florence, Italy, ¹⁹University Hospital Careggi, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy

Study Group

YAU WORKING GROUP RENAL CELL CARCINOMA(Arnhem, The Netherlands)

Establishment and external validation of a prognostic prediction model for renal epithelioid angiomyolipoma: A multicenter retrospective study**Authors**

Tang Y., Lei C., Shi J., Ge H., Le Q.

Institutions

Nanjing Jinling Hospital, Dept. of Urology, Nanjing, China

Cancer-specific survival in renal cell carcinoma: histological subtype-specific analysis of a single high-volume center with 15 years of follow-up**Authors**

Nocera L.¹, Sciotta M.¹, Donnini I.¹, Cristinelli L.¹, Martucci P.¹, Moroni A.¹, Matarese S.¹, Rodella F.¹, Carbotti G.¹, Di Naro A.¹, Arrigoni F.¹, Giacomelli G.¹, Solari M.¹, Romani M.¹, Daja J.¹, Furlan M.¹, Mirabella G.¹, Cancino Estrada J.E.H.², Scanzi M.¹, El Khatteeb H.¹, Zanotelli T.¹, Antonelli A.³, Lonati C.¹, Suardi N.R.¹

Institutions

¹ASST Spedali Civili, Dept. of Urology, Brescia, Italy, ²Univeristy of Ljubljana, Dept. of Artificial Intelligence, Ljubljana, Slovenia, ³Azienda Ospedaliera Universitaria di Verona, Dept. of Urology, Verona, Italy

Friday 13 March
13:00 - 14:30

Location Orange Area, EGPT 2

Chairs E.A. Hernandez Mendez, Mexico City (MX)
M. Wenzel, Frankfurt (DE)
T. Zilli, Bellinzona (CH)

13:00 - 13:35

Systemic treatment choice in mHSPC

P0145

Longitudinal Real-World Comparison of Triplet and Doublet Therapies in Metastatic Hormone-Sensitive Prostate Cancer: A Propensity-Matched Analysis at 6 and 36 Months

Authors

[Hsu J.Y.](#), Lin Y.S., Hsu C.Y., Ou Y.C., Tung M.C.

Institutions

Tungs' Taichung MetroHarbor Hospital, Division of Urology, Taichung, Taiwan

P0146

Epidemiology and treatment patterns of metastatic hormone-sensitive prostate cancer in France (EPICAP): Insights from a retrospective claims database study

Authors

[Chapet O.](#)¹, Scailteux L.M.², Inchboard L.³, Laborey M.³, David A.³, Dumont R.⁴, Sterin V.⁵, Khan N.⁶, Culine S.⁷, Vincendeau S.⁸

Institutions

¹Lyon South Hospital Center - Pierre Benite, Dept. of Radiation Oncology, Lyon, France, ²Rennes University Hospital, Rennes University, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, Rennes, France, ³Horiana, Secondary Department, Bordeaux, France, ⁴Bayer HealthCare Pharmaceuticals, La Garenne-Colombes, France, ⁵Bayer HealthCare Pharmaceuticals, Lille, France, ⁶Bayer HealthCare Pharmaceuticals, Whippany, United States of America, ⁷Saint-Louis Hospital, Dept. of Medical Oncology, Paris, France, ⁸Saint-Grégoire Private Hospital (Vivalto Santé), Dept. of Urology, Saint-Grégoire, France

P0147

Comparative efficacy of prostate radiotherapy and androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: an integrated network and reconstructed patient-level analysis

Authors

[Chen W.](#)¹, Yoshida S.¹, Yajima S.², Arita Y.³, Woo S.⁴, Tanabe K.¹, Fujiwara M.⁵, Fukushima H.¹, Tanaka H.¹, Masuda H.², Fujii Y.¹

Institutions

¹Institute of Science Tokyo, Dept. of Urology, Tokyo, Japan, ²National Cancer Center Hospital East, Dept. of Urology, Chiba, Japan, ³Memorial Sloan Kettering Cancer Center, Dept. of Radiology, New York, United States of America, ⁴NYU Langone Health, Dept. of Radiology, New York, United States of America, ⁵Teikyo University Hospital, Dept. of Urology, Tokyo, Japan

P0148

Drug-drug interaction between ARPI and statin via CYP3A4 induction: the first real-world report of worsened lipid control

Authors

Liu A.Q., Wu D., Teoh J.Y.C., Chiu P.K.F., Ng C.F.

Institutions

The Chinese University of Hong Kong, S.H. Ho Urology Centre, Hong Kong, Hong Kong

P0149

Potential for Drug-Drug Interactions with novel ARTAs and concomitant medications: analysis based on the Metastatic Hormone Sensitive Prostate Cancer (MHSPC) patients in the Real-World Evidence (RWE) RECOMMEND study

Authors

Bahl A.¹, Challapalli A.¹, Gregory K.¹, Ramsden A.L.¹, Logarajah A.¹, Lau H.H.T.¹, Stones R.¹, Das P.², Sharma A.³, Bhana R.⁴, Birtle A.⁵, Muthukumar D.⁶, Randhawa M.⁷, Sundar S.⁸, Prentice M.⁹, Bianchini D.¹⁰, Capo Mir M.¹¹, Syndikus I.¹², Jayaprakash K.T.¹³, Elumalai T.¹⁴, Goodwin S.¹⁵, Parikh O.¹⁶, White P.¹⁷, Foulstone E.¹

Institutions

¹University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Haematology and Oncology Centre, Bristol, United Kingdom, ²University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby, United Kingdom, ³Hillingdon Hospitals NHS Foundation Trust, Mount Vernon Hospital, Middlesex, United Kingdom, ⁴University Hospitals of North Midlands NHS Trust, Royal Stoke University Hospital, Stoke, United Kingdom, ⁵Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital, Preston, United Kingdom, ⁶East Suffolk and North Essex NHS Foundation Trust, Colchester General Hospital, Colchester, United Kingdom, ⁷NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom, ⁸Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom, ⁹Royal Free Hospital NHS Foundation Trust, Royal Free Hospital, London, United Kingdom, ¹⁰Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Maidstone Hospital, Maidstone, United Kingdom, ¹¹East Kent Hospitals NHS Foundation Trust, Kent and Canterbury Hospital, Canterbury, United Kingdom, ¹²The Clatterbridge Cancer Centre NHS Foundation Trust, The Clatterbridge Cancer Centre, Wirral, United Kingdom, ¹³The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, The Queen Elizabeth Hospital, King's Lynn, United Kingdom, ¹⁴Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom, ¹⁵East Sussex Healthcare NHS Trust, Conquest Hospital, St. Leonards-on-Sea, United Kingdom, ¹⁶East Lancashire Hospitals NHS Foundation Trust, Royal Blackburn Teaching Hospital, Blackburn, United Kingdom, ¹⁷University of the West of England, Faculty of Engineering, Design and Mathematics, Bristol, United Kingdom

P0150

Regret After Treatment Decisions in Advanced Prostate Cancer: What Do We Know - a Systematic Review

Authors

Birch R.¹, Neve M.², Chen C.³, Alice C.³, Tet Y.³

Institutions

¹King's College London, Dept. of Medicine, London, United Kingdom, ²King's College London, Dept. of Medicine GKT, London, United Kingdom, ³Guy's and St Thomas's NHS Foundation Trust, Dept. of Urology, London, United Kingdom

P0151

Implementing the EAU Guidelines Bot in urological tumor boards: a real-world analysis of impact and lessons learned

Authors

Romero Crespo A., Carrasco Gomez D., Fernandez Siles J., Marti Flores J.M., Perez Serrano C., Hernandez Alcaraz D., Morales Jimenez P., Garcia Galisteo E., Espana Navarro R.

Institutions

Hospital Regional Universitario Malaga, Dept. of Uro-Oncology, Málaga, Spain

13:35 - 14:15

Cytoreductive treatment in mHSPC

P0152

Evaluation of the feasibility and safety of darolutamide-based triplet therapy combined with cytoreductive prostatectomy in the treatment of metastatic hormone-sensitive prostate cancer

Authors

Wang S.¹, Shen Z.¹, Zhang K.¹, Zhang C.¹, Shi R.², Dong L.³, Zhao R.¹, Wang Y.¹, Hua L.¹

Institutions

¹Jiangsu Province Hospital, Dept. of Urology, Nanjing, China, ²Nanjing First Hospital, Dept. of Urology, Nanjing, China, ³Zhangjiagang Hospital of Traditional Chinese Medicine, Dept. of Urology, Suzhou, China

P0153

Cytoreductive radical prostatectomy for patients with newly diagnosed high-volume metastatic prostate cancer: a multicentre, prospective cohort study

Authors

Huang C., Heng G., Xuesong L., Liqun Z.

Institutions

Peking University First Hospital, Dept. of Urology, Beijing, China

P0155

Results of a prospective, single-center phase-II study on modern androgen deprivation therapy followed by cytoreductive radical prostatectomy in men with de novo metastatic hormone-sensitive prostate cancer (mHSPC)

Authors

Heidenreich A., Heidenreich J., Rieger C., Weiten R., Steenbock O., Pfister D.

Institutions

University Hospital Cologne, Dept. of Urology and Uro-Oncology, Cologne, Germany

P0156

Effect of cytoreductive radical prostatectomy combined with hormonal therapy in patients with oligometastatic prostate cancer—a multicentered prospective non-randomized control study

Authors

Chen X.¹, Qi Y.¹, Lin W.², Qu Y.¹, Lu Y.³, Xi W.¹, Jia S.¹, Wang H.¹, Guo J.¹, Xu L.¹

Institutions

¹Zhongshan Hospital Fudan University, Dept. of Urology, Shanghai, China, ²Shanghai Xuhui District Central Hospital, Dept. of Urology, Shanghai, China, ³Zhongshan Hospital, Fudan University (Xiamen Branch), Dept. of Urology, Xiamen, China

P0157

Do cytoreductive treatments improve symptomatic adverse local events and urinary patients reported outcome measures in de novo metastatic prostate cancer? Analysis from a phase II randomised study (IP2-ATLANTA)

Authors

Connor M.J.¹, Shah T.T.¹, Morris S.J.¹, Sukumar J.¹, Fiorentino F.², Heath C.³, Horan G.⁴, Johnson N.¹, Khoo V.⁵, Khoubehi B.⁶, Klimowska-Nassar N.¹, Mangar S.⁷, McGrath J.⁸, Nohpal de la Rosa C.¹, Smith A.¹, Price D.¹, Rai B.¹, Sarwar N.¹, Staffurth J.N.⁹, Tam H.¹⁰, Thippu Jayaprakash K.¹¹, Winkler M.¹, Dudderidge T.¹², Ahmed H.U.¹

Institutions

¹Imperial College London, Division of Surgery, London, United Kingdom, ²Leeds University, Clinical Trials Research Unit, Leeds, United Kingdom, ³University Hospital Southampton, Dept. of Oncology, Southampton, United Kingdom, ⁴The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, Dept. of Oncology, Kings Lynn, United Kingdom, ⁵The Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, ⁶Chelsea and Westminster Hospital, Dept. of Urology, London, United Kingdom, ⁷Imperial College Healthcare NHS Trust, Dept. of Oncology, London, United Kingdom, ⁸Royal Devon and Exeter NHS Foundation Trust, Dept. of Urology, Exeter, United Kingdom, ⁹Cardiff University, Dept. of Oncology, Cardiff, United Kingdom, ¹⁰Imperial College Healthcare NHS Trust, Dept. of Radiology, London, United Kingdom, ¹¹Addenbrooke's Hospital, Dept. of Oncology, Cambridge, United Kingdom, ¹²University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom

Study Group

IP2-ATLANTA Trial Investigators(London, United Kingdom)

P0158

Oncological outcomes of high-and low-volume metastatic prostate cancer treated with cytoreductive prostatectomy in a multidisciplinary setting

Authors

Reitano G.¹, Roberson D.S.², Ahmed M.E.², Pfister D.³, Heidenreich A.³, Karnes R.J.²

Institutions

¹University of Padova, Dept. of Surgery Oncology and Gastroenterology, Padova, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³University of Cologne, Dept. of Urology, Cologne, Germany

P0159

Health-Related Quality of Life (HRQOL) following cytoreductive radical prostatectomy in patients with nonregional lymph node metastases

Authors

Berg E.¹, Askari D.¹, Buchner A.¹, Eismann L.¹, Chaloupka M.¹, Weinhold P.¹, Becker A.¹, Kretschmer A.², Stief C.¹, Westhofen T.³

Institutions

¹LMU University Hospital, Dept. of Urology, Munich, Germany, ²Janssen Global, Dept. of Research and Development, Los Angeles, United States of America, ³University Hospital Augsburg, Dept. of Urology, Augsburg, Germany

14:15 - 14:30

Metastasis-directed radiotherapy in mHSPC

P0160

Efficacy and Safety of All-Site Radiotherapy in Combination with Standard of Care in High Gleason Score metastatic Prostate Cancer: Six-year Results from a Single-Institution

Authors

Chen H., Ma M., Gao X., Li H., Chen J., Ren X.

Institutions

Peking University First Hospital, Dept. of Radiotherapy, Beijing, China

P0161

ROLE OF RADIOTHERAPY IN NODE METASTASES FROM PROSTATE CANCER: ANALYSIS OF A LARGE SINGLE-INSTITUTION COHORT

Authors

Giannini L.¹, Fodor A.¹, Vincenzi M.M.², Deantoni C.L.¹, Torrasi M.¹, Fiorino C.², Tummineri R.¹, Broggi S.², Di Muzio N.¹

Institutions

¹IRCCS Ospedale San Raffaele, Dept. of Radiation Oncology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Medical Physics, Milan, Italy

P0162

Oncological Outcomes Following Prostate Specific Membrane Antigen PET/CT-Guided Salvage Whole-Pelvis Radiotherapy for Recurrent Prostate Cancer

Authors

Jansen A.¹, Zuur L.G.¹, van der Graaf S.H.¹, de Bie K.C.C.², Schaake E.E.³, Pos F.J.³, Vis A.N.², van der Poel H.G.¹, Vogel W.⁴, van Leeuwen P.J.¹

Institutions

¹Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ²Amsterdam University Medical Center, Dept. of Urology, Amsterdam, The Netherlands, ³Netherlands Cancer Institute, Dept. of Radiation Oncology, Amsterdam, The Netherlands, ⁴Netherlands Cancer Institute, Dept. of Nuclear Medicine, Amsterdam, The Netherlands

Refining risk stratification in non-muscle-invasive bladder cancer

EGPT 12

**Friday 13 March
13:00 - 14:30**

Location

Orange Area, EGPT 5

Chairs

L.S. Mertens, Amsterdam (NL)

J. Rautiola, Solna (SE)

J.Y.C. Teoh, Hong Kong (HK)

13:00 - 13:25

Predisposition to bladder cancer and active surveillance for low-risk non-muscle invasive bladder cancer

P0199

Air pollutants, genetic susceptibility, and bladder cancer risk: a prospective study

Authors

Jianyong L.¹, Runhua T.², Haoran W.³, Shuhang L.², Jianye W.², Pengjie W.²

Institutions

¹Shenzhen Cancer Hospital, Dept. of Urology, Shenzhen, China, ²Beijing Hospital, Dept. of Urology, Beijing, China, ³Chinese PLA General Hospital, Dept. of Urology, Beijing, China

P0200

Life's Essential 8, genetic susceptibility, and risk of bladder cancer: A prospective cohort study

Authors

Liu W., Yu S., Wang Z., Zhang S.

Institutions

Peking University Third Hospital, Dept. of Urology, Beijing, China

P0201

Guideline Adherence for Hematuria Evaluation in the Real World: Evidence from 1.9 million Patients in Epic COSMOS

Authors

Silvani C.¹, Santangelo A.¹, Stephens A.², Considine J.¹, Haddad L.¹, Shafau F.¹, Sood A.³, Nazzani S.⁴, Salonia A.⁵, Briganti A.⁵, Montorsi F.⁵, Nicolai N.⁴, Montanari E.⁶, Rogers C.¹, Abdollah F.¹

Institutions

¹VUI Center for Outcomes Research Analysis and Evaluation Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Dept. of Urology, Columbus, United States of America, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy, ⁵IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ⁶Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy

P0202

Update from the bladder cancer Italian active surveillance (BIAS) project for low-grade bladder tumors: long-term oncological outcomes of patients under active surveillance

Authors

Finocchiaro A.¹, Sormani F.¹, Piccolini A.¹, Brin P.¹, Beatrici E.¹, Cella L.¹, Aljoulan M.¹, Casale P.², Saita A.², Buffi N.M.¹, Lughezzani G.¹, Lazzeri M.², Hurle R.¹

Institutions

¹Humanitas University, Dept. of Urology, Pieve Emanuele, Italy, ²Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

P0203

Active Surveillance in Recurrent Low-Grade Non-Muscle-Invasive Bladder Cancer: Experience from Our Center

Authors

Pujol Sanjuan C., Campistol Torres M., Lozano Palacio F., Carrión Puig A., Raventós Busquets C.X., Trilla Herrera E.

Institutions

Vall d'Hebron Barcelona Hospital Campus, Dept. of Urology, Barcelona, Spain

13:25 - 13:55

The risk of recurrence in non-muscle invasive bladder cancer

P0204

Clinical validation of the International Bladder Cancer Group's intermediate-risk non-muscle-invasive bladder cancer stratification model

Authors

Siva JS¹, Jonnalagadda R.¹, Aydogdu C.¹, Diaz G.M.¹, Heller N.¹, Campbell R.¹, Olivares R.¹, Autorino R.¹, Almassi N.¹, Weight C.J.¹, Kamat A.², Bukavina L.¹

Institutions

¹Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ²University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America

Recurrence-free survival after Checklist adoption in non-muscle invasive bladder cancer: insights from a single-center experience

Authors

Occhi A.¹, De Angelis M.¹, Scilipoti P.¹, Longoni M.¹, Zaurito P.¹, Viti A.¹, Cosenza A.¹, Disabato N.¹, Brancaccio M.¹, Galdieri A.¹, Santangelo A.¹, Tremolada G.¹, Necchi A.², Tenace N.³, Colecchia M.³, Burgio G.¹, Colombo R.¹, Rosiello G.¹, Gandaglia G.¹, Salonia A.¹, Briganti A.¹, Montorsi F.¹, Moschini M.¹

Institutions

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Oncology, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy

Homogeneity of EAU Intermediate Risk group : a multicenter external validation. Retrospective multicentric analysis on behalf of Young Academic Urologist : Urothelial Cancer Working Group

Authors

Livoti S.¹, Rosazza M.¹, Moschini M.², De Angelis M.², Del Giudice F.³, Pichler R.⁴, Hurle R.⁵, Mancon S.⁵, Carrion D.M.⁶, Krajewski W.⁷, Mertens L.S.⁸, D'Andrea D.⁹, Mari A.¹⁰, Di Maida F.¹⁰, Dutto D.¹, Colucci F.¹, Laukhtina E.⁹, Albisinni S.¹¹, Pradere B.¹², Teoh J.Y.C.¹³, Shariat S.F.⁹, Briganti A.², Soria F.¹, Gontero P.¹

Institutions

¹AOU Città della Salute e della Scienza di Torino - University of Turin School of Medicine, Dept. of Urology, Turin, Italy, ²IRCCS San Raffaele Scientific Institute, San Raffaele Hospital, Dept. of Urology, Milan, Italy, ³University Sapienza, Dept. of Urology, Rome, Italy, ⁴Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ⁵Humanitas Clinical and Research Hospital, Dept. of Urology, Rozzano, Italy, ⁶Torrejon University Hospital, Dept. of Urology, Madrid, Spain, ⁷Wroclaw Medical University, Dept. of Urology and Oncologic Urology, Wroclaw, Poland, ⁸Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁹Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹⁰Careggi Hospital, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Dept. of Urology, Florence, Italy, ¹¹Tor Vergata University Hospital, Tor Vergata University of Rome, Unit of Urology, Department of Surgical Sciences, Rome, Italy, ¹²UROSUD, La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ¹³S.H. Ho Urology Centre, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, China

RECURxNCE-BCa, an artificial intelligence-based tool to predict recurrence in non-muscle invasive bladder cancer using the WHO 2004/2022 grading system**Authors**

Kwong J.¹, Kim K.¹, Ringa M.², Feifer A.², Lajkosz K.³, Wettstein M.S.⁴, Lee T.⁵, Kassouf W.⁶, Black P.C.⁷, St-Laurent M.P.⁷, Breau R.H.⁸, Lodde M.⁹, Fairey A.¹⁰, Lattouf J.B.¹¹, Jeldres C.¹², Rendon R.¹³, Diamand R.¹⁴, Gontero P.¹⁵, Sylvester R.J.¹⁶, van Rhijn B.W.G.¹⁷, Kamat A.M.⁵, Johnson A.E.W.¹⁸, Zlotta A.R.¹⁹, Kulkarni G.S.⁴

Institutions

¹University of Toronto, Dept. of Surgery, Toronto, Canada, ²Trillium Health Partners, Dept. of Surgery, Mississauga, Canada, ³University Health Network, Dept. of Biostatistics, Toronto, Canada, ⁴University Health Network, Dept. of Surgery, Toronto, Canada, ⁵University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁶McGill University Health Centre, Dept. of Urology, Montréal, Canada, ⁷University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ⁸The Ottawa Hospital Research Institute, Dept. of Surgery, Ottawa, Canada, ⁹CHU de Québec-Université Laval, Dept. of Surgery, Quebec City, Canada, ¹⁰University of Alberta, Dept. of Surgery, Edmonton, Canada, ¹¹Centre Hospitalier de l'Université de Montréal, Dept. of Surgery, Montréal, Canada, ¹²Université de Sherbrooke, Dept. of Surgery, Sherbrooke, Canada, ¹³Dalhousie University, Dept. of Urology, Halifax, Canada, ¹⁴Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Dept. of Urology, Brussels, Belgium, ¹⁵Città della Salute e della Scienza, University of Torino School of Medicine, Dept. of Urology, Turin, Italy, ¹⁶European Organization for Research and Treatment of Cancer, Dept. of Biostatistics, Brussels, Belgium, ¹⁷Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Surgical Oncology (Urology), Amsterdam, The Netherlands, ¹⁸University of Toronto, Temerty Centre for AI Research and Education in Medicine, Toronto, Canada, ¹⁹Mount Sinai Hospital, Dept. of Surgery, Toronto, Canada

Multi-Institutional External Validation of the European Risk Classification for High-Grade Ta Non-Muscle-Invasive Bladder Cancer

Authors

Cournède M.¹, Gabriel P.E.², Lottin M.³, Moschini M.⁴, Soria F.⁵, D'Andrea D.⁶, Shariat S.F.⁷, Budowski A.⁸, Poyet C.⁹, Roumiguie M.¹⁰, Álvarez Maestro M.¹¹, Briganti A.¹², Krajewski W.¹³, Hendricksen K.¹⁴, Veerman H.¹⁵, Afferi L.¹⁶, Mattei A.¹⁶, Di Bona C.¹⁶, Zamboni S.¹⁷, Simeone C.¹⁷, Thenault R.¹⁸, Verhoest G.¹⁸, Gontero P.⁵, Xylinas E.²

Institutions

¹Amiens University Hospital, Dept. of Urology, Amiens, France, ²Bichat Claude-Bernard Hospital, Assistance Publique-Hôpitaux de Paris Nord, University Paris Cité, Dept. of Urology, Paris, France, ³Amiens University Hospital, Dept. of Oncology, Amiens, France, ⁴IRCCS San Raffaele Hospital, Urological Research Institute, Milan, Italy, ⁵Città della Salute e della Scienza, University of Torino School of Medicine, Dept. of Urology, Turin, Italy, ⁶Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁷Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Dept. of Urology, Prague, Czech Republic, ⁸University of Zurich, University Hospital Zurich, Dept. of Anesthesiology, Zurich, Switzerland, ⁹Stadtspital Triemli, Dept. of Urology, Zurich, Switzerland, ¹⁰Institut Universitaire du Cancer Toulouse, Dept. of Oncopole, Toulouse, France, ¹¹La Paz University Hospital, Dept. of Urology, Madrid, Spain, ¹²Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ¹³Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cancer Research UK, Cambridge, United Kingdom, ¹⁴Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ¹⁵The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ¹⁶Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ¹⁷ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Dept. of Urology, Brescia, Italy, ¹⁸Rennes University Hospital, Hôpital Pontchaillou, Dept. of Urology, Rennes, France

Predictors of Disease Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer Following En Bloc Resection of Bladder Tumour: Insights from The Global ERBT Registry.

Authors

Pastore A.L.¹, Wu K.², De Nunzio C.³, Soukup V.⁴, Lim B.T.Y.⁵, Barzaghi P.⁶, Garcia Rojo E.⁷, Wrocławski M.⁸, Danurdoro A.⁹, Micali S.¹⁰, Tully K.H.¹¹, Syed Mohammed G.¹², Lopes L.¹³, Zulfiquar A.¹⁴, Pirola G.M.¹⁵, Zawadzki M.¹⁶, Gontero P.¹⁷, Shariat S.¹⁸, Gauhar V.¹⁹, Nicoletti R.²⁰, Leung C.H.²¹, Wong C.H.M.²¹, Teoh J.Y.C.²¹

Institutions

¹Sapienza University of Rome, Dept. of Urology, Rome, Italy, ²First Affiliated Hospital of Xi'an Jiaotong University, Dept. of Urology, Xi'an, China, ³Ospedale Sant'Andrea, Sapienza University of Rome, Dept. of Urology, Rome, Italy, ⁴General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Dept. of Urology, Prague, Czech Republic, ⁵Sengkang General Hospital, Dept. of Urology, Singapore, Singapore, ⁶ASST Papa Giovanni XXIII, Bergamo - University of Milano-Bicocca, Dept. of Urology, Milan, Italy, ⁷HM Sanchinarro Hospital, Dept. of Urology, Madrid, Spain, ⁸BP - a Beneficência Portuguesa de São Paulo, Dept. of Urology, São Paulo, Brazil, ⁹West Nusa Tenggara Province Hospital, Dept. of Urology, Mataram, Indonesia, ¹⁰Università degli Studi di Modena e Reggio Emilia, Dept. of Urology, Emilia-Romagna, Italy, ¹¹Marien Hospital Herne, Ruhr University Bochum, Dept. of Urology and Neurourology, Herne, Germany, ¹²Asian Institute of Nephrology and Urology, Dept. of Urology, Hyderabad, India, ¹³Santa Casa de Belo Horizonte, Dept. of Urology, Belo Horizonte, Brazil, ¹⁴Rumah Sakit Umum Kaliwates, Dept. of Urology, Jember, Indonesia, ¹⁵San Giuseppe Hospital, IRCCS Multimedica, Dept. of Urology, Milan, Italy, ¹⁶EMC Piaseczno St. Anna Hospital, Dept. of Urology, Piaseczno, Poland, ¹⁷The University of Studies of Torino, Dept. of Urology, Turin, Italy, ¹⁸Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹⁹Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ²⁰Careggi University Hospital, Dept. of Urology, Florence, Italy, ²¹The Chinese University of Hong Kong, S.H. Ho Urology Centre, Hong Kong, Hong Kong

Study Group

The Global ERBT Registry Working Group(Hong Kong, Hong Kong)

EAU21 Risk stratification misclassifies prognosis in BCG-treated bladder carcinoma in situ: a multicenter analysis integrating cure fractions and conditional survival estimates

Authors

Garach Fernandez S.¹, Artiles A.¹, Subiela J.D.¹, Krajewski W.², Pichler R.³, De la Parra I.¹, Mínguez C.S.¹, González-Padilla D.A.⁴, Aumatell J.L.⁵, Scilipoti P.⁶, Longoni M.⁶, de Angelis M.⁶, Contieri R.⁷, Gallioli A.⁸, Del Giudice F.⁹, Soria F.¹⁰, Ślusarczyk A.¹¹, Grobet-Jeandin E.¹², Moschini M.⁶, Pradere B.¹³, Burgos F.J.¹

Institutions

¹Hospital Universitario Ramón y Cajal, Dept. of Urology, Madrid, Spain, ²Wrocław Medical University, Dept. of Minimally Invasive Robotic Urology, Wrocław, Poland, ³Comprehensive Cancer Center Innsbruck, Dept. of Urology, Innsbruck, Austria, ⁴Clínica Universidad de Navarra, Dept. of Urology, Madrid, Spain, ⁵Hospital Universitario Rey Juan Carlos, Dept. of Urology, Móstoles, Spain, ⁶Urological Research Institute, Dept. of Urology, Milan, Italy, ⁷Humanitas Clinical and Research Institute IRCCS, Dept. of Urology, Milan, Italy, ⁸Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁹Policlinico Umberto I Hospital, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ¹⁰San Giovanni Battista Hospital, Dept. of Surgical Sciences, Turin, Italy, ¹¹Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ¹²Geneva University Hospitals, Dept. of Urology, Geneva, Switzerland, ¹³La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France

Performance of the EAU Risk Classification in Predicting Progression in Primary vs. Recurrent Non-Muscle-Invasive Bladder Cancer: Do We Need New Tools

Authors

Longoni M.¹, Scilipoti P.¹, de Angelis M.¹, Zaurito P.¹, Tremolada G.¹, Santangelo A.¹, Simone G.², Mastroianni R.², Lonati C.³, Suardi N.³, Marcq G.⁴, Cano Velasco J.⁵, Lafuente Puenteadura A.⁵, Subiela J.D.⁶, Del Olmo Durán P.⁶, Ślusarczyk A.⁷, Karakiewicz P.I.⁸, Pradere B.⁹, Soria F.¹⁰, Gontero P.¹⁰, Montorsi F.¹, Salonia A.¹, Briganti A.¹, Moschini M.¹

Institutions

¹IRCCS Ospedale San Raffaele, Unit of Urology, Milan, Italy, ²IRCCS Regina Elena National Cancer Institute, Uro-oncology Program, Rome, Italy, ³ASST Spedali Civili di Brescia, University of Brescia, Urology Unit, Dept. of Medical and Surgical Specialties, Radiological Science and Public Health, Brescia, Italy, ⁴Claude Huriez Hospital, Dept. of Urology, Lille, France, ⁵Hospital General Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain, ⁶Ramón y Cajal University Hospital, IRYCIS, University of Alcalá, Dept. of Urology, Madrid, Spain, ⁷Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ⁸University of Montréal Health Centre, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montréal, Canada, ⁹La Croix du Sud Hospital, Dept. of Urology, UROSUD, Quint-Fonsegrives, France, ¹⁰San Giovanni Battista Hospital, University of Studies of Torino, Division of Urology, Dept. of Surgical Sciences, Turin, Italy

Refining the Classification of BCG Failure in Non-Muscle-Invasive Bladder Cancer: An Exploration of the IBCG Definitions within an International Multicenter Cohort

Authors

Ślusarczyk A.¹, Scilipoti P.², Krajewski W.³, Contieri R.⁴, Claps F.⁵, Subiela J.D.⁶, Mertens L.S.⁷, Mori K.⁸, Grobet-Jeandin E.⁹, Cano Velasco J.¹⁰, Tully K.¹¹, Soria F.¹², Del Olmo Duran P.⁶, Lijnen R.⁷, Lafuente Pueuntedura A.¹³, Del Giudice F.¹⁴, Radziszewski P.¹, Moschini M.², Pradere B.¹⁵

Institutions

¹Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ²IRCCS Ospedale San Raffaele, Dept. of Experimental Oncology/Unit of Urology, Milan, Italy, ³Wrocław Medical University, Dept. of Urology and Oncologic Urology, Wrocław, Poland, ⁴Humanitas Clinical and Research Institute IRCCS, Rozzano, Dept. of Urology, Milan, Italy, ⁵University of Trieste, Urological Clinic, Dept. of Medicine, Surgery and Health Sciences, Trieste, Italy, ⁶Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Dept. of Urology, Madrid, Spain, ⁷Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁸The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁹Geneva University Hospitals, Division of Urology, Geneva, Switzerland, ¹⁰Clínica Universidad de Navarra, Cancer Center, Dept. of Urology, Pamplona, Spain, ¹¹Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology and Neurourology, Herne, Germany, ¹²San Giovanni Battista Hospital, University of Studies of Torino, Division of Urology, Dept. of Surgical Sciences, Turin, Italy, ¹³Gregorio Marañón University Hospital, Dept. of Urology, Madrid, Spain, ¹⁴Sapienza University of Rome, Policlinico Umberto I Hospital, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ¹⁵UROSUD, La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France

Predicting Cancer-Specific Mortality in Non-Muscle-Invasive Bladder Cancer: Comparative Performance of AUA vs EAU Risk Classifications

Authors

Longoni M.¹, Scilipoti P.¹, de Angelis M.¹, Zaurito P.¹, Santangelo A.¹, Simone G.², Mastroianni R.², Lonati C.³, Suardi N.³, Marcq G.⁴, Cano Velasco J.⁵, Lafuente Pueuntedura A.⁵, Subiela J.D.⁶, Del Olmo Durán P.⁶, Ślusarczyk A.⁷, Karakiewicz P.I.⁸, Pradere B.⁹, Soria F.¹⁰, Gontero P.¹⁰, Montorsi F.¹, Salonia A.¹, Briganti A.¹, Moschini M.¹

Institutions

¹IRCCS Ospedale San Raffaele, Unit of Urology, Milan, Italy, ²IRCCS Regina Elena National Cancer Institute, Uro-oncology Program, Rome, Italy, ³ASST Spedali Civili di Brescia, Dept. of Medical and Surgical Specialties, Radiological Science and Public Health, Brescia, Italy, ⁴Claude Huriez Hospital, Dept. of Urology, Lille, France, ⁵Hospital General Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain, ⁶Ramón y Cajal University Hospital, IRYCIS, University of Alcalá, Dept. of Urology, Madrid, Spain, ⁷Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ⁸University of Montréal Health Centre, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montréal, Canada, ⁹La Croix du Sud Hospital, Dept. of Urology, UROSUD, Quint-Fonsegrives, France, ¹⁰San Giovanni Battista Hospital, University of Studies of Torino, Division of Urology, Dept. of Surgical Sciences, Turin, Italy

P0214

Translational Insights from CORE-008 Cohort A- Phase 2 Study of Intravesical Crebstimogene Grenadenorepvec in Patients with High-Risk BCG-Naïve Non-Muscle Invasive Bladder Cancer

Authors

Dinney C.¹, Pearce S.², Belkoff L.³, Mazarella B.⁴, Pieczonka C.⁵, Shore N.⁶, Henderson J.⁷, Steinberg G.⁸, Daneshmand S.⁹, Bivalacqua T.¹⁰

Institutions

¹University of Rochester Medical Center, Dept. of Urology, Rochester, United States of America, ²Spokane Urology, Dept. of Urology, Spokane, United States of America, ³MidLantic Urology, Dept. of Urology, Bala Cynwyd, United States of America, ⁴Urology Austin, Dept. of Urology, Austin, United States of America, ⁵Associated Medical Professionals of New York (an affiliate of US Urology Partners), Dept. of Urology, Syracuse, United States of America, ⁶START Carolinas/Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, ⁷Arkansas Urology, Dept. of Urology, Little Rock, United States of America, ⁸Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ⁹University of Southern California/Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ¹⁰University of Pennsylvania, Dept. of Urology, Philadelphia, United States of America

P0215

Optimizing Candidates for Repeated TURBT in Non-Muscle-Invasive Bladder Cancer Using Urinary Low-Depth Sequencing: A Prospective Multicenter Study

Authors

Yang X., Lyu Q., Cao Q., Cai L.

Institutions

The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

P0216

Nomogram for Predicting Tumor Persistence at Second-Look TURBT in Non-Muscle-Invasive Bladder Cancer

Authors

De Angelis M.¹, Brancaccio M.¹, Scilipoti P.¹, Longoni M.¹, Zaurito P.¹, Viti A.¹, Cosenza A.¹, Disabato N.¹, Occhi A.¹, Galdieri A.¹, Santangelo A.¹, Tremolada G.¹, Maiorano B.², Necchi A.², Mercinelli C.², Tenace N.³, Colecchia M.³, Burgio G.¹, Rosiello G.¹, Salonia A.¹, Briganti A.¹, Montorsi F.¹, Moschini M.¹

Institutions

¹IRCCS San Raffaele Scientific Institute - 'Vita-Salute' San Raffaele University, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Oncology, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy

Laparoscopy for beginners: From theory to practice

ESU Course 14

Friday 13 March
13:30 - 15:30

Location Red Area, Room 3

Chair D. Veneziano, New York (US)

Voting will be available via the EAU26 App or via www.qna.at/eau

Learning objectives

Over the past decades laparoscopy has played a major role in the therapeutic options of most urological conditions. Nevertheless, the steep learning curve associated with laparoscopic surgery makes it a challenging technique to master.

The aim of this ESU course is to provide you not only the basics of laparoscopic surgery, but also the tips and tricks to develop your laparoscopic skills.

- Peritoneal access and pneumoperitoneum
- How to choose and use the best laparoscopic instruments
- Indications and contraindications of the laparoscopic approach
- How to prevent and manage complications

Video and lively discussions will aid beginners shortening their learning curve and optimizing the success of their laparoscopic procedures.

Laparoscopy: Historical perspective

D. Veneziano, New York (US)

Basic principles of laparoscopic surgery and pneumoperitoneum

T.M. Ribeiro De Oliveira, Lisbon (PT)

Laparoscopic equipment and trocar placement

D. Veneziano, New York (US)

Indications for laparoscopic surgery in urology

T.M. Ribeiro De Oliveira, Lisbon (PT)

Managing complications in laparoscopic surgery

D. Veneziano, New York (US)

Friday 13 March
13:30 - 15:30

Location Red Area, Room 12

Chair K. Pang, Surrey (GB)

Learning objectives

This is a state of the art course focused on the management of andrological emergencies. The faculty consists of experienced international experts from high volume centres which manage andrological emergencies. The primary learning objectives include understanding the diagnostic approaches and both medical and surgical management of common andrological emergencies, with a particular emphasis on step-by-step surgical techniques.

The delegate will gain an understanding of:

- The presentation, assessment and investigation of common andrological emergencies (priapism, testis and penile injury, Fournier's gangrene and prosthetic infections)
- The medical and step-by-step operative techniques

Introduction

K. Pang, Surrey (GB)

Priapism

K. Pang, Surrey (GB)

Testicular torsion and trauma

K. Pang, Surrey (GB)

Iatrogenic penile injuries including fracture, avulsion and amputation

G. Fallara, Milan (IT)

Fournier's gangrene

K. Pang, Surrey (GB)

Prosthetic infections

G. Fallara, Milan (IT)

Closing remarks, feedback and discussion

G. Fallara, Milan (IT)

K. Pang, Surrey (GB)

Kidney stones made simple: A comprehensive update for all urologists

ESU Course 12

Friday 13 March
13:30 - 15:30

Location Red Area, Room 11

Chair T.E. Şener, Istanbul (TR)

Learning objectives

The aims and objectives of this course is to provide a complete overview of kidney stone treatment to urologists. At the end the participants will be able to learn all the current concepts of kidney stone management. It is targeted to all urologists who commonly deal with kidney stones in their practice. It is a more practice based real life clinical management with more emphasis on common clinical scenarios.

Welcome and introduction

T.E. Şener, Istanbul (TR)

Diagnosis and imaging

T.E. Şener, Istanbul (TR)

Medical management made simple

T.E. Şener, Istanbul (TR)

Best clinical practice and preventing complications: SWL

B. Ballesta Martinez, Alicante (ES)

Best clinical practice ureteroscopy (including scopes, suction, pressure)

M.A. Corrales Acosta, Clermont Ferrand (FR)

Lasers (types, pulse modulation, temperature)

M.A. Corrales Acosta, Clermont Ferrand (FR)

Best clinical practice puncture/disintegration/exiting and preventing complications: PCNL

B. Ballesta Martinez, Alicante (ES)

Case discussion Case discussion and management of index cases

B. Ballesta Martinez, Alicante (ES)

M.A. Corrales Acosta, Clermont Ferrand (FR)

T.E. Şener, Istanbul (TR)

2026 EAU Guidelines update – Trauma, paediatric urology and urethral strictures: What has changed

ESU Course 15

Friday 13 March
13:30 - 16:30

Location Red Area, Room 13

Chair M. Waterloos, Ghent (BE)

Learning objectives

This course highlights some updates in the guidelines on urological trauma, pediatric urology, and urethral strictures.

- Understand how the management of urological trauma is evolving toward increasingly minimally invasive approaches.
- Recognize when, and more importantly when not, to use drug-coated balloon dilatation for urethral strictures.
- Learn practical strategies for managing enuresis, a frequently encountered issue in everyday clinical practice.
- Enhance your knowledge of duplication pathologies in children.

Welcome and introduction

M. Waterloos, Ghent (BE)

Managing urological trauma: Focus on urinary drainage and antibiotic prophylaxis

C. Ochoa Vargas, Bristol (GB)

Urological trauma: Can we get even more minimally invasive?

C. Ochoa Vargas, Bristol (GB)

Enuresis: Current guidelines and updates

A. Van Uitert, Nijmegen (NL)

Duplication pathologies with special focus on ureterocele and ectopic ureter

A. Van Uitert, Nijmegen (NL)

Drug-coated balloon dilatation: Current guidelines and expanding indications

M. Waterloos, Ghent (BE)

Standard of care in male urethroplasty

M. Waterloos, Ghent (BE)

Hands-on Training in Urological Ultrasound

HOT Ultrasound - 1.1

Friday 13 March
13:30 - 16:30

Location Red Area, Room 4

Chairs P. Martino, Bari (IT)
V. Scattoni, Milan (IT)

Learning objectives

The Hands-on Training in Urological ultrasound is designed to provide healthcare professionals with a thorough understanding of urology diagnostics. The course blends expert presentations and practical hands-on sessions, offering participants a solid foundation in urological ultrasound examinations.

By the end of this course, participants will be equipped with the necessary baseline training to implement abdominal ultrasound as well as transrectal ultrasound of the prostate as a routine diagnostic tool in daily practice. The training covers urological ultrasound examinations following standardised procedures, accurately identify normal and pathological findings, and confidently conduct assessments of the urinary tract and genital organs, as well as valuable insights and skills that can be immediately applied to enhance patient care and diagnostic accuracy.

13:30 - 13:35

Introduction

To be confirmed

13:35 - 13:40

Standard operating procedure for ultrasound examination urinary tract: Kidney and bladder

C.B. Maccagnano, Milan (IT)

13:40 - 13:45

Ultrasound of the kidney and bladder: tip and tricks

To be confirmed

13:45 - 13:50

Standard operating procedure for ultrasound examination genital organs: Prostate and testis

To be confirmed

13:50 - 13:55

Ultrasound of prostate and testis: Tips and tricks

To be confirmed

13:55 - 16:25

Hands-on Training: Kidney and bladder / Prostate & testis Tutors:

Tutors

To be confirmed

To be confirmed

C.B. Maccagnano, Milan (IT)

P. Martino, Bari (IT)

V. Scattoni, Milan (IT)

To be confirmed

16:25 - 16:30

Conclusions

V. Scattoni, Milan (IT)

Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 1.2

Friday 13 March
13:45 - 14:35

Location Red Area, Room 1

Tutors M. Elmussareh, Dubai (AE)
V. Novak, Praha (CZ)

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 1.2

Friday 13 March
13:45 - 14:35

Location Red Area, Room 1

Tutors A.C. Bouma - Houwert, Amsterdam (NL)
M. Talso, Milan (IT)
To be confirmed

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 1.2

Friday 13 March
13:45 - 14:35

Location	Red Area, Room 1
Tutors	To be confirmed To be confirmed

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 1.2

Friday 13 March
13:45 - 14:35

Location	Red Area, Room 1
Tutor	To be confirmed

Learning objectives

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 1.2

Friday 13 March
13:45 - 14:35

Location Red Area, Room 1

Tutors M. Goossens, Aalst (BE)
M.C. Klitsch, Vienna (AT)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 1.2

Friday 13 March
13:45 - 14:35

Location Red Area, Room 1

Tutors I. Kartalas Goumas, Vigevano (IT)
To be confirmed
To be confirmed

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 1.2

Friday 13 March
13:45 - 14:35

Location Red Area, Room 1

Tutors To be confirmed
M. Paciotti, Rozzano, Milan (IT)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Sleep deprivation in urology patients

Patient Advocacy Roundtable



Friday 13 March
14:15 - 15:15

Location Red Area, Room 14

Chair A. De santis, ROMA (IT)

Learning objectives

Raise awareness of how urological conditions contribute to sleep deprivation.

Explore the physical and psychological consequences of poor sleep in patients.

Share patient experiences and perspectives on sleep disruption.

Discuss practical strategies and recommendations to improve sleep quality in urology patients.

14:15 - 14:20

Welcome & introduction
A. De santis, ROMA (IT)

14:20 - 14:30

Sleep science insights: Understanding sleep deprivation and behavioural sleep medicine in urology patients
H. Selsick, London (GB)

14:30 - 14:40

Clinical perspectives: Managing nocturia, incontinence, and sleep disruption in practice
T. Kelly, Galway (IE)

14:40 - 14:50

Patient experience: Living with nocturia and incontinence and their impact on sleep
L. Brett, London (GB)

14:50 - 15:00

Patient experience: Living with overactive bladder and impact on sleep

W. Gough, (GB)

15:00 - 15:15

Q&A and closing

A. De santis, ROMA (IT)

APCCC meets EAU

Thematic Session

Friday 13 March

14:45 - 16:15

Location

Orange Area, Room 3

Chairs

S. Gillessen Sommer, Bellinzona (CH)

B. Tombal, Brussels (BE)

Learning objectives

Learn about the new options/data in high risk non metastatic disease. Learn about the new data in the metastatic hormone sensitive disease setting. Understand the factors to take into account for choosing the optimal treatment for an individual patient.

14:45 - 14:50

Introduction

14:50 - 14:55

Case presentation & voting Patient with high-risk nmHSPC

To be confirmed

14:55 - 15:05

Presentation of APCCC 2024/2025 results on high-risk nmHSPC & Voting

A. Omlin, Zürich (CH)

15:05 - 15:13

Update on high-risk nmHSPC

I. Heidegger, Innsbruck (AT)

15:13 - 15:21

Macroscopic local relapse after RP in the context of high-risk nmHSPC

To be confirmed

15:21 - 15:31

Panel discussion & voting What is the best treatment for patients with high-risk biochemical relapse

Panel

I. Heidegger, Innsbruck (AT)

To be confirmed

A. Omlin, Zürich (CH)

To be confirmed

15:31 - 15:36

Case presentation & voting Patient with synchronous high-volume mHSPC

M.C. Roesch, Lübeck (DE)

15:36 - 15:46

Presentation of APCCC 2024/2025 results on synchronous high-volume mHSPC & Voting

F. Turco, Bellinzona (CH)

15:46 - 15:54

News in the mHSPC setting, PARP inhibitors and more

K. Fizazi, Villejuif (FR)

15:54 - 16:02

What do you need for decision making in mHSPC in 2026?

B. Tombal, Brussels (BE)

16:02 - 16:12

Panel discussion & voting Which triplet therapy to give to whom in 2026?

Panel

K. Fizazi, Villejuif (FR)

M.C. Roesch, Lübeck (DE)

B. Tombal, Brussels (BE)

F. Turco, Bellinzona (CH)

16:12 - 16:15

Closing remarks

S. Gillessen Sommer, Bellinzona (CH)

Infections 2: Predictors of urological infections and outcomes

Abstract Session 04

Friday 13 March
14:45 - 16:15

Location

Red Area, Room 17

Chairs

M. Chen, Taipei (TW)

To be confirmed

To be confirmed

14:45 - 15:00

Genital Infections

A0055

Evaluating the Role of the 9-Valent HPV Vaccine in Preventing Recurrence of Genital Warts

Authors

Eigner E.¹, Faza N.¹, Nsair A.¹, Atallah M.¹, Malshy K.², Amiel G.¹, Mullerad M.¹

Institutions

¹Rambam Health Care Campus, Dept. of Urology, Haifa, Israel, ²University of Rochester Medical Center, Dept. of Urology, Rochester, United States of America

A0057

Transurethral vs. Suprapubic Catheterization in Acute Bacterial Prostatitis: Clinical Predictors and Outcomes

Authors

Handke A.E., Gassen C.G., Rausch P., Ferber L., Orf C., Bahlburg H., Bach P., Noldus J., Roghmann F., Tully K.

Institutions

Marienhospital Herne, Dept. of Urology, Herne, Germany

15:00 - 15:10

Controversies in treatment of infections

A0058

Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Nitrofurantoin) for the Treatment of Localised Urinary Tract Infections in Women: A Retrospective, Real-World, Parallel-Group, Multicentre Study

Authors

Kadihasanoglu M.¹, Cinislioglu E.², Cinislioglu N.³, Odabas O.⁴, Uzun E.⁴, Canat H.L.⁵, Sevik C.⁵, Otunctemur A.⁶, Danis E.⁶, Altay B.⁷, Ogut N.⁷, Kadioglu A.⁸

Institutions

¹Istanbul University Cerrahpasa Cerrahpasa Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ²Erzurum City Hospital, Dept. of Urology, Erzurum, Turkey, ³Erzurum City Hospital, Dept. of Infectious Diseases and Clinical Microbiology, Erzurum, Turkey, ⁴Ankara Bilkent City Hospital, Dept. of Urology, Ankara, Turkey, ⁵Basaksehir Cam and Sakura City Hospital, Dept. of Urology, İstanbul, Turkey, ⁶Istanbul Prof. Dr. Cemil Tascioglu City Hospital, Dept. of Urology, İstanbul, Turkey, ⁷Ege University Faculty of Medicine, Dept. of Urology, İzmir, Turkey, ⁸Istanbul University, Istanbul Medical School, Dept. of Urology, İstanbul, Turkey

A0059

To Treat or Not to Treat? A Systematic Review and Updated Meta-Analysis on the Management of Asymptomatic Bacteriuria

Authors

Almeida A.S.¹, Porto B.C.¹, Terada B.D.¹, Gonçalves F.G.A.¹, Hobaica N.C.², Gonçalves E.³, Passerotti C.C.¹, Sardenberg R.A.S.⁴, Maia R.S.⁵, Shiomi da Cruz J.A.⁴

Institutions

¹Universidade de Sao Paulo, Faculty of Medicine, São Paulo, Brazil, ²Pontifical Catholic University, Dept. of Medicine, Sorocaba, Brazil, ³Universidade Estadual de Campinas, Dept. of Medicine, Campinas, Brazil, ⁴Federal University of Sao Paulo, Dept. of Urology, São Paulo, Brazil, ⁵Federal University of Sao Paulo, Dept. of Urology, São Paulo, Brazil

15:10 - 15:20

Recurrent UTI's

A0060

Recurrent UTI Care in the Real World: Low Guideline Adherence, High Investigation Burden, and Suboptimal Outcomes

Authors

Toska U., Patel A., Patel N., Arameshfard S., Darku S., Pedersen A., Maj I., Khan F., Pushkaran A., Bodean V.

Institutions

Luton and Dunstable University Hospital, Dept. of Urology, Luton, United Kingdom

A0061

A randomized placebo-controlled trial of combined medical treatment A randomized placebo-controlled trial of combined medical treatment for recurrent UTI prevention

Authors

Moskvina Z.V.¹, Morozov A.O.¹, Boldyreva M.N.², Rossolovskaya K.A.¹, Vinarov A.Z.¹, Spivak L.¹

Institutions

¹Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia, ²Federal Medical and Biological Agency of Russia, State Research Center Institute of Immunology, Moscow, Russia

15:20 - 15:30

Interstitial Cystitis

A0062

Urinary Inflammatory and Oxidative Stress Biomarkers Changes After Intravesical Platelet-Rich Plasma or Botulinum Toxin A Injection in Interstitial Cystitis

Authors

Jiang Y-H., Kuo H.C.

Institutions

Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Urology, Hualien, Taiwan

A0063

Comparison of Therapeutic Efficacy among Different Bladder Monotherapy and Multimodal Therapy for Patients with Interstitial Cystitis/ Bladder Pain Syndrome

Authors

Yu W.R.¹, Jhang J.F.², Lee Y.S.³, Yang C.C.³, Huang T.H.³, Liu M.C.³, Chang T.L.³, Jiang Y.H.³, Kuo H.C.³

Institutions

¹Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Nursing, Hualien, Taiwan, ²Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Urology, Hualien, Taiwan, ³Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Urology, Hualien, Taiwan

15:30 - 16:00

Procedure-related infections

A0064

Outcomes of single-dose/day vs extended prophylactic antibiotics for endourological surgeries: a randomized controlled study

Authors

Nayyar R.¹, Shetty R.S.¹, Mahapatra S.², Seth A.¹

Institutions

¹All India Institute of Medical Sciences, Dept. of Urology, Delhi, India, ²All India Institute of Medical Sciences, Dept. of Microbiology, Delhi, India

A0065

Out- patient cystoscopy and risk of urinary tract infection. A nationwide 5-year cohort study.

Authors

Lund L.¹, Froekiar C.¹, Szépligeti S.², Noergaard M.²

Institutions

¹Odense University Hospital, Dept. of Urology, Odense, Denmark, ²Aarhus University Hospital, Dept. of Clinical Epidemiology, Aarhus, Denmark

A0066

REPLACE or RETAIN? A global look at catheter management in CAUTI

Authors

Schippers E.C.¹, van Uhm J.I.M.², Brehm T.J.³, Lafaurie M.⁴, Tandogdu Z.⁵, Trautner B.W.⁶, Huttner A.⁷, Geerlings S.E.⁸, Lambregts M.M.C.⁹

Institutions

¹Leiden University Medical Center, Dept. of Urology and Infectious Diseases, Leiden, The Netherlands, ²Leiden University Medical Center, Dept. of Urology, Leiden, The Netherlands, ³Baylor College of Medicine, Dept. of Infectious Diseases, Houston, United States of America, ⁴Assistance Publique-Hôpitaux de Paris (AP-HP), Dept. of Infectious Diseases, Paris, France, ⁵University College London Hospitals, Dept. of Urology, London, United Kingdom, ⁶Washington University, Dept. of Infectious Diseases, St. Louis, United States of America, ⁷Geneva University Hospitals and Faculty of Medicine, Dept. of Infectious Diseases, Geneva, Switzerland, ⁸Amsterdam University Medical Center, Dept. of Infectious Diseases, Amsterdam, The Netherlands, ⁹Leiden University Medical Center, Dept. of Infectious Diseases, Leiden, The Netherlands

A0067

Risk factors and adverse outcomes following ureteroscopy for urolithiasis: A nationwide analysis of 90,807 procedures in the English NHS

Authors

Somani B.¹, Boulmani M.², Dell'Isola A.³

Institutions

¹University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ²Boston Scientific, Dept. of Urology and Pelvic Health, Paris, France, ³Boston Scientific, HEMA Specialist, Madrid, Spain

A0068

Post-operative complications and morbidity following Ureteroscopy – 12 years of cases from a university teaching hospital

Authors

Fernandes S.¹, Grossmann N.¹, Frasccheri M.F.¹, Boulmani M.², Chaussee E.², Tabesh N.², Pietropaolo A.¹, Somani B.¹

Institutions

¹University hospital Southampton, Dept. of Urology, Southampton, United Kingdom, ²Boston Scientific, Boston Scientific, Hempstead, United Kingdom

A0069

Saving money while preventing infections: Economic analysis of nurse-led preoperative asymptomatic bacteriuria screening in endourology

Authors

Affentranger A., De Maio A., Arnold D., Nussbaumer D., Baumeister P., Mattei A., Fankhauser C.D., Grossmann C.N.

Institutions

University Teaching and Research Hospital of the University of Lucerne, Dept. of Urology, Lucerne, Switzerland

16:00 - 16:15

TRUS biopsy

A0070

Ciprofloxacin versus Fosfomycin for Prophylaxis Before Transrectal Prostate Biopsy: A Prospective Comparative Study of Clinical and Microbiological Outcomes

Authors

Buržinskis E.¹, Janulaityte I.¹, Skaudickas D.², Jievaltas M.², Vitkauskiene A.¹

Institutions

¹Lithuanian University of Health Sciences, Laboratory Medicine, Kaunas, Lithuania,

²Lithuanian University of Health Sciences, Dept. of Urology, Kaunas, Lithuania

A0071

Perioperative antibiotic prophylaxis and infection rates after transperineal prostate biopsy

Authors

Sandberg M.¹, Smith R.², Bissette R.¹, Sandberg M.³, Rodriguez A.¹, Tsivian M.²

Institutions

¹Wake Forest Baptist Medical Center, Dept. of Urology, Winston Salem, United States of America,

²Medical University of South Carolina, Dept. of Urology, Charleston, United States of America,

³University of Michigan-Ann Arbor, Dept. of Biology, Ann Arbor, United States of America

A0072

Rectal Swab-Based Targeted Prophylactic Antibiotics Reduces Infectious Complications after Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Authors

Tsuboi I., Sadahira T., Kawada T., Katayama S., Iwata T., Beck K., Araki M.

Institutions

Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Dept. of Urology, Okayama, Japan

Renal cell carcinoma: From detection to prediction through novel imaging and biomarkers

Abstract Session 03

Friday 13 March
14:45 - 16:15

Location Blue Area, Victoria 4
Chairs T. Kuusk, London (GB)
E. Roussel, Leuven (BE)
T.T-C. Wei, Taipei City (TW)

14:45 - 15:00

Screening

A0037

Trends and Regional Burden of Kidney Cancer in Europe, 1990–2040: An Analysis Based on the Global Burden of Disease Study 2023

Authors

Jingyu X., Sun J., Huang Y.

Institutions

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Dept. and Institute of Urology, Wuhan, China

A0039

Cardiovascular Health Scores Predict Incidence and Mortality of Renal cell carcinoma: A Large Cohort Prospective Study

Authors

Luo S.¹, Tang R.², Liu M.¹

Institutions

¹Chinese Academy of Medical Sciences and Peking Union Medical College, Dept. of Urology, Beijing, China, ²Beijing Hospital, Dept. of Urology, Beijing, China

15:00 - 15:25

Risk stratification

A0040

A Step Forward in RCC Staging: External Validation of the EAU-Proposed M staging

Authors

Bertini A.¹, Re C.¹, Salerno L.¹, Musso G.¹, Cei F.¹, Piacentini M.², Guanadalin G.², Rosiello G.¹, Piccolo C.¹, Disabato N.¹, Campugiani A.¹, Montesano M.¹, Ficarra G.¹, Cigliola A.², Mercinelli C.², Tateo V.², Maiorano B.², Necchi A.², Briganti A.¹, Bertini R.¹, Salonia A.¹, Montorsi F.¹, Larcher A.¹, Capitanio U.¹

Institutions

¹IRCCS San Raffaele Scientific Institute. URI - Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Dept. of Medical Oncology, Milan, Italy

A0041

KURADS (Kidney URologic Assessment Data Score): Leveling Up Prediction of High-Risk RCC in Solid Renal Masses

Authors

Musso G.¹, Puri D.¹, Saitta C.², Yuen K.L.², Nguyen M.², Meagher M.F.², Dabbas M.², Karamcheti S.², Garofano G.², Baker B.², Liss M.², Capitanio U.¹, Larcher A.¹, Montorsi F.¹, Derweesh I.H.³

Institutions

¹University of California San Diego School of Medicine, Dept. of Urology, La Jolla, United States of America, ²University of California San Diego School of Medicine, Dept. of Urology, La Jolla, United States of America, ³RUSH-MD Anderson Cancer Center, Dept. of Urology, Chicago, United States of America

A0042

Comparative analysis of EAU-refined staging criteria, 8th Edition AJCC and a novel 5 tier classification of Localized (pT1/pT2) Renal Cell Carcinoma. An International Multicenter Analysis

Authors

Saitta C.¹, Garofano G.¹, Musso G.², Meagher M.², Liss M.², Karamcheti S.³, Vourganti S.³, Casale P.¹, Lughezzani G.¹, Cherullo E.³, Montorsi F.⁴, Capitanio U.⁴, Buffi N.M.¹, Derweesh I.³

Institutions

¹IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy, ²UC San Diego Health System, Dept. of Urology, San Diego, United States of America, ³Rush University, Dept. of Urology, Chicago, United States of America, ⁴Division of Experimental Oncology, Dept. of Urology, Milan, Italy

A0043

Radiomics signatures of intratumoral and perirenal adipose regions predict immune microenvironment heterogeneity and prognosis in renal cell carcinoma

Authors

Xiao-Hui W., Ning X.

Institutions

The First Affiliated Hospital of Fujian Medical University, Dept. of Urology, Fuzhou, China

A0044

Comprehensive Pathological Analysis of 1,369 Renal Cell Carcinoma Patients Reveals Novel Biomarkers and Establishes a Predictive Model for Clinical Outcomes

Authors

Wang C., Gong K., Qiu J

Institutions

Peking University First Hospital, Dept. of Urology, Peking, China

15:25 - 15:55

Imaging

A0045

Comprehensive evaluation of 68Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear cell renal cell carcinoma patients

Authors

Gao J., Wang X., Cheng L., Guo H.

Institutions

Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China

A0046

[89Zr]Zr-girentuximab PET/CT in the non-invasive characterization of indeterminate renal lesions: Initial real-world clinical experience

Authors

Hübner-Resch I.¹, Patronas E-M.², Shariat S.F.¹, Hacker M.², Schmidinger M.¹, Rasul S.²

Institutions

¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²Medical University of Vienna, Biomedical Imaging and Image-guided Therapy, Vienna, Austria

A0047

First-in-human phase I evaluation of [⁶⁸Ga]Ga-OncoCAIX PET/CT in clear cell renal cell carcinoma: Preliminary diagnostic performance, safety and biodistribution

Authors

Gelardi F.¹, Sollini M.², Pini C.², Antunovic L.¹, Busnardo E.¹, Larcher A.³, Capitanio U.³, Bertini R.³, Briganti A.², Salonia A.², Montorsi F.², Maielli A.¹, Petrelli R.¹, Bonfitto G.R.¹, Tudda A.⁴, Minotti M.G.¹, Mock J.⁵, Cazzamalli S.⁵, Oehler S.⁵, Muller M.⁵, Neri D.⁵, Alessi A.⁶, Erba P.A.⁷, Chiti A.²

Institutions

¹IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, ²Università Vita-Salute San Raffaele, Faculty of Medicine, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ⁴IRCCS Ospedale San Raffaele, Dept. of Medical Physics, Milan, Italy, ⁵Philochem AG, Otelfingen, Switzerland, ⁶Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Dept. of Nuclear Medicine, Milan, Italy, ⁷ASST Papa Giovanni XXIII Hospital, Nuclear Medicine Unit, Bergamo, Italy

A0048

Impact of 89Zr-girentuximab PET versus conventional imaging on clinical decision-making in patients with indeterminate renal masses (ZIRCON-X)

Authors

Shuch B.¹, Goffin K.², Wagner T.³, Ceci F.⁴, Raman S.S.¹, Calais J.¹, Donin N.¹, Joniau S.², Albersen M.², Bex A.⁵, Walkden M.⁵, Mumtaz F.⁵, Orsi F.⁴, Musi G.⁴, Ferris M.⁶, Liu D.⁶

Institutions

¹University of California Los Angeles, Dept. of Urologic Oncology, Los Angeles, United States of America, ²University Hospital of Leuven, Dept. of Nuclear Medicine, Leuven, Belgium, ³Royal Free London, Dept. of Nuclear Medicine, London, United Kingdom, ⁴European Institute of Oncology, Dept. of Oncology, Milan, Italy, ⁵Centre for Medical Imaging, Dept. of Urology, UCL, United Kingdom, ⁶Telix Pharmaceuticals, Dept. of Medical Affairs, North Melbourne, Australia

A0049

Malignancy risk of complex renal cystic masses: Subclassification and histopathologic correlation of Bosniak III cysts

Authors

Alcin A.¹, Cakici M.C.¹, Kazan H.O.¹, Karatas B.C.², Gunduz N.², Inkaya A.³, Kucuk E.V.³, Yildirim A.¹

Institutions

¹Istanbul Medeniyet University Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ²Istanbul Medeniyet University Faculty of Medicine, Dept. of Radiology, Istanbul, Turkey, ³Umraniye Training and Research Hospital, Dept. of Urology, Istanbul, Turkey

A0050

Bosniak IIF Renal Cysts: Natural History and Impact of Lesion Size on Progression

Authors

Fernandez-Mardomingo Diaz A.¹, Artiles Medina A.¹, Lopez Curtis D.¹, Minguez Ojeda C.¹, Subiela Henriquez J.D.¹, Sanz Mayayo E.¹, De la Parra Sánchez I.¹, Del Olmo Duran P.¹, Martin Serrano G.¹, Gonzalez Tello F.², Gomez Dos Santos V.¹, Burgos Revilla F.J.¹

Institutions

¹Hospital Universitario Ramón y Cajal, Dept. of Urology, Madrid, Spain, ²Hospital Universitario Ramón y Cajal, Dept. of Radiology, Madrid, Spain

15:55 - 16:15

Hereditary syndromes

A0051

Common VHL mutations and the genotype-phenotype correlation: a retrospective study of 1172 patients with von Hippel-Lindau syndrome in China

Authors

Wang C., Gong K.

Institutions

Peking University First Hospital, Dept. of Urology, Peking, China

A0052

Analysis of High-Frequency Mutations and Protein Stability of the VHL Gene in Patients with von Hippel-Lindau Syndrome

Authors

Wang C., Gong K., Liu T.

Institutions

Peking University First Hospital, Dept. of Urology, Peking, China

A0053

Evaluation of Renal Imaging in patients with Birt-Hogg-Dubé Syndrome

Authors

Angel A.¹, Ousager L.B.², Schuster A.³, Olesen T.H.⁴, Davidsen J.R.M.⁵, Lund L.¹

Institutions

¹Odense University Hospital, Dept. of Urology, Odense, Denmark, ²Odense University Hospital, Dept. of Clinical Genetics, Odense, Denmark, ³Odense University Hospital, Dept. of Dermatology and Allergy Centre, Odense, Denmark, ⁴Odense University Hospital, Dept. of Radiology, Odense, Denmark, ⁵Odense University Hospital, South Danish Center for Interstitial Lung Diseases (SCILS), Dept. of Respiratory Medicine, Odense, Denmark

A0054

Integrated Genomic and Metabolomic Profiling of 60 Patients with Von Hippel-Lindau Syndrome Reveals Key Metabolic Alterations and Predictive Biomarkers of Disease Progression

Authors

Wang C., Gong K., Song Z.

Institutions

Peking University First Hospital, Dept. of Urology, Peking, China

Robotic urinary diversion: Neobladder, ileal conduit and precision techniques in female cystectomy

Video Session 03

Friday 13 March
14:45 - 16:15

Location Blue Area, George 3
Chairs To be confirmed
To be confirmed
To be confirmed

V015 (□: 7 min.)

Robotic Partial Cystectomy for Urachal Carcinoma: surgical steps and case series
M. Ferriero, Rome (IT)

V016 (□: 5 min.)

Radical nerve-sparing cystectomy in women: surgical technique preservation of sexual and urinary function
To be confirmed

V017 (□: 7 min.)

Female Genital-Sparing Robotic Radical Cystectomy with Robotic Intracorporeal Karolinska Orthotopic Neobladder Reconstruction: Technique and Early Outcomes
U. Vaswani, Mumbai (IN)

V018 (□: 4 min.)

First Experience with the Hugo™ RAS Robotic LigaSure™ Device During Female Radical Cystectomy: Technical Feasibility and Early Outcomes
D. Fettucciari, Rome (IT)

V019 (□: 7 min.)

Simplifying stoma creation in intracorporeal ileal conduit diversion
K. Fukuta, tokushima (JP)

V020 (□: 6 min.)

Robotic Ileal Conduit Reconstruction: a 10-Step Guide
S. Maggiorelli, Modena (IT)

V021 (□: 8 min.)

Robotic Intracorporeal Urinary Diversion: Technical Insights and Head-to-Head Comparison between Ileal Conduit and Orthotopic Neobladder
R. Mastroianni, Rome (IT)

V022 (□: 7 min.)

Stentless Totally Intracorporeal "Delta" Neobladder: Perioperative Outcomes and 12-months Urodynamic Evaluation
F. Tedesco, Rome (IT)

Redefining urology: Prostate cancer challenges and endourology innovations

Urology Beyond Europe: Joint Session of the European Association of Urology (EAU) and the Confederación Americana de Urología (CAU)

Friday 13 March
14:45 - 16:45

Location Orange Area, eURO Auditorium 2

Chairs M.J. Ribal Caparros, Barcelona (ES)
H. Zampolli, São Paulo (BR)

Learning objectives

This joint EAU–CAU session will provide delegates with up-to-date insights into two challenging fields of urology: prostate cancer and endourology. Participants will explore how biomarkers are shaping precision diagnosis and treatment in localised prostate cancer, review surgical strategies for complex anastomotic strictures, and examine salvage options after radiotherapy failure. The session will also address controversial issues in endourology, including en bloc resection, bilateral RIRS, and complex ureteral stricture management, highlighting innovative solutions and global perspectives.

14:45 - 14:47

Welcome and introduction

H. Zampolli, São Paulo (BR)

14:47 - 15:41

Prostate cancer challenges: Precision tools and surgical solutions

14:47 - 14:57

Unlocking the future: Biomarkers in localised prostate cancer

C. Moore, London (GB)

Surgical challenges: How to tackle anastomotic strictures

14:57 - 15:05

Robotic Solution

R. Cadillo-Chavez, Bayamon (PR)

15:05 - 15:13

Open approach

D.E. Andrich, London (GB)

15:13 - 15:19

Panel discussion

When radiotherapy fails: Salvage options that work

15:19 - 15:24

HIFU

M. Emberton, London (GB)

15:24 - 15:29

Cryotherapy

E. Barret, Paris (FR)

15:29 - 15:34

Robotic surgery

R. Coelho, Sao Paulo (BR)

15:34 - 15:41

Panel discussion

15:41 - 16:41

Endourology 360°: Resection, RIRS and reconstruction

En bloc resection: Always the best choice?

15:41 - 15:51

Yes

A. Breda, Barcelona (ES)

15:51 - 16:01

No

M. Pichardo, santo domingo (DO)

Bilateral RIRS: Double benefit or double trouble?

16:01 - 16:11

Yes

P.N. Contreras, Buenos Aires (AR)

16:11 - 16:21

No

A. Sierra Del Rio, Barcelona (ES)

Complex ureteral strictures: Endo vs robotic battle

16:21 - 16:31

Endourological approach

E. Liatsikos, Patras (GR)

16:31 - 16:41

Robotic-assisted reconstruction

L. Ruiz, Panama (PA)

16:41 - 16:45

Take home messages and closing remarks

Speaker

M.J. Ribal Caparros, Barcelona (ES)

Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 1.3

Friday 13 March

14:45 - 15:35

Location

Red Area, Room 1

Tutors

To be confirmed

To be confirmed

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 1.3

Friday 13 March
14:45 - 15:35

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 1.3

Friday 13 March
14:45 - 15:35

Location Red Area, Room 1

Tutor To be confirmed

Learning objectives

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 1.3

Friday 13 March
14:45 - 15:35

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed
M. Talso, Milan (IT)

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 1.3

Friday 13 March
14:45 - 15:35

Location Red Area, Room 1

Tutors M. Goossens, Aalst (BE)
To be confirmed

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 1.3

Friday 13 March
14:45 - 15:35

Location Red Area, Room 1

Tutors I. Kartalas Goumas, Vigevano (IT)
J.B. Roche, Bordeaux (FR)
To be confirmed

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 1.3

Friday 13 March
14:45 - 15:35

Location Red Area, Room 1

Tutors M. Paciotti, Rozzano, Milan (IT)
A. Tuncel, Ankara (TR)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Friday 13 March
14:45 - 16:15

Location Orange Area, EGPT 5
Chairs S. Howles, High Wycombe (GB)
P. Kallidonis, Patras (GR)
G.H. Zeng, Guangzhou (CN)

14:45 - 14:55

Epidemiology and cohort based associations

P0289

The Association Between Plasma Fatty Acid Levels and the Risk of Kidney Stone Formation: A Prospective Cohort Study Based on the UK Biobank

Authors

Zhang J.¹, Sun Z.¹, Huang L.², Qian Y.³, Tang Z.¹, Wang J.¹, Cong H.¹, Wu H.¹, Tang F.¹, [He Z.¹](#)

Institutions

¹The Eighth Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Shenzhen, China, ²The First Affiliated Hospital of Guangzhou Medical University, Dept. of Endocrinology, Shenzhen, China, ³Shenzhen University, School of Medicine, Shenzhen, China

P0290

Association between sarcopenic obesity and kidney stones: results from a UK Biobank prospective cohort study

Authors

Zhang J.¹, Jiang S.², Huang L.³, Ling K.², Tang Z.¹, Wang J.¹, Cong H.¹, Wu H.¹, Qian Y.¹, Tang F.¹, [He Z.¹](#)

Institutions

¹The Eighth Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Shenzhen, China, ²Sun Yat-sen University, School of Medicine, Shenzhen, China, ³The First Affiliated Hospital of Guangzhou Medical University, Dept. of Endocrinology, Shenzhen, China

14:55 - 15:30

Novel therapeutics and targets

P0291

Caffeine and its metabolites inhibit calcium oxalate stone formation through the NRF2/HO-1 pathway

Authors

[Dang K.](#), Yang Y., Cui T., Wang X., Zhao Q., Ruan J., Zhou Y., Liu J., Xiao J.

Institutions

Beijing Friendship Hospital, Dept. of Urology, Beijing, China

P0292

Novel marine-derived peptide FWEK prevents calcium oxalate stone formation via Keap1-Nrf2 activation: From computational discovery to in vivo validation

Authors

Xu H.¹, Li Z.², Shen S.³, Hou J.¹

Institutions

¹The Fourth Affiliated Hospital of Soochow University, Dept. of Urology, Suzhou, China, ²Suzhou Chien-Shiung Institute of Technology, Dept. of Biomedical and Pharmaceutical Sciences, Suzhou, China, ³School of Basic Medical Sciences, Suzhou Medical College, Soochow University, Dept. of Cell Biology, Suzhou, China

P0293

Finerenone-associated nephrolithiasis risk compared to spironolactone, SGLT2 inhibitors, and ACEi/ARB: Insights from a large TriNetX cohort study

Authors

Zhu Z.-J.¹, Chen Y.H.², Liu C.J.³

Institutions

¹National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, ²National Cheng Kung University, School of Medicine, College of Medicine, Tainan, Taiwan, ³National Cheng Kung University, Dept. of Urology, College of Medicine, Tainan, Taiwan

P0294

The Hippo-YAP1/TEAD1-SLC7A5 axis: Uncovering a novel therapeutic target for oxalate-induced renal tubular ferroptosis

Authors

Junyi Y., Wenlong W., Yang X., Xiao Y.

Institutions

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China

P0295

Targeting Ferroptosis and Macrophage-to-Myofibroblast Transition in Renal Fibrosis Induced by Urinary Obstruction: Deciphering the Multitarget Therapeutic Effects of A Modified Carbon Dots

Authors

Wentai W.¹, Guoqiang G.¹, Cui L.², Kaijie W.¹

Institutions

¹First Affiliated Hospital of Xi'an Jiaotong University, Dept. of Urology, Xi'an, China, ²School of Pharmaceutical Sciences, Chongqing University, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Innovative Drug Research Center, Chongqing, China

P0296

High-fat diet exacerbates calcium oxalate crystal-induced kidney injury via inhibiting Echs1-mediated fatty acid metabolism

Authors

Chen Y.¹, Yang S.¹, Chen L.², Qi S.¹

Institutions

¹The Second Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China, ²Tianjin University, Medical College, Academy of Medical Engineering and Translational Medicine, Tianjin, China

P0297

Iteratively Designed Multifunctional Carbon Dots Nanoplatfom for Targeted Celastrol Delivery and Combination Therapy of Kidney Stones

Authors

Zhu X.¹, Jiang H.¹, Liu J.¹, Tan S.²

Institutions

¹Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China, ²Tongji Medical College of Huazhong University of Science and Technology, School of Pharmacy, Wuhan, China

15:30 - 16:05

Immunity, inflammation and microenvironment

P0298

Gut microbiota-mediated tryptophan metabolism attenuates calcium oxalate nephropathy by suppressing renal tubular cell apoptosis through the AhR/SOCS3/STAT1 axis

Authors

Li Y., Wang M.H., Jin X., Wang K.J.

Institutions

West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China

P0299

Temporal Dynamics of Calcium Oxalate Nephrolithiasis and Molecular Responses in a Glyoxylate-Induced Mouse Model

Authors

Lee P-H.¹, Wang W.H.¹, Tsai Y.S.², Liu C.J.¹

Institutions

¹National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, ²College of Medicine, National Cheng Kung University, Institute of Basic Medical Sciences, Tainan, Taiwan

P0300

Mechanism of obesity induced ACSM5 deficiency promoting calcium oxalate induced renal tubular epithelial cell injury

Authors

Xiangyang Y.¹, Jiaqi H.², Hua X.², Hongbing M.¹

Institutions

¹The First Affiliated Hospital of Shenzhen University, Dept. of Urology, Shen Zhen, China, ²Wuhan University Zhongnan Hospital, Dept. of Urology, Wuhan, China

P0301

A Role for Endoplasmic Reticulum Stress in Calcium Oxalate Crystal-Induced Renal Injury: Insights from Transcriptome Sequencing

Authors

Hong S-Y., Yang Y.Y., Wang S.G.

Institutions

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China

P0302

A Bifidobacterium metabolite inhibits kidney stone formation by dampening T cell activation

Authors

Yang Y., Li X.M., Xun Y., Yu X., Wang S.G.

Institutions

Tongji Hospital, Dept. of Urology, Wuhan, China

P0303	<p>The role and mechanism of alternative splicing of PKM2 by RNA binding protein LGALS3 in metabolic reprogramming of renal tubular epithelial cells in renal injury induced by calcium oxalate crystals</p> <p>Authors Ye Z., Yu W., Cheng F.</p> <p>Institutions Renmin Hospital of Wuhan University, Dept. of Urology, Wuhan, China</p>
P0304	<p>Extracellular Vesicle-circPHAF1 Promotes the Formation of Calcium Oxalate Urolithiasis by Mediating the Recruitment and Polarization of Macrophages</p> <p>Authors Yongda L., Renfei L., Tao H.</p> <p>Institutions The First Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangzhou, China</p>
<hr/>	
16:05 - 16:25	Biomarkers and risk prediction
P0305	<p>Machine learning analysis of plasma proteomics identifies CALCA and STC1 as early biomarkers for urolithiasis</p> <p>Authors Tang R., Luo S., Wang J., Wang J.</p> <p>Institutions Beijing Hospital, Dept. of Urology, Beijing, China</p>
P0306	<p>A Multi-Omics-Based Predictive Model for Kidney Stone Formation: Integrating Gut Microbial and Metabolic Features with Clinical Parameters</p> <p>Authors Dang K., Cui T., Yang Y., Wang X., Zhao Q., Zhou Y., Liu J., Xiao J.</p> <p>Institutions Beijing Friendship Hospital, Dept. of Urology, Beijing, China</p>
P0307	<p>Associations of estimated glucose disposal rate with kidney stones: results from two prospective cohorts</p> <p>Authors Wang J., Zheng S., Guo X., Song Z., Mao S., Li Y.</p> <p>Institutions Affiliated Hospital of Yangzhou University, Dept. of Urology, Yangzhou, China</p>
P0308	<p>Development and Validation of a Predictive Model for Kidney Stone Recurrence: Integrating Gut Multi-Omics and Clinical Profiles</p> <p>Authors Dang K., Cui T., Yang Y., Wang X., Zhao Q., Zhou Y., Liu J., Xiao J.</p> <p>Institutions Beijing Friendship Hospital, Capital Medical University, Dept. of Urology, Beijing, China</p>

Friday 13 March
14:45 - 16:15

Location Orange Area, EGPT 2
Chairs K.L.S. Stern, Phoenix (US)
J. Vesper, Vienna (AT)
C. Waked, hadat (LB)

14:45 - 15:10

Different stent types

P0235

Enhancing patient safety through digitalisation: A two-cycle audit of ureteric stent documentation before and after implementation of an online ureteric stent database system

Authors

Elmadani A.

Institutions

Kettering General Hospital NHS Trust, Dept. of Urology, Kettering, United Kingdom

P0236

Magnetic versus conventional ureteral stents: preliminary evidence of improved patient tolerance and cost efficiency from a randomized trial in an Eastern European tertiary center

Authors

Calinoiu Petrino C., Nechita O.C., Badescu D.L., Jinga V., Rascu S.A.C.

Institutions

Clinic Hospital of Urology Bucharest Romania, Dept. of Urology, Bucharest, Romania

P0237

Comparison of stent related symptoms between regular double-J stent versus Comfi-J stent: A single blinded randomized control trial.

Authors

Shrestha A., Shah A.K., Adhikari B., Mishra U., Chitrakar A., Dahal R., Manoj J.K., Sharma R.

Institutions

Bir Hospital, Dept. of Urology, Kathmandu, Nepal

P0238

Prospective, multicenter, non-randomized trial clinical study to evaluate the Uriprene® degradable stent

Authors

Stern K.L.S.¹, Humphreys M.R.¹, Sur R.², Seth B.², Monga M.², Knudsen B.³, Lee M.³, Sourial M.³, Bird V.⁴, DiBianco J.⁴, Scotland K.⁵, Dunn M.⁵, Chew B.⁶

Institutions

¹Mayo Clinic Arizona, Dept. of Urology, Phoenix, United States of America, ²University of California, San Diego, Dept. of Urology, San Diego, United States of America, ³The Ohio State University Wexner Medical Center, Dept. of Urology, Columbus, United States of America, ⁴University of Florida, Dept. of Urology, Gainesville, United States of America, ⁵University of California Los Angeles, Dept. of Urology, Santa Monica, United States of America, ⁶Vancouver General Hospital, Dept. of Urology, Vancouver, Canada

P0239

Tandem Ureteral Stent in Malignant Ureteral Obstruction: Developing Clinically Based Risk-Adapted Follow-Up Protocol

Authors

Hemo O., [Lasmanovich R.](#), Greenstein I., Zilberman D.E., Dotan Z.A., Shvero A., Kleinmann N.

Institutions

Sheba Medical Center, Dept. of Urology, Ramat Gan, Israel

15:10 - 15:20

Stent encrustation

P0240

The Association of Urinary Metabolites and Indwelling Time with Double J Stent Encrustation

Authors

Albayrak E., Gudeloglu A., [Tekgül S.](#)

Institutions

Hacettepe University Faculty of Medicine, Dept. of Urology, Ankara, Turkey

P0241

Phytherapeutic prophylaxis to limit biofilm and encrustation on ureteral stents: early results from a randomized, placebo-controlled study

Authors

Pavan N.¹, Simonato F.A.¹, [Ferrante G.](#)¹, Salzano A.¹, Cosentino D.¹, Cantavenera V.¹, Gonzalez Benitez P.A.¹, Enia G.¹, Cardillo F.¹, Settiani V.¹, Contarino S.F.¹, Crisci A.², Diretto E.², Mariottini R.³, Scalia R.¹, Tulone G.¹, Giaimo R.¹, Simonato A.¹

Institutions

¹AOUP Paolo Giaccone University of Palermo, Dept. of Urology, Palermo, Italy, ²University of Florence, Dept. of Clinical and Experimental Medicine, Sesto Fiorentino Florence, Italy, ³AOU Careggi, SOD Andrologica and Robotic Mini-invasive Urology, Careggi, Italy

15:20 - 15:45

Stent symptoms

P0242

Predicting emergency department visits for stent-related symptoms in patients with stone disease

Authors

[Shafran Y.](#), Faza'a N., Eigner E., Amiel G.E., Goldin O., Mullerad M., Hoffman A.

Institutions

Rambam Health Care Campus, Dept. of Urology, Haifa, Israel

P0243

EFFICACY OF LEVOCETIRIZINE IN REDUCING DOUBLE J STENT-RELATED SYMPTOMS: A DOUBLE-BLIND PILOT RANDOMIZED CONTROLLED TRIAL

Authors

[Elias M.](#)¹, Halaby R.¹, Anthony M.¹, Azar Z.², Assaf S.¹, El Khoury G.², Ghosh M.¹, Breidy S.¹, Hachem C.¹, Dabal C.¹, Kassis A.¹, El Khoury R.¹, Saad R.¹

Institutions

¹Notre-Dame des Secours University Hospital, Dept. of Urology, Byblos, Lebanon, ²Holy Spirit University of Kaslik, School of Medicine and Medical Sciences, Jounieh, Lebanon

P0244

A prospective randomized controlled trial on comparison of 5 Fr and 6 Fr ureteral stents on stent-related symptoms following ureterorenoscopy

Authors

Puliyath N., Tc F., Parol S., Kv S., AV V.

Institutions

Government Medical College Kozhikode, Dept. of Urology, Calicut, India

P0245

Is There a Relationship Between Bladder Neck–Meatus Distance, Intravesical Double-J Stent Length, and Stent-Related Symptoms?

Authors

Sridi C., Ben Hadj Alouane H., Dridi A., Oueslati A., Ben Rhouma S.

Institutions

Habib Thameur Hospital, Dept. of Urology, Tunis, Tunisia

P0246

Do stent durometer and diameter affect patient outcomes in long-term stented patients?

Authors

Forbes C.¹, Algonaim A.¹, Andrew A.S.², Chew B.H.¹

Institutions

¹University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ²Boston Scientific Corporation, Dept. of Urology, Marlborough, United States of America

15:45 - 16:00

Strictures

P0247

Ureteral Strictures after Ureteral stones treatment: Insights from a Decade of Real-World Data in EpicCosmos

Authors

Tamborino F.¹, Turcan A.², Carletti F.³, Morgantini L.A.⁴, Alkassis M.⁴, Santarelli V.⁵, Santodirocco L.⁵, Marchioni M.¹, Crivellaro S.⁴

Institutions

¹Università G. D'Annunzio, Dept. of Oral and Medical Sciences - Urology, Chieti, Italy, ²University of Turin, Dept. of Urology, Turin, Italy, ³University of Padua, Dept. of Urology, Padua, Italy, ⁴University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America, ⁵Sapienza University of Rome, Dept. of Medical Surgical Sciences, Rome, Italy

P0248

Preoperative prediction of factors associated with impacted ureteral stones and construction of a nomogram model

Authors

Xinyu S., Mohan G., Wenhao C., Yunxiang Z., Xiaofu W., Changbao C.

Institutions

The Second Affiliated Hospital of Zhengzhou University, Dept. of Urology, Zhengzhou, China

Endoscopic Management of Iatrogenic Ureteral Strictures: Risk Factors for Treatment Failure

Authors

Moretto S.¹, Traxer O.², Saita A.¹, Somani B.K.³, Liatsikos E.⁴, Emiliani E.⁵, Skolarikos A.⁶, Ajayi L.⁷, Pietropaolo A.³, Doizi S.², De Coninck V.⁸, Kallidonis P.⁴, Sener T.E.⁹, Ventimiglia E.¹⁰, Pérez-Fentes D.¹¹, Aquati P.¹², Panthier F.², Villa L.¹⁰, Andras I.¹³, Ragonese M.¹⁴, Shrestha A.¹⁵, Tonyali S.¹⁶, Tzelves L.⁶, Buffi N.M.¹

Institutions

¹IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy, ²Hopital Tenon, Sorbonne Université, Dept. of Urology, Paris, France, ³University Hospitals Southampton, NHS Trust, Dept. of Urology, Southampton, United Kingdom, ⁴University Hospital of Patras, Dept. of Urology, Athens, Greece, ⁵Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁶Sismanogleio National and Kapodistrian University of Athens, Dept. of Urology, Athens, Greece, ⁷Royal Free Hospital, Dept. of Urology, London, United Kingdom, ⁸AZ Klina, Dept. of Urology, Brasschaat, Belgium, ⁹Marmara University, Dept. of Urology, Marmara, Turkey, ¹⁰IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ¹¹Complejo Hospitalario Universitario de Santiago de Compostela, Dept. of Urology, Santiago de Compostela, Spain, ¹²IRCCS Policlinico San Donato Hospital, Dept. of Urology, Milan, Italy, ¹³Iuliu Hatieganu University of Medicine and Pharmacy, Dept. of Urology, Cluj-Napoca, Romania, ¹⁴Policlinico Universitario A. Gemelli, Dept. of Urology, Rome, Italy, ¹⁵National Academy of Medical Sciences, BIR Hospital, Dept. of Urology, Kathmandu, Nepal, ¹⁶Istanbul University, Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Turkey

16:00 - 16:15

Shockwave Lithotripsy

P0250

Risk factors for urinary tract infection after shock wave lithotripsy for urolithiasis: A secondary analysis of the international APPEAL trial

Authors

Tondroanamag F.¹, Tornberg S.V.², Violette P.D.³, Mikkola A.², Horstia S.¹, Abdelkareem M.⁴, Abdulmajid Z.⁵, Azhar R.A.⁶, Bausch K.⁷, Gadzhiev N.⁸, Hajebrahimi S.⁹, Halme A.L.E.¹, Hussain S.A.⁴, Järvinen P.², Kilpeläinen T.P.², de Almeida Luz M.¹⁰, Nordlund N.K.¹, Richard P.O.¹¹, Salehi Pourmehr H.⁹, Soleimanzadeh F.⁹, Taily T.¹², Parpia S.¹³, Guyatt G.H.¹³, Tikkinen K.A.O.²

Institutions

¹University of Helsinki, Faculty of Medicine, Helsinki, Finland, ²University of Helsinki and Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ³McMaster University, Dept. of surgery, Hamilton, Canada, ⁴Hamad Medical Corporation, Dept. of surgery, Doha, Qatar, ⁵Hamad Medical Corporation, Dept. of Pharmacy, Doha, Qatar, ⁶King Abdulaziz University, Dept. of Urology, Jeddah, Saudi Arabia, ⁷University Hospital Basel, Dept. of Urology, Basel, Switzerland, ⁸Saint Petersburg State University Hospital, Dept. of Urology, Saint Petersburg, Russia, ⁹Tabriz University of Medical Sciences, Research Center for Evidence-Based Medicine, Tabriz, Iran, ¹⁰Rede D'Or São Luiz, Dept. of Urology, São Paulo, Brazil, ¹¹University Hospital of Sherbrooke, Dept. of Surgery, Sherbrooke, Canada, ¹²University Hospital Ghent, Dept. of Urology, Ghent, Belgium, ¹³McMaster University, Dept. of Health Research Methods, Evidence and Impact, Hamilton, Canada

P0251

Exploring the impact of virtual reality to improve the consent process and provide counselling for patients undergoing shock wave lithotripsy

Authors

[Bracey S.](#), Bamerni D., Tear L., Davis T., Frascheri M., Pietropaolo A., Somani B.

Institutions

Southampton General Hospital, Dept. of Urology, Southampton, United Kingdom

P0252

Development of Automated AI Extracorporeal Shock Wave Lithotripsy Robot

Authors

[Li C.](#), Xun Y., Lu Y.

Institutions

Tongji Hospital, Dept. of Urology, Wuhan, China

Robot-assisted Radical Prostatectomy: Outcomes across platforms

EGPT 13

Friday 13 March
14:45 - 16:15

Location

Orange Area, EGPT 1

Chairs

To be confirmed

A.E. Canda, Istanbul (TR)

To be confirmed

14:45 - 15:10

HUGO RAS

P0217

Multicentre Outcomes of Robot-Assisted Radical Prostatectomy Using the Hugo™ RAS System: Results from a Large Italian Experience

Authors

[Prata F.](#)¹, Barretta A.², Dell'Oglio P.³, Bertolo R.⁴, Sighinolfi M.C.⁵, Mottaran A.², Mazzone E.³, Russo P.⁵, Tappero S.³, Piazza P.², Turri F.⁵, Montanaro F.⁴, Veccia A.⁴, Tedesco F.¹, Civitella A.¹, Cavarra V.⁵, Ragusa A.¹, Bianchi L.², Muto G.⁶, Rocco B.⁵, Antonelli A.⁴, Galfano A.³, Schiavina R.², Papalia R.¹

Institutions

¹Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy, ²I.R.C.C.S. Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola, Division of Urology, Bologna, Italy, ³ASST Grande Ospedale Metropolitano Niguarda, Division of Urology, Milan, Italy, ⁴A.O.U.I. Verona, University of Verona, Urology Unit, Dept. of Surgery, Dentistry, Pediatrics and Gynecology, Verona, Italy, ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Dept. of Urology, Rome, Italy, ⁶GVM - Maria Pia Hospital, Dept. of Urology, Turin, Italy

P0218

Perioperative outcomes in the First Worldwide Obese Cohort Undergoing RARP with the Hugo™ RAS: A Multicenter Series

Authors

[Ragusa A.](#)¹, Iannuzzi A.¹, Prata F.², Tedesco F.¹, Muto G.³, Civitella A.², Papalia R.², Muto G.³

Institutions

¹Università Campus Bio-Medico di Roma, Research Unit of Urology, Dept. of Medicine and Surgery, Rome, Italy, ²Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy, ³GVM - Maria Pia Hospital, Dept. of Urology, Turin, Italy

P0219

Robotic Radical Prostatectomy Using the HUGO™ RAS Robotic Surgical System: The First Clinical Experience in Turkiye

Authors

Esen B.¹, Gurbuz A.¹, Koseoglu E.¹, Karaarslan U.C.¹, Muduroglu M.¹, Tilki D.², Canda A.E.¹, Kordan Y.¹, Balbay M.D.¹, Esen T.¹

Institutions

¹Koç University, Dept. of Urology, Istanbul, Turkey, ²Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

P0220

Extraperitoneal robot-assisted radical prostatectomy with the Hugo™ RAS system: 100 consecutive cases 1 year outcomes and learning-curve analysis

Authors

Filomena G.¹, Scarcia M.¹, Montesi M.¹, Testori N.¹, Russo P.², Gavi F.², Marino F.², Bizzarri F.P.², Cotrufo S.¹, Maselli F.P.¹, Moretto S.³, Fiorentino A.⁴, Sighinolfi M.C.², Rocco B.M.C.², Cormio L.¹, Ludovico G.M.¹, Zazzara M.¹

Institutions

¹Ospedale Generale Regionale F. Miulli, Dept. of Urology, Acquaviva delle Fonti Bari, Italy, ²Fondazione Policlinico Universitario A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, Dept. of Urology, Rome, Italy, ³Humanitas Clinical and Research Institute IRCCS, Dept. of Urology, Rozzano, Italy, ⁴Ospedale Generale Regionale F. Miulli, Dept. of Radiation Oncology, Rome, Italy

P0221

First Comparative Evidence of Oncological and Functional Outcomes of Retzius-sparing Versus Anterior RARP using Hugo-RAS

Authors

Mazzone E.¹, Prata F.², Tappero S.¹, Bertolo R.G.³, Civitella A.², Piazza P.⁴, Turri F.⁵, Mottaran A.⁴, Russo P.⁵, Tedesco F.², Cavarra V.⁵, Montanaro F.³, Sighinolfi M.C.⁵, Ragusa A.², Iannuzzi A.², Veccia A.³, Bianchi L.⁴, Muto G.⁶, Schiavina R.⁴, Antonelli A.³, Rocco B.⁵, Galfano A.¹, Papalia R.², Dell'Oglio P.¹

Institutions

¹ASST Grande Ospedale Metropolitano Niguarda, Division of Urology, Milan, Italy, ²Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy, ³University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Dept. of Urology, Verona, Italy, ⁴IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, Italy, ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Dept. of Urology, Rome, Italy, ⁶Maria Pia Hospital, Dept. of Urology, Turin, Italy

15:10 - 15:35

Single port

P0222

Single Port Italian Network (SPIN) RARP: assessing feasibility, safety and early functional outcomes with different reconstructive techniques

Authors

Amparore D.¹, Piramide F.², Checcucci E.¹, De Cillis S.T.², Volpi G.¹, Sica M.¹, Alessio P.¹, Brassetti A.³, Galfano A.⁴, Luzzago S.⁵, Dell'Oglio P.⁴, Tufano A.⁶, Costi G.C.⁷, Oderda M.⁸, Pellegrino F.⁹, Briganti A.⁹, Gaboardi F.⁷, De Cobelli O.⁵, Perdonà S.⁹, Gontero P.⁸, Simone G.³, Manfredi M.², Fiori C.², Porpiglia F.¹

Institutions

¹Candiolo Cancer Institute FPO-IRCCS, Dept. of Urology, Candiolo, Italy, ²AOU San Luigi Gonzaga, Dept. of Urology, Orbassano, Italy, ³IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁴Ospedale Niguarda, Dept. of Urology, Milan, Italy, ⁵IEO European Institute of Oncology, IRCCS, Dept. of Urology, Milan, Italy, ⁶Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Dept. of Urology, Naples, Italy, ⁷European Training Centre of Endourology (ETCE), IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ⁸Molinette Hospital, University of Turin, Dept. of Urology, Turin, Italy, ⁹Urological Research Institute, IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy

P0223

Preoperative Predictors of Immediate Urine Continence Following Single Port Transvesical Robotic Radical Prostatectomy

Authors

Soputro N., Gelikman D., Wang L., Al-Bayati A., Daher K., Bernardino R.M., Autorino R., Kaouk J.

Institutions

Cleveland Clinic, Glickman Urological Institute, Cleveland, United States of America

P0224

The Impact of Prostate Size on Single Port Robot-Assisted Radical Prostatectomy Surgical Outcomes.

Authors

Finocchiaro A.¹, Aljoulani M.², Almajedi M.³, Viganó S.¹, Bertini A.¹, Biasatti A.⁴, Valenzi F.M.², Ficarra V.⁵, Sorce G.⁵, Salonia A.⁶, Briganti A.⁶, Montorsi F.⁶, Lughezzani G.⁷, Buffi N.M.⁷, Vourganti S.⁴, Autorino R.⁴, Crivellaro S.², Nelson R.⁸, Craig R.¹, Abdollah F.¹

Institutions

¹Vattikuti Urology Institute, Dept. of Urology, Detroit, United States of America, ²University of Illinois, Dept. of Urology, Chicago, United States of America, ³Henry Ford Macomb, Dept. of Urology, Detroit, United States of America, ⁴Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ⁵University of Messina, Dept. of Urology and Renal Transplantation, Messina, Italy, ⁶IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ⁷Humanitas University, Dept. of Biomedical Sciences, Pieve Emanuele, Italy, ⁸Michigan Institute of Urology, Dept. of Urology, Detroit, United States of America

P0225

Assessing the impact of learning curve on perioperative and pathologic outcomes of single port robotic radical prostatectomy in a center with established multiport robotic program

Authors

Tuderti G., Mastroianni R., Bove A.M., Brassetti A., Anceschi U., Chiacchio G., D'Annunzio S., Ferriero M., Flammia R.S., Misuraca L., Proietti F., Licari L., Bologna E., Guaglianone S., Leonardo C., Simone G.

Institutions

IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy

P0226

Early discharge after Robot-assisted Radical Prostatectomy: the impact of Single Port surgery

Authors

Biasatti A.¹, Valenzi F.M.², Tamborino F.², Santarelli V.², Turcan A.², Carletti F.², Vourganti S.¹, Porpiglia F.³, Pastore A.L.⁴, Carbone A.⁴, Sciarra A.⁵, Schips L.⁶, Dal Moro F.⁷, Liguori G.⁸, Crivellaro S.², Autorino R.⁹

Institutions

¹Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ²University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America, ³University of Turin, San Luigi Gonzaga Hospital, Dept. of Oncology, Division of Urology, Orbassano, Italy, ⁴Sapienza University of Rome, Urology Unit, Dept. of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Latina, Italy, ⁵Sapienza University of Rome, Umberto I Hospital, Dept. of Maternal-Infant and Urological Sciences, Rome, Italy, ⁶Università degli Studi "G. d'Annunzio" of Chieti, Dept. of Medical Oral and Biotechnological Science, Chieti, Italy, ⁷University of Padova, Dept. of Surgery, Oncology and Gastroenterology, Urologic Unit, Padova, Italy, ⁸University of Trieste, Urological Clinic, Dept. of Medicine, Surgery and Health Sciences, Trieste, Italy, ⁹Cleveland Clinic, Glickman Urological Institute, Cleveland, United States of America

15:35 - 15:50

Toumai

P0227

First prospective comparative evaluation of on-site versus telesurgical robot-assisted radical prostatectomy using the Toumai® system

Authors

Beatrici E., Barretta A., Frego N., Brancelli C., De Angelis M., Cavarra V., Pepillo F., Guidotti A., Rodriguez Penaranda N., Prata F., Carl N., D'Hondt F., Lambert E., De Groote R., De Naeyer G., Mottrie A.

Institutions

AZORG Hospital, Dept. of Urology, Aalst, Belgium

P0228

Feasibility and safety of robot-assisted radical prostatectomy with the Toumai system: Initial experience from a European robotic referral center

Authors

Brancelli C.¹, De Angelis M.², Beatrici E.³, Pepillo V.³, Pepillo F.³, Barretta A.³, Guidotti A.³, Rodriguez Penaranda N.³, Prata F.⁴, Vecchio E.³, Tamburini S.³, De Groote R.³, De Naeyer G.³, Lambert E.³, D'Hondt F.³, Mottrie A.³

Institutions

¹Azienda Ospedaliera Universitaria Integrata di Verona, Dept. of Urology, Verona, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ³Onze-Lieve-Vrouweziekenhuis Hospital, Dept. of Urology, Aalst, Belgium, ⁴Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy

P0229

Robotic-Assisted Radical Prostatectomy (RARP) using the Medbot Toumai System : First African experience

Authors

Ouzzane A., Imane A., Tibari Y., Ej-jennane A., Faik H., Labyad A., Bouab A., Zemrag J., Touzani A.

Institutions

Centre International d'Oncologie Casablanca, Dept. of Urology, Casablanca, Morocco

15:50 - 16:00

hinotori

P0230

Evaluating learning curves and robotic skill transfer from da Vinci® to hinotori™: CUSUM analysis of multi-surgeon learning curves after a complete platform conversion in radical prostatectomy

Authors

Yu L.¹, Lee A.Y.², Teh M.W.¹, Loh E.K.Y.², Brodie B.A.², Sujon S.², Lee H.J.², Tan Y.G.², Tay K.J.², Ho H.S.S.², Yuen J.S.P.², Chen K.²

Institutions

¹Duke-NUS Graduate Medical School, Doctor of Medicine Programme, Singapore, Singapore, ²Singapore General Hospital, Dept. of Urology, Singapore, Singapore

P0231

hinotori vs. da Vinci: A Multi-Institutional Study on RARP Outcomes

Authors

Takahashi K., Ueki H., Wakita N., Okamura Y., Suzuki K., Bando Y., Hara T., Terakawa T., Tiba K., Yao A., Teishima J., Miyake H.

Institutions

Kobe University Graduate School of Medicine, Dept. of Urology, Hyogo, Japan

16:00 - 16:15

Comparison of different platforms

P0232

Single-Boom or Multi-Cart? Surgical times Comparison in Robot-Assisted Radical Prostatectomy: Toumai MT-1000 versus Hugo RAS First Twenty Cases

Authors

Sighinolfi M.C., Rossi F., Pallotta G., Silvestri A., Filomena G.B., Gavi F., Presutti S., Panio E., Montesi M., Schubert O., Fettucciari D., Del Proposto A., Cavarra V., Russo P., Assumma S.T., Gandi C., Foschi N., Totaro A., Turri F.M., Bientinesi R., Rocco B.M.C.

Institutions

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dept. of Urology, Rome, Italy

P0233

Cost-minimization of Hugo RAS vs Da Vinci Xi in robot-assisted radical prostatectomy: a detailed micro-costing analysis

Authors

Piazza P., Mottaran A., Bianchi L., Droghetti M., Catanzaro C., Barretta A., Scarlatti R., Mignona C., Dababneh H., Presutti M., Pultrone C.V., Pasquali F., Bevilacqua F., Corsini I., Schiavina R.

Institutions

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Division of Urology, Bologna, Italy

P0234

Comparative experience with three robotic platforms for radical prostatectomy: Da Vinci Xi, Medtronic Hugo™ RAS and Da Vinci Single Port

Authors

Brime Menéndez R., Paesano N.E., García Rojo E., Barrientos Moll F., Justo Quintas J., Lista Mateos F., Espinales Castro G.M., Belkahia G., Pérez Ruiz J.M., Briand Barriga C., Romero-Otero J.

Institutions

ROC Clinic HM Hospitales, Dept. of Urology, Madrid, Spain

Friday 13 March
14:45 - 16:15

Location Orange Area, EGPT 4
Chairs E. Fong, Auckland (NZ)
E. Illiano, Terni (IT)
M-A. Perrouin Verbe, Nantes (FR)

14:45 - 15:15

Pelvic organ prolapse

P0271

Robotic fascia lata sacrocolpopexy : a single center study

Authors

Chommeloux M.¹, Blondeau A.², Paris H.¹, Bertail T.¹, Batt N.³, Haudebert C.¹, Richard C.¹, Dubois A.¹, Penafiel J.¹, Manunta A.¹, Hascoet J.¹, Peyronnet B.¹

Institutions

¹CHU Rennes, Dept. of Urology, Rennes, France, ²CHU Nancy, Dept. of Urology, Nancy, France, ³Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Dept. of Urology, Newcastle upon Tyne, United Kingdom

P0272

Efficacy and safety of robot-assisted sacrocolpopexy for cystocele

Authors

Lee J., Koo M.J., Sung S.H., Lee J.H., Ko K.J., Lee K.S.

Institutions

Samsung Medical Center Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea

P0273

Analysis of the Impact of Robot-Assisted Sacrocolpopexy on Lower Urinary Tract Symptoms

Authors

Kimura Y., Yamamoto A., Omatsu R., Yamane H., Teraoka S., Nishikawa R., Yamaguchi N., Morizane S., Hikita K., Takenaka A.

Institutions

Tottori University Faculty of Medicine, Dept. of Urology, Yonago, Japan

P0274

Can colpocleisis with continuous innovative barbed suture decrease urinary complications after masculinizing genital gender affirmation surgery?

Authors

Bencic M., Pusica S., Stojanovic B., Bizic M., Djordjevic M.L.

Institutions

Belgrade Center for Urogenital Reconstructive Surgery, Dept. of Urology, Belgrade, Serbia

P0275

Laparoscopic Burch Colposuspension versus Transobturator Tape for the Treatment of Stress Urinary Incontinence in Egyptian Women: A 12-Month Randomized Controlled Trial

Authors

Abughanima M.¹, Elazab A.¹, Shalaby M.¹, Aboelhayagan M.¹, Mohamed H.¹, [Tarek M.](#)², Abdelrahman M.¹

Institutions

¹Assiut University, Faculty of Medicine, Dept. of Urology, Assuit, Egypt, ²United Lincolnshire Teaching Hospitals NHS Trust, Dept. of Urology, Lincoln, United Kingdom

P0276

Sexual Function Outcomes After Modified Posterior Colporrhaphy Versus Traditional Vaginoplasty for Vaginal Laxity: A Comparative Study with over 2 Years of Follow-up

Authors

[Shen S.H.](#), Han Y., Shen H., Luo D.

Institutions

West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China

15:15 - 15:30

Chronic pelvic pain

P0277

Accuracy, readability, and understandability of EAU guidelines bot for female LUTS.

Authors

[Pillitteri E.](#), Santioni M., Lombardo R., Romagnoli M., Coppola L.M., Malavasi G., Piccini G.P., Pacini G., Umbaca M., Pierri E., Lorenti C., Nacchia A., Cicione A., Tema G., Franco A., Pastore A., Al Salhi Y., Fuschi A., Tubaro A., De Nunzio C.

Institutions

Sapienza University of Rome, Dept. of Urology, Rome, Italy

15:30 - 15:40

Urodynamics

P0280

Sympathetic–parasympathetic interactions and urodynamic patterns in women with OAB

Authors

[Ivanov M.](#)¹, Ceban I.², Murea M.¹, Mitu A.¹, Lacusta V.³, Ceban E.¹, Galescu A.¹

Institutions

¹State University of Medicine and Pharmacy Nicolae Testemitanu, Dept. of Urology, Chisinau, Moldova, ²University of Medicine and Pharmacy Carol Davila, Dept. of Urology, Bucuresti, Romania, ³State University of Medicine and Pharmacy Nicolae Testemitanu, Dept. of Alternative and Complementary Medicine, Chisinau, Moldova

P0281

Are urodynamic parameters associated with pain during outpatient intravesical botulinum toxin instillation in women with overactive bladder?

Authors

[Alonso Grandes M.](#), Herranz Yagüe J.A., Márquez Negro A.M., Cabrera Chamba A., Arroyo Rojas Y., Ripalda Ferreti E., Cernuda Pereira C., Pena Vallejo E., Alonso Bartolomé M.B., García Fuentes C., Dorado Valentín M.

Institutions

University Hospital of Fuenlabrada, Dept. of Urology, Madrid, Spain

15:40 - 16:00

Basic science in female LUTs

P0282

Sex differences in cardiovascular and metabolic correlates of nocturnal polyuria: Insights from the EpiNP study

Authors

Van de Steen L.¹, Everaert K.¹, Lazar J.², Weiss J.³

Institutions

¹University hospital of Ghent, Dept. of Urology, Ghent, Belgium, ²SUNY Downstate Health Sciences University, Dept. of Cardiology, Brooklyn, United States of America, ³SUNY Downstate Health Sciences University, Dept. of Urology, Brooklyn, United States of America

P0283

Therapeutic Efficacy of Urine-Derived Stem Cells Combined with Platelet Lysate in a Rat Model of Stress Urinary Incontinence

Authors

Yun OJ¹, Lee S.H.¹, Kang J.K.¹, Chung J.W.¹, Ha Y.S.¹, Choi S.H.¹, Kim H.T.¹, Kim T.H.¹, Yoo E.S.¹, Kwon T.G.¹, Lee E.H.², Yoon B.H.², Jeon M.², Kim B.S.¹

Institutions

¹Kyungpook National University School of Medicine, Dept. of Urology, Daegu, South Korea, ²Kyungpook National University, Joint Institute of Regenerative Medicine, Daegu, South Korea

P0284

A Piezocatalytic Hydrogel Dressing for In-Situ Gas Therapy of Urinary Incontinence Complications

Authors

Wang J., Wu J.

Institutions

Fujian Provincial Hospital, Dept. of Urology, Fuzhou, China

P0285

Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treating Overactive Bladder: A Prospective Mechanistic Study Integrating Advanced Neuroimaging and Clinical Assessments

Authors

Yang X., Wu Z., Liao R., Wu P.

Institutions

Nanfeng Hospital of Southern Medical University, Dept. of Urology, Guangzhou, China

16:00 - 16:15

Surgical treatments

P0286

Cumulative Social Disadvantage and Risk of Overactive Bladder: A National Cross-Sectional Study with Machine Learning and Mediation Analysis

Authors

Lin W., Huang H.

Institutions

Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China

P0287

Functional outcomes of robot-assisted artificial urinary sphincter (rAUS) implantation in women

Authors

Moriconi M., Gallo M.L., Khalil N., Hour M., Abi Tayeh G., Phé V.

Institutions

Tenon Hospital - Sorbonne University, Dept. of Urology, Paris, France

Factors Affecting Success in Laparoscopic Transperitoneal Vesicovaginal Fistula Repair: A Retrospective Study from a Tertiary care centre from Eastern India.

Authors

Singh S., Sunny B., Chnadra V., Kumar N., Gunjan K.

Institutions

All India Institute of Medical Sciences, Dept. of Urology, Patna, India

Minimally-invasive surgery in localised renal tumour

EGPT 15

Friday 13 March

14:45 - 16:15

Location

Orange Area, EGPT 3

Chairs

To be confirmed

M. Tran, London (GB)

A. Tursunkulov, Tashkent (UZ)

14:45 - 15:00

Predictors of surgical complexity & quality of life

P0253

Correlation between Mayo Adhesive Probability score (MAP) and surgical outcomes in robot-assisted partial nephrectomy.

Authors

Turinetti T., Palumbo C., Nicolazzini M., Taurino M., Bosio A., Berra M., Bondonno G., De Angelis P., Volpe A.

Institutions

University of Eastern Piedmont Maggiore della Carità Hospital, Division of Urology, Dept. of Translational Medicine, Novara, Italy

P0254

The negligible role of Mayo Adhesive Probability (MAP) Score on Surgical Outcomes of off-clamp Robotic Partial Nephrectomy

Authors

Bologna E., Licari L.C., Brassetti A., Proietti F., Flammia R.S., Bove A.M., Mastroianni R., Tuderti G., Ferriero M.C., Misuraca L., Anceschi U., Chiacchio G., D'Annunzio S., Guaglianone S., Leonardo C., Simone G.

Institutions

IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

P0255

Longitudinal assessment of health-related quality of life after renal tumour surgery: Combined impact of surgical technique and access

Authors

Kuliniec I., Płaza P., Mitura P., Godzisz M., Sudoł D., Bar K.

Institutions

Medical University in Lublin, Dept. of Urology and Urological Oncology, Lublin, Poland

15:00 - 15:25

Surgical nuances in minimally invasive treatment

P0256

Three-Dimensional Laparoscopic Partial Nephrectomy for Hilar versus Non-Hilar Tumors: Outcomes from a Large Contemporary Series

Authors

Karavitakis M., Nikitakis F., Zabaftis C., Bouxalakis A., Tsela S., Tsogka S., Rempelou M., Grivas N.

Institutions

Lefkos Stavros-The Athens Clinic, Dept of. Urology, Athens, Greece

P0257

Transperitoneal versus retroperitoneal approach does not alter arterial clamping strategy during robot-assisted partial nephrectomy: interim results from the PODRACING trial

Authors

Vangeneugden J.¹, Vermijs S.², Berquin C.¹, De Kuyper P.³, Baekelandt F.⁴, Ghysel C.⁴, Raskin Y.⁵, Bynens B.⁵, Lumen N.¹, Mestdagh K.¹, De Visschere P.⁶, De Backer P.⁷, Debbaut C.², Decaestecker K.³, Van Praet C.¹

Institutions

¹Ghent University Hospital ERN eUROGEN accredited centre, Dept. of Urology, Ghent, Belgium, ²Ghent University IBiTech-BioMMeda, Dept. of Electronics and Information Systems, Ghent, Belgium, ³AZ Maria Middelaes, Dept. of Urology, Ghent, Belgium, ⁴AZ Sint-Jan Brugge, Dept. of Urology, Bruges, Belgium, ⁵Ziekenhuis Oost-Limburg (ZOL) Genk, Dept. of Urology, Genk, Belgium, ⁶Ghent University Hospital ERN eUROGEN accredited centre, Dept. of Radiology and Nuclear Medicine, Ghent, Belgium, ⁷AZORG, Dept. of Urology, Aalst, Belgium

P0258

Feasibility, Perioperative and Pain Outcomes of Low-Pressure Robot-Assisted Partial Nephrectomy: Results from the Randomized P-NeLoP Trial (UroCCR 85)

Authors

Margue G.L.¹, Bigot P.², Ingels A.³, Roupret M.⁴, Waeckel T.⁵, Long J.A.⁶, Pignot G.⁷, Bensalah K.⁸, Lang H.⁹, Olivier J.¹⁰, Bruyere F.¹¹, Durand M.¹², Beauval J.B.¹³, Mallet R.¹⁴, Parier B.¹⁵, De La Taille A.³, Bernhard J.C.¹

Institutions

¹Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ²Angers University Hospital, Dept. of Urology, Angers, France, ³Henri Mondor Hospital, Dept. of Urology, Paris, France, ⁴La Pitié Salpêtrière, Dept. of Urology, Paris, France, ⁵Caen University Hospital, Dept. of Urology, Caen, France, ⁶Grenoble Alpes University Hospital, Dept. of Urology, Grenoble, France, ⁷Paoli Calmette Institute, Dept. of Urology, Marseille, France, ⁸Rennes University Hospital, Dept. of Urology, Rennes, France, ⁹Strasbourg University Hospital, Dept. of Urology, Strasbourg, France, ¹⁰Lille University Hospital, Dept. of Urology, Lille, France, ¹¹Tours University Hospital, Dept. of Urology, Tours, France, ¹²Nice University Hospital, Dept. of Urology, Nice, France, ¹³La croix du Sud, Dept. of Urology, Toulouse, France, ¹⁴Clinique Francheville, Dept. of Urology, Périgueux, France, ¹⁵Kremlin Bicêtre, Dept. of Urology, Paris, France

P0260

Robot-Assisted Partial Nephrectomy for Polar Renal Masses Using the Hugo™ RAS System: Comparative Outcomes and Technical Insights from a Novel Upper-Pole Configuration

Authors

Prata E., Civitella A., Tedesco F., Ragusa A., Iannuzzi A., Fantozzi M., Rosca V., Cirillo R., De Giuseppe A., Leccese F., Raso G., Callè P., Liaci F., Santaniello A.M., De Carlo C., Liburdi I., Ruggeri S., De Stefano L., Piergiorgio T., Papalia R.

Institutions

Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy

- P0261** **Impact of 3D Virtual Models on trifecta rates during Laparoscopic Partial Nephrectomy for Complex Renal Masses (PADUA \geq 9)**
- Authors**
Pecoraro A., Trovato F., Bertoloni R., Grosso S., Marciano A., Marini M., Gaetano M., Nazaraj A., Rapisarda S., Polara A., Grosso G.
- Institutions**
Pederzoli Hospital, Dept. of Urology, Peschiera del Garda, Italy
- P0262** **Virtual Reality–Derived Anatomical Intelligence: A paradigm shift in enhancing Predictive Precision and Operative Outcomes in Partial Nephrectomy**
- Authors**
Raja T., Palaniswamy V., Kothapalli S., Reddy P., Meyyappan V., Palaniyandi V., Sekar H., Krishnamoorthy S.
- Institutions**
Sri Ramachandra Medical College and Research Institute, Dept. of Urology, Chennai, India
- P0263** **Feedback on the implementation of image-guided robot-assisted partial nephrectomy (3D-IGRAPN) over a 7-year period (UroCCR-186)**
- Authors**
Pitout A.¹, Margue G.¹, Rubat Baleuri F.¹, Khaddad A.¹, Pattou M.¹, Jambon E.², Bladou F.¹, Robert G.¹, Bernhard J.C.¹
- Institutions**
¹Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ²Bordeaux University Hospital, Dept. of Radiology, Bordeaux, France
- P0264** **Transabdominal lumbar approach (TALA) shows advantages over the retroperitoneal approach in robot-assisted renal surgery: First randomised controlled trial (PIONEER-OPTICS)**
- Authors**
Bieri U.¹, Heining F.¹, Javadov A.², Maletzki P.¹, Adank J.P.¹, Hefermehl L.¹
- Institutions**
¹Kantonsspital Baden, Dept. of Urology, Baden, Switzerland, ²ETH Zürich, Mobiliar Lab for Analytics, Dept. of Management, Technology and Economics, Zurich, Switzerland
- P0265** **A Patient-Centered Perspective on Single-Session Bilateral Robot-Assisted Partial Nephrectomy**
- Authors**
Di Domenico A.¹, Sequi M.², Germinale F.¹, Guano G.¹, Carbone A.², Introini C.¹
- Institutions**
¹E.O. Ospedali Galliera, Dept. of Abdominal Surgery, Urology Unit, Genoa, Italy, ²Sapienza University of Rome, Dept. of Medico-Surgical Sciences and Biotechnologies, Urology Unit ICOT, Latina, Italy

P0266

Robot-Assisted Partial Nephrectomy with the Hugo™ RAS System versus the Da Vinci® Platform: Updated Propensity Score-Matched Comparison after Learning Curve Consolidation

Authors

Prata F.¹, Mastroianni R.², Simone G.², Tedesco F.¹, Anceschi U.², Ragusa A.¹, Civitella A.¹, Brassetti A.², Bove A.M.², Iannuzzi A.¹, Fantozzi M.¹, Cirillo R.¹, Liaci F.¹, De Giuseppe A.¹, D'Annunzio S.², Ferriero M.², Flammia R.S.², Guaglianone S.², Misuraca L.², Proietti F.², Tuderti G.², Leonardo C.², Papalia R.¹

Institutions

¹Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy, ²IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy

15:55 - 16:15

Suture vs sutureless RAPN

P0268

Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy

Authors

Lazarovich A.Y.¹, Tremblay S.¹, Nottingham C.², Lescay H.¹, Nusbaum D.¹, Labbate C.³, Bristol S.¹, Karrison T.⁴, Shalhav A.L.¹, Eggenger S.¹

Institutions

¹University of Chicago, Dept. of Urology, Chicago, United States of America, ²Mercy Urology, Dept. of Urology, Washington, United States of America, ³Endeavor Health, Dept. of Urology, Chicago, United States of America, ⁴University of Chicago, Dept. of Public Health Sciences, Chicago, United States of America

P0269

Cost comparison between sutureless and renorrhaphy off-clamp robotic partial nephrectomy: results from a single-center randomized controlled trial

Authors

Brassetti A., Cosma G., Flammia R.S., Anceschi U., Bove A.M., Bologna E., Capecci L., Chiacchio G., D'Annunzio S., Denaro C., Di Luzio A., Ferriero M., Guaglianone S., Iuculano S., Leonardo C., Licari L.C., Mastroianni R., Misuraca L., Proietti F., Tuderti G., Simone G.

Institutions

IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy

P0270

Single-port retroperitoneal lower anterior Robotic partial nephrectomy: impact of surgical access on intraoperative anesthesiologic parameters

Authors

Tuderti G.¹, Covotta M.², Mastroianni R.¹, Anceschi U.¹, Brassetti A.¹, Bove A.M.¹, Chiacchio G.¹, D'Annunzio S.¹, Ferriero M.¹, Flammia R.S.¹, Misuraca L.¹, Proietti F.¹, Licari L.¹, Bologna E.¹, Guaglianone S.¹, Leonardo C.¹, Torregiani G.², Simone G.¹

Institutions

¹IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy, ²IRCCS Regina Elena National Cancer Institute, Dept. of Anaesthesiology, Rome, Italy

Surgery in Motion: Urethral stricture unplugged - Innovative surgical options

Thematic Session

Friday 13 March
15:15 - 16:15

Location Blue Area, Victoria 2

Chairs R. De Groote, Aalst (BE)
M. Fisch, Hamburg (DE)

Learning objectives

Learn how to deal with urethral strictures on different levels, of different lengths and in different kind of patients. Experts will guide you through the options of diagnostic work-up and therapeutic management.

15:15 - 15:23

Semi-live video Long peno bulbar urethral reconstruction
S. Kulkarni, Pune (IN)

15:23 - 15:27

Discussion

15:27 - 15:35

Semi-live video Ventral vs. dorsal approach in buccal mucosa graft urethroplasty
E.M.F. Palminteri, Arezzo (IT)

15:35 - 15:39

Discussion

15:39 - 15:47

Semi-live video Posterior urethral stricture management
F.E. Martins, Lisbon (PT)

15:47 - 15:51

Discussion

15:51 - 15:59

Semi-live video Urethroplasty in females
To be confirmed

15:59 - 16:03

Discussion

16:03 - 16:11

Urethral stricture repair in transgender patients
W. Verla, Ghent (BE)

16:11 - 16:15

Discussion

Urolithiasis: Laser technology, pressure and temperature

Abstract Session 06

Friday 13 March
15:15 - 16:45

Location Blue Area, Victoria 5

Chairs A. Budía Alba, Valencia (ES)
O.R. Durutovic, Belgrade (RS)
A. Tsaturyan, Yerevan (AM)

A0091

Energy Efficiency Index (EEI) predicts stone-free outcome after ureteroscopy: pilot analysis of a prospective cohort**Authors**

Tzikoulis V., Roidos C., Symeonidis A., Tsiakaras S., Memmos D., Mykoniatis I., Sountoulides P., Dimitriadis F., Toutziaris C., Baniotis P., Papathanasiou K., Pantazis N., Ntoulgeris D., Kalaitzis R., Tsakiridis N., Vakalopoulos I., Dimitriadis G., Anastasiadis A.

Institutions

Aristotle University of Thessaloniki, 1st Dept. of Urology, Thessaloniki, Greece

A0092

High-peak TFL enables sustained conical cavitation with lower retropulsion in stone lithotripsy: ex vivo ultra-high-speed imaging versus baseline TFL and long-pulse/low-peak Ho:YAG**Authors**

Kanne M.C.¹, Schmitz U.², Luximun Y.², Contreras P.³, Gerullis H.⁴

Institutions

¹Evangelical Hospital Queen Elisabeth Herzberge, Dept. of Urology, Berlin, Germany, ²Asclepion Laser Technologies GmbH, Dept. of Research and Development, Jena, Germany, ³German Hospital, Dept. of Urology, Buenos Aires, Argentina, ⁴Klinik am Ring, Dept. of Urology, Cologne, Germany

A0093

Laser settings: how do they impact on visibility during ureteroscopic laser lithotripsy? A YAU Endourology and PEARLS study**Authors**

Kachlik P.¹, Kwok J.L.², Panthier F.³, De Coninck V.⁴, Pauchard F.⁵, Sierra A.⁶, Tailly T.⁷, Sener E.⁸, JuliebØ-Jones P.⁹, Esperto F.¹⁰, Tzelves L.¹¹, Emiliani E.¹², Gauhar V.¹³, Pietropaolo A.¹⁴, Somani B.¹⁴, Traxer O.³, Möbus M.¹⁵, Eberli D.¹, Keller E.X.¹

Institutions

¹University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, ²Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore, ³Hôpital Tenon, Assistance-Publique Hôpitaux de Paris, Dept. of Urology, Paris, France, ⁴AZ Klina, Dept. of Urology, Brasschaat, Belgium, ⁵University Hospitals, Urology Institute, Cleveland, United States of America, ⁶Hospital Clinic de Barcelona, Dept. of Urology, Barcelona, Spain, ⁷Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ⁸Marmara University, School of Medicine, Dept. of Urology, Istanbul, Turkey, ⁹Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ¹⁰Campus Biomedico University of Rome, Dept. of Urology, Rome, Italy, ¹¹Sismanoglio General Hospital, National and Kapodistrian University of Athens (NKUA), 2nd Dept. of Urology, Athens, Greece, ¹²NYU Langone Health. NYU Grossman School of Medicine, Dept. of Urology, New York, United States of America, ¹³Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ¹⁴University Hospital Southampton NHS Foundation Trus, Dept. of Urology, Southampton, United Kingdom, ¹⁵ETH Zurich, Dept. of Computer Science, Zurich, Switzerland

A0094

Ex-Vivo and In-Vivo Evaluation of an Automated Target Recognition System for Thulium Fiber Laser Lithotripsy

Authors

Traxer O.¹, Zorzi F.¹, Yaroslavsky I.², Kovalenko A.², Andreeva V.³, Childs J.², Altshuler G.²

Institutions

¹Sorbonne Université, Groupe de Recherche Clinique sur la Lithiase Urinaire n20, Paris, France, ²IPG Medical, Research and Development Unit, Marlborough, United States of America, ³VPG LaserOne, Research and Development Unit, Fryazino, Russia

A0095

AI-assisted in-vitro assessment of dusting performance with Ho:YAG laser with Magneto technology and direct in-scope suction

Authors

Cretì A.¹, Perri D.², Robesti D.³, Di Rocco F.⁴, Bevilacqua L.⁵, Oliva I.⁵, Tondelli E.⁵, Villa L.³, Folcia A.³, Pietropaolo A.⁶, Tsaturyan A.⁷, Traxer O.⁸, Bozzini G.², Somani B.K.⁶, Goumas I.K.⁵, Ventimiglia E.⁹

Institutions

¹Università Cattolica del Sacro Cuore, Dept. of Urology, Rome, Italy, ²Azienda Socio Sanitaria Territoriale Lariana, Sant'Anna Hospital, Dept. of Urology, San Fermo Della Battaglia, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ⁴Tor Vergata University, Unit of Urology, Department of Surgical Sciences, Rome, Italy, ⁵Istituto Clinico Beato Matteo, Dept. of Urology, Vigevano, Italy, ⁶University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom, ⁷Yerevan State Medical University after Mkhitar Heratsi, Dept. of Urology, Yerevan, Armenia, ⁸enon Hospital, Hôpitaux Universitaires Paris-EST, Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie, Dept. of Urology, Paris, France, ⁹Uppsala University Hospital, Dept. of Urology, Uppsala, Sweden

A0096

Initial physician experience with MOSES Raydar™: A bench test to discover the potential of fiber-stone proximity approximation

Authors

Pietropaolo A.¹, Kamphuis G.², Angerri O.³, Benelli A.⁴, Khan F.⁵, Shaw M.⁶, Chaussee E.⁷, Shachrai I.⁷, Birman T.⁷, Venkatraman G.⁷, Turney B.⁸

Institutions

¹University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ²Amsterdam University Medical Center, Dept. of Urology, Amsterdam, The Netherlands, ³Fundacio Puigvert (IUNA), Dept. of Urology, Barcelona, Spain, ⁴Galliera Hospital, Dept. of Urology, Liguria, Italy, ⁵Luton & Dunstable University Hospital, Dept. of Urology, Bedfordshire, United Kingdom, ⁶Freeman Hospital, Dept. of Urology, Newcastle upon Tyne, United Kingdom, ⁷Boston Scientific Corporation, Dept. of Urology, Marlborough, United States of America, ⁸Nuffield Health The Manor Hospital, Dept. of Urology, Oxford, United Kingdom

15:45 - 15:55

Laser - Outcomes

A0097

Outcomes of utilization of Magneto Ho:YAG in flexible ureterorenoscopy with flexible and navigable suction access sheath (FANS) from Global FLEXOR-F Registry: An EAU- Endourology initiative

Authors

Yuen S.¹, Fong K.Y.², Castellani D.³, Zawadzki M.⁴, Tan K.⁵, Kwok J.L.⁶, Tan Y.Q.⁷, Rico L.⁸, Conteras P.⁸, Traxer O.⁹, Ng C.F.¹, Heng C.T.⁷, Somani B.K.¹⁰, Gauhar V.⁷

Institutions

¹The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ²Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ³Azienda Ospedaliero- Universitaria delle Marche, Dept. of Urology, Ancona, Italy, ⁴St. Anna Hospital, Urology Unit, Piaseczno, Poland, ⁵Veterans Memorial Medical Center, Dept. of Urology, Quezon City, Philippines, ⁶Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore, ⁷Ng Teng Fong General Hospital, Division of Urology, Singapore, Singapore, ⁸Hospital Alemán de Buenos Aires, Dept. of Urology, Buenos Aires, Argentina, ⁹Sorbonne University, AP-HP, Hôpital Tenon, Dept. of Urology, Paris, France, ¹⁰University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom

A0098

Flexible Ureteroscopy and Lithotripsy with Pulsed Thulium:YAG Laser: A Multicenter Retrospective Study

Authors

Gonzalez Gonzalez C.¹, Kwok J.L.², Sierra A.³, Berth L.⁴, Zorzi F.¹, Nannola N.¹, Werth H.¹, Doizi S.¹, Traxer O.¹, Panthier F.D.R.¹

Institutions

¹Endolase Lab GRC n20 Sorbonne University, PIMM Lab Arts et Métiers ParisTech, Paris, France, ²Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore, ³Hospital Clínic de Barcelona, Dept. of Urology, Barcelona, Spain, ⁴PIMM, UMR 8006 CNRS–Arts et Métiers ParisTech, Dept. of Mechanical Engineering / PIMM Laboratory (Procédés et Ingénierie en Mécanique et Matériaux), Paris, France

15:55 - 16:15

Lasers - Comparative trials

A0099

Comparative Performance of Virtual Basket + Magneto Pulse Modulations Versus Standard Pulse Holmium Laser Lithotripsy for Urinary Stones: A Multicenter Study

Authors

Rodríguez Socarrás M.E.¹, Perri D.², Kanashiro Azabache A.³, Valle J.⁴, Rico L.⁵

Institutions

¹Instituto de Cirugia Urologica Avanzada ICUA Clinica Centro, Dept. of Urology, Madrid, Spain, ²Sant'Anna Hospital, Dept. of Urology, Como, Italy, ³Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁴Clinica Cardio Centro - Hospicor, Dept. of Urology, Manabí, Ecuador, ⁵Hospital Aleman, Dept. of Urology, Buenos Aires, Argentina

A0100

High- vs Low-Power Thulium Fiber Laser Ureteroscopic lithotripsy: Results from a Randomised Clinical Trial

Authors

Asoy M.S.R., Juliebø-Jones P., Gjengstø P., Beisland C., Ulvik Ø.

Institutions

Haukeland University Hospital, Dept. of Urology, Bergen, Norway

A0101

Dual Laser Showdown: Holmium vs. Thulium in Ureterolithotripsy: Efficacy and Safety Unveiled

Authors

Esperto F.¹, [Cacciatore L.](#)¹, Minore A.¹, Salerno A.M.¹, Contessa P.², Testa A.¹, Bonanno L.², Basile S.¹, Iannello A.R.², Scarpa R.M.¹, Papalia R.¹

Institutions

¹Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy, ²IRCCS Centro Neurolesi, Bonino Pulejo, Piemonte Hospital, Dept. of Urology, Messina, Italy

A0102

Laser Analysis for Stone Treatment (LAST): An Ex-Vivo Comparative Study of Magneto Holmium:YAG and Fiber Dust Thulium Fiber Lasers – Primary Effects on Ablation, Retropulsion, Fragmentation, and Heat Generation Using Phantom Urologic Stones

Authors

[Luna A.V.](#)¹, Tan K.M.¹, Sta. Ana J.C.¹, Kwok J.L.², Yuen S.K.K.³, Traxer O.⁴, Gauhar V.⁵

Institutions

¹Veterans Memorial Medical Center, Dept. of Urology, Quezon City, Philippines, ²Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore, ³Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ⁴Tenon Hospital - Sorbonne University, Dept. of Urology, Paris, France, ⁵Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore

16:15 - 16:30

Temperature

A0103

Preliminary application of intelligent temperature-and pressure-controlled flexible ureteroscope combined with negative pressure suction sheath in holmium laser lithotripsy for upper urinary tract calculi

Authors

[Xinyu S.](#)¹, Wenhao C.¹, Mohan G.¹, Yunxiang Z.¹, Xiaofu W.¹, Changbao X.²

Institutions

¹The Second Affiliated Hospital of Zhengzhou University, Dept. of Urology, Zhengzhou, China, ²Henan Provincial Center for Diagnosis and Treatment of Urinary Calculi, Dept. of Urology, Zhengzhou, China

A0104

Balancing Heat and Efficiency in Robot-assisted laser lithotripsy: Preliminary Validation of the Laser:Stop Ratio (LS ratio)

Authors

Cho S.Y.¹, Lee H.Y.², Lee J.H.¹, Elises J.C.R.³, Kim E.¹, Kim J.H.⁴, Pae H.K.⁴, Kim S.E.⁴, Kwon D.S.⁵

Institutions

¹Seoul National University Hospital, Dept. of Urology, Seoul, South Korea, ²Kaohsiung Medical University Hospital, Dept. of Urology, Kaohsiung, Taiwan, ³Philippine General Hospital, Dept. of Urology, Manila, Philippines, ⁴ROEN Surgical, Inc., Clinical Research, Seoul, South Korea, ⁵ROEN Surgical, Inc, Seoul, South Korea

A0105

Intrarenal temperature during retrograde intrarenal surgery using flexible ureteroscopes with integrated direct in-scope suction: An experimental in-vitro study

Authors

Ballesta Martinez B.¹, Peteinaris A.², Manzi Orezza P.¹, Lopez Vivo F.J.¹, Pietropaolo A.³, Gauhar V.⁴, Dragos L.⁵, Kronenberg P.⁶, Tsaturyan A.⁷, Kar Kei Yuen S.⁸, Spinos T.², Liatsikos E.², Kallidonis P.², Angerri O.⁹, Tatanis V.², Sanchez Caballero L.¹, Rodriguez Romero M.A.¹, Somani B.³

Institutions

¹University Hospital del Vinalopo, Dept. of Urology, Elche, Spain, ²University Hospital of Patras, Dept. of Urology, Patras, Greece, ³University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ⁴Ng Teng Fong General Hospital, National University Health System, Dept. of Urology, Singapore, Singapore, ⁵University of Cambridge NHS Trust, Dept. of Urology, Cambridge, United Kingdom, ⁶Hospital CUF Descobertas, Dept. of Urology, Lisbon, Portugal, ⁷Yerevan State Medical University, Dept. of Urology, Yerevan, Armenia, ⁸The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ⁹Fundació Puigvert, Dept. of Urology, Barcelona, Spain

Study Group

Young Academic Urologists and EAU Section of Endourology(Arnhem, The Netherlands)

16:30 - 16:45

Pressure

A0106

Influence of Ureteral Access Sheaths and Irrigation Techniques on Intrarenal Pressure in a Porcine Model

Authors

Gadzhiev N.¹, Aloyan A.¹, Gauhar V.², Yuen S.K.K.³, Güven S.⁴, Semeniakin I.⁵

Institutions

¹Saint Petersburg State University Hospital, Dept. of Urology, Saint Petersburg, Russia, ²Ng Teng Fong Hospital, Dept. of Urology, Singapore, Singapore, ³S.H. Ho Urology Centre, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ⁴Necmettin Erbakan University Meram School of Medicine, Dept. of Urology, Konya, Turkey, ⁵MEDSI Clinical and Diagnostic Centre, Dept. of Urology, Saint Petersburg, Russia

A0107

A physics-based simulation of intrarenal fluid pressure and flow during suction ureteroscopy

Authors

Li T.¹, Papalazarou P.L.², Lee J.³, Shaikh S.⁴, Carrillo B.⁵, Farcas M.⁶

Institutions

¹University of Toronto, Division of Urology, Toronto, Canada, ²McMaster University, Dept. of Interdisciplinary Sciences, Hamilton, Canada, ³McMaster University, Michael G. DeGroot School of Medicine, Hamilton, Canada, ⁴University of Toronto, Institute of Medical Science, Toronto, Canada, ⁵Wellspring Research, Dept. of Research & Development, Toronto, Canada, ⁶St. Michael's Hospital, Division of Urology, Dept. of Surgery, Toronto, Canada

Real-Time Intrarenal Pressure (IRP) Monitoring and Intelligent Autoregulation during Flexible Ureterorenoscopy Using an IRP-monitoring Flexible and Navigable Suction Ureteral Access Sheath (FANS) with iMimer™: A Pilot Study

Authors

Yuen S.¹, Gauhar V.², Kwok J.L.³, Somani B.K.⁴, Ng C.F.¹

Institutions

¹The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ²Ng Teng Fong Hospital, Dept. of Urology, Singapore, Singapore, ³Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore, ⁴University Hospital Southampton, NHS Trust, Dept. of Urology, Southampton, United Kingdom

High-risk NMIBC: Evolving BCG–immunotherapy strategies and technical advances in TURB

Abstract Session 05

Friday 13 March
15:15 - 16:45

Location

Blue Area, George 1

Chairs

To be confirmed

R. Seiler-Blarer, Biel (CH)

To be confirmed

15:15 - 15:55

Novel therapies for BCG unresponsive non-muscle invasive bladder cancer

Development and Validation of a Model to Predict BCG-Unresponsiveness in High-Grade Non-Muscle-Invasive Bladder Cancer: An International Multicenter Study

Authors

Ślusarczyk A.¹, Moschini M.², Krajewski W.³, Scilipoti P.², Contieri R.⁴, Claps F.⁵, Subiela J.D.⁶, Mertens L.S.⁷, Mori K.⁸, Cano Velasco J.⁹, Soria F.¹⁰, Grobet-Jeandin E.¹¹, Tully K.¹², Garbas K.¹, Del Olmo Duran P.⁶, Lijnen R.⁷, Lafuente Puentedura A.¹³, Fertitta G.¹⁰, Reynard M.¹¹, Katzendorn O.¹⁴, Del Giudice F.¹⁵, Afferi L.¹⁶, Radziszewski P.¹, Pradere B.¹⁴

Institutions

¹Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ²IRCCS Ospedale San Raffaele, Dept. of Experimental Oncology/Unit of Urology, Milan, Italy, ³Wrocław Medical University, Dept. of Urology and Oncologic Urology, Wrocław, Poland, ⁴Humanitas Clinical and Research Institute IRCCS, Rozzano, Dept. of Urology, Milan, Italy, ⁵University of Trieste, Urological Clinic, Dept. of Medicine, Surgery and Health Sciences, Trieste, Italy, ⁶Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Dept. of Urology, Madrid, Spain, ⁷Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁸The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁹Clinica Universidad de Navarra, Cancer Center, Dept. of Urology, Pamplona, Spain, ¹⁰San Giovanni Battista Hospital, University of Studies of Torino, Dept. of Surgical Sciences, Division of Urology, Turin, Italy, ¹¹Geneva University Hospitals, Division of Urology, Geneva, Switzerland, ¹²Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology and Neurourology, Herne, Germany, ¹³Gregorio Marañón University Hospital, Dept. of Urology, Madrid, Spain, ¹⁴UROSUD, La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ¹⁵Sapienza University of Rome, Policlinico Umberto I Hospital, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ¹⁶Aarau Kantonsspital, Dept. of Urology, Aarau, Switzerland

Phase 1/2 study of an anti-PD-L1/IL-15 variant fusion protein (SIM0237) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC)

Authors

Ye D-W.¹, Xu H.¹, Hu H.L.², Jiang S.S.³, Zhang S.D.⁴, Yu Z.X.⁵, Liu Z.W.⁶, Niu H.T.⁷, Cao Y.⁸, Shi B.⁹, Dai T.³, Wu T.¹⁰, Xu J.J.¹⁰, Sun R.¹⁰, Zhang N.T.¹⁰, Sun H.L.¹⁰

Institutions

¹Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ²The Second Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China, ³Hunan Cancer Hospital, Dept. of Urology Surgery, Changsha, China, ⁴Peking University Third Hospital, Dept. of Urology, Beijing, China, ⁵The 1st Affiliated Hospital of WMU, Dept. of Urology, Wenzhou, China, ⁶Sun Yat-sen University Cancer Center, Dept. of Urology, Guangzhou, China, ⁷The Affiliated Hospital of Qingdao University, Dept. of Urology, Qingdao, China, ⁸The Affiliated Hospital of Qingdao University, Phase I Clinical Research Center, Qingdao, China, ⁹Qilu Hospital of Shandong University, Dept. of Urology, Jinan, China, ¹⁰Simcere Zaiming Pharmaceutical Co., Ltd., State Key Laboratory of Neurology and Oncology Drug Development, Shanghai, China

A0076

Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ

Authors

Kulkarni G.¹, Black P.C.², Richards K.³, Jayram G.⁴, Rendon R.⁵, Agarwal P.⁶, Shore N.⁷, Inman B.⁸, Saltzstein D.⁹, Kramalowsky E.¹⁰, Kamat A.¹¹, O'Donnell M.¹², Mandel A.¹³, DuMoulin-White R.¹³, Kassouf W.¹⁴

Institutions

¹Princess Margaret Cancer Centre University of Toronto, Dept. of Surgery, Toronto, Canada, ²Vancouver General Hospital University of British Columbia, Urologic Sciences, Vancouver, Canada, ³VA Urology University of Wisconsin-Madison, Dept. of Urology, Madison, United States of America, ⁴Urology Associates P.C., Dept. of Urology, Nashville, United States of America, ⁵Beatrice Hunter Cancer Research Institute Nova Scotia Health Authority, Dept. of Urology, Halifax, Canada, ⁶University of Chicago, Dept. of Urology, Chicago, United States of America, ⁷START Carolinas/Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, ⁸London Health Sciences Center, Lawson Health Research Institute, Western University, Dept. of Urology, London, Canada, ⁹Urology San Antonio P.A., Dept. of Urology, San Antonio, United States of America, ¹⁰Virginia Urology, Dept. of Urology, Richmond, United States of America, ¹¹University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ¹²University of Iowa, Dept. of Urology, Iowa City, United States of America, ¹³Theralase® Technologies Inc, Dept. of Science, Toronto, Canada, ¹⁴McGill University Health Centre, McGill University, Dept. of Surgery, Montréal, Canada

A0077

Building a Synthetic Benchmark for Efficacy Evaluation in BCG-Unresponsive Carcinoma in Situ Trials

Authors

Robesti D.¹, Kamat A.M.², Ploussard G.³, Fallara G.⁴, Briganti A.¹, Montorsi F.¹, van der Heijden A.G.⁵, Malavaud B.³, Pohar K.⁶, Shore N.⁷, Dinney C.P.², Martini A.⁸

Institutions

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²The University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ³Institut Universitaire du Cancer Toulouse-Oncopôle, Dept. of Urology, Toulouse, France, ⁴Santi Paolo e Carlo, Dept. of Urology, Milan, Italy, ⁵Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ⁶The Ohio State University Wexner Medical Center, Dept. of Urology, Columbus, United States of America, ⁷Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, ⁸University of Cincinnati College of Medicine, Dept. of Urology, Cincinnati, United States of America

A0078

Omitting Pelvic Lymph Node Dissection during Radical Cystectomy for NMIBC: An Interim Analysis of a Prospective, Multicenter, Randomized Trial

Authors

Lyu Q., Yang X., Cao Q., Bai R.

Institutions

the First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

Comparative effectiveness of nogapendekin alfa inbakicept (NAI) +BCG versus other bladder-sparing therapies in BCG-unresponsive NMIBC with CIS ± Ta/T1 papillary disease: an external control arm study (d-uo, Germany)

Authors

Doehn C.¹, Todenhöfer T.², Trusch C.³, Hempel E.³, Reiher J.⁴, Jablonska K.⁵, Leahy T.P.⁶, Brown B.⁷, Reddy S.⁷, Soon-Shiong P.⁷

Institutions

¹Urologikum Lübeck, Lübeck, Germany, ²Studienpraxis Urologie, Nürtingen, Germany, ³Deutsche Uro-Onkologen e. V., Berlin, Germany, ⁴SolemEU GmbH, Münster, Germany, ⁵Putnam, Dept. of RWE & Biostatistics, Krakow, Poland, ⁶Putnam, Dept. of RWE & Biostatistics, Toronto, Canada, ⁷ImmunityBio, Inc., Culver City, United States of America

Study Group

d-uo(Berlin, Germany)

Durvalumab (D) in combination with bacillus Calmette-Guérin (BCG) induction (I) and maintenance (M) therapy for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): outcomes for patients (pts) aged ≥65 years from POTOMAC

Authors

Palou J.¹, Nishiyama H.², Shore N.³, Krawczyński M.⁴, Seyitkuliev A.⁵, Guerrero-Ramos F.⁶, Zukov R.⁷, Kato M.⁸, Kawahara T.⁹, Goeman L.¹⁰, Puente J.¹¹, Radziszewski P.¹², Hellmis E.¹³, Powles T.¹⁴, Gust K.M.¹⁵, Vasey P.¹⁶, Bigot P.¹⁷, Fradet Y.¹⁸, Hunting J.¹⁹, Rao-Melacini P.²⁰, Dąbrowska A.²¹, Gupta A.²², De Santis M.²³

Institutions

¹Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ²University of Tsukuba, Dept. of Urology, Ibaraki, Japan, ³Carolina Urologic Research Center, START Carolinas, South Carolina, United States of America, ⁴Clinical Research Centre Sp, Poznan, Poland, ⁵St. Petersburg Hospital of the Russian Academy of Sciences, ., Saint Petersburg, Russia, ⁶Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ⁷Krasnoyarsk Regional Clinical Cancer Center, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ⁸Osaka Metropolitan University, Dept. of Urology, Osaka, Japan, ⁹Yokohama City University Medical Center, Dept. of Urology and Renal Transplantation, Yokohama, Japan, ¹⁰University Hospitals Leuven, Dept. of Development and Regeneration, Leuven, Belgium, ¹¹Hospital Clínico San Carlos, Dept. of Medical Oncology, Madrid, Spain, ¹²Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ¹³Urologicum-Duisburg, Duisburg, Germany, ¹⁴Queen Mary University of London, Barts Health NHS Trust, Barts Cancer Institute Biomedical Research Centre, London, United Kingdom, ¹⁵Medical University of Vienna, Dept. of Urology and Comprehensive Cancer Centre, Vienna, Austria, ¹⁶Icon Cancer Centre Wesley, Auchenflower, Australia, ¹⁷Angers University Hospital, Dept. of Urology, Angers, France, ¹⁸Oncology Division, CHU de Québec, Université Laval, Centre de Recherche du CHU de Québec, Quebec, Canada, ¹⁹St. Antonius Hospital, Dept. of Medical Oncology, Utrecht, The Netherlands, ²⁰AstraZeneca, Dept. of Oncology Biometrics, Mississauga, Canada, ²¹AstraZeneca, Dept. of Late-stage Development Oncology R&D, Warsaw, Poland, ²²AstraZeneca, Dept. of Late-stage Development Oncology R&D, New York, United States of America, ²³Medical University of Vienna and Charité Universitätsmedizin, Dept. of Urology, Charité Universitätsmedizin, Berlin, Germany, and Dept. of Urology, Medical University of Vienna, Berlin, Germany

A0081

The Global En Bloc Resection of Bladder Tumour Registry – First Descriptive Analysis on Safety and Technical Feasibility Outcomes.

Authors

Yanagisawa T.¹, D'Andrea D.², Barillaro F.³, Ko Y.H.⁴, Elshal A.⁵, Ali A.⁶, Manera A.⁷, Hota T.⁸, Lee H.Y.⁹, Guven S.U.¹⁰, Katayama S.¹¹, Villoldo G.¹², Omar M.¹³, Tan K.M.¹⁴, Tujillo-Santamaria H.¹⁵, Kazan H.O.¹⁶, Siregar A.¹⁷, Herrmann T.¹⁸, Babjuk M.¹⁹, Nicoletti R.²⁰, Leung C.H.²¹, Wong C.H.M.²¹, Teoh J.Y.C.²¹

Institutions

¹Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ²Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³USL Umbria 2, Dept. of Urology, Foligno, Italy, ⁴Ewha University, Dept. of Urology, Seoul, South Korea, ⁵Mansoura University, Dept. of Urology and Nephrology Center, Mansoura, Egypt, ⁶Frimley Health NHS Foundation Trust, Dept. of Urology, Frimley, United Kingdom, ⁷Azienda Ospedaliera Universitaria Senese, U.O.C. Urologia, Siena, Italy, ⁸Hospital Nossa Senhora das Graças, Dept. of Urology, Curitiba, Brazil, ⁹Kaohsiung Medical University Hospital, Dept. of Urology, Kaohsiung, Taiwan, ¹⁰Necmettin Erbakan University, Dept. of Urology, Konya, Turkey, ¹¹Okayama University Hospital, Dept. of Urology, Okayama, Japan, ¹²Instituto Alexander Fleming, Dept. of Urology, Buenos Aires, Argentina, ¹³Menoufia University, Dept. of Urology, Al Minufiyah, Egypt, ¹⁴Veterans Memorial Medical Center, Dept. of Urology, Manila, Philippines, ¹⁵Confederación Americana de Urología, Urología Santa María Veracruz, Veracruz, Mexico, ¹⁶Istanbul Medeniyet University, Dept. of Urology, Istanbul, Turkey, ¹⁷Indonesian Urology Association, Persahabatan General Hospital, Jakarta, Indonesia, ¹⁸Spital Thurgau AG, Dept. of Urology, Frauenfeld, Switzerland, ¹⁹Second Faculty of Medicine of Charles University, Dept. of Urology, Prague, Czech Republic, ²⁰Careggi University Hospital, Dept. of Urology, Florence, Italy, ²¹The Chinese University of Hong Kong, S.H. Ho Urology Centre, Hong Kong, Hong Kong

Study Group

The Global ERBT Registry Working Group(Hong Kong, Hong Kong)

A0082

Translating Visual Benefit to Oncologic Benefit: Blue-Light TURBT Reduces Recurrence in T1 and High-Risk NMIBC

Authors

Binti Mohd Rizal S., Gestopa P., Barrass B., Khan F., Pushkaran A., Bodean V.

Institutions

Luton and Dunstable University Hospital, Dept. of Urology, Luton, United Kingdom

A0083

The feasibility of treating NMIBC in an outpatient-based setting with local anaesthetic TULA in a TURBT naïve population; an EORTC risk-matched 1 & 5 year recurrence & progression analysis

Authors

Lim Wann Jie N., Yamada K.Y., Ho Z., Sayd H., Anwar S., Janardanan S., Agrawal S.

Institutions

Ashford and St. Peter's Hospitals, Dept. of Urology, Chertsey, United Kingdom

A0084

Safety & Efficacy of Thulium Laser Endoscopic En Bloc Resection versus Conventional Trans urethral resection of Bladder Tumors, for treatment of Non muscle invasive bladder tumors: A prospective Randomized trial

Authors

Abd El Hamid M., Kassem A., Assem A., Abd El Wahed M., Lotfi A., Abd Allah A., Hassan H.

Institutions

Cairo University, Dept. of Urology, Cairo, Egypt

A0085

Single-Center Prospective Study of Transurethral Cystoscopic Bladder Tumor Resection with Ultrasonic Scalpel Under CO₂ Pneumovesicium: Report on Technical Feasibility and Preliminary Efficacy

Authors

Yang S., Du Q., Wang H., Huang S., Chen G., Zhang X., Sun S.

Institutions

People's Liberation Army General Hospital, Dept. of Urology, Beijing, China

16:20 - 16:45

Local and systemic immunotherapy in the treatment of non-muscle invasive bladder cancer

A0086

BCG plus mitomycin (BCG+MM) versus BCG-alone as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer (NMIBC): effects on urinary symptoms and other aspects of health-related quality of life (HRQL) in a randomised trial (BCGMM, ANZUP 1301)

Authors

Hayne D.¹, Zhang A.Y.², Thomas H.², Krieger L.³, Ischia J.⁴, Anderson P.⁵, Srivastav R.⁶, Green W.⁷, Grummet J.⁸, Bastick P.⁹, Beardsley E.¹⁰, Blatt A.¹¹, Patel M.¹², Mitterdorfer A.¹³, Roberts M.¹⁴, Sengupta S.¹⁵, Winter M.¹⁶, Cheung L.², Hawks C.¹⁷, Martin A.¹⁸, McCombie S.P.¹⁷, Redfern A.D.¹, Davis I.¹⁵, Stockler M.R.¹⁹

Institutions

¹University of Western Australia, UWA Medical School, Perth, Australia, ²University of Sydney, NHMRC Clinical Trials Centre, Sydney, Australia, ³GenesisCare, Dept. of Medical Oncology, Sydney, Australia, ⁴University of Melbourne, Dept. of Surgery, Melbourne, Australia, ⁵Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia, ⁶Tweed Valley Hospital, Tweed Heads, Cudgen, Australia, ⁷Nottingham University Hospital, Dept. of Urology, Nottingham, United Kingdom, ⁸Monash University, Dept. of Surgery, Melbourne, Australia, ⁹Southside Cancer Care Centre, Dept. of Medical Oncology, Kogarah, Australia, ¹⁰Frankston Hospital, Dept. of Medical Oncology, Frankston, Australia, ¹¹John Hunter Hospital, Dept. of Urology, Newcastle, Australia, ¹²University of Sydney, Sydney Medical School, Sydney, Australia, ¹³Concord Repatriation General Hospital, Dept. of Urology, Sydney, Australia, ¹⁴Redcliffe Hospital, Dept. of Urology, Redcliffe, Australia, ¹⁵Monash University, Eastern Health Clinical School, Box Hill, Australia, ¹⁶Nepean Hospital, Department of Urology, Sydney, Australia, ¹⁷Fiona Stanley Hospital, Dept. of Urology, Perth, Australia, ¹⁸University of Queensland, ULTRA The University of Queensland Clinical Trials Capability, Brisbane, Australia, ¹⁹University of Sydney, NHMRC Clinical Trials Centre, Sydney, Australia

Study Group

Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group(Sydney, Australia)

A0087

Side Effects of Bacillus Calmette-Guérin (BCG) in Intermediate- and High-Risk NMIBC: One-Year Results from the Randomised Controlled NORTH-REG Dwell Time Study

Authors

Munk L.¹, Hyldgaard J.², Kumasegaram V.³, Hjort P.B.¹, Milling R.¹, Brandt S.¹, Vásquez J.⁴, Fabrin K.³, Lam G.W.⁵, Bro L.⁶, Graugaard-Jensen C.¹, Gudjónsson S.⁷, Ströck V.⁸, Jerlström T.⁹, Thiel T.¹⁰, Jensen J.B.¹¹

Institutions

¹Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ²Aarhus University Hospital, Dept. of Gynaecology and Obstetrics, Aarhus, Denmark, ³Aalborg University Hospital, Dept. of Urology, Aalborg, Denmark, ⁴Zealand University Hospital, Dept. of Urology, Roskilde, Denmark, ⁵Herlev Regional Hospital, Dept. of Urology, Herlev, Denmark, ⁶Odense Universitets Hospital, Dept. of Urology, Odense, Denmark, ⁷Landspítali University Hospital, Dept. of Urology, Reykjavík, Iceland, ⁸Region Västra Götaland, Sahlgrenska University Hospital, Dept. of Urology, Gothenburg, Sweden, ⁹Örebro University Hospital, Dept. of Urology, Örebro, Sweden, ¹⁰Karolinska University Hospital, Dept. of Urology, Stockholm, Sweden, ¹¹Queen Ingrid's Hospital, Dept. of Urology, Nuuk, Greenland

A0088

Bacillus Calmette-Guérin (BCG) with or without Immune Checkpoint Inhibitors in BCG-Naive High-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-Analysis

Authors

Saad M.A.¹, Taleb I.¹, Antari A.¹, EL OMRI S.¹, Traore H.¹, Chahbounia I.¹, Sella I.¹, Poudiougou A.K.¹, Sano F.D.¹, Omri L.², ELM'HADI C.¹, Lamine S.¹, Mokhlis M.A.¹, Aalaoui L.¹, Khmamouche M.R.¹, ALAOUI SLIMANI K.¹, Sbitti Y.¹, Mahfoud T.¹, Errihani H.¹, Tanz R.¹

Institutions

¹Mohammed V Military Teaching Hospital, Dept. of Medical Oncology, Rabat, Morocco, ²National Institute of Oncology, Dept. of Medical Oncology, Rabat, Morocco

A0089

Paradigm 1 - A multi-center Phase 1 Study evaluating the safety and clinical effect of a novel microbial immunotherapeutic (ZH9) in patients with relapsed NMIBC – A first Interim Review

Authors

Shore N.¹, Oefelein M.G.², Shah A.³, Zainfeld D.⁴, Deban L.⁵, Holz J.B.⁵

Institutions

¹Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, ²Bakersfield Institute of Advanced Urology, Dept. of Urology, Bakersfield, United States of America, ³Duke Health – Duke Cancer Center, Dept. of Urology, Durham, United States of America, ⁴Medical Center San Antonio, Urology San Antonio, San Antonio, United States of America, ⁵Prokarium Ltd., Dept. of Clinical Research, London, United Kingdom

A0090

Disitamab Vedotin Alone or Combined with PD-1 Inhibitors in High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicenter Real-World Study

Authors

Guo X., Wang S., Chen Y., Hao H., He Z., Gong Y., Zhang C.

Institutions

Peking University First Hospital, Dept. of Urology, Beijing, China

Modern solutions for upper ureteral strictures: Robotic repair, graft substitution and ileal ureter reconstruction

Video Session 04

Friday 13 March
15:15 - 16:45

Location Blue Area, Victoria 6

Chairs To be confirmed

To be confirmed

F. Van Der Aa, Leuven (BE)

V023 (□: 8 min.)

Beyond buccal - alternative tissue transfer techniques in upper tract reconstruction

R.A. Keenan, Dublin 14 (IE)

V024 (□: 8 min.)

Upper urinary tract reconstruction for the treatment of ureteral stricture in a duplex collecting system: Our experience

Y. Huang, Beijing (CN)

V025 (□: 8 min.)

Robotic assisted laparoscopic management of upper ureteric strictures

C. Mallikarjuna, Hyderabad (IN)

V026 (□: 5 min.)

Description of surgical techniques for ileal ureter replacement and ileocystoplasty in the treatment of bilateral ureteral stenosis

Y. Gu, Beijing (CN)

V027 (□: 8 min.)

Robot-Assisted Ileal Ureteroplasty for the Treatment of Ureteral Avulsion Caused by Ureteroscopy

P. Song, Beijing (CN)

V028 (□: 6 min.)

Robot-Assisted Buccal Mucosal Graft Ureteroplasty and Pyeloplasty: A Single-Port Series

L. Santodirocco, Monte Sant'Angelo (IT)

V029 (□: 8 min.)

Intraoperative Diuretic Drainage Test to Guide Laparoscopic Vascular Hitch vs. Laparoscopic Dismembered Pyeloplasty in UPJO with Crossing Vessels

P. Kwok, Scarborough (CA)

Friday 13 March
15:30 - 16:30

Location Red Area, Room 14

Chair R. Cornes, London (GB)

Learning objectives

Recognise the psychological challenges faced by men with penile cancer throughout diagnosis, treatment, and survivorship, including isolation, body image, and emotional distress.

Understand the impact on intimacy and partner relationships, and the shared psychosocial burden involved.

Identify opportunities to improve psychological and psychosexual support pathways in clinical practice.

Explore patient and partner perspectives to inform more personalised and holistic care models.

15:30 - 15:40

Welcome & introduction

R. Cornes, London (GB)

15:40 - 15:50

Patient-led insights: Findings from the penile cancer experience survey

J. Osborne, Nottingham (GB)

15:50 - 16:00

Clinical perspectives on mental health, body image, and intimacy in penile cancer care

To be confirmed

16:00 - 16:05

Living with penile cancer: A patient's perspective on quality-of-life challenges

To be confirmed

16:05 - 16:15

Patient and partner experiences: How penile cancer affects mental health, relationships, and intimacy

R. Jackson, (GB)

P. Meehan, (GB)

16:15 - 16:25

Psychosexual support in practice: A sexologist's perspective on improving care

C. Roumieux, Etterbeek (BE)

16:25 - 16:30

Q&A and closing

R. Cornes, London (GB)

Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 1.4

Friday 13 March
15:45 - 16:35

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 1.4

Friday 13 March
15:45 - 16:35

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed
M. Talso, Milan (IT)

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 1.4

Friday 13 March
15:45 - 16:35

Location	Red Area, Room 1
Tutors	To be confirmed To be confirmed

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 1.4

Friday 13 March
15:45 - 16:35

Location	Red Area, Room 1
Tutor	To be confirmed

Learning objectives

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 1.4

Friday 13 March
15:45 - 16:35

Location Red Area, Room 1

Tutors M. Goossens, Aalst (BE)
To be confirmed

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 1.4

Friday 13 March
15:45 - 16:35

Location Red Area, Room 1

Tutors I. Kartalas Goumas, Vigevano (IT)
J.B. Roche, Bordeaux (FR)
To be confirmed

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 1.4

Friday 13 March
15:45 - 16:35

Location Red Area, Room 1

Tutors M. Paciotti, Rozzano, Milan (IT)
A. Tuncel, Ankara (TR)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

EAU Opening Ceremony

Special Session

Friday 13 March
18:00 - 19:30

Location Orange Area, eURO Auditorium 1

Opening performance

Opening address

Announcement of the new EAU Honorary Members

Presentation of the EAU Willy Gregoir Medal 2026

Presentation of the EAU Frans Debruyne Life Time Achievement Award 2026

Presentation of the EAU Crystal Matula Award 2026

Presentation of the EAU Hans Marberger Award 2026

Presentation of the EAU Innovators in Urology Award 2026

Presentation of the EAU Ernest Desnos Prize 2026

Presentation of the EAU Prostate Cancer Research Award 2026

Presentation of the EAU Patient Advocacy Medal of Excellence 2026

Closing performance

Lights on urinary retention and underactive bladder in BPO patients

Plenary Session

Saturday 14 March
08:00 - 09:45

Location Orange Area, eURO Auditorium 1

Chairs C. De Nunzio, Rome (IT)
K.A.O. Tikkinen, Helsinki (FI)

Learning objectives

This session will address the current understanding of underactive bladder (UAB) and acute (AUR) and chronic urinary retention (CUR) in male. Despite the significant impact of UAB and CUR on patients' quality of life, many aspects require further investigation and deeper understanding. The discussion will focus in detail on: pathophysiology; appropriate diagnosis (kidney function evaluation, US, MRI, urodynamics) and the initial management of acute and chronic urinary retention (indwelling catheter vs cystostomy vs intermittent catheterization). Management of patients with UAB and BPO will be evaluated. Experts will engage in debates over paradigmatic clinical cases throughout the session.

08:00 - 08:01

Introduction

08:01 - 08:09

CAU lecture The natural history of benign prostatic obstruction

M.S. Gonzalez, Buenos Aires (AR)

08:09 - 08:17

State-of-the-art lecture Acute and chronic urinary retention: Epidemiology and risk factor

To be confirmed

08:17 - 08:31

Urinary retention - Diagnosis

08:17 - 08:19

Case presentation

M. Creta, Naples (IT)

08:19 - 08:28

Panel discussion and voting

Moderator

M.A. Averbeck, Porto Alegre (BR)

Panel

S. Arlandis, Valencia (ES)

S. Biers, Cambridge (GB)

C. Persu, Bucharest (RO)

S. Sinha, Hyderabad (IN)

08:28 - 08:31

Live interview Take away messages

Interviewer

V. Parry, London (GB)

Speaker

J. Heesakkers, Maastricht (NL)

08:31 - 08:53

Debate Urinary retention: Initial management

08:31 - 08:33

Continuation case: What is most beneficial for the patient?

M. Creta, Naples (IT)

08:33 - 08:36

Indwelling catheter

L. Moris, Leuven (BE)

08:36 - 08:39

Suprapubic catheter

B.Y. Padilla Fernandez, Zamora (ES)

08:39 - 08:42

Aseptic intermittent catheterisation

M-A. Perrouin Verbe, Nantes (FR)

08:42 - 08:50

Discussion

08:50 - 08:53

Live interview Take away messages

Interviewer

V. Parry, London (GB)

Speaker

J. Heesakkers, Maastricht (NL)

08:53 - 09:01

State-of-the-art lecture Detrusor underactivity and underactive bladder: Definition and clinical implication

T. Tarcan, Istanbul (TR)

09:01 - 09:16

How to manage detrusor underactivity before and after BPO surgery

09:01 - 09:04

Case presentation

M. Creta, Naples (IT)

09:04 - 09:13

Panel discussion and voting

Moderator

M. Rieken, Zürich (CH)

Panel

T. Antunes Lopes, Porto (PT)

M. Drake, London (GB)

S. Gravas, Larissa (GR)

09:13 - 09:16

Live interview Take away messages

Interviewer

V. Parry, London (GB)

Speaker

J. Heesakkers, Maastricht (NL)

09:16 - 09:36

Debate BPO surgery: Remove, cook or compress?

09:16 - 09:21

Video-based presentation Enucleation or resection

T.R.W. Herrmann, Frauenfeld (CH)

09:21 - 09:26

Video-based presentation Ablative MISTs

S. Secco, Milan (IT)

09:26 - 09:31

Video-based presentation Temporary stents

D. Elterman, Toronto (CA)

09:31 - 09:36

Discussion

09:36 - 09:44

State-of-the-art lecture Should you operate every patient with retention?

E. Finazzi Agrò, Rome (IT)

09:44 - 09:45

Closure

Urothelial cancer: Towards integrated therapeutic strategies

Plenary Session

Saturday 14 March
08:00 - 10:00

Location Orange Area, eURO Auditorium 2

Chairs L.S. Mertens, Amsterdam (NL)
M. Rouprêt, Paris (FR)

Learning objectives

This plenary session will explore the evolving landscape of bladder cancer management, from novel strategies in BCG-naïve and BCG-unresponsive NMIBC to real-world approaches for bladder-sparing in MIBC. Faculty will highlight how de-intensification, new systemic and intravesical combinations, and biomarker-driven decisions such as ctDNA can optimize outcomes. Finally, the session will address emerging standards and sequencing in metastatic UC, with a focus on integrating innovation while preserving patient-centered care.

08:00 - 08:01

Welcome and introduction

08:01 - 08:14

Minimally invasive, maximally effective: The new era of NMIBC therapy

08:01 - 08:09

State-of-the-art lecture **BCG-Naïve NMIBC in 2025: Are we moving beyond BCG alone?**

E.N. Xylinas, Paris (FR)

08:09 - 08:14

State-of-the-art lecture **Treatment de-intensification in NMIBC**

R. Contieri, Naples (IT)

08:14 - 08:57

Case-based panel discussion **High-risk NMIBC post-BCG failure: Spare the bladder?**

Moderator S. Psutka, Seattle (US)

08:14 - 08:17

Case presentation and voting

Y. Abu Ghanem, London (GB)

08:17 - 08:22

Bladder sparing: Trial overview ICB (combinations)

M. Moschini, Milan (IT)

08:22 - 08:27

Bladder sparing: Trial overview intravesical gene therapy (combinations)

Y. Loriot, Villejuif (FR)

08:27 - 08:32

Bladder sparing: Trial overview other intravesical options

J.W.F. Catto, Sheffield (GB)

08:32 - 08:37

Cystectomy is still relevant

A. Van Der Heijden, Nijmegen (NL)

08:37 - 08:42

How do cystectomy and bladder sparing compare when we ask patients?

K. Gessner, Chapel Hill (US)

08:42 - 08:52

Panel discussion

Panel

Y. Abu Ghanem, London (GB)

J.W.F. Catto, Sheffield (GB)

K. Gessner, Chapel Hill (US)

Y. Lorient, Villejuif (FR)

M. Moschini, Milan (IT)

A. Van Der Heijden, Nijmegen (NL)

08:52 - 08:57

Take-away messages

S. Psutka, Seattle (US)

08:57 - 09:15

Debate Beyond the muscle: Redefining MIBC management

08:57 - 09:00

Case presentation and voting: Measurable ctDNA after radical cystectomy

E. Grobet-Jeandin, Geneva (CH)

09:00 - 09:05

Pro: ctDNA should guide adjuvant decisions

J. Bjerggaard Jensen, Aarhus (DK)

09:05 - 09:10

Con: Evidence still lacking for clinical use

A. Masson-Lecomte, Paris (FR)

09:10 - 09:15

Rebuttals

09:15 - 09:23

State-of-the-art lecture Bladder-sparing in MIBC: The real-world evidence

J.Y.C. Teoh, Hong Kong (HK)

09:23 - 09:31

State-of-the-art lecture Who really needs surgery after neo-adjuvant chemotherapy?

A.R. Zlotta, Toronto (CA)

09:31 - 09:58

Case-based panel discussion Beyond platinum: Evolving frontlines in mUC

09:31 - 09:34

Case presentation and voting: Metastatic UC – patient unfit for platinum

A. Ślusarczyk, Warsaw (PL)

09:34 - 09:42

What should be the standard treatment in 2026?

T. Powles, London (GB)

09:42 - 09:50

Where do ADCs fit in the sequencing?

M. Galsky, New York (US)

09:50 - 09:58

Panel discussion

Panel

M. Galsky, New York (US)

T. Powles, London (GB)

A. Ślusarczyk, Warsaw (PL)

09:58 - 10:00

Closure

Artificial Intelligence 1 - Basic

ESU Course 16

Saturday 14 March
08:30 - 10:30

Location Red Area, Room 7

Learning objectives

This introductory course provides a clear and practical overview of Artificial Intelligence in urology. Participants will learn key terminology (AI, ML, Deep Learning, GAI, agentic AI, Foundation Models, LLMs) and discover available tools and how to use them effectively – and responsibly – in clinical and research contexts. Through hands-on examples, prompting exercises, and practical cheat sheets, the course encourages participants to explore how AI can be applied in daily work.

TBC

P. De Backer, Ghent (BE)

TBC

S. Rodler, Kiel (DE)

Treatment of localised renal masses: Tips and tricks

ESU Course 21

Saturday 14 March
08:30 - 11:30

Location Red Area, Room 12

Chair A. Minervini, Florence (IT)

Learning objectives

- Learn tips and tricks for successfully managing challenging cases of localised renal tumours through interactive case discussion
- Become familiar with the current standards of minimally-invasive surgical techniques and ablative therapies for localized renal tumours
- Understand the benefits of robotics and 3D reconstruction for surgical conservative treatment in challenging scenarios through interactive cases and surgical videos
- Review and analyse the patterns and predictors of recurrence in localized RCC through analysis of clinical trial evidence

Partial nephrectomy: Indications and surgical steps

M.J. Ribal Caparros, Barcelona (ES)

Radical Nephrectomy: Indications and surgical steps

A. Minervini, Florence (IT)

Ablative treatment: Technologies, indications and results

M.G. Pitoni, Milan (IT)

Discussion

Surgical treatment in challenging cases and bilateral renal tumours

A. Minervini, Florence (IT)

Ablative treatment in challenging cases: Tips and tricks

M.G. Pitoni, Milan (IT)

Adjuvant therapy in localised RCC: Patterns and predictors of recurrence and evidences from clinical trials

M.J. Ribal Caparros, Barcelona (ES)

Interactive case reports discussion

A. Minervini, Florence (IT)

M.G. Pitoni, Milan (IT)

M.J. Ribal Caparros, Barcelona (ES)

Tips and tricks in cystectomy

ESU Course 20

Saturday 14 March
08:30 - 11:30

Location Red Area, Room 11

Chair J. Palou, Barcelona (ES)

Voting will be available via the EAU26 App or via www.qna.at/eau

Learning objectives

The aim of this course is to describe the surgical technique of radical cystectomy.

There are different approaches for radical surgery depending on the expertise and economical possibilities of the centers, and even there are some differences on the results, it is important to follow some basic principles.

The main differences according to the surgical approach will be described (open, laparoscopic and robotic).

Tips and tricks of each approach will be presented in order to show the most important steps of each procedure, and also according to execute a nerve sparing or organ spring procedure.

Finally the most common complications will be analysed in order prevent and improve their management.

Objectives:

- Describe the rational to choose an specific urinary diversions
- Describe the main details of the different approaches and treatment anatomy related to nerve sparing, organ sparing, intracorporeal diversion
- Provide tips and tricks to improve the efficacy and results of the operation
- Explain the complications including their prevention and management

Introduction

J. Palou, Barcelona (ES)

Which diversion for which patient?

J. Palou, Barcelona (ES)

Open cystectomy in male (nerve and no nerve sparing)

B. Ali-El-Dein, Mansoura (EG)

Laparoscopic female cystectomy (organ and non- organ sparing)

M. Karavitakis, Pagkrati - Athens (GR)

Robotic intracorporeal ileal conduit and neobladder diversion

B. Pradère, Toulouse (FR)

Global tricks to decrease complications

J. Palou, Barcelona (ES)

Post surgical infections in urology – prevention and management

ESU Course 17

Saturday 14 March

08:30 - 10:30

Location Red Area, Room 8

Chair To be confirmed

Learning objectives

This ESU course on post-surgical infections in urology provides a concise, practice-oriented overview of one of the most relevant peri-operative challenges in modern urology. Increasing surgical complexity, ageing patients and antimicrobial resistance all contribute to a rising burden of infections after urological procedures. The course will review current evidence and guideline recommendations on prevention bundles, rational peri-operative antibiotic use and early recognition of complications. Practical case discussions will focus on typical problem scenarios and severe infections such as urosepsis after endourological, prosthetic and reconstructive surgery.

- Risk factors and classification of post-surgical infections after common urological procedures as a basis for prevention
- Evidence-based strategies for peri-operative prophylaxis, infection-prevention bundles and optimisation of high-risk patients
- Diagnostic work-up and stepwise management of post-operative infections, including source control and antimicrobial therapy
- Management of complex situations: prosthetic material, multidrug-resistant pathogens and severe complications such as urosepsis

08:30 - 10:30

Welcome and course objectives

To be confirmed

08:30 - 10:30

Epidemiology, risk factors and classification of post-surgical infections in urology

To be confirmed

08:30 - 10:30

Antibiotic prophylaxis in urological surgery: Guidelines, timing and duration

To be confirmed

08:30 - 10:30

Management of early post-operative infections and surgical site infections after common urological procedures

M. Vallée, Poitiers (FR)

08:30 - 10:30

Case-based discussion: Severe complications and urosepsis after urological surgery (stones, endourology, prosthetic and reconstructive surgery)

M. Vallée, Poitiers (FR)

08:30 - 10:30

Take-home messages and final Q&A

To be confirmed

M. Vallée, Poitiers (FR)

Enhanced recovery after surgery (ERAS) in urological surgery

ESU Course 18

Saturday 14 March

08:30 - 11:30

Location

Red Area, Room 9

Chair

J. Walz, Marseille (FR)

Learning objectives

Enhanced recovery after surgery (ERAS) has become a mainstay in modern surgical management. The aim of this concept is to optimize and standardize perioperative management to reduce the risk of complications, and promote faster recovery and shorter hospital stays. Key elements of ERAS include increasing the use of minimally invasive surgical approaches and standardized clinical pathways starting before surgery and continuing through recovery, as well as a proactive approach to increasing patient mobilization and return to oral nutrition. ERAS is grounded in a multidisciplinary approach to proactively facilitating recovery. The course provides a detailed overview of the current standard ERAS protocols and pathways as well as practical tips on how to get started with an ERAS programme.

The concept of ERAS

J. Walz, Marseille (FR)

The surgical tools

J.W.F. Catto, Sheffield (GB)

The organizational tools

S. Psutka, Seattle (US)

The anesthesia tools

J. Walz, Marseille (FR)

Protocols for endoscopy

J.W.F. Catto, Sheffield (GB)

Protocols for nephrectomy

S. Psutka, Seattle (US)

Protocols for radical prostatectomy

J. Walz, Marseille (FR)

Protocols for cystectomy

J.W.F. Catto, Sheffield (GB)

Personalized risk stratification

S. Psutka, Seattle (US)

How to get started with ERAS?

J. Walz, Marseille (FR)

Questions and answers

2025 EAU Guidelines update - Renal, bladder and prostate cancer: What has changed?

ESU Course 22

Saturday 14 March
08:30 - 11:30

Location

Red Area, Room 13

Chair

J.L. Domínguez Escrig, Valencia (ES)

Learning objectives

During the course, recent practice changing alterations in the EAU Guidelines will be discussed. Based on the clinical recommendations, the highlights of the guidelines on prostate, renal and bladder cancer changed in the 2022 updates, will be presented and illustrated by clinical cases. A basic knowledge of the guidelines information is assumed for participating trainees.

Welcome and introduction

J.L. Domínguez Escrig, Valencia (ES)

Update renal cancer: Localised

To be confirmed

Discussion**Update renal cancer: Metastasised**

To be confirmed

Discussion**Update bladder cancer: Non-muscle invasive**

J.L. Domínguez Escrig, Valencia (ES)

Discussion**Update bladder cancer: Muscle invasive**

J.L. Domínguez Escrig, Valencia (ES)

Discussion**Update prostate cancer: Localised**

D. Tilki, Hamburg (DE)

Discussion

Discussion

Advanced course on urethral stricture surgery

ESU Course 19

Saturday 14 March
08:30 - 11:30

Location Red Area, Room 10

Chair F. Campos Juanatey, Santander (ES)

Voting will be available via the EAU26 App or via www.qna.at/eau

Learning objectives

The advanced urethral stricture course will cover the assessment and surgical treatment of strictures of the penile, bulbar and posterior urethra. General principles of assessment and follow-up, oral mucosa harvest and complications will be reviewed with evidence. Techniques of penile, bulbar and full length urethroplasty will be discussed and compared and cases reviewed with audience participation encouraged.

Pelvic fracture urethral injuries will also be discussed together with management techniques. Female urethroplasty will also be discussed and assessed.

Prior knowledge of relevant anatomy and basic endoscopic techniques will be helpful to those attending the course.

General principles in urethral stricture surgery. Preoperative workup and follow-up. Indications of endourological treatments.

M.W. Vetterlein, Hamburg (DE)

Penile urethroplasty. Lichen sclerosus.

M.W. Vetterlein, Hamburg (DE)

Bulbar urethroplasty. Grafts, anastomotic and combined techniques, Perineal urethrostomy.

F. Campos Juanatey, Santander (ES)

Posterior urethroplasty (pelvic fracture distraction injuries, bladder neck contractures).

V. Kojovic, Belgrade (RS)

Female urethroplasty

F. Campos Juanatey, Santander (ES)

Discussion / Cases

F. Campos Juanatey, Santander (ES)

V. Kojovic, Belgrade (RS)

M.W. Vetterlein, Hamburg (DE)

Saturday 14 March
08:30 - 10:00

Location Orange Area, EGPT 4

Chairs B. Bañuelos Marco, Madrid (ES)
To be confirmed
S. Tekgül, Ankara (TR)

08:30 - 08:55

Hypospadias

P0327

Long-Term Outcomes of Meatoplasty for Isolated Meatal Stenosis Following Hypospadias Repair

Authors

Bashi T., Ilay R., Kidron A., Efrat O., Fischelevitz A., Bar-Yaakov N., Ben-Chaim J., [Bar-Yosef Y.](#)

Institutions

Tel Aviv Medical Center, Dept. of Pediatric Urology, Tel Aviv, Israel

P0328

Preoperative narrow meatus as a predictor of complications after hypospadias repair: a prospective study.

Authors

[Itshak A.](#)¹, Visman Y.², Neheman A.¹, Schwartz Gildor O.¹

Institutions

¹Meir Medical Center, Dept. of Urology, Kfar Saba, Israel, ²Shamir (Assaf Harofeh) Medical Center, Dept. of Urology, Beer Yaakov, Israel

P0329

A randomized study of antibiotic prophylaxis after hypospadias repair in children

Authors

[Manasherova D.](#)¹, Kozyrev G.², Kasyan G.¹, Pushkar D.¹

Institutions

¹Botkin Hospital Moscow Urology Center, Dept. of Urogynecology, Moscow, Russia, ²Peoples' Friendship University of Russia, Dept. of Pediatric Urology, Moscow, Russia

P0330

Distal urethral plate augmentation with preputial skin graft in long tubularized incised plate urethroplasty for proximal hypospadias repair

Authors

[Bencic M.](#), Stojanovic B., Bizic M., Djordjevic M.L.

Institutions

University Children's Hospital, Dept. of Pediatric Urology, Belgrade, Serbia

P0331

Integrated Histology and Transcriptomics Identify Novel Fibrotic Targets in Hypospadias

Authors

[Yu M.](#), Ding Y., Huang Y., Chen F.

Institutions

Shanghai Children's Hospital, Dept. of urology, Shanghai, China

08:55 - 09:15

Testis

P0332

Prospective evaluation of the TWIST score in pediatric testicular torsion

Authors

Yasar C.¹, Andersson M.¹, [Salö M.J.](#)²

Institutions

¹Sahlgrenska Academy, Women's and Children's Health, Queen Silvia's Children's Hospital, Dept. of Pediatric Surgery, Gothenburg, Sweden, ²Skåne University Hospital, Dept. of Pediatric Surgery, Lund, Sweden

P0333

Diagnostic value of contrast-enhanced MRI in acute scrotum: real-world clinical experience for 20 years at a single institution

Authors

[Murakami K.](#), Sugihara S., Kitora S., Onishi T., Matsuda I., Okuno T., Sunada T., Utsunomiya N., Terai A., Inoue K.

Institutions

Kurashiki Central Hospital, Dept. of Urology, Kurashiki, Japan

P0334

WHAT ARE THE IDEAL FETAL PARAMETERS FOR THE TESTICULAR MIGRATION PROCESS TO BE COMPLETED?

Authors

[Favorito L.A.](#), Miranda Morais Favorito L., Sampaio F.J.B.

Institutions

State University from Rio de Janeiro, Dept. of Anatomy, Rio de Janeiro, Brazil

P0335

A Cross-Sectional Study on Gonadal Hormone Levels in Pediatric and Adolescent Patients with Varicocele

Authors

[Teraoka S.](#)¹, Yoshimasa B.¹, Satoshi T.¹, Shintaro O.¹, Shuichi M.², Atsushi T.², Koji S.¹

Institutions

¹Yamaguchi University, Dept. of Urology, Ube Yamaguchi, Japan, ²Tottori University, Division of Urology, Dept. of Surgery, Faculty of Medicine, Yonago, Japan

09:15 - 09:40

DIAGNOSIS

P0336

Clinical relevance of postoperative biomarkers in pediatric endourology: Is procalcitonin telling the truth?

Authors

Genc Y.E.¹, Arslan F.¹, Seyidov M.¹, [Ozkan O.C.](#)², Sener T.E.¹, Tanidir Y.³, Yucel S.², Cam K.¹, Tarcan T.⁴, Sekerci C.A.²

Institutions

¹Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey, ²Marmara University School of Medicine, Dept. of Pediatric Urology, Istanbul, Turkey, ³Medicana Atasehir Hospital, Dept. of Urology, Istanbul, Turkey, ⁴Marmara University School of Medicine, Koç University School of Medicine, Dept. of Urology, Istanbul, Turkey

P0337

Analysis of the Association of Pediatric Urinary Stone Composition with Clinical Features and Laboratory Indicators: A 15-Year, Single-Center, Propensity Score-Matched Retrospective Study

Authors

[Yuan C.](#), Lan Y., Tang X., Huang Y.

Institutions

West China Hospital Sichuan University, Dept. of Pediatric Surgery, Chengdu, China

P0338

Immobilisation Hypercalciuria causing calcium phosphate stones is a significant contributor to stone burden in the paediatric population

Authors

Edison E.¹, Monks F.¹, Ashraf S.¹, Ratnayake A.¹, Sinha M.², Taghizadeh A.¹, Glass J.¹, Willis S.¹

Institutions

¹Guy's and St Thomas' NHS Trust, Dept. of Urology, London, United Kingdom, ²Guy's and St Thomas' NHS Trust, Dept. of Paediatric Nephrology, London, United Kingdom

P0339

Prognostic Value of Cystatin C for Chronic Kidney Disease in Pediatric Urologic Malformations

Authors

Yang Y-H.¹, Lin S.Y.²

Institutions

¹Taipei Wan Fang Hospital, Dept. of Urology, Taipei, Taiwan, ²Chang Gung Memorial Hospital, Dept. of Pediatric, Taipei, Taiwan

P0340

Alteration of microbiome in boys with phimosis with histological proof of Lichen sclerosus – A prospective study

Authors

Promm M.¹, Neissner C.¹, Zöhrer P.¹, Goßler C.², Rösch W.H.¹, Otto W.², Kirtschig G.³, Zustin J.⁴, Troci A.⁵, Bang C.⁵, Promm L.M.¹

Institutions

¹Clinic St. Hedwig, Dept. of Pediatric Urology, Regensburg, Germany, ²University of Regensburg, Caritas St. Josef Medical Center, Dept. of Urology, Regensburg, Germany, ³Medbase Health Centre, Dept. of Dermatology, Frauenfeld, Switzerland, ⁴Institute of Histopathology, Dept. of Pathology, Regensburg, Germany, ⁵Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany

09:40 - 09:50

Social

P0341

The impact of socioeconomic deprivation on non-attendance at paediatric urology outpatient clinics

Authors

Sohawon R., Ansari A., Abed A., Polson P.

Institutions

The Royal Wolverhampton NHS Trust, Dept. of Urology, Wolverhampton, United Kingdom

P0342

Multi-center survey on gender preference in pediatric urology: who do parents want when choosing a specialist?

Authors

Ebner B.¹, Blajan I.¹, Ivanova T.¹, Askari D.¹, Heinrich M.², Kunz Y.³, Partl A.³, Ebert A.K.⁴, Winkler A.K.⁴, Haid B.⁵, Luz H.⁶, Szavay P.⁶, Tamalunas A.¹, Buchner A.¹, Waidelich R.¹, Stief C.G.¹, Stredele R.¹

Institutions

¹LMU University Hospital, Dept. of Urology, Munich, Germany, ²Dr. von Hauner Children's Hospital, LMU University Hospital, Dept. of Pediatric Surgery, Munich, Germany, ³Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ⁴University Hospital Ulm, Dept. of Pediatric Urology, Ulm, Germany, ⁵Ordensklinikum Linz, Hospital of the Sisters of Charity, Dept. of Pediatric Urology, Linz, Austria, ⁶Children's Hospital Lucerne, Dept. of Pediatric Surgery, Lucerne, Switzerland

09:50 - 10:00

URETER

P0343

Continent vesicostomy with distal ureter in children: Technique and outcomes

Authors

Stojanovic B., [Bencic M.](#), Bizic M., Djordjevic M.L.

Institutions

University Children's Hospital, Dept. of Pediatric Urology, Belgrade, Serbia

P0344

Ureteral dilation is a clinically significant risk factor for urinary tract infections in children with prenatal hydronephrosis

Authors

[Khondker A.](#), Rickard M., Maher S., Chua M., Romao R., Dos Santos J., Lorenzo A.

Institutions

The Hospital for Sick Children, Dept. of Urology, Toronto, Canada

Kidney transplantation: From basics to surgery

EGPT 18

Saturday 14 March
08:30 - 10:00

Location

Orange Area, EGPT 3

Chairs

R. Boissier, Marseille (FR)

To be confirmed

V. Gomez Dos Santos, Madrid (ES)

08:30 - 08:45

Basic & translational research

P0309

C1q+ Macrophages Drive CD8+ T Cell Exhaustion via the Cr11/NF- κ B/Tox Axis to Promote Kidney Allotransplant Tolerance

Authors

Ding Z., [Ge J.](#), Xu Z., Tang Z., Zhang F., Qiu J., Liu Z.

Institutions

Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai General Hospital, Shanghai, China

P0310

Visceral-to-Subcutaneous Fat Ratio as a Predictor of Chronic Kidney Disease in Living Kidney Donors

Authors

[Trujillo Martinez G.](#)¹, Serrano-Heredia J.S.², Lagos-Beitz H.E.¹, Escalante-Armenta R.¹, Martinez-Delgado G.H.¹, Gabilondo-Pliego B.¹, Rodriguez-Covarrubias F.T.¹, Gonzalez-Mendez G.T.¹, Alcacio Mendoza J.A.¹

Institutions

¹National Institute of Medical Sciences and Nutrition Salvador Zubirán, Dept. of Urology, Mexico City, Mexico, ²National Institute of Medical Sciences and Nutrition Salvador Zubirán, Dept. of Radiology, Mexico City, Mexico

P0311

Gut microbe-derived ursodeoxycholic acid promotes fatty acid oxidation to protect against renal ischemia-reperfusion injury

Authors

Xie M., Zheng J., Yu Y., Wu P.

Institutions

Nanfang Hospital Southern Medical University, Dept. of Urology, Guangzhou, China

08:45 - 09:00

Oncology & kidney transplantation

P0312

Viral infections and tumour-specific mortality after kidney transplantation: distinct CMV and EBV patterns across tumour types and stages

Authors

Lopez Abad A.¹, Belmonte M.¹, López Cubillana P.¹, Cao Avellaneda E.¹, Yago Giménez P.¹, Herrero Vidal L.¹, García-Rivas Carmona F.¹, Guzmán Martínez-Valls P.L.¹, Prudhomme T.², Mercier J.², Sallusto F.², Kamar N.², Di Bello F.³, Breda A.³, Pecoraro A.⁴, Campi R.⁴, Masieri L.⁴, Serni S.⁴, Territo A.³

Institutions

¹Virgen de la Arrixaca University Hospital, Dept. of Urology, Murcia, Spain, ²Toulouse Rangueil University Hospital, Dept. of Urology, Toulouse, France, ³Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁴Careggi University Hospital, Dept. of Urology, Florence, Italy

P0313

Distinct Clinicopathological Aggressiveness of Upper Tract Urothelial Carcinoma Compared to Bladder Cancer in Renal Transplant Recipients: A Case-Control Study

Authors

Li X., Xu C., Xu X., Han W., Shen C., Li X., Lin J.

Institutions

Peking University First Hospital, Dept. of Urology, Beijing, China

P0314

Renal Cell Carcinoma of the Transplanted Kidney: From Treatment to Origin

Authors

Isaev T., Trushkin R.N., Sokolov S.A., Sokolov A.A., Sheglov N.E.

Institutions

Moscow City Clinical Hospital 52, Dept. of Urology, Moscow, Russia

09:00 - 09:30

Outcomes in kidney transplantation

P0315

Global Comparison of Kidney Transplantation and Dialysis Outcomes: Mortality and Major Cardiovascular Events from the TriNetX Network

Authors

Hsu J.Y., Lin Y.S., Hsu C.Y., Ou Y.C., Tung M.C.

Institutions

Tungs' Taichung MetroHarbor Hospital, Division of Urology, Taichung, Taiwan

P0316

Risk Factors for Incisional Hernia Following Open Kidney Transplantation: A 10-Year Retrospective Case–Control Study

Authors

Boiko O.¹, [De la Mata J.](#)¹, Zarraga S.², Sanz J.¹, Iliuta F.¹, Gonzalez D.¹, Garcia A.¹, Rodriguez A.¹, Lazaro D.¹, Delgado M.¹, Arauzo I.¹, Iturregui A.¹, Garcia-Olaverri J.¹, Estrade O.¹, Franco O.¹, Lecumberri D.¹

Institutions

¹University Hospital of Cruces, Dept. of Urology, Bilbao, Spain, ²University Hospital of Cruces, Dept. of Nefrology, Bilbao, Spain

P0317

Outcomes of total extraperitoneal technique on pediatric kidney transplantation

Authors

[Bong LS](#)¹, Ng Kai Xin C.¹, Koh Z.J.², Mali V.², Nyo Y.L.², Yap H.K.³, Ng K.H.³, Tiong H.Y.⁴

Institutions

¹National University of Singapore, Yong Loo Lin School of Medicine, Singapore, Singapore, ²National University Hospital, Dept. of Paediatric Surgery, Singapore, Singapore, ³National University Hospital, Dept. of Paediatric Nephrology, Singapore, Singapore, ⁴National University Hospital, Dept. of Urology, Singapore, Singapore

P0318

Tadalafil Improves Cardiovascular and Renal Outcomes in Kidney Transplant Recipients with Benign Prostate Hyperplasia or Erectile Dysfunction

Authors

[Hsu J.](#), Li J.R., Yang C.J.

Institutions

Taichung Veterans General Hospital, Dept. of Urology, Taichung, Taiwan

P0319

Association of Ureteric Stent Dwell Time and Bladder Catheterization with Post-Transplant Urinary Tract Infections

Authors

[Boiko O.](#)¹, Llorente A.¹, Delgado M.¹, Rodriguez A.¹, Iliuta F.¹, Sanz J.¹, Gonzalez D.¹, De la Mata J.¹, Lazaro D.¹, Arauzo I.¹, Garcia-Olaverri J.¹, Iturregui A.¹, Franco O.¹, Estrade O.¹, Zarraga S.², Lecumberri D.¹

Institutions

¹University Hospital of Cruces, Dept. of Urology, Bilbao, Spain, ²University Hospital of Cruces, Dept. of Nefrology, Bilbao, Spain

P0320

Nomogram for Predicting Graft Outcomes in Deceased Donor Kidney Transplantation from Acute Kidney Injury Donors: Analysis of the Japanese National Registry

Authors

[Hori S.](#)¹, Tomizawa M.¹, Inoue K.¹, Yoneda T.¹, Onishi K.¹, Morizawa Y.¹, Gotoh D.¹, Nakai Y.¹, Miyake M.¹, Tanaka N.², Fujimoto K.¹

Institutions

¹Nara Medical University, Dept. of Urology, Kashihara, Japan, ²Nara Medical University, Dept. of Prostate Brachytherapy, Kashihara, Japan

09:30 - 09:55

Ultimate techniques in transplantation

P0321

The Hidden Incision: Transvaginal Specimen Extraction Enhances Recovery, Cosmesis, and Quality of Life for Living Kidney Donors

Authors

Singh M., Jain M., Chowdary R., Prashar V., Bhirud D., Navriya S., Choudhary G., Sandhu A.

Institutions

All India Institute of Medical Sciences, Dept. of Urology, Jodhpur, India

P0322

Impact of Graft Laterality on Surgical and Functional Outcomes in Robot-assisted Kidney Transplantation: Experience from a High-volume Transplant Centre

Authors

Kushwaha S.¹, Aggarwal A.¹, Desai P.², Chaturvedi S.², Kumar A.²

Institutions

¹Max Super Speciality Hospital Vaishali, Dept. of Urology Uro-Oncology Robotics and Renal Transplant, Ghaziabad, India, ²Max Super Speciality Hospital Saket, Dept. of Urology Uro-Oncology Robotics and Renal Transplant, New Delhi, India

P0323

Robot-assisted lumboscopic radical nephrectomy in patients with polycystic kidney disease: a single-center observational study

Authors

Dubois Fresney S.¹, Beaugerie A.², Parra J.², Dubourg Q.², Vaessen C.², Arzouk N.³, Montagne S.⁴, Tourret A.³, Cazenave M.³, Mohammadou I.³, Francois H.³, Ourahma S.⁵, Glasman P.⁵, Drouin S.²

Institutions

¹University Hospital of Angers, Dept. of Urology, Angers, France, ²Pitié-Salpêtrière University Hospital, Dept. of Urology, Paris, France, ³Pitié-Salpêtrière University Hospital, Dept. of Nephrology, Paris, France, ⁴Pitié-Salpêtrière University Hospital, Dept. of Radiology, Paris, France, ⁵Pitié-Salpêtrière University Hospital, Anesthesiology and Intensive Care, Paris, France

P0324

RECONSTRUCTIVE SURGERY FOR URETERAL STRICTURES IN RENAL TRANSPLANT PATIENTS: A COMPARATIVE ANALYSIS BETWEEN ROBOTIC AND OPEN SURGERY

Authors

Bonet Vilanova JM, Ecthverry Giadrosich B., Bardella Altarriba C., Ferrando V., Fiol Riera M., Buisan Rueda O., Pérez Reggeti J.I., Suárez Novo J.F., Castells Esteve M., Vigués Julià F.

Institutions

Hospital Universitari de Bellvitge, Dept. of Urology, L'Hospitalet de Llobregat, Spain

P0325

An Evaluation of YouTube Videos on Kidney Xenotransplantation: Educational Content and Quality Assessment

Authors

Olcucuoglu E.¹, Polat M.E.¹, Çelik M.², Karaaslan M.³, Ceviz K.¹, Bardakci A.¹, Sirin M.E.⁴, Tastemur S.¹, Territo A.⁵, Yilmaz M.⁶

Institutions

¹Ankara Bilkent City Hospital, Dept. of Urology, Ankara, Turkey, ²Ergani State Hospital, Dept. of Urology, Diyarbakir, Turkey, ³Bayindir Kavaklidere Hospital, Dept. of Urology, Ankara, Turkey, ⁴Inova Private Hospital, Dept. of Urology, Aksaray, Turkey, ⁵Fundació Puigvert, Autònoma University of Barcelona, Dept. of Urology, Barcelona, Spain, ⁶MediClin Kraichgau-Klinik, Dept. of Urology, Bad Rappenau, Germany

A deep learning-based model for multiphase CT image segmentation and single-kidney renal function estimation: A multi-disease multicenter retrospective cohort study

Authors

Bao L., Lv S., Wei Q.

Institutions

Guangdong Provincial People's Hospital, Dept. of Urology, Guangzhou, China

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 2.1

Saturday 14 March
09:00 - 09:50

Location

Red Area, Room 1

Tutors

M.F. Frascheri, Southampton (GB)

C. Netsch, Hamburg (DE)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 2.1

Saturday 14 March
09:00 - 09:50

Location

Red Area, Room 1

Tutors

B. Ballesta Martinez, Alicante (ES)

F. Esperto, Rome (IT)

H. Ismail, Cottbus (DE)

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 2.1

Saturday 14 March
09:00 - 09:50

Location Red Area, Room 1

Tutors S. Erdem, Istanbul (TR)
To be confirmed

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 2.1

Saturday 14 March
09:00 - 09:50

Location Red Area, Room 1

Tutors M. Jarzemski, Bydgoszcz (PL)
G. Pini, Como (IT)

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 2.1

Saturday 14 March
09:00 - 09:50

Location Red Area, Room 1

Tutor To be confirmed

Learning objectives

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 2.1

Saturday 14 March
09:00 - 09:50

Location Red Area, Room 1

Tutors M.I. Gökce, Ankara (TR)
D. Perri, Como (IT)
T.E. Şener, Istanbul (TR)

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 2.1

Saturday 14 March
09:00 - 09:50

Location Red Area, Room 1

Tutors A. Papatsoris, Athens (GR)
To be confirmed

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Hands-on Training in Urodynamics

HOT UDS - 2.1

Saturday 14 March
09:30 - 12:30

Location Red Area, Room 3

Chair H. Hashim, Bristol (GB)

Learning objectives

This hands-on training course is designed to help participants enhance their knowledge and technical skills in urodynamics, with a strong emphasis on practical, real-world application. Through guided instruction and supervised practice, participants will gain experience in each step of the urodynamic study (UDS) process, including equipment setup, test execution, troubleshooting common technical and clinical issues, and accurate data interpretation. The course aims to build confidence and competence in performing and analyzing urodynamic studies in a clinical setting.

09:30 - 09:45

Introduction

H. Hashim, Bristol (GB)

09:45 - 11:05

Hands-on Training: Rotation 1

09:45 - 11:05

Setting up

Tutor A. Gammie, Bristol (GB)

09:45 - 11:05

Running a test

Tutor D.A.W. Janssen, Nijmegen (NL)

11:05 - 12:25

Hands-on Training: Rotation 2

11:05 - 12:25

Troubleshooting

Tutor

L. Thomas, Bristol (GB)

11:05 - 12:25

Interpretation

Tutor

To be confirmed

12:25 - 12:30

Questions and conclusions

H. Hashim, Bristol (GB)

Patient advocacy plaza - Engaging patients in research.



Special Session

Saturday 14 March

09:45 - 10:15

Location

Patient Advocacy Plaza

Chair

To be confirmed

09:45 - 10:15

EAU guidelines office

To be confirmed

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 2.2

Saturday 14 March

10:00 - 10:50

Location

Red Area, Room 1

Tutors

M.F. Frasccheri, Southampton (GB)

C. Netsch, Hamburg (DE)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 2.2

Saturday 14 March
10:00 - 10:50

Location Red Area, Room 1

Tutors B. Ballesta Martinez, Alicante (ES)
F. Esperto, Rome (IT)
H. Ismail, Cottbus (DE)

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 2.2

Saturday 14 March
10:00 - 10:50

Location Red Area, Room 1

Tutors S. Erdem, Istanbul (TR)
To be confirmed

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 2.2

Saturday 14 March
10:00 - 10:50

Location Red Area, Room 1

Tutors M. Jarzemski, Bydgoszcz (PL)
G. Pini, Como (IT)

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 2.2

Saturday 14 March
10:00 - 10:50

Location Red Area, Room 1

Tutor To be confirmed

Learning objectives

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 2.2

Saturday 14 March
10:00 - 10:50

Location Red Area, Room 1

Tutors E.D. Demirkiran, Zonguldak (TR)
M.I. Gökce, Ankara (TR)
D. Perri, Como (IT)

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 2.2

Saturday 14 March
10:00 - 10:50

Location Red Area, Room 1

Tutors A. Papatsoris, Athens (GR)
To be confirmed

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

EAU26 Live Surgery

Special Session

Saturday 14 March
10:15 - 17:45

Location Orange Area, eURO Auditorium 1

10:15 - 10:45

Part 1

Channel 0 Retrograde intrarenal surgery (RIRS) with aScope 5 Uretero

Moderators A. Sierra Del Rio, Barcelona (ES)
To be confirmed

Surgeon L.B. Dragoş, Cambridge (GB)

Channel 1 Semi-live: Endoscopic combined intra renal surgery (ECRIS) with dual view

Semi-live presenter O. Angerri Feu, Barcelona (ES)
A.S.K. Kanashiro Azabache, Barcelona (ES)

Moderators H.U. Jung, Vejle (DK)
V.M. Moreira Guerra Dos Santos Cavadas, Porto (PT)

Channel 2 En-Bloc EEP

Moderators S. Kutchukian, Poitiers Cedex (FR)
R. Miano, Rome (IT)

Surgeon C.M. Scoffone, Turin (IT)

Channel 3 Radical prostatectomy

Moderators C. Berquin, Gent (BE)
R. De Groot, Aalst (BE)

Surgeon B.J. Challacombe, London (GB)

10:45 - 11:15

Part 2

Channel 0 HoLEP with MOSES Technology

Moderators A. Madden, Cork (IE)
R. Mallet, Périgueux (FR)

Surgeon T. Aho, Cambridge (GB)

Channel 1 Semi-live Flexible ureteroscopy with LithoVue Elite and MOSES Raydar laser system

Semi-live presenter O. Wiseman, Cambridge (GB)

Moderators E.K. Bres-Niewada, Pruszkow (PL)
T.E. Şener, Istanbul (TR)

Channel 2 GreenLight - Advanced technique

Moderators To be confirmed
L.M.I. Jannello, Milan (IT)

Surgeon A. Emara, Basingstoke (GB)

Channel 3 Radical prostatectomy

Moderators C. Berquin, Gent (BE)
R. De Groot, Aalst (BE)

Surgeon B.J. Challacombe, London (GB)

Part 3**Channel 0 ECIRS with SOLTIVE thulium**

Moderators A.C. Bravo Balado, Barcelona (ES)
G. Giusti, Milan (IT)

Surgeons M.M. Popiolek, Örebro (SE)
Ø. Ulvik, Bergen (NO)

Channel 1 Semi-live: iTind: Reshaping BPH treatment

Semi-live presenter S. Secco, Milan (IT)

Moderators B. Ballesta Martinez, Alicante (ES)
S. Doizi, Paris (FR)

Channel 2 Thulium fiber laser enucleation of prostate with SOLTIVE

Moderators G. Kamphuis, Amsterdam (NL)
F. Zorzi, Trieste (IT)

Surgeon J. Romero-Otero, Madrid (ES)

Channel 3 RARP

Moderators S. Nathan, London (GB)
P.J. Zondervan, Amsterdam (NL)

Surgeon To be confirmed

Part 4**Channel 0 Semi-live: Flexible ureteroscopy**

Semi-live presenter F. Al Jaafari, Kirkcaldy (GB)

Moderators S. Ferretti, Modena (IT)
W. Gamal, Sohag (EG)

Channel 1 Semi-live robotic RIRS

Semi-live presenter S.Y. Cho, Seoul (KR)

Moderators To be confirmed
S. Yuen, Hong Kong (HK)

Channel 2 RIRS with FANS

Moderators To be confirmed
L. Villa, Milan (IT)

Surgeon T. Tailly, Ghent (BE)

Channel 3 RARP

Moderators S. Nathan, London (GB)
P.J. Zondervan, Amsterdam (NL)

Surgeon P. Dasgupta, London (GB)

Part 5

Channel 0 Semi-live UTUC

Semi-live presenter J. Baard, Amsterdam (NL)

Moderators V. Gauhar, Singapore (SG)
S. Proietti, Milan (IT)

Channel 1 Semi-live UTUC

Semi-live presenter A. Territo, Barcelona (ES)

Moderators A. Bosio, Torino (IT)
A. Masson-Lecomte, Paris (FR)

Channel 1 Semi-live: TURBT

Semi-live presenter C.M. Scoffone, Turin (IT)

Moderators E. Altobelli, Groningen (NL)
J.L. Vásquez, Copenhagen (DK)

Channel 2 RIRS

Moderators To be confirmed
L. Villa, Milan (IT)

Surgeon L. Ajayi, London (GB)

Channel 3 Partial Nephrectomy

Moderators S. Nathan, London (GB)
P.J. Zondervan, Amsterdam (NL)

Surgeons To be confirmed
G. De Naeyer, Aalst (BE)

12:45 - 13:15

Part 6

Channel 0 Part I: Holep

Moderators To be confirmed
G. Bozzini, Como (IT)

Surgeon F. Gomez Sancha, Madrid (ES)

Channel 1 Semi-live: Pulsed Tm: YAG - the ideal laser for FANS & ECIRS?

Semi-live presenter To be confirmed

Moderators R. Cansino, Madrid (ES)
M.A. Corrales Acosta, Clermont Ferrand (FR)

Channel 1 Semi-live Pulsed Tm: YAG - the ideal laser for Mini-PCNL?

Semi-live presenter G. Giusti, Milan (IT)

Moderators V.M.J. De Coninck, Brasschaat (BE)
T. Tefik, Istanbul (TR)

Channel 2 Anatomical Endoscopic Enucleation of the Prostate (AEEP)

Moderators To be confirmed
S. Moretto, Milano (IT)

Surgeon T. Nitkunan, Sutton (GB)

Channel 3 Semi-live En-Bloc TUR-BT using PDD

Semi-live presenter L. Lusuardi, Salzburg (AT)

Moderators L. Candela, Paris (FR)
P. Kallidonis, Patras (GR)

Channel 3 Semi-live: BipolEP

Semi-live presenter T.R.W. Herrmann, Frauenfeld (CH)

Moderators L.B. Dragoş, Cambridge (GB)
K. Lehrich, Berlin (DE)

13:15 - 13:45

Part 7

Channel 0 Part II: Holep

Moderators To be confirmed
G. Bozzini, Como (IT)

Surgeon F. Gomez Sancha, Madrid (ES)

Channel 0 Semi-live: RIRS

Semi-live presenter B. Somani, Southampton (GB)

Moderators C. Nedbal, Milan (IT)
A. Skolarikos, Athens (GR)

Channel 1 Semi-live: RIRS with suction and coagulation-controlled fragment extraction using hydrogel

Semi-live presenter M. Straub, Munich (DE)

Moderators To be confirmed
M.L. Letouche, Tours (FR)

Channel 2 Part I: ECIRS

Moderators C.M. Cracco, Torino (IT)
M. Talso, Milan (IT)

Surgeons O. Angerri Feu, Barcelona (ES)
A. Pietropaolo, Southampton (GB)

Channel 3 Semi-live RIRS

Semi-live presenter B. Ballesta Martinez, Alicante (ES)

Moderators A. Abdel Karim, Alexandria (EG)
To be confirmed

13:45 - 14:15

Part 8

Channel 0 Semi-live Penile Implant

Semi-live presenter M. Hamdan, Amman (JO)

Moderators A. Budía Alba, Valencia (ES)
To be confirmed

Channel 1 Semi-live: NMIBC - The power of NBI

Semi-live presenter H. Burden, Bristol (GB)

Moderators B. Geavlete, Bucharest (RO)
To be confirmed

Channel 2 Part II: ECIRS

Moderators C.M. Cracco, Torino (IT)
M. Talso, Milan (IT)

Surgeons O. Angerri Feu, Barcelona (ES)
A. Pietropaolo, Southampton (GB)

Channel 3 Semi-live: Pulsed Tm: YAG - the ideal laser for organ sparing UTUC treatment?

Semi-live presenter M. Brehmer, Stockholm (SE)

Moderators A. Abdel Karim, Alexandria (EG)
C. Netsch, Hamburg (DE)

Channel 3 Semi-live: Pulsed Tm: YAG - the ideal laser for enucleation?

Semi-live presenter I. Kartalas Goumas, Vigevano (IT)

Moderators E. Barret, Paris (FR)
To be confirmed

15:15 - 16:15

Part 9

Channel 0 DV5 prostate

Moderators G. Basile, London (GB)
V. Phé, Paris (FR)

Surgeon C. Wagner, Gronau (DE)

Channel 1 Semi-live: DV5

Semi-live presenter To be confirmed

Moderators To be confirmed
P. Kallidonis, Patras (GR)

Channel 2 - Single Port Kidney case

Moderators J-C. Bernhard, Bordeaux (FR)
N.N. Harke, Hannover (DE)

Surgeon K. Decaestecker, Gent (BE)

Channel 3 - Single Port Prostate case

<i>Moderators</i>	B.M.C. Rocco, Rome (IT) S. Secco, Milan (IT)
<i>Surgeon</i>	C. Schwentner, Stuttgart (DE)

16:15 - 16:45

Part 10

Channel 0 RARP

<i>Moderators</i>	P. Juárez Del Dago Anaya, Las Palmas de G.C. (ES) G. Shaw, London (GB)
<i>Surgeon</i>	P. Wisz, Warsaw (PL)

Channel 1 Semi-live: Cystectomy

<i>Semi-live presenter</i>	To be confirmed
<i>Moderators</i>	R. Barod, London (GB) A. Minervini, Florence (IT)

Channel 2 Prostatectomy

<i>Moderators</i>	I. Andras, Cluj (RO) J.M. Gaya Sopena, Barcelona (ES)
<i>Surgeon</i>	A. Haese, Hamburg (DE)

Channel 3 RARP

<i>Semi-live presenter</i>	To be confirmed
<i>Moderators</i>	To be confirmed To be confirmed

16:45 - 17:15

Part 11

Channel 0 tbc

Speaker

Channel 1 RARP

<i>Semi-live presenter</i>	A. Breda, Barcelona (ES)
<i>Moderators</i>	R. Barod, London (GB) A. Minervini, Florence (IT)

Channel 2 tbc

Speaker

Channel 3 tbc

Speaker

17:15 - 17:45

Part 12

17:15 - 17:45

Channel 0 tbc
To be confirmed

Urology to the rescue: Reconstruction and diversion beyond boundaries

Thematic Session

Saturday 14 March
10:30 - 12:00

Location Orange Area, Room 3

Chairs E.J. Redmond, Cork (IE)
F. Van Der Aa, Leuven (BE)

Learning objectives

Discover how to prevent and manage ureteral injuries with real-world cases and expert video demonstrations. Learn when to choose immediate versus delayed repair and what the EAU guidelines recommend. Explore cutting-edge management of urosymphyseal fistulae and osteitis pubis, from conservative to surgical options. See robotic techniques for urinary diversion in benign disease, including ileal conduit, Indiana pouch, and Mitrofanoff. Engage with leading experts in dynamic discussions designed to sharpen your reconstructive skills.

10:30 - 10:32

Welcome and introduction

10:32 - 11:01

Case-based discussion Ureteral injury during a gynecological surgical procedure

10:32 - 10:35

Case presentation

A. Bourillon, Rennes (FR)

10:35 - 10:41

Video-based presentation Immediate repair and how

To be confirmed

10:41 - 10:47

Video-based presentation Delayed repair and how

B. McGuire, Dublin (IE)

10:47 - 10:53

Prevention, repair, MDT: What do the EAU guidelines say?

M. Waterloos, Ghent (BE)

10:53 - 11:01

Panel discussion

11:01 - 11:35

Case-based discussion Management of urosymphyseal fistulae and osteitis pubis

11:01 - 11:04

Case presentation

R. Barratt, London (GB)

11:04 - 11:11

Non-surgical management

To be confirmed

11:11 - 11:18

Bladder sparing surgical treatment

B.R. Viers, Rochester (US)

11:18 - 11:28

Non conservative surgical treatment/urinary diversion

Speakers

M. Herteleer, (BE)

S. Joniau, Leuven (BE)

11:28 - 11:35

Panel discussion

11:35 - 11:53

How I do it: Robotic urinary diversion for benign condition

11:35 - 11:41

Robotic ileal conduit

M-A. Perrouin Verbe, Nantes (FR)

11:41 - 11:47

Robotic Indiana pouch

L. Zhao, New York (US)

11:47 - 11:53

Robotic Mitrofanoff

B. Peyronnet, Rennes (FR)

11:53 - 12:00

Summary and conclusion

EAU Data initiatives

Thematic Session

Saturday 14 March

10:30 - 12:00

Location

Blue Area, Victoria 6

Chairs

P. Cornford, Cork (IE)

J. N'Dow, Aberdeen (GB)

10:30 - 10:38

Adapting to innovation: EAU's engagement with big data and real-world evidence

J. N'Dow, Aberdeen (GB)

10:38 - 10:48

UroEvidenceHub: Building the evidence ecosystem for smarter urological care

S. Evans Axelsson, ystad (SE)

10:48 - 10:58

Complementing tradition: The role of real-world evidence in modern guideline development

A. Golozar, New York (US)

10:58 - 11:08

PIONEER in practice: Changing care through collaboration and data

R. Nicoletti, Florence (IT)

11:08 - 11:18

Transforming clinical practice: Bridging rule-based systems and empiric models

P. Cornford, Cork (IE)

11:18 - 11:28

Harnessing AI to transform systematic reviews: Faster, smarter, scalable

S. Canfield, Houston (US)

11:28 - 11:38

Enhancing guideline dissemination with Chatbots: A digital companion for clinical practice

M.J. Ribal Caparros, Barcelona (ES)

11:38 - 11:48

Driving adherence, improving outcomes: The role of IMAGINE in urological care

N.M. Pereira Azevedo, Porto (PT)

11:48 - 11:58

How EHDS will support the use of RWE for clinical research and evidence-based decision making

F. Raffaelli, (BE)

11:58 - 12:00

Closing remarks

P. Cornford, Cork (IE)

Saturday 14 March
10:30 - 12:00

Location Blue Area, George 4
Chairs To be confirmed
W. Gamal, Sohag (EG)
To be confirmed

10:30 - 11:20

Stones

A0109

Flexible ureterorenoscopy and laser lithotripsy using direct-in-scope-suction (DISS) in the paediatric population – first worldwide pilot study from a tertiary paediatric endourology referral centre

Authors

Dassanayake S.¹, Green P.², Griffin S.², Somani B.¹

Institutions

¹University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ²University Hospital Southampton NHS Foundation Trust, Dept. of Paediatric Surgery, Southampton, United Kingdom

A0110

Impact of lower pole stone location on outcomes of paediatric flexible ureteroscopy: Results from EAU Endourology multicentre cohort study

Authors

Fuligni D.¹, Nedbal C.², Numan B.³, Tosun H.⁴, Demirci D.⁵, Keles M.T.⁶, Ragoori D.⁷, Yuen S.⁸, Vaddi C.M.⁹, Soundarya G.⁹, Traxer O.¹⁰, Castellani D.¹¹, Madarriaga Y.Q.¹², Bujons Tur A.¹³, Somani B.K.¹, Gauhar V.¹⁴

Institutions

¹University Hospitals Southampton, NHS Trust, Southampton, United Kingdom, ²Università Politecnica Delle Marche, Dept. of Urology, Ancona, Italy, ³Erciyes University Medical School, Dept. of Urology, Kayseri, Turkey, ⁴Erciyes University Medical Faculty, Dept. of Urology, Kayseri, Turkey, ⁵Uskudar University, Faculty of Health Sciences, Istanbul, Turkey, ⁶Education and Research Hospital, Ordu University, Dept. of Urology, Ordu, Turkey, ⁷Asian Institute of Nephrology and Urology, Dept. of Urology, Hyderabad, India, ⁸S. H. Ho Urology Centre, The Chinese University of Hong Kong, Ma Liu Shui, Dept. of Surgery, Hong Kong, China, ⁹Preeti Urology and Kidney Hospital, Dept. of Urology, Telangana, India, ¹⁰Sorbonne University, Tenon Hospital, Dept. of Urology, Paris, France, ¹¹Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Polytechnic University delle Marche, Urology Division, Ancona, Italy, ¹²Fundació Puigvert, Carrer de Cartagena, Dept. of Urology, Barcelona, Spain, ¹³Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ¹⁴Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore

A0111

Efficacy and safety of ureteroscopy in children with lower pole renal stones – a machine learning predictive model from the EAU section of Endourology

Authors

Nedbal C.¹, Gauhar V.², Gite S.³, Maurya R.³, Jaiswal P.³, Kashyap K.³, Gregori A.¹, Antomarchi F.¹, Panthier F.D.R.⁴, Tanidir Y.⁵, Singh A.⁶, Soebhali B.⁷, Lee H.Y.⁸, Yuen S.K.K.⁹, Lim E.J.¹⁰, Traxer O.¹¹, Somani B.K.¹²

Institutions

¹IRCCS San Gerardo di Monza, Dept. of Urology, Monza, Italy, ²Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ³Symbiosis Institute of Technology, Dept. of Engineering, Pune, India, ⁴Tenon Hospital, Dept. of Urology, Paris, France, ⁵Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey, ⁶Muljibhai Patel Urological Hospital, Dept. of Urology, Nadiad, India, ⁷Abdul Wahab Sjahranie Hospital Medical Faculty, Muliawarman University, Dept. of Urology, Samarinda, Indonesia, ⁸Kaohsiung Medical University, Dept. of Urology, Kaohsiung, Taiwan, ⁹The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, Hong Kong, ¹⁰Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ¹¹Sorbonne University, Dept. of Urology, Paris, France, ¹²Southampton University Hospital - NHS, Dept. of Urology, Southampton, United Kingdom

A0112

Pediatric Ureteral Stenting: Indications, Dwell Time, and Outcomes – A Systematic Review by the EAU Section of Endourology

Authors

Altunhan A.¹, Soy Turk S.¹, Hermann T.², Gauhar V.³, Tokas T.⁴, Sultan S.⁵, Bujons A.⁶, Silay M.S.⁷, Somani B.K.⁸, Guven S.¹

Institutions

¹Necmettin Erbakan University, Dept. of Urology, Konya, Turkey, ²Kantonspital Frauenfeld, Spital Thurgau AG, Dept. of Urology, Frauenfeld, Switzerland, ³Ng Teng Fong General Hospital, Dept. of Urology, Jurong East, Singapore, ⁴General Hospital Hall i.T, Hall, Dept. of Urology and Andrology, Tirol, Austria, ⁵Sindh Institute of Urology and Transplantation (SIUT), Dept. of Pediatric Urology, Karachi, Pakistan, ⁶Fundació Puigvert, Universitat Autònoma de Barcelona, Division of Pediatric Urology, Dept. of Urology, Barcelona, Spain, ⁷Medipol Acibadem Hospital, Clinic of Pediatric Urology, Istanbul, Turkey, ⁸University Hospital Southampton, NHS Trust, Dept. of Urology, Southampton, United Kingdom

A0113

Comparative Effectiveness of Thulium-Fiber and Holmium:YAG Lasers in Pediatric Retrograde Intrarenal Surgery: A Multicenter Study

Authors

Keles M.¹, Quiroz Madarriaga Y.², Baydilli N.³, Gauhar V.⁴, Tosun H.³, Demirci D.³, Jiménez Corro R.O.², Osorio Iriarte J.², Nedbal C.⁵, Ragoori D.⁶, Yuen S.⁷, Vaddi C.M.⁸, Ganesan S.⁸, Traxer O.⁹, Castellani D.¹⁰, Somani B.K.¹¹, Bujons Tur A.²

Institutions

¹Ordu University, Dept. of Urology, Ordu, Turkey, ²Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ³Erciyes University, Dept. of Pediatric Urology, Kayseri, Turkey, ⁴Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ⁵Azienda Ospedaliero-Universitaria delle Marche, Università, Dept. of Urology, Ancona, Italy, ⁶Asian Institute of Nephrology and Urology, Dept. of Urology, Telangana, India, ⁷Chinese University of Hong Kong (CUHK), Dept. of Urology, Sheung Shui, Hong Kong, ⁸Preeti Urology and Kidney Hospital, Dept. of Urology, Telangana, India, ⁹Sorbonne University, Dept. of Urology, Paris, France, ¹⁰Azienda ospedaliero-universitaria Ospedali riuniti di Ancona, Università, Dept. of Urology, Ancona, Italy, ¹¹University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, Dept. of Urology, Southampton, United Kingdom

A0114

Utilization of Explainable Machine Learning Models in predicting Stone-Free outcome in Pediatric Laser Lithotripsy

Authors

Chua M.¹, Concio M.¹, Maher S.¹, Ibrahim H.², Iwano K.¹, Dos Santos J.², Rickard M.², Lorenzo A.¹

Institutions

¹University of Toronto, Division of Urology, Toronto, Canada, ²Hospital for Sick Children, Division of Urology, Toronto, Canada

A0115

Feasibility and Outcomes of Supine Mini-PCNL in Children Using a Digital Disposable Nephroscope with Vacuum-Assisted Suction Access Sheath: Early Clinical Experience

Authors

Kalathia J.A.¹, Patel K.¹, Khetarpal A.¹, Valiya A.¹, Agrawal K.¹, Agrawal S.¹, Talreja B.¹, Gauhar V.², Khant S.¹

Institutions

¹Fortune Urology Clinic, Dept. of Urology, Botad, India, ²Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore

A0116

Supine Mini Tubeless Percutaneous Nephrolithotomy for management of renal stones in paediatric population: A prospective single-centre experience

Authors

Kumar N.¹, Somani B.²

Institutions

¹Ford Hospital and Research Centre, Dept. of Urology, Patna, India, ²University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom

A0117

Step-by-Step Endoscopic Management of Pediatric Endogenous Simple Renal Cysts with fURS and Needle-Perc PCN

Authors

Hu Q., Yan X., Ru W.

Institutions

Children's Hospital Zhejiang University School of Medicine, Dept. of Urology, Hangzhou, China

A0118

Comparative Outcomes of Vacuum-Assisted Versus Conventional Access Sheaths in Single-Tract Pediatric Supine Mini-PCNL

Authors

Sezer A., Turedi B.

Institutions

Konya City Hospital, Dept. of Pediatric Urology, Konya, Turkey

11:20 - 12:00

Laparoscopy & robotic surgery in children

A0119

Robotic-assisted laparoscopic oral mucosal graft ureteroplasty for the treatment of long-segment ureteral defects

Authors

Yang Y., Tao T., Ma L., Zhou X., Zhao Y., Li P., Zhou H.

Institutions

Chinese PLA General Hospital, Senior Dept. of Pediatrics, Beijing, China

A0120

Single-Center Experience with 3049 Pediatric Robotic Urological Surgeries

Authors

Huixia Z., Pin L., Tian T., Hualin C., Yuandong T., Yang Z., Xiaoguang Z., Lifei M., Xiaowei Z.

Institutions

Chinese People's Liberation Army General Hospital, Senior Dept. of Pediatrics, Beijing, China

A0121

Comparative outcomes of laparoscopic and pneumovesicoscopic politano-leadbetter ureteral reimplantation for pediatric vesicoureteral reflux

Authors

Shen Y.M.¹, Fu Y.W.²

Institutions

¹Changhua Christian Hospital, Dept. of Urology, Changhua, Taiwan, ²Changhua Christian Hospital, Dept. of Surgery, Changhua, Taiwan

A0122

Outcomes of infant versus older pediatric robot-assisted laparoscopic pyeloplasty: A single-surgeon experience

Authors

Arias J., Zubair Z., Fu D., Kim D., Gundeti M.

Institutions

University of Chicago, Section of Urology, Dept. of Surgery, Comer Children's Hospital, Chicago, United States of America

A0123

Pediatric robotic-assisted ureteral reconstruction for long-segment strictures associated with UPJO: outcomes from a single-center cohort

Authors

Jia H., Pin L., YuanDong Y., Lifei M., Yangyang W., Xiaoyu Y., Chen D., Huixia Z.

Institutions

The Seventh Medical Center of Chinese PLA General Hospital, Dept. of Pediatric Urology, Beijing, China

A0124

Applications and Outcomes of Indocyanine Green-Guided Near-Infrared Fluorescence in Paediatric Urological Surgery: A Systematic Review

Authors

Nikolinakos P.¹, Lani E.², Vouza R.¹, Bishara S.¹, Donkov I.¹, Alexandrou I.³, Pang K.¹, Zavras N.⁴

Institutions

¹Chelsea and Westminster Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ²Attikon University General Hospital, Athens Medical School, National and Kapodistrian University, 2nd Dept. of Neurosurgery, Athens, Greece, ³Penteli Children's Hospital, Dept. of Pediatric Surgery, Athens, Greece, ⁴School of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Dept. of Pediatric Surgery, Athens, Greece

A0125

Defining the learning curve for pediatric robotic-assisted laparoscopic ureteral reimplantation

Authors

Fu D., Arias J., Zubair Z., Kalidoss S., Gam K., Xing M., Kim D., Gundeti M.

Institutions

University of Chicago, Dept. of Surgery-Section of Urology, Chicago, United States of America

A0126

Trifecta-Based Comparison of Mini-Laparoscopic and Standard Pyeloplasty in the Pediatric Population

Authors

Özden Ö.¹, Mercimek M.N.², Gülsen M.³, Köse E.⁴, Sarikaya S.³, Özden E.³

Institutions

¹Çukurova University, Dept. of Pediatric Surgery, Adana, Turkey, ²Atasam Hospital, Dept. of Urology, Samsun, Turkey, ³Ondokuz Mayıs University, Dept. of Urology, Samsun, Turkey, ⁴Gazi State Hospital, Dept. of Urology, Samsun, Turkey

Infections 1: From bench to bedside

Abstract Session 09

Saturday 14 March
10:30 - 12:00

Location

Blue Area, Victoria 5

Chairs

K. Bausch, Basel (CH)

E. Moshokoa, Midrand (ZA)

To be confirmed

10:30 - 10:50

Antibiotic prophylaxis before urological procedures

A0133

Evaluating the Rapid Uropathogen Identifier Lodestar Dx against Standard Culture and Dipstick for Pre-operative screening.

Authors

Musabyimana C., Kazi S., Yang B.

Institutions

Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom

A0134

Adherence to EAU Recommendations Against Antibiotic Prophylaxis Before Cystoscopy: Results from the Impact Assessment of Guidelines Implementation and Education (IMAGINE) Audit of 12,037 Patients Across 29 European Countries

Authors

Pereira Azevedo N.M.¹, Pilatz A.², Bonkat G.³, Geerlings S.⁴, Kranz J.⁵, Skolarus T.A.⁶, Nieboer D.⁷, Schouten N.⁸, Smith E.J.⁸, N'Dow J.⁹, Ribal M.J.¹⁰, Vynckier P.¹¹, MacLennan S.⁹, Roobol M.J.¹²

Institutions

¹Entre o Douro e Vouga Local Health Unit, Dept. of Urology, Santa Maria da Feira, Portugal, ²Justus-Liebig-University Giessen, Clinic for Urology, Pediatric Urology and Andrology, Giessen, Germany, ³University Basel, alta uro AG, Merian Iselin Klinik, Center of Biomechanics & Calorimetry, Basel, Switzerland, ⁴Amsterdam University Medical Center, Dept. of Internal Medicine, Amsterdam, The Netherlands, ⁵RWTH Aachen University, Dept. of Urology and Pediatric Urology, Aachen, Germany, ⁶University of Chicago, Urology Section, Dept. of Surgery, Chicago, United States of America, ⁷Erasmus MC, University Medical Center, Dept. of Public Health, Rotterdam, The Netherlands, ⁸European Association of Urology, Guidelines Office, Arnhem, The Netherlands, ⁹Institute of Applied Health Sciences, University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ¹⁰Hospital Clinic, University of Barcelona, Uro-Oncology Unit, Barcelona, Spain, ¹¹Ghent University, Dept. of Public Health and Primary Care, Interuniversity Centre for Health Economics Research, Ghent, Belgium, ¹²Erasmus MC, University Medical Center, Dept. of Urology, Rotterdam, The Netherlands

A0135

Optimizing antibiotic stewardship in urodynamic studies through a standardized risk-based prophylaxis protocol

Authors

Azuero J., Garcia Perez V., Ruiz L., Rojas-Rivillas M., Rincon D., Gutierrez A.F., Plata M.

Institutions

Fundación Santa Fe de Bogotá, Dept. of Urology, Bogotá, Colombia

A0136

UROPRIME (UROlogical Prosthetic Infection Model Evaluation): Development of a European Multicenter Nomogram Predicting Perioperative Infectious Risk in Urological Prosthetic Surgery

Authors

Bucca B.¹, Flammia R.S.², Lo Re M.³, Cocci A.³, Falcone M.⁴, Gobbi L.M.¹, Basile G.¹, Acanfora R.¹, Anna R.⁵, Sollazzi E.⁶, Zaccaro C.⁷, Ramón-Calderón J.C.S.⁸, Alonso-Isa M.⁸, García-Gómez B.⁸, Gobbo A.⁹, Lee W.G.⁹, Moncada Iribarren I.⁷, Morgenstern S.¹⁰, Djordjevic M.¹¹, Gozzi C.¹², Franco G.¹, Bettocchi C.⁵, Ralph D.⁹

Institutions

¹University of Rome La Sapienza, Dept. of Urology, Rome, Italy, ²IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ³University of Florence, Dept. of Urology, Florence, Italy, ⁴AOU Città della Salute e della Scienza, University of Turin, Dept. of Urology, Turin, Italy, ⁵University of Foggia, Dept. of Urology and Kidney Transplant, Foggia, Italy, ⁶Azienda Ospedaliero Universitaria Pisana, Dept. of Urology, Pisa, Italy, ⁷Hospital Sanitas La Zarzuela, Dept. of Urology, Madrid, Spain, ⁸Salud Integran del Varón, Instituto de Investigación Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ⁹University College London Hospital, Dept. of Urology, London, United Kingdom, ¹⁰Agaplesion Markus Krankenhaus, Dept. of Reconstructive Urology, Frankfurt, Germany, ¹¹Belgrade Center for Genotourinary Surgery, Dept. of Reconstructive Urology, Belgrade, Serbia, ¹²CityClinic, Dept. of Reconstructive Urology, Bolzano, Italy

10:50 - 10:55

Screening

A0137

Urological Exposomics Analysis Platform: Quantifying the Influence of Dynamic Exposomic Profiles Across Life Stages on Urological Health

Authors

Wei C., Wu Y., Luo Y., He Y., Jin Y., Zhang Z., Zhou X., Yang L., Wei Q., [Qiu S.](#)

Institutions

West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China

10:55 - 11:05

Urosepsis

A0138

Elevation of MNDA during the transition of dendritic cells can serve as an early indicator of urosepsis

Authors

[Zhenglin C.](#), Guohua Z., Siyu S., Hongkai Z., Weizhi Z., Yizhan Y.

Institutions

The First Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangzhou, China

A0139

Construction and validation of a machine learning-based prediction model for urosepsis

Authors

[Ke W.](#), Lianhua Z.

Institutions

Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China

11:05 - 11:35

Diagnosis

A0140

When mpMRI Falls Short: Diagnostic Insights from a LATP Biopsy Cohort

Authors

[Kanwal N.](#)¹, Adenipekun A.¹, Hussain M.², Birring A.¹, Ubee S.¹, Shafik A.¹

Institutions

¹Russells Hall Hospital, Dept. of Urology, Dudley, United Kingdom, ²Queen Elizabeth Hospital, Dept. of Urology, Birmingham, United Kingdom

A0141

tNGS is a rapid and accurate detection method for diagnosing urinary tract infections.

Authors

[Wenzhi G.](#)¹, Yaming G.¹, Wencong H.², Zheng C.²

Institutions

¹Peking University First Hospital, Miyun Hospital, Dept. of Urology, Beijing, China, ²Peking University First Hospital, Dept. of Urology, Beijing, China

A0142

Rapid and Accurate Diagnosis of Urinary Tract Infections Using Targeted Next-Generation Sequencing: A Multicenter Comparative Study with Metagenomic Sequencing and Traditional Culture Methods

Authors

[Zhenglin C.](#), Guohua Z., Yiping L., Runyou T., Jiayi L., Yanqiong Z., Juncheng Y.

Institutions

The First Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangzhou, China

A0143

Impact of Sysmex PA-100 AST System for rapid antibiotic susceptibility test in the management of localised cystitis in a Primary Care setting

Authors

Medina Polo J.¹, Largo Rojo G.², Menendez Fernandez A.I.², Solano Villarrubia C.², Fuentes Romero M.A.², Martínez-Berganza Asensio L.²

Institutions

¹Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ²Centro de Salud Ensanche de Vallecas, Servicio Madrileño de Salud, Dept. of Family and Community Medicine, Madrid, Spain

A0144

How statistically robust are the 2025 EAU guidelines on urological infections? A Fragility Index–based analysis

Authors

Reich N., Yosef E., Shaked Y., Itshak A., Levin N., Neheman A., Vainrib M., Schwartz Gildor O.

Institutions

Meir Medical Center, Dept. of Urology, Kfar Saba, Israel

A0145

External validation of a mortality prediction score in emphysematous pyelonephritis: A multicentric study from tertiary care centers

Authors

Bibi M.¹, Sakly A.², Ben Hmida M.², Karmous J.¹, Bougossa R.³, Chakroun A.², Mosbahi B.⁴, Ouanness Y.¹, Zakhama W.², Binous Y.², Noura Y.¹

Institutions

¹La Rabta University Hospital, Dept. of Urology, Tunis, Tunisia, ²Tahar Sfar University Hospital, Dept. of Urology, Mahdia, Tunisia, ³Tahar Sfar University Hospital, Dept. of Infectious Diseases, Mahdia, Tunisia, ⁴La Rabta University Hospital, Dept. of Anesthesiology, Tunis, Tunisia

11:35 - 12:00

Complicated UTI's

A0146

Randomized controlled trials (RCTs) on complicated urinary tract infection (cUTI) show low adherence to the FDA research guidance, high heterogeneity and poor comparability

Authors

Bjerklund Johansen T.E.¹, Bahrs C.², Bruyere F.³, Cai T.⁴, Etienne M.⁵, Joseph A.⁶, Koves B.⁷, Livermore D.⁸, Oliva A.⁹, Soriano A.¹⁰, Zahl P.H.¹¹, Wagenlehner F.M.E.¹²

Institutions

¹University of Oslo, Dept. of Urology, Oslo, Norway, ²University of Vienna, Dept. of Medicine, Vienna, Austria, ³CHRU Tours, Dept. of Urology, Tours, France, ⁴Santa Chiara Regional Hospital, Dept. of Urology, Trento, Italy, ⁵CHU Rouen, Dept. of Infectious Diseases, Rouen, France, ⁶Nottingham University Hospitals NHS Trust, Dept. of Clinical Microbiology, Nottingham, United Kingdom, ⁷South-Pest Teaching Hospital, Dept. of Urology, Budapest, Hungary, ⁸University of East Anglia, Norwich Medical School, Norwich, United Kingdom, ⁹Sapienza University of Rome, Dept. of Public Health and Infectious Diseases, Rome, Italy, ¹⁰Hospital Clínic of Barcelona, Dept. of Infectious Diseases, Barcelona, Spain, ¹¹Norwegian Institute of Public Health, Division for Mental and Physical Health, Oslo, Norway, ¹²Justus Liebig University Giessen, Dept. of Urology, Pediatric Urology and Andrology, Giessen, Germany

A0147

Accurate and rapid turnaround of four hours for the diagnosis of complicated UTIs using metagenomics

Authors

Ahmad R.¹, Bellankimath A.B.¹, Branders S.¹, Kegel I.², Ali J.¹, Asadi F.¹, Johansen T.E.B.³, Imirzalioglu C.², Hain T.², Wagenlehner F.⁴

Institutions

¹University of Inland Norway, Biotechnology, Hamar, Norway, ²Justus Liebig University Giessen, Institute of Medical Microbiology, Giessen, Germany, ³University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ⁴Justus Liebig University Giessen, Clinic for Urology, Pediatric Urology and Andrology, Giessen, Germany

A0148

Bringing Metagenomics to the Bedside: Personalized Management of cUTIs for Patient Care

Authors

Ahmad R.¹, Bellankimath A.B.¹, Kegel I.², Branders S.¹, Johansen T.E.B.³, Imirzalioglu C.², Hain T.², Wagenlehner F.⁴

Institutions

¹University of Inland Norway, Dept. of Biotechnology, Hamar, Norway, ²Justus Liebig University Giessen, Institute of Medical Microbiology, Giessen, Germany, ³University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ⁴Justus Liebig University Giessen, Clinic for Urology, Pediatric Urology and Andrology, Giessen, Germany

A0149

Efficacy of Vaginal Laser Therapy for Recurrent Cystitis in Postmenopausal Women: First Real-World Clinical Evidence

Authors

Urabe F.¹, Kawaharada A.², Ogihara Y.¹, Kasuya E.¹, Nakata M.¹, Nakazono M.¹, Kimura T.¹, Abe H.³

Institutions

¹The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ²Nihonbashi Pelvic Floor Clinic, Dept. of Urology, Tokyo, Japan, ³Kameda Medical Center, Dept. of Urology, Chiba, Japan

Heterogeneity causes unacceptable risks of bias in studies on new antibiotics and requires abandonment of the concept of complicated urinary tract infection (cUTI)

Authors

Bjerklund Johansen T.E.¹, Bahrs C.², Batura D.³, Bruyere F.⁴, Cai T.⁵, Etienne M.⁶, Graugaard-Jensen C.⁷, Joseph A.⁸, Kaye K.S.⁹, Koves B.¹⁰, Kranz J.¹¹, Lanzafame M.¹², Livermore D.M.¹³, Medina-Polo J.¹⁴, de Novales F.J.M.¹⁵, Naber K.G.¹⁶, Nickel J.C.¹⁷, Oliva A.¹⁸, Schneidewind L.¹⁹, Soriano A.²⁰, Tandogdu Z.²¹, Wagenlehner F.M.E.²², Zahl P.H.²³

Institutions

¹University of Oslo, Dept. of Urology, Oslo, Norway, ²Medical University of Vienna, Dept. of Medicine, Vienna, Austria, ³North West University Healthcare Trust, Dept. of Urology, London, United Kingdom, ⁴CHRU Tours, Dept. of Urology, Tours, France, ⁵Santa Chiara Regional Hospital, Dept. of Urology, Trieste, Italy, ⁶CHU Rouen, Dept. of Infectious Diseases, Rouen, France, ⁷Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ⁸Nottingham University Hospitals, Dept. of Clinical Microbiology, Nottingham, United Kingdom, ⁹Rutgers Robert Wood Johnson Medical School, Dept. of Medicine, New Brunswick, United States of America, ¹⁰South-Pest Teaching Hospital, Dept. of Urology, Budapest, Hungary, ¹¹Uniklinik RWTH Aachen, Dept. of Urology and Pediatric Urology, Aachen, Germany, ¹²Santa Chiara Hospital, Dept. of Infectious Diseases, Trento, Italy, ¹³University of East Anglia, Norwich Medical School, Norwich, United Kingdom, ¹⁴Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ¹⁵Hospital Central de la Defensa Gómez Ulla, CBRN and Infectious Diseases Department, Madrid, Spain, ¹⁶Technical University of Munich, Dept. of Urology, Munich, Germany, ¹⁷Queens University, Dept. of Urology, Kingston, Canada, ¹⁸Sapienza University of Rome, Dept. of Public Health and Infectious Diseases, Rome, Italy, ¹⁹University Hospital Bern, Dept. of Urology, Bern, Switzerland, ²⁰Hospital Clínic of Barcelona, Dept. of Infectious Diseases, Barcelona, Spain, ²¹University College London Hospitals, Dept. of Urology, London, United Kingdom, ²²Justus Liebig University Giessen, Dept. of Urology, Pediatric Urology and Andrology, Giessen, Germany, ²³Norwegian Institute of Public Health, Division for Mental and Physical Health, Oslo, Norway

Saturday 14 March
10:30 - 12:00

Location Blue Area, Victoria 4

Chairs
L. Bukavina, Cleveland (US)
L. Dyrskjøt, Aarhus (DK)
E.A. Gibb, Vancouver (CA)

10:30 - 11:00

Tumour microenvironment and immune regulation

[A0127](#)

Gut Microbiome Shapes the Tumour Immune Microenvironment and Predicts Benefit to RC-48 plus Tislelizumab in Urothelial Bladder Cancer: A Multicentre Cohort with Translational Validation

Authors

[Cheng B.](#), Wu P.

Institutions

Nanfeng hospital Southern Medical University, Dept. of Urology, Guangzhou, China

[A0128](#)

Microbiome Immunogenicity in Bladder Cancer - Associations of Systemic Antibody Repertoires with Treatment Response

Authors

[Suleja A.](#)¹, Hörstke N.², Reyna-Blanco C.², Innocenti G.², Trgovec-Greif L.², Grausenburger R.¹, Prinzensteiner M.², Laukhtina E.¹, Shariat S.F.¹, Szarvas T.³, Vogl T.², Englinger B.¹

Institutions

¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²Medical University of Vienna, Center for Cancer Research, Vienna, Austria, ³Semmelweis University, Dept. of Urology, Budapest, Hungary

A0129

Tumour Microenvironment Analysis by Spatial Transcriptomics in Muscle-Invasive Bladder Cancer to Delineate Therapy Response Biology: Results from the TOMBOLA Trial

Authors

Kohler J.¹, Strandgaard T.¹, Divita T.J.¹, Ginnerup Andreasen T.¹, Thorsen K.¹, Viborg Lindskrog S.¹, Nordentoft I.¹, Lam G.², Hammer Dohn L.³, Fabrin K.⁴, Carus A.⁵, Petersen A.⁶, Nordström Joensen U.⁷, Pappot H.⁸, Søndergaard Holt P.⁹, Viggo Jensen N.¹⁰, Nuhn P.¹¹, Agerbaek M.¹², Bjerggaard Jensen J.¹³, Dyrskjøt L.¹

Institutions

¹Aarhus University Hospital, Dept. of Molecular Medicine, Aarhus, Denmark, ²Herlev Hospital, Dept. of Urology, Herlev, Denmark, ³Herlev Hospital, Dept. of Oncology, Herlev, Denmark, ⁴Aalborg University Hospital, Dept. of Urology, Aalborg, Denmark, ⁵Aalborg University Hospital, Dept. of Oncology & Clinical Cancer Research Center, Aalborg, Denmark, ⁶Aalborg University Hospital, Dept. of Pathology, Aalborg, Denmark, ⁷Copenhagen University Hospital Rigshospitalet, Dept. of Urology, Copenhagen, Denmark, ⁸Rigshospitalet, Dept. of Oncology, Copenhagen, Denmark, ⁹Odense University Hospital, Dept. of Urology, Odense, Denmark, ¹⁰Odense University Hospital, Dept. of Oncology, Odense, Denmark, ¹¹University Hospital Schleswig Holstein, Dept. of Urology, Kiel, Germany, ¹²Aarhus University Hospital, Dept. of Oncology, Aarhus, Denmark, ¹³Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark

A0130

A universal molecular map of bladder cancer: from cell lines in vitro to tumors and back using co-regulatory networks

Authors

Marcq G.¹, Geles K.², Dhifli W.², Eriksson P.³, Bernardo C.³, Guenes C.⁴, Bernard-Pierrot I.⁵, Sjö Dahl G.³, Allory Y.⁵, Radvanyi F.⁵, Elati M.²

Institutions

¹Lille University, Dept. of Urology, Lille, France, ²Univ. Lille, CNRS, Inserm, CHU Lille, CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France, ³Lund University, Skåne University Hospital, Division of Urological Research, Department of Translational Medicine, Malmö, Sweden, ⁴Ulm University, Dept. of Urology, Ulm, Germany, ⁵PSL Research University, CNRS UMR144, Institut Curie, Paris, France

A0131

CAF-derived exosomal ncRNAs reprogram chromatin looping and innate sensing to promote prostate cancer dissemination

Authors

Yu H

Institutions

Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Dept. of Urology, Hangzhou, China

Cancer-associated fibroblast niche drives tumor growth in non-muscle-invasive bladder cancer

Authors

Olislagers M.¹, de Jong F.C.¹, Nakauma-González A.¹, Vermeulen S.², Deiter C.S.³, van Leenders G.J.L.H.⁴, van den Bosch T.P.P.⁴, Roshani H.⁵, Costello J.C.⁶, Mahmoudi T.⁴, Zuiverloon T.C.M.¹

Institutions

¹Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands,

²Radboudumc, Iq Health Science Department, Nijmegen, The Netherlands,

³University of Colorado Anschutz Medical Campus, Dept. of Pharmacology, Aurora, United States of America, ⁴Erasmus MC Cancer Institute, Dept. of Pathology,

Rotterdam, The Netherlands, ⁵Haga Teaching Hospital, Dept. of Urology, The Hague,

The Netherlands, ⁶University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, United States of America

Reconstructive penile and distal urethral surgery: From Peyronie's repair to organ-preserving cancer techniques

Video Session 05

Saturday 14 March
10:30 - 12:00

Location Blue Area, Victoria 1

Chairs To be confirmed

To be confirmed

To be confirmed

V030 (□: 8 min.)

Inflatable Penile Prosthesis Placement & modified Egydio Tunica Expansion Procedure (TEP) for the treatment of severe curvature in Peyronie's disease with concomitant Erectile Dysfunction

L. Karapanos, Leverkusen (DE)

V031 (□: 7 min.)

Outcomes of adult acquired buried penis reconstruction: a multicentre cohort study

To be confirmed

V032 (□: 6 min.)

Diode LASER for the management of PeIN in the outpatient setting - a single centre experience

A.J. Bochinski, Leicester City (GB)

V033 (□: 6 min.)

Glansectomy and Neoglans Reconstruction Using a Free Skin Graft

M.C. Conde Redondo, Valladolid (ES)

V034 (□: 8 min.)

Urethroplasty using double-face buccal mucosa grafts for obliterative penile urethral strictures involving the fossa navicularis

L. Karapanos, Leverkusen (DE)

V035 (□: 5 min.)

Dorso-lateral preputial graft augmentation in panurethral stricture by penile invagination

To be confirmed

Frontiers in functional urology: Emerging challenges and innovations

EAU Section of Functional Urology

Saturday 14 March
10:30 - 12:00**Location** Blue Area, Victoria 2**Chairs** S. Arlandis, Valencia (ES)
E. Finazzi Agrò, Rome (IT)**Learning objectives**

The session will explore some hot topics in functional urology: The role of surgery in this subspecialty and new devices for male incontinence; how to manage voiding dysfunction in female patients and in patients with multiple sclerosis. The aim of this session is to increase the knowledge of the urologists on new technical possibilities and old problems in this subspecialty.

10:30 - 10:33**Introduction**

E. Finazzi Agrò, Rome (IT)

10:33 - 10:43**Is functional urologist a surgeon? - Differences and sometimes underestimated surgical indications in our subspecialty.**

T.J. Greenwell, London (GB)

J. Ockrim, London (GB)

10:43 - 10:48**Discussion****10:48 - 11:18****Debate Female urology: Voiding dysfunction in women***Moderators*

E. Costantini, Perugia (IT)

S. Mourad, Heliopolis (EG)

10:48 - 10:51**Clinical case**

N.I. Osman, Sheffield (GB)

10:51 - 10:54**Is there a role for disobstruction in women?**

B.Y. Padilla Fernandez, Zamora (ES)

10:54 - 10:57**The role of urodynamics**

T. Tarcan, Istanbul (TR)

10:57 - 11:00**Which are the good candidates for neuromodulation?**

M.A. Averbeck, Porto Alegre (BR)

11:00 - 11:15**Debate**

T. Antunes Lopes, Porto (PT)

E. Illiano, Terni (IT)

M.R. Van Balken, Arnhem (NL)

11:15 - 11:18**Clinical Case: How it ended**

N.I. Osman, Sheffield (GB)

11:18 - 11:23

New devices for male incontinence

E. Chartier-Kastler, Paris (FR)

11:23 - 11:28

Discussion

11:28 - 11:58

Debate Neurourology: Challenges in multiple sclerosis patients

Moderators

C. Konstantinidis, Athens (GR)

C. Persu, Bucharest (RO)

11:28 - 11:31

Clinical case

V. Birkhäuser, Zürich (CH)

11:31 - 11:34

Coexisting detrusor under and overactivity in multiple sclerosis patients

N. Mangir Bolat, Ankara (TR)

11:34 - 11:37

How to manage BPO in MS patients

T.M. Kessler, Zurich (CH)

11:37 - 11:40

Sacral or tibial neuromodulation - or..?

J. Krhut, Ostrava (CZ)

11:40 - 11:55

Debate

F. Cruz, Porto (PT)

S. Musco, Florence (IT)

M. Przydacz, Krakow (PL)

K-D. Sievert, Detmold (DE)

11:55 - 11:58

Clinical case: How it ended...

V. Birkhäuser, Zürich (CH)

11:58 - 12:00

Closing remarks

E. Finazzi Agrò, Rome (IT)

Saturday 14 March
10:30 - 12:00

Location Blue Area, George 3

Chairs M. Benyó, Debrecen (HU)
F. Dimitriadis, Thessaloniki (GR)
L.P. Zapala, Warsaw (PL)

Learning objectives

Step into the forefront of urological innovation with ESUO's scientific video session. Experts delve into cutting-edge advancements and refined surgical techniques. Attendees will explore the cultural and medical dimensions of circumcision, the precision of HOLEP for prostate health, and the transformative role of sperm extraction in fertility treatments. The session covers varicocelectomy's impact on vascular health, ureteroscopic lithotripsy's efficiency in stone management, and neuromodulation's effectiveness in treating urinary urgency. Also, attendees will gain insight into vasovasostomy's meticulous approach to restoring fertility post-vasectomy. Elevate your expertise with comprehensive videos and expert insights in modern urology.

10:30 - 10:31

Welcome and introduction

F. Dimitriadis, Thessaloniki (GR)

10:31 - 10:40

Circumcision: Tradition, technique, and modern advancements

A. Khelaia, Tbilisi (GE)

10:40 - 10:43

Questions, comments and discussion

10:43 - 10:52

HOLEP: Laser enucleation of the prostate

W. Krajewski, Wrocław (PL)

10:52 - 10:55

Questions, comments and discussion

10:55 - 11:19

Helmut Haas Session

10:55 - 11:04

Beyond the barrier: Sperm extraction from the vas deferens

N. Sofikitis, Ioannina (GR)

11:04 - 11:07

Questions, comments and discussion

11:07 - 11:16

Breaking stones: Ureteroscopic lithotripsy in action

T.H. Kuru, Köln (DE)

11:16 - 11:19

Questions, comments and discussion

Returning to the general session

11:19 - 11:28

Varicocelectomy: Restoring vascular health for fertility

G. Semini, Tirane (AL)

11:28 - 11:31

Questions, comments and discussion

11:31 - 11:40	Neuromodulation unveiled: Managing urinary urgency with sacral stimulation To be confirmed
11:40 - 11:43	Questions, comments and discussion
11:43 - 11:52	Vasovasostomy: Reversing vasectomy with precision surgery Z. Kopa, Budapest (HU)
11:52 - 11:55	Questions, comments and discussion
11:55 - 12:00	Helmut Haas Award
11:55 - 11:57	In memoriam Helmut Haas and presentation of the Helmut Haas award 2026 winner S.M. Haensel, Rotterdam (NL)
11:57 - 12:00	Winner To be confirmed
12:00 - 12:00	Closing remarks M. Benyó, Debrecen (HU)

EAU Section of Oncological Urology

EAU Oncology

EAU Section of Oncological Urology

Saturday 14 March
10:30 - 12:00

Location Blue Area, George 1

Chairs
G. Giannarini, Udine (IT)
M-O. Grimm, Jena (DE)
A. Volpe, Novara (IT)

Learning objectives

This session led by the EAU Oncology Section aims to enhance participants' understanding of complex decision-making in prostate, bladder and penile cancers. Through expert debates and case-based discussions, attendees will explore multidisciplinary approaches, ethical dilemmas, and emerging strategies in imaging, biomarkers and treatment planning. The program emphasizes bridging clinical trials with real-world practice, reducing surgical morbidity, and evaluating bladder-preserving techniques versus radical interventions - all to improve patient-centered care in oncological urology.

10:30 - 10:32	Introduction
10:32 - 10:52	Hot topics in prostate cancer
10:32 - 10:35	Nightmare case discussion: How NOT to treat a young man with a locally advanced prostate cancer in the PSMA PET era G. Marvaso, Milan (IT)
10:35 - 10:39	What I would have done: Urologist G. Ploussard, Toulouse (FR)
10:39 - 10:43	What I would have done: Radiation oncologist To be confirmed

10:43 - 10:47	What I would have done: Medical oncologist C. Mercinelli, Milan (IT)
10:47 - 10:52	Discussion and take home messages
10:52 - 11:12	Building bridges between trials and practice in advanced prostate cancer
10:52 - 11:02	Current controversies in mHSPC treatment E. Castro, Madrid (ES)
11:02 - 11:12	Legal and ethical dilemmas: When guidelines clash with real world To be confirmed
11:12 - 11:27	Hot topics in penile cancer
11:12 - 11:24	Decreasing morbidity of inguinal lymphadenectomy: Where are we? A. Muneer, London (GB)
11:24 - 11:27	Discussion
11:27 - 11:42	Hot topics in muscle invasive bladder cancer
11:27 - 11:30	Case: I want to keep my bladder - strategies to safely avoid cystectomy in MIBC E. Mensah, London (GB)
11:30 - 11:34	Role of biomarkers L. Dyrskjöt, Aarhus (DK)
11:34 - 11:38	Role of MRI/imaging T. Barrett, Cambridge (GB)
11:38 - 11:42	Role of endoscopic evaluation M. Moschini, Milan (IT)
11:42 - 11:57	Radical treatment is still the standard
11:42 - 11:47	Pro S. Psutka, Seattle (US)
11:47 - 11:52	Con: Let's save the bladder S. Gupta, Cleveland (US)
11:52 - 11:57	Discussion
11:57 - 12:00	Closing remarks

Patient advocacy plaza - Information on prostate cancer in non-specialized books, periodical publications and newspapers



Special Session

Saturday 14 March
10:30 - 11:00

Location Patient Advocacy Plaza
Chair To be confirmed

Hands-on Training in prostate MRI reading for urologists

HOT MRI - 2.1

Saturday 14 March
10:30 - 14:00
Location Red Area, Room 6

Learning objectives

This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on a provided computer using realistic software, followed by a reference reading provided by expert radiologists and pathological verification.

10:30 - 10:35
Course overview

V. Kasivisvanathan, London (GB)

10:35 - 10:45
Lecture: The importance of prostate MRI to the urologist

To be confirmed

10:45 - 11:15
Lecture: Introduction to MRI sequences, scoring systems, PI-RADS

J.A. Hernández Mancera, Barcelona (ES)

11:15 - 11:45
Lecture: Interactive case discussion – reporting MRI using PI-RADS

M. Pecoraro, Rome (IT)

11:45 - 11:50
Introduction to the software for MRI interpretation

V. Kasivisvanathan, London (GB)

11:50 - 12:20
Diagnosis I: Practical MRI diagnosis
12:20 - 12:50
Review of the findings I

J.A. Hernández Mancera, Barcelona (ES)

12:50 - 13:20
Diagnosis II: Practical MRI diagnosis
13:20 - 13:50
Review of the findings II

M. Pecoraro, Rome (IT)

13:50 - 14:00
Discussion, feedback & closure

To be confirmed

Hands-on Training in Urological Ultrasound

HOT Ultrasound - 2.1

Saturday 14 March
10:30 - 13:30

Location Red Area, Room 4

Chairs P. Martino, Bari (IT)
V. Scattoni, Milan (IT)

Learning objectives

The Hands-on Training in Urological ultrasound is designed to provide healthcare professionals with a thorough understanding of urology diagnostics. The course blends expert presentations and practical hands-on sessions, offering participants a solid foundation in urological ultrasound examinations.

By the end of this course, participants will be equipped with the necessary baseline training to implement abdominal ultrasound as well as transrectal ultrasound of the prostate as a routine diagnostic tool in daily practice. The training covers urological ultrasound examinations following standardised procedures, accurately identify normal and pathological findings, and confidently conduct assessments of the urinary tract and genital organs, as well as valuable insights and skills that can be immediately applied to enhance patient care and diagnostic accuracy.

10:30 - 10:35

Introduction

P. Martino, Bari (IT)

10:35 - 10:40

Standard operating procedure for ultrasound examination urinary tract: Kidney and bladder

To be confirmed

10:40 - 10:45

Ultrasound of the kidney and bladder: tip and tricks

To be confirmed

10:45 - 10:50

Ultrasound of prostate and testis: Tips and tricks

To be confirmed

10:50 - 13:20

Hands-on Training: Kidney and bladder / Prostate & testis

Tutors

To be confirmed

To be confirmed

C.B. Maccagnano, Milan (IT)

P. Martino, Bari (IT)

V. Scattoni, Milan (IT)

To be confirmed

13:20 - 13:25

Conclusions

V. Scattoni, Milan (IT)

Saturday 14 March
10:30 - 12:00

Location Orange Area, EGPT 3

Chairs M. Hora, Plzen (CZ)
G.L. Margue, Bordeaux (FR)
To be confirmed

10:30 - 10:55

Local treatment outcomes

[P0381](#)

The impact of Area Deprivation Index on treatment selection for Small Renal Masses. A state-wide analysis

Authors

Santangelo A.¹, Viganò S.¹, Tylecki A.², Silvani C.¹, Considine J.¹, Haddad L.¹, Saeedi N.¹, Niculcea M.¹, Nazzani S.³, Nicolai N.³, Montanari E.⁴, Salonia A.⁵, Montorsi F.⁵, Briganti A.⁵, Rogers C.¹, Abdollah F.¹

Institutions

¹VUI Center for Outcomes Research Analysis and Evaluation Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Urology Unit, Milan, Italy, ⁴Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ⁵IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy

[P0382](#)

16 years of DISSRM experience elucidate the relationship in using both tumor size and growth rate for clinical decisions in patients with small renal masses

Authors

Alkhatib K.¹, Singla N.², Chang P.³, Wagner A.A.³, Pavlovich C.P.², McKiernan J.M.⁴, Guzzo T.J.¹, Allaf M.E.², Pierorazio P.M.⁵

Institutions

¹University of Pennsylvania, Division of Urology, Philadelphia, United States of America, ²The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America, ³Beth Israel Deaconess Medical Center, Division of Urology, Boston, United States of America, ⁴Columbia University Medical Center, Dept. of Urology, New York, United States of America, ⁵University of Pennsylvania, Leonard Davis Institute of Health Economics (Penn LDI), Philadelphia, United States of America

P0383

Aggressive pathologic features and recurrence risk in small renal masses up to 2 centimetres

Authors

Salerno L.¹, Cei F.¹, Re C.¹, Musso G.¹, Piccolo C.¹, Disabato N.¹, Belladelli F.¹, Barretta A.², Ficarra G.¹, Campugiani A.¹, Montesano M.¹, Mercinelli C.³, Maiorano B.³, Tateo V.³, Rosiello G.¹, Matloob R.¹, Bertini R.¹, Vickers A.⁴, Necchi A.³, Briganti A.¹, Salonia A.¹, Montorsi F.¹, Larcher A.¹, Capitanio U.¹

Institutions

¹IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Urology, Bologna, Italy, ³IRCCS San Raffaele Scientific Institute, Dept. of Medical Oncology, Milan, Italy, ⁴Memorial Sloan Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, Milan, Italy

P0384

The current landscape of robotic surgery in patients with cT1 renal masses: a collaborative analysis from the EAU-YAU RCC and US-KIDNET collaborative

Authors

Lambertini L.¹, Okhawere K.E.², Campi R.³, Bertolo R.⁴, Carbonara U.⁵, Marandino L.⁶, Marchioni M.⁷, Palumbo C.⁸, Stifelman M.D.⁹, Roussel E.¹⁰, Sopotro N.¹¹, Rosiello G.¹², Warren H.¹³, Wu Z.¹⁴, Zuluaga L.², Calvo R.S.¹⁵, Crivellaro S.¹⁶, Kaouk J.H.¹¹, Amparore D.¹⁷, Badani K.K.²

Institutions

¹Unit of Oncologic Minimally Invasive Urology and Andrology Careggi Hospital, Dept. of Experimental and Clinical Medicine University of Florence, Florence, Italy, ²Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ³Urological Robotic Surgery and Renal Transplantation Unit, Dept. of Experimental and Clinical Medicine Careggi Hospital University of Florence, Florence, Italy, ⁴University of Verona Azienda Ospedaliera Universitaria Integrata, Dept. of Urology, Verona, Italy, ⁵Unit of Andrology and Kidney Transplantation, Dept. of Emergency and Organ Transplantation Urology Bari, Bari, Italy, ⁶Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, United Kingdom, ⁷Università degli Studi "G. d'Annunzio" of Chieti, Dept. of Medical Oral and Biotechnological Science, Chieti, Italy, ⁸Maggiore della Carità Hospital, Unit of Urology, Novara, Italy, ⁹Hackensack University Medical Center, Dept. of Urology, Hackensack, United States of America, ¹⁰University Hospitals of Leuven, Dept. of Urology, Leuven, Belgium, ¹¹Glickman Urological and Kidney Institute, Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ¹²IRCCS San Raffaele Scientific Institute, Urological Research Institute URI, Milan, Italy, ¹³University College London, Dept. of Urology, London, United Kingdom, ¹⁴Changhai Hospital Naval Medical University, Dept. of Urology, Shanghai, China, ¹⁵University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America, ¹⁶University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America, ¹⁷Candiolo Cancer Institute FPO IRCCS, University of Turin, Division of Urology, Dept. of Oncology and Dept. of Surgery, Turin, Italy

P0385

Simple nephrectomy is not always simple – comparing outcomes of simple versus radical nephrectomy

Authors

Ng T., Zhuo G., Ho M.H., Yong D., Leow J.

Institutions

Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore

P0386

Beyond the Learning Curve: Continuous Improvement in Surgical Precision and Functional Outcomes during Robot-Assisted Partial Nephrectomy with the Hugo™ RAS System

Authors

Prata F., Tedesco F., Ragusa A., Iannuzzi A., Fantozzi M., Rosca V., Cirillo R., Liaci F., De Giuseppe A., Raso G., Leccese F., De Carlo C., Santaniello A.M., De Stefano L., Ruggeri S., Liburdi I., Tuzzolo P., Civitella A., Papalia R.

Institutions

Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy

P0387

Beyond Case Count: A Risk-Adjusted Learning Curve Model for Robotic Partial Nephrectomy

Authors

Singh R., Tarigopula V., Tiwari A., Addla S.

Institutions

Apollo Cancer Institutes, Dept. of Uro-Oncology, Hyderabad, India

P0388

MASTERING SINGLE PORT ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY WITH THE LOW ANTERIOR ACCESS: A LEARNING CURVE ANALYSIS WITH COMPARISON OF PERIOPERATIVE OUTCOMES

Authors

Santarelli V.¹, Haberal H.B.², Morgantini L.A.², Carletti F.², Turcan A.², Tamborino F.², Valenzi F.M.², Del Giudice F.¹, Sciarra A.¹, Crivellaro S.²

Institutions

¹Sapienza University of Rome, Dept. of Maternal Infant and Urological Sciences, Rome, Italy, ²University of Illinois Chicago, Dept. of Urology, Chicago, United States of America

P0389

Quantifying surgical experience and performance improvement in Robot-Assisted Partial Nephrectomy using intraoperative analytics

Authors

Prata F.¹, De Backer P.², Mezzina M.², Sys T.², Carl N.², Beatrice E.³, Barretta A.³, Brancelli C.³, Cavarra V.³, De Angelis M.³, Guidotti A.³, Pepillo F.³, Rodriguez N.P.³, Tedesco F.¹, Ragusa A.¹, Iannuzzi A.¹, Fantozzi M.¹, Rosca V.¹, Cirillo R.¹, Liaci F.¹, Civitella A.¹, De Groote R.³, Papalia R.¹, Mottrie A.³

Institutions

¹Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy, ²ORSI Academy, ORSI Innotech, Melle, Belgium, ³AZORG Hospital, Dept. of Urology, Aalst, Belgium

P0390

Learning curve and perioperative outcomes of single-port vs. multi-port robot-assisted partial nephrectomy: First European comparative analysis

Authors

Ernest K., David A., Fanconi M., Sigg S., Baumeister P., Mattei A., Fankhauser C.D., Affentranger A.

Institutions

University Teaching and Research Hospital of the University of Lucerne, Dept. of Urology, Lucerne, Switzerland

Decision-making discordance between multidisciplinary tumor board (MDT), EAU Guidelines artificial intelligence (AI) Chatbot, and ChatGPT for patients with renal cancer: a single-Centre prospective cohort study

Authors

Granata S.¹, Crescente A.², Dibilio E.², Bocu G.³, Pecoraro A.⁴, Sessa F.⁴, Doni L.⁵, Micol Mela M.⁵, Francini E.⁵, Rossi V.⁵, Garlatti P.⁶, Francolini G.⁶, Aquilano M.⁶, Agostini S.⁷, Vaggelli L.⁸, Raspollini M.R.⁹, Serni S.⁴, Masieri L.⁴, Campi R.⁴

Institutions

¹AOU Careggi, Urological Robotic Surgery and Renal Transplantation Unit and Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy, ²AOU Careggi, Urological Robotic Surgery and Renal Transplantation Unit and Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy, ³University of Florence, Dept. of Experimental and Clinical Medicine, Florence, Italy, ⁴AOU Careggi, Dept. of Urology and Renal Transplantation, Florence, Italy, ⁵AOU Careggi, Dept. of Oncology, Florence, Italy, ⁶AOU Careggi, Radiation Oncology Unit, Florence, Italy, ⁷AOU Careggi, Dept. of Radiology, Florence, Italy, ⁸AOU Careggi, Nuclear Medicine Division, Florence, Italy, ⁹AOU Careggi, Dept. of Histopathology and Molecular Diagnostics, Florence, Italy

Defining Standards for Retroperitoneal Single-Port Robotic Surgery: the ARISE International Delphi Consensus

Authors

Spena G.¹, Contieri R.¹, Paciotti M.², Briganti A.³, Buffi N.M.², De Groot R.⁴, Dell'Oglio P.⁵, Galfano A.⁵, Aveta A.¹, Gontero P.⁶, Izzo A.¹, Kaouk J.⁷, Nathan S.⁸, Porpiglia F.⁹, Simone G.¹⁰, Zhenjie W.¹¹, Crivellaro S.¹², Autorino R.⁷, Perdonà S.¹

Institutions

¹Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Dept. of Urology, Naples, Italy, ²Humanitas Research Hospital - IRCCS, Dept. of Urology, Rozzano, Italy, ³IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁴Onze-Lieve-Vrouw Hospital, Dept. of Urology, Aalst, Belgium, ⁵ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ⁶University of Torino School of Medicine, Dept. of Urology, Turin, Italy, ⁷Glickman Urological Institute, Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ⁸University College London Hospital, Dept. of Urology, London, United Kingdom, ⁹University of Turin, San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, ¹⁰IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹¹Changhai Hospital, Naval Medical University, Dept. of Urology, Shanghai, China, ¹²University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America

Multi-center real-world evidence on preoperative systemic therapy for clear cell renal cell carcinoma patients with inferior vena cava tumor thrombus

Authors

Wang Y.¹, Wu Z.², Zou X.³, Peng Y.³, Zhu S.⁴, Yang W.⁵, Xing J.⁶, Ji C.⁵, Zhang Z.³, Huang J.², Ma X.¹, Zhang X.¹, Liangyou G.¹

Institutions

¹Chinese PLA General Hospital, Senior Dept. of Urology, Beijing, China, ²Renji Hospital Affiliated to Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China, ³Sun Yat-Sen University Cancer Center, Dept. of Urology, Guangzhou, China, ⁴The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China, ⁵Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China, ⁶The First Affiliated Hospital of Xiamen University, Dept. of Urology, Xiamen, China

P0394

**What is required to deliver practice changing neoadjuvant trials in kidney cancer?
An International Neoadjuvant Kidney Cancer Consortium Delphi study**

Authors

Rossi S.¹, Choueiri T.K.², Jewett M.³, Jones J.O.⁴, Laird A.⁵, Lewis B.⁶, Tippu Z.⁷, Van Der Mijn J.C.K.⁸, Bex A.⁹, Stewart G.D.¹

Institutions

¹University of Cambridge, Dept. of Surgery, Cambridge, United Kingdom, ²Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, United States of America, ³Princess Margaret Cancer Centre, University Health Network and University of Toronto, Dept. of Surgery, Toronto, United Kingdom, ⁴University of Cambridge, Dept. of Oncology, Cambridge, United Kingdom, ⁵Western General Hospital, Dept. of Urology, Udimburgh, United Kingdom, ⁶KidneyCAN, KidneyCAN, Philadelphia, United States of America, ⁷Francis Crick Institute, Francis Crick Institute, London, United Kingdom, ⁸Netherlands Cancer Institute, Dept. of Medical Oncology, Amsterdam, The Netherlands, ⁹Royal Free London NHS Foundation Trust, University College London, Dept. of Surgery, London, United Kingdom

P0395

A Phase II Study of Neoadjuvant Lenvatinib and Cadonilimab in High-Risk Localized and Locally Advanced Renal Cell Carcinoma (POST-RCC-01): Achieving Primary Endpoint in Simon's First Stage

Authors

Dong W., Zheng J., Huang M., Liu Q., Qi Y.

Institutions

Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China

P0396

Adjuvant Pembrolizumab for Surgically Treated Clear Cell Renal Cell Carcinoma: the first experience of high-volume referral centers

Authors

Sordelli F.¹, Basile G.², Kuvda V.³, Nally E.⁴, Hughes D.³, Barod R.², Reekhaye A.², Yao M.², Hani A.², Prasad P.², Mumtaz F.², El Sheikh S.⁵, Buffi N.M.¹, Rullan A.³, Powels T.⁴, Bex A.²

Institutions

¹Humanitas University, Dept. of Biomedical Sciences, Pieve Emanuele, Italy, ²Royal Free Hospital, Dept. of Urology, London, United Kingdom, ³Royal Free Hospital, Dept. of Oncology, London, United Kingdom, ⁴Barts Cancer Institute, Dept. of Oncology, London, United Kingdom, ⁵Royal Free Hospital, Dept. of Pathology, London, United Kingdom

P0398

Eligibility for Adjuvant Pembrolizumab and Real-World Survival Outcomes in Portuguese Clear Cell Renal Cell Carcinoma: A Multicenter National Study

Authors

Oliveira B.¹, Bastos S.², Quintas F.³, Chambel V.⁴, Sousa T.⁵, Vasconcelos M.⁶, Fernandes P.L.⁷, Oliveira V.T.², Palma dos Reis J.P.³, Fraga A.¹, Ramos M.¹

Institutions

¹Unidade Local de Saúde de Santo António, Dept. of Urology, Porto, Portugal, ²Unidade Local de Saúde de Vila Nova de Gaia/Espinho, Dept. of Urology, Vila Nova de Gaia, Portugal, ³Unidade Local de Saúde de Lisboa Norte, Dept. of Urology, Lisbon, Portugal, ⁴Unidade Local de Saúde de Lisboa Ocidental, Dept. of Urology, Lisbon, Portugal, ⁵Unidade Local de Saúde de Coimbra, Dept. of Urology, Coimbra, Portugal, ⁶Unidade Local de Saúde de Almada-Seixal, Dept. of Urology, Almada, Portugal, ⁷Unidade Local de Saúde do Alto Ave, Dept. of Urology, Guimarães, Portugal

Saturday 14 March
10:30 - 12:00

Location Orange Area, EGPT 5

Chairs
A. Abdel Karim, Alexandria (EG)
E.K. Bres-Niewada, Pruszkow (PL)
M. Fernández, Santiago (CL)

10:30 - 10:40

Predicting success

[P0417](#)

Residual Stone Volume, Rather Than Stone-Free Status, Predicts Downstream Healthcare Utilization After Ureteroscopy: Secondary Analysis of the ASPIRE Trial

Authors

Johnson B.¹, Stern K.², Chi T.³, Lipkin M.⁴, Wolf S.⁵, Preminger G.⁴, Matlaga B.⁶

Institutions

¹University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, ²May Clinic Arizona, Dept. of Urology, Phoenix, United States of America, ³University of Alabama Birmingham, Dept. of Urology, Birmingham, United States of America, ⁴Duke University, Dept. of Urology, Durham, United States of America, ⁵University of Texas Austin, Dept. of Urology, Austin, United States of America, ⁶Johns Hopkins University, Dept. of Urology, Baltimore, United States of America

[P0418](#)

Gout is Associated with Increased Risk for Surgical Recurrence in Calcium Oxalate Stone Formers: A Propensity-Score Matched Cohort Study

Authors

Tamir H.B., Aviv T., Darawshe A.A., Erlich Y., Golan S., Lifshitz D.

Institutions

Rabin Medical Center, Dept. of Urology, Petah Tikva, Israel

10:40 - 10:45

Stone passage

[P0419](#)

Double versus Triple Drug Regimen for Ureteric Stone Medical Expulsion Therapy - A Prospective Study from Central India.

Authors

Kaushal D.¹, Rathor K.¹, Balakrishnan S.², Madhavan K.¹, Sharma J.¹, Sood A.¹

Institutions

¹All India Institute of Medical Sciences, Dept. of Urology, Bhopal, India, ²All India Institute of Medical Sciences, Dept. of Pharmacology, Bhopal, India

10:45 - 11:10

Follow-up

P0420

Characterizing Pain Interference after Ureteroscopy: Who Does It Affect and for How Long?

Authors

Uy MU¹, Seibel C.¹, Daignault-Newton S.¹, Kleer E.², Pimental H.³, Seifman B.⁴, Sui W.¹, Dauw C.¹, Ghani K.¹

Institutions

¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²Trinity Health IHA Medical Group, Dept. of Urology, Ann Arbor, United States of America, ³Corewell Health, Dept. of Urology, Grand Rapids, United States of America, ⁴Michigan Institute of Urology, Dept. of Urology, Rochester Hills, United States of America

P0421

Patient Quality of Life and Caregiver Strain after Ureteroscopy for Stone Disease

Authors

Ziamba J.¹, Johny A.², Wang S.L.W.¹, Li N.³, Stambakio H.¹, Tasian G.E.T.⁴, Huang J.⁵

Institutions

¹Perelman School of Medicine at the University of Pennsylvania, Division of Urology, Philadelphia, United States of America, ²Chesapeake Urology Associates, Dept. of Urology, Bethesda, United States of America, ³Children's Hospital of Philadelphia, Dept. of Biostatistics and Data Management Core, Philadelphia, United States of America, ⁴Children's Hospital of Philadelphia, Division of Urology, Philadelphia, United States of America, ⁵Perelman School of Medicine at the University of Pennsylvania, Dept. of Biostatistics, Epidemiology and Informatics, Philadelphia, United States of America

P0422

Assessing financial toxicity in Cystinuria: The impact on healthcare utilization and out-of-pocket spending

Authors

Cabo J.¹, Vaughan A.¹, Bultitude M.², Thomas K.², Edison E.², Humphreys M.R.H.¹, Stern K.L.S.¹

Institutions

¹Mayo Clinic Arizona, Dept. of Urology, Phoenix, United States of America, ²Guy's and St. Thomas Hospital, Dept. of Urology, London, United Kingdom

P0423

Modelling the Health Economic Impact of the EAU Urolithiasis Follow-Up Algorithm

Authors

Geraghty R.¹, Reicher J.², Rogers A.¹, Dickinson A.³, Joshi H.⁴, Howles S.⁵, Sayer J.⁶, Sagoo G.⁷

Institutions

¹Freeman Hospital, Dept. of Urology, Newcastle upon Tyne, United Kingdom, ²Freeman Hospital, Dept. of Interventional Radiology, Newcastle upon Tyne, United Kingdom, ³Plymouth University Hospital, Dept. of Urology, Plymouth, United Kingdom, ⁴University Hospital of Wales, Dept. of Urology, Cardiff, United Kingdom, ⁵Oxford University Hospital, Dept. of Urology, Oxford, United Kingdom, ⁶Freeman Hospital, Dept. of Nephrology, Newcastle upon Tyne, United Kingdom, ⁷Newcastle University, Dept. of Health Economics, Newcastle upon Tyne, United Kingdom

P0424

The Role of a WhatsApp-Based Interactive Follow-up Protocol in Reducing Non-Adherence and Forgotten Stents in Urolithiasis Patients

Authors

Patil A., Kamble A., Sharma S.

Institutions

Grant Government Medical College and Sir J.J. Group of Hospitals, Dept. of Urology, Mumbai, India

11:10 - 11:25

Urine and serum monitoring

P0425

A home device measuring urine quality for preventing recurrent urolithiasis

Authors

Tsai V.F.S.¹, Tseng S.S.¹, Chen C.C.¹, Tsai P.H.¹, Tsai Y.C.¹, Pong Y.H.², Chung W.Y.³, Ramezani R.F.³, Silverio A.A.³

Institutions

¹Taipei Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation, Dept. of Urology, New Taipei City, Taiwan, ²Ten-Chen General Hospital, Dept. of Urology, Taoyuan, Taiwan, ³Chung Yuan Christian University, Dept. of Electronic Engineering, Taoyuan, Taiwan

P0426

Chemiluminescence of urine as a predictor of recurrent stone formation

Authors

Kutluev M.¹, Grigoriev N.², Kotov S.³

Institutions

¹MMCC Kommunarka, Dept. of Oncological Urology, Moscow, Russia, ²Group of companies European Medical Center, Dept. of Urology, Moscow, Russia, ³Pirogov Russian National Research Medical University, Dept. of Urology and Andrology, Moscow, Russia

P0427

Serum cystatin C and globulin as independent risk factors for recurrence of calcium oxalate stones: A retrospective cohort study

Authors

Xia K., Yu J., Hao Z.

Institutions

The First Affiliated Hospital of Anhui Medical University, Dept. of Urology, Hefei, China

11:25 - 11:30

Radiological Detection

P0428

Leveraging high-resolution 3D micro-CT imaging to predict calcium oxalate and uric acid compositions in kidney stones

Authors

Hammoud A.¹, Hughes G.², Lee J.³, Wong R.¹, Berjaoui M.B.¹, Mookerji N.¹, Safi T.⁴, Carillo B.⁵, Farcas M.¹

Institutions

¹St. Michael's Hospital, Division of Urology, Toronto, Canada, ²University of Toronto, Temerty Faculty of Medicine, Toronto, Canada, ³McMaster University, Faculty of Health Sciences, Department of Medicine, Hamilton, Canada, ⁴Royal College of Surgeons in Ireland, Faculty of Medicine, Dublin, Ireland, ⁵Wellspring Research, Toronto, Canada

11:30 - 12:00

Stone prevention

P0429

Urinary supersaturation in a Randomized trial among Individuals with Nephrolithiasis comparing Empiric versus selective therapy (URINE)

Authors

Hsi R.¹, Lee A.², Koyama T.², Widmer A.³, Silver H.³, Goldfarb D.⁴

Institutions

¹University of California Irvine, Dept. of Urology, Orange, United States of America, ²Vanderbilt University Medical Center, Dept. of Biostatistics, Nashville, United States of America, ³Vanderbilt University Medical Center, Dept. of Medicine, Nashville, United States of America, ⁴NYU Langone Health and NYU Grossman School of Medicine, Dept. of Medicine, New York, United States of America

P0430

Impact of a Multidisciplinary Clinic on Patient Adherence to Preventive Treatment for Kidney Stones – A Prospective Study

Authors

Golomb D.¹, Confino I.¹, Atamna F.¹, Avda Y.¹, Leiba A.², Hausmann M.², Cooper A.¹, Raz O.¹

Institutions

¹Assuta Ashdod University Hospital, Dept. of Urology, Ashdod, Israel, ²Assuta Ashdod University Hospital, Dept. of Nephrology, Ashdod, Israel

P0431

Economic and clinical impact of Potassium Citrate in kidney stone disease: a systematic review and economic evidence synthesis

Authors

Pischetola A.¹, Talyshinskii A.², Somani B.³

Institutions

¹University Campus Bio-Medico of Rome, Dept. of Medicine, Rome, Italy, ²Astana Medical University, Dept. of Urology, Astana, Kazakhstan, ³University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom

P0432

Role of SGLT2 inhibitors in urinary stone prevention

Authors

Iereidis S., Alotaibi T., Alturki A., Khan Y., Bjazevic J., Razvi H.

Institutions

Western University, Dept. of Urology, London, Canada

P0433

Balancing renal risk and stone prevention: real-world outcomes of febuxostat versus allopurinol

Authors

Su S-C., Lin Y.S., Hsu C.Y., Ou Y.C., Tung M.C.

Institutions

Tungs' Taichung MetroHarbor Hospital, Dept. of Urology, Taichung, Taiwan

Saturday 14 March
10:30 - 12:00

Location Orange Area, EGPT 2

Chairs
C. Cano Garcia, Frankfurt am Main (DE)
P. Mariappan, Edinburgh (GB)
I. Minčík, Presov (SK)

10:30 - 11:00

Response to neoadjuvant chemotherapy in muscle-invasive bladder cancer

P0363

How far are we from bladder sparing after complete response to neoadjuvant chemotherapy?

Authors

Robesti D.¹, Ploussard G.², Fallara G.³, Briganti A.¹, Montorsi F.¹, van der Heijden A.G.⁴, Malavaud B.², Martini A.⁵

Institutions

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Institut Universitaire du Cancer Toulouse-Oncopôle, Dept. of Urology, Toulouse, France, ³Santi Paolo e Carlo, Dept. of Urology, Milan, Italy, ⁴Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ⁵University of Cincinnati College of Medicine, Dept. of Urology, Cincinnati, United States of America

P0364

Contemporary Trends and Predictors of pT0 at Radical Cystectomy Specimens among Non-Muscle or Muscle Invasive Bladder Cancer Patients: A Propensity Score-Matched Analysis from a Single Tertiary Centre in the United Kingdom

Authors

Asero V.¹, Del Giudice F.¹, Santarelli V.¹, Corvino R.¹, Spurna K.², Ali Kirmani S.G.², Bhatti N.H.², Abu-Ghanem Y.², Challacome B.², Razeto E.¹, Sciarra A.¹, De Berardinis E.¹, Chung B.I.³, Thuraraja R.², Khan M.S.², Nair R.²

Institutions

¹Sapienza University of Rome, Umberto I Hospital, Dept. of Maternal-Infant and Urological Sciences, Rome, Italy, ²Guy's Hospital London, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, ³Stanford University School of Medicine, Dept. of Urology, Stanford, United States of America

P0365

Short-Term Impact of Neoadjuvant Chemotherapy on Urinary Complications After Radical Cystectomy and Ileal Neobladder

Authors

Yoon Y.¹, Ko Y.H.¹, Jo J.², Kim M.S.¹, Shin J.H.¹, Ryu H.¹, Shin T.Y.¹, Park S.³, Lee H.J.⁴, Jung W.⁵, Kim W.¹, Chung W.S.¹, Kim C.S.¹, Lee D.H.¹

Institutions

¹Ewha Womans University Mokdong Hospital, Dept. of Urology, Seoul, South Korea, ²Ewha Womans University College of Medicine, Dept. of Oncology, Seoul, South Korea, ³Ewha Womans University College of Medicine, Dept. of Pathology, Seoul, South Korea, ⁴Ewha Womans University College of Medicine, Dept. of Radiology, Seoul, South Korea, ⁵Ewha Womans University College of Medicine, Dept. of Radiation Oncology, Seoul, South Korea

P0366

Diagnostic Accuracy of the nacVI-RADS Scoring System Using Bi-parametric 3-Tesla MRI After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

Authors

Laymon M.¹, El-sawy A.¹, Elkarta A.¹, Badawy M.¹, Elsorogy A.¹, Mahmoud O.², Abol-Enein H.¹

Institutions

¹Mansoura University, Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt, ²South Valley University, Dept. of Urology, Qena, Egypt

P0367

Machine learning analysis for predicting pathological complete response after chemoradiotherapy in patients with muscle-invasive bladder cancer

Authors

Fujiwara M.¹, Tanaka H.¹, Hirahara D.², Saho T.³, Takaya E.⁴, Ito T.¹, Muta E.¹, Urushido M.¹, Matsumoto S.¹, Kobayashi M.¹, Nakamura Y.¹, Chen W.¹, Ishikawa Y.¹, Fukushima H.¹, Fukuda S.¹, Waseda Y.¹, Yasuda Y.¹, Yoshida S.¹, Fujii Y.¹

Institutions

¹Institute of Science Tokyo, Dept. of Urology, Tokyo, Japan, ²Harada Academy, Dept. of AI Research Lab, Kagoshima, Japan, ³Kokura Memorial Hospital, Dept. of Radiological Technology, Fukuoka, Japan, ⁴Tohoku University Hospital, AI Laboratory, Miyagi, Japan

P0368

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Improves Long-Term Oncological Control Over Gemcitabine–Cisplatin in Muscle-Invasive Bladder Cancer: A Real-World Emulation of the VESPER Trial Using a Cure Modeling Approach

Authors

Subiela Henriquez J.D.¹, Scilipoti P.², de Angelis M.², Grobet-Jeandin E.³, Thibault C.⁴, Diamant E.⁵, Gabriel P.E.⁶, Harber T.O.⁷, Colombel M.⁷, Hanquiez P.⁸, Duquesne I.⁹, Verhoest G.¹⁰, Surlemont L.¹¹, Masson-Lecomte A.¹², Lebacle C.D.¹³, Léon P.¹⁴, Larré S.P.¹⁵, Gautier M.¹⁶, Artiles A.¹, Pichler R.¹⁷, Pradere B.¹⁸, Moschini M.², Roupret M.⁶, Seisen T.⁶

Institutions

¹Hospital Universitario Ramón y Cajal, Dept. of Urology, Madrid, Spain, ²IRCCS Ospedale San Raffaele, Dept. of Experimental Oncology/Unit of Urology, Milan, Italy, ³Geneva University Hospitals, Division of Urology, Geneva, Switzerland, ⁴Hopital Européen Georges Pompidou, APHP Centre, Institut du Cancer Paris CARPEM, Dept. of Medical Oncology, Paris, France, ⁵Henri Mondor Hospital, University of Paris Est Créteil, Dept. of Urology, Paris, France, ⁶Pitie-Salpetriere Hospital, Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Paris, Spain, ⁷Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Dept. of Urology, Pierre-Bénite, France, ⁸Lyon Sud Hospital, Dept. of Urology, Lyon, France, ⁹Cochin Hospital, APHP, Université Paris Cité, Dept. of Urology, Paris, France, ¹⁰University Hospital of Rennes, Dept. of Urology, Rennes, France, ¹¹Rouen University Hospital, Dept. of Urology, Rouen, France, ¹²Saint Louis Hospital, Université Paris Cité, Dept. of Urology, Paris, France, ¹³University Hospital of Bicêtre-Paris Sud-Saclay University, Le Kremlin Bicêtre, Dept. of Urology, Paris, France, ¹⁴Clinique Pasteur, Dept. of Urology, Royan, France, ¹⁵Reims University Hospital, Dept. of Urology, Reims, France, ¹⁶Claude Huriez Hospital, Dept. of Urology, Lille, France, ¹⁷Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ¹⁸La Croix Du Sud Hospital, Quint-Fonsegrives, Dept. of Urology, Toulouse, France

P0369

Using the severity of hematuria at the emergency department to identify patients at risk for Muscle-Invasive Bladder Cancer

Authors

Shafran Y., Fazaa N., Eigner E., Amiel G.E., Hoffman A.

Institutions

Rambam Health Care Campus, Dept. of Urology, Haifa, Israel

P0370

Introducing MRI into the diagnostic pathway for bladder masses: a health economic analysis

Authors

Sathianathan N., Lawrentschuk N., Ischia J., Perera M., Bolton D.

Institutions

University of Melbourne, Dept. of Surgery, Melbourne, Australia

P0371

Prospective Study on Biparametric MRI-based multi-planar VI-RADS for assessing muscle invasion in bladder cancer

Authors

Yang X., Cao Q., Lyu Q., Wang C.

Institutions

The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

P0372

Development of a Deep Learning Model for MRI of Muscle - Invasive Bladder Cancer Based on Teacher - Student Knowledge Distillation

Authors

Hao Z.H.¹, Li D.Y.², Guo H.Q.¹, Yang R.¹

Institutions

¹Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Dept. of Urology, Nanjing, China, ²Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Dept. of Radiology, Nanjing, China

P0373

Predicting Gene Expression and Patient Outcomes in Muscle-Invasive Bladder Cancer using Integrated Foundation Model Ensemble

Authors

Koll F.J.¹, Mathisen I.F.², Mayer R.², Laib A.², Reis H.², Bein J.², Wenzel M.³, Chun F.K.H.³, Koellermann J.², Schulz M.⁴, Flinner N.², Wild P.²

Institutions

¹Medical University of Graz, Dept. of Urology, Graz, Austria, ²Goethe-University Frankfurt, Dr. Senckenberg Institutes of Pathology and Human Genetics, Frankfurt am Main, Germany, ³University Hospital Frankfurt, Dept. of Urology, Frankfurt am Main, Germany, ⁴Goethe-University Frankfurt, Institute for Computational Genomic Medicine, Frankfurt am Main, Germany

P0374

Component and Total Healthcare-Related Costs of Bladder Cancer in a Universal Healthcare System

Authors

Cheung D.¹, May J.², Bremner K.¹, Papasideris M.¹, Black P.³, Kassouf W.⁴, Wong W.², Kulkarni G.¹

Institutions

¹University of Toronto, Dept. of Surgery Division of Urology, Toronto, Canada, ²University of Waterloo, School of Pharmacy, Waterloo, Canada, ³University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ⁴McGill University Health Center, Dept. of Surgery Division of Urology, Montréal, Canada

P0375

Intervention strategy selection for bladder preservation maintenance therapy in MIBC patients: a multi-center retrospective study

Authors

Ou Z.¹, Shi W.T.¹, Xu D.M.², Wu L.X.¹, Mo M.¹, Li N.N.³, Wang J.⁴, Chen M.F.¹

Institutions

¹Xiangya Hospital Central South University, Dept. of Urology, Changsha, China, ²Sun Yat-sen University Cancer Center, Dept. of Urology, Guangzhou, China, ³The Affiliated Changsha Hospital of Xiangya School of Medicine CentralSouth University, Dept. of Urology, Changsha, China, ⁴Hunan Cancer Hospital, Dept. of Radiotherapy, Changsha, China

11:35 - 12:00

Risk of metastatic disease in localised muscle-invasive bladder cancer

P0376

Prognostic Value of Perioperative ctDNA Dynamics in Patients Undergoing Radical Cystectomy for Bladder Cancer

Authors

Zhu A.¹, Eraky A.¹, Gupta R.¹, Ben-David R.², Mehrazin R.¹, Wiklund P.¹, Sfakianos J.¹

Institutions

¹Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ²Tel Aviv Sourasky Medical Center, Dept. of Urology, Tel Aviv, Israel

P0377

Utilization of Perioperative Systemic Therapy in Muscle-Invasive Bladder Cancer: A Real-World Survey-based Analysis of 323 Patients in Germany

Authors

Rausch S.¹, Dostalova Z.², Strobel K.², Friese M.², Rückert M.²

Institutions

¹Eberhard-Karls-University Tübingen, Dept. of Urology, Tübingen, Germany, ²Trientx Oncology, CancerDataNet GmbH, Freiburg, Germany

P0378

Ex vivo culture to evaluate dynamic changes in the tumor microenvironment following durvalumab treatment.

Authors

Gris T., Shore H., Boibessot C., Menard C., Fradet V., Lacombe L., Pouliot F., Fradet Y., Toren P.

Institutions

CHU de Québec-Université Laval, Dept. of Surgery, Quebec City, Canada

P0379

Surgical Bladder Preservation in Muscle-Invasive Bladder Cancer: Early oncological and safety results in a contemporary series

Authors

[González-Padilla D.A.](#)¹, Cano-Velasco J.², Muñoz-Bastidas C.¹, Yanez-Ruiz C.³, Sánchez-Zalabardo D.², Villacampa-Aubá F.⁴, Minana-López B.⁴

Institutions

¹Clínica Universidad de Navarra, Dept. of Urology, Bladder and Kidney Cancer Unit, Madrid, Spain, ²Clínica Universidad de Navarra, Dept. of Urology (Bladder and Kidney Cancer Unit), Pamplona, Spain, ³Clínica Universidad de Navarra, Dept. of Urology, Pamplona, Spain, ⁴Clínica Universidad de Navarra, Dept. of Urology (Bladder and Kidney Cancer Unit), Madrid, Spain

P0380

Peptides translation of IncLRRTM4 sustains the lymphatic metastasis of bladder cancer

Authors

[Chen C.](#), Li Y.

Institutions

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Dept. of Urology, Guangzhou, China

High-risk and locally-advanced Prostate Cancer: Neoadjuvant Strategies and Radical Prostatectomy Outcomes

EGPT 20

Saturday 14 March
10:30 - 12:00

Location

Orange Area, EGPT 1

Chairs

T. Esen, Istanbul (TR)
N. Fossati, Lugano (CH)
S.T. Pang, Taipei (TW)

10:30 - 11:15

Neoadjuvant treatment before radical prostatectomy

P0345

Impact of Neoadjuvant Hormonal Therapy Duration on PSA Response and Pathological Outcomes in High-Risk Prostate Cancer: A Retrospective Analysis

Authors

[Huang Y.](#), Pang X., Wen Z.P., Long X., Zeng B., Liang J., Sha H., Yang J., Wang Y., Xie T., Zhong J., Li M., Liu Y., Gu D.

Institutions

The First Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangzhou, China

P0346

Response-Adapted Neoadjuvant Intensification with Abiraterone and LHRH Agonist ± Docetaxel Before Radical Prostatectomy in High-Risk Localized Prostate Cancer: A Prospective Cohort Study Emulating a Target Trial

Authors

Luo S., [Wang X.](#), Hou H., Tang R., Liu M.

Institutions

Beijing Hospital, Dept. of Urology, Beijing, China

P0347

INDUCTive Apalutamide therapy combined with radical prostatectomy in patients with locally inoperable T4 high risk prostate cancer - first results of the prospective Phase II INDUCTA trial

Authors

Saar M.¹, Linxweiler J.², Kranz J.¹, Hoffmann M.¹, Siemer S.², Junker K.², Stöckle M.²

Institutions

¹University Hospital RWTH Aachen, Dept. of Urology, Aachen, Germany, ²Saarland University, Dept. of Urology, Homburg, Germany

P0348

Treatment Transformation in Very High-Risk Prostate Cancer: Impact of Neoadjuvant Chemohormonal Therapy Before Robot-Assisted Radical Prostatectomy

Authors

Morizane S.¹, Koyama Y.¹, Yamamoto A.¹, Yamane H.¹, Makishima K.², Nishikawa R.¹, Kimura Y.¹, Yamaguchi N.¹, Hikita K.¹, Umekita Y.², Takenaka A.¹

Institutions

¹Tottori University, Dept. of Urology, Yonago, Japan, ²Tottori University, Dept. of Pathology, Yonago, Japan

P0349

Efficacy of neoadjuvant docetaxel + darolutamide versus darolutamide in patients with locally advanced prostate cancer: A phase II trial in China

Authors

Pei X., Gao Y., Liang L., Tian G., Chen X., Zhang Q., Li L., Xie H.

Institutions

First Affiliated Hospital of Xi 'an Jiaotong University, Dept. of Urology, xian, China

P0350

Biochemical recurrence and safety in patients with high-risk localised prostate cancer treated with [177Lu] Lu-PSMA-617 prior to prostatectomy: Follow-up of the LuTectomy trial

Authors

Hennes D.¹, Eapen R.S.¹, Thomson A.¹, Al-Khanaty A.¹, Jackson P.², Mitchell C.³, Oon S.F.⁴, McIntosh L.², Dhiantravan N.², Azad A.A.⁵, Haskali M.B.⁶, Moon D.⁷, Lawrentschuk N.¹, Neeson P.J.⁸, Murphy D.G.¹, Hofman M.S.², Buteau J.P.²

Institutions

¹Peter MacCallum Cancer Centre, Division of Cancer Surgery, Melbourne, Australia, ²Peter MacCallum Cancer Centre, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Melbourne, Australia, ³Peter MacCallum Cancer Centre, Dept. of Anatomical Pathology, Melbourne, Australia, ⁴Peter MacCallum Cancer Centre, Dept. of Cancer Imaging, Melbourne, Australia, ⁵Peter MacCallum Cancer Centre, Dept. of Medical Oncology, Melbourne, Australia, ⁶Peter MacCallum Cancer Centre, Dept. of Radiopharmaceutical Sciences, Cancer Imaging, Melbourne, Australia, ⁷University of Melbourne, Royal Melbourne Clinical School, Melbourne, Australia, ⁸Peter MacCallum Cancer Centre, Cancer Immunology Program, Melbourne, Australia

P0351

Impact of PSA Response to Neoadjuvant Androgen Deprivation Therapy on Outcomes After Robot-Assisted Radical Prostatectomy

Authors

Todaka M.¹, Utsumiya T.¹, Nakata Y.¹, Ohno S.¹, Abe S.¹, Suzuki S.¹, Kai H.¹, Fujinami H.¹, Yamanaka N.¹, Hata S.¹, Inoue T.¹, Ando T.², Shin T.¹

Institutions

¹Oita University Faculty of Medicine, Dept. of Urology, Yufu, Japan, ²Oita University Faculty of Medicine, Organ Transplant Promotion Project, Yufu, Japan

P0352

The Impact of Neoadjuvant Therapy on Early Postoperative Continence Recovery after Radical Prostatectomy

Authors

Wang C., Chen S., Wu S., Wang Y., Pang R., Shi B.

Institutions

Qilu Hospital of Shandong University, Dept. of Urology, Jinan, China

P0353

Does neoadjuvant androgen deprivation therapy worsen continence and potency in prostate cancer patients undergoing radical prostatectomy?

Authors

Le D.Q.C.¹, Siech C.¹, Wenzel M.¹, Preisser F.², Tilki D.², Graefen M.², Maurer T.², Kriegmair M.C.³, Saad F.⁴, Karakiewicz P.I.⁴, Chun F.K.H.¹, Mandel P.²

Institutions

¹Goethe University Frankfurt, Dept. of Urology, Frankfurt, Germany, ²Martini Klinik Hamburg, Dept. of Urology, Hamburg, Germany, ³Urological Hospital Munich-Planegg, Dept. of Urology, Munich, Germany, ⁴Centre de Hospitalier de l'Universite de Montreal, Dept. of Urology, Montréal, Canada

11:15 - 12:00

Outcomes after radical prostatectomy

P0354

Oncological outcomes after radical prostatectomy for high-risk prostate cancer: A systematic review and meta-analysis

Authors

Giesen A.¹, Koi T.², Van de Steen L.¹, Vickers A.³, Speeche P.¹, Fazekas T.⁴, Yuan C.Y.⁵, Touijer K.⁶, Lestingi J.F.P.⁷, Bill-Axelson A.⁸, Murtola T.⁹, Harke N.¹⁰, Urbanova K.¹¹, de Pablos-Rodriguez P.¹², Moris L.¹, Devos G.¹, Everaerts W.¹, Van den Broeck T.¹, Joniau S.¹

Institutions

¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²Budapest University of Technology and Economics, Dept. of Stochastics, Budapest, Hungary, ³Memorial Sloan Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, New York, United States of America, ⁴Semmelweis University, Dept. of Urology, Budapest, Hungary, ⁵McMaster University, Dept. of Medicine, Hamilton, Canada, ⁶Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ⁷Hospital das Clinicas HCFMUSP, Dept. of Urology, São Paulo, Brazil, ⁸Uppsala University Hospital, Dept. of Surgical Sciences, Uppsala, Sweden, ⁹Tampere University Hospital, Dept. of Urology, Tampere, Finland, ¹⁰Essen University Hospital, Dept. of Urology, Essen, Germany, ¹¹St. Antonius Hospital, Dept. of Urology, Gronau, Germany, ¹²Instituto Valenciano de Oncologia, Dept. of Urology, Valencia, Spain

P0355

Feasibility and Outcomes of Robot-Assisted Radical Prostatectomy with the Hugo™ RAS System in Patients with Locally Advanced Prostate Cancer: Insights from a Multicentric Cohort

Authors

Barretta A.¹, Prata F.², Dell'Oglio P.³, Bertolo R.⁴, Sighinolfi M.C.⁵, Mottaran A.¹, Mazzone E.³, Russo P.⁵, Tappero S.³, Piazza P.¹, Turri F.⁵, Montanaro F.⁴, Veccia A.⁴, Tedesco F.², Civitella A.², Cavarra V.⁵, Ragusa A.², Bianchi L.¹, Muto G.⁶, Bernardo R.⁵, Antonelli A.⁴, Galfano A.³, Papalia R.², Schiavina R.¹

Institutions

¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Urology, Bologna, Italy, ²Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy, ³ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ⁴A.O.U.I. Verona, University of Verona, Urology Unit, Dept. of Surgery, Dentistry, Pediatrics and Gynecology, Verona, Italy, ⁵Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dept. of Urology, Rome, Italy, ⁶GVM - Maria Pia Hospital, Dept. of Urology, Turin, Italy

P0356

Oncological outcomes of robot-assisted radical prostatectomy in International Society of Urological Pathology Grade 5 prostate cancer: 10-years follow up

Authors

Govorov A., Kolontarev K., Pushkar D.

Institutions

Botkin Hospital and ROSUNIMED, Dept. of Urology, Moscow, Russia

P0357

Radical Prostatectomy in STAMPEDE-Defined High-Risk Prostate Cancer: Long-Term Oncologic and Perioperative Outcomes from a Large Single-Center Cohort

Authors

Scuderi S.L.A.¹, Stabile A.¹, Bianchi M.¹, Barletta F.M.¹, Quarta L.¹, Zaurito P.¹, Viti A.¹, Santangelo A.¹, Brancaccio M.¹, Galdieri A.¹, Occhi A.¹, Necchi A.², Maiorano B.², Mercinelli C.², Moschini M.¹, Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Division of Oncology, Milan, Italy

P0358

Robot-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Oncological Potential and Limitations as the Primary Treatment

Authors

Miura N.¹, Shimbo M.², Shishido K.¹, Nobumori S.¹, Sugihara N.¹, Sawada T.¹, Haga S.¹, Arai H.¹, Nishida K.¹, Arai O.¹, Onishi T.¹, Watanabe R.¹, Nishimura K.¹, Fukumoto T.¹, Miyauchi Y.¹, Kikugawa T.¹, Nishino T.², Endo F.², Hattori K.², Saika T.¹

Institutions

¹Ehime University Graduate School of Medicine, Dept. of Urology, Toon, Japan, ²St. Luke's International Hospital, Dept. of Urology, Tokyo, Japan

P0359

PSMA Imaging-Based Stratification of Men with High-Risk Prostate Cancer Candidates for Radical Prostatectomy: Beyond Clinical Risk Factors

Authors

Barletta F.M.¹, Marra G.², Zattoni F.³, Rajwa P.⁴, Van den Bergh R.⁵, Kesch C.⁶, Gomez-Rivas J.⁷, Sigle A.⁸, Zhuang J.⁹, Soeterik T.⁵, Mottrie A.¹⁰, Murphy D.¹¹, Chiti A.¹², Di Nardo N.¹³, Fankhauser C.¹³, Fiori C.¹⁴, Schiavina R.¹⁵, Dal Moro F.³, Fendler W.¹⁶, Heidegger I.¹⁷, Joniau S.¹⁸, Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹IRCSS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ²Città della Salute e della Scienza, Dept. of Urology, Turin, Italy, ³University of Padua, Dept. of Surgery, Oncology and Gastroenterology, Padua, Italy, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁵St. Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ⁶Essen University Hospital, Dept. of Urology, Essen, Germany, ⁷Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ⁸Freiburg University Hospital, Dept. of Urology, Freiburg, Germany, ⁹Medical School of Nanjing University, Dept. of Urology, Nanjing, China, ¹⁰OLV Ziekenhuis Aalst, Dept. of Urology, Melle, Belgium, ¹¹Peter MacCallum Cancer Centre, Division of Cancer Surgery, Melbourne, Australia, ¹²IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, ¹³University Teaching and Research Hospital of the University of Lucerne, Dept. of Urology, Lucerne, Switzerland, ¹⁴San Luigi Hospital, Division of Urology, Dept. of Oncology, Turin, Italy, ¹⁵IRCCS Azienda Ospedaliero Universitaria di Bologna, Division of Urology, Bologna, Italy, ¹⁶Essen University Hospital, Dept. of Nuclear Medicine, Essen, Germany, ¹⁷University Hospital of Innsbruck, Dept. of Urology, Innsbruck, Austria, ¹⁸University Hospitals Leuven, Dept. of Urology, Leuven, Belgium

P0360

Achieving Functional Preservation in High-Risk Prostate Cancer: Erectile Function Outcomes of the “Lisbon-Zero-Clip” RARP

Authors

Distante A.¹, Costa Moretti T.B.¹, Freire F.¹, Guerra A.², Maes K.¹

Institutions

¹Hospital Da Luz, Dept. of Urology, Lisbon, Portugal, ²Hospital Da Luz, Dept. of Radiology, Lisbon, Portugal

P0361

Preoperative Surgical Planning for High-Risk Prostate Cancer: Maximising Continence While Maintaining Oncological Safety of Nerve-Sparing Robotic Prostatectomy

Authors

Bilé Silva A.¹, Prabhakar R.², Lamb B.², Özalevli M.¹, Dickinson L.³, Collins J.⁴, Kelkar A.⁴, Kelly J.⁴, Nathan S.⁴, Shaw G.⁴, Sooriakumaran P.⁴, Sridhar A.⁴, Tandogdu Z.¹

Institutions

¹University College of London, Dept. of Targeted Intervention, London, United Kingdom, ²Barts Health NHS Trust, Dept. of Urology, London, United Kingdom, ³University College London Hospitals NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, ⁴University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom

Oncological Outcomes of Patients Undergoing Radical Prostatectomy with Extended versus Indocyanine-Guided Lymphadenectomy: Mid-Term Follow-Up of PersonalymPCa Clinical Trial

Authors

Anagua Melendres J.F.¹, De Pablos-Rodriguez P.², Martínez Osorio C.A.², Gomez-Ferrer Lozano A.², Beamud Cortés M.², Calatrava Fons A.², Patino Aliaga J.², Hassi Román M.², Rodríguez Part V.², Wong Gutierrez A.², Casanova Ramon Borja J.², Ramirez Backhaus M.²

Institutions

¹Hospital de Bellvitge, Dept. of Urology, BARCELONA, Spain, ²Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain

Advancements in male fertility: From global burden to innovative treatments

EGPT 23

Saturday 14 March
10:30 - 12:00

Location

Orange Area, EGPT 4

Chairs

P. Capogrosso, Varese (IT)
To be confirmed
To be confirmed

10:30 - 10:50

Sperm decline and risk factors

P0399

Male Infertility: Global Burden and Spatiotemporal Trends from 1990–2021 and Projected Trajectories to 2050

Authors

Zhou X., Wei C., Qiu S.

Institutions

West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China

P0400

Pathomorphological changes in spermatozoa following SARS-CoV-2 infection (COVID-19)

Authors

Ibishev K.¹, Ismailov R.S.¹, Sinelnik E.A.², Prokop Y.¹, Kogan M.I.¹

Institutions

¹Rostov State Medical University, Dept. of Urology and Paediatric Urology-andrology, Rostov-on-Don, Russia, ²Rostov State Medical University, Division of Pathology, Rostov-on-Don, Russia

P0401

Finasteride 1 mg: Silent Impacts on Male Fertility Despite Preserved Hormonal Balance

Authors

Marquardt Filho N.¹, Teixeira T.A.², Ruggeri M.¹, Fraga L.G.¹, Filho J.S.T.¹, Sanvido L.V.¹, Lozano A.F.V.Q.³, Gismondi J.P.¹, Hallak J.¹

Institutions

¹Universidade de Sao Paulo, Dept. of Urology, São Paulo, Brazil, ²Amapa Federal University Hospital, Dept. of Urology, Amapa, Brazil, ³Androscience Institute for Science, Education & Advanced Projects in Male Health, Dept. of Urology, São Paulo, Brazil

P0402

Testosterone levels and sperm quality improve in men treated with GLP1 inhibitors

Authors

Persu C., Chirca N., Toma C., Cartas R.N., Popescu G., Jinga V.

Institutions

Carol Davila University of Medicine and Pharmacy, Dept. of Urology, Bucharest, Romania

10:50 - 11:05

Varicocele management

P0403

The Effect of Varicocele Embolization on Sperm DNA Fragmentation and Assisted Reproductive Outcomes

Authors

Clark C.¹, Nyantakyi A.¹, Ferguson R.¹, Lewis S.², Thum L.³, Bracewell-Milnes T.³, Moore T.³, Das R.³, Al- Hussini M.³, Nicopoullou J.³, Minhas S.⁴, Ramsay J.³, Yap T.¹

Institutions

¹Guys and St Thomas NHS Trust, Dept. of Urology, London, United Kingdom, ²Examen, Dept. of Fertility, Belfast, United Kingdom, ³Lister Fertility Unit, Dept. of Fertility, London, United Kingdom, ⁴Imperial College London, Dept. of Urology, London, United Kingdom

P0404

Can a novel ultrasound protocol improve the diagnosis of varicocele?

Authors

Reid T.H.¹, Jahangeer A.², Zahid H.³, Azam A.³, Chen C.⁴, Cotton A.⁴, Yap T.¹

Institutions

¹Guy's and St. Thomas' Hospital, Dept. of Urology, London, United Kingdom, ²University Hospital Leicester, Dept. of Radiology, Leicester, United Kingdom, ³Guy's and St. Thomas' Hospital, Dept. of Radiology, London, United Kingdom, ⁴King's College London, Dept. of Urology, London, United Kingdom

P0405

Microsurgical Varicocelectomy Reverses the Abnormality of Seminal Microbiome in Patients with Varicocele

Authors

Xi W., Lu Y., Yang N., Guo J.

Institutions

Zhongshan Hospital, Dept. of Urology, Shanghai, China

11:05 - 11:30

Translational studies

P0406

Coenzyme Q2 Enhances Heat Stress-Induced Anti-Proliferative and Pro-Apoptotic Effects via AMPK Pathway Inactivation in Mouse Testicular Cell Lines

Authors

Wu Y., Xue K., Luo X., Liu C.

Institutions

The Third Affiliated Hospital of Southern Medical University, Dept. of Urology, Guangzhou, China

P0408

Machine learning-based seminal plasma metabolomics for the diagnosis of non-obstructive azoospermia and prediction of microTESE success rate

Authors

Zhu S., Yang J., Wang T.

Institutions

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Dept. of Urology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China

P0410

Biomimetic nanotechnology overcoming the Blood-Testis barrier for testicular protection in chemotherapy

Authors

Zhao X.¹, An C.¹, Sun J.¹, Ma A.¹, Mei Q.², Liu B.¹, Lu L.¹, Yang Y.¹, Yu W.¹, Song T.¹, Gao Q.¹, Shi L.¹, Yue Q.¹, Wei H.²

Institutions

¹Nanjing Drum Tower Hospital, Nanjing, China, ²Nanjing University, Nanjing University, Nanjing, China

11:30 - 12:00

Male infertility

P0411

Impact of Early versus Late Colchicine Therapy on Male Fertility in Patients with Familial Mediterranean Fever

Authors

Tonoyan D.

Institutions

Center of Medical Genetic and Primary Health Care, Dept. of Andrology, Yerevan, Armenia

P0412

Impact of primary chemotherapy for Hodgkin lymphoma on hormonal profile and spermatogenesis: results from a single-tertiary referral centre

Authors

De Rocco Ponce M.¹, Bertini A.², Raffo M.², Malca Caballero L.¹, Pozzi E.², d'Arma A.², Montorsi F.², Salonia A.², Ruiz-Castane E.¹

Institutions

¹Fundación Puigvert, Dept. of Andrology, Barcelona, Spain, ²IRCCS Ospedale San Raffaele, Unit of Urology, Milan, Italy

P0413

Induction of spermatogenesis and its predictors in men with prepubertal-onset hypogonadotropic hypogonadism undergoing gonadotropin therapy
Induction of spermatogenesis and its predictors in men with prepubertal-onset hypogonadotropic hypogonadism undergoing gonadotropin therapy

Authors

Lee H.H.¹, Kim S.W.¹, Cho M.C.²

Institutions

¹Seoul National University Hospital, Dept. of Urology, Seoul, South Korea, ²Seoul National University Boramae Medical Center, Dept. of Urology, Seoul, South Korea

P0414

Association between preoperative body mass index (BMI) and postoperative hypogonadism after microdissection testicular sperm extraction (micro- TESE)

Authors

Khoury S., Moshe S., Dekel Y., Kabha M.

Institutions

Carmel Medical Centre, Dept. of Urology, Haifa, Israel

P0415

Missed karyotype abnormalities and Y-chromosome microdeletions in male infertility: trial simulation challenges current European Association of Urology guidelines genetic testing thresholds

Authors

Pozzi E.¹, Negri F.¹, Raffo M.¹, Bertini A.¹, Oddo M.¹, Piccolo C.¹, Birolini G.², De Luca S.², Boeri L.³, Sucapuca R.¹, d'Arma A.¹, Montorsi F.¹, Salonia A.¹

Institutions

¹IRCCS San Raffaele Scientific Institute, Division of Experimental Oncology - Unit of Urology - Urological Research Institute, Milan, Italy, ²Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ³IRCCS Fondazione Ca' Granda, Dept. of Urology, Milan, Italy

P0416

Single-cell landscape reveals Activin A-driven inflammatory and fibrotic mechanism in hypospermatogenesis-related non-obstructive azoospermia with cryptorchidism

Authors

Zhu S., Hu P., Wang T., Yang J.

Institutions

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Dept. of Urology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China

Talkshow: Physicians' well-being and sustainable performance – joint session with the Young Urologists Office

Thematic Session

**Saturday 14 March
10:45 - 12:00**

Location

Orange Area, eURO Auditorium 2

Chairs

M.C. Mir Maresma, Valencia (ES)
P.M. Pierorazio, Philadelphia (US)

Sidekick

J.L. Vázquez, Copenhagen (DK)

Learning objectives

To Understand the importance of aligning career choices with personal values, and recognise common pitfalls in goal-setting for high-performing professionals. To Understand how sleep, light exposure and exercise influence cognitive performance and mental health. Provide science-backed, time-efficient strategies to improve well-being. To recognise the emotional impact of complications on physicians (the "second victim" phenomenon), and discuss strategies for emotional regulation and professional recovery after adverse events.

10:45 - 10:50

Welcome

10:50 - 11:30

Living your core values for physical and mental well-being

Speakers

S. Brookman-May, Munich (DE)

J. Howlett, Rødovre (DK)

Opening question and voting

The concept of core values

Common pitfalls in goal-setting

Case example

Strategies for alignment

Final take-home messages

11:30 - 12:10

Beyond the OR: Emotional management of surgical and non-surgical complications

Speakers

P.M. Pierorazio, Philadelphia (US)

K.J. Turner, Bournemouth, Dorset (GB)

Introduction

Understanding the emotional impact

Case study: Emotional journey through a complication

Framework for emotional management

Final takeaways and audience reflection

12:10 - 12:15

Closing remarks

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 2.3

Saturday 14 March

11:00 - 11:50

Location

Red Area, Room 1

Tutors

M.F. Frasccheri, Southampton (GB)

C. Netsch, Hamburg (DE)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 2.3

Saturday 14 March
11:00 - 11:50

Location Red Area, Room 1

Tutors O.R. Durutovic, Belgrade (RS)
M. Henderickx, Wilrijk (BE)
To be confirmed

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 2.3

Saturday 14 March
11:00 - 11:50

Location Red Area, Room 1

Tutors To be confirmed
P. Umari, London (GB)

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 2.3

Saturday 14 March
11:00 - 11:50

Location Red Area, Room 1

Tutors M. Jarzemski, Bydgoszcz (PL)
G. Pini, Como (IT)

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 2.3

Saturday 14 March
11:00 - 11:50

Location Red Area, Room 1

Tutor To be confirmed

Learning objectives

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 2.3

Saturday 14 March
11:00 - 11:50

Location Red Area, Room 1

Tutors E.D. Demirkiran, Zonguldak (TR)
M.I. Gökce, Ankara (TR)
D. Perri, Como (IT)

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 2.3

Saturday 14 March
11:00 - 11:50

Location Red Area, Room 1

Tutors A. Papatsoris, Athens (GR)
To be confirmed

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Saturday 14 March
11:15 - 11:45

Location Patient Advocacy Plaza

Chair To be confirmed

11:15 - 11:45

World Federation of Incontinence and Pelvic Problems (WFIPP)

To be confirmed

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 2.4

Saturday 14 March
12:00 - 12:50

Location Red Area, Room 1

Tutors To be confirmed

A. Olivero, Milan (IT)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 2.4

Saturday 14 March
12:00 - 12:50

Location Red Area, Room 1

Tutors O.R. Durutovic, Belgrade (RS)
M. Henderickx, Wilrijk (BE)
G. Kamphuis, Amsterdam (NL)

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 2.4

Saturday 14 March
12:00 - 12:50

Location Red Area, Room 1

Tutors To be confirmed
P. Umari, London (GB)

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 2.4

Saturday 14 March
12:00 - 12:50

Location Red Area, Room 1

Tutors S. García Barreras, Madrid (ES)
To be confirmed

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 2.4

Saturday 14 March
12:00 - 12:50

Location Red Area, Room 1

Tutor D. Elterman, Toronto (CA)

Learning objectives

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 2.4

Saturday 14 March
12:00 - 12:50

Location Red Area, Room 1

Tutors M. Arslan, Istanbul (TR)
E.D. Demirkiran, Zonguldak (TR)
To be confirmed

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 2.4

Saturday 14 March
12:00 - 12:50

Location Red Area, Room 1

Tutors M. Paciotti, Rozzano, Milan (IT)
A. Tuncel, Ankara (TR)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

How far have we come with PCa screening in the EU?

Thematic Session

Saturday 14 March
12:15 - 13:45

Location Orange Area, eURO Auditorium 2

Chairs
P. Albers, Düsseldorf (DE)
E. Briers, Hasselt (BE)
H. Van Poppel, Leuven (BE)

Learning objectives

This session will provide an update on current prostate cancer screening trials within the EU-funded PRAISE-U initiative and other screening pilots which have been initiated throughout Europe. The trial results will be discussed in the context of the European Health Initiatives.

12:15 - 12:22

Highlight achievements of PRAISE U so far

M.J. van Harten, Rotterdam (NL)

12:22 - 13:02

The good, the bad, and the ugly: Results from PRAISE U pilots

12:22 - 12:28

Galicia

To be confirmed

12:28 - 12:34

Ireland

D.J. Galvin, Dublin (IE)

12:34 - 12:40

Poland

K. Tupikowski, Wroclaw (PL)

12:40 - 12:46

Manresa

J. Vilaseca, Barcelona (ES)

12:46 - 12:52

Lithuania

A. Patasius, Vilnius (LT)

12:52 - 13:02

Discussion

13:02 - 13:09

OPT programme in Sweden - lessons learned after 4 years of piloting

O. Bratt, Gothenburg (SE)

13:09 - 13:16

Czech Republic experience of quality control of its PCa pilot

O. Majek, Brno (CZ)

13:16 - 13:23

How cost effective is PCa screening?

P. Vynckier, Ghent (BE)

13:23 - 13:30

What psycho-social impact does screening have on men?

P. Kirkegaard, (DK)

13:30 - 13:37


GU cancer and comprehensive cancer centres

T. Albreht, Ljubljana (SI)

13:37 - 13:42

An update on the PRAISE U knowledge hub

M.J. Roobol, Rotterdam (NL)



Saturday 14 March
12:15 - 13:45

Location Blue Area, Victoria 4

Chairs L. Dyrskjød, Aarhus (DK)
J. Paramio, Madrid (ES)

12:15 - 12:17

Introduction

L. Dyrskjød, Aarhus (DK)

12:17 - 12:27

Introduction to tumour immunity for urologists

L. Bukavina, Cleveland (US)

12:27 - 12:37

State-of-the-art lecture Mechanisms of immune resistance in prostate cancer and opportunities for modulation

G. von Amsberg, Hamburg (DE)

12:37 - 12:39

Discussion

12:39 - 12:49

State-of-the-art lecture Adoptive T cell strategies in renal cell carcinoma: Challenges and prospects

To be confirmed

12:49 - 12:51

Discussion

12:51 - 13:01

State-of-the-art lecture Immune privilege in testicular germ cell tumours: Biology, resistance, and translational insights

To be confirmed

13:01 - 13:03

Discussion

13:03 - 13:13

State-of-the-art lecture Emerging immune checkpoints and rationale for combinatorial strategies

M.S. Van Der Heijden, Amsterdam (NL)

13:13 - 13:15

Discussion

13:15 - 13:25

State-of-the-art lecture Neoadjuvant vs. adjuvant immunotherapy: A comparative perspective on biology

A. Bex, London (GB)

13:25 - 13:27

Discussion

13:27 - 13:42

Panel discussion Translating immune mechanisms into therapeutic strategies

Panel

A. Bex, London (GB)

L. Bukavina, Cleveland (US)

To be confirmed

To be confirmed

M.S. Van Der Heijden, Amsterdam (NL)

G. von Amsberg, Hamburg (DE)

13:42 - 13:45

Wrap-up: Immune modulation and therapeutic opportunity in urological cancer

L. Dyrskjöt, Aarhus (DK)

LUTS/BPO surgery: Master in disaster

Thematic Session

Saturday 14 March

12:15 - 13:45

Location

Orange Area, Room 3

Chairs

C. De Nunzio, Rome (IT)

K.A.O. Tikkinen, Helsinki (FI)

Learning objectives

This session provides a practical approach to managing complications of BPO surgery, including bleeding, incontinence, strictures, and ejaculatory dysfunction. Through real-world cases and expert insights, participants will learn to recognize, prevent, and treat complications across various techniques such as TURP, HoLEP as well as after minimally invasive treatments. Emphasis will be placed on perioperative decision-making and tailored strategies for complex patients. The goal is to enhance surgical safety, reduce reintervention rates, and improve patient outcomes in everyday urological practice.

12:15 - 12:16

Introduction

12:16 - 12:25

How we define success and failure in LUTS/BPO surgery?

R. Autorino, Chicago (US)

12:25 - 12:45

Video case presentation Perioperative pitfalls in TURP, laser and simple prostatectomy

Presenter

I. Kartalas Goumas, Vigevano (IT)

Discussants

S. Ahyai, Graz (AT)

B. Geavlete, Bucharest (RO)

K. Lehrich, Berlin (DE)

12:45 - 13:05

Video case presentation Perioperative pitfalls in new BPO treatments

Presenter

L. Cindolo, Salerno (IT)

Discussants

E. García Rojo, Madrid (ES)

J.H. Kim, Seoul (KR)

K.C. Zorn, Montreal (CA)

13:05 - 13:25

Case-based discussion **Complicated BPO cases**

Presenter

T.R.W. Herrmann, Frauenfeld (CH)

Discussants

N.R. Bhatt, Cambridge (GB)

M. Gacci, Florence (IT)

N.I. Osman, Sheffield (GB)

13:25 - 13:34

Present and future of BPO surgery

J-N.L. Cornu, Rouen (FR)

13:34 - 13:43

Patient decision aids in BPO surgery

S. Malde, London (GB)

13:43 - 13:45

Summary

History of Urology

Abstract Session 13

Saturday 14 March

12:15 - 13:45

Location

Red Area, Room 7

Chairs

J. Angulo Cuesta, Getafe (ES)

J.C. Goddard, Leicester (GB)

To be confirmed

A0205

LHRH in Prostate Cancer Treatment: From Breakthrough Discovery to Modern Therapeutic Approaches

S. Benisti, Montreal (CA)

A0206

Votes for Women!

O. Olaitan, Leicester (GB)

A0207

The principles of Sir Pendrill Varrier-Jones: Blueprints for future generations or just 'old hat'?

J.K. Badawi, Luzern (CH)

A0209

Urethral Sub-incision and Circumcision – Historical Urogenital Initiation Rituals in Aboriginal Australian Communities

K. Keane, Perth (AU)

A0210

Angioneurectomy: A Pre-endocrine Concept in the Early Medical Treatment of Prostatic Disease (Albarrán & Motz, 1897)

J.J. Szczesniewski, Getafe (ES)

A0211

From Steinach to Survivor: The Urological and Endocrine Legacy of Conversion Therapy Targeting Homosexuality

M. Agrawal, LONDON (GB)

A0212

Tracing the Historical Development of Endoscopic Urethroplasty: From Inception to Experimental Advances from 1978-2024

A. Anwaar, Lahore (PK)

A0213	“Cure without danger, pain and bloodshed” - Docteur Bazénerie and his electrical treatment methods for urological diseases J.K. Badawi, Luzern (CH)
A0214	Alessandri Massariae Praelectiones de morbis mulierum, conceptus et partus: Massaria’s Contribution to Urogynecology in Seventeenth-Century Italy between Tradition and Innovation C. D'Elia, Bolzano (IT)
A0215	From General Surgery to Specialized Practice: The Historical Journey of Urology in Ecuador R. Arevalo, Madrid (ES)
A0216	The genius Joaquín Albarran was once a kid, and a poet! J. Angulo Cuesta, Getafe (ES)
A0217	Viennese urology – a mirror of science and medicine that is participating in the building and maintaining of empires To be confirmed
A0218	History of the Urology Service in the Central Lisbon Hospital University Centre P. Silva, Almada (PT)
A0219	Even His Majesty's doctors were censured by the Inquisition: The case of Andres Laguna and his Dioscorides translation. J. Angulo Cuesta, Getafe (ES)

Urolithiasis: Suction Technology

Abstract Session 10

Saturday 14 March
12:15 - 13:45

Location Blue Area, George 1
Chairs B. Ballesta Martinez, Alicante (ES)
B.H. Chew, Vancouver (CA)
To be confirmed

12:15 - 12:30

FANS vs. conventional access sheaths

A0151

Conventional versus Flexible and Navigable Suction Ureteral Access Sheaths: An In Vitro Evaluation on Ureteral Temperature Modulation during high power Holmium YAG Laser Lithotripsy

Authors

Yuen S.¹, Gauhar V.², Huang Y.³, Liu S.⁴, Pang X.⁴, Zhang G.⁴, Liu W.⁴, Zhou J.³, Huang Q.³, Somani B.K.⁵, Zeng G.⁴, Zhu W.⁴

Institutions

¹The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ²Ng Teng Fong Hospital, Dept. of Urology, Singapore, Singapore, ³The First Affiliated Hospital Hengyang Medical School University of South China, Dept. of Urology, Hunan, China, ⁴The First Affiliated Hospital of Guangzhou Medical University, Dept. of Urology and Guangdong Key Laboratory of Urology, Guangdong, China, ⁵University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom

A0152

A Propensity-Matched Comparison of Clinical Outcomes of RIRS Using a Flexible Suctioning Ureteral Access Sheath Versus a Conventional Access Sheath

Authors

Soundarya G., Chandramohan V., Hemnath A., Ramakrishna P., Rakesh P.

Institutions

Preeti Urology and Kidney hospital, Dept. of Urology, Hyderabad, India

A0153

COMPARISON OF FLEXIBLE VACUUM-ASSISTED VERSUS CONVENTIONAL URETERAL ACCESS IN RETROGRADE INTRARENAL SURGERY: A RANDOMIZED CONTROLLED PROSPECTIVE RIRSEARCH GROUP STUDY

Authors

Sahin M.F.¹, Dogan C.¹, Teke K.², Simsekoglu M.F.³, Tuna M.B.⁴, Ozman O.⁵, Cakir H.⁴, Basatac C.⁶, Cinar O.⁷, Akgul M.⁸, Siddikoglu D.⁹, Yazici C.M.¹, Sancak E.B.¹⁰, Baseskioglu B.¹¹, Akpinar H.¹², Onal B.³

Institutions

¹Tekirdag Namık Kemal University, Dept. of Urology, Tekirdag, Turkey, ²Kocaeli University, Dept. of Urology, Kocaeli, Turkey, ³Cerrahpasa Medical Faculty, Dept. of Urology, Istanbul, Turkey, ⁴Fulya Acibadem Hospital, Dept. of Urology, İstanbul, Turkey, ⁵Memorial Health Group, Dept. of Urology, İstanbul, Turkey, ⁶Demiroglu Bilim University, Dept. of Urology, İstanbul, Turkey, ⁷Medicana International, Dept. of Urology, Samsun, Turkey, ⁸Umraniye Training and Research Hospital, Dept. of Urology, İstanbul, Turkey, ⁹Canakkale Onsekiz Mart University, Dept. of Biostatistics, Canakkale, Turkey, ¹⁰Canakkale Onsekiz Mart University, Dept. of Urology, Canakkale, Turkey, ¹¹Eskisehir Urology Clinic, Dept. of Urology, Eskisehir, Turkey, ¹²Florence Nightingale Hospital, Dept. of Urology, İstanbul, Turkey

Study Group

Rirsearch(Istanbul, Turkey)

12:30 - 12:45

Suction ureteroscopy vs PCNL

A0154

Flexible ureteroscopy with a flexible vacuum-assisted ureteral access sheath versus mini-percutaneous nephrolithotomy in patients with 2-3 cm upper urinary tract stones: a multicenter randomized clinical trial

Authors

Wang R., Liu C.

Institutions

The Second Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China

A0155

Utility and Challenges of Flexible and Navigable Suction Ureteral Access Sheath (FANS) vs. Suction Mini-PCNL in Children: A Comparative Analysis

Authors

Lim E.J.¹, Yuen S.K.K.², Herrmann T.R.W.³, Sarica K.⁴, Tur A.B.⁵, Teng R.Z.S.¹, Quiroz Y.M.⁶, Kalathia J.⁷, Tak G.R.⁸, Chong T.W.¹, Fong K.Y.¹, Tursunkulov A.N.⁹, Tanidir Y.¹⁰, Joshi R.¹¹, Mohan V.C.¹², Traxer O.¹³, Castellani D.¹⁴, Gauhar V.¹⁵

Institutions

¹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ²The Chinese University of Hong Kong, S.H. Ho Urology Centre, Dept. of Surgery, Hong Kong, China, ³University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ⁴Biruni University Hospital, Dept. of Urology, Istanbul, Turkey, ⁵Autonomous University of Barcelona, Dept. of Urology, Barcelona, Spain, ⁶Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁷Fortune Urology Clinic, Dept. of Urology, Gujarat, India, ⁸Asian Institute of Nephrology and Urology, Dept. of Urology, Hyderabad, India, ⁹AkfaMedline Hospital, Urology Division, Tashkent, Uzbekistan, ¹⁰Medicana Atasehir Hospital, Dept. of Urology, Istanbul, Turkey, ¹¹Aarna Superspeciality Hospital, Dept. of Urology, Gujarat, India, ¹²Preeti Urology and Kidney Hospital, Dept. of Urology, Hyderabad, India, ¹³Sorbonne University, Dept. of Urology, Paris, France, ¹⁴Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Urology Division, Ancona, Italy, ¹⁵Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore

A0156

CVAC 2.0 vs Mini PCNL: a Real-world Comparison for Moderate Size Stones

Authors

Johnson B., Gonzalez A., Tse J., Pearle M.S.

Institutions

University of Texas Southwestern, Dept. of Urology, Dallas, United States of America

12:45 - 13:10

Comparative studies

A0157

Introducing FIRST technique , FLEXIBLE INTEGRATED RETROGRADE SUCTION-URETEROSCOPY TECHNIQUE (FIRST) combinig the power of Flexible and navigable suction access sheath (FANS) and Direct in scope suction (DISS) for a 100% single stage stone free rate, An EAU-Endourology audit study

Authors

Ragoori D.¹, Somani B.K.², Chiruvella M.¹, Kar Kei Yuen S.³, Castellani D.⁴, Heng C.T.⁵, Traxer O.⁶, Gauhar V.⁵

Institutions

¹Asian Institute of Nephrology and Urology, Dept. of Urology, Hyderabad, India, ²University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ³SH Ho Urology Centre, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ⁴Azienda Ospedaliero-Universitaria delle Marche, Università Politecnica delle Marche, Dept. of Urology, Ancona, Italy, ⁵Ng Teng Fong general hospital, Dept. of Urology, Singapore, Singapore, ⁶Sorbonne University, Tenon Hospital, AP-HP, Dept. of urology, Paris, France

A0158

Simulated Kidney Study of CVAC 2.0 vs FANS: Fragment Clearance and Surgeon Workload

Authors

Winoker J.¹, Lee H.², Jaekel D.²

Institutions

¹Northwell Health, Lenox Hill Hospital, Dept. of Urology, New York, United States of America, ²Calyxo, Inc., Dept. of Research and Development, Pleasanton, United States of America

A0159

Multicenter Comparison of Stone Clearance with CVAC Aspiration Ureteroscope and Flexible and Navigable Ureteral Access Sheaths

Authors

Cabo J.¹, Ballantyne C.¹, Ren R.², Harrington S.³, Bowers L.⁴, Foss H.⁵, Ungerer G.⁵, Chien A.⁶, Turin D.⁵, Potretzke A.⁵, Pais V.³, Hannallah J.⁶, Forbes C.², Chew B.², Hsi R.⁴, Miller N.⁴, Tzou D.Z.⁶, Wymer K.⁵, Humphreys M.R.H.¹, Stern K.L.S.¹

Institutions

¹Mayo Clinic Arizona, Dept. of Urology, Phoenix, United States of America, ²University of British Columbia, Dept. of Urology, Vancouver, Canada, ³Dartmouth-Hitchcock Medical Center, Dept. of Urology, Lebanon, United States of America, ⁴Vanderbilt University Medical Center, Dept. of Urology, Nashville, United States of America, ⁵Mayo Clinic Rochester, Dept. of Urology, Rochester, United States of America, ⁶University of Arizona, Dept. of Urology, Tucson, United States of America

A0160

Comparing the Efficacy, Safety and Pressure Dynamics of FANS versus DISS-Assisted RIRS for Renal Stones less than 1.5 cm: A Prospective Randomised Study.

Authors

Palanisamy V., Sriskandharaja T., Kothapalli S., Katamreddy P.R., Meyyappan V., Palaniyandi V., Sekar H., Krishnamoorthy S.

Institutions

Sri Ramachandra Institute of Higher Education and Research, Dept. of Urology, Chennai, India

A0161

Real-time monitoring with DISS and FANS systems to assure safe and effective stone treatment: Insights from ex-vivo experimental study.

Authors

Tsaturyan A.¹, Jahrreiss V.², Gauhar V.³, Musayelyan A.¹, Grigoryan H.¹, Muradyan A.¹, Ventimiglia E.⁴, Liatsikos E.⁵, Kallidonis P.⁵, Lattarulo M.⁶, Prontera P.P.⁶, Kar Kei Yuen S.⁷, Traxer O.⁸, Ballesta Martínez B.⁹, Somani B.¹⁰, Pietropaolo A.¹⁰

Institutions

¹Yerevan State Medical University after Mkhitar Heratsi, Dept. of Urology and Andrology, Yerevan, Armenia, ²Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ⁴Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ⁵University of Patras, Dept. of Urology, Patras, Greece, ⁶S.S Annunziata Hospital, Dept. of Urology, Taranto, Italy, ⁷The Chinese University of Hong Kong, SH Ho Urology Centre, Dept. of Surgery, Hong Kong, China, ⁸Sorbonne Université, Hôpital Tenon, GRC N°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Paris, France, ⁹Hospital Universitario Nuestra Señora de Candelaria, Dept. of Urology, Alicante, Spain, ¹⁰University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom

Fragment Size Distribution in a Clinical Study of a Novel Integrated System Combining Flexible DISS and Thulium Fiber Laser Lithotripsy

Authors

Traxer O.¹, Zorzi F.¹, Martov A.², Tursunkulov A.³, Boutoussov D.⁴, Yaroslavsky I.⁴, Kovalenko A.⁴, Altshuler G.⁴

Institutions

¹Sorbonne Université, Groupe de Recherche Clinique sur la Lithiase Urinaire n20, Paris, France, ²MBU INO FSBI SSC FMBC, Named After A.I. Burnazyan FMBA of Russia, Moscow, Russia, ³AKFA Medline University Hospital, Tashkent City, Uzbekistan, ⁴IPG medical, Research and Development Unit, Marlborough, United States of America

Outcomes of direct in-scope suction for renal and/or ureteric stones: The DISS-Global database

Authors

Fong K.Y.¹, Yuen S.K.K.², Somani B.K.³, Rico L.⁴, Ballesta-Martinez B.⁵, Tsaturyan A.⁶, El Hajj A.⁷, Lim B.T.Y.⁸, Kwok J.L.⁹, Tan Y.Q.¹⁰, Becker B.¹¹, Pietropaolo A.³, Ragoori D.¹², Traxer O.¹³, Castellani D.¹⁴, Gauhar V.¹⁰

Institutions

¹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ²The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, China, ³University Hospitals Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom, ⁴Hospital Aleman, Dept. of Urology, Buenos Aires, Argentina, ⁵Hospital del Vinalopó, Dept. of Urology, Alicante, Spain, ⁶Astghik Medical Center, Dept. of Urology, Yerevan, Armenia, ⁷American University of Beirut, Dept. of Urology, Beirut, Lebanon, ⁸Sengkang General Hospital, Dept. of Urology, Singapore, Singapore, ⁹Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore, ¹⁰Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ¹¹Asklepios Klinik Barmbek, Dept. of Urology, Hamburg, Germany, ¹²Asian Institute of Nephrology and Urology, Dept. of Urology, Hyderabad, India, ¹³Sorbonne University, AP-HP, Hôpital Tenon, Dept. of Urology, Paris, France, ¹⁴Azienda Ospedaliero-Universitaria delle Marche, Dept. of Urology, Ancona, Italy

Reproducible Stone Evacuation with CVAC Technology: Pooled Analyses of the ASPIRE and CLEARANCE Trials

Authors

Pathak N.¹, Sur R.², Preminger G.³, Johnson B.⁴, Chi T.⁵, Lipkin M.³, Mueller T.⁶, Stern K.⁷, Wolf S.⁸, Matlaga B.⁹, Eisner B.¹⁰, Desai M.¹

Institutions

¹Muljibhai Patel Urological Hospital, Dept. of Urology, Nadiad, India, ²UC San Diego Health, Dept. of Urology, San Diego, United States of America, ³Duke University Health System, Dept. of Urology, Durham, United States of America, ⁴University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ⁵University of Alabama at Birmingham, Dept. of Urology, Birmingham, United States of America, ⁶New Jersey Urology, Summit Health, Dept. of Urology, Sewell, United States of America, ⁷Mayo Clinic, Dept. of Urology, Phoenix, United States of America, ⁸University of Texas at Austin, Dell Medical School, Dept. of Urology, Austin, United States of America, ⁹John Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America, ¹⁰Tulane School of Medicine, Dept. of Urology, New Orleans, United States of America

The Global Flexible and Navigable Suction Ureteral Access Sheaths (FANS) Survey on Utility, Practices and Future Needs in Flexible Ureteroscopy - An EAU, YAU Endourology and IAU collaboration

Authors

Yuen S.¹, Somani B.K.², Pietropaolo A.², Castellani D.³, Zhong W.⁴, Zhu W.⁴, Tsaturyan A.⁵, Kwok J.L.⁶, Tefik T.⁷, Tanidir Y.⁸, Chai C.A.⁹, Persaud S.¹⁰, Kamal W.¹¹, Soebhali B.¹², Ragoori D.¹³, Elshazly M.¹⁴, Shrestha A.¹⁵, Chew B.H.¹⁶, Bhojani N.¹⁷, Ng C.F.¹, Zeng G.⁴, Gauhar V.¹⁸

Institutions

¹The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ²University Hospital Southampton, NHS Trust, Dept. of Urology, Southampton, United Kingdom, ³Azienda Ospedaliero-Universitaria Delle Marche, Urology Unit, Ancona, Italy, ⁴The First Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangzhou, China, ⁵Erebouni Medical Center, Dept. of Urology, Yerevan, Armenia, ⁶Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore, ⁷Istanbul University Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ⁸Medicana Atasehir Hospital, Dept. of Urology, Istanbul, Turkey, ⁹University of Malaya, Dept. of Surgery, Urology Unit, Kuala Lumpur, Malaysia, ¹⁰University of the West Indies, Division of Clinical Surgical Sciences, St. Augustine, Trinidad and Tobago, ¹¹King Fahd General Hospital, Urology Unit, Jeddah, Saudi Arabia, ¹²Abdul Wahab Sjahranie Hospital Medical Faculty, Muliawarman University, Dept. of Urology, Samarinda, Indonesia, ¹³Asian Institute of Nephrology & Urology, Irram Manzil Colony, Dept. of Urology, Hyderabad, India, ¹⁴Menoufia University, Urology Unit, Shibin el Kom, Egypt, ¹⁵National Academy of Medical Sciences, Bir Hospital, Dept. of Urology, Kathmandu, Nepal, ¹⁶University of British Columbia, Dept. of Urology, Vancouver, Canada, ¹⁷University of Montreal Hospital Center, Division of Urology, Montréal, Canada, ¹⁸Ng Teng Fong Hospital, Dept. of Urology, Singapore, Singapore

Optimal Pressure and Sheath Setting for Safe and Efficient Stone Removal with Flexible and Navigable Suction Ureteral Access Sheath

Authors

So S.W.¹, Elises J.C.², Alzahrani F.³, Sulaiman O.⁴, Lee H.¹, Joo H.J.¹, Villegas P.⁵, Yen C.H.⁶, Almuji M.⁷, Cho S.Y.¹

Institutions

¹Seoul National University Hospital, Dept. of Urology, Seoul, South Korea, ²University of the Philippines - Philippine General Hospital, Division of Urology, Dept. of Surgery, Manila, Philippines, ³East Jeddah Hospital, Dept. of Urology, Jeddah, Saudi Arabia, ⁴King Fahd General Hospital, Dept. of Urology, Jeddah, Saudi Arabia, ⁵Cebu South Medical Center, Dept. of Urology, Cebu, Philippines, ⁶Tri-service General Hospital Songshan Branch, Division of Urology Dept. of Surgery, Taipei, Taiwan, ⁷King Faisal University, Dept. of Urology, Alahssa, Saudi Arabia

How do we choose the optimal length of a Flexible and Navigable Suction Ureteral Access Sheaths (FANS): An EAU Endourology and AUSET prospective analysis

Authors

Yuen S.¹, Castellani D.², El Hajj A.³, Soebhali B.⁴, Fong K.Y.⁵, Chai C.A.⁶, Ketsuwan C.⁷, Geavlete P.⁸, Gokce M.I.⁹, Tan K.¹⁰, Kwok J.L.¹¹, Tan Y.Q.¹², Petkova K.¹³, Sundaram P.¹⁴, Tzelves L.¹⁵, Lu Y.⁵, Malkhasyan V.¹⁶, Nariman G.¹⁷, Kamal W.¹⁸, Rico L.¹⁹, Conteras P.¹⁹, Pirola G.M.²⁰, Somani B.²¹, Gauhar V.¹²

Institutions

¹The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ²Azienda Ospedaliero-Universitaria Delle Marche, Dept. of Urology, Ancona, Italy, ³American University of Beirut, Medical Center, Dept. of Urology, Beirut, Lebanon, ⁴Abdul Wahab Sjahranie Hospital Medical Faculty, Muliawarman University, Dept. of Urology, Samarinda, Indonesia, ⁵Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ⁶University of Malaya, Dept. of Surgery, Kuala Lumpur, Malaysia, ⁷Faculty of Medicine Ramathibodi Hospital, Mahidol University, Dept. of Surgery, Bangkok, Thailand, ⁸Carol Davila University of Medicine and Pharmacy, Dept. of Urology, Bucharest, Romania, ⁹Ankara University School of Medicine, Dept. of Urology, Ankara, Turkey, ¹⁰Veterans Memorial Medical Center, Dept. of Urology, Quezon City, Philippines, ¹¹Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore, ¹²Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ¹³Military Medical Academy, Dept. of Urology and Nephrology, Sofia, Bulgaria, ¹⁴Sengkang General Hospital, Dept. of Urology, Singapore, Singapore, ¹⁵Sismanoglio Hospital, National and Kapodistrian University of Athens, Dept. of Urology, Athens, Greece, ¹⁶A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Dept. of Endourology, Moscow, Russia, ¹⁷Saint Petersburg State University Hospital, Dept. of Urology, Saint Petersburg, Russia, ¹⁸King Fahd General Hospital, Dept. of Urology, Jeddah, Saudi Arabia, ¹⁹Hospital Alemán de Buenos Aires, Dept. of Urology, Buenos Aires, Argentina, ²⁰IRCCS Multimedica, Ospedale San Giuseppe, Dept. of Urology, Milan, Italy, ²¹University Hospital Southampton, NHS Trust, Dept. of Urology, Southampton, United Kingdom

The safety and effectiveness analysis of Vacuum-assisted Dedusting Lithotripsy using flexible and navigable suction ureteral access sheath under local anesthesia with monitored anesthesia care: a prospective, randomized controlled clinical trial

Authors

Xie H., Li J., Huang J., Zhang X., Liu C.

Institutions

The Second Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China

Paediatric urology 2: Congenital abnormalities and voiding dysfunction

Abstract Session 12

Saturday 14 March
12:15 - 13:45

Location

Blue Area, Victoria 6

Chairs

J.M. Chung, Yangsan-si (KR)

C. Gernhold, Linz (AT)

T.M. Oktar, Istanbul (TR)

A0187

The impact of transurethral catheterisation on urodynamic results in paediatric patients

Authors

Tseng S.

Institutions

Taipei Tzu Chi Hospital, Dept. of Urology, Taipei, Taiwan

A0188

Transcutaneous posterior tibial nerve stimulation (TPTNS) for refractory overactive bladder symptoms in pediatric patients: A subgroup analysis in the philippine setting

Authors

Timkang J.C.¹, Bolong D.T.²

Institutions

¹University of Santo Tomas Hospital, Dept. of Surgery, Section of Urology, Manila City, Philippines, ²University of Santo Tomas Hospital, Dept. of Surgery, Section of Urology, Manila City, Philippines

A0190

Factors affecting the clinical response to desmopressin treatment for primary monosymptomatic nocturnal enuresis in children

Authors

Selvi I.¹, Canbaz F.A.²

Institutions

¹Health Science University Gazi Yasargil Training and Research Hospital, Dept. of Pediatric Urology, Diyarbakir, Turkey, ²Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, Dept. of Pediatric Urology, Istanbul, Turkey

A0191

Efficacy and Safety of Mirabegron Versus Solifenacin in the Treatment of Overactive Bladder in Children: A Systematic Review and Meta-Analysis

Authors

Shaheen M.¹, Ali O.M.¹, Draz A.A.², Barakat A.K.², Elghattas A.², Elbaz T.¹, Walid I.², Tarboush T.², Elsayed A.², Mahmoud T.¹, Elkhateeb E.M.¹, Nofal A.A.², Samaan E.³, Badr A.⁴

Institutions

¹Mansoura University, Faculty of Medicine, Mansoura, Egypt, ²Mansoura University, Faculty of Medicine, Mansoura Manchester Program for Medical Education, Mansoura, Egypt, ³Mansoura University, Faculty of Medicine, Dept. of Internal Medicine and Nephrology, Mansoura, Egypt, ⁴Liverpool University Hospital Foundation Trust, Dept. of Urology, Liverpool, United Kingdom

A0192

Efficacy and tolerability of Mirabegron versus Oxybutynin in children with Posterior urethral valves after adequate fulguration: A randomized prospective study

Authors

Bawa M., Patil P., Malik M., Peters N.J., Mahajan J.K.

Institutions

Postgraduate Institute of Medical Education and Research, Dept. of Pediatric Surgery, Chandigarh, India

A0193

The Effectiveness of Different Therapy Modalities in Refractory Monosymptomatic Enuresis in Children: A Systematic Review by The EAU-YAU Paediatric Urology Working Group

Authors

Selvi I.¹, Marco B.B.², Donmez M.I.³, Baydilli N.⁴, Madarriaga Y.Q.⁵, Gernhold C.⁶, Lammers R.J.M.⁷, Bogaerts Q.⁸, Tatanis V.⁹, Bindi E.¹⁰, Pierucci U.M.¹¹, 't Hoen L.A.⁸

Institutions

¹Health Science University Gazi Yasargil Training and Research Hospital, Dept. of Pediatric Urology, Diyarbakir, Turkey, ²University Hospital Clinico San Carlos, Dept. of Pediatric Urology, Madrid, Spain, ³Istanbul University, İstanbul Faculty of Medicine, Dept. of Pediatric Urology, Istanbul, Turkey, ⁴Erciyes University Faculty of Medicine, Dept. of Pediatric Urology, Kayseri, Turkey, ⁵Fundació Puigvert, Dept. of Pediatric Urology, Barcelona, Spain, ⁶Ordensklinikum Linz Hospital of the Sisters of Charity, Dept. of Pediatric Urology, Linz, Austria, ⁷University Medical Center Groningen, Dept. of Pediatric Urology, Groningen, The Netherlands, ⁸Sophia Children's Hospital, Erasmus University Medical Center, Dept. of Pediatric Urology, Rotterdam, The Netherlands, ⁹University Hospital of Patras, Dept. of Pediatric Urology, Patras, Greece, ¹⁰Ospedale Pediatrico G Salesi, Dept. of Pediatric Surgery, Ancona, Italy, ¹¹Buzzi Children's Hospital, Dept. of Pediatric Surgery, Milan, Italy

12:50 - 13:15

Transition

A0194

Associations and Moderation by Baseline Knowledge on Effects of a Structured Urologic Transition Program on Transition Readiness and Emergency Department Use

Authors

Chua M.¹, Varghese A.², Tse N.L.¹, Dos Santos J.², Concio M.¹, Rickard M.², Lorenzo A.²

Institutions

¹University of Toronto, Division of Urology, Toronto, Canada, ²Hospital for Sick Children, Division of Urology, Toronto, Canada

A0195

STREAMWAY – Perceptions and Barriers to Transition in Urological Care among Adolescents – Intermediate analysis

Authors

Van den Ende M.¹, Spinoit A.F.¹, Hoebeke P.¹, Dossche L.², Goessaert A.S.¹, Van den Wyngaert K.³, Bou Kheir G.¹, Vandamme E.¹, Waterschoot M.¹, Raes A.², Everaert K.¹, Van Laecke E.¹, Hervé F.¹

Institutions

¹Ghent University Hospital ERN eUROGEN accredited center, Dept. of Urology, Ghent, Belgium, ²Ghent University Hospital ERN ERKNET Centre, Dept. of pediatric nephrology, Ghent, Belgium, ³Ghent University Hospital, Dept. of Pediatrics and Internal Diseases, Ghent, Belgium

A0196

Bridging the Gap: Implementing a Structured Transition Pathway for Young Adults with Complex Neurourological Disorders

Authors

Silva P., Campos Pinheiro L., Pinheiro H., Severo L., Gil M., Cunha J.

Institutions

Central Lisbon University Hospital Centre, Dept. of Urology, Lisbon, Portugal

A0197

Long-Term Renal Outcomes in Posterior Urethral Valves: A 10-Year Follow-Up Study from a Tertiary Paediatric Urology Centre

Authors

Potdar O.

Institutions

Grant Government Medical College and JJ group of Hospitals Mumbai, Dept. of Urology, Mumbai, India

A0198

Long-Term Renal Outcomes in Children with Posterior Urethral Valves: Impact of Early Versus Delayed Valve Ablation

Authors

Potdar O.

Institutions

Grant Government Medical College and JJ group of Hospitals Mumbai, Dept. of Urology, Mumbai, India

13:15 - 13:45

Congenital and genital

A0199

Hot vs cold knife for endoscopic ablation of posterior urethral valves: A systematic review by the EAU-YAU Paediatric Urology Working Group

Authors

't Hoen L.A.¹, Quiroz Y.², Gernhold C.³, Baydilli N.⁴, Banuelos Marco B.⁵, Bindi E.⁶, Lammers R.J.M.⁷, Sevi I.⁸, Pierucci U.M.⁹, Bogaerts Q.¹⁰, Tatanis V.¹¹, Dönmez M.I.⁸

Institutions

¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Fundación Puigvert, Dept. of Urology, Barcelona, Spain, ³Ordensklinikum Linz Hospital of the Sisters of Charity Linz, Dept. of Paediatric Urology, Linz, Austria, ⁴Erciyes University School of Medicine, Dept. of Paediatric Urology, Kaysiri, Turkey, ⁵Hospital Universitario Clínico San Carlos, Dept. of Urology, Madrid, Spain, ⁶Ospedale Pediatrico G Salesi, Dept. of Pediatric Surgery, Ancona, Italy, ⁷University Medical Center Groningen, Dept. of Urology, Groningen, The Netherlands, ⁸Istanbul University Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ⁹Buzzi Children's Hospital, Dept. of Paediatric Surgery, Milan, Italy, ¹⁰Erasmus MC, Dept. of Paediatric Urology, Rotterdam, The Netherlands, ¹¹University Hospital of Patras, Dept. of Urology, Patras, Greece

A0200

"To circ or not to circ" – that is the question for patients with posterior urethral valves

Authors

Bae H.¹, Wong A.¹, Jin F.¹, Chae H.², Zhang Q.¹, AlShalan A.³, Matsell D.⁴, Bone J.¹, Afshar K.³, Skarsgard E.⁵, MacNeily A.³, Kim S.³

Institutions

¹BC Children's Hospital Research Institute, Dept. of Urology, Vancouver, Canada, ²University of British Columbia, Dept. of Medicine, Vancouver, Canada, ³University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ⁴University of British Columbia, Dept. of Pediatrics, Vancouver, Canada, ⁵BC Children's Hospital, Dept. of Surgery, Vancouver, Canada

A0201

The Clinical Significance of Ureteropelvic Junction Stenosis in Children with Reflux Treated Endoscopically

Authors

Fruher M., Alper L., Hendel H., Yakubovitz S., May T., Lask A., Ben-Meir D.

Institutions

Schneider Medical Center, Dept. of Urology, Petah Tikva, Israel

A0202

CDKN2B inhibits Vascular Smooth Muscle Phenotypic Switching in Corpus Spongiosum surrounding the urethral plate in hypospadias

Authors

huang Y., Chen F., Yu M., Ding Y., Lyu Y., Ying X., Huang J.

Institutions

Shanghai Children's Hospital, Dept. of Urology, Shanghai, China

A0203

A clinical pathway incorporating the TWIST score and ultrasound for low risk cases safely decreases the negative exploration rate and time to theatre in testicular torsion

Authors

Folkard S.¹, Tyler G.¹, Hart E.¹, Chipeta C.¹, Kemp M.², AlBinali S.¹, Rudd I.¹, Henderson A.¹

Institutions

¹Maidstone and Tunbridge Wells NHS Trust, Dept. of Urology, London, United Kingdom, ²Kent & Medway Medical School, Dept. of Urology, Canterbury, United Kingdom

A0204

Obesity and testicular function in children with micropenis

Authors

Chung J.M., Lee S.D.

Institutions

Pusan National University Yangsan Hospital, Dept. of Urology, Yangsan-Si, South Korea

Training, gender disparities & perioperative challenges of urologists

Abstract Session 17

**Saturday 14 March
12:15 - 13:45**

Location

Red Area, Room 11

Chairs

M.G.R. Asmundo, Catania (IT)
To be confirmed
G.K. Çalik, Istanbul (TR)

12:15 - 12:40

Gender

A0274

Gender distribution of invited speakers at major international, pan-surgical conferences: A retrospective open cohort study

Authors

Asif A.¹, Georgi M.W.², Raja A.K.³, Gargan A.⁴, Gargan K.⁵, Fricker M.², Patel S.¹, Lee K.⁶, Leung K.H.C.¹, Kamboj R.⁷, Thamilmaran A.¹, Burton O.E.⁸, Shah A.¹, Abdi Z.⁹, Haque S.¹⁰, Nathan A.S.¹, Moore C.M.¹

Institutions

¹University College London, Division of Surgery and Interventional Science, London, United Kingdom, ²Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, ³University of Edinburgh, Division of Medicine, Edinburgh, United Kingdom, ⁴St George's University Hospital, Dept. of Plastic and Reconstructive Surgery, London, United Kingdom, ⁵St Thomas' Hospital, Dept. of Plastic and Reconstructive Surgery, London, United Kingdom, ⁶Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, ⁷University of Bristol, Bristol Medical School, Bristol, United Kingdom, ⁸University of Plymouth, Dept. of Neurosurgery, Plymouth, United Kingdom, ⁹Queen Mary University of London, Barts and The London School of Medicine and Dentistry, London, United Kingdom, ¹⁰Maastricht University, Dept. of Medicine, Maastricht, The Netherlands

A0275

Career Paths in Urology and Gender Structure: Persistent Glass Ceilings

Authors

Bañuelos Marco B.¹, Dönmez M.I.², Lammers R.J.M.³, Selvi I.², Maria Pierucci U.⁴, Bogaerts Q.⁵, Gernhold C.⁶, Tatanis V.⁷, Bindi E.⁸, Baydilli N.⁹, t Hoen L.A.⁵

Institutions

¹University Hospital Clinico San Carlos, Dept. of Urology, Madrid, Spain, ²Dept. of Urology, Istanbul University Istanbul Faculty of Medicine, Division of Pediatric Urology, Istanbul, Turkey, ³University Medical Center Groningen, Dept. of Urology, Groningen, The Netherlands, ⁴Buzzi Children's Hospita, Dept. of Pediatric Surgery, Milan, Italy, ⁵Erasmus MC Sophia Kinderziekenhuis, Dept. of Paediatric Urology, Rotterdam, The Netherlands, ⁶Ordensklinikum Linz Hospital of the Sisters of Charity Linz, Dept. of Paediatric Urology, Linz, Austria, ⁷University Hospital of Patras, Dept. of Urology, Patras, Greece, ⁸Ospedale Pediatrico G Salesi, Dept. of Pediatric Surgery, Ancona, Italy, ⁹Erciyes University School of Medicine, Division of Pediatric Urology, Kayseri, Turkey

Study Group

YAU PAEDIATRIC UROLOGY - EAU(Arnhem, The Netherlands)

A0276

Gender-specific ergonomic challenges in endourology: a Dutch national survey

Authors

Altobelli E.¹, Alt C.², Bus M.T.J.¹, Roemeling S.¹, van Oort I.M.¹

Institutions

¹University Medical Centre Groningen UMCG, Dept. of Urology, Groningen, The Netherlands, ²University Medical Centre Groningen UMCG, Dept. of Occupational Health, Groningen, The Netherlands

A0277

Pregnancy and parenthood during urology residency across Europe: Opinions do not differ between childbearing and non-childbearing urologists

Authors

Afferi L.¹, Faye H.¹, Margue G.², Toribio-Vázquez C.³, Melsert B.⁴, Baekelandt L.⁵, Goujon A.⁶, Ozalevli M.⁷, Checcucci E.⁸, Gugerli Lazos A.⁹, Siech C.¹⁰, Vázquez J.L.¹¹, Mertens L.S.¹², Liatsikos E.¹³, Somani B.K.¹⁴, Pradere B.¹⁵, Wyler S.¹, Phé V.¹⁶, Rangel E.¹⁷

Institutions

¹Kantonsspital Aarau, Dept. of Urology, Aarau, Switzerland, ²Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ³HLA Moncloa University Hospital, Dept. of Urology, Madrid, Spain, ⁴Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Surgical Oncology (Urology), Amsterdam, The Netherlands, ⁵University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁶Rennes University Hospital, Dept. of Urology, Rennes, France, ⁷Gaziosmanpaşa Training and Research Hospital, Dept. of Urology, Istanbul, Turkey, ⁸FPO-IRCCS Candiolo Cancer Institute, Dept. of Surgery, Candiolo, Italy, ⁹Universitätsspital Zürich, Dept. of Urology, Zürich, Switzerland, ¹⁰Goethe University Frankfurt, University Hospital, Dept. of Urology, Frankfurt, Germany, ¹¹Copenhagen University Hospital - Zealand University Hospital Roskilde, Dept. of Urology, Roskilde, Denmark, ¹²Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Surgical Oncology (Urology), Amsterdam, The Netherlands, ¹³University Hospital of Rion, Dept. of Urology, Patras, Greece, ¹⁴University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom, ¹⁵UROSUD, La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ¹⁶Assistance Publique-Hôpitaux de Paris, Tenon Academic Hospital, Sorbonne University, Dept. of Urology, Paris, France, ¹⁷Center for Surgery and Public Health, Brigham and Women's Hospital, Dept. of Surgery, Boston, United States of America

A0278

Gender Disparities in Academic Authorship, Leadership, and Compensation in Urology: A Systematic Review of Quantitative Evidence

Authors

Silva P., Campos Pinheiro L., Severo L., Gil M., Cunha J.

Institutions

Central Lisbon University Hospital Centre, Dept. of Urology, Lisbon, Portugal

12:40 - 13:10

Training

A0279

Anatomical training using Anatomage Table® 3D reconstruction for novice learners: a randomized controlled trial

Authors

Rossin G., Fontanel E., Biasatti A., Zorzi F., Sartori S., Rizzo M., Umari P., Liguori G.

Institutions

University of Trieste, Dept. of Urology, Trieste, Italy

Robotic Surgery Across Surgical Specialties in Italy: A Nationwide Survey on Implementation, Training, and Satisfaction Levels Among Residents and Young Attendings - on behalf of the Italian Polyspecialistic Society of Young Surgeons (SPIGC)

Authors

Santarelli V.¹, Fiori G.², Mastrovito S.³, Marinucci B.⁴, Mantovani S.⁵, Bolletta A.⁶, Rovere G.⁷, Di Giorgio D.⁸, Oddi F.M.⁹, Carino D.¹, Di Bartolomeo M.¹⁰, Chung B.I.¹¹, Crocetto F.¹², Maruccia M.¹³, Corvino R.¹, Meniconi R.¹⁴, Pasculli A.¹⁵, Angrisani M.¹⁴, Del Giudice F.¹

Institutions

¹Sapienza University of Rome, Dept. of Maternal Infant and Urological Sciences, Rome, Italy, ²San Giovanni Addolorata Hospital, Dept. of Surgery, Rome, Italy, ³University Hospital Agostino Gemelli, Dept. of Obstetrics and Gynaecology, Rome, Italy, ⁴Sant'Andrea Hospital, Dept. of Thoracic Surgery, Rome, Italy, ⁵San Camillo Forlanini Hospital, Dept. of Thoracic Surgery, Rome, Italy, ⁶University of Bari, Dept. of Plastic Surgery, Bari, Italy, ⁷University of Rome Tor Vergata, Dept. of Orthopaedics and Traumatology, Rome, Italy, ⁸Sapienza University of Rome, Dept. of Maxillofacial Surgery, Rome, Italy, ⁹Biomedicine and prevention, Vascular Surgery Unit, Rome, Italy, ¹⁰University of Verona, Dept. of Maxillofacial Surgery, Verona, Italy, ¹¹Stanford University, Dept. of Urology, Stanford, United States of America, ¹²University of Naples, Dept. of Neurosciences, Reproductive Sciences and Odontostomatology, Naples, Italy, ¹³University of Bari, Dept. of Emergency and Transplantation, Bari, Italy, ¹⁴San Camillo Forlanini Hospital, Dept. of Surgery, Rome, Italy, ¹⁵University of Bari, Dept. of Precision Medicine, Bari, Italy

Advancing laparoscopic training in Urology: Establishing the LUSs3 cadaveric model within the European School of Urology (ESU) curriculum

Authors

Ribeiro De Oliveira T.M.¹, Domingues N.², Gomez Rivas J.³, Zondervan P.⁴, Brinkman W.⁵, Rodriguez Socarras M.⁶, Garcia Barreras S.⁷, Pischetola A.⁸, Veneziano D.⁹, Palmas A.¹⁰, Pais D.¹¹, Goyri-ONeill J.¹¹, Biyani C.S.¹², Somani B.¹³, Liatsikos E.¹⁴

Institutions

¹Armed Forces Hospital, Dept. of Urology, Lisbon, Portugal, ²Cascais Hospital, Dept. of Urology, Cascais, Portugal, ³Hospital Clinico San Carlos, Dept. of Urology, Madrid, Spain, ⁴Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ⁵University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands, ⁶Instituto Cirugia Urologica Avanzada Madrid, Dept. of Urology, Madrid, Spain, ⁷Hospital Universitario Ramon y Cajal, Dept. of Urology, Madrid, Spain, ⁸Universita Campus Bio-Medico di Roma, International Master's Degree Course in Medicine and Surgery, Rome, Italy, ⁹Northwell Health, The Smith Institute of Urology, New York, United States of America, ¹⁰Champalimaud Foundation, Dept. of Urology, Lisbon, Portugal, ¹¹Nova Medical School, Dept. of Anatomy, Lisbon, Portugal, ¹²Leeds Teaching Hospital, Dept. of Urology, Leeds, United Kingdom, ¹³University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ¹⁴University Hospital of Patras, Dept. of Urology, Patras, Greece

Application of the IQQA Practice Teaching Model in Standardized Clinical Training for Renal Tumors: A Randomized Controlled Study

Authors

Sun X., Ma J., Zhang T.

Institutions

Second Affiliated Hospital of Anhui Medical University, Dept. of Urology, Hefei, China

The European School of Urology (ESU) Urology Boot Camp (ESU-UBC) program for first-year residents: Results from flagship European Association of Urology (EAU) program

Authors

Ribeiro De Oliveira T.M.¹, Biyani C.S.², Van Cleynenbreugel B.³, Henriques Pereira S.⁴, Osório L.⁵, Jarzemski M.⁶, Oliveira Reis D.¹, Sousa Castro A.⁷, Brito Ramos R.⁷, Dellis A.⁸, Durutovic O.⁹, Vuksanović A.⁹, Oswald D.¹⁰, Steinkellner L.¹¹, Aniulis P.¹², Okas R.¹³, Novák V.¹⁴, Paciotti M.¹⁵, Buffi N.M.¹⁵, Dragos L.¹⁶, Toribio-Vázquez C.¹⁷, Somani B.¹⁸, Liatsikos E.¹⁹

Institutions

¹Armed Forces Hospital, Dept. of Urology, Lisbon, Portugal, ²Leeds Teaching Hospital, Dept. of Urology, Leeds, United Kingdom, ³Universitair Ziekenhuis Leuven, Dept. of Urology, Leuven, Belgium, ⁴Lisbon Medical Academic Center, Dept. of Urology, Lisbon, Portugal, ⁵Lusíadas Hospital Porto, Dept. of Urology, Porto, Portugal, ⁶Jan Bizieli University Hospital, Dept. of Urology, Bydgoszcz, Poland, ⁷Portuguese Oncology Institute Lisbon Francisco Gentil, Dept. of Urology, Lisbon, Portugal, ⁸National and Kapodistrian University of Athens, Dept. of Urology, Athens, Greece, ⁹Clinical Centre of Serbia, Dept. of Urology, Belgrade, Serbia, ¹⁰University Hospital Salzburg, Dept. of Urology, Salzburg, Austria, ¹¹Linz Hospital, Dept. of Urology, Linz, Austria, ¹²Lietuvos Sveikatos Mokslų Universitetas, Dept. of Urology, Kaunas, Lithuania, ¹³Ida-Tallinna Keskhaigla, Dept. of Urology, Tallinn, Estonia, ¹⁴University Hospital Motol, Dept. of Urology, Prague, Czech Republic, ¹⁵Humanitas University, Dept. of Urology, Milan, Italy, ¹⁶Addenbrooke's Hospital, Dept. of Urology, Cambridge, United Kingdom, ¹⁷MD Anderson Madrid, Dept. of Urology, Madrid, Spain, ¹⁸University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ¹⁹University Hospital of Patras, Dept. of Urology, Patras, Greece

Validation and Benchmarking of Intermediate Laparoscopic Simulation Modules: An ESU Laparoscopic Working Initiative

Authors

Pischetola A.¹, Brinkman W.², Rodriguez Socarras M.³, de Oliveira T.R.⁴, García Barreras S.⁵, Ortega Polledo L.E.⁶, Zondervan P.J.⁷, Kraft P.⁸, Navratil P.⁹, Gómez Rivas J.⁶

Institutions

¹University Campus Bio-Medico of Rome, Faculty of Medicine, Rome, Italy, ²University Medical Centrum Utrecht, Dept. of Oncological Urology, Utrecht, The Netherlands, ³Clínica CEMTRO, Institute of Advanced Urological Surgery (ICUA), Madrid, Spain, ⁴Armed Forces Hospital, Dept. of Urology, Lisbon, Portugal, ⁵Hospital Universitario Ramón y Cajal, Dept. of Urology, Madrid, Spain, ⁶Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ⁷Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, Dept. of Urology, Amsterdam, The Netherlands, ⁸University of Toronto, Princess Margaret Cancer Centre, University Health Network, Division of Urology, Dept. of Surgery, Toronto, Canada, ⁹University Hospital Hradec Kralove, Dept. of Urology, Hradec Králové, Czech Republic

A0285

Supporting surgeons after adverse events: our experience of implementing a multi-centre peer support programme

Authors

Scrimgeour G.¹, Greville-Harris M.², Donnelly O.³, Wezyk A.⁴, King E.⁵, Tatar B.⁴, Thomas K.⁴, Turner K.⁵

Institutions

¹Salisbury NHS Foundation Trust, Dept. of Urology, Salisbury, United Kingdom, ²Exeter University, Dept. of Psychology, Exeter, United Kingdom, ³North Bristol NHS Trust, Staff Psychology Service, Bristol, United Kingdom, ⁴Bournemouth University, Dept. of Psychology, Bournemouth, United Kingdom, ⁵University Hospitals Dorset NHS Foundation Trust, Dept. of Ear, Nose and Throat, Bournemouth, United Kingdom

A0286

Surgeons inhale what they cauterize: Quantitative assessment of VOC exposure during TURBT

Authors

Hwang W.K., Kim H.J., Lee T.H., Jo S.B., Ahn S.T., Oh M.M., Park H.S., Moon D.G., Kim J.W.

Institutions

Korea university Guro Hospital, Dept. of Urology, Seoul, South Korea

13:20 - 13:35

Artificial Intelligence

A0287

Development and validation of an AI-assisted scoring system for abstract evaluation in urology: comparison with human reviewers at a national meeting

Authors

Lopez Joannon J.F.

Institutions

Pontificia Universidad Católica de Chile, Dept. of Urology, Santiago, Chile

A0288

Evaluating Interactions of Patients with Large Language Models for Medical Information

Authors

Carl N.¹, Michel M.S.¹, Brinker T.J.², Wessels F.¹

Institutions

¹University Medical Centre Mannheim University of Heidelberg, Dept. of Urology, Mannheim, Germany, ²German Cancer Research Center Heidelberg, Division of Digital Prevention, Diagnostics and Therapy Guidance, Heidelberg, Germany

Development of a ChatGPT-Based Assistant in Multidisciplinary Team Discussions in Oncological Urology: The UroMDT Advisor Study

Authors

Lombardo R.¹, Santioni M.¹, Pagliarulo V.², Gallo G.², Marzio S.², Secco S.³, Dell'Oglio P.³, Galfano A.³, Olivero A.⁴, De Cillis S.⁴, Quarà A.⁴, Amparore D.⁴, Porpiglia F.⁴, Lo Re M.⁵, Fuligni E.⁵, Cadenar A.⁵, Pezzoli M.⁵, Cocci A.⁵, Zarraonandia A.⁶, Ruibal Gago L.⁶, Russo G.I.⁷, De Lorenzis E.⁸, Montanari E.⁸, Albisinni S.⁹, Tubaro A.¹, De Nunzio C.¹

Institutions

¹Sant'Andrea Hospital Sapienza University of Rome, Dept. of Urology, Rome, Italy, ²Vito Fazzi Hospital, Dept. of Urology, Lecce, Italy, ³ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ⁴San Luigi Hospital, Dept. of Urology, Orbassano, Italy, ⁵Careggi Hospital University of Florence, Dept. of Urology, Florence, Italy, ⁶Complexo Hospitalario Universitario de Pontevedra, Dept. of Urology, Pontevedra, Spain, ⁷University of Catania, Dept. of Urology, Catania, Italy, ⁸Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ⁹Tor Vergata University, Dept. of Urology, Rome, Italy

13:35 - 13:45

Controversies

A0290

Quantifying the Environmental Impact of Robotic Urological Surgery by Calculating Greenhouse Gas

Authors

Hiroshi Y., Shuichi M., Takehiro H., Atsushi Y., Rumiko O., Ryoma N., Shogo T., Kimura Y., Noriya Y., Katsuya H., Atsushi T.

Institutions

Tottori University, Division of Urology, Dept. of Surgery Faculty of Medicine, Yonago, Japan

A0291

Bike-saddle and LUTS, bad surprises?

Authors

Tasso G.T.¹, Giorgi A.², Alberti A.³, Martinez-González B.⁴, Nicoletti R.⁵, Lanzi F.¹, Chini T.¹, Cecconi F.¹, Pizzirusso G.¹, Gentile F.¹, Barbanti G.¹

Institutions

¹Azienda Ospedaliero-Universitaria Senese, Dept. of Urology, Siena, Italy, ²Azienda USL Toscana-Southeast, Dept. of Internal Medicine, Specialist Medicine and Rehabilitation, Siena, Italy, ³Istituto Fondazione G. Giglio, Dept. of Urology, Cefalù, Italy, ⁴University of Kent, Kent and Medway Medical School, Canterbury, United Kingdom, ⁵Careggi Hospital, University of Florence, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy

Kidney cancer conundrums: Assessing function, prognosis, and patient perspectives

Abstract Session 16

Saturday 14 March
12:15 - 13:45

Location

Red Area, Room 10

Chairs

R.G. Bertolo, Verona (IT)
H-P. Marti, Bergen (NO)
Z. Wu, Shanghai (CN)

A0256

Comparison of patients with and without tumor pseudocapsule rupture during robot-assisted partial nephrectomy at a High-Volume Tertiary Care Referral Center

Authors

Presutti M.¹, Romei F.¹, Catanzaro C.¹, Pissavini A.¹, Stradaoli A.¹, Sernaglia G.¹, Berardesca A.¹, Gaudio C.², Renò E.², Giunchi F.³, Piazza P.¹, Pultrone C.V.¹, Bianchi L.¹, Schiavina R.¹

Institutions

¹IRCCS Azienda Ospedaliero Universitaria di Bologna, Division of Urology, Bologna, Italy, ²IRCCS Azienda Ospedaliero Universitaria di Bologna, Dept. of Radiology, Casina, Italy, ³IRCCS Azienda Ospedaliero Universitaria di Bologna, Dept. of Pathology, Bologna, Italy

A0257

When Complications Strike: The Role of Age in Failure-to-Rescue After Partial Nephrectomy

Authors

Alame N., Balaghi A., Mazloun M.A., Farchoukh W., El Hajj A., Chahrour D.

Institutions

American University of Beirut, Medical Center, Dept. of Urology, Beirut, Lebanon

A0258

In Partial Nephrectomy Time Matters only when there are comorbidities

Authors

Piccolo C.¹, Scilipoti P.¹, Bertini A.¹, Re C.¹, Salerno L.¹, Musso G.¹, Cei F.¹, Rosiello G.¹, Belladelli F.¹, Disabato N.¹, Barretta A.², Campugiani A.¹, Montesano M.¹, Trevisani F.¹, Ficarra G.¹, Briganti A.¹, Bertini R.¹, Salonia A.¹, Montorsi F.¹, Larcher A.¹, Capitanio U.¹

Institutions

¹IRCCS San Raffaele Scientific Institute. URI - Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²IRCCS Azienda Ospedaliero - Universitaria di Bologna, Dept. of Urology, Bologna, Italy

A0259

Robotic vs. Open Partial Nephrectomy in Complex Cases: Real-World Benchmarking of the OpeRa Trial

Authors

Musso G.¹, Cei F.¹, Re C.¹, Scilipoti P.¹, Bertini A.¹, Salerno L.¹, Piccolo C.¹, Disabato N.¹, Belladelli F.¹, Ficarra G.¹, Campugiani A.¹, Montesano M.¹, Rosiello G.¹, Bertini R.¹, Matloob R.¹, Gandaglia G.¹, Briganti A.¹, Barletta F.¹, Salonia A.¹, Montorsi F.¹, Derweesh I.H.², Mottrie A.³, Larcher A.¹, Capitanio U.¹

Institutions

¹IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²RUSH-MD Anderson Cancer Center, Dept. of Urology, Chicago, United States of America, ³Onze Lieve Vrouw Hospital, Dept. of Urology, Aalst, Belgium

A0260

Risk factors of prolonged hospitalization after radical nephrectomy and thrombectomy: Based on 656 patients with renal cell carcinoma and tumor thrombus

Authors

Yu S., Liu W., Wang Z., Zhang S.

Institutions

Peking University Third Hospital, Dept. of Urology, Beijing, China

A0261

Functional Status at Admission Predicts Prolonged Hospital Stay After Renal Surgery: The Hidden Value of Nursing Assessments

Authors

Salerno L.¹, Cei F.¹, Piccolo C.¹, Scilipoti P.¹, Bertini A.¹, Re C.¹, Musso G.¹, Rosiello G.¹, Trevisani F.¹, Boarin M.¹, Leggio N.¹, Belladelli F.¹, Disabato N.¹, Montesano M.¹, Barretta A.², Bertini R.¹, Matloob R.¹, Gandaglia G.¹, Briganti A.¹, Salonia A.¹, Vickers A.³, Montorsi F.¹, Larcher A.¹, Capitanio U.¹

Institutions

¹IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Urology, Bologna, Italy, ³Memorial Sloan Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, New York, United States of America

12:45 - 13:15

Renal function after nephrectomy

A0262

Computed Tomography Radiomics-Derived Nomogram for Predicting Early Renal Function Decline after Partial Nephrectomy in Renal Cell Carcinoma: A Multicenter Development/Validation Study

Authors

Chen S., Xiao-Hui W., Ning X.

Institutions

The First Affiliated Hospital of Fujian Medical University, Dept. of Urology, Fuzhou, China

A0263

Evaluating the role of measured eGFR in the post-operative management of single kidney patients after radical nephrectomy for kidney cancer.

Authors

Trevisani F., Rosiello G., Cei F., Musso G., Re C., Scilipoti P., Belladelli F., Salerno L., Bertini A., Piccolo C., Disabato N., Montesano M., Campugiani A., Ficarra G., Bertini R., Gandaglia G., Briganti A., Salonia A., Montorsi F., Larcher A., Capitanio U.

Institutions

IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy

A0264

External Validation of the RENSAFE Model for Predicting Acute and Chronic Kidney Failure in Patients Undergoing Nephrectomy

Authors

Kaptzan B.¹, Fraifeld Y.², Moshe S.², Neheman A.¹, Haifler M.¹

Institutions

¹Meir medical center, Dept. of Urology, Kfar Saba, Israel, ²Carmel medical center, Dept. of Urology, Haifa, Israel

A0265

When the Thrombus Rises: Inferior Vena Cava Involvement Impairs Preoperative Renal Function in Renal Cell Carcinoma

Authors

Musso G.¹, Trevisani F.¹, Cei F.¹, Re C.¹, Scilipoti P.¹, Longoni M.¹, Bertini A.¹, Salerno L.¹, Piccolo C.¹, Disabato N.¹, Belladelli F.¹, Montesano M.¹, Ficarra G.¹, Campugiani A.¹, Rosiello G.¹, Bertini R.¹, Matloob R.¹, Gandaglia G.¹, Briganti A.¹, Salonia A.¹, Montorsi F.¹, Derweesh I.H.², Larcher A.¹, Capitanio U.¹

Institutions

¹IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²RUSH-MD Anderson Cancer Center, Dept. of Urology, Chicago, United States of America

A0266

Renal Functional Following Angioembolization After Partial Nephrectomy

Authors

Cei F.¹, Peschechera M.¹, Cosenza S.¹, Musso G.¹, Barretta A.¹, Bertini A.¹, Re C.¹, Belladelli F.¹, Salerno L.¹, Piccolo C.¹, Disabato N.¹, Trevisani F.¹, De Cobelli F.², Brembilla G.², Gusmini S.², Palumbo D.², Colombo M.², Imperiale G.², Rosiello G.¹, Bertini R.¹, Salonia A.¹, Montorsi F.¹, Larcher A.¹, Capitanio U.¹

Institutions

¹IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy

A0267

Beyond creatinine: Early biomarkers of AKI and impact on medium-term CKD following robotic renal surgery

Authors

La Mura R., Paladini A., Mangione P., Massa G., Ricci F., Pagnotta J., Giardino G., Del Zingaro M., Cochetti G., Mearini E.

Institutions

University of Perugia, Dept. of Medicine and Surgery, Urology Clinic, Perugia, Italy

13:15 - 13:30

Prognosis and recurrence

A0268

Reassessing Prognosis in RCC with Venous Tumor Thrombus: Prospective Cohort Study from 46 Cases

Authors

Meyyappan V., Sharma R., Mohan A., Balagangatharan P., Janaki K.L., Krishna G.

Institutions

Basavatarakam Indo-American Cancer Hospital, Dept. of Uro-Oncology, Hyderabad, India

A0269

Development and validation of a multimodal predictive recurrence score (MPRS) integrating clinical, radiological, and histopathological information for multicenter patients with clear cell renal cell carcinoma (ccRCC)

Authors

Zheng J.

Institutions

Renji Hospital, Dept. of urology, Shanghai, China

DaRenCa risk score: a prognostic tool to assess risk of recurrence in patients with clear cell renal cell carcinoma

Authors

[Hedegaard P.](#)¹, Petersson R.D.¹, Al-Husseinawi H.², Heeno E.³, Lunetcas M.⁴, Tolouee S.⁵, Bak R.⁶, Pedersen O.B.⁷, Vásquez J.L.¹, Lund L.³, Thomsen F.F.¹

Institutions

¹Zealand University Hospital, Dept. of Urology, Roskilde, Denmark, ²Aalborg University Hospital, Dept. of Urology, Aalborg, Denmark, ³Odense University Hospital, Dept. of Urology, Odense, Denmark, ⁴Zealand University Hospital, Dept. of Radiology, Roskilde, Denmark, ⁵Herlev-Gentofte Hospital, Dept. of Urology, Herlev, Denmark, ⁶Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ⁷Zealand University Hospital, Dept. of Clinical Immunology, Køge, Denmark

13:30 - 13:45

Patient and clinician perspective on RCC

A0271

Kidney function (KF) issues and related emotional concerns among patients with kidney cancer (KC) in Europe: Findings from the International Kidney Cancer Coalition (IKCC) global patient survey (GPS)

Authors

Jonasch E.¹, Maskens D.², [Bex A.](#)³, Collins C.⁴, Dabestani S.⁵, Erdem S.⁶, Hickey M.⁷, Kastrati K.⁸, Shah J.P.⁹, Sosnowski R.¹⁰, Ürün Y.¹¹, Jewett M.¹²

Institutions

¹The University of Texas MD Anderson Cancer Center, Dept. of Genitourinary Medical Oncology, Houston, United States of America, ²International Kidney Cancer Coalition, Board Ambassador, Utrecht, The Netherlands, ³Royal Free London NHS Foundation Trust, University College London, and The Netherlands Cancer Institute, Dept. of Surgery and Interventional Science, London, United Kingdom, ⁴Kidney Cancer Canada, Mississauga, Canada, ⁵Kristianstad Central Hospital, Region Skane, and Lund University, Dept. of Urology, Kristianstad, Sweden, ⁶Istanbul University Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ⁷International Kidney Cancer Coalition, Board of Directors, Utrecht, The Netherlands, ⁸Nierenkrebs-Netzwerk Deutschland e.V., Wölfersheim, Germany, ⁹V Care Foundation, Maharashtra, India, ¹⁰Warmian-Masurian Cancer Center, Dept. of Urology and Oncological Urology, Olsztyn, Poland, ¹¹Ankara University School of Medicine, Dept. of Medical Oncology, Ankara, Turkey, ¹²Princess Margaret Cancer Centre and The University of Toronto, Dept. of Surgery, Toronto, Canada

A0273

Awareness and Perspectives on Hereditary Renal Cell Carcinoma and Genetic Testing in Clinical Practice: A Multi-National Survey

Authors

[Re C.](#)¹, Amparore D.², Campi R.³, Warren H.⁴, Marandino L.⁵

Institutions

¹IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Division of Urology, Dept. of Surgery, Turin, Italy, ³University of Florence, Careggi Hospital, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ⁴Division of Surgery and Interventional Sciences, University College London, London, United Kingdom, ⁵The Royal Marsden NHS Foundation Trust, Dept. of Medical Oncology, London, United Kingdom

Saturday 14 March
12:15 - 13:45

Location Red Area, Room 12
Chairs To be confirmed
S. Erdem, Istanbul (TR)
To be confirmed

12:15 - 12:25

New treatment strategies in metastatic kidney cancer

[A0292](#)

Fruquintinib Plus Serplulimab as First-Line Therapy in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (nccRCC): Updated Efficacy and Safety Data from a Multicenter, Single-Arm, Phase II Trial

Authors

Ding Y.¹, Huang J.¹, Hu X.², Wang H.², Guo J.², Zhang H.³, Dong P.⁴, Xue W.¹

Institutions

¹Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of urology, Shanghai, China, ²Zhongshan Hospital, Fudan University, Dept. of urology, Shanghai, China, ³Peking University Third Hospital, Dept. of urology, Beijing, China, ⁴Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Dept. of Urology Oncology, Guangzhou, China

[A0293](#)

Prognostic significance of time-of-day administration (ToDA) of immune checkpoint inhibitor (ICI) in patients with metastatic renal cell carcinoma (mRCC) treated with first-line therapies

Authors

Nakama D.¹, Inoue M.¹, Yuasa T.¹, Maj D.², Zarba M.², Baumgarten P.², Basappa N.S.³, Oki R.⁴, Urasaki T.⁴, Numao N.¹, Yonese J.¹, Endo F.⁵, Hattori K.⁵, Miura Y.⁴, Heng D.Y.C.², Takemura K.¹

Institutions

¹Japanese Foundation for Cancer Research, Dept. of Genitourinary Oncology, Tokyo, Japan, ²Arthur J.E. Child Comprehensive Cancer Centre, Dept. of Oncology, Calgary, Canada, ³Cross Cancer Institute, Dept. of Oncology, Edmonton, Canada, ⁴Japanese Foundation for Cancer Research, Dept. of Medical Oncology, Tokyo, Japan, ⁵St Luke's International Hospital, Dept. of Urology, Tokyo, Japan

12:25 - 12:40

Staging and treatment of advanced renal cancer in clinical practice

[A0294](#)

Integrating Next-Generation Sequencing into Real-World Management of Renal Cell Carcinoma: A 40-Patient Institutional Experience from India

Authors

Jain A., Goel V., Talwar V.

Institutions

Rajiv Gandhi Cancer Institute and Research Centre, Dept. of Medical Oncology, Delhi, India

A0295

A majority of patients with high grade renal cell carcinoma and early lung recurrence are initially miss-staged

Authors

Sundquist F., Bergkvist M., Hosseini A., Kjellman A., Thor A., Thiel T., Hermann M., Dastaviz N., Lundgren P-O.

Institutions

Karolinska Institutet, Dept. of Urology, Stockholm, Sweden

A0296

Real-world incidence and clinical impact of grade 3–4 adverse events in patients with metastatic renal cell carcinoma treated with first-line immune combinations: ARON-1 study

Authors

Maiorano B.A.¹, Valdez-Sandoval P.², Scagliarini S.³, Beas-Lozano E.L.², Bilen M.A.⁴, Bamias A.⁵, Li H.⁶, Fita M.J.J.⁷, Kopecky J.⁸, Manneh Kopp R.⁹, Ghosn M.¹⁰, Poisl Fay A.¹¹, Bhuvu D.¹², Molina-Cerrillo J.¹³, Soares A.¹⁴, Buti S.¹⁵, Marques Monteiro F.S.¹⁶, Massari F.¹⁷, Bournon M.T.², Santoni M.¹⁸

Institutions

¹IRCCS San Raffaele, Dept. of Medical Oncology, Milan, Italy, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Dept. of Hemato-Oncology, Mexico City, Mexico, ³Cardarelli Hospital, Dept. of Oncology, Naples, Italy, ⁴Emory University School of Medicine, Dept. of Hematology and Oncology, Atlanta, United States of America, ⁵Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 2nd Propaedeutic Department of Internal Medicine, Athens, Greece, ⁶University of Kansas Cancer Center, Dept. of Internal Medicine, Kansas City, United States of America, ⁷Fundación Instituto Valenciano de Oncología, Dept. of Medical Oncology, Valencia, Spain, ⁸University Hospital in Hradec Králové, Dept. of Oncology, Hradec Králové, Czech Republic, ⁹Sociedad de Oncología y Hematología del Cesar, Dept. of Oncology, Valledupar, Colombia, ¹⁰Saint Joseph University of Beirut, Dept. of Hematology-Oncology, Beirut, Lebanon, ¹¹Hospital Nora Teixeira-Irmandade Santa Casa de Misericórdia de Porto Alegre (ISCOMPA), Porto Alegre, Brazil, ¹²Army Hospital Research and Referral, Dept. of Medical Oncology, New Delhi, India, ¹³Hospital Ramón y Cajal, Dept. of Medical Oncology, Madrid, Spain, ¹⁴Hospital Israelita Albert Einstein, Dept. of Oncology, São Paulo, Brazil, ¹⁵University Hospital of Parma, Dept. of Medical Oncology, Parma, Italy, ¹⁶Hospital Sírío Libanês, Dept. of Oncology and Hematology, Brasilia, Brazil, ¹⁷IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Medical Oncology, Bologna, Italy, ¹⁸Macerata Hospital, Dept. of Medical Oncology, Macerata, Italy

12:40 - 13:10

Role of nephrectomy in the current metastatic kidney cancer scenario

A0297

SCREENING smarter: outperforming IMDC in predicting first-year mortality among patients undergoing cytoreductive nephrectomy

Authors

Yu L.¹, Lee A.Y.M.², Tan Y.G.², Tay K.J.², Tan W.C.³, Chan J.³, Wong Y.N.S.³, Ho H.S.S.², Yuen J.S.P.², Kanesvaran R.³, Chen K.²

Institutions

¹Duke-NUS Graduate Medical School, Doctor of Medicine Programme, Singapore, Singapore, ²Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ³National Cancer Centre Singapore, Division of Medical Oncology, Singapore, Singapore

- A0298** **Efficacy and Safety of deferred nephrectomy following targeted therapy combined with immunotherapy in patients with unresectable/advanced renal cell carcinoma: A prospective, single-arm trial**
- Authors**
Wang Y., Zhou Y., Liang Q., Wang D., Peng C., Huang Q., Ma X., Zhang X., [Liangyou G.](#)
- Institutions**
Chinese PLA General Hospital, Senior Dept. of Urology, Beijing, China
- A0299** **Feasibility and Outcomes of Deferred Cytoablative Nephrectomy Following Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Therapy in Metastatic Clear Cell Renal Cell Carcinoma**
- Authors**
[Hsu C.H.](#), Chang Y.H., Wei T.C., Huang T.H., Huang E.Y.H.
- Institutions**
Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan
- A0300** **Cytoablative Nephrectomy with Venous Tumor Thrombectomy: Comparing Outcomes of Historical Upfront vs Modern Deferred Treatment A single center experience**
- Authors**
[Packham R.](#)¹, Mang B.¹, Pruthi D.K.²
- Institutions**
¹UT Health - San Antonio Long School of Medicine, Dept. of Urology, San Antonio, United States of America, ²UT Health - San Antonio, Dept. of Urology, San Antonio, United States of America
- A0301** **Impact of Nephrectomy in the Era of Combined Immunotherapy for Intermediate-Poor Risk Metastatic Renal Cell Carcinoma**
- Authors**
[Mita Y.](#), Teishima J., Ueki H., Wakita N., Hara T., Bando Y., Suzuki K., Terakawa T., Chiba K., Miyake H.
- Institutions**
Kobe University Graduate School of Medicine, Dept. of Urology, Kobe, Japan
- A0302** **The Impact of Local Therapy on the Prognosis of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma**
- Authors**
[Wei X.](#), Liang J., Liu H., Tang Y., Shi X., Zhang X., Zhao J., Chen J., Sun G., Hu X., Shen P., Zeng H., Liu Z.
- Institutions**
West china Hospital, Sichuan University, Dept. of Urology, Chengdu, China

13:10 - 13:40

Prognostic factors in metastatic kidney cancer

A0303

Effect of prior nephrectomy and bone metastases on real-world efficacy of Ipilimumab/Nivolumab and Pembrolizumab with TKI in metastatic clear-cell RCC

Authors

Surovtsova I.¹, Morakis P.²

Institutions

¹Baden-Wuerttemberg Cancer Registry, Clinical state registry, Stuttgart, Germany,

²Baden-Wuerttemberg Cancer Registry, Quality Conferences Office at the Clinical State Registry Baden-Wuerttemberg, Stuttgart, Germany

A0304

Cancer-Specific Survival After Synchronous or Metachronous Metastasis Following Surgery for Renal Tumors: A 10-Year Comparative Analysis

Authors

Donnini I.¹, Nocera L.¹, Lonati C.¹, Sciotta M.¹, Zamboni S.¹, Carbotti G.¹, Rodella F.¹, Mirabella G.¹, Antonelli A.², Suardi N.R.¹

Institutions

¹ASST Spedali Civili, Dept. of Urology, Brescia, Italy, ²Azienda Ospedaliera

Universitaria di Verona, Dept. of Urology, Verona, Italy

A0305

Landmark Complete Metabolic Response on FDG-PET/CT at One Year: A Powerful Surrogate for Survival Benefit in Metastatic Renal Cell Carcinoma Treated with Immunotherapy

Authors

Lei C.¹, Cai Y.¹, Tang Y.¹, Ji H.², Zhu J.², Gao H.³, Li X.⁴, Cai H.⁴, Zang S.⁵, Ge Y.⁶, Li Q.⁷, Wu J.², Wang F.⁵, Qu L.¹

Institutions

¹Jinling Hospital Affiliated to the Medical School of Nanjing University, Dept. of Urology, Nanjing, China, ²Jinling Hospital Affiliated to the Medical School of Nanjing University, Dept. of Nuclear Medicine, Nanjing, China, ³Jinling Hospital Affiliated to the Medical School of Nanjing University, Dept. of Radiology, Nanjing, China, ⁴Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research and the Affiliated Cancer Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China, ⁵Nanjing First Hospital Affiliated to Nanjing Medical University, Dept. of Nuclear Medicine, Nanjing, China, ⁶Nanjing First Hospital Affiliated to Nanjing Medical University, Dept. of Urology, Nanjing, China, ⁷Zhongda Hospital Affiliated to Southeast University, Dept. of Nuclear Medicine, Nanjing, China

A0306

Ultra-Early PIV Kinetics Predict Survival in Metastatic Renal Cell Carcinoma: Identification of the "PIV Boost" Phenomenon

Authors

Inoue T.¹, Naito S.², Tsuchiya N.², Kobayashi S.³, Numakura K.³, Kikuchi H.⁴, Osawa T.⁴, Abe T.⁴, Naito H.⁵, Sugimoto M.⁵, Ueda K.⁶, Sakai Y.⁶, Matsuda T.⁷, Ohba K.⁷, Sekine Y.⁸, Habuchi T.⁸, Shin T.¹

Institutions

¹Oita University, Dept. of Urology, Yufu, Japan, ²Yamagata University Faculty of Medicine, Dept. of Urology, Yamagata, Japan, ³Asahikawa Medical University, Dept. of Renal and Urologic Surgery, Asahikawa, Japan, ⁴Hokkaido University, Dept. of Renal and Genitourinary Surgery, Graduate School of Medicine, Sapporo, Japan, ⁵Kagawa University Graduate School of Medicine, Dept. of Urology, Takamatsu, Japan, ⁶Kurume University School of Medicine, Dept. of Urology, Kurume, Japan, ⁷Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan, ⁸Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan

A0307

A Study on the Utility of the Glasgow Prognostic Score (GPS) in Treatment Selection for Metastatic Renal Cell Carcinoma

Authors

Yoneyama E.¹, Kodama H.¹, Narita T.¹, Kojima Y.¹, Mikami J.¹, Fujita N.¹, Okamoto T.¹, Yamamoto H.¹, Imai A.¹, Narita S.², Sato S.³, Habuchi T.², Ohyama C.¹, Hatakeyama S.¹

Institutions

¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ³Ageo Central General Hospital, Dept. of Urology, Ageo, Japan

A0308

Serum IgG: A novel biomarker for efficacy and prognosis in metastatic clear cell renal cell carcinoma patients receiving first-line immunotherapy combined with tyrosine kinase inhibitors.

Authors

Han T.¹, Du G.¹, Wang H.¹, Cui H.², Bi X.¹, Guan Y.¹, Shi H.¹, Shou J.¹

Institutions

¹National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Dept. of Urology, Beijing, China, ²The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Dept. of Urology, Zhengzhou, China

Testicular cancer: From diagnosis to survivorship

Abstract Session 19

**Saturday 14 March
12:15 - 13:45**

Location

Red Area, Room 13

Chairs

To be confirmed
R. Hamilton, Toronto (CA)
To be confirmed

12:15 - 12:30

Indeterminate lesions and primary diagnosis

A0309

How reliable are serum tumor markers in the diagnosis of small testicular masses? A multicentric analysis from the Milan Testis Cancer Alliance

Authors

Corsini C.¹, Raffo M.¹, Nazzani S.², Silvani C.², Mazzone E.³, Giudici S.³, Dell'Oglio P.³, Boeri L.⁴, Passarelli F.⁴, Basadonna L.M.⁴, Garofano G.⁵, Paciotti M.⁵, Lughezzani G.⁵, Triggiani A.⁶, Fallara G.⁶, Ferro M.⁶, Montorsi F.¹, Salonia A.¹, Bandini M.¹

Institutions

¹IRCCS Ospedale San Raffaele, Division of Experimental Oncology - Unit of Urology, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Dept. of Urology, Milan, Italy, ³ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ⁴IRCCS Fondazione Ca' Granda, Policlinico di Milano, Dept. of Urology, Milan, Italy, ⁵IRCCS Humanitas Clinical and Research Institute, Dept. of Urology, Milan, Italy, ⁶ASST Santi Paolo e Carlo, Dept. of Urology, Milan, Italy

A0310

Role of Elastography in the Evaluation of Testicular Neoplasms: Correlation Between Tissue Stiffness (kPa) and Histological Type

Authors

De Marzo E.¹, Di Pippa E.¹, Magistro R.¹, Rubino U.², Balestra A.², Liguigli S.², Di Lena S.²

Institutions

¹ASL Taranto San Pio Hospital, Dept. of Nephro-urology, Castellaneta, Italy, ²ASL Taranto Valle D'Itria Hospital, Dept. of Nephro-urology, Martina Franca, Italy

A0311

Chest CT in Testicular Mass Evaluation: A Stepwise Approach to Minimize Radiation Exposure

Authors

Eigner E.¹, Malshy K.², Fazaa N.¹, Nsair A.¹, Atallah M.¹, Amiel G.¹, Hoffman A.¹

Institutions

¹Rambam Health Care Campus, Dept. of Urology, Haifa, Israel, ²University of Rochester Medical Center, Dept. of Urology, Rochester, United States of America

12:30 - 12:45

Relapse risk & adjuvant therapy decisions

A0312

Comparative effects of adjuvant single-shot Carboplatin versus PEB in men with testis cancer: the case for sexual hormones and sperm parameters

Authors

De Rocco Ponce M.¹, Bertini A.², Raffo M.², Malca Caballero L.¹, Pozzi E.², d'Arma A.², Montorsi F.², Salonia A.², Ruiz-Castane E.¹

Institutions

¹Fundacio Puigvert, Dept. of Andrology, Barcelona, Spain, ²IRCCS Ospedale San Raffaele, Unit of Urology, Milan, Italy

A0313

Establishment of a miRNA signature for individual prognostic evaluation of seminoma patients

Authors

Junker K.¹, Zohari F.¹, Eckhardt L.², Ayoubian H.¹, Lenhof H.P.², Bohle R.³, Bremmer F.⁴, Gayer F.⁵, Che Y.⁶, Vermeulen-Spohn M.⁶, Nestler T.⁷, Paffenholz P.⁸, Heidenreich A.⁸, Stöckle M.¹, Heinzlbecker J.¹

Institutions

¹Saarland University, Dept. of Urology and Pediatric Urology, Homburg, Germany, ²Saarland University, Center for Bioinformatics, Saarland Informatics Campus, Saarbrücken, Germany, ³Saarland University, Institute of Pathology, Homburg, Germany, ⁴University Medical Center Göttingen, Institute of Pathology, Göttingen, Germany, ⁵University Medical Center Göttingen, Dept. of Urology, Göttingen, Germany, ⁶Heinrich-Heine University, Dept. of Urology, Düsseldorf, Germany, ⁷Federal Armed Forces Hospital Koblenz, Dept. of Urology, Koblenz, Germany, ⁸Faculty of Medicine and University Hospital Cologne, Dept. of Urology, Cologne, Germany

A0314

Pure testicular seminomas that relapse with nonseminomatous elements: clinical patterns and management

Authors

Kraft P.¹, Mousa A.¹, Amiri A.¹, Anson-Catwright L.¹, Tan I.¹, Bedard P.², Jiang D.M.², Glicksman R.M.³, Chung P.³, Warde P.³, Prendeville S.⁴, Jewett M.A.S.¹, Hamilton R.J.¹

Institutions

¹Princess Margaret Cancer Centre, University Health Network, University of Toronto, Division of Urology, Dept. of Surgery, Toronto, Canada, ²University of Toronto, Division of Medical Oncology, Dept. of Medicine, Toronto, Canada, ³University of Toronto, Dept. of Radiation Oncology, Toronto, Canada, ⁴University of Toronto, Dept. of Laboratory Medicine & Pathobiology, Toronto, Canada

12:45 - 13:05

RPLND: Outcomes and complications

A0315

Quantifying the Spectrum of Perioperative Morbidity in 444 Retroperitoneal Lymph Node Dissection for Testicular Cancer Using the ClassIntra and Clavien-Dindo Classification Systems

Authors

Prakash G., Thimiri Mallikarjun N., Pal M., Arora A., Misra A., Gujela A., Godse S., Bakshi G.

Institutions

Tata Memorial Hospital, Homi Bhabha National Institute, Division of Uro-Oncology, Dept. of Surgical Oncology, Mumbai, India

A0316

Primary retroperitoneal lymph node dissection (RPLND) for clinical stage IIA/IIB seminoma – updated population-based results from The Swedish and Norwegian testicular cancer group (SWENOTECA)

Authors

Thor A.¹, Almås B.², Cohn-Cedermark G.³, Gerdtsson A.⁴, Grenabo Bergdahl A.⁵, Glimelius I.⁶, Halvorsen D.⁷, Habberstad A.⁸, Sagstuen Haugnes H.⁹, Hedlund A.¹⁰, Hellström M.¹¹, Jansson A.K.⁶, Johannsdottir B.³, Karlsdottir A.¹², Kjellman A.¹, Langberg C.W.¹³, Melsen Larsen S.⁸, Negaard H.¹³, Ståhl O.¹⁴, Tandstad T.¹⁵

Institutions

¹Karolinska University Hospital, Dept. of Urology, Stockholm, Sweden, ²Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ³Karolinska University Hospital, Dept. of Oncology, Stockholm, Sweden, ⁴Skåne University Hospital, Dept. of Urology, Malmö, Sweden, ⁵Sahlgrenska University Hospital, Dept. of Urology, Gothenburg, Sweden, ⁶Uppsala University Hospital, Dept. of Oncology, Uppsala, Sweden, ⁷St Olavs University Hospital, Dept. of Urology, Trondheim, Norway, ⁸Oslo University Hospital, Dept. of Urology, Oslo, Norway, ⁹University of North Norway, Dept. of Oncology, Tromsø, Norway, ¹⁰Sahlgrenska University Hospital, Dept. of Oncology, Gothenburg, Sweden, ¹¹Umeå University Hospital, Dept. of Oncology, Umeå, Sweden, ¹²Haukeland University Hospital, Dept. of Oncology, Bergen, Norway, ¹³Oslo University Hospital, Dept. of Oncology, Oslo, Norway, ¹⁴Skåne University Hospital, Dept. of Oncology, Lund, Sweden, ¹⁵St Olavs University Hospital, Dept. of Oncology, Trondheim, Norway

Cure without consolidation: long-term outcomes of a surveillance-based approach after post-chemotherapy RPLND in metastatic nonseminomatous germ cell tumors

Authors

Mousa A.¹, Anson-Cartwright L.¹, Ateafu E.G.², Bedard P.³, Jiang D.M.³, Glicksman R.⁴, Chung P.⁴, Warde P.⁴, O'Malley M.⁵, Prendeville S.⁶, Jewett M.A.S.¹, Hamilton R.J.¹

Institutions

¹Princess Margaret Cancer Centre, Dept. of Surgery, Toronto, Canada, ²Princess Margaret Cancer Centre, Dept. of Biostatistics, Toronto, Canada, ³Princess Margaret Cancer Centre, Dept. of Medicine, Toronto, Canada, ⁴Princess Margaret Cancer Centre, Dept. of Radiation Oncology, Toronto, Canada, ⁵Princess Margaret Cancer Centre, Dept. of Radiology, Toronto, Canada, ⁶Princess Margaret Cancer Centre, Dept. of Laboratory Medicine & Pathobiology, Toronto, Canada

Propensity Score-Matched Comparison of Laparoscopic and Open Post-Chemotherapy Retroperitoneal Lymph Node Dissection (RPLND) in Nonseminomatous Germ Cell Tumors (NSGCT)

Authors

Saitta C.¹, Nazzani S.², Silvani C.², Bernasconi V.², Giannatempo P.², Claps M.², Macchi A.², Torelli T.², Stagni S.², Marmioli A.², Tesone A.², Lughezzani G.¹, Paciotti M.², Buffi N.M.¹, Cascella T.², Lanocita R.², Barella M.², Catanzaro M.A.², BIASONI D.², Nicolai N.²

Institutions

¹IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy

RPLND: Can we predict histology?

Clinical evaluation of the role of miRNA 371 in early stage II germ-cell tumors (GCT) of the testis in histology prediction and relapse monitoring. Results of the "Internal" Trial

Authors

Nazzani S.¹, Busico A.², Silvani C.¹, Bernasconi V.¹, Saitta C.¹, Marmioli A.¹, Macchi A.¹, Tesone A.¹, Stagni S.¹, Torelli T.¹, Giannatempo P.³, Claps M.³, Barella M.², Paolini B.², Avuzzi B.⁴, Cascella T.⁵, Lanocita R.⁵, BIASONI D.¹, Catanzaro M.A.¹, Montanari E.⁶, Nicolai N.¹

Institutions

¹Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Pathology, Milan, Italy, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Oncology, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiotherapy, Milan, Italy, ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiology, Milan, Italy, ⁶Fondazione Ca' Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy

A0320

Serum levels of microRNA-371a-3p (M371) for prediction of histology in chemotherapy-naïve patients with testicular germ cell tumours undergoing lymph node dissection - a retrospective analysis of 57 cases

Authors

Angerer M.¹, Dieckmann K.P.¹, Dumlupinar C.², Fiedeldey L.², Harms A.³, Otte K.M.⁴, Wülfing C.¹, Belge G.²

Institutions

¹Asklepios Klinik Altona, Dept. of Urology, Hamburg, Germany, ²University of Bremen, Dept. of Tumour Genetics, Bremen, Germany, ³Medizinisches Versorgungszentrum Hanse Histologikum, Dept. of Pathology, Hamburg, Germany, ⁴Medilys Laborgesellschaft mbH, Laboratory Medicine, Hamburg, Germany

A0321

Evaluation of miRNA-371a-3p (miR371a) assay to predict final pathohistology in patients undergoing primary nerve-sparing retroperitoneal lymphadenectomy (nsRPLND) for stage IIA/B seminomas and non-seminomas (NSGCT)

Authors

Heidenreich J., Pfister D., Steenbock O., Rieger C., Weiten R., Heidenreich A.

Institutions

University of Cologne, Dept of Urology, Cologne, Germany

A0322

Three-Dimensional CT-Based Volumetric Shrinkage as an Independent Predictor of Residual Pathology in Post-Chemotherapy Non-Seminomatous Germ Cell Tumors

Authors

Sahin K.¹, Irmak F.², Yilmaz B.², Simsekoglu M.F.², Demirdag C.², Onal B.²

Institutions

¹Bayrampasa State Hospital, Dept. of Urology, Istanbul, Turkey, ²Istanbul University - Cerrahpasa, Cerrahpasa Faculty of Medicine, Dept. of Urology, Istanbul, Turkey

A0323

Screening for circulating biomarkers in therapy-resistant subtypes of testicular germ cell tumors

Authors

Pongratanakul P.¹, Bremmer F.², Poschmann G.³, Wollnitzke P.⁴, Skowron M.A.⁵, Kraemer R.⁶, Fuß J.⁶, Stuehler K.³, Levkau B.⁴, Che Y.¹, Albers P.¹, Nettersheim D.⁵

Institutions

¹University Hospital Düsseldorf, Dept. of Urology, Düsseldorf, Germany, ²University Medical Center Göttingen, Institute of Pathology, Göttingen, Germany, ³Biological and Medical Research Center, Medical Faculty and University Hospital Düsseldorf, Molecular Proteomics Laboratory, Düsseldorf, Germany, ⁴Medical Faculty and University Hospital Düsseldorf, Institute for Molecular Medicine, Düsseldorf, Germany, ⁵Medical Faculty and University Hospital Düsseldorf, Urological Research Laboratory, Düsseldorf, Germany, ⁶Institute of Clinical Molecular Biology, Competence Centre of Genomic Analysis, Kiel, Germany

13:30 - 13:45

QOL and follow-up

A0324

Incidence of ototoxicity in testicular cancer survivors: A nationwide retrospective cohort study

Authors

Musso G.¹, Toscano Bello F.¹, Morgan K.¹, Puri D.¹, Baker B.¹, Dabbas M.¹, Azari S.¹, Pandit K.¹, Meagher M.F.¹, Yuen K.L.¹, Millard F.², Bagrodia A.¹

Institutions

¹University of California San Diego School of Medicine, Dept. of Urology, La Jolla, United States of America, ²University of California San Diego School of Medicine, Dept. of Medical Oncology, La Jolla, United States of America

A0325

A qualitative study of health-related quality of life and supportive care needs of testicular cancer survivors after 1 year post-treatment

Authors

Fox L.¹, Lawlor A.¹, Hauser T.², Kaid-Adeti O.¹, Holwell R.³, Champion P.³, Kinsella N.³, Van Hemelrijck M.¹, Cazzaniga W.³, Nicol D.³

Institutions

¹King's College London, Comprehensive Cancer Centre, London, United Kingdom, ²Barmherzige Brueder Hospital Munich, Dept. of Urology, Munich, Germany, ³The Royal Marsden NHS Foundation Trust, Urology Unit, London, United Kingdom

A0326

Impact of primary treatment for testicular tumours on hormonal profile and spermatogenesis: results from a single-tertiary referral centre

Authors

De Rocco Ponce M.¹, Bertini A.², Raffo M.², Malca Caballero L.¹, Pozzi E.², d'Arma A.², Montorsi F.², Salonia A.², Ruiz-Castane E.¹

Institutions

¹Fundació Puigvert, Dept. of Andrology, Barcelona, Spain, ²IRCCS Ospedale San Raffaele, Unit of Urology, Milan, Italy

Oncologic, surgical & functional outcomes in localised renal tumour

Abstract Session 11

**Saturday 14 March
12:15 - 13:45**

Location

Blue Area, George 4

Chairs

C.K. Bensalah, Rennes (FR)

C. Palumbo, Novara (IT)

T. Takagi, Tokyo (JP)

12:15 - 12:45

Oncologic outcomes

A0169

The impact of time to local tumor destruction on cancer-specific mortality in pT1a renal cell carcinoma

Authors

Lee N.¹, Nicolazzini M.², Polverino F.³, Quarta L.⁴, Filzmayer M.⁵, Petix M.⁶, Goyal J.¹, Longo N.³, Musi G.⁶, Chun F.⁵, Briganti A.⁴, Shariat S.⁷, Saad F.¹, Karakiewicz P.¹

Institutions

¹University of Montreal, Dept. of Urology, Montréal, Canada, ²University of Turin, Dept. of Urology, Turin, Italy, ³University of Naples Federico II, Dept. of Urology, Naples, Italy, ⁴Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁵Goethe University Frankfurt, Dept. of Urology, Frankfurt, Germany, ⁶Università degli Studi di Milano, Dept. of Urology, Milan, Italy, ⁷Medical University of Vienna, Dept. of Urology, Vienna, Austria

A0170

Partial Nephrectomy for cT1 RCC: Reassuring Oncological Outcomes Despite Pathological Upstaging

Authors

Leung D.K-W.¹, Amparore D.², Bertolo R.G.³, Marchioni M.⁴, Wu Z.J.⁵, Campi R.⁶, Palumbo C.⁷, Marandino L.⁸, Roussel E.⁹

Institutions

¹The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, Hong Kong, ²University of Turin, Dept. of Oncology, Turin, Italy, ³Cleveland Clinic, Dept. of Surgery, Ohio, United States of America, ⁴University of Chieti, Dept. of Urology, Chieti, Italy, ⁵Changhai Hospital, Dept. of Surgery, Shanghai, China, ⁶Careggi Hospital, Dept. of Surgery, Florence, Italy, ⁷University of Eastern Piedmont, Dept. of Urology, Novara, Italy, ⁸National Cancer Institute Foundation, Dept. of Surgery, Milan, Italy, ⁹University Hospitals Leuven, Dept. of Uro-Oncology, Leuven, Belgium

Study Group

EAU YAU RCC Working Group(Hong Kong, Italy)

A0171

Two-year follow-up on oncological, functional and quality of life outcomes of the randomized ROBOt-assisted versus Conventional Open Partial nephrectomy (ROBOCOP) II trial

Authors

Haney C.M.¹, Gottstein L.², Sidoti Abate M.A.², Menold H.S.², Fattal W.¹, Neuberger M.², Nuhn P.², Westhoff N.², Honeck P.², Michel M.S.², Kriegmayr M.C.², Kowalewski K.F.²

Institutions

¹German Cancer Research Center, Dept. of Intelligent Systems and Robotics in Urology, Heidelberg, Germany, ²University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Dept. of Urology and Urosurgery, Mannheim, Germany

A0172

sPaRT2 - Partial versus Radical Nephrectomy for cT2 Renal Cell Carcinoma: A National Matched-Pair Analysis (UroCCR 235)

Authors

Et-Touzani R.¹, Bernhard J.C.², Margue G.²

Institutions

¹CHU Dijon, Dept. of Urology, Dijon, France, ²CHU Bordeaux, Dept. of Urology, Bordeaux, France

A0173

Competing Risk Regression Analysis of Cancer-Specific and Other-Cause Mortality After Partial vs. Radical Nephrectomy in T3aN0M0 Renal Cell Carcinoma

Authors

Li X., Ai J., Wei Q.

Institutions

West China hospital, Dept. of Urology, Chengdu, China

A0174

Prognostic Implications of Nodal Status in Localized and Locally-Advanced Renal Cell Carcinoma: Analysis from the NCDB

Authors

Musso G.¹, Vourganti S.², Salonia A.¹, Meagher M.F.³, Baker B.³, Puri D.³, Karamcheti S.³, Agrawal L.⁴, Sabir W.², Liss M.³, Cherullo E.², Capitanio U.¹, Larcher A.¹, Montorsi F.¹, Derweesh I.H.²

Institutions

¹IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology, Milan, Italy, ²RUSH-MD Anderson Cancer Center, Dept. of Urology, Chicago, United States of America, ³University of California San Diego School of Medicine, Dept. of Urology, La Jolla, United States of America, ⁴UT Health Houston, Dept. of Urology, Houston, United States of America

12:45 - 13:15

Functional outcomes

A0175

Investigation of the effects of mannitol and mirabegron in terms of hypoxia-triggered mechanisms and angiogenesis in renal ischemia reperfusion injury

Authors

Karabacak N.¹, Cetin S.¹, Ogut B.², Yilmaz C.³

Institutions

¹Gazi University School of Medicine, Dept. of Urology, Ankara, Turkey, ²Gazi University School of Medicine, Dept. of Medical Pathology, Ankara, Turkey, ³Gazi University School of Medicine, Dept. of Medical Biochemistry, Ankara, Turkey

A0176

Personalized Predictors Of Renal Recovery After Partial Nephrectomy

Authors

Salerno L.¹, Scilipoti P.¹, Trevisani F.¹, Bettiga A.¹, Longoni M.¹, Bertini A.¹, Re C.¹, Musso G.¹, Derweesh I.², Cei F.¹, Rosiello G.¹, Belladelli F.¹, Piccolo C.¹, Disabato N.¹, Ficarra G.¹, Campugiani A.¹, Montesano M.¹, Bertini R.¹, Salonia A.¹, Montorsi F.¹, Larcher A.¹, Capitanio U.¹

Institutions

¹IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²RUSH-MD Anderson Cancer Center, Dept. of Urology, Chicago, United States of America

A0177

Baseline renal function predicts survival in patients undergoing small renal mass ablation

Authors

Golijanin B.¹, Che R.¹, Glebocki R.¹, Jay B.², Collins S.², Maxwell A.², Dubel G.², Khaleel S.¹, Golijanin D.¹

Institutions

¹The Minimally Invasive Urology Institute at The Miriam Hospital and Brown University, Dept. of Urology, Providence, United States of America, ²Brown University, Dept. of Interventional Radiology, Providence, United States of America

A0178

Sutureless Off-Clamp Robot-Assisted Partial Nephrectomy: Adoption, Learning Curve, and Propensity-Score Matched Outcomes in a Large Single-Center Cohort

Authors

Flammia R.S., Brassetti A., Tuderti G., Anceschi U., Ferriero M.C., Bove A., Proietti F., Misuraca L., Bologna E., D'Annunzio S., Mastroianni R., Licari L.C., Chiacchio G., Leonardo C., Guaglianone S., Simone G.

Institutions

IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy

A0179

Sutureless Purely Off-Clamp Robotic Partial Nephrectomy: evidence from a randomized controlled non-inferiority trial

Authors

Brassetti A., Tuderti G., Anceschi U., Bove A.M., Bologna E., Capecchi L., Chiacchio G., D'Annunzio S., Ferriero M., Flammia R.S., Guaglianone S., Iuculano S., Denaro C., Di Luzio A., Leonardo C., Licari L.C., Mastroianni R., Misuraca L., Proietti F., Simone G.

Institutions

IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

A0180

Effects of argon-beam-coagulator suture-free and conventional suture technique on renal function after partial nephrectomy (ASSURE): A multi-center open-label randomized controlled study

Authors

Wang J.Y.¹, Xiao C.W.², Huang J.W.³, Zheng L.Q.⁴, Qu L.⁵, Xue W.³, Wang L.H.², Xu B.¹

Institutions

¹Shanghai Ninth People's Hospital affiliated to Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shanghai, China, ²Changhai Hospital Naval Medical University, Dept. of Urology, Shanghai, China, ³Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China, ⁴International Peace Maternity & Child Health Hospital Shanghai Jiao Tong University School of Medicine, Clinical Research Center, Shanghai, China, ⁵Jinling Hospital Clinical School of Nanjing University Medical College, Dept. of Urology, Nanjing, China

13:15 - 13:45

Surgical outcomes

A0181

CORE-Renal: A fully automated, data-driven comprehensive scoring system for the precise prediction of perioperative risks in renal tumor surgery

Authors

Zhao Z.¹, Wang S.², Wang L.², Li Z.², Liu C.², Liu M.², You Y.², Yu N.¹

Institutions

¹Qilu Hospital of Shandong University, Dept. of Urology, Jinan, China, ²Shandong University, First Clinical Medical College, Jinan, China

A0182

Predicting Surgical Outcomes in Single-Port Robot-Assisted Partial Nephrectomy: External Validation and comparative analysis of PADUA, RENAL, and SPARE Scores

Authors

Carletti F.¹, Valenzi F.M.¹, Tamborino F.¹, Turcan A.¹, Santarelli V.¹, Biasatti A.¹, Morgantini L.A.¹, Haberal H.B.¹, Vourganti S.², Dal Moro F.³, Autorino R.², Crivellaro S.¹

Institutions

¹University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America, ²Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ³University of Padua, Urology Clinic, Dept. of Surgery, Oncology and Gastroenterology, Padua, Italy

A0183

Surgical Quality Metrics Predict Clinically Meaningful Outcomes in Nephrectomy for Renal Cell Carcinoma (RCC): Lessons from 10,991 Nephrectomies

Authors

Leung D.K-W.¹, Amparore D.², Bertolo R.G.³, Marchioni M.M.⁴, Wu Z.J.⁵, Campi R.⁶, Palumbo C.⁷, Marandino L.M.⁸, Roussel E.⁹

Institutions

¹The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, Hong Kong, ²University of Turin, Dept. of Oncology, Turin, Italy, ³University of Verona, Dept. of Oncology, Verona, Italy, ⁴University of Chieti, Dept. of Surgery, Chieti, Italy, ⁵Changhai Hospital, Dept. of Surgery, Shanghai, China, ⁶Careggi Hospital, Dept. of Urology, Florence, Italy, ⁷University of Eastern Piedmont, Dept. of Urology, Novara, Italy, ⁸San Raffaele University, Dept. of Oncology, Milan, Italy, ⁹University Hospital Leuven, Dept. of Urology, Leuven, Belgium

Study Group

EAU YAU RCC Working Group(Hong Kong, Italy)

A0184

Optimization of Postoperative Care for Nephrectomy Patients Using the UroConnect Telemonitoring Tool (UroCCR n°129)

Authors

Margue G.L.¹, Ricard S.¹, Geshkovska A.¹, Calleda E.¹, Dubernet C.¹, Picard F.¹, Herman G.¹, Autheman M.², Morichau-Beauchant P.², Alezra E.¹, Capon G.¹, Estrade V.¹, Bladou F.¹, Robert G.¹, Bernhard J.C.¹

Institutions

¹Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ²Resilience Care, Dept. of Oncology, Paris, France

A0185

Three-Dimensional Image-Guided Robot-Assisted Partial Nephrectomy for Tumors in Horseshoe Kidneys: A European Multicentre Case Series (YAU RCC – UroCCR)

Authors

Margue G.L.¹, Rubat Baleuri F.¹, Vangeneugden J.², Bernhard J.C.¹, Van Praet C.², Decaestecker K.², Grosso A.A.³, Minervini A.³, Suardi N.⁴, Carbonara U.⁵, Di Tonno P.⁵, Roussel E.⁶, Porpiglia F.⁷, Campi R.⁸, Amparore D.⁷

Institutions

¹Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ²Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ³University of Florence, Dept. of Urology, Florence, Italy, ⁴Ospedali Civili of Brescia, Dept. of Urology, Brescia, Italy, ⁵University of Bari, Dept. of Urology, Bari, Italy, ⁶University Hospitals of Leuven, Dept. of Urology, Leuven, Belgium, ⁷University of Turin, Dept. of Urology, Turin, Italy, ⁸Careggi University Hospital, Dept. of Urology, Florence, Italy

Study Group

EAU - YAU Renal cancer working group(Amsterdam, The Netherlands)

A0186

Robotic Surgery of Wilms Tumour: Time to expand the frontiers of minimally invasive surgery? Preliminary results from a tertiary center

Authors

Pierucci U.M.¹, Planchamp T.¹, Berrebi D.², Lemelle L.³, Orbach D.⁴, Philippe-Chomette P.¹, Peycelon M.¹

Institutions

¹University Hospital Robert-Debré - APHP - University Paris Cité, Dept. of Pediatric Surgery and Urology - National Reference Centre for Rare Urinary Tract Malformations - MARVU - ERN eUROGEN accredited center, Paris, France, ²Hôpital Necker-Enfants Malades, Dept. of Pathology, Paris, France, ³Institut Curie, Dept. of Pediatric Oncology, Paris, France, ⁴Institut Curie, SIREDO Oncology Center - Care, Innovation and Research for Children and AYA with Cancer - PSL Research University, Paris, France

Kidney transplantation: Expanding indications through new technologies

Abstract Session 15

Saturday 14 March
12:15 - 13:45

Location

Red Area, Room 9

Chairs

K. Decaestecker, Gent (BE)

To be confirmed

M. Musquera Felip, Barcelona (ES)

12:15 - 12:40

Basic & translational research

A0238

XBP1s-GAS1 mediates the formation of tertiary lymphoid structures after kidney transplantation in elderly donors through the Hedgehog signaling pathway

Authors

Ruan J.¹, Yan H.¹, Shang Z.¹, Gong N.², Ou T.¹

Institutions

¹Xuanwu Hospital Capital Medical University, Dept. of Urology, Beijing, China, ²Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Institute of Organ Transplantation, Wuhan, China

A0239

Dynamic Donor-Derived cfDNA Normalization After Kidney Transplantation: Preliminary Results from a Personalized NGS and AI-Based Monitoring Platform

Authors

Polat M.E.¹, Ceviz K.¹, Ergin B.², Karimzade K.¹, Mirioglu I.¹, Das B.³, Ceylaner G.², Olcucuoglu E.¹

Institutions

¹University of Health Sciences Ankara Bilkent City Hospital, Dept. of Urology and Kidney Transplantation, Ankara, Turkey, ²Intergen Genetics and Rare Diseases Diagnosis Center, Dept. of Genetics, Ankara, Turkey, ³Firat University, Faculty of Technology, Dept. of Software Engineering, Elazig, Turkey

A0240

TGF- β Drives Memory-like NK Cell Formation and Transplant Rejection through AP-1-mediated Epigenetic Reprogramming

Authors

Xu Z., Ge J., Ding Z., Tang Z., Qiu J., Liu Z.

Institutions

Shanghai General Hospital, Dept. of Urology, Shanghai, China

A0241

Normothermic machine perfusion of murine kidneys leads to intragraft ferroptosis and cellular stress

Authors

Friedersdorff E., Kemper D.R., Siegle J., Yang Y., Camiletti R., Kotsch K.

Institutions

Charité University Hospital Berlin, Dept. of Urology, Berlin, Germany

A0242

An ex-vivo normothermic perfusion model to study metabolic interplay between liver and kidney: a proof-of-concept study.

Authors

Panis A.¹, Hadchouel J.², Samson C.², Galichon P.³, Drouin S.¹

Institutions

¹Hopital Pitie Salpetriere, Dept. of Urology, Paris, France, ²INSERM 1155, Hopital Tenon, Research Department, Paris, France, ³Hopital Pitie Salpetriere, Dept. of Nephrology, Paris, France

12:40 - 13:05

Robotic-assisted kidney transplantation & simulation

A0243

Trifecta in Robot-Assisted Kidney Transplantation (RAKT) from living donors: Insights from 8-years ERUS-RAKT experience

Authors

Territo A.¹, Avesani G.¹, Di Bello F.¹, Belarmino A.¹, Gallioli A.¹, Campi R.², Afferi L.³, Gaya J.M.¹, Pecoraro A.⁴, Decaestecker K.⁵, Musquera M.⁶, Etcheverry B.⁷, Vangeneugden J.⁸, De Mesa Rodriguez B.L.⁶, Mercier J.⁹, Ortvad M.¹⁰, Zeuschner P.¹¹, Volpe A.¹², Idu M.¹³, Kocak B.¹⁴, Vignes F.⁷, Alcaraz A.⁶, Serni S.⁴, Breda A.¹

Institutions

¹Fundació Puigvert, Dept. of Urology and Renal Transplantation, Barcelona, Spain, ²University of Florence, Dept. of Experimental and Clinical Medicine, Florence, Italy, ³Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ⁴Careggi Hospital, University of Florence, Unit of Urological Minimally Invasive, Robotic Surgery and Kidney Transplantation, Florence, Italy, ⁵University Hospital Ghent, Dept. of Urology, Ghent, Belgium, ⁶IDIBAPS Hospital Clinic, University of Barcelona, Dept. of Urology, Barcelona, Spain, ⁷University Hospital of Bellvitge, Le'Hospitalet de Llobregat, Dept. of Urology, Barcelona, Spain, ⁸University Hospital of Ghent, ERN eUROGEN Accredited Centre, Dept. of Urology, Ghent, Belgium, ⁹University Hospital of Rangueil, Dept. of Urology and Renal Transplantation, Toulouse, France, ¹⁰Center for Cancer and Organ Diseases, Copenhagen University Hospital - Rigshospitalet, Urological Research, Dept. of Urology, Copenhagen, Denmark, ¹¹Saarland University, Dept. of Urology and Pediatric Urology, Homburg, Germany, ¹²University of Eastern Piedmont, Maggiore della Carità Hospital, Dept. of Urology and Translational Medicine, Novara, Italy, ¹³Academic Medical Center Amsterdam, Dept. of Surgery, Amsterdam, The Netherlands, ¹⁴Koç University Hospital Organ Transplant Center, Koç University School of Medicine, Dept. of Urology, Istanbul, Turkey

A0244

Robot assisted kidney transplantation with double artery allografts: perioperative and graft survival outcome comparison of different anastomotic techniques from a tertiary centre

Authors

Kumar Pal A., Mathew J., Ramaprasad M., Prabhakaran S., Unni V.N., Kishore T.

Institutions

Aster Medcity, Dept. of Urology, Kochi, India

A0245

Single-Port Robotic Retroperitoneal Living Donor Nephrectomy using the supine anterior retroperitoneal approach (SARA): Toward a New Standard in Minimally Invasive Kidney Transplantation

Authors

Yen T-H., Chen C.C., Li J.R., Hu J.C.

Institutions

Taichung Veterans General Hospital, Division of Urology, Taichung, Taiwan

A0247

Design and Implementation of a High-Fidelity 3D-Printed Kidney Transplantation Simulator

Authors

Kassir J.¹, Matillon X.¹, Badet L.¹, Drouin S.², Timsit M.O.³, Boissier R.⁴, Prudhomme T.⁵, Branchereau J.⁶, Terrier N.⁷, Seizilles de Mazancourt E.⁸

Institutions

¹Edouard Herriot Hospital, Dept. of Urology, Lyon, France, ²Pitié Salpêtrière Hospital, Dept. of Urology, Paris, France, ³Hôpital Européen Georges Pompidou, Dept. of Urology, Paris, France, ⁴Conception Hospital, Dept. of Urology, Marseille, France, ⁵Toulouse University Hospital, Dept. of Urology, Toulouse, France, ⁶Nantes University Hospital, Dept. of Urology, Nantes, France, ⁷La Tronche Hospital, Dept. of Urology, Grenoble, France, ⁸Saint Louis Hospital, Dept. of Urology, Paris, France

13:05 - 13:25

Robotic vs open surgery

A0248

Open versus robotic-assisted orthotopic kidney transplantation: a comparative retrospective cohort study

Authors

Bardella Altarriba C., Etcheverry Giadrosich B., Vigués Julià F., Ferrando V., Bonet Vilanova J.M., Fiol Riera M., Suárez Novo J.F., Pérez Reggeti J.I., Buisan Rueda O., Castells Esteve M., Puig Ortuno L., Anagua Melendres J.F., Riera Canals L.S.

Institutions

Bellvitge University Hospital, Dept. of Urology, Hospitalet de Llobregat, Spain

A0249

Comparative Outcomes of Multi-Vessel Robot-Assisted versus Open Kidney Transplantation: A Propensity-Matched Analysis from a High-Volume Tertiary Centre

Authors

Kushwaha S.¹, Mitra S.¹, Sharma A.², Aggarwal A.¹, Desai P.², Chaturvedi S.², Jha M.S.², Kumar A.²

Institutions

¹Max Super Speciality Hospital Vaishali, Dept. of Urology Uro-Oncology Robotics and Renal Transplant, Ghaziabad, India, ²Max Super Speciality Hospital Saket, Dept. of Urology Uro-Oncology Robotics and Renal Transplant, New Delhi, India

A0250

Age-stratified length of stay benefit of robotic versus open approach in deceased-donor kidney transplantation: evidence from a European multicenter registry

Authors

Belarmino A.¹, Territo A.², Avesani G.², Di Bello F.², Gallioli A.², Gaya J.M.², Rodriguez Faba O.², Gavrillov P.², Breda A.²

Institutions

¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²Fundació Puigvert, Dept. of Oncology, Transplant, Barcelona, Spain

Study Group

ERUS-RAKT Working Group(Barcelona, Spain)

A0251

Body-mass index and postoperative recovery after robotic versus open deceased-donor kidney transplantation: a European multicenter registry analysis

Authors

Belarmino A.¹, Territo A.², Di Bello F.², Avesani G.², Gallioli A.², Gaya J.M.², Faba O.R.², Gavrillov P.², Breda A.²

Institutions

¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²Fundació Puigvert, Dept. of Transplant, Oncology, Barcelona, Spain

Study Group

ERUS-RAKT Working Group(Barcelona, Spain)

13:25 - 13:45

Expanding the donors' pool

A0252

Outcomes of simultaneous liver-kidney transplantation using graft from controlled donors after circulatory death

Authors

Navarrete Espinosa D¹, Martínez C.², Esforzado N.³, Miret Alomar E.⁴, Navarro Parets M.⁴, Torres Velazquez A.N.⁴, Parra López M.A.D.L.⁵, León D. E.⁵, Gómez Bravo M.N.⁶, Ramos Cebrián M.A.⁷, Budía Alba A.⁷, Espinosa J.N.⁷, López-Abad A.⁸, Belmonte M.⁸, Guzmán Martínez-Valls P.L.⁸, Gutierrez B. J.L.⁹, Domínguez Esteban M.⁹, Ballester Diego R.⁹, Gómez Dos Santos V.¹⁰, Burgos Revilla F.J.¹⁰, Galeano Alvarez C.¹¹, Fundora Suárez Y.¹², Musquera Felip M.¹³

Institutions

¹Hospital Clinic, Liver and Kidney Transplant Unit, Barcelona, Spain, ²Hospital Clinic, Dept. of Urology, Barcelona, Spain, ³Hospital Clinic, Dept. of Nephrology, Barcelona, Spain, ⁴Vall d'Hebron University Hospital, Dept. of Urology, Barcelona, Spain, ⁵Virgen del Rocío University Hospital, Dept. of Urology, Sevilla, Spain, ⁶Virgen del Rocío University Hospital, Hepatobiliary and Pancreatic Surgery (HPB) and Transplant Unit, Sevilla, Spain, ⁷La Fe University and Polytechnic Hospital, Dept. of Urology, Valencia, Spain, ⁸University Clinical Hospital Virgen de la Arrixaca, Dept. of Urology, Murcia, Spain, ⁹Marqués de Valdecilla University Hospital, Dept. of Urology, Santander, Spain, ¹⁰Ramón y Cajal University Hospital, Dept. of Urology, Madrid, Spain, ¹¹Hospital Universitario Ramón y Cajal, Dept. of Nephrology, Santander, Spain, ¹²Hospital Clinic, Hepatobiliary and Pancreatic Surgery (HPB) and Liver Transplant Unit, Barcelona, Spain, ¹³Hospital Clinic, Urology and Kidney Transplant Unit, Barcelona, Spain

A0253

Mobile Surgical Unit for Organ Retrieval in Controlled DCD Donors

Authors

Seizilles de Mazancourt E.¹, Lefaucheur C.², Antoine C.², Roussin F.³, Gaudet F.¹

Institutions

¹Saint Louis Hospital, Dept. of Urology, Paris, France, ²Saint Louis Hospital, Dept. of Nephrology, Paris, France, ³Saint Louis Hospital, Dept. of Organ Procurement, Paris, France

A0254

Expanding the donor pool: Multicentric outcomes of kidney transplantation from donors with small renal tumors

Authors

[Martinez Garcia C.](#)¹, Ajami T.¹, Sierra A.¹, Payet G.¹, Francès A.², Etcheverry B.³, Gómez V.⁴, Álvarez-Maestro M.⁵, Medina J.⁶, Rodríguez-Fava O.⁷, Ide P.¹, Checcini LI.², Fiol M.³, Peri L.¹, Alcaraz A.¹, Musquera M.¹

Institutions

¹H. Clínic of Barcelona, Dept. of Urology, Barcelona, Spain, ²H. del Mar, Dept. of Urology, Barcelona, Spain, ³H. Bellvitge, Dept. of Urology, Barcelona, Spain, ⁴Hospital Universitario Ramón y Cajal, Dept. of Urology, Madrid, Spain, ⁵H. Universitario La Paz, Dept. of Urology, Madrid, Spain, ⁶H. 12 de Octubre, Dept. of Urology, Madrid, Spain, ⁷Fundación Puigvert, Dept. of Urology, Barcelona, Spain

A0255

External validation of the Kidney Transplantation Outcome Predictions models

Authors

[González Serrano A.](#), Guldris García R.J., Ruiz Hernández M., Pieras Ayala E.C.

Institutions

Hospital Universitari Son Espases, Dept. of Urology, Palma, Spain

Genitourinary reconstruction

Abstract Session 14

Saturday 14 March
12:15 - 13:45

Location

Red Area, Room 8

Chairs

X-S. Li, Beijing (CN)

P. Neuville, LYON (FR)

A-F. Spinoit, Ghent (BE)

12:15 - 13:00

Upper urinary tract reconstruction

A0220

Does keloid predisposition predict the prognosis of ureteral stricture reconstruction surgery ?

Authors

Zhou L., [Jiang Y.](#), Liu T., Wang K.

Institutions

West China Hospital, Dept. of Urology, Chengdu, China

A0221

Real-Time Intraluminal Optical Coherence Tomography Predicts Ureteral Stricture Formation in a Bama Minipig Model

Authors

[Zhu Y.](#), Chen M., Zhang G.

Institutions

Affiliated Zhongda Hospital of Southeast University, Dept. of Urology, Nanjing, China

A0222

Robotic-assisted Gonadal Vein Transposition for Nutcracker Syndrome: Surgical Technique and Results

Authors

Seizilles de Mazancourt E.¹, Kassir J.², Matillon X.², Campello P.V.², Badet L.², Abid N.², Terrier N.³, Cruzet S.²

Institutions

¹Saint Louis Hospital, Dept. of Urology, Paris, France, ²Edouard Herriot Hospital, Dept. of Urology, Lyon, France, ³La Tronche Hospital, Dept. of Urology, Grenoble, France

A0223

Clinical and Functional Outcomes of Robotic-Assisted Buccal Mucosal Graft Ureteroplasty (RU-BMG) for Complex Recurrent Ureteric Strictures: A Multicentre Experience

Authors

Clark C.¹, Ashraf S.¹, Elbaroni W.¹, Lutfi B.¹, Folkard S.¹, Sri D.², Sharma D.², Chetwood A.³, Michael B.³, Hussain M.³, Manar M.³, Haq K.¹, Shabbir M.¹, Nair R.¹

Institutions

¹Guys and St Thomas NHS Trust, Dept. of Urology, London, United Kingdom, ²St Georges NHS Trust, Dept. of Urology, London, United Kingdom, ³Frimley Health NHS Trust, Dept. of Urology, London, United Kingdom

A0224

Robotic vs. open ureteral reimplantation: a retrospective comparative single-center series

Authors

Bourillon A., Freton L., Verhoest G., Hascoet J., Richard C., Haudebert C., Mathieu R., Zhao L.C., Bensalah K., Peyronnet B.

Institutions

University Hospital of Rennes, Dept. of Urology, Rennes, France

A0225

Ten years of robot-assisted laparoscopic ureterolysis (RALU): the solution to problematic ureteric obstruction caused by Retroperitoneal Fibrosis

Authors

Fernando A.¹, Viney Z.², D'Cruz D.³, Azizi E.¹, Simpson S.¹, La Rosa A.¹, O'Brien T.¹

Institutions

¹Guy's and St Thomas' Hospital, Dept. of Urology, London, United Kingdom, ²Guy's and St Thomas' Hospital, Dept. of Radiology, London, United Kingdom, ³Guy's and St Thomas' Hospital, Dept. of Rheumatology, London, United Kingdom

A0226

Comparative Analysis of 30-Day Postoperative Outcomes Between Robotic and Laparoscopic Pyeloplasty in Adults: Evidence from a Large National Prospective Database from 2022 and 2023

Authors

Touma Sawaya R., Zein M., Abdessater M.

Institutions

American University of Beirut, Medical Center, Dept. of Urology, Beirut, Lebanon

A0227

Predictors of adverse outcomes after ureteral reconstructive surgery: insights from an international multicenter study

Authors

Moretto S.¹, Saita A.¹, Minervini A.², Hubert J.³, Shrestha A.⁴, Terrone C.⁵, Ahyai S.⁶, Leitsmann M.⁶, Iulia A.⁷, Liatsikos E.⁸, Fiori C.⁹, Heiniger Y.³, Spinou T.⁸, Grosso A.A.², Mantica G.⁵, Tatanis V.⁸, De Carne F.¹, Chitrakar A.⁴, Arena P.¹, Buzoianu M.⁷, Turcan A.⁹, Ismaylov A.⁶, Paciotti M.¹, Buffi N.M.¹

Institutions

¹Humanitas University, Dept. of Urology, Milan, Italy, ²Careggi Hospital, University of Florence, Dept. of Urology, Florence, Italy, ³Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland, ⁴National Academy of Medical Sciences, BIR Hospital, Dept. of Urology, Kathmandu, Nepal, ⁵IRCCS Policlinico San Martino, Dept. of Urology, Genova, Italy, ⁶Medical University Graz, Dept. of Urology, Graz, Austria, ⁷Iuliu Hatieganu University of Medicine and Pharmacy, Dept. of Urology, Cluj-Napoca, Romania, ⁸University Hospital of Patras, Dept. of Urology, Patras, Greece, ⁹San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy

A0228

Robot-assisted bilateral ileal ureter replacement for the treatment of bilateral long ureteral strictures: technique and outcomes from multi-institutional database

Authors

Wang X.¹, Yang J.¹, Li Z.¹, Li X.¹, Han G.¹, Huang C.², Wang B.¹, Zhang P.³, Zhu H.², Yang K.¹, Zhou L.¹, Zhang K.¹, Li X.¹

Institutions

¹Peking University First Hospital, Dept. of Urology, Beijing, China, ²Beijing Jiangong Hospital, Dept. of Urology, Beijing, China, ³Emergency General Hospital, Dept. of Urology, Beijing, China

13:00 - 13:25

Gender affirming surgery

A0229

Long-term patient-reported outcomes of salvage ileocecal vaginoplasty after failed penile inversion in trans women

Authors

Schulz R.J., Fisch M., Ludwig T.A., Vetterlein M.W.

Institutions

University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

International Delphi Consensus on Indications, Contraindications, and Complication Management in Masculinizing Genital Surgery for Assigned-Female-at-Birth Individuals

Authors

Lo Re M.¹, Pezzoli M.¹, Carlino A.¹, Lee W.G.², Falcone M.³, Preto M.³, Mantica G.⁴, Chierigo F.⁵, Vettelein M.⁶, Madec F.X.⁷, Neuville P.⁸, Morgenstern S.⁹, Waterloos M.¹⁰, Verla W.¹¹, Bialek L.¹², Tinajero J.D.¹³, Schernuk J.N.¹⁴, Ludwig T.⁶, Riechardt S.¹⁵, Szyper L.¹⁶, Wenk M.¹⁷, Heß J.¹⁸, Bohr J.¹⁹, Cocci A.¹

Institutions

¹University of Florence, Dept. of Urology, Florence, Italy, ²University College London Hospitals NHS Foundation Trust, Dept. of Urology and Andrology, London, United Kingdom, ³University of Turin, Dept. of Urology, Città della Salute e della Scienza di Torino, Turin, Italy, ⁴University of Genoa, IRCCS Ospedale Policlinico San Martino, Dept. of Surgical and Diagnostic Integrated Sciences (DISC), Genoa, Italy, ⁵University of Genoa, Dept. of Urology, IRCCS San Martino University Hospital, Genoa, Italy, ⁶University Medical Center Hamburg-Eppendorf (UKE), Dept. of Urology, Hamburg, Germany, ⁷Hôpital Foch, Dept. of Urology, Suresnes, France, ⁸Hospices Civils de Lyon, Hôpital Lyon Sud, Dept. of Urology, Pierre-Bénite, France, ⁹Agaplesion MarkusHospital, Dept. of Urology, Frankfurt am Main, Germany, ¹⁰AZ Maria Middelaes Gent, Dept. of Urology, Ghent, Belgium, ¹¹Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ¹²Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ¹³Chelsea and Westminster Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ¹⁴Hospital Italiano de Buenos Aires, Dept. of Urology, Buenos Aires, Argentina, ¹⁵University Medical Center Hamburg Eppendorf (UKE), Dept. of Urology and Paediatric Urology, Hamburg, Germany, ¹⁶MVZ Dr. Lubos Medizin Pasing, Dept. of Urology, Munich, Germany, ¹⁷University Medical Center Mannheim, University of Heidelberg, Dept. of Urology and Urological Surgery, Mannheim, Germany, ¹⁸University Hospital Essen, University of Duisburg-Essen, Dept. of Urology, Essen, Germany, ¹⁹Kliniken Essen Mitte, Ev. Huysens Stiftung, Dept. of Urology, Essen, Germany

Mechanical failure rates are high following inflatable penile prosthesis insertion in transgender patients

Authors

Gobbo A., di Giovanni A., Ralph D.J., Christopher A.N., Lee W.G.

Institutions

New Victoria Hospital, Gender Dysphoria Service, London, United Kingdom

International Delphi Consensus on Indications and Management for Feminizing Genital Surgery in Assigned-Male-at-Birth Individuals

Authors

Pezzoli M.¹, Lo Re M.¹, Cadenar A.¹, Falcone M.², Preto M.², Rizzo M.³, Mantica G.⁴, Chierigo F.⁵, Vettelein M.⁶, Madec F.X.⁷, Neuville P.⁸, Morgenstern S.⁹, Waterloos M.¹⁰, Verla W.¹¹, Bialek L.¹², Tinajero J.D.¹³, Schernuk J.N.¹⁴, Ludwig T.⁶, Riechardt S.¹⁵, Szyper L.¹⁶, Wenk M.¹⁷, Heß J.¹⁸, Bohr J.¹⁹, Cocci A.¹

Institutions

¹University of Florence, Dept. of Urology, Florence, Italy, ²University of Turin, Dept. of Urology, Città della Salute e della Scienza di Torino, Turin, Italy, ³University of Trieste, Dept. of Urology, Trieste, Italy, ⁴University of Genoa, IRCCS Ospedale Policlinico San Martino, Dept. of Surgical and Diagnostic Integrated Sciences (DISC), Genoa, Italy, ⁵IRCCS San Martino University Hospital, University of Genoa, Dept. of Urology, Genoa, Italy, ⁶University Medical Center Hamburg-Eppendorf (UKE), Dept. of Urology, Hamburg, Germany, ⁷Hôpital Foch, Dept. of Urology, Suresnes, France, ⁸Hospices Civils de Lyon, Hôpital Lyon Sud, Dept. of Urology, Pierre-Bénite, France, ⁹Agaplesion Markus-Hospital, Dept. of Urology, Frankfurt am Main, Germany, ¹⁰AZ Maria Middelaes Gent, Dept. of Urology, Ghent, Belgium, ¹¹Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ¹²Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ¹³Chelsea and Westminster Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ¹⁴Hospital Italiano de Buenos Aires, Dept. of Urology, Buenos Aires, Argentina, ¹⁵University Medical Center Hamburg-Eppendorf (UKE), Dept. of Urology and Paediatric Urology, Hamburg, Germany, ¹⁶MVZ Dr. Lubos Medizin Pasing, Dept. of Urology, Munich, Germany, ¹⁷University Medical Center Mannheim, University of Heidelberg, Dept. of Urology and Urological Surgery, Mannheim, Germany, ¹⁸University Hospital Essen, University of Duisburg-Essen, Dept. of Urology, Essen, Germany, ¹⁹Kliniken EssenMitte, Dept. of Urology, Essen, Germany

A multi-institutional analysis of outcomes after vaginal sparing metoidioplasty

Authors

Yin A.¹, Purohit R.S.¹, Venkatesan K.², Kent M.³, Bizic M.⁴, Stojanovic B.⁴, Torres C.⁵, Buddala K.², Markel M.J.², Callahan D.⁶, Djordjevic M.⁴

Institutions

¹Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ²Georgetown University School of Medicine, Dept. of Urology, Washington, United States of America, ³Beth Israel Deaconess Medical Center, Dept. of Urology, Boston, United States of America, ⁴University of Belgrade School of Medicine, Dept. of Urology and Surgery, Belgrade, Serbia, ⁵Crane Center for Transgender Surgery, Dept. of Urology, Austin, United States of America, ⁶Dell Medical School at the University of Texas at Austin, Dept. of Urology, Austin, United States of America

Fistulas genitourinary reconstruction

Laparoscopic Transvesical vs Extravesical Repair for Supratrigonal VVF: A Randomized Trial

Authors

Chowdhury P., Muhammed H., Das M., Nayak P., Mandal S., Tripathy S., Barik K., Rathod V., Yadav M.

Institutions

AllIMS Bhubaneswar, Dept. of Urology, Bhubaneswar, India

A0235

York Mason repair of rectourethral fistula: 10 year experience

Authors

[Hu M.Y.](#)¹, [Waldoch B.](#)¹, [Mantyh C.](#)², [Peterson A.](#)¹

Institutions

¹Duke University Medical Center, Dept. of Urology, Durham, United States of America,

²Duke University Medical Center, Dept. of Surgery, Durham, United States of America

A0236

Quality of Life and Sexual Function Before and After Transvaginal Vesicovaginal Fistula Repair Using Autologous Flap Versus Synthetic Interposition: A Prospective Randomized Study

Authors

[Singh V.](#)

Institutions

King George's Medical University, Dept. of Urology, Lucknow, India

A0237

Transvaginal Fascial Patch Repair for Circumferential Urethral Diverticulum: Five-Year Experience in 68 Cases

Authors

[Shen S.H.](#), [Shen H.](#), [Luo D.](#)

Institutions

West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China

Into the vein: Innovations in robotic kidney cancer surgery

Video Session 06

Saturday 14 March
12:15 - 13:45

Location

Blue Area, Victoria 1

Chairs

To be confirmed

To be confirmed

To be confirmed

V038 (□: 7 min.)

Renal tumor with Level IV thrombus: Comparing the transdiaphragmatic and sternotomy approaches

[C.H. Yee](#), Hong Kong (HK)

V039 (□: 8 min.)

Robot-assisted IVC Thrombectomy: Insights from over a Decade of Experience

[L. Misuraca](#), Rome (IT)

V040 (□: 8 min.)

Robot-assisted Partial Nephrectomy and Thrombectomy in a Patient with Angiomyolipoma and Renal Venous Thrombus under Hypothermia Perfusion

[Z. Wu](#), Shanghai (CN)

V041 (□: 7 min.)

Superior Mesenteric Artery (SMA) injury during robot-assisted thrombectomy, always a nightmare?

To be confirmed

V042 (□: 8 min.)

3D Image guided robot-assisted heminephrectomy with IVC thrombectomy on a single kidney

[M. Odin](#), (FR)

V043 (□: 8 min.)

Kidney cancer with segmental venous invasion : tips and tricks for 3D Image-Guided Robotic Assisted Partial Nephrectomy (3D IGRAPN)

G.L. Margue, Bordeaux (FR)

V044 (□: 7 min.)

Robot-Assisted Nephron-Sparing Surgery and Tumor Thrombectomy in Patient with Renal Angiomyolipoma and Inferior Vena Cava Tumor Thrombus: Step-by-Step Technique Description and Preliminary Results

C. Xu, Beijing (CN)

Urological infections in the era of AMR: Rethinking prevention, management and surgical strategy

EAU Infections

EAU Section of Infections in Urology

Saturday 14 March
12:15 - 13:45

Location Blue Area, Victoria 2

Chairs J. Kranz, Aachen (DE)
Z. Tandođdu, London (GB)

Learning objectives

By the end of this session, participants will be able to critically evaluate evolving perioperative prophylaxis strategies and their impact on infection prevention; recognise the real-world challenges posed by antimicrobial resistance (AMR) in urological surgery, including case-based complications such as wound breakdowns and fungal infections; assess the relative merits of transperitoneal versus retro-/extraperitoneal surgical approaches in infection-prone contexts; apply principles of surgical stewardship to reduce infection risk and advance AMR control; transition from passive to proactive management of antibiotic resistance in daily urological practice; appraise future therapeutic innovations including new antibiotics, bacteriophages, vaccines, and microbiome-based therapies; and engage in evidence-based debate on whether the future of urology should prioritise investment in novel antibiotics or focus on non-antibiotic strategies to combat AMR.

12:15 - 12:17

Introduction

Z. Tandođdu, London (GB)

12:17 - 12:57

Safe surgery and sepsis in the AMR era

12:17 - 12:27

Prophylaxis and practice: Game-changing studies that shift the needle (APPEAL, DEEP URO, updated periop protocols)

K.A.O. Tikkinen, Helsinki (FI)

12:27 - 12:37

AMR in the real world: Post-surgical infections and long-term impact

L. Tzelves, Athens (GR)

Debate Should the transperitoneal route be phased out in favour of retro-/extraperitoneal when infection risk is high?

12:37 - 12:42

Pro: Surgical safety and infection avoidance

T.E. Bjerklund Johansen, Oslo (NO)

12:42 - 12:47

Con: Oncologic access, learning curve, patient anatomy

K. Touijer, New York (US)

12:47 - 12:57

Discussion and Q&A

Panel

T.E. Bjerklund Johansen, Oslo (NO)

K.A.O. Tikkinen, Helsinki (FI)

K. Touijer, New York (US)

L. Tzelves, Athens (GR)

12:57 - 13:27

Future-proofing urology against AMR

12:57 - 13:07

Antibiotic resistance and urology: From passive to proactive

J. Medina Polo, Madrid (ES)

13:07 - 13:17

What's coming? New antibiotics and non-antibiotic tools for urology (including bacteriophages, vaccines, microbiome therapies)

F.M.E. Wagenlehner, Giessen (DE)

13:17 - 13:27

Surgical stewardship in action: How urologists can lead the next phase of AMR control

T. Cai, Trento (IT)

13:27 - 13:45

Debate New antibiotics or no antibiotics: What should urologists bet on to beat AMR?

Moderator

Z. Tandođdu, London (GB)

13:27 - 13:30

Introduction

Z. Tandođdu, London (GB)

13:30 - 13:33

Side A: Invest in new antibiotics

J. Kranz, Aachen (DE)

13:33 - 13:36

Side B: Prioritise non-antibiotic strategies

C. Harding, Newcastle upon Tyne (GB)

13:36 - 13:38

Audience Vote

13:38 - 13:40

Rebuttal: Side A

13:40 - 13:42

Rebuttal: Side B

13:42 - 13:45

Final votes and closing remarks

Saturday 14 March
12:15 - 13:45

Location Blue Area, George 3

Chair F. Sanguedolce, Barcelona (ES)

Learning objectives

Imaging in prostate cancer is revolutionising patients' management, from screening and early diagnosis, to local treatment planning and systemic therapy. In order to better understand how and which imaging modalities play a major role in the decision making or in the treatment guidance, the session involves experts from different disciplines including representatives from the European Society of the Urogenital Radiology and from the European Association of Nuclear Medicine.

Key topics will be:

- The current role of AI and new imaging modalities in diagnosis
- How the prostate biopsy strategies may influence local treatment management
- Everything the urologists should know about theranostics in prostate cancer

12:15 - 12:16

Welcome and introduction

F. Sanguedolce, Barcelona (ES)

12:16 - 12:42

Screening and early detection

Moderators

F. Giganti, London (GB)

G. Lughezzani, Rozzano (IT)

12:16 - 12:22

MRI and artificial Intelligence in prostate cancer detection

I.G. Schoots, Rotterdam (NL)

Rapid-fire debate New ultrasound technologies in Pca detection: A contender to MRI?

12:22 - 12:27

The trend is promising

L.H. Klotz, Toronto (CA)

12:27 - 12:32

Too soon to tell

R. Girometti, Udine (IT)

12:32 - 12:35

Q&A

12:35 - 12:42

Does PSMA PET/CT have a role in early detection?

D. Murphy, Melbourne (AU)

12:42 - 13:11

Biopsy and surgical planning

Moderators

D. Murphy, Melbourne (AU)

V. Panebianco, Rome (IT)

12:42 - 12:48

Challenging the guidelines What is the evidence in support of target and perilesional biopsy?

P. Cornford, Cork (IE)

...and what next? Perilesional biopsy is enough to undertake my surgeries?

12:48 - 12:53	Yes indeed! F. Sanguedolce, Barcelona (ES)
12:53 - 12:58	No way... I need what's in the contralateral lobe! E. Barret, Paris (FR)
12:58 - 13:01	Q&A
	Rapid-fire debate The cN1 PSMA positive and CT negative
13:01 - 13:06	A case for radiotherapy + abiraterone B.A. Jereczek-Fossa, Milan (IT)
13:06 - 13:11	A case for prostatectomy + lymphadenectomy G. Giannarini, Udine (IT)
<hr/>	
13:11 - 13:42	All urologists needs to know on theranostics in prostate cancer <i>Moderators</i> D. Oprea-Lager, Nijmegen (NL) F. Sanguedolce, Barcelona (ES)
13:11 - 13:17	Theranostics in hormone-sensitive PCa: Evidence and ongoing trials D. Oprea-Lager, Nijmegen (NL)
	Rapid-fire debate Oligometastatic recurrent PCa on PSMA PET
13:17 - 13:22	Perfect scenario for theranostics K. Goffin, Leuven (BE)
13:22 - 13:27	Perfect scenario for SBRT (+/- ARSI) B.A. Jereczek-Fossa, Milan (IT)
13:27 - 13:32	...and what about surgery role? L. Budäus, Hamburg (DE)
13:32 - 13:35	Q&A
13:35 - 13:42	Alpha, beta emitters and future development W. Fendler, Essen (DE)
<hr/>	
13:42 - 13:45	EAU Imaging Vision Award 2026 and closure F. Sanguedolce, Barcelona (ES)

YUORday Part I

Special Session

Saturday 14 March
12:15 - 14:15

Location Blue Area, Victoria 5

Chairs To be confirmed

To be confirmed

12:15 - 12:25

Welcome and introduction

To be confirmed

To be confirmed

12:25 - 13:15

European urology scholarship programme (EUSP)

12:25 - 12:40

Updates on EUSP programme and how to apply

To be confirmed

12:40 - 12:55

Introducing the endourology fellowships

To be confirmed

12:55 - 13:10

My experience being a tutor and what I have advised

To be confirmed

13:10 - 13:13

Best scholar winner: Clinical research Diagnostic accuracy of MRI-guided transperineal prostate biopsy using a low-field, portable, office-based, open MRI device vs traditional MRI/ultrasound fusion-guided prostate biopsy: A prospective, multicenter, single-arm, open-label pilot study

Winner

To be confirmed

13:15 - 14:15

Development as a young urologist

Moderators

To be confirmed

To be confirmed

To be confirmed

13:15 - 13:30

Climbing the ladder within the EAU: From resident to leadership

To be confirmed

13:30 - 13:45

Go green as urologist?

To be confirmed

13:45 - 14:00

Starting your first research project: What should you know?

To be confirmed

14:00 - 14:15

Health economics for urologists: Understanding costs, value and decision-making

To be confirmed

Saturday 14 March
12:15 - 13:45

Location Orange Area, EGPT 1

Chairs C.L. Dickinson, Surrey (GB)
To be confirmed
A. Stabile, Milan (IT)

12:15 - 12:40

Biopsy strategy

P0435

One plane or two? A randomized comparison of biplanar versus monoplanar prostate biopsy strategies

Authors

Zeng Z.¹, Yuan R.²

Institutions

¹Sun Yat-Sen Memorial Hospital, Dept. of Urology, Guangzhou, China, ²Shanghai General Hospital, Dept. of Urology, shanghai, China

P0436

Diagnostic Value of Combined Transperineal MRI-Targeted and Systematic Mapping Biopsies: Diagnostic Contribution of Secondary and Tertiary Lesions

Authors

Paesano N.E., Justo Quintas J., García Barreras S., Romero-Otero J.

Institutions

ROC Clinic HM Hospitales, Dept. of Urology, Madrid, Spain

P0437

Can we drop systematic cores? Predictors supporting cognitive TP biopsy as a stand-alone strategy

Authors

Canbolat M., Dagli I., Uzel T., Cayirli A., Ozturk E.

Institutions

University of Health Sciences Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Dept. of Urology, Ankara, Turkey

P0438

Diagnostic Value of Perilesional Sampling to the Detection of Clinically Significant Prostate Cancer in Software-Based Multiparametric MRI-Targeted Biopsies: Early Results of a Prospective Study

Authors

Karabacak N.¹, Cetin S.¹, Tatli Sahin D.N.¹, Bulut E.C.¹, Koparal M.Y.¹, Ucar M.², Gonul I.I.³, Kupeli B.¹, Sozen S.¹

Institutions

¹Gazi University School of Medicine, Dept. of Urology, Ankara, Turkey, ²Gazi University School of Medicine, Dept. of Radiology, Ankara, Turkey, ³Gazi University School of Medicine, Dept. of Medical Pathology, Ankara, Turkey

12:40 - 13:00

Basic science

P0441

Identification and prognostic significance of tertiary lymphoid structures in prostate cancer

Authors

Liu X, Liu S., [Dong Q.](#)

Institutions

West China Hospital Sichuan University Chengdu China, Dept. of Urology, Chengdu, China

P0442

Development and clinical validation of a urine-based DNA methylation assay for noninvasive detection of prostate cancer: a prospective study

Authors

[nianzeng X.](#), Wang M.

Institutions

National Cancer Center Chinese Academy of Medical Sciences and Peking Union Medical College, Urology and State Key Laboratory of Molecular Oncology, Beijing, China

P0443

Comprehensive single-cell spatial profiling of prostate cancer reveals ecosystem dynamics in 23.5 million cells

Authors

Zheng Z.¹, Cheng S.², Dong L.¹, Xue W.¹, Gao D.², [Pan J-H.](#)¹

Institutions

¹Renji Hospital Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China, ²Chinese Academy of Sciences, Shanghai Institute of Biochemistry and Cell Biology, Shanghai, China

13:00 - 13:05

Complications post biopsy

P0444

The SETABA Trial: Tadalafil plus Serenoa repens Combination Improves Post-Biopsy Functional Recovery After Transperineal Prostate Biopsy

Authors

[Proietti F.](#)¹, Albisinni S.², Al Salhi Y.³, Brassetti A.¹, Patruno G.⁴, Presicce F.⁵

Institutions

¹Fondazione Vincenzo Pansadoro, Dept. of Urology, Rome, Italy, ²Policlinico di Torvergata, Dept. of Urology, Rome, Italy, ³ICOT Sapienza University of Rome, Dept. of Urology, Latina, Italy, ⁴San Giovanni Addolorata Hospital, Dept. of Urology, Rome, Italy, ⁵San Filippo Neri Hospital, Dept. of Urology, Rome, Italy

13:05 - 13:20

Race, genetics and socio-economic status

P0445

The impact of Area Deprivation Index on receiving appropriate work-up on patients presenting with an elevated PSA

Authors

Santangelo A.¹, Silvani C.¹, Stephens A.², Haddad L.¹, Shafau F.¹, Kumar N.¹, Salka B.¹, Considine J.¹, Catanzaro M.³, Nicolai N.³, Montanari E.⁴, Salonia A.⁵, Montorsi F.⁵, Rogers C.¹, Abdollah F.¹

Institutions

¹VUI Center for Outcomes Research Analysis and Evaluation Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Urology Unit, Milan, Italy, ⁴Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ⁵IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy

P0446

The impact of Race on oncological outcomes in patients with an initial negative prostate biopsy: results from a contemporary North America cohort

Authors

Bertini A.¹, Stephens A.¹, Finocchiaro A.¹, Viganò S.¹, Perri A.¹, Lughezzani G.², Buffi N.², Sorce G.³, Ficarra V.³, Briganti A.⁴, Salonia A.⁴, Montorsi F.⁴, Rogers C.¹, Abdollah F.¹

Institutions

¹VUI Center for Outcomes Research Analysis and Evaluation Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²IRCCS Humanitas Research Hospital Humanitas University, Dept. of Urology, Milan, Italy, ³AOU G. Martino University of Messina, Dept. of Clinical and Experimental Medicine Oncology, Messina, Italy, ⁴IRCCS Ospedale San Raffaele Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy

P0447

The prevalence of BRCA1 and BRCA2 gene deleterious alterations in advanced prostate cancer: Analysis of the nationwide cancer genomic database in Japan.

Authors

Tsumura H.¹, Koguchi D.¹, Shimura S.¹, Ikeda M.¹, Takahashi K.², Araki N.², Tabata K.I.¹, Satoh T.¹, Takada F.², Matsumoto K.¹

Institutions

¹Kitasato University School of Medicine, Dept. of Urology, Sagamihara, Japan, ²Kitasato University School of Medicine, Genetics Division, Dept. of Genetics, Sagamihara, Japan

13:20 - 13:35

PSA and other biomarkers

P0448

Prostate Health Index Combined with Pi-Rads Score Enhances Prostate Cancer Diagnosis: Insights From a Large Chinese Cohort

Authors

Zhong X.Y., Xiong Y., Gong X., Zeng N., Xia Q., Wang S.

Institutions

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Dept. and Institute of Urology, Wuhan, China

P0449

Evidence-based PSA Reference Ranges: Results from the Norwegian Prostate Cancer Consortium (NPCC)

Authors

Aas K.¹, Fjose J.Ø.², Nome R.³, Stensvold A.⁴, Albertsen P.C.⁵, Bjerner L.J.², Oldenburg J.⁶

Institutions

¹Akershus University Hospital, Dept. of Urology, Lørenskog, Norway, ²Fürst Medical Laboratory, Clinical Chemistry, Oslo, Norway, ³Oslo University Hospital, Dept. of Medical Biochemistry, Oslo, Norway, ⁴Kalnes hospital, Dept. of Oncology, Grålum, Norway, ⁵UConn Health, Dept. of Urology, Farmington, United States of America, ⁶Akershus University Hospital, Dept. of Oncology, Lørenskog, Norway

P0450

Validation of Stockholm3 for Prostate Cancer Detection in a Swiss Non-Referral Cohort: Balancing Biopsy Reduction and Diagnostic Performance

Authors

Giudici N.¹, Benjamin B.¹, Mudlagk J.², Minder O.², Palsdottir T.³, Lantz A.³, Cornelius J.², Di Bona C.², Arnold N.¹, Roth B.¹, Mordasini L.²

Institutions

¹University Hospital Insel, Dept. of Urology, Bern, Switzerland, ²Uroviva AG, Dept. of Urology, Sursee, Switzerland, ³Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden

13:35 - 13:45

Additional imaging beyond MRI

P0451

Coupling MRI Voxel-wise Spatial Heterogeneity with TRUS Dynamic Deep Features Endows High Discernability for Clinically Significant Prostate Cancer

Authors

Zhang W.¹, Wei P.¹, Ye X.², Hong J.H.³, Wong K.C.W.⁴, Xu J.², Zheng Y.P.¹, Cai J.⁵, Lam S.K.¹

Institutions

¹The Hong Kong Polytechnic University, Dept. of Biomedical Engineering, Hong Kong, Hong Kong, ²Shenzhen People's Hospital, The Second Clinical Medical College, Dept. of Ultrasound, Shenzhen, China, ³National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan, ⁴Prince of Wales Hospital, Dept. of Clinical Oncology, Hong Kong, Hong Kong, ⁵The Hong Kong Polytechnic University, Dept. of Health Technology and Informatics, Hong Kong, Hong Kong

P0452

Second-line PSMA PET/MRI-guided prostate biopsies after MRI-first in men assessed for prostate cancer - clinical testing against systematic biopsies

Authors

Jochumsen M.R.¹, Medrud L.², Kezunovic S.V.³, Bjaerre J.¹, Andersen M.H.³, Berg K.D.⁴

Institutions

¹Aarhus University Hospital, Dept. of Nuclear Medicine, Aarhus, Denmark, ²Aarhus University Hospital, Dept. of Radiology, Aarhus, Denmark, ³Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ⁴Goedstrup Hospital, Dept. of Urology, Herning, Denmark

Saturday 14 March
12:15 - 13:45

Location Orange Area, EGPT 4

Chairs To be confirmed
M. Gül, Konya (TR)
M. Skrodzka, London (GB)

12:15 - 13:00

Erectile dysfunction

P0487

Phase I clinical trial: Pilot study of somatic-autonomic nerve grafting technique to restore erectile function in patients with persistent erectile dysfunction post radical prostatectomy

Authors

Sadri I.¹, Delli Colli L.², Alshamsi H.¹, Loutochin O.³, Tholomier C.³, Rompre-Brodeur A.¹, McPherson V.³

Institutions

¹McGill University, Division of Urology, Montréal, Canada, ²McGill University, Faculty of Medicine, Montréal, Canada, ³Jewish General Hospital, Division of Urology, Montréal, Canada

P0488

Classic versus stapler circumcision: effects on penile length, sensitivity and sexual function

Authors

Gondek J., Czajkowski M., Blaczowska A., Grudzińska M., Dolny M., Matuszewski M.

Institutions

Medical University of Gdansk, Dept. of Urology, Gdańsk, Poland

P0489

The Presence Of A Dose Response Relationship Between Obstructive Sleep Apnoea And Erectile Dysfunction: A Systematic Review

Authors

Pang K.¹, Tong K.S.², Muneer A.¹, Alnajjar H.M.¹

Institutions

¹University College London, Division of Surgery and Interventional Science, London, United Kingdom, ²The University of Hong Kong, MBBS, Hong Kong, Hong Kong

P0490

Optimal sexual frequency may exist and help mitigate depression odds in young and middle-aged U.S. citizens: A cross-sectional study

Authors

zhang_Z

Institutions

Shenzhen Second People's Hospital, Dept. of Urology, Shen Zhen, China

P0491

Increased Risk of Erectile and Testicular Dysfunction among Young Men with Type 2 Diabetes Treated with Semaglutide: A Global TriNetX Cohort Analysis

Authors

Hsu J.Y., Lin Y.S., Hsu C.Y., Ou Y.C., Tung M.C.

Institutions

Tungs' Taichung MetroHarbor Hospital, Division of Urology, Taichung, Taiwan

P0492

Surgical treatment of rupture of the corpora cavernosa: Sexual outcomes and predictive factors for erectile dysfunction

Authors

Chaker K.¹, Mosbahi B.², Gharbia N.¹, Ammar R.², Tebini S.², Marzouki W.¹, Chakroun A.¹, Ouanes Y.¹, Bibi M.¹, Ben Chedly W.¹, Ammous A.², Nouria Y.¹

Institutions

¹La Rabta Hospital, Dept. of Urology, Tunis, Tunisia, ²La Rabta Hospital, Dept. of Anesthesiology, Tunis, Tunisia

P0493

The anatomical relationships in the space of Retzius after robotic-assisted radical prostatectomy: An MRI-based analysis

Authors

Mendelson T.¹, Neeman R.², Fenton C.², Biran G.³, Tsur G.¹, Yossepowitch O.¹, Dekalo S.¹

Institutions

¹Tel Aviv Sourasky Medical Center, Dept. of Urology, Tel Aviv, Israel, ²Tel Aviv Sourasky Medical Center, Dept. of Radiology, Tel Aviv, Israel, ³Tel Aviv University, School of Medicine, Tel Aviv, Israel

P0494

Superselective Angioplasty of Pudendal Arteries with Sirolimus-Coated Balloon: Percutaneous Intervention for Arteriogenic Erectile Dysfunction

Authors

De Cillis S.T.¹, Piana A.¹, Piramide F.¹, Volpi G.¹, Sica M.¹, Ragni F.S.A.M.¹, Manfredi M.¹, Amparore D.², Checcucci E.², Quarà A.¹, Clsero E.¹, Gatti C.¹, Cidda D.¹, Ribolzi B.S.¹, Rosi F.¹, Ferrando L.¹, Turcan A.¹, Garnerò F.¹, Flores Zevallos C.S.¹, Fiori C.¹, Porpiglia F.²

Institutions

¹AOU San Luigi Gonzaga University of Turin, Dept. of Urology, Turin, Italy, ²IRCCS Candiolo, Dept. of Urology, Turin, Italy

P0495

Living with loss: the impact of testicular prosthesis on sexual function, self-esteem, and postoperative well-being after orchifuniclectomy

Authors

Menzio M.¹, Perri D.², Orlandi F.³, Gastaldi C.², Ferrari I.¹, Carelli C.¹, Hoxha S.¹, Livio V.², Maltagliati M.², Calcagnile T.², Sene N.³, De Faveri A.³, Giovannalberto P.², Maruccia S.², Demirkiran E.D.⁴, Bozzini G.², Micali S.³

Institutions

¹University of Modena and Reggio Emilia, Dept. of Urology, Como, Italy, ²ASST Lariana, Sant'Anna Hospital Como, Dept. of Urology, Como, Italy, ³Università di Modena e Reggio Emilia, Ospedale Civile di Baggiovara, Dept. of Urology, Modena, Italy, ⁴Zonguldak Bulent Ecevit University, Dept. of Urology, Zonguldak, Turkey

P0496

The Effect of Closed Suction Drain Usage on Postoperative Outcomes After Three-Piece Inflatable Penile Prosthesis Surgery: A Retrospective Comparative Study

Authors

Ortac M.¹, Cetin B.², Onuk O.², Özerverli M.F.¹, Ergul R.B.¹, Aydin R.³, Kadioglu A.¹

Institutions

¹Istanbul University Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ²Altinbas University Bahcelievler Medicalpark Hospital, Dept. of Urology, Istanbul, Turkey, ³Haseki Training and Research Hospital, Dept. of Urology, Istanbul, Turkey

P0497

International Multicenter Validated Tool Assessment of Patient Satisfaction after Inflatable Penile Prosthesis (IPP)

Authors

Al-Mitwalli A.¹, Bernie H.L.², Pereira T.², Amorim L.², Shah M.¹, Di Giovanni A.¹, Hammad M.³, Abou Chawareb E.³, Liso N.B.⁴, Lee W.G.¹, Yafi F.³, Nelson C.⁴, Flores J.M.⁴, Ralph D.¹, Mulhall J.P.⁴

Institutions

¹University College London Hospitals, Dept. of Andrology, London, United Kingdom, ²Indiana University, Dept. of Andrology, Indianapolis, United States of America, ³University of California,, Dept. of Andrology, Irvine, United States of America, ⁴Memorial Sloan Kettering, Dept. of Andrology, New York, United States of America

P0498

Postoperative complication severity prediction in penile prosthesis implantation: a machine learning-based predictive modeling study

Authors

Unal A.¹, Sahin A.², Altan M.³, Demir I.B.³, Ure I.⁴, Mazlum H.A.⁴, Cirigliano L.⁵, Preto M.⁵, Falcone M.⁵, Gül M.²

Institutions

¹Oltu State Hospital, Dept. of Urology, Erzurum, Turkey, ²Selcuk University, Dept. of Urology, Konya, Turkey, ³Hacettepe University, Dept. of Urology, Ankara, Turkey, ⁴Eskişehir Osmangazi University, Dept. of Urology, Eskişehir, Turkey, ⁵Molinette Hospital, University of Torino, AOU Città della Salute e della Scienza di Torino, Dept. of Urology, Turin, Italy

P0499

Twelve-Week Outcomes and Complications Following Penile Prosthesis Implantation: Data From the EAU Research Foundation PHOENIX Registry

Authors

De Bruyn H.¹, Ralph D.², Moncada I.³, Caris C.⁴, Witjes W.⁴, Van Renterghem K.⁵

Institutions

¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²UCLH, Dept. of Urology, London, United Kingdom, ³Hospital Universitario La Zarzuela, Dept. of Urology, Madrid, Spain, ⁴EAU, Research Foundation, Arnhem, The Netherlands, ⁵Jessa Hospital, Dept. of Urology, Hasselt, Belgium

Study Group

EAU RF Phoenix Registry group(Arnhem, The Netherlands)

P0500

Comparative outcomes of early versus delayed penile prosthesis insertion in patients with ischaemic priapism

Authors

Tong K.S.¹, [Pang K.](#)², Lau J.T.Y.¹, Ralph D.J.³, Muneer A.², Alnajjar H.M.²

Institutions

¹The University of Hong Kong, MBBS, Hong Kong, Hong Kong, ²University College London, Division of Surgery and Interventional Science, London, United Kingdom, ³University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom

13:25 - 13:45

Premature ejaculation

P0501

Dual-Site Botulinum Toxin Injection for Lifelong Premature Ejaculation: A Prospective Randomized Controlled Trial

Authors

[Mahmoud Abdalla Shello H.E.](#)¹, Anwer Abdelmageed M.², Kamal Mahmoud R.³, Elhendawy A.⁴, Al Ayman Abdelaal O.¹

Institutions

¹Zagazig University Hospitals, Faculty of Medicine, Dept. of Urology, Zagazig, Egypt, ²Al Mouwasat Hospital, Dept. of Urology, Riyadh, Saudi Arabia, ³Al Mouwasat Hospital, OB/GYN, Riyadh, Saudi Arabia, ⁴Al Mouwasat Hospital, Dept. of General Surgery, Riyadh, Saudi Arabia

P0502

Effectiveness of tramadol vs SSRI in the treatment of premature ejaculation.

Authors

[Ullah F.](#), Ahmad W.

Institutions

Khalifa Gul Nawaz Teaching Hospital Bannu, Dept. of Urology, Bannu, Pakistan

P0503

A digital health application to reduce premature ejaculation symptoms: Final results of the German CLIMACS study.

Authors

Kormann F.¹, Karschuck P.², Huber J.², [Groeben C.](#)²

Institutions

¹University hospital UKGM Marburg, Dept. of Urology, Marburg, Germany, ²University hospital Heidelberg, Dept. of Urology, Heidelberg, Germany

P0504

Early Postoperative Erectile Fullness as a Predictor of Orgasmic Function After Robotic-Assisted Radical Prostatectomy with the Hood Technique

Authors

[Wang J.](#), Khanmammadova N., Hanna K., Gao A., Vu J., Tran K., Gomez R., Yu B., Fung C., Nguyen C., Yafi F., Shahait M., Lee D.

Institutions

University of California Irvine, Dept. of Urology, Irvine, United States of America

Upper tract urothelial carcinoma: Navigating diagnostics, treatment, and recurrence

EGPT 27

Saturday 14 March
12:15 - 13:45

Location Orange Area, EGPT 3
Chairs T.A. Drewa, Bydgoszcz (PL)
M.T. Grabbert, Freiburg (DE)
To be confirmed

12:15 - 12:40

UTUC staging

P0469

A novel AI system for preoperative depth prediction in UTUC

Authors

Fukuta K.¹, Daizumoto K.¹, Yoshikawa K.², Osafune N.², Torii K.², Nishimura R.³, Uehara H.⁴, Minato R.¹, Sasaki Y.¹, Tomida R.¹, Kusuhara Y.¹, Fukawa T.¹, Furukawa J.¹

Institutions

¹Tokushima University Graduate School of Biomedical Sciences, Dept. of Urology, Tokushima, Japan, ²Tokushima University, Center for Design-Oriented AI Education and Research, Tokushima, Japan, ³Tokushima University, Faculty of Science and Technology, Tokushima, Japan, ⁴Tokushima University Hospital, Division of Pathology, Tokushima, Japan

P0470

Diagnostic yield and clinical significance of ureteroscopy in patients with CT scan suggesting upper tract urothelial carcinoma.

Authors

Bille S., Savopoulos V., Hogg C., Palit V.

Institutions

Leeds teaching hospitals, Dept. of Urology, Leeds, United Kingdom

P0471

Diagnostic Value and Clinical Impact of Staging [¹⁸F]FDG-PET/CT for Upper Tract Urothelial Carcinoma

Authors

Lijnen R.A.G.¹, Ringia J.B.¹, Hendricksen K.¹, Vogel W.², Boellaard T.N.³, Braat A.J.A.T.⁴, van Rhijn B.W.G.¹, Mertens L.S.¹

Institutions

¹Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Antoni van Leeuwenhoek Hospital, Dept. of Radiotherapy and Nuclear Medicine, Amsterdam, The Netherlands, ³Antoni van Leeuwenhoek Hospital, Dept. of Radiology, Amsterdam, The Netherlands, ⁴Antoni van Leeuwenhoek Hospital, Dept. of Nuclear Medicine, Amsterdam, The Netherlands

Artificial Intelligence vs clinicians in Upper Tract Urothelial Cancer Management: accuracy and decision-making

Authors

Fernandes C.¹, Capinha M.², Portugal F.³, Freitas R.⁴, Silva C.¹, Silva J.¹, Morais A.N.⁴, Braga I.⁴

Institutions

¹Unidade Local de Saúde do Sao Joao, Dept. of Urology, Porto, Portugal, ²Unidade Local de Saúde de Braga, Dept. of Urology, Braga, Portugal, ³Unidade Local de Saúde Lisboa Ocidental, Dept. of Urology, Lisbon, Portugal, ⁴Instituto Português de Oncologia do Porto, Dept. of Urology, Porto, Portugal

Development and internal validation of machine-learning models to predict adverse pathological features in upper tract urothelial carcinoma using data from the ROBUUST 3.0 collaborative

Authors

Korn P.¹, Lokeshwar S.², Musso G.³, Wu Z.⁴, Djaladat H.⁵, Lee R.⁶, Margulis V.⁷, Antonelli A.⁸, Simone G.⁹, Minervini A.¹⁰, Abdollah F.¹¹, Takashi Y.¹², Shiota M.¹³, Sundaram C.P.¹⁴, Gonzalgo M.L.¹⁵, Perdonà S.¹⁶, Ferro M.¹⁷, Rais-Bahrami S.¹⁸, Porpiglia F.¹⁹, Mehrazin R.²⁰, Ghodoussipour S.²¹, Derweesh I.H.³, Autorino R.²², Singla N.²

Institutions

¹TUM School of Medicine and Health, Dept. of Urology, Munich, Germany, ²Johns Hopkins Medicine, The Brady Urological Institute, Baltimore, United States of America, ³Rush University, Dept. of Urology, Chicago, United States of America, ⁴Naval Medical University, Dept. of Urology, Shanghai, China, ⁵University of Southern California, Dept. of Urology, Los Angeles, United States of America, ⁶Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ⁷UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ⁸Azienda Ospedaliera Universitaria Integrata Verona (AOUI), Dept. of Urology, Verona, Italy, ⁹IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹⁰University of Florence-Unit of Oncologic Minimally Invasive Urology and Andrology, Dept. of Urology, Florence, Italy, ¹¹Henry Ford Health System, Vattikuti Urology Institute, Detroit, United States of America, ¹²Kansai Medical University, Dept. of Urology and Andrology, Osaka, Japan, ¹³Kyushu University, Dept. of Urology, Fukuoka, Japan, ¹⁴Indiana University, Dept. of Urology, Indianapolis, United States of America, ¹⁵University of Miami Miller School of Medicine, Desai Sethi Urology Institute, Miami, United States of America, ¹⁶IRCCS Fondazione G. Pascale, Istituto Nazionale Tumori Di Napoli, Naples, Italy, ¹⁷University of Milan, Dept. of Urology, Milan, Italy, ¹⁸University of Alabama at Birmingham Heersink School of Medicine, Dept. of Urology, Birmingham, United States of America, ¹⁹Candiolo Cancer Institute, FPO-IRCCS, Dept. of Surgery, Turin, Italy, ²⁰Icahn School of Medicine at Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ²¹Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, Section of Urologic Oncology, New Brunswick, United States of America, ²²Cleveland Clinic, Glickman Urological Institute, Cleveland, United States of America

Conditional survival and bladder cancer free survival of upper tract urothelial carcinoma treated with endoscopic kidney-sparing surgery: a YAU Urothelial group perspective

Authors

Avesani G.¹, Di Bello F.¹, Gallioli A.¹, Belarmino A.¹, Del Giudice F.², Soria F.³, Zattoni F.⁴, Afferi L.⁵, D'Andrea D.⁶, Krajewski W.⁷, Marcq G.⁸, De Lorenzis E.⁹, Moschini M.¹⁰, Contieri R.¹¹, Mari A.¹², Mertens L.¹³, Albisinni S.¹⁴, Ghanem A.A.¹⁵, Ślusarczyk A.¹⁶, Chung B.I.¹⁷, Velasco J.C.¹⁸, Pradere B.¹⁹, Palou J.¹, Breda A.¹

Institutions

¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²Sapienza University of Rome, Policlinico Umberto I Hospital, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ³University of Turin and Città della Salute e della Scienza, Dept. of Surgical Sciences, Turin, Italy, ⁴Azienda Ospedale-Università Padova, Dept. of Urology, Padova, Italy, ⁵Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ⁶Comprehensive Cancer Center and Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁷Wroclaw Medical University, Dept. of Minimally Invasive and Robotic Urology, Wroclaw, Poland, ⁸Claude Huriez Hospital, Dept. of Urology, Lille, France, ⁹University of Milan, Clinical Sciences and Community Health, Milan, Italy, ¹⁰IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ¹¹National Cancer Institute, IRCCS Fondazione G. Pascale, Dept. of Urology, Naples, Italy, ¹²University of Florence and Careggi Hospital, Dept. of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ¹³Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ¹⁴University of Tor Vergata, Dept. of Urology, Rome, Italy, ¹⁵Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, Dept. of Urology, London, United Kingdom, ¹⁶Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ¹⁷Stanford University School of Medicine, Dept. of Urology, Stanford, United States of America, ¹⁸Hospital General Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain, ¹⁹UROSUD, La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France

Endoscopic Management of Upper Tract Urothelial Carcinoma: A Multicenter Study on the Efficacy and Safety of Holmium laser with Vapor Tunnel, Holmium laser with Magneto technology and Thulium Fiber Laser

Authors

Perri D.¹, Rico L.², Alvarez Jaramillo J.², Calcagnile T.¹, Bozzini G.¹, Contreras P.²

Institutions

¹ASST Lariana Sant'Anna Hospital, Dept. of Urology, Como, Italy, ²Hospital Alemán, Dept. of Urology, Buenos Aires, Argentina

Other-cause mortality in upper tract urothelial cancer patients receiving second-look ureteroscopy: multicenter EAU-YAU Urothelial study

Authors

Di Bello F.¹, Gallioli A.², D'Andrea D.³, Zattoni F.⁴, Soria F.⁵, Laukhtina E.³, Afferi L.⁶, Del Giudice F.⁷, Krajewski W.⁸, Marcq G.⁹, De Lorenzis E.¹⁰, Moschini M.¹¹, Mari A.¹², Mertens L.¹³, Ślusarczyk A.¹⁴, Cano Velasco J.¹⁵, Contieri R.¹⁶, Chun B.I.¹⁷, Avesani G.¹¹, Belarmino A.², Palou J.², Pradere B.¹⁸, Breda A.²

Institutions

¹Università degli studi di Napoli Federico II, Dept. of Neurosciences, Reproductive Sciences and Odontostomatology, Napoli, Italy, ²Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ³Comprehensive Cancer Center, Dept. of Urology, Vienna, Austria, ⁴University of Padova, Dept. of Urology, Padova, Italy, ⁵University of Turin and Città della Salute e della Scienza, Dept. of Urology, Turin, Italy, ⁶Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ⁷La Sapienza University of Rome, Dept. of Urology, Rome, Italy, ⁸Wroclaw Medical University, Dept. of Urology, Wroclaw, Poland, ⁹Claude Huriez Hospital, Dept. of Urology, Lille, France, ¹⁰University of Milan, Dept. of Urology, Milan, Italy, ¹¹IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ¹²University of Florence, Dept. of Urology, Florence, Italy, ¹³Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ¹⁴Medical University of Warsaw, Dept. of Urology, Warsaw, Poland, ¹⁵Hospital General Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain, ¹⁶IRCCS Fondazione G. Pascale, Dept. of Urology, Napoli, Italy, ¹⁷Stanford University School of Medicine, Dept. of Urology, Stanford, United States of America, ¹⁸UROSUD, La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France

Study Group

EAU-YAU Urothelial Working Group and Ureteroscopic Treatment of upper tract Urothelial Carcinoma (UTUC) registry(Barcelona, Spain)

Ultrasound-Guided Endoscopic Combined IntraRenal Surgery for Nephron-Sparing Management of Upper Tract Urothelial Carcinoma: Technique and Outcomes

Authors

Ding Y., Xia L., Wang Y., Huang J., Chen Q., Xue W.

Institutions

Renji Hospital Shanghai Jiaotong University School of Medicine, Dept. of Urology, Shanghai, China

Kidney-sparing surgery versus radical nephroureterectomy for high-grade organ-confined upper tract urothelial carcinoma: Analysis of the ROBUUST Registry

Authors

Proietti F.¹, Tuderti G.¹, Autorino R.², Derweesh I.H.³, Wu Z.⁴, Singla N.⁵, Djaladat H.⁶, Lee R.⁷, Margulis V.⁸, Antonelli A.⁹, Minervini A.¹⁰, Abdollah F.¹¹, Yoshida T.¹², Shiota M.¹³, Sundaram C.P.¹⁴, Gonzalgo M.L.¹⁵, Perdonà S.¹⁶, Ferro M.¹⁷, Rais-Bahrami S.¹⁸, Porpiglia F.¹⁹, Mehrazin R.²⁰, Ghodoussipour S.²¹, Simone G.¹

Institutions

¹IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy, ²Cleveland Clinic, Glickman Urological Institute, Cleveland, United States of America, ³Rush University, Dept. of Urology, Chicago, United States of America, ⁴Shanghai Hospital, Naval Medical University, Dept. of Urology, Shanghai, China, ⁵Brady Urological Institute, Johns Hopkins University, Dept. of Urology and Oncology, Baltimore, United States of America, ⁶Norris Cancer Center, University of Southern California, Dept. of Urology, Los Angeles, United States of America, ⁷Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ⁸UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ⁹Azienda Ospedaliera Universitaria Integrata Verona, Dept. of Urology, Verona, Italy, ¹⁰Careggi Hospital, University of Florence, Unit of Oncologic Minimally Invasive Urology and Andrology, Dept. of Experimental and Clinical Medicine, Florence, Italy, ¹¹Vattikuti Urology Institute, Henry Ford Health System, Detroit, United States of America, ¹²Kansai Medical University, Dept. of Urology and Andrology, Osaka, Japan, ¹³Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan, ¹⁴Indiana University, Dept. of Urology, Indianapolis, United States of America, ¹⁵Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, Miami, United States of America, ¹⁶Istituto Nazionale Tumori Di Napoli, IRCCS Fondazione G. Pascale, Naples, Italy, ¹⁷ASST Santi Paolo e Carlo, University of Milan, Dept. of Urology, Milan, Italy, ¹⁸University of Alabama at Birmingham Heersink School of Medicine, Dept. of Urology, Birmingham, United States of America, ¹⁹Candiolo Cancer Institute, FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ²⁰Icahn School of Medicine at Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ²¹Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, Dept. of Urologic Oncology, New Brunswick, United States of America

Study Group

ROBUUST Registry(Cleveland, United States of America)

13:05 - 13:15

Minimally invasive techniques

P0479

Report on a Single-Center Experience with 24 Cases of Da Vinci Robot-Assisted Single-Port Laparoscopic Retroperitoneal Approach in Single-Position Nephroureterectomy

Authors

Zheng M., Wang Z.J., Shen L.M., Gu M., Zhu Q.Y.

Institutions

The Second Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

Single-Port Versus Multi-Port Robotic Nephroureterectomy: A Multi-Institutional Contemporary Comparison of Perioperative Outcomes and Tetrafecta Achievement from the ROBUUST & SPARC Collaborative Groups

Authors

Spena G.¹, Contieri R.¹, Ditonno F.², Soputro N.A.³, Ferro M.⁴, Decobelli O.⁵, Lee R.⁶, Ghodoussipour S.⁷, Rogers C.⁸, Mehrazin R.⁹, Djaladat H.¹⁰, Rais-Bahrami S.¹¹, Kaouk J.³, Derweesh I.¹², Antonelli A.², Gontero P.¹³, Mattei A.¹⁴, Minervini A.¹⁵, Simone G.¹⁶, Porpiglia F.¹⁷, Fankhauser C.¹⁴, Crivellaro S.¹⁸, Autorino R.³, Perdonà S.¹

Institutions

¹Istituto Nazionale Tumori IRCCS G. Pascale, Dept. of Urology, Naples, Italy, ²University of Verona, Dept. of Urology, Verona, Italy, ³GUI Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ⁴ASST Santi Paolo e Carlo, Dept. of Urology, Milan, Italy, ⁵European Institute of Oncology IRCCS, Dept. of Urology, Milan, Italy, ⁶Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ⁷Rutgers Cancer Institute, Dept. of Urology, New Brunswick, Italy, ⁸HFS Vattikuti Urology Institute, Dept. of Urology, Detroit, United States of America, ⁹Icahn School of Medicine at Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ¹⁰USC Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ¹¹University of Alabama at Birmingham (UAB), Dept. of Urology, Birmingham, United States of America, ¹²Rush University, Dept. of Urology, Chicago, United States of America, ¹³University of Turin Ospedale Molinette, Dept. of Urology, Turin, Italy, ¹⁴Lucerne Cantonal Hospital, Dept. of Urology, Lucerne, Switzerland, ¹⁵University of Florence, Dept. of Urology, Florence, Italy, ¹⁶IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹⁷Candiolo Cancer Institute FPO-IRCCS, Dept. of Urology, Turin, Italy, ¹⁸University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America

13:15 - 13:45

Recurrence and adjuvant therapies

P0482

Bladder Cuff Excision and Intravesical Recurrence After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Cohort Study

Authors

Rössler N.¹, von Deimling M.¹, Vetterlein M.W.¹, Miszczyk M.², Gontero P.³, Soria F.⁴, Pradere B.⁵, N'Dow J.⁶, Shariat S.F.², Tsai Y.C.⁷, D'Andrea D.²

Institutions

¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Comprehensive Cancer Center Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³Città della Salute e della Scienza, University of Torino School of Medicine, Dept. of Urology, Turin, Italy, ⁴Torino School of Medicine, Division of Urology, Dept. of Surgical Sciences, Turin, Italy, ⁵La Croix du Sud Hospital, Quint Fonsegrives, Dept. of Urology, UROSUD, Quint-Fonsegrives, France, ⁶University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ⁷Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, Division of Urology Dept. of Surgery, New Taipei, Taiwan

P0483

The Worse Impact of Diagnostic Ureteroscopy with Biopsy Prior to Radical Nephroureterectomy on Intravesical Recurrence-Free Survival in Patients with Upper Tract Urothelial Carcinoma

Authors

Matsumoto T., Sumikawa R., Tsukahara S., Tanegashima T., Kobayashi S., Shiota M., Eto M.

Institutions

Kyushu University, Dept. of Urology, Fukuoka, Japan

P0484

Contralateral Recurrence after Surgery for Upper Tract Urothelial Carcinoma: Risk Factors, Timing, and Treatment Patterns from the ROBUUST 3.0 International Registry

Authors

Ditunno F.¹, Bertolo R.², Ghodoussipour S.³, Mehrazin R.⁴, Poriglia F.⁵, Rais-Bahrami S.⁶, Ferro M.⁷, Perdonà S.⁸, Gonzalgo M.L.⁹, Sundaram C.P.¹⁰, Shiota M.¹¹, Yoshida T.¹², Abdollah F.¹³, Minervini A.¹⁴, Simone G.¹⁵, Tuderti G.¹⁵, Margulis V.¹⁶, Lee R.¹⁷, Djaladat H.¹⁸, Singla N.¹⁹, Wu Z.²⁰, Derweesh I.H.²¹, Autorino R.²², Antonelli A.¹

Institutions

¹University of Verona, Dept. of Urology, Verona, Italy, ²University of Verona, Dept. of Urology, Verona, Italy, ³Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, Section of Urologic Oncology, New Brunswick, United States of America, ⁴Icahn School of Medicine at Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ⁵Candiolo Cancer Institute, Dept. of Surgery, Turin, Italy, ⁶University of Alabama at Birmingham Heersink School of Medicine, Dept. of Urology, Birmingham, United States of America, ⁷University of Milan, Dept. of Health Science, Milan, Italy, ⁸Istituto Nazionale Tumori Di Napoli, IRCCS Fondazione G. Pascale, Dept. of Urology, Naples, Italy, ⁹University of Miami Miller School of Medicine, Desai Sethi Urology Institute, Miami, United States of America, ¹⁰Indiana University, Dept. of Urology, Indianapolis, United States of America, ¹¹Kyushu University, Dept. of Urology, Fukuoka, Japan, ¹²Kansai Medical University, Dept. of Urology and Andrology, Osaka, Japan, ¹³Henry Ford Health System, Vattikuti Urology Institute, Detroit, United States of America, ¹⁴University of Florence, Dept. of Experimental and Clinical Medicine, Florence, Italy, ¹⁵IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹⁶UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ¹⁷Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ¹⁸University of Southern California, Institute of Urology, Los Angeles, United States of America, ¹⁹Johns Hopkins University School of Medicine, Dept. of Urology and Oncology, Baltimore, United States of America, ²⁰Changhai Hospital, Dept. of Urology, Shanghai, China, ²¹Rush University, Dept. of Urology, Chicago, United States of America, ²²Cleveland Clinic, Dept. of Urology, Cleveland, United States of America

P0485

Adjuvant Chemotherapy for pT2 Upper Tract Urothelial Carcinoma: Evidence from an Institutional Cohort and SEER Validation

Authors

Tiancheng L., Jianjun Y., Qiang W., Bao Y.

Institutions

West China Hospital of Sichuan University, Dept. of Urology and Institute of Urology, Chengdu, China

P0481

Do We Need to Redefine Recurrence-Free Survival in Patients with Localized Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy?

Authors

Hsu C.H., Chen J.C., Lin A.T.L., Chang Y.H., Huang W.J.S., Chung H.J., Lin C.C., Huang I.S., Huang T.H., Chen W.J., Ku M.H., Huang E.Y.H.

Institutions

Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan

P0486

Impact of adjuvant intracavitary therapy on recurrence of upper tract urothelial carcinoma following endoscopic management

Authors

Korn P.¹, Pallauf M.², Herrera-Caceres J.O.³, Lokeshwar S.⁴, Small A.⁵, Raskolnikov D.⁵, Kleinmann N.⁶, Shvero A.⁶, Matin S.F.⁷, Labbate C.⁷, Kaimakliotis H.⁸, Tachibana I.⁸, Linehan J.⁹, Choe J.⁹, Shah O.¹⁰, Movassaghi M.¹⁰, Persily J.¹¹, Perelman A.¹², Canes D.¹², Rodrigues R.¹³, Potretzke A.¹³, Raman J.D.³, Singla N.⁴

Institutions

¹TUM School of Medicine and Health, Dept. of Urology, Munich, Germany, ²Paracelsus Medical University, Dept. of Urology, Salzburg, Austria, ³Penn State Milton S. Hershey Medical Center, Dept. of Urology, Hershey, United States of America, ⁴Johns Hopkins School of Medicine, The Brady Urological Institute, Baltimore, United States of America, ⁵Albert Einstein College of Medicine, Montefiore Department of Urology, New York, United States of America, ⁶The Sackler School of Medicine, Dept. of Urology, Tel Aviv, Israel, ⁷The University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁸Indiana University Medical Center, Dept. of Urology, Indianapolis, United States of America, ⁹Providence Specialty Medical Group, Dept. of Urology, Santa Monica, United States of America, ¹⁰Columbia University College of Physicians and Surgeons, Dept. of Urology, New York, United States of America, ¹¹New York University Grossman School of Medicine New York, Dept. of Urology, New York, United States of America, ¹²Lahey Hospital and Medical Center, Dept. of Urology, Burlington, United States of America, ¹³Mayo Clinic, Dept. of Urology, Rochester, United States of America

Advanced RCC management: Real-world data and prognostic indicators

EGPT 26

Saturday 14 March
12:15 - 13:45

Location

Orange Area, EGPT 2

Chairs

To be confirmed

To be confirmed

V. Mollica, Bologna (IT)

12:15 - 12:25

Role of radiotherapy in advanced renal cancer

P0453

Radiotherapy without regimen switch preserved survival in RCC immunotherapy

Authors

Naito S.¹, Narisawa T.¹, Ueda K.², Osawa T.³, Numakura K.⁴, Sekine Y.⁵, Inoue T.⁶, Ohba K.⁷, Naito H.⁸, Matsuda T.⁷, Sakai Y.², Kikuchi H.³, Sugimoto M.⁸, Kobayashi S.⁴, Habuchi T.⁵, Shin T.⁶, Tsuchiya N.¹

Institutions

¹Yamagata University Faculty of Medicine, Dept. of Urology, Yamagata, Japan, ²Kurume University School of Medicine, Dept. of Urology, Kurume, Japan, ³Graduate School of Medicine, Hokkaido University, Dept. of Urology, Sapporo, Japan, ⁴Asahikawa Medical University, Dept. of Urology, Asahikawa, Japan, ⁵Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ⁶Faculty of Medicine, Oita University, Dept. of Urology, Oita, Japan, ⁷Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan, ⁸Kagawa University Graduate School of Medicine, Dept. of Urology, Kagawa, Japan

Study Group

IMPACT8(Sapporo, Japan)

P0454

Efficacy and Safety of Targeted-Immunotherapy With or Without Stereotactic Radiotherapy for Recurrent/Metastatic Renal Cell Carcinoma: Interim Analysis of a Multicenter Ambidirectional Cohort Study

Authors

Hu K., Ma M.W., Gao X.S.

Institutions

Peking University First Hospital, Dept. of Radiation Oncology, Beijing, China

12:25 - 12:50

Improving patient stratification in advanced renal cancer

P0455

Prognostic Impact of Metastatic Organ Burden and Site in Patients Treated with Nivolumab plus Ipilimumab for Metastatic Renal Cell Carcinoma: A Multi-institutional Study

Authors

Matsuda T.¹, Ohba K.¹, Oki M.¹, Shin T.², Inoue T.², Naito S.³, Tsuchiya N.³, Ueda K.⁴, Sakai Y.⁴, Osawa T.⁵, Kikuchi H.⁵, Sekine Y.⁶, Habuchi T.⁶, Numakura K.⁷, Kobayashi S.⁷, Naito H.⁸, Sugimoto M.⁸, Imamura R.¹

Institutions

¹Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan, ²Oita University, Dept. of Urology, Faculty of Medicine, Oita, Japan, ³Yamagata University Faculty of Medicine., Dept. of Urology, Yamagata, Japan, ⁴Kurume University School of Medicine, Dept. of Urology, Kurume, Japan, ⁵Hokkaido University, Dept. of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido, Japan, ⁶Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ⁷Asahikawa Medical University, Dept. of Renal and Urologic Surgery, Asahikawa, Japan, ⁸Kagawa University Graduate School of Medicine, Dept. of Urology, Kagawa, Japan

P0456

Lung Immune Prognostic Index and Subcutaneous Fat Index were prognostic factors for combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma

Authors

Yamaguchi N., Morizane S., Yamamoto A., Omatsu R., Yamane H., Teraoka S., Nishikawa R., Kimura Y., Hikita K., Takenaka A.

Institutions

Tottori University, Dept. of Urology, Yonago, Japan

P0457

IMPACT8 Criteria: IO-Specific Risk Models for Locally Advanced Metastatic RCC Across IO–IO and IO–TKI Therapies

Authors

Naito H.¹, Sugimoto M.¹, Sakai Y.², Matsuda T.³, Sekine Y.⁴, Kobayashi S.⁵, Ueda K.², Inoue T.⁶, Osawa T.⁷, Naito S.⁸, Ohba K.³, Numakura K.⁵, Shin T.⁶, Abe T.⁷, Tsuchiya N.⁸, Habuchi T.⁴

Institutions

¹Kagawa University Graduate School of Medicine, Dept. of Urology, Kagawa, Japan, ²Kurume University School of Medicine, Dept. of Urology, Kurume, Japan, ³Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan, ⁴Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ⁵Asahikawa Medical University, Dept. of Renal and Urologic Surgery, Asahikawa, Japan, ⁶Faculty of Medicine, Oita University, Dept. of Urology, Yufu, Japan, ⁷Graduate School of Medicine, Hokkaido University, Dept. of Urology, Sapporo, Japan, ⁸Yamagata University Faculty of Medicine, Dept. of Urology, Yamagata, Japan

P0458

Impact of Histological Subtype and Metastatic Burden on Overall Survival After Cytoreductive Nephrectomy for Metastatic RCC in the Immunotherapy Era: Insights from the National Cancer Database

Authors

Garofano G.¹, Saitta C.¹, Fontana G.¹, Musso G.², Cherullo E.³, Vourganti S.³, Dabbas M.⁴, Capitanio U.², Montorsi F.², Lughezzani G.¹, Casale P.¹, Buffi N.M.¹, Derweesh I.H.³

Institutions

¹Humanitas University, Dept. of Urology, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ³Glickman Urological and Kidney Institute, Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ⁴UC San Diego Health System, Dept. of Urology, San Diego, United States of America

P0459

Prediction of immune-related adverse events in urological cancer during checkpoint inhibitor immunotherapy through immunohistochemical analysis of tumorous LCP1/ADPGK

Authors

Xu L., Tao Z., Li X., Tang Q.

Institutions

Peking University First Hospital, Dept. of Urology, Beijing, China

12:50 - 13:35

Outcomes of metastatic renal cancer in the real world

P0460

Impact of metastatectomy on survival in metastatic clear cell renal carcinoma: In the era of systemic and targeted therapy

Authors

Pon Avudaiappan A.¹, Ganiyani M.A.¹, Iqbal A.S.², Valagni G.³, Khosla A.A.⁴, Pustake M.⁵, Morye Y.S.⁶, Syed F.⁷, Jatwani K.⁸, Garje R.¹

Institutions

¹Miami Cancer Institute, Dept. of GU Medical Oncology, Miami, United States of America, ²Allama Iqbal Medical School, Dept. of Internal Medicine, Lahore, Pakistan, ³Saint Joseph Hospital, Dept. of Internal Medicine, Chicago, United States of America, ⁴Corewell Health William Beaumont University Hospital, Dept. of Internal Medicine, Royal Oak, United States of America, ⁵Texas Tech University Health Sciences Center, Dept. of Internal Medicine, Texas, United States of America, ⁶Montefiore Medical Center and Albert Einstein College of Medicine, Dept. of Internal Medicine, New York, United States of America, ⁷Charleston Area Medical Center, Dept. of Internal Medicine, Charleston, United States of America, ⁸The George Washington, Dept. of Internal Medicine, Washington, United States of America

P0461

Real-World Outcomes of Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study

Authors

Däuwel M.¹, Hoeh B.², Mattigk A.³, Becker P.⁴, Schwinger M.¹, Jahn M.⁵, Le Q.C.⁶, Sondermann M.², Banek S.², Zengerling F.³, Gschwend J.R.⁵, Erdmann K.², Zeuschner P.⁴, Kalogirou C.¹, Cano Garcia C.⁶

Institutions

¹University Medical Centre of Würzburg, Dept. of Urology and Paediatric Urology, Würzburg, Germany, ²University Hospital Carl Gustav Carus Dresden, Dept. of Urology, Dresden, Germany, ³University Hospital Ulm, Dept. of Urology and Paediatric Urology, Ulm, Germany, ⁴Saarland University Homburg, Dept. of Urology and Paediatric Urology, Homburg, Germany, ⁵Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Dept. of Urology, Munich, Germany, ⁶University Hospital Frankfurt, Goethe University Frankfurt am Main, Dept. of Urology, Frankfurt, Germany

P0462

First-line treatment outcomes in metastatic renal cell carcinoma (mRCC) patients with pancreatic and/or thyroid metastases (PM/TM): results from the IMDC

Authors

Zarba M.¹, Roussel E.², Maj D.¹, Baumgarten P.¹, Wells C.¹, El Hajj Chehade R.³, Kinget L.², McTaggart E.S.², Mammone G.², Bjarnason G.A.⁴, Lee J.L.⁵, Wood L.A.⁶, Ozay Z.⁷, Suarez C.⁸, Takemura K.⁹, Lalani A.K.A.¹⁰, Powles T.¹¹, Choueiri T.K.³, Beuselinck B.², Heng D.¹

Institutions

¹Arthur JE Child Comprehensive Cancer Center, Dept. of Medical Oncology, Calgary, Canada, ²UZ Leuven, Dept. of Medical Oncology, Leuven, Belgium, ³Dana Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, ⁴Sunnybrook Health Sciences Centre, Odette Cancer Centre, Dept. of Medical Oncology, Toronto, Canada, ⁵Asan Medical Center, Dept. of Medical Oncology, Seoul, South Korea, ⁶Dalhousie University, Dept. of Medical Oncology, Halifax, Canada, ⁷Huntsman Cancer Institute, Dept. of Medical Oncology, Utah, United States of America, ⁸Vall d'Hebron University Hospital, Dept. of Medical Oncology, Barcelona, Spain, ⁹Japanese Foundation for Cancer Research, Dept. of Urology, Tokyo, Japan, ¹⁰Juravinski Cancer Centre, Dept. of Medical Oncology, Hamilton, Canada, ¹¹Barts Cancer Institute, Dept. of Medical Oncology, London, United Kingdom

P0463

Real-world Comparison of Nivolumab–Ipilimumab and Nivolumab–Cabozantinib in Metastatic RCC

Authors

Lan YT, Li J.R., Wang S.S.

Institutions

Taichung Veterans General Hospital, Dept. of Urology, Taichung, Taiwan

P0464

Impact of Age on Outcomes in Metastatic Non–Clear Cell Renal Cell Carcinoma (mccRCC): A Real-World TriNetX Analysis

Authors

Cigliola A.¹, Dizman N.², Mercinelli C.¹, Zhu Y.³, Carlo M.⁴, Psutka S.P.⁵, Berg S.A.⁶, Prakash G.⁷, Aragon-Ching J.B.⁸, Oualla K.⁹, Linville L.⁸, Nguyen C.¹⁰, Yip W.¹⁰, Tateo V.¹, Maiorano B.A.¹, Spiess P.¹¹, Pal S.K.¹⁰, Necchi A.¹

Institutions

¹IRCCS San Raffaele Hospital, Dept. of Medical Oncology, Milan, Italy, ²MD Anderson Cancer Center, Dept. of Hematology & Oncology, Houston, United States of America, ³Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ⁴Memorial Sloan Kettering Cancer Center (MSKCC), Genitourinary Oncology Service, Division of Solid Tumor Oncology, New York, United States of America, ⁵University of Washington, Dept. of Urology, Seattle, United States of America, ⁶Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, United States of America, ⁷Tata Memorial Hospital, Homi Bhabha National Institute, Division of Uro-Oncology, Dept. of Surgical Oncology, Mumbai, India, ⁸Inova Schar Cancer Institute, Genitourinary Cancers, Fairfax, United States of America, ⁹Hassan II University, Dept. of Medical Oncology, Fès, Morocco, ¹⁰City of Hope Comprehensive Cancer Center, Dept. of Medical Oncology, Duarte, United States of America, ¹¹Moffitt Cancer Center, Dept. of Genitourinary Oncology, Tampa, United States of America

P0465

Are Real-World Patients with mRCC Receiving Sequential Therapies as in Trials? A Comparative Study

Authors

Sato H.¹, Sekine Y.², Shinohara M.³, Kawashima Y.³, Mori K.², Kobayashi M.², Numakura K.², Kodama H.¹, Mikami J.¹, Fujita N.¹, Okamoto T.¹, Yamamoto H.¹, Yoneyama T.⁴, Narita S.², Sato S.³, Habuchi T.², Ohyama C.⁵, Hatakeyama S.¹

Institutions

¹Hirosaki University, Dept. of Urology, Hirosaki, Japan, ²Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ³Ageo Central General Hospital, Dept. of Urology, Ageo, Japan, ⁴Tsugaru General Hospital, Dept. of Urology, Goshogawara, Japan, ⁵Hirosaki University Graduate School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan

P0466

Characteristics and first-line treatment of patients with advanced renal cell carcinoma (aRCC) in the UK

Authors

Ceruso M.¹, Chalk A.², Nolan A.³, Poonam D.¹

Institutions

¹Ipsen Biopharm Ltd, Medical Department, London, United Kingdom, ²IQVIA Ltd, Real World Evidence and Commercial & Marketing Solutions, United Kingdom & Ireland, London, United Kingdom, ³Ipsen Biopharm Ltd, Dept. of Global Medical Affairs, London, United Kingdom

P0467

First-line ICI+ICI versus ICI+TKI for metastatic renal cell carcinoma: Results from the Immune-checkpoint inhibitor Multi-institutional Project for Advanced Renal Cancer Therapy (IMPACT-8)

Authors

Ohba K.¹, Matsuda T.¹, Oki M.¹, Osawa T.², Abe T.², Inoue T.³, Shin T.³, Sekine Y.⁴, Habuchi T.⁴, Naito S.⁵, Tsuchiya N.⁵, Naito H.⁶, Sugimoto M.⁶, Numakura K.⁷, Kobayashi S.⁷, Sakai Y.⁸, Ueda K.⁸, Mitsunari K.¹, Matsuo T.¹, Imamura R.¹

Institutions

¹Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan, ²Hokkaido University Hospital, Dept. of Urology, Sapporo, Japan, ³Oita University Faculty of Medicine, Dept. of Urology, Oita, Japan, ⁴Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ⁵Yamagata University Faculty of Medicine, Dept. of Urology, Yamagata, Japan, ⁶Kagawa University Graduate School of Medicine, Dept. of Urology, Kagawa, Japan, ⁷Asahikawa Medical University, Dept. of Renal and Urologic Surgery, Asahikawa, Japan, ⁸Kurume University School of Medicine, Dept. of Urology, Kurume, Japan

P0468

Occurrence, number of organs, and grade of irAEs in combination therapy of nivolumab plus ipilimumab predict the prognosis: A retrospective, multi-institutional study

Authors

Oki M.¹, Ohba K.¹, Matsuda T.¹, Shin T.², Inoue T.², Naito S.³, Tsuchiya N.³, Ueda K.⁴, Sakai Y.⁴, Osawa T.⁵, Kikuchi H.⁵, Sekine Y.⁶, Habuchi T.⁶, Numakura K.⁷, Kobayashi S.⁷, Naito H.⁸, Sugimoto M.⁸, Imamura R.¹

Institutions

¹Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology and Renal Transplantation, Nagasaki, Japan, ²Oita University faculty of Medicine, Dept. of Urology, Oita, Japan, ³Yamagata University faculty of Medicine, Dept. of Urology, Yamagata, Japan, ⁴Kurume University school of Medicine, Dept. of Urology, Kurume, Japan, ⁵Hokkaido University Graduate School of Medicine, Dept. of Renal and Genitourinary Surgery, Hokkaido, Japan, ⁶Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ⁷Asahikawa Medical University, Dept. of Renal and Urologic Surgery, Asahikawa, Japan, ⁸Kagawa University Graduate School of Medicine, Dept. of Urology, Kagawa, Japan

Innovations and insights in urinary incontinence management

EGPT 29

Saturday 14 March
12:15 - 13:45

Location

Orange Area, EGPT 5

Chairs

To be confirmed

N. Sihra, London (GB)

T. Tarcan, Istanbul (TR)

12:15 - 13:00

Female incontinence

P0505

Fractional CO₂ Laser versus Biofeedback Therapy in Mild to Moderate Female Stress Urinary Incontinence: A Prospective Randomized Controlled Trial

Authors

Ke J., Huang J., Xie J., Liu Z., Zhang C., Zhou X., Li W., Liu B.

Institutions

Third Affiliated Hospital of Sun Yat-Sen University, Dept. of Urology, Guangzhou, China

P0506

Vaginal microbiota in women before and after surgical treatment of SUI

Authors

Sevastyanov L.¹, Turgunov Y.¹, Lavrinenko A.²

Institutions

¹Karaganda Medical University, Dept. of Surgical Diseases, Karaganda, Kazakhstan, ²Karaganda Medical University, Scientific Research Laboratory, Karaganda, Kazakhstan

P0507

Autologous Fascia Lata Sling in Patients with Stress Urinary Incontinence: A decade of institutional experience

Authors

Witlox L., Van der Aa F., Moris L.

Institutions

KU Leuven, Dept. of Urology, Leuven, Belgium

P0508

Effect of Diabetes on Quality-of-Life Improvement After Platelet-Rich Plasma Therapy for Women with Stress Urinary Incontinence

Authors

Borislavski A.¹, Petca R.C.², Petca A.¹

Institutions

¹Carol Davila University of Medicine and Pharmacy, Dept. of Obstetrics and Gynecology, Bucharest, Romania, ²Carol Davila University of Medicine and Pharmacy, Dept. of Urology, Bucharest, Romania

P0509

Predicting Persistent SUI After Weight-Loss Surgery: A Clinical Risk Score

Authors

Rodrigues A.F.¹, Junior W.R.D.², Toledo L.G.M.³

Institutions

¹Hospital Einstein Goiania, Dept. of Urology and Robotic Surgery, Goiania, Brazil, ²Faculty of Medical Sciences of Santa Casa de São Paulo, Dept. of Bariatric Surgery, São Paulo, Brazil, ³Faculdade de Ciências Médicas da Santa Casa de São Paulo, Dept. of Urology, São Paulo, Brazil

P0510

Hybrid Allogeneic–Synthetic Sling in the Surgical Management of Female Stress Urinary Incontinence: A Prospective Comparative Study

Authors

Pavlov V.N.¹, Robertson S.², Akinyemi S.¹, Urmantsev M.¹, Jha A.³

Institutions

¹Bashkir state medical university, Dept. of urology and oncology, Ufa, Russia, ²James Cook University Hospital, Dept. of Urology, Middlesbrough, United Kingdom, ³Sunderland Royal Hospital, Dept. of Urology, Sunderland, United Kingdom

P0511

Trends in Urinary Incontinence among U.S. Women with Overweight/Obesity: A Pre- and Post-Pandemic Analysis (2017-2023)

Authors

Huang J., Zhang Z., Li W., Wang Z., Yang F., Zhou X., [Liu B.](#)

Institutions

The Third Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Guangzhou, China

P0512

Complications and Causes of Readmission Following Midurethral Sling Surgery for Stress Urinary Incontinence in 88,880 Patients

Authors

[Blondeau A.](#)¹, Pitout A.¹, Larose C.¹, Koffi D.², Gaudry J.L.², Eschwege P.¹, Paris A.¹, Mazeaud C.¹

Institutions

¹CHU, Dept. of Urology, Nancy, France, ²Tekkare, Startup, Montrouge, France

P0513

The Australasian pelvic floor procedure registry: a maturing SUI registry cohort

Authors

[Ahern S.](#), Whale R., Matthews B., Honardoost M.A.

Institutions

Monash University, Clinical Outcomes Reporting and Research, Melbourne, Australia

13:00 - 13:45

male incontinence

P0514

Single-center experience in the surgical treatment of cuff-related urethral erosion in men with artificial urinary sphincters

Authors

[Mas Grilló L.](#), Martínez Barea V., Lopez Valls M., Petit Acosta M.L., Castillo Carvajal L., Quevedo Monroy S., Sánchez Molina R., Palou Redorta J., Errando Smet C.

Institutions

Fundació Puigvert, Dept. of Urology, Barcelona, Spain

P0515

Barriers to Post-Prostatectomy Stress Incontinence Care: Knowledge Gaps, Patient Concerns, and Urologist Communication

Authors

[Menzel V.](#)¹, Groeben C.², Hoffmann F.³, Chun F.K.H.⁴, Weissbach L.⁵, Thomas C.¹, Huber J.², Baunacke M.¹

Institutions

¹University Hospital Carl Gustav Carus Technische Universität Dresden, Dept. of Urology, Dresden, Germany, ²University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ³Carl von Ossietzky University, Dept. of Health Services Research, Oldenburg, Germany, ⁴Goethe-University-Hospital, Dept. of Urology, Frankfurt, Germany, ⁵Health Research for Men gGmbH, Health Research for Men, Gfm, Berlin, Germany

P0516

Urodynamic risk factors for transient urinary incontinence after endoscopic enucleation of prostate hyperplasia

Authors

Nesterova O., Sorokin N.I., Chochlov M.A., Kamalov D.M., Strigunov A.A., Kamalov A.A.

Institutions

Moscow State University, Dept. of Urology and Andrology, Moscow, Russia

P0517

Impact of pyrethroid metabolite exposure on male stress urinary incontinence: Epidemiological evidence and mechanistic insights

Authors

Xia X., Wang W., Jin T.

Institutions

West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China

P0518

Artificial urinary sphincter in men aged 75 Years and Older: Is it worth implanting? A single-center experience

Authors

Buksh O., Henrique Bitar Siqueira M., Shprits S., Radomski S.

Institutions

University of Toronto, Dept. of Urology, Toronto, Canada

P0519

Evaluating the Impact of Radiotherapy on the Adjustable Transobturator Male System (ATOMS) Efficacy for Post-Prostatectomy Incontinence

Authors

Kidess M.¹, Lederer E.¹, Georgieva T.¹, Hermans J.¹, Stadelmeier L.¹, Hoffmann M.¹, Keller P.¹, Bauer R.², Stief C.¹, Volz Y.¹

Institutions

¹LMU University Hospital, Dept. of Urology, Munich, Germany, ²Urologie Maximilianstrasse, Munich, Germany

P0520

Early Multicenter Experience with the Adjustable Artificial Urinary Sphincter VICTO™ for the Treatment of Severe Male Stress Urinary Incontinence

Authors

Fraile Poblador A.¹, Sollazzi E.², Costa Grau M.³, Carracedo Calvo D.¹, Martínez-Sapina I.⁴, González Dacal J.A.⁵, Alcaraz Asensio A.³, González López R.⁶, Garcia Rojo E.¹, Romero Otero J.¹, Peri Cusí L.³

Institutions

¹ROC Clinic, Dept. of Urology, Madrid, Spain, ²University Hospital of Pisa, Dept. of Urology, Pisa, Italy, ³Hospital Clinic of Barcelona, Dept. of Urology, Barcelona, Spain, ⁴Complejo Hospitalario Universitario de Vigo, Dept. of Urology, Vigo, Spain, ⁵Complejo Hospitalario Universitario de Pontevedra, Dept. of Urology, Pontevedra, Spain, ⁶Hospital Universitario Fundación Jiménez Díaz, Dept. of Urology, Madrid, Spain

P0521

Prospective PROXIMAL trial: 6-month outcomes after proximal ATOMS implantation in a challenging male incontinence cohort

Authors

[Queißert F.](#)¹, Brücher B.¹, von Garrelt M.¹, Dinkel H.¹, Volz J.², Schrader A.J.¹

Institutions

¹University Hospital Muenster, Dept. of Urology and Pediatric Urology, Muenster, Germany, ²LMU University Hospital, Dept. of Urology, Munich, Germany

P0522

Impact of Salvage Radiotherapy on Delayed Referral for Artificial Urinary Sphincter Implantation After Radical Prostatectomy

Authors

Yuma W.¹, Shunya M.¹, Ryo O.¹, Takaharu H.¹, Ryotaro S.¹, Wataru T.¹, Shinkyō C.¹, Tomoya M.¹, Yuki S.¹, Yoshitomo Y.¹, Madoka U.¹, [Kobayashi M.](#)¹, Yudai I.¹, Hiroshi F.¹, Yosuke Y.¹, Shohei F.¹, Hajime T.¹, Soichiro Y.¹, Masumi A.², Yasuhisa F.¹

Institutions

¹Institute of Science Tokyo, Dept. of Urology, Tokyo, Japan, ²Institute of Science Tokyo, Dept. of Insured Medical Care Management, Tokyo, Japan

Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 2.5

Saturday 14 March
13:00 - 13:50

Location

Red Area, Room 1

Tutors

O.R. Durutovic, Belgrade (RS)

M. Henderickx, Wilrijk (BE)

G. Kamphuis, Amsterdam (NL)

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 2.5

Saturday 14 March
13:00 - 13:50

Location Red Area, Room 1

Tutor D. Elterman, Toronto (CA)

Learning objectives

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 2.5

Saturday 14 March
13:00 - 13:50

Location Red Area, Room 1

Tutors To be confirmed
P. Umari, London (GB)

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 2.5

Saturday 14 March
13:00 - 13:50

Location Red Area, Room 1

Tutors To be confirmed
A. Olivero, Milan (IT)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 2.5

Saturday 14 March
13:00 - 13:50

Location Red Area, Room 1

Tutors S. García Barreras, Madrid (ES)
To be confirmed

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 2.5

Saturday 14 March
13:00 - 13:50

Location Red Area, Room 1

Tutors M. Arslan, Istanbul (TR)
E.D. Demirkiran, Zonguldak (TR)
To be confirmed

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 2.5

Saturday 14 March
13:00 - 13:50

Location Red Area, Room 1

Tutors M. Paciotti, Rozzano, Milan (IT)
A. Tuncel, Ankara (TR)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Patient advocacy plaza - Women's health and the involvement of WFIPP in European and global initiatives. In collaboration with the Global Health Connector

Special Session

Saturday 14 March
13:30 - 14:00

Location Patient Advocacy Plaza

Chair To be confirmed

13:30 - 14:00

World Federation of Incontinence and Pelvic Problems (WFIPP)

To be confirmed

Patient advocacy plaza - Shared decision-making from the patient perspective and current WFIPP initiatives in urological/gynaecological context

Special Session

Saturday 14 March
14:15 - 14:45

Location Patient Advocacy Plaza

Chair To be confirmed

14:15 - 14:45

World Federation of Incontinence and Pelvic Problems (WFIPP)

To be confirmed

Special Session

Saturday 14 March
15:00 - 15:30

Location Patient Advocacy Plaza
Chairs To be confirmed
To be confirmed

15:00 - 15:30

EAU Patient Office & Cancer UK-Salone
To be confirmed
To be confirmed

YUORday Part II

Special Session

Saturday 14 March
15:15 - 17:30

Location Blue Area, Victoria 5
Chairs To be confirmed
To be confirmed

15:15 - 15:36

Surgery tips and tricks

Moderators To be confirmed
To be confirmed
To be confirmed

15:15 - 15:22

Orchidopexy
To be confirmed

15:22 - 15:29

RALP
To be confirmed

15:29 - 15:36

PCNL: Mini and ultra-mini
To be confirmed

15:36 - 15:57

Nightmare cases

Moderators To be confirmed
To be confirmed
To be confirmed

15:36 - 15:43

Case I
To be confirmed

15:43 - 15:50

Case II
To be confirmed

15:50 - 15:57

Case III
To be confirmed

15:57 - 16:42	Urology made simple: Complex topics simplified
	<i>Moderators</i> To be confirmed To be confirmed
15:57 - 16:07	Urodynamics made simple To be confirmed
16:07 - 16:12	Discussion
16:12 - 16:22	Erectile dysfunction: Assessment and strategy To be confirmed
16:22 - 16:27	Discussion
16:27 - 16:37	How AI in urology actually works To be confirmed
16:37 - 16:42	Discussion
16:42 - 17:42	Guidelines cup
	<i>Moderators</i> To be confirmed To be confirmed
16:42 - 17:42	Guidelines Cup finalists
17:42 - 17:48	Best abstract by a resident awards
	1st prize
	2nd prize
	3rd prize
17:48 - 17:53	Award ceremony guidelines cup
17:53 - 17:55	Final remarks and closing

Hands-on Training in Urodynamics

HOT UDS - 2.2

Saturday 14 March
15:15 - 18:15

Location Red Area, Room 3

Chair H. Hashim, Bristol (GB)

Learning objectives

This hands-on training course is designed to help participants enhance their knowledge and technical skills in urodynamics, with a strong emphasis on practical, real-world application. Through guided instruction and supervised practice, participants will gain experience in each step of the urodynamic study (UDS) process, including equipment setup, test execution, troubleshooting common technical and clinical issues, and accurate data interpretation. The course aims to build confidence and competence in performing and analyzing urodynamic studies in a clinical setting.

15:15 - 15:30	Introduction H. Hashim, Bristol (GB)
15:30 - 16:50	Hands-on Training: Rotation 1
15:30 - 16:50	Setting up <i>Tutor</i> A. Gammie, Bristol (GB)
15:30 - 16:50	Running a test <i>Tutor</i> A. Garcia Mora, Hummelstown (US)
16:50 - 18:10	Hands-on Training: Rotation 2
16:50 - 18:10	Troubleshooting <i>Tutor</i> L. Thomas, Bristol (GB)
16:50 - 18:10	Interpretation <i>Tutor</i> To be confirmed
18:10 - 18:15	Questions and conclusion H. Hashim, Bristol (GB)

Evolving strategies in active surveillance, focal therapy and lymph node management

Thematic Session

Saturday 14 March
15:30 - 17:00

Location Orange Area, eURO Auditorium 2

Chairs J. Stranne, Göteborg (SE)
D. Tilki, Hamburg (DE)

Learning objectives

Delegates will gain an updated understanding of advances in active surveillance, focal therapy, and lymph node management in prostate cancer. The session will highlight evolving evidence and compare differing expert perspectives on active surveillance approaches, focal treatment outcomes, and lymph node dissection.

15:30 - 15:32	Introduction
15:32 - 16:02	Active surveillance 2.0
15:32 - 15:37	Debate Repeat biopsies are necessary in active surveillance Yes R. Van Den Bergh, Rotterdam (NL)
15:37 - 15:42	No, MRI is sufficient M. Emberton, London (GB)

15:42 - 16:02

Round-table discussion

Moderator

M. Emberton, London (GB)

Speakers

A. Borkowetz, Rostock (DE)

S. Carlsson, Heidelberg (DE)

M. Gleave, Vancouver (CA)

R. Van Den Bergh, Rotterdam (NL)

16:02 - 16:30

Focal therapy in localised prostate cancer

16:02 - 16:10

State-of-the-art lecture Evidence base and outcomes of focal treatment

V. Kasivisvanathan, London (GB)

16:10 - 16:30

Round-table discussion

Moderator

V. Kasivisvanathan, London (GB)

Speakers

M. Dall'era, Sacramento (US)

C. Moore, London (GB)

G. Ploussard, Toulouse (FR)

R. Sanchez-Salas, Montreal (CA)

16:30 - 16:58

Management of lymph nodes in prostate cancer

16:30 - 16:38

State-of-the-art lecture Role of lymph node dissection at the time of RP for localised PCa

T. Esen, Istanbul (TR)

16:38 - 16:58

Round-table discussion

Moderator

T. Esen, Istanbul (TR)

Speakers

G. Gandaglia, Milan (IT)

A. Henry, Leeds (GB)

D. Murphy, Melbourne (AU)

M. Roberts, Brisbane (AU)

16:58 - 17:00

Closing remarks

Evidence-based medicine made easy for urologists

Thematic Session

Saturday 14 March

15:30 - 17:00

Location

Orange Area, Room 3

Chairs

M.J. Ribal Caparros, Barcelona (ES)

K.A.O. Tikkinen, Helsinki (FI)

15:30 - 15:31

Welcome and Introduction

M.J. Ribal Caparros, Barcelona (ES)

15:31 - 15:38

State-of-the-art lecture How to understand a diagnostic accuracy study?

C. Moore, London (GB)

15:38 - 15:45	State-of-the-art lecture How to understand a prognostic study? G. Guyatt, Hamilton (CA)
15:45 - 15:52	State-of-the-art lecture What if it's an AI/ML study? S. Yuen, Hong Kong (HK)
15:52 - 15:59	Discussion <i>Panel</i> G. Guyatt, Hamilton (CA) C. Moore, London (GB) S. Yuen, Hong Kong (HK)
15:59 - 16:06	State-of-the-art lecture How to understand a randomised trial? R. Breau, Ottawa (CA)
16:06 - 16:13	State-of-the-art lecture How to understand a meta-analysis? P. Dahm, Minneapolis (US)
16:13 - 16:20	State-of-the-art lecture P OR [95% CI] for urologists R. L. Dunn, Ann Arbor (US)
16:20 - 16:27	Discussion <i>Panel</i> R. Breau, Ottawa (CA) P. Dahm, Minneapolis (US) R. L. Dunn, Ann Arbor (US)
16:27 - 16:34	State-of-the-art lecture How data becomes part of EAU Guidelines? S. Canfield, Houston (US)
16:34 - 16:44	Keynote lecture What is core GRADE? G. Guyatt, Hamilton (CA)
16:44 - 16:51	State-of-the-art lecture Patient values and preferences To be confirmed
16:51 - 16:58	Discussion <i>Panel</i> S. Canfield, Houston (US) G. Guyatt, Hamilton (CA) To be confirmed
16:58 - 17:00	Closing remarks K.A.O. Tikkinen, Helsinki (FI)

Saturday 14 March
15:30 - 17:00

Location Blue Area, Victoria 2

Chairs C.F.S. Jensen, Herlev (DK)
H.J. Park, Busan (KR)
G.I. Russo, Catania (IT)

15:30 - 16:25

Sperm quality in male infertility

A0363

Age-stratified metabolic, endocrine, and immune profiling in primary male infertility: Insights from a real-world cross-sectional study

Authors

Pozzi E.¹, Negri F.¹, Raffo M.¹, Bertini A.¹, Piccolo C.¹, Corsini C.¹, Boeri L.², d'Arma A.¹, Montorsi F.¹, Amodio G.³, Gregori S.³, Salonia A.¹

Institutions

¹IRCCS San Raffaele Scientific Institute, Division of Experimental Oncology, Unit of Urology, Milan, Italy, ²IRCCS Fondazione Ca' Granda, Dept. of Urology, Milan, Italy, ³IRCCS San Raffaele Scientific Institute, Telethon Institute for Gene Therapy (SR-TIGET), Milan, Italy

A0364

Advantages of the Transjugular Approach for Varicocele Embolization: Reduced Radiation Exposure

Authors

Yosef E., Shaked Y., Livne Segev D., Neheman A., Schwarztuch Gildor O.

Institutions

Meir medical center, Dept. of Urology, Kfar-Saba, Israel

A0365

The economics of sperm donation: A cross-continental analysis of compensation, profitability, and emerging direct-to-recipient trends

Authors

Patil A., Kamble A., Sharma S.

Institutions

Grant Government Medical College and Sir J.J. Group of Hospitals, Dept. of Urology, Mumbai, India

A0366

Comparative Effects of Finasteride and Dutasteride on Semen Parameters in Young Men with Androgenic Alopecia: A Randomized Controlled Study

Authors

Park H.J.

Institutions

Pusan National University School of Medicine Pusan National University Hospital, Dept. of Urology, Busan, South Korea

A0367

Inflammatory signatures and sperm concentration in fertile and infertile men: an age-stratified cohort analysis

Authors

Pozzi E.¹, Raffo M.¹, Negri F.¹, Bertini A.¹, Piccolo C.¹, Boeri L.², d'Arma A.¹, Alfano M.¹, Montorsi F.¹, Amodio G.³, Gregori S.³, Salonia A.¹

Institutions

¹IRCCS Ospedale San Raffaele, Division of Experimental Oncology - Unit of Urology - Urological Research Institute, Milan, Italy, ²IRCCS Fondazione Ca' Granda, Dept. of Urology, Milan, Italy, ³IRCCS San Raffaele Scientific Institute, San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), Milan, Italy

A0368

Phenotyping testicular reserve: What real-life data reveal

Authors

Pozzi E.¹, Negri F.¹, Raffo M.¹, Bertini A.¹, Piccolo C.¹, Boeri L.², Matloob R.¹, d'Arma A.¹, Alfano M.¹, Montorsi F.¹, Salonia A.¹

Institutions

¹IRCCS San Raffaele Scientific Institute, Division of Experimental Oncology, Unit of Urology, Urological Research Institute, Milan, Italy, ²IRCCS Fondazione Ca' Granda, Dept. of Urology, Milan, Italy

A0369

Seminal Microbiote Shifts After Varicocele Treatment: A Genus-Level Comparative Analysis Before and After Intervention

Authors

Russo G.I.¹, Asmundo M.G.R.¹, Bongiorno D.², Musso N.³, Pennisi P.⁴, Nicitra E.⁵, Cocci A.⁶

Institutions

¹University of Catania, Dept. of Urology, Catania, Italy, ²University of Bologna, Dept. of Biomedical and Neuromotor Sciences, Bologna, Italy, ³University of Kore, Faculty of Medicine and Surgery, Enna, Italy, ⁴Centro Diagnostico Ionia, Dept. of Pathology, Catania, Italy, ⁵University of Catania, Dept. of Biomedical and Biotechnology Sciences, Catania, Italy, ⁶University of Florence, Dept. of Urology, Florence, Italy

A0370

Second semen analysis after first assessment: Challenging the current European Association of Urology guidelines using a trial emulation design study

Authors

Negri F.¹, Pozzi E.¹, Raffo M.¹, Bertini A.¹, Oddo M.¹, Piccolo C.¹, Corsini C.¹, Birolini G.², De Luca S.², Boeri L.³, Sucapuca R.¹, Matloob R.¹, d'Arma A.¹, Eisenberg M.L.⁴, Montorsi F.¹, Salonia A.¹

Institutions

¹IRCCS Ospedale San Raffaele, Division of Experimental Oncology - Unit of Urology - Urological Research Institute, Milan, Italy, ²Vita-Salute San Raffaele University, Faculty of Medicine and Surgery, Milan, Italy, ³IRCCS Fondazione Ca' Granda, Dept. of Urology, Milan, Italy, ⁴Stanford University, Dept. of Urology, Stanford, United States of America

A0371

Flow cytometry sperm apoptosis test can predict sperm DNA fragmentation and can be used as an effective and easy-to-perform screening method for males from infertile couples

Authors

Novák J.¹, Vik V.², Fürst T.³, Thon V.⁴, Krátká Z.⁵

Institutions

¹General University Hospital and First Faculty of Medicine, Charles University, Dept. of Urology, Prague, Czech Republic, ²IVF Clinic GENNET, Dept. of Urology and Andrology, Prague, Czech Republic, ³Faculty of Science, Palacky University Olomouc, Dept. of Mathematical Analysis and Application of Mathematics, Olomouc, Czech Republic, ⁴Faculty of Science, Masaryk University, RECETOX, Brno, Czech Republic, ⁵IVF Clinic GENNET, Laboratory of Immunology, Prague, Czech Republic

A0372

Comparison of demographic and contraceptive patterns in men undergoing vasectomy before and after the COVID-19 pandemic in Barcelona, Spain

Authors

Raffo M.¹, Sanchez Curbelo J.R.², De Rocco Ponce M.², Malca Caballero L.², Arrus Soldi J.A.², Contreras Garcia R.², Dumas S.², Adalid G.², Montorsi F.¹, Salonia A.¹, Ruiz-Castane E.², Vantman Luft D.²

Institutions

¹IRCCS Ospedale San Raffaele, Unit of Urology, Milan, Italy, ²Fundacio Puigvert, Dept. of Andrology, Barcelona, Spain

A0373

Impact of body fat and body fact distribution on testicular function in men with primary infertility

Authors

Negri F.¹, Pozzi E.¹, Raffo M.¹, Piccolo C.¹, Bertini A.¹, Oddo M.¹, Corsini C.¹, Birolini G.², De Luca S.², Boeri L.³, Sucapuca R.¹, Matloob R.¹, d'Arma A.¹, Eisenberg M.L.⁴, Montorsi F.¹, Salonia A.¹

Institutions

¹IRCCS Ospedale San Raffaele, Division of Experimental Oncology - Unit of Urology - Urological Research Institute, Milan, Italy, ²Vita-Salute San Raffaele University, Faculty of Medicine and Surgery, Milan, Italy, ³IRCCS Fondazione Ca' Granda, Dept. of Urology, Milan, Italy, ⁴Stanford University, Dept. of Urology, Stanford, United States of America

16:25 - 16:35

Traslational biomedicine

A0374

Single-Cell Transcriptomic Landscape of Spermatogenic Abnormalities in Diabetes

Authors

Zhang Z., Xu Y., Bi J.

Institutions

First Hospital of China Medical University, Dept. of Urology, Shenyang, China

A0375

HIGH-FAT DIET AND RENIN-ANGIOTENSIN SYSTEM INHIBITION CAUSES STRUCTURAL CHANGES IN THE TESTIS STRUCTURE? AN EXPERIMENTAL MODEL

Authors

Alves Pereira J.L.¹, Ribeiro E.², corte frantz E.³, Sampaio F.J.², Favorito L.A.²

Institutions

¹IDOMED, Dept. of Anatomy, Rio de Janeiro, Brazil, ²State University from Rio de Janeiro, Dept. of Anatomy, Rio de Janeiro, Brazil, ³Universiade Federal Fluminense, Dept. of Morfology, Rio de Janeiro, Brazil

A0376

From PI-RADS to Te-RADS: Testicular MRI biomarkers predicting sperm retrieval in non-obstructive azoospermia

Authors

Pacheco-Rendón R.M.¹, [Luján Marco S.](#)², Hervás I.¹, Aquerreta Escribano J.³, Ten-Esteve A.³, Talaya-Penalver A.³, Martí-Bonmatí L.³, Gil Juliá M.¹, Budía A.², Garrido N.¹, Remohí J.⁴

Institutions

¹IVI Foundation, Instituto de Investigación Sanitaria (IIS) La Fe, Dept. of Andrology, Valencia, Spain, ²Hospital Universitari i Politècnic La Fe, Dept. of Urology, Valencia, Spain, ³La Fe Health Research Institute, Biomedical Imaging Research Group (GIBI230-PREBI) and Imaging La Fe node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), Dept. of Radiology, Valencia, Spain, ⁴IVIRMA, Dept. of Gynecology, Valencia, Spain

A0377

Predictive Value of PCNA, DMC1, TEX101, and SPACA1 Expression in Sperm Retrieval: A Comparative Study of MicroTESE-Negative and Ejaculatory Sperm Cases

Authors

Erol B.¹, [Ucar T.](#)², Gültomruk M.³, Aktuna S.⁴, Bahçeci M.⁵

Institutions

¹Bahceci IVF center, Dept. of Urology, İstanbul, Turkey, ²Bahceci IVF center, Dept. of Urology, Bursa, Turkey, ³Bahceci IVF center, Dept. of Genetics, İstanbul, Turkey, ⁴Microgen Genetic Diagnosis Laboratories, Dept. of Genetics, Ankara, Turkey, ⁵Bahceci IVF center, Dept. of Obstetric and Gynecology, İstanbul, Turkey

A0378

AI-Enhanced microdissection testicular sperm extraction: Smart Detection of Spermatogenic Tubules

Authors

[Fang Y.](#), Zhigao H., Hong K.

Institutions

Peking University Third Hospital, Dept. of Urology, Beijing, China

A0379

Novel Hormonal Spermatogenic Index (HSI) Predicts Micro-TESE Success in Non-Obstructive Azoospermia: A Pilot Study

Authors

[Uluç I.](#), Özkürkçügil C., Çulha M.M.

Institutions

Kocaeli University, Faculty of Medicine, Dept. of Urology, Kocaeli, Turkey

Sperm retrieval outcomes in men with Y chromosome AZFc microdeletion undergoing testicular sperm extraction: real-world data from a large multicenter cohort

Authors

Passarelli F.¹, Graziani A.², Manfredi C.³, Ortensi I.⁴, Gul M.⁵, Gentile G.⁶, Franceschelli A.⁶, Iafrate M.², Cocci A.⁷, Russo G.I.⁸, Preto M.⁹, Arrighi N.¹⁰, Martorello V.¹¹, Fallara G.¹², Negri F.¹³, Pozzi E.¹³, Ortensi A.¹⁴, Arcaniolo D.³, Magliocchetti M.¹⁵, Ferro M.¹², Palmieri A.¹⁵, Ferlin A.², Salonia A.¹³, Boeri L.¹

Institutions

¹IRCCS Fondazione Ca Granda Policlinico di Milano, Dept. of Urology, Milan, Italy, ²Azienda Ospedale Università Padova, Dept. of Andrology and Sexual Medicine, Padua, Italy, ³University of Campania "Luigi Vanvitelli", Dept. of Urology, Naples, Italy, ⁴Altamedica Fertility Centre, Fertility Centre, Rome, Italy, ⁵Selcuk University School of Medicine, Dept. of Urology, Konya, Turkey, ⁶Policlinico Sant'Orsola, Dept. of Urology, Bologna, Italy, ⁷AOU Careggi, Dept. of Urology and Andrology, Florence, Italy, ⁸Policlinico - Vittorio Emanuele, Dept. of Urology, Catania, Italy, ⁹Androteam Medical Center, Dept. of Andrology, Turin, Italy, ¹⁰Istituto Clinico Città di Brescia, Dept. of Urology, Brescia, Italy, ¹¹ASST Fatebenefratelli-Sacco Hospital, Dept. of Urology, Milan, Italy, ¹²ASST Santi Paolo e Carlo, Dept. of Urology, Milan, Italy, ¹³IRCCS Ospedale San Raffaele, Division of Experimental Oncology, Unit of Urology, Urological Research Institute, Milan, Italy, ¹⁴Sapienza Università di Roma, Dept. of Urology, Rome, Italy, ¹⁵Università Federico II, Dept. of Urology, Naples, Italy

Enucleation is enucleation: Comparing efficacies across technologies

Abstract Session 21

Saturday 14 March
15:30 - 17:00

Location Blue Area, George 4
Chairs To be confirmed
J.H. Hong, Taipei (TW)
T. Hüscher, Mainz (DE)

15:30 - 16:10

Laser prostatectomy: Setting the standard for the next decade

A0345

A Decade of Surgical Trends in BPO Management: Real-World Evidence from a High-Volume LUTS Center Demonstrating the Shift Towards Laser Enucleation over TURP

Authors

Stadelmeier L.F., Nicola P., Berger L., Keller P., Weinhold P., Atzler M., Pyrgidis N., Papadopoulos I., Marcon J., Stief C.G., Tamalunas A.

Institutions

LMU Munich, Dept. of Urology, Munich, Germany

A0346

Associated factors for achieving the Trifecta after Holmium Laser Enucleation of the Prostate (HoLEP): Evidence from a Prospective Cohort

Authors

Fernandez Siles J., Martí Flores J.M., Romero Crespo A., Carrasco Gómez D., Losa Calero J.M., Arroyo Ruíz A.R., Martínez Morales M.M., Rivero Esteban J.A., García Galisterio E., Espana Navarro R.

Institutions

Regional University Hospital of Malaga, Dept. of Urology, Malaga, Spain

A0347

Impact of Moses technology on HoLEP day-case success rate: a monocentric matched paired cohort study

Authors

Klein C., Lacroix X., Capon G., Alezra E., Blanc P., Estrade V., Margue G., Bernhard J.C., Bladou F., Robert G.

Institutions

Bordeaux University Hospital, Dept. of Urology, Bordeaux, France

A0348

Multicenter prospective comparative study to evaluate the safety and efficiency of same day catheter removal after en block holmium laser enucleation of prostate

Authors

Pastore A.L.¹, Al Salhli Y.¹, Fuschi A.¹, Suraci P.¹, Sequi M.B.¹, Valenzi F.M.¹, Rera O.A.¹, Antonioni A.¹, Graziani D.¹, Martino G.¹, Candita G.¹, Gianfrancesco F.¹, Benanti P.¹, Lombardo R.², De Nunzio C.², Tema G.², Carbone A.¹

Institutions

¹Sapienza University of Rome, Dept. of Medico-Surgical Sciences and Biotechnologies, Urology Unit, Latina, Italy, ²Sapienza University of Rome, Dept. of Urology Sant'Andrea Hospital, Rome, Italy

A0349

Size Matters: Outcomes and Complications of HoLEP in Large and Very Large Prostates

Authors

Herrmann J.¹, Wielander D.¹, Matheisen T.¹, Lehrich K.²

Institutions

¹Vivantes Auguste Viktoria Klinikum, Dept. of Urology, Berlin, Germany, ²MEO Clinic, Dept. of Urology, Berlin, Germany

A0350

Holmium:YAG laser enucleation of the prostate using the new Cyber Ho generator with Magneto technology: does it provide any advantages compared to Thulium:YAG prostate enucleation?

Authors

Perri D.¹, Besana U.¹, Pini G.¹, Calcagnile T.¹, Maltagliati M.¹, Ferrari I.¹, Livio V.¹, Carelli C.¹, Maruccia S.¹, Ventimiglia E.², Kartalas Goumas I.³, Romero Otero J.⁴, Bozzini G.¹

Institutions

¹ASST Lariana Sant'Anna Hospital, Dept. of Urology, Como, Italy, ²Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ³Beato Matteo Hospital, Dept. of Urology, Vigevano, Italy, ⁴ROC Clinic and HM Hospitales, Dept. of Urology, Madrid, Spain

A0351

Prospective multicenter real-world study of the Magneto laser in endoscopic enucleation of the prostate: 3-month outcomes

Authors

Fong K.Y.¹, Castellani D.², Yuen S.K.K.³, Zawadzki M.⁴, Tan K.⁵, Goumas I.K.⁶, Biligere S.⁷, Hota T.⁸, Bozzini G.⁹, Gauhar V.⁷, Herrmann T.¹⁰

Institutions

¹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ²Azienda Ospedaliero-Universitaria delle Marche, Dept. of Urology, Ancona, Italy, ³The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, China, ⁴Maria Curie-Skłodowska University, Dept. of Urology, Lublin, Poland, ⁵Online Urology Clinic, Dept. of Urology, Quezon, Philippines, ⁶Istituto Clinico Beato Matteo, Dept. of Urology, Vigevano, Italy, ⁷Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ⁸Hospital do Idoso Zilda Arns, Dept. of Urology, Curitiba, Brazil, ⁹ASST Lariana, Dept. of Urology, Como, Italy, ¹⁰Spital Thurgau AG, Dept. of Urology, Thurgau, Switzerland

A0352

Thulium fiber versus Holmium laser enucleation: 24-months results of a prospective randomized non-inferiority trial

Authors

Filzmayer M.¹, Cano Garcia C.¹, Traumann M.I.¹, Müller M.J.¹, Humke C.¹, Mandel P.C.¹, Kluth L.A.², Becker A.³, Chun F.K.H.¹, Kosiba M.¹

Institutions

¹University Hospital of Goethe University Frankfurt, Dept. of Urology, Frankfurt, Germany, ²Asklepios Paulinen Clinic, Dept. of Urology, Wiesbaden, Germany, ³Urological Center at Boxberg, Dept. of Urology, Neunkirchen, Germany

16:10 - 16:35

Miniaturized enucleation: Outcomes and safety

A0353

The MILES trial: Prospective randomized trial of safety and efficacy of minimally-invasive versus standard laser enucleation of the prostate

Authors

Petov V.¹, Azilgareeva C.¹, Bazarkin A.¹, Dymov A.M.¹, Li I.¹, Karakotov T.¹, Sukhanov R.¹, Chivalov L.¹, Tsarichenko D.¹, Enikeev M.¹, Gazimiev M.¹, Rapoport L.¹, Figueiredo F.C.A.²

Institutions

¹Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia, ²Pompéia Hospital, Dept. of Urology, Caxias do Sul, Brazil

A0354

Implementation of mini-HoLEP (MiLEP) in Very Large Prostates: A Propensity Score-Matched Study

Authors

Mendelson T., Schwartz Gildor O., Bashi T., Kidron A., Lifshitz K., Veredgorn Y., Yossepowitch O., Sofer M.

Institutions

Tel Aviv Sourasky Medical Center, Dept. of Urology, Tel Aviv, Israel

A0355

Comparison instrument miniaturization on surgical efficiency between Holmium Laser (HoLEP) and Slim Holmium (MiLEP) in prostate enucleation

Authors

Gomez Regalado F.¹, Ruiz Guerrero L.², Galland Novelo M.², Figueroa Garcia A.², Castro Zazueta S.², Tejada Andrade C.²

Institutions

¹Hospital Angeles, Dept. of Urology, Coahuila, Mexico, ²Hospital Angeles, Dept. of Urology, Guadalajara, Mexico

A0356

Prospective Multicenter Comparison of Aquablation and Anatomical Endoscopic Enucleation in Patients with Prostate Volumes over 100 ml: A 4-Year Follow-up Analysis

Authors

Becker B.¹, Filmar S.¹, Bormann L.¹, Hook S.¹, Engel O.², Wülfing C.³, Hartung F.O.¹, Netsch C.¹

Institutions

¹Asklepios Hospital Barmbek, Dept. of Urology, Hamburg, Germany, ²Asklepios Hospital Harburg, Dept. of Urology, Hamburg, Germany, ³Asklepios Hospital Altona, Dept. of Urology, Hamburg, Germany

A0357

One-year results of a randomized controlled trial comparing slim 22-F miniaturized holmium laser enucleation of the prostate (MiLEP) and standard 26-F holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia

Authors

Elmasy H.¹, Mousa A.², Hodhod A.³, Khan N.², Alhelal S.², Alaradi H.², Alotaibi K.², Zakaria A.S.²

Institutions

¹Houston Methodist Hospital, Dept. of Urology, Houston, United States of America, ²Northern Ontario School of Medicine and Thunder Bay Regional Health Sciences Centre, Dept. of Urology, Thunder Bay, Canada, ³King Abdulaziz Medical City, National Guard Health Affairs, Dept. of Urology, Riyadh, Saudi Arabia

16:35 - 17:00

Robotic assisted simple prostatectomy: An alternative for the large prostate

A0358

Multi-Institutional Outcomes of Robot-Assisted Simple Prostatectomy: A Retrospective Study by the ERUS Scientific Reconstructive Working Group

Authors

Heiniger YH¹, Lautenschlager S.¹, Foerster B.¹, Crivellaro S.², Rochat C.H.³, Schwentner C.⁴, Wagner C.⁵, Hirtsiefer C.⁶, Heinzlbecker J.⁷, Yilmaz E.⁷, Franz T.⁸, Stolzenburg J.U.⁸, Saar M.⁹, Kranz J.⁹, Umari P.¹⁰, Rocco B.¹¹, Grosso A.A.¹², Porphiglia F.¹³, Pinar U.¹⁴, Denaeyer G.¹⁵, Ayllón H.¹⁶, Uvin P.¹⁷, Eriksson M.¹⁸, John H.¹

Institutions

¹Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland, ²University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America, ³Clinic Générale- Beaulieu, Dept. of Urology, Geneva, Switzerland, ⁴Diakonieklinik Stuttgart, Dept. of Urology, Stuttgart, Germany, ⁵St. Antonius- Hospital, Dept. of Urology, Gronau, Germany, ⁶Universitätsklinik Carl Gustav Carus, Dept. of Urology, Dresden, Germany, ⁷Saarland University Medical Center and Saarland University, Dept. of Urology, Homburg, Germany, ⁸University of Leipzig, Dept. of Urology, Leipzig, Germany, ⁹University Medical Center RWTH, Dept. of Urology and Pediatric Urology, Aachen, Germany, ¹⁰St. George's University Hospital, Dept. of Urology, London, United Kingdom, ¹¹Gemelli Hospital, Dept. of Urology, Rome, Italy, ¹²Careggi Hospital, University of Florence, Unit of Urology and Andrology, Florence, Italy, ¹³Università di Torino, Dept. of Urology, Turin, Italy, ¹⁴Hôpital la Pitié-Salpêtrière, Dept. of Urology, Paris, France, ¹⁵Onze Lieve Vrouw Clinic, Dept. of Urology, Gent, Belgium, ¹⁶Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain, ¹⁷AZ Sint-Jan, Dept. of Urology, Bruges, Belgium, ¹⁸Danderyd Hospital, Dept. of Urology, Stockholm, Sweden

Study Group

ERUS Scientific Reconstructive Working Group(Winterthur, Switzerland)

A0359

Comparative Analysis of Functional and Perioperative Outcomes Among HoLEP, RASP, and Aquablation: A Multicenter triple Matched-Pair Study

Authors

Russo G.I.¹, Asmundo M.G.R.², Salvaggio A.², Lo Re M.³, Anceschi U.⁴, Justo-Quintas J.⁵, García-Rojo E.⁵, Romero-Otero J.⁵, Mancini M.C.⁶, Patruno G.⁶, Cocci A.³

Institutions

¹University of Catania, Dept. of Urology, Catania, Italy, ²Humanitas, Istituto Clinico Catanese, Dept. of Urology, Catania, Italy, ³University of Florence, Dept. of Urology, Florence, Italy, ⁴IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁵ROC Clinic HM Hospitales, Dept. of Urology, Madrid, Spain, ⁶AO San Giovanni Addolorata, Dept. of Urology, Catania, Italy

A0360

The SPRAMHO trial: single-port robot-assisted madigan resection of the prostate versus holmium laser enucleation of the prostate for large-volume(≥80 mL) benign prostatic hyperplasia – A randomized controlled study with a 1-year follow-up

Authors

Chen Y.B., Xu H., Gu M., Chen Q., Xu B.

Institutions

Shanghai Ninth People's Hospital Shanghai JiaoTong University School of Medicine, Dept. of Urology, Shanghai, China

A0361

Functional outcomes and safety profile of Thulium:YAG laser enucleation (ThuLEP) versus robot-assisted simple prostatectomy (RASP) facing very large (≥ 150 ml) prostates

Authors

Perri D.¹, Pini G.¹, Besana U.¹, Calcagnile T.¹, Pacchetti A.¹, Maltagliati M.¹, Ferrari I.¹, Haxho S.¹, Menozzi M.¹, Maruccia S.¹, Romero Otero J.², Roche J.B.³, Bozzini G.¹

Institutions

¹ASST Lariana Sant'Anna Hospital, Dept. of Urology, Como, Italy, ²ROC Clinic and HM Hospitales, Dept. of Urology, Madrid, Spain, ³Clinique Saint Augustin, Dept. of Urology, Bordeaux, France

A0362

Same-Day Discharge Following Multiport Robot-Assisted Simple Prostatectomy: A Prospective Feasibility Study of Outcomes, Costs, and Post-Discharge Healthcare Utilization

Authors

Khanmammadova N., Wang J., Afyouni A., Hanna K., Gao A., Vu J., Tran K., Myklak K., Fung C., Nguyen C., Shahait M., Lee D.

Institutions

University of California Irvine, Dept. of Urology, Irvine, United States of America

Localised renal tumour treatment: Technology at its best!

Abstract Session 20

Saturday 14 March
15:30 - 17:00

Location

Blue Area, George 3

Chairs

D. Amparore, Orbassano (Turin) (IT)
I. Gkialas, Athens (GR)
S. Psutka, Seattle (US)

15:30 - 15:55

3D model & augmented reality

A0327

The Impact of 3D Reconstruction in Preoperative Planning for Partial Nephrectomy: A Prospective Study

Authors

Nuthalapati M., Medam M.R., Pooleri G.K.

Institutions

Amrita Institute of Medical Sciences, Dept. of Uro-Oncology, Kochi, India

Development of Biomimetic 3D-Printed Models for Training in Robot-Assisted Partial Nephrectomy: Toward Realistic Surgical Simulation of the Human Kidney

Authors

Margue G.L.¹, Courtine C.², Lacroix G.², Tamer M.³, Pattou M.¹, Rubat Baleuri F.¹, Pitout A.¹, Jaffredo M.¹, Sarrazin J.⁴, Faessel M.⁴, Sabatier J.⁵, Leng J.³, Mondain-Monval O.², Bernhard J.C.¹

Institutions

¹Bordeaux University Hospital, Dept. of urology, Bordeaux, France, ²University of Bordeaux, Centre de Recherche Paul Pascal, Bordeaux, France, ³University of Bordeaux, Laboratory of the Future, Bordeaux, France, ⁴Bordeaux Institute of Technology, Fablab Technoshop - Coh@bit, Bordeaux, France, ⁵Bordeaux University, IMS Laboratory, UMR 5218 CNRS, Bordeaux, France

3D perfusion zone models allow for more accurate and more frequent selective arterial clamping during robot-assisted partial nephrectomy: interim results of the multicentric PODRACING randomized controlled trial

Authors

Vangeneugden J.¹, Vermijs S.², De Backer P.³, De Kuyper P.⁴, Berquin C.¹, Lumen N.¹, Baekelandt F.⁵, Ghysel C.⁵, Raskin Y.⁶, Bynens B.⁶, Mestdagh K.¹, De Visschere P.⁷, Debbaut C.², Decaestecker K.⁴, Van Praet C.¹

Institutions

¹Ghent University Hospital ERN eUROGEN accredited centre, Dept. of Urology, Ghent, Belgium, ²Ghent University IBiTech-BioMMeda, Dept. of Electronics and Information Systems, Ghent, Belgium, ³AZORG, Dept. of Urology, Aalst, Belgium, ⁴AZ Maria Middelaes, Dept. of Urology, Ghent, Belgium, ⁵AZ Sint-Jan Brugge, Dept. of Urology, Bruges, Belgium, ⁶Ziekenhuis Oost-Limburg (ZOL) Genk, Dept. of Urology, Genk, Belgium, ⁷Ghent University Hospital ERN eUROGEN accredited centre, Dept. of Radiology and Nuclear Medicine, Ghent, Belgium

Three-Dimensional Image-Guided Robot-Assisted Partial Nephrectomy in Ischemia-Sensitive Patients: Surgical and Functional Outcomes from a Large Cohort with Propensity Score Matching (IRC-3D-IGRAPN - UroCCR 238).

Authors

Pattou M.¹, Rubat Baleuri F.¹, Schurdi-Levraud L.², Pitout A.², Herman G.¹, Geshkovska A.¹, Jaffredo M.¹, Ricard S.¹, Bensalah K.³, Ricolleau C.⁴, Michel C.⁵, Fontenil A.⁶, Bigot P.⁷, Sarrazin C.⁸, Beauval J.B.⁹, Panthier F.¹⁰, Patard J.J.¹¹, Champy C.¹², Bruyère F.¹³, Fantoni J.C.¹⁴, Belas O.¹⁵, Margue G.², Bernhard J.C.²

Institutions

¹Care Integrated research and innovation program for kidney cancer, Dept. of Urology, Bordeaux, France, ²Bordeaux teaching hospital, Dept. of Urology, Bordeaux, France, ³Rennes Teaching Hospital, Dept. of Urology, Rennes, France, ⁴Poitiers Teaching Hospital, Dept. of Urology, Poitiers, France, ⁵Hopital Saint Joseph, Dept. of Urology, Paris, France, ⁶Nimes Teaching Hospital, Dept. of Urology, Nimes, France, ⁷Angers Teaching hospital, Dept. of Urology, Angers, France, ⁸Grenoble Teaching Hospital, Dept. of Urology, Grenoble, France, ⁹Clinique La Croix du Sud, Dept. of Urology, Toulouse, France, ¹⁰Tenon Hospital, Dept. of Urology, Paris, France, ¹¹CHI Mont de Marsan, Dept. of Urology, Mont de Marsan, France, ¹²Henri-Mondor Hospital, Dept. of Urology, Créteil, France, ¹³Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland, ¹⁴Lille Teaching hospital, Dept. of Urology, Lille, France, ¹⁵Pôle Santé Sud le Mans, Dept. of Urology, Le Mans, France

A0331

Stereoscopic Registration Improves 3D Model Overlay Precision in RAPN with Augmented Reality Compared to Monocular Registration.

Authors

Pattou M.¹, Rubat-Baleuri F.¹, Margue G.², Nguyen G.³, Pitout A.¹, Bourdel N.³, Bernhard J.C.², Bartoli A.⁴

Institutions

¹Care Integrated research and innovation program for kidney cancer, Dept. of Urology, Bordeaux, France, ²Bordeaux Teaching hospital, Dept. of Urology, Bordeaux, France, ³Surgar, Surgical Augmented Reality, Clermont-Ferrand, France, ⁴Institut Pascal, UMR6602, Clermont-Ferrand, France

15:55 - 16:25

AI

A0332

Head-to-Head Challenge: AI Versus the operating surgeon in Real-Time Anatomy Recognition during Single Port Retroperitoneal Surgery

Authors

Tamborino F.¹, Turcan A.², Carletti F.³, Morgantini L.A.⁴, Valenzi F.M.⁵, Cruciani L.⁶, Santarelli V.⁵, Haberal B.⁴, Alkassis M.⁴, Calzolari Lettieri A.⁷, Schiavina L.⁸, Schips L.⁹, Crivellaro S.⁴

Institutions

¹Università G. D'Annunzio, Dept. of Oral and Medical Sciences - Urology, Chieti, Italy, ²University of Turin, Dept. of Urology, Turin, Italy, ³University of Padua, Dept. of Urology, Padua, Italy, ⁴University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America, ⁵Sapienza University of Rome, Dept. of Urology, Rome, Italy, ⁶Politecnico Milano, Dept. of Electronics, Information and Bioengineering, Milan, Italy, ⁷Humanitas University, Dept. of Medicine, Milan, Italy, ⁸Charles University, Dept. of Medicine, Prague, Czech Republic, ⁹UniCamillus, Dept. of Urology, Rome, Italy

A0333

Application of Real-time Digital Twin Navigation and Warning System Based on Deep Learning and Augmented Reality Technology Platform (AI+AR) in Robot-assisted and Laparoscopic Partial Nephrectomy (NCT07020169)

Authors

Zhang S., Miao C., Zhao R., Yang C., Shao P., Li J.

Institutions

The First Affiliated Hospital With Nanjing Medical University, Dept. of Urology, Nanjing, China

A0334

Artificial intelligence-driven three-dimensional reconstruction and surgical planning optimization for "fan-shaped pre-suturing zero-ischemia resection" in the treatment of renal tumors

Authors

Zhao Z.¹, You Y.², Wang L.², Wang S.², Li Z.², Liu C.², Liu M.², Yu N.¹

Institutions

¹Qilu Hospital of Shandong University, Dept. of Urology, Jinan, China, ²Shandong University, First Clinical Medical College, Jinan, China

A0335

SRE-RAPN50: A Multi-Task Dataset for Instrument–Anatomy Segmentation, Articulation Prediction, Surgical Action Recognition and Motion Estimation in Robot-Assisted Partial Nephrectomy

Authors

Li S., Jia T., Ma X., Zhang X., [Tailai Z.](#)

Institutions

Chinese PLA General Hospital, Dept. of Urology, Beijing, China

A0336

From Image to Insight: Radiomics Accuracy in Predicting Renal Malignancy

Authors

[Silva P.](#), Campos Pinheiro L., Severo L., Gil M., Cunha J.

Institutions

Central Lisbon University Hospital Centre, Dept. of Urology, Lisbon, Portugal

A0337

Workflow analysis with computer-vision algorithm to extract information from DaVinci head-up-display: A Proof-of-Concept study using RAPN video data

Authors

[Carl N.](#)¹, Bogaert W.², Simoens J.², Prata F.³, Kowalewski K.F.¹, Mottrie A.², De Backer P.²

Institutions

¹University Medical Centre Mannheim University of Heidelberg, Dept. of Urology, Mannheim, Germany, ²ORSI Academy, Innotech, Melle, Belgium, ³Fondazione Policlinico Universitario Campus Bio-Medico, Dept. of Urology, Rome, Italy

16:25 - 16:45

New robots on the block

A0338

Revo-i versus Da Vinci for Robot-Assisted Partial Nephrectomy: First Clinical Comparison in Human Patients

Authors

Heo J.E., [Park C.R.](#), Lee J.H., Kang K., Han H.H., Jang W.S., Han W.K., Choi Y.D., Lee J.

Institutions

Severance Hospital Urological Science Institute Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea

A0339

Outcomes of Single-Port Urologic Procedures Using Low Anterior Access: Outcomes of Single-Port Urologic Procedures Using Low Anterior Access: A Retrospective Multicenter Study

Authors

[Valenzi F.M.](#)¹, Biasatti A.², Tamborino F.³, Turcan A.⁴, Carletti F.⁵, Santarelli V.⁶, Pastore A.L.¹, Carbone A.¹, Sciarra A.⁶, Dal Moro F.⁵, Liguori G.², Porpiglia F.⁴, Autorino R.⁷, Crivellaro S.⁸

Institutions

¹Sapienza University of Rome, Dept. of Medico-Surgical Sciences and Biotechnologies, Latina, Italy, ²University of Trieste, Dept. of Medicine, Surgery and Health Sciences, Trieste, Italy, ³Università degli Studi "G. d'Annunzio" of Chieti, Dept. of Medical Oral and Biotechnological Science, Chieti, Italy, ⁴University of Turin, San Luigi Gonzaga Hospital, Dept. of Oncology, Division of Urology, Orbassano, Italy, ⁵University of Padova, Dept. of Surgery, Oncology and Gastroenterology, Padova, Italy, ⁶Sapienza University of Rome, Dept. of Maternal-Infant and Urological Sciences, Rome, Italy, ⁷Cleveland Clinic, Glickman Urological & Kidney Institute, Cleveland, United States of America, ⁸University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America

Evaluating the learning curve of single-port partial nephrectomy: a multi-institutional cohort analysis**Authors**

Santangelo A.¹, Silvani C.¹, Stephens A.², Considine J.¹, Gishto R.¹, Tinsley S.¹, Aljoulani M.³, Valenzi F.M.³, Vourganti S.⁴, Autorino R.⁵, Crivellaro S.³, Nelson R.J.⁶, Catanzaro M.⁷, Nicolai N.⁷, Montanari E.⁸, Salonia A.⁹, Montorsi F.⁹, Briganti A.⁹, Rogers C.¹, Abdollah F.¹

Institutions

¹VUI Center for Outcomes Research Analysis and Evaluation Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ³University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America, ⁴Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ⁵Glickman Urological Institute, Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ⁶Michigan Institute of Urology, Dept. of Urology, Detroit, United States of America, ⁷Fondazione IRCCS Istituto Nazionale dei Tumori, Unit of Urology, Milan, Italy, ⁸Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ⁹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy

Initial Experience with Single-Port Robot-Assisted Partial Nephrectomy Using the Low Anterior Access Technique: Feasibility, Perioperative Outcomes and Learning Curve Analysis in a SP-naive Robotic Referral Center**Authors**

Van Eecke H.¹, Grammens J.¹, De Kuyper P.¹, Verla W.¹, Ameye F.¹, Crivellaro S.², Decaestecker K.¹

Institutions

¹AZ Maria Middelaers, Dept. of Urology, Ghent, Belgium, ²University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America

A0342

5-Year Outcomes of Stereotactic Radiotherapy for Primary Renal Cell Carcinoma from the Pooled Analysis of the FASTRACK Trials

Authors

Siva S.¹, Ali M.¹, Hardcastle N.¹, Kron T.¹, Higgs B.², Foroudi F.³, Ruben J.⁴, Appu S.⁵, Martin J.⁶, Sridharan S.⁶, Montgomery R.⁷, Davey R.⁷, Lin C.⁸, Shaw M.¹, Sidhom M.⁹, Vanneste B.G.L.¹⁰, Murphy D.¹¹, Lawrentschuk N.¹¹, Pryor D.¹², Wood S.¹², Bressel M.¹³, Moon D.¹⁴

Institutions

¹Peter MacCallum Cancer Centre, Dept. of Radiation Oncology, Melbourne, Australia, ²Royal Adelaide Hospital, Dept. of Radiation Oncology, Adelaide, Australia, ³Olivia Newton-John Cancer Centre, Dept. of Radiation Oncology, Heidelberg, Australia, ⁴Alfred Health, Dept. of Radiation Oncology, Melbourne, Australia, ⁵Cabrini Research Division, Dept. of Urology, Melbourne, Australia, ⁶Calvary Mater Newcastle, Dept. of Radiation Oncology, Waratah, Australia, ⁷TransTasman Radiation Oncology Group (TROG) Cancer Research, Dept. of Research Development, Newcastle, Australia, ⁸Royal Brisbane and Women's Hospital, Dept. of Radiation Oncology, Brisbane, Australia, ⁹University of New South Wales, South West Sydney Clinical School, Sydney, Australia, ¹⁰Ghent University Hospital, Dept. of Radiation Oncology, Ghent, Belgium, ¹¹Peter MacCallum Cancer Centre, Division of Cancer Surgery, Melbourne, Australia, ¹²Princess Alexandra Hospital, Dept. of Urology and Radiation Oncology, Woolloongabba, Australia, ¹³Peter MacCallum Cancer Centre, Dept. of Biostatistics and Clinical Trials, Melbourne, Australia, ¹⁴University of Melbourne, Royal Melbourne Clinical School, Melbourne, Australia

A0343

Spatial and functional analysis of PSMA-positive tumor vessels as predictors of recurrence and potential therapeutic targets in renal cell carcinoma

Authors

Watanabe R.¹, Shishido K.¹, Nobumori S.¹, Sugihara N.¹, Nishida K.¹, Arai H.¹, Sawada T.¹, Haga S.¹, Arai O.¹, Onishi T.¹, Nishimura K.¹, Fukumoto T.¹, Miura N.¹, Kurata M.², Kitazawa R.³, Miyauchi Y.¹, Kikugawa T.¹, Saika T.¹

Institutions

¹Ehime University Hospital, Dept. of Urology, Toon, Japan, ²Ehime University Graduate School of Medicine, Dept. of Analytical Pathology, Toon, Japan, ³Ehime University Hospital, Division of Diagnostic Pathology, Toon, Japan

A0344

Iridium Photosensitizers Drive Pyroptosis–Necroptosis Synergy for Multi-Network Photoimmunotherapy of Renal Cell Carcinoma

Authors

Qin X., Wang Y., Wang Q., Yu N.

Institutions

Qilu Hospital of Shandong University, Dept. of Urology, Jinan, China

Saturday 14 March
15:30 - 17:00

Location Blue Area, Victoria 4
Chairs M. Eckstein, Erlangen (DE)
To be confirmed
T. Strandgaard, Aarhus (DK)

15:30 - 15:50

Urothelial cancer

[A0381](#)

Intratumoral Microbiome Programs the Immune Microenvironment and Predicts Response to Intravesical BCG in NMIBC

Authors

[Cheng B.](#), Wu P.

Institutions

Nanfeng hospital Southern Medical University, Dept. of Urology, Guangzhou, China

[A0382](#)

SLBP-mediated remodeling of the immunosuppressive microenvironment as a potential therapeutic target: Insights from multi-omics analyses

Authors

[Zhang Q.](#), Yang Z.Y., Zhang X.K., Cheng J.H., Feng D., Chen J.Q., Huang T.X., Gu D.

Institutions

The First Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangzhou, China

[A0383](#)

Entinostat Overcomes Cisplatin Resistance in Bladder Cancer by Promoting H3K18la-Mediated DHRS2 Expression to Suppress the AKR1C3-Androgen Axis

Authors

[Xu G.](#), Zheng M., Wu Z., Guo H., Zhuang J.

Institutions

Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China

[A0384](#)

TGF- β inhibition upregulates Nectin-4 surface expression and enhances Enfortumab Vedotin efficacy in urothelial carcinoma

Authors

[Heslich A.](#)¹, Below E.¹, Tan E.¹, Alajati A.², Ritter M.², Toma M.³, Eckstein M.⁴, Klümper N.², Hölzel M.¹

Institutions

¹University Medical Center Bonn, Institute of Experimental Oncology, Bonn, Germany,

²University Medical Center Bonn, Dept. of Urology and Pediatric Urology, Bonn,

Germany, ³University Medical Center Bonn, Insitute of Pathology, Bonn, Germany,

⁴University Hospital Erlangen, Institute of Pathology, Erlangen, Germany

15:50 - 16:30

Renal cancer

A0385

Integrative Deep Learning of Histopathology and Immune Microenvironment for Predicting Prognosis and Treatment Response in Renal Cell Carcinoma

Authors

Hou N., Zheng J.

Institutions

Renji hospital, Dept. of Urology, Shanghai, China

A0386

Transcriptomic Subtyping of Metastases in Renal Cell Carcinoma Reveals Distinct Tissue-Specific Molecular Niches with Differential Immunotherapy Response: Moving Beyond One-Size-Fits-All Molecular Tumor Classifications

Authors

Kalogirou C.¹, Eckstein M.²

Institutions

¹University Hospital of Würzburg, Dept. of Urology and Pediatric Urology, Würzburg, Germany, ²University Hospital of Erlangen, Institute of Pathology, Erlangen, Germany

A0387

Genomic alterations in geriatric renal cell carcinoma

Authors

Shirzadi S.¹, Riazalhosseini Y.², Tanguay S.³, Rompré-Brodeur A.³

Institutions

¹McGill University, Dept. of Surgical and Interventional Sciences, Montréal, Canada, ²McGill University, Dept. of Genetics, Montréal, Canada, ³McGill University, Dept. of Urology, Montréal, Canada

A0388

Integrative Multi-omics Analysis for Prioritizing Prognostic lncRNAs Biomarker in Papillary Renal Cell Carcinoma

Authors

Wei C.¹, Yu Q.², Li Z.³, Xie J.⁴, Qiu S.¹

Institutions

¹West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China, ²West China Hospital of Sichuan University, Dept. of Otolaryngology - Head & Neck Surgery, Chengdu, China, ³The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Dept. of Oncology, Qingyuan, China, ⁴The Sixth Affiliated Hospital of Jinan University, Dept. of Urology, Dongguan, China

A0389

High-Throughput Screening of a Human Endogenous Metabolite Library Identifies Vitamin K4 as a Novel Therapeutic Candidate for Attenuating Renal Ischemia-Reperfusion Injury"

Authors

Li B.¹, Chen J.¹, Song Q.², Chen J.¹, Chen X.¹, Longfei L.¹, He Y.¹, Gan Y.¹, Li M.¹, Xu X.¹, Huang J.¹, Cheng K.¹

Institutions

¹Xiangya Hospital Central South University, Dept. of Urology, Changsha, China, ²Changhai Hospital, Dept. of Urology, Shanghai, China

A0390

BIRC3 promotes proliferation of kidney cancer by regulating IFN signaling

Authors

Liu W., Yu S., Wang Z., Zhang S.

Institutions

Peking University Third Hospital, Dept. of Urology, Beijing, China

A0391

Divergent Evolution in Hereditary VHL-Associated and Sporadic Clear Cell Renal Cell Carcinoma

Authors

Zhang Z., Wang Y., Gong K.

Institutions

Peking University First Hospital, Dept. of Urology, Beijing, China

A0392

Loss-of-function genetic screening identifies IL1RAP as an essential driver for RCC progression under hypoxia

Authors

Zhehao X.¹, Min X.²

Institutions

¹Sir Run Run Shaw Hospital, Dept. of Urology, Hangzhou, China, ²Jinhua Municipal Central Hospital, Dept. of Urology, Jinhua, China

16:30 - 16:55

Prostate cancer

A0393

Subtypes and Treatment Strategies of non-pCR High-Risk /Locally Advanced Prostate Cancer Post-Neoadjuvant Hormonal Therapy

Authors

Tang G.¹, Gao X.², Liu J.³, Chen M.⁴, Wang L.¹, Yuan K.⁵, Qi L.⁴, Fang P.⁶, Cai Y.⁴

Institutions

¹The Third Xiangya Hospital Central South University, Dept. of Urology, Changsha, China, ²Xiangya Hospital Central South University, Dept. of Pathology, Changsha, China, ³Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University, Dept. of PET/CT Center, Changsha, China, ⁴Xiangya Hospital Central South University, Dept. of Urology, Changsha, China, ⁵Xiangya Hospital Central South University, Hunan Key Laboratory of Molecular Precision Medicine, Changsha, China, ⁶Chinese Academy of Sciences, Shanghai Institute of Organic Chemistry, Changsha, China

A0394

Molecular Evolution and Resistance Mechanisms after Lu-177-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer

Authors

Pe Benito R.¹, Mohammed S.², Nathasingh B.¹, Jairam S.¹, Gordon S.³, Kong E.³, Chandwani S.¹

Institutions

¹ConcertAI, LLC, Cambridge, United States of America, ²ConcertAI, LLC, Bengaluru, India, ³Guardant Health, Palo Alto, United States of America

A0395

Epigenetic Profiling Reveals Divergent Methylation Landscapes in MRI-Targeted and Systematic Biopsy Prostate Cancer

Authors

Bandini M.¹, Barletta F.M.¹, Zaurito P.¹, Cirulli G.O.¹, De Cobelli F.², Esposito A.², Brembilla G.², Lucianò R.³, Tenace N.³, Scarfò F.³, Colecchia M.³, Ponzoni M.³, Doglioni C.³, Tascini A.S.⁴, Genova F.⁴, Giannese F.⁴, Oneto C.⁴, Morelli M.⁴, Scotti G.M.⁴, Lazarevic D.⁵, Tonon G.⁵, Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy, ⁴Center for Omics Sciences, IRCCS San Raffaele Scientific Institute-Vita-Salute San Raffaele University, Dept. of Genomics, Milan, Italy, ⁵Center for Translational Genomics and Bioinformatics (CTGB), IRCCS Ospedale San Raffaele, Dept. of Genomics, Milan, Italy

A0396

Tumour cell evolution within patient-derived models of localised hereditary prostate cancer

Authors

Bristow R.G.¹, Lyons S.², Scaramuzza S.², Pirhady P.¹, Rebello R.J.³, Goel N.¹, Trivedi U.¹, Palhares L.¹, Risbridger G.⁴, Taylor R.⁴, Rogan J.⁵, Hudson A.⁶, Sanchez D.², Oates J.⁷, Lau M.⁷, Ramani V.⁷, Hart C.¹, Oliveira P.⁵, Thorne H.⁸, Clarke N.⁶, Woodward E.¹, Lawrence M.⁴, Wedge D.C.¹, Sachdeva A.⁶

Institutions

¹University of Manchester, Division of Cancer Sciences, FMBH, Manchester, United Kingdom, ²University of Manchester, CRUK Manchester Institute - Translational Oncogenomics, Manchester, United Kingdom, ³University of Melbourne, Collaborative Centre for Genomic Cancer Medicine, Melbourne, Australia, ⁴Monash University, Monash Biomedicine Discovery Institute, Melbourne, Australia, ⁵University of Manchester, Manchester Cancer Research Centre, Manchester, United Kingdom, ⁶University of Manchester, Genito Urinary Cancer Research Group, Manchester, United Kingdom, ⁷The Christie Hospital NHS Trust, Dept. of Surgery, Manchester, United Kingdom, ⁸Peter McCallum Cancer Centre, Dept. of Oncology, Melbourne, Australia

A0397

CGRP-RAMP1 signaling axis mediates sensory nerve-cancer bidirectional interaction and immune suppression to drive prostate cancer progression

Authors

Zhuo T.¹, Huang H.²

Institutions

¹The Fifth Affiliated Hospital of Xinjiang Medical University, Dept. of Urinary Surgery, Urumqi, China, ²Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Dept. of Urinary Surgery, Guangzhou, China

16:55 - 17:00

Penile cancer

Authors

Li Z.¹, Li X.², Chen B.³, Zuo Z.⁴, Guo Y.¹, Huang G.¹, Peng X.¹, Zhang X.¹, Chen Z.¹, Han H.⁵

Institutions

¹Shenzhen People's Hospital, Dept. of Urology, Shenzhen, China, ²The Seventh Affiliated Hospital Sun Yat-sen University, Dept. of Oncology, Shenzhen, China, ³Sir Y.K. Pao Cancer Center, Prince of Wales Hospital, Dept. of Anatomical and Cellular Patholog Oncology, Hong Kong, Hong Kong, ⁴Guangzhou University of Chinese Medicine, Clinical Medicine, Guangzhou, China, ⁵Sun Yat-sen University Cancer Center, Dept. of Urology, Guangzhou, China

Urogenital reconstruction: Female continence surgery, fistula repair and robotic pelvic restoration

Video Session 08

Saturday 14 March
15:30 - 17:00

Location

Blue Area, Victoria 1

Chairs

T.J. Greenwell, London (GB)

H. John, Winterthur (CH)

H. Veiby Holm, Oslo (NO)

V053 (□: 7 min.)

Modified technique of Robot assisted laparoscopic repair of vesicovaginal fistula

C. Mallikarjuna, Hyderabad (IN)

V054 (□: 6 min.)

Vesicovaginal fistula repair via vNOTES in a patient with a hostile abdomen.

C. García-Rayó, Madrid (ES)

V055 (□: 8 min.)

12 key steps to overcome difficulties in female artificial urinary sphincter implantation

A. Dubois, Rennes (FR)

V056 (□: 8 min.)

Single Port (SP) Robotic Sacrocolopexy and Hysterectomy: Tips and Tricks

L. Hoang Roberts, Cleveland (US)

V057 (□: 7 min.)

Could the 'Urachus-Based Peritoneal Hinge-Flap' be used for Bladder Augmentation? Illustrated Proposed Technique and a Fresh Cadaver-based Surgical Video

M. Garcia, Los angeles (US)

V058 (□: 3 min.)

Robot-assisted buccal mucosa graft ureteroplasty for ureteral stricture: a European multicenter case-series

A. Bourillon, Rennes (FR)

V059 (□: 8 min.)

Victo artificial urinary sphincter implantation and outcomes

R.B.M. Bali Moreira, Sao Paulo (BR)

Next-gen endourology: AR guidance, intelligent lasers and smarter stone solutions

Video Session 07

Saturday 14 March
15:30 - 17:00

Location Blue Area, George 1

Chairs To be confirmed
W. Krajewski, Wrocław (PL)
S. Kutchukian, Poitiers Cedex (FR)

V045 (□: 8 min.)

The Fast and the Frictionless: Capabilities of a 6.3Fr Single-Use Digital Flexible Ureteroscope

MU Uy, Ann Arbor (US)

V046 (□: 8 min.)

Clinical efficacy of the Automatic Tissue Recognition Function in a Super-pulsed Thulium Fiber Laser: A Multicenter Lithotripsy Study

A.G. Martov, Moscow (RU)

V047 (□: 4 min.)

Introducing Augmented Reality Retrograde IntraRenal Surgery (AR-RIRS): First Clinical Implementation of the Surgeree™ Platform

F. Cianflone, Pavia (IT)

V048 (□: 7 min.)

StoneMetricAI by Medannot - One click, real volume: smarter stone assessment starts here

C. Slots, Kortrijk (BE)

V049 (□: 4 min.)

Demonstration of a Simple and Cost-Effective Technique for Non-Cystoscopic Ureteral Stent Removal Using Suture Loop

H. Donaldson, Chicago (US)

V050 (□: 8 min.)

Suction sheath in retrograde intrarenal surgery: comparative analysis and five illustrative cases

J.J. Szczesniewski, Getafe (ES)

V051 (□: 7 min.)

Laser hits stone – first preliminary study on multi-physics simulation of the laser-stone interaction

G. Magistro, Hamburg (DE)

V052 (□: 5 min.)

A Feasibility Study on Clinical Utility and Efficacy of the Novel Vortex Intelligence Stone Optimized Removal (VISOR) System in Retrograde Intrarenal Surgery for Upper Urinary Tract Stones

B. Wang, Hangzhou (CN)

Saturday 14 March
15:30 - 17:00

Location Blue Area, Victoria 6

Chairs A. Bujons Tur, Barcelona (ES)
V. Tatanis, Patras (GR)

Learning objectives

This session aims to equip participants with a comprehensive understanding of how paediatric urological conditions evolve into adulthood and how best to manage their long-term consequences. Attendees will learn key principles for establishing effective transitional urology services, including the integration of patient-reported outcome measures to guide care during the transition period. The programme will deepen knowledge of lifelong sequelae associated with conditions such as posterior urethral valves and provide practical insights through case-based discussions on common transition challenges and safe, evidence-based solutions. Participants will also review current EAU/ESPU guideline recommendations and enhance their ability to manage adult complications of neurogenic bladder surgery, including stoma revisions, bladder stones, and issues related to sexuality and pregnancy. Overall, the session supports clinicians in delivering seamless, patient-centered care for individuals with paediatric-onset urological disorders as they move into adulthood

15:30 - 15:37

How to establish a transitional urology section?

G. De Win, Edegem (BE)

15:37 - 15:44

Patient reported outcome measures and how to use them during transition period?

L.A. 't Hoen, Rotterdam (NL)

15:44 - 15:51

PUV and lifelong consequences

J.S.L.T. Quaedackers, Groningen (NL)

15:51 - 16:01

ESPU Lecture - Long-term renal transplant outcomes in patients with end-stage renal disease secondary to bladder dysfunction in childhood

S. Tekgül, Ankara (TR)

16:01 - 16:04

Discussion with audience

16:04 - 16:21

Clinical Case Discussion Transition problems and safe solutions: Roundtable discussion based on clinical scenarios

Presenter M.I Dönmez, Istanbul (TR)

Discussants R.J.M. Lammers, Groningen (NL)

To be confirmed

To be confirmed

16:21 - 16:26

Summary of EAU/ESPU guidelines

To be confirmed

16:26 - 16:29

Discussion with audience

16:29 - 16:31

Managing long-term complications of neurogenic bladder surgery

Moderator

G. Bogaert, Leuven (BE)

16:29 - 16:31

Introduction

G. Bogaert, Leuven (BE)

16:31 - 16:38

Stoma revisions

T.M. Oktar, Istanbul (TR)

16:38 - 16:45

Bladder stones

G. Mosiello, Rome (IT)

16:45 - 16:52

Sexuality & pregnancy

M. Promm, Regensburg (DE)

16:52 - 16:55

Expert summary

G. Bogaert, Leuven (BE)

16:55 - 17:00

Discussion with audience

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 2.6

Saturday 14 March

15:30 - 16:20

Location

Red Area, Room 1

Tutors

To be confirmed

S.M. Haensel, Rotterdam (NL)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 2.6

Saturday 14 March
15:30 - 16:20

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed
A. Sierra Del Rio, Barcelona (ES)

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 2.6

Saturday 14 March
15:30 - 16:20

Location Red Area, Room 1

Tutors O. Stakhovskyi, Kyiv (UA)
L. Vendrell, Ciudad - Mendoza (AR)

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 2.6

Saturday 14 March
15:30 - 16:20

Location Red Area, Room 1

Tutors S. García Barreras, Madrid (ES)
To be confirmed

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 2.6

Saturday 14 March
15:30 - 16:20

Location Red Area, Room 1

Tutor S. Secco, Milan (IT)

Learning objectives

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

Hands-on Training in Kidney transplantation surgery

HOT KT - 3.1

Saturday 14 March
15:30 - 18:00

Location Red Area, Room 2

Chairs To be confirmed
M. Musquera Felip, Barcelona (ES)

Learning objectives

Kidney transplantation is the treatment of choice for patients with end-stage renal disease (ESRD), providing improved survival and quality of life compared to dialysis. The gold standard procedure for kidney transplantation is the open kidney transplant, which involves several intricate techniques, including vascular anastomoses and graft handling. This hands-on course is designed to introduce the fundamental skills and techniques necessary for performing open kidney transplants, focusing on graft preparation and vascular anastomosis.

15:30 - 15:35

Introduction

M. Musquera Felip, Barcelona (ES)

15:35 - 15:45

Lecture and explanation of procedure: Kidney graft bench surgery

15:45 - 16:30

Hands-on Training: Kidney graft bench surgery

Tutors

To be confirmed
J. Branchereau, Nantes (FR)
To be confirmed
B.R. Etcheverry Giadrosich, Barcelona (ES)
V. Gomez Dos Santos, Madrid (ES)
T. Prudhomme, Toulouse (FR)
To be confirmed

16:30 - 16:40

Lecture and explanation of procedure: Open kidney transplant

16:40 - 17:25

Hands-on Training: Open kidney transplant procedure

Tutors

To be confirmed
J. Branchereau, Nantes (FR)
To be confirmed
B.R. Etcheverry Giadrosich, Barcelona (ES)
V. Gomez Dos Santos, Madrid (ES)
T. Prudhomme, Toulouse (FR)
To be confirmed

17:25 - 17:55

Demonstration

17:55 - 18:00

Q&A and close

M. Musquera Felip, Barcelona (ES)

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 2.6

Saturday 14 March
15:30 - 16:20

Location	Red Area, Room 1
Tutors	G. Bozzini, Como (IT) I. Kartalas Goumas, Vigevano (IT) J.B. Roche, Bordeaux (FR)

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 2.6

Saturday 14 March
15:30 - 16:20

Location	Red Area, Room 1
Tutors	To be confirmed To be confirmed

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Saturday 14 March
15:30 - 17:00

Location Orange Area, EGPT 2

Chairs
B. Ali-El-Dein, Mansoura (EG)
R. Ben David, Tel Aviv (IL)
M. Moschini, Milan (IT)

15:30 - 16:00

Translational and liquid biospies in urothelial cancer

[P0539](#)

Mediator complex subunit 8 promotes bladder cancer progression via stearyl-coA desaturase

Authors

[Zhang H.](#), Mei H.

Institutions

The First Affiliated Hospital of Shenzhen University, Dept. of Urology, Shenzhen, China

[P0540](#)

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial

Authors

[Na Y.](#)¹, Xiaohao R.²

Institutions

¹The University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ²Ruijin Hospital, Shanghai jiaotong University School of Medicine, Dept. of Urology, Shanghai, China

[P0541](#)

RPL19-25aa Cryptic Peptide Derived from circRPL19 Enhances Antitumor Immunity by Optimizing HLA-TCR Presentation in Bladder Cancer

Authors

[Chen C.](#), Chen J.

Institutions

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Dept. of Urology, Guangzhou, China

Feasibility and interim results from the prospective international LS-URO study: urine tumor DNA-based screening for urothelial cancer in Lynch syndrome carriers (NCT06218433)

Authors

Nikkola J.¹, Ryyppö L.², Vuorinen J.², Bacon J.³, Pham J.³, Singh S.⁴, Zheng C.⁴, Selin H.², Deneault L.³, Martikainen P.², Bernales C.³, Koudjanian M.³, Pylvänäinen K.⁵, Nykter M.², Veitonmäki T.¹, Mecklin J.P.⁵, Wyatt A.³, Schrader K.⁴, Seppälä T.T.⁶, Black P.³, Vandekerkhove G.³, Annala M.²

Institutions

¹Tampere University Hospital, Dept. of Urology, Tampere, Finland, ²Tampere University and Tays Cancer Centre, Faculty of Medicine and Health Technology, Tampere, Finland, ³University of British Columbia, Vancouver Prostate Centre, Dept. of Urologic Sciences, Vancouver, Canada, ⁴University of British Columbia, British Columbia Cancer Agency, Hereditary Cancer Program, Dept. of Medical Genetics, Vancouver, Canada, ⁵The Wellbeing Services County of Central Finland, Dept. of Education and Research, Jyväskylä, Finland, ⁶Tampere University Hospital, Dept. of Gastroenterology and Alimentary Tract Surgery, Tampere, Finland

Improving long-term monitoring in NMIBC: digital Uromonitor® as a complementary tool to cystoscopy for predicting two-year recurrence (EVALUATION-CUETO study)

Authors

Rubio Briones J.¹, Guerrero Ramos F.², Mercadé Sánchez A.³, Bezana Abadía I.⁴, Martín Rodríguez R.², Alcaraz A.³, Miqueleiz Legaz M.⁴, Lozano F.⁵, Arrabal Martín M.⁶, Luis Cardo A.⁷, Gonzalo Rodríguez V.⁸, Cano Velasco J.⁹, Serrano Liesa M.¹⁰, Ferreiro Pareja C.¹¹, Espílez Ortiz R.¹², González-Valcárcel de Torres I.¹³, Sánchez Zalabardo D.¹⁴, Guijarro A.¹⁵, Mengual L.¹⁶, Borque-Fernando A.¹², Esteban Escano L.M.¹⁷, Palou Redorta J.¹⁸, Witjes F.¹⁹, Martínez Pineiro L.¹⁰

Institutions

¹Hospital VITHAS 9 de Octubre, Dept. of Urology, Valencia, Spain, ²Hospital 12 de Octubre, Dept. of Urology, Madrid, Spain, ³Hospital Clínic, Dept. of Urology, Barcelona, Spain, ⁴Complejo Hospitalario de Navarra, Dept. of Urology, Pamplona, Spain, ⁵Hospital Universitario Valle Hebrón, Dept. of Urology, Barcelona, Spain, ⁶Hospital Universitario San Cecilio, Dept. of Urology, Granada, Spain, ⁷Complejo Hospitalario de Toledo, Dept. of Urology, Toledo, Spain, ⁸Complejo Asistencial Universitario de Burgos, Dept. of Urology, Burgos, Spain, ⁹Hospital General Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain, ¹⁰Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain, ¹¹Hospital Universitari Bellvitge, Dept. of Urology, Barcelona, Spain, ¹²Hospital Universitario Miguel Servet, Dept. of Urology, IIS-Aragón, Zaragoza, Spain, ¹³Hospital Universitario Infanta Sofía, Dept. of Urology, Madrid, Spain, ¹⁴Clínica Universitaria de Navarra, Dept. of Urology, Pamplona, Spain, ¹⁵Hospital Universitario Fundación Alcorcón, Dept. of Urology, Madrid, Spain, ¹⁶Hospital Clínic, Dept. of Genetics, University of Barcelona, Barcelona, Spain, ¹⁷Escuela Universitaria Politécnica de la Almunia, Dept. of Applied Mathematics, Almunia de Doña Godina, Spain, ¹⁸Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ¹⁹University of Nijmegen, Dept. of Urology, Nijmegen, The Netherlands

Study Group

EVALUATION CUETO investigators (Valencia, Spain)

P0544

Impact of the BCG shortage on the treatment and survival of high-grade non-muscle-invasive bladder cancer (NMIBC): 3 years results from Northern France general cancer registries (SHORT Study).

Authors

[Saint F.](#)¹, Maraud E.², Demarest V.², Ganry O.³, Marcq G.⁴, Tesson J.R.⁵, Leroy X.⁶, Bonnal J.L.⁴, Lapotre Ledoux B.N.D.³, Plouvier S.²

Institutions

¹CHU Amiens Picardie, Dept. of Urology and Transplantation, Amiens, France, ²CHU Lille, General Cancer Register (GCR), Lille, France, ³CHU Amiens Picardie, Dept. of Public Health and General Cancer Register de la Somme, Amiens, France, ⁴CHU Lille, Dept. of Urology, Lille, France, ⁵CHU Amiens Picardie, Dept. of Pathology, Amiens, France, ⁶CHU Lille, Dept. of Pathology, Lille, France

16:00 - 16:20

Staging and prognosis of muscle-invasive bladder cancer

P0545

Predictive Value of Immunohistochemistry-Based Molecular Subtyping for Neoadjuvant Therapy Sensitivity

Authors

[Yang X.](#), Lyu Q., Cao Q., Chen Y.

Institutions

The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

P0546

Predicting prognosis of muscle-invasive bladder cancer patients using an artificial intelligence deep learning model

Authors

Jin D., [Zhang R.](#), Wu Y., Chen H.

Institutions

Ren Ji Hospital School of Medicine Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China

P0547

Integrative Molecular–Radiopathomic Characterization of AIRE-Driven Immune Subtypes in Bladder Cancer

Authors

[Liu J.](#)

Institutions

Shanghai Tenth People's Hospital, Dept. of Urology, Shanghai, China

P0548

Awareness of genetic risk of Bladder Cancer associated to germline variants in DNA-repair genes (gDRGs) in Caucasian ancestry families

Authors

Lughezzani G., [Tiscione M.](#), Trovato R., Garofano G., Finocchiaro A., Piccolini A., Mallia V., Arena P., Fasulo V., Avolio P.P., Paciotti M., Casale P., Saita A., Hurle R., Buffi N.M., Lazzeri M.

Institutions

Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

16:20 - 16:45

Molecular targets of therapy response and resistance in muscle-invasive bladder cancer

P0549

A Multifunctional Patient-Derived Platform for Bladder Cancer: Assessing Chemotherapy Responses and CAR-T Efficacy in Personalized Settings

Authors

[Lu J.](#), Jie K., Liu C., Lin T., Chen X.

Institutions

Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China

P0550

Identification of novel therapeutic vulnerabilities in bladder cancer using patient-derived organoids

Authors

Tschan V.J.¹, Garioni M.¹, [Heuzeroth F.](#)¹, Wang J.¹, Roma L.², Elyan A.¹, Pueschel H.³, Vlajnic T.², Seifert H.H.³, Bubendorf L.², Rentsch C.A.³, Le Magnen C.¹

Institutions

¹University Hospital of Basel - University of Basel, Dept. of Urology, Dept. of Biomedicine, Institute of Pathology, Basel, Switzerland, ²University Hospital of Basel, Institute of Pathology, Basel, Switzerland, ³University Hospital of Basel, Dept. of Urology, Basel, Switzerland

P0551

In Vivo Generation of Multiplexed CAR-Immune Cells via Virus-Mimicking Extracellular Vesicles for Bladder Cancer Therapy

Authors

[Zhan H.](#), Pan B., Huang R., Lin T., Chen X.

Institutions

Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China

P0552

The CDK1/HIF-1 α Axis Drives Glycolysis-Dependent Progression of FGFR3-Mutant Bladder Cancer

Authors

[Ming J.](#), Zhu G., Yang K., Shi M., Niu Y.

Institutions

Beijing Friendship Hospital, Dept. of Urology, Beijing, China

P0553

TMEM11 promotes cisplatin resistance by inhibiting BNIP3-mediated mitophagy in bladder cancer

Authors

[Li E.](#), Huang Y., Tan W.

Institutions

Southern Medical University, Dept. of Urology, Guangzhou, China

16:45 - 17:00

Advanced urothelial cancer

P0554

Evaluation of the role of pelvic lymph node dissection in urachal carcinoma

Authors

[Pon Avudaiappan A.](#)¹, Prabhakar P.¹, Muina A.², Mahendra A.³, Raja Iyub M.J.¹, Ozambela Jr. M.¹, Manoharan M.¹

Institutions

¹Miami Cancer Institute, Dept. of Genitourinary Surgical Oncology, Miami, United States of America, ²St. George's University School of Medicine, Dept. of GU Surgical Oncology, Grenada, United States of America, ³University of Florida, Dept. of GU Oncology, Gainesville, United States of America

P0555

Metastatic non-muscle invasive bladder cancer: Insights on metastatic profile and survival outcomes from the National Cancer Database

Authors

Raja lyub M.J., Prabhakar P., Sakthivel D.K., Chandrasekaran A., Ozambela Jr M., Eldefrawy A.H., Manoharan M.

Institutions

Miami Cancer Institute, Dept. of Genitourinary Surgical Oncology, Miami, United States of America

P0556

Re-evaluating First-Line Treatments for Advanced Urothelial Carcinoma Using Restricted Mean Survival Time: A Systematic Review and Network Meta-analysis

Authors

Yajima S.¹, Yoshida S.², Chen W.², Okumura G.¹, Hirose K.¹, Sato H.³, Hirakawa A.³, Fujiwara M.⁴, Yamaguchi Y.², Matsumoto S.², Tanabe K.², Kobayashi M.², Fukushima H.², Yasuda Y.², Waseda Y.², Tanaka H.², Fujii Y.², Masuda H.¹

Institutions

¹National Cancer Center Hospital East, Dept. of Urology, Kashiwa, Japan, ²Institute of Science Tokyo, Dept. of Urology, Yushima, Japan, ³Institute of Science Tokyo, Dept. of Clinical Biostatistics, Yushima, Japan, ⁴Teikyo University hospital, Dept. of Urology, Kawasaki, Japan

Innovations in Urinary Tract Dysfunction: From Neurogenic Bladders to Novel Therapeutics

EGPT 34

**Saturday 14 March
15:30 - 17:00**

Location

Orange Area, EGPT 5

Chairs

M. Madanelo, Porto (PT)

To be confirmed

M. Przydacz, Krakow (PL)

15:30 - 15:55

neurogenic bladder

P0593

Development and validation of the fourth-generation participatory assessment tool for patients with neurogenic bladder

Authors

Qin S., Cheng W., Gao J., Gao K.

Institutions

First Hospital of Shanxi Medical University, Dept. of Urology, TaiYuan ShanXi, China

P0594

Inosine Rebalances Neuroimmune Crosstalk to Restore Bladder Function in Experimental Autoimmune Encephalomyelitis (EAE)

Authors

Bahou C.¹, Nagar P.¹, Besic M.¹, Bouillet E.², Heller M.³, Uldry A.C.³, Haghayegh Jahromi N.⁴, Engelhardt B.², Enzmann G.², Burkhard F.⁵, Röthlisberger R.⁵, Roth B.⁵, Monastyrskaya K.⁵, Hashemi Gheinani A.⁵

Institutions

¹University of bern, Functional Urology Lab - Dept. of BioMedical Research, Bern, Switzerland, ²University of bern, Theodor Kocher Institute, Bern, Switzerland, ³University of bern, Core Facility Proteomics & Mass Spectrometry (PMSCF), Bern, Switzerland, ⁴Phillip Morris International, Dept. of Preclinical Science & Toxicology, Neuchatel, Switzerland, ⁵Inselspital, Dept. of Urology, Bern, Switzerland

P0595

miR-21-5p regulates macrophage M2 polarization and mediates bladder fibrosis after spinal cord injury

Authors

Ruan J., Shang Z., Ou T.

Institutions

Xuanwu Hospital Capital Medical University, Dept. of Urology, Beijing, China

P0596

Ambulatory urodynamics for complex neurogenic LUTS: diagnostic value and safety

Authors

Maltagliati M.¹, Ferrari I.¹, Perri D.¹, Menozzi M.¹, Livio V.¹, Hoxha S.¹, Calcagnile T.¹, Carelli C.¹, Pini G.¹, Micali S.², Bozzini G.¹

Institutions

¹ASST Lariana, Dept. of Urology, Como, Italy, ²Università degli Studi di Modena e Reggio Emilia, Dept. of Urology, Modena, Italy

P0597

BILATERAL PUDENDAL NERVE BLOCK REDUCES MAXIMUM URETHRAL PRESSURE IN SCI PATIENTS WITH DESD

Authors

Chermansky C.J.C.¹, Polanco-Garcia V.¹, Moyer A.², de Groat W.³, Tai C.¹

Institutions

¹University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America, ²University of Pittsburgh Medical Center, Center for Clinical Neurophysiology, Pittsburgh, United States of America, ³University of Pittsburgh School of Medicine, Dept. of Pharmacology and Chemical Biology, Pittsburgh, United States of America

15:55 - 16:40

non neurogenic voiding dysfunction

P0598

Interobserver agreement of filling cystometry and pressure-flow study parameters

Authors

Genc Y.E.¹, Arslan F.¹, Ozkan O.C.², Akyuz O.³, Guctas A.O.¹, Sekerci C.A.², Yucel S.², Cam K.¹, Tarcan T.⁴

Institutions

¹Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey, ²Marmara University School of Medicine, Dept. of Pediatric Urology, Istanbul, Turkey, ³Kanuni Training and Research Hospital, Dept. of Urology, Trabzon, Turkey, ⁴Marmara University School of Medicine, Koç Üniversitesi School of Medicine, Dept. of Urology, Istanbul, Turkey

P0599

The Impact of Dynamic Depression Trajectories on Incident Urination and Defecation Disorders: A Nationwide Cohort Study

Authors

Zihao L., Yifei M., Zhenlong W.

Institutions

Xibei Hospital, Dept. of Urology, Xi An, China

P0600

A Nomogram to Predict Urinary Tract Infection After Urodynamic Study: Development, Validation, and Clinical Utility

Authors

Schwarztuch Gildor O., Itshak A., Levin N., Yosef E., Shaked Y., Vainrib R., Neheman A., Vainrib M.

Institutions

Meir Medical Center, Dept. of Urology, Kfar Saba, Israel

P0601

Impact of continuous bladder drainage on bladder function in patients with detrusor underactivity: A urodynamic-based retrospective study

Authors

Yao KF, Yang Y., Wu S.L., Zhang K., Chen Y.K., Jiang Y.

Institutions

Peking University First Hospital, Dept. of Urology, Beijing, China

P0602

Single-nucleus RNA sequencing identifies local stem cell engagement and TGF- β pathway modulation by human umbilical cord mesenchymal stem cells in bladder outlet obstruction–induced detrusor underactivity

Authors

Chen Y-H., Chen K.Y., Sheu J.Y., Chang S.J., Chueh J.S.C.

Institutions

National Taiwan University Hospital, Dept. of Urology, Taipei City, Taiwan

P0603

Correlation of patient's global impression of improvement and visual analog scale of satisfaction with clinical and urodynamic outcomes of sacral neuromodulation in non-obstructive urinary retention.

Authors

Dequirez PL.D., Biardeau X.

Institutions

CHU de Lille, Dept. of Urology, Lille, France

P0604

Resveratrol ameliorates bladder outlet obstruction–induced bladder dysfunction in rats via modulation of TGF- β –associated pathways: Integrative transcriptomic and proteomic evidence

Authors

Chen Y-H., Chen K.Y., Sheu J.Y., Chang S.J., Chueh J.S.C., Yeh Y.H.

Institutions

National Taiwan University Hospital, Dept. of Urology, Taipei City, Taiwan

P0605

The Clinical Utility of Urethral Pressure Profilometry in Diagnosing and Guiding Treatment of Men with Voiding Dysfunction

Authors

Ng C., Johnston L., Butt A., Aleksejeva K., Yasmin H., Gresty H., Ockrim J., Greenwell T., Pakzad M.

Institutions

University College London Hospitals NHS Foundation Trust, Dept. of Functional Reconstructive and Adolescent Urology, London, United Kingdom

P0606

Smooth muscle-derived TGF- β signaling drives extracellular matrix remodeling in bladder outlet obstruction-induced detrusor underactivity: Insights from single-nucleus RNA sequencing

Authors

Chen Y-H., Chen K., Sheu J.Y., Chang S.J., Chueh J.S.C.

Institutions

National Taiwan University Hospital, Dept. of Urology, Taipei City, Taiwan

16:40 - 17:00

From nocturia to BPO

P0607

High Fat Diet Exacerbates Long-Term Air Pollutants Exposure Associated Benign prostatic hyperplasia: Large-scale Prospective Population Evidences

Authors

Wei C., Wu Y., Huang W., Zhou X., Wei Q., Yang L., Qiu S.

Institutions

West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China

P0608

Combined Prostate Columnar Water-Balloon Dilation and Bladder Hydrodistention for the Treatment of Interstitial Cystitis in Male Patients

Authors

Huang B.

Institutions

Zhejiang Provincial People's Hospital, Dept. of Urology, Hangzhou, China

P0609

Nocturnal Bladder Capacity Index Assessment To Improve Nocturia Management In Patients With Lower Urinary Tract Symptoms Related To Benign Prostatic Hyperplasia

Authors

Sequi M.¹, Pastore A.L.¹, Fuschi A.¹, Suraci P.P.¹, Al Salhi Y.¹, Valenzi F.¹, Rera O.A.¹, Antonioni A.¹, Graziani D.¹, Gianfrancesco F.¹, Candita G.¹, Martino G.¹, Benanti P.¹, Di Gregorio G.¹, Erra L.¹, Lombardo R.², De Nunzio C.², Carbone A.¹

Institutions

¹Sapienza University of Rome, Faculty of Pharmacy and Medicine, Dept. of Medico-Surgical Sciences and Biotechnologies, Urology Unit ICOT, Latina, Italy, ²Sapienza University of Rome, Dept. of Urology Sant'Andrea Hospital, Rome, Italy

Integrative Transcriptomic and Proteomic Analysis Reveals Anti-inflammatory, Metabolic, and Antifibrotic Mechanisms of hUCMSC Therapy in Bladder Outlet Obstruction

Authors

[Yeh Y.H.](#)¹, Peng Y.H.², Wong S.M.¹, Chang S.J.¹

Institutions

¹National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan, ²National Taiwan University Hospital Yunlin Branch, Dept. of Urology, Yunlin, Taiwan

Exploring the Frontiers of Prostate Cancer Care: Complications, Technology-Driven Solutions and Patient Experiences

EGPT 30

Saturday 14 March
15:30 - 17:00

Location

Orange Area, EGPT 1

Chairs

E. Barret, Paris (FR)

G. Palapattu, Ann Arbor (US)

A.S. Zribi, Tunis (TN)

15:30 - 15:50

Optimising outcomes of treatment for prostate cancer

P0531

Single-Port Robotic Prostatectomy Under Neuraxial Anesthesia with Virtual Reality Support: A Step Toward Minimal Surgical Impact

Authors

[Amparore D.](#)¹, Checcucci E.¹, De Cillis S.T.², Piana A.², Piramide F.², Volpi G.¹, Sica M.¹, Quarà A.², Cisero E.², Sterrantino A.², Ortenzi M.², Cidda D.², Bignante G.², Rosi F.², Garino D.², Liguori S.², Zevallos Flores C.S.², Manfredi M.², Fiori C.², Porphiglia F.¹

Institutions

¹Candiolo Cancer Institute FPO-IRCCS, Division of Urology, Dept. of Surgery, Candiolo, Italy, ²AOU San Luigi Gonzaga - University of Turin, Dept. of Urology, Orbassano, Italy

P0532

Precision irreversible electroporation for localized prostate cancer guided by a novel system based on artificial intelligence and electromagnetic navigation system

Authors

[Wang M.](#), Zhengtong L., Huimin H., Xuan W., Ming L.

Institutions

Beijing Hospital, Dept. of Urology, Beijing, China

P0535

Does Efficiency Equal Surgical Quality? A Multicenter Study of Robotic Vesicourethral Anastomosis

Authors

[Cella L.](#)¹, Kim J.², Denmark A.², Lughezzani G.¹, Buffi N.M.¹, Wager P.², Hung J.A.²

Institutions

¹Humanitas University, Dept. of Urology, Milan, Italy, ²Cedars Sinai Medical Center, Dept. of Urology, Los Angeles, United States of America

P0527

Transurethral bladder neck resection combines with intraoperative and postoperative regular injection of triamcinolone acetonide for the treatment of bladder neck contracture after robot-assisted radical prostatectomy

Authors

Zheng X., Liu S., Zhang L., [Yang L.](#)

Institutions

First Affiliated Hospital of Xi'an Jiaotong University, Dept. of Urology, Xi'an, China

Advancing BPO treatment: From aquablation to enucleation

EGPT 33

**Saturday 14 March
15:30 - 17:00**

Location

Orange Area, EGPT 4

Chairs

S.T. De Cillis, Turin (IT)

To be confirmed

B. Geavlete, Bucharest (RO)

15:30 - 16:00

New insights aquablation procedures: Outcomes in selected patients and comparative trials

P0575

Aquablation of the prostate: The untold story of long-term complications

Authors

[Lasmanovich R.](#), Luder A., Cavairo-Lopez I., Grinstein I., Adar R., Kleinmann N., Dotan Z.A., Shvero A.

Institutions

Sheba Medical Center, Dept. of Urology, Ramat Gan, Israel

P0576

Aquablation Real-World Hemostasis Evolution from 100,000 Patients

Authors

Bitar M.¹, Helfand B.², Ajayi L.³, Quintas J.J.⁴, Liatsikos E.⁵, Barber N.⁶, Zorn K.C.⁷, Chughtai B.⁸, Bhojani N.⁹, Kaplan S.¹⁰, McVary K.¹¹, [Elterman D.](#)¹

Institutions

¹University of Toronto, Dept. of Urology, Toronto, Canada, ²NorthShore University HealthSystem, Dept. of Urology, Chicago, United States of America, ³Royal Free London NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁴HM Hospitales, Dept. of Urology, Madrid, Spain, ⁵University Hospital of Patras, Dept. of Urology, Patras, Greece, ⁶Frimley Health NHS Foundation Trust, Dept. of Urology, Camberley, United Kingdom, ⁷BPH Canada, Prostate Surgical Institute, Dept. of Urology, Montréal, Canada, ⁸Plainview Hospital, Smith Institute of Urology, Dept. of Urology, Syosset, United States of America, ⁹Centre Hospitalier de l'Université de Montréal, Dept. of Urology, Montréal, Canada, ¹⁰Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ¹¹Loyola University Medical Center, Dept. of Urology, Maywood, United States of America

P0577

The Impact of Aquablation Treatment in Patients with Concomitant Overactive Bladder Syndrome: functional and patient self-reported outcomes.

Authors

Stira J., Guidotti A., Turchi B., Gravina C., Lombardo R., Romagnoli M., Riolo S., Santoro G., Santioni M., Sciarra A., Carbone A., Franco G., Tubaro A., De Nunzio C.

Institutions

Sapienza University of Rome, Dept. of Urology, Rome, Italy

P0578

Six-Month Outcomes of the WATER III Trial: Aquablation versus Transurethral Laser Enucleation (HoLEP/ThuLEP) for Large Prostates (80–180 mL) in Benign Prostatic Hyperplasia

Authors

Stein J.¹, Gloger S.², Barber N.³, Kalsi J.³, Popert R.⁴, Bass E.⁴, Németh R.⁵, Schmid M.⁵, Miernik A.⁶, Gratzke C.⁶, Ritter M.¹, Ubrig B.²

Institutions

¹University Hospital Bonn, Dept. of Urology and Pediatric Urology, Bonn, Germany, ²Augusta Kliniken, Clinic of Urology, Bochum, Germany, ³Frimley Health NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁴Guy's and St. Thomas' Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁵University of Bonn, Institute for Medical Biometry, Informatics and Epidemiology (IMBIE), Bonn, Germany, ⁶University Medical Center Freiburg, Faculty of Medicine, Dept. of Urology, Freiburg, Germany

P0579

Comparison of Aquablation and Rezūm in the management of patients with medium prostate volume: a propensity score matching analysis

Authors

Basadonna L.M.¹, Graps G.¹, Passarelli F.¹, Marengi C.², Ratti D.², Montanari E.³, Longo F.¹, Varca V.², Boeri L.¹

Institutions

¹Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico University of Milan, Dept. of Urology, Milan, Italy, ²ASST Rhodense-Presidio di Garbagnate Milanese, Urologic Unit, Milan, Italy, ³University of Milan, Dept. of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, Milan, Italy

P0580

Man versus Robot: comparative urinary and sexual outcomes of Ejaculation-Sparing endoscopic Photoselective Vaporization of the Prostate and Aquablation for the treatment of patients with Benign Prostatic Obstruction.

Authors

Sibona M.¹, Boeri L.², Bonino G.¹, Graps G.², Destefanis P.¹, Basadonna L.M.², Vercelli E.¹, Passarelli F.², Montanari E.², Gontero P.¹

Institutions

¹A.O.U. Città della Salute e della Scienza, Molinette Hospital, Dept. of Urology, Turin, Italy, ²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy

16:00 - 16:30

New insights laser prostatectomy: Outcomes in selected patients and comparative trials

P0581

The optimal hospital caseload to improve perioperative outcomes during Transurethral Resection of the Prostate or Prostate Enucleation: Results from the GRAND study

Authors

Pyrgidis N., Schulz G.B., Weinhold P., Volz Y., Papadopoulos I., Stief C., Marcon J., Keller P.

Institutions

University Hospital Munich Ludwig-Maximilian-University, Dept. of Urology, Munich, Germany

P0582

Assessment of the Effect of Prostate Volume on Surgical Complications and Outcomes in Antithrombotic-Treated Patients Undergoing Endoscopic Enucleation: Findings from the EAU Endourology Collaborative Study

Authors

Giulioni C.¹, Castellani D.², Yuen S.K.K.³, Cafarelli A.¹, Falsetti F.¹, Tanidir Y.⁴, Doizi S.⁵, Moretto S.⁵, Zawadzki M.⁶, Gökce M.I.⁷, Sytnik D.⁸, Becker B.⁹, Aydin C.¹⁰, Akdogan N.¹¹, De Coninck V.¹², Gadzhiev N.¹³, Malkhasyan V.¹⁴, Mazzon G.¹⁵, Sarvajit B.P.¹⁶, Cormio A.¹⁷, Somani B.K.¹⁸, Herrmann T.¹⁹, Gauhar V.¹⁶

Institutions

¹Casa di Cura Villa Igea, Dept. of Urology, Ancona, Italy, ²Azienda Ospedaliero-Universitaria delle Marche, Dept. of Urology, Ancona, Italy, ³The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, Hong Kong, ⁴Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey, ⁵Sorbonne University, Dept. of Urology, Paris, France, ⁶St. Anna Hospital, Dept. of Urology, Piaseczno, Poland, ⁷Ankara University School of Medicine, Dept. of Urology, Ankara, Turkey, ⁸St.Luke's Clinical Hospital, Dept. of Urology, Saint Petersburg, Russia, ⁹Asklepios Hospital Barmbek, Dept. of Urology, Hamburg, Germany, ¹⁰Hitit University, Dept. of Urology, Corum, Turkey, ¹¹Cukurova University, Dept. of Urology, Corum, Turkey, ¹²AZ Klina, Dept. of Urology, Brasschaat, Belgium, ¹³Saint Petersburg State University Hospital, Dept. of Urology, Saint Petersburg, Russia, ¹⁴Russian University of Medicine, Dept. of Urology, Moscow, Russia, ¹⁵University College Hospital London, Dept. of Urology, London, United Kingdom, ¹⁶Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ¹⁷University of Foggia, Dept. of Urology, Foggia, Italy, ¹⁸University Hospitals Southampton, Dept. of Urology, Southampton, United Kingdom, ¹⁹Kantonsspital Frauenfeld, Dept. of Urology, Frauenfeld, Switzerland

P0583

A Randomized, Placebo-Controlled Trial Evaluating Tadalafil 5 mg for Management of Early Storage Symptoms and Erectile Dysfunction After HoLEP

Authors

Aljabiri M., El-Tabey N., Shehab Eldein A., Laymon M.

Institutions

Mansoura University, Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt

P0584

A Prospective Non-Randomized Trial Comparing the Efficacy and Safety of Pulsed Thulium:YAG Versus Holmium:YAG Lasers for Prostate Enucleation

Authors

Ozsoy F., Maras M.E., Sahin Y.H., Atakli A., Karaburun M., Akpınar C., Ibis M.A., Gokce M.I.

Institutions

Ankara University School of Medicine, Dept. of Urology, Ankara, Turkey

P0585

Thulium YAG laser versus bipolar enucleation for management of benign prostate obstruction secondary to large prostates (>80 gm): A multicenter prospective randomized study

Authors

Abd El Hamid M.¹, Saker H.², El Adawy M.², Yehia A.¹, Kasem A.¹, El Ghani M.¹

Institutions

¹Cairo University, Dept. of Urology, Cairo, Egypt, ²Fayoum University, Dept. of Urology, Fayoum, Egypt

P0586

Holmium enucleation of the prostate versus robotic aquablation- is there a difference?

Authors

Reddy D.T., Rajain S., Malde S., Mensah E., El Hage O., Noel J., Popert R., Challacombe B.

Institutions

Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom

16:30 - 17:00

How to improve training: From mentorship to simulators

P0587

Face and Content Validation of Laser Enucleation of Prostate Simulation Model: An EAU European School of Urology (ESU) Lower Urinary Tract Endoscopy Working Group Study

Authors

Şener T.E.¹, Oliveira T.R.², Demirkiran E.D.³, Perri D.⁴, Pereira S.⁵, Caballero J.P.⁶, Osorio L.⁷, Goumas I.G.⁸, Goossens M.⁹, Schoensee B.¹⁰, Dragos L.¹¹, Veneziano D.¹², Biyani C.S.¹³, Somani B.¹⁴, Liatsikos E.¹⁵

Institutions

¹Marmara University, Dept. of Urology, Istanbul, Turkey, ²Armed Forces Hospital, Dept. of Urology, Lisbon, Portugal, ³Zonguldak Bülent Ecevit University, Dept. of Urology, Zonguldak, Turkey, ⁴Azienda Socio Sanitaria Territoriale Lariana, Dept. of Urology, Como, Italy, ⁵Lisbon Medical Academic Centre, Dept. of Urology, Lisbon, Portugal, ⁶University General Hospital, Dept. of Urology, Alicante, Spain, ⁷Lusíadas Porto Hospital, Dept. of Urology, Porto, Portugal, ⁸Istituto Clinico Beato Matteo, Dept. of Urology, Vigevano, Italy, ⁹OLV Hospital Aalst, Dept. of Urology, Aalst, Belgium, ¹⁰Urologie Berlin Adlershof, Dept. of Urology, Berlin, Germany, ¹¹Cambridge University Hospitals NHS Foundation Trust, Dept. of Urology, Cambridge, United Kingdom, ¹²Smith Institute for Urology, Northwell Health, Dept. of Urology, New York, United States of America, ¹³St James's University Hospital, Dept. of Urology, Leeds, United Kingdom, ¹⁴University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ¹⁵University Hospital Patras, Dept. of Urology, Patras, Greece

P0588

Face and Content Validation of TURP and TURB Simulation Models: An EAU European School of Urology (ESU) Lower Urinary Tract Endoscopy Working Group Study

Authors

Sener T.E.¹, Oliveira T.², Demirkiran E.D.³, Perri D.⁴, Pereira S.⁵, Caballero J.P.⁶, Osorio L.⁷, Kartalas I.G.⁸, Ramos R.⁹, Castro A.S.⁹, Reis D.O.², Paciotti M.¹⁰, Mariappan P.¹¹, Diana P.¹², Dragos L.¹³, Biyani C.S.¹⁴, Somani B.¹⁵, Liatsikos E.¹⁶

Institutions

¹Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey, ²Armed Forces Hospital, Dept. of Urology, Lisbon, Portugal, ³Zonguldak Bülent Ecevit University, School of Medicine, Dept. of Urology, Zonguldak, Turkey, ⁴Azienda Socio Sanitaria Territoriale Lariana, Dept. of Urology, Como, Italy, ⁵Lisbon Medical Academic Centre, Dept. of Urology, Lisbon, Portugal, ⁶University General Hospital, Dept. of Urology, Alicante, Spain, ⁷Lusíadas Porto Hospital, Dept. of Urology, Porto, Portugal, ⁸Istituto Clinico Beato Matteo, Dept. of Urology, Vigevano, Italy, ⁹Portuguese Institute of Oncology Lisboa, Dept. of Urology, Lisbon, Portugal, ¹⁰IRCCS Humanitas Research Hospital Rozzano, Dept. of Urology, Milan, Italy, ¹¹Edinburgh Bladder Cancer Surgery, Western General Hospital, University of Edinburgh, Dept. of Urology, Edinburgh, United Kingdom, ¹²Fundacio Puigvert, Dept. of Urology, Barcelona, Spain, ¹³Cambridge University Hospitals NHS Foundation Trust, Dept. of Urology, Cambridge, United Kingdom, ¹⁴St James's University Hospital, Dept. of Urology, Leeds, United Kingdom, ¹⁵University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ¹⁶University Hospital Patras, Dept. of Urology, Patras, Greece

P0589

Face and content validation of a novel Aquablation training simulator within the EAU European School of Urology educational framework

Authors

Demirkiran E.D.¹, Perri D.², Sener T.E.³, Ribeiro de Oliveira T.⁴, Pereira S.⁵, Caballero J.P.⁶, Osorio L.⁷, Kartalas Goumas I.⁸, Dragos L.⁹, Veneziano D.¹⁰, Biyani C.S.¹¹, Somani B.¹², Liatsikos E.¹³

Institutions

¹Zonguldak Bulent Ecevit University School of Medicine, Dept. of Urology, Zonguldak, Turkey, ²Azienda Socio Sanitaria Territoriale Lariana, Dept. of Urology, Como, Italy, ³Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey, ⁴Armed Forces Hospital, Dept. of Urology, Lisbon, Portugal, ⁵Lisbon Medical Academic Centre, Dept. of Urology, Lisbon, Portugal, ⁶University General Hospital, Dept. of Urology, Alicante, Spain, ⁷Lusíadas Porto Hospital, Dept. of Urology, Porto, Portugal, ⁸Istituto Clinico Beato Matteo, Dept. of Urology, Vigevano, Italy, ⁹Cambridge University Hospitals NHS Foundation Trust, Dept. of Urology, Cambridge, United Kingdom, ¹⁰Smith Institute for Urology, Northwell Health, Dept. of Urology, New York, United States of America, ¹¹St James's University Hospital, Dept. of Urology, Leeds, United Kingdom, ¹²University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ¹³University Hospital Patras, Dept. of Urology, Patras, Greece

P0590

Impact of learning curve on perioperative outcomes of robot assisted simple prostatectomy (RASP); single center comparison of outcomes between trainees versus expert series

Authors

Bove A.M., Anceschi U., Ferriero M., Tuderti G., Flammia R.S., Misuraca L., D'Annunzio S., Brassetti A., Proietti F., Leonardo C., Simone G.

Institutions

IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy

P0591

Simulation based training versus mentorship in the initial learning curve of Holmium Laser Enucleation of the Prostate (HoLEP) Surgery. The Effects of Simulation Training on Surgical Success, Complication Rates, and Surgeon Workload: A Prospective Comparative Study

Authors

Ceviz K.¹, Tonyali S.², Tastemur S.¹, Kasap Y.¹, Uzun E.¹, Yildiz A.K.¹, Polat M.E.¹, Yahsi S.¹, Esengen S.¹, Senel S.¹, Odabas O.¹

Institutions

¹Ankara Bilkent City Hospital, Dept. of Urology, Ankara, Turkey, ²Istanbul University, Dept. of Urology, Istanbul, Turkey

P0592

Learning Curve of Aquablation: Insights from the First 252 Consecutive Cases in a High-Volume European Centre

Authors

Rodrigues T.¹, Guerra J.¹, Vilas Boas V.¹, Pardal H.¹, Apolinario M.¹, Zorn K.C.², Gomes J.M.¹

Institutions

¹Hospital Cruz Vermelha, Dept. of Urology, Lisbon, Portugal, ²BPH Canada, Canadian Prostate Surgical Institute, Dept. of Urology, Montréal, Canada

NMIBC: Surgery, intravesical therapy and follow-up

EGPT 32

Saturday 14 March
15:30 - 17:00

Location

Orange Area, EGPT 3

Chairs

A. Masson-Lecomte, Paris (FR)

A. Minervini, Florence (IT)

To be confirmed

15:30 - 16:00

TURB, re-staging and risk stratification

P0557

Prospective evaluation of ureteral stenting during TURBT for tumors involving the ureteral orifice and its impact on metachronous upper tract carcinoma

Authors

Pyrgidis N.¹, Engelmann P.¹, Ebner B.¹, Kidess M.¹, Keller P.¹, Puhr-Westerheide D.², Schulz G.B.¹, Stief C.¹, Volz Y.¹

Institutions

¹Ludwig-Maximilian-University, Dept. of Urology, Munich, Germany, ²Ludwig-Maximilian University, Dept. of Radiology, Munich, Germany

P0558

Early BCG Instillation Outweighs Second TURBT Timing for Recurrence-Free Survival in High-Risk NMIBC

Authors

Liu Z., Liang H., Renjie D., Xiangdong L., Zhiyong L., Cheng L., Kai Y., Zike Q., Zhuowei L., Yunlin Y.

Institutions

Sun Yat-sen University Cancer Center, Dept. of Urology, Guangzhou, China

Recurrent Papillary (pTa) Non–Muscle-Invasive Bladder Cancer: Identifying Patients Beyond the Reach of Intravesical Therapy

Authors

Longoni M.¹, Cosenza A.¹, Scilipoti P.¹, de Angelis M.¹, Zaurito P.¹, Tremolada G.¹, Simone G.², Mastroianni R.², Zamboni S.³, Suardi N.³, Marcq G.⁴, Szostek A.⁴, Velasco J.C.⁵, Lafuente Puenteadura A.⁵, Subiela J.D.⁶, Del Olmo Durán P.⁶, Ślusarczyk A.⁷, Karakiewicz P.I.⁸, Pradere B.⁹, Gontero P.¹⁰, Montorsi F.¹, Salonia A.¹, Briganti A.¹, Moschini M.¹

Institutions

¹IRCCS San Raffaele Scientific Institute, Unit of Urology, Milan, Italy, ²Uro-oncology Program, IRCCS “Regina Elena” National Cancer Institute, Dept. of Urology, Rome, Italy, ³ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Dept. of Urology, Brescia, Italy, ⁴Claude Huriez Hospital, Dept. of Urology, Lille, France, ⁵Hospital General Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain, ⁶Ramón y Cajal University Hospital, IRYCIS, University of Alcalá, Dept. of Urology, Madrid, Spain, ⁷Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ⁸University of Montréal Health Centre, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montréal, Canada, ⁹UROSUD, La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ¹⁰San Giovanni Battista Hospital, University of Studies of Torino, Dept. of Surgical Sciences, Turin, Italy

The impact of en-bloc resection of tumor technique on histopathological outcomes, subsequent management, and early recurrence in newly diagnosed bladder cancer: A retrospective analysis of single-institution experience

Authors

Erdem S.¹, Ates Y.², Erden M.E.², Hurdogan O.³, Degirmenci E.², Ozluk Y.³, Sanli O.¹, Ozcan F.¹

Institutions

¹Istanbul University Istanbul Faculty of Medicine, Division of Urologic Oncology, Dept. of Urology, Istanbul, Turkey, ²Istanbul University Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ³Istanbul University Istanbul Faculty of Medicine, Dept. of Pathology, Istanbul, Turkey

Real-World Data Support Restaging at reTURB for Prognostic Re-Stratification of EAU 2021 Risk Groups in High-Grade T1 Non–Muscle-Invasive Bladder Cancer: A Data-Driven, Risk-Adapted Guide to Timely Radical Cystectomy Decisions

Authors

Fernandez-Mardomingo Diaz A.¹, Subiela Henriquez J.D.¹, Minguez Ojeda C.¹, Artiles Medina A.¹, Del Olmo Duran P.¹, Martin Serrano G.¹, Gomez Dos Santos V.¹, Krajewski W.², Pichler R.³, Scilipoti P.⁴, Longoni M.⁴, De Angelis M.⁴, Moschini M.⁴, Cano Velasco J.⁵, Aumatell J.⁶, Contieri R.⁷, Gallioli A.⁸, Ślusarczyk A.⁹, Grobet-Jeandin E.¹⁰, Del Giudice F.¹¹, Soria F.¹², Mertens L.¹³, Pradere B.¹⁴, Burgos Revilla F.J.¹

Institutions

¹Hospital Universitario Ramón y Cajal, Dept. of Urology, Madrid, Spain, ²University Center of Excellence in Urology, Dept. of Minimally Invasive and Robotic Urology, Wrocław, Poland, ³Comprehensive Cancer Center Innsbruck, Dept. of Urology, Innsbruck, Austria, ⁴IRCCS San Raffaele Hospital, Dept. of Experimental Oncology/Unit of Urology, Milan, Italy, ⁵Hospital General Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain, ⁶Hospital Universitario Rey Juan Carlos, Dept. of Urology, Madrid, Spain, ⁷Humanitas Clinical and Research Institute IRCCS, Dept. of Urology, Milan, Italy, ⁸Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁹Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ¹⁰Geneva University Hospitals, Dept. of Urology, Geneva, Switzerland, ¹¹Policlinico Umberto I Hospital, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ¹²San Giovanni Battista Hospital, Dept. of Surgical Sciences, Turin, Italy, ¹³Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ¹⁴La Croix Du Sud Hospital, Dept. of Urology, UROSUD, Quint-Fonsegrives, France

En-Bloc Resection of Bladder Tumour vs. conventional TURBT: long-term oncological outcomes from a single-center prospective

Authors

Avesani G., Di Bello F., Diana P., Lopez M., Belarmino A., Gallioli A., Gaya J.M., Territo A., Palou J., Breda A.

Institutions

Fundació Puigvert, Dept. of Urology, Barcelona, Spain

BCG-rechallenge after treatment failure: long-term outcomes from a multi-institutional cohort

Authors

Zaurito P.¹, Scilipoti P.¹, Longoni M.¹, De Angelis M.¹, Galdieri A.¹, Ślusarczyk A.², Soria F.³, Pradere B.⁴, D'Andrea D.⁵, Pichler R.⁶, Subiela J.D.⁷, Mertens L.⁸, Laukhtina E.⁵, Elena J.L.R.⁹, Aranda J.⁹, Radziszewski P.², Shariat S.⁵, Gontero P.³, Xylinas E.¹⁰, Roupret M.¹¹, Montorsi F.¹, Salonia A.¹, Briganti A.¹, Moschini M.¹

Institutions

¹IRCCS Ospedale San Raffaele, Unit of Urology, Milan, Italy, ²Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ³San Giovanni Battista Hospital, University of Studies of Torino, Division of Urology, Dept. of Surgical Sciences, Turin, Italy, ⁴UROSUD, La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ⁵Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁶Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ⁷Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Dept. of Urology, Madrid, Spain, ⁸Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁹Hospital Universitario de Cáceres, Dept. of Urology, Cáceres, Spain, ¹⁰Bichat-Claude Bernard Hospital, Dept. of Urology, Paris, France, ¹¹Hôpital Pitié-Salpêtrière, Dept. of Urology, Paris, France

Real-World Outcomes of Bladder-Sparing Strategies for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: A Multicenter Study Study

Authors

Scilipoti P.¹, Ślusarczyk A.², Krajewski W.³, Aranda J.⁴, Hurle R.⁵, Subiela J.⁶, Marcq G.⁷, Simone G.⁸, Pichler R.⁹, Álvarez-Maestro M.¹⁰, Buisan O.¹¹, Zazzara M.¹², Ludovico G.M.¹², Carando R.¹³, Radziszewski P.², Soria F.¹⁴, Pradere B.¹⁵, D'Andrea D.¹⁶, Shariat S.F.¹⁶, Montorsi F.¹, Briganti A.¹, Gontero P.¹⁴, Xylinas E.¹⁷, Moschini M.¹

Institutions

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ³Wrocław Medical University, Dept. of Urology and Oncologic Urology, Wrocław, Poland, ⁴Hospital Universitario de Cáceres, Dept. of Urology, Cáceres, Spain, ⁵Humanitas Clinical and Research Institute IRCCS, Dept. of Urology, Rozzano, Italy, ⁶Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Dept. of Urology, Madrid, Spain, ⁷Claude Huriez Hospital, CHU Lille, Dept. of Urology, Lille, France, ⁸IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy, ⁹Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ¹⁰Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain, ¹¹Hospital Universitari de Bellvitge, Dept. of Urology, Barcelona, Spain, ¹²Ente Ecclesiastico Ospedale Generale Regionale "F. Miulli", Dept. of Urology, Acquaviva delle Fonti, Italy, ¹³Clinica Luganese Moncucco, Dept. of Urology, Lugano, Switzerland, ¹⁴San Giovanni Battista Hospital, University of Studies of Torino, Division of Urology, Dept. of Surgical Sciences, Turin, Italy, ¹⁵La Croix Du Sud Hospital, Dept. of Urology, UROSUD, Quint-Fonsegrives, France, ¹⁶Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹⁷Bichat-Claude Bernard Hospital, AP-HP, Université de Paris Cité, Dept. of Urology, Paris, France

P0565

IntIntravesical Gemcitabine versus BCG for Intermediate-/High-Risk NMIBC during the BCG Shortage: Safety, Efficacy, and Cost-Effectiveness

Authors

Costa T.¹, de Carvalho Fernandes R.², Morato de Toledo L.G.², Alves de Andrade V.³, Bali Moreira R.², Albano F.³, Riserio Fernandes L.¹, Fernandes L. R.¹, Demartino G.²

Institutions

¹FCMSCSP, Dept. of Urology, São Paulo, Brazil, ²ISCMSP, Dept. of Urology, São Paulo, Brazil, ³ISCMSP, Dept. of General Surgery, São Paulo, Brazil

P0566

Gemcitabine-Docetaxel Intravesical Synchronous CO-administration (G-DISCO); A first-in-human evaluation of synchronous gemcitabine-docetaxel

Authors

Keane K.¹, Hawks C.², McCombie S.², Oh E.L.², Twycross M.³, Lim J.¹, Meehan K.¹, Redfern A.¹, Hayne D.¹

Institutions

¹University of Western Australia, UWA Medical School, Perth, Australia, ²Fiona Stanley Hospital, Dept. of Urology, Perth, Australia, ³Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Consumer Advisory Panel, Sydney, Australia

Study Group

Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group(Sydney, Australia)

P0567

Optimizing Mitomycin C Maintenance for Intermediate-Risk Ta NMIBC: A Multicenter Analysis on Instillation Duration

Authors

Contieri R.¹, Jannello L.M.I.², Cella L.³, Da Pozzo L.⁴, Bove P.⁵, Madonia M.⁶, Russo G.I.⁷, Simone G.⁸, Di Stasi S.M.⁵, De nunzio C.⁹, Carmignani L.¹⁰, Liguori G.¹¹, Porreca A.¹², Antonelli A.¹³, Dal Moro F.¹⁴, Carrieri G.¹⁵, Terrone C.¹⁶, Porpiglia F.¹⁷, Perdonà S.¹, Rocco B.¹⁸, Hurle R.¹⁹, Catellani M.⁴, Ferro M.²

Institutions

¹IRCCS Istituto Nazionale Tumori Fondazione G. Pascale, Dept. of Urology, Naples, Italy, ²University of Milan, ASST Santi Paolo e Carlo, Dept. of Urology, Milan, Italy, ³Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ⁴ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy, ⁵University of Rome Tor Vergata, Torvergata Oncoscience Research Centre of Excellence (TOR), Dept. of Experimental Medicine, Rome, Italy, ⁶Università degli Studi di Sassari, Dept. of Medicine, Surgery and Pharmacy, Sassari, Italy, ⁷University of Catania, Dept. of Urology, Catania, Italy, ⁸IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁹Sapienza Rome University, Dept. of Urology, Rome, Italy, ¹⁰IRCCS Ospedale Galeazzi - Sant'Ambrogio, Dept. of Urology, Milan, Italy, ¹¹University of Trieste, Cattinara Hospital-ASUGI, Dept. of Urology, Trieste, Italy, ¹²Humanitas Gavazzeni, Dept. of Urology, Bergamo, Italy, ¹³University of Verona, Dept. of Urology, Verona, Italy, ¹⁴University of Padua, Dept. of Urology, Padua, Italy, ¹⁵University of Foggia, Dept. of Urology and Kidney Transplantation, Foggia, Italy, ¹⁶University of Genoa, Dept. of Surgical and Integrated Diagnostic Sciences, Genoa, Italy, ¹⁷School of Medicine, San Luigi Hospital, University of Turin, Division of Urology, Dept. of Oncology, Turin, Italy, ¹⁸Fondazione Policlinico Universitario A. Gemelli IRCCS, U.O.C. Urology Clinic, University Dept. of Translational Medicine and Surgery, Rome, Italy, ¹⁹IRCCS Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

Phase III, single-arm study to evaluate the efficacy and safety of intravesical paclitaxel-hyaluronic acid conjugate in patients with BCG-unresponsive Carcinoma in situ of the bladder +/- Ta-T1 papillary disease (Orion-BC study)

Authors

Xylinas E.N.¹, Amodeo A.², Antonelli A.³, Chessa F.⁴, Dominguez-Escrig J.⁵, Guerrero Ramos F.⁶, Guy L.⁷, Macchi A.⁸, Moschini M.⁹, Pignot G.R.¹⁰, Rabade Ferreiro A.¹¹, Raventos Busquets C.X.¹², Ribal Caparros M.J.¹³, Robert G.G.¹⁴, Smolski M.¹⁵, Soria F.¹⁶, Szabados B.¹⁷, Vigués F.¹⁸, Walczak R.¹⁹, Hurle R.²⁰

Institutions

¹Bichat Claude Bernard Hospital Paris Cité Université, Dept. of Urology, Paris, France, ²Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale San Giacomo, Dept. of Urology, Castelfranco Veneto, Italy, ³Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento, Dept. of Urology, Verona, Italy, ⁴IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola, Dept. of Urology, Bologna, Italy, ⁵Instituto Valenciano de Oncologia, Dept. of Urology, Valencia, Spain, ⁶Centro Integral Oncologico Clara Campal C. de Oña, and Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ⁷CHU de Clermont-Ferrand - Hopital Gabriel Montpied, Dept. of Urology, Clermont-Ferrand, France, ⁸ondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy, ⁹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ¹⁰Institut Paoli-Calmettes, Dept. of Urology, Marseille, France, ¹¹Hospital Universitario de Basurto, Dept. of Urology, Bizkaia, Spain, ¹²Hospital Universitario Vall d'Hebron, Dept. of Urology, Barcelona, Spain, ¹³Hospital Clinic Barcelona, Dept. of Urology, Barcelona, Spain, ¹⁴CHU Bordeaux - Hopital Pellegrin, Pl. Amélie Raba Léon, Dept. of Urology, Bordeaux, France, ¹⁵Royal Preston Hospital, Dept. of Urology, Preston, United Kingdom, ¹⁶AOU Città della Salute e della Scienza di Torino - Ospedale le Molinette, Corso Bramante, Dept. of Urology, Turin, Italy, ¹⁷Barts Health NHS Trust, The Royal Hospital, Whitechapel Rd, London E1 1BB, United Kindom, Dept. of Urology, London, United Kingdom, ¹⁸Hospital Universitari de Bellvitge, Dept. of Urology, Barcelona, Spain, ¹⁹Wojewodzki Szpital im Sw. Ojca Pio w Przemyslu, Urological Oncology Unit, Dept. of Urology, Przemyśl, Poland, ²⁰Istituto Clinico Humanitas, Dept. of Urology, Rozzano, Italy

16:30 - 17:00

Decision-making, biomarkers, surveillance and quality of life

P0569

Bladder-sparing Therapy versus Upfront Radical Cystectomy for High-risk Non-muscle-invasive Bladder Cancer: A Propensity Score Matching Analysis

Authors

Li P., Hong T., Chen H., Zhao C., Li J.

Institutions

The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

P0570

Trial Design Drives Outcomes: Harmonizing Efficacy Across BCG-Unresponsive Bladder Carcinoma in Situ Trials

Authors

Robesti D.¹, Kamat A.M.², Ploussard G.³, Fallara G.⁴, Briganti A.¹, Montorsi F.¹, van der Heijden A.⁵, Malavaud B.³, Pohar K.⁶, Shore N.⁷, Dinney C.P.², Martini A.⁸

Institutions

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²The University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ³Institut Universitaire du Cancer Toulouse-Oncopôle, Dept. of Urology, Toulouse, France, ⁴Santi Paolo e Carlo, Dept. of Urology, Milan, Italy, ⁵Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ⁶The Ohio State University Wexner Medical Center, Dept. of Urology, Columbus, United States of America, ⁷Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, ⁸University of Cincinnati College of Medicine, Dept. of Urology, Cincinnati, United States of America

P0571

SYMPTOMS, HEALTH-RELATED QUALITY OF LIFE, AND BURDEN AMONG PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER AND CAREGIVERS

Authors

Aning J.¹, Andersen L.², Jain R.², Cote S.³, Mulhern-Haughey S.⁴, Bertzos K.⁵, Unsworth M.⁶, Manuel L.⁶, Brown E.⁶, Cookson J.⁶, Fujita K.⁷, He Z.⁸

Institutions

¹Bristol Urological Institute, North Bristol NHS Trust, London, United Kingdom, ²Johnson & Johnson, Dept. of Market Access, Raritan, United States of America, ³Johnson & Johnson, Dept. of Medical Affairs, Toronto, Canada, ⁴Janssen Sciences Ireland, Johnson & Johnson, Market Access, Dublin, Ireland, ⁵Johnson & Johnson, Dept. of Market Access, Horsham, United States of America, ⁶Adelphi Real World, Dept. of Oncology, Bollington, United Kingdom, ⁷Kindai University Hospital, Dept. of Medicine, Osaka, Japan, ⁸Peking University First Hospital, Dept. of Urology, Beijing, China

P0572

Longitudinal assessment of patient-reported quality of life and mental health during active surveillance for low-grade NMIBC

Authors

Paciotti M., Sormani F., Piccolini A., Tiscione M., Finocchiaro A., Cella L., Contieri R., Avolio P.P., Fasulo V., Saita A., Lughezzani G., Buffi N.M., Lazzeri M., Casale P., Hurle R.

Institutions

IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy

P0573

Randomized trial of urinary tumor DNA (utDNA) testing-guided cystoscopy in high-risk/very high-risk non-muscle-invasive bladder cancer (NMIBC): TRUCE-LB02

Authors

Hu H.¹, Chen X.², Qie Y.¹, Xue Z.¹, Yu W.³, Wang Y.⁴, Wang L.⁵, Li N.⁶, Wang C.⁷, Wang H.⁸, Shen H.⁹, Zhu G.¹⁰, Sun F.¹¹, Liang T.¹², Wei J.¹³

Institutions

¹The Second Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China, ²Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Dept. of Urology, Guangzhou, China, ³Peking University First Hospital, Dept. of Urology, Beijing, China, ⁴The Affiliated Hospital of Qingdao University, Dept. of Urology, Qingdao, China, ⁵Second Hospital of Dalian Medical University, Dept. of Urology, Dalian, China, ⁶The Fourth Affiliated Hospital of China Medical University, Dept. of Urology, Shenyang, China, ⁷The First Affiliated Hospital of Harbin Medical University, Dept. of Urology, Harbin, China, ⁸The Second Affiliated Hospital of Kunming Medical University, Dept. of Urology, Kunming, China, ⁹Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Dept. of Urology, Tianjin, China, ¹⁰Tianjin Hospital, Dept. of Urology, Tianjin, China, ¹¹People's Hospital of Huanghua, Dept. of Urology, Cangzhou, China, ¹²Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Dept. of Urology, Nanning, China, ¹³Xingtai People's Hospital, Dept. of Urology, Xingtai, China

P0574

Beyond the guidelines: A real-world assessment of NMIBC surveillance in the Scottish National Health Service and potential cost-effectiveness of the Epicheck biomarker.

Authors

Hart-Brooke J.¹, Chabut D.², Verdonck S.², Mariappan P.¹

Institutions

¹Edinburgh Bladder Cancer Surgery, Dept. of Urology, Edinburgh, United Kingdom, ²Menarini Diagnostics GmbH, Biomarker, Basel-Stadt, Switzerland

Patient advocacy plaza - Patient reported outcomes after chemotherapy and prostate cancer



Special Session

**Saturday 14 March
15:45 - 16:15**

Location Patient Advocacy Plaza

Chair To be confirmed

15:45 - 16:15

Europa Uomo
To be confirmed

Artificial Intelligence 2 - Advanced

ESU Course 23

Saturday 14 March
16:00 - 18:00

Location Red Area, Room 7

Learning objectives

This advanced session dives deeper into the technical and strategic aspects of AI. It covers Big Data management, AI-ready datasets, data harmonization, and the evolution towards agentic and generalist AI. Participants will explore data harvesting, validation, and training challenges such as imbalance and multimodality (video, imaging, audio, tabular data). The course also offers an overview of emerging trends in AI research – empowering clinicians and researchers to integrate cutting-edge methods into urological practice.

16:00 - 16:00

TBC

M. Bussmann, Dresden (DE)

16:00 - 16:00

TBC

B. De Meulder, Larajasse (FR)

2026 EAU Guidelines update – Testicular and penile cancer and sexual health: What has changed?

ESU Course 28

Saturday 14 March
16:00 - 18:00

Location Red Area, Room 12

Chair O. Brouwer, Amsterdam (NL)

Welcome and introduction

O. Brouwer, Amsterdam (NL)

Principles of systemic therapy in testicular cancer across disease stages

To be confirmed

EAU ASCO Penile Cancer Guidelines: Key recommendations and remaining challenges

O. Brouwer, Amsterdam (NL)

Penile size abnormalities and dysmorphophobia – Does size matter? Summary of the EAU Guidelines

P. Capogrosso, Varese (IT)

Prostate cancer made simple: A comprehensive update for all urologists

ESU Course 27

Saturday 14 March
16:00 - 18:00

Location Red Area, Room 11

Chair D. Eberli, Zürich (CH)

Learning objectives

A general update on prostate cancer. Who needs early prostate cancer detection? What is the optimal method of biopsies? What is the best imaging approach? Are surgery and radiotherapy equal options for localised prostate cancer? What is state-of-the-art androgen deprivation therapy for metastasized disease and what are the options at castration resistance. All these topic will be comprehensively discussed during the course.

Early detection and heredity in prostate cancer

D. Eberli, Zürich (CH)

MRI imaging and biopsy strategy for local diagnosis and staging

P. Rajwa, Warsaw (PL)

PSMA pet imaging

C. Surcel, Bucharest (RO)

Indications for active surveillance and watchfull waiting

D. Eberli, Zürich (CH)

Indications for localised treatment (surgery, radiotherapy and focal therapy)

C. Surcel, Bucharest (RO)

Androgen deprivation in advanced prostate cancer management

D. Eberli, Zürich (CH)

The options for men with castration-resistant prostate cancer

P. Rajwa, Warsaw (PL)

Case discussion Case discussion

D. Eberli, Zürich (CH)

P. Rajwa, Warsaw (PL)

C. Surcel, Bucharest (RO)

A to Z of recurrent Urinary Tract Infections (UTIs)

ESU Course 24

Saturday 14 March
16:00 - 18:00

Location Red Area, Room 8

Chair J. Medina Polo, Madrid (ES)

Voting will be available via the EAU26 App or via www.qna.at/eau

Learning objectives

Recurrent urinary tract infections (UTIs) are one of the most common reasons for medical consultation. It is estimated that 2.4% of women will experience recurrent urinary tract infections. The first step in preventing recurrent UTIs is to identify any predisposing factors. The second step involves non-antimicrobial measures, and finally, antimicrobial prophylaxis is recommended. This course will review the available evidence on various non-antibiotic measures, including topical oestrogen treatment, American cranberry extract, D-mannose, probiotics, immunoactive prophylaxis, and intravesical instillations containing hyaluronic acid. Emerging therapies will also be reviewed. The evidence will be presented with a practical approach, encouraging interaction with attendees.

Introduction and risk factors

C. Harding, Newcastle upon Tyne (GB)

Diagnosis work-up

J. Medina Polo, Madrid (ES)

Nutraceuticals

J. Medina Polo, Madrid (ES)

Non-antibiotic management (Immunoprophylaxis & Methenamine Hippurate)

C. Harding, Newcastle upon Tyne (GB)

New emerging tolos

J. Medina Polo, Madrid (ES)

Challenging cases: Urinary catheters, neurogenic bladder etc.

C. Harding, Newcastle upon Tyne (GB)

J. Medina Polo, Madrid (ES)

Bring your clinical cases

C. Harding, Newcastle upon Tyne (GB)

J. Medina Polo, Madrid (ES)

Surgical management of BPO: From resection to ablation of prostate adenoma

ESU Course 25

Saturday 14 March
16:00 - 18:00

Location Red Area, Room 9

Chair N. Barber, Camberley (GB)

Introduction: Why so called standard techniques will prevail despite trends. Sociodemographics, Socioeconomy and skill set spread

N. Barber, Camberley (GB)

EAU Guidelines Recommendations on BPO Surgical Treatment: Resection / Ablation

D. Perri, Como (IT)

532 nm ("Greenlight") laser vaporisation of the prostate: settings (in house, ambulatory), techniques and outcomes

N. Barber, Camberley (GB)

Evidence of Transurethral resection (TURP) and transurethral electrovaporization: Evolution of bipolar technology - When – How what

D. Perri, Como (IT)

Challenging TURP – Aquaablation: Settings, techniques (small, medum, large) and outcomes

N. Barber, Camberley (GB)

Rezum and Angioembolisation as a challenger of PVP? Settings, techniques (small, medum, large) and outcomes

N. Barber, Camberley (GB)

Case discussion Interactive case discussion

N. Barber, Camberley (GB)

D. Perri, Como (IT)

Closing remarks

N. Barber, Camberley (GB)

Practical tips for pelvic laparoscopic surgery: Cystectomy, radical prostatectomy adenomectomy and sacrocolpopexy

ESU Course 26

Saturday 14 March
16:00 - 18:00

Location Red Area, Room 10

Chair J.M. Gaya Sopena, Barcelona (ES)

Learning objectives

Patient positioning and trocar placement

J.M. Gaya Sopena, Barcelona (ES)

Laparoscopic adenectomy and radical prostatectomy

P. Kallidonis, Patras (GR)

Laparoscopic radical cystectomy

J.M. Gaya Sopena, Barcelona (ES)

Laparoscopic reconstructive surgery of the pelvic floor and sacrocolpopexy

P. Kallidonis, Patras (GR)

Identify and solve complications

J.M. Gaya Sopena, Barcelona (ES)

Planning, designing and executing randomised clinical trials in urology

ESU Course 29

Saturday 14 March
16:00 - 18:00

Location Red Area, Room 13

Chair K. Touijer, New York (US)

Voting will be available via the EAU26 App or via www.qna.at/eau

Learning objectives

Describe and apply best practices in clinical trial design.

Identify appropriate inclusion/exclusion criteria and outcome measures for trials.

Discuss statistical models commonly used in clinical trials.

Execute efficient protocol writing and trial activation tasks.

Competencies developed:

Ability to formulate research questions and design actionable clinical trials.

Experience in protocol preparation, team-based collaboration, and communication of scientific results.

Introduction and objectives

K. Touijer, New York (US)

Protocol development

K. Touijer, New York (US)

Key roles in clinical trials

A.J. Vickers, New York (US)

Trial logistics and operations

A.J. Vickers, New York (US)

Why do RCTs fail 25 min

K. Touijer, New York (US)

A.J. Vickers, New York (US)

Interactive workshop

K. Touijer, New York (US)

A.J. Vickers, New York (US)

Q&A & Wrap up

A.J. Vickers, New York (US)

Patient advocacy plaza - Discrimination of male patients with incontinence and hot-flushes



Special Session

Saturday 14 March
16:30 - 17:00

Location Patient Advocacy Plaza

Chair To be confirmed

16:30 - 17:00

Europa Uomo
To be confirmed

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 2.7

Saturday 14 March
16:30 - 17:20

Location Red Area, Room 1

Tutors To be confirmed
S.M. Haensel, Rotterdam (NL)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Hands-on Training in Endoscopic stone treatment - Step 1

HOT ESTs1 - 2.7

Saturday 14 March
16:30 - 17:20

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed
A. Sierra Del Rio, Barcelona (ES)

Learning objectives

This Basic Endoscopic Stone Treatment course is the first step in the Endoscopic Stone Treatment (EST) curriculum. It is designed to provide urologists with a fundamental understanding of endoscopic stone treatment and enhance their skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in endoscopy and wish to improve their proficiency in key techniques for endoscopic stone management. The curriculum includes four key exercises that provide hands-on experience and practical training: Flexible Cystoscopy, Rigid Cystoscopy, Semi-Rigid Ureteroscopy, and Flexible Ureteroscopy.

Hands-on Training in Laparoscopic urological skills - Step 1

HOT LUSs1 - 2.7

Saturday 14 March
16:30 - 17:20

Location Red Area, Room 1

Tutors O. Stakhovskyi, Kyiv (UA)
L. Vendrell, Ciudad - Mendoza (AR)

Learning objectives

This basic laparoscopic training course is the first step in the Laparoscopic Urological Skills (LUS) curriculum. It's designed to provide urologists with a fundamental understanding of laparoscopy and enhance their laparoscopic skills. This comprehensive training is specifically tailored for urologists who want to gain a basic level of knowledge in laparoscopy and wish to improve their proficiency in key laparoscopic techniques. The course comprises four essential exercises aimed at honing skills related to depth perception and bimanual dexterity: Peg Transfer, Circle Cut, Needle Guidance, and Knot Tying.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 2.7

Saturday 14 March
16:30 - 17:20

Location Red Area, Room 1

Tutors S. García Barreras, Madrid (ES)
To be confirmed

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Temporary Implantable Nitinol Device (iTind)

HOT iTind - 2.7

Saturday 14 March
16:30 - 17:20

Location Red Area, Room 1

Tutor To be confirmed

Learning objectives

The Hands-on Training in iTind (Temporary Implantable Nitinol Device) is designed to offer an in-depth and personalised educational experience. Each participant will receive one-on-one instruction from an experienced specialist, ensuring tailored guidance and expert insights. Utilising advanced anatomical models that accurately replicate human anatomy, attendees will practice the entire iTind implantation process, from insertion to removal. This course focuses on enhancing procedural proficiency through direct, hands-on practice, equipping participants with the skills and confidence necessary to perform iTind procedures effectively*.

*Olympus has a mandatory training program for HCPs who wish to adopt the iTind procedure into their healthcare institution. Enrolment onto this course does not allow HCPs to perform the procedure without the prior completion of the Olympus iTind training program.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 2.7

Saturday 14 March
16:30 - 17:20

Location Red Area, Room 1

Tutors G. Bozzini, Como (IT)
I. Kartalas Goumas, Vigevano (IT)
J.B. Roche, Bordeaux (FR)

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 2.7

Saturday 14 March
16:30 - 17:20

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Live podcasting session: Challenge the UROmigos

Special Session

Saturday 14 March
17:15 - 18:00

Location Orange Area, eURO Auditorium 2

Learning objectives

The Uromigos podcast is a successful urology cancer weekly podcast which has had over half a million listeners worldwide. Prof Brian Rini and Prof Tom Powles lead lively debates with invited speakers on key topics. They have channels in 4 languages including mandarin and Japanese.

Latest advances in bladder and kidney cancer

Speakers T. Powles, London (GB)
B. Rini, Nashville (US)

Making technology work for us in upper tract endourology

Plenary Session

Sunday 15 March
08:00 - 10:00

Location Orange Area, eURO Auditorium 2

Chairs M. Bultitude, London (GB)
P.J.S. Osther, Vejle (DK)

Learning objectives

Review historical and recent advances in laser technology for upper tract endourology, including Holmium YAG, Thulium Fibre, and Thulium YAG systems. Understand strategies for optimising laser performance in clinical practice through expert discussion and case examples. Learn about innovations in suction technology and features of disposable scopes to enhance endourological outcomes. Evaluate the integration of robotic platforms and AI tools in ureteroscopy and PCNL, focusing on prognostic and surgical applications. Critically compare and debate treatment approaches—shockwave lithotripsy, flexible ureteroscopy, and conservative management—for renal stones, including future techniques like burst wave lithotripsy.

08:00 - 08:02

Introduction

08:02 - 08:12

Spotlight talk **The history of laser development**

J. Denstedt, London (CA)

08:12 - 08:32

Round-table discussion **Keeping your finger on the pulse: Optimising my laser**

Moderator P.M. Kronenberg, Lisbon (PT)

08:12 - 08:16

Holmium YAG

E.K. Bres-Niewada, Pruszkow (PL)

08:16 - 08:20

Thulium Fibre

K.L.S. Stern, Phoenix (US)

08:20 - 08:24	Thulium YAG W. Kamal, Jeddah (SA)
08:24 - 08:32	Discussion
08:32 - 08:40	State-of-the-art lecture UTUC: Pushing the boundaries in endoscopic management A. Gallioli, Barcelona (ES)
08:40 - 08:48	State-of-the-art lecture Choosing a disposable scope - features galore! A. Pietropaolo, Southampton (GB)
08:48 - 09:08	Panel discussion How to get the most out of suction technology <i>Moderator</i> S. Yuen, Hong Kong (HK)
08:48 - 08:53	In scope suction technology V. Gauhar, Singapore (SG)
08:53 - 08:58	Flexible and navigable suction access sheaths D. Castellani, Ancona (IT)
08:58 - 09:03	PCNL and suction L. Tzelves, Athens (GR)
09:03 - 09:08	Discussion
09:08 - 09:18	Société Internationale d'Urologie (SIU) lecture Can robotic platforms become mainstream for ureteroscopy and PCNL? S.Y. Cho, Seoul (KR)
09:18 - 09:48	AI in the upper tract
09:18 - 09:28	State-of-the-art lecture AI: Prognostic tools and surgical application To be confirmed
	Rapid fire debate Back to the future: Treating an incidental 8mm renal stone <i>Moderator</i> T. Tailly, Ghent (BE)
09:28 - 09:30	Case presentation T. Tailly, Ghent (BE)
09:30 - 09:34	Shockwave lithotripsy To be confirmed
09:34 - 09:38	Flexible ureteroscopy S.M. Croghan, Dublin (IE)
09:38 - 09:42	Watch and wait: Not all stones need treating P. Juliebø-Jones, Bergen (NO)
09:42 - 09:48	Rebuttal and discussion
09:48 - 09:58	Spotlight talk Back to the future: Burst wave lithotripsy B.H. Chew, Vancouver (CA)
09:58 - 10:00	Conclusions

Evolving landscape in prostate cancer screening and AI-assisted diagnosis

Plenary Session

Sunday 15 March
08:00 - 10:00

Location Orange Area, eURO Auditorium 1

Chairs V. Kasivisvanathan, London (GB)
T. Nordström, Stockholm (SE)

08:00 - 08:01

Welcome

08:01 - 08:08

Introduction EAU Guidelines 2026: What's new in early detection?
J. Stranne, Göteborg (SE)

08:08 - 08:21

Final year of PRAISE-U

08:08 - 08:16

Screening across Europe: Key findings from the PRAISE-U
M.J. Roobol, Rotterdam (NL)

08:16 - 08:21

Live interview Scaling sustainable organised prostate cancer testing

Interviewer V. Parry, London (GB)

Speaker A. Chandran, Lyon (FR)

08:21 - 08:54

Individualising screening

08:21 - 08:27

Endpoint of early detection: What are we really screening for?
A.P. Auvinen, Tampere (FI)

08:27 - 08:33

Age matters: A guide to risk-adaptive screening
P. Albers, Düsseldorf (DE)

08:33 - 08:39

Screening intervals: When and how should we de-escalate?
J. Hugosson, Gothenburg (SE)

08:39 - 08:45

What is the role of biomarkers?
M.R. Cooperberg, San Francisco (US)

08:45 - 08:54

Discussion

08:54 - 09:04

State-of-the-art lecture Genomic tools in screening: Are we ready for the next step?
V. Hayes, Saratoga (AU)

09:04 - 09:48

Imaging: Scaling and quality

09:04 - 09:11

Performance of MRI for screening in 2026
C. Moore, London (GB)

09:11 - 09:18

MRI in the Real World: Challenges of quality and access
H.P.S. Schlemmer, Heidelberg (DE)

09:18 - 09:25

AI-assisted MRI, ready for prime-time
M. De Rooij, Nijmegen (NL)

09:25 - 09:32

AI-assisted MRI, not yet
G. Brembilla, Milan (IT)

09:32 - 09:39

Beyond MRI? The case for micro-ultrasound

L.H. Klotz, Toronto (CA)

09:39 - 09:48

Discussion

09:48 - 09:58

Early detection and screening – Where should we be heading?

F.C. Hamdy, Oxford (GB)

09:58 - 10:00

Closing remarks

Practical approach to paediatric urology

ESU Course 30

Sunday 15 March

08:30 - 11:30

Location

Red Area, Room 7

Chair

R.J.M. Lammers, Groningen (NL)

Learning objectives

In this course, we will explore the most common paediatric urological conditions, using interactive case presentations. We will discuss diagnostics, treatment options and follow-up strategies. As many children with congenital anomalies will present to the adult urologist with long-term sequelae, we also discuss transition of care into adulthood. Thus, we give an overview of paediatric urology for the adult urologist.

Vesico-ureteral reflux (VUR)

A-F. Spinoit, Ghent (BE)

Bladder- and bowel dysfunction and LUTS

R.J.M. Lammers, Groningen (NL)

Ureteropelvic junction (UPJ) and uterovesical junction (UVJ) stenosis

B. Burgu, Ankara (TR)

Neurogenic bladder

R.J.M. Lammers, Groningen (NL)

Penile anomalies

B. Burgu, Ankara (TR)

Scrotal anomalies

B. Burgu, Ankara (TR)

Transition of care into adulthood

A-F. Spinoit, Ghent (BE)

Sunday 15 March

08:30 - 11:30

Location Red Area, Room 13

Chair T.M. Kessler, Zurich (CH)

Learning objectives

- Learn which nerve centres control the lower urinary tract, and the general principles of how functions change in neurological disease
- Understand key aspects of neuro-urological assessments as described in the EAU guidelines
- Discuss key factors when deciding on therapy

Introduction: What can go wrong with the lower urinary tract?

T.M. Kessler, Zurich (CH)

Neuro-urological assessments

S.T. De Cillis, Turin (IT)

Treatment: Key issues

N. Sihra, London (GB)

Clinical case discussion

S.T. De Cillis, Turin (IT)

T.M. Kessler, Zurich (CH)

N. Sihra, London (GB)

Conclusion

T.M. Kessler, Zurich (CH)

Percutaneous nephrolithotripsy (PCNL)

ESU Course 35

Sunday 15 March
08:30 - 11:30

Location Red Area, Room 12

Chair A. Skolarikos, Athens (GR)

Voting will be available via the EAU26 App or via www.qna.at/eau

Learning objectives

The aim of this course is to describe the surgical techniques of all available treatment options in percutaneous surgery of renal stones in details. In addition to tips and tricks aiming into improving the efficacy of the operation, the most common complications associated with the procedure will be reviewed focusing on prevention and proper management.

Objectives:

- describe the main indications for percutaneous nephrolithotomy and the best clinical practice based on the EAU Guidelines
- Describe the basic percutaneous nephrolithotomy techniques step by step
- Provide tips and tricks to improve the efficacy of the operation
- Identify associate complications including their management

Guidelines on stone treatment

E.K. Bres-Niewada, Pruszkow (PL)

PCNL instrumentation – Suite organisation, wires, dilators and lithotriptors

E.K. Bres-Niewada, Pruszkow (PL)

From skin to stone: Step-by-step access using only fluoroscopy (Prone position)

A. Skolarikos, Athens (GR)

From skin to stone: Step-by-step access using ultrasonography (US) and fluoroscopy (Supine position)

O.R. Durutovic, Belgrade (RS)

MiniPerc- Indications, equipment and technique

A. Skolarikos, Athens (GR)

Tips and tricks in PCNL

O.R. Durutovic, Belgrade (RS)

Round table: Complications of PCNL: Diagnosis, management, prevention

E.K. Bres-Niewada, Pruszkow (PL)

O.R. Durutovic, Belgrade (RS)

A. Skolarikos, Athens (GR)

Sunday 15 March
08:30 - 11:30

Location Red Area, Room 8

Chair A. Van Der Heijden, Nijmegen (NL)

Learning objectives

- Gain up-to-date insight into diagnostics and staging of MIBC, including the role of advanced imaging techniques, pathological assessment and subtypes;
- Critically appraise current and emerging treatment strategies, neoadjuvant treatment, surgery, bladder-sparing options, and adjuvant or palliative systemic treatment;
- Apply recent evidence to clinical decision-making in both localized and metastatic settings, including management of oligometastatic disease and follow-up.

Diagnosis and initial work-up

A. Van Der Heijden, Nijmegen (NL)

Perioperative therapy

R. Cathomas, Chur (CH)

Surgery

L.S. Mertens, Amsterdam (NL)

Bladder preserving treatment

A. Van Der Heijden, Nijmegen (NL)

Metastatic disease

R. Cathomas, Chur (CH)

Oligometastatic disease and follow up

L.S. Mertens, Amsterdam (NL)

2026 EAU Guidelines update and controversies – Urolithiasis, female and male LUTS and infections: What has changed?

ESU Course 33

Sunday 15 March
08:30 - 11:30

Location Red Area, Room 10

Chair A.K. Nambiar, Newcastle-upon-Tyne (GB)

Learning objectives

This course will focus on three non-oncology Guidelines (Non-Neurogenic Female and Male LUTS, and Urolithiasis) and there will be a brief review of the EAU Guidelines methodology and process of guideline development.

The course will then involve an interactive discussion of the main new changes to these guidelines, challenges in development, areas of inconsistency and opportunities for further research.

Welcome and introduction

A.K. Nambiar, Newcastle-upon-Tyne (GB)

Urolithiasis guideline: New diagnostic algorithms, best clinical practice in urinary stone intervention, how and how often to follow up and time to discharge urinary stone patients after treatment

R. Geraghty, Newcastle upon Tyne (GB)

Non-neurogenic male LUTS guideline: Updates and controversies

J-N.L. Cornu, Rouen (FR)

Female Non-neurogenic LUTS: A re-birth, revamp and re-naming. Changes to expect in 2025

A.K. Nambiar, Newcastle-upon-Tyne (GB)

Updates from the EAU Guidelines on infections – Recurrent UTI, ABU and the EMA stance on fluoroquinolones

G. Bonkat, Basel (CH)

Surgical genital reconstruction - Step by step video demonstration of common procedures

ESU Course 34

Sunday 15 March
08:30 - 11:30

Location Red Area, Room 11

Chair S.C. Morgenstern, Frankfurt am Main (DE)

Learning objectives

This new ESU course by the EAU reconstruction section addresses the needs of urologists from first interest in genital reconstruction to those in their early years of reconstructive practise. Based on short surgical step-by-step- videos with a high emphasis on participant-interaction, renown experts share their tips and tricks out of their vast surgical experience on the most common procedures in genio-urethral reconstruction.

Introduction

S.C. Morgenstern, Frankfurt am Main (DE)

Penile surgeries

General pre- and post OP tips and tricks

S.C. Morgenstern, Frankfurt am Main (DE)

Complications after circumcision and lichen

S.C. Morgenstern, Frankfurt am Main (DE)

Penile Implants

D.J. Ralph, London (GB)

Peyronies

S.C. Morgenstern, Frankfurt am Main (DE)

D.J. Ralph, London (GB)

Penile emergancies

Penile fracture

D.J. Ralph, London (GB)

Priapism

S.C. Morgenstern, Frankfurt am Main (DE)

D.J. Ralph, London (GB)

Basic urethral reconstruction

Meatus stenosis and anterior urethral stricture

D. Hernández Hernández, San Cristóbal de La Laguna (ES)

S.C. Morgenstern, Frankfurt am Main (DE)

Basic male incontinence

Incontinence

D. Hernández Hernández, San Cristóbal de La Laguna (ES)

Evaluation and closure

S.C. Morgenstern, Frankfurt am Main (DE)

D.J. Ralph, London (GB)

Robotic-assisted laparoscopic prostatectomy

ESU Course 32

Sunday 15 March
08:30 - 11:30

Location Red Area, Room 9

Chair A. De La Taille, Créteil (FR)

Learning objectives

The objectives are to explain, using videos and step-by-step explanations, robotic assisted radical prostatectomy with three presenters using three different approaches: Transperitoneal, preperitoneal and retzius-sparing techniques.

General principles regarding port placement, prostate anatomy and surgical landmarks will be also reminded considering the different possible options and the different types of robotic systems used. Finally, the course will present the possible intraoperative risks of complications and how-to-manage-them strategies.

This course will be interactive including direct and/or multichoice questions to the audience.

Introduction

A. De La Taille, Créteil (FR)

Anatomical reminders

F. Annino, Arezzo (IT)

RALP by steps: Anterior transperitoneal

A. Haese, Hamburg (DE)

RALP by steps: Retius sparing

F. Annino, Arezzo (IT)

Tips and Tricks

How to avoid positive margins during nerve-sparing

A. Haese, Hamburg (DE)

How to preserve bladder neck

F. Annino, Arezzo (IT)

How to avoid and manage urine leakage

A. De La Taille, Créteil (FR)

Tricky cases

Prostatectomy after TURP/Enucleation

A. Haese, Hamburg (DE)

How to manage median lobe and prostate > 100 grms

F. Annino, Arezzo (IT)

Salvage prostatectomy

A. De La Taille, Créteil (FR)

Beware of complications

Bleeding

A. Haese, Hamburg (DE)

Ureteral lesion

F. Annino, Arezzo (IT)

Manage bladder strictures

A. De La Taille, Créteil (FR)

Discussion: Quality control during the learning curve

A. Haese, Hamburg (DE)

Conclusion

A. De La Taille, Créteil (FR)

Hands-on Training in prostate MRI reading for urologists

HOT MRI - 3.1

Sunday 15 March
09:00 - 12:30

Location Red Area, Room 6

Learning objectives

This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on a provided computer using realistic software, followed by a reference reading provided by expert radiologists and pathological verification.

09:00 - 09:05

Course overview

J. Walz, Marseille (FR)

09:05 - 09:15

Lecture: The importance of prostate MRI to the Urologist

J.P. Radtke, Düsseldorf (DE)

09:15 - 09:45

Lecture: Introduction to MRI sequences, scoring systems, PI-RADS

F. Giganti, London (GB)

09:45 - 10:15

Lecture: Interactive case discussion – reporting MRI using PI-RADS

T. Barrett, Cambridge (GB)

10:15 - 10:20

Introduction to the software for MRI interpretation

J. Walz, Marseille (FR)

10:20 - 10:50

Diagnosis I: Practical MRI diagnosis

10:50 - 11:20

Review of the findings I

F. Giganti, London (GB)

11:20 - 11:50

Diagnosis II: Practical MRI diagnosis

11:50 - 12:20

Review of the findings II

T. Barrett, Cambridge (GB)

12:20 - 12:30

Discussion, feedback & closure

J.P. Radtke, Düsseldorf (DE)

Hands-on Training in Botulinum Toxin Injection

HOT Botox - 3.1

Sunday 15 March
09:00 - 10:30

Location

Red Area, Room 3

Chairs

H. Hashim, Bristol (GB)

To be confirmed

Learning objectives

Botulinum toxin type A has become established in urological practice over the past decades. Onabotulinum-toxin A (BTX-A) is licensed for the treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO) refractory to conservative and medical therapy.

This European Association of Urology (EAU) Hands-on Training (HOT) course is procedure-focused and teaches the practical aspects of intradetrusor onabotulinum-toxin-A administration through hands-on training using bladder models. Participants will learn safe reconstitution, injection techniques, using flexible and rigid cystoscopic equipment.

09:00 - 09:15

Introduction

H. Hashim, Bristol (GB)

Learning objectives of this presentation

- Role of onabotulinumtoxinA (BTX-A) in the OAB and NDO treatment pathway
- Evidence-base and EAU guideline recommendations
- Injection paradigms, dosing, and patient counselling
- Overview of other functional urological applications (off-label)

09:15 - 10:15

Hands-on Rotation

09:15 - 10:15

Station 1: Onabotulinum-toxin-A reconstitution

Tutor

A. Sahai, London (GB)

09:15 - 10:15

Station 2: Intradetrusor injection using flexible cystoscopy

Tutor

To be confirmed

09:15 - 10:15

Station 3: Intradetrusor injection using rigid cystoscopy

Tutor

M.A. Averbeck, Porto Alegre (BR)

10:15 - 10:30

Wrap-up and Q&A

To be confirmed

Learning objectives of this presentation

- Key learning points
- Discussion of complications and practical considerations

E-BLUS Exam

HOT EBLUS EXAM - 3.1

Sunday 15 March
09:00 - 09:55

Location Red Area, Room 1

Tutors V. Novak, Praha (CZ)
To be confirmed

Learning objectives

In this exam, your psychomotor skills such as depth perception and bimanual dexterity will be tested and your mastery of basic laparoscopy skills such as instrument handling, pattern cutting and intracorporeal suturing will be assessed by experienced examiners.

The exam is aimed at candidates with intermediate and advanced laparoscopy experience or those who have sufficiently trained to meet the exercises time and quality criteria. Passing the E-BLUS exam will be rewarded with a certificate that serves as a recommendation to continue your laparoscopy training by assisting laparoscopic procedures in the OR.

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 3.1

Sunday 15 March
09:00 - 09:50

Location Red Area, Room 1

Tutors N.C. Grossmann, Lucerne (CH)
A. Tsaturyan, Yerevan (AM)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

ESTs1 Exam

HOT EST EXAM 3.1

Sunday 15 March
09:00 - 09:50

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed
A. Papatsoris, Athens (GR)

Learning objectives

In this exam, candidates' psychomotor and endoscopic skills are assessed, with a focus on the safe and effective performance of core endourological procedures such as rigid cystoscopy, flexible cystoscopy, semi-rigid ureteroscopy, and flexible ureteroscopy. Candidates are evaluated by experienced examiners on instrument handling, scope control, orientation, and respect for tissue within a simulated setting. The exam is aimed at candidates with basic to intermediate endourology experience or those who have completed sufficient training to meet the required performance standards, and successful completion is rewarded with a certificate recommending progression to supervised endourological procedures in the operating room.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 3.1

Sunday 15 March
09:00 - 09:50

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 3.1

Sunday 15 March
09:00 - 09:50

Location Red Area, Room 1

Tutors M. Arslan, Istanbul (TR)
G. Bozzini, Como (IT)
D. Perri, Como (IT)

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 3.1

Sunday 15 March
09:00 - 09:50

Location Red Area, Room 1

Tutors H. Ismail, Cottbus (DE)
To be confirmed

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Hands-on Training in TP Biopsy and MRI fusion

HOT TPB - MRI - 3.1

Sunday 15 March
09:30 - 12:30

Location Red Area, Room 2

Chair To be confirmed

Learning objectives

This course is designed to provide a comprehensive overview of office based transperineal (TP) biopsy techniques in local anaesthesia. It includes the integration of MRI fusion technology into daily clinical practice. Participants will begin with an introduction to the importance of TP biopsy and detailed instructions on performing the procedure by themselves..

The hands-on training sessions are the core of the course, where participants will practice:

- Basic superficial local anesthesia
- Deep periprostatic block
- Basic perineal with probe
- Basics of targeting and fusion
- Basics of hitting
- Single incision biopsies

09:30 - 09:35

Introduction

To be confirmed

09:35 - 09:50

Why TP biopsy & how to do TP biopsy

To be confirmed

09:50 - 10:00

Technical comparison

To be confirmed

10:00 - 11:55

Hands-on Training

Tutors

H.U. Ahmed, London (GB)

J. Anract, PARIS (FR)

M. Jahnen, Munich (DE)

To be confirmed

11:55 - 12:25

Circulate among stations

12:25 - 12:30

Closing remarks

To be confirmed

E-BLUS Exam

HOT EBLUS EXAM - 3.2

Sunday 15 March
10:00 - 10:55

Location Red Area, Room 1

Tutors V. Novak, Praha (CZ)
To be confirmed

Learning objectives

In this exam, your psychomotor skills such as depth perception and bimanual dexterity will be tested and your mastery of basic laparoscopy skills such as instrument handling, pattern cutting and intracorporeal suturing will be assessed by experienced examiners.

The exam is aimed at candidates with intermediate and advanced laparoscopy experience or those who have sufficiently trained to meet the exercises time and quality criteria. Passing the E-BLUS exam will be rewarded with a certificate that serves as a recommendation to continue your laparoscopy training by assisting laparoscopic procedures in the OR.

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 3.2

Sunday 15 March
10:00 - 10:50

Location Red Area, Room 1

Tutors N.C. Grossmann, Lucerne (CH)
A. Tsaturyan, Yerevan (AM)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

ESTs1 Exam

HOT EST EXAM 3.2

Sunday 15 March
10:00 - 10:50

Location Red Area, Room 1

Tutors A.C. Bouma - Houwert, Amsterdam (NL)
To be confirmed
A. Papatsoris, Athens (GR)

Learning objectives

In this exam, candidates' psychomotor and endoscopic skills are assessed, with a focus on the safe and effective performance of core endourological procedures such as rigid cystoscopy, flexible cystoscopy, semi-rigid ureteroscopy, and flexible ureteroscopy. Candidates are evaluated by experienced examiners on instrument handling, scope control, orientation, and respect for tissue within a simulated setting. The exam is aimed at candidates with basic to intermediate endourology experience or those who have completed sufficient training to meet the required performance standards, and successful completion is rewarded with a certificate recommending progression to supervised endourological procedures in the operating room.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 3.2

Sunday 15 March
10:00 - 10:50

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 3.2

Sunday 15 March
10:00 - 10:50

Location Red Area, Room 1

Tutors M. Arslan, Istanbul (TR)
G. Bozzini, Como (IT)
D. Perri, Como (IT)

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 3.2

Sunday 15 March
10:00 - 10:50

Location Red Area, Room 1

Tutors H. Ismail, Cottbus (DE)
To be confirmed

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Paediatric penile surgeries

Thematic Session

Sunday 15 March
10:30 - 12:00

Location Orange Area, Room 3

Chairs C. Gernhold, Linz (AT)
M.S. Silay, Istanbul (TR)

Learning objectives

This video-based session will describe the indications, techniques and postoperative management of common paediatric penile surgeries; recognize and prevent potential complications; and apply evidence-based decision making to optimize functional and cosmetic outcomes in children undergoing penile reconstruction.

10:30 - 10:58

Most common penile surgeries

10:30 - 10:37

Semi-live video presentation Male circumcision

B. Bañuelos Marco, Madrid (ES)

10:37 - 10:44

Semi-live video presentation Buried penis

Y.T. Soygür, Ankara (TR)

10:44 - 10:51

Semi-live video presentation Webbed penis

A. Morlacco, Padova (IT)

10:51 - 10:58

Discussion

10:58 - 11:35

Hypospadias

10:58 - 11:08

Distal hypospadias repair techniques

N. Pakkasjarvi, Turku (FI)

11:08 - 11:18

Flaps and grafts during distal hypospadias repair: Where to use them?

R. Subramaniam, Leeds (GB)

11:18 - 11:28

Management of most common distal hypospadias repair complications: Fistula, stenosis and glans dehiscence

P. Hoebeke, Ghent (BE)

11:28 - 11:35

Discussion

11:35 - 11:42

Semi-live video presentation An unpleasant surprise: Megameatus intact prepuce

B. Burgu, Ankara (TR)

11:42 - 11:49

Semi-live video presentation Congenital penile curvature

M. Peycelon, Paris (FR)

11:49 - 11:56

Semi-live video presentation Treatment of benign penile lesions

To be confirmed

11:56 - 12:00

Discussion

Sunday 15 March
10:30 - 12:00

Location Blue Area, Victoria 5
Chairs B.J. Challacombe, London (GB)
S.D. Pandolfo, Naples (IT)
M. Wroclawski, Sao Paulo (BR)

10:30 - 10:50

ctDNA: What's happening in kidney cancer?

A0459

Application of Individualized molecular residual disease in risk stratification, recurrence monitoring, and drug efficacy prediction for renal cell carcinoma

Authors

Wang A.¹, Chen M.¹, Jiang J.², Gu D.³, Huang Y.⁴, Shao P.⁵, Li P.⁶

Institutions

¹Shanghai Changzheng Hospital of Naval Medical University, Dept. of Urology, Shagnhai, China, ²The First Affiliated Hospital of Ningbo University, Dept. of Urology, Ningbo, China, ³The First Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangzhou, China, ⁴The First Affiliated Hospital of Soochow University, Dept. of Urology, Suzhou, China, ⁵Jiangsu Province Hospital, Dept. of Urology, Nanjing, China, ⁶Huzhou Central Hospital, Dept. of Urology, Huzhou, China

A0460

Multicenter Establishment and Validation of cM0 (i+) Stage Criteria in Localized Renal Cell Carcinoma Based on Postoperative Circulating Tumor Cell Monitoring

Authors

Chong Y.¹, Li Z.¹, Wei Q.², Wang S.³, Bi J.⁴, Shao J.⁵, Zhang X.⁶, Gou X.⁶, Shen W.⁷, He W.⁶, Cao X.⁸, Xiong W.⁹, Chen G.¹⁰, Yang X.¹¹, Qiu J.¹², Li Y.¹³, Liu J.¹⁴, Shen Y.¹⁵, Chong T.¹, Wang Z.L.¹

Institutions

¹The Second Affiliated Hospital of Xi'an Jiaotong University, Dept. of Urology, Xi'an, China, ²West China Medical Center, Sichuan Medical University, Dept. of Urology, Chengdu, China, ³Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Dept. of Urology, Wuhan, China, ⁴The First Hospital of China Medical University, Dept. of Urology, Shenyang, China, ⁵Shanxi Provincial People's Hospital, Dept. of Urology, Taiyuan, China, ⁶First Affiliated Hospital of Chongqing Medical University, Dept. of Urology, Chongqing, China, ⁷The First Affiliated Hospital (Southwest Hospital) of Third Military Medical University, Dept. of Urology, Chongqing, China, ⁸The First Hospital of Shanxi Medical University, Dept. of Urology, Taiyuan, China, ⁹Sichuan Provincial People's Hospital, Dept. of Urology, Chengdu, China, ¹⁰Qinghai University Affiliated Hospital, Dept. of Urology, Xining, China, ¹¹Xijing Hospital, Air Force Military Medical University, Dept. of Urology, Xi'an, China, ¹²Air Force Medical University the Second Affiliated Tangdu Hospital, Dept. of Urology, Xi'an, China, ¹³Baoji People's Hospital, Dept. of Urology, Baoji, China, ¹⁴Baoji City Central Hospital, Dept. of Urology, Baoji, China, ¹⁵Xi'an Jiaotong University, Dept. of Epidemiology and Biostatistics, Xi'an, China

A0461

Undetectable ctDNA in patients with localized renal cell carcinoma is associated with improved oncological outcomes and may be amenable to a less intense imaging surveillance protocol

Authors

Ben David R.¹, Eraky A.², Kalola H.², Mandel A.², Zhu A.², Sfakianos J.P.², Wiklund P.², Mehrazin R.²

Institutions

¹Tel Aviv Medical Center, Dept. of Urology, Tel Aviv, Israel, ²Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America

A0462

ctDNA-Based MRD Monitoring in Genitourinary Cancers Early Relapse Prediction and Clinical Implications

Authors

Liu T.¹, Zhang H.¹, Man X.¹, Li X.¹, Zhan B.¹, Xu X.¹, Chen Y.¹, Cheng S.², Jiang Y.J.¹

Institutions

¹The First Affiliated Hospital of China Medical University, Dept. of Urology, Shenyang, China, ²HaploX Biotechnology, Dept. of Oncology, Shenzhen, China

10:50 - 11:25

Biomarkers for risk stratification RCC

A0463

Diagnostic and Prognostic Role of Prostate-Specific Membrane Antigen Expression in Clear Cell Renal Cell Carcinoma

Authors

Hamidzada I.¹, Cakici M.C.¹, Aknar F.², Kazan O.¹, Kir G.², Yildirim A.¹

Institutions

¹Istanbul Medeniyet University, Dept. of Urology, Istanbul, Turkey, ²Istanbul Medeniyet University, Dept. of Pathology, Istanbul, Turkey

A0464

Radiomics Analysis of CT Imaging for Predicting MIT Family Translocation Renal Cell Carcinoma: A Multicenter Retrospective Clinical Study

Authors

Chen S., Xiao-Hui W., Ning X.

Institutions

The First Affiliated Hospital of Fujian Medical University, Dept. of Urology, Fuzhou, China

A0465

Establishment of screening criteria for progressive ccRCC subtypes- a prospective study

Authors

Hou Y., Chen K., Hu J., Liu L.

Institutions

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China

A0466

Endothelial PSMA expression correlates with vascular remodeling, hypoxia and immunosuppressive microenvironment of clear-cell renal cell carcinoma

Authors

Gao J., Wang X., Cheng L., Guo H.

Institutions

Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China

A0467

Endothelial PSMA expression correlates with EMT, microvascular invasion and metastasis of clear-cell renal cell carcinoma

Authors

Gao J., Wang X., Cheng L., Guo H.

Institutions

Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China

A0468

From waste to diagnosis: Urinary extracellular vesicle proteomics reveals diagnostic and risk-associated biomarkers in clear-cell renal cell carcinoma

Authors

de Haan L.T.¹, Xu L.², Piersma S.R.², Pham T.V.², Bijnsdorp I.¹, Jimenez C.R.², Zondervan P.J.¹

Institutions

¹Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ²Amsterdam UMC, Dept. of Medical Oncology, OncoProteomics Lab, Amsterdam, The Netherlands

A0469

First-In-Human Ex-Vivo Validation Of Carbonic Anhydrase IX-Target PET For High-Risk Renal Cancer: Tumor Heterogeneity, Lymph Nodes And Metastases (CAT-VHL - PNRR-POC-2023-12377493 - Cohort B)

Authors

Cei F.¹, Gelardi F.², Antunovic L.², Savi A.², Olivieri M.², Rainone P.², Sollini M.², Moresco R.M.², Re C.¹, Belladelli F.¹, Musso G.¹, Salerno L.¹, Corea F.¹, De Cobelli F.³, Brembilla G.³, Tenace N.⁴, Ponzoni M.⁴, Bertini R.¹, Briganti A.¹, Montorsi F.¹, Capitanio U.¹, Salonia A.¹, Chiti A.², Larcher A.¹

Institutions

¹IRCCS San Raffaele Scientific Institute. URI Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Dept. of Nuclear Medicine, Milan, Italy, ³IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy, ⁴IRCCS San Raffaele Hospital, Dept. of Pathology, Milan, Italy

11:25 - 11:50

Renal biopsy

High versus Low Center Use of Preoperative Renal Biopsy: Oncological Outcomes after Nephrectomy for Small Renal Masses

Authors

Sarkis J.¹, Champy C.M.², Bigot P.³, Doumerc N.⁴, Bruyere F.⁵, Roupret M.⁶, Branger N.⁷, Surlemont L.⁸, Michel C.⁹, Waeckel T.¹⁰, Parier B.¹¹, Beauval J.B.¹², Lang H.¹³, Vallee M.¹⁴, Guillotreau J.¹⁵, Patard J.J.¹⁶, Sarrazin C.M.¹⁷, DE VERGIE S.¹⁸, Belas O.¹⁹, Mallet R.²⁰, Bernhard J.C.²¹, Ingels A.²

Institutions

¹Grand Hopital de l'Est-Francilien, Dept. of Urology, Meaux, France, ²Henri Mondor University Hospital, AP-HP, Dept. of Urology, Creteil, France, ³CHU Angers, Dept. of Urology, Angers, France, ⁴CHU Rangueil, Dept. of Urology, Toulouse, France, ⁵CHRU Tours, Dept. of Urology, Tours, France, ⁶CHU La Pitié Salpêtrière, Dept. of Urology, Paris, France, ⁷Institut Paoli Calmettes, Dept. of Urology, Marseille, France, ⁸CHU Rouen, Dept. of Urology, Rouen, France, ⁹Hôpital St Joseph, Dept. of Urology, Paris, France, ¹⁰CHU Caen, Dept. of Urology, Caen, France, ¹¹Hôpital Bicêtre, Dept. of Urology, Paris, France, ¹²Clinique La Croix du Sud, Dept. of Urology, Toulouse, France, ¹³CHRU Strasbourg, Dept. of Urology, Strasbourg, France, ¹⁴CHU Poitiers, Dept. of Urology, Poitiers, France, ¹⁵Clinique Pasteur, Dept. of Urology, Toulouse, France, ¹⁶CH Mont-de-Marsan, Dept. of Urology, Mont-de-Marsan, France, ¹⁷CHU Grenoble, Dept. of Urology, Grenoble, France, ¹⁸CHU Nantes, Dept. of Urology, Nantes, France, ¹⁹Pole Santé Sud, Dept. of Urology, Nantes, France, ²⁰Polyclinique Francheville, Dept. of Urology, Perigueux, France, ²¹CHU Bordeaux, Dept. of Urology, Bordeaux, France

Study Group

UroCCR French Research Network for Kidney Cancer(Bordeaux, France)

Biopsy and Identification of Risk Factors for Discordance in Renal Tumor : Results from the BIRD study (UroCCR n°230)

Authors

Kutchukian S.¹, Margue G.², Branger N.³, Bigot P.⁴, Fontenil A.⁵, Boissier R.⁶, Thomas P.⁷, Michel C.⁸, Chatain V.R.⁹, Waeckel T.¹⁰, Beauval J.B.¹¹, Champy C.¹², Vallée M.¹, Lang H.¹³, De Vergie S.P.¹⁴, Vignot L.¹⁵, Parier B.¹⁶, Taha F.¹⁷, Surlemont L.¹⁸, Bernhard J.C.², Audenet F.O.¹⁹

Institutions

¹Poitiers University Hospital, Dept. of Urology, Poitiers, France, ²Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ³Institut Paoli-Calmettes, Dept. of Urology, Marseille, France, ⁴Angers University Hospital, Dept. of Urology, Angers, France, ⁵Nimes University Hospital, Dept. of Urology, Nimes, France, ⁶Marseille University Hospital, La Conception, Dept. of Urology, Marseille, France, ⁷Toulouse University Hospital, Dept. of Urology, Toulouse, France, ⁸Saint Joseph Hospital, Dept. of Urology, Paris, France, ⁹Lyon University Hospital, Dept. of Urology, Lyon, France, ¹⁰Caen University Hospital, Dept. of Urology, Caen, France, ¹¹Croix du Sud Hospital, Dept. of Urology, Toulouse, France, ¹²Henri Mondor University Hospital, Dept. of Urology, Paris, France, ¹³Strasbourg University Hospital, Dept. of Urology, Strasbourg, France, ¹⁴Nantes University Hospital, Dept. of Urology, Nantes, France, ¹⁵Nice University Hospital, Dept. of Urology, Nice, France, ¹⁶Bicetre University Hospital, Dept. of Urology, Paris, France, ¹⁷Reims University Hospital, Dept. of Urology, Reims, France, ¹⁸Rouen University Hospital, Dept. of Urology, Rouen, France, ¹⁹Georges Pompidou University Hospital, Dept. of Urology, Paris, France

A0472

Higher harmonic generation microscopy for rapid, label-free imaging of renal cancer tissue: Preliminary results from the INTelligent Imaging RCC (INTIMA) study

Authors

Duijn M.¹, Spies S.², de Bruin M.³, van der Voorn J.P.⁴, Lange M.M.⁴, Savci C.D.⁴, van Delden O.M.⁵, van den Brink L.¹, Groot M.L.², Zondervan P.J.¹

Institutions

¹Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ²Vrije Universiteit, Dept. of Biophotonics and Medical Imaging, Amsterdam, The Netherlands, ³Amsterdam UMC, Dept. of Biomedical engineer and Physics, Amsterdam, The Netherlands, ⁴Amsterdam UMC, Dept. of Pathology, Amsterdam, The Netherlands, ⁵Amsterdam UMC, Dept. of Radiology, Amsterdam, The Netherlands

A0473

Breaking The Myth Of Tumor Seeding: Renal Tumor Biopsy Does Not Increase Relapse Or Progression Risk

Authors

Belladelli F.¹, Santangelo A.¹, Bertini A.¹, Longoni M.¹, Piccolo C.¹, Cattafi F.¹, Re C.¹, Cei F.¹, Musso G.¹, Rosiello G.¹, Salerno L.¹, Matloob R.¹, Bertini R.¹, Briganti A.¹, Salonia A.¹, De Cobelli F.², Brembilla G.², Gusmini S.², Imperiale G.², Guazzarotti G.², Montorsi F.¹, Larcher A.¹, Capitanio U.¹

Institutions

¹IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy

A0474

Bridging the Diagnostic Gap: A Novel-Invasive Biomarker to Differentiate Chromophobe RCC from Oncocytoma

Authors

Bothe P., Berg F.L., Ni Y., Humbert B.T., Bouillon B., Nestler T., Wirtz R., Freifrau von Brandenstein M., Heidenreich A., Storz E.

Institutions

University Hospital Cologne, Dept. of Urology, Cologne, Germany

11:50 - 12:00

Small renal mass

A0475

Refining Surveillance for Small Renal Masses: Predicting Aggressiveness and Oncologic Outcomes Based on Tumour Size and Patient Characteristics

Authors

Salerno L.¹, Cei F.¹, Piccolo C.¹, Scilipoti P.¹, Bertini A.¹, Re C.¹, Musso G.¹, Rosiello G.¹, Belladelli F.¹, Disabato N.¹, Cigliola A.², Necchi A.², Tenace N.³, Colecchia M.³, Ponzoni M.³, Bertini R.¹, Matloob R.¹, Briganti A.¹, Salonia A.¹, Vickers A.⁴, Montorsi F.¹, Larcher A.¹, Capitanio U.¹

Institutions

¹IRCCS San Raffaele Scientific Institute. URI-Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Dept. of Medical Oncology, Milan, Italy, ³IRCCS San Raffaele Hospital, Dept. of Pathology, Milan, Italy, ⁴Memorial Sloan Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, New York, United States of America

When Silence Speaks Loud: Decoding Symptomatic Presentation in Small Renal Masses

Authors

Bertini A.¹, Re C.¹, Salerno L.¹, Musso G.¹, Cei F.¹, Rosiello G.¹, Belladelli F.¹, Piccolo C.¹, Disabato N.¹, Barretta A.¹, Ficarra G.¹, Campugiani A.¹, Montesano M.¹, Tenace N.², Colecchia M.², Ponzoni M.², Brembilla G.³, De Cobelli F.³, Briganti A.¹, Bertini R.¹, Salonia A.¹, Montorsi F.¹, Larcher A.¹, Capitanio U.¹

Institutions

¹IRCCS San Raffaele Scientific Institute. URI - Urological Research Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Dept. of Pathology, Milan, Italy, ³IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy

Lights and shadows in LUTS/BPO management: From pharmacotherapy to MISTs

Abstract Session 26

Sunday 15 March
10:30 - 12:00

Location

Blue Area, Victoria 2

Chairs

M.A. Averbeck, Porto Alegre (BR)

S. Secco, Milan (IT)

K.C. Zorn, Montreal (CA)

10:30 - 10:45

Medical treatment

A0435

Real-world evaluation of clinically meaningful improvement in symptoms and quality of life in Greek patients with benign prostatic hyperplasia after six months of treatment with the fixed dose combination of dutasteride/tamsulosin. Pooled analysis of the PROSPERITY I and II studies.

Authors

Hatzimouratidis K.¹, Liatsikos E.², Kallidonis P.², Skrepetis K.³, Stamatiou K.⁴, Georgopoulos P.², Ginis A.⁵, Loutriotis A.⁵, Papanastasiou P.⁵, Tsioumas G.⁵, Dimitriadis G.⁶

Institutions

¹School of Medicine, Aristotle University of Thessaloniki, Second Dept. of Urology, Thessaloniki, Greece, ²University Hospital of Rion, Dept. of Urology, Patras, Greece, ³General Hospital of Messinia, Dept. of Urology, Kalamata, Greece, ⁴Tzaneio General Hospital, Dept. of Urology, Piraeus, Greece, ⁵ELPEN Pharmaceutical Co. Inc., Medical Department, Athens, Greece, ⁶School of Medicine, Aristotle University of Thessaloniki, First Dept. of Urology, Thessaloniki, Greece

A0436

Signal Detection of Depression and Suicidality with the 5-Alpha Reductase Inhibitors: Evidence from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database

Authors

Villano A.¹, Chiappini S.², Schifano N.¹, Corkery J.M.³, Guirguis A.⁴, Mosca A.⁵, Arillotta D.⁶, Martinotti G.⁵, Schifano F.³, Dehò F.¹

Institutions

¹ASST settelaghi, Dept. of Urology, Varese, Italy, ²UniCamillus University Rome, Dept. of Psychiatry, Rome, Italy, ³Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, Hertfordshire Medical School, University of Hertfordshire, Dept. of Pharmacology, Hertfordshire, United Kingdom, ⁴Swansea University Medical School, Swansea University, Dept. of Pharmacology, Swansea, United Kingdom, ⁵G. D'Annunzio University, Dept. of Neuroscience, Imaging and Clinical Sciences, Chieti, Italy, ⁶University of Florence, Dept. of Neurosciences, Psychology, Drug Research, and Child Health, Section of Pharmacology and Toxicology, Florence, Italy

A0437

Five-Year Retreatment and Medication Restart Rates Following Benign Prostate Hyperplasia Treatments: A Nationwide Real-World Analysis Using Epic Cosmos

Authors

Carletti F.¹, Tamborino F.¹, Turcan A.¹, Santarelli V.¹, Valenzi F.M.¹, Morgantini L.A.¹, Haberal H.B.¹, Dal Moro F.², Crivellaro S.¹

Institutions

¹University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America, ²University of Padova, Dept. of Surgery, Oncology and Gastroenterology, Urologic Unit, Padua, Italy

10:45 - 11:35

Non-ablative MISTs

A0438

Multicenter 24-month outcomes of Rivermark FloStent™: the RAPID-II study

Authors

Chin P.¹, Sanchez J.², Gilling P.³, Ordones F.³, Vermeulen W.³, Ischia J.⁴, Elterman D.⁵

Institutions

¹South Coast Urology, Dept. of Urology, Wollongong, Australia, ²Hospital Angeles Leon, Dept. of Urology, Leon, Mexico, ³Tauranga Urology, Dept. of Urology, Tauranga, New Zealand, ⁴Austin Health, Dept. of Urology, Melbourne, Australia, ⁵University of Toronto, Dept. of Urology, Toronto, Canada

A0439

Interim 24-month outcomes from a randomized, sham controlled study evaluating a novel prostatic urethral stent for the treatment of BPH

Authors

Kaplan S.A.¹, Parekattil S.J.², Wu N.Z.³, Mazzearella B.⁴, Trotter M.⁵, Freedman S.⁶, Lawindy S.⁷, Bukkapatman R.⁸, Schwartz B.F.⁹, Jones B.¹⁰, Sethi P.¹¹, Jalkut M.W.¹², Liu J.S.¹³, Elterman D.¹⁴, Gheiler E.¹⁵, Gonzalez R.R.¹⁶, Kaminetsky J.¹⁷, Te A.¹, Lerner L.B.¹⁸, Motola J.A.¹⁹, Chapple C.²⁰, Lynch T.H.¹⁰

Institutions

¹Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ²Avant Concierge Urology, Dept. of Urology, Winter Garden, United States of America, ³Comprehensive Urologic Care, Dept. of Urology, Lake Barrington, United States of America, ⁴Urology Austin, Dept. of Urology, Austin, United States of America, ⁵Midtown Urology Associates, Dept. of Urology, Austin, United States of America, ⁶Freedman Urology, Dept. of Urology, Las Vegas, United States of America, ⁷Advanced Urology Institute, Dept. of Urology, Daytona Beach, United States of America, ⁸Florida Urology Partners, Dept. of Urology, Tampa, United States of America, ⁹SIU Medicine, Dept. of Urology, Springfield, United States of America, ¹⁰St. James's Hospital, Dept. of Urology, Dublin, Ireland, ¹¹Golden State Urology, Dept. of Urology, Stockton, United States of America, ¹²Associated Urologists of North Carolina, Dept. of Urology, Raleigh, United States of America, ¹³Urology of Virginia, Dept. of Urology, Virginia Beach, United States of America, ¹⁴University of Toronto, Dept. of Urology, Toronto, Canada, ¹⁵Urology Specialist Group, Dept. of Urology, Miami, United States of America, ¹⁶Houston Methodist Hospital, Dept. of Urology, Houston, United States of America, ¹⁷Advanced Urology Centers of New York, Dept. of Urology, New York, United States of America, ¹⁸Boston University School of Medicine, Dept. of Urology, Boston, United States of America, ¹⁹NYU Langone Health, Dept. of Urology, New York, United States of America, ²⁰Sheffield Teaching Hospitals NHS Foundation, Dept. of Urology, Sheffield, United Kingdom

A0440

Cost-effectiveness of the prostatic urethral lift compared with endoscopic surgery: interim analysis of the ECOLIFT Study

Authors

Robert G.Y.¹, Ruffion A.², Bénard A.³, Barry Delongchamps N.⁴

Institutions

¹Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ²HCL Lyon Sud, Dept. of Urology, Lyon, France, ³Bordeaux University Hospital, Clinical Research Support Unit, Bordeaux, France, ⁴APHP Hôpital Cochin, Dept. of Urology, Paris, France

Study Group

ECOLIFT Study group(Bordeaux, France)

A0441

Predicting Functional Outcomes After Prostatic UroLift: The latest nomogram for prediction of urological outcomes

Authors

Tocci E.¹, Ciampoli A.¹, Capone L.¹, Bruno M.¹, Checchia A.A.¹, D'altilia N.², Mazzotta L.¹, Annese P.¹

Institutions

¹Casa Sollievo Della Sofferenza, Dept. of Urology, San Giovanni Rotondo, Italy, ²Policlinico Riuniti, Dept. of Urology, Foggia, Italy

Authors

Chughtai B.¹, Kella N.², Barber N.³, Rochester M.⁴, Abbott J.⁵, Patel K.⁶, Krane L.⁷, Niu S.⁸, Sethi P.⁹, Stewart A.¹⁰, Al-Jafaari F.¹¹, Gandhi N.¹², McClintock T.¹³, Schiff W.¹⁴, Helfand B.¹⁵

Institutions

¹Northwell Health, Dept. of Urology, New Hyde Park, United States of America, ²The Urology Place, Dept. of Urology, San Antonio, United States of America, ³Frimley Park Hospital, Dept. of Urology, Camberley, United Kingdom, ⁴Norfolk and Norwich University Hospital, Dept. of Urology, Norwich, United Kingdom, ⁵Pacific West Urology, Dept. of Urology, Las Vegas, United States of America, ⁶Arizona Urology Specialists, Dept. of Urology, Tucson, United States of America, ⁷Southeast Louisiana Veterans Health Care System, Dept. of Urology, New Orleans, United States of America, ⁸Adult & Pediatric Urology, Dept. of Urology, Omaha, United States of America, ⁹Golden State Urology, Dept. of Urology, Sacramento, United States of America, ¹⁰Conrad Pearson Clinic, Dept. of Urology, Germantown, United States of America, ¹¹Queen Margaret Hospital, Dept. of Urology, Dunfermline, United Kingdom, ¹²Potomac Urology, Dept. of Urology, Alexandria, United States of America, ¹³Midtown Urology, Dept. of Urology, Austin, United States of America, ¹⁴UACC Fresno, Dept. of Urology, Fresno, United States of America, ¹⁵NorthShore University Health System Research Institute, Dept. of Urology, Evanston, United States of America

Patient satisfaction and decision regret in patients undergone Temporary Implantable Nitinol Device (iTIND) procedure: an Italian, real life, multicenter study**Authors**

Salvaggio M.D.¹, Cindolo L.¹, Castellucci R.¹, Vittori G.², Lambertini L.², Gallo F.³, Turbanti A.⁴, Piccolotti D.⁵, Lombardo R.⁶, De Nunzio C.⁶, Olivero A.⁷, Secco S.⁷

Institutions

¹Centro Urologico Europeo - Hesperia Hospital, Dept. of Urology, Modena, Italy, ²Careggi Hospital, Dept. of Urology, Florence, Italy, ³San Paolo Hospital, Dept. of Urology, Savona, Italy, ⁴University of Rome Tor Vergata, Dept. of Urology, Rome, Italy, ⁵Schiavonia Hospital, Dept. of Urology, Monselice, Italy, ⁶Sapienza Università di Roma, Dept. of Urology, Rome, Italy, ⁷ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy

Outcomes of Out-Patient In-Office TURBO OptilumeBPH MIST: Peri-Operative Results, 30-day Patient Recovery Experience and 3-Month Clinical Outcomes**Authors**

Arezki A.¹, AlAmeeri A.¹, Al Jaafari F.², Elterman D.³, Silvia S.⁴, Chughtai B.⁵, Kaplan S.⁶, Te A.⁷, Mehan R.⁸, Pohlman G.⁹, Zorn K.C.¹⁰

Institutions

¹McGill University, Dept. of Urology, Montréal, Canada, ²NHS Fife – Victoria Hospital, Dept. of Urology, Kirkcaldy, United Kingdom, ³University Health Network, Dept. of Urology, Toronto, Canada, ⁴ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ⁵Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, ⁶Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ⁷Cornell University Medical Center, Dept. of Urology, New York, United States of America, ⁸East Valley Urology Center, Dept. of Urology, Mesa, United States of America, ⁹Kearney Urology Center, Dept. of Urology, Kearney, United States of America, ¹⁰BPH Canada, Prostate Surgical Institute, Dept. of Urology, Montréal, Canada

A0445

The SUMMIT Study: A real-world, prospective, multi-center study to evaluate the performance of the Optilume® BPH Catheter System in men with symptomatic Benign Prostatic Hyperplasia (BPH)

Authors

Henrique Bitar Siqueira M.¹, Bhojani N.², Zorn K.C.³, Chughtai B.⁴, Meskawi M.², Patel P.⁵, Matsumoto E.⁶, Zakaria A.⁷, Elmansy H.⁸, Elterman D.¹

Institutions

¹University of Toronto, Dept. of Urology, Toronto, Canada, ²University of Montreal Hospital Center, Dept. of Urology, Montréal, Canada, ³BPH Canada, Prostate Surgical Institute, Dept. of Urology, Montréal, Canada, ⁴Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Dept. of Urology, Syosset, Canada, ⁵University of Manitoba, Dept. of Urology, Winnipeg, Canada, ⁶St. Joseph Hospital, Hamilton, Dept. of Urology, Hamilton, Canada, ⁷Thunder Bay Regional Health Research Institute, Dept. of Urology, Thunder Bay, Canada, ⁸Houston Methodist Hospital, Dept. of Urology, Houston, United States of America

A0446

Durable Symptom Relief and Functional Preservation: Final 3-Year Results from the PINNACLE Trial of the Optilume® BPH Catheter System

Authors

Kaplan S.A.

Institutions

Mount Sinai Health System, Dept. of Urology, New York, United States of America

Study Group

PINNACLE Investigators(-, United States of America)

A0447

Optilume BPH: A Promising Minimally Invasive Treatment for Benign Prostatic Hyperplasia in Larger Prostates

Authors

Zorn K.C.¹, Arezki A.², Pohlman G.³, Elterman D.⁴, Glaser A.⁵, Mehan R.⁶, Chughtai B.⁷, Te A.⁸, Feras A.J.⁹, Kaplan S.¹⁰

Institutions

¹BPH Canada, Prostate Surgical Institute, Dept. of Urology, Montréal, Canada, ²McGill University, Dept. of Urology, Montréal, Canada, ³Kearney Urology Center, Dept. of Urology, Kearney, United States of America, ⁴University Health Network, Dept. of Urology, Toronto, Canada, ⁵Endeavor Health, Dept. of Urology, Chicago, United States of America, ⁶East Valley Urology Center, Dept. of Urology, Mesa, United States of America, ⁷Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, ⁸Cornell University Medical Center, Dept. of Urology, New York, United States of America, ⁹NHS Fife – Victoria Hospital, Dept. of Urology, Kirkcaldy, United Kingdom, ¹⁰Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America

11:35 - 12:00

Ablative MISTs

A0448

Do Patients Rezum Medications? A Real-World Analysis of Medical Retreatment After Water Vapor Thermal Therapy

Authors

Nguyen V.¹, Tran E.², Cerrato C.³, Finegan J.L.², Leach M.C.⁴, Bechis S.K.²

Institutions

¹University of Washington, Dept. of Urology, Seattle, United States of America, ²UC San Diego Health, Dept. of Urology, San Diego, United States of America, ³University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom, ⁴Hawaii Permanente Medical Group, Dept. of Urology, Honolulu, United States of America

A0449

Real-World 3-Year Outcomes of Rezūm Water Vapor Therapy in Men with Large (≥80 mL) Prostates: A Multi-Center Study

Authors

Henrique Bitar Siqueira M.¹, Bhojani N.², Zorn K.C.³, Chughtai B.⁴, Cindolo L.⁵, Ferrari G.⁵, Lajkosz K.⁶, Elterman D.¹

Institutions

¹University of Toronto, Dept. of Urology, Toronto, Canada, ²University of Montreal Hospital Center, Dept. of Urology, Montréal, Canada, ³BPH Canada, Prostate Surgical Institute, Dept. of Urology, Montréal, Canada, ⁴Plainview Hospital, Smith Institute of Urology, Dept. of Urology, Syosset, United States of America, ⁵Hesperia Hospital, CUR E Group, Dept. of Urology, Modena, Italy, ⁶University Health Network, Dept. of Biostatistics, Toronto, Canada

A0450

Three-Year Reintervention Outcomes After Rezum vs UroLift: A TriNetX Comparative Analysis

Authors

Chen P.C.¹, Lu Y.C.¹, Chiu A.W.¹, Ho C.H.¹, Wu C.W.¹, Shao Y.H.²

Institutions

¹Shin Kong Wu Ho-Su Memorial Hospital, Dept. of Urology, Taipei City, Taiwan, ²Taipei Medical University, Graduate Institute of Biomedical Informatics, Taipei City, Taiwan

A0451

Risk of death after aquablation and minimally invasive surgical treatment for LUTS/BPH: analysis of the Food and Drug Administration's Manufacturer and User Facility Device Experience Database

Authors

Nacchia A., Santioni M., Franco A., Tema G., Lombardo R., Cicione A., Al Salhi Y., Pastore A., Fuschi A., Tubaro A., De Nunzio C.

Institutions

Sant'Andrea Hospital Sapienza University of Rome, Dept. of Urology, Rome, Italy

A0452

Functional outcomes of benign prostatic hyperplasia surgery in octogenarians: the role of minimally invasive techniques

Authors

Lombardo R.¹, Santioni M.¹, Albisinni S.², Cerrelli G.², Finazzi Agrò E.², Russo G.I.³, Secco S.⁴, Dell'Oglio P.⁴, Galfano A.⁴, Olivero A.⁴, Tema G.¹, Franco A.¹, Nacchia A.¹, Al Salhi Y.¹, Fuschi A.¹, Pastore A.¹, Cicione A.¹, Tubaro A.¹, De Nunzio C.¹

Institutions

¹Sant'Andrea Hospital Sapienza University of Rome, Dept. of Urology, Rome, Italy, ²Tor Vergata University, Dept. of Urology, Rome, Italy, ³Universita di Catania, Dept. of Urology, Catania, Italy, ⁴ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy

Risk stratification, reflex testing, and long-term outcomes in prostate cancer screening

Abstract Session 24

Sunday 15 March
10:30 - 12:00

Location Blue Area, George 1

Chairs O. Bratt, Gothenburg (SE)
S. Carlsson, Heidelberg (DE)
To be confirmed

10:30 - 10:45

Impact of participation and patient characteristics on screening outcomes

A0399

Prognostic features in prostate cancers diagnosed in the ProScreen trial

Authors

[Auvinen A.P.](#)¹, Hallikainen J.¹, Mirtti T.², Lilja H.³, Kenttämies A.⁴, Rinta-Kiikka I.⁵, Tolonen T.⁶, Riikonen J.⁷, Kilpeläinen T.⁸, Matikainen M.⁸, Nevalainen J.¹, Natunen K.¹, Raitanen J.¹, Lehtomäki T.⁹, Tammela T.L.J.¹⁰, Rannikko A.⁸

Institutions

¹Tampere University, Unit of Health Sciences, Tampere, Finland, ²University of Helsinki, Dept. of Pathology, Helsinki, Finland, ³University of Lund, Dept. of Translational Medicine, Malmö, Sweden, ⁴Helsinki University Hospital, Dept. of Radiology, Helsinki, Finland, ⁵Tampere University Hospital, Dept. of Radiology, Tampere, Finland, ⁶FimLab Laboratories, Dept. of Pathology, Tampere, Finland, ⁷Tampere University Hospital, Dept. of Urology, Tampere, Finland, ⁸Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ⁹FimLab Laboratories, Dept. of Clinical Chemistry, Tampere, Finland, ¹⁰Tampere University, Dept. of Urology, Tampere, Finland

10-year results of the randomized PROBASE prostate cancer risk-adapted screening trial: comparison of screening outcomes by starting age of 45 years versus 50 years

Authors

Albers P.¹, Krilaviciute A.¹, Seibold P.¹, Carlsson S.², Benner A.³, Lakes J.⁴, Al-Monajjed R.⁴, Kuczyk M.⁵, Harke N.N.⁵, Debus J.⁶, Grott C.A.⁶, Gschwend J.E.⁷, Herkommer K.⁷, Antoch G.⁸, Schimmöller L.⁹, Boschheidgen M.⁸, Wacker F.¹⁰, Schlemmer H.P.¹¹, Makowski M.¹², Kristiansen G.¹³, Hadaschik B.¹⁴, Arsov C.¹⁵, Kaaks R.¹⁶, Becker N.¹

Institutions

¹German Cancer Research Center, Division of Personalized Early Detection of Prostate Cancer, Heidelberg, Germany, ²German Cancer Research Center, Division of Clinical Epidemiology of Early Cancer Detection, Heidelberg, Germany, ³German Cancer Research Center, Division of Biostatistics, Heidelberg, Germany, ⁴Düsseldorf University, Dept. of Urology, Düsseldorf, Germany, ⁵Hannover Medical School, Dept. of Urology, Hannover, Germany, ⁶Heidelberg University, Dept. of Radiation Oncology, Heidelberg, Germany, ⁷Technical University Munich, Dept. of Urology, Munich, Germany, ⁸Düsseldorf University, Institute of Diagnostic and Interventional Radiology, Düsseldorf, Germany, ⁹Bochum University, Institute of Diagnostic and Interventional Radiology, Bochum, Germany, ¹⁰Hannover Medical School, Institute of Diagnostic and Interventional Radiology, Hannover, Germany, ¹¹German Cancer Research Center, Division of Radiology, Heidelberg, Germany, ¹²Technical University Munich, Institute of Diagnostic and Interventional Radiology, Munich, Germany, ¹³Bonn University, Dept. of Pathology, Bonn, Germany, ¹⁴Essen University, Dept. of Urology, Essen, Germany, ¹⁵Municipal Hospital Mönchengladbach, Dept. of Urology, Mönchengladbach, Germany, ¹⁶German Cancer Research Center, Dept. of Cancer Epidemiology, Heidelberg, Germany

Study Group

PROBASE Investigators Study Group(Heidelberg, Germany)

Does the effect of screening on prostate cancer-specific mortality differ in men with or without comorbidities? Long-term follow-up of ERSPC Rotterdam

Authors

Westerhout S.F.¹, Remmers S.¹, Bangma C.H.¹, van Leenders G.J.L.H.², van Leeuwen P.J.³, Roobol M.J.¹

Institutions

¹Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC Cancer Institute, Dept. of Pathology and Clinical Bioinformatics, Rotterdam, The Netherlands, ³Antoni van Leeuwenhoek - Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands

Study Group

ERSPC Rotterdam study group(Rotterdam, The Netherlands)

A0402

Does the effect of screening on prostate cancer mortality differ in men with or without a family history? Long-term follow-up of ERSPC Rotterdam

Authors

Westerhout S.F.¹, Remmers S.¹, Bangma C.H.¹, van Leeuwen P.J.², Roobol M.J.¹

Institutions

¹Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, ²Antoni van Leeuwenhoek - Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands

Study Group

ERSPC Rotterdam Study Group(Rotterdam, The Netherlands)

A0403

Risk stratification of national comprehensive cancer network (NCCN) defined family history and prostate cancer development in the biomarkers of prostate cancer prevention and environment (BIOCaPPE) multicenter observational prospective study

Authors

Chys B.¹, Larose C.¹, Tourigny R.², Aprikian A.³, Carmel M.⁴, Saad F.⁵, Fradet Y.¹, Robitaille K.², Fradet V.¹

Institutions

¹Faculty of Medecine Université Laval, Québec, Canada, ²CHU de Québec-Université Laval, Research Center, Oncology Program, Québec, Canada, ³McGill University Health Center, Montréal, Canada, ⁴CHUS Research Center, Québec, Canada, ⁵CHUM Research Center, Montréal, Canada

Study Group

BIOCaPPE Network(Québec, Canada)

A0404

Refining prostate cancer screening with family history: 10-year results from the STHLM3 screening trial

Authors

Mariaz M.¹, Micoli C.¹, Foley G.¹, Discacciati A.¹, Everett Palm E.¹, Ugalde Morales E.¹, Kibel A.S.², Nordström T.¹, Eklund M.¹, Grönberg H.¹, Clements M.¹, Lantz A.¹, Wiklund F.¹, Plym A.¹

Institutions

¹Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Solna, Sweden, ²Brigham and Women's Hospital, Harvard Medical School, Dept. of Urology, Boston, United States of America

A0405

Targeted prostate cancer screening in BRCA1 or BRCA2 pathogenic germline variant carriers detects clinically relevant disease

Authors

Eeles R.A.¹, Bancroft E.K.², Page E.C.¹, McHugh J.¹, Brook M.N.¹, Kote-Jarai Z.¹

Institutions

¹The Institute of Cancer Research, Oncogenetics Team, London, United Kingdom, ²The Royal Marsden NHS Foundation Trust, Oncogenetics Team, London, United Kingdom

Study Group

The IMPACT Study Collaborators and Steering Committee(London, United Kingdom)

11:05 - 11:15

DRE in screening: Any value?

Is the digital rectal exam (DRE) still relevant in the era of MRI imaging? Results of an international multi-institutional study

Authors

Gupta N.¹, Kwong J.¹, Wu J.¹, Nguyen D.D.¹, Punnen S.², Eklund M.³, Diamand R.⁴, Dong L.⁵, Xue W.⁵, Fukuokaya W.⁶, Kimura T.⁶, Mori K.⁶, Tan G.H.⁷, Buckley R.⁸, Feifer A.⁹, Ringa M.⁹, Tiwari R.V.¹⁰, Chan T.¹⁰, Tay K.J.¹¹, Wallis C.J.D.¹², Fleshner N.E.¹³, Kulkarni G.S.¹³, Nordstrom T.³, Zlotta A.R.¹²

Institutions

¹University of Toronto, Dept. of Surgery, Toronto, Canada, ²University of Miami Miller School of Medicine, Desai Sethi Urology Institute, Miami, United States of America, ³Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ⁴Jules Bordet Institute, Dept. of Surgery, Brussels, Belgium, ⁵Renji Hospital, Dept. of Urology, Shanghai, China, ⁶The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁷Sunway Medical Centre, Dept. of Urology, Selangor, Malaysia, ⁸North York General Hospital, Dept. of Surgery, Toronto, Canada, ⁹Trillium Health Partners, Dept. of Surgery, Mississauga, Canada, ¹⁰Sengkang General Hospital, Dept. of Urology, Sengkang, Singapore, ¹¹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ¹²Mount Sinai Hospital, Dept. of Surgery, Toronto, Canada, ¹³University Health Network, Dept. of Surgery, Toronto, Canada

Selective Digital Rectal Examination in the PSA–mpMRI Era: Diagnostic Yield, Rapid Learning Curve, and Educational Implications

Authors

Lagos Beitz H.E., González-Quirós C.A., Trujillo Martinez G., Martinez Delgado G., Escalante Armenta R., Castillejos-Molina R.A., Tena-Gonzalez Mendez G., Alcacio-Mendoza J.A.

Institutions

Instituto Nacional de Ciencias Médicas y Nutrición, Dept. of Urology, Mexico City, Mexico

A0408

Confirmation of Prostate-specific Antigen (PSA) Values Improves Prostate Cancer Screening for Young Men – Data from the PROBASE Trial

Authors

Krilaviciute A.¹, Carlsson S.V.², Al-Monajjed R.³, Lakes J.³, Herkommer K.⁴, Gschwend J.E.⁴, Göldner V.A.⁴, Kuczyk M.⁵, Harke N.N.⁵, Kanaan M.R.⁵, Debus J.⁶, Grott C.A.⁶, Stertz L.M.⁶, Kristiansen G.⁷, Arsov C.⁸, Hadaschik B.⁹, Schimmöller L.¹⁰, Antoch G.¹¹, Benner A.¹², Seibold P.¹, Kaaks R.¹³, Becker N.¹, Albers P.¹

Institutions

¹DKFZ, Division of Personalized Early Detection of Prostate Cancer, Heidelberg, Germany, ²DKFZ, Division of Clinical Epidemiology of Early Cancer Detection, Heidelberg, Germany, ³Düsseldorf University, Dept. of Urology, Düsseldorf, Germany, ⁴Technical University Munich, Dept. of Urology, Munich, Germany, ⁵Hannover Medical School, Dept. of Urology, Hannover, Germany, ⁶Heidelberg University, Dept. of Radiation Oncology, Heidelberg, Germany, ⁷Bonn University, Dept. of Pathology, Bonn, Germany, ⁸Municipal Hospital Mönchengladbach, Dept. of Urology, Mönchengladbach, Germany, ⁹Essen University, Dept. of Urology, Essen, Germany, ¹⁰Bochum University, Institute of Diagnostic and Interventional Radiology, Bochum, Germany, ¹¹Düsseldorf University, Institute of Diagnostic and Interventional Radiology, Düsseldorf, Germany, ¹²DKFZ, Division of Biostatistics, Heidelberg, Germany, ¹³DKFZ, Dept. of Cancer Epidemiology, Heidelberg, Germany

Study Group

The PROBASE trial investigators group(Heidelberg, Germany)

A0409

Assessment of a home capillary PSA test in Population based Prostate Cancer Screening

Authors

Galvin D.J.¹, Horgan G.¹, Negi R.¹, Watson W.¹, Murray P.¹, Molloy B.¹, Fitzpatrick P.¹, Sweeney P.², Smith A.³

Institutions

¹University College Dublin, Dept. of Urology, Dublin, Ireland, ²Mercy Hospital, Dept. of Urology, Cork, Ireland, ³National Screening Service, Dept. of Public Health, Dublin, Ireland

A0410

Age-related PSA-cutoffs on cancer detection: Results from ERSPC Rotterdam

Authors

Meenderink J.J.L.¹, De Vos I.I.¹, Remmers S.¹, Bangma C.H.¹, Van Leenders G.², Van den Bergh R.C.N.¹, Roobol M.J.¹

Institutions

¹Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC Cancer Institute, Dept. of Pathology, Rotterdam, The Netherlands

Study Group

ERSPC Rotterdam(Rotterdam, The Netherlands)

11:30 - 11:50

Improving risk-stratification by using reflex blood-tests

A0411

Evaluation of the 4Kscore as a reflex test among men with PSA between 1.8 and 3.0 ng/ml in the Göteborg-2 Screening Trial

Authors

Möller F.¹, Månsson M.¹, Lilja H.², Carlsson S.³, Hugosson J.¹, Arnsrud Godtman R.¹, Josefsson A.¹

Institutions

¹Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Dept. of Urology, Gothenburg, Sweden, ²Memorial Sloan Kettering Cancer Center, Dept. of Pathology and Laboratory Medicine, New York, United States of America, ³German Cancer Research Center (DKFZ), Clinical Epidemiology of Early Cancer Detection, Heidelberg, Germany

A0413

Stockholm3 Test Performance for Reducing MRI in Organised Prostate Cancer Testing (OPT)

Authors

Falagarío U.G.¹, Akre O.², Carlsson S.², Abbadi A.³, Arvendell M.², Phillips L.², Hao S.³, Sundquist F.⁴, Jiborn T.⁵, Arnsrud Godtman R.⁶, Bratt O.⁶, Lantz A.²

Institutions

¹University of Foggia, Dept. of Urology, Foggia, Italy, ²Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ³Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ⁴Karolinska Institutet, Dept. of Women's and Children's Health, Stockholm, Sweden, ⁵Skåne University Hospital, Dept. of Urology, Malmö, Sweden, ⁶Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Dept. of Urology, Gothenburg, Sweden

A0412

Value of Stockholm3 in Men with PSA 1.5–3 ng/mL: Evidence from the Swedish Prostate Cancer Registry

Authors

Micoli C.¹, Abbadi A.¹, Söderbäck H.¹, Jäderling F.², Bergman M.³, Eklund M.¹, Tilki D.⁴, Grönberg H.¹, Nordström T.¹, Palsdottir T.¹, Vigneswaran H.T.¹

Institutions

¹Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ²Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ³Capio Urokirurgiskt Centrum, Dept. of Urology, Stockholm, Sweden, ⁴University Hospital Hamburg Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany

A0414

Experience of the Stockholm3-test as a reflex-test in population-based organized PSA-screening programme

Authors

Waldén M.¹, Alkasier M.¹, Daouacher G.¹, Palsdottir T.², Swanholm P.¹, Ugge H.³

Institutions

¹Central Hospital, Dept. of Urology, Karlstad, Sweden, ²Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ³Örebro University, School of Medical Sciences, Örebro, Sweden

11:50 - 12:00

Defining outcomes and putting screening in context

A0415

Time to prostate cancer diagnosis and mortality: results from the randomized STHLM3 trial.

Authors

Micoli C.¹, Discacciati A.¹, Grönberg H.¹, Abbadi A.¹, Vigneswaran H.¹, Palsdottir T.¹, Clements M.¹, Crippa A.¹, Egevad L.², Nordström T.¹, Eklund M.¹

Institutions

¹Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ²Karolinska Institutet, Dept. of Oncology-Pathology, Stockholm, Sweden

A0416

Risk-adapted prostate cancer screening achieves mammography-like benefits - Results from the PROBASE trial

Authors

Carlsson S.¹, Krilaviciute A.², Al-Monajjed R.³, Seibold P.², Markus K.⁴, Gschwend J.E.⁵, Jürgen D.⁶, Antoch G.⁷, Schimmöller L.⁸, Schlemmer H.P.⁹, Kristiansen G.¹⁰, Kaaks R.¹¹, Becker N.², Albers P.²

Institutions

¹German Cancer Research Center, Division of Clinical Epidemiology of Early Cancer Detection, Heidelberg, Germany, ²German Cancer Research Center, Division of Personalized Early Detection of Prostate Cancer, Heidelberg, Germany, ³University Dusseldorf, Dept. of Urology, Düsseldorf, Germany, ⁴Hannover Medical School, Dept. of Urology, Hannover, Germany, ⁵Technical University of Munich, Dept. of Urology, Munich, Germany, ⁶Heidelberg University Hospital, Dept. of Radiation Oncology, Heidelberg, Germany, ⁷Düsseldorf University, Dept. of Diagnostic and Interventional Radiology, Düsseldorf, Germany, ⁸University Hospital of the Ruhr, Dept. of Diagnostic and Interventional Radiology and Nuclear Medicine, Herne, Germany, ⁹German Cancer Research Center, Division of Radiology, Heidelberg, Germany, ¹⁰University Hospital Bonn, Institute of Pathology, Bonn, Germany, ¹¹German Cancer Research Center, Division of CancerEpidemiology, Heidelberg, Germany

Study Group

on behalf of the PROBASE study group(Heidelberg, Germany)

Urolithiasis: Robotics, AI and Imaging

Abstract Session 25

Sunday 15 March
10:30 - 12:00

Location

Blue Area, George 4

Chairs

S.Y. Cho, Seoul (KR)
C.M. Cracco, Torino (IT)
K. Ghani, Ann Arbor (US)

10:30 - 10:50

Imaging

A0417

Performance of automated and semi-automated methods for measuring kidney stone volumes: Can machine replace man?

Authors

Cabo J., Ballantyne C., Ostergar A., Humphreys M.R., Stern K.L.S.

Institutions

Mayo Clinic Arizona, Dept. of Urology, Phoenix, United States of America

A0418

Does one-dimensional stone measurement support clinical decision-making? A retrospective cohort analysis of surface area and stone volume.

Authors

Bakaleyschik P.¹, Verhovsky G.², Zisman A.¹, Gnessin E.¹, Sabler I.M.¹

Institutions

¹Shamir Medical Center, Dept. of Urology, Tzrifin, Israel, ²Lincoln Hospital, Dept. of Urology, New York, United States of America

A0419

Ureter wall thickness measurement on computed tomography does not predict pathological ureteral wall thickness.

Authors

O'Meara S.¹, Rohan P.², Cullivan O.¹, O'Brien F.J.³, O'Shea A.², Davis N.F.⁴

Institutions

¹Royal College of Surgeons in Ireland, Dept. of Surgery, Dublin, Ireland, ²Beaumont Hospital, Dept. of Radiology, Dublin, Ireland, ³Royal College of Surgeons of Ireland, Tissue Engineering and Research Group (TERG), Dublin, Ireland, ⁴Beaumont Hospital, Dept. of Urology, Dublin, Ireland

A0420

Radiation Dose Reduction through the Development of a Novel Pediatric Low-Dose Computed Tomography Protocol for Urolithiasis Assessment

Authors

MacNevin W.¹, Kraus M.S.², Gamache C.², Tonkopi E.², O'Brien K.², Milford K.³, MacLellan D.L.⁴, Keefe D.T.⁴

Institutions

¹Dalhousie University, Dept. of Urology, Halifax, Canada, ²IWK Health Centre, Dept. of Diagnostic Radiology, Halifax, Canada, ³Dalhousie University, Dept. of Pediatric Surgery/Pediatric Urology, Halifax, Canada, ⁴Dalhousie University, Dept. of Pediatric Urology, Halifax, Canada

10:50 - 11:05

AI in stone disease: Diagnosis

A0421

UroMAS: A Multi-Agent System for Automated Patient Interview, Clinical Documentation, and Initial Management Planning in Urolithiasis

Authors

Chen Y.¹, Huangwei C.², Yalong C.¹, Junyao X.¹, Lifeng D.¹, Lei W.², Jiajun B.², Gonghui L.¹

Institutions

¹Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Dept. of Urology, Hangzhou, China, ²Zhejiang University, College of Computer Science and Technology, Hangzhou, China

A0422

Application of artificial intelligence in computed tomography for the diagnosis of urolithiasis - a single-center study

Authors

Isaev T., Sokolov S.A., Trushkin R.N., Sokolov A.A.

Institutions

Moscow City Clinical Hospital 52, Dept. of Urology, Moscow, Russia

A0423

Assessing the Quality and Readability of Patient Information Available for Uteroscopy: Human versus Artificial Intelligence Comparison of Resources and Quality Measurement – A Benchmarking Study from EAU Endourology

Authors

Baskaran R.¹, Al-Gholmy O.¹, Traxer O.², Juliebø-Jones P.³, Tzelvels L.⁴, Davies N.⁵, Somani B.¹

Institutions

¹University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom, ²Sorbonne University, Tenon Hospital, Dept. of Urology AP-HP, Paris, France, ³Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ⁴Sismanogleio Hospital, National and Kapodistrian University of Athens, Dept. of Urology, Athens, Greece, ⁵Beaumont University Hospital, Dept. of Urology, Dublin, Ireland

11:05 - 11:35

AI in stone disease: Predicting outcomes

A0424

Validation and clinical implementation of a Machine Learning model for predicting sepsis following ureteroscopy: a web-based decision support tool from EAU Urotechnology

Authors

Nedbal C.¹, Gauhar V.², Maurya R.³, Jaiswal P.³, Kashyap K.³, Gite S.³, Sevalia H.³, Castellani D.⁴, Panthier F.D.R.⁵, Teoh J.Y.C.⁶, Chew B.H.⁷, Fong K.Y.⁸, Gadzhiev N.⁹, Herrmann T.R.W.¹⁰, Traxer O.¹¹, Gregori A.¹², Galosi A.B.¹, Somani B.K.¹³

Institutions

¹Polytechnic University of Le Marche, Dept. of Urology, Ancona, Italy, ²Ng Teng Fong General Hospital, Dept. of Engineering, Singapore, Singapore, ³Symbiosis Institute of Technology, Symbiosis International (Deemed University), Dept. of Engineering, Pune, India, ⁴Ospedali Riuniti di Ancona, Dept. of Urology, Ancona, Italy, ⁵Tenon Hospital, Dept. of Urology, Paris, France, ⁶The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, Hong Kong, ⁷University of British Columbia, Dept. of Urology, Vancouver, Canada, ⁸Sengkang General Hospital, Dept. of Urology, Singapore, Singapore, ⁹Pavlov First Saint Petersburg State Medical University, Dept. of Urology, Saint Petersburg, Russia, ¹⁰Kantonspital Frauenfeld, Spital Thurgau AG, Dept. of Urology, Frauenfeld, Switzerland, ¹¹Sorbonne University, Dept. of Urology, Paris, France, ¹²IRCCS San Gerardo di Monza, Dept. of Urology, Monza, Italy, ¹³Southampton University Hospital - NHS, Dept. of Urology, Southampton, United Kingdom

A0425

Artificial Intelligence-Based Prediction of Postoperative Sepsis in Patients Undergoing Suction Mini-Percutaneous Nephrolithotomy: A Multicenter Analysis from the Global STUMPS Registry

Authors

Tefik T.¹, Ergul R.B.¹, Özerverli M.F.¹, Castellani D.², Lim E.J.³, Yuen S.K.K.⁴, Nedbal C.², Herrmann T.R.W.⁵, Somani B.K.⁶, Gauhar V.⁷

Institutions

¹Istanbul University Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ²Azienda Ospedaliero-Universitaria Delle Marche, Dept. of Urology, Ancona, Italy, ³Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ⁴S.H. Ho Urology Centre, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, China, ⁵Spital Thurgau AG Kantonsspital Frauenfeld, Dept. of Urology, Frauenfeld, Switzerland, ⁶University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom, ⁷Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore

Managing urolithiasis in pregnancy: can machine learning refine our surgical strategy?

Authors

Nedbal C.¹, Juliebø-Jones P.², Gauhar V.³, De S.⁴, Ulvik Y.², Beisland C.², Gite S.⁵, Sevalia H.⁵, Tanidir Y.⁶, Akdogan N.⁷, Aydi C.⁸, Contreras P.⁹, Frasccheri M.F.¹⁰, Pizzarello J.⁹, Ragoori D.¹¹, Tzelves L.¹², Gjengstø P.², Esøy M.S.R.², El Hajj A.¹³, Desouky E.⁴, Bautista-Perez-Gavilan A.⁴, Malkhasyan V.¹⁴, Gregori A.¹, Somani B.K.¹⁰

Institutions

¹IRCCS San Gerardo di Monza, Dept. of Urology, Monza, Italy, ²Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ³Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ⁴Cleveland Clinic Glickman Urological & Kidney Institute, Dept. of Urology, Cleveland, United States of America, ⁵Symbiosis Institute of Technology, Dept. of Engineering, Pune, India, ⁶Medicana Atasehir Hospital, Dept. of Urology, Istanbul, Turkey, ⁷Çukurova University, Dept. of Urology, Adana, Turkey, ⁸Hitit University School of Medicine, Dept. of Urology, Corum, Turkey, ⁹Hospital Alemán de Buenos Aires, Dept. of Urology, Buenos Aires, Argentina, ¹⁰Southampton University Hospital - NHS, Dept. of Urology, Southampton, United Kingdom, ¹¹Asian Institute of Nephrology and Urology, Dept. of Urology, Hyderabad, India, ¹²National and Kapodistrian University of Athens, Sismanogleio General Hospital, Dept. of Urology, Athens, Greece, ¹³American University of Beirut, Medical Center, Dept. of Urology, Beirut, Lebanon, ¹⁴Endourology Academy, Dept. of Urology, Istanbul, Turkey

AI Laser-Integrated Vision System for Lithotripsy: Real-time Stone Composition Detection

Authors

Martov A.G.¹, Sorokin N.², Dymov A.³, Ibragimova P.⁴, Baytsaeva O.⁴, Golubev I.⁴, Lesnykh D.⁴, Khramov T.⁴, Andreeva V.⁴

Institutions

¹IPPE of A.I. Burnazyan SSC FMBC FMBA, Dept. of Urology and Andrology, Moscow, Russia, ²Lomonosov Moscow State University, Faculty of Fundamental Medicine, Dept. of Urology and Andrology, Moscow, Russia, ³Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia, ⁴VPG LaserOne, Medical Laser Department, Fryazino, Russia

Is CHATGPT an expert in endoscopic urinary stone recognition? Results of a preliminary study

Authors

Kutchukian S.¹, Chicaud M.², Bravo-Balado A.³, Moretto S.⁴, Zorzi F.⁴, Candela L.⁵, Panthier F.⁵, Letouche M.L.⁶, Touzani A.⁷, Almeras C.⁷

Institutions

¹Poitiers University Hospital, Dept. of Urology, Poitiers, France, ²Limoges University Hospital, Dept. of Urology, Poitiers, France, ³Fundacio Puigvert and Autonomous University of Barcelona, Dept. of Urology, Barcelona, Spain, ⁴Progress and Collaboration in Endourology Group (PACE), Dept. of Urology, Paris, France, ⁵Tenon Hospital, Dept. of Urology, Paris, France, ⁶Tours University Hospital, Dept. of Urology, Tours, France, ⁷Croix du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France

A0430

Convolutional Neural Network for CT-Based Kidney Stone Detection and Needle Trajectory Mapping in Percutaneous Nephrolithotomy

Authors

Abdessater M., Touma Sawaya R., Nasrallah O.

Institutions

American University of Beirut, Medical Center, Dept. of Urology, Beirut, Lebanon

A0431

Apple vision pro used in retrograde intrarenal surgery: the pioneer experience in the real world

Authors

Wen C-Y.¹, Wu J.C.H.², Lin S.Y.¹, Huang S.W.³

Institutions

¹Changhua Show Chwan Memorial Hospital, Dept. of Urology, Changhua, Taiwan, ²Changbing Show Chwan Memorial Hospital, Dept. of Urology, Changhua, Taiwan, ³Changhua Show Chwan Memorial Hospital, Dept. of General Surgery, Changhua, Taiwan

A0432

From Artifact-Laden Signals to Reliable IRP on LithoVue Elite via AI Correction

Authors

Yanase T.¹, Hamamoto S.¹, Unno R.¹, Yuen S.², Vineet G.³, Sasaki Y.⁴, Chaya R.⁴, Okada A.², Taguchi K.⁵, Yasui T.¹

Institutions

¹Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-urology, Nagoya, Japan, ²SH Ho Urology Centre, The Chinese University of Hong Kong, Dept. of Surgery, Sha Tin, Hong Kong, ³Ng Teng Fong General Hospital, Dept. of Urology, Jurong East, Singapore, ⁴The University of Osaka, Graduate School of Information Science and Technology, Osaka, Japan, ⁵University of Alabama, Dept. of Urology, Birmingham, United States of America

A0433

Feasibility of AI-assisted respiratory synchronization independent of operator timing in robotic laser lithotripsy

Authors

Kim J.C.¹, Song K.S.¹, Lee D.G.¹, Lee D.H.¹, Kim J.H.¹, Elises J.C.², Lee H.M.³, Kwon D.S.⁴, Cho S.Y.³

Institutions

¹ROEN Surgical, Research Institute, Seoul, South Korea, ²Philippine General Hospital, Dept. of Urology, Manila, Philippines, ³Seoul National University Hospital, Dept. of Urology, Seoul, South Korea, ⁴Korea Advanced Institute of Science and Technology, Dept. of Mechanical Engineering, Daejeon, South Korea

11:55 - 12:00

Robotics in Stones

A0434

Ultrasound Navigation in Robot-Assisted Percutaneous Access

Authors

Bazzani S.¹, Minelli M.¹, Ferretti S.², Puliatti S.³, Bianchi G.³, Secchi C.¹, Ferraguti F.¹

Institutions

¹University of Modena and Reggio Emilia, Dept. of Sciences and Methods for Engineering, Reggio Emilia, Italy, ²Azienda Ospedaliero-Universitaria Modena, Dept. of Urology, Modena, Italy, ³University of Modena and Reggio Emilia, Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, Modena, Italy

Sunday 15 March
10:30 - 12:00

Location Blue Area, Victoria 4
Chairs C. Jerónimo, Porto (PT)
Z. Tippu, London (GB)
T. Zuiverloon, Den Haag (NL)

10:30 - 11:00

Innovations in molecular diagnostics & AI

A0453

Plasma Proteomic Profiling Identifies HAVCR1 and CXADR as Early Predictive Biomarkers for Kidney Cancer

Authors

Chen Y., Hou H.M., Liu M.

Institutions

Beijing Hospital, Dept. of Urology, Beijing, China

A0454

RenalCLIP: a visual-language foundation model for characterization, diagnosis and prognosis of renal tumors

Authors

Xiong Y.¹, Tao Y.², Wang S.², Guo J.¹

Institutions

¹Zhongshan Hospital, Dept. of Urology, Shanghai, China, ²Fudan University, Digital Medical Research Center, Shanghai, China

A0455

Deep learning-based CD8+ T cell inflammation model for predicting prognosis and combination of targeted and immunotherapy benefit from digital pathology in clear cell renal cell carcinoma

Authors

Chen S., Zheng J.

Institutions

Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China

A0456

Innovative Preclinical Models For Precision Medicine In Advanced Prostate Cancer: Preliminary Results From The INSIDE Study

Authors

Opattova A.¹, Bizzozero L.¹, Znideric K.¹, Bellomo S.¹, Berrino E.¹, Tonelli L.¹, Napoli F.², De Iazzari G.¹, Gilardi S.¹, De Cillis S.T.³, Bollito E.², Volante M.², Amparore D.⁴, Checcucci E.⁴, Rosi F.³, Fiori C.³, Sapino A.¹, Rescigno P.¹, Marchiò C.¹, Poriglia F.³, Arena S.¹

Institutions

¹Candiolo Cancer Institute, FPO-IRCCS, Dept. of Clinical Molecular Oncology, Candiolo, Italy, ²AOU San Luigi Gonzaga University Hospital, Dept. of Pathology, Orbassano, Italy, ³AOU San Luigi Gonzaga University of Turin, Dept. of Urology, Orbassano, Italy, ⁴Candiolo Cancer Institute FPO-IRCCS, Division of Urology, Dept. of Surgery, Candiolo, Italy

A0457

External validation of an AI-assisted bladder tumor segmentation model on mpMRI in patients with muscle-invasive bladder cancer: towards improved response assessment and personalized management

Authors

Greidanus J.¹, van Dijk - de Haan M.C.², Mertens L.S.³, Beets-Tan R.G.H.², van der Poel H.G.³, Giannatempo P.⁴, Delli Pizzi A.⁵, Dehghanpour A.⁶, Pecoraro M.⁶, Panebianco V.⁶, Chen A.⁷, Weintraub L.⁷, Lewis S.⁸, Galsky M.⁸, van Rhijn B.W.G.³, van der Heijden M.S.⁹, Boellard T.N.², Trebeschi S.²

Institutions

¹Netherlands Cancer Institute, Dept. of Surgical Oncology Urology, Dept. of Radiology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute, Dept. of Radiology, Amsterdam, The Netherlands, ³Netherlands Cancer Institute, Dept. of Surgical Oncology (Urology), Amsterdam, The Netherlands, ⁴Fondazione IRCSS istituto Nazionale tumori, Dept. of Medical Oncology, Milan, Italy, ⁵Santissima Annunziata Hospital, Dept. of Radiology, Chieti, Italy, ⁶Sapienza University of Rome, Dept. of Radiology, Rome, Italy, ⁷Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States of America, ⁸The Mount Sinai Hospital, Dept. of Molecular and Interventional Radiology, New York, United States of America, ⁹Netherlands Cancer Institute, Dept. of Medical Oncology, Amsterdam, The Netherlands

A0458

Expanding the treatment landscape of FGFR-targeted therapy in bladder cancer: Integrative genomic and functional profiling of patient-derived organoids

Authors

Solanki V.¹, Olislagers M.¹, Pappan K.L.², Beebe K.D.², Mahmoudi T.¹, Zuiverloon T.¹

Institutions

¹Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, ²GeneCentric Therapeutics, Inc., GeneCentric Therapeutics, Inc., Durham, United States of America

Sutureless and off-clamp robotic partial nephrectomy

Video Session 09

Sunday 15 March
10:30 - 12:00

Location

Blue Area, Victoria 1

Chairs

U. Capitanio, Milan (IT)

O. Katzendorn, Hannover (DE)

To be confirmed

V060 (□: 8 min.)

Off-Clamp Robot-Assisted Partial Nephrectomy: The Paradox of Complexity

R. Mastroianni, Rome (IT)

V061 (□: 8 min.)

Purely Off-Clamp Robotic Partial Nephrectomy: Perioperative and Functional after 1000 Cases

F. Proietti, Rome (IT)

V062 (□: 7 min.)

Off-clamp sutureless robotic-assisted partial nephrectomy for small renal masses

P. Shao, Nanjing (CN)

V063 (□: 8 min.)

Sutureless retroperitoneal robot assisted partial nephrectomy: initial experience with Veriset™ hemostatic patch

A. Kumar Pal, Kolkata (IN)

V064 (□: 6 min.)

Robotic Sutureless Partial Nephrectomy Using a 3D-Conformed Renal Sutureless Device: A Step-by-Step Video of a Trifecta-Oriented Innovation

To be confirmed

V065 (□: 8 min.)

Sutureless Robotic Partial Nephrectomy: Adoption, Learning Curve and Propensity-Score Matched Outcomes in a Large Single-Center Cohort

L. Misuraca, Rome (IT)

V066 (□: 8 min.)

Single-port Off-clamp Robotic Partial Nephrectomy: Surgical Technique, perioperative, pathologic and early functional outcomes of a single center series

G. Tuderti, Roma (IT)

Innovations in BPH surgery: From AR-guided training to robotic and single-port adenomectomy

Video Session 11

**Sunday 15 March
10:30 - 12:00**

Location

Orange Area, EGPT 1

Chairs

J. O'Riordan, Cork (IE)

To be confirmed

C. Würnschimmel, Lucerne (CH)

V075 (□: 7 min.)

Eye-tracking and latency-free AR visualization with HoloLase MD

G. Magistro, Hamburg (DE)

V076 (□: 3 min.)

Exploring the role of eye-tracking technology in surgical education: Insights from HoLEP

L. Viola, Florence (IT)

V077 (□: 6 min.)

SIAMLEP: an Anatomical simulator for prostate enucleation and morcellation in the same training device

S. Fernández-Pello Montes, Gijón (ES)

V078 (□: 8 min.)

When Size Matters: Technical Refinements in Robot-Assisted Simple Prostatectomy for Large Prostatic Adenoma

S. Kushwaha, GHAZIABAD (IN)

V079 (□: 6 min.)

Urethra-Sparing Robotic Adenomectomy: Redefining Sexual Function Preservation in the Surgical Treatment of Large Benign Prostatic Hyperplasia

J. Romero-Otero, Madrid (ES)

V080 (□: 7 min.)

Single-Port Transvesical Simple Prostatectomy: Technical Insights and Early Outcomes with the Da Vinci SP System introducing the force bipolar instrument

K. Schnell, Lucerne (CH)

V081 (□: 7 min.)

Single-port robot-assisted simple prostatectomy: Techniques via an extraperitoneal approach

To be confirmed

Complex reconstructive urology: From transplant robotics to gender-affirming and functional genital surgery

Video Session 10

**Sunday 15 March
10:30 - 12:00**

Location Blue Area, Victoria 6

Chairs A.J. Figueiredo, Coimbra (PT)

To be confirmed

To be confirmed

V067 (□: 8 min.)

Nontechnical skills and the outcomes in minimal invasive surgery

A. Mandhani, Gurgaon (IN)

V068 (□: 8 min.)

Robotic approach for graft-to-native ureteroureterostomy in a kidney transplant recipient with previous Boari flap reconstruction

N. Ortiz Benitez, Cadiz (ES)

V069 (□: 6 min.)

Robot-Assisted Partial Nephrectomy for Allograft Renal Cell Carcinoma: A Case Report

S. Forte, Bari (IT)

V070 (□: 5 min.)

The outcomes of augmented dorsal inlay graft metoidioplasty

M. Preto, Turin (IT)

V071 (□: 7 min.)

Re-do Salvage Colon Vaginoplasty After Vaginal Canal Stenosis

M. Garcia, Los angeles (US)

V072 (□: 7 min.)

Reduction of Dysphoria-Causing Erections in Transgender Women – A Novel Surgical Technique to Gender Dysphoria Caused by Penile Erection: Bilateral Crural Artery Ligation & Transection

M. Garcia, Los angeles (US)

V073 (□: 8 min.)

Robot assisted Vasovasostomy : A technological advancement in male infertility surgery

A.P. Sharma, SAS Nagar (IN)

V074 (□: 6 min.)

A Multicenter Comparative Study of Microsurgical Spermatic Cord Revascularization (shunt) and Microsurgical Ligation of the Spermatic Veins for Severe Varicocele

Z. Wan, Guangzhou (CN)

Sunday 15 March
10:30 - 12:00

Location Blue Area, George 3

Chair C. Bettocchi, Foggia (IT)

Learning objectives

The main targets are education and best practice on controversial topics in the field of male infertility, male hormones and sexual dysfunction, either focused on medical and surgical management.

10:30 - 10:31

Welcome and introduction

C. Bettocchi, Foggia (IT)

10:31 - 11:05

Sexual dysfunction

Moderators

C. Bettocchi, Foggia (IT)

R. Djinnovic, Belgrade (RS)

D.J. Ralph, London (GB)

10:31 - 10:36

Regenerative treatments for ED and Peyronie's – results from monotherapy and combined treatments

A. Cocci, Florence (IT)

10:36 - 10:41

Botox and erectile dysfunction

A. Faix, Montpellier (FR)

10:41 - 10:46

Andrology uncovered: What it means now, and where the field is heading?

M.M. Fode, Herlev (DK)

10:46 - 10:51

Andrology in the age of Instagram: How social media is disrupting the field?

G.I. Russo, Catania (IT)

10:51 - 10:56

Penile size: A real issue or do we have a solution?

O. Sedigh, Torino (IT)

10:56 - 11:01

Penile Doppler: Tips and tricks behind understanding the investigation

P.A.S. Vendeira, Porto (PT)

11:01 - 11:05

Discussion

11:05 - 11:55

Male hormones and infertility

Moderators

G. Corona, Bologna (IT)

M. Dinkelman-Smit, Rotterdam (NL)

N. Sofikitis, Ioannina (GR)

11:05 - 11:10

Male infertility: A warning sign for men's overall health?

P. Sangster, London (GB)

11:10 - 11:15

Sperm under attack: Can drugs hijack male fertility?

A. Zachariou, Ioannina (GR)

11:15 - 11:20

Varicocele and testicular pain: When is surgery the right call?

D. Mai Ba Tien, Ho Chi Minh City (VN)

11:20 - 11:25

Treatment with antioxidants before or after the varicocele surgery?

A. Salonia, Milan (IT)

11:25 - 11:30

Varicocele surgery 2.0: Expert hacks for a successful second round

A. Khelaia, Tbilisi (GE)

11:30 - 11:35

Sperm sorting... ICSI/PIMSI/PICSI, is there science or just profit behind them?

R.W. Rees, Southampton (GB)

11:35 - 11:40

Epididymovasostomy – where and why along the epididymis to reconstruct?

G. Franco, Roma (IT)

11:40 - 11:45

Male fertility treatments: Why are we stagnant while IVF booms?

E. Ruiz-Castañé, Barcelona (ES)

11:45 - 11:50

FSH stimulation to improve spermatogenesis

S. Minhas, London (GB)

11:50 - 11:55

Klinefelter's syndrome – surgical sperm retrieval. Why is there such worldwide variation in success?

S. Kliesch, Münster (DE)

11:55 - 12:00

Discussion and closing remarks

C. Bettocchi, Foggia (IT)

Bladder cancer innovations: Personalised therapies and advanced diagnostics

EGPT 36

Sunday 15 March
10:30 - 12:00

Location

Orange Area, EGPT 3

Chairs

T. Bivalacqua, Philadelphia (US)

B. Der, Budapest (HU)

S. Shariat, Vienna (AT)

10:30 - 11:00

Towards improved diagnostics and surveillance of muscle-invasive bladder cancer

P0629

Urothelial cancer prevalence in microscopic hematuria patients following the national guideline

Authors

Tomassen Y.L.¹, Moll J.M.², Cauberg E.C.³, Witte L.P.W.³, Van Soest R.⁴, Wijburg C.J.⁵, Wijsman B.P.⁶, Leijte J.A.P.⁷, Roshani H.⁸, De Jong J.J.¹, Kessel K.E.M.¹, Boormans J.L.¹

Institutions

¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Treant Zorggroep, Dept. of Urology, Emmen, The Netherlands, ³Isala, Dept. of Urology, Zwolle, The Netherlands, ⁴Franciscus Gasthuis en Vlietland, Dept. of Urology, Rotterdam, The Netherlands, ⁵Rijnstate, Dept. of Urology, Arnhem, The Netherlands, ⁶Elisabeth TweeSteden, Dept. of Urology, Tilburg, The Netherlands, ⁷Amphia, Dept. of Urology, Breda, The Netherlands, ⁸HagaZiekenhuis, Dept. of Urology, The Hague, The Netherlands

P0630

A visually interpretable radiomics model for bladder cancer grading using white light cystoscopy images

Authors

Choi Y.¹, Cho S.W.², Hong J.H.³, Lee J.⁴, Kim H.Y.⁵, Lee K.S.⁴

Institutions

¹Yonsei University College of Medicine, Dept. of Integrative Medicine, Seoul, South Korea, ²Yonsei University College of Medicine, Division of Endocrinology, Seoul, South Korea, ³Yonsei University, Dept. of Artificial Intelligence, Seoul, South Korea, ⁴Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ⁵Yonsei University College of Medicine, Dept. of Neurosurgery, Seoul, South Korea

P0631

Single-cell analysis on H&E slides enables robust prognostic stratification and tumor biology assessment in patients with bladder cancer

Authors

Semko S.¹, Zhang B.², Eckstein M.³, Büttner R.², Heidenreich A.¹, Tolkach Y.²

Institutions

¹University Hospital Cologne, Clinic of Urology, Cologne, Germany, ²University Hospital Cologne, Institute of Pathology, Cologne, Germany, ³University Hospital Erlangen, Institute of Pathology, Erlangen, Germany

P0632

Prospective evaluation of [68Ga]-FAPI-PET/MRI for loco-regional staging of muscle-invasive bladder cancer

Authors

Laukhtina E.¹, Shariat S.¹, Hassler-Di Fratta M.¹, Hacker M.², Muin D.²

Institutions

¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²Medical University of Vienna, Dept. of Biomedical Imaging and Image-guided Therapy, Vienna, Austria

P0633

Tumour-agnostic ctDNA monitoring: a clinically feasible approach for post-cystectomy surveillance in muscle-invasive bladder cancer

Authors

Figueras M.¹, Ingelmo-Torres M.², Roldan F.L.², Juana P.², Oriola J.¹, Alcaraz A.³, Mengual L.¹

Institutions

¹Universitat de Barcelona, Dept. of Biomedical Sciences, Barcelona, Spain, ²Hospital Clinic Barcelona, Dept. and Laboratory of Urology, Barcelona, Spain, ³Universitat de Barcelona, Dept. of Surgery and Medical Specialities, Barcelona, Spain

P0634

Clinical and genomic correlates of circulating tumor DNA in muscle-invasive bladder cancer after curative-intent therapy

Authors

Aydogdu C.¹, Wang B.¹, McSweeney S.T.¹, Diaz G.¹, Baer M.¹, Guzman T.¹, Ram Dewala S.¹, Arja R.¹, Davis L.E.², Nizam A.³, Moningi S.⁴, Pieretti A.⁵, Weight C.¹, Almassi N.¹, Haywood S.¹, Campbell R.¹, Sindhani M.¹, Abouassaly R.⁶, Bukavina L.¹

Institutions

¹Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ²Case Western Reserve University Hospitals, Urology Institute, Cleveland, United States of America, ³Cleveland Clinic, Dept. of Hematology and Oncology, Cleveland, United States of America, ⁴Cleveland Clinic, Dept. of Radiation Oncology, Cleveland, United States of America, ⁵Cleveland Clinic Florida, Dept. of Urology, Weston, United States of America, ⁶Cleveland Clinic Abu Dhabi, Dept. of Urology, Abu Dhabi, United Arab Emirates

P0635

Teaching robot-assisted radical cystectomy (RARC) is safe - Results from the prospective Swiss Society of Urology database

Authors

Schneidewind L., Scherrer M., Brunaiova L., Koneval L., Roth B.

Institutions

University of Bern, Dept. of Urology, Bern, Switzerland

P0636

A machine learning algorithm for survival prediction in bladder cancer patients undergoing radical cystectomy

Authors

Russo P.¹, Foschi N.¹, Causio A.², De Vita V.², Maioriello G.¹, Bizzarri F.P.¹, Sighinolfi M.C.¹, Rocco B.M.C.¹

Institutions

¹Fondazione Policlinic A.Gemelli Roma, Dept. of Urology, Rome, Italy, ²Fondazione Policlinic A.Gemelli Roma, Section of Hygiene and Public Health, Dept. of Life Science and Public Health, Rome, Italy

P0637

Performance of FRAX® to Guide DXA Use and Anti-osteoporotic Treatment in Men with Ileal Urinary Diversion after Radical Cystectomy: Underestimation of Fracture Risk and the Added Value of BMD and TBS Adjustments

Authors

Domínguez García A.¹, Casado Burgos E.², Zegri de Olivar M.E.¹, Fuertes D.³, Centeno Álvarez C.¹, De Verdonces Román L.¹, Gavalda Guillén A.¹, Masip i Boix N.¹, Millar Monfort A.¹, Capdevila Gonzalo M.¹, Mayordomo Ferrer O.¹, Ferran Carpintero A.¹, Pla Terradellas C.¹, Azuara Invernón P.¹, Cuadrench Solórzano S.¹, Gallardo Diaz E.⁴, Bonfill Abella T.⁴, Sierra Boada M.⁴, Grubicy M.A.L.⁵, Muñoz Rodríguez J.¹

Institutions

¹Hospital Universitari Parc Taulí, Dept. of Urology, Barcelona, Spain, ²Hospital Universitari Parc Taulí, Dept. of Reumatology, Barcelona, Spain, ³Hospital Universitari Parc Taulí, Research Support Unit, Barcelona, Spain, ⁴Hospital Universitari Parc Taulí, Dept. of Medical Oncology, Barcelona, Spain, ⁵Cetir Ascires, Dept. of Imaging Diagnosis, Barcelona, Spain

P0638

Robot-Assisted Partial Cystectomy, Distal Ureterectomy, and Reimplantation for Organ Preservation in Ureterovesical Junction Tumors

Authors

Jin D., Qian L., Zhang R., Chen H.

Institutions

Renji Hospital, Dept. of Urology, Shanghai, China

P0639

Reproductive organ-sparing radical cystectomy is associated with maintained quality-of-life and sexual function in women

Authors

Wang S.¹, Williams C.¹, Avulova S.², McNamara M.³, Patel S.H.³, Kates M.³, Lee D.J.¹, Guzzo T.J.¹, Smith A.K.³, Boorjian S.A.⁴, Bivalacqua T.J.¹

Institutions

¹University of Pennsylvania, Division of Urology, Philadelphia, United States of America, ²Carl T. Hayden Veterans' Administration Medical Center, Dept. of Urology, Phoenix, United States of America, ³Johns Hopkins University School of Medicine, Brady Urological Institute, Baltimore, United States of America, ⁴Mayo Clinic, Dept. of Urology, Rochester, United States of America

P0640

Impact of histologic variants on nodal involvement, lymphadenectomy outcomes, and survival after radical cystectomy for bladder cancer.

Authors

Licari L.C., Bologna E., Flammia R.S., Proietti F., Ferriero M., Anceschi U., Misuraca L., D'annunzio S., Mastroianni R., Tuderti G., Brassetti A., Bove A.M., Chiacchio G., Guaglianone S., Leonardo C., Simone G.

Institutions

IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Dept. of Urology, Rome, Italy

P0641

Would you choose a neobladder again? Impact of quality of life and continence on long-term decision regret after radical cystectomy with ileal neobladder reconstruction

Authors

Pyrgidis N., Volz Y., Benedikt E., Stief C., Schulz G.B.

Institutions

University Hospital Munich Ludwig-Maximilian-University, Dept. of Urology, Munich, Germany

P0642

Prognostic Impact of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer in patients with Low Geriatric Nutritional Risk Index: A Retrospective Cohort Study

Authors

Omizo S.¹, Fujita N.¹, Kobayashi M.², Kandori S.³, Ikarashi D.⁴, Fukuhara H.⁵, Sato T.⁶, Myoen S.⁷, Uemura M.⁸, Inoue T.⁹, Morozumi K.¹⁰, Kaiho Y.⁹, Miyazaki J.⁹, Kojima Y.⁸, Adachi H.⁷, Ito A.⁶, Tsuchiya N.⁵, Obara W.⁴, Nishiyama H.³, Habuchi T.², Narita S.², Ohyama C.¹, Hatakeyama S.¹

Institutions

¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki-Shi, Japan, ²Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ³Institute of Medicine, University of Tsukuba, Dept. of Urology, Tsukuba, Japan, ⁴Iwate Medical University, Dept. of Urology, Morioka, Japan, ⁵Yamagata University Graduate School of Medicine, Dept. of Urology, Yamagata, Japan, ⁶Tohoku University Graduate School of Medicine, Dept. of Urology, Sendai, Japan, ⁷Miyagi Cancer Center, Dept. of Urology, Natori, Japan, ⁸Fukushima Medical University, Dept. of Urology, Fukushima, Japan, ⁹International University of Health and Welfare Narita Hospital, Dept. of Renal and Urological Surgery, Narita, Japan, ¹⁰Tohoku Medical and Pharmaceutical University, Division of Urology, Sendai, Japan

P0643

Development and preliminary validation of the HARPI Index. A promising questionnaire to support decisions on urinary diversion in patients with bladder cancer

Authors

Carl N.¹, Grüne B.¹, Alpers G.W.², Michel M.S.¹, Kriegmair M.C.³

Institutions

¹University Medical Centre Mannheim University of Heidelberg, Dept. of Urology, Mannheim, Germany, ²Mannheim School of Social Sciences University of Mannheim, Clinical and Biological Psychology and Psychotherapy, Mannheim, Germany, ³Urological Hospital Munich-Planegg, Dept. of Urology, Munich-Planegg, Germany

11:45 - 12:00

Socio-economic background of patients with bladder cancer

P0644

Financial Toxicity in Uro-Oncology at a Public Tertiary Centre: Prevalence and Determinants Using the Spanish FACIT-COST

Authors

Lagos Beitz H.E., Neri-Moguel G., Sanchez-Torres S., Ramos-Rodriguez L.G., Escalante-Armenta R., Rodríguez-Covarrubias F.T.S., Castillejos-Molina R.A.

Institutions

Instituto Nacional de Ciencias Médicas y Nutrición, Dept. of Urology, Mexico City, Mexico

P0645

Suicide risk among patients with urologic malignancies: A population-based study using Canadian census-linked cohorts

Authors

Scanlon L.¹, Kailavasan M.², Palii I.³, Power N.², Haan M.³

Institutions

¹Western University, Dept. of Urology, London, Canada, ²Western University, Dept. of Urology, London, Canada, ³Western University, Dept. of Sociology, London, Canada

P0646

Social Deprivation and Bladder Cancer: A Spatial Analysis of the Somme area of France

Authors

Vendar J.¹, Saint F.², Trecherel E.¹, Lapotre-Ledoux B.N.D.¹, Garry O.¹

Institutions

¹Amiens-Picardie University Hospital, Somme Cancer Registry, Amiens, France, ²Amiens-Picardie University Hospital, Dept. of Urological Transplantation, Amiens, France

Intraoperative margin assessment during radical prostatectomy

EGPT 35

**Sunday 15 March
10:30 - 12:00**

Location

Orange Area, EGPT 2

Chairs

F. Ambrosini, Genova (IT)

M. Kivi, Tallinn (EE)

Z. Tandođdu, London (GB)

10:30 - 10:35

Introduction

P0611

Frozen Section vs Confocal Microscopy in Surgical Margin Assessment: Meta-Analysis of Diagnostic Test Accuracy

Authors

Tomczak W.T., Łaszkiewicz J., Nowak Ł., Chorbińska J., Szydełko T., Krajewski W.

Institutions

Wrocław Medical University, Dept. of Minimally Invasive and Robotic Urology, Wrocław, Poland

10:35 - 11:10

NeuroSAFE

P0612

Effect of NeuroSAFE-guided RARP versus standard RARP on erectile and overall sexual function recovery in patients with localized prostate cancer: a longitudinal follow-up analysis from the NeuroSAFE PROOF study

Authors

Zhang X., Asif M., Greg S., Ricardo A.M.

Institutions

University College London, Dept. of Surgery and Interventional Science, London, United Kingdom

P0613

NeuroSAFE PROOF study: 24-month functional and oncological outcomes from a patient-blinded, multicentre, randomised controlled phase 3 trial

Authors

Almeida-Magana R.¹, Dinneen E.², Pan S.³, Leurent B.³, Haider A.⁴, Roberts N.⁵, Al-Hammouri T.⁵, Freeman A.⁴, Brew-Graves C.⁵, Grierson J.¹, Clow R.⁵, Walton T.⁶, Aning J.⁷, Persad R.⁷, Oxley J.⁸, Oakley N.⁹, Ahmad I.¹⁰, Dutto L.¹⁰, Tandogdu Z.¹¹, Kelly J.¹¹, Shaw G.¹¹

Institutions

¹University College London, Dept. of Targeted Intervention, London, United Kingdom, ²Peter MacCallum Cancer Centre, Division of Cancer Surgery, Melbourne, Australia, ³University College London, Dept. of Statistical Science, London, United Kingdom, ⁴University College London Hospitals NHS Foundation Trust, Dept. of Histopathology, London, United Kingdom, ⁵University College London, Centre for Medical Imaging, London, United Kingdom, ⁶Nottingham University Hospital NHS Trust, Dept. of Urology, Nottingham, United Kingdom, ⁷North Bristol Hospitals Trust, Dept. of Urology, Bristol, United Kingdom, ⁸North Bristol Hospitals Trust, Dept. of Histopathology, Bristol, United Kingdom, ⁹Sheffield Teaching Hospitals NHS Trust, Dept. of Urology, Sheffield, United Kingdom, ¹⁰Greater Glasgow and Clyde NHS Trust, Dept. of Urology, Glasgow, United Kingdom, ¹¹University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom

P0614

Assessing the accuracy of intra-operative frozen section during NeuroSafe robotic prostatectomy to predict final margin histology and guide subsequent neurovascular bundle excision

Authors

Feyissa M., Gubbay E., Morgan A., Muheilan M., Philippou Y., Brodie A., Lane T., Adshead J., Pullar B., Agarwal S., Vasdev N.

Institutions

Lister Hospital - East and North Herts Trust, Dept. of Urology, Stevenage, United Kingdom

P0615

Margin analysis accuracy metrics of the NeuroSAFE technique: a frozen section versus final paraffin analysis comparison within the NeuroSAFE PROOF Study

Authors

Menon A.¹, [Almeida-Magana R.](#)², Dinneen E.³, Al-Hammouri T.⁴, Roberts N.⁵, Brew-Graves C.⁵, Ahmad I.⁶, Dutto L.⁶, Oakley N.⁷, Persad R.⁸, Aning J.⁸, Oxley J.⁹, Walton T.¹⁰, Freeman A.¹, Kelly J.⁴, Shaw G.⁴, Haider A.⁴

Institutions

¹University College London Hospitals NHS Foundation Trust, Dept. of Histopathology, London, United Kingdom, ²University College London, Dept. of Targeted Intervention, London, United Kingdom, ³Peter MacCallum Cancer Centre, Division of Cancer Surgery, Melbourne, Australia, ⁴University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁵University College London, Centre for Medical Imaging, London, United Kingdom, ⁶Greater Glasgow and Clyde NHS Trust, Dept. of Urology, Glasgow, United Kingdom, ⁷Sheffield Teaching Hospitals NHS Trust, Dept. of Urology, Sheffield, United Kingdom, ⁸North Bristol Hospitals Trust, Dept. of Urology, Bristol, United Kingdom, ⁹Greater Glasgow and Clyde NHS Trust, Dept. of Histopathology, Bristol, United Kingdom, ¹⁰Nottingham University Hospital NHS Trust, Dept. of Urology, Nottingham, United Kingdom

P0616

Cost-utility of NeuroSAFE-guided RARP versus standard RARP in men with localised prostate cancer in England

Authors

[Wang J.](#)¹, Almeida Magana R.², Dinneen E.², Pan S.³, Leurent B.³, Roberts N.⁴, Brew Graves C.⁴, Williams N.⁴, Haider A.⁵, Shaw G.⁴, Pizzo E.¹

Institutions

¹University College London, Dept. of Primary Care and Population Health, London, United Kingdom, ²University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³University College London, Dept. of Statistical Science, London, United Kingdom, ⁴University College London, Division of Surgery and Interventional Science, London, United Kingdom, ⁵University College London Hospitals NHS Foundation Trust, Dept. of Histopathology, London, United Kingdom

P0617

Impact of NeuroSAFE results on biochemical recurrence after radical prostatectomy: positive NeuroSAFE margins matter

Authors

[van de Mortel X.](#)¹, van Drumpt J.N.H.¹, de Baaij J.M.S.¹, Hoekstra R.J.², Bellaar Spruyt J.A.³, Sedelaar J.P.M.⁴, Küsters-Vandeveldel H.V.N.⁵, Somford D.M.¹, van Basten J.P.A.¹

Institutions

¹Canisius Wilhelmina Hospital, Dept. of Urology, Nijmegen, The Netherlands, ²Catharina Hospital, Dept. of Urology, Eindhoven, The Netherlands, ³Máxima Medical Centre, Dept. of Urology, Veldhoven, The Netherlands, ⁴Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ⁵Canisius Wilhelmina Hospital, Dept. of Pathology, Nijmegen, The Netherlands

P0618

Integrating EndoScell into NeuroSAFE: A Real-Time Imaging Approach for Precision Prostate Surgery

Authors

Zhang W.¹, [He H.](#)¹, Li X.², Gao X.¹

Institutions

¹Changhai Hospital, Dept. of Urology, Shanghai, China, ²Changhai Hospital, Dept. of Pathology, Shanghai, China

11:10 - 11:25

Fluorescence confocal microscopy (Histolog scanner)

P0619

Initial Experience with Large Field-Of-View Confocal Laser Scanning Microscopy for Real-Time Margin Assessment During Robotic-Assisted Radical Prostatectomy

Authors

Wang J., Khanmammadova N., Hanna K., Gao A., Shahait M., Lee D.

Institutions

University of California Irvine, Dept. of Urology, Irvine, United States of America

P0620

Development and validation of a deep learning tool for automated reading of fluorescence confocal microscopy images in radical prostatectomy

Authors

Fang L.¹, Mayor N.¹, Silvanto A.², Haider A.², Light A.¹, Gopalakrishnan A.¹, Almeida-Magana R.³, Dinneen E.³, Connor M.J.¹, Shah T.T.¹, Ahmed H.U.¹, Fiorentino F.⁴, Giannarou S.⁵, Winkler M.¹

Institutions

¹Imperial College London, Dept. of Urology, London, United Kingdom, ²University College London Hospitals NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ³University College London, Dept. of Urology, London, United Kingdom, ⁴University of Leeds, Leeds Clinical Trial Unit, Leeds, United Kingdom, ⁵Imperial College London, Hamlyn Centre for Robotic Surgery, London, United Kingdom

P0621

Performance Comparison and Downstream Workflow Analysis of Fluorescence Confocal Microscopy Versus Frozen Section During Robot-Assisted Nerve Sparing Radical Prostatectomy

Authors

Scheipner L.¹, Skok K.², Mannweiler S.², Kashofer K.², Aigelsreiter A.², Milosevic I.², Leitsmann C.², Augustin H.², Rößmann-Tsybrovskyy M.², Ahyai S.¹, Liegl-Atzwanger B.², Mischinger J.¹

Institutions

¹Medical University of Graz, Dept. of Urology, Graz, Austria, ²Medical University of Graz, Dept. of Pathology, Graz, Austria

11:25 - 11:30

Confocal laser scanning microscopy (VivaScope)

P0622

Randomized trial on real-time surgical margin evaluation with confocal microscopy in robot-assisted radical prostatectomy: preliminary results

Authors

Rodriguez N.¹, Vella J.¹, Puliatti S.¹, Lugli N.¹, Sene N.¹, Ansaloni S.¹, Resca S.¹, De Faveri A.¹, Di Bari S.¹, Bibi S.¹, Venturelli E.¹, Azzoni P.², Bertoni L.², Reggiani Bonetti L.³, Ticonosco M.¹, Amato M.¹, Micali S.¹

Institutions

¹University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, ²University of Modena and Reggio Emilia, Dept. of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplant, Oncology and Regenerative Medicine, Modena, Italy, ³University of Modena and Reggio Emilia, Dept. of Medical and Surgical Sciences for Children and Adults, Modena, Italy

11:30 - 12:00

Surgical margins

P0623

PSMA Radioguided Surgery for Predicting Tumor Location, Positive Surgical Margins and Local Staging in Prostate Cancer Patients Undergoing RARP with ePLND: Final Results of a Prospective Phase 2 Study

Authors

Quarta L.¹, Zaurito P.¹, Pellegrino A.¹, Viti A.¹, Scuderi S.¹, Barletta F.¹, Cucchiara V.¹, Stabile A.¹, Calado A.¹, Dambrosio L.¹, Sollini M.², Samanes Gajate A.M.², Antunovic L.², Pini C.², Chiti A.², Montorsi F.¹, Briganti A.¹, Gandaglia G.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy

P0624

An international delphi consensus on the use of ex-vivo fluorescent confocal microscopy for intraoperative margin assessment during robot-assisted radical prostatectomy

Authors

Beatrice E.¹, De Angelis M.², Almeida-Magana R.³, Al-Hammouri T.³, Fiori C.⁴, Piramide F.⁴, Frego N.⁵, Schiavina R.⁶, Eapen R.S.⁷, Mazzone E.⁸, Winkler M.⁹, Mayor N.¹⁰, Ferretti S.¹¹, Bianchi G.¹¹, Autorino R.¹², Kaouk J.¹², Sighinolfi M.C.¹³, Murphy D.G.⁷, Wiklund P.¹⁴, Hamdy F.C.¹⁵, Puliatti S.¹¹, Mottrie A.⁵, Shaw G.³, De Groot R.⁵

Institutions

¹AZORG Hospital, Dept. of Urology, Aalst, Belgium, ²IRCCS Ospedale San Raffaele, Division of Experimental Oncology, Unit of Urology, URI, Milan, Italy, ³University College London Hospitals NHS Trust, Dept. of Urology, London, United Kingdom, ⁴San Luigi Gonzaga Hospital, Division of Urology, Orbassano, Italy, ⁵AZORG Hospital, Dept. of Urology, Aalst, Belgium, ⁶IRCCS Azienda Ospedaliero Universitaria di Bologna, Division of Urology, Bologna, Italy, ⁷Peter MacCallum, University of Melbourne, Dept. of Oncology, Melbourne, Australia, ⁸ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ⁹Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, ¹⁰Imperial College Healthcare National Health Service (NHS) Trust, Dept. of Urology, London, United Kingdom, ¹¹University Hospital of Modena, Dept. of Urology, Modena, Italy, ¹²Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ¹³Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dept. of Urology, Rome, Italy, ¹⁴Icahn School of Medicine at Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ¹⁵University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom

Study Group

International Delphi Consensus Group on Fluorescent Confocal Microscopy during Robot-Assisted Radical Prostatectomy(Melle, Belgium)

P0625

Early versus delayed specimen inking: the impact on margin status in Retzius-sparing robot-assisted radical prostatectomy - a comparative analysis

Authors

Kumar Pal A., Rakesh P., Mathew J., Ramaprasad M., Prabhakaran S., Kishore T.A.

Institutions

Aster Medcity, Dept. of Urology, Kochi, India

P0626

Significant Asymmetry in Positive Surgical Margins During Robot-Assisted Radical Prostatectomy: A Higher Incidence on the Left Side

Authors

Yao KE, Jiang R., Zhang K., Meng Y.S., Shen C., Tian Y., Zuo C.

Institutions

Peking University First Hospital, Dept. of Urology, Beijing, China

P0627

Development and Validation of a Machine Learning–Enhanced Preoperative Nomogram for Predicting Positive Surgical Margins after Radical Prostatectomy

Authors

Zhou J., Wang Z., Cai L., Kan G.

Institutions

Peking University First Hospital, Dept. of Urology, Beijing, China

P0628

Prognostic Impact of Surgical Margin Status on Biochemical Recurrence-Free Survival after Robot-Assisted Radical Prostatectomy: Stratification by Stage, Grade, and Nodal Involvement

Authors

Oderda M., Merani U.M., Calvo P., Sasia A., Dematteis A., Venturi A., Marquis A., Callaris G., Marra G., Gontero P.

Institutions

University of Turin, Dept. of Urology, Turin, Italy

NMIBC: From basic and translational studies to clinical practice

EGPT 37

**Sunday 15 March
10:30 - 12:00**

Location

Orange Area, EGPT 4

Chairs

J. Bjerggaard Jensen, Aarhus (DK)

J. Gadu Campos Salcedo, Huixquilucan (MX)

G. Pignot, Marseille (FR)

10:30 - 11:05

Liquid biopsy and precision diagnostics

P0647

Machine learning–based analysis of urinary exosomal miRNAs for the detection, prognosis, and immune profiling of urological malignancies

Authors

Baba Y¹, Tanaka N.¹, Iwasa S.¹, Cortal A.², Yamaguchi H.², Ando Y.², Mikami M.², Mizunuma M.², Yuki I.³, Kato Y.⁴, Oya M.¹

Institutions

¹Keio University School of Medicine, Dept. of Urology, Tokyo, Japan, ²Craif. Inc, Research & Development Division, Nagoya, Japan, ³Nagoya University, Institute of Innovation for Future Society, Nagoya, Japan, ⁴Keio University School of Medicine, Center for Cancer Genomics, Tokyo, Japan

P0648

A Plasma Metabolomic Signature for Non–Muscle-Invasive Bladder Cancer Independent of Hematuria Status

Authors

Iacovelli V.¹, Carilli M.¹, Vittori M.¹, Speziale R.², Cipriani C.³, Leoni G.⁴, Puca F.⁵, Anzillotti L.², Carugo A.⁵, Brocca C.⁶, Stella G.⁶, Saccà F.A.M.⁶, Antonucci M.¹, Maiorino F.¹, Signoretti M.¹, Petta F.¹, Toniatti C.⁵, Bove P.⁶

Institutions

¹Tor Vergata University Hospital, Dept. of Surgery - Robotic and Minimally Invasive Urology, Rome, Italy, ²IRBM SpA, Dept. of DMPK, Pomezia, Italy, ³University of Rome Tor Vergata, Dept. of Experimental Medicine, Rome, Italy, ⁴IRBM SpA, Dept. of Bioinformatic, Pomezia, Italy, ⁵IRBM SpA, Dept. of Oncology, Pomezia, Italy, ⁶University of Rome Tor Vergata, Dept. of Surgery - Robotic and Minimally Invasive Urology, Rome, Italy

P0649

Precision diagnostics of FGFR pathway activation by simultaneous mutation, fusion and overexpression assessment across all bladder cancer stages - the Bladder BRIDGister Experience

Authors

Wirtz R.¹, Veltrup E.¹, Weissbach R.², Weber A.², Schubert T.², Grunwald V.², Hake R.³, Görgens D.³, Eidt S.³, Graff J.⁴, König L.⁴, Althenhövel G.⁴, Waldner M.⁴, Storz E.⁵, von Brandenstein M.⁵, Weiten R.⁵, Heidenreich A.⁵, Ecke T.⁶

Institutions

¹STRATIFYER Molecular Pathology GmbH, Dept. of Molecular Research, Cologne, Germany, ²Biotype GmbH, Dept. of Molecular Development, Dresden, Germany, ³Institute of Pathology at the St. Elisabeth Hospital Cologne, Dept. of Uropathology, Cologne, Germany, ⁴St. Elisabeth Krankenhaus Köln-Hohenlind, Dept. of Urology, Cologne, Germany, ⁵University Clinic Cologne, Dept. of Urology, Cologne, Germany, ⁶Helios Kliniken, Dept. of Urology, Bad Saarow, Germany

P0650

Epigenetic Profiling of Peripheral Blood Mononuclear Cells (PBMC) Methylation Patterns in Bladder Cancer and Healthy Subjects

Authors

Lim Y.K.¹, Tsang W.C.², Tham S.M.¹, Wang K.Y.², Taam B.Y.K.², Law T.², Mallari J.Z.², Ooi D.S.Q.³, Rahmat J.N.B.¹, Mahendran R.¹, Chiong E.²

Institutions

¹National University of Singapore, Dept. of Surgery, Singapore, Singapore, ²National University Hospital, Dept. of Urology, Singapore, Singapore, ³National University of Singapore, Dept. of Paediatrics, Singapore, Singapore

P0651

World wide experience in urine based diagnostics for bladder cancer: Results from the UBioBCa project

Authors

Ecke T.¹, Le Calvez-Kelm F.², Avogbe P.², Forey N.², Vian E.³, Manel A.⁴, Rabien A.⁵, Raue L.⁵, Raisch J.⁶, Martel A.⁷, Bergeron A.⁸, Camirand-Lemyre F.L.⁹, Jeldres C.¹⁰, Hosen I.¹¹, Boisvert F.O.M.⁶

Institutions

¹Helios Hospital Bad Saarow, Dept. of Urology, Bad Saarow, Germany, ²International Agency for Research on Cancer (IARC), Dept. of Genomic Epidemiology, Lyon, France, ³Infirmierie Protestante de Lyon, Dept. of Urology, Lyon, France, ⁴Le Creusot Hospital, Dept. of Urology, Le Creusot, France, ⁵Charité Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ⁶Faculty of Medicine and Health Sciences, Université de Sherbrooke, Dept. of Immunology and Cell Biology, Sherbrooke, Canada, ⁷Goodman Cancer Institute, McGill University, Interdisciplinary Cancer Science Program, Montréal, Canada, ⁸Centre de Consultation Statistique, CESC, Dept. of Statistics, Sherbrooke, Canada, ⁹Faculty of Sciences, Université de Sherbrooke, Dept. of Mathematics, Sherbrooke, Canada, ¹⁰Faculty of Medicine and Health Sciences, Université de Sherbrooke, Dept. of Urology, Sherbrooke, Canada, ¹¹University Dhaka, Dept. of Biochemistry & Molecular Biology, Dhaka, Bangladesh

P0652

Digital PCR (dPCR) Enhances the Diagnostic Accuracy of Uromonitor® for Detecting Recurrence of Bladder Cancer Compared with quantitative PCR (qPCR) and Cytology

Authors

Ecke T.¹, Schlomm T.², Rabien A.², Meisl C.³, Rong D.¹, Friedersdorff F.⁴, Sommerfeldt L.⁴, Gagel N.⁴, Veltrup E.⁵, Koch S.⁶, May M.⁷, Kravchuk A.⁷, Otto T.⁸, Barski D.⁹, Göschl A.⁹, Bug R.¹⁰, Brás J.¹¹, Vinagre J.¹², Wirtz R.⁵

Institutions

¹Helios Hospital Bad Saarow, Dept. of Urology, Bad Saarow, Germany, ²Charité Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ³Spital Thurgau, Kantonsspital Frauenfeld, Dept. of Urology, Frauenfeld, Switzerland, ⁴Evangelisches Krankenhaus Königin Elisabeth Herzberge, Dept. of Urology, Berlin, Germany, ⁵STRATIFYER GmbH, Dept. of Molecular Pathology, Cologne, Germany, ⁶Medizinische Hochschule Brandenburg, Dept. of Pathology, Brandenburg an der Havel, Germany, ⁷Elisabeth Hospital, Dept. of Urology, Straubing, Germany, ⁸University Essen, Medical Faculty, Essen, Germany, ⁹Rheinlandklinikum Neuss, Dept. of Urology, Neuss, Germany, ¹⁰Rheinlandklinikum Neuss, Dept. of Pathology, Neuss, Germany, ¹¹Universidade do Porto, Instituto de Investigação e Inovação em Saúde (i3S), Porto, Portugal, ¹²Universidade do Porto, Instituto de Patologia e Imunologia Molecular (Ipatimup), Porto, Portugal

P0653

Urinary exosomal netrin-1 as a novel biomarker for diagnosis and prognosis in bladder cancer: A multi-center study

Authors

Li HZ, Senyu Z., Zheyu W., Xiaolong H., Yuyan Z.

Institutions

The First Hospital of China Medical University, Dept. of Urology, Shenyang, China

11:05 - 11:20

Antibody-drug conjugates and organoid-guided intravesical therapy

P0654

Thermo-sensitive Hydrogel System Enables Sustained Intravesical Delivery of Antibody–Drug Conjugates for Effective Treatment of Non–Muscle-Invasive Bladder Cancer

Authors

Fu S.¹, Wang H.¹, Li N.¹, Xiong Q.¹, Shi H.¹, Zhu M.²

Institutions

¹The Second Affiliated Hospital of Kunming Medical University, Dept. of Urology, Kunming, China, ²East China Normal University, Shanghai Key Laboratory of Magnetic Resonance, Shanghai, China

P0655

Intravesical Disitamab Vedotin (RC48) for BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicenter Phase I Trial

Authors

Chen X.¹, Huang M.¹, Jiang S.², Hu H.³, Liu Z.⁴, Lv Q.⁵, Zhang P.⁶, Huang J.¹, Lin T.¹

Institutions

¹Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China, ²Hunan Cancer Hospital, Dept. of Urology, Changsha, China, ³The Second Hospital of Tianjin Medical University, Dept. of Urology, Tianjin, China, ⁴Tongji Hospital, Dept. of Urology, Wuhan, China, ⁵The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China, ⁶West China Hospital, Dept. of Urology, Chengdu, China

P0656

Organoid-on-a-Chip Guided Postoperative Intravesical Instillation for Early Bladder Cancer: Feasibility and Safety Study of EV-ADC and SG-ADC

Authors

Zhang L.¹, Zhang Y.², Gong Y.Q.¹, Li X.S.¹

Institutions

¹Peking University First Hospital, Dept. of Urology, Beijing, China, ²Beijing Institute of Technology, Dept. of Life Science and Technology, Beijing, China

11:20 - 11:40

Novel intravesical agents and immune modulation

P0657

A triphenylamine-bridged bis-boronate probe for mitochondria-targeted and ROS-bidirectional therapy of bladder cancer

Authors

Zhang Z.¹, Jin D.², Zhang L.¹, Zhang X.¹, Cao S.², Wang K.², Yu N.¹

Institutions

¹Qilu Hospital of Shandong University, Dept. of Urology, Jinan, China, ²Shandong University, State Key Laboratory of Crystal Materials, Jinan, China

P0658

Therapy-Induced Tertiary Lymphoid Structures Reflect Immune Reprogramming After Intravesical Bacillus Calmette-Guerin for non-muscle invasive bladder cancer

Authors

Ikarashi D.¹, Kitano S.², Kawamura T.¹, Takahashi K.¹, Ito A.¹, Shiomi E.¹, Abe M.¹, Maekawa S.¹, Kato R.¹, Kanehira M.¹, Obara W.¹

Institutions

¹Iwate medical university, Dept. of Urology, Iwate, Japan, ²The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Dept. of Advanced Medical Development, Tokyo, Japan

P0659

Androgen receptor blockade enhances intravesical BCG efficacy in non-muscle invasive bladder cancer: a propensity score-matched cohort study

Authors

Ou Z., Chen L.X., Luo Z.H., Li Y., He W., Chen M.F.

Institutions

Xiangya Hospital Central South University, Dept. of Urology, Changsha, China

P0660

Efficacy of epirubicin versus gemcitabine as a single, immediate, post-operative intravesical instillation after TURB: Preliminary results of a double-blind randomized prospective study

Authors

Telli E., Öztürk Y.Y., Kara O.

Institutions

Kocaeli University, Dept. of Urology, Kocaeli, Turkey

11:40 - 12:00

Optimising TURBT and perioperative management

P0661

Therapeutic intervention for control of LUTS after TURBT: prospective comparison between tamsulosin, oxybutynin and control

Authors

Capinha M.¹, Pinheiro A.R.², Araújo A.S.¹, Pinto L.S.¹, Coutinho A.¹, Santos A.M.¹, Cardoso A.¹, Dias E.¹

Institutions

¹Unidade Local de Saúde de Braga, Dept. of Urology, Braga, Portugal, ²Universidade do Minho, Dept. of Urology, Braga, Portugal

P0662

The Application Effect of Different Bladder Irrigation Solution Warming Methods in Postoperative Patients Undergoing Bladder Irrigation

Authors

Hou Z., Han X.

Institutions

Shenzhen Second People's Hospital, Dept. of Urology, Shen Zhen, China

P0663

Utility of restaging TURBT in patients with primary high grade Ta NMIBC

Authors

Mebroukine S.¹, Klein C.M.¹, Yacoub M.², Bladou F.¹, Bernhard J.C.¹, Robert G.G.¹

Institutions

¹University Hospital of Bordeaux, Dept. of Urology, Bordeaux, France, ²University Hospital of Bordeaux, Dept. of Pathology, Bordeaux, France

P0664

Prognostic Value of the Extent of Lymphadenectomy for Overall Survival Among Patients with Non-muscle Invasive Bladder Cancer, A Retrospective Cohort Study

Authors

Lai C-H.¹, Ji J.², Xu T.¹, Hu H.¹

Institutions

¹Peking University People's Hospital, Dept. of Urology, Beijing, China, ²Xuanwu Hospital Capital Medical University, Dept. of Urology, Beijing, China

Sunday 15 March
10:30 - 12:00

Location Orange Area, EGPT 5

Chairs
A. Giammò, Torino (IT)
M. Hennenberg, Munich (DE)
K-D. Sievert, Detmold (DE)

10:30 - 11:00

Mechanisms

P0665

Local hydrogel delivery of antifibrotic agents blocks DDX3X-NLRP3 inflammasome activation and reduces wound fibrosis after BPH surgery

Authors

Chenghao Z., Wenhao W., Li T., Xia S.

Institutions

Shanghai General Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Urology Medical Center, Shanghai, China

P0666

Hormonal imbalance-induced CNR1 activation drives stromal fibrosis progression in benign prostatic hyperplasia via the Rap1 pathway

Authors

Liu Z., Jin S., Ming J., Wu H., Guo W., Niu Y.

Institutions

Beijing Friendship Hospital, Dept. of Urology, Beijing, China

P0667

Mechanism of the Piezo1/Notch1/CTGF signaling axis mediating urothelial cell-fibroblast crosstalk in bladder fibrosis after bladder outlet obstruction

Authors

Li Z., Lin D., Wei P., Li K., Kuang W., Cheng L., Gong Y., Cui K., Chen Z.

Institutions

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Dept. of Urology, Wuhan City, China

P0668

LPCAT2-driven phosphatidylcholine metabolic dysregulation in fibroblasts promotes BPH progression

Authors

Zeng Z.

Institutions

Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China

P0669

Differential Downregulation of PIEZO1 and PIEZO2 in Patients With BPH and Chronic Urinary Retention

Authors

Albuquerque L.¹, Schreiter V.G.², Thangavel C.³, Reis S.T.², Leite K.R.M.², Riccetto E.¹, Birder L.⁴, Antunes A.¹, Nahas W.C.¹, Boopathi E.⁵, Gomes C.M.¹

Institutions

¹Sao Paulo University, Dept. of Urology, São Paulo, Brazil, ²University of Sao Paulo School of Medicine, Laboratory of Medical Investigation (LIM55), São Paulo, Brazil, ³Thomas Jefferson University, Dept. of Radiation Oncology, Philadelphia, United States of America, ⁴University of Pittsburgh, School of Medicine, Pittsburgh, United States of America, ⁵Thomas Jefferson University, Center for Translational Medicine, Philadelphia, United States of America

P0670

Dysregulation of DNA repair processes in persistent detrusor overactivity after transurethral resection of the prostate (TURP) and in SCI-induced NDO

Authors

Monastyrskaya K.¹, Nilsen O.J.², Glott T.³, Burkhard F.¹, Roth B.⁴, Hashemi Gheinani A.¹

Institutions

¹Inselspital Bern, Functional Urology Research Lab DBMR, Dept. of Urology, Bern, Switzerland, ²Oslo University Hospital, Dept. of Urology, Oslo, Norway, ³Sunnaas Rehabilitation Hospital, Spinal Unit, Nesodden, Norway, ⁴Inselspital University Hospital, Dept. of Urology, Bern, Switzerland

11:00 - 11:30

Biomarkers and beyond

P0671

Targeting of CDC42BPA by siRNA or the inhibitor BDP9066 suppresses contraction and growth-related functions in cultured prostate stromal cells and in human prostate tissues

Authors

Xu Y., Ciotkowska A., Zhu W., Tamalunas A., Stief C.G., Hennenberg M.

Institutions

LMU Munich, Dept. of Urology, Munich, Germany

P0672

Plasma Proteomic Profiling Identifies TSPAN1 as a Key Predictor of Benign Prostatic Hyperplasia Risk in a Large Prospective Cohort

Authors

Chen Y., Hou H.M., Liu M.

Institutions

Beijing Hospital, Dept. of Urology, Beijing, China

P0673

Distinct SRD5A2-reduced Subtypes of Benign Prostatic Hyperplasia Exhibit p-AMPK/Rab9a/PLIN3-Mediated Lipophagic Compensation for Androgen Signaling Defects

Authors

Lin Z.¹, Liu Z.², Yinong N.²

Institutions

¹Beijing Shijitan Hospital Affiliated to Capital Medical University, Dept. of Urology, Beijing, China, ²Beijing Friendship Hospital Affiliated to Capital Medical University, Dept. of Urology, Beijing, China

P0674

Deciphering the Therapeutic Mechanisms of Resveratrol in Benign Prostatic Hyperplasia through Multi-Omics and Experimental Validation

Authors

Jinze L.¹, Dong L.¹, Peihai Z.²

Institutions

¹People's Hospital of Deyang City-Chengdu University of Traditional Chinese Medicine, Dept. of Urology, Deyang, China, ²Hospital of Chengdu University of Traditional Chinese Medicine, Dept. of Urology, Chengdu, China

P0675

TRMT61A-mediated tRNA m1A modification promotes benign prostatic hyperplasia via efficient Hippo pathway translation

Authors

Liu Y., Yu L., Liao X., Chen J., Mei H.

Institutions

Shenzhen Second People's Hospital, Dept. of Urology, Shen Zhen, China

P0676

Neuronal myosins as potential novel drug targets in lower urinary tract symptoms, identified by off-target inhibition of neurogenic prostate and bladder smooth muscle contractions by the myosin inhibitor mavacamten

Authors

Keller P., Brandstetter M., Xu Y., Tamalunas A., Weinhold P., Stief C.G., Hennenberg M.

Institutions

LMU Munich, Dept. of Urology, Munich, Germany

11:30 - 12:00

AI, perioperative care and sustainability

P0677

Noise in the operating room (OR) and new laser technologies: a prospective comparative study in Endoscopic Enucleation of the Prostate

Authors

Mallet R.¹, Flores Violante M.², Heringer J.³, Baboudjian M.⁴, Doizi S.⁵

Institutions

¹Polyclinique Francheville, Dept. of Urology, Périgueux, France, ²Alispharm, Clinical Department, Lyon, France, ³Coloplast interventional Urology, Dept. of Medical Affairs, Le Plessis Robinson, France, ⁴Marseille Public University Hospital, North Hospital, Dept. of Urology, Marseille, France, ⁵Sorbonne University, Paris, France, GRC n°39, Santé de l'homme, Hôpital Tenon, Dept. of Urology, Paris, France

P0678

AI-based Support System for Urination Patients

Authors

Kang H.S.¹, Park J.M.², Na Y.G.², Lim J.S.¹, Song K.H.¹, Lee J.Y.¹, Lee C.L.¹, Shin J.H.¹, Kim K.H.²

Institutions

¹Chungnam National University Hospital, Dept. of Urology, Daejeon, South Korea, ²Chungnam National University Sejong Hospital, Dept. of Urology, Sejong, South Korea

P0679

Clinical evaluation of AI-based software for predicting pharmacologic response in benign prostatic hyperplasia

Authors

Lee J., Koo M.J., Sung S.H., Ko K.J., Han D.H., Lee K.S.

Institutions

Samsung Medical Center Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea

P0680

Development of a Cognitive Task Analysis and Delphi Consensus on Transurethral Resection of the Prostate (TURP): An Educational Project of the European School of Urology

Authors

Caballero J.P.¹, Perri D.², Osorio L.³, Oliviera T.R.⁴, Pereira S.⁵, Şener T.E.⁶, Dragos L.⁷, Paciotti M.⁸, Veneziano D.⁹, Biyani C.S.¹⁰, Somani B.¹¹, Liatsikos E.¹²

Institutions

¹University General Hospital, Dept. of Urology, Alicante, Spain, ²Azienda Socio Sanitaria Territoriale Lariana, Dept. of Urology, Como, Italy, ³Hospital de Santo António. C.H.P., Dept. of Urology, Porto, Portugal, ⁴Armed Forces Hospital, Dept. of Urology, Lisbon, Portugal, ⁵Lisbon Medical Academic Centre, Dept. of Urology, Lisbon, Portugal, ⁶Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey, ⁷Cambridge University Hospitals NHS Foundation Trust, Dept. of Urology, Cambridge, United Kingdom, ⁸IRCCS Humanitas Research Hospital Rozzano, Dept. of Urology, Milan, Italy, ⁹Smith Institute for Urology, Northwell Health, Dept. of Urology, New York, United States of America, ¹⁰St James's University Hospital, Dept. of Urology, Leeds, United Kingdom, ¹¹University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ¹²University Hospital Patras, Dept. of Urology, Patras, Greece

P0681

Life Cycle Assessment of HoLEP: Quantifying Environmental Impact and Opportunities for Sustainable Urologic Surgery

Authors

Klein C.¹, Humbert V.², Meune M.³, Tubiana-Dussin F.¹, Charon S.¹, Lamouroux K.¹, Capon G.¹, Alezra E.¹, Estrade V.¹, Blanc P.¹, Margue G.¹, Bernhard J.C.¹, Robert G.¹, Bladou F.¹

Institutions

¹Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ²CV Développement, LCA and Carbon Footprint Practitioner, Bordeaux, France, ³Bordeaux University Hospital, Directorate for Ecological Transformation, Bordeaux, France

P0682

Clean intermittent self-catheterization versus indwelling catheter before endoscopic surgery for benign prostatic hyperplasia: impact on perioperative outcomes

Authors

Chaoui I.¹, Bruyère F.², Manach Q.³, Durand X.³, Bourgi A.¹

Institutions

¹Centre Hospitalier Universitaire de Tours, Dept. of Urology, Tours, France, ²University Hospital of Lausanne, Dept. of Urology, Lausanne, Switzerland, ³Hôpital Paris Saint-Joseph, Dept. of Urology, Paris, France

Hormone sensitive metastatic prostate cancer

Thematic Session

Sunday 15 March
10:45 - 12:15

Location Orange Area, eURO Auditorium 1

Chairs E. Castro, Madrid (ES)
G. Giannarini, Udine (IT)

Learning objectives

Upon completion of this session, participants should be able to: 1) Describe the discrepancies between evidence generated in randomised trials and real-world outcomes in patients with mHSPC. 2) Assess the indications, benefits, and limitations of treatment intensification strategies, including systemic therapies and local approaches. 3) Evaluate emerging data on novel agents and optimal timing of treatment escalation or de-escalation. 4) Integrate patient-, disease-, and treatment-related factors into personalised therapeutic decision-making in mHSPC.

10:45 - 10:55

Disconnect between evidence and real-world data in metastatic prostate cancer

C. Sweeney, Adelaide (AU)

10:55 - 10:59

Clinical case presentation & voting: Controversial high-volume disease

S. Hallamies, Helsinki (FI)

10:59 - 11:49

Round-table discussion

10:59 - 11:09

Who benefits from intensification with docetaxel?

G. Kramer, Vienna (AT)

11:09 - 11:19

What evidence do we have from intensification with SBRT?

V. Fonteyne, Ghent (BE)

11:19 - 11:29

RT to primary tumor, what for?

A. Bossi, La Garenne Colombes (FR)

11:29 - 11:39

PARPi in mHSPC or should we wait until mCRPC?

G. von Amsberg, Hamburg (DE)

11:39 - 11:49

Other intensification strategies in mHSPC

D. Murphy, Melbourne (AU)

11:49 - 11:51

Re-do voting case 1

11:51 - 11:55

Clinical case presentation and voting: Recurrent low volume >5 years after RP, that achieves negative PSA at 3months of apalutamide

P. Rajwa, Warsaw (PL)

11:55 - 12:05

Treatment de-intensification: reality or myth?

B. Tombal, Brussels (BE)

12:05 - 12:07

Re-do voting case 2

12:07 - 12:15

Questions and answers

High-risk NMIBC and UTUC: Real-world decisions

Thematic Session

Sunday 15 March
10:45 - 12:15

Location Orange Area, eURO Auditorium 2
Chairs J. Boormans, Rotterdam (NL)
B.A. Inman, London (CA)

10:45 - 10:50 **Clinical case presentation**
L. Afferi, Aarau (CH)

10:50 - 10:55 **Voting What treatment would you recommend?**
L. Afferi, Aarau (CH)

10:55 - 11:15 **Panel discussion**
Moderator B.A. Inman, London (CA)
Panel J. Aning, Bristol (GB)
M. Eckstein, Erlangen (DE)
S. Psutka, Seattle (US)
A. Vilaseca, Barcelona (ES)

11:15 - 11:20 **Continuation clinical case**
L. Afferi, Aarau (CH)

11:20 - 11:25 **Voting What treatment would you recommend?**
L. Afferi, Aarau (CH)

11:25 - 11:45 **Panel discussion**
Moderator J. Boormans, Rotterdam (NL)
Panel J. Baard, Amsterdam (NL)
E. Compérat, Vienna (AT)
M. Costin, Chinnor (GB)
O. Rodriguez Faba, Barcelona (ES)

11:45 - 11:50 **Continuation clinical case**
L. Afferi, Aarau (CH)

11:50 - 12:10 **Panel discussion**
Moderator B.A. Inman, London (CA)
Panel A.J Birtle, Preston (GB)
A. Masson-Lecomte, Paris (FR)
A. Territo, Barcelona (ES)

12:10 - 12:15 **Closing remarks**

Sunday 15 March
10:45 - 11:15

Location Patient Advocacy Plaza

Chair To be confirmed

10:45 - 11:15

Patient Inclusive Advocacy Foundation (PIAF)

To be confirmed

Hands-on Training in Botulinum Toxin Injection

HOT Botox - 3.2

Sunday 15 March
10:45 - 12:15

Location Red Area, Room 3

Chairs H. Hashim, Bristol (GB)

To be confirmed

Learning objectives

Botulinum toxin type A has become established in urological practice over the past decades. Onabotulinum-toxin A (BTX-A) is licensed for the treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO) refractory to conservative and medical therapy.

This European Association of Urology (EAU) Hands-on Training (HOT) course is procedure-focused and teaches the practical aspects of intradetrusor onabotulinum-toxin-A administration through hands-on training using bladder models. Participants will learn safe reconstitution, injection techniques, using flexible and rigid cystoscopic equipment.

10:45 - 11:00

Introduction

To be confirmed

Learning objectives of this presentation

- Role of onabotulinumtoxinA (BTX-A) in the OAB and NDO treatment pathway
- Evidence-base and EAU guideline recommendations
- Injection paradigms, dosing, and patient counselling
- Overview of other functional urological applications (off-label)

11:00 - 12:00

Hands-on Rotation

11:00 - 12:00

Station 1: Onabotulinum-toxin-A reconstitution

Tutor M.G. Çulha, Istanbul (TR)

11:00 - 12:00

Station 2: Intradetrusor injection using flexible cystoscopy

Tutor To be confirmed

11:00 - 12:00

Station 3: Intradetrusor injection using rigid cystoscopy

Tutor

P. Bueno Garcia Reyes, Mexico City (MX)

12:00 - 12:15

Wrap-up and Q&A

H. Hashim, Bristol (GB)

Learning objectives of this presentation

- Key learning points
- Discussion of complications and practical considerations

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 3.3

Sunday 15 March
11:00 - 11:50

Location

Red Area, Room 1

Tutors

N.C. Grossmann, Lucerne (CH)

A. Tsaturyan, Yerevan (AM)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

E-BLUS Exam

HOT EBLUS EXAM - 3.3

Sunday 15 March
11:00 - 11:55

Location

Red Area, Room 1

Tutors

S. Erdem, Istanbul (TR)

L. Vendrell, Ciudad - Mendoza (AR)

Learning objectives

In this exam, your psychomotor skills such as depth perception and bimanual dexterity will be tested and your mastery of basic laparoscopy skills such as instrument handling, pattern cutting and intracorporeal suturing will be assessed by experienced examiners.

The exam is aimed at candidates with intermediate and advanced laparoscopy experience or those who have sufficiently trained to meet the exercises time and quality criteria. Passing the E-BLUS exam will be rewarded with a certificate that serves as a recommendation to continue your laparoscopy training by assisting laparoscopic procedures in the OR.

ESTs1 Exam

HOT EST EXAM 3.3

Sunday 15 March
11:00 - 11:50

Location Red Area, Room 1

Tutors A.C. Bouma - Houwert, Amsterdam (NL)
To be confirmed
A. Papatsoris, Athens (GR)

Learning objectives

In this exam, candidates' psychomotor and endoscopic skills are assessed, with a focus on the safe and effective performance of core endourological procedures such as rigid cystoscopy, flexible cystoscopy, semi-rigid ureteroscopy, and flexible ureteroscopy. Candidates are evaluated by experienced examiners on instrument handling, scope control, orientation, and respect for tissue within a simulated setting. The exam is aimed at candidates with basic to intermediate endourology experience or those who have completed sufficient training to meet the required performance standards, and successful completion is rewarded with a certificate recommending progression to supervised endourological procedures in the operating room.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 3.3

Sunday 15 March
11:00 - 11:50

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 3.3

Sunday 15 March
11:00 - 11:50

Location Red Area, Room 1

Tutors M. Arslan, Istanbul (TR)
G. Bozzini, Como (IT)
D. Perri, Como (IT)

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 3.3

Sunday 15 March
11:00 - 11:50

Location Red Area, Room 1

Tutors H. Ismail, Cottbus (DE)
To be confirmed

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Patient advocacy plaza - The language of care: Why words matter in patient experience

Special Session

Sunday 15 March
11:30 - 12:00

Location Patient Advocacy Plaza
Chair To be confirmed

11:30 - 12:00

Patient Inclusive Advocacy Foundation (PIAF)
To be confirmed

Patient advocacy plaza - Patient and partner involvement in prostate cancer research – Insights from the PRO-ACT study

Special Session

Sunday 15 March
13:30 - 14:00

Location Patient Advocacy Plaza
Chair To be confirmed

13:30 - 14:00

East Galway & Midlands (EGM) Cancer Support
To be confirmed

Hands-on Training in prostate MRI reading for urologists

HOT MRI - 3.2

Sunday 15 March
13:30 - 17:00

Location Red Area, Room 6

Learning objectives

This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on a provided computer using realistic software, followed by a reference reading provided by expert radiologists and pathological verification.

13:30 - 13:35

Course overview

F. Sanguedolce, Barcelona (ES)

13:35 - 13:45

Lecture: The importance of prostate MRI to the Urologist

To be confirmed

13:45 - 14:15	Lecture: Introduction to MRI sequences, scoring systems, PI-RADS F. Giganti, London (GB)
14:15 - 14:45	Lecture: Interactive case discussion – reporting MRI using PI-RADS G. Brembilla, Milan (IT)
14:45 - 14:50	Introduction to the software for MRI interpretation F. Sanguedolce, Barcelona (ES)
14:50 - 15:20	Diagnosis I: Practical MRI diagnosis
15:20 - 15:50	Review of the findings I F. Giganti, London (GB)
15:50 - 16:20	Diagnosis II: Practical MRI diagnosis
16:20 - 16:50	Review of the findings II G. Brembilla, Milan (IT)
16:50 - 17:00	Discussion, feedback, & closure To be confirmed

Joint session of the EAU, EANM, ESMO and ESTRO

Thematic Session

Sunday 15 March
13:45 - 15:15

Location Orange Area, eURO Auditorium 2

Chairs To be confirmed
P. Erba, Milan (IT)
B.A. Jereczek-Fossa, Milan (IT)
J. Walz, Marseille (FR)

Learning objectives

Lear how to deliver the best oncological care based on the multidisciplinary approach and specific patient situation in genitourinary cancer

13:45 - 13:49	Case I - Bladder CR after EV-Pembro for M1 disease: Local treatment? How to restage? Follow-up? L.S. Mertens, Amsterdam (NL)
----------------------	--

13:49 - 13:59	Round-table discussion <i>Panel</i> To be confirmed J.W.F. Catto, Sheffield (GB) V. Fonteyne, Ghent (BE) Y. Lortot, Villejuif (FR) A. Masson-Lecomte, Paris (FR)
----------------------	--

13:59 - 14:03

Case II - Bladder High-risk UTUC (T1 HG): Staging? Neoadjuvant vs. adjuvant vs. conservative treatment?

L.S. Mertens, Amsterdam (NL)

14:03 - 14:15

Round-table discussion

Panel

To be confirmed

J.W.F. Catto, Sheffield (GB)

V. Fonteyne, Ghent (BE)

Y. Loriot, Villejuif (FR)

A. Masson-Lecomte, Paris (FR)

14:15 - 14:19

Case I - Testis Stage I seminoma high risk: Staging? Surveillance vs. chemo vs. RT?

M. Christodoulidou, Leicester (GB)

14:19 - 14:29

Round-table discussion

Panel

To be confirmed

Y. Che, Düsseldorf (DE)

L. Nappi, Vancouver (CA)

A. Papachristofilou, Basel (CH)

14:29 - 14:33

Case II - Testis Stage II seminoma: Staging?; Surgery vs. chemo vs. RT?

M. Christodoulidou, Leicester (GB)

14:33 - 14:45

Round-table discussion

Panel

To be confirmed

Y. Che, Düsseldorf (DE)

L. Nappi, Vancouver (CA)

A. Papachristofilou, Basel (CH)

14:45 - 14:50

Case I - Renal Cystic kidney with solid mass: Staging? Diagnosis, treatment?

G.L. Margue, Bordeaux (FR)

14:50 - 15:00

Round-table discussion

Panel

M. Bauckneht, Genoa (IT)

A. Bex, London (GB)

G. De Velasco, Madrid (ES)

G. Francolini, Firenze (IT)

G. Pignot, Marseille (FR)

15:00 - 15:05

Case II - Renal T3b ccRCC, solitary bone lesion: Staging? Neoadjuvant treatment? Surgery + RT? Adjuvant treatment

G.L. Margue, Bordeaux (FR)

15:05 - 15:15

Round-table discussion

Panel

M. Bauckneht, Genoa (IT)

A. Bex, London (GB)

G. De Velasco, Madrid (ES)

G. Francolini, Firenze (IT)

G. Pignot, Marseille (FR)

Future of robotic surgery

Thematic Session

Sunday 15 March
13:45 - 15:15

Location Orange Area, eURO Auditorium 1

Chairs To be confirmed
C. Fiori, Orbassano (IT)

Learning objectives

This session provides an overview of emerging technologies in robotic urological surgery, focusing on augmented reality, telesurgery, and artificial intelligence. Experts will address technical, legal, and educational implications, with a particular focus on telementoring as a tool to expand surgical expertise. A comparative debate on robotic platforms will highlight key features. Delegates will gain up-to-date insights into current trends and future directions in training, innovation, and clinical application.

13:45 - 13:46

Introduction

13:46 - 13:54

State-of-the-art lecture **Augmented reality in robotic surgery: Enhancing precision, vision and outcomes**
P. De Backer, Ghent (BE)

13:54 - 14:24

Panel discussion **Telesurgery/telementoring**

13:54 - 13:59

Where do we stand in 2026?
A. Breda, Barcelona (ES)

13:59 - 14:04

Technical implications
To be confirmed

14:04 - 14:09

Legal implications
B. Leigh, London (GB)

14:09 - 14:14

Is telementoring a way to expand surgical expertise beyond the borders?
S. Nathan, London (GB)

14:14 - 14:24

Discussion

14:24 - 14:42

Debate **Which robot to choose?**

14:24 - 14:30

Open console
J.M. Gaya Sopena, Barcelona (ES)

14:30 - 14:36

Closed console
V. Phé, Paris (FR)

14:36 - 14:42

Discussion

14:42 - 15:06

Panel discussion Artificial intelligence in urological surgery

14:42 - 14:48

Diagnostic

P. Dasgupta, London (GB)

14:48 - 14:54

Surgery: The European experience

K-F. Kowalewski, Mannheim (DE)

14:54 - 15:00

Surgery: The US experience

M. Stifelman, Hackensack (US)

15:00 - 15:06

Urological Association of Asia Lecture (UAA) Surgery: The Asian experience

X. Ma, Beijing (CN)

15:06 - 15:14

State-of-the-art lecture Education in robotic surgery: What is the future of training?

A. Mottrie, Aalst (BE)

15:14 - 15:15

Conclusion

Redefining mHSPC management: From diagnosis and risk assessment to optimising treatment

Abstract Session 31

Sunday 15 March

13:45 - 15:15

Location

Blue Area, Victoria 2

Chairs

To be confirmed

K. Goffin, Leuven (BE)

A. Omlin, Zürich (CH)

13:45 - 14:05

Diagnosis of metastatic disease by PSMA-PET

[A0512](#)

Redefining EMBARK-like Patients in the PSMA Era: Impact of PSMA-PET Restaging on Disease Classification and Management

Authors

Viti A.¹, Stabile A.¹, Cucchiara V.¹, Scuderi S.¹, Robesti D.¹, Scilipoti P.¹, Quarta L.¹, Zaurito P.¹, Santangelo A.¹, Brancaccio M.¹, Simonetti A.P.¹, Colistro A.¹, Necchi A.², Maiorano B.A.², Mercinelli C.², Chiti A.³, Sollini M.³, Pini C.³, Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Division of Oncology, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy

A0513

Stage Migration of Prostate Cancer due to PET Scan Utilization

Authors

Mason J.B.¹, Feinberg N.², Modi P.K.¹, Skolarus T.A.¹

Institutions

¹The University of Chicago, Dept. of Urology, Chicago, United States of America, ²The University of Chicago, Dept. of Radiology, Chicago, United States of America

A0514

PSMA PET/CT for staging favourable intermediate-risk prostate cancer: an international multicenter study

Authors

Han L.¹, Fu M.H.², Hong A.², Wong L.M.³, Miao W.¹, Shuaitao X.¹, Ming L.¹

Institutions

¹Beijing Hospital, Dept. of Urology, Beijing, China, ²Austin Hospital, Dept. of Urology, Melbourne, Australia, ³St. Vincent's, Dept. of Urology, Melbourne, Australia

A0515

Triple-tracer comparison of 18F-FDG, 68Ga-PSMA, and 18F-FAPI PET for tumor heterogeneity detection and treatment response assessment in newly diagnosed high-risk prostate cancer

Authors

Zhang W.¹, Xu L.², Dong Y.¹, Liao P.¹, Zhu Y.¹, Du X.¹, Hu C.¹, Lai L.¹, Zheng Z.¹, Chen R.², Liu J.², Pan J.¹, Dong L.¹, Xue W.¹

Institutions

¹Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China, ²Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of Nuclear Medicine, Shanghai, China

14:05 - 14:20

Management of oligometastatic prostate cancer

Outcomes of local treatment for oligometastatic prostate cancer diagnosed using PSMA PET imaging: the OLIGOMET study

Authors

Fazekas T.¹, Miszczyk M.², Bilski M.³, Soeterik T.⁴, Giesen A.⁵, Joniau S.⁵, Tayara O.⁶, Nyk L.⁶, Ofner H.², Bauckneht M.⁷, Heidegger I.⁸, Nastassija A.⁸, Checcucci E.⁹, Marra G.¹⁰, Rivas J.G.M.¹¹, Cisero E.¹², Zattoni F.¹³, Amparore D.¹⁴, Heidenreich A.¹⁵, Semko S.¹⁵, Briganti A.¹⁶, Gandaglia G.¹⁶, Shariats S.², Rajwa P.²

Institutions

¹Semmelweis University, Dept. of Urology, Budapest, Hungary, ²Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³Medical University of Lublin, Dept. of Radiotherapy, Lublin, Poland, ⁴St. Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ⁵University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁶Centre of Postgraduate Medical Education, Second Department of Urology, Warsaw, Poland, ⁷IRCCS Ospedale Policlinico San Martino, Dept. of Health Sciences, Genova, Italy, ⁸Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ⁹Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Dept. of Surgery, Turin, Italy, ¹⁰University of Turin and Città della Salute e della Scienza, Division of Urology, Dept. of Surgical Sciences, Turin, Italy, ¹¹Health Research Institute, Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ¹²San Luigi Gonzaga Hospital, Dept. of Oncology, Division of Urology, University of Turin, Turin, Italy, ¹³University of Padova, Dept. of Surgery, Oncology, and Gastroenterology, Urological Unit, Padova, Italy, ¹⁴Candiolo Cancer Institute, Dept. of Surgery, Turin, Italy, ¹⁵University Hospital Cologne, Dept. of Urology, Uro-Oncology, Robot-assisted and Specialized Urologic Surgery, Cologne, Germany, ¹⁶IRCCS Ospedale San Raffaele, Unit of Urology, Division of Oncology, Milan, Italy

Study Group

YAU Prostate Cancer Working Group(Arnhem, The Netherlands)

Duration of systemic treatment as part of MDT in metachronous PSMA PET-staged oligometastatic prostate cancer

Authors

Erard R.¹, Giesen A.¹, Franssen M.¹, Izci S.¹, Everaerts W.¹, De Meerleer G.², Joniau S.¹

Institutions

¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²UZ Leuven, Dept. of Radiation Oncology, Leuven, Belgium

PSMA-PET Staging Refines Patient Selection in Oligometastatic Prostate Cancer: Translating RAMPP Trial Findings into Contemporary Practice

Authors

Scuderi S.L.A.¹, Stabile A.¹, Cucchiara V.¹, Barletta F.M.¹, Quarta L.¹, Zaurito P.¹, Viti A.¹, Santangelo A.¹, Ceria F.¹, Roca G.¹, Necchi A.², Cigliola A.², Maiorano B.², Picchio M.³, Sollini M.³, Pini C.³, Karakiewicz P.⁴, Shariat S.⁵, Chiti A.³, Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Division of Oncology, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, ⁴Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montréal, Canada, ⁵Medical University of Vienna, Dept. of Urology, Vienna, Austria

A0519

Uptake of doublet and triplet therapy for men with de novo metastatic castration sensitive prostate cancer. Population-based study

Authors

Zaurito P.¹, Gedeberg R.², Garmo H.², Ventimiglia E.², Alhberg M.², Stattin P.², Westerberg M.²

Institutions

¹IRCCS San Raffaele Scientific Institute - 'Vita-Salute' San Raffaele University, Dept. of Urology, Milan, Italy, ²Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden

A0520

Whole-body Tumor burden stratification via 18F-PSMA-1007 PET/CT identifies optimal candidates with de novo high-volume metastatic hormone-sensitive prostate cancer for intensified triplet therapy

Authors

Junjie F.¹, Ke X.¹, Qiyuan K.¹, Chaosheng G.¹, Dalin H.¹, XiaoYi D.², Kaijie W.¹

Institutions

¹First Affiliated Hospital of Xi'an Jiaotong University, Dept. of Urology, Xi'an, China, ²First Affiliated Hospital of Xi'an Jiaotong University, PET/CT imaging, Xi'an, China

A0521

Risk stratification in high-volume mHSPC: Challenges in applying prognostic models to the triplet era

Authors

Miyajima K.¹, Yanagisawa T.¹, Fukuokaya W.¹, Sakakibara R.¹, Uchida N.¹, Matsukawa A.¹, Urabe F.¹, Mori K.¹, Mischczyk M.², Fujita N.³, Narita S.⁴, Hatakeyama S.³, Habuchi T.⁴, Shariat S.F.², Kimura T.¹

Institutions

¹The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ²Medical University of Vienna, Dept. of Urology, Comprehensive Cancer Center, Vienna, Austria, ³Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ⁴Akita University School of Medicine, Dept. of Urology, Akita, Japan

Complete pathological response of the primary tumour and implications for cytoreductive treatment in de novo metastatic prostate cancer: Analysis from the IP2-ATLANTA phase II randomised study

Authors

Connor M.J.¹, Shah T.T.¹, [Gopalakrishnan A.](#)¹, Sukumar J.¹, Fiorentino F.², Heath C.³, Horan G.⁴, Johnson N.¹, Khoo V.⁵, Khoubehi B.⁶, Klimowska-Nassar N.¹, Mangar S.¹, McGrath J.⁷, Nohpal de la Rosa C.¹, Price D.¹, Rai B.⁸, Sarwar N.⁹, Staffurth J.¹⁰, Tam H.¹¹, Thippu Jayaprakash K.¹², Winkler M.¹, Dudderidge T.¹³, Smith A.¹⁴, Ahmed H.U.¹

Institutions

¹Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, ²Leeds University, Clinical Trials Research Unit, Leeds, United Kingdom, ³University Hospital Southampton, Dept. of Oncology, Southampton, United Kingdom, ⁴The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, Dept. of Oncology, Kings Lynn, United Kingdom, ⁵The Royal Marsden Hospital, Dept. of Oncology, London, United Kingdom, ⁶Chelsea and Westminster Hospital, Dept. of Urology, London, United Kingdom, ⁷Royal Devon & Exeter Hospital, Dept. of Urology, Exeter, United Kingdom, ⁸Newcastle Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, ⁹Imperial College Healthcare NHS Trust, Dept. of Oncology, London, United Kingdom, ¹⁰Cardiff University, Dept. of Oncology, Cardiff, United Kingdom, ¹¹Imperial College Healthcare NHS Trust, Dept. of Radiology, London, United Kingdom, ¹²Addenbrooke's Hospital, Dept. of Oncology, Cambridge, United Kingdom, ¹³University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom, ¹⁴Imperial College Healthcare NHS Trust, Dept. of Histopathology, London, United Kingdom

Study Group

IP2-ATLANTA Trial Investigators(London, United Kingdom)

Efficacy and feasibility of new generation androgen receptor signaling inhibitors in very elderly patients (≥80 years) with metastatic castration-sensitive prostate cancer

Authors

[Suzuki K.](#), Wakita N., Ueki H., Okamura Y., Hara T., Terakawa T., Chiba K., Teishima J., Miyake H.

Institutions

Kobe University Graduate School of Medicine, Division of Urology, Kobe, Japan

Time to subsequent chemotherapy with capivasertib (capi) + abiraterone (abi) versus placebo (pbo) + abi in patients (pts) with PTEN deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281

Authors

Clarke N.¹, George D.J.², De Santis M.³, Uemura H.⁴, Fay A.P.⁵, Karadurmus N.⁶, Kwiatkowski M.⁷, Alvarez-Fernandez C.⁸, Jiang S.⁹, Sotelo M.¹⁰, Özgüroglu M.¹¹, Roubaud G.¹², Castellano D.¹³, Sugimoto M.¹⁴, Shi L.¹⁵, Talreja V.¹⁶, Yeste-Velasco M.¹⁷, Lima A.R.¹⁷, Gresty C.¹⁸, Fizazi K.¹⁹

Institutions

¹The Christie and Salford Royal NHS Foundation Trusts, Dept. of Urology, Manchester, United Kingdom, ²Duke University Cancer Institute, Dept. of Medicine, Durham, United States of America, ³Charite Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ⁴Kindai University Hospital, Dept. of Urology, Osaka, Japan, ⁵Hospital Nora Teixeira and PUCRS School of Medicine, Dept. of Medical Oncology, Porto Alegre, Brazil, ⁶SBU Gulhane Training and Research Hospital, Dept. of Medical Oncology, Ankara, Turkey, ⁷Szpital Wojewódzki w Koszalinie, Dept. of Oncology, Koszalin, Poland, ⁸Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias, Dept. of Medical Oncology, Oviedo, Spain, ⁹Hunan Cancer Hospital, Dept. of Urology, Hunan, China, ¹⁰Hospital Maria Auxiliadora, Dept. of Medical Oncology, Lima, Peru, ¹¹Cerrahpaşa School of Medicine, Istanbul University-Cerrahpaşa, Dept. of Internal Medicine, Division of Medical Oncology, Istanbul, Turkey, ¹²Institut Bergonié, Dept. of Medical Oncology, Bordeaux, France, ¹³Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ¹⁴Kagawa University Hospital, Dept. of Urology, Kagawa, Japan, ¹⁵Yantai Yuhuangding Hospital, Dept. of Urology, Yantai, China, ¹⁶Regency Hospital Cancer and Gastro Care Centre, Dept. of Urology, Kanpur, India, ¹⁷AstraZeneca, Dept. of Global Development, Barcelona, Spain, ¹⁸AstraZeneca, Dept. of Global Development, Cambridge, United Kingdom, ¹⁹Institut Gustave Roussy, Centre Oscar Lambret, University of Paris Saclay, Dept. of Cancer Medicine, Lille, France

14:50 - 15:10

Prognostic factors and competing health risks in metastatic prostate cancer

A0525

Prostate cancer stage vs. leading causes of death

Authors

Falkenbach F.¹, Marmiroli A.¹, Longoni M.¹, Le Q.C.¹, Nicolazzini M.¹, Catanzaro C.¹, Polverino F.¹, Goyal J.A.¹, Schiavina R.², Volpe A.³, Musi G.⁴, Longo N.⁵, Chun F.K.H.⁶, Briganti A.⁷, Saad F.¹, Shariat S.F.⁸, Budäus L.⁹, von Amsberg G.¹⁰, Graefen M.⁹, Karakiewicz P.I.¹

Institutions

¹University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montréal, Canada, ²University of Bologna, St. Orsola-Malpighi Hospital, Dept. of Urology, Bologna, Italy, ³University of Turin, Division of Urology, Turin, Italy, ⁴University of Eastern Piedmont, Maggiore della Carità Hospital, Division of Urology, Dept. of Translational Medicine, Novara, Italy, ⁵University of Naples Federico II, Dept. of Neurosciences, Science of Reproduction and Odontostomatology, Naples, Italy, ⁶Goethe University Frankfurt, Dept. of Urology, Frankfurt, Germany, ⁷IRCCS San Raffaele Scientific Institute, Division of Experimental Oncology, Unit of Urology, Milan, Italy, ⁸Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁹University Medical Center Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, ¹⁰University Medical Center Hamburg-Eppendorf, Dept. of Hematology and Oncology, Hamburg, Germany

A0526

Identifying and Predicting Non-Cancer Mortality risk in mHSPC following Doublet Therapy in the STAMPEDE Trial

Authors

[El-Taji O.](#)¹, Gray S.¹, McSweeney D.², Brown M.¹, Brown L.³, Attard G.⁴, Parmar M.³, James N.⁵, Garrett J.⁶, Pickhardt P.⁶, Clarke N.¹, Sachdeva A.⁷

Institutions

¹The Christie NHS Trust, Dept. of Urological Surgery, Manchester, United Kingdom, ²The Christie NHS Trust, Dept. of Radiotherapy Research, Manchester, United Kingdom, ³University College London, Clinical Trials Unit, London, United Kingdom, ⁴University College London, Dept. of Cancer Sciences, London, United Kingdom, ⁵Institute of Cancer Research, Dept. of Oncology, London, United Kingdom, ⁶University of Wisconsin, Dept. of Radiology, Madison, United States of America, ⁷University of Manchester, Dept. of Cancer Sciences, Manchester, United Kingdom

A0527

Skeletal muscle index as a prognostic and predictive biomarker in de novo hormone sensitive prostate cancer: an exploratory analysis of four trials embedded within the STAMPEDE platform.

Authors

[Gray S.](#)¹, McSweeney D.², El-Taji O.¹, Dutey-Magni P.³, Jones C.⁴, Brown M.⁵, Brown L.³, Parmar M.³, Attard G.⁶, James N.⁷, McWilliam A.², Clarke N.¹, Sachdeva A.⁵

Institutions

¹The University of Manchester, Genito Urinary Cancer Research Group, Manchester, United Kingdom, ²The University of Manchester, Radiotherapy Related Research, Manchester, United Kingdom, ³University College London, MRC Clinical Trials Unit, London, United Kingdom, ⁴Stockport NHS Foundation Trust, Dept. of Urology, Stockport, United Kingdom, ⁵The University of Manchester, Genito Urinary Cancer Research Group, Manchester, United Kingdom, ⁶University College London, Cancer Institute, London, United Kingdom, ⁷Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom

A0528

The impact of metformin on body composition in metastatic hormone sensitive prostate cancer: exploratory analysis of the STAMPEDE metformin trial

Authors

McSweeney D.¹, [Gray S.](#)¹, El-Taji O.¹, Dutey-Magni P.², Brown L.², Brown M.¹, Attard G.³, James N.⁴, Gillissen S.⁵, Clarke N.¹, Sachdeva A.¹, McWilliam A.¹

Institutions

¹University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom, ²University College London, MRC Clinical Trials Unit, London, United Kingdom, ³University College London, Research Department of Oncology, London, United Kingdom, ⁴The Institute of Cancer Research, Prostate and Bladder Cancer Research Group, London, United Kingdom, ⁵Università della Svizzera Italiana, Dept. of Medical Oncology, Lugano, Italy

Sunday 15 March
13:45 - 15:15

Location Blue Area, George 4
Chairs Y-C. Chen, Kaohsiung (TW)
To be confirmed
C. Hentzen, Paris (FR)

13:45 - 14:00

Catheterisation

A0495

Patient-reported outcomes of reusable versus single-use catheters in intermittent catheterization for urinary retention: a prospective, randomized, multicenter study (COMPARE-trial)

Authors

Christiaans C.H.H.¹, van Veen F.E.E.¹, Berendsen S.A.¹, van Doorn T.¹, Boekhorst J.L.¹, Koedood S.¹, Kuenen M.², Roelofs A.W.T.M.³, Witte L.W.P.⁴, Dijkstra S.⁵, van Brakel J.⁶, van Wielen G.J.⁷, Roelofs L.A.J.⁸, Wolterbeek J.H.⁹, Koldewijn E.L.¹⁰, Van Asten J.¹¹, Bleumer I.¹², Hansen B.E.¹³, Scheepe J.R.¹, Blok B.F.M.¹

Institutions

¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Zuyderland MC, Dept. of Urology, Heerlen, The Netherlands, ³Rijnstate, Dept. of Urology, Arnhem, The Netherlands, ⁴Isala, Dept. of Urology, Zwolle, The Netherlands, ⁵Canisius Wilhelmina Ziekenhuis, Dept. of Urology, Nijmegen, The Netherlands, ⁶Amphia, Dept. of Urology, Breda, The Netherlands, ⁷Haaglanden MC, Dept. of Urology, The Hague, The Netherlands, ⁸Treant, Dept. of Urology, Emmen, The Netherlands, ⁹Franciscus, Dept. of Urology, Rotterdam, The Netherlands, ¹⁰Catharina Ziekenhuis, Dept. of Urology, Eindhoven, The Netherlands, ¹¹HagaZiekenhuis, Dept. of Urology, The Hague, The Netherlands, ¹²St. Jansdal, Dept. of Urology, Harderwijk, The Netherlands, ¹³Erasmus MC, Dept. of Epidemiology and Biostatistics, Rotterdam, The Netherlands

A0496

A randomised trial comparing combined reusable and single-use catheters (Mixed-use) with single-use catheters only

Authors

Fader M.¹, Macaulay M.¹, Wilson N.², Chadwick T.², Goudie N.³, Watson G.³, Wood R.³, Sach T.¹, McClurg D.⁴, Guerrero K.⁵, Hagen S.⁴, Murphy C.¹

Institutions

¹University of Southampton, School of Health Sciences, Southampton, United Kingdom, ²Newcastle University, Population Health Sciences Institute, Newcastle, United Kingdom, ³Newcastle University, Clinical Trials Unit, Newcastle, United Kingdom, ⁴Glasgow Caledonian University, Nursing, Midwifery and Allied Health Professions Research Unit, Glasgow, United Kingdom, ⁵Glasgow & Greater Clyde NHS Foundation Trust, Dept. of Uro-gynaecology, Glasgow, United Kingdom

A0497

A health economic analysis of mixed-use (multi- and single-use) intermittent catheter management compared with single-use only.

Authors

McCloskey S.¹, Sach T.¹, Macaulay M.¹, Avery M.¹, Chadwick T.², Bridget C.¹, Dickson S.³, Goudie N.², Guerrero K.⁴, Hagen S.³, Murphy C.¹, Watson G.², Wilson N.², Wood R.², Fader M.¹

Institutions

¹University of Southampton, Dept. of Medicine, Southampton, United Kingdom, ²Newcastle University, Dept. of Medicine, Newcastle, United Kingdom, ³Glasgow Caledonian University, Dept. of Medicine, Glasgow, United Kingdom, ⁴Queen Elizabeth University Hospital, Dept. of Medicine, Glasgow, United Kingdom

14:00 - 14:20

Non-neurogenic voiding dysfunction

A0498

Association Between Psoas Muscle Index and Bladder Contractility Index in Men

Authors

Santos H.O.D., Wroclawski M.L., Beraldo G.L., Rios L.A.S., Coelho F.M., Carneiro A., Bianco B., Baroni R.H.

Institutions

Hospital Israelita Albert Einstein, Dept. of Urology, São Paulo, Brazil

A0499

Diagnostic Clues for Low-Pressure Female Bladder Outlet Obstruction Missed by Conventional Urodynamics

Authors

Chen K.F.¹, Fan Y.H.¹, Cheng W.M.², Lin A.T.L.¹, Lin C.C.¹, Ku M.H.¹, Huang E.Y.H.¹

Institutions

¹Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ²Taipei City Hospital, Zhongxiao Branch, Division of Urology Dept. of Surgery, Taipei, Taiwan

A0500

Post-Micturition Dribbling: New Insights into the Role of Post-Void Residual Volume and After-Constrictions – A Prospective Study

Authors

Yacobi Y.¹, Zisman A.¹, Stav K.¹, Beberashvili I.²

Institutions

¹Shamir Medical Center, Dept. of Urology, Tzrifin, Israel, ²Shamir Medical Center, Dept. of Nephrology, Tzrifin, Israel

A0501

External Validation of a Simple Office-Based Model to Predict Detrusor Underactivity in Women With LUTS

Authors

Schwarzttuch Gildor O., Yosef E., Itshak A., Levin N., Shaked Y., Vainrib R., Neheman A., Vainrib M.

Institutions

Meir Medical Center, Dept. of Urology, Kfar Saba, Israel

14:20 - 14:40

Neuromodulation

A0502

A Structured Management Protocol to Sustain Sacral Neuromodulation (SNM) for Lower Urinary Tract Dysfunction (LUTD): 8-Year Outcomes

Authors

Ng C.¹, Jenks J.¹, Imran M.², Snooks A.², Shadananan V.³, Audu T.³, Hamid R.¹, Barratt R.¹, Nobrega R.¹, Noah A.¹, Gresty H.¹, Greenwell T.¹, Ockrim J.¹, Pakzad M.¹

Institutions

¹University College London Hospitals NHS Foundation Trust, Dept. of Functional Reconstructive and Adolescent Urology, London, United Kingdom, ²University College London Medical School, London, United Kingdom, ³University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom

A0503

Multimodal Image-Guided Optical Navigation for Precision Sacral Neuromodulation Electrode Implantation: A Randomized Controlled Trial

Authors

Lyu R., Song X., Lv J., Lv T., Fang W., Huang J.

Institutions

Shanghai Pudong New Area Gongli Hospital, Dept. of urology, Shanghai, China

A0504

Predictors of Success of Sacral Neuromodulation for Non-Obstructive Urinary Retention

Authors

Schwarzttuch Gildor O., Itshak A., Shaked Y., Neheman A., Vainrib M.

Institutions

Meir Medical Center, Dept. of Urology, Kfar Saba, Israel

A0505

Sacral Neuromodulation Device Explantation: A 12-Year Experience from a High-Volume Tertiary Center

Authors

Henrique Bitar Siqueira M.¹, Fiorido C.², Elterman D.¹

Institutions

¹University of Toronto, Dept. of Urology, Toronto, Canada, ²University Health Network, Dept. of Urology, Toronto, Canada

14:40 - 15:10

Neurourology

A0506

NEUDOTOX Project: Toward a Urinary Microbiota Signature Associated with Response to Intradetrusor Botulinum Toxin in Neurogenic Detrusor Overactivity after Spinal Cord Injury

Authors

Perrouin Verbe M-A.¹, Charrier A.², Simon A.¹, Puisset S.¹, Trehorel M.L.³, Trottier C.⁴, Marchix J.⁴, Bessard A.⁴, Lefevre C.³, Perrouin-Verbe B.³, Neunlist M.⁴

Institutions

¹Centre Hospitalo-Universitaire de Nantes, Dept. of Urology, Nantes, France, ²Centre Hospitalo-Universitaire de Nantes, Dept. of Urology, Nantes, France, ³Centre Hospitalo-Universitaire de Nantes, Dept. of Physical Medicine and Rehabilitation, Nantes, France, ⁴Nantes Université, INSERM U 1235 TENS, The enteric nervous system in gut and brain disorders, Nantes, France

A0507

Pelvic organ prolapse is highly prevalent in women with spina bifida

Authors

Dubois A.¹, Malandain B.¹, Hascoet J.¹, Haudebert C.¹, Brochard C.², Richard C.¹, Voiry C.³, NYANGO TIMOH K.⁴, Manunta A.¹, Samson E.³, Peyronnet B.¹

Institutions

¹Rennes University Hospital, Dept. of Urology, Rennes, France, ²Rennes University Hospital, Dept. of Gastro Enterology, Rennes, France, ³Rennes University Hospital, Dept. of Physical Medicine and Readaptation, Rennes, France, ⁴Rennes University Hospital, Dept. of Obstetrics and Gynecology, Rennes, France

A0508

Upper Urinary Tract Protection and Patient Classification Following Sacral Neuromodulation in Neurogenic Bladder with Hydronephrosis: A Multicenter Study with 2-Year Follow-Up

Authors

Chen P., Huang H., Huang H.

Institutions

Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China

A0509

A multi-disciplinary approach to managing ketamine uropathy

Authors

Sarna S., Manley K., Bhatt N., Saunders A., Isaac M., Wood S., Dunford C., Doherty R.

Institutions

Norfolk and Norwich University Hospital, Dept. of Urology, Norwich, United Kingdom

A0510

Functional outcomes and complication rates following Mitrofanoff stoma creation in adults: a 15-year institutional experience

Authors

Stelzl D., Wagner M.C., Klemm J., Koelker M., Roessler N., von Deimling M., Dahlem R., Fisch M., Vetterlein M.W.

Institutions

University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

A0511

Long-term adherence to intermittent catheterisation in people with multiple sclerosis: findings from a multi-country retrospective survey

Authors

Barken K.B., Zeeberg R.

Institutions

Coloplast, Dept. of Medical Affairs, Humlebaek, Denmark

Navigating the spectrum of BPO management: Surgical advances and patient-reported outcomes

Abstract Session 32

**Sunday 15 March
13:45 - 15:15**

Location

Blue Area, Victoria 5

Chairs

M.S. Guemmoudi, Bir Mourad Rais (DZ)

L. Moris, Leuven (BE)

To be confirmed

A0529

Perioperative outcomes and prevalence of urethral strictures during surgery for benign prostatic hyperplasia: results from the GRAND study

Authors

Pyrgidis N., Schulz G.B., Weinhold P., Volz Y., Papadopoulos I., Stief C., Marcon J., Keller P.

Institutions

University Hospital Munich Ludwig-Maximilian-University, Dept. of Urology, Munich, Germany

A0530

When TURP Meets PVP(XPS): Superior Flow and Resection Efficiency in Large-Volume BPH (>80 g)

Authors

Hwang W.K., Lee T.H., Kim H.J., Jo S.B., Ahn S.T., Kim J.W., Oh M.M., Moon D.G.

Institutions

Korea university Guro Hospital, Dept. of Urology, Seoul, South Korea

A0531

Ejaculation-Preserving Bladder Neck Symmetrical Incision at 3 and 9 o'clock: Insights from a Large Multicenter Experience

Authors

Dagnino F.¹, Marino F.², Chiarelli G.¹, Galioto D.², Micheli F.², Di Gianfrancesco L.², De Marchi D.², Giampaoli M.², Simonetti F.², D'Agostino D.², Casale P.³, Lughezzani G.¹, Buffi N.M.B.¹, Porreca A.¹

Institutions

¹Humanitas University, Dept. of Biomedical Science, Pieve Emanuele, Italy, ²Humanitas Gavazzeni Hospital, Dept. of Urology, Bergamo, Italy, ³Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

A0532

Endoscopic enucleation of the prostate in patients on blood thinners: outcomes, a real-life prospective multicenter study of 932 cases.

Authors

Castellani D.¹, Yuen S.K.K.², Fong K.Y.³, Giulioni C.⁴, Chiruvella M.⁵, Somani B.K.⁶, Herrmann T.R.W.⁷, Gauhar V.⁸

Institutions

¹Azienda Ospedaliero Universitaria delle Marche, Dept. of Urology, Ancona, Italy, ²S.H. Ho Urology Centre, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, China, ³Sengkang General Hospital, Dept. of Urology, Singapore, Singapore, ⁴Villa Igea Private Hospital, Dept. of Urology, Ancona, Italy, ⁵Asian Institute of Nephrology and Urology, Dept. of Urology, Hyderabad, India, ⁶Southampton University, Dept. of Urology, Southampton, United Kingdom, ⁷Kantonspital Frauenfeld, Spital Thurgau AG, Dept. of Urology, Frauenfeld, Switzerland, ⁸Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore

Study Group

Enucleation in Anticoagulated Patients (EAP)(Singapore, Singapore)

A0533

Prospective Multicentre Analysis of Prostate Enucleation in Patients with Prostate Volumes Below and Above 100 ml: 3-Year Follow-Up on Safety and Efficacy

Authors

Hook S.H.¹, Netsch C.¹, Gross A.J.¹, Rosenbaum C.M.², Filmar S.¹, Engel O.³, Wülfing C.⁴, Becker B.¹

Institutions

¹Asklepios Barmbek Hospital, Dept. of Urology, Hamburg, Germany, ²Asklepios Paulinen Hospital, Dept. of Urology, Wiesbaden, Germany, ³Asklepios Hospital Harburg, Dept. of Urology, Hamburg, Germany, ⁴Asklepios Hospital Altona, Dept. of Urology, Hamburg, Germany

14:10 - 14:55

Ablative MISTs: outcomes, retreatments and comparative trials

A0534

Pharmacological re-treatment after minimally invasive surgical treatments for benign prostate obstruction.

Authors

Campobasso D.¹, Olivero A.², Fourmarier M.³, Barber N.⁴, Palagonia E.², Karaca E.⁴, Ferretti S.⁵, Chaudhary A.⁴, Galfano A.², Ng K.L.⁴, Binsaleh S.⁶, Cindolo L.⁷, Secco S.²

Institutions

¹San Camillo de Lellis Hospital ASL Rieti, Dept. of Urology, Rieti, Italy, ²ASST Grande Ospedale Metropolitano Niguarda, Dept. of Urology, Milan, Italy, ³Centre Hospitalier du Pays d'Aix, Dept. of Urology, Aix-en-Provence, France, ⁴Frimley Park NHS Trust, Dept. of Urology, Frimley, United Kingdom, ⁵Azienda Ospedaliero-Universitaria of Modena University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, ⁶Faculty of Medicine, King Saud University, Dept. of Urology, Riyadh, Saudi Arabia, ⁷Villa Stuart Private Hospital, Dept. of Urology, Rome, Italy

A0535

Predictors of Surgical Retreatment Following Rezūm Water Vapor Therapy: A Multi-Center Real-World Analysis

Authors

Henrique Bitar Siqueira M.¹, Bhojani N.², Chughtai B.³, Zorn K.C.⁴, Cindolo L.⁵, Ferrari G.⁵, Lajkosz K.⁶, Elterman D.¹

Institutions

¹University of Toronto, Dept. of Urology, Toronto, Canada, ²Centre Hospitalier de l'Université de Montréal, Dept. of Urology, Montréal, Canada, ³Plainview Hospital, Smith Institute of Urology, Dept. of Urology, Syosset, United States of America, ⁴BPH Canada, Prostate Surgical Institute, Dept. of Urology, Montréal, Canada, ⁵Hesperia Hospital, CUrE Group, Dept. of Urology, Modena, Italy, ⁶University Health Network, Dept. of Biostatistics, Toronto, Canada

A0536

Modified Clavien-Dindo Classification for Hematuria Assessment in Rezūm Therapy with Continued Antithrombotic Therapy

Authors

Moriwake T.¹, Tominaga Y.¹, Katayama S.¹, Kaku H.², Tsuboi I.¹, Yoshinaga K.¹, Yamanoi T.¹, Kawada T.¹, Sadahira T.¹, Iwata T.¹, Nishimura S.¹, Bekku K.¹, Katayama Y.², Araki M.¹

Institutions

¹Okayama University, Dept. of Urology, Okayama, Japan, ²Okamura Isshindo Hospital, Dept. of Urology, Okayama, Japan

Study Group

Okamura isshindo hospital(Okayama, Japan)

A0537

Comparative study of the effect of holmium laser enucleation of the prostate versus water vapor therapy on sexual function

Authors

Fathy H., Abdallah R., Almarakby A.

Institutions

BeniSuef University, Faculty of Medicine, Dept. of Urology, BeniSuef, Egypt

A0538

12 Month CLEAR RCT: Better Early Recovery with UroLift PUL vs Rezum with Comparable 12-Month Durability

Authors

Rochester M.¹, Barber N.², Mazzarella B.³, Cantrill C.⁴, Chughtai B.⁵, Cinman A.⁶, Schiff J.⁷, Roehrborn C.⁸

Institutions

¹Norfolk and Norwich University Hospital, Dept. of Urology, Norwich, United Kingdom, ²Frimley Park Hospital, Dept. of Urology, Frimley, United Kingdom, ³Urology Austin, Dept. of Urology, Austin, United States of America, ⁴Urology San Antonio, Dept. of Urology, San Antonio, United States of America, ⁵Plainview Hospital, Dept. of Urology, Syosset, United States of America, ⁶Tower Urology, Dept. of Urology, Los Angeles, United States of America, ⁷NYU Langone, Dept. of Urology, New York, United States of America, ⁸UT Southwestern, Dept. of Urology, Dallas, United States of America

A0539

Clinical Prostate Score (CLIPS) Prediction Outcome for 3 Year Follow-up Minimal Invasive Surgical Therapy (MIST) of Prostate

Authors

Pek X.W.G., Taam B.Y.K., Tay W.K., Chua W.J., Chiong E., Consigliere D., Tsang W.C.

Institutions

National University Hospital, Dept. of Urology, Singapore, Singapore

A0540

Three-Year Outcomes of EchoLaser Transperineal Ablation for Benign Prostatic Hyperplasia: The First Middle Eastern Experience in 245 Patients

Authors

Abou Taleb A.A.¹, Zahran A.¹, Mondy A.², Noah K.¹

Institutions

¹Benha University, Dept. of Urology, Benha, Egypt, ²Cairo University, Dept. of Urology, Cairo, Egypt

A0541

Functional and sexual middle-term outcomes following transperineal laser ablation (TPLA) vs TURP for benign prostatic obstruction: a randomized trial

Authors

Zingarelli M.¹, De Rienzo G.¹, Carbonara U.¹, Minafra P.², Filograsso F.¹, Rella L.¹, Lippolis G.¹, Lasorsa F.¹, Lucarelli G.³, Spilotros M.¹, Ditunno P.¹

Institutions

¹Bari Policlinico Hospital, Dept. of Precision and Regenerative Medicine and Ionian Area - DiMePre-J, Bari, Italy, ²Mater Dei Hospital, Dept. of urology, Bari, Italy, ³Oncology Institute 'Giovanni Paolo II' I.R.C.C.S., Dept. of urology, Bari, Italy

A0542

Assessing efficacy and safety of transperineal laser ablation of the prostate (TPLA) in patients with large prostate volumes ($\geq 80\text{ml}$): Results from a prospective single-center registry

Authors

Polverino P.¹, Granata S.², Moscardi L.², Lo Re M.², Caneschi C.², Pecoraro A.², Li Marzi V.³, Campi R.², Tuccio A.¹, Serni S.², Sessa F.²

Institutions

¹San Giuseppe Hospital, Dept. of Urology, Empoli, Italy, ²University of Florence, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ³University of Siena, Dept. of Urology, Siena, Italy

14:55 - 15:15

Patients' perspectives and regrets

A0543

Treatment regret in patients undergoing minimally invasive treatments for benign prostatic hyperplasia

Authors

Lombardo R.¹, Pastore A.¹, Turchi B.¹, Santoro G.¹, Santioni M.¹, Franco A.¹, Al Salhi Y.¹, Fuschi A.¹, Fiori C.², Secco S.³, Porphiglia F.², Olivero A.², Nacchia A.¹, Cicione A.¹, Tema G.¹, Tubaro A.¹, De Nunzio C.¹

Institutions

¹Sapienza University of Rome, Dept. of Urology, Rome, Italy, ²San Luigi Hospital, Dept. of Urology, Orbassano, Italy, ³Niguarda Hospital, Dept. of Urology, Milan, Italy

A0544

Surgical outcomes and satisfaction of patients with unfavourable UPSTREAM criteria

Authors

Gallo G.¹, Guercio A.¹, Lombardo R.¹, Franco G.¹, Pastore A.¹, Al Salhi Y.¹, Fuschi A.¹, Valenzi F.M.¹, Candita G.¹, Secco S.², Fiori C.³, Porphiglia F.³, Quarà A.³, Nacchia A.¹, Cicione A.¹, Guarnotta G.¹, Carbone A.¹, Sciarra A.¹, Tubaro A.¹, Finazzi Agrò E.¹, De Luca S.³, Busacca G.³, De Cillis S.³, De Nunzio C.¹

Institutions

¹Sapienza University of Rome, Dept. of Urology, Rome, Italy, ²Niguarda, Dept. of Urology, Milan, Italy, ³San Luigi Hospital, Dept. of Urology, Orbassano, Italy

A0545

Integrating patient priorities into personalized surgical decision-making for BPH: A patient-centered digital interactive decision aid

Authors

Cheetham M.¹, Wetterauer C.², Wetterauer C.³

Institutions

¹University Hospital Zurich, Dept. of Internal Medicine, Zurich, Switzerland, ²University Hospital Basel (USB), Clinical Ethics Unit, Basel, Switzerland, ³University Hospital Basel (USB), Dept. of Urology, Basel, Switzerland

Association Between Symptom Improvement and Patients' Willingness to Pay After Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms

Authors

Henrique Bitar Siqueira M.¹, Rojanasarot S.², Ezekekwa E.², Tsacogianis T.², Ferreira R.³, Chughtai B.⁴, Zorn K.C.⁵, Katherine L.⁶, Bhojani N.⁷, Elterman D.¹

Institutions

¹University of Toronto, Dept. of Urology, Toronto, Canada, ²Boston Scientific, Dept. of Health Economics and Market Access, Marlborough, United States of America, ³Western University, Dept. of Urology, London, Canada, ⁴Zucker School of Medicine at Hofstra/Northwell, Dept. of Urology, New York, United States of America, ⁵BPH Canada, Dept. of Urology, Montréal, Canada, ⁶University Health Network, Dept. of Biostatistics, Toronto, Canada, ⁷Centre Hospitalier de l'Université de Montreal, Dept. of Urology, Montréal, Canada

The future of prostate cancer diagnosis

Abstract Session 29

Sunday 15 March
13:45 - 15:15

Location

Blue Area, George 1

Chairs

R. Arnsrud Godtman, Göteborg (SE)

G. Giannarini, Udine (IT)

To be confirmed

13:45 - 14:05

Epidemiological trends

A0477

Fewer hospitalizations after the shift to transperineal prostate biopsy: real world evidence from a Danish Prostate Cancer Registry.

Authors

Fojacki G.¹, Atrakhimovich E.¹, Pedersen T.¹, Borre M.², Møller H.³

Institutions

¹Odense University Hospital, Dept. of Urology, Odense, Denmark, ²Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ³Aalborg University, Dept. of Clinical Medicine, Aalborg, Denmark

A0478

Trends in the prevalence of prostate cancer among U.S. men with diabetes from 2003 to 2023

Authors

Huang J., Li W., Wang Z., Liu Z., Zhang C., Zhou X., Liu B.

Institutions

The Third Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Guangzhou, China

A0479

Nationwide population-based longitudinal data on magnetic resonance imaging of the prostate and subsequent prostate biopsy results

Authors

Zaurito P.¹, Ventimiglia E.², Gedeberg R.², [Westerberg M.](#)², Jäderling F.², Stattin P.², Garmo H.²

Institutions

¹Unit of Urology - Division of Oncology - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden

A0480

Prospective associations of smoking and body mass index with prostate cancer: A UK Biobank cohort study

Authors

[Yang X](#)¹, Chen H.², Wang M.³, Xue D.⁴, Pang J.¹

Institutions

¹The Seventh Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Shenzhen, China, ²The Chinese University of Hong Kong, The Nethersole School of Nursing, Hong Kong, China, ³The Chinese University of Hong Kong, Dept. of Sports Science and Physical Education, Hong Kong, China, ⁴Gongli Hospital of Shanghai Pudong New Area, Dept. of Nursing, Shanghai, China

14:05 - 14:25

Ultrasound based imaging

A0481

External Validation of the PRI-MUS Scoring System: A Secondary Analysis of the OPTIMUM Randomized Controlled Trial

Authors

[Lazarovich A.Y.](#)¹, Klotz L.², Kinnaird A.¹

Institutions

¹University of Alberta, Dept. of Urology, Edmonton, Canada, ²Sunnybrook Health Sciences Center, Dept. of Urology, Toronto, Canada

Study Group

OPTIMUM(Edmonton, Canada)

A0482

Incremental value of micro-ultrasound targeted prostate biopsy cores - a secondary analysis of the OPTIMUM randomized trial

Authors

Ushko J.¹, Klotz L.², [Kinnaird A.](#)¹

Institutions

¹University of Alberta, Dept. of Surgery and Oncology, Edmonton, Canada, ²Sunnybrook Health Sciences Center, Division of Urology, Toronto, Canada

Study Group

For the OPTIMUM Investigators(Edmonton, Canada)

A0483

The Value of combining Ultrasound Real-Time Elastography-Guided Targeted Biopsy and MRI-Ultrasound Fusion Targeted Biopsy in Prostate Biopsy: A prospective single-center study

Authors

Su R., Shi J.Y., Li C., [Yan Z.](#), Ma Q.

Institutions

The First Affiliated Hospital of Ningbo University, Dept. of Urology, Ningbo, China

A0484

Enhanced Diagnostic Accuracy of Micro-Ultrasound in Prostate Cancer Detection: An Updated Series from a Single-Center Prospective Study

Authors

Calabrese B.¹, Avolio P.P.¹, Piccolini A.¹, Finocchiaro A.¹, Sormani F.¹, Canneto R.¹, Striano V.¹, Tiscione M.¹, Trovato R.¹, Buffi N.M.¹, Lazzeri M.², Fasulo V.¹, Paciotti M.¹, Lughezzani G.¹

Institutions

¹Humanitas University, Dept. of Urology, Pieve Emanuele, Italy, ²Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

14:25 - 14:45

AI in prostate cancer diagnosis

A0485

Improving biopsy decision-making in prostate cancer using AI-assisted biparametric MRI

Authors

Sighinolfi M.C.¹, Pallotta G.¹, Russo L.², Bottazzi S.², Presutti S.¹, Gavi F.¹, Scarciglia E.¹, Gui B.², Rocco B.C.M.¹

Institutions

¹Policlinico Universitario Agostino Gemelli IRCCS, Dept. of Urology, Rome, Italy, ²Policlinico Universitario Agostino Gemelli IRCCS, Dept. of Bioimaging, Radiation Oncology and Hematology, Rome, Italy

A0486

AI-assisted planning for mpMRI-guided transperineal prostate biopsy: A prospective cohort study

Authors

Zeng Z.

Institutions

Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China

A0487

A Foundation Model for Prostate Pathological Evaluation to Assist Urologist in Clinical Work

Authors

Chen R.¹, Xia Y.², Ren L.¹, Deng L.³, Song Z.¹, Li W.⁴, Yu Z.²

Institutions

¹Renji Hospital, Dept. of Urology, Shanghai, China, ²Shanghai Jiao Tong University, School of Translational Medicine, Shanghai, China, ³Shanghai Changhai Hospital, The Second Military Medical University, Dept. of Urology, Shanghai, China, ⁴Shanghai Changzheng Hospital, The Second Military Medical University, Dept. of Urology, Shanghai, China

A prospective, paired-cohort, blinded, validation of the Ibex Prostate Artificial Intelligence Pathology system compared to expert uro-pathology reporting of prostate biopsies: the Cancer Histology Artificial Intelligence Reliability Study (IP6-CHAIROS)

Authors

[Ahmed H.U.](#)¹, Sukumar J.¹, Markham H.², Al-Sam S.³, Lloyd J.³, Smith A.³, Tilley C.², Silvanto A.⁴, Snead D.⁵, Freeman A.⁴, Dalton R.¹, Orczyk C.⁶, Duddderidge T.⁷, Winkler M.⁸, Khoubehi B.⁹, Magdy N.⁴, Prasad C.³, Gopinath P.¹⁰, Klimowska-Nassar N.¹, Vecsler M.¹¹, Linhart C.¹¹, Cullen E.¹, Lane E.¹², Brentnall A.¹²

Institutions

¹Imperial College London, Imperial Prostate, Dept. of Surgery and Cancer, London, United Kingdom, ²University Hospitals Southampton NHS Trust, Dept. of Pathology, Southampton, United Kingdom, ³Imperial College Healthcare NHS Trust, Dept. of Pathology, London, United Kingdom, ⁴University College London Hospitals, Dept. of Pathology, London, United Kingdom, ⁵University Hospitals Of Coventry & Warwickshire NHS Trust, Dept. of Pathology, Warwick, United Kingdom, ⁶University College London Hospitals, Dept. of Urology, London, United Kingdom, ⁷University Hospitals Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom, ⁸Chelsea & Westminster NHS Trust: West Middlesex Site, Dept. of Urology, London, United Kingdom, ⁹Chelsea & Westminster NHS Trust: Chelsea Site, Dept. of Urology, London, United Kingdom, ¹⁰Princess Alexandra Hospital NHS Trust, Dept. of Pathology, Harlow, United Kingdom, ¹¹Ibex Medical Analytics, Ibex Prostate, Tel Aviv, Israel, ¹²Queen Mary - University of London, Wolfson Institute of Population Health, London, United Kingdom

Study Group

IP6-CHAIROS Study Group(London, United Kingdom)

14:45 - 15:15

Diagnostic pathways

A0489

Impact of a Fast-Track Diagnostic Pathway on Psychological and Physiological Stress in Men with Suspected Prostate Cancer: A Randomized Clinical Trial

Authors

Udumyan R.¹, Davidsson S.², Carlsson J.², [Ugge H.](#)³, Andrén O.², Andersson S.O.², Messing A.⁴, Valdimarsdottir U.⁵, Fang F.⁵, Montgomery S.¹, Fall K.³

Institutions

¹Örebro University, Dept. of Clinical Epidemiology and Biostatistics, Örebro, Sweden, ²Örebro University, Dept. of Urology, Örebro, Sweden, ³Örebro University, School of Medical Sciences, Örebro, Sweden, ⁴Örebro University, School of Health Sciences, Örebro, Sweden, ⁵Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden

A0490

The Impact of PI-QUAL Score on Diagnostic and Economic Efficiency of mpMRI for Prostate Cancer: Results from a Prospective Evaluation of External Scans After Central Review

Authors

Longoni M.¹, Scilipoti P.¹, Cannoletta D.¹, Quarta L.¹, Zaurito P.¹, Porzi M.E.¹, Barletta F.M.¹, Scuderi S.¹, Cucchiara V.¹, Camisassa E.², Pennella R.², Cosenza M.², Russo T.², Brembilla G.², Esposito A.², De Cobelli F.², Lucianò R.³, Tenace N.³, Colecchia M.³, Ponzoni M.³, Stabile A.¹, Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ²Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy

A0491

Impact of pubic bone anatomy on targeted biopsy misses in transperineal fusion-prostate biopsy using a template-guided approach

Authors

Mori B.¹, Kobayashi M.¹, Fukui K.², Yamaguchi Y.¹, Matsumoto S.¹, Ishikawa Y.¹, Fukushima H.¹, Waseda Y.¹, Yasuda Y.¹, Tanaka H.¹, Yoshida S.¹, Fujii Y.¹

Institutions

¹Institute of Science Tokyo, Dept. of Urology, Tokyo, Japan, ²Institute of Science Tokyo, Dept. of Radiology, Tokyo, Japan

A0492

Transperineal biopsy septicaemia is associated with less antimicrobial resistance than transrectal biopsy: insights from real world bacteriology evidence

Authors

Liu A.Q., Yee S.C.H., Teoh J.Y.C., Chiu P.K.F., Ng C.F.

Institutions

The Chinese University of Hong Kong, S.H. Ho Urology Centre, Hong Kong, Hong Kong

A0493

Comparison of topical diltiazem, diclofenac suppository and periprostatic nerve block with periprostatic nerve block alone for pain control during transrectal ultrasonography-guided prostate biopsy: An RCT

Authors

Sahoo S

Institutions

Kalinga Institute Of Medical Sciences, Dept. of Urology, Bhubaneswar, India

A0494

Does periprostatic lidocaine block add value during sedated prostate biopsy? A randomized prospective trial

Authors

Bima Y., Fernández Alberti J.F.A., De Miceu S., Rios Pita H., Borghi M., Becher E.

Institutions

Centro de Urologia, Dept. of Urology, Buenos Aires, Argentina

Innovation in paediatric urology and kidney transplantation

Video Session 13

Sunday 15 March
13:45 - 15:15

Location Blue Area, Victoria 6

Chairs To be confirmed
A.O. Noah, London (GB)
To be confirmed

V089 (□: 6 min.)

First results of the daVinci SP Robot in adolescence

S. Rogenhofer, Aschaffenburg (DE)

V090 (□: 5 min.)

Dextran/Paclitaxel-Coated Balloon Dilatation in Pediatric Posterior Urethral Valve

J. Pizzarello, Caba (AR)

V091 (□: 5 min.)

Robotic pyeloplasty: single-port "Window" technique for ureteropelvic junction obstruction

To be confirmed

V092 (□: 7 min.)

Pneumovesicoscopic Politano-Leadbetter Ureteral Reimplantation for Children with Veiscoureteral Reflux

P-S. Liang, Kaohsiung (TW)

V093 (□: 9 min.)

Robotic-Assisted Renal Transplantation in Morbidly Obese Patients: A Challenge to accept.

S. Karkamar, SINGUR (IN)

V094 (□: 3 min.)

Development of a Multilingual Animated Educational Video for Patient Information in Live Donor Kidney Transplantation

M.E. Polat, Ankara (TR)

V095 (□: 5 min.)

Laparoscopic hand-assisted donor nephrectomy: our clinical experience of 700 cases

To be confirmed

Emerging minimally invasive therapies in urology: From endoscopic reconstruction to novel prostate interventions

Video Session 14

Sunday 15 March
13:45 - 15:15

Location Orange Area, EGPT 1

Chairs C.V. Kesch, Essen (DE)
A. Larcher, Milan (IT)
G. Ploussard, Toulouse (FR)

V096 (□: 7 min.)

High-Intensity Focused Ultrasound (HIFU) For Prostate Cancer - Step by Step Technique

N.E. Paesano, Barcelona (ES)

V097 (□: 6 min.)	Holmium Laser Peripheric Endoscopic Prostatectomy (HoLPEP) as a Focal Therapy for Prostate Cancer with Concomitant LUTS L. Labairu Huerta, Lumbier (ES)
V098 (□: 8 min.)	ROBOT ASSISTED TRANSVESICAL RADICAL PROSTATECTOMY WITH MULTIPOINT DA VINCI XI SYSTEM To be confirmed
V099 (□: 5 min.)	An initial experience of Peri-Rectal spacer use for Prostate Radiotherapy: An Instructional Video L.T.Y. Benjamin, Singapore (SG)
V100 (□: 8 min.)	Step-by-step perineal repair of post-prostatectomy urethrorectal fistula with gracilis muscle interposition flap A. Escoffier, Dijon (FR)
V101 (□: 8 min.)	Balloon Dilation of a Ureteral Stricture using Near Eye Augmented Reality (NEAR) N. Stone, Vail (US)
V102 (□: 8 min.)	Minimally Invasive Transurethral Treatment of Large and Recurrent Renal Sinus Cysts Using a Thulium Fiber Laser A.G. Martov, Moscow (RU)
V103 (□: 6 min.)	Endoscopic treatment of ureteroileal anastomosis structures with the use of metallic, self-expanding stents. F. Kowalski, Bydgoszcz (PL)

New approaches and intraoperative problem solving in robotic renal and retroperitoneal surgery

Video Session 12

Sunday 15 March
13:45 - 15:15

Location Blue Area, Victoria 1
Chairs S. Albisinni, Rome (IT)
N. Liakos, Freiburg (DE)
R.J.A. Van Moorselaar, Amsterdam (NL)

V082 (□: 8 min.)	Single-Port Robotic Surgery in Awake Patients Using Virtual Reality: A Case Series of Patients Treated for Kidney and Prostate Cancer. F. Lavagno, Turin (IT)
V083 (□: 7 min.)	Elbow Wide: Optimizing Dexterity and Ergonomics in Single-Port Robotic Surgery A. Turcan, Calenzano (IT)
V084 (□: 5 min.)	Early intravesical control of the ureteral orifice during minimally invasive nephroureterectomy for upper urinary tract cancer V Sobenin, Tyumen (RU)
V085 (□: 8 min.)	Intraoperative complications and management of robotic-assisted renal tumor surgery Z. Wang, Beijing (CN)

V086 (□: 8 min.)

First reported clinical case series on ETHIZIA hemostatic patch use in partial nephrectomy: Different scenarios, different techniques, different effects

C.H.F. Wong, Hong Kong (HK)

V087 (□: 7 min.)

Intraoperative vascular complications in minimally invasive retroperitoneal lymph node dissection

H.O.D. Santos, São Paulo (BR)

V088 (□: 7 min.)

Retroperitoneal robot-assisted partial nephrectomy in prone position: an option for posterior tumors

D. Vazquez-Martul, A Coruña (ES)

Current controversies of urethral reconstruction and male incontinence

EAU Reconstruction

EAU Section of Genitourinary Reconstructive Surgeons

Sunday 15 March
13:45 - 15:15

Location Blue Area, George 3

Chair D.J. Ralph, London (GB)

Learning objectives

This session aims to enhance participants' understanding of contemporary controversies in urethral reconstruction and male incontinence by reviewing evidence-based approaches to bulbar strictures, including minimally invasive options, non-transecting techniques, and anastomotic repair. Learners will explore decision-making in complex scenarios such as lichen sclerosus-associated panurethral disease and compare strategies ranging from perineal urethrostomy to full-length reconstruction. The programme also seeks to deepen knowledge of male incontinence management by clarifying indications for artificial urinary sphincters versus male slings, examining advanced AUS techniques, and introducing emerging device innovations. Through case discussions and expert perspectives, attendees will refine their ability to select and tailor reconstructive and continence procedures to individual patient needs.

13:45 - 13:46

Welcome and introduction

D.J. Ralph, London (GB)

13:46 - 14:03

Urethral reconstruction

Moderators F. Campos Juanatey, Santander (ES)
M. Waterloos, Ghent (BE)

13:46 - 13:48

Case presentation 3 cm bulbar stricture/1.5 cm recurrent bulbar stricture: Minimally invasive techniques for bulbar strictures. Which one is the best?

F. Campos Juanatey, Santander (ES)
M. Waterloos, Ghent (BE)

13:48 - 13:53

Internal urethrotomy

D. Hernández Hernández, San Cristóbal de La Laguna (ES)

13:53 - 13:58

Optilume balloon dilatation

N.I. Osman, Sheffield (GB)

13:58 - 14:03

Discussion

The best approach for a short bulbar stricture?

14:03 - 14:08

Non-transecting dorsal approach

M. Bandini, Milan (IT)

14:08 - 14:13

Non-transecting ventral approach

H. Veiby Holm, Oslo (NO)

14:13 - 14:18

Anastomotic repair

O.J. Nilsen, Oslo (NO)

14:18 - 14:23

Discussion

How would I manage a lichen sclerosus panurethral stricture?

14:23 - 14:28

Perineal urethrostomy

L. Karapanos, Leverkusen (DE)

14:28 - 14:33

Full-length reconstruction

P. Joshi, Pune (IN)

14:33 - 14:38

Discussion

14:38 - 15:15

Male incontinence

Moderators

T.J. Greenwell, London (GB)

K. Van Renterghem, Hasselt (BE)

14:38 - 14:46

AUS or male sling? Indications and contraindications

M.W. Vetterlein, Hamburg (DE)

14:46 - 14:54

Complex AUS surgery: Double cuff, transcorporeal

E. Lledó García, Madrid (ES)

14:54 - 15:02

AUS combined with IPP, sling, mini-jupette

S. Ward, Bruxelles (BE)

15:02 - 15:10

New AUS devices

L. Lenfant, Paris (FR)

15:10 - 15:15

Discussion and closing remarks

EAU Lab: New horizons in genitourinary cancers: from molecular mechanisms to precision therapies

EAU Section of Uro pathology and EAU Section of Urological Research

Sunday 15 March
13:45 - 15:15

Location

Blue Area, Victoria 4

Chairs

M. Colecchia, Milan (IT)

C. Jerónimo, Porto (PT)

Learning objectives

This session explores emerging mechanisms and therapies in genitourinary cancers, from metabolic and epigenetic reprogramming to advanced disease modeling. It also highlights novel treatment strategies, including synthetic lethality, biomarker-guided trials, and new therapies for bladder cancer, advancing precision medicine in the GU diseases.

13:45 - 13:49

Welcome and introduction

M. Colecchia, Milan (IT)

C. Jerónimo, Porto (PT)

13:49 - 14:32

Metabolic and biological drivers of urological diseases

Moderators

M. Albersen, Leuven (BE)

Y. Allory, Saint-Cloud (FR)

C. Le Magnen, Basel (CH)

13:49 - 14:01

Metabolic adaptation in prostate cancer: Beyond androgen signaling

A. Carracedo, Bilbao (ES)

14:01 - 14:13

Metabolic vulnerabilities in pediatric kidney tumours

J. Drost, Utrecht (NL)

14:13 - 14:25

The impact of biological sex on bladder diseases

M. Ingersoll, Paris (FR)

14:25 - 14:32

Discussion

14:32 - 15:15

Emerging cancer therapies in genitourinary cancers

Moderators

M. Eckstein, Erlangen (DE)

To be confirmed

J. Paramio, Madrid (ES)

14:32 - 14:44

Synthetic lethality strategies for genitourinary cancers

F. Demichelis, Trento (IT)

14:44 - 14:56

Biomarker driven trials in mPCa

H. Gronberg, Stockholm (SE)

14:56 - 15:08

New therapeutic options in bladder cancer

T. Powles, London (GB)

15:08 - 15:15

Discussion

Sunday 15 March
13:45 - 16:45

Location Red Area, Room 13

Chair V.M.J. De Coninck, Brasschaat (BE)

Learning objectives

The aims and objectives of this course are to provide a complete overview of complications related to endourological procedures.

- Extracorporeal shock wave lithotripsy (ESWL)
- Retrograde intrarenal surgery (RIRS)
- Percutaneous nephrolithotomy (PCNL)
- Transurethral resection of the bladder (TURB) and prostate (TURP), anatomical endoscopic enucleation of the prostate (AEEP), cystolithotripsy/cystolitholapaxy, internal urethrotomy/urethral dilation

This ESU course has the goal to fill the knowledge gap for early identification of complications during endourological procedures and to describe their management, in order to prevent further harm. At the end of the course, the participants will be able to increase their knowledge about complications in endourology and to identify them according to their etiology. They will also know how most endourological complications can be managed and prevented. Lastly, clinicians will use the increased knowledge to provide better care to their patients.

Extracorporeal shock wave lithotripsy

E.X. Keller, Zürich (CH)

RIRS

V.M.J. De Coninck, Brasschaat (BE)

PCNL

E.X. Keller, Zürich (CH)

TURB, TURP, AEEP, cystolithotripsy/cystolitholapaxy

K. Lehrich, Berlin (DE)

Internal urethrotomy, urethral dilation

K. Lehrich, Berlin (DE)

Complications related to fluoroscopy and imaging

V.M.J. De Coninck, Brasschaat (BE)

Improving prostate cancer screening - From implementation pilots to improved interventions

EGPT 39

Sunday 15 March
13:45 - 15:15

Location	Orange Area, EGPT 2
Chairs	A.S. Rannikko, Espoo (FI) M.J. Roobol, Rotterdam (NL) I. Tomašković, Zagreb (HR)

13:45 - 14:05

Organised testing in Europe

P0683

Prospective multicentre pilot study on prostate cancer risk-based screening in Estonia

Authors

Veskimäe P.¹, Kivi M.², Innos K.³, Baum P.⁴, Kahu J.¹

Institutions

¹Tartu University Hospital, Dept. of Urology and Kidney Transplantation, Tartu, Estonia, ²East Tallinn Central Hospital, Dept. of Urology, Tallinn, Estonia, ³The Estonian Institute for Health Development, Research Director, Tallinn, Estonia, ⁴North Estonia Medical Centre, Dept. of Urology, Tallinn, Estonia

P0684

CROState pilot program for prostate cancer screening in Croatia – eighteen-month results

Authors

Kuliš T.¹, Grubisic I.², Brkic Bilos I.³, Sarajlic G.³, Prutki M.⁴, Bubas M.⁵, Capak K.⁶, Kastelan Z.²

Institutions

¹University hospital centre Zagreb, Dept. of Urology, Zagreb, Croatia, ²University Hospital Center Sestre Milosrdnice, Dept. of Urology, Zagreb, Croatia, ³Croatian Institute of Public Health, Dept. of Epidemiology and Prevention of Noncommunicable Chronic Diseases, Zagreb, Croatia, ⁴University hospital centre Zagreb, Dept. of Diagnostic and Interventional Radiology, Zagreb, Croatia, ⁵Ministry of Health, Ministry of Health, Zagreb, Croatia, ⁶Croatian Institute of Public Health, Croatian Institute of Public Health, Zagreb, Croatia

P0685

Pre-MRI risk stratification in a population-based PCa screening setting: first results of the PRAISE-U initiative

Authors

van Harten M.J.¹, van den Bergh R.C.N.¹, Collen S.², Chandran A.³, Venderbos L.D.F.¹, Willemse P.M.⁴, Vilsaseca J.⁵, Patasius A.⁶, Tupikowski K.⁷, Galvin D.⁸, Terrazo Anteol A.⁹, van Poppel H.¹⁰, Roobol M.J.¹

Institutions

¹Erasmus MC Cancer Institute, University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²European Association of Urology, Arnhem, The Netherlands, ³International Agency for Research on Cancer, IARC, Lyon, France, ⁴Cancer Center, University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands, ⁵Xarxa Assistencial Universitària de Manresa, Althaia, Manresa, Spain, ⁶Institute of Clinical Medicine, Institute of Clinical Medicine, Vilnius, Lithuania, ⁷Wroclaw University of Science and Technology, Lower Silesian Center for Oncology, Pulmonology and Hematology, Dept. of Oncology and Haematology, Wroclaw, Poland, ⁸University College Dublin, Dept. of Urology, Dublin, Ireland, ⁹Ministry of Health, Service for Population Screening Programmes, San Lazaro, Spain, ¹⁰KU Leuven, Dept. of Urology, Leuven, Belgium

Study Group

PRAISE-U consortium(Arnhem, The Netherlands)

P0686

From Pilot to Practice: Lessons from European PRAISE-U Sites on Implementing Risk-Stratified Prostate Cancer Screening

Authors

Palaniraja S.¹, Chandran A.¹, Singh D.¹, Venderbos L.², Collen S.³, Van Poppel H.³, Robol M.², van den Bergh R.², Basu P.¹

Institutions

¹International Agency for Research on Cancer, Early Detection Prevention and Infections branch, Lyon, France, ²Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, ³European Association of Urology, Arnhem, The Netherlands

14:05 - 14:15

Early prostate cancer detection beyond Europe

P0687

Burden and trend of early onset prostate cancer in BRICS from 1990 to 2021 and predictions for 2040

Authors

Zhang JH, Jiang H.W., Zhou Q., Zhang L.M., Ou Y.X., Feng C.J.

Institutions

Huashan Hospital, Dept. of Urology, Shanghai, China

COMPACT Study: Real-World Impact of Community-Based PSA Screening on Prostate Cancer in China

Authors

Gu D.¹, Huang Y.¹, Bai Z.², Chen L.³, He W.⁴, Wei Q.⁵, Wu W.⁶, Xu A.⁷, Zhong W.⁸, Cai C.¹, Chen B.⁷, Gan S.², Gu C.², Huang S.⁵, Li M.¹, Liang Y.⁸, Liu Y.¹, Liu H.⁴, Mo C.³, Wang B.⁹, Zhao Y.¹, Zheng Y.⁶, Zeng G.¹, Zhang X.⁹

Institutions

¹The First Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangzhou, China, ²Guangdong Traditional Chinese Medicine Hospital, Dept. of Urology, Guangzhou, China, ³The First Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Guangzhou, China, ⁴Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Dept. of Urology, Guangzhou, China, ⁵Guangdong Provincial People's Hospital, Dept. of Urology, Guangzhou, China, ⁶The Second Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangzhou, China, ⁷Zhujiang Hospital of Southern Medical University, Dept. of Urology, Guangzhou, China, ⁸Guangzhou First People's Hospital, Dept. of Urology, Guangzhou, China, ⁹Chinese PLA General Hospital, Dept. of Urology, Guangzhou, China

14:15 - 14:30

Testing behaviour and psychological consequences

P0689

Re-Attendance in Prostate Cancer Screening: Associations with Investigations in the First Screening Round and Individual-Level Factors

Authors

Svensson L.¹, Månsson M.², Bratt O.¹, Wallström J.³, Arnsrud Godtman R.¹, Hugosson J.¹

Institutions

¹Sahlgrenska University Hospital, Dept. of Urology, Gothenburg, Sweden, ²Sahlgrenska Academy, University of Gothenburg, Dept. of Urology, Institute of Clinical Sciences, Gothenburg, Sweden, ³Sahlgrenska University Hospital, Dept. of Radiology, Gothenburg, Sweden

P0690

PSA retesting behaviour and prostate cancer incidence by risk group during 10 years of follow-up: the STHLM3 screening trial

Authors

Micoli C.¹, Discacciati A.¹, Nordström T.¹, Mariaz M.¹, Palsdottir T.¹, Vigneswaran H.¹, Crippa A.¹, Clements M.¹, Egevad L.², Grönberg H.¹, Eklund M.¹

Institutions

¹Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ²Karolinska Institutet, Dept. of Oncology-Pathology, Stockholm, Sweden

P0691

Psychological consequences associated with the diagnostic process in the Göteborg-2 prostate cancer screening trial in men with raised PSA

Authors

Svensson L.¹, Hugosson J.¹, Månsson M.², Stinesen K.³, Wallström J.⁴, Arnsrud Godtman R.¹, Bratt O.¹

Institutions

¹Sahlgrenska University Hospital, Dept. of Urology, Gothenburg, Sweden, ²Sahlgrenska Academy, University of Gothenburg, Dept. of Urology, Institute of Clinical Sciences, Gothenburg, Sweden, ³University of Gothenburg, Dept. of Social Work, Gothenburg, Sweden, ⁴Sahlgrenska University Hospital, Dept. of Radiology, Gothenburg, Sweden

P0692

Acquisition, reporting, and outcomes of upfront screening MRI in prostate cancer: a systematic review and meta-analysis**Authors**

Mayor N.¹, Light A.¹, Eeles R.², Emberton M.³, Gabe R.⁴, Heer R.¹, Moore C.³, Shah T.T.¹, Ahmed H.U.¹

Institutions

¹Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, ²Institute of Cancer Research, Dept. of Oncogenetics, London, United Kingdom, ³University College London, Dept. of Urology, London, United Kingdom, ⁴Queen Mary, University of London, Barts Clinical Trials Unit, Wolfson Institute of Population Health, London, United Kingdom

P0693

Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): international consensus recommendations**Authors**

Mayor N.¹, Light A.¹, Gopalakrishnan A.¹, Barrett T.², Bratt O.³, Dudderidge T.⁴, Emberton M.⁵, Giganti F.⁶, Haider A.⁷, Haider M.⁸, Hulson O.⁹, Lakhani A.¹⁰, Moore C.⁵, Nordstrom T.¹¹, Padhani A.R.¹², Schoots I.¹³, Tam H.¹⁰, Valerio M.¹⁴, Verma S.¹⁵, Withey S.¹⁶, Punwani S.⁶, Shah T.T.¹, van der Meulen J.¹⁷, Ahmed H.U.¹

Institutions

¹Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, ²University of Cambridge, Dept. of Radiology, Cambridge, United Kingdom, ³University of Gothenburg, Dept. of Epidemiology, Gothenburg, Sweden, ⁴University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ⁵University College London, Dept. of Urology, London, United Kingdom, ⁶University College London, Dept. of Radiology, London, United Kingdom, ⁷University College London, Dept. of Pathology, London, United Kingdom, ⁸University of Toronto, Dept. of Medical Imaging, Toronto, Canada, ⁹The Leeds Teaching Hospitals NHS Trust, Dept. of Radiology, Leeds, United Kingdom, ¹⁰Imperial College London, Dept. of Radiology, London, United Kingdom, ¹¹Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ¹²Institute of Cancer Research, Dept. of Radiology, London, United Kingdom, ¹³Erasmus University Medical Center, Dept. of Radiology and Nuclear Medicine, Rotterdam, The Netherlands, ¹⁴Geneva University Hospital, Dept. of Urology, Geneva, Switzerland, ¹⁵University of Cincinnati, Dept. of Radiology, Ohio, United States of America, ¹⁶The Royal Marsden NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, ¹⁷London School of Hygiene & Tropical Medicine, Health Services Research & Policy, London, United Kingdom

P0694

AI-assigned versus radiologist-assigned PI-RADS in population-based prostate cancer screening: results from the ProScreen trial

Authors

Shadbahr T.¹, Ketola J.², Kauppinen E.³, Grimm R.⁴, Natunen K.⁵, Raitanen J.⁶, Kiviluoto I.², Busch H.V.⁴, Mirtti T.⁷, Ronkainen J.⁸, Kenttämies A.², Rinta-Kiikka I.⁸, Auvinen A.⁵, Rannikko A.⁹

Institutions

¹University of Helsinki, Research Program in Systems Oncology - Faculty of Medicine, Helsinki, Finland, ²Helsinki University Hospital, Dept. of Radiology, HUS Diagnostic Centre, Helsinki, Finland, ³Siemens Healthcare Oy, Espoo, Finland, ⁴Siemens Healthineers AG, Forchheim, Germany, ⁵Tampere University, Unit of Health Sciences, Faculty of Social Sciences, Tampere, Finland, ⁶UKK-Institute for Health Promotion Research, Tampere, Finland, ⁷Helsinki University Hospital, Dept. of Pathology, HUS Diagnostic Centre, Helsinki, Finland, ⁸Tampere University Hospital, Dept. of Radiology, Tampere, Finland, ⁹Helsinki University Hospital, Dept. of Urology, Helsinki, Finland

P0695

Limited benefit of contralateral biopsies in PSA- and MRI-based prostate cancer screening

Authors

Alterbeck M.¹, Bratt O.², Lantz A.³, Jiborn T.⁴, Thimansson E.⁵, Bobjer J.¹, Nordström T.³, Bjartell A.⁶, Carlsson S.⁷

Institutions

¹Skåne University Hospital, Dept. of Urology, Malmö, Sweden, ²Sahlgrenska University Hospital, Dept. of Urology, Gothenburg, Sweden, ³Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ⁴Helsingborg Hospital, Dept. of Urology, Helsingborg, Sweden, ⁵Helsingborg Hospital, Dept. of Radiology, Helsingborg, Sweden, ⁶Lund University, Dept. of Translational Medicine, Lund, Sweden, ⁷German Cancer Research Center (DKFZ), Dept. of Clinical Epidemiology of Early Cancer Detection, Heidelberg, Germany

P0696

Low Infection Rate After Transrectal Ultrasound Prostate Biopsy in Population-based Screening with PSA and MRI – Results from the Göteborg Prostate Cancer Screening 2 Trial

Authors

Andreasson A., Månsson M., Kohestani K., Arnsrud Godtman R., Palsdottir K., Stranne J., Hugosson J.

Institutions

Sahlgrenska University Hospital, Dept. of Urology, Gothenburg, Sweden

P0697

Impact of a PSA density threshold as a criterion for referral to secondary care for suspected prostate cancer

Authors

Adasonla K.O., Omidiora O., Almezal A., Aizad A., Liyanage S., Acher P.

Institutions

Southend University Hospital, Dept. of Urology, Southend, United Kingdom

15:00 - 15:10

Understanding screening - from health economy to bayesian re-analysis of screening outcomes

P0698

Post-Hoc Bayesian Re-Analysis of 21-Year Follow-Up Data from the Rotterdam Section of the ERSPC: Examining robustness of findings to varying prior assumptions

Authors

Nguyen D-D.¹, Roobol M.J.², Zlotta A.R.¹, Rosella L.³, Kulkarni G.S.¹, Liu K.⁴, Remmers S.²

Institutions

¹University of Toronto, Division of Urology, Toronto, Canada, ²Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ³University of Toronto, Dept. of Epidemiology, Toronto, Canada, ⁴University of Toronto, Institute of Health Policy, Management and Evaluation, Toronto, Canada

Study Group

ERSPC Rotterdam Investigators(Rotterdam, The Netherlands)

P0699

Cost-effectiveness of early detection for prostate cancer: evidence from rescreening in the STHLM3-MRI trial

Authors

Skalt D., Nordström T., Lantz A., Clements M., Hao S.

Institutions

Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden

Rare male genital tumors: Testis and penile cancers

EGPT 40

**Sunday 15 March
13:45 - 15:15**

Location

Orange Area, EGPT 3

Chairs

A. Parnham, Manchester (GB)

A. Thor, Stockholm (SE)

Y. Zhu, Shanghai (CN)

13:45 - 14:15

Testis cancer: Early tumours and diagnosis

P0700

Germline HOXB13 G84E Mutation and Risk of Testicular Cancers: results from the UK Biobank

Authors

Jong B-E.¹, Tsai P.H.¹, Tseng S.S.¹, Tsai Y.C.¹, Wu C.H.W.²

Institutions

¹Taipei Tzu Chi Hospital, Dept. of Urology, New Taipei City, Taiwan, ²The University of Alabama at Birmingham, School of Medicine, Dept. of Urology, Birmingham, United States of America

P0701

Contrast-Enhanced Ultrasound Versus Magnetic Resonance Imaging for Indeterminate Testicular Lesions: A Systematic Review and Meta-analysis

Authors

Ibis M.A.¹, Satchi M.², Raison N.², Haberal H.B.³, Musaev A.¹, Yap T.⁴, Territo A.⁵, Akpınar C.¹, Giuseppe F.⁶, Huang D.Y.⁷, Gul M.⁸, Muneer A.⁹, Ruffo A.¹⁰, Cakir O.O.¹¹, Castiglione F.¹¹

Institutions

¹Ankara University School of Medicine, Dept. of Urology, Ankara, Turkey, ²King's College Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³Ankara Atatürk Sanatoryum Training and Research Hospital, Ministry of Health, University of Health Sciences, Dept. of Urology, Ankara, Turkey, ⁴Guy's Hospital, Dept. of Urology, London, United Kingdom, ⁵Fundació Puigvert, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ⁶ASST Santi Paolo e Carlo, University of Milan, Dept. of Urology, Milan, Italy, ⁷King's College Hospital NHS Foundation Trust, Dept. of Clinical Radiology, London, United Kingdom, ⁸Selçuk University School of Medicine, Dept. of Andrology, Konya, Turkey, ⁹UCL, Division of Surgery and Interventional Science, London, United Kingdom, ¹⁰Vincenzo Tiberio, Dept. of Medicine and Health Sciences, Termoli, Italy, ¹¹King's College London, School of Biomedical Engineering and Imaging Sciences, London, United Kingdom

P0702

Machine learning-based prognostic evaluation of diagnostic delay in testicular cancer

Authors

Anceno A.¹, Cantellano-Orozco M.², Silva-Mendoza C.S.², Garzón-Ortega V.², Angulo-Sánchez J.³, Magdaleno-Rodríguez D.², Miranda-Blasnich H.C.², Cervantes-Zorrilla R.², Martínez-Arroyo C.², Fernández-Noyola G.², Morales-Montor G.², Ortega-González M.², Pacheco-Gahbler C.²

Institutions

¹University of Southern California, Dept. of Urology, Los Angeles, United States of America, ²Hospital General Dr. Manuel Gea González, Dept. of Urology, Mexico City, Mexico, ³Tecnológico de Monterrey, Dept. of Biotechnology Engineering, Mexico City, Mexico

P0703

Sperm Banking and Testicular Prosthesis in Radical Orchidectomy: Impact on Surgical Timelines and Post-Operative Outcomes

Authors

Desai C., Ahmad T., Ehsanullah S.A.

Institutions

Shrewsbury and Telford Hospital NHS Trust, Dept. of Urology, Shrewsbury, United Kingdom

P0704

Testicular Prosthesis and Decisional Regret Following Radical Orchiectomy: Real-World Experience from a High-Volume Oncologic Center

Authors

Bologna E., Flammia R.S., Proietti F., Licari L.C., Chiacchio G., Brassetti A., Bove A.M., Tuderti G., Mastroianni R., Ferriero M.C., D'Annunzio S., Misuraca L., Anceschi U., Guaglianone S., Leonardo C., Simone G.

Institutions

Uro-Oncology Program - IRCCS - Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

P0705

Can ChatGPT-5 Match the Experts? Second Opinions in Early Testicular Cancer

Authors

Hirtsiefer C.¹, Strauch A.², Schoch J.², Menzel V.¹, Leitsmann M.³, Schrader M.⁴, Schmelz H.², Heinzlbecker J.⁵, Heidenreich A.⁶, Nestler T.²

Institutions

¹University Hospital of Dresden, Dept of Urology, Dresden, Germany, ²Federal Armed Forces Hospital Koblenz, Dept of Urology, Koblenz, Germany, ³University Hospital of Graz, Dept. of Urology, Graz, Austria, ⁴Helios Klinikum Berlin-Buch, Dept of Urology, Berlin, Germany, ⁵Saarland University Medical Center and Saarland University, Dept. of Urology and Pediatric Urology, Homburg, Germany, ⁶University Hospital of Cologne, Dept of Urology, Cologne, Germany

14:15 - 14:35

Testis Cancer: RPLND considerations

P0706

Salvage Post-Chemotherapy Retroperitoneal Lymph-Node Dissection: Evolving Paradigm for Marker-Positive non-seminomatous germ-cell tumors management.

Authors

Nazzani S.¹, Carlo S.¹, Saitta C.¹, Bernasconi V.¹, Macchi A.¹, Stagni S.¹, Torelli T.¹, Tesone A.¹, Giannatempo P.¹, Claps M.¹, Lanocita R.², Cascella T.², Catanzaro M.A.¹, BIASONI D.¹, Montanari E.³, Nicolai N.¹

Institutions

¹Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiology, Milan, Italy, ³Fondazione Ca' Granda IRCCS Policlinico di Milano, Dept. of Urology, Milan, Italy

P0707

Same-Day Discharge Following Robotic Retroperitoneal Lymph Node Dissection: A Single-Institution Case Series

Authors

Musso G.¹, Baker B.¹, Dabbas M.¹, Toscano Bello F.¹, Azari S.¹, Pandit K.¹, Puri D.¹, Meagher M.F.¹, Yuen K.L.¹, Millard F.², Bagrodia A.¹

Institutions

¹University of California San Diego School of Medicine, Dept. of Urology, La Jolla, United States of America, ²University of California San Diego School of Medicine, Dept. of Medical Oncology, La Jolla, United States of America

P0708

Contemporary trends of primary retroperitoneal lymph node dissection in stage I and IIa-b nonseminomatous germ cell tumors of the testis

Authors

Lee N.¹, Polverino F.², Quarta L.³, Filzmayer M.⁴, Petix M.⁵, Goyal J.¹, Longo N.², Musi G.⁵, Chun F.⁴, Briganti A.³, Shariat S.⁶, Saad F.¹, Karakiewicz P.¹

Institutions

¹University of Montreal, Dept. of Urology, Montréal, Canada, ²University of Naples Federico II, Dept. of Urology, Naples, Italy, ³Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁴Goethe University Frankfurt, Dept. of Urology, Frankfurt, Germany, ⁵Università degli Studi di Milano, Dept. of Urology, Milan, Italy, ⁶Medical University of Vienna, Dept. of Urology, Vienna, Austria

P0709

A Decade of RPLND for Testicular Germ Cell Tumors: Survival Outcomes from India's Largest Institutional Experience

Authors

Prakash G.¹, Thimiri Mallikarjun N.¹, Pal M.¹, Arora A.¹, Misra A.¹, Gujela A.¹, Godse S.¹, Menon S.², Joshi A.³

Institutions

¹Tata Memorial Hospital, Homi Bhabha National Institute, Division of Uro-Oncology, Dept. of Surgical Oncology, Mumbai, India, ²Tata Memorial Hospital, Homi Bhabha National Institute, Division of Uro-Oncology, Dept. of Pathology, Mumbai, India, ³Tata Memorial Hospital, Homi Bhabha National Institute, Division of Uro-Oncology, Dept. of Medical Oncology, Mumbai, India

14:35 - 14:55

Penile cancer: Risk factors, primary treatment and surgical staging

P0710

Association Between Neighborhood Deprivation and Stage at Diagnosis in Penile Squamous Cell Carcinoma

Authors

Silvani C.¹, Tylecki A.², Santangelo A.¹, Considine J.¹, Msska A.¹, Robinson B.¹, Salka B.¹, Nazzani S.³, Salonia A.⁴, Briganti A.⁴, Montorsi F.⁴, Nicolai N.³, Montanari E.⁵, Rogers C.¹, Abdollah F.¹

Institutions

¹VUI Center for Outcomes Research Analysis and Evaluation Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy, ⁴IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ⁵Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy

P0711

Contemporary outcomes of extramammary Paget's disease: a single-institution retrospective analysis

Authors

Kang J.S., Sung H.H.

Institutions

Samsung Medical Center Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea

P0712

Oncological and sexual outcomes after glans reconstruction with inverted urethral flap: results from a single center study

Authors

Sansalone S.¹, Foti M.², Falsaperla M.³, Dibitetto F.², Akhundov A.², Castellucci R.², Stracci D.², Minore A.², De Dominicis M.²

Institutions

¹Policlinico Tor Vergata, Dept. of Urology, Rome, Italy, ²Uroclinic - Casa di Cura Nuova Villa Claudia, Dept. of Urology, Rome, Italy, ³Arnas Garibaldi, Dept. of Urology, Catania, Italy

P0713

BelPen study: Prospective evaluation of MRI with Magtrace for sentinel node biopsy in penile cancer

Authors

Semal A.¹, Elst L.¹, Vandermaesen K.¹, Xiu X.¹, Baldewijns M.², Goffin K.³, De Wever L.⁴, Albersen M.¹

Institutions

¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²UZ Leuven, Dept. of Pathology, Leuven, Belgium, ³UZ Leuven, Dept. of Nuclear Medicine, Leuven, Belgium, ⁴UZ Leuven, Dept. of Radiology, Leuven, Belgium

14:55 - 15:15

Treatment of advanced penile cancer and new therapies

P0714

Transition from Open to Multi- and Single-Port Robotic Inguinal Lymphadenectomy for Bulky Nodal Disease in Penile Cancer: A Consecutive Series Comparison

Authors

Brassetti A., Bove A.M., Proietti F., Anceschi U., Bologna E., Cartolano S., Chiacchio G., D'Annunzio S., Ferriero M., Flammia R.S., Guaglianone S., Leonardo C., Licari L.C., Mastroianni R., Misuraca L., Tuderti G., Simone G.

Institutions

IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy

P0715

Survival of the fittest: Outcomes in node positive penile cancer patients where non-surgical management is utilised in place of RILND

Authors

Hyett V.¹, McCollum C.², Boyle C.², Huey R.², Vint R.², Johnston A.², Fraser M.², Hendry D.³, Salmond J.⁴, Rewhorn M.²

Institutions

¹University Hospital Monklands, Dept. of Urology, Airdrie, United Kingdom, ²Glasgow Royal Infirmary, Dept. of Urology, Glasgow, United Kingdom, ³Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, ⁴Glasgow Royal Infirmary, Dept. of Pathology, Glasgow, United Kingdom

P0716

Lymph node surgery after centralization of penile cancer care in Sweden – extent of use and complications

Authors

Warnolf Å.B.¹, Baseckas G.², Glombik D.³, Hagberg O.¹, Kirrander P.³, Kohestani K.⁴, Liedberg F.¹, Nordlund P.⁵, Persson E.⁶, Gerdtsen A.¹

Institutions

¹Lund University, Dept. of Translational Medicine, Malmö, Sweden, ²Malmö University Hospital, Dept. of Urology, Malmö, Sweden, ³Örebro University, Dept. of Urology, Faculty of Medicine and Health, Örebro, Sweden, ⁴Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Dept. of Urology, Gothenburg, Sweden, ⁵Södersjukhuset, Dept. of Urology, Stockholm, Sweden, ⁶Regional Cancer Center Uppsala Örebro, Uppsala, Sweden

Target-dependent in-vitro efficacy of Sacituzumab govitecan and Enfortumab vedotin in penile cancer

Authors

Mink J.¹, Tan E.², Schneppenheim F.², Linxweiler J.¹, Lohse S.³, Eckstein M.⁴, Kalthoff H.⁵, Naumann C.M.⁶, Klümper N.⁷, Junker K.¹, Hölzel M.²

Institutions

¹Saarland University, Dept. of Urology and Paediatric Urology, Homburg, Germany, ²University Hospital Bonn, Institute of Experimental Oncology, Bonn, Germany, ³Saarland University, Institute of Virology, Homburg, Germany, ⁴University Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany, ⁵University Kiel, Institute for Experimental Cancer Research, Kiel, Germany, ⁶Marienhause Clinic St. Elisabeth, Dept. of Urology and Paediatric Urology, Neuwied, Germany, ⁷University Hospital Bonn, Dept. of Urology and Paediatric Urology, Bonn, Germany

Male LUTS/BPO: From care pathways to procedures

EGPT 41

Sunday 15 March
13:45 - 15:15

Location Orange Area, EGPT 4

Chairs M. Karavitakis, Pagkrati - Athens (GR)
M. Tutolo, Milan (IT)
P.D. Violette, Woodstock (CA)

13:45 - 14:25

Care pathways, diagnostics & patient priorities

P0718

Impact and burden of postponing elective surgeries in patients with urological conditions

Authors

Simunovic I.¹, Zurl H.¹, Altziebler J.¹, Leitsmann C.¹, Scheipner L.¹, Mischinger J.¹, Schmidberger H.¹, Frank A.², Weiss A.³, Bachmaier G.⁴, Ahyai S.¹, Leitsmann M.¹

Institutions

¹Medical University of Graz, Dept. of Urology, Graz, Austria, ²University Hospital Graz, Dept. of Medical Care Planning, Graz, Austria, ³University Hospital Graz, Dept. of Medical Psychology, Graz, Austria, ⁴Medical University of Graz, Institute for Medical informatics, statistics and documentation, Graz, Austria

P0719

Unplanned Healthcare Utilization after Benign Prostate Intervention

Authors

DiBianco J.M.¹, Uy MU², Mansour S.³, Daignault-Newton S.², Ayyash N.², Lonsway J.⁴, Mirza M.², Bradshaw M.⁵, Narender Singh K.⁵, Ghani K.², Dauw C.², Sui W.²

Institutions

¹University of Florida, Dept. of Urology, Gainesville, United States of America, ²University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ³Comprehensive Urology, Dept. of Urology, Lapeer, United States of America, ⁴Western Michigan Urological Associates, Dept. of Urology, Holland, United States of America, ⁵Michigan Value Collaborative, MVC, Ann Arbor, United States of America

P0720

Clinical Applicability and Extended Symptom Profiling with the LURN SI-10 Questionnaire in Spanish Men with LUTS

Authors

España Navarro R.¹, Gomez-Gomez E.², De-La-Torre J.³, Ortega-Polledo L.⁴, Fernández-Siles J.⁵, Carrasco-Gómez D.⁵, García-Galisteo E.⁵, García-Gómez B.⁶, Gómez-Sancha F.⁷, Griffith J.⁸

Institutions

¹Regional University Hospital. TAUS Clinics, Dept. of Urology, Malaga, Spain, ²Reina Sofia Hospital, Dept. of Urology, Córdoba, Spain, ³Santa Ana Regional Hospital, Dept. of Urology, Motril, Spain, ⁴San Carlos Clinical Hospital, Dept. of Urology, Madrid, Spain, ⁵Regional University Hospital, Dept. of Urology, Málaga, Spain, ⁶12 de Octubre Hospital, Dept. of Urology, Madrid, Spain, ⁷ICUA-Centro Clinic, Dept. of Urology, Madrid, Spain, ⁸Feinberg School of Medicine, Northwestern University, Dept. of Medical Social Sciences, Chicago, United States of America

P0721

Clinical evaluation of AI-based software for diagnosing bladder outlet obstruction and detrusor underactivity in men with lower urinary tract symptoms

Authors

Lee J., Koo M.J., Sung S.H., Ko K.J., Han D.H., Lee K.S.

Institutions

Samsung Medical Center Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea

P0722

Novel non-invasive urodynamic system based on hyper electrophysiological mapping: Prospective comparative study with conventional urodynamics

Authors

Shprits S., Avidor Y., Kitrey N.

Institutions

Sheba Tel Hashomer, Dept. of Urology, Ramat Gan, Israel

P0723

Understanding Patient and Surgeon Priorities in Prostate Enucleation Surgery: Insights from the ENUC-TR Multicenter Cross-Sectional Study

Authors

Kazan H.O.¹, Basaran A.¹, Canakci C.², Dincer E.², Eryildirim B.², Inkaya A.³, Iplikci A.⁴, Nuroglu T.¹, Kucuk E.V.³, Yildirim A.¹

Institutions

¹Istanbul Medeniyet University School of Medicine, Dept. of Urology, Istanbul, Turkey, ²Health Sciences University, Kartal Dr. Lutfi Kirdar City Hospital, Dept. of Urology, Istanbul, Turkey, ³Health Sciences University, Umraniye Training and Research Hospital, Dept. of Urology, Istanbul, Turkey, ⁴Boyabat State Hospital, Dept. of Urology, Sinop, Turkey

P0724

Beyond LUTS: Broad Mental Health and Cognitive Benefits of BPH Surgery—Evidence from the TriNetX Global Network.

Authors

Cheng W.Y.¹, Kao S.K.², Yu Y.T.³, Tseng W.H.¹

Institutions

¹Chi Mei Medical Center, Dept. of Urology, Tainan, Taiwan, ²Taipei Veterans General Hospital, Dept. of Psychiatry, Taipei, Taiwan, ³Landseed International Hospital, Dept. of Community Medicine, Taoyuan, Taiwan

P0725

Long-Term Trajectories of Metabolic and Inflammatory Biomarkers and the Risk of Incident Benign Prostatic Hyperplasia: A 13-Year Longitudinal Study in a Large-Scale Western China Cohort

Authors

Lyu X.Y.¹, Li H.R.², Fu T.T.³, Xia L.M.², Wang L.³, Luo D.Y.², Huang J.³, Lin Y.F.³

Institutions

¹West China Hospital Sichuan University, Dept. of urology, Chengdu, China, ²West China Hospital, Sichuan University, Dept. of Urology, Chengdu, China, ³West China Hospital, Sichuan University, Innovation Institute for Integration of Medicine and Engineering, Chengdu, China

14:25 - 14:55

Efficacy, durability and outcomes of modern interventions

P0726

Long-Term Real-World Efficacy of Rezūm Therapy: Three-Year Multicentre International

Authors

Henrique Bitar Siqueira M.¹, Bhojani N.², Zorn K.C.³, Chughtai B.⁴, Cindolo L.⁵, Ferrari G.⁵, Lajkosz K.⁶, Elterman D.¹

Institutions

¹University of Toronto, Dept. of Urology, Toronto, Canada, ²Centre Hospitalier de l'Université de Montréal, Dept. of Urology, Montréal, Canada, ³BPH Canada, Prostate Surgical Institute, Dept. of Urology, Montréal, Canada, ⁴Plainview Hospital, Smith Institute of Urology, Northwell Health, Dept. of Urology, Syosset, United States of America, ⁵Hesperia Hospital, CURE Group, Dept. of Urology, Modena, Italy, ⁶University Health Network, Dept. of Biostatistics, Toronto, Canada

P0727

Sexual function outcomes of the 5-year treatment with Rezum compared to doxazosin, finasteride and combination drug therapy for men with BPH: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial.

Authors

Mcvary K., Han T., Joyce C., Feffer M.

Institutions

Loyola Stritch School of Medicine Loyola University Medical Center, Dept. of Urology, Maywood, United States of America

P0728

Durability of contemporary BPH Surgery: Real-World Reoperation Rates Across Eight Procedures

Authors

Uy MU¹, DiBianco J.M.², Mansour S.³, Daignault-Newton S.¹, Ayyash N.¹, Lonsway J.⁴, Mirza M.¹, Bradshaw M.⁵, Narender Singh K.⁵, Ghani K.¹, Dauw C.¹, Sui W.¹

Institutions

¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Florida, Dept. of Urology, Gainesville, United States of America, ³Comprehensive Urology, Dept. of Urology, Lapeer, United States of America, ⁴Western Michigan Urological Associates, Dept. of Urology, Holland, United States of America, ⁵Michigan Value Collaborative, MVC, Ann Arbor, United States of America

P0729

ROLE OF PROSTATIC ANTERIOR APEX PRESERVATION: SHORT-TERM FUNCTIONAL OUTCOMES OF MODIFIED HOLEP TECHNIQUE

Authors

Pagnotta J., Cochetti G., Vitale A., Massa G., Paladini A., Vacilotto G., Mearini E.

Institutions

University of Perugia, Dept. of Urology, Perugia, Italy

P0730

Construction of Anatomical Risk Map for Post-HoLEP Stress Urinary Incontinence Based on MRI

Authors

Kong J., Xinxiang F., Chun J.

Institutions

Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China

P0731

Influence of Intraoperative Tranexamic Acid on Bleeding Outcomes in Patients Receiving Antithrombotic Therapy Undergoing Endoscopic Enucleation of the Prostate: A Multicenter Prospective Study by the Endourology Section of EAU.

Authors

Cormio A.¹, Gauhar V.², Herrmann T.R.W.³, Kar-Kei Yuen S.⁴, Fong K.Y.², Moretto S.⁵, Zawadzki M.⁶, Mahajan A.⁷, Sytnik D.⁸, Alkandari A.⁹, Becker B.¹⁰, Aydin C.¹¹, Akdogan N.¹², Bulut E.C.¹³, De Coninck V.¹⁴, Tan K.¹⁵, Lim Y.W.², Laymon M.N.I.¹⁶, Mazzon G.¹⁷, Sarvajit B.P.², AbdelAziz O.¹⁸, Chiruvella M.¹⁹, Somani B.K.²⁰, Castellani D.²¹

Institutions

¹Università Politecnica Delle Marche, Dept. of Urology, Ancona, Italy, ²Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore, ³Kantonspital Frauenfeld, Spital Thurgau AG, Dept. of Urology, Frauenfeld, Switzerland, ⁴S.H. Ho Urology Centre, The Chinese University of Hong Kong, Dept. of urology, Hong Kong, Hong Kong, ⁵Sorbonne University, Tenon Hospital, Dept. of urology, Paris, France, ⁶St. Anna Hospital, Dept. of Urology, Piaseczno, Poland, ⁷Sai Urology Hospital and MGM Medical College, Dept. of Urology, Maharashtra, India, ⁸St.Luke's Clinical Hospital, Dept. of Urology, Saint Petersburg, Russia, ⁹Thunder Bay Regional Health Sciences Centre, Northern Ontario School of Medicine, Dept. of urology, Ontario, Canada, ¹⁰Asklepios Hospital Barmbek, Dept. of Urology, Hamburg, Germany, ¹¹Hitit University, School of Medicine, Dept. of Urology, Çorum, Turkey, ¹²Faculty of Medicine, Cukurova University, Dept. of Urology, Adana, Turkey, ¹³Faculty of Medicine, Gazi University, Dept. of Urology, Ankara, Turkey, ¹⁴AZ Klina, Dept. of Urology, Brasschaat, Belgium, ¹⁵Veterans Memorial Medical Center, Dept. of Urology, Quezon City, Philippines, ¹⁶Mansoura University, Dept. of Urology and Nephrology Center, Mansoura, Egypt, ¹⁷University College Hospital London, Dept. of Urology, London, United Kingdom, ¹⁸Cairo University, Kasr AlAiny Medical School, Dept. of Urology, Cairo, Egypt, ¹⁹Asian Institute of Nephrology and Urology, Dept. of Urology, Hyderabad, India, ²⁰University Hospital Southampton, NHS Trust, Dept. of Urology, Southampton, United Kingdom, ²¹Azienda Ospedaliero-Universitaria delle Marche, Dept. of Urology, Ancona, Italy

14:55 - 15:15

Bladder injury and bladder neck contracture

P0732

Bladder Injury During Anatomic Endoscopic Enucleation of the Prostate: A Prospective Multicenter Evaluation Using the BICEP Classification (EAU Endo Study)

Authors

Soytürk S.¹, Fernando Lista Mateos F.L.², Sönmez G.K.³, Ortner G.⁴, Torres D.², Tozsin A.⁵, Barlas S.⁶, Turan A.⁷, Rechner R.⁸, Ferretti S.⁹, Erkurt B.¹⁰, Karabulut I.⁷, Sönmez M.G.¹, Kaçtan M.C.¹⁰, Akdere H.⁵, Balasar M.¹, Gadzhiev N.¹¹, Somani B.¹², Otero J.R.², Herrmann T.⁸, Güven S.¹

Institutions

¹Necmettin Erbakan University, Dept. of Urology, Konya, Turkey, ²University Hospital HM Montepíncipe, HM Hospitales; Instituto de Investigación Sanitaria HM Hospitales; ROC Clinic; School of Medicine, Dept. of Urology, Madrid, Spain, ³Erciyes University, Dept. of Urology, Kayseri, Turkey, ⁴General Hospital Hall in Tirol, Dept. of Urology and Andrology, Tirol, Austria, ⁵Trakya University, Dept. of Urology, Edirne, Turkey, ⁶Acıbadem Ankara Hospital, Dept. of Urology, Ankara, Turkey, ⁷Erzurum Regional Training and Research Hospital, Dept. of Urology, Erzurum, Turkey, ⁸Kantonsspital Frauenfeld, Spital Thurgau AG, Dept. of Urology, Frauenfeld, Switzerland, ⁹University Hospital of Modena, Dept. of Urology, Modena, Italy, ¹⁰Istanbul Medipol University, Dept. of Urology, Istanbul, Turkey, ¹¹Saint Petersburg State University Hospital, Dept. of Urology, Saint Petersburg, Russia, ¹²University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom

P0733

Risk Factors and Prediction Model for Bladder Neck Contracture after Transurethral Laser Enucleation of the Prostate

Authors

Hu Q., Yuan Q.

Institutions

Chinese PLA General Hospital, Dept. of Urology, Peking, China

P0734

Risk factors for bladder neck contracture after holmium laser enucleation of the prostate

Authors

Gossler C., von Bohlen N.K., Schnabel M.J., Oppolzer I.A., Pickl C., Burger M., Breyer J.

Institutions

University of Regensburg, Dept. of Urology, Regensburg, Germany

P0735

Fifteen-Year Retrospective Multivariate Analysis of Predictors for Bladder Neck Contracture Following Transurethral Prostate Surgery

Authors

Hung C.C., Tang C., Wang Y.C., Lin C.M., Hsieh T.S., Chen K.C., Lo W.O., Wang S.F., Tsai S.W.

Institutions

Cathay General Hospital, Division of Urology Dept. of Surgery, Taipei City, Taiwan

Sunday 15 March
13:45 - 15:15

Location Orange Area, EGPT 5

Chairs L. Birder, Pittsburgh (US)
To be confirmed
To be confirmed

13:45 - 14:55

Basic science in functional urology

P0736

Anchoring Gene Therapy to the Bladder: A Mucoadhesive Microsphere System for Effective Intravesical TLR3 Gene Silencing in Inflammatory Bladder Diseases

Authors

Xu X.¹, Guo C.², Peng L.¹, Chen J.¹, Luo D.¹

Institutions

¹West China Hospital of Sichuan University, Dept. of Urology and Institute of Urology, Chengdu, China, ²West China Hospital of Sichuan University, Dept. of Orthopedic Surgery and Orthopedic Research Institute, Chengdu, China

P0737

Cell crosstalk in a mouse chronic cystitis model disrupts epithelial differentiation and reshapes the urothelium

Authors

Dai Y.

Institutions

West China Fourth Hospital, Dept. of urology, Chengdu, China

P0738

Investigating the role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the pathogenesis and treatment of Hunner-type interstitial cystitis

Authors

Ke H.¹, Xu K.², Wang K.¹

Institutions

¹West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China, ²Peking University People's Hospital, Dept. of Urology, Beijing, China

P0739

"From Urine, For the Bladder": Intravesical Delivery of Urine-Derived Stem Cell Extracellular Vesicles via Adhesive Microspheres for Treating Bladder Inflammation

Authors

Xu X.¹, Guo C.², Peng L.¹, Chen J.¹, Luo D.¹

Institutions

¹West China Hospital of Sichuan University, Dept. of Urology and Institute of Urology, Chengdu, China, ²West China Hospital of Sichuan University, Dept. of Orthopedic Surgery and Orthopedic Research Institute, Chengdu, China

P0740

Hyaluronic acid-based composite nanoparticles promote urothelium repair in interstitial cystitis/ bladder pain syndrome

Authors

Liu M.¹, Peng L.², Xiao Y.³, Luo D.²

Institutions

¹Beijing Friendship Hospital Capital Medical University, Dept. of Urology, Beijing, China, ²Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Dept. of Urology, Chengdu, China, ³College of Biomedical Engineering, Sichuan University, National Engineering Research Center for Biomaterials, Chengdu, China

P0741

Differences in Functional Brain Regions in Patients with Interstitial Cystitis/Painful Bladder Syndrome: A Resting-State Functional Magnetic Resonance Imaging Study

Authors

Meng L.¹, Yan Z.¹, Zhang Y.¹, Wang X.², Wang J.¹, Wang J.¹

Institutions

¹Beijing Hospital, Dept. of Urology, Beijing, China, ²Beijing Hospital, Dept. of Radiology, Beijing, China

P0742

Selective Androgen Receptor Modulation Restores Detrusor Contractility in an Animal Model of Detrusor Underactivity

Authors

Yang H.C.¹, Ho D.R.¹, Huang W.P.¹, Chen C.S.¹, Wang S.H.², Liu Y.L.¹, Huang K.T.¹, Huang Y.C.¹, Lin W.Y.¹, Lin J.H.¹

Institutions

¹Chiayi Chang Gung Memorial Hospital, Dept. of Urology, Chiayi, Taiwan, ²Chiayi Chang Gung Memorial Hospital, Dept. of Pediatric Surgery, Chiayi, Taiwan

P0743

Antler Stem Cell Exosomes Ameliorate Interstitial Cystitis via Mitochondrial Component Transfer to Reprogramming Macrophage Polarization

Authors

Wan Y., Huang J., Liu Z., Li W., Zhou X., Liu B.

Institutions

The Third Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Guangzhou, China

P0744

VesiVis™ (multi-molecular-weight hyaluronic acid) restores urothelial barrier and voiding function in a murine model of ketamine-induced cystitis

Authors

Tseng S.

Institutions

Taipei Tzu Chi Hospital, Dept. of Urology, Taipei, Taiwan

P0745

Restorative Effects of Urine-Derived Stem Cells Combined with Platelet Lysate on Bladder Dysfunction in a Neurogenic Bladder Model

Authors

Yun OJ¹, Lee S.H.¹, Kang J.K.¹, Chung J.W.¹, Ha Y.S.¹, Choi S.H.¹, Kim H.T.¹, Kim T.H.¹, Yoo E.S.¹, Kwon T.G.¹, Lee E.H.², Yoon B.H.², Jeon M.², Kim B.S.¹

Institutions

¹Kyungpook National University School of Medicine, Dept. of Urology, Daegu, South Korea, ²Kyungpook National University, Joint Institute of Regenerative Medicine, Daegu, South Korea

P0746

Mechano-metabolic crosstalk orchestrates bladder fibrotic remodeling in bladder underactivity

Authors

Jiawei J.W., Shen H., Luo D.Y.

Institutions

West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China

P0747

Upregulated mitophagy and mitochondrial abnormalities in the external urethral sphincter of elderly humans

Authors

Hata S.¹, Kai H.¹, Shinohara M.¹, Mimata H.², Shin T.¹

Institutions

¹Oita University, Dept. of Urology, Oita, Japan, ²Shinbeppu Hospital, Dept. of Urology, Beppu, Japan

P0748

Mechanism of hydroxyapatite/hyaluronic acid composite hydrogel in promoting urethral repair in stress urinary incontinence

Authors

Liu M.¹, Peng L.², Shen H.², Xiao Y.³, Luo D.²

Institutions

¹Beijing Friendship Hospital Capital Medical University, Dept. of Urology, Beijing, China, ²Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Dept. of Urology, Chengdu, China, ³College of Biomedical Engineering, Sichuan University, National Engineering Research Center for Biomaterials, Chengdu, China

P0749

Functional neuroimaging of the interaction between the periaqueductal gray and the pontine micturition center during a strong desire to void

Authors

Knops A.¹, Fernández Chadily S.², van Houtum N.¹, Halewijn J.², Schoutens Y.², Heesakkers J.¹, van Koevinge G.¹, van den Hurk J.³, De Rijk M.²

Institutions

¹Maastricht University Medical Centre+, Dept. of Urology, Maastricht, The Netherlands, ²Mental Health and Neuroscience Research Institute - Faculty of Health Medicine and Life Sciences - Maastricht University, Dept. of Urology, Maastricht, The Netherlands, ³Scannexus Ultra-High-Field MRI Centre, Science Department, Maastricht, The Netherlands

P0750

Performance assessment of large language models in urodynamic study trace interpretation

Authors

Peralta J., Rodrigues R., Xambre L., Lourenco M., Sabenca A., Maciel R., Bastos S., Silva J., Nascimento M.I.

Institutions

ULS Gaia Espinho, Dept. of Urology, Porto, Portugal

P0751

Reliability of ChatGPT response in clinical decision-making for neurogenic bladder cases: A preliminary evaluation of its compliance with international guidelines

Authors

Hegazy M., Wadie B.S.

Institutions

Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt

P0752

Evaluation of ChatGPT-5 Reliability in Urodynamic Study Interpretation

Authors

Dekel N., Aharony S., Golan S., Shenhar C., Buchler A.

Institutions

Rabin Medical Center, Dept. of Urology, Petah Tikva, Israel

P0753

Can AI Judge Urodynamic Study Quality? Validation Using the Bristol UTraQ Scale

Authors

Oliveira J.P., Henriques M., Vale L., Ferreira C., Cruz F., Silva J., Antunes-Lopes T.

Institutions

Unidade Local de Saúde de Sao Joao, Dept. of Urology, Porto, Portugal

Hands-on Training in TP Biopsy and MRI fusion

HOT TPB - MRI - 3.2

Sunday 15 March
14:00 - 17:00

Location Red Area, Room 2

Chair To be confirmed

Learning objectives

This course is designed to provide a comprehensive overview of office based transperineal (TP) biopsy techniques in local anaesthesia. It includes the integration of MRI fusion technology into daily clinical practice. Participants will begin with an introduction to the importance of TP biopsy and detailed instructions on performing the procedure by themselves..

The hands-on training sessions are the core of the course, where participants will practice:

- Basic superficial local anesthesia
- Deep periprostatic block
- Basic perineal with probe
- Basics of targeting and fusion
- Basics of hitting
- Single incision biopsies

14:00 - 14:05

Introduction

To be confirmed

14:05 - 14:20

Why TP biopsy & how to do TP biopsy

To be confirmed

14:20 - 14:30

Technical comparison

To be confirmed

14:30 - 16:25

Hands-on Training

Tutors

S. Bott, Frimley, Surrey (GB)

M. Jahnen, Munich (DE)

To be confirmed

To be confirmed

16:25 - 16:55

Circulate among stations

16:55 - 17:00

Closing remarks

To be confirmed

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 3.4

Sunday 15 March
14:00 - 14:50

Location Red Area, Room 1

Tutors A.J. Antunes Loureiro Nunes, Lisbon (PT)
C. Netsch, Hamburg (DE)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

E-BLUS Exam

HOT EBLUS EXAM - 3.4

Sunday 15 March
14:00 - 14:55

Location Red Area, Room 1

Tutors S. Erdem, Istanbul (TR)
L. Vendrell, Ciudad - Mendoza (AR)

Learning objectives

In this exam, your psychomotor skills such as depth perception and bimanual dexterity will be tested and your mastery of basic laparoscopy skills such as instrument handling, pattern cutting and intracorporeal suturing will be assessed by experienced examiners.

The exam is aimed at candidates with intermediate and advanced laparoscopy experience or those who have sufficiently trained to meet the exercises time and quality criteria. Passing the E-BLUS exam will be rewarded with a certificate that serves as a recommendation to continue your laparoscopy training by assisting laparoscopic procedures in the OR.

ESTs1 Exam

HOT EST EXAM 3.4

Sunday 15 March
14:00 - 14:50

Location Red Area, Room 1

Tutors To be confirmed
A. Pietropaolo, Southampton (GB)
I.M. Tjiam, Poortugaal (NL)

Learning objectives

In this exam, candidates' psychomotor and endoscopic skills are assessed, with a focus on the safe and effective performance of core endourological procedures such as rigid cystoscopy, flexible cystoscopy, semi-rigid ureteroscopy, and flexible ureteroscopy. Candidates are evaluated by experienced examiners on instrument handling, scope control, orientation, and respect for tissue within a simulated setting. The exam is aimed at candidates with basic to intermediate endourology experience or those who have completed sufficient training to meet the required performance standards, and successful completion is rewarded with a certificate recommending progression to supervised endourological procedures in the operating room.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 3.4

Sunday 15 March
14:00 - 14:50

Location Red Area, Room 1

Tutors To be confirmed
J. Gómez Rivas, Madrid (ES)

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 3.4

Sunday 15 March
14:00 - 14:50

Location Red Area, Room 1

Tutors E.D. Demirkiran, Zonguldak (TR)
M.I. Gökce, Ankara (TR)
T.E. Şener, Istanbul (TR)

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 3.4

Sunday 15 March
14:00 - 14:50

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Sunday 15 March
14:15 - 14:45

Location Patient Advocacy Plaza
Chair To be confirmed

14:15 - 14:45

ORCHID
To be confirmed

Enucleation of the prostate for BPO treatment: The anatomical solution to various challenges

ESU Course 38

Sunday 15 March
14:30 - 17:30

Location Red Area, Room 8
Chair T.R.W. Herrmann, Frauenfeld (CH)

Voting will be available via the EAU26 App or via www.qna.at/eau

Learning objectives

Subject of the course is the content of the surgical chapter of the EAU Non Neurogenic Male Luts Guidelines.

The Course will display:

- The surgical treatment algorithm of the EAU Guidelines
- The Rational behind the subdivision in Vaporisation, Resection and Enucleation
- Positioning and leverage of each surgical modality and evidence
- Enucleating modalities: endoscopic enucleation, vs Robotic / laparoscopic adenomectomy vs. Open adenomectomy
- Treatment related side effects, esp. QOL, sexual function

Introduction: Why enucleation is a good idea for now and the future

T.R.W. Herrmann, Frauenfeld (CH)

Surgical treatment pattern of the current EAU guidelines

T.R.W. Herrmann, Frauenfeld (CH)

Worldwide standard for the treatment of large prostates: Techniqe and outcome of contemporary open prostatectomy

L. Lusuardi, Salzburg (AT)

What to know and not to know about current lasers for BPO treatment?

C.M. Scoffone, Turin (IT)

Endoscopic enucleation of the prostate: Surgical principles & outcomes

T.R.W. Herrmann, Frauenfeld (CH)

Defining the role of laparoscopic and robotic surgery in BPO surgery: Different techniques and outcome

L. Lusuardi, Salzburg (AT)

Ejaculation-preserving techniques: Technique and outcomes, patient selection and critical comparison to MIST

C.M. Scoffone, Turin (IT)

Interactive case discussions

T.R.W. Herrmann, Frauenfeld (CH)

L. Lusuardi, Salzburg (AT)

C.M. Scoffone, Turin (IT)

Office management of male sexual dysfunction

ESU Course 42

Sunday 15 March
14:30 - 17:30

Location Red Area, Room 12

Chair M.M. Fode, Herlev (DK)

Learning objectives

The course will enable participants to perform a basic diagnostic evaluation and give knowledge of advanced diagnostic methods. Participants will learn when testosterone replacement therapy is indicated and how to apply it and how to tailor PDE5-Is to the individual patient. Further, participants will gain insight into more advanced medical and mechanical ED treatments. The course will also include discussions of management/controversies regarding:

- Ejaculatory dysfunction
- Priapism
- Recurrent priapism
- Sexual rehabilitation following radical prostatectomy

Introduction

M.M. Fode, Herlev (DK)

Diagnostics: What is necessary?

D. Hatzichristou, Thessaloniki (GR)

Testosterone replacement

E.C. Şerefoğlu, Istanbul (TR)

Oral therapy for erectile dysfunction

M.M. Fode, Herlev (DK)

Therapy of erectile dysfunction when pills fail

D. Hatzichristou, Thessaloniki (GR)

Management of ejaculatory dysfunction

E.C. Şerefoğlu, Istanbul (TR)

Peyronie's disease

D. Hatzichristou, Thessaloniki (GR)

What to do after radical prostatectomy?

M.M. Fode, Herlev (DK)

Tips, tricks and questions from the audience

M.M. Fode, Herlev (DK)

D. Hatzichristou, Thessaloniki (GR)

E.C. Şerefoğlu, Istanbul (TR)

Transgender surgery course

ESU Course 39

Sunday 15 March
14:30 - 17:30

Location Red Area, Room 9

Chair M. Garcia, Los angeles (US)

Voting will be available via the EAU26 App or via www.qna.at/eau

Learning objectives

1. Describe common primary and salvage feminising & masculinising genital gender affirming surgeries (gGAS)
2. Recognise and explain the most common complications associated with feminizing & masculinizing gGAS, and management
3. Describe at least 3 ways that the *general* urologist can provide effective care to transgender women/men
4. Summarise at least 4 key organisational features and practices of a successful trans-surgery programme

Feminizing genital gender affirming surgery

Overview of primary vaginoplasty surgery options

M. Garcia, Los angeles (US)

S. Riechardt, Itzehoe (DE)

Pre-surgery preparation & post-surgery care

S. Riechardt, Itzehoe (DE)

Complications: Incidence, diagnosis, and management

M. Garcia, Los angeles (US)

S. Riechardt, Itzehoe (DE)

Revision & salvage surgeries: Care algorithms & surgical techniques

M. Garcia, Los angeles (US)

Topics open for debate: Role of peritoneal vaginoplasty? Non-standard genital surgery requests?

M. Garcia, Los angeles (US)

S. Riechardt, Itzehoe (DE)

Masculinizing genital gender affirming surgery

Overview of primary surgery options: Metoidioplasty & phalloplasty

M. Falcone, Turin (IT)

M. Garcia, Los angeles (US)

W.G. Lee, London (GB)

Pre-surgery preparation and post-surgery care

M. Falcone, Turin (IT)

M. Garcia, Los angeles (US)

W.G. Lee, London (GB)

Complications: Incidence, diagnosis, and management

M. Falcone, Turin (IT)

M. Garcia, Los angeles (US)

W.G. Lee, London (GB)

Penile and testicle prosthetics: Primary & revision

M. Falcone, Turin (IT)

M. Garcia, Los angeles (US)

W.G. Lee, London (GB)

Topics open for debate: Surgery staging; Choice for vascular pedicle?

M. Falcone, Turin (IT)

M. Garcia, Los angeles (US)

W.G. Lee, London (GB)

Panel discussion

M. Falcone, Turin (IT)

M. Garcia, Los angeles (US)

W.G. Lee, London (GB)

S. Riechardt, Itzehoe (DE)

Prostate cancer update: 2025-2026

ESU Course 40

Sunday 15 March
14:30 - 17:30

Location Red Area, Room 10

Chair M. Graefen, Hamburg (DE)

Learning objectives

This course is aimed at critically reviewing key manuscripts published during the previous 12 months and devoted to the management of prostate cancer patients with a particular focus on basic research, screening, diagnosis, staging, and local and systemic therapies. Practice-changing manuscripts published in peer-reviewed journals will be identified and discussed for each topic. For every paper a clear take home message applicable to the every-day clinical practice will be identified and discussed. The main objective of the course is to inform participants on the latest and most significant novelties related to the contemporary management of prostate cancer patients.

Clinical implications of basic research

C. Moore, London (GB)

Screening: Novel biomarkers and strategies

C. Evans, Sacramento (US)

Diagnosis: Role of mpMRI and PET PSMA in detecting prostate lesions. Fusion biopsies

C. Moore, London (GB)

Staging: Imaging and predictive models

M. Graefen, Hamburg (DE)

Treatment of localised prostate cancer: Radical prostatectomy

M. Graefen, Hamburg (DE)

Treatment of localised prostate cancer: Focal therapy

C. Moore, London (GB)

Treatment of localised prostate cancer: Radiation therapy

M. Graefen, Hamburg (DE)

Management of recurrence after curative treatment

M. Graefen, Hamburg (DE)

Management of hormone sensitive metastatic prostate cancer

C. Evans, Sacramento (US)

Management of castration-resistant prostate cancer

C. Evans, Sacramento (US)

Practical management of non-muscle invasive bladder cancer (NMIBC)

ESU Course 41

Sunday 15 March
14:30 - 17:30

Location Red Area, Room 11

Chair E.N. Xylinas, Paris (FR)

Learning objectives

Our main objective is to not only enrich what you know about NMIBC, but to also equip you with frontline strategies when dealing with common and complex patient cases.

This course will commence with discussions on NMIBC diagnostic opportunities and then proceed to the best practices and the pitfalls to avoid in transurethral resection (TUR). Get to know the techniques, tips and tricks, potential problems/complications, TUR with enhanced imaging, en-bloc resection and more through videos and lively discussions with key opinion leaders.

Further into the course, you will familiarise yourself with the new modalities and the limitations of recommendations on additional risk-adapted intravesical treatment. These will be followed by deliberations on typical problems encountered, complications during and after intravesical therapy, and strategies on how you can prevent them.

Another course highlight you can look forward to is how you can deal with abnormal cytology including locations outside the bladder.

Introduction

E.N. Xylinas, Paris (FR)

Urine-based markers ready for prime time?

E.N. Xylinas, Paris (FR)

Optimal TURB: Tips and tricks; En bloc resection; Re-TUR; Optical enhancement

P. Gontero, Turin (IT)

Discussion

P. Gontero, Turin (IT)

F. Guerrero-Ramos, Madrid (ES)

E.N. Xylinas, Paris (FR)

Risk-stratification

F. Guerrero-Ramos, Madrid (ES)

Standard of care treatment for low- and intermediate risk patients

F. Guerrero-Ramos, Madrid (ES)

Discussion

P. Gontero, Turin (IT)

F. Guerrero-Ramos, Madrid (ES)

E.N. Xylinas, Paris (FR)

Standard of care treatment for high- and very-high risk patients

E.N. Xylinas, Paris (FR)

BCG-unresponsive disease definition and therapeutic options

P. Gontero, Turin (IT)

Case-based discussion

P. Gontero, Turin (IT)

F. Guerrero-Ramos, Madrid (ES)

E.N. Xylinas, Paris (FR)

Take home messages and conclusion

E.N. Xylinas, Paris (FR)

The infertile couple: Urological aspects

ESU Course 37

Sunday 15 March
14:30 - 17:30

Location Red Area, Room 7

Chair M. Dinkelman-Smit, Rotterdam (NL)

Voting will be available via the EAU26 App or via www.qna.at/eau

Learning objectives

This course provides state-of-the-art information on urological aspects of diagnosis and therapy of modern reproductive medicine. Diagnostic procedures should be standardised and coordinated in a timely fashion for both partners, focusing on the possible urological, hormonal and genetic causes of male infertility.

In terms of therapy, this course will provide updated information on evidence-based data and discuss the importance of varicoceles in male infertility. We will show microsurgical techniques on video and explain why proper training and skills perfection is key to successful case management. A successful IVF/ICSI outcome depends upon the use of state-of-the-art techniques for sperm retrieval and sperm preparation.

We will also provide information on genetic aspects and stress the responsibility of the urologist as an adviser and gatekeeper for the treatment of the infertile couple.

Introduction. Couple infertility: The rationale for male reproductive health assessment for all

M. Dinkelman-Smit, Rotterdam (NL)

Part 1: Diagnostic modalities in male infertility assessment: Interpretation, pitfalls and updates

Semen analysis. WHO parameters, sperm DNA fragmentation, oxidative stress biomarker testing

P. Sangster, London (GB)

Male reproductive endocrinology. Endocrine regulation of spermatogenesis, hypogonadism, prolactine

D. Hauptman, Zagreb (HR)

Physical examination and imaging. What not to miss, when to look for what

P. Sangster, London (GB)

Genetics. Phenotype driven genetic testing oligospermia, sperm motility/morphology, azoospermia
M. Dinkelman-Smit, Rotterdam (NL)

Part 2: Treatment modalities to improve male reproductive potential for natural and assisted reproduction

Preconceptional lifestyle modification, weight loss, GLP1 agonist
M. Dinkelman-Smit, Rotterdam (NL)

Medical treatment, including hormonal stimulation, antioxidants, hormonal therapy, and new agents
D. Hauptman, Zagreb (HR)

(micro)Surgical treatment of varicocele and obstructive azoospermia
P. Sangster, London (GB)

Sperm retrieval methods in ejaculation disorders, obstructive and non-obstructive azoospermia, Klinefelter Syndrome, re-do cases
D. Hauptman, Zagreb (HR)

Patient advocacy plaza - Understanding and overcoming patient barriers to discussing urinary symptoms linked to bladder cancer



Special Session

Sunday 15 March
15:00 - 15:30

Location Patient Advocacy Plaza

Chair To be confirmed

15:00 - 15:30

World Bladder Cancer Patient Coalition (WBCPC)
To be confirmed

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 3.5

Sunday 15 March
15:00 - 15:50

Location Red Area, Room 1

Tutors A.J. Antunes Loureiro Nunes, Lisbon (PT)
C. Netsch, Hamburg (DE)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

E-BLUS Exam

HOT EBLUS EXAM - 3.5

Sunday 15 March
15:00 - 15:55

Location Red Area, Room 1

Tutors O. Stakhovskyi, Kyiv (UA)
P. Umari, London (GB)

Learning objectives

In this exam, your psychomotor skills such as depth perception and bimanual dexterity will be tested and your mastery of basic laparoscopy skills such as instrument handling, pattern cutting and intracorporeal suturing will be assessed by experienced examiners.

The exam is aimed at candidates with intermediate and advanced laparoscopy experience or those who have sufficiently trained to meet the exercises time and quality criteria. Passing the E-BLUS exam will be rewarded with a certificate that serves as a recommendation to continue your laparoscopy training by assisting laparoscopic procedures in the OR.

ESTs1 Exam

HOT EST EXAM 3.5

Sunday 15 March
15:00 - 15:50

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed
A. Pietropaolo, Southampton (GB)

Learning objectives

In this exam, candidates' psychomotor and endoscopic skills are assessed, with a focus on the safe and effective performance of core endourological procedures such as rigid cystoscopy, flexible cystoscopy, semi-rigid ureteroscopy, and flexible ureteroscopy. Candidates are evaluated by experienced examiners on instrument handling, scope control, orientation, and respect for tissue within a simulated setting. The exam is aimed at candidates with basic to intermediate endourology experience or those who have completed sufficient training to meet the required performance standards, and successful completion is rewarded with a certificate recommending progression to supervised endourological procedures in the operating room.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 3.5

Sunday 15 March
15:00 - 15:50

Location Red Area, Room 1

Tutors To be confirmed
J. Gómez Rivas, Madrid (ES)

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Sacral Neuromodulation (SNM)

HOT SNM - 3.1

Sunday 15 March
15:00 - 17:00

Location Red Area, Room 3

Chair H. Hashim, Bristol (GB)

Learning objectives

This Hands-on Training is designed to equip participants with the fundamental skills to perform sacral neuromodulation (SNM) procedures effectively. Participants will have the opportunity to practice each step of the SNM procedure, including primary percutaneous nerve evaluation, tined lead and battery implantation, programming, and troubleshooting.

15:00 - 15:05

Welcome and introduction

H. Hashim, Bristol (GB)

15:05 - 15:20

SNM indications, guidelines, and outcomes

15:20 - 15:35

SNM patient selection, technique, and complications

15:35 - 16:00

Hands-on Training 1

15:35 - 16:00

PNE Station 1

Tutor To be confirmed

15:35 - 16:00

PNE Station 2

Tutor To be confirmed

15:35 - 16:00

PNE Station 3

Tutor To be confirmed

15:35 - 16:00	Tined Lead Station 1	
	<i>Tutor</i>	S. Arlandis, Valencia (ES)
15:35 - 16:00	Tined Lead Station 2	
	<i>Tutor</i>	P. Bueno Garcia Reyes, Mexico City (MX)
15:35 - 16:00	Tined Lead Station 3	
	<i>Tutor</i>	E. Huri, Ankara (TR)
15:35 - 16:00	Programming Station	
	<i>Tutor</i>	L. Thomas, Bristol (GB)
<hr/>		
16:00 - 16:25	Hands-on Training 2	
16:00 - 16:25	PNE Station 1	
	<i>Tutor</i>	To be confirmed
16:00 - 16:25	PNE Station 2	
	<i>Tutor</i>	To be confirmed
16:00 - 16:25	PNE Station 3	
	<i>Tutor</i>	To be confirmed
16:00 - 16:25	Tined Lead Station 1	
	<i>Tutor</i>	S. Arlandis, Valencia (ES)
16:00 - 16:25	Tined Lead Station 2	
	<i>Tutor</i>	P. Bueno Garcia Reyes, Mexico City (MX)
16:00 - 16:25	Tined Lead Station 3	
	<i>Tutor</i>	E. Huri, Ankara (TR)
16:00 - 16:25	Programming Station	
	<i>Tutor</i>	L. Thomas, Bristol (GB)
<hr/>		
16:25 - 16:50	Hands-on Training 3	
16:25 - 16:50	PNE Station 1	
	<i>Tutor</i>	To be confirmed
16:25 - 16:50	PNE Station 2	
	<i>Tutor</i>	To be confirmed
16:25 - 16:50	PNE Station 3	
	<i>Tutor</i>	To be confirmed
16:25 - 16:50	Tined Lead Station 1	
	<i>Tutor</i>	S. Arlandis, Valencia (ES)
16:25 - 16:50	Tined Lead Station 2	
	<i>Tutor</i>	P. Bueno Garcia Reyes, Mexico City (MX)

16:25 - 16:50

Tined Lead Station 3

Tutor

E. Huri, Ankara (TR)

16:25 - 16:50

Programming Station

Tutor

L. Thomas, Bristol (GB)

16:50 - 17:00

Discussions and conclusions

H. Hashim, Bristol (GB)

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 3.5

Sunday 15 March

15:00 - 15:50

Location

Red Area, Room 1

Tutors

E.D. Demirkiran, Zonguldak (TR)

M.I. Gökce, Ankara (TR)

T.E. Şener, Istanbul (TR)

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 3.5

Sunday 15 March

15:00 - 15:50

Location

Red Area, Room 1

Tutors

To be confirmed

To be confirmed

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Prostate cancer: PARPis finally explained

Thematic Session

Sunday 15 March
15:30 - 17:00

Location Orange Area, eURO Auditorium 2

Chairs E. Castro, Madrid (ES)
I. Van Oort, Groningen (NL)

Learning objectives

After this session, participants will be able to:

- Identify when genetic testing is indicated in prostate cancer.
- Interpret germline and somatic alterations in a clinical context.
- Select appropriate biopsy and ctDNA approaches for molecular diagnostics.
- Understand the mechanism, timing, and clinical application of PARP inhibitors in mHSPC and mCRPC.

15:30 - 15:34

Welcome and introduction

15:34 - 16:24

Round-table discussion

Moderator H. Beltran, Boston (US)

15:34 - 15:41

Indications of genetic testing in prostate cancer

I. Van Oort, Groningen (NL)

15:41 - 15:48

How to optimise tissue biopsy acquisition?

B. Herrera Imbroda, Malaga (ES)

15:48 - 15:55

When to use ctDNA in prostate cancer?

A. Wyatt, Vancouver (CA)

15:55 - 16:02

How to read a genetic report for clinical practice?

H. Beltran, Boston (US)

16:02 - 16:09

How to optimise germline and somatic testing in prostate cancer?

N. Mehra, Nijmegen (NL)

16:09 - 16:24

Discussion

16:24 - 16:34

State-of-the-art lecture Why are germline and somatic alterations in PC important?

D. Olmos, Madrid (ES)

16:34 - 16:44

State-of-the-art lecture PARPi in mHSPC and mCRPC-

G. Attard, London (GB)

16:44 - 16:54

Challenging the expert (PARPi)

Interviewer H. Beltran, Boston (US)

Speaker G. Attard, London (GB)

16:54 - 17:00

Take home messages

E. Castro, Madrid (ES)

ERN eUROGEN: Update on rare & complex urology

Thematic Session

Sunday 15 March
15:30 - 17:00

Location Blue Area, Victoria 6
Chairs M. Batty, Nijmegen (NL)
P. Mulders, Nijmegen (NL)

-
- 15:30 - 15:40** **Introduction and ERN eUROGEN update**
P. Mulders, Nijmegen (NL)
-
- 15:40 - 16:00** **ERN eUROGEN Patient Advocacy Group (ePAG)**
- 15:40 - 15:50** **Penile cancer patient survey: Report**
Speakers K. Manzie, Glasgow (GB)
J. Osborne, Nottingham (GB)
-
- 15:50 - 16:00** **Urological concerns in anorectal malformation: The importance of lifelong care**
D. Aminoff, Rome (IT)
-
- 16:00 - 16:20** **ERN eUROGEN Workstream 1: Rare congenital uro-recto-genital anomalies**
- 16:00 - 16:10** **Mapping centres for rare and complex diseases: How to improve management of Spina Bifida and other malformations**
G. Mosiello, Rome (IT)
- 16:10 - 16:20** **Surgical and non-surgical treatment options for creation of neovagina in patients with XX-DSD, XY-DSD and vaginal reconstruction options in patients with complex obstructing Müllerian duct malformations**
A. Höller, Tuebingen (DE)
-
- 16:20 - 16:40** **ERN eUROGEN Workstream 2: Functional urogenital conditions requiring highly specialised surgery**
- 16:20 - 16:30** **Genital lichen sclerosis: Complex reconstruction beyond the urethra**
F. Campos Juanatey, Santander (ES)
- 16:30 - 16:40** **Phalloplasty in cripple penis: The last resort?**
A-F. Spinoit, Ghent (BE)
-
- 16:40 - 17:00** **ERN eUROGEN Workstream 3: Rare urogenital tumours**
- 16:40 - 16:50** **Using PROMS to promote holistic consultations and help address unmet psychosocial needs in patients with penile cancer**
B.E. Ayres, London (GB)
- 16:50 - 17:00** **Surgical management of retroperitoneal sarcoma**
To be confirmed
-

BCG meets immunotherapy in high-risk NMIBC: Key lessons for urologists from POTOMAC, ALBAN, and CREST

Thematic Session

Sunday 15 March
15:30 - 17:00

Location Orange Area, Room 3
Chairs M. Babjuk, Prague (CZ)
A. Van Der Heijden, Nijmegen (NL)

15:30 - 15:35

Welcome word
M. Babjuk, Prague (CZ)

15:35 - 16:10

Trial highlights

15:35 - 15:45

1 POTOMAC - Durvalumab + BCG (Positive)
M. De Santis, Berlin (DE)

15:45 - 15:55

2 ALBAN - Atezolizumab + BCG (Negative)
M. Rouprêt, Paris (FR)

15:55 - 16:05

CREST – Sasanlimab + BCG (Positive)
To be confirmed

16:05 - 16:10

Questions and Answers

16:10 - 16:10

Round-table discussions

16:10 - 16:25

Round-table 1: Quality of TURBT and baseline bias

Discussant M. Babjuk, Prague (CZ)

Panel M. De Santis, Berlin (DE)
To be confirmed
J. Palou, Barcelona (ES)
M. Rouprêt, Paris (FR)
To be confirmed

- Second-look TURBT and residual tumour rates

- Impact of pathology centralisation on EFS

- How “surgical quality bias” may explain differences between trials

16:25 - 16:40

Round-table 2: Endpoints and BCG Schedules

Discussant E. Grande, Madrid (ES)

Panel M. De Santis, Berlin (DE)
To be confirmed
J. Palou, Barcelona (ES)
M. Rouprêt, Paris (FR)
To be confirmed

- Harmonising EFS vs. DFS definitions for regulatory acceptance

- BCG strain and duration (1- vs. 2-year maintenance)

16:40 - 16:55

Round-table 3: Systemic toxicity and biomarker selection

Discussant A.J Birtle, Preston (GB)

Panel M. De Santis, Berlin (DE)

To be confirmed

J. Palou, Barcelona (ES)

M. Rouprêt, Paris (FR)

To be confirmed

- TRAEs \geq G3 and immune-related AEs: How to quantify “acceptable toxicity” in localised disease

- Biomarker approaches (PD-L1 SP263, immune gene signatures, ctDNA)

- Framework for next-generation biomarker-driven EAU/GETUG trials

16:55 - 17:00

Closing remarks

M. Babjuk, Prague (CZ)

A. Van Der Heijden, Nijmegen (NL)

Exploring the frontier of upper tract urothelial carcinoma: Diagnostic tools, adjuvant therapies, and surgical approaches

Abstract Session 34

Sunday 15 March

15:30 - 17:00

Location Blue Area, Victoria 2

Chairs To be confirmed

G. Marcq, Lille (FR)

To be confirmed

15:30 - 15:55

Endoscopic management of upper tract urothelial carcinoma

Comparative performance of EAU and AUA risk stratification systems in predicting recurrence and progression after nephron-sparing management of upper-tract urothelial carcinoma – A YAU Urothelial Group Study

Authors

Belarmino A.¹, Di Bello F.¹, Basile G.¹, Gallioli A.¹, Zattoni F.², D'Andrea D.³, Laukhtina E.³, Soria F.⁴, Afferi L.⁵, Del Giudice F.⁶, Krajewski W.⁷, Marcq G.⁸, De Lorenzis E.⁹, Moschini M.¹⁰, Avesani G.¹, Mari A.¹¹, Mertens L.¹², Cano Velasco J.¹³, Diéguez L.A.¹, Izquierdo P.¹, I. Chung B.¹⁴, Palou J.¹, Pradere B.¹⁵, Breda A.¹

Institutions

¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²Azienda Ospedale-Università Padova, Dept. of Urology, Padova, Italy, ³Comprehensive Cancer Center and Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁴University of Turin and Città della Salute e della Scienza, Dept. of Surgical Sciences, Turin, Italy, ⁵Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ⁶Sapienza University of Rome, Policlinico Umberto I Hospital, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ⁷Wroclaw Medical University, Dept. of Minimally Invasive and Robotic Urology, Wroclaw, Poland, ⁸Claude Huriez Hospital, Dept. of Urology, Lille, France, ⁹University of Milan, Foundation IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Clinical Sciences and Community Health, Urology, Milan, Italy, ¹⁰IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ¹¹University of Florence and Careggi Hospital, Dept. of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ¹²Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ¹³Hospital General Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain, ¹⁴Stanford University School of Medicine, Dept. of Urology, Stanford, United States of America, ¹⁵Humanitas Clinical and Research Institute IRCCS, Dept. of Urology, Rozzano, Italy

Study Group

YAU Urothelial Group (Barcelona, Spain)

Validation of the Diagnostic Accuracy of a Urine-based DNA Methylation Marker Test in Patients with Upper Urinary Tract lesions

Authors

Kaufmann E.¹, Röthlin K.¹, Baumeister P.¹, Mattei A.¹, Piatti P.², Chew Y.C.², Fankhauser C.D.¹

Institutions

¹University Teaching and Research Hospital of the University of Lucerne, Dept. of Urology, Lucerne, Switzerland, ²Zymo Research Corp., Irvine, United States of America

Risk of recurrence and progression after endoscopic kidney-sparing surgery for upper tract urothelial carcinoma: a EAU-YAU Urothelial proposal

Authors

Gallioli A.¹, Di Bello F.², D'Andrea D.³, Zattoni F.⁴, Soria F.⁵, Krajewski W.⁶, Laukhtina E.³, Marcq G.⁷, Moschini M.⁸, Izquierdo P.¹, Afferi L.⁹, Mari A.¹⁰, Del Giudice F.¹¹, Dieguez L.¹, Donnini I.¹², Avesani G.⁸, Subiela J.D.¹³, Basile G.¹, De Lorenzis E.¹⁴, Chung B.I.¹⁵, Territo A.¹, Palou J.¹, Pradere B.¹⁶, Breda A.¹

Institutions

¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²University of Naples Federico II, Dept. of Neurosciences, Reproductive Sciences and Odontostomatology, Napoli, Italy, ³Comprehensive Cancer Center, Dept. of Urology, Vienna, Austria, ⁴University of Padova, Dept. of Surgery Oncology and Gastroenterology, Padova, Italy, ⁵University of Turin and Città della Salute e della Scienza, Dept. of Surgical Sciences, Turin, Italy, ⁶Wroclaw Medical University, Dept. of Minimally Invasive and Robotic Urology, Wroclaw, Poland, ⁷Claude Huriez Hospital, Dept. of Urology, Lille, France, ⁸IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ⁹Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ¹⁰University of Florence, Dept. of Urology, Florence, Italy, ¹¹Sapienza University of Rome, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ¹²University of Brescia, Dept. of Urology, Brescia, Italy, ¹³IRYCIS Universidad de Alcalá, Dept. of Urology, Madrid, Spain, ¹⁴University of Milan, Clinical Sciences and Community Health, Milan, Italy, ¹⁵Stanford University School of Medicine, Dept. of Urology, Stanford, United States of America, ¹⁶UROSUD, La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France

Study Group

EAU-YAU Urothelial Working Group and Ureterosopic Treatment of upper tract Urothelial Carcinoma (UTUC) registry (Barcelona, Spain)

Efficacy and Safety of Padeliporfin Vascular-Targeted Photodynamic Therapy (VTP) in the ENLIGHTED Phase 3 Study for Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC)

Authors

Shvero A.¹, Kaufman R.², Djaladat H.³, Raman J.⁴, Shabsigh A.⁵, Marcq G.⁶, Psutka S.⁷, Margulis V.⁸, Shore N.⁹, Uchio E.¹⁰, Colombel M.¹¹, Aller M.¹², Rausch S.¹³, Grubb R.¹⁴, Ogan K.¹⁵, Singla N.¹⁶, Medvedchikov A.¹⁷, Pecen L.¹⁷, Alpert G.¹⁸, Scherz A.¹⁹, Coleman J.²⁰

Institutions

¹Sheba Medical Center, Dept. of Urology, Ramat Gan, Israel, ²Albany Medical College, Dept. of Urology, Albany, United States of America, ³University of Southern California, Keck School of Medicine, Dept. of Urology, Los Angeles, United States of America, ⁴The Pennsylvania State University (Penn State) Milton S. Hershey Medical Center, Dept. of Urology, Hershey, United States of America, ⁵The Ohio State University (OSU), Dept. of Urology, Columbus, United States of America, ⁶CHU de Lille - Hopital Claude Huriez, Dept. of Urology, Lille, France, ⁷University of Washington, Dept. of Urology, Seattle, United States of America, ⁸University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, ⁹Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, ¹⁰University of California - Irvine Medical Center, Dept. of Urology, Irvine, United States of America, ¹¹HCL Hopital Edouard Herriot, Dept. of Urology, Lyon, France, ¹²Hospital Universitario de A Coruna, Dept. of Urology, Coruna, Spain, ¹³Eberhard Karls University, Dept. of Urology, Tübingen, Germany, ¹⁴Medical University of South Carolina (MUSC), Dept. of Urology, Charleston, United States of America, ¹⁵Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, ¹⁶Johns Hopkins University, Brady Urological Institute, Dept. of Urology, Baltimore, United States of America, ¹⁷Steba France SAS, Dept. of Clinical Development, Versailles, France, ¹⁸Steba/Impact Biotech Ltd, Clinical Development, Ness Ziona, Israel, ¹⁹The Weizmann Institute of Science, Dept. of Plants and Environmental Sciences, Rehovot, Israel, ²⁰Memorial Sloan Kettering Cancer Center, David H. Koch Center for Cancer Care, Dept. of Urology, New York, United States of America

The impact of II-look ureteroscopy on survival in upper tract urothelial carcinoma: results from EAU-YAU experience

Authors

Gallioli A.¹, [Di Bello F.](#)², Celso F.G.³, Krajewski W.⁴, Soria F.⁵, Laukhtina E.⁶, Beltrami P.³, Subiela J.D.⁷, D'Andrea D.⁶, Afferi L.⁸, Del Giudice F.⁹, De Lorenzis E.¹⁰, Marcq G.¹¹, Moschini M.¹², Mari A.¹³, Dieguez L.¹, Territo A.¹, Baboudjian M.¹⁴, Avesani G.¹², Basile G.¹, Izquierdo P.¹, Palou J.¹, Pradere B.I.¹⁵, Breda A.¹

Institutions

¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²University of Naples Federico II, Dept. of Neurosciences, Reproductive Sciences and Odontostomatology, Napoli, Italy, ³University of Padova, Dept. of Urology, Padova, Italy, ⁴Wroclaw Medical University, Dept. of Minimally Invasive and Robotic Urology, Wroclaw, Poland, ⁵University of Turin and Città della Salute e della Scienza, Dept. of Surgical Sciences, Turin, Italy, ⁶Comprehensive Cancer Center, Dept. of Urology, Vienna, Austria, ⁷IRYCIS Universidad de Alcalá, Dept. of Urology, Madrid, Spain, ⁸Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ⁹Sapienza University of Rome, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ¹⁰University of Milan, Clinical Sciences and Community Health, Milan, Italy, ¹¹Claude Huriez Hospital, Dept. of Urology, Lille, France, ¹²IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ¹³University of Florence, Dept. of Urology, Florence, Italy, ¹⁴APHM North Academic Hospital, Dept. of Urology, Marseille, France, ¹⁵UROSUD, La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France

Study Group

EAU-YAU Urothelial Working Group and Ureteroscopic Treatment of upper tract Urothelial Carcinoma (UTUC) registry(Barcelona, Spain)

15:55 - 16:30

Radical surgery for upper tract urothelial carcinoma

A0570

Predictable Patterns of Lymph Node Metastasis in Upper Tract Urothelial Carcinoma: Implications for Surgical Planning

Authors

Lei Z., [Jianjun Y.](#), Qiang W., Bao Y.

Institutions

West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China

A0571

The Impact of Surgical Approach on the Performance of Adequate Lymph Node Dissection During Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma: Results From a Large Multicenter International Cohort

Authors

[Bosio A.](#), Fertitta G., Polonio L., Dutto D., Livoti S., Rosazza M., Colucci F., Fiameni C., Soria F., Gontero P.

Institutions

Ospedale San Giovanni Battista - Molinette, Dept. of Urology, Turin, Italy

Transperitoneal versus Retroperitoneal Single Port Robotic Nephroureterectomy: Multi-Institutional Comparison Analysis from the Single Port Advanced Research Consortium (SPARC).

Authors

Lavagno F.¹, Soputro N.A.², Fankhauser C.³, Contieri R.⁴, Ingrassano S.¹, Deghanmanshadi A.⁵, Considine J.⁶, Moran M.⁷, Kaufman E.³, Sauer-Calvo R.⁸, Daher K.², Zhu A.⁹, Nix J.W.⁵, Mehrazin R.⁹, Ghodoussipour S.⁷, Abdollah F.⁶, Rogers C.⁶, Silvani C.⁶, Santangelo A.⁶, Perdona S.⁴, Elsamra S.⁷, Rais-Bahrami S.⁵, Kaouk J.², Mattei A.³, Crivellaro S.⁸, Autorino R.², Gontero P.¹

Institutions

Atrium Health Wake Forest Baptist Urology, Winston-Salem, United States of America, RUSH University Medical Center Chicago, Dept. of Urology, Chicago, United States of America, ¹Ospedale Molinette, University of Turin, Division of Urology, Dept. of Surgical Sciences, Turin, Italy, ²Glickman Urological Institute, Cleveland Clinic, Cleveland, United States of America, ³Lucerne Cantonal Hospital, Lucerne, Switzerland, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, ⁵University of Alabama at Birmingham (UAB), Birmingham, United States of America, ⁶Henry Ford Health System, Detroit, United States of America, ⁷Robert Wood Johnson University Hospital, New Brunswick, United States of America, ⁸University of Illinois at Chicago (UIC), Chicago, United States of America, ⁹Mount Sinai Hospital, New York, United States of America

Comparative Performance of EUA and AUA Risk Stratification Models and Development of an Integrated Model for Predicting \geq T2 Upper Tract Urothelial Carcinoma: A ROBUUST Analysis

Authors

Musso G.¹, Autorino R.², Meagher M.F.¹, Wu Z.³, Simone G.⁴, Ferro M.⁵, Sundaram C.⁶, Ghodoussipour S.⁷, Yoshida T.⁸, Porter J.⁹, Lee R.¹⁰, Minervini A.¹¹, Porpiglia F.¹², Liss M.¹, Contieri R.¹³, Perdonà S.¹³, Gonzalgo M.¹⁴, Margulis V.¹⁵, Abdollah F.¹⁶, Antonelli A.¹⁷, Rais-Bahrami S.¹⁸, Djaladat H.¹⁹, Mehrazin A.²⁰, Derweesh I.²¹

Institutions

¹University of California San Diego School of Medicine, Dept. of Urology, La Jolla, United States of America, ²Cleveland Clinic, Glickman Urological Institute, Cleveland, United States of America, ³Changhai Hospital, Naval Medical University, Dept. of Urology, Shanghai, China, ⁴IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ⁵University of Milan, ASST Santi Paolo e Carlo, Dept. of Urology, Dept. of Health Science, Milan, Italy, ⁶Indiana University, Dept. of Urology, Indianapolis, United States of America, ⁷Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, Section of Urologic Oncology, New Brunswick, United States of America, ⁸Kansai Medical University, Dept. of Urology and Andrology, Osaka, Japan, ⁹Swedish Medical Center and Providence St. Joseph Health, Swedish Urology Group, Seattle, United States of America, ¹⁰Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ¹¹Careggi Hospital, Dept. of Experimental and Clinical Medicine, University of Florence-Unit of Oncologic Minimally Invasive Urology and Andrology, Florence, Italy, ¹²Candiolo Cancer Institute, FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ¹³Istituto Nazionale Tumori Di Napoli, IRCCS Fondazione G. Pascale, Dept. of Urology, Naples, Italy, ¹⁴University of Miami Miller School of Medicine, Desai Sethi Urology Institute, Miami, United States of America, ¹⁵UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ¹⁶Henry Ford Health System, Vattikuti Urology Institute, Detroit, United States of America, ¹⁷Azienda Ospedaliera Universitaria Integrata Verona (AOUI), Unit of Urology, Verona, Italy, ¹⁸University of Alabama at Birmingham Heersink School of Medicine, Dept. of Urology, Birmingham, United States of America, ¹⁹Norris Cancer Center, University of Southern California, Institute of Urology, Los Angeles, United States of America, ²⁰Icahn School of Medicine at Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ²¹RUSH-MD Anderson Cancer Center, Dept. of Urology, Chicago, United States of America

Prognostic value of histological subtypes in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from the ROBUUST database

Authors

Contieri R.¹, Spena G.¹, Izzo A.¹, Derweesh I.H.², Wu Z.³, Singla N.⁴, Djaladat H.⁵, Lee R.⁶, Margulis V.⁷, Antonelli A.⁸, Simone G.⁹, Minervini A.¹⁰, Abdollah F.¹¹, Yoshida T.¹², Shiota M.¹³, Sundaram C.P.¹⁴, Gonzalgo M.L.¹⁵, Ferro M.¹⁶, Rais-Bahrami S.¹⁷, Porpiglia F.¹⁸, Mehrazin R.¹⁹, Ghodoussipour S.²⁰, Perdonà S.¹, Autorino R.²¹

Institutions

¹IRCCS Istituto Nazionale Tumori Fondazione G. Pascale, Dept. of Urology, Naples, Italy, ²Rush University, Dept. of Urology, Chicago, United States of America, ³Changhai Hospital, Naval Medical University, Dept. of Urology, Shanghai, China, ⁴Brady Urological Institute, Johns Hopkins University School of Medicine, Dept. of Urology and Oncology, Baltimore, United States of America, ⁵Norris Cancer Center, University of Southern California, Institute of Urology, Los Angeles, United States of America, ⁶Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ⁷UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ⁸Azienda Ospedaliera Universitaria Integrata Verona (AOUI), Unit of Urology, Verona, Italy, ⁹IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹⁰University of Florence-Unit of Oncologic Minimally Invasive Urology and Andrology, Dept. of Experimental and Clinical Medicine, Florence, Italy, ¹¹Henry Ford Health System, Vattikuti Urology Institute, Detroit, United States of America, ¹²Kansai Medical University, Dept. of Urology and Andrology, Osaka, United States of America, ¹³Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan, ¹⁴Indiana University, Dept. of Urology, Indianapolis, United States of America, ¹⁵University of Miami Miller School of Medicine, Desai Sethi Urology Institute, Miami, United States of America, ¹⁶University of Milan, ASST Santi Paolo e Carlo, Dept. of Urology, Dept. of Health Science, Milan, Italy, ¹⁷University of Alabama at Birmingham Heersink School of Medicine, Dept. of Urology, Birmingham, United States of America, ¹⁸Candiolo Cancer Institute, FPO-IRCCS, Dept. of Surgery, Candiolo, Italy, ¹⁹Icahn School of Medicine at Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ²⁰Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, Section of Urologic Oncology, New Brunswick, United States of America, ²¹Cleveland Clinic, Glickman Urological Institute, Cleveland, United States of America

A0575

Nephroureterectomy for Upper Tract Urothelial Carcinoma Recurrence among Bladder Cancer Patients previously treated with Radical Cystectomy: An International Multicentre Propensity-Score Matched Analysis on Survival Outcomes

Authors

Del Giudice F.¹, Santarelli V.¹, Asero V.¹, Corvino R.¹, Nair R.², Abu-Ghanem Y.², Krajewski W.³, Mori K.⁴, Mertens L.⁵, Claps F.⁶, Moschini M.⁷, De Angelis M.⁷, Contieri R.⁸, Subiela J.D.⁹, Soria F.¹⁰, D'Andrea D.¹¹, Ślusarczyk A.¹², Pichler R.¹³, Laukhtina E.¹¹, Mayr R.¹⁴, Crocetto F.¹⁵, Simone G.¹⁶, Porreca A.¹⁷, Pradere B.¹⁸

Institutions

¹Sapienza University of Rome, Policlinico Umberto I Hospital, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ²Guy's and St. Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³University Center of Excellence in Urology Wroclaw Medical University, Dept. of Minimally Invasive and Robotic Urology, Wroclaw, Poland, ⁴The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁵The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁶Veneto Institute of Oncology IOV, Dept. of Urology, Padua, Italy, ⁷IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ⁸National Cancer Institute IRCCS Fondazione G. Pascale, Dept. of Urology, Naples, Italy, ⁹Universidad de Alcala, Hospital Universitario Ramon y Cajal, IRYCIS, Dept. of Urology, Alcala, Spain, ¹⁰University of Turin, Dept. of Surgical Sciences, Turin, Italy, ¹¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹²Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ¹³Medical University of Innsbruck, Dept. of Urology, Comprehensive Cancer Centre Innsbruck, Innsbruck, Germany, ¹⁴University of Regensburg, Dept. of Urology, St. Josef Medical Center,, Regensburg, Germany, ¹⁵University of Naples Federico II, Dept. of Neurosciences, Reproductive Sciences and Odontostomatology, Naples, Italy, ¹⁶IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹⁷Humanitas University, Dept. of Urology, Bergamo, Italy, ¹⁸La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France

A0576

Impact of atherosclerosis on acute kidney injury after radical cystectomy or nephroureterectomy

Authors

Ishii N.¹, Fujita N.¹, Tanaka T.¹, Hosogoe S.¹, Kato S.², Shinohara M.², Kawashima Y.², Tabata R.³, Sato S.², Hatakeyama S.¹

Institutions

¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Ageo Central General Hospital, Dept. of Urology, Ageo, Japan, ³Sano Kosei General Hospital, Dept. of Urology, Sano, Japan

16:30 - 17:00

Adjuvant strategies for upper tract urothelial carcinoma

A0577

Development and validation of DNA Methylation-Based machine-learning models to guide adjuvant therapy in nonmetastatic high risk upper tract urothelial carcinoma: A multicenter, bidirectional cohort study.

Authors

Fu S.¹, Guo B.², Xu C.¹, Hao H.¹, Zhou L.¹, Li X.¹

Institutions

¹Peking University first hospital, Dept. of Urology, Beijing, China, ²Chinese Academy of Sciences, Institute of Genomics, Beijing, China

A0578

Adjuvant Radiotherapy Combined Immunotherapy and Lymphovascular Invasion Associate With Better Disease-free Survival of Locally Progressive Upper Tract Urothelial Carcinoma

Authors

Xu C.¹, Li X.², Tang Q.¹, Lin J.¹, Zhou L.¹, Li X.¹

Institutions

¹Peking University First Hospital, Dept. of Urology, Beijing, China, ²Peking University First Hospital, Dept. of Radiation Oncology, Beijing, China

A0579

Efficacy and safety of disitamab vedotin (DV) combined with tislelizumab as adjuvant therapy after radical surgery for patients with HER2-expression upper tract urothelial carcinoma (UTUC): a prospective, controlled, phase II study

Authors

Tang J.L., Cheng Q., Feng Y., Lv Z.X., Guo B.Y., Zhang H.Y., Ai Q., Li S.C., Zhang Y., Zhang X., Li H.Z., Liangyou G.

Institutions

Chinese PLA General Hospital, Dept. of Urology, Beijing, China

A0580

Preliminary results of a phase II study to evaluate the efficacy and safety of disitamab vedotin (RC48-ADC) in combination with radiotherapy for adjuvant therapy in upper tract urothelial carcinoma

Authors

Tao Z.¹, Guo X.¹, Xu C.¹, Li X.², Tang Q.¹, Li X.¹

Institutions

¹Peking University First Hospital, Dept. of Urology, Beijing, China, ²Peking University First Hospital, Dept. of Radiotherapy, Beijing, China

A0581

Peritumoral tertiary lymphoid structures foster potent antitumor immunity and predict clinical outcomes in upper tract urothelial carcinoma

Authors

Huang Y., Tao Z., Li X., Zhang K.

Institutions

Peking University First Hospital, Dept. of Urology, Beijing, China

A0582

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma (CURATE-UTUC): A Multicenter Prospective Longitudinal Cohort Study

Authors

Huang J.¹, Ding Y.¹, Ng C.¹, Chen Q.¹, Wang X.¹, Kong W.¹, Shi W.², Ye L.², Bao Y.³, Pan J.¹, Xue W.¹

Institutions

¹Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of urology, Shanghai, China, ²LeapX Biotechnology (Suzhou) Inc., Suzhou, China, ³West China Hospital, Dept. of urology, Chengdu, China

Lymphadenectomy during radical prostatectomy: Predictive tools and comparative outcomes

Abstract Session 33

Sunday 15 March
15:30 - 17:00

Location Blue Area, George 3

Chairs F. Abdollah, Detroit (US)
P. Cathcart, London (GB)
R. Eapen, Melbourne (AU)

15:30 - 16:10

A0547

PSMA-PET-CT for assessment of lymph node invasion

Assessing the Risk of False Positive Findings of PSMA-PET in Nodal Staging in Patients Treated With Radical Prostatectomy and Extend Pelvic Lymph-Node Dissection

Authors

Barletta F.M.¹, Marra G.², Bianchi L.³, Zattoni F.⁴, Rajwa P.⁵, Van den Berg R.⁶, Kesch C.⁷, Gomez-Rivas J.⁸, Sigle A.⁹, Reitano G.⁴, Zhuang J.¹⁰, Soeterik T.⁶, Giesen A.¹¹, Murphy D.¹², Chiti A.¹³, Fankhauser C.¹⁴, Di Nardo N.¹⁴, Schiavina R.³, Porpiglia F.¹⁵, Heidegger I.¹⁶, Joniau S.¹¹, Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Città della Salute e della Scienza, University of Turin, Dept. of Urology, Turin, Italy, ³IRCCS Azienda Ospedaliero Universitaria di Bologna, Division of Urology, Bologna, Italy, ⁴University of Padua, Dept. of Surgery, Oncology and Gastroenterology, Padua, Italy, ⁵Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁶St. Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ⁷Essen University Hospital, Dept. of Urology, Essen, Germany, ⁸Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ⁹Freiburg University Hospital, Dept. of Urology, Freiburg, Germany, ¹⁰Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Dept. of Urology, Jiangsu, China, ¹¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹²Peter MacCallum Cancer Centre, Division of Cancer Surgery, Melbourne, Australia, ¹³IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, ¹⁴University of Lucerne, University Teaching and Research Hospital of the University of Lucerne; University of Zurich, Faculty of Health Sciences and Medicine, Dept. of Urology, Lucerne, Switzerland, ¹⁵School of Medicine, San Luigi Hospital, University of Turin, Division of Urology, Dept. of Oncology, Turin, Italy, ¹⁶University Hospital of Innsbruck, Dept. of Urology, Innsbruck, Austria

A0548

Assessing the Number Needed to Treat for an Extended Pelvic Lymph Node Dissection in PSMA-PET Negative Patients: Contextualizing MSKCC Trial Findings in The Molecular Imaging Era

Authors

Barletta F.M., Stabile A., Scuderi S., Scilipoti P., Longoni M., Quarta L., Zaurito P., Viti A., Santangelo A., Cosenza A., Montorsi F., Gandaglia G., Briganti A.

Institutions

Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy

Pelvic Lymph Node Dissection Can Be Omitted in PSMA-PET/CT–Negative Prostate Cancer: Evidence from a Multicenter Study

Authors

Zattoni F.¹, Reitano G.¹, Preisser F.², Rajwa P.³, Taimur S.⁴, Barletta F.⁵, Checcucci E.⁶, Amparore D.⁶, Nicoletti R.⁷, Russo G.I.⁸, Crocetto F.⁹, Zhuang J.¹⁰, Scheltema M.¹¹, Teoh J.Y.C.¹², Bauckneht M.¹³, Sengupta S.¹⁴, Vasdev N.¹⁵, Karnes G.R.¹⁶, Gontero P.¹⁷, Novara G.¹, Dal Moro F.¹, Soeterik T.F.W.¹⁸, Gandaglia G.⁵, Marra G.¹⁷

Institutions

¹University of Padua, Dept. of Surgery Oncology and Gastroenterology, Padua, Italy, ²Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Dept. of Urology, Hamburg, Germany, ³Comprehensive Cancer Center, Medical University of Vienna, Vienna, Dept. of Urology, Vienna, Austria, ⁴Imperial College London, Dept. of Urology, London, United Kingdom, ⁵Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Unit of Urology, Division of Oncology, Milan, Italy, ⁶Candiolo Cancer Institute, FPO-IRCCS, Dept. of Surgery, Turin, Italy, ⁷University of Florence, Dept. of Experimental and Clinical Biomedical Science, Florence, Italy, ⁸University of Catania, Dept. of Urology, Catania, Italy, ⁹Federico II University Hospital, Dept. of Neurosciences, Reproductive Sciences and Odontomatology, Naples, Italy, ¹⁰Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Dept. of Urology, Nanjing, China, ¹¹St. Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ¹²The Chinese University of Hong Kong, S.H. Ho Urology Centre, Dept. of Surgery, Faculty of Medicine, Hong Kong, China, ¹³IRCCS Ospedale Policlinico San Martino, Dept. of Urology, Genoa, Italy, ¹⁴Eastern Health Clinical School, Monash University, Dept. of Urology, Box Hill, Australia, ¹⁵Hertfordshire Medical School, University of Hertfordshire, Dept. of Urology, Hertfordshire, United Kingdom, ¹⁶Mayo Clinic, Dept. of Urology, Rochester, United States of America, ¹⁷Molinette Hospital, University of Turin, Division of Urology, Dept. of Surgical Sciences, Turin, Italy, ¹⁸University Medical Center Utrecht, Dept. of Radiation Oncology, Utrecht, The Netherlands

Impact of Negative PSMA PET on the Decision to Perform a Pelvic Lymph Node Dissection during Radical Prostatectomy for Intermediate to High-Risk Prostate Cancer Patients. Results of an International Survey

Authors

Zattoni F.¹, Pawel R.², Kasivisvanathan V.³, Rodriguez Sanchez L.⁴, Fazekas T.S.⁵, Preisser F.⁶, Kesch C.⁷, Martini A.⁸, Reitano G.¹, Sigle A.⁹, Olivier J.¹⁰, Nicoletti R.¹¹, Bernardino R.¹², Heidegger I.¹³, Bianchi L.¹⁴, Bauckneht M.¹⁵, Giese A.¹⁶, Soeterik T.¹⁷, van den Bergh R.¹⁸, Rivas J.G.¹⁹, Dal Moro F.¹, Russo G.I.²⁰, Gandaglia G.²¹, Marra G.²²

Institutions

¹University of Padova, Dept. of Surgery Oncology and Gastroenterology, Padua, Italy, ²Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³University College London, Centre for Urology Imaging, Prostate, AI and Surgical Studies (COMPASS) Research Group, Division of Surgery and Interventional Science, London, United Kingdom, ⁴Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, ⁵Semmelweis University, Dept. of Urology, Vienna, Austria, ⁶Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Dept. of Urology, Hamburg, Germany, ⁷University Hospital Essen, Dept. of Urology, Essen, Germany, ⁸MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁹Faculty of Medicine, Medical Centre, University of Freiburg, Dept. of Urology, Freiburg, Germany, ¹⁰Claude Huriez Hospital, CHU Lille, Dept. of Urology, Lille, France, ¹¹Careggi Hospital, University of Florence, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ¹²Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ¹³Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria, ¹⁴IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Dept. of Urology, Bologna, Italy, ¹⁵IRCCS Ospedale Policlinico San Martino, Dept. of Urology, Genoa, Italy, ¹⁶UZ Leuven, Dept. of Urology, Leuven, Belgium, ¹⁷University Medical Center Utrecht, Dept. of Radiation Oncology, Utrecht, The Netherlands, ¹⁸Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ¹⁹Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ²⁰University of Catania, Dept. of Urology, Catania, Italy, ²¹Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Unit of Urology, Division of Oncology, Milan, Italy, ²²University Hospital S Giovanni Battista, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Dept. of Urology, Turin, Italy

Diagnostic accuracy of preoperative PSMA PET/CT for nodal staging in patients undergoing radical prostatectomy and extended lymph node dissection (ePLND)

Authors

Piccolini A.¹, Finocchiaro A.¹, Dagnino F.¹, Tallari A.¹, Tiscione M.¹, Mallia V.¹, Trovato R.¹, Canneto R.¹, Aljoulani M.¹, Avolio P.P.¹, Paciotti M.¹, Fasulo V.¹, Saita A.¹, Lazzeri M.², Hurle R.², Casale P.², Buffi N.M.¹, Lughezzani G.¹

Institutions

¹Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ²IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy

Impact of PSMA-PET on pelvic lymph node dissection trends in Australia: national compared with insights from the largest single-centre cohort in Australia

Authors

Yang J.¹, Le A.², Arianayagam M.¹, Canagasingham B.¹, Jeffery N.¹, Khadra M.¹, Ko R.¹, Varol C.¹, Mehan N.¹, Nalavenkata S.¹, Thangasamy I.¹, Kam J.¹, Myint M.¹

Institutions

¹Nepean Blue Mountains Local Health District, Dept. of Urology, Sydney, Australia, ²University of Sydney, Medicine School, Sydney, Australia

Recurrence Patterns in PSMA-Negative Prostate Cancer with High preoperative Lymph Node Invasion Risk: Comparing Outcomes with and without Pelvic Lymph Node Dissection

Authors

Zattoni F.¹, Reitano G.¹, Preisser F.², Taimur S.³, Barletta F.⁴, Amparore D.⁵, Checcucci E.⁵, Campobasso D.⁶, Nicoletti R.⁷, Russo G.I.⁸, Crocetto F.⁹, Del Giudice F.¹⁰, Zhuang J.¹¹, Sweere V.¹², Scheltema M.¹³, Teoh J.Y.C.¹⁴, Leung S.¹⁴, Bauckneht M.¹⁵, Page F.¹⁶, Sengupta S.¹⁶, Dal Moro F.¹, Karnes J.R.¹⁷, Vasdev N.¹⁶, Marra G.¹⁸

Institutions

¹Urology Clinic University of Padua, Dept. of Urology, Padua, Italy, ²Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Dept. of Urology, Hamburg, Germany, ³Imperial College, Dept. of Urology, London, United Kingdom, ⁴Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Unit of Urology/Division of Oncology, Milan, Italy, ⁵Candiolo Cancer Institute, FPO-IRCCS, Dept. of Surgery, Turin, Italy, ⁶University Hospital of Parma, Dept. of Urology, Parma, Italy, ⁷Careggi Hospital, University of Florence, Dept. of Urology, Unit of Urological Robotic Surgery and Renal Transplantation, Florence, Italy, ⁸University of Catania, Dept. of Urology, Catania, Italy, ⁹Federico II University Hospital, Dept. of Neurosciences, Reproductive Sciences and Odontomatology, Naples, Italy, ¹⁰Sapienza University of Rome, Umberto I Hospital, Dept. of Maternal-Infant and Urological Sciences, Rome, Italy, ¹¹Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Dept. of Urology, Nanjing, China, ¹²St. Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ¹³St. Vincent's Prostate Cancer Research Centre, Dept. of Urology, Sydney, Australia, ¹⁴S.H. Ho Urology Centre, Faculty of Medicine, Dept. of Surgery, Hong Kong, China, ¹⁵IRCCS Ospedale Policlinico San Martino, Dept. of Urology, Genoa, Italy, ¹⁶Eastern Health Clinical School, Monash University, Dept. of Urology, Box Hill, Australia, ¹⁷Mayo Clinic, Dept. of Urology, Rochester, United States of America, ¹⁸Molinette Hospital, University of Turin, Division of Urology, Dept. of Surgical Sciences, Turin, Italy

Identifying Candidates for Radical Prostatectomy and Extended Pelvic Lymph Node Dissection among Prostate Cancer Patients with PSMA-PET-Detected Nodal Disease (miN1): The Combined Role of MRI Staging and Quantitative PSMA Parameters

Authors

Scuderi S.L.A.¹, Marra G.², Bianchi L.³, Zattoni F.⁴, Rajwa P.⁵, Van den Bergh R.⁶, Kesch C.⁷, Gomez-Rivas J.⁸, Sigle A.⁹, Zhuang J.¹⁰, Soeterik T.⁶, Chiti A.¹¹, Mattei A.¹², Fiori C.¹³, Schiavina R.³, Dal Moro F.⁴, Fendler W.¹⁴, Heidegger I.¹⁵, Joniau S.¹⁶, Montorsi F.¹, Briganti A.¹, Gandaglia G.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Città della Salute e della Scienza, University of Turin, Dept. of Urology, Turin, Italy, ³IRCCS Azienda Ospedaliero Universitaria di Bologna, Division of Urology, Bologna, Italy, ⁴University of Padua, Dept. of Surgery, Oncology and Gastroenterology, Padua, Italy, ⁵Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁶St. Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ⁷Essen University Hospital, Dept. of Urology, Essen, Germany, ⁸Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ⁹Freiburg University Hospital, Dept. of Urology, Freiburg, Germany, ¹⁰Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Dept. of Urology, Jiangsu, China, ¹¹IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, ¹²Klinik für Urologie, Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ¹³School of Medicine, San Luigi Hospital, University of Turin, Division of Urology, Dept. of Oncology, Turin, Italy, ¹⁴Essen University Hospital, Dept. of Nuclear Medicine, Essen, Germany, ¹⁵University Hospital of Innsbruck, Dept. of Urology, Innsbruck, Austria, ¹⁶University Hospitals Leuven, Dept. of Urology, Leuven, Belgium

16:10 - 16:45

Nomograms predicting lymph node invasion

A0555

Multicentre validation of the 2019 Briganti nomogram: one threshold does not fit all

Authors

Peyrottes A.¹, Orhac F.², Colau A.³, Pattou M.⁴, Neuzillet Y.⁴, Taha F.⁵, Larré S.⁵, Desgrandchamps F.¹, Mongiat-Artus P.¹, Allory Y.⁶, Masson-Lecomte A.¹

Institutions

¹Saint-Louis Hospital, Dept. of Urology, Paris, France, ²Institut Curie, Laboratoire d'Imagerie Translationnelle en Oncologie, Inserm U1288, Paris, France, ³La Croix Saint Simon, Dept. of Urology, Paris, France, ⁴Foch Hospital, Dept. of Urology, Paris, France, ⁵Reims University Hospital, Dept. of Urology, Reims, France, ⁶Institut Curie, Dept. of Pathology, Saint-Cloud, France

A0556

Predicting lymph node invasion risk according to Briganti nomogram 2019 using unilateral biopsy scheme. A retrospective multicenter study.

Authors

Chernysheva D.¹, Avesani G.², Di Bello F.³, Longo N.³, Malevich S.⁴, Jourdan M.⁵, Breda A.¹, Palou Redorta J.¹, Baboudjian M.⁵, Sanguedolce F.¹

Institutions

¹Fundació Puigvert, Dept. of Oncologic Urology, Barcelona, Spain, ²San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ³University of Naples Federico II, Dept. of Urology, Naples, Italy, ⁴St Luca's City Hospital, Dept. of Urology, Saint Petersburg, Russia, ⁵Aix-Marseille University & Assistance Publique-Hôpitaux de Marseille (AP-HM), Dept. of Urology, Marseille, France

A0557

Comparative study of four predictive nomograms for the indication of lymph node dissection in prostate cancer

Authors

Iedeuil V.¹, Peyrottes A.², Colau A.², Kissel A.¹, Larre S.¹, Taha F.¹

Institutions

¹Reims University Hospital, Dept. of Urology, Reims, France, ²Saint-Louis Hospital, Dept. of Urology, Paris, France

A0558

Incorporating PSMA PET/CT Parameters into Clinicopathologic Nomograms for Predicting Lymph Node Involvement in Intermediate- and High-Risk Prostate Cancer

Authors

Ahmed M.¹, Li E.¹, Vasdev R.¹, Ahmed E.¹, Dizdar N.², Rhodes L.¹, Kurata Y.², Kido A.², Takahashi N.², Gettman M.¹, Takahashi H.², Karnes R.J.¹

Institutions

¹Mayo Clinic, Dept. of Urology, Rochester, United States of America, ²Mayo Clinic, Dept. of Radiology, Rochester, United States of America

A0559

Nomogram-Guided Omission of Pelvic Lymph Node Dissection at Robotic Radical Prostatectomy: What Are We Really Missing?

Authors

Anceschi U., Basile S., Flammia R.S., D'Annunzio S., Brassetti A., Proietti F., Bologna E., Chiacchio G., Misuraca L., Bove A.M., Licari L.C., Tuderti G., Mastroianni R., Nardi M., Spadaro G., Ferriero M., Prata F., Guaglianone S., Leonardo C., Simone G.

Institutions

IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy

A0560

Evaluation of new cut-off values for nerve-sparing radical prostatectomy and lymphadenectomy based on a prospective external validation of the MSKCC and Martini nomograms

Authors

Bierlein J.¹, Nothhof D.¹, Hollerung J.¹, Frey L.J.¹, Rölz N.¹, Jost L.M.¹, Haack M.¹, Tsaour I.², Kamal M.M.¹, Mager R.¹, Brandt M.P.¹, Haferkamp A.¹, Höfner T.³, Duwe G.¹

Institutions

¹University Medical Center of the Johannes Gutenberg-University Mainz, Dept. of Urology and Pediatric Urology, Mainz, Germany, ²University Hospital and Faculty of Medicine Eberhard Karls University Tuebingen, Dept. of Urology, Tübingen, Germany, ³Ordensklinikum Linz Elisabethinen, Dept. of Urology, Linz, Austria

A0561

Stress-Testing PLND Nomograms against Adverse Pathology after Robotic Radical Prostatectomy: results from a 5-year tertiary-centre series

Authors

Anceschi U., Basile S., Prata F., Flammia R.S., Licari L.C., Bologna E., Proietti F., Iori M., Nardi M., Spadaro G., D'Annunzio S., Brassetti A., Ferriero M., Tuderti G., Mastroianni R., Misuraca L., Bove A.M., Guaglianone S., Leonardo C., Simone G.

Institutions

IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy

16:45 - 17:00

Complications

A0562

Comparative Perioperative Outcomes of Extended Versus Limited Pelvic Lymph Node Dissection in Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer: A Phase III Randomized Trial

Authors

[Ruggeri M.](#), Cordeiro M., Coelho R., Guglielmetti G., Pontes J., Nahas W., Lestingi J.

Institutions

University of Sao Paulo, Dept. of Uro-Oncology, São Paulo, Brazil

A0563

The Impact of the Peritoneal Flap on Lymphocele Formation Following Robotic Assisted Radical Prostatectomy with Pelvic Lymph Node Dissection: A Systematic Review and Meta-analysis

Authors

Yildiz H.¹, [Adhoni M.Z.U.](#)², Byrnes K.², Lamb B.³, I. Lee D.⁴, Shahait M.⁴

Institutions

¹Darent Valley Hospital, Dept. of Urology, Dartford, United Kingdom, ²Royal London Hospital, Dept. of Urology, London, United Kingdom, ³Queen Mary University of London, London, United Kingdom, ⁴University of California Irvine, Dept. of Urology, Irvine, United States of America

A0564

Evaluation of the frequency of postoperative lymphatic complications after robot-assisted radical prostatectomy and pelvic lymph node dissection using radioguided surgery

Authors

[Trishkin M.](#), Shpot' E., Chinenov D., Chernov Y., Votyakov A., Kurepta I., Smirnova E., Hizriev H., Astakhova X.

Institutions

Institute of Urology and Human Reproductive Health I.M. Sechenov First Moscow State Medical University, Dept. of Oncourology, Moscow, Russia

EAU Lab: Molecular diagnostics, biomarkers & AI

Abstract Session 35

Sunday 15 March
15:30 - 17:00

Location

Blue Area, Victoria 4

Chairs

R.T. Bryan, Birmingham (GB)

B. Kiemeney, Nijmegen (NL)

To be confirmed

15:30 - 16:15

Urothelial cancer

A0583

Urinary TERT Promoter Mutations as a Non-Invasive Biomarker for Early Detection of Bladder Cancer Recurrence and Progression

Authors

Avogbe H.P.¹, Domingues A.¹, Forey N.¹, Vian E.², Manel A.³, Abedi-Ardekani B.¹, Hosen M.I.⁴, Sheikh M.¹, Le Calvez-Kelm F.¹

Institutions

¹International Agency for Research on Cancer, Dept. of Genomic Epidemiology, Lyon, France, ²Protestant Clinic of Lyon, Dept. of Urology, Caluire-et-Cuire, France, ³Le Creusot Hospital, Dept. of Urology, Le Creusot, France, ⁴University of Dhaka, Faculty of Biological Sciences, Dhaka, Bangladesh

A0584

Early detection of treatment failure and disease dissemination in BCG-treated NMIBC using liquid biopsies and urine proteomics

Authors

Strandgaard T.¹, Andreassen T.G.¹, Nordentoft I.¹, Fryd N.D.², Lamy P.³, Harrits J.P.¹, Oklander B.⁴, Afterman D.⁴, Ezov T.K.⁴, Bourzgui I.⁴, Jakobsen J.⁵, Juul K.⁵, Jensen J.B.¹, Dyrskjøt L.¹

Institutions

¹Aarhus University, Dept. of Clinical Medicine, Aarhus, Denmark, ²Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ³Aarhus University Hospital, Dept. of Molecular Medicine, Aarhus, Denmark, ⁴Veracyte, Haifa, Israel, ⁵Ferring Pharmaceuticals, A/S, Kastrup, Denmark

A0585

BlaDimiR and BlaDimiRplus: Clinically validated urine-based assays for diagnosis, monitoring, and immunotherapy response prediction in bladder cancer

Authors

Guerrero-Ramos F.¹, Gómez-Canizo C.¹, Hernández-Arroyo M.¹, Garrido J.¹, Yang F.¹, Castellano D.², Suárez-Cabrera C.³, Martín-Bernardo A.³, Montesino E.³, Arévalo I.³, Rubio C.³, García L.³, Belda L.³, Paramio J.³, Rodríguez-Antolín A.¹, Duenas M.³

Institutions

¹Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ²Hospital Universitario 12 de Octubre, Dept. of Medical Oncology, Madrid, Spain, ³CIEMAT, FIB Hospital 12 de Octubre, Madrid, Spain

A0586

Circulating Tumor DNA Detection and Dynamics Predict Early Response to Neoadjuvant Immunotherapy and Survival in Muscle-Invasive Bladder Cancer – An Exploratory Analysis in the AURA Trial.

Authors

Blanc J.¹, Venet D.², Martinez Chanza N.¹, Carnot A.³, Barthélémy P.⁴, Awada A.⁵, Sotiriou C.², Rothé F.²

Institutions

¹Jules Bordet Institute, Dept. of Medical Oncology, Brussels, Belgium, ²Jules Bordet Institute, Breast Cancer Translational Research Laboratory, Brussels, Belgium, ³Centre Oscar Lambret, Dept. of Medical Oncology, Lille, France, ⁴Hôpitaux Universitaires de Strasbourg, Dept. of Medical Oncology, Strasbourg, France, ⁵Cancer CHIREC Institute, Dept. of Medical Oncology, Brussels, Belgium

A0587

Non-luminal molecular subtypes demonstrate highest complete response rates after neoadjuvant chemo-immune therapy for Muscle-invasive Bladder Cancer: Biomarker Analyses of NURE-combo & BLASST-01 phase 2 clinical trials

Authors

De Jong J.J.¹, Mercinelli C.², Basile G.³, Proudfoot J.⁴, Cigliola A.³, Tateo V.², Maiorano B.², Davicioni E.⁵, Colecchia M.⁶, Moschini M.³, Brembilla G.⁶, De Cobelli F.⁷, Briganti A.³, Montorsi F.³, Gupta S.⁸, Necchi A.²

Institutions

¹Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²IRCCS Ospedale San Raffaele, Dept. of Medical Oncology, Milan, Italy, ³Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁴Veracyte Inc., Dept. of Biostatistics, San Diego, United States of America, ⁵Veracyte Inc., Dept. of Urology, San Diego, United States of America, ⁶IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy, ⁷IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy, ⁸Cleveland Clinic, Dept. of Medical Oncology, Cleveland, United States of America

A0588

Application of transcriptomic bladder-cancer subtypes to upper-tract urothelial carcinoma (UTUC) across international cohorts reveals racial differences and translational limitations

Authors

Scurll J.M.¹, Bahlburg H.¹, Heard J.², Phung T.A.T.¹, Hashimoto M.³, Fujita K.³, Luthringer D.⁴, Sakatani T.⁵, Murakami K.⁵, Rosser C.J.², Gibb E.A.¹, Black P.C.¹, Furuya H.⁶

Institutions

¹Vancouver Prostate Centre, University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ²Cedars-Sinai Medical Center, Dept. of Urology, Los Angeles, United States of America, ³Kindai University, Dept. of Urology, Osaka, Japan, ⁴Cedars-Sinai Medical Center, Dept. of Pathology, Los Angeles, United States of America, ⁵Cedars-Sinai Medical Center, Samuel Oschin Cancer Center, Los Angeles, United States of America, ⁶Cedars-Sinai Medical Center, Dept. of Biomedical Sciences, Los Angeles, United States of America

A0589

Establishment and Multidimensional Validation of a Rapid Drug Screening Platform Using a Patient-Derived Zebrafish Xenograft Model of Upper Tract Urothelial Carcinoma

Authors

Long X., Wang Y., Huang Y., Wen Z., Sha H., Huang T., Gu D.

Institutions

The First Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Guangzhou, China

A0590

Development and validation of a DNA methylation risk score system for prognosis stratification in urothelial carcinoma

Authors

Fu S.¹, Guo B.², Xu C.¹, Hao H.¹, Zhou L.¹, Li X.¹

Institutions

¹Peking University First Hospital, Dept. of Urology, Beijing, China, ²Chinese Academy of Sciences, Institute of Genomics, Beijing, China

Longitudinal assessment of urine tumor DNA in high-risk non-muscle invasive bladder cancer patients

Authors

Catto J.W.F.¹, Daneshmand S.², Zaucha R.³, Tran B.⁴, Master V.⁵, Lotan Y.⁶, Pignot G.⁷, Tubaro A.⁸, Shimizu N.⁹, Vasdev N.¹⁰, Lee E.K.¹¹, Procopio G.¹², Galanternik F.¹³, Fischer D.S.¹⁴, Levin T.G.¹⁴, Zhang J.¹⁵, Thomas S.¹⁶, Stone N.¹⁶, Triantos S.¹⁶, Beeharry N.¹⁶

Institutions

¹School of Medicine and Population Health University of Sheffield, Division of Clinical Medicine, Sheffield, United Kingdom, ²University of Southern California, Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ³Faculty of Medicine, Medical University of Gdańsk, Dept. of Clinical Oncology and Radiotherapy, Gdańsk, Poland, ⁴Peter MacCallum Cancer Centre, Dept. of Oncology, Melbourne, Australia, ⁵Emory University, Dept. of Urology, Atlanta, United States of America, ⁶UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ⁷Institut Paoli-Calmettes, Dept. of Surgical Oncology 2, Marseille, France, ⁸Sant'Andrea Hospital, Dept. of Urology, Rome, Italy, ⁹Gunma Prefectural Cancer Center, Dept. of Urology, Gunma, Japan, ¹⁰Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, East and North Herts NHS Trust, Stevenage; School of Life and Medical Sciences, University of Hertford, Dept. of Urology, Hatfield, United Kingdom, ¹¹University of Kansas Health System, Dept. of Urology, Kansas City, United States of America, ¹²Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Dept. of Medical Oncology, Milan, Italy, ¹³Centro de Educación Médica e Investigaciones Clínicas, Clinical Oncology Service, Buenos Aires, Argentina, ¹⁴Convergent Genomics, Dept. of Research and Development, San Francisco, United States of America, ¹⁵Johnson & Johnson, Dept. of Research & Development, Cambridge, United States of America, ¹⁶Johnson & Johnson, Dept. of Research & Development, Spring House, United States of America

16:15 - 16:30

Renal cancer

A0592

Preoperative Circulating Tumor DNA Reflects Tumor Biology and Risk Stratification in Localized Clear Cell Renal Cell Carcinoma

Authors

Eraky A., Ben David R., Zhu A., Mandel A., Mehrazin R., Sfakianos J.P.

Institutions

Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America

A0593

A prospective diagnostic cohort study of longitudinal plasma ctDNA based tumor-informed MRD detection for recurrence monitoring in nonmetastatic ccRCC

Authors

Wu Z.¹, Dabestani S.², Gan X.³, Chen Q.⁴, Shi W.⁵, Jiang W.³, Ding J.³, Wang L.³

Institutions

¹Shanghai Changhai Hospital Affiliated to Naval Medical University, EAU Young Academic Urologists Renal Cancer Working Group, Dept. of Urology, Shanghai, China, ²Kristianstad Central Hospital, Dept. of Urology, Kristianstad, Sweden, ³Shanghai Changhai Hospital Affiliated to Naval Medical University, Dept. of Urology, Shanghai, China, ⁴Naval Medical University, Health Statistics, Shanghai, China, ⁵LeapX Biotechnology (Suzhou) Inc, Dept. of Biotechnology, Suzhou, China

A0594

Drug-Testing in Patient-Derived Renal Cell Carcinoma Organoids Reveals Pathways of Vulnerability and Resistance

Authors

Steven M.¹, Nallandhighal S.¹, Triner D.¹, Duan Z.¹, Knuth Z.¹, Abusamra S.¹, Dhanasekaran S.M.², Udager A.M.³, Cotta B.H.⁴, Su F.², Madhi H.⁵, Kikuchi H.¹, Hafez K.¹, Singhal U.¹, Kaffenberger S.¹, Nagrath S.⁵, Chinnaiyan A.¹, Morgan T.¹, Zaslavsky A.¹, Palapattu G.¹, Vaishampayan U.⁵, Merrill N.⁵, Salami S.¹

Institutions

¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Michigan Center of Translational Pathology, Ann Arbor, United States of America, ³University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, ⁴The University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁵University of Michigan, Rogel Cancer Center, Ann Arbor, United States of America

16:30 - 17:00

Prostate cancer

A0595

Early Metabolic Biomarker Changes with GnRH Agonist versus Antagonist Therapy in Prostate Cancer: Results from a Single Centre Prospective Study

Authors

Viti A., Stabile A., Cucchiara V., Scilipoti P., Santangelo A., Cosenza A., Brancaccio M., Galdieri A., Occhi A., Porzi M.E., Finocchio N., Castello Serrano I., Ben Ayed R., Ferrara A.M., Salonia A., Montorsi F., Gandaglia G., Briganti A.

Institutions

Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy

A0596

Circulating CD44⁺/CD133⁺ Cancer Stem Cell Signatures as Liquid Biopsy Biomarkers in Castration-Resistant Metastatic Prostate Cancer (CRPC)

Authors

Verma P.

Institutions

Sanjay Gandhi Postgraduate Institute of Medical Science, Dept. of Urology and Renal Transplantation, Lucknow, India

A0597

Application of a PSMA/STEAP1 Dual-Targeted Smart Liposomal Nanoplatfom Loaded with AIE-MNPs for Integrated Diagnosis and Therapy of Prostate Cancer

Authors

Jingyu X.¹, Sun J.¹, An Y.², Xiang J.¹

Institutions

¹Tongji Hospital, Dept. and Institute of Urology, Wuhan, China, ²The First People's Hospital of Yunnan Province, Dept. of Urology, Kunming, China

A0598

Comprehensive Genomic Landscape of Prostate Cancer and Clinical Outcomes of BRCA1/2 Pathogenic Variants in the Metastatic Castration-Resistant Setting

Authors

Urabe F.¹, Tashiro K.¹, Iida K.², Matsui Y.², Yoshihara K.¹, Matsuzaki J.², Kimura T.¹, Saito Y.²

Institutions

¹The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ²Keio University Faculty of Pharmacy, Division of Pharmacotherapeutics, Tokyo, Japan

A0599

Purinergic Signaling Modulation: A Novel Promising Therapeutic Strategy for Prostate Cancer

Authors

Viti A.¹, Stabile A.¹, Robesti D.¹, Quarta L.¹, Reale A.¹, Salonia A.¹, Ben Ayed R.¹, Castello Serrano I.¹, Tenace N.², Colecchia M.², Ponzoni M.², Doglioni C.², Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy

A0600

Impact of homologous recombination repair gene alterations on treatment and survival in metastatic castration-resistant prostate cancer

Authors

Mehra N.¹, Laskowska N.¹, van Lenthe S.¹, Luna-Velez V.M.², Bervoets S.³, Slootbeek P.H.J.¹

Institutions

¹Radboudumc, Dept. of Medical Oncology, Nijmegen, The Netherlands, ²Radboudumc, Dept. of Experiment Urology, Nijmegen, The Netherlands, ³Radboudumc, Radboudumc Technology Center Bioinformatics, Nijmegen, The Netherlands

Therapeutic strategies and surgical outcomes in prostate cancer and BPH

Abstract Session 36

Sunday 15 March
15:30 - 17:00

Location

Blue Area, Victoria 5

Chairs

S. Ahyai, Graz (AT)

S. Guillaumier, Dunfermline (GB)

To be confirmed

15:30 - 15:40

Early phase and minimal invasive treatments

A0601

A Phase 1 Safety, PK and Preliminary Efficacy Study of Localized Therapy using Enolen® (Enzalutamide) Implants for Early-Stage Prostate Cancer

Authors

Millan B.¹, Gurrarn S.¹, Turkbey B.¹, Citrin D.¹, Evans K.¹, Holcomb K.¹, Rairkar M.², Munster P.³, Pinto P.¹

Institutions

¹Nih, Dept. of Urologic Oncology, Bethesda, United States of America, ²Alessa Therapeutics, Dept. of R&D, San Carlos, United States of America, ³University of California, San Francisco, Dept. of Medicine, Division of Hematology and Oncology, San Francisco, United States of America

A0602

Patient Experience with Water Vapor Therapy for The Management of Prostate Cancer: The VAPOR 2 Study

Authors

George A.K.¹, Taneja S.²

Institutions

¹Johns Hopkins University, Dept. of Urology, Baltimore, United States of America, ²Northwell Health, Zucker School of Medicine, Dept. of Urology, New Hyde Park, United States of America

15:40 - 16:40

Radical treatment

A0603

PSMA Radioguided Surgery for Lymph Node Metastases Detection in Prostate Cancer Patients Undergoing RARP with ePLND: Final Results of a Prospective Phase 2 Study

Authors

Quarta L.¹, Zaurito P.¹, Scilipoti P.¹, Viti A.¹, Santangelo A.¹, Barletta F.¹, Scuderi S.¹, Cucchiara V.¹, Stabile A.¹, Dambrosio L.¹, De Cobelli F.², Esposito A.², Brembilla G.², Picchio M.³, Sollini M.³, Samanes Gajate A.M.³, Antunovic L.³, Pini C.³, Chiti A.³, Montorsi F.¹, Briganti A.¹, Gandaglia G.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy

A0604

A phase I/IIa, single-arm, open-label trial of DGPR1008 for intraoperative fluorescence imaging of prostate-specific membrane antigen-positive prostate cancer

Authors

Li S., Yang X., Niu H.

Institutions

The Affiliated Hospital of Qingdao University, Dept. of Urology, Qingdao, China

A0605

Dehydrated Human Amniotic Membrane for Early Return of Erectile Function After Robotic Radical Prostatectomy: A 10-Year Journey and Lessons Learned

Authors

Razdan S.¹, Fathollahi A.², Armache A.², Razdan S.³

Institutions

¹Miami Robotic Surgery, Dept. of Urology, Miami, United States of America, ²Palmetto General Hospital, Dept. of Urology, Miami, United States of America, ³International Robotic Institute for Prostate Cancer, Dept. of Urology, Miami, United States of America

A0606

Indications for robot-assisted laparoscopic radical prostatectomy based on postoperative urinary function

Authors

Onishi T., Suzuki S., Tabata Y., Masui S., Shibahara T.

Institutions

Ise Redcross Hospital, Dept. of Urology, Ise, Japan

A0607

Developing a Periprostatic Vascular Map to Optimize Nerve-Sparing for Robot-Assisted Radical Prostatectomy: Initial Report from a Prospective Feasibility Study

Authors

Khanmammadova N.¹, Wang J.¹, Cumpanas A.¹, Hanna K.¹, Gao A.¹, Chang P.², Ali S.¹, Lee D.¹

Institutions

¹University of California Irvine, Dept. of Urology, Irvine, United States of America,
²University of California Irvine, Dept. of Radiological Sciences, Irvine, United States of America

A0608

An Innovative AI System Combining Machine Learning and Generative AI for Tailored Surgical Planning and Outcome Forecasting in Robot-Assisted Radical Prostatectomy

Authors

Amparore D.¹, Checcucci E.¹, Manfredi M.², De Cillis S.T.², Piana A.², Piramide F.², Volpi G.¹, Sica M.¹, Alessio P.¹, Quarà A.², Cisero E.², Gatti C.², Sterrantino A.², Colombo M.², Garzena V.², Ferrando L.², Turcan A.², Liguori S.², Zevallos Florez C.S.², Fiori C.², Di Dio M.³, Porpiglia F.¹

Institutions

¹Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery Division of Urology, Candiolo, Italy, ²AOU San Luigi Gonzaga - University of Turin, Dept. of Urology, Orbassano, Italy, ³Annunziata Hospital, Dept. of Surgery Division of Urology, Cosenza, Italy

A0609

Anterior vs Posterior Robot-assisted radical prostatectomy: insights from 10 years follow-up of a randomized controlled trial

Authors

Santangelo A.¹, Silvani C.¹, Jeong W.¹, Considine J.¹, Salka B.¹, Gishto R.¹, Tinsley S.¹, Nazzani S.², Nicolai N.², Montanari E.³, Salonia A.⁴, Briganti A.⁴, Montorsi F.⁴, Rogers C.¹, Menon M.¹, Abdollah F.¹

Institutions

¹VUI Center for Outcomes Research Analysis and Evaluation Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy, ³Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ⁴IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy

A0610

Survivorship after curative treatment: Results of 20 years of follow-up from ERSPC Rotterdam

Authors

Remmers S., Nieboer D., Bangma C.H., Roobol M.J.

Institutions

Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands

Study Group

ERSPC Rotterdam Study Group(Rotterdam, The Netherlands)

A0611

Complications and Retreatment Rates of Radiation Therapy for Prostate Cancer compared to Radical Prostatectomy: A Real-Life, Nation-Wide Observational Study using the Epic Cosmos Collaborative Database

Authors

Santarelli V.¹, Turcan A.², Tamborino F.², Carletti F.², Morgantini L.A.², Del Giudice F.¹, Sciarra A.¹, De Berardinis E.¹, Crivellaro S.²

Institutions

¹Sapienza University of Rome, Dept. of Maternal Infant and Urological Sciences, Rome, Italy, ²University of Illinois Chicago, Dept. of Urology, Chicago, United States of America

A0613

Celecoxib Combined with Low-dose-rate Brachytherapy Improves Long-term Metastasis-free Rate in Non-metastatic Prostate Cancer: 10-year Post-hoc Randomized Study

Authors

Nakai Y.¹, Tanaka N.², Onishi K.¹, Yamaki K.³, Fujimoto K.¹

Institutions

¹Nara Medical University, Dept. of Urology, Kashihara, Japan, ²Nara Medical University, Dept. of Prostate Brachytherapy, Kashihara, Japan, ³Nara Medical University, Dept. of Radiation Oncology, Kashihara, Japan

A0614

Prior TURP does not affect perioperative outcomes at radical prostatectomy: a pair-matched analysis of a single center series

Authors

Lovati L.A., Nicolazzini M., Pesce D.P., Marchioro G., Billia M., Palumbo C., Volpe A.

Institutions

University of Eastern Piedmont Maggiore della Carità Hospital, Division of Urology, Dept. of Translational Medicine, Novara, Italy

A0612

Incisional hernia after minimally invasive radical prostatectomy: an underestimated complication requiring greater awareness

Authors

Peyrottes A.¹, Dariane C.², Colau A.³, Pattou M.⁴, Neculescu A.¹, Méjean A.², Desgrandchamps F.¹, Mongiat-Artus P.¹, Oberlin O.⁵, Ploussard G.⁶, Masson-Lecomte A.¹

Institutions

¹Saint-Louis Hospital, Dept. of Urology, Paris, France, ²European Hospital Georges Pompidou, Dept. of Urology, Paris, France, ³La Croix Saint Simon, Dept. of Urology, Paris, France, ⁴Foch Hospital, Dept. of Urology, Paris, France, ⁵Groupe Hospitalier Privé Ambroise-Paré - Hartmann, Dept. of General Surgery, Paris, France, ⁶La Croix du Sud Hospital, Dept. of Urology, Toulouse, France

16:40 - 17:00

BPH

A0615

Automatic object detection in prostate morcellation using deep learning

Authors

Albrechts K.¹, Jansen F.², Buschermöhle M.³, Winter A.², Hein A.¹, Hellmers S.¹

Institutions

¹Carl von Ossietzky Universität Oldenburg, School of Medicine and Health Sciences - Dept. of Health Services Research, Oldenburg, Germany, ²Carl von Ossietzky Universität Oldenburg, School of Medicine and Health Sciences - Dept. of Human Medicine - Klinikum Oldenburg - University Hospital for Urology, Oldenburg, Germany, ³KIZMO GmbH, Oldenburg, Germany

A0616

Pelvic floor muscle thickness as a predictor of transient urinary incontinence after prostatic laser enucleation: a prospective study with MRI correlation

Authors

Menozzi M.¹, Perri D.², Calcagnile T.², Berti L.², Micali S.³, Bozzini G.²

Institutions

¹Università di Modena e Reggio Emilia, Dept. of Urology, Como, Italy, ²ASST Lariana, Sant'Anna Hospital Como, Dept. of Urology, Como, Italy, ³Università di Modena e Reggio Emilia, Dept. of Urology, Modena, Italy

A0617

Membranous urethral length as a predictor for urinary incontinence after Holmium Enucleation of the Prostate (HoLEP) for benign prostatic hyperplasia

Authors

Lee N.¹, Benzouak T.², Nguyen D.D.³, Belliveau S.¹, Murad L.², Kadi L.⁴, Perlis N.³, Breau R.⁵, Elterman D.³, Chughtai B.⁶, Gralnek D.⁷, Olivie D.⁴, Meskawi M.¹, Negrean C.¹, Bhojani N.¹

Institutions

¹University of Montreal, Dept. of Urology, Montréal, Canada, ²McGill University, Dept. of Urology, Montréal, Canada, ³University of Toronto, Dept. of Urology, Toronto, Canada, ⁴University of Montreal, Dept. of Radiology, Montréal, Canada, ⁵University of Ottawa, Dept. of Urology, Ottawa, Canada, ⁶Northwell Health, Dept. of Urology, Manhasset, United States of America, ⁷University of Wisconsin School of Medicine and Public Health, Dept. of Urology, Madison, United States of America

A0618

Accuracy, readability, and understandability of EAU guidelines bot for male non-neurogenic LUTS guidelines.

Authors

Pillitteri E., Santioni M., Lombardo R., Romagnoli M., Coppola L.M., Malavasi G., Piccini G.P., Pacini G., Umbaca M., Pierri E., Lorenti C., Nacchia A., Cicione A., Tema G., Franco A., Pastore A., Al Salhi Y., Fuschi A., Tubaro A., De Nunzio C.

Institutions

Sapienza University of Rome, Dept. of Urology, Rome, Italy

Sunday 15 March
15:30 - 18:00

Location Blue Area, George 4

Chair A. Breda, Barcelona (ES)

Learning objectives

To provide to the audience a practical guide to perform the most common surgeries in urology. The audience will be able to learn from among the best surgeons in the world.

15:30 - 16:00

New technology

Moderators S. Nathan, London (GB)
H.G. Van Der Poel, Amsterdam (NL)

15:30 - 15:40

Should we train surgeons on the new systems?

A. Mottrie, Aalst (BE)

15:40 - 15:50

Telesurgery: What now?

A. Breda, Barcelona (ES)

15:50 - 16:00

Single port surgery: Where do we stand?

B.J. Challacombe, London (GB)

16:00 - 16:56

Nightmare cases in robotic surgery

Moderators V. Phé, Paris (FR)
S. Secco, Milan (IT)

16:00 - 16:14

Prostate cancer

M.C. Sighinolfi, Milan (IT)

16:14 - 16:28

Kidney cancer

J-C. Bernhard, Bordeaux (FR)

16:28 - 16:42

Bladder cancer

P. Wiklund, Stockholm (SE)

16:42 - 16:56

Functional urology

B. Peyronnet, Rennes (FR)

16:56 - 17:55

Tips and tricks from the expert

Moderators N.N. Harke, Hannover (DE)
C. Wagner, Gronau (DE)

16:56 - 17:06

Tips and tricks of retroperitoneal LDN for testis cancer

J. Porter, Seattle (US)

17:06 - 17:16

Tips and tricks of renal enucleation surgery

A. Minervini, Florence (IT)

17:16 - 17:26

Tips and tricks of nerve sparing surgery

R. Gaston, Bordeaux (FR)

17:26 - 17:36

Tips and tricks of vesico-urethral anastomosis

B.M.C. Rocco, Rome (IT)

17:36 - 17:46

Tips and tricks of vesico-vaginal fistula repair

V. Phé, Paris (FR)

17:46 - 17:55

Tips and tricks of robotic kidney transplantation

M. Musquera Felip, Barcelona (ES)

17:55 - 18:00

Alex Mottrie Award

Moderator

A. Breda, Barcelona (ES)

Winner

Expanding the donor pool and preserving graft quality in kidney transplantation

eeu Transplantation

EAU Section of Transplantation Urology

Sunday 15 March

15:30 - 17:00

Location

Blue Area, Victoria 1

Chair

M. Musquera Felip, Barcelona (ES)

Learning objectives

This session aims to deepen participants' understanding of how to expand the kidney donor pool while safeguarding graft quality through advances in policy, technology, and surgical practice. Attendees will explore current realities of cadaveric donation across Europe, assess emerging techniques such as regional normothermic reperfusion, and review best practices in organ harvesting and preservation to minimise graft loss. The programme also seeks to familiarise surgeons with the growing role of robotics in kidney transplantation, from initiating a robotic cadaveric transplant programme to managing ureteral complications. Finally, participants will reflect on strategies to strengthen urologist involvement in transplantation pathways, equipping them with the knowledge needed to optimise donor utilisation and improve long-term transplant outcomes.

15:30 - 15:32

Opening remarks

M. Musquera Felip, Barcelona (ES)

15:32 - 15:52

Saving lives, shaping the future: Organ donation across Europe and beyond

Moderators

S Drouin, Paris (FR)

O. Rodriguez Faba, Barcelona (ES)

15:32 - 15:42

Cadaveric donation in Europe: Policies and realities

C. Antoine, (FR)

15:42 - 15:52

Regional normothermic reperfusion – is it the future?

A. Romano, Stockholm (SE)

15:52 - 16:13

Protecting the gift: How surgeons keep donated kidneys working

Moderators

J. Branchereau, Nantes (FR)

V. Gomez Dos Santos, Madrid (ES)

15:52 - 16:02

Harvesting techniques: How to avoid graft loss

A.J. Figueiredo, Coimbra (PT)

16:02 - 16:13

Preservation techniques: What works best for kidney grafts?

M. Foguene, (BE)

16:13 - 16:38

A high-tech helping hand: How robotics is changing kidney transplants

Moderators

T. Prudhomme, Toulouse (FR)

R.H. Zakri, London (GB)

16:13 - 16:23

Starting a robotic cadaveric kidney transplant programme

R. Campi, Florence (IT)

16:23 - 16:31

Semi-live: Robotic cadaveric kidney transplantation

T. Ajami Fardoun, Barcelona (ES)

16:31 - 16:38

Semi-live: Robotic approach for ureteral complications

B.R. Etcheverry Giadrosich, Barcelona (ES)

16:38 - 16:48

Increasing urologist involvement in kidney transplantation

R. Boissier, Marseille (FR)

16:48 - 16:53

Rene Küss Award

Presenters

F.J. Burgos Revilla, Madrid (ES)

E. Lledó García, Madrid (ES)

Winner

16:53 - 17:00

Panel discussion and Q&A

M. Musquera Felip, Barcelona (ES)

From molecules to machines: The endourology experience

EAU Endourology

EAU Section of Endourology

Sunday 15 March

15:30 - 18:00

Location

Blue Area, George 1

Chairs

B. Somani, Southampton (GB)

O. Traxer, Paris (FR)

Learning objectives

This session aims to provide participants with a comprehensive update on contemporary and emerging practices in endourology. Attendees will gain insights into medical and imaging-based management of urinary stones, including drug therapies, imaging assessment, and vitamin D's role in stone risk. Surgical topics will explore advancements in PCNL vs. RIRS, robotic platforms, and sustainable engineering. The programme also covers innovations in laser settings, outpatient bladder tumor treatment, robotic techniques for UTUC, and focal therapies for prostate cancer. Additionally, debates on BPH management strategies and the future role of AI and simulation in endourological training and practice will equip clinicians with critical knowledge for evidence-based decision-making and future readiness.

15:30 - 15:31

Welcome and introduction

O. Traxer, Paris (FR)

15:31 - 16:01

Stone medical: Image and medication

Moderators

M. Straub, Munich (DE)

C.A. Wagner, Zurich (CH)

15:31 - 15:32

Introduction

M. Straub, Munich (DE)

C.A. Wagner, Zurich (CH)

15:32 - 15:39

Drug-based therapy of stones

C.A. Wagner, Zurich (CH)

15:39 - 15:46

Structured assessment in stone imaging

To be confirmed

15:46 - 15:53

Vitamin D and stone risk

P.M. Ferraro

15:53 - 16:01

Discussion

16:01 - 16:22

Stone surgical: PCNL vs. RIRS – the final fight?

Moderators

O. Angerri Feu, Barcelona (ES)

H.U. Jung, Vejle (DK)

To be confirmed

16:01 - 16:02

Introduction

O. Angerri Feu, Barcelona (ES)

16:02 - 16:07

Integrated suction and IRP monitoring - fact or myth?

O. Wiseman, Cambridge (GB)

16:07 - 16:12

Is PCNL dead?

M.S. Pearle, Dallas (US)

16:12 - 16:17

Intelligent new robotic ureteroscopy platform

S. Yuen, Hong Kong (HK)

16:17 - 16:22

Sustainable engineering in endourology: Revolutionary ureteroscopy systems

V. Gauhar, Singapore (SG)

16:22 - 16:36

Debate Lasers pre-settings for stone treatment – should we trust or not?

16:22 - 16:27

Yes, we trust

G. Kamphuis, Amsterdam (NL)

16:27 - 16:32

No, we don't

A. Sierra Del Rio, Barcelona (ES)

16:32 - 16:36

Discussion

Bladder, BPH, UTUC, focal and LAP

Moderators

J. Baard, Amsterdam (NL)

E. Barret, Paris (FR)

G. Bozzini, Como (IT)

T.R.W. Herrmann, Frauenfeld (CH)

16:36 - 16:55

Bladder and UTUC: What's new?

16:36 - 16:37	Introduction J. Baard, Amsterdam (NL) G. Bozzini, Como (IT)
16:37 - 16:42	Outpatient laser ablation of bladder tumours J.L. Vázquez, Copenhagen (DK)
16:42 - 16:47	Robotic ERBT: A paradigm shift J.Y.C. Teoh, Hong Kong (HK)
16:47 - 16:52	UTUC: Evolution of guidelines in the last 15 years M. Brehmer, Stockholm (SE)
16:52 - 16:55	Discussion
<hr/>	
16:55 - 17:09	Management of favorable intermediate-risk prostate cancer
16:55 - 16:56	Introduction E. Barret, Paris (FR)
16:56 - 17:01	Focal therapy C. Orczyk, London (GB)
17:01 - 17:06	Minimally invasive surgery A. Galloli, Barcelona (ES)
17:06 - 17:09	Discussion
<hr/>	
17:09 - 17:28	BPH MIST vs. enucleation: The real-world debate
17:09 - 17:10	Introduction T.R.W. Herrmann, Frauenfeld (CH)
17:10 - 17:15	Is morcellation the Achilles heel of prostatic enucleation? S. Doizi, Paris (FR)
17:15 - 17:20	The downside of MIST: Are we just delaying the “real” surgery? What is the future of MIST and is it really what patients want? M.S. Agrawal, Agra (IN)
17:20 - 17:25	Retreatments and costs of MIST and other BPO techniques D. Enikeev, Vienna (AT)
17:25 - 17:28	Discussion
<hr/>	
17:28 - 17:54	Round-table discussion AI and simulation everywhere <i>Moderators</i> P. Kallidonis, Patras (GR) To be confirmed T. Tailly, Ghent (BE)
17:28 - 17:29	Introduction
17:29 - 17:34	Smart endoscopy: AI-assisted composition recognition of kidney stones V. Estrade, Angouleme Cedex 9 (FR)
17:34 - 17:39	Revolutionising surgical training via virtual reality and simulation protocols: How to train the endourologists of tomorrow
17:39 - 17:44	AI in endourology: Is it ready for clinical application C. Nedbal, Milan (IT)

17:44 - 17:49

AI assisted robotic puncture

G.H. Zeng, Guangzhou (CN)

17:49 - 17:54

Discussion

17:54 - 17:55

Conclusions

O. Traxer, Paris (FR)

Urolithiasis: Epidemiology and outcomes

EGPT 43

Sunday 15 March
15:30 - 17:00

Location Orange Area, EGPT 1

Chairs To be confirmed
F. Esperto, Rome (IT)
M.L. Letouche, Tours (FR)

15:30 - 15:50

Demographic and epidemiological factors

P0754

Air pollution and kidney stone risk: A large-scale nationwide case-crossover study

Authors

[Zhu Z.-J.](#)¹, [Wu C.D.](#)², [Lai E.C.C.](#)³, [Liu C.J.](#)⁴

Institutions

¹National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, ²National Cheng Kung University, Dept. of Geomatics, Tainan, Taiwan, ³National Cheng Kung University, School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, Tainan, Taiwan, ⁴National Cheng Kung University, Dept. of Urology, College of Medicine, Tainan, Taiwan

P0755

Age and gender characteristics of urolithiasis: analysis of 5-year prevalence rates among men and women

Authors

[Kamalov A.A.](#)¹, [Nesterova O.](#)¹, [Tahirzade A.M.](#)², [Karpov V.](#)¹, [Panferov A.S.](#)³, [Osmanov O.A.](#)¹, [Strigunov A.A.](#)¹, [Sorokin N.I.](#)¹

Institutions

¹Moscow State University, Dept. of Urology and Andrology, Moscow, Russia, ²Urology Division of the GBUZ City Clinical Hospital No. 31 Named After Academician G.M. Savelieva of Moscow Healthcare Department, Dept. of Urology and Andrology, Moscow, Russia, ³The Urology Center of the Medassist Medical Center, Medscan group, Dept. of Urology and Andrology, Moscow, Russia

P0756

Age-Related Decline in Male-to-Female Risk Ratio of Kidney Stone Incidence

Authors

[Huang C.-Y.](#)¹, [Wu C.H.](#)²

Institutions

¹National Taiwan University Hospital, University of Alabama at Birmingham, Case Western Reserve University, Dept. of Urology, Taipei, Taiwan, ²University of Alabama at Birmingham, Case Western Reserve University, Dept. of Urology, Genetics, Birmingham, United States of America

P0757

Bidirectional association between hypertension and the risk of kidney stones disease: A prospective study based on the UK Biobank

Authors

Cong H., He Z., Tang Z., Tang F., Zhang J., Sun Z.

Institutions

The Eighth Affiliated Hospital Sun Yat-sen University, Dept. of Urology, Shenzhen, China

15:50 - 16:00

Drugs and stone risk

P0758

Comparative Risk of Nephrolithiasis in Obesity Pharmacotherapy: A Real-World Analysis of Semaglutide, Tirzepatide, and Orlistat in Type 2 Diabetes

Authors

Lee P-H.¹, Chen Y.H.², Liu C.J.¹

Institutions

¹National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, ²National Cheng Kung University, School of Medicine, College of Medicine, Tainan, Taiwan

P0759

The association between GLP-1 and dual GIP/GLP-1 agonists and severe urolithiasis requiring surgery: a global real-world cohort study

Authors

Lee S.E., Li J.R., Wang S.C.

Institutions

Taichung veterans general hospital, Dept. of Urology, Taichung, Taiwan

16:00 - 16:25

Obesity and dietary factors

P0760

Adiposity increases risk of kidney stone disease via effects on renal fat depots and urinary sodium excretion

Authors

Lovegrove C.¹, Thanaj M.², Basty N.², Whitcher B.², Bell J.D.², Thomas L.², Howles S.³

Institutions

¹University of Glasgow, School of Cardiovascular and Metabolic Health, Glasgow, United Kingdom, ²University of Westminster, School of Life Sciences, London, United Kingdom, ³University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom

P0761

High-Fat Diet Exacerbates Renal Crystal Deposition via a Gut-Kidney Axis Mechanism

Authors

Hong S-Y., Yang Y.Y., Wang S.G.

Institutions

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China

P0762

Dietary protein intake and kidney stone risk: new evidence from a large population-based study

Authors

Wang M., Wang K.

Institutions

West China Hospital, Dept. of Urology, Chengdu, China

P0763

Differential associations and mechanistic evidence of dietary sweeteners on kidney stones: integrating the UK Biobank prospective cohort study and a translational animal study

Authors

Zhang J.¹, Wang J.¹, Chi Y.², Yang M.³, Wu H.¹, Huang L.⁴, Tang Z.¹, Cong H.¹, Sun Z.¹, He M.⁴, Zhao H.⁵, Qian Y.¹, Tang F.¹, He Z.¹

Institutions

¹The Eighth Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Shenzhen, China, ²Sun Yat-sen University, School of Medicine, Shenzhen, China, ³Sun Yat-sen University, School of Public Health, Guangzhou, China, ⁴The First Affiliated Hospital of Guangzhou Medical University, Dept. of Endocrinology, Guangzhou, China, ⁵Affiliated Qingyuan Hospital of Guangzhou Medical University, Dept. of Urology, Qingyuan, China

P0764

Bidirectional Association between Hypertension and the Risk of Kidney Stones: Association between special diets and the risk of kidney stones disease: A prospective study based on the UK Biobank

Authors

Cong H., Tang F., He Z., Tang Z.

Institutions

The Eighth Affiliated Hospital Sun Yat-sen University, Dept. of Urology, Shenzhen, China

16:25 - 17:00

Outcomes

P0765

External Validation of the MIMIC calculator for predicting successful spontaneous stone passage in patients managed conservatively for ureteric colic

Authors

Hussein I.¹, Khadouri S.¹, Nathan A.², Chow B.², Byrnes K.³, Bhatt N.⁴, Kasivisvanathan V.²

Institutions

¹Western General Hospital, Dept. of Surgery, Edinburgh, United Kingdom, ²University College London, Dept. of Surgery, London, United Kingdom, ³The Royal London Hospital, Dept. of Surgery, London, United Kingdom, ⁴Cambridge University Hospitals NHS Foundation Trust, Dept. of Surgery, Cambridge, United Kingdom

P0766

HbA1c-Based Analysis of Metabolic Profiles and Stone Composition in Patients with Urolithiasis

Authors

Kim K., Choi H., Lee W.S., Moon S., Kim W.T., Kim Y.J., Yun S.J., Lee S.C.

Institutions

Chungbuk National University Hospital, Dept. of Urology, Chengju, South Korea

P0767

High-risk Pathogens and Factors to Postoperative Infection after Upper Urinary Tract Calculi Surgery: A Retrospective Analysis of 4,018 Patients

Authors

Lin J., Ye L-F., Hong Y., Guo P., Yang Z.

Institutions

Fuzhou University Affiliated Provincial Hospital, Dept. of Urology, Fuzhou, China

P0768

The experience of post operative flank pains at elevated intrarenal pressures

Authors

Hong A., Jack G., Bolton D.

Institutions

Austin Health, Dept. of Urology, Melbourne, Australia

P0769

MATCH Score: A Predictive Model for Intraoperative Conversion During Ureteroscopic Laser Lithotripsy for Impacted Ureteral Stones

Authors

Wang Y.B., Tianyu C.

Institutions

First Hospital of Jilin University, Dept. of Urology, Changchun, China

P0770

One-year outcomes of flexible ureterorenoscopy using a flexible and navigable suction access sheath (FANS): An EAU-Endourology initiative

Authors

Fong K.Y.¹, Yuen S.K.K.², Castellani D.³, Soebhali B.⁴, Elshazly M.⁵, Malkhasyan V.⁶, Tan K.⁷, Rico L.⁸, Gokce M.I.⁹, Lee H.J.¹, Gadzhiev N.¹⁰, Tefik T.¹¹, Cao J.¹², El Hajj A.¹³, Teoh J.², Chew B.¹⁴, Traxer O.¹⁵, Somani B.K.¹⁶, Gauhar V.¹⁷

Institutions

¹Singapore General Hospital, Dept. of Urology, Singapore, Singapore, ²The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, China, ³Azienda Ospedaliero-Universitaria delle Marche, Dept. of Urology, Ancona, Italy, ⁴Abdul Wahab Sjahranie Hospital Medical Faculty, Dept. of Urology, Samarinda, Indonesia, ⁵Menoufia University, Dept. of Urology, Shibin el Kom, Egypt, ⁶A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia, ⁷Veterans Memorial Medical Center, Dept. of Urology, Quezon, Philippines, ⁸Hospital Aleman, Dept. of Urology, Buenos Aires, Argentina, ⁹Ankara University, Dept. of Urology, Ankara, Turkey, ¹⁰St. Petersburg State University Hospital, Dept. of Urology, Saint Petersburg, Russia, ¹¹Istanbul University Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ¹²Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China, ¹³American University of Beirut, Dept. of Urology, Beirut, Lebanon, ¹⁴University of British Columbia, Dept. of Urology, Vancouver, Canada, ¹⁵Sorbonne University Tenon Hospital, Dept. of Urology, Paris, France, ¹⁶University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom, ¹⁷Ng Teng Fong General Hospital, Dept. of Urology, Singapore, Singapore

Global Pilot Prospective Multicentre study to classify Flexible ureteroscopy with FANS and report peri and 30 day post operative outcomes in a multicentre real world setup by EAU Endourology

Authors

Gauhar V.¹, Castellani D.², Fong K.Y.³, Angerri O.⁴, Soebhali B.⁵, Du J.³, Tanidir Y.⁶, Tzelves L.⁷, Petkova K.⁸, Rico L.⁹, Sen V.¹⁰, Tefik T.¹¹, Demirkiran E.D.¹², Idrissa S.¹³, Politi Vidal E.¹⁴, Sytnik D.¹⁵, Parikesit D.¹⁶, Tsaturyan A.¹⁷, Mazzon G.¹⁸, Elshazly M.¹⁹, Geavlete P.²⁰, Ferreti S.²¹, Somani B.K.²², Yuen S.K.K.²³

Institutions

¹Ng Teng Fong general hospital, Dept. of Urology, Singapore, Singapore, ²Azienda Ospedaliero-Universitaria delle Marche, Università Politecnica delle Marche, Dept. of Urology, Ancona, Italy, ³Singapore General hospital, Dept. of Urology, Singapore, Singapore, ⁴Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁵Abdul Wahab Sjahranie Hospital, Medical Faculty, Mulawarman University, Dept. of Urology, Samarinda, Indonesia, ⁶Istanbul Kent University, Vocational school of Health Services, Dept. of Urology, Istanbul, Turkey, ⁷National and Kapodistrian University of Athens, Dept. of Urology, Athens, Greece, ⁸Military Medical Hospital, Dept. of Urology, Sofia, Bulgaria, ⁹Hospital Aleman, Dept. of Urology, Buenos Aires, Argentina, ¹⁰Dokuz Eylul University School of Medicine, Dept. of Urology, Izmir, Turkey, ¹¹Istanbul University Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ¹²Zonguldak Bülent Ecevit University, Dept. of Urology, Zonguldak, Turkey, ¹³Kati University Hospital, Dept. of urology, Kati, Mali, ¹⁴Hospital Central Ramon Carrillo, Dept. of Urology, San Luis Province, Argentina, ¹⁵St Lukes Hospital, Dept. of Urology, Moscow, Russia, ¹⁶Eka Hospital, University of Indonesia, Dept. of Urology, Riau, Indonesia, ¹⁷Yerevan State Medical University after Mkhitar Heratsi, Dept. of Urology, Yerevan, Armenia, ¹⁸University College Hospital London, Dept. of Urology, London, United Kingdom, ¹⁹Menoufia University, Dept. of Urology, Shibin el Kom, Egypt, ²⁰Carol Davila" University of Medicine and Pharmacy, Dept. of Urology, Bucharest, Romania, ²¹Azienda Ospedaliero-Universitaria of Modena, University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, ²²University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ²³SH Ho Urology Centre, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong

Study Group

Flexible ureteroscopy with Flexible and navigable suction access sheath registry (FLEXOR-F)(Hongkong, Hong Kong)

Refining active surveillance: Predictive factors and long-term results

EGPT 44

Sunday 15 March
15:30 - 17:00

Location

Orange Area, EGPT 2

Chairs

S. Knipper, Berlin (DE)

R. Van Den Bergh, Rotterdam (NL)

A.R. Zlotta, Toronto (CA)

15:30 - 16:05

Predictors of Progression

P0772

Predictors of Progression and Clinical Outcomes in Men Managed with Active Surveillance for Prostate Cancer

Authors

Khalil I.A., Sadiq G., Rahhal M.O., Al-Zoubi R.M., Al-Qudimat A.R., Al Rumaihi K.

Institutions

Hamad Medical Corporation, Dept. of Urology, Doha, Qatar

P0773

Long-term prognostic value of the Prostate Urine Risk (PUR) biomarker in an active surveillance cohort

Authors

Smith S.¹, Llanaez Lago S.¹, Manley K.², Ali O.³, Quinn C.³, Clark J.¹, Mills R.³, Cooper C.¹, Brewer D.¹

Institutions

¹University of East Anglia, Norwich Medical School, Norwich, United Kingdom,

²James Paget University Hospitals NHS Foundation Trust, Dept. of Urology, Gorleston, United Kingdom, ³Norfolk and Norwich University Hospital, Dept. of Urology, Norwich, United Kingdom

P0774

Do we need the PRECISE score when we already have the PI-RADS score to predict upgrading on active surveillance?

Authors

Denijs F.B.¹, Remmers S.¹, Marengi C.², Lozano-Urunuela F.³, Graefen M.⁴, Rannikko A.⁵, Staerman F.⁶, Sugimoto M.⁷, Somford D.⁸, van den Bergh R.C.N.¹, Roobol M.J.¹

Institutions

¹Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands,

²Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy,

³Hospital Universitario de Navarra, Dept. of Urology, Pamplona, Spain, ⁴Martini Klinik,

Dept. of Urology, Hamburg, Germany, ⁵University of Helsinki, Research Program in

Systems Oncology, Helsinki, Finland, ⁶Polyclinique Reims-Bezannes, Dept. of Urology,

Bezannes, France, ⁷Kagawa University, Dept. of Urology, Faculty of Medicine,

Kagawa, Japan, ⁸Canisius Wilhelmina Hospital, Dept. of Urology, Nijmegen, The

Netherlands

P0776

Circulating biomarkers related to progression in low-risk prostate cancer monitored by active surveillance

Authors

Cockburn J.¹, Mejia A.¹, Bakthavaksalan B.¹, Lakosz K.², Chowdhary S.¹, Wagner H.¹, Montenegro Burke R.³, Fleshner N.¹

Institutions

¹University Health Network, Dept. of Surgical Oncology, Toronto, Canada, ²University

Health Network, Dept. of Biostatistics, Toronto, Canada, ³University of Toronto,

Donnelly Centre, Toronto, Canada

P0777

Micro-Ultrasound as a complementary imaging modality for clinically significant PCa detection in active surveillance: A prospective clinical trial

Authors

Roldan Testillano R., Covarrubias C., Anidjar M., Sanchez-Salas R.

Institutions

McGill University, Dept. of Urology, Montréal, Canada

P0778

Predictors of Progression During Active Surveillance for Grade Group 1 Prostate Cancer in the mpMRI Era: Implications for Follow-up Strategies

Authors

Leni R.¹, Stabile A.¹, Barletta F.M.¹, Scuderi S.¹, Cannoletta D.¹, Scilipoti P.¹, Quarta L.¹, Zaurito P.¹, Viti A.¹, Cosenza A.¹, Brancaccio M.¹, Ceria F.¹, Maestroni V.¹, Bonavia L.M.¹, Lucianò R.², Tenace N.², Scarfò F.², Colecchia M.², Ponzoni M.², Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy

16:05 - 16:30

Follow-up

P0779

Favorable Grade Group 1 Prostate Cancer at Confirmatory Biopsy: Toward Personalized Active Surveillance Follow-up Strategies

Authors

Leni R.¹, Stabile A.¹, Barletta F.M.¹, Scuderi S.¹, Cannoletta D.¹, Longoni M.¹, Quarta L.¹, Zaurito P.¹, Viti A.¹, Santangelo A.¹, Cosenza A.¹, Occhi A.¹, Porzi M.E.¹, Simonetti A.¹, Colistro A.¹, Roca G.¹, Lucianò R.², Tenace N.², Scarfò F.², Colecchia M.², Ponzoni M.², Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy

P0780

The impact of a computerized remote PSA surveillance program on patient clinic attendance for active surveillance and the resulting cost savings.

Authors

Iqbal N.¹, Bright E.²

Institutions

¹Altnagelvin Hospital, Dept. of Urology, Derry, United Kingdom, ²Royal Cornwall Hospital, Dept. of Urology, Truro, United Kingdom

P0781

When can we stop monitoring men on active surveillance: results from the PRIAS study

Authors

Lodder J.¹, Remmers S.¹, Marengi C.², van den Bergh R.¹, Lozano-Urunuela F.³, Graefen M.⁴, Rannikko A.⁵, Staerman F.⁶, Sugimoto M.⁷, Somford D.⁸, Roobol M.¹

Institutions

¹Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy, ³Hospital Universitario de Navarra, Dept. of Urology, Pamplona, Spain, ⁴Martini Klinik, Dept. of Urology, Hamburg, Germany, ⁵University of Helsinki, Research Program in Systems Oncology, Helsinki, Finland, ⁶Polyclinique Reims-Bezannes, Dept. of Urology, Bezannes, France, ⁷Kagawa University, Dept. of Urology, Kagawa, Japan, ⁸Canisius Wilhelmina Hospital, Dept. of Urology, Nijmegen, The Netherlands

P0782

A Risk-Based Model to Identify Active Surveillance Patients Requiring Confirmatory Biopsy: A Contemporary MRI-Based Cohort Study

Authors

Scilipoti P.¹, Stabile A.¹, Cucchiara V.¹, Scuderi S.¹, Leni R.¹, Robesti D.¹, Longoni M.¹, Santangelo A.¹, Cosenza A.¹, Brancaccio M.¹, Zaffuto E.², Capitanio U.¹, Larcher A.¹, De Cobelli F.³, Esposito A.³, Brembilla G.³, Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Ospedale di Circolo and Macchi Foundation, Dept. of Urology, Varese, Italy, ³Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy

P0783

The Diagnostic Benefit of Perilesional Sampling at the Time of Confirmatory Biopsy in Patients Managed with Active Surveillance for ISUP-GG 1 Prostate Cancer

Authors

Quarta L.¹, Leni R.¹, Robesti D.¹, Scilipoti P.¹, Zaurito P.¹, Viti A.¹, Cosenza A.¹, Brancaccio M.¹, Galdieri A.¹, Maestroni V.¹, Ceria F.¹, Scuderi S.¹, Cucchiara V.¹, Stabile A.¹, Lucianò R.², Tenace N.², Scarfò F.², Colecchia M.², Ponzoni M.², Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy

16:30 - 16:45

Outcomes

P0784

Does Active Surveillance Prior to Radical Prostatectomy Affect Pathological or Oncological Outcomes?

Authors

Hannestad I.¹, Aas K.¹, Myklebust T.Å.², Fosså S.D.³

Institutions

¹Akershus University Hospital, Dept. of Urology, Lørenskog, Norway, ²Cancer Registry of Norway, Dept. of Registration, Oslo, Norway, ³Oslo University Hospital, Dept. of Oncology, Oslo, Norway

Study Group

Institute of Clinical Medicine, University of Oslo(Oslo, Norway)

P0785

Long-Term outcomes of low-risk prostate cancer managed with active surveillance: the Brazilian experience

Authors

Souza A.¹, Campos F.², Dias A.³, Lott F.³, Campos M.⁴, Oliveira R.⁵, Hauschild L.⁵, Senra V.¹

Institutions

¹Instituto Nacional do Cancer- INCA, Prostate Cancer Diagnostic Center (CDCP), Rio de Janeiro, Brazil, ²Instituto Nacional do Cancer- INCA, Dept. of Urology, Rio de Janeiro, Brazil, ³Instituto Nacional do Cancer- INCA, Dept. of Urology, Rio de Janeiro, Brazil, ⁴Instituto Nacional do Cancer- INCA, Dept. of Informática, Rio de Janeiro, Brazil, ⁵Instituto Nacional do Cancer- INCA, Dept. of Urology, Rio de Janeiro, Brazil

P0786

Is Extraprostatic Extension Truly Rare in Patients with Gleason Score 6 Prostate Cancer?

Authors

Esen B.¹, Kordan Y.¹, Akinci B.¹, Gurbuz A.¹, Karaarslan U.C.¹, Muduroglu M.¹, Canda A.E.¹, Balbay M.D.¹, Ertoy Baydar D.², Esen T.¹

Institutions

¹Koç University School of Medicine, Dept. of Urology, Istanbul, Turkey, ²Koç University School of Medicine, Dept. of Pathology, Istanbul, Turkey

16:45 - 17:00

Active surveillance in Grade Group 2 patients

P0787

Active surveillance in ISUP grade 2 prostate cancer: a retrospective analysis of discontinuation rates and predictive factors.

Authors

Rodriguez-Sanchez L.¹, Barletta F.², Giganti F.³, Kasivisvanathan V.⁴, Giesen A.⁵, Peyrottes A.⁶, Baboudjian M.⁷, Leni R.², Merani U.⁸, Khalil N.¹, Mischczyk M.⁹, Ladman B.⁹, Hübner N.A.⁹, Marra G.⁸

Institutions

¹Institut Médico-chirurgical Montsouris, Dept. of Urology, Paris, France, ²Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Division of Oncology, Unit of Urology, Milan, Italy, ³University College London Hospitals NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, ⁴University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁵University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁶CHU Saint-Louis, Dept. of Urology, Paris, France, ⁷Hôpital Nord, AP-HM, Université Aix-Marseille, Dept. of Urology, Marseille, France, ⁸University of Turin, Città della Salute e della Scienza, Dept. of Urology, Turin, Italy, ⁹Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria

Study Group

EAU-YAU Prostate Cancer Working Party(Amsterdam, The Netherlands)

P0788

Risk Factors for Adverse Pathology in Biopsy Gleason 3+4 Prostate Cancer: Refining Criteria for Safe Active Surveillance

Authors

Ozawa Y.¹, Marcio C.M.¹, Sharma R.¹, Sandri M.², Bubishate S.¹, Saikali S.¹, Diamond A.³, Rogers T.¹, Vipul P.¹

Institutions

¹AdventHealth Global Robotics Institute, Dept. of Urology, Celebration, United States of America, ²University of Brescia, Big and Open Data Innovation Laboratory (BODaL-Lab) and Data Methods and Systems Statistical, Brescia, Italy, ³University of Central Florida (UCF), College of Medicine, Orlando, United States of America

P0789

How much pattern 4 is too much? Defining the threshold for safe active surveillance in ISUP grade 2 prostate cancer

Authors

Regis L.¹, Perez C.¹, Semidey M.E.², Cuadras M.¹, Planas J.¹, Celma A.¹, Trilla E.¹

Institutions

¹Vall Hebron University Hospital, Dept. of Urology, Barcelona, Spain, ²Vall Hebron University Hospital, Dept. of Pathology, Barcelona, Spain

Sunday 15 March
15:30 - 17:00

Location Orange Area, EGPT 3

Chairs L. De Kort, Utrecht (NL)
S. Kulkarni, Pune (IN)
N. Pavan, Santa Flavia (IT)

15:30 - 15:45

The role of Imaging vs endoscopy in urethral strictures diagnosis and follow-up

P0790

Is routine retrograde urethrography necessary after urethroplasty?

Authors

Nsair A., Zisman A., Orabi N., Amiel G., Eigner E., Badaan S.

Institutions

Rambam Health Care Campus, Dept. of Urology, Haifa, Israel

P0791

Value of systematic uroflowmetry and cystoscopy in the follow-up after oral mucosa graft urethroplasty: are they necessary in asymptomatic patients?

Authors

Dieguez Alvarez L.¹, Martínez-Montava E.², Martínez-García R.¹, Castelló-Porcar A.¹, Ortiz-Seller D.¹, Martínez-Jabaloyas J.M.¹

Institutions

¹Hospital Clínico de Valencia, Dept. of Urology, Valencia, Spain, ²Hospital Lluís Alcanyís de Játiva, Dept. of Urology, Jávea, Spain

P0792

: Magnetic Resonance Urethrography–Derived Geometric Predictors of Surgical Complexity and Outcomes in Pelvic Fracture Urethral Injury Repair

Authors

Bhusal I.¹, Jain S.¹, Gupta M.¹, Chandola S.², Sharma S.², Seth A.¹, Nayyar R.¹, Kumar M.¹, Kumar S.¹

Institutions

¹All India Institute of Medical Sciences, Dept. of Urology, New Delhi, India, ²All India Institute of Medical Sciences, Dept. of Radiodiagnosis and Interventional Radiology, New delhi, India

15:45 - 16:05

Treatment pathways: Internal urethrotomy vs drug-coated balloon

P0793

Cost-effectiveness of Optilume® drug-coated balloon versus standard urethrotomy for recurrent bulbar strictures: a 24-month Italian experience

Authors

Sansalone S.¹, Foti M.², Stracci D.², Ruffo A.³, Falsaperla M.⁴, Minore A.², Castellucci R.², Akhundov A.², Dibitetto F.², De Dominicis M.²

Institutions

¹Policlinico Tor Vergata, Dept. of Urology, Rome, Italy, ²Uroclinic - Casa di Cura Nuova Villa Claudia, Dept. of Urology, Rome, Italy, ³Clinica Nostra Signora Di Lourdes, Dept. of Urology, Naples, Italy, ⁴Arnas Garibaldi, Dept. of Urology, Catania, Italy

P0794

Direct Vision Internal Urethrotomy vs Urethroplasty for Uncomplicated Bulbar Strictures (<2cm): A Proposed Decision Making Tool

Authors

Talamas A., [Garcia M.](#), Solomon J.

Institutions

Cedars Sinai Medical Center, Dept. of Urology, Los Angeles, United States of America

P0795

“Direct Vision Internal Urethrotomy vs. Non-Transecting Urethroplasty in Short Bulbar Strictures: 1-Year Patient-Reported Outcomes”

Authors

[Chawla A.K.](#), Singh S.

Institutions

KMC Manipal, Dept. of Urology and Transplant, Manipal, India

P0796

A new endoscopic benchmark: paclitaxel-coated balloon vs DVIU for short bulbar urethral strictures

Authors

[Sansalone S.](#)¹, Foti M.², Stracci D.², Falsaperla M.³, Ruffo A.⁴, Dibitto F.², Akhundov A.², Minore A.², Castellucci R.², De Dominicis M.²

Institutions

¹Policlinico Tor Vergata, Dept. of Urology, Rome, Italy, ²Uroclinic - Casa di Cura Nuova Villa Claudia, Dept. of Urology, Rome, Italy, ³Arnas Garibaldi, Dept. of Urology, Catania, Italy, ⁴Clinica Nostra Signora Di Lourdes, Dept. of Urology, Naples, Italy

16:05 - 16:35

Patient reported outcomes and risk of retreatment

P0797

An observational study on the evaluation of the sexual functions in post urethroplasty Patients

Authors

[Pal T.](#), Kumar S.

Institutions

Government Medical College Thiruvananthapuram, Dept. of Urology, Thiruvananthapuram, India

P0798

Assessment of risk factors for the development of sexual disorders in men after urethroplasty

Authors

[Kotov S.V.](#), Mantsov A.A., Guspanov R.I., Yusufov A.G., Alekberov E.M., Klimenko A.A., Litvinov S.O., Rybin A.A.

Institutions

Pirogov Russian State Medical University, Dept. of Urology, Moscow, Russia

P0799

Patient expectations prior to first-time anterior urethroplasty: preliminary results from an international multi-institutional prospective study

Authors

Klemm J.¹, Campos-Juanatey F.², Arnaiz Jiménez F.², Karapanos L.³, Mantica G.⁴, Redmond E.⁵, Schernuk J.⁶, Białek Ł.⁷, Oszczudłowski M.⁷, Vetterlein M.W.¹

Institutions

¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Marqués de Valdecilla University Hospital, Dept. of Urology, Santander, Spain, ³Leverkusen General Hospital, Dept. of Urology, Leverkusen, Germany, ⁴University of Genoa, Dept. of Surgical and Diagnostic Integrated Sciences (DISC), Genoa, Italy, ⁵Cork University Hospital, Dept. of Urology, Cork, Ireland, ⁶Hospital Italiano de Buenos Aires, Dept. of Urology, Buenos Aires, Argentina, ⁷Centre of Postgraduate Medical Education, Dept. of Urology, Warsaw, Poland

Study Group

Trauma and Reconstructive Urology Working Party of the European Association of Urology Young Academic Urologists(Amsterdam, The Netherlands)

P0800

Routine Low-Dose Tadalafil Following Buccal Mucosal Graft Urethroplasty for Bulbar Urethral Strictures: Influence on Urinary, Sexual, and Patient-Reported Functional Outcomes – A Prospective Cohort of 170 Patients

Authors

Bafna S., Jain N., Ragavan N., Tiwary M., Velan M.

Institutions

Apollo Hospitals, Dept. of Urology, Chennai, India

P0801

Predictors of recurrence after bulbar urethroplasty following BPH surgery: A multicenter retrospective study

Authors

Deger M.¹, Arikan M.G.², Gulpinar O.³, Zumrutbas A.E.⁴, Ergun K.E.⁵, Dogan C.⁶, Aybek Z.⁷

Institutions

¹Cukurova University School of Medicine, Dept. of Urology, Adana, Turkey, ²Cukurova University School of Medicine, Dept. of Urology, Adana, Turkey, ³Ankara University School of Medicine, Dept. of Urology, Ankara, Turkey, ⁴Pamukkale University School of Medicine, Dept. of Urology, Adana, Turkey, ⁵Ege University School of Medicine, Dept. of Urology, İzmir, Turkey, ⁶Tekirdağ Namık Kemal University School of Medicine, Dept. of Urology, Tekirdag, Turkey, ⁷Pamukkale University School of Medicine, Dept. of Urology, Denizli, Turkey

Study Group

Reconstructive Urology, Minimally Invasive and "Hands-on Training" Working Group of Turkish Continence Society(Ankara, Turkey)

P0802

Predicting urethral stricture recurrence after urethroplasty: Key risk factors and postoperative indicators

Authors

Arabi N.¹, Nsair A.², Zisman A.², Badaan S.¹

Institutions

¹Nazareth Hospital EMMS, Dept. of Urology, Nazareth, Israel, ²Rambam Health Care Campus, Dept. of Urology, Haifa, Israel

16:35 - 17:00

Innovations in complex bladder neck stenosis

P0803

Postoperative outcome of robot-assisted YV-plasty for recurrent bladder neck stenosis

Authors

Buatkala O.¹, Linxweiler J.¹, Stöckle M.¹, Siemer S.¹, John H.², Obrecht F.², Schwentner C.³, Hintermeier S.³, Ubrig B.⁴, Saar M.⁵, Janssen M.⁶, Gratzke C.⁷, Liakos N.⁷, Farzat M.⁸, Heinzlbecker J.¹

Institutions

¹Universitätsklinikum des Saarlandes, Dept. of Urology, Homburg, Germany, ²Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland, ³Diakonie Klinikum Stuttgart, Dept. of Urology, Stuttgart, Germany, ⁴Augusta Kliniken Bochum, Dept. of Urology, Bochum, Germany, ⁵Universitätsklinikum Aachen, Dept. of Urology, Aachen, Germany, ⁶Universitätsklinikum Münster, Dept. of Urology, Münster, Germany, ⁷Universitätsklinikum Freiburg, Dept. of Urology, Freiburg, Germany, ⁸Diakonie Klinikum Jung-Stilling, Dept. of Urology, Siegen, Germany

P0804

Robotic YV plasty for bladder neck contracture : results from a multicentre experience

Authors

Freton L.¹, Salin A.², Tollon C.², Blanc J.¹, Richard C.¹, Vesval Q.¹, Bourillon A.¹, Dubois A.¹, Chommeloux M.¹, Mathieu R.¹, Pradere B.², Peyronnet B.¹

Institutions

¹CHU Rennes, Dept. of Urology, Rennes, France, ²Clinique Croix du Sud, Dept. of Urology, Toulouse, France

P0805

Effect of early detubularization on urethro-intestinal anastomosis during robot-assisted radical cystectomy and intracorporeal neobladder among bladder cancer patients

Authors

Park J.H., Lee H., Lee S., Hong S.K., Byun S.S., Oh J.J.

Institutions

Seoul National University Bundang Hospital, Dept. of Urology, Seongnam-si, South Korea

P0806

Single Intraoperative Triamcinolone Injection Prevents Recurrent Bladder Neck Contracture After BPH Surgery

Authors

Shi Y., Liu B., Zheng X.

Institutions

First Affiliated Hospital of Zhejiang University School of Medicine, Dept. of Urology, Hangzhou, China

Authors

San Cayetano Talegon S.¹, Campos-Juanatey F.², Calleja Hermosa P.², Varea Malo R.², García Herrero J.², Sánchez Gil M.², Azcárraga Aranegui G.², Onrubia Pereira M.A.², Zubillaga Guerrero S.², Gorría Cardesa O.³, Mallén Mateo E.⁴, Puche Sanz I.⁵, Amir Nicolau B.⁶, Barroso Deyne E.⁷, Gutiérrez Aguilar A.⁸, Gutiérrez Banos J.L.²

Institutions

¹Hospital Universitario Galdakao Usansolo, Dept. of Urology, Bilbao, Spain, ²Hospital Universitario Marqués de Valdecilla, Dept. of Urology, Santander, Spain, ³Hospital Universitario de Navarra, Dept. of Urology, Pamplona, Spain, ⁴Hospital Universitario Miguel Servet, Dept. of Urology, Zaragoza, Spain, ⁵Hospital Universitario Virgen de las Nieves, Dept. of Urology, Granada, Spain, ⁶Hospital Universitario Nuestra Señora de la Candelaria, Dept. of Urology, Santa Cruz de Tenerife, Spain, ⁷Hospital Insular, Dept. of Urology, Las Palmas de Gran Canaria, Spain, ⁸Hospital Universitario de Badajoz, Dept. of Urology, Badajoz, Spain

Testosterone frontiers: Therapy, aging, and urological health

EGPT 46

Sunday 15 March
15:30 - 17:00

Location

Orange Area, EGPT 4

Chairs

A. Kadioglu, Istanbul (TR)

To be confirmed

E. Pozzi, Milan (IT)

15:30 - 15:50

Testosterone replacement therapy

P0808

Clomiphene Citrate versus Testosterone Replacement Therapy in Late-Onset Hypogonadism: A Systematic Review of the Literature and Meta-Analysis**Authors**

Constantinou Taveira B.¹, Benedicto B.¹, Galligani L.¹, Schiavon B.¹, Petri G M.M.¹, Uzueli B.¹, Mendes C.¹, Sardenberg R.A.S.², Passerotti C.C.³, Maia R.S.⁴, Shiomi da Cruz J.A.⁴

Institutions

¹Ninth of July University, Dept. of General Surgery, Sao Bernardo do Campo, Brazil, ²Hapvida NotreDame, Research Department, São Paulo, Brazil, ³University of Sao Paulo, Dept. of Surgical Techniques, São Paulo, Brazil, ⁴Federal University of Sao Paulo, Dept. of Urology, São Paulo, Brazil

P0809

Up to 17 years of testosterone therapy in men with functional hypogonadism and diabetes type 2 is associated with improved voiding function**Authors**

Haider K.S.¹, Haider A.¹, Doros G.², Traish A.³

Institutions

¹Praxis Dr.Haider, Dept. of Urology, Bremerhaven, Germany, ²Boston University School of Public Health, Dept. of Epidemiology and Statistics, Boston, United States of America, ³Boston University School of Medicine, Dept. of Biochemistry and Dept. of Urology, Boston, United States of America

P0810

Hypogonadism and Testosterone Replacement Therapy in advanced Bladder Cancer – Improving Quality of Life and Symptom Control

Authors

Macdonald N.¹, Birch R.², Cotton A.³, Chen C.H.³, Yap T.³

Institutions

¹King's College London, Dept. of Medicine, London, United Kingdom, ²King's College London, GKT Department of Medicine, London, United Kingdom, ³Guy's and St. Thomas's NHS Foundation Trust, Dept. of Urology, London, United Kingdom

P0811

Risk factors of osteoporosis in transgender men receiving long-term testosterone therapy

Authors

Tominaga Y.¹, Moriwake T.¹, Ozaki N.¹, Kobayashi T.², Sadahira T.¹, Katayama S.¹, Iwata T.¹, Nishimura S.¹, Bekku K.¹, Araki M.¹

Institutions

¹Okayama University Graduate School of Medicine, Dept. of Urology, Okayama, Japan, ²Miyabi Urogynae Clinic, Dept. of Urology, Okayama, Japan

15:50 - 16:10

Translational biomedicine

P0812

Prediction of Intratesticular Testosterone Concentrations Following Exogenous Testosterone Administration Using Serum Testosterone Precursors in a Rat Model

Authors

Huang I-S.¹, Tsai S.J.¹, Li L.H.², Chang C.H.³, Wu Y.X.³, Huang E.Y.¹, Huang W.J.¹

Institutions

¹Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ²Taipei Veterans General Hospital, Dept. of Pathology, Taipei, Taiwan, ³National Yang Ming Chiao Tung University, Dept. of Physiology, Taipei, Taiwan

P0813

Single-cell RNA-seq Suggests a Shift in Cholesterol Transport Mechanisms during Human Leydig Cell Aging

Authors

Sato K., Tsubotani K., Kin C., Yamashita Y., Kawamura S., Okada K., Chiba K., Miyake H.

Institutions

Kobe University Graduate School of Medicine, Division of Urology, Kobe, Japan

P0814

Establishment of a human leydig cell senescence model using human iPS cell-derived cells and comprehensive gene expression analysis

Authors

Kin C.¹, Yamashita Y.¹, Tsubotani K.¹, Kawamura S.¹, Sato K.¹, Okada K.¹, Koyanagi-Aoi M.², Chiba K.¹, Aoi T.², Miyake H.¹

Institutions

¹Kobe University, Dept. of Urology, Kobe, Japan, ²Kobe University, Stem Cell Medicine, Kobe, Japan

P0815

Targeting Leydig cells to promote autophagy-mediated cholesterol uptake ameliorates age-related testicular lipid metabolic disorders

Authors

Ningjing O., Liangyu Z., Jiarong X., Biao L., Yuxin T.

Institutions

The Fifth Affiliated Hospital of Sun Yat-sen University, Dept. of urology, Zhuhai, China

16:10 - 17:00

Testosterone deficiency

P0816

The Longitudinal Association Between Lower Urinary Tract Symptoms Severity and Sarcopenia Progression in Community-Dwelling Men: A 4-Year Study

Authors

Okamoto T.¹, Sato H.¹, Hamaya T.¹, Kodama H.¹, Narita T.¹, Mikami J.¹, Fujita N.¹, Yamamoto H.¹, Imai A.¹, Nakaji S.², Hatakeyama S.¹

Institutions

¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Hirosaki University Graduate School of Medicine, Social Medicine, Hirosaki, Japan

P0817

Testosterone-symptom severity associations in men evaluated for hypogonadism: an analysis of over 2,000 men

Authors

Clift A.¹, Reisel D.², Johnson H.³, Huang D.¹

Institutions

¹Manual, Dept. of Clinical Innovation and Research, London, United Kingdom, ²EGA Institute for Women's Health University College London, Dept. of Women's Health, London, United Kingdom, ³University of Bristol, Dept. of Digital Health and Care, Bristol, United Kingdom

P0818

Testosterone deficiency and sexual performance in the setting of radical prostatectomy: a lead for sexual rehabilitation?

Authors

van Drumpt J.N.H.¹, van den Wildenberg A.M.², van de Mortel X.¹, Baas D.J.H.², Hoekstra R.J.³, Bellaar Spruyt J.A.⁴, Sedelaar J.P.M.², van Basten J.P.A.¹, Somford D.M.¹

Institutions

¹Canisius Wilhelmina Hospital, Dept. of Urology, Nijmegen, The Netherlands, ²Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ³Catharina Hospital, Dept. of Urology, Eindhoven, The Netherlands, ⁴Máxima Medical Centre, Dept. of Urology, Veldhoven, The Netherlands

P0819

Trends and dynamics of total serum testosterone decline: a systematic review and meta-regression analysis

Authors

Negri F.¹, Jiang T.², Langroudi A.², Raffo M.¹, Sellke N.², Zhang C.A.², Montorsi F.¹, Salonia A.¹, Eisenberg M.L.²

Institutions

¹IRCCS Ospedale San Raffaele, Division of Experimental Oncology - Unit of Urology, Milan, Italy, ²Stanford University, Dept. of Urology, Stanford, United States of America

P0820

Association Between Serum Testosterone Levels and Calcium Oxalate Stone Formation: A Propensity Score–Matched Case–Control Study

Authors

Park S.¹, Lee J.²

Institutions

¹Cardiff university, School of Medicine, Cardiff, United Kingdom, ²Nowon Eulji Medical Center, Dept. of Urology, Seoul, South Korea

P0821

Association of Lifestyle and Body Composition with Steroid Profiles and Prostate Cancer Risk– Results from the Prospective Promic-study

Authors

Boström P.J.¹, Evstafev I.², Heiskanen E.¹, Högerman M.¹, Kalinen S.³, Rui Jian C.¹, Lamminen T.¹, Olesova D.², Krakström M.², Vasankari T.⁴, Taimen P.⁵, Poutanen M.⁶, Dickens A.²

Institutions

¹Turku University Hospital and University of Turku, Dept. of Urology, Turku, Finland, ²Turku Bioscience Centre, University of Turku, Dept. of Life Technologies, Turku, Finland, ³Turku University Hospital, University of Turku, Dept. of Microbiology, Turku, Finland, ⁴UKK Institute for Health Promoting Research, Dept. of Physical Activity, Tampere, Finland, ⁵Turku University Hospital and University of Turku, Dept. of Pathology, Turku, Finland, ⁶Institute of Biomedicine, University of Turku, Dept. of Physiology, Turku, Finland

Study Group

Promic-Study Group(Turku, Finland)

P0822

Post-Cycle Therapy After Short-Term Anabolic-Androgenic Steroid Use: Comparative Outcomes in Recreational Bodybuilders

Authors

Ibis M.A.¹, Yap T.², Satchi M.³, Ghazanfar N.³, Karaburun M.C.¹, Cakir O.O.³, Yaman O.¹, Castiglione F.⁴

Institutions

¹Ankara University School of Medicine, Dept. of Urology, Ankara, Turkey, ²Guy's Hospital, Dept. of Urology, London, United Kingdom, ³King's College Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁴King's College London, School of Biomedical Engineering and Imaging Sciences, London, United Kingdom

P0823

Are reference intervals for free testosterone in healthy men reliable also in infertile men? Findings from a cross-sectional study

Authors

Passarelli F.¹, Boeri L.¹, Pozzi E.², Negri F.², Raffo M.², Bertini A.², Piccolo C.², Birolini G.³, De Luca S.³, Zahiti L.⁴, Mattei A.⁴, Montanari E.¹, D'Arma A.², Montorsi F.², Salonia A.²

Institutions

¹IRCCS Fondazione Ca' Granda Policlinico, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Division of Experimental Oncology - Unit of Urology - Urological Research Institute, Milan, Italy, ³Vita-Salute San Raffaele University, Faculty of Medicine and Surgery, Milan, Italy, ⁴Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland

P0824

Association Between Dietary Viable Microorganism Intake and the Risk of Testosterone Deficiency in Men

Authors

Qianfeng Z., Xingliang F., Wei X., Yiming C., Mingran Z., Saiyang L.

Institutions

The Third Affiliated Hospital of Soochow University, Dept. of Urology, Changzhou, China

P0825

Prevalence of testosterone deficiency and surgical impact on testosterone levels in robot-assisted radical prostatectomy patients

Authors

Van den Wildenberg A.¹, van Drumpt J.N.H.², van de Mortel X.², Baas D.J.H.², Hoekstra R.J.³, Bellaar Spruyt J.A.⁴, Sedelaar J.P.M.⁵, van Basten J.P.A.², Somford D.M.²

Institutions

¹Canisius Wilhelmina Hospital, Dept. of Urology, Nijmegen, The Netherlands, ²Canisius Wilhelmina Hospital, Dept. of Urology, Nijmegen, The Netherlands, ³Catharina Hospital, Dept. of Urology, Eindhoven, The Netherlands, ⁴Máxima Medical Centre, Dept. of Urology, Veldhoven, The Netherlands, ⁵Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands

Urothelial carcinoma - Basic and translational research

EGPT 47

Sunday 15 March
15:30 - 17:00

Location

Orange Area, EGPT 5

Chairs

J. Damrauer, Durham (US)
To be confirmed
A. Vlahou, Athens (GR)

P0898

Spatial transcriptomics identifies an invasive front gene expression profile in bladder cancer using en bloc transurethral resection specimens

K. Yoshihara, Tokyo (JP)

P0899

Patient-derived Immunocompetent Tumor Organoids Reveal Immunostimulatory Effects of Microbial Therapy

Z. Zihan, Nanjing (CN)

P0900

SLAMF9+ TAM aggravates CD8+ T cell non-response to immune checkpoint blockade via SLAMF9/CD137 interaction

C. Chen, Guangzhou (CN)

P0901

MRI radiomic phenotypes stratify response and define immune states in very high-risk non-muscle-invasive bladder cancer treated with tislelizumab plus nab-paclitaxel

H. Hu, Tianjin (CN)

P0903

Predicting neoadjuvant chemotherapy response in bladder cancer patients using an artificial intelligence deep learning model

To be confirmed

P0904	Unlocking novel tumor-draining lymph node-derived T cell immunotherapy for bladder cancer through glycan labeling X. Wu, Nanjing (CN)
P0905	KAT8-mediated NSUN2 lactylation promotes bladder cancer progression via m5C modification on HELZ2 To be confirmed
P0906	Impact of Disease Stage and Genetic Alterations on Clinical Outcomes in Micropapillary Variant Urothelial Carcinoma S. McSweeney, Cleveland (US)
P0907	Vitamin D and its receptor VDR regulate the invasive capacity of bladder cancer cells through physical interactions with AKT kinases C. Bolenz, Ulm (DE)
P0908	RNA based liquid biopsy testing of urine to monitor response of muscle invasive bladder cancer towards neoadjuvant chemotherapy - the NeoBRIDGister experience R. Wirtz, Cologne (DE)
P0909	A composite biomarker approach to withhold neoadjuvant chemotherapy in select muscle-invasive bladder cancer patients To be confirmed
P0910	Targeting lactate production or key lactylated proteins sensitizes bladder cancer to cisplatin therapy J. Qian, Beijing (CN)
P0911	Development and preclinical evaluation of novel FGFR3-targeting antibody-drug conjugates in bladder cancer To be confirmed
P0912	A spatially resolved atlas of upper tract urothelial carcinoma characterizes immunosuppressive niches driving tumor progression S. Xiong, Beijing (CN)
P0913	Novel precision cancer model reveals epigenetic reprogramming induces variant histologic phenotype in upper tract urothelial carcinoma To be confirmed
P0914	HER2 Protein Expression and its Clinicopathological Significance in Upper Urinary Tract Urothelial Carcinoma G. Bao, Beijing (CN)
P0915	Longitudinal utDNA Dynamics Predict Recurrence Risk in UTUC W. Zuo, Beijing (CN)

Sunday 15 March
15:45 - 16:15

Location Patient Advocacy Plaza
Chair To be confirmed

15:45 - 16:15

World Bladder Cancer Patient Coalition (WBCPC)
To be confirmed

Hands-on Training in Transurethral treatment - Step 2 (TURP)

HOT TURP - 3.6

Sunday 15 March
16:00 - 16:50

Location Red Area, Room 1
Tutors To be confirmed
C. Netsch, Hamburg (DE)

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the prostate and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

E-BLUS Exam

HOT EBLUS EXAM - 3.6

Sunday 15 March
16:00 - 16:55

Location Red Area, Room 1

Tutors O. Stakhovskyi, Kyiv (UA)
P. Umari, London (GB)

Learning objectives

In this exam, your psychomotor skills such as depth perception and bimanual dexterity will be tested and your mastery of basic laparoscopy skills such as instrument handling, pattern cutting and intracorporeal suturing will be assessed by experienced examiners.

The exam is aimed at candidates with intermediate and advanced laparoscopy experience or those who have sufficiently trained to meet the exercises time and quality criteria. Passing the E-BLUS exam will be rewarded with a certificate that serves as a recommendation to continue your laparoscopy training by assisting laparoscopic procedures in the OR.

ESTs1 Exam

HOT EST EXAM 3.6

Sunday 15 March
16:00 - 16:50

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed
A. Pietropaolo, Southampton (GB)

Learning objectives

In this exam, candidates' psychomotor and endoscopic skills are assessed, with a focus on the safe and effective performance of core endourological procedures such as rigid cystoscopy, flexible cystoscopy, semi-rigid ureteroscopy, and flexible ureteroscopy. Candidates are evaluated by experienced examiners on instrument handling, scope control, orientation, and respect for tissue within a simulated setting. The exam is aimed at candidates with basic to intermediate endourology experience or those who have completed sufficient training to meet the required performance standards, and successful completion is rewarded with a certificate recommending progression to supervised endourological procedures in the operating room.

Hands-on Training in Laparoscopic urological skills - Step 2

HOT LUSs2 - 3.6

Sunday 15 March
16:00 - 16:50

Location Red Area, Room 1

Tutors To be confirmed
To be confirmed

Learning objectives

The Intermediate Laparoscopic Training (LUSs2) is designed to provide urologists with a comprehensive training experience on complex laparoscopic procedures. Using state of the art models, participants are trained by expert surgeons on essential techniques for Major Vessel Injury Repair, VU Anastomosis or Partial Nephrectomy. This training equips healthcare professionals with the necessary skills and dexterity to handle intricate laparoscopic procedures effectively and hone their operating skills.

Hands-on Training in Transurethral treatment - Step 3 (ThuLEP)

HOT ThuLEP - 3.6

Sunday 15 March
16:00 - 16:50

Location Red Area, Room 1

Tutors E.D. Demirkiran, Zonguldak (TR)
M.I. Gökce, Ankara (TR)
T.E. Şener, Istanbul (TR)

Learning objectives

This advanced training course represents the third step in the Transurethral Treatment (TUT) curriculum and is designed to provide urologists with a solid foundational understanding of thulium laser enucleation of the prostate (ThuLEP). The course offers a comprehensive and structured introduction for urologists seeking to develop proficiency in this technique, combining theoretical principles with hands-on experience. Using a step-by-step approach, expert faculty will guide participants through each phase of the ThuLEP procedure on state-of-the-art training models, helping them build familiarity with the procedural workflow, gain confidence in handling the laser and endoscopic equipment, and develop a clear understanding of best practices, safety considerations, and operative efficiency.

Hands-on Training in Transurethral treatment - Step 2 (TURBT)

HOT TURBT - 3.6

Sunday 15 March
16:00 - 16:50

Location Red Area, Room 1
Tutors To be confirmed
To be confirmed

Learning objectives

This intermediate transurethral treatment training course is the second step in the Transurethral Treatment (TUT) curriculum. It is designed to provide urologists with a fundamental understanding of transurethral resection of the bladder and enhance their skills. This comprehensive training is specifically tailored for urologists who want to improve their proficiency in resection techniques. Experts will lead participants through the resection on state of the art models, ensuring a familiarity with the process, recognition of the equipment and how to handle it, and an understanding of best practice for the procedure.

Patient advocacy plaza - Radio-ligand-therapy in prostate cancer, patient view on access-availability and affordability



Special Session

Sunday 15 March
16:30 - 17:00

Location Patient Advocacy Plaza
Chair To be confirmed

16:30 - 17:00

Europa Uomo
To be confirmed

Surgery in Motion: Ejaculation-sparing BPO surgery illustrated

Thematic Session

Sunday 15 March
17:15 - 18:15

Location Orange Area, eURO Auditorium 1
Chairs M. Rieken, Zürich (CH)
J. Romero-Otero, Madrid (ES)

Learning objectives

This thematic session focuses on various ejaculated sparing techniques for BPO surgery. Pathophysiology, indications, functional outcomes and treatment-associated comorbidities will be discussed. Experts will share their experience and provide helpful guidance by showcasing selected videos of the respective techniques.

17:15 - 17:22

Semi-live video Ejaculation: Importance and physiology
B. Pradère, Toulouse (FR)

17:22 - 17:25	Discussion
17:25 - 17:32	Semi-live video Rezum + Aquablation M. Ritter, Bonn (DE)
17:32 - 17:35	Discussion
17:35 - 17:42	Semi-live video Ejaculation-sparing laser prostatectomy To be confirmed
17:42 - 17:45	Discussion
17:45 - 17:52	Semi-live video Ejaculation-sparing TURP I. Sokolakis, Thessaloniki (GR)
17:52 - 17:55	Discussion
17:55 - 18:02	Semi-live video Seminal vesiculoscopy M.K.M. Omar, Shibin El Kom (EG)
18:02 - 18:05	Discussion
18:05 - 18:12	Semi-live video UROLift + iTind S. Secco, Milan (IT)
18:12 - 18:15	Discussion

Surgery in Motion: Renal and bladder transplant

Thematic Session

Sunday 15 March
17:15 - 18:15

Location Orange Area, Room 3

Chairs A.J. Figueiredo, Coimbra (PT)
J.D. Olsburgh, London (GB)

Learning objectives

Current state of the art semi-live video presentations of key transplant surgical topics including those relevant to general and robotic urologists: Bench preparation, surgical complications and nightmare situations in kidney transplant will be shown and discussed. Latest developments in robotic heterotopic and orthotopic kidney transplant Step by step robotic surgical techniques for kidney auto-transplant Latest update on bladder transplantation - indications, approach and developments

17:15 - 17:22	Semi-live video presentation Bench surgery: How to prepare the kidney for transplantation A. Territo, Barcelona (ES)
17:22 - 17:29	Semi-live video presentation Robotic assisted kidney transplantation: Step-by-step M. Musquera Felip, Barcelona (ES)

17:29 - 17:32	Discussion
17:32 - 17:39	Semi-live video presentation Robotic assisted kidney auto-transplantation: Indications and step-by-step K. Decaestecker, Gent (BE)
17:39 - 17:42	Discussion
17:42 - 17:49	Semi-live video presentation Robotic orthotopic kidney transplantation: The best choice for impossible transplants F. Vignes Julia, Barcelona (ES)
17:49 - 17:52	Discussion
17:52 - 17:59	Semi-live video presentation Surgical complications and nightmares in kidney transplantation To be confirmed
17:59 - 18:02	Discussion
18:02 - 18:09	Semi-live video presentation Bladder transplantation To be confirmed
18:09 - 18:15	Discussion

Management of major genitourethral trauma

EAU Andrology EAU Reconstruction

Joint session of EAU section of Andrological Urology and EAU Section of Genitourinary reconstructive surgeons

Sunday 15 March
17:15 - 18:15

Location Blue Area, George 3

Chairs C. Bettocchi, Foggia (IT)
D.J. Ralph, London (GB)

Learning objectives

This session will address the contemporary management of major genitourethral trauma, with an additional focus on injuries arising in war and conflict settings – sadly an increasingly relevant challenge even in Europe today. Delegates will gain insights into reconstructive strategies for penile, urethral, scrotal, and testicular trauma, as well as the management of complex ureteral and pelvic injuries. Expert discussions will enhance understanding of surgical decision-making and multidisciplinary care in severe trauma scenarios.

17:15 - 17:25	Mine-explosive trauma of male genital organs and possibilities of reconstructive urology M. Panasovskyi, Kharkiv (UA)
17:25 - 17:27	Discussion

17:27 - 17:37

Treatment of combat-related ureteral injuries in the modern era

D. Shchukin, Kharkiv (UA)

17:37 - 17:39

Discussion

17:39 - 17:46

The management of penile amputation

A. di Giovanni, London (GB)

17:46 - 17:48

Discussion

17:48 - 17:55

Current management of pelvic fracture and urethral disruption injuries

P. Anderson, Dudley (GB)

17:55 - 17:57

Discussion

17:57 - 18:05

Scrotal / testicular trauma

G.I. Russo, Catania (IT)

18:05 - 18:13

Catastrophic complications during penile prosthesis insertion

O. Sedigh, Torino (IT)

18:13 - 18:15

Q&A and closing remarks

GU Cast Podcast

Special Session

Sunday 15 March
17:15 - 18:00

Location

Orange Area, eURO Auditorium 2

17:15 - 18:00

Topic to be confirmed

Speakers

R. Eapen, Melbourne (AU)

D. Murphy, Melbourne (AU)

Managing advanced disease in renal and rare cancers

Plenary Session

Monday 16 March
08:00 - 10:00

Location

Orange Area, eURO Auditorium 1

Chairs

M. Albersen, Leuven (BE)

M.C. Mir Maresma, Valencia (ES)

08:00 - 08:02

Introduction

08:02 - 08:29

Debate Cut, zap, or chill? Tackling the primary tumour in mRCC

08:02 - 08:04	Introduction Would you treat the primary tumour in a patient with mRCC today? T. Kuusk, London (GB)
08:04 - 08:09	You can't ignore the beast in the kidney P.J. Zondervan, Amsterdam (NL)
08:09 - 08:14	Why cut when you can zap? A.K. Lalani, Hamilton (CA)
08:14 - 08:19	What if we asked the patient first? Surveillance of primary W. Yip, Duarte (US)
08:19 - 08:29	Discussion
08:29 - 08:34	Live interview Adaptative clinical trial design in kidney cancer <i>Interviewer</i> V. Parry, London (GB) <i>Speaker</i> To be confirmed
08:34 - 08:44	State-of-the-art lecture Decoding the evolutionary biology of kidney cancer: Insights from the primary tumour to precision therapy Z. Tippu, London (GB)
08:44 - 08:54	State-of-the-art lecture Reprogramming immunity: Microbiota-centered approaches in kidney cancer L. Derosa, Villejuif (FR)
08:54 - 09:09	Rare cancers
08:54 - 08:57	Case presentation A. Larcher, Milan (IT)
08:57 - 08:59	Voting
08:59 - 09:09	Society of Urologic Oncology (SUO) lecture Rare renal tumours: What should the general urologist know? B. Shuch, (US)
09:09 - 09:25	Penile cancer: Patient reported outcomes
09:09 - 09:19	Penile cancer and quality of life: Hearing the patient's voice J. Osborne, Nottingham (GB)
09:19 - 09:25	Discussant: How will PROMs shape the future guidelines? J.K. Jakobsen, Aarhus N (DK)
09:25 - 09:48	Testicular cancer : Stage II Seminoma
09:25 - 09:33	De-escalation approaches: Can we do less? A. Thor, Stockholm (SE)
09:33 - 09:38	RPLND: Tips and tricks for a speedy recovery - Open S. Daneshmand, Los Angeles (US)
09:38 - 09:43	RPLND: Tips and tricks for a speedy recovery - Robot C. Schwentner, Stuttgart (DE)
09:43 - 09:48	Discussion

09:48 - 09:58

Ongoing trials in rare genitourinary cancers

F.C. Maluf, São Paulo (BR)

09:58 - 10:00

Closing remarks

Global men's health crisis

Plenary Session

Monday 16 March

08:00 - 10:00

Location

Orange Area, eURO Auditorium 2

Chairs

C.F.S. Jensen, Herlev (DK)

G.I. Russo, Catania (IT)

Learning objectives

This session will provide delegates with an overview of the key challenges driving the global men's health crisis, including disparities in life expectancy, lifestyle-related risk factors, and access to preventive care. Participants will gain insights into the biological, psychological, and social determinants that shape men's health worldwide. The session will also highlight evidence-based strategies and policies aimed at improving outcomes, fostering awareness, and promoting equity in men's health across diverse populations.

08:00 - 08:02

Introduction

08:02 - 08:10

State-of-the-art lecture Testicular health in decline: Trends in sperm quality, testicular dysgenesis syndrome, cancer incidence and hypogonadism

M. Dinkelman-Smit, Rotterdam (NL)

08:10 - 08:18

State-of-the-art lecture The future of fertility: Social, economic, and genetic drivers of declining birth rates

R. Cannarella, Catania (IT)

08:18 - 08:44

Panel debate Obesity and male sexual and reproductive health: Lifestyle vs. GLP-1 Agonists vs. testosterone

Moderator

M.M. Fode, Herlev (DK)

08:18 - 08:20

Introduction

M.M. Fode, Herlev (DK)

08:20 - 08:24

Lifestyle modification - "Go to the gym"

E. Maseroli, Florence (IT)

08:24 - 08:28

GLP1 agonist - "Take the pill"

G. Rastrelli, Florence (IT)

08:28 - 08:32

Testosterone therapy - "Top up your levels"

J.P. Mulhall, New York (US)

08:32 - 08:44

Discussion and voting

Moderators

M.M. Fode, Herlev (DK)

C.F.S. Jensen, Herlev (DK)

G.I. Russo, Catania (IT)

Panel

E. Maseroli, Florence (IT)

J.P. Mulhall, New York (US)

G. Rastrelli, Florence (IT)

08:44 - 09:13

Round-table discussion **Global male fertility crisis**

Moderator

J.O.R. Sønksen, Herlev (DK)

08:44 - 08:45

Introduction

J.O.R. Sønksen, Herlev (DK)

08:45 - 08:49

Genvironment: The genetics–environment interface in male fertility

D.J. Lamb, Kansas City (US)

08:49 - 08:53

Environmental toxicology and microplastics: Hidden threats to reproductive health

P. Sangster, London (GB)

08:53 - 08:57

Genetics and male aging: Biological limits to fertility

F. Tüttelmann, Münster (DE)

08:57 - 09:01

Societal reflections: Fertility decline from a couples perspective

To be confirmed

09:01 - 09:13

Discussion and voting

Moderators

C.F.S. Jensen, Herlev (DK)

G.I. Russo, Catania (IT)

J.O.R. Sønksen, Herlev (DK)

09:13 - 09:23

Spotlight talk **About male sexuality: Does SoMe help to uncover pathology in men or turn them into patients?**

F. Milhouse, Chicago (US)

09:23 - 09:50

Round-table discussion **Global male sexual health crisis: Modern challenges in male sexual health**

Moderator

G. De Win, Edegem (BE)

09:23 - 09:27

Modern challenges in male sexual health: Understanding pressures, pathology and perspectives

Sidekick

F. Castiglione, London (GB)

09:27 - 09:31

Decline in sexual health in young men: Mental Health, masculinity, and modern pressures

W.G. Lee, London (GB)

09:31 - 09:35

Treating sexual symptoms: Navigating normal psychosexual development, pathology, and the impact of social media

F. Nimbi, Rome (IT)

09:35 - 09:39

The highs and lows of modern relationships

G. Polloni, Como (IT)

09:39 - 09:50

Discussion and voting

Moderators

G. De Win, Edegem (BE)

C.F.S. Jensen, Herlev (DK)

G.I. Russo, Catania (IT)

09:50 - 09:58

State-of-the-art lecture **Reversing the men's health crisis: Strategies for the next decade**

A. Salonia, Milan (IT)

09:58 - 10:00

Closure

POP (pelvic organ prolapse) surgery in real life: Tips, tricks & troubleshooting

ESU Course 45

Monday 16 March

08:30 - 11:30

Location

Red Area, Room 8

Chair

V. Phé, Paris (FR)

Learning objectives

The objective of this course is to provide a complete overview of pelvic organ prolapse diagnosis, investigations (place of urodynamics) and treatment including conservative management and surgeries from open to laparoscopic and robotic approaches.

Clinical cases of POP, POP associated with stress and urge urinary incontinence and complications of surgeries will be discussed methodically.

At the end, the participants will know the diagnostic strategies, the techniques to perform POP surgeries and how to counsel the patients.

- To learn about clinical diagnosis of POP
- To learn about urodynamics and indications
- To learn step by step how to perform a sacrocolpopexy and tips and tricks
- To learn how to manage POP surgery complications

Patient selection & procedure planning (conservative vs vaginal vs abdominal)

F. Cancrini, Rome (IT)

Vaginal native-tissue repair – Step-by-step

N. Khalil, Beirut (LB)

Robotic/laparoscopic sacrocolpopexy, the tips to make it right – Step-by-Step

V. Phé, Paris (FR)

Complications, redo & guidelines – Pitfalls, rescue & what to apply tomorrow (complications of vaginal surgery, complications of abdominal surgery, interactive videos, case discussions)

F. Cancrini, Rome (IT)

N. Khalil, Beirut (LB)

V. Phé, Paris (FR)

Monday 16 March
08:30 - 11:30

Location Red Area, Room 9

Chair H. John, Winterthur (CH)

Learning objectives

Reconstructive and re-do robotic urology is a rapidly evolving field. Growing experience and new technology allow to reconstruct lower and upper urinary tract more and more by minimal invasive robotic technology with good functional outcomes, thus preventing often relaparotomies.

Introduction

H. John, Winterthur (CH)

Distal ureteric strictures – overview of techniques

H. John, Winterthur (CH)

Proximal ureteric strictures – overview of techniques

B. McGuire, Dublin (IE)

Alternative options: Appendix onlay, round ligament and bladder ureteroplasty

B. McGuire, Dublin (IE)

Anti-Reflux techniques in ureteral reconstruction: Yes or no

B. McGuire, Dublin (IE)

Retroperitoneal fibrosis - technique for ureterolysis and omental wrap

B. McGuire, Dublin (IE)

Fascia lata sacrocolpopexy

B. Peyronnet, Rennes (FR)

Mesh removal-full TOT removal

B. Peyronnet, Rennes (FR)

Vesico-vaginal and vesico-rectal fistulae

H. John, Winterthur (CH)

YV plasty technique for bladder neck stenosis

H. John, Winterthur (CH)

Augmentation cystoplasty and mitrofanoff

B. Peyronnet, Rennes (FR)

Closure

H. John, Winterthur (CH)

Monday 16 March
08:30 - 11:30

Location Red Area, Room 7

Chair A. Breda, Barcelona (ES)

Learning objectives

This course will cover all principal indications for robotic surgery of the upper urinary tract. The standard techniques will be explained in a video-based fashion and will be followed by discussing advanced cases as well as troubleshooting and complication management. On top of that, technical innovations and new applications will be discussed as well.

Don't miss this course, a must for all robotic surgeons expect:

- Video-based step-by-step approach
- Standard techniques
- Complex cases
- Troubleshooting and complication management
- Technical innovations: What's new in robotics?

Introduction

A. Breda, Barcelona (ES)

Patient positioning, trocar positioning, trans- and retroperitoneal access in renal robotic surgery

A. Breda, Barcelona (ES)

Robotic pyeloplasty: Multichannel or single technique

A. Antonelli, Verona (IT)

Renal surgery: Nephrectomy and nephroureterectomy: How I do it

A. Breda, Barcelona (ES)

Partial nephrectomy I: Step 1: Isolation of renal hilum; Step 2: Mobilisation of the kidney; Step 3: Clamping of renal pedicle: Different techniques

A. Antonelli, Verona (IT)

Partial nephrectomy II: Step 4: Different tumour resection techniques

R. De Groot, Aalst (BE)

Partial nephrectomy III: Step 5: Different renography techniques

A. Breda, Barcelona (ES)

Partial nephrectomy IV: Special and difficult indications

R. De Groot, Aalst (BE)

Complications, new tools and advanced radical nephrectomy

R. De Groot, Aalst (BE)

Wrap up and conclusions

A. Breda, Barcelona (ES)

Surgical complications during laparoscopic/robotic urological procedures: Prevention, diagnosis, management and complications

ESU Course 49

Monday 16 March
08:30 - 11:30

Location Red Area, Room 12

Chair B.M.C. Rocco, Rome (IT)

Learning objectives

- The risk of complication is a major issue for laparoscopic and robotic surgeons; the knowledge of complication is key to maximize the safety of urological procedures.
- The course provides a comprehensive overview about the topic, summarizing how to prevent, recognize, grade and fix surgical issues. - An interactive video session will merge trainees' and experts' experience to approach minor, major and harmful drawback of common urological interventions.

Introduction - Aims of the course

B.M.C. Rocco, Rome (IT)

Lectures: Frequency, risk factors, prevention and key aspects

Vascular lesions

A.E. Canda, Istanbul (TR)

Intestinal lesions

B.M.C. Rocco, Rome (IT)

Urinary, neuronal and solid organ lesions

T. Tokas, Heraklion (GR)

How to minimize the risk of complications in robotic surgery? - Tricks of the trade

B.M.C. Rocco, Rome (IT)

Risk factors and grading of complications: The patient's and the surgeon's factor

T. Tokas, Heraklion (GR)

How to train complications management: Tips and tricks from the training models

A.E. Canda, Istanbul (TR)

Video presentation and case management - A video collection from experts

A.E. Canda, Istanbul (TR)

T. Tokas, Heraklion (GR)

Questions and answers

B.M.C. Rocco, Rome (IT)

Flexible ureterorenoscopy and retrograde intrarenal surgery: Instrumentation, technique, tips, tricks and indications

ESU Course 47

Monday 16 March
08:30 - 11:30

Location Red Area, Room 10

Chair B. Somani, Southampton (GB)

Learning objectives

The aims and objectives of this course is to provide a complete overview of instruments, endoscopes, indications, technique and special tips and tricks concerning Retrograde IntraRenal Surgery (RIRS) using flexible ureterorenoscopes and Holmium YAG lasers. At the end the participants will know the equipment and the technique to perform flexible ureterorenoscopy in the best conditions. • To learn about equipment. • To learn about technique and indications. • To learn how to use an Holmium Laser. • To learn tips and tricks for special circumstances.

Welcome and introduction

B. Somani, Southampton (GB)

Instrumentation: Endoscopes

N. Davis, Dublin (IE)

Instrumentation: Laser and lithotripsy devices

B. Somani, Southampton (GB)

Instrumentation: Disposable (wires, retrieving devices, ureteral access sheath (UAS), irrigation devices and others)

H.U. Jung, Vejle (DK)

Technique: Stones

N. Davis, Dublin (IE)

Technique: Urothelial tumours and strictures

B. Somani, Southampton (GB)

Tips and tricks and special circumstances

N. Davis, Dublin (IE)

Indications (guidelines) and clinical cases

H.U. Jung, Vejle (DK)

Conclusions

B. Somani, Southampton (GB)

Metabolic workup and non-surgical management of urinary stone disease: What a urologist must know

ESU Course 48

Monday 16 March
08:30 - 11:30

Location Red Area, Room 11

Chair O. Traxer, Paris (FR)

Learning objectives

Urolithiasis is an increasingly prevalent worldwide disease with recurrence rates up to 50% over 5 years. Metabolic assessment to identify predisposing factors and prevention therefore play an important role in patient management. This course will address common findings on dietary and metabolic workup and highlight medical and non-medical treatment options for these metabolic abnormalities in the prevention of stone recurrence.

The goal of the course is for participants to be able to:

- Identify patients that would benefit from metabolic workup.
- Interpret standard metabolic workup, including dietary and medical history and biochemical analyses.
- Understand what the guidelines say on targeted medical treatment for prevention of urinary stone disease.
- Understand the influence of dietary changes on metabolic urinary values and provide dietary counselling.

Introduction

O. Traxer, Paris (FR)

Metabolic evaluation: What the Guidelines say? A summary

A. Sierra Del Rio, Barcelona (ES)

Stone composition: What the stones are telling you?

O. Traxer, Paris (FR)

Metabolic evaluation: Back to the basics

O. Wiseman, Cambridge (GB)

Diet and stones

O. Traxer, Paris (FR)

Medical treatment: What, when and for which patient?

O. Wiseman, Cambridge (GB)

How to manage a patient with hypercalciuria

O. Traxer, Paris (FR)

Cystinuria

A. Sierra Del Rio, Barcelona (ES)

Stones and metabolic syndrome

O. Wiseman, Cambridge (GB)

Clinical cases

A. Sierra Del Rio, Barcelona (ES)

O. Traxer, Paris (FR)

O. Wiseman, Cambridge (GB)

Hands-on Training in prostate MRI reading for urologists

HOT MRI - 4.1

Monday 16 March
09:00 - 12:30

Location Red Area, Room 6

Learning objectives

This course will provide interactive teaching from expert faculty in prostate MRI reading and interpretation and help urologists to understand the role MRI plays in the management of patients with prostate cancer and how to use the information generated by prostate MRI. The course will address how to use an imaging workstation, how to understand the basic concepts/principles behind different MRI sequences (T2-weighted imaging, DWI-imaging and DCE-imaging), in which order to view the different sequences when interpreting prostate MRI, how to use the PI-RADS scoring system to score MRIs, and finally to understand what are the standards for a prostate MRI and what quality criteria need to be fulfilled. The participants will do hands on reading and assessment of prostate MRI scans on a provided computer using realistic software, followed by a reference reading provided by expert radiologists and pathological verification.

09:00 - 09:05

Course overview

J. Gómez Rivas, Madrid (ES)

09:05 - 09:15

Lecture: The importance of prostate MRI to the Urologist

C.V. Kesch, Essen (DE)

09:15 - 09:45

Lecture: Introduction to MRI sequences, scoring systems, PI-RADS

To be confirmed

09:45 - 10:15

Lecture: Interactive case discussion – reporting MRI using PI-RADS

J.A. Hernández Mancera, Barcelona (ES)

10:15 - 10:20

Introduction to the software for MRI interpretation

J. Gómez Rivas, Madrid (ES)

10:20 - 10:50

Diagnosis I: Practical MRI diagnosis

10:50 - 11:20

Review of the findings I

To be confirmed

11:20 - 11:50

Diagnosis II: Practical MRI diagnosis

11:50 - 12:20

Review of the findings II

J.A. Hernández Mancera, Barcelona (ES)

Hands-on Training in TP Biopsy and MRI fusion

HOT TPB - MRI - 4.1

Monday 16 March
09:00 - 12:00

Location Red Area, Room 2

Chair To be confirmed

Learning objectives

This course is designed to provide a comprehensive overview of office based transperineal (TP) biopsy techniques in local anaesthesia. It includes the integration of MRI fusion technology into daily clinical practice. Participants will begin with an introduction to the importance of TP biopsy and detailed instructions on performing the procedure by themselves..

The hands-on training sessions are the core of the course, where participants will practice:

- Basic superficial local anesthesia
- Deep periprostatic block
- Basic perineal with probe
- Basics of targeting and fusion
- Basics of hitting
- Single incision biopsies

09:00 - 09:05

Introduction

To be confirmed

09:05 - 09:20

Why TP biopsy and how to do TP biopsy

To be confirmed

09:20 - 09:30

Technical comparison

To be confirmed

09:30 - 11:25

Hands-on Training

Tutors

M. Essam El Din, Basingstoke (GB)

M. Jahnen, Munich (DE)

To be confirmed

To be confirmed

11:25 - 11:55

Circulate among stations

11:55 - 12:00

Closing remarks

To be confirmed

Monday 16 March
10:45 - 12:15

Location Blue Area, Victoria 4
Chairs I. Ahmad, Glasgow (GB)
T. Fazekas, Budapest (HU)
L. Rodriguez-Sanchez, Paris (FR)

10:45 - 11:20

Biomarkers influencing biopsy strategy

A0691

To biopsy or not to biopsy? The utility of Prostate Health Index in men with PIRADS 4 lesions

Authors

Wang K., [Tsang W.C.](#), Seah C.H.X., Wang Z., Chiong E.

Institutions

National University Hospital, Dept. of Urology, Singapore, Singapore

A0693

Normalized periprostatic adipose tissue thickness: an imaging marker associated with prostate biopsy outcomes among patients with PI-RADS 3 and PSA 4–10 ng/mL

Authors

[Xiong T.](#)¹, Shen L.², Yunpeng F.¹, Zhanliang L.¹, Jin S.¹, Wu H.¹, Yang Z.², Yinong Y.N.¹

Institutions

¹Beijing Friendship Hospital, Dept. of Urology, Beijing, China, ²Beijing Friendship Hospital, Dept. of Radiology, Beijing, China

A0694

Effect of recent ejaculation on prostate-specific antigen levels in middle-aged men: implications for patient counselling prior prostate-specific antigen testing

Authors

[Meissner V.H.](#)¹, Müseler N.¹, Ankerst D.P.², Schiele S.¹, Gschwend J.E.¹, Herkommer K.¹

Institutions

¹Technical University of Munich - School of Medicine and Health - TUM University Hospital, Dept. of Urology, Munich, Germany, ²Technical University of Munich, Dept. of Mathematics and Life Sciences, Munich, Germany

A0695

Utilization of Biomarkers to Guide Biopsy Decisions for PI-RADS 3 Prostate Lesions

Authors

Youssef R., [Knoerzer M.](#), Hammad M., Tran V., Yacoub M., Kim D., Avila I.

Institutions

University of California Irvine, Dept. of Urology, Orange, United States of America

A0696

Associations of 2923 plasma proteins with incident prostate cancer in a prospective cohort study and genetic analysis

Authors

[Yichen L.](#), Yibo Y., Guofa L., Yuming J., Zilong Z., Chuzhong W., Xianghong Z., Lu Y., Qiang W., Shi Q.

Institutions

West China Hospital of Sichuan University, Dept. of urology, Chengdu, China

A0697

Can PHI and mpMRI-targeted biopsy alone avoid systematic biopsy in patients suspicious for prostate cancer? An interim analysis of the prospective multicenter PROSPIN study.

Authors

Meiser S.¹, Malleier M.¹, Rosta G.², Mun D.H.², Peters J.³, Strathmeyer S.⁴, Ameismeier T.⁴, Neuwirt H.⁵, Kafka M.⁶, Artamonova N.⁶, Giannini G.⁶, Heidegger I.⁶, Bektic J.⁶, Tulchiner G.⁶, Lackner F.⁶, Aigner G.⁶, Laschober G.⁶, Lusuardi L.³, Fajkovic H.², Böld T.⁴, Drettwan D.⁴, Aufderklamm S.¹, Eder I.⁶, Ladurner M.⁶

Institutions

¹Landeskrankenhaus Bregenz, Dept. of Urology, Bregenz, Austria, ²University Clinic of St. Pölten, Dept. of Urology, St. Pölten, Austria, ³Medical University of Salzburg, Dept. of Urology, Salzburg, Austria, ⁴Lifespın GmbH, Studys and Clinical Affairs, Regensburg, Germany, ⁵Medical University of Innsbruck, Internal Medicine IV, Nephrology and Hypertension, Innsbruck, Austria, ⁶Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria

11:20 - 11:55

Risk stratification

A0698

GENITOURINARY MICROBIOME AND VOLATILE PROFILING IN PATIENTS WITH PROSTATIC ADENOCARCINOMA SUBMITTED TO RADICAL PROSTATECTOMY

Authors

Santodirocco L.S.¹, Di Pierro G.B.¹, Gobbi L.¹, Sciarra A.¹, Franco G.¹, Bevilacqua G.¹, Salciccia S.¹, Maurizi L.², Longhi C.²

Institutions

¹La Sapienza Università di Roma, Maternal-Child and Urogynecological Sciences, Rome, Italy, ²La Sapienza Università di Roma, Dept. of Public Health and Infectious Diseases, Rome, Italy

Effect of 5-Alpha Reductase Inhibitor Therapy on Second MRI and Re-biopsy Results after an Initial Negative mpMRI-Targeted and Systematic Biopsy for PI-RADS ≥ 3 Lesions

Authors

Zattoni F.¹, Giganti F.², Hogenhout R.E.³, Reitano G.¹, Novara G.¹, Fazekas T.S.⁴, Soeterik T.F.W.⁵, Olivier J.⁶, Puche-Sanz I.⁷, Maggi M.⁸, Campi R.⁹, Amparore D.¹⁰, Junlong Z.¹¹, Guo H.¹¹, Marquis A.¹², Barletta F.¹³, Leni R.¹³, Kasivisvanathan V.¹⁴, Antonelli A.¹⁵, Rivas J.G.¹⁶, van den Bergh R.C.N.³, Dal Moro F.¹, Gandaglia G.¹³, Giancarlo M.¹²

Institutions

¹University of Padua, Dept. of Urology, Padua, Italy, ²University College London Hospitals NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, ³Erasmus MC Cancer Institute, University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ⁴Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Budapest, Hungary, ⁵University Medical Center Utrecht, Dept. of Radiation Oncology, Utrecht, The Netherlands, ⁶Lille University, Dept. of Urology, Lille, France, ⁷Instituto de Investigación Biosanitaria ibs.Granada, Hospital Universitario Virgen de las Nieves (HUVN), Dept. of Urology, Granada, Spain, ⁸ASST Santi Paolo and Carlo, Unit of Urology, Dept. of Health Science, Milan, Italy, ⁹Careggi Hospital, University of Florence, Unit of Urology and Renal Transplantation, Dept. of Urology, Florence, Italy, ¹⁰San Luigi Gonzaga Hospital, University of Turin, School of Medicine, Division of Urology, Dept. of Oncology, Turin, Italy, ¹¹Medical School of Nanjing University, Dept. of Urology, Nanjing, China, ¹²Molinette Hospital, University of Turin, Division of Urology, Dept. of Surgical Sciences, Turin, Italy, ¹³IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ¹⁴Centre for Urology Imaging, Prostate, AI and Surgical Studies (COMPASS) Research Group, Division of Surgery and Interventional Science, University College London, London, United Kingdom, Dept. of Urology, London, United Kingdom, ¹⁵Azienda Ospedaliera Universitaria Integrata Verona, Dept. of Urology, Verona, Italy, ¹⁶Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain

Is There a Need for PSA Re-testing Before Specialist Referral? Insights from from the Norwegian Prostate Cancer Consortium (NPCC)

Authors

Aas K.¹, Thomas O.², Bjerner L.J.³, Albertsen P.C.⁴, Carlsson S.V.⁵, Oldenburg J.⁶

Institutions

¹Akershus University Hospital - Ahus, Dept. of Urology, Lørenskog, Norway, ²Akershus University Hospital (ahus), Biostatistics, Lørenskog, Norway, ³Fürst Medical Laboratory, Clinical Chemistry, Oslo, Norway, ⁴UConn Health, Dept. of Urology, Farmington, United States of America, ⁵German Cancer Research Center (DKFZ), Clinical Epidemiology of Early Cancer Detection, Heidelberg, Germany, ⁶Akershus University Hospital (ahus), Dept. of Oncology, Lørenskog, Norway

A0701

Exploring the Diagnostic Yield of Prostate MRI for Prostate Cancer Detection in Younger Men: Implications for MRI interpretation across Different Age Thresholds

Authors

Scilipoti P.¹, Stabile A.¹, Bandini M.¹, Cucchiara V.¹, Barletta F.M.¹, Scuderi S.¹, Longoni M.¹, Quarta L.¹, Zaurito P.¹, Viti A.¹, Brancaccio M.¹, Porzi M.E.¹, Maestroni V.¹, Colistro A.¹, Bonavia L.¹, De Cobelli F.², Esposito A.², Brembilla G.², Russo T.², Cosenza M.², Pennella R.², Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy

A0702

Does lesion volume play a role in the decision to perform targeted biopsy in pirads 3 lesions? A new psa derivative

Authors

Erten K.S.¹, Cetin S.¹, Sariduman N.¹, Bulut E.C.¹, Onaran M.¹, Yesil S.¹, Ucar M.², Gonul I.I.³, Sozen T.S.¹

Institutions

¹Gazi University Faculty of Medicine, Dept. of Urology, Ankara, Turkey, ²Gazi University Faculty of Medicine, Dept. of Radiology, Ankara, Turkey, ³Gazi University Faculty of Medicine, Dept. of pathology, Ankara, Turkey

A0703

A Highly Sensitive DNA Mutation Assay for Prostate Cancer Diagnosis

Authors

Zhong X.Y., Xia Q., Wang S.

Institutions

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Dept. and Institute of Urology, Wuhan, China

A0704

A Comprehensive Decision-Making Framework for Prostate Biopsy in PI-RADS 3 Patients: Integrating Periprostatic Adipose Tissue Thickness and PSA Density

Authors

Xiong T.¹, Zhu X.¹, Shen L.², Liu Z.¹, Jin S.¹, Fan Y.¹, Yang Z.², Niu Y.¹

Institutions

¹Beijing Friendship Hospital, Dept. of Urology, Beijing, China, ²Beijing Friendship Hospital, Dept. of Radiology, Beijing, China

11:55 - 12:00

PSMA PET in diagnosis

Fully hybrid 18F-PSMA PET/MRI as a One-Stop Approach for the Diagnosis of Clinically-Significant Prostate Cancer: Preplanned Interim Results from a Phase II Prospective Trial

Authors

Scuderi S.L.A.¹, Stabile A.¹, Cucchiara V.¹, Barletta F.M.¹, Quarta L.¹, Zaurito P.¹, Maestroni V.G.¹, De Cobelli F.², Esposito A.², Brembilla G.², Russo T.², Cosenza M.², Pennella R.², Camisassa E.², Sollini M.³, Ghezzi S.³, Pini C.³, Chiti A.³, Picchio M.³, Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy

12:00 - 12:05

Learning curve for biopsy

A0706

Evaluating the learning curve of transperineal MRI-guided prostate biopsies: procedure efficiency and diagnostic outcomes in a single-center cohort of more than 3,300 cases

Authors

Hoeh B.¹, Hallaschek M.¹, Platzek I.², Boehm K.¹, Baunacke M.¹, Borkowetz A.³, Thomas C.¹, Herout R.¹

Institutions

¹University Hospital Carl Gustav Carus, Dept. of Urology, Dresden, Germany, ²University Hospital Carl Gustav Carus, Dept. of Radiology, Dresden, Germany, ³University Medical Centre Rostock, Dept. of Urology, Rostock, Germany

Focal therapy of prostate cancer: Patient selection, long-term outcomes and emerging techniques

Abstract Session 40

Monday 16 March
10:45 - 12:15

Location

Blue Area, Victoria 2

Chairs

C. Moore, London (GB)

R. Sanchez-Salas, Montreal (CA)

C. Varol, Sydney (AU)

10:45 - 11:10

Patient selection

Comparison of contemporary patient selection criteria for focal therapy: An analysis of 2658 patients from the prospective HEAT and ICE registries

Authors

Light A.¹, Peters M.², Morris S.¹, Arya M.³, Bertocelli Tanaka M.³, Doherty A.⁴, Dudderidge T.⁵, Emara A.⁶, Emberton M.⁷, Grey A.⁷, Hindley R.⁶, Laniado M.⁸, McCracken S.⁹, Moore C.M.⁷, Nigam R.¹⁰, Noureldin M.⁶, Orczyk C.⁷, Rakauskas A.³, Simmons L.¹¹, Virdi J.¹², Withington J.⁷, Zakikhani P.¹³, Ahmed H.U.¹, Shah T.T.¹

Institutions

¹Imperial College London, Imperial Prostate, London, United Kingdom, ²Radiotherapiegroep, Dept. of Radiotherapy, Deventer, The Netherlands, ³Imperial College Healthcare NHS Trust, Imperial Urology, Charing Cross Hospital, London, United Kingdom, ⁴University Hospitals Birmingham NHS Foundation Trust, Dept. of Urology, Queen Elizabeth Hospital, London, United Kingdom, ⁵University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton General Hospital, Southampton, United Kingdom, ⁶Hampshire Hospitals NHS Foundation Trust, Dept. of Urology, Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom, ⁷University College London, Division of Surgery and Interventional Science, London, United Kingdom, ⁸Frimley Health NHS Foundation Trust, Dept. of Urology, Wexham Park Hospital, Slough, United Kingdom, ⁹South Tyneside and Sunderland NHS Foundation Trust, Dept. of Urology, Sunderland Royal Hospital, Sunderland, United Kingdom, ¹⁰Royal Surrey NHS Foundation Trust, Dept. of Urology, Royal Surrey County Hospital, Guildford, United Kingdom, ¹¹Royal United Hospitals Bath NHS Foundation Trust, Dept. of Urology, Royal United Hospital, Bath, United Kingdom, ¹²The Princess Alexandra Hospital NHS Trust, Dept. of Urology, Princess Alexandra Hospital, Harlow, United Kingdom, ¹³University Hospitals Sussex NHS Foundation Trust, Dept. of Urology, Princess Royal Hospital, Haywards Heath, United Kingdom

Study Group

HEAT and ICE Users Group(London, United Kingdom)

Presence of Contralateral Clinically Significant Prostate Cancer in Radical Prostatectomy Specimens of Patients with Unilateral MRI Lesions and Its Influence on eligibility Patient Selection for Focal Therapy

Authors

Marques Monteiro M.¹, Oliveira J.P.², Barret E.², Macek P.², Cathala N.², Mombet A.², Cathelineau X.², Rodríguez Sánchez L.²

Institutions

¹Centro Hospitalar Universitário de Santo António, Dept. of Urology, Porto, Portugal, ²Institut Montsouris, Dept. of Urology, Paris, France

Can we avoid contralateral biopsies when considering focal therapy? What can we miss?

Authors

Marques Monteiro M.¹, Oliveira J.P.², Barret E.², Cathala N.², Mombet A.², Cathelineau X.², Macek P.², Rodríguez Sánchez L.²

Institutions

¹Centro Hospitalar Universitário de Santo António, Dept. of Urology, Porto, Portugal, ²Institut Montsouris, Dept. of Urology, Paris, France

A0676

Concordance Between MRI, Biopsy, and Radical Prostatectomy in Assessing Prostate Cancer Laterality for Focal Therapy Candidates

Authors

Marques Monteiro M.¹, Oliveira J.P.², Barret E.², Mombet A.², Cathala N.², Macek P.², Cathelineau X.², Rodríguez Sánchez L.²

Institutions

¹Centro Hospitalar Universitário de Santo António, Dept. of Urology, Porto, Portugal, ²Institut Montsouris, Dept. of Urology, Paris, France

A0677

Focal Therapy for Localised Prostate Cancer: Clinical and Imaging Predictors of Failure in a 4-Year Prospective Cohort

Authors

Tallari A.¹, Mallia V.¹, Evangelista L.¹, Cella L.¹, Finocchiaro A.¹, Piccolini A.¹, Avolio P.P.¹, Paciotti M.¹, Maffei D.¹, Hurle R.², Saita A.², Casale P.², Buffi N.M.¹, Fasulo V.¹, Lazzeri M.², Lughezzani G.¹

Institutions

¹Humanitas University, Dept. of Biomedical Sciences, Milan, Italy, ²Humanitas Research Hospital - IRCCS, Dept. of Urology, Milan, Italy

11:10 - 11:50

HIFU and cryoablation

A0678

10-year oncological outcomes following focal HIFU and cryotherapy for treatment of non-metastatic prostate cancer: An analysis of 3471 patients from the prospective HEAT and ICE registries

Authors

Light A.¹, Peters M.², Mayor N.¹, Arya M.³, Bertonecchi Tanaka M.³, Doherty A.⁴, Dudderidge T.⁵, Emara A.⁶, Emberton M.⁷, Grey A.⁷, Hindley R.⁶, Laniado M.⁸, McCracken S.⁹, Moore C.M.⁷, Nigam R.¹⁰, Noureldin M.⁶, Orczyk C.⁷, Rakauskas A.³, Simmons L.¹¹, Viridi J.¹², Withington J.⁷, Zakikhani P.¹³, Ahmed H.U.¹, Shah T.T.¹

Institutions

¹Imperial College London, Imperial Prostate, London, United Kingdom, ²Radiotherapiegroep, Dept. of Radiotherapy, Deventer, The Netherlands, ³Imperial College Healthcare NHS Trust, Imperial Urology, Charing Cross Hospital, London, United Kingdom, ⁴University Hospitals Birmingham NHS Foundation Trust, Dept. of Urology, Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁵University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton General Hospital, Southampton, United Kingdom, ⁶Hampshire Hospitals NHS Foundation Trust, Dept. of Urology, Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom, ⁷University College London, Division of Surgery and Interventional Science, London, United Kingdom, ⁸Frimley Health NHS Foundation Trust, Dept. of Urology, Wexham Park Hospital, Slough, United Kingdom, ⁹South Tyneside and Sunderland NHS Foundation Trust, Dept. of Urology, Sunderland Royal Hospital, Sunderland, United Kingdom, ¹⁰Royal Surrey NHS Foundation Trust, Dept. of Urology, Royal Surrey County Hospital, Guildford, United Kingdom, ¹¹Royal United Hospitals Bath NHS Foundation Trust, Dept. of Urology, Royal United Hospital, Bath, United Kingdom, ¹²The Princess Alexandra Hospital NHS Trust, Dept. of Urology, Princess Alexandra Hospital, Harlow, United Kingdom, ¹³University Hospitals Sussex NHS Foundation Trust, Dept. of Urology, Princess Royal Hospital, Haywards Heath, United Kingdom

Study Group

HEAT and ICE Users Group(London, United Kingdom)

A0679

Prognostic value of preoperative SUV in patients who underwent focal therapy HIFU: early prospective results from a single-center cohort

Authors

Mallia V.¹, Fasulo V.¹, Tallari A.¹, Evangelista L.¹, Tiscione M.¹, Sormani F.¹, Maffei D.¹, Avolio P.P.¹, Paciotti M.¹, Casale P.², Saita A.², Hurle R.², Buffi N.M.¹, Lughezzani G.¹, Lazzeri M.²

Institutions

¹Humanitas University, Dept. of Biochemical Sciences, Milan, Italy, ²IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy

A0680

Single-tap versus double-tap high-intensity focused ultrasound (HIFU) for localized prostate cancer: a propensity score-matched analysis.

Authors

Rodriguez-Sanchez L.¹, Baiamonte G.¹, Dante T.², Rodriguez-Serrano A.¹, Segulier D.³, Olivier J.³, Kaufmann B.⁴, Daniel E.⁴, Ebner A.⁴, Maiolino G.⁵, Martínez-Salamanca J.I.⁵, Linares-Espinós E.⁵, Nagaraj Y.⁶, Cathelineau X.¹, Salomon G.⁶, Sanchez-Salas R.⁷, Polascik T.J.⁸

Institutions

¹Institut Médico-chirurgical Montsouris, Dept. of Urology, Paris, France, ²Faculty of Engineering and Business, Universidad de Las Américas, Data Science Research Center, Santiago, Chile, ³Claude Huriez Hospital, CHU Lille, Dept. of Urology, Lille, France, ⁴University Hospital Zurich, University of Zurich, Dept. of Urology, Zurich, Switzerland, ⁵Lyx Institute of Urology, Universidad Francisco de Vitoria, Dept. of Urology, Madrid, Spain, ⁶Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁷McGill University, Dept. of Urology, Montréal, Canada, ⁸Duke Cancer Centre, Dept. of Urology, Durham, United States of America

A0681

Microultrasound for Post-HIFU Surveillance in Localized Prostate Cancer: A Prospective Experience

Authors

Avolio P.P.¹, Fasulo V.¹, Paciotti M.¹, Piccolini A.¹, Finocchiaro A.¹, Mallia V.¹, Lazzeri M.², Casale P.², Buffi N.M.¹, Lughezzani G.¹

Institutions

¹Humanitas University, Dept. of Biomedical Science, Pieve Emauele, Italy, ²Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

A0682

Hemigland vs. Whole Gland Primary Cryoablation for Localised Prostate Cancer: a Comparative Analysis Evaluating Perioperative, Oncological, and Functional Outcomes

Authors

Misuraca L., Anceschi U., Brassetti A., Bove A.M., Bologna E., Chiacchio G., D'Annunzio S., Ferriero M., Flammia R.S., Guaglianone S., Leonardo C., Licari L.C., Mastroianni R., Proietti F., Tuderti G., Simone G.

Institutions

IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Dept. of Urology, Rome, Italy

5-year outcomes after index lesion ablation of multifocal prostate cancer using focal HIFU and cryotherapy: An analysis of 1050 patients

Authors

Light A.¹, Peters M.², Gopalakrishnan A.¹, Mayor N.¹, Cullen E.¹, Boaz J.³, Norris J.³, Morris S.¹, Rakauskas A.³, Bertoncelli Tanaka M.³, Arya M.³, Ahmed H.U.¹, Shah T.T.¹

Institutions

¹Imperial College London, Imperial Prostate, London, United Kingdom, ²Radiotherapiegroep, Dept. of Radiotherapy, Deventer, The Netherlands, ³Charing Cross Hospital, Imperial College Healthcare NHS Trust, Imperial Urology, London, United Kingdom

A multicenter evaluation of infield recurrence rates in patients treated with focal HIFU or cryotherapy

Authors

Reddy D.T.¹, Fan R.², Kaneko M.³, Freitas P.⁴, Fainberg J.⁵, Wang B.⁶, Bahar P.⁷, Tayebi S.⁸, Sidana A.⁹, Ayenew M.¹, Hayek O.¹⁰, Rais- Bahrami S.¹¹, Wood A.⁷, Olivares R.⁶, Nahar B.⁴, Sonn G.², George A.¹, Abreu A.³

Institutions

¹Johns Hopkins University, Dept. of Urology, Baltimore, United States of America, ²Stanford University, Dept. of Urology, Stanford, United States of America, ³University of Southern California, Dept. of Urology, Los Angeles, United States of America, ⁴University of Miami Miller School of Medicine, Dept. of Urology, Miami, United States of America, ⁵Memorial Sloane Kettering Cancer Centre, Dept. of Urology, New York, United States of America, ⁶Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ⁷University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ⁸University of Cincinnati, Dept. of Urology, Cincinnati, United States of America, ⁹University of Chicago, Dept. of Urology, Chicago, United States of America, ¹⁰University of Alabama, Dept. of Urology, Birmingham, United States of America, ¹¹Wake Forest University, Dept. of Urology, Winston Salem, United States of America

A multi-institution analysis of oncological and safety outcomes following focal therapy in the USA

Authors

Reddy D.T.¹, Fan R.², Kaneko M.³, Freitas P.⁴, Fainberg J.⁵, Wang B.⁶, Bahar P.⁷, Tayebi S.⁸, Sidana A.⁹, Hayek O.¹⁰, Ayenew M.¹, Rais- Bahrami S.¹¹, Wood A.⁷, Olivares R.⁶, Nahar B.⁴, Abreu A.³, George A.¹, Sonn G.²

Institutions

¹Johns Hopkins University, Dept. of Urology, Baltimore, United States of America, ²Stanford University, Dept. of Urology, Stanford, United States of America, ³University of Southern California, Dept. of Urology, Los Angeles, United States of America, ⁴University of Miami Miller School of Medicine, Dept. of Urology, Miami, United States of America, ⁵Memorial Sloane Kettering Cancer Centre, Dept. of Urology, New York, United States of America, ⁶Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ⁷University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ⁸University of Cincinnati, Dept. of Urology, Cincinnati, United States of America, ⁹University of Chicago, Dept. of Urology, Chicago, United States of America, ¹⁰University of Alabama, Dept. of Urology, Birmingham, United States of America, ¹¹Wake Forest University, Dept. of Urology, Winston Salem, United States of America

A0686

ProFocal™ cooled focal laser ablation for localised prostate cancer: 12-month outcomes from the PFLT-PC trial.

Authors

McAuliffe H¹, Kam J.², Arianayagam M.², Canagasingham B.², Goolam A.², Jeffery N.², Khadra M.², Myint M.², Ko R.², Mehan N.², Thangasamy I.², Varol C.³

Institutions

¹The University of Sydney, Sydney Medical School, Sydney, Australia, ²Nepean Urology Research Group, Nepean Hospital, Kingswood, Australia, ³Medlogical Innovations, ProFocal™, Sydney, Australia

A0687

Evaluating Safety and Efficacy of Focal Laser Ablation with ProFocal® in Localised Prostate Cancer: Histopathological and Adverse Outcomes at Three Months

Authors

Bushati Y¹, McAuliffe H.¹, Kam J.², Canagasingham B.², Goolam A.³, Wang N.⁴, Hadley A.³, Louie-Johnsun M.⁵, Myint M.², Gillatt D.⁶, Winter M.², Khadra M.², Mehan N.², Arianayagam M.², Thangasamy I.², Varol C.²

Institutions

¹Nepean Urology Research Group, Dept. of Urology, Kingswood, Australia, ²Nepean Hospital, Dept. of Urology, Kingswood, Australia, ³Sydney Adventist Hospital, Dept. of Urology, Wahroonga, Australia, ⁴Nepean Hospital, Dept. of Radiology, Kingswood, Australia, ⁵Mater Private Hospital, Dept. of Urology, Redland, Australia, ⁶Macquarie University Hospital, Dept. of Urology, Macquarie Park, Australia

Study Group

Nepean Urology Research Group(Kingswood, Australia)

A0688

Validation of the ePI-FAB Score to Predict Residual Disease Following Cooled Focal Laser Ablation with ProFocal™ in Prostate Cancer

Authors

Bushati Y¹, McAuliffe H.¹, Kam J.², Canagasingham B.², Goolam A.³, Hadley A.³, Louie-Johnsun M.⁴, Myint M.², Gillatt D.⁵, Winter M.², Khadra M.², Mehan N.², Arianayagam M.², Thangasamy I.², Varol C.², Wang N.⁶

Institutions

¹Nepean Urology Research Group, Dept. of Urology, Sydney, Australia, ²Nepean Hospital, Dept. of Urology, Kingswood, Australia, ³Sydney Adventist Hospital, Dept. of Urology, Wahroonga, Australia, ⁴Mater Private Hospital, Dept. of Urology, Redland, Australia, ⁵Macquarie University Hospital, Dept. of Urology, Macquarie Park, Australia, ⁶Nepean Hospital, Dept. of Radiology, Kingswood, Australia

12:05 - 12:10

IRE

Combination of PSA kinetics and MRI for the diagnosis of Persistent Prostate Cancer following Irreversible Electroporation Focal Therapy

Authors

Zhang K.¹, Teoh J.², Laguna P.³, Dominguez-Escrig P.⁴, Barret E.⁵, Muir G.⁶, Bohr J.⁷, de Reijke T.M.⁸, Sanchez-Salas R.⁹, de la Rosette J.³, Casanova Ramon-Borja J.⁴, Bohang S.¹⁰, Gang Z.¹, Ng C.F.²

Institutions

¹Beijing United Family Hospital and Clinics, Dept. of Urology, Beijing, China, ²The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, China, ³Medipol Mega Hospital, Dept. of Urology, Istanbul, Turkey, ⁴Fundación Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain, ⁵Institut Mutualiste Montsouris, Dept. of urology, Paris, France, ⁶King's College Hospital, Dept. of Urology, London, United Kingdom, ⁷Kliniken Essen-Mitte, Ev. Huysens-Stiftung, Dept. of Urology, Essen, Germany, ⁸Amsterdam University Medical Center, Dept. of Urology, Amsterdam, The Netherlands, ⁹McGill University Hospital, Dept. of urology, Montréal, Canada, ¹⁰University of California, Los Angeles, Dept. of Life Science, Los Angeles, United States of America

12:10 - 12:15

Head-to-head comparison

A0690

Hemigland Cryoablation versus HIFU for Localized Prostate Cancer: A Propensity-Weighted 2-yrs Comparison of Functional and Oncologic Outcomes from a single tertiary-care center

Authors

Anceschi U., Basile S., Flammia R.S., Brassetti A., Proietti F., Tuderti G., Mastroianni R., Ferriero M., Misuraca L., D'annunzio S., Bove A.M., Licari L.C., Bologna E., Chiacchio G., Iori M., Guaglianone S., Leonardo C., Simone G.

Institutions

Uro-Oncology Program - IRCCS - Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

Urolithiasis: Ureteroscopy

Abstract Session 39

Monday 16 March
10:45 - 12:15

Location

Blue Area, George 4

Chairs

To be confirmed

M. Talso, Milan (IT)

S. Yuen, Hong Kong (HK)

10:45 - 11:05

Gaining access up the ureter

A0655

Predictive model for failure in primary ureteroscopy insertion during retrograde intrarenal surgery: Development and validation of a dynamic nomogram

Authors

Li J., Tang H.

Institutions

The First Affiliated Hospital Of Chongqing Medical University, Dept. of Urology, Chongqing, China

A0656

Balancing Cost and Benefit: Pre-Stenting, Alpha-Blockers, or No Pre-Treatment Before RIRS for Intrarenal Stones

Authors

Pauwaert K.¹, Joris F.², Boeykens M.³, Slots C.¹, De Smedt D.⁴, Taily T.¹

Institutions

¹Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ²Ghent University, Faculty of Medicine and Health Sciences, Ghent, Belgium, ³AZ Delta, Dept. of Urology, Roeselare, Belgium, ⁴Ghent University, Dept. of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent, Belgium

A0657

Comparison of stone-free rate and surgical outcomes between pre-stented and non-pre-stented patients undergoing Retrograde Intrarenal Surgery (RIRS) for renal stones: A prospective randomized study

Authors

Sharma A., Alam P.

Institutions

All India Institute of Medical Sciences Raipur CG, Dept. of Urology and Renal Transplant, Raipur CG, India

A0658

Application of flexible and navigable suction ureteral access sheaths (FANS) in the treatment of impacted ureteral stone in the middle and lower segments

Authors

Wang D., Zhi Y., Long X., Zhou Y., Guo H.

Institutions

The Second Affiliated Hospital of Kunming Medical University, Dept. of Urology, Kunming, China

11:05 - 11:25

Ureteroscope design

A0659

Real-World Cost and Environmental Impact Analysis of Reusable versus Single-Use Flexible Ureteroscopes in High-Volume European Centre

Authors

Zorzi F.¹, Werth H.¹, Quarà A.¹, Abi Tayeh G.¹, Bravo A.¹, Moretto S.¹, Gonzalez Gonzalez C.¹, Nannola N.¹, Jannello L.M.¹, Candela L.², Doizi S.¹, Traxer O.¹, Panthier F.D.R.¹

Institutions

¹Endolase LabnGRC n20nSorbonne University PIMM Lab Arts et Métiers ParisTech, Dept. of Urology, Paris, France, ²Assistance-Publique Hôpitaux de Paris, Sorbonne University, Tenon Hospital, Dept. of Urology, Paris, France

A0660

RIRS-ZS SYSTEM(DSA+DISS):: Novel RIRS system making “total endoluminal endourology” practice a reality in future

Authors

Saleem M.¹, Arundati R.²

Institutions

¹APIS Kidney Stone Institute - Baby Memorial Hospital, Dept. of Urology, Kasargod And Kannur, India, ²APIS Kidney Stone Institute - Win-Touch Multi speciality Hospital, Dept. of Urology, Kasargod, India

A0661

MacroLux 7.5F Single-Use Digital Ureteroscope with Enhanced Deflection in Treating 2–4 cm Lower Pole Renal Stones: A Multicenter Randomized Controlled Trial

Authors

Li Z., Weizhe F., Ke S., Donglai S., Baohui Z., Hairui C., Xu Z., Haixing M., [Du S.](#)

Institutions

Chinese PLA General Hospital, Dept. of Urology, Beijing, China

A0662

Does Ureteroscope Miniaturization Affect the Efficacy of Thulium Fiber Laser Flexible Ureteroscopy in Non-Pre-Stented Patients? A Randomized Comparative Study

Authors

[Zorzi F.](#)¹, Werth H.¹, Quarà A.¹, Malvestiti M.¹, Bravo-Balado A.¹, Moretto S.¹, Gonzalez Gonzalez C.¹, Nicola N.¹, Ippolita Jannello L.M.¹, Candela L.², Doizi S.¹, Traxer O.¹, Panthier F.D.R.¹

Institutions

¹Endolase Lab GRC n20 Sorbonne University PIMM Lab Arts et Métiers ParisTech, Dept. of Urology, Paris, France, ²Assistance-Publique Hôpitaux de Paris, Sorbonne University, Tenon Hospital, Dept. of Urology, Paris, France

11:25 - 11:35

Single use ureteroscopes

A0663

Comprehensive Comparative Evaluation of 18 Single-Use Flexible Ureteroscopes: Preliminary In Vitro and In Vivo Results from a Multimodal Performance Study

Authors

[Demirkiran E.D.](#)¹, Menozzi M.², Pini G.², Bozzini G.², Perri D.²

Institutions

¹Zonguldak Bulent Ecevit University School of Medicine, Dept. of Urology, Zonguldak, Turkey, ²Azienda Socio Sanitaria Territoriale Lariana, Dept. of Urology, Como, Italy

A0664

Preliminary experience with a 6.3-Fr single-use flexible ureteroscope for pediatric upper urinary tract stones

Authors

[Hu Q.](#), Yan X.

Institutions

Children's Hospital Zhejiang University School of Medicine, Dept. of Urology, Hangzhou, China

11:35 - 11:55

Irrigation and fluid management

A0665

Intrarenal pressure and flow dynamics in an ex vivo kidney perfusion model using different suction ureteral access sheaths

Authors

Corsini C.¹, Scilipoti P.¹, Ramadani R.¹, [Folcia A.](#)¹, Occhi A.¹, Galdieri A.¹, Robesti D.¹, Rosiello G.¹, Ventimiglia E.², Candela L.³, Traxer O.³, Montorsi F.¹, Briganti A.¹, Salonia A.¹, Villa L.¹

Institutions

¹IRCCS Ospedale San Raffaele, Division of Experimental Oncology - Unit of Urology - URI, Milan, Italy, ²Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ³GRC n°20, Groupe de Recherche Clinique sur la Lithiase Urinaire, Hôpital Tenon, Dept. of Urology, Paris, France

A0666

Fluid Dynamics of Gravel Removal in Flexible Ureteroscopic Lithotripsy with FANS

Authors

Zhang B., Han S., Zhang X., Liang X., Cao X.

Institutions

The first hospital of Shanxi medical university, Dept. of Urology, Taiyuan, China

A0667

Functional Evaluation of the TIDOR Fluid Management System for Ureteroscopy in Simulated Clinical Settings

Authors

Menzies-Wilson R.¹, Akan M.E.², Turney B.¹

Institutions

¹Oxford University Hospitals NHS Trust, Dept. of Urology, Oxford, United Kingdom, ²SBU Sisli Hamidiye Etfal Research and Training Hospital, Dept. of Urology, İstanbul, Turkey

A0668

Closed-loop Temperature and Pressure Control Ureteroscopy Combined With Moses Laser for Ureteroscopic Lithotripsy: An Innovative Technology Integrating Laser Dynamics and Fluid Management

Authors

Jun L., Tian C., Hao H., Xiong L.L., Xu T.

Institutions

Peking University People's Hospital, Dept. of Urology, Beijing, China

11:55 - 12:15

Improving stone-free rates

A0669

Reassessing the 90-Minute Limit: Impact of Operative Duration on Outcomes Using Flexible and Navigable Suction Access Sheaths (FANS) in Ureteroscopy

Authors

Adhoni M.Z.U.¹, Gauhar V.², Traxer O.³, Herrman T.⁴, Castellani D.⁵, Yuen S.K.K.⁶, Somani B.⁷

Institutions

¹Whipps Cross University Hospital, Dept. of Urology, London, United Kingdom, ²Ng Teng Fong Hospital, Dept. of Urology, Singapore, Singapore, ³Tenon Hospital, Dept. of Urology, Paris, France, ⁴Kantonspital Thurgau AG Pfaffenholzstrasse, Dept. of Urology, Frauenfeld, Switzerland, ⁵Azienda Ospedaliero-Universitaria delle Marche, Dept. of Urology, Ancona, Italy, ⁶The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, China, ⁷University of Southampton, Dept. of Urology, Southampton, United Kingdom

A0670

Feasibility and cross-validation of fURS video-based fiducial-marker analysis of respiratory ureteroscope–kidney motion interaction for robotic respiratory synchronization

Authors

Kim J.C.¹, Lee H.M.², Elises J.C.³, Song K.S.¹, Lee D.G.¹, Lee D.H.¹, Kim J.H.¹, Kwon D.S.⁴, Cho S.Y.²

Institutions

¹ROEN Surgical, Research Institute, Seoul, South Korea, ²Seoul National University Hospital, Dept. of Urology, Seoul, South Korea, ³Philippine General Hospital, Dept. of Urology, Manila, Philippines, ⁴Korea Advanced Institute of Science and Technology, Dept. of Mechanical Engineering, Seoul, South Korea

A0671

Beyond Stone Diameter: Volumetric cutoff point and the role of stone density in predicting stone free rate in Flexible Ureteroscopy

Authors

Benitez-Filselcker A.¹, Gil A.¹, Andriola M.¹, Avila C.¹, Heskia S.², Punte T.³, Barahona J.³, Consigliere L.³, De La Llera J.F.³, Vizuete E.³, Marchant F.¹, Aguila F.³

Institutions

¹Hospital Clinico Universidad de Chile, Dept. of Urology, Santiago, Chile, ²Universidad de Chile, Faculty of Medicine, Santiago, Chile, ³Hospital San José, Urinary Lithiasis Subunit, Santiago, Chile

A0672

Simultaneous Bilateral Endoscopic Surgery (SBES): a Seven-Year Retrospective Analysis from a High-Volume Tertiary Center

Authors

Fila L., Hernández P., Más L., Verri P., Izquierdo P., Bravo P., Kanashiro A.S., Angerri O.

Institutions

Fundació Puigvert, Dept. of Urolithiasis, Barcelona, Spain

Urology trials in bladder and prostate cancer

Abstract Session 38

Monday 16 March
10:45 - 12:15

Location

Blue Area, George 3

Chairs

To be confirmed

F. Liedberg, Malmö (SE)

A. Mortezaei, Zürich (CH)

10:45 - 11:00

Improving outcomes by frailty-assessment: Coping-strategies and pre-habilitation

A0637

DaBlaCa-19: Comprehensive geriatric assessment for perioperative optimization in older, frail patients undergoing radical cystectomy (COMPETENCE-study) – A national randomized controlled trial

Authors

Skovhus K.¹, Ørum M.², Jensen B.T.³, Gregersen M.², Junker T.⁴, Rasmussen S.H.⁵, Ryg J.⁶, Livbjerg A.H.⁷, Pedersen A.⁸, Jensen J.B.⁹, Kingo P.S.³

Institutions

¹Aarhus University Hospital, Dept. of Urology and Dept. of Geriatrics, Aarhus, Denmark, ²Aarhus University Hospital, Dept. of Geriatrics, Aarhus, Denmark, ³Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ⁴Odense University Hospital, Dept. of Urology, Odense, Denmark, ⁵Odense University Hospital, Dept. of Geriatrics, Odense, Denmark, ⁶Copenhagen University Hospital - Herlev and Gentofte, Dept. of Medicine Geriatric Section, Copenhagen, Denmark, ⁷Aalborg University Hospital, Dept. of Urology, Aalborg, Denmark, ⁸Aalborg University Hospital, Dept. of Geriatrics, Aalborg, Denmark, ⁹Aarhus University, Dept. of Clinical Medicine, Aarhus, Denmark

A0638

Geriatric prehabilitation prior to surgery for kidney tumors: Study protocol for Pre-KiT - a randomized controlled trial

Authors

Juul-Haslund M.¹, Lund C.M.², Dolin T.G.², Schou-Jensen K.¹, Østergren P.B.¹, Vinther A.³, Thomsen F.F.V.⁴, Fode M.¹

Institutions

¹Copenhagen University Hospital - Herlev and Gentofte, Dept. of Urology, Herlev, Denmark, ²Copenhagen University Hospital - Herlev and Gentofte Hospital, Dept. of Medicine, Herlev, Denmark, ³Copenhagen University Hospital - Herlev and Gentofte Hospital, Dept. of Physiotherapy and Occupational Therapy, Herlev, Denmark, ⁴Zealand University Hospital, Dept. of Urology, Roskilde, Denmark

A0639

Improving Coping and Quality of Life Through Digital Psycho-Oncology: The COPE-WELL Study

Authors

Enzinger B., Kolligs F., Semmler M., Brinkmann I., Hoffmann M., Stadelmeier L., Casuscelli J.

Institutions

LMU Hospital, Dept. of Urology, Munich, Germany

11:00 - 11:40

Prostate cancer

A0640

Prostate cancer and diet – a randomized controlled trial assessing the effect of a dietary intervention on quality of life of men and serum nutrient levels in their blood

Authors

Venderbos L.D.F.¹, Borggreven N.V.¹, Remmers G.², Voshol P.³, van der Lely N.⁴, Bangma C.H.¹

Institutions

¹Erasmus University Medical Center, Erasmus Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, ²Stichting Mijn Data Onze Gezondheid, Amsterdam, The Netherlands, ³Life Growth, Culemborg, The Netherlands, ⁴Greenport West-Holland, Bleiswijk, The Netherlands

A0641

Evaluation of intra-operative contrast-enhanced ultrasound during focal therapy for localised prostate cancer: The Imperial Prostate 14-Focal therapy using Contrast-enhanced UltraSound (IP14-FOCUS) trial

Authors

Light A.¹, Perreau T.², Gopalakrishnan A.¹, Mayor N.¹, Cullen E.¹, Kaneko M.³, Abreu A.³, Fiorentino F.⁴, Ahmed H.U.¹, Shah T.T.¹

Institutions

¹Imperial College London, Imperial Prostate, London, United Kingdom, ²Imperial College London, Imperial Experimental Cancer Medicine Centre, London, United Kingdom, ³University of Southern California, USC Institute of Urology, Keck School of Medicine, Los Angeles, United States of America, ⁴University of Leeds, Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, United Kingdom

A0642

DISSECTION 2.0 Extended pelvic lymph node dissection vs. no pelvic lymph node dissection at radical prostatectomy in PSMA PET negative staged men: A multicenter, randomized phase III trial

Authors

Engesser C.H.¹, Seifert H.¹, Subotic S.², Fankhauser C.³, Prause L.⁴, Boxler S.⁵, Roth B.⁶, Seiler-Blarer R.⁷, Strebel R.⁸, Valerio M.⁹, Lucca I.¹⁰, Gallina A.¹¹, Nguyen D.¹², Engeler D.¹³, Müntener M.¹⁴, Mortezaei A.¹⁵, Cathomas R.¹⁶, Papachristofilou A.¹⁷, Hayoz S.¹⁸, Grobholz R.¹⁹, Nicolas G.²⁰, Heye T.²¹, Rentsch C.¹

Institutions

¹Universitätsspital Basel, Dept. of Urology, Basel, Switzerland, ²Kantonsspital Liestal, Dept. of Urology, Liestal, Switzerland, ³Kantonsspital Luzern, Dept. of Urology, Luzern, Switzerland, ⁴Kantonsspital Aarau, Dept. of Urology, Aarau, Switzerland, ⁵Lindenhof Hospital, Dept. of Urology, Bern, Switzerland, ⁶Inselspital Bern, Dept. of Urology, Bern, Switzerland, ⁷Kantonsspital Biel, Dept. of Urology, Biel, Switzerland, ⁸Kantonsspital Chur, Dept. of Urology, Chur, Switzerland, ⁹Hôpitaux universitaires de Genève, Dept. of Urology, Genf, Switzerland, ¹⁰Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland, ¹¹Ospedale Regionale di Lugano, Dept. of Urology, Lugano, Switzerland, ¹²Réseau Hospitalier Neuchâtelois, Dept. of Urology, Neuchâtel, Switzerland, ¹³Kantonsspital St. Gallen, Dept. of Urology, St. Gallen, Switzerland, ¹⁴Stadtspital Zürich Triemli, Dept. of Urology, Zürich, Switzerland, ¹⁵Universitätsspital Zürich, Dept. of Urology, Zürich, Switzerland, ¹⁶Kantonsspital Chur, Dept. of Oncology, Chur, Switzerland, ¹⁷Universitätsspital Basel, Dept. of Radiooncology, Basel, Switzerland, ¹⁸Swiss Cancer Institute, Dept. of Statistics, Bern, Switzerland, ¹⁹Kantonsspital Aarau, Dept. of Pathology, Aarau, Switzerland, ²⁰Universitätsspital Basel, Dept. of Nuclear Medicine, Basel, Switzerland, ²¹Universitätsspital Basel, Dept. of Radiology, Basel, Switzerland

A0643

A study protocol to evaluate the accuracy metrics of en-face fluorescence confocal microscopy (LaserSAFE) for margin analysis during radical prostatectomy.

Authors

Yousaf A., Almeida-Magana R., Menon A., Dinneen E., Al-Hammouri T., Roberts N., Freeman A., Haider A., Silvanto A., Shaw G.

Institutions

University College London, Division of Surgery and Interventional Science, London, United Kingdom

A0644

PRESIDENT: PRostatEctomy Surgery In Disseminated low-volume metastatic hormone sensitive prostate cancer with Endpoint assessment using Nuclear imaging Technology using PSMA (Prostate-Specific Membrane Antigen) PET/CT (Positron Emission Tomography/Computed Tomography) imaging: a definitive randomised controlled trial

Authors

Sooriakumaran P.¹, Hamdy F.², Cook J.³, Massa M.S.³, Aning J.⁴, Bahl A.⁵, Burns R.⁶, Bryant R.¹, Cui H.¹, Collier A.⁷

Institutions

¹University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom, ²University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom, ³University of Oxford, Centre for Statistics in Medicine, Oxford, United Kingdom, ⁴University of Bristol, Dept. of Urological Oncology, Bristol, United Kingdom, ⁵University of Bristol, Dept. of Radiotherapy, Bristol, United Kingdom, ⁶Atlantic Technological University, Dept. of Statistics, Sligo, Ireland, ⁷Tackle Prostate Cancer, Todmorden, United Kingdom

A0645

A Randomized, Double-Blind, Prospective, Multicenter Trial of LIPUS Therapy for Urinary Incontinence Recovery Following Robot-Assisted Radical Prostatectomy

Authors

Cui D., Li X., Han B.

Institutions

Shanghai General Hospital, Dept. of Urology, Shanghai, China

A0646

Prostate Progress: A UK-based patient-centric data platform integrating patient-reported outcomes and clinical data for prostate cancer research

Authors

James D.¹, Spink J.², Vegliani F.², Ajmal A.³, Baskaran D.³

Institutions

¹Prostate Cancer Research, Patient Projects, London, United Kingdom, ²Prostate Cancer Research, Dept. of Translational Research, London, United Kingdom, ³IQVIA, Real World Solutions, London, United Kingdom

A0647

Building and Application of a Prostate Cancer Specialty Database: A Real-World Data Platform for Clinical Research and Precision Medicine

Authors

Zhu H., Yinjie Z., Liang D., Xinxing D., Jiahua P.

Institutions

Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China

11:40 - 12:15

Non-muscle-invasive bladder cancer

A0648

VI-RADS & PDD-TURBT to avoid Second-look and Resection (Re-TURBT) in Non-Muscle Invasive Bladder Cancers: The CUT-less Randomized Clinical Trial

Authors

Del Giudice F.¹, Vestri A.², Alunni Fegatelli D.³, Hüscher T.⁴, Besley J.⁵, Nair R.⁶, Skinner E.C.⁷, Chung B.I.⁷, Pecoraro M.⁸, Sciarra A.¹, Franco G.¹, Santarelli V.¹, Asero V.¹, Carino D.¹, Corvino R.¹, Pradere B.⁹, Gazzinga P.¹⁰, Panebianco V.⁸, De Berardinis E.¹

Institutions

¹Sapienza University of Rome, Dept. of Urology, Rome, Italy, ²Sapienza University of Rome, Dept. of Public Health and Infectious Diseases, Rome, Italy, ³Link Campus University, Dept. of Life Sciences, Health and Health Professions, Rome, Italy, ⁴University Medical Centre of Johannes-Gutenberg University, Dept. of Urology, Mainz, Italy, ⁵JB Medical Ltd, Dept. of Biostatistics, London, United Kingdom, ⁶Guy and St. Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁷Stanford University, Dept. of Urology, Stanford, United States of America, ⁸Sapienza University of Rome, Dept. of Radiology, Rome, Italy, ⁹La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ¹⁰Sapienza University of Rome, Dept. of Molecular Medicine, Rome, Italy

A0649

Trial in progress: Evaluation of urinary minimal residual disease and outcomes in high-risk non-muscle invasive bladder cancer surveilled with blue light compared to white light cystoscopy

Authors

McNamara M., Rodriguez D., Patel S., Kates M., Smith A.K.

Institutions

Johns Hopkins University, Brady Urologic Institute, Baltimore, United States of America

A0650

A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with FGFR3-Altered Low-Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Authors

Jayram G.¹, Shore N.², Salmasi A.³, Aguilar L.⁴, Burn T.C.⁵, Lihou C.⁶, Degaonkar V.⁶, Goluboff E.⁶, Ganapathy D.⁷, Lerner S.P.⁸

Institutions

¹Urology Associates of Nashville PC, Dept. of Urology, Nashville, United States of America, ²Atlantic Urology Clinics, Dept. of Urology, Myrtle Beach, United States of America, ³UC San Diego Health System, Dept. of Urology, La Jolla, United States of America, ⁴Tyra Biosciences, Dept. of Clinical Operations, Carlsbad, United States of America, ⁵Tyra Biosciences, Dept. of Translational Sciences, Carlsbad, United States of America, ⁶Tyra Biosciences, Dept. of Clinical Development, Carlsbad, United States of America, ⁷Tyra Biosciences, Dept. of Medical Affairs and Clinical Development, Carlsbad, United States of America, ⁸Baylor College of Medicine, Dept. of Urology, Houston, United States of America

A0651

A phase III randomised controlled clinical trial of radiotherapy with radiosensitisation versus intravesical Bacillus Calmette-Geurin therapy for high-risk non-muscle invasive bladder cancer: TRAIN (Trials in Progress)

Authors

Choudhury A.¹, Griffiths D.², Dunkley D.², Ewings S.², Hoskin P.¹, Cole A.², Lawrence M.², Johnson L.², Reeves K.¹, Sangar V.³, Dyer J.⁴, Narahari K.⁵, Cooper K.⁶, Finch P.², Robertson L.², Crabb S.², Griffiths G.²

Institutions

¹University of Manchester and The Christie NHS Foundation Trust, Division of Cancer Sciences, Manchester, United Kingdom, ²University of Southampton and University Hospital Southampton NHS Foundation Trust, Cancer Research UK Southampton, Clinical Trials Unit, Southampton, United Kingdom, ³Manchester University NHS Foundation Trust, Dept. of Surgical Oncology, Manchester, United Kingdom, ⁴Stockport NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom, ⁵Cardiff and Vale University Health Board, Dept. of Urology, Cardiff, United Kingdom, ⁶University of Southampton, Southampton Health Technology Assessments Centre, Southampton, United Kingdom

A0652

CORE-008 Cohort B: Evaluating Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk, BCG-Exposed Non-Muscle Invasive Bladder Cancer

Authors

Bivalacqua T.¹, Daneshmand S.², Cone E.³, Pieczonka C.⁴, Belkoff L.⁵, Mossanen M.⁶, Narayan V.⁷, Steinberg G.⁸

Institutions

¹University of Pennsylvania, Dept. of Urology, Philadelphia, United States of America, ²University of Southern California/Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ³Urology of Indiana, Dept. of Urology, Greenwood, United States of America, ⁴Associated Medical Professionals of New York (an affiliate of US Urology Partners), Dept. of Urology, Syracuse, United States of America, ⁵MidLantic Urology, Dept. of Urology, Bala Cynwyd, United States of America, ⁶Brigham and Women's Hospital, Dept. of Urology, Boston, United States of America, ⁷Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, ⁸Rush University Medical Center, Dept. of Urology, Chicago, United States of America

A0653

A Phase III, Randomized, Open-Label Trial of Disitamab Vedotin (DV) Plus Bacillus Calmette–Guérin (BCG) in BCG-Naïve Patients with HER2-Expressing High-Risk Non–Muscle Invasive Bladder Cancer(HERO)

Authors

Shen Y.J., Lu X.L., Gu W.J., Ma C.G., Li X.Q., Shen Y., Ye D.W.

Institutions

Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

A0654

The COBRA study: Chemoablation or bladder resection with adjuvant chemotherapy in recurrent non-muscle invasive bladder cancer

Authors

Klingenberg S.¹, Lindgren M.S.¹, Jakobsen J.K.¹, Jensen J.R.B.², Kingo P.S.¹

Institutions

¹Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ²Aarhus University, Dept. of Clinical Medicine, Aarhus, Denmark

Understanding penile cancer: From biology to prognosis

Abstract Session 43

Monday 16 March
10:45 - 12:15

Location

Blue Area, Victoria 6

Chairs

F.L. Heldwein, Florianopolis (BR)

To be confirmed

K. Vandermaesen, Leuven (BE)

10:45 - 11:20

Carcinogenesis and biomarkers

A0725

The Heterogenous Genomic Landscape of HPV-Positive Squamous Cell Carcinoma: An Analysis of 30 Cases.

Authors

Lim X.X.¹, Sanchez D.F.², Fernandez-Nestosa M.J.³, Lau M.⁴, Christopoulos P.⁴, Parnham A.⁴, Sachdeva A.⁴, Sangar V.⁴, Wedge D.⁵, Oliveira P.¹, Bristol R.G.⁶

Institutions

¹The Christie NHS Foundation Trust, Dept. of Histopathology, Manchester, United Kingdom, ²Manchester Cancer Research Centre and Cancer Research UK - Manchester Institute, Translational Oncogenomics Group, Manchester, United Kingdom, ³Universidad Nacional de Asuncion, Polytechnic Faculty, San Lorenzo, Paraguay, ⁴The Christie NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom, ⁵Manchester Cancer Research Center, Division of Cancer Sciences, Manchester, United Kingdom, ⁶Manchester Cancer Research Centre and University of Manchester, Translational Oncogenomics Group, Manchester, United Kingdom

A0726

Functional Relevance of the PARP1–JAK2–STAT3 Axis and Its Therapeutic Targetability in Advanced Penile Squamous Cell Carcinoma

Authors

Thomas A.¹, Slade K.¹, Stenzel P.², Roth W.², Schindeldecker M.², Dotzauer R.¹, Rothweiler F.³, Haferkamp A.¹, Cinatl J.³, Tsaour I.⁴

Institutions

¹University Medical Center Mainz, Dept. of Urology and Pediatric Urology, Mainz, Germany, ²University Medical Center Mainz, Dept. of Pathology, Mainz, Germany, ³University Medical Center Frankfurt, Dept. of Medical Virology, Frankfurt, Germany, ⁴University Medical Center Tübingen, Dept. of Urology, Tübingen, Germany

A0727

Immune Checkpoint Status and the Tumour Immune Microenvironment in Primary and Lymph Node Metastatic Penile Cancer

Authors

Azhar F.¹, Hart C.A.², Brown M.D.², Sanchez-Martinez D.³, Oliveira P.³, Parnham A.⁴, Sangar V.⁴, Clarke N.W.⁴, Sachdeva A.⁴

Institutions

¹The Christie NHS Foundation Trust and Salford Royal NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom, ²The University of Manchester, Genito Urinary Cancer Research Group, Manchester, United Kingdom, ³The Christie NHS Foundation Trust, Dept. of Pathology, Manchester, United Kingdom, ⁴The Christie NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom

A0728

B cell recruitment by CCL21⁺ CAFs drives TLS maturation via the CCL21-CCR7 axis in penile squamous cell carcinoma

Authors

Li Z.¹, Li X.², Guo Y.¹, Chen D.¹, Chen B.³, Xue T.⁴, Chen Z.¹, Han H.⁴

Institutions

¹Shenzhen People's Hospital, Dept. of Urology, Shenzhen, China, ²The Seventh Affiliated Hospital Sun Yat-sen University, Dept. of Oncology, Shenzhen, China, ³Sir Y.K. Pao Cancer Center, Prince of Wales Hospital, Dept. of Anatomical and Cellular Pathology, Hong Kong, Hong Kong, ⁴Sun Yat-sen University Cancer Center, Dept. of Urology, Guangzhou, China

A0729

Construction of an integrated proteomic atlas for penile squamous cell carcinoma

Authors

Yin F.¹, Tong Y.², Pang X.¹, Ning E.¹, Jiang H.¹, Zhang C.¹, Dai L.¹, Yin J.³, Zheng Y.¹, Li J.¹, Yang Z.¹, Zhang K.¹, Zhu B.⁴, Wang Y.¹, Wu M.¹, Tang Z.¹, Wang H.⁵, Bai Y.¹

Institutions

¹Yunnan Cancer Hospital, Dept. of Urology, Kunming, China, ²Office of Yunnan Cancer Research Institute, Dept. of Biological Therapy Center, Kunming, China, ³The Second People's Hospital of Zhaotong, Dept. of Thyroid and Breast Surgery, Zhaotong, China, ⁴The Affiliated Chengdu 363 Hospital of Southwest Medical University, Dept. of Urology, Chengdu, China, ⁵32268 Military Hospital, Dept. of General Surgery, Dali, China

A0730

Expression of HER2, EGFR and HDAC6 as Potential Therapeutic Targets in Penile Cancer

Authors

Mink J.¹, Boehle J.¹, Eckstein M.², Khalmurzaev O.³, Pryalukhin A.⁴, Geppert C.², Lohse S.⁵, Bende K.², Lobo J.⁶, Henrique R.⁶, Loertzer H.⁷, Steffens J.⁸, Jeronimo C.⁶, Wunderlich H.⁹, Bohle R.M.⁴, Stoeckle M.¹, Matveev V.³, Hartmann A.⁴, Junker K.¹

Institutions

¹Saarland University, Dept. of Urology and Paediatric Urology, Homburg, Germany, ²University Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany, ³N.N. Blokhin National Medical Research Center of Oncology, Dept. of Urology, Moscow, Russia, ⁴Saarland University, Institute of Pathology, Homburg, Germany, ⁵Saarland University, Institute of Virology, Homburg, Germany, ⁶Portuguese Oncology Institute of Porto, Porto Comprehensive Cancer Center Raquel Seruca, Dept. of Pathology and Cancer Biology and Epigenetics Group, Porto, Portugal, ⁷Westpfalz Clinic, Dept. of Urology and Paediatric Urology, Kaiserslautern, Germany, ⁸St.-Antonius-Hospital, Dept. of Urology and Paediatric Urology, Eschweiler, Germany, ⁹St. Georg Clinic, Dept. of Urology and Paediatric Urology, Eisenach, Germany

A0731

Preliminary report on the feasibility of brush and contact cytology as a non-invasive diagnostic tool for superficial penile lesions

Authors

Lodde M.¹, Atallah C.², Veilleux C.², Bedard M.², Tremblay-Boily M.³, Besançon M.³, Cazes E.¹, Bergeron A.³

Institutions

¹Laval University, Dept. of Urology, Quebec, Canada, ²Laval University, Dept. of Pathology, Quebec, Canada, ³Laval University, Research Center Urology, Quebec, Canada

11:20 - 11:55

Diagnosis and risk of nodal disease

A0732

Automated 3D CT-based Tumor Geometry Predicts Nodal Risk and Survival in Penile Cancer: 162-Patient Cohort

Authors

Li Z.¹, Li X.², Chen B.³, Xue T.⁴, Xiao Z.¹, Huang G.¹, XueQi Z.¹, Han H.⁴, Chen Z.¹

Institutions

¹Shenzhen People's Hospital, Dept. of Urology, Shenzhen, China, ²The Seventh Affiliated Hospital Sun Yat-sen University, Dept. of Oncology, Shenzhen, China, ³Sir Y.K. Pao Cancer Center, Prince of Wales Hospital, Dept. of Anatomical and Cellular Pathology, Hong Kong, Hong Kong, ⁴Sun Yat-sen University Cancer Center, Dept. of Urology, Guangzhou, China

A0733

Surveillance of clinically negative groins in penile cancer using (18F) FDG PET-CT: Single-centre evaluation of its non-invasive accuracy in identifying early inguinal lymph node metastasis and guiding timely management.

Authors

Yuvaraja T.B., Shah A.M., Zalse R.P., Pednekar A., Bajpai A., Vaswani U., Kunte M., Mohd S.A., Agarwal R., Jani I., Shah M., Pethkar T.

Institutions

Kokilaben Dhirubhai Ambani Hospital, Centre for Urooncology and Robotics, Mumbai, India

A0734

Machine-learning prediction of lymph node metastasis after dynamic sentinel node biopsy in penile cancer: a gradient boosting analysis

Authors

Saitta C.¹, Nazzani S.², Silvani C.², Bernasconi V.², Macchi A.², Torelli T.², Stagni S.², Marmiroli A.², Tesone A.², Lughezzani G.¹, Casale P.¹, Buffi N.M.¹, Cascella T.², Catanzaro M.A.², BIASONI D.², Nicolai N.²

Institutions

¹IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy

A0735

Optimizing Sentinel Node Mapping in Penile Cancer: Triple Dye versus Dual Dye Prospective Evaluation

Authors

Gopal Krishna S., Amaresh M., Praveen B., Janaki K., Rakesh M., Subramanyeshwar T.

Institutions

Basavatarakam Indo American Cancer Hospital and Research Institute, Dept. of Urology, Hyderabad, India

A0736

Incidence and outcomes of non-visualisation during dynamic sentinel lymph node biopsies for penile cancer: A contemporary high volume centre retrospective analysis

Authors

Ziada M., Ahmad A., Sahdev V., Nigam R., Hadway P., Muneer A., Alnajjar H.

Institutions

University College London Hospitals, Dept. of Urology, London, United Kingdom

A0737

Which penile cancer patients with positive sentinel node metastases can be spared of lymphadenectomy without compromising oncological safety? - Development of a prediction model

Authors

Mølsted J.¹, Bjerggaard Jensen J.², Als A.B.³, Jakobsen J.K.¹, Aagaard M.⁴

Institutions

¹Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ²Aarhus University, Institute of Clinical Medicine, Aarhus, Denmark, ³Aarhus University Hospital, Dept. of Oncology, Aarhus, Denmark, ⁴Copenhagen University Hospital, Dept. of Urology, Copenhagen, Denmark

A0738

18F-FAPI-42 PET/CT Outperforms 18F-FDG PET/CT in Detecting Inguinal Nodal Metastasis in Penile Squamous Cell Carcinoma: A Prospective Head-to-Head Comparison Study

Authors

Wang L.¹, Ouyang W.¹, Tong X.², Zhao M.²

Institutions

¹The Third Xiangya Hospital, Dept. of Urology, Changsha, China, ²The Third Xiangya Hospital, Dept. of Nuclear Medicine, Changsha, China

11:55 - 12:15

Prognosis, follow-up and QOL

A0739

Survival trends in HPV-independent and HPV-associated PSCC at a large single site centre: A retrospective analysis of 800 patients.

Authors

Tuffa N.¹, Walsh R.¹, Tan J.K.¹, Brennan-Calland J.², Lim X.X.², Sachdeva A.³, Parnham A.³, Sangar V.³, Sanchez D.F.⁴, Oliveira P.²

Institutions

¹University of Manchester, Faculty of Biology Medicine and Health, Manchester, United Kingdom, ²The Christie NHS Foundation Trust, Dept. of Histopathology, Manchester, United Kingdom, ³The Christie NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom, ⁴Manchester Cancer Research Centre and Cancer Research UK - Manchester Institute, Translational Oncogenomics Group, Manchester, United Kingdom

A0740

Inguinal extranodal extension and pelvic lymph node metastases are prognostically equivalent in N3 penile cancer patients staged with PET/CT

Authors

Verdijk R.W.A., Loeff V., Van Rhijn B.W.G., Hendricksen K., Graafland N., Mertens L.S., Van Der Poel H.G., Brouwer O.R.

Institutions

NKI-AVL, Dept. of Urology, Amsterdam, The Netherlands

A0741

Mapping penile cancer recurrence patterns: Data-Driven surveillance strategies

Authors

Kadam A.¹, Arora A.¹, Prakash G.¹, Pal M.¹, Mohan A.¹, Chandankhede U.¹, Tummala M.¹, Gujela A.¹, Godse S.¹, Shirke A.¹, Patel S.¹, Menon S.², Joshi A.³, Murthy V.⁴, Maitre P.⁴, Bakshi G.¹, Ramya N.¹

Institutions

¹Tata Memorial Hospital, Homi Bhabha National Institute, Division of Uro-Oncology, Dept. of Surgical Oncology, Mumbai, India, ²Tata Memorial Hospital, Homi Bhabha National Institute, Dept. of Pathology, Mumbai, India, ³Tata Memorial Hospital, Homi Bhabha National Institute, Dept. of Medical Oncology, Mumbai, India, ⁴Tata Memorial Hospital, Homi Bhabha National Institute, Dept. of Radiation Oncology, Mumbai, India

A0742

Audit of ePROMs uptake and patient-reported outcomes following penectomy and nodal surgery

Authors

Chowdhury M.¹, Hodgson S.², Parnham A.¹, Christopoulos P.¹, Lau M.¹, Capper S.¹, Sangar V.¹

Institutions

¹The Christie Hospital NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom, ²The Christie Hospital NHS Foundation Trust, Dept. of Data Science and Statistics, Manchester, United Kingdom

Monday 16 March
10:45 - 12:15

Location Blue Area, Victoria 5

Chairs
A. Galfano, Milano (IT)
R. Sosnowski, Olsztyn (PL)
I. Tsaur, Tuebingen (DE)

10:50 - 11:05

Complications

[A0716](#)

Adverse events and device malfunctions in da Vinci robotic surgery: Analysis of MAUDE data from the recent ten years

Authors

Hsieh T.Y.¹, Chen M.H.², Huang K.H.¹

Institutions

¹National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan, ²Cardinal Tien Hospital, Fu Jen Catholic University, Division of Urology Dept. of Surgery, New Taipei City, Taiwan

[A0721](#)

Reduced Incidence of Incisional Hernia with Left Paramedian Access During RARP: A UK-Based Analysis

Authors

Cahill T.P.¹, Tazi M.², Cahill D.¹, Self D.¹, Orrason A.W.¹, Rusby J.¹

Institutions

¹Royal Marsden NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ²King's College London, Guy's Cancer Comprehensive Cancer Centre, London, United Kingdom

[A0723](#)

De novo lower urinary tract symptoms after Robot Assisted Radical Prostatectomy: Evaluation Of incidence and risk factors

Authors

Pastore A.L.¹, Sequi M.B.¹, Fuschi A.¹, Suraci P.P.¹, Valenzi F.M.¹, Antonioni A.¹, Rera O.A.¹, Graziani D.¹, Candita G.¹, Benanti P.¹, Gianfrancesco F.¹, Martino G.¹, Erra L.¹, Di Gregorio G.¹, Cicione A.², De Nunzio C.², Carbone A.¹

Institutions

¹Sapienza University of Rome, Dept. of Medico-Surgical Sciences and Biotechnologies, Urology Unit, Latina, Italy, ²Sapienza University of Rome, Dept. of Urology Sant'Andrea Hospital, Rome, Italy

Monday 16 March
10:45 - 12:15

Location Orange Area, Room 3

Chairs K.K. Bree, Houston (US)
R. Meijer, Utrecht (NL)
N. Vasdev, Stevenage (GB)

10:45 - 11:10

Clinical staging of muscle-invasive bladder cancer

A0619

Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Final survival analysis from the BladderPath trial

Authors

James N.¹, Jackson N.², Pirrie S.J.², Liu W.², Gallagher J.², Hughes A.², Jefferson K.³, Nanton V.⁴, Knight A.⁵, Mintz H.², Pope A.², Ward D.⁶, Hafeez S.⁷, Patel P.⁸, Catto J.⁹, Bryan R.T.⁶

Institutions

¹Institute of Cancer Research, Dept. of Radiotherapy and Imaging, London, United Kingdom, ²University of Birmingham, CRCTU, Birmingham, United Kingdom, ³University Hospitals Coventry and Warwick, Dept. of Urology, Coventry, United Kingdom, ⁴University of Warwick, Dept. of Medicine, Coventry, United Kingdom, ⁵Action Bladder Cancer, Patient and Advisory Panel, Tetbury, United Kingdom, ⁶University of Birmingham, Bladder Cancer Centre, Birmingham, United Kingdom, ⁷Royal Marsden Hospital, Dept. of Radiotherapy and Oncology, London, United Kingdom, ⁸University College London Hospital, Dept. of Urology, London, United Kingdom, ⁹University of Sheffield, Dept. of Urology, Sheffield, United Kingdom

A0620

Redefining the muscle invasive bladder cancer pathway: a multicentre study examining the real world potential impact of implementing BladderPath

Authors

Malik T.¹, Theinka Lin H.¹, Buba A.², Mohammed L.¹, Aung Han L.¹, Denfhy J.¹, Babureddy K.³, Dudley S.⁴, Aning J.¹

Institutions

¹Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom, ²Royal United Hospitals Bath NHS Foundation Trust, Dept. of Urology, Bath, United Kingdom, ³Gloucestershire Hospitals NHS Foundation Trust, Dept. of Urology, Gloucester, United Kingdom, ⁴Great Western Hospitals NHS Foundation Trust, Dept. of Urology, Swindon, United Kingdom

A0621

bp-VI-RADS Combined with Normalized ADC Enhances Diagnostic Efficacy for Muscle-Invasive Bladder Cancer

Authors

Hao Z.H.¹, Li D.Y.², Guo H.Q.¹, Yang R.¹

Institutions

¹Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Dept. of Urology, Nanjing, China, ²Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Dept. of Radiology, Nanjing, China

A0622

VI-RADS Score Performance in the Post-TURBT Setting: Exploring the Need for Modification

Authors

Dehghanpour A., Pecoraro M., Messina E., Borrelli A., Laschena L., Panebianco V.

Institutions

Sapienza University of Rome, Dept. of Radiology, Rome, Italy

A0623

Comparison of Diagnostic Efficacy Between Post-Treatment VI-RADS Based on Biparametric MRI and Multiparametric MRI in Assessing Residual Tumor and Muscle Invasion After Treatment for Bladder Cancer

Authors

Lyu Q., Yang X., Cao Q., Wang C.

Institutions

the First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

11:10 - 11:40

Pre-operative strategies in radical surgery for muscle-invasive bladder cancer

A0624

Preoperative Circulating Tumor DNA as a Predictor of Recurrence Following Radical Cystectomy for Bladder Cancer: Revisiting the Role of Clinical Stage in the Molecular Era

Authors

Zhu A.¹, Eraky A.¹, Ben-David R.², Gupta R.¹, Mehrazin R.¹, Wiklund P.¹, Sfakianos J.¹

Institutions

¹Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ²Tel Aviv Sourasky Medical Center, Dept. of Urology, Tel Aviv, Israel

A0625

Pre-cystectomy ctDNA burden may identify patients who can benefit from upfront radical cystectomy

Authors

Ben David R.¹, Moran M.², Eraky A.³, Kolanukuduru K.P.³, Gupta R.³, Consalvo A.², Fu M.Z.⁴, Golombos D.M.⁴, Jang T.L.⁴, Packiam V.T.⁴, Wiklund P.³, Mehrazin R.³, Ghodoussipour S.⁴, Sfakianos J.P.³

Institutions

¹Tel Aviv Medical Center, Dept. of Urology, Tel Aviv, Israel, ²Rutgers Robert Wood Johnson Medical School, Division of Urology, Dept. of Surgery, New Brunswick, United States of America, ³Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ⁴Rutgers Cancer Institute, Section of Urologic Oncology, New Brunswick, United States of America

A0626

Naloxegol does not improve gastrointestinal recovery after radical cystectomy within contemporary ERAS protocols: a multicenter prospective cohort study

Authors

Ringia J.¹, Dekker M.¹, Lijnen R.A.G.¹, van de Kamp M.W.¹, Mertens L.S.¹, Nieuwenhuijzen J.A.², van der Poel H.G.¹, van Rhijn B.W.G.¹, Vis A.N.², Wit E.M.K.¹, Oddens J.R.², Hendricksen K.¹

Institutions

¹NKI-AVL, Dept. of Urology, Amsterdam, The Netherlands, ²Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands

A0627

Structured prehabilitation reduces ICU admission and transfusion rates after radical cystectomy – interim analysis of the PRACTICE randomized trial (NCT06806059)

Authors

Volz Y., Scheuringer R., Hermans J., Ebner B., Pyrgidis N., Keller P., Stief C., Schulz G.

Institutions

Ludwig-Maximilian-University Hospital, Dept. of Urology, Munich, Germany

A0628

Impact of Prior Pelvic irradiation on Peri-operative Safety, Early and Late Complications of Robotic-assisted Cystectomy with Intra-corporeal Diversion: A Matched Paired comparison.

Authors

Ibrahim Y., Rajain S., Abughanem Y., Ribeiro L., Del Guidice F., Khan M.S., Nair R., Thurairaja R.

Institutions

Guys and St Thomas Hospital, Dept. of Urology, London, United Kingdom

A0629

10-year Urothelial Fellowship in Robotic-assisted Radical Cystectomy and Intracorporeal Ileal Conduit (RARC/ICIC) Urinary Diversion: Trends in Surgical Practice, Perioperative Outcomes, and Predictors of ERUS Clinical Modular Competency

Authors

Del Giudice F.¹, Santarelli V.¹, Kam J.², Lobo N.³, Furrer M.⁴, Rai S.⁵, Doerge E.², Moran D.⁶, Tan T.W.⁷, Parsons B.², Nair R.², Challacombe B.², Hegazy M.², Abu-Ghanem Y.², Thuraraja R.², Asero V.¹, Basile G.⁸, Sciarra A.¹, De Berardinis E.¹, Chung B.I.⁹, Khan M.S.²

Institutions

¹Sapienza University of Rome, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ²Guy and St. Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³Cambridge University Hospital, Dept. of Urology, Cambridge, United Kingdom, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁵Milton Keynes University Hospital, Dept. of Urology, Milton Keynes, United Kingdom, ⁶St Vincent's University Hospital, Dept. of Urology, Dublin, Ireland, ⁷Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore, ⁸Vita Salute San Raffaele Hospital, Dept. of Urology, Milan, Italy, ⁹Stanford University, Dept. of Urology, Stanford, United States of America

11:40 - 12:15

Strategies to improve patient outcomes after radical cystectomy

Risk of lymph-node invasion after radical cystectomy according to histological subtypes: results from a large multi-institutional cohort

Authors

Santangelo A.¹, De Angelis M.¹, Scilipoti P.¹, Longoni M.¹, Pellegrino F.², Soria F.³, D'Andrea D.⁴, Pradere B.⁵, Albissini S.⁶, Gontero P.⁷, Roupert M.⁸, Antonelli A.⁹, Carme Mir M.¹⁰, Simone G.¹¹, Schulz G.B.¹², Theo J.¹³, Del Giudice F.¹⁴, Pichler R.¹⁵, Mottrie A.¹⁶, Suardi N.¹⁷, Musi G.¹⁸, Montorsi F.¹, Briganti A.¹, Moschini M.¹

Institutions

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²ASST Santi Paolo e Carlo, Dept. of Urology, Milan, Italy, ³San Giovanni Battista Hospital, University of Studies of Torino, Dept. of Surgical Sciences, Division of Urology, Turin, Italy, ⁴Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁵La Croix du Sud Hôpital, Dept. of Urology, Quint-Fonsegrives, France, ⁶University of Tor Vergata, Dept. of Urology, Rome, Italy, ⁷San Giovanni Battista Hospital, University of Studies of Torino, Dept. of Urology, Turin, Italy, ⁸Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Dept. of Urology, Paris, France, ⁹Azienda Ospedaliera Universitaria Integrata Verona, Dept. of Urology, Verona, Italy, ¹⁰IMED Hospital, Dept. of Urology, Valencia, Spain, ¹¹Regina Elena National Cancer Institute, IRCCS, Dept. of Urology, Rome, Italy, ¹²Urologische Klinik und Poliklinik, Klinikum Großhadern der LMU München, Dept. of Urology, Munich, Germany, ¹³S.H. Ho Urology Centre, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, China, ¹⁴Sapienza University of Rome, Policlinico Umberto I Hospital, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ¹⁵Medical University of Innsbruck, Comprehensive Cancer Center Innsbruck (CCCI), Dept. of Urology, Innsbruck, Austria, ¹⁶Onze-Lieve-Vrouwziekenhuis Hospital, Dept. of Urology, Aalst, Belgium, ¹⁷Spedali Civili of Brescia, Dept. of Urology, Brescia, Italy, ¹⁸European Institute of Oncology (IEO), IRCCS, University of Milan, Dept. of Oncology and Hematology-Oncology, Milan, Italy

A0631

Extended versus Standard Lymphadenectomy in Muscle-Invasive Bladder Cancer: Real-World data confirming trial-Based evidence and the Prognostic Role of Pathological Staging

Authors

De Angelis M.¹, Scilipoti P.¹, Longoni M.¹, Pellegrino F.², Soria F.³, D'Andrea D.⁴, Pradere B.⁵, Albissini S.⁶, Gontero P.³, Roupert M.⁷, Antonelli A.⁸, Carme Mir M.⁹, Simone G.¹⁰, Schulz G.B.¹¹, Teoh J.¹², Del Giudice F.¹³, Pichler R.¹⁴, Mottrie A.¹⁵, Suardi N.¹⁶, Musi G.¹⁷, Montorsi F.¹, Briganti A.¹, Moschini M.¹

Institutions

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²ASST Santi Paolo e Carlo, Dept. of Urology, Milan, Italy, ³San Giovanni Battista Hospital, University of Studies of Torino, Dept. of Surgical Sciences, Division of Urology, Turin, Italy, ⁴Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁵La Croix du Sud Hôpital, Dept. of Urology, Quint-Fonsegrives, France, ⁶University of Tor Vergata, Dept. of Urology, Rome, Italy, ⁷Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Dept. of Urology, Paris, France, ⁸Azienda Ospedaliera Universitaria Integrata Verona, Dept. of Urology, Verona, Italy, ⁹IMED Hospital, Dept. of Urology, Valencia, Spain, ¹⁰Regina Elena National Cancer Institute, IRCCS, Dept. of Urology, Rome, Italy, ¹¹Urologische Klinik und Poliklinik, Klinikum Großhadern der LMU München, Dept. of Urology, Munich, Germany, ¹²S.H. Ho Urology Centre, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, China, ¹³Sapienza University of Rome, Policlinico Umberto I Hospital, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ¹⁴Medical University of Innsbruck, Comprehensive Cancer Center Innsbruck (CCCI), Dept. of Urology, Innsbruck, Austria, ¹⁵Onze-Lieve-Vrouwziekenhuis Hospital, Dept. of Urology, Aalst, Belgium, ¹⁶Spedali Civili of Brescia, Dept. of Urology, Brescia, Italy, ¹⁷European Institute of Oncology (IEO), IRCCS, Dept. of Oncology and Hematology-Oncology, Milan, Italy

A0632

Perioperative Outcomes and Survival of Plasmacytoid Variant Urothelial Carcinoma after Radical Cystectomy: A Multicenter Real-World Cohort

Authors

Kim S.H.¹, Jong Jin O.²

Institutions

¹Soonchunhyang University Cheonan Hospital, Dept. of Urology, Cheonan, South Korea, ²Seoul National University Bundang Hospital, Dept. of Urology, Bundang, South Korea

A0633

The impact of manual vs stapler sewn ileoileal anastomosis on the incidence and the management of the postoperative complications in patients underwent radical cystectomy with ileal conduit: a randomized prospective single center trial (PUMA trial)

Authors

Rodriguez Faba O., Gavrilov P., Avesani G., Di Bello F., Chernysheva D., Gallioli A., Territo A., Huguet H., Casadevall M., Serrallach A., Grijalva C., Gaya J.M., Palou J., Breda A.

Institutions

Fundació Puigvert, Dept. of Urology, Barcelona, Spain

A0634

Urodynamic and Functional Outcomes After Δ -Shaped Versus Y-Shaped Robotic Intracorporeal Orthotopic Neobladder Reconstruction

Authors

De Cillis S.T.¹, Piramide F.¹, Amparore D.², Checcucci E.², Piana A.¹, Volpi G.², Sica M.², Quarà A.¹, Cisero E.¹, Gatti C.¹, Sterrantino A.¹, Pini F.¹, Ferrando L.¹, Ribolzi B.¹, Trapella G.¹, Liguori S.¹, La Gatta A.¹, Manfredi M.¹, Fiori C.¹, Porpiglia F.²

Institutions

¹AOU San Luigi Gonzaga - University of Turin, Dept. of Urology, Orbassano, Italy,
²Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy

A0635

Functional updates after 4 years of the Stentless Florence Robotic Intracorporeal Neobladder (FloRIN) randomized clinical trial

Authors

Lambertini L., Lipparini F., Saladino M., Conte F., Posanzini S., Kucuku N., Carli G., Valastro F., Di Maida F., Grosso A.A., Oriti R., Vittori G., Mari A., Minervini A.

Institutions

Unit of Oncologic Minimally Invasive Urology and Andrology Careggi Hospital, Dept. of Experimental and Clinical Medicine University of Florence, Florence, Italy

A0636

Contemporary Practice Patterns in Female Radical Cystectomy: Results of a UK and Ireland Survey

Authors

Day E.¹, Waive E.², Martin R.³, Pio Bizzari F.⁴, Nelson A.⁴, Colquhoun A.⁴, Burden H.⁵, Ayres B.⁶, Hanchanale V.⁷, Aning J.⁵, Lobo N.⁴

Institutions

¹University Hospital Ayr, Dept. of Urology, Ayr, United Kingdom, ²Royal Devon University Hospital, Dept. of Urology, Devon, United Kingdom, ³Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, ⁴Cambridge University Hospital, Dept. of Urology, Cambridge, United Kingdom, ⁵Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom, ⁶St Georges University Hospital, Dept. of Urology, London, United Kingdom, ⁷Royal Liverpool University Hospital, Dept. of Urology, Liverpool, United Kingdom

Robotic RPLND and inguinal LND redefined

Video Session 16

Monday 16 March
10:45 - 12:15

Location

Blue Area, Victoria 1

Chairs

To be confirmed

M. Bandini, Milan (IT)

J. Chorbińska, Wrocław (PL)

V110 (□: 8 min.)

Transitioning from Open to Robotics in Challenging RPLND: Top Ten Tips

Y. Ibrahim, London (GB)

V111 (□: 8 min.)

AUGMENTED REALITY-GUIDED ROBOT ASSISTED RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR POST-CHEMOTHERAPY NSGCT: A HIGH-VOLUME CENTRE CASE DEMONSTRATION

G. Spina, Naples (IT)

V112 (□: 9 min.)

RAISN – Robotic-assisted ICG-guided sentinel lymph node biopsy in patients with stage I testicular cancer

M. Vermeulen-Spohn, Düsseldorf (DE)

V113 (□: 7 min.)

Post chemotherapy retroperitoneal lymph node dissection for testicular cancer with Single Port robotic approach

E. Lievore, Milan (IT)

V114 (□: 8 min.)

Robotic Excellence: Supine Extra peritoneal RPLND for testicular cancer (RASE-RPLND Technique):Step by Step

G.K. Pooleri, Kochi (IN)

V115 (□: 8 min.)

Robot-Assisted Salvage Retroperitoneal Lymphadenectomy for Testicular Cancer: Experience from a Tertiary Referral Center

F. Proietti, Rome (IT)

V116 (□: 7 min.)

SINGLE PORT ROBOT-ASSISTED INGUINAL LYMPHADENECTOMY: A STEP-BY-STEP SURGICAL TECHNIQUE

E. Lievore, Milan (IT)

Beyond daily routine: Managing large, hilar and anatomically variant renal tumors robotically

Video Session 15

**Monday 16 March
10:45 - 12:15**

Location

Blue Area, George 1

Chairs

I. Andras, Cluj (RO)

To be confirmed

R. De Groote, Aalst (BE)

V104 (□: 7 min.)

Head-to-head comparison of robot-assisted partial nephrectomy for upper versus lower pole renal masses using the Hugo™ RAS System: surgical set-up and initial experience

F. Tedesco, Rome (IT)

V105 (□: 7 min.)

Hugo™ RAS System robot-assisted partial nephrectomy for moderate to highly complex renal masses: oncological and functional outcomes at short-term follow-up

F. Tedesco, Rome (IT)

V106 (□: 6 min.)

Robotic Surgical Approach for Very Large Upper Tract Masses ≥ 10 cm (Renal and Adrenal): Tips and Outcome Adrenal): Tips and Outcome

A. Almuhrij, Dammam (SA)

V107 (□: 8 min.)

Is Seeing Beyond 2D Required? Robot-assisted Partial Nephrectomy in Complex Hilar Renal Tumors with 3D Virtual Model

S. Kushwaha, GHAZIABAD (IN)

V108 (□: 8 min.)

Pre and intraoperative planning with 3D virtual models for challenging oncological cases in horseshoe kidneys

F.J. Burgos Revilla, Madrid (ES)

From radical interventions to postoperative quality of life in prostate cancer

EGPT 48

Monday 16 March
10:45 - 12:15**Location** Orange Area, EGPT 1**Chairs** To be confirmed

A. Lantz, Danderyd (SE)

P.B. Østergren, Copenhagen (DK)

10:55 - 11:40

Functional outcomes after treatment

P0831

Sexual activity and practices five years after radical prostatectomy**Authors**Goeldner V.A.¹, Wich R.¹, Schmalbrock L.J.¹, Werner J.¹, Schulwitz H.¹, Koehn F.M.², Gschwend J.E.¹, Herkommer K.¹**Institutions**¹Technical University of Munich I School of Medicine and Health I TUM University Hospital, Dept. of Urology, Munich, Germany, ²Andrologicum Munich, Dept. of Andrology, Munich, Germany

P0837

Impact of Prostate Weight on Return to Potency in Prepotent Men Following RARP**Authors**Yang C., Yeagyyeong H., Haddadin E., Nguyen M.X., Mendoza G., Fung C., Ahlering T.**Institutions**

UCI Medical Center, Dept. of Urology, Orange, United States of America

P0834

Safety, Efficiency and Environmental Impact of Virtual At-Home Catheter Removal Following Robotic-Assisted Radical Prostatectomy**Authors**Tolbert S.¹, Vasdev R.¹, Hamandi A.², Frank I.¹, Shah P.¹, Sharma V.¹, Khanna A.¹, Potretzke A.¹, Karnes J.¹, Boorjian S.¹, Tollefson M.¹, Gettman M.¹**Institutions**¹Mayo Clinic, Dept. of Urology, Rochester, United States of America, ²Alix School of Medicine, Mayo Clinic, Rochester, United States of America

P0830

A Qualitative Study on the Avoidance Behavior of Seeking Help for Sexual Health after Radical Prostatectomy from the Perspectives of Patients and Physicians

Authors

Yi H¹, Hu Y.², Fu C.³, Peng M.⁴

Institutions

¹The First Affiliated Hospital of Chongqing Medical University, Dept. of Urology, Chongqing, China, ²Sun Yat-Sen University Cancer Center, Dept. of Urology, Guangzhou, China, ³The Second Xiangya Hospital, Central South University, Dept. of Oncology, Changsha, China, ⁴Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Dept. of Oncology, Guangzhou, China

P0826

Effect of different treatment options on the urinary function of prostate cancer patients in the TrueNTH Global (UK dataset): a multicentre cohort analysis study

Authors

Adebusoye B.¹, Maffei D.², Parry M.², Mallet S.³, Withington J.², Gunnelson L.², Foster B.⁴, Foster C.⁴, Moore C.M.²

Institutions

¹University College London, Centre for Medical Imaging, London, United Kingdom, ²University College London, Dept. of Surgery and Interventional Science, London, United Kingdom, ³University College London, Centre for Medical Imaging, London, United Kingdom, ⁴University of Southampton, Centre for Psychosocial Research in Cancer, Southampton, United Kingdom

P0843

Ten-Year Patient-Reported Outcomes After Low-Dose-Rate Brachytherapy for Prostate Cancer: Quality of Life and Treatment Satisfaction

Authors

Nakai Y.¹, Onishi K.¹, Yamaki K.¹, Fujimoto K.¹, Tanaka N.²

Institutions

¹Nara Medical University, Dept. of Urology, Kashihara, Japan, ²Nara Medical University, Dept. of Radiation Oncology, Kashihara, Japan

11:40 - 12:15

Oncological outcomes after localised treatment

P0840

Cribriform pattern correlates with adverse pathological features and predicts biochemical recurrence after radical prostatectomy

Authors

Medina Marquez C.A.¹, Rojas-Rivillas M.¹, Cote Martinez M.A.², Caicedo J.I.¹, Trujillo C.G.¹, Plata M.¹, Gutierrez A.F.¹

Institutions

¹Fundación Santa Fe de Bogotá, Dept. of Urology, Bogotá, Colombia, ²Universidad del Rosario, Dept. of Urology, Bogotá, Colombia

P0838

A comprehensive analysis of the role and potential targets of plasticizer exposure in prostate cancer progression: evidence from Chinese and American populations and preclinical studies.

Authors

Zhou X., Wei C., Yang L., Wei Q., Qiu S.

Institutions

West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China

P0841

From Prediction to Clinical Value: Decision-Analytic Validation of the Focal Risk Group (FRG) Score in Men Undergoing Focal Therapy for Localized Prostate Cancer

Authors

Anceschi U., Basile S., Flammia R.S., Proietti F., Mastroianni R., Brassetti A., Tuderti G., Bove A.M., Ferriero M., D'annunzio S., Misuraca L., Capecchi R., Capecchi L., Licari L.C., Bologna E., Lugnani F., Chiaccio G., Guaglianone S., Leonardo C., Simone G.

Institutions

Uro-Oncology Program - IRCCS - Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

P0835

Racial impact (Asians vs. Caucasians/Whites) on biochemical recurrence-free survival after robot-assisted radical prostatectomy: A propensity score matching study from 2012 to 2018

Authors

Sasaki T.¹, Ebara S.², Tatenuma T.³, Ikehata Y.⁴, Nakayama A.⁵, Kawase M.⁶, Toide M.⁷, Yoneda T.⁸, Sakaguchi K.⁹, Teishima J.¹⁰, Wang Y.¹¹, Makiyama K.³, Kitamura H.⁴, Saito K.⁵, Koie T.⁶, Koga F.⁷, Urakami S.⁹, Inoue T.¹, Miyamoto H.¹²

Institutions

¹Mie University Graduate School of Medicine, Dept. of Nephro-Urologic Surgery and Andrology, Mie, Japan, ²Hiroshima City Hiroshima Citizens Hospital, Dept. of Urology, Hiroshima, Japan, ³Yokohama City University, Dept. of Urology, Yokohama, Japan, ⁴University of Toyama, Dept. of Urology, Toyama, Japan, ⁵Dokkyo Medical University Saitama Medical Center, Dept. of Urology, Saitama, Japan, ⁶Gifu University Graduate School of Medicine, Dept. of Urology, Gifu, Japan, ⁷Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan, ⁸Seirei Hamamatsu General Hospital, Dept. of Urology, Shizuoka, Japan, ⁹Toranomon Hospital, Dept. of Urology, Tokyo, Japan, ¹⁰Kobe University Graduate School of Medicine, Dept. of Urology, Hyogo, Japan, ¹¹University of Rochester Medical Center, Dept. of Pathology and Laboratory Medicine, New York, United States of America, ¹²University of Rochester Medical Center, Dept. of Pathology and Laboratory Medicine, Dept. of Urology, New York, United States of America

P0839

Clinical characteristics of secondary bladder cancer following low-dose-rate brachytherapy for localized prostate cancer

Authors

Kawada T., Kawagou Y., Watanabe T., Ozaki N., Horii S., Moriwake T., Tsuboi I., Yoshinaga K., Yamanoi T., Sadahira T., Tominaga Y., Katayama S., Iwata T., Nishimura S., Bekku K., Araki M.

Institutions

Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Dept. of Urology, Okayama, Japan

P0833

Perineural Invasion Density: A Novel Quantitative Prognostic Marker in Prostate Cancer

Authors

Liu B., Li X., Cai Q., Luo Y.

Institutions

The Third Affiliated Hospital of Sun Yat-sen University, Dept. of urology, Guangzhou, China

P0832

The prognostic value of PTEN expression in localized prostate cancer

Authors

Bellouti A.¹, Siratine N.², Roumeguere T.¹, Peltier A.¹, Diamand R.¹

Institutions

¹Institut Jules Bordet - Hopital Universitaire de Bruxelles H.U.B, Dept. of Urology, Brussels, Belgium, ²Institut Jules Bordet - Hopital Universitaire de Bruxelles H.U.B, Dept. of Pathology, Brussels, Belgium

P0828

BCR definitioto compare prostate cancer mortality between Radiotherapy and Radical prostatectomy

Authors

Falagario U.G.¹, Pellegrino F.¹, Akre O.¹, Abbadi A.², Nordström T.², Eklund M.², Carrieri G.³, Gronberg H.², Aly M.¹, Lantz A.¹, Wiklund P.¹

Institutions

¹Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ²Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ³University of Foggia, Dept. of Urology, Foggia, Italy

P0836

Impact of Preoperative TT-cFT Discordance on Oncological Outcomes in Men with Prostate Cancer Post-RARP Under 65 Years of Age

Authors

Wada K., Yeagyong H., Nguyen M.X., Haddadin E., Yang C., Lee M., Mendoza G., Castillejos V., Fung C., Ahlering T.

Institutions

UCI Medical Center, Dept. of Urology, Orange, United States of America

P0842

Post-diagnosis smoking and risk of all-cause and prostate cancer-specific mortality: Evidence from the UK Biobank

Authors

Yang X¹, Chen H.², Xu X.², Wang M.³, Pang J.¹

Institutions

¹The Seventh Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Shenzhen, China, ²The Chinese University of Hong Kong, The Nethersole School of Nursing, Hong Kong, China, ³The Chinese University of Hong Kong, Dept. of Sports Science and Physical Education, Hong Kong, China

12:15 - 12:15

Locally advanced prostate cancer

P0829

The Evolving Management of pN1 Prostate Cancer: Temporal Trends in Adjuvant Radiotherapy versus Observation ± Salvage RT Over 20 Years at a Tertiary Referral Centre

Authors

Zaurito P.¹, Barletta F.¹, Stabile A.¹, Scuderi S.¹, Cucchiara V.¹, Moschini M.¹, Bianchi M.¹, Scilipoti P.¹, Quarta L.¹, Viti A.¹, Cosenza A.¹, Occhi A.¹, Dambrosio L.¹, Gallina A.², Fossati N.², Zaffuto E.³, Dehò F.³, Suardi N.⁴, Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Ente Ospedaliero Cantonale, Università della Svizzera Italiana, Dept. of Urology, Lugano, Switzerland, ³Ospedale di Circolo and Macchi Foundation, Dept. of Urology, Varese, Italy, ⁴University of Brescia, Dept. of Urology, Brescia, Italy

Impact of Negative Primary Staging with PSMA-PET versus Conventional Imaging Among Patients With Lymph Node Invasion After Radical Prostatectomy

Authors

Barletta F.M.¹, Marra G.², Bianchi L.³, Zattoni F.⁴, Rajwa P.⁵, Van den Bergh R.⁶, Gomez-Rivas J.⁷, Sigle A.⁸, Amparore D.⁹, Zhuang J.¹⁰, Soeterik T.⁶, Mottrie A.¹¹, Murphy D.¹², Chiti A.¹³, Fankhauser C.¹⁴, Fendler W.¹⁵, Schiavina R.³, Dal Moro F.⁴, Porpiglia F.⁹, Heidegger I.¹⁶, Joniau S.¹⁷, Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Città della Salute e della Scienza, University of Turin, Dept. of Urology, Turin, Italy, ³IRCCS Azienda Ospedaliero Universitaria di Bologna, Division of Urology, Bologna, Italy, ⁴University of Padua, Dept. of Surgery, Oncology and Gastroenterology, Padua, Italy, ⁵Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁶St. Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands, ⁷Hospital Clínico San Carlos, Dept. of Urology, Madrid, Spain, ⁸Freiburg University Hospital, Dept. of Urology, Freiburg, Germany, ⁹School of Medicine, San Luigi Hospital, University of Turin, Division of Urology, Dept. of Oncology, Turin, Italy, ¹⁰Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Dept. of Urology, Jiangsu, China, ¹¹OLV Ziekenhuis Aalst, Dept. of Urology, Melle, Belgium, ¹²Peter MacCallum Cancer Centre, Division of Cancer Surgery, Melbourne, Australia, ¹³IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, ¹⁴University of Lucerne, University Teaching and Research Hospital of the University of Lucerne; University of Zurich, Faculty of Health Sciences and Medicine, Dept. of Urology, Lucerne, Switzerland, ¹⁵Essen University Hospital, Dept. of Nuclear Medicine, Essen, Germany, ¹⁶University Hospital of Innsbruck, Dept. of Urology, Innsbruck, Austria, ¹⁷University Hospitals Leuven, Dept. of Urology, Leuven, Belgium

Prostate cancer: Imaging, biopsy and targeted treatments

EGPT 49

Monday 16 March
10:45 - 12:15

Location Orange Area, EGPT 2

Chairs D. Eberli, Zürich (CH)

To be confirmed

To be confirmed

11:05 - 11:25

Biopsy strategy

P0859

TRANSRECTAL SOFTWARE-GUIDED FUSION PROSTATE BIOPSY: DOES SYSTEMATIC BIOPSY ADD VALUE? A RETROSPECTIVE ANALYSIS.

Authors

Marchant A.¹, Arrué K.¹, Vinambres J.², Cajales M.², Castiglioni E.³, Westermeier D.², Kreisberg M.², Vildósola C.², Lopez J.F.¹

Institutions

¹Pontificia Universidad Católica de Chile, Dept. of Urology, Santiago, Chile, ²Pontificia Universidad Católica de Chile, School of Medicine, Santiago, Chile, ³Pontificia Universidad Católica de Chile, Simulation Center, Santiago, Chile

P0844

Real-world impact of omitting standard biopsies in MRI-targeted prostate biopsy

Authors

Umbaca M., [Malavasi G.](#), Santioni M., Pierri E., Romagnoli M., Santoro G., Nacchia A., Franco A., Tema G., Lombardo R., Cicione A., Al Salhi Y., Pastore A., Fuschi A., Tubaro A., De Nunzio C.

Institutions

Sapienza University of Rome, Dept. of Urology, Rome, Italy

P0860

Perineal Prostate Biopsies in Lateral Decubitus Position Under Sedation: A Novel Approach Improving Safety, Efficiency, and Patient Comfort

Authors

Rahnama'i M.S., [Beukens S.](#), Posthumus R., Müller T.

Institutions

Nij Smellinghe, Dept. of Urology, Drachten, The Netherlands

P0861

Perilesional biopsy in – systematic out? Comparative analysis of targeted, perilesional and systematic approaches with robotic-assisted transperineal MRI/US fusion prostate biopsy

Authors

[Alargkof V.](#)¹, Walter M.², Engesser C.¹, Seifert H.H.¹, Breit H.C.³, Winkel D.J.³, Wetterauer C.¹, Trotsenko P.⁴

Institutions

¹University Hospital Basel, Dept. of Urology, Basel, Switzerland, ²Hospital of Bozen (SABES-ASDAA), Dept. of Urology, Bozen-Bolzano, Italy, ³University Hospital Basel, Dept. of Radiology, Basel, Switzerland, ⁴Medical University of Graz, Dept. of Urology, Graz, Austria

Bladder cancer surgery evolving: From neoadjuvant strategies to long-term survival analysis

EGPT 50

Monday 16 March
10:45 - 12:15

Location

Orange Area, EGPT 3

Chairs

R. Contieri, Naples (IT)

K. Mouw, Boston (US)

T. Szarvas, Budapest (HU)

10:45 - 11:10

Technical developments in radical cystectomy

P0862

Temporal trends in urinary diversion selection after radical cystectomy: A 25-year single-center analysis

Authors

[Nocera L.](#), Zamboni S., Sciotta M., Furlan M., Lonati C., Belotti S., Mondini F., Arrigoni F., Donnini I., Romani M., Mirabella G., Suardi R.N.

Institutions

ASST Spedali Civili, Dept. of Urology, Brescia, Italy

P0863

Impact of Early Surgical Experience on Ureteroenteric Stricture Risk after Robotic Intracorporeal Orthotopic Neobladder Reconstruction

Authors

Basile S., Anceschi U., Flammia R.S., Proietti F., Tuderti G., Mastroianni R., Brassetti A., Bove A.M., Ferriero M., Misuraca L., D'annunzio S., Licari L.C., Bologna E., Chiacchio G., Guaglianone S., Leonardo C., Simone G.

Institutions

Uro-Oncology Program - IRCCS - Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

P0864

Five-year oncologic outcomes of Open vs Robot-Assisted Radical Cystectomy with totally intracorporeal Urinary Diversion: results from a single centre Randomized Controlled Trial

Authors

Mastroianni R., Tuderti G., Anceschi U., Bove A.M., Brassetti A., D'Annunzio S., Ferriero M., Flammia R.S., Guaglianone S., Anselmi M., Bologna E., Chiacchio G., Licari L.C., Misuraca L., Proietti F., Leonardo C., Simone G.

Institutions

Uro-oncology Program IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

P0865

Single Port Robotic Radical Cystectomy: A Multi-Institutional Experience of the Single Port Advanced Research Consortium (SPARC)

Authors

Contieri R.¹, Spena G.¹, Soputro N.A.², O'Hara J.³, Zhu A.⁴, Stifelman M.D.³, Wicklund P.⁴, Mehrazin R.⁴, Yuh B.⁵, Rais-Bahrami S.⁶, Kaouk J.², Autorino R.², Ahmed M.³, Perdonà S.¹

Institutions

¹Istituto Nazionale Tumori IRCCS G. Pascale, Dept. of Urology, Naples, Italy, ²Glickman Urological Institute, Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, ³Hackensack University Medical Center, Dept. of Urology, Hackensack, United States of America, ⁴Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ⁵City of Hope Hospital, Dept. of Urology, Duarte, United States of America, ⁶University of Alabama at Birmingham (UAB), Dept. of Urology, Birmingham, United States of America

P0866

Early experience with the Toumai® robotic system in radical cystectomy: results of the first 10 cases at a high-volume European centre

Authors

Guidotti A., Barretta A., Brancelli C., Pepillo F., Cavarra V., De Angelis M., Prata F., Beatrice E., Rodriguez N., Lambert E., Carl N., De Naeyer G., De Groote R., D'Hondt F., Mottrie A.

Institutions

AZORG Hospital, Dept. of Urology, Aalst, Belgium

11:10 - 11:50

Patient outcomes after radical surgery for muscle-invasive bladder cancer

P0867

Radical cystectomy and orthotopic neobladder in patients with pre-operative chronic kidney disease: peri-operative and functional outcomes

Authors

Tuderti G., Mastroianni R., Anceschi U., Bove A.M., Brassetti A., D'Annunzio S., Ferriero M., Flammia S., Misuraca L., Proietti F., Chiacchio G., Licari L., Bologna E., Guaglianone S., Leonardo C., Simone G.

Institutions

IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy

P0868

A Non-invasive MRI-based Multimodal Fusion Deep Learning Model (MF-DLM) for Predicting Overall Survival in Bladder Cancer: A Multicenter Retrospective Study

Authors

Lyu Q., Yang X., Cao Q., Cai L.

Institutions

the First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

P0869

Marked Variation in Cystectomy Outcomes Across Swiss Hospitals: A Machine Learning-Based National Morbidity Assessment Using Administrative Data

Authors

Hecker M.¹, Sautebin M.L.², Abt D.¹, Seiler R.¹, Müller T.², Blarer J.¹

Institutions

¹Spitalzentrum Biel-Centre hospitalier Bienne, Dept. of Urology, Biel, Switzerland, ²Bern University of Applied Sciences, Institute of Health Economics and Health Politics, Bern, Switzerland

P0870

Closing the Gender Gap: Standardized Multidisciplinary Care Achieves Equal Survival After Radical Cystectomy

Authors

Ceria E., Gad M., Del Giudice F., Ibrahim Y., Thuraiaraja R., Nair R., Mensah E., Khan M.S., Abu Ghanem Y.

Institutions

Department of Urology - Guy's Hospital - Guy's and St Thomas' Foundation Trust, Dept. of Urology, London, United Kingdom

P0871

Role of inflammatory markers and frailty index as predictors of adverse pathological stage and complications in patients undergoing radical cystectomy for bladder cancer: a multicenter analysis

Authors

De Nunzio C.¹, Lombardo R.¹, Tema G.¹, Nacchia A.¹, Cicione A.¹, Proietti F.¹, Costantino L.¹, Mastroianni A.², Simone G.², D'Annunzio S.², Stefano S.³, Francesco E.⁴, Ghezzi N.¹, Tubaro A.¹

Institutions

¹Sapienza University of Rome, Dept. of Urology, Rome, Italy, ²IRCCS Istituto Nazionale Tumori Regina Elena, Dept. of Urology, Rome, Italy, ³Ospedale Sant'Eugenio, Dept. of Urology, Rome, Italy, ⁴Campus Biomedico di Roma, Dept. of Urology, Rome, Italy

P0872

Time to treatment Initiation and Survival in patients with Muscle-Invasive Bladder Cancer: a National Cancer Database (NCDB) analysis

Authors

Piccolini A.¹, Korn S.¹, Zhiyu Q.¹, Brin P.¹, Pohl K.¹, Zurl H.¹, Boyuan X.², Lughezzani G.³, Buffi N.M.³, Trinh Q.D.⁴, Cole A.P.¹

Institutions

¹Brigham and Women's Hospital, Dept. of Urology, Boston, United States of America, ²Boston University Chobanian and Avedisian, School of Medicine, Boston, United States of America, ³Humanitas University, Dept. of Urology, Milan, Italy, ⁴University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America

P0873

Timing Matters: The Predictive Role of Early Infections in Ureteroenteric Strictures after Bricker Diversion

Authors

Aneschi U., Basile S., Flammia R.S., Brassetti A., Misuraca L., Tuderti G., Proietti F., Mastroianni R., Bove A.M., Ferriero M., Chiaccio G., D'annunzio S., Anselmi M., Licari L.C., Bologna E., Guaglianone S., Leonardo C., Simone G.

Institutions

Uro-Oncology Program - IRCCS - Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

P0874

Perioperative Management of Direct Oral Anticoagulants in Urological Surgery – The prospective PAUSE-URO Trial

Authors

Carl N.¹, Dempfle C.E.², Halber E.¹, Löschner D.¹, Schöttler J.³, Beck G.³, Dürschmied D.⁴, Michel M.S.¹, Kowalewski K.F.¹

Institutions

¹University Medical Centre Mannheim University of Heidelberg, Dept. of Urology, Mannheim, Germany, ²Coagulation Center Mannheim, Mannheim, Germany, ³University Medical Centre Mannheim University of Heidelberg, Dept. of Anesthesiology, Mannheim, Germany, ⁴University Medical Centre Mannheim University of Heidelberg, Dept. of Medicine, Cardiology, Angiology, Hemostasis and Intensive Care Medicine, Mannheim, Germany

11:50 - 12:15

Neoadjuvant strategies in muscle-invasive bladder cancer

P0875

Cost-Effectiveness Analysis of New Perioperative Treatment Regimens for Muscle-Invasive Bladder Cancer

Authors

Rieger C.¹, Schluechtermann J.², Pfister D.¹, Heidenreich J.¹, Weiten R.¹, Schmid F.¹, Heidenreich A.¹

Institutions

¹University Hospital Cologne, Dept. of Urology, Cologne, Germany, ²University Bayreuth, Faculty of Law, Business and Economics, Bayreuth, Germany

P0876

Evaluating the Surrogacy of Intermediate Clinical Endpoints for Overall Survival after Perioperative Treatment in Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy

Authors

Scilipoti P.¹, Ślusarczyk A.², Thibault C.³, Necchi A.⁴, Montorsi F.¹, Salonia A.¹, Briganti A.¹, Moschini M.¹, Roupret M.⁵, Seisen T.⁵

Institutions

¹IRCCS Ospedale San Raffaele, Unit of Urology, Milan, Italy, ²Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ³Hopital Européen Georges Pompidou, APHP Centre, Institut du Cancer Paris CARPEM, Dept. of Medical Oncology, Paris, France, ⁴IRCCS Ospedale San Raffaele, Dept. of Oncology, Milan, Italy, ⁵Pitie-Salpetriere Hospital, AP-HP, Dept. of Urology, Paris, France

P0878

Impact of Neoadjuvant Therapy on Oncologic Outcomes in Patients With Undetectable Pre-Cystectomy Circulating Tumor DNA

Authors

Zhu A.¹, Eraky A.¹, Gupta R.¹, Ben-David R.², Mehrazin R.¹, Wiklund P.¹, Sfakianos J.¹

Institutions

¹Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ²Tel Aviv Sourasky Medical Center, Dept. of Urology, Tel Aviv, Israel

P0879

Utility of nacVI-RADS for predicting pathological complete response after chemoradiotherapy in muscle-invasive bladder cancer

Authors

Kobayashi M.¹, Yoshida S.¹, Fukui K.², Yamagiwa K.², Arita Y.³, Fukuda S.¹, Fukushima H.¹, Waseda Y.¹, Yasuda Y.¹, Tanaka H.¹, Tsuchiya J.², Tateishi U.², Fujii Y.¹

Institutions

¹Institute of Science Tokyo, Dept. of Urology, Tokyo, Japan, ²Institute of Science Tokyo, Dept. of Diagnostic Radiology and Nuclear Medicine, Tokyo, Japan, ³Memorial Sloan Kettering Cancer Center, Dept. of Radiology, Tokyo, Japan

Urolithiasis: Percutaneous nephrolithotomy

EGPT 51

Monday 16 March
10:45 - 12:15

Location Orange Area, EGPT 4
Chairs M.S. Agrawal, Agra (IN)
M.C. Rassweiler-Seyfried, Mannheim (DE)
To be confirmed

10:45 - 10:55

PCNL - Trends and learning curve

P0880

Resident Learning Curve in Percutaneous Nephrolithotomy (PCNL): A Prospective Evaluation Using Objective Structured Assessment of Technical Skills (OSATS)

Authors

Patil A., Kamble A., Sharma S.

Institutions

Grant Government Medical College and Sir J.J. Group of Hospitals, Dept. of Urology, Mumbai, India

P0881

Perioperative Complications of Percutaneous Nephrolithotomy and Combined Percutaneous Nephrolithotomy with Uni- and Bilateral Ureterorenoscopic Stone Therapy: Results of the GRAND Study

Authors

Chaloupka M., Ebner B., Pfitzinger P., Georgieva T., Blajan I., Karatas D., Happe M., Volz Y., Apfelbeck M., Stief C., Pyrgidis N.

Institutions

University Hospital Munich Ludwig-Maximilian-University, Dept. of Urology, Munich, Germany

10:55 - 11:15

PCNL Access

P0882

Integrating Virtual-Reality Imaging into Pre-operative PCNL Planning: Early Clinical Outcomes in Patients with Abnormal Renal Anatomy

Authors

Kothapalli S., Palanisamy V., Raja T., Reddy P., Meyyappan V., Palaniappan V., Sekar H., Kumaresan N., Krishnamoorthy S.

Institutions

Sri Ramachandra Institute of Higher Education and Research, Dept. of Urology and Renal Transplantation, Chennai, India

P0883

Ultrasound guided percutaneous nephrolithotomy : is it better than flouroscopic guided percutaneous nephrolithotomy?

Authors

Mughal R.A.

Institutions

Benazir Bhutto Hospital Rawalpindi, Dept. of Urology and Renal Transplantation, Rawalpindi, Pakistan

P0884

A Novel CT-Ultrasound Fusion Navigation System Enhances Precision and Safety of Percutaneous Nephrolithotomy: Results from a Multicenter Randomized Trial

Authors

Li B., Ruan Y., Rao T., Yu W., [Cheng E.](#)

Institutions

Renmin Hospital of Wuhan University, Dept. of Urology, Wuhan, China

P0885

Occupational Exposure Reduction in Endoscopic Combined Intrarenal Surgery in fresh frozen cadaver study

Authors

[Shiozaki K.](#)¹, Yutaro S.¹, Marika A.¹, Fumiya K.¹, Tetsuhiro Y.¹, Saki K.¹, Ryohei M.¹, Mitsuki N.¹, Kei D.¹, Ryotaro T.¹, Yoshito K.¹, Kunihisa Y.¹, Yasuyo Y.¹, Tomoya F.¹, Koichi T.², Junya F.¹

Institutions

¹Tokushima University Graduate School of Biomedical Sciences, Dept. of Urology, Tokushima, Japan, ²Tokushima University Graduate School of Biomedical Sciences, Dept. of Anatomy and Developmental Neurobiology, Tokushima, Japan

Study Group

Tokushima University Graduate School of Biomedical Sciences(Tokushima, Japan)

11:15 - 11:45

Mini PCNL

P0886

Digital disposable nephroscopes (DDN) with suction mini PCNL (SM-PCNL).Do we have a winning combination for kidney stone management?:A prospective real world 30 day feasibility study in 300 patients

Authors

[Kalathia J.A.](#)¹, Somani B.K.², Fong K.Y.³, Castellani D.⁴, Yuen S.K.K.⁵, Gauhar V.⁶

Institutions

¹Fortune Urology Clinic, Dept. of Urology, Gujarat, India, ²University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ³Singapore General hospital, Dept. of Urology, Singapore, Singapore, ⁴Azienda Ospedaliero-Universitaria delle Marche, Università Politecnica delle Marche, Dept. of Urology, Ancona, Italy, ⁵SH Ho Urology Centre, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong, ⁶Ng Teng Fong general hospital, Dept. of Urology, Singapore, Singapore

P0887

A Multicentric Prospective Randomised controlled study between Miniperc and RIRS using Thulium fiber laser for Lower pole stones of 10-20mm size

Authors

[Soundarya G.](#)¹, Chandramohan V.¹, Abhishek S.², Aruj S.², Hemnath A.¹, Rakesh P.¹, Ravindra S.², Mahesh D.²

Institutions

¹Preeti Urology and Kidney hospital, Dept. of Urology, Hyderabad, India, ²Muljhibhai Patel Urological Hospital, Dept. of Urology, Nadiad, India

P0888

Safety and Efficacy Results from a Randomized Controlled Trial Comparing Thulium Fiber Laser and Holmium: YAG Laser Lithotripsy in Mini-Percutaneous Nephrolithotomy

Authors

Chawla A.K., Venkat S., Pillai S., Singh S., Hegde P.

Institutions

Kasturba Medical College, Dept. of Urology and Renal Transplant, Manipal, India

P0889

Clinical comparison of vacuum-assisted mini PCNL versus standard PCNL with multiple access tracts for large kidney stones: a real-life study

Authors

Zanetti S.P.¹, Bonacina E.¹, Passarelli F.¹, Basadonna L.M.¹, Parolin V.¹, Graps G.¹, Ciamarra F.¹, Sorba E.¹, Ripa F.¹, Lucignani G.¹, Longo F.¹, De Lorenzis E.², Albo G.², Montanari E.², Boeri L.¹

Institutions

¹IRCCS Fondazione Ca Granda Ospedale Maggiore Policlinico Milano, Dept. of Urology, Milan, Italy, ²University of Milan, Dept. of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, Milan, Italy

P0890

MINI-PCNL AS A DAY CASE; A CLINICAL AUDIT IN A SINGLE NHS TRUST

Authors

Faheem M.K., Ertemi H., Sheikh N.

Institutions

Mid and South Essex NHS Trust, Dept. of Urology, Basildon, United Kingdom

P0891

Comparison of Suction Sheath-Assisted Mini Percutaneous Nephrolithotomy and Conventional Ultra-Mini PCNL: Shortened Operative Time With Comparable 3-Month Outcomes

Authors

Chae H.K., Jeong H.C., Han J.Y., Yang D.Y., Ko K.

Institutions

Kangdong Sacred Heart Hospital Hallym University College of Medicine, Dept. of Urology, Seoul, South Korea

11:45 - 12:15

PCNL - Outcomes

P0892

Value of Nephrolithiasis Treatment in AGEd patients: the "ViNTAGE study" on the safety and efficacy of mPCNL in the geriatric population

Authors

Passarelli F.¹, Bonacina E.¹, Ciamarra F.¹, Sorba E.¹, Basadonna L.M.¹, Parolin V.¹, Graps G.¹, Ripa F.¹, Lucignani G.¹, Zanetti S.P.¹, Longo F.¹, De Lorenzis E.², Albo G.², Montanari E.², Boeri L.¹

Institutions

¹IRCCS Fondazione Ca Granda Ospedale Maggiore Policlinico Milano, Dept. of Urology, Milan, Italy, ²University of Milan, Dept. of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, Milan, Italy

P0893

Predicting complications and hospitalization after percutaneous nephrolithotomy using machine learning models

Authors

Espinosa Vano J.¹, Shalabayeva L.², Castillo D.J.¹, Martínez-Barbero J.¹, Ramada E.¹, Romeu M.², Díaz J.², Vivas D.², Mata M.¹, López-Acón J.D.¹, Moratalla L.M.¹, Bahilo P.¹, Budía A.¹

Institutions

¹Hospital Universitari i Politècnic La Fe, Dept. of Urology, Valencia, Spain,

²Polytechnic University of Valencia, Research Unit for Health Economics and Management, Valencia, Spain

P0894

Staff workload comparison in percutaneous nephrolithotomy with versus without intraoperative cone-beam CT: 18-month randomized trial follow-up

Authors

Suijker C.A.¹, van Ee R.¹, van Asselt A.D.I.², van Oort I.M.¹, Kingma R.A.¹, Roemeling S.¹

Institutions

¹University Medical Center Groningen, Dept. of Urology, Groningen, The Netherlands,

²University Medical Center Groningen, Dept. of Health Sciences, Groningen, The Netherlands

P0895

Predictors of Stone-Free Rate After Supine Percutaneous Nephrolithotomy (S-PCNL) With or Without Endoscopic Combined Intrarenal Surgery (ECIRS): A Nomogram to Guide Preoperative Counseling and Surgical Planning

Authors

Basile G.¹, Pauwaert K.¹, Allen D.¹, Logrado L.¹, Fonseka T.¹, Dionisio F.¹, Goode A.², Yu D.², Goyal A.¹, Ellis G.¹, Singh P.¹, Kucheria R.¹, Ajayi L.¹

Institutions

¹Royal Free London NHS Foundation Trust, Dept. of Urology, London, United

Kingdom, ²Royal Free London NHS Foundation Trust, Dept. of Radiology, London, United Kingdom

P0896

Sepsis after percutaneous nephrolithotomy - the significance of kidney stone endotoxin

Authors

Tzou D.¹, Anwar F.², Hofmann C.³, Chien A.L.³, On T.A.⁴, Hsu C.H.⁵, Lange D.⁶, Stoller M.L.¹, Chi T.⁷, Lainhart W.⁸, Vedantam G.²

Institutions

¹University of California San Francisco, Dept. of Urology, San Francisco, United

States of America, ²University of Arizona, College of Animal Sciences, Tucson, United

States of America, ³University of Arizona, Dept. of Urology, Tucson, United States of

America, ⁴University of Arizona, College of Medicine, Tucson, United States of

America, ⁵University of Arizona, Dept. of Epidemiology & Biostatistics, Tucson, United

States of America, ⁶University of British Columbia, Dept. of Urologic Sciences,

Vancouver, Canada, ⁷University of Alabama Birmingham, Dept. of Urology,

Birmingham, United States of America, ⁸University of Arizona, Dept. of Pathology &

Laboratory Medicine, Tucson, United States of America

Comparative Impact of Retrograde Intrarenal Surgery and Mini-Percutaneous Nephrolithotomy on Postoperative Renal Function

Authors

Candela L.¹, Scilipoti P.², Villa L.², Ventimiglia E.², Mariela C.¹, Sierra del Rio A.³, Solano C.⁴, Doizi S.¹, Boeri L.⁵, Zanetti S.⁵, Ciamarra F.⁵, Panthier F.¹, Montanari E.⁵, Salonia A.², Traxer O.¹

Institutions

¹Tenon Hospital - APHP - Sorbonne University, Dept. of Urology, Paris, France, ²Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ³Hospital Clinic, Dept. of Urology, Barcelona, Spain, ⁴Uroclin, Dept. of Urology, Medellin, Colombia, ⁵Policlinico Universitario di Milano, Dept. of Urology, Milan, Italy

Renal cancer - Basic and translational research

EGPT 52

Monday 16 March
10:45 - 12:15

Location

Orange Area, EGPT 5

Chairs

I.L. Heimann, Aarhus (DK)

K. Junker, Homburg (DE)

T. Mitchell, Cambridge (GB)

P0988

Multi-Omics profiling of long noncoding RNAs in clear cell renal cell carcinoma for characterization and clinical applications

To be confirmed

P0990

CT Radiomics and AI for Differentiating Oncocytoma from Renal Cell Carcinoma

V. Gomez Dos Santos, Madrid (ES)

P0993

A Soutlangiolide A-Derived Inhibitor Disrupts the FAM120A-SREBP1-PPAR γ Metabolic Loop and Synergizes with HIF-2 α Blockade in Clear Cell Renal Cell Carcinoma

Z. Song, Beijing (CN)

P0995

Targeting tRNA-Derived Fragment tRF-21 Enhances Immunotherapy Efficacy by Reducing PMN-MDSCs Accumulation in Renal Cell Carcinoma

X. Qin, Jinan (CN)

P0996

Combinatorial Immunotherapy with IL-12/shVEGF-Expressing Oncolytic Adenovirus for Renal Cell Carcinoma: Organ-on-a-Chip and In Vivo Evaluation

J. Shim, Daejeon (KR)

P0999

GPNMB+ Tumor-Associated Macrophages Drive CD8+ T Cell Exhaustion to Facilitate Clear Cell Renal Cell Carcinoma Progression

Y. Tao, Shanghai (CN)

P1000

Hyperspectral Imaging Reveals Superior Preservation of Renal Microcirculatory Oxygenation With Crystalloid-Based Resuscitation During Hemorrhagic Shock in a Porcine Model

P. Grützner, Worms (DE)

P1002	Multimodal deep learning model for AI-based functional prognostic risk stratification in patients undergoing radical nephrectomy To be confirmed
P1004	Integrative multi-omics profiling reveals molecular mechanisms and targetable pathways of Belzutifan resistance in renal cell carcinoma To be confirmed
P1007	Nuclear translocation of TFEB enhances autophagy and PD-L1 expression promoting invasion, metastasis, and immune escape of FH-deficient renal cell carcinoma W. Tao, Beijing (CN)
P1008	TRANSLATING TUMOR BIOLOGY INTO CLINICAL PRACTICE USING PATIENT-DERIVED ORGANOID IN RENAL CELL CARCINOMA A. Shahini, Montreal (CA)
P1011	CENPT Inhibits Ferroptosis and Promotes Renal Cell Carcinoma Progression via a CENPT-GCLC-GSH Positive Feedback Loop To be confirmed
P1012	Tumor-infiltrating intracellular microbiota promote metastatic colonization in clear cell renal cell carcinoma B. You, Harbin (CN)
P1014	The role of piR-1742 in malignant progression and clinical translation of renal cell carcinoma Z. Wentao, Shanghai (CN)
P1016	A TLS-Based Molecular Signature Predicts Prognosis and Immune Escape in Clear Cell Renal Cell Carcinoma W. Liu, Beijing (CN)
P1019	Spatially Resolved Myeloid Cell Driven Tissue Reorganization Shapes Immunotherapy Outcomes in Advanced Renal Cell Carcinoma W. Zhai, Shanghai (CN)
P1020	Development and Validation of a Novel Plasma Metabolomic Signature for the Detection of Renal Cell Carcinoma To be confirmed
P1023	Metabolic Reprogramming in Early-Onset VHL-Associated Clear Cell Renal Cell Carcinoma: A Multi-Omics Study Reveals Amino Acid Oxidation and Lipid Remodeling as Key Drivers of Systemic Rewiring Z. Song, Beijing (CN)

Prostate cancer survivorship and sexuality: A session in collaboration with the ISSM/ESSM & Movember

Thematic Session

Monday 16 March
12:30 - 14:00

Location Orange Area, eURO Auditorium 2

Chairs
C. Bettocchi, Foggia (IT)
E. Rogers, Roscommon (IE)
R. Wang, Houston (US)

Learning objectives

To introduce what ISSM Movember partnership is and has done to promote Sexual Health related to prostate cancer treatment. To provide brief about guidelines recently published about managing sexual dysfunction after prostate cancer treatment.

12:30 - 12:35

Introduction to the ISSM Movember partnership

R. Wang, Houston (US)

12:35 - 12:44

State-of-the-art lecture Sexual problems in prostate cancer: Looking beyond ED

M.M. Fode, Herlev (DK)

12:44 - 12:53

State-of-the-art lecture Psychological issues and pearls of treatment for the clinician

A. Matthew, Toronto (CA)

12:53 - 13:25

Case-based discussion Shared decision making

12:53 - 12:58

Case presentation Intermediate risk prostate cancer in sexually active patient

E. Briers, Hasselt (BE)

12:58 - 13:03

Pro: Active surveillance

S. Knipper, Berlin (DE)

13:03 - 13:08

Pro: Radical prostatectomy & intraoperative margin assessment

N.N. Harke, Hannover (DE)

13:08 - 13:13

Pro: RT + ADT: The quiet power of combination therapy

N. Sundahl, Kortrijk (BE)

13:13 - 13:25

Panel discussion Patient challenges panel with discussions

Moderator J.P. Mulhall, New York (US)

Panel
E. Briers, Hasselt (BE)
N.N. Harke, Hannover (DE)
S. Knipper, Berlin (DE)
N. Sundahl, Kortrijk (BE)

13:25 - 14:00

Panel discussion What is new in sexual rehabilitation

13:25 - 13:30

Preparing patients for their road ahead

P. Capogrosso, Varese (IT)

13:30 - 13:35

Partner issues and lifestyle

S. Loeb, New York (US)

13:35 - 13:40

Dyadic aspects and couple issues

D. Wittmann, Ann Arbor (US)

13:40 - 13:45

Sexual orientation and gender identity

T.L. Yap, London (GB)

13:45 - 13:50

Novelties in sexual rehabilitation

J.P. Mulhall, New York (US)

13:50 - 14:00

Panel discussion What entails modern sexual rehabilitation for prostate cancer patients

Panel

P. Capogrosso, Varese (IT)

S. Loeb, New York (US)

J.P. Mulhall, New York (US)

D. Wittmann, Ann Arbor (US)

T.L. Yap, London (GB)

Incontinence uncovered: Managing urgency without stress

Thematic Session

Monday 16 March
12:30 - 14:00

Location

Orange Area, eURO Auditorium 1

Chairs

E. Finazzi Agrò, Rome (IT)

B. Peyronnet, Rennes (FR)

Learning objectives

In this session, it will be possible to discuss the latest prevention strategies, diagnostic pathways and treatments of overactive bladder (in both male and female patients) and stress urinary incontinence in female patients. Well known experts will bring their experience to the audience to provide the most updated evidence on the management of these common conditions.

12:30 - 12:32

Welcome and introduction

12:32 - 12:42

State-of-the-art lecture Update on the Urge to Act campaign

M.R. Van Balken, Arnhem (NL)

12:42 - 13:18

Round-table discussion What is the best first-line treatment for OAB?

12:42 - 12:47

App-based self management

L. Wiemer, Berlin (DE)

12:47 - 12:52

Physiotherapy

To be confirmed

12:52 - 12:57

Transcutaneous tibial nerve stimulation

C. Hentzen, Paris (FR)

12:57 - 13:02

Antimuscarinics

M.C. Lapitan, Manila (PH)

13:02 - 13:07

Beta 3 agonists

To be confirmed

13:07 - 13:12

We need to move to a tailored "non-step" approach

G. Bou Kheir, Gent (BE)

13:12 - 13:18

Panel discussion

13:18 - 13:34

Debate Beyond the future (trial): Current role of urodynamics in OAB

13:18 - 13:24

Very limited

M.S. Abdel-Fattah, Aberdeen (GB)

13:24 - 13:30

Still paramount

T. Tarcan, Istanbul (TR)

13:30 - 13:34

Discussion

13:34 - 13:44

State-of-the-art lecture The importance of shared decision making nowadays

M. Belal, Birmingham (GB)

13:44 - 14:00

Debate Should we still implant synthetic midurethral slings for female SUI?

13:44 - 13:50

Yes, of course

E. Costantini, Perugia (IT)

13:50 - 13:56

No, that's too risky

T.J. Greenwell, London (GB)

13:56 - 14:00

Discussion

Innovations in muscle invasive bladder cancer management: From neoadjuvant therapies to preservation strategies

Abstract Session 51

Monday 16 March

12:30 - 14:00

Location

Blue Area, Victoria 6

Chairs

Y. Abu Ghanem, London (GB)

J.L. Domínguez Escrig, Valencia (ES)

To be confirmed

12:30 - 12:50

Bladder preservation strategies for non-metastatic muscle-invasive bladder cancer

Radical Cystectomy vs Trimodal Therapy for Non-Metastatic Bladder Cancer in the United States: Contemporary Trends of Practice Patterns, Perioperative/Health-care Costs and Progression-Free Survival Outcomes

Authors

Del Giudice F.¹, Łaskiewicz J.², Santarelli V.¹, Li S.³, Corvino R.¹, Asero V.¹, Basile G.⁴, Khan A.⁵, Nair R.⁶, Ramesh T.⁶, Khan M.S.⁶, Abu-Ghanem Y.⁶, Krajewski W.⁷, Rocco B.⁸, De Berardinis E.¹, Crocetto F.⁹, Pichler R.¹⁰, Moschini M.⁴, Ślusarczyk A.¹¹, Mari A.¹², Soria F.¹³, Pradere B.¹⁴, Jamie Casas S.³, Chung B.I.³

Institutions

¹Sapienza University of Rome, Dept. of Urology, Rome, Italy, ²University Center of Excellence in Urology, Wrocław Medical University, Dept. of Minimally Invasive and Robotic Urology, Wrocław, Poland, ³Stanford University School of Medicine, Dept. of Urology, Stanford, United States of America, ⁴IRCCS Ospedale San Raffaele, Division of Experimental Oncology, Unit of Urology, Milan, Italy, ⁵University of Maryland School of Medicine, Division of Urology, Baltimore, United States of America, ⁶Guy's and St. Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁷University Center of Excellence in Urology, Dept. of Minimally Invasive and Robotic Urology, Wrocław, Poland, ⁸IRCCS A. Gemelli University Polyclinic Foundation, Sacred Heart Catholic University, Dept. of Urology, Rome, Italy, ⁹University of Naples Federico II, Dept. of Neurosciences, Reproductive Sciences and Odontostomatology, Naples, Italy, ¹⁰Medical University of Innsbruck, Dept. of Urology, Comprehensive Cancer Center Innsbruck, Innsbruck, Italy, ¹¹Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ¹²Careggi Hospital, University of Florence, Urological Robotic Surgery and Renal Transplantation Unit, Florence, Italy, ¹³San Giovanni Battista Hospital, University of Studies of Torino, Division of Urology, Dept. of Surgical Sciences, Turin, Italy, ¹⁴La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France

Bladder preservation in patients with muscle-invasive bladder cancer who refused/unwilling to radical cystectomy after complete response to neoadjuvant systemic and local (chemo/immune) therapy. A 24-years single centre experience.

Authors

Di Stasi S.M.¹, Carilli M.², Iacovelli R.³, Di Stasi E.⁴, Redon S.⁵, Iacovelli V.², Vittori M.², Signoretti M.², Brocca C.², Bove P.¹

Institutions

¹University of Rome Tor Vergata, Dept. of Surgical Sciences, Rome, Italy, ²Fondazione Policlinico Tor Vergata, Robotic and Minimally-Invasive Urology Unit, Rome, Italy, ³Fondazione Policlinico Universitario Agostino Gemelli, Dept. of Oncology, Rome, Italy, ⁴Catholic University of the Sacred Heart, Faculty of Medicine and Surgery, Rome, Italy, ⁵Catholic University "Our Lady of Good Counsel", Faculty of Medicine and Surgery, Tirane, Albania

A0868

Mapping real-world recurrence and treatment patterns after trimodal therapy in older adults with muscle invasive bladder cancer using a novel SEER-Medicare algorithm

Authors

Mamtani R.¹, Raut M.², Yapici H.O.³, Jiao W.³, Su F.³, Davies A.⁴, Lai Y.⁵, Li H.², Davis N.⁶

Institutions

¹Perelman School of Medicine at the University of Pennsylvania, Abramson Cancer Center, Philadelphia, United States of America, ²Merck and Co. Inc., Outcomes Research, Rahway, United States of America, ³Boston Strategic Partners, Inc., HEOR, Boston, United States of America, ⁴Merck Sharp & Dohme (UK) Ltd., Dept. of Health Economics and Decision Sciences, London, United Kingdom, ⁵Merck and Co. Inc., Dept. of Health Economics and Decision Sciences, Rahway, United States of America, ⁶Merck and Co. Inc., Early Bladder Program Development Team, Rahway, United States of America

A0869

Efficacy of RC48-ADC in combination with toripalimab in patients with HER2-positive muscle-invasive urothelial bladder cancer and the prospect of bladder preservation

Authors

Li C.¹, Zhu J.¹, Chen Z.¹, Zhu H.¹, Song C.¹, Li H.¹, Yuan J.¹, Zhou X.¹, Li X.¹, Pan S.¹, Zhao S.¹, Liu C.¹, Deng H.², Yu W.¹, Cheng F.¹

Institutions

¹Renmin Hospital of Wuhan Hospital, Dept. of Urology, Wuhan, China, ²The First Affiliated Hospital of Yangtze University, Dept. of Urology, Jingzhou, China

12:50 - 13:15

Treatment strategies for node-positive muscle-invasive bladder cancer

A0870

Sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – interim results of the CHASIT study

Authors

Rutten V.C.¹, Salhi Y.², van Leenders G.J.L.H.³, van der Heijden A.G.⁴, Franken M.D.⁵, Westgeest H.⁶, Leijte J.A.P.⁷, van der Heijden M.S.⁸, Mertens L.S.⁹, Somford D.¹⁰, Berends M.¹¹, de Wit R.², Robbrecht D.G.J.², Zuiverloon T.C.M.¹, Boormans J.L.¹

Institutions

¹Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC Cancer Institute, Dept. of Medical Oncology, Rotterdam, The Netherlands, ³Erasmus MC Cancer Institute, Dept. of Pathology, Rotterdam, The Netherlands, ⁴Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ⁵Radboud University Medical Center, Dept. of Medical Oncology, Nijmegen, The Netherlands, ⁶Amphia Hospital, Dept. of Internal Medicine, Breda, The Netherlands, ⁷Amphia Hospital, Dept. of Urology, Breda, The Netherlands, ⁸Netherlands Cancer Institute, Dept. of Medical Oncology, Amsterdam, The Netherlands, ⁹Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ¹⁰Canisius Wilhelmina hospital, Dept. of Urology, Nijmegen, The Netherlands, ¹¹Canisius Wilhelmina hospital, Dept. of Medical Oncology, Nijmegen, The Netherlands

A0871

Natural History of cN2 M0 Bladder Cancer: Implications for Patient Selection for Consolidative Surgery

Authors

von Deimling M.¹, Furrer M.², Tendijck G.A.H.³, Maas M.⁴, Bianchi A.⁵, Mari A.⁶, Li R.⁷, Taylor J.⁸, Soria F.⁹, Moschini M.¹⁰, Pichler R.¹¹, del Giudice F.¹², Tully K.H.¹³, Lotan Y.⁸, Spiess P.E.⁷, Minervini A.⁶, Antonelli A.⁵, Black P.C.¹⁴, Mertens L.S.³, Fisch M.¹, Pradere B.¹⁵, Shariat S.F.¹⁶

Institutions

¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Solothurner Spitäler AG, Dept. of Urology, Olten and Solothurn, Switzerland, ³The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁴Eberhard Karls University Tübingen, Dept. of Urology, Tübingen, Germany, ⁵University of Verona, Azienda Ospedaliera Universitaria Integrata, Dept. of Urology, Verona, Italy, ⁶Careggi Hospital, University of Florence, Dept. of Experimental and Clinical Medicine, Florence, Italy, ⁷H. Lee Moffitt Cancer Center and Research Institute, Dept. of Genitourinary Oncology, Tampa, United States of America, ⁸University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, ⁹San Giovanni Battista Hospital, University of Studies of Torino, Dept. of Surgical Sciences, Turin, Italy, ¹⁰Urological Research Institute, Vita-Salute San Raffaele, Dept. of Urology, Milan, Italy, ¹¹Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ¹²Sapienza University of Rome, Policlinico Umberto I Hospital, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ¹³Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology and Neurourology, Herne, Germany, ¹⁴University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ¹⁵UROSUD, La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ¹⁶Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria

Study Group

CLIPOLY(Vienna, Austria)

A0872

Diagnostic Value of [¹⁸F]FDG-PET/CT in Staging Histological Subtypes of Invasive Bladder Cancer

Authors

Lijnen R.A.G.¹, Ringia J.B.¹, Claps F.¹, Vogel W.², Boellaard T.N.³, Braat A.J.A.T.⁴, van Rhijn B.W.G.¹, Mertens L.S.¹

Institutions

¹Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Antoni van Leeuwenhoek Hospital, Dept. of Radiotherapy and Nuclear Medicine, Amsterdam, The Netherlands, ³Antoni van Leeuwenhoek Hospital, Dept. of Radiology, Amsterdam, The Netherlands, ⁴Antoni van Leeuwenhoek Hospital, Dept. of Nuclear Medicine, Amsterdam, The Netherlands

A0873

Lymphovascular invasion and nodal positivity as useful markers for selecting candidates for adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma

Authors

Shimoda H.¹, Numao N.¹, Oki R.², Urasaki T.², Tamiya T.¹, Takemura K.¹, Fujiwara R.¹, Inoue M.¹, Miura Y.², Yuasa T.¹, Yonese J.¹

Institutions

¹Cancer Institute Hospital, Dept. of Genitourinary oncology, Tokyo, Japan, ²Cancer Institute Hospital, Dept. of Medical Oncology, Tokyo, Japan

Oncological and survival outcomes after Robot Assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion in cN+ patients, a single high-volume center experience

Authors

Lambertini L., Lipparini F., Posanzini S., Kucuku N., Zeni G., Carli G., Cadenar A., Valastro F., Di Maida F., Grosso A.A., Saladino M., Oriti R., Vittori G., Mari A., Minervini A.

Institutions

Unit of Oncologic Minimally Invasive Urology and Andrology Careggi Hospital, Dept. of Experimental and Clinical Medicine University of Florence, Florence, Italy

13:15 - 13:35

Antibody drug conjugates in localised muscle-invasive bladder cancer

A0875

KEYNOTE-905 study of neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: assessment of surgical outcomes

Authors

Shore N.¹, Rausch S.², Sabadash M.³, Vulsteke C.⁴, O'Donnell P.H.⁵, Galsky M.D.⁶, Lorient Y.⁷, Goger Y.E.⁸, Rodriguez-Vida A.⁹, Kulkarni G.¹⁰, Kaimakliotis H.Z.¹¹, Kang S.-H.¹², Ullén A.¹³, Paramonov V.¹⁴, Lichfield J.¹⁵, Meng C.¹⁶, Huang C.D.¹⁷, Ramamurthy C.¹⁷, Homet Moreno B.¹⁷, Bedke J.¹⁸

Institutions

¹Carolina Urologic Research Center, Dept. of Urologic Research, Myrtle Beach, United States of America, ²Eberhard Karls University Tübingen, Dept. of Urology, Tübingen, Germany, ³Lviv State Regional Oncological Center, Dept. of Oncology, Lviv, Ukraine, ⁴Integrated Cancer Center Ghent, AZ Maria Middelaers, Dept. of Oncology, Antwerp, Belgium, ⁵The University of Chicago, Dept. of Hematology and Oncology, Chicago, United States of America, ⁶Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, Dept. of Genitourinary Oncology, New York, United States of America, ⁷Institut Gustave Roussy, Université Paris-Saclay, Dept. of Oncology, Villejuif, France, ⁸Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi Hastanesi, Dept. of Urology, Konya, Turkey, ⁹Hospital del Mar, Dept. of Medical Oncology, Barcelona, Spain, ¹⁰Princess Margaret Cancer Centre, Dept. of Surgical Oncology, Toronto, Canada, ¹¹Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Dept. of Urology, Indianapolis, United States of America, ¹²Korea University Anam Hospital, Dept. of Urology, Seoul, South Korea, ¹³Karolinska Institutet, Oncology-Pathology, and Karolinska University Hospital, Dept. of Pelvic Cancer, Genitourinary Oncology and Urology Unit, Stockholm, Sweden, ¹⁴Cherkasy Regional Oncology Dispensary, Dept. of Oncology, Cherkasy, Ukraine, ¹⁵Astellas Pharma Europe Ltd, Dept. of Clinical Lead, Addlestone, United Kingdom, ¹⁶Pfizer, Dept. of Oncology Research and Development, Bothell, United States of America, ¹⁷Merck & Co., Inc., Dept. of Oncology, Rahway, United States of America, ¹⁸Eva Mayr-Stihl Cancer Center, Dept. of Urology and Transplantation Surgery, Stuttgart, Germany

A0876

Enfortumab Vedotin-related Skin Toxicity as a Predictor of Survival among Patients with Advanced Urothelial Carcinoma: A Systematic Review and Meta-analysis

Authors

[Alqahtani A.](#)¹, Akihiro M.², Mischczyk M.¹, Dematteis A.³, Roessler N.¹, Alfarhan A.R.A.¹, Miyajima K.¹, Inoue S.¹, Yanagisawa T.², Szabados B.E.⁴, Rajwa P.⁵, Kimura T.², Oliveira Reis L.⁶, I Karakiewicz P.⁷, Roupret M.⁸, Shariat S.F.¹

Institutions

¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ³AOU Città della Salute e della Scienza at Molinette Hospital and University of Turin, Dept. of Urology, Turin, Italy, ⁴Barts Cancer Institute, Queen Mary University of London, London, UK, Dept. of Oncology, London, United Kingdom, ⁵Centre of Postgraduate Medical Education, Second Department of Urology, Warsaw, Poland, ⁶UroScience, School of Medical Sciences, State University of Campinas, Dept. of Urology, Campinas, Brazil, ⁷University of Montréal Health Center, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montréal, Canada, ⁸GRC 5 Predictive Onco-Uro, Sorbonne University, AP-HP, Urology, Pitie-Salpetriere Hospital, Dept. of Urology, Paris, France

A0877

Final results of a multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive bladder cancer—Hope-03

Authors

Deng J.¹, Feng W.¹, Tianhai L.², Ping T.², Min R.¹, Mengni Z.³, Xiaonan Z.², [Zhang P.](#)², Yali S.¹

Institutions

¹West China Hospital of Sichuan University, Abdominal Oncology Ward and Division of Radiation Oncology of Cancer Center, Chengdu, China, ²West China Hospital of Sichuan University, Dept. of Urology, Chengdu, China, ³West China Hospital of Sichuan University, Dept. of Pathology, Chengdu, China

A0878

Temporal and Spatial Dynamics of ADC Targets and Immune Contexture in Bladder Cancer

Authors

[Kato M.](#)¹, Yamagata M.¹, Yamamoto S.¹, Hamada K.¹, Yamasaki T.¹, Shiohara M.², Ohe C.³, Kohashi K.², Uchida J.¹

Institutions

¹Osaka Metropolitan University, Dept. of Urology, Osaka, Japan, ²Osaka Metropolitan University, Dept. of Pathology, Osaka, Japan, ³Hyogo Medical University, Dept. of Surgical Pathology, Nishinomiya, Japan

13:35 - 14:00

Neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer

A0879

Histologic subtypes as a prognostic factor for postoperative survival outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy

Authors

[Fujiwara R.](#), Numao N., Inoue M., Takemura K., Tamiya T., Shimoda H., Nakama D., Hasegawa A., Ishida A., Ishii K., Yuasa T., Yonese J.

Institutions

Cancer Institute Hospital, Japanese Foundation for Cancer Research, Dept. of Genitourinary Oncology, Tokyo, Japan

A0880

Impact of Neoadjuvant Chemotherapy Cycle Number on Nutritional Status and Perioperative Risk in Robot-Assisted Radical Cystectomy: A Multicenter Analysis

Authors

[Atagi Y.](#)¹, Kei D.², Kyotaro F.¹, Keisuke O.¹, Takeshi N.¹, Ryoichi N.¹, Kazuyoshi I.³, Iku N.⁴, Hirofumi I.¹, Junya F.²

Institutions

¹Tokusima Prefetural Central Hospital, Dept. of Urology, Tokushima, Japan, ²Tokusima University, Dept. of Urology, Tokushima, Japan, ³Takamatsu Red Cross Hospital, Dept. of Urology, Takamatsu, Japan, ⁴Ehime Prefectural Central Hospital, Dept. of Urology, Takamatsu, Japan

A0881

Evaluation of the MODAPLEX multiplex mRNA assay in muscle-invasive bladder cancer: comparison of responders and non-responders after neoadjuvant gemcitabine/cisplatin therapy

Authors

[Rausch P.C.](#)¹, Christmann J.², Küpper C.¹, Brehmer M.¹, Hoppe C.³, Braun R.³, Klümper N.⁴, Eckstein M.⁵, Bolenz C.⁶, Tannapfel A.², Tully K.¹, Roghmann F.¹

Institutions

¹Marien Hospital Ruhr-University Bochum, Dept. of Urology, Herne, Germany, ²Ruhr-University Bochum, Dept. of Pathology, Bochum, Germany, ³BIOTYPE GmbH, Assay Development, Dresden, Germany, ⁴University Hospital Bonn, Dept. of Urology and Pediatric Urology, Bonn, Germany, ⁵University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Dept. of Pathology, Erlangen, Germany, ⁶University Hospital Ulm, University of Ulm, Dept. of Urology and Pediatric Urology, Ulm, Germany

A0882

Subsequent treatment patterns and outcomes among patients with Muscle Invasive Bladder Cancer (MIBC) receiving neoadjuvant treatments: a real-world data analysis

Authors

[Necchi A.](#)¹, Chang S.S.², Almeida L.³, Caplan E.O.⁴, Pisano S.⁵, Pe Benito R.⁵, Bourla A.³, Sun R.³, Greshock J.³, Crist W.³, Kim W.³, Bhanvadia S.³

Institutions

¹IRCCS San Raffaele Hospital, Dept. of Medical Oncology, Milan, Italy, ²Vanderbilt University Medical Center, Dept. of Urology, Nashville, United States of America, ³Johnson & Johnson, Dept. of Innovative Medicine, Raritan, United States of America, ⁴Johnson & Johnson, Dept. of Innovative Medicine, Titusville, United States of America, ⁵Concert AI LLC, Data Science, Cambridge, United States of America

A0883

Comparable Prognostic Utility of Circulating Tumor DNA in Patients with Pure and Variant Histology Bladder Cancer Undergoing Radical Cystectomy

Authors

[Zhu A.](#)¹, Eraky A.¹, Gupta R.¹, Ben-David R.², Mehrazin R.¹, Wiklund P.¹, Sfakianos J.¹

Institutions

¹Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ²Tel Aviv Sourasky Medical Center, Dept. of Urology, Tel Aviv, Israel

Monday 16 March
12:30 - 14:00

Location Orange Area, Room 3
Chairs A. Henry, Leeds (GB)
U. Mete, Chandigarh (IN)
M. Roberts, Brisbane (AU)

12:30 - 12:40

PSA follow-up and definition of BCR

A0743

Optimizing PSA Follow-Up After Radical Prostatectomy: A Population-Based Analysis of Biochemical Recurrence Patterns

Authors

Pellegrino F.¹, Falagario U.G.¹, Akre O.¹, Aly M.¹, Nordström T.², Grönberg H.², Egevad L.³, Ferro M.⁴, Lantz A.¹, Wiklund P.N.¹

Institutions

¹Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ²Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ³Karolinska Institutet, Dept. of Oncology and Pathology, Stockholm, Sweden, ⁴ASST Santi Paolo e Carlo, Dept. of Urology, Milan, Italy

A0744

Defining biochemical recurrence after Radiotherapy for Prostate Cancer with PSA cut-offs below Phoenix criteria

Authors

Falagario U.G.¹, Pellegrino F.², Abbadì A.³, Valdman A.⁴, Eriksson M.H.⁵, Carrieri G.¹, Ferro M.², Gandaglia G.⁶, Briganti A.⁶, Montorsi F.⁶, Marra G.⁷, Bianchi L.⁸, Aly M.⁹, Palsdottir T.³, Eklund M.³, Nordström T.³, Grönberg H.³, Lantz A.⁹, Akre O.⁹, Wiklund P.⁹

Institutions

¹University of Foggia, Dept. of Urology, Foggia, Italy, ²ASST Santi Paolo E Carlo, Dept. of Urology, Milan, Italy, ³Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ⁴Karolinska Institutet, Dept. of Oncology-Pathology, Stockholm, Sweden, ⁵St. Göran Hospital, Dept. of Oncology, Stockholm, Sweden, ⁶IRCCS San Raffaele Hospital, Unit of Urology, Division of Oncology, Milan, Italy, ⁷Molinette Hospital, Città della Salute e della Scienza and University of Turin, Dept. of Urology, Turin, Italy, ⁸IRCCS Azienda Ospedaliero-universitaria di Bologna, Division of Urology, Bologna, Italy, ⁹Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden

12:40 - 13:00

Risk classification of BCR

A0745

Are the EAU risk categories for biochemical recurrence in prostate cancer after primary radiotherapy still clinically applicable?

Authors

van Altena E.J.E.¹, Jansen B.H.E.¹, Ten Kate D.C.¹, Van der Voort van Zyp J.R.N.², Lam M.G.E.H.³, Scheltema M.J.V.⁴, Vis A.N.¹

Institutions

¹Amsterdam University Medical Center, Dept. of Urology, Amsterdam, The Netherlands, ²University Medical Center Utrecht, Dept. of Radiotherapy, Utrecht, The Netherlands, ³University Medical Center Utrecht, Dept. of Radiology and Nuclear Medicine, Utrecht, The Netherlands, ⁴St. Antonius Hospital, Dept. of Urology, Utrecht, The Netherlands

A0746

Development and Validation of a Risk Model to Identify Clinically Insignificant Biochemical Recurrence After Radical Prostatectomy

Authors

Pellegrino A.A.¹, Tin A.², Mazzone E.¹, Barletta F.¹, Gandaglia G.¹, Montorsi F.¹, Briganti A.¹, Eastham J.², Vickers A.²

Institutions

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Memorial Sloan Kettering Cancer Center, Dept. of Biostatistics, New York, United States of America

A0747

Outcomes and Treatment Patterns of Prostate Cancer Patients with Low Risk Biochemical Recurrence After Radical Prostatectomy Managed With Initial Observation

Authors

Barletta F.¹, Stabile A.¹, Cucchiara V.¹, Moschini M.¹, Scuderi S.¹, Quarta L.¹, Zaurito P.¹, Cosenza A.¹, Galdieri A.¹, Reale A.¹, Bonavia L.¹, Roca G.¹, Gallina A.², Fossati N.², Zaffuto E.³, Capitanio U.¹, Larcher A.¹, Tenace N.⁴, Colecchia M.⁴, Ponzoni M.⁴, Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Ente Ospedaliero Cantonale, Università della Svizzera Italiana, Dept. of Urology, Lugano, Switzerland, ³Ospedale di Circolo and Macchi Foundation, Dept. of Urology, Varese, Italy, ⁴IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy

A0748

Refining PSA Doubling Time Thresholds to Predict Metastases after Biochemical Recurrence in Prostate Cancer Patients Treated with Radical Prostatectomy

Authors

Zaurito P.¹, Barletta F.M.¹, Scuderi S.¹, Stabile A.¹, Cucchiara V.¹, Bianchi M.¹, Quarta L.¹, Cosenza A.¹, Galdieri A.¹, Ceria F.¹, Simonetti A.P.¹, Maestroni V.G.¹, Bonavia L.M.¹, Roca G.¹, Capitanio U.¹, Larcher A.¹, Dehò F.², Suardi N.³, Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²Ospedale di Circolo and Macchi Foundation, Dept. of Urology, Varese, Italy, ³University of Brescia, Dept. of Urology, Brescia, Italy

A0749

The Role of PSMA PET for PSA Persistence After Radical Prostatectomy In Patients Primarily Staged with PSMA PET/CT

Authors

Esen B.¹, Gurbuz A.¹, Caglar A.E.¹, Demirkol M.O.², Canda A.E.¹, Kordan Y.¹, Balbay M.D.¹, Esen T.¹

Institutions

¹Koç University School of Medicine, Dept. of Urology, Istanbul, Turkey, ²Koç University School of Medicine, Dept. of Nuclear Medicine, Istanbul, Turkey

A0750

Prospective comparison of 64Copper [64Cu]SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for prostate cancer detection in patients with biochemical recurrence after radical prostatectomy (Co-PSMA trial).

Authors

Emmett L.¹, Papa N.², Ayati N.³, Nguyen A.¹, Wong K.¹, Chen J.¹, Ho B.¹, Idiare J.¹, Sidhom G.³, Eade T.⁴, Roberts M.⁵, Thompson J.⁶, Sharma S.¹, Weir S.¹, Devitt K.¹, Kooner R.⁶, Lieng H.⁷, Rasiah K.⁴, Olphert J.⁸, de Leon J.⁹, Hruby G.¹⁰, Stricker P.⁶, Kneebone A.¹⁰, Khan S.¹

Institutions

¹St Vincent's Hospital, Theranostics and Nuclear Medicine, Sydney, Australia, ²Garvan Institute of Medical Research, Garvan Institute of Medical Research, Sydney, Australia, ³St Vincent's Hospital, Theranostics and Nuclear Medicine Department, Sydney, Australia, ⁴Royal North Shore Hospital, St Leonards, Northern Sydney Cancer Centre, Sydney, Australia, ⁵Royal Brisbane and Women's (RBWH), Surgical Treatment and Rehabilitation Service (STARS), Queensland Health, Brisbane, Australia, ⁶St Vincent's Hospital Darlinghurst, Dept. of Urology, Sydney, Australia, ⁷Central Coast Cancer Centre, Gosford Hospital, Dept. of Radiation Oncology, Gosford, Australia, ⁸St George Hospital, Dept. of Urology, Sydney, Australia, ⁹St Vincent's GenesisCare Darlinghurst, GenesisCare, Sydney, Australia, ¹⁰Royal North Shore Hospital, Northern Sydney Local Health District, St. Leonards, Dept. of Radiation Oncology, School of Life Sciences, Sydney, Australia

13:10 - 13:45

Prediction of BCR

A0751

Validation of the Cambridge, EAU, and STARCAP Prognostic Score in Predicting Biochemical Recurrence in Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy in the MRI Era

Authors

Scuderi S.L.A., Stabile A., Cucchiara V., Barletta F.M., Cannoletta D., Scilipoti P., Quarta L., Zaurito P., Viti A., Colistro A., Roca G., Farinati D., Montorsi F., Gandaglia G., Briganti A.

Institutions

Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy

A0752

Machine Learning-Based Prediction of Biochemical Recurrence in Localized Prostate Cancer using Radiogenomic Data

Authors

Ajami Fardoun T.¹, Soler A.², Inglemo M.¹, Rodriguez L.³, Aladid R.¹, Nicolau C.², Alcaraz A.¹, Mengual L.¹

Institutions

¹Hospital Clinic of Barcelona, Dept. of Urology, Barcelona, Spain, ²Hospital Clinic of Barcelona, Dept. of Radiology, Barcelona, Spain, ³Hospital Clinic of Barcelona, Dept. of Pathology, Barcelona, Spain

A0753

Validation of the EAU Favorable and Unfavorable Intermediate-Risk Prognostic Groups for Predicting Biochemical Recurrence After Radical Prostatectomy in Contemporary Prostate Cancer Patients: The Added Value of MRI-Features

Authors

Scuderi S.L.A., Stabile A., Cucchiara V., Barletta F.M., Scilipoti P., Quarta L., Zaurito P., Viti A., Brancaccio M., Reale A., Maestroni V.G., Colistro A., Roca G., Montorsi F., Gandaglia G., Briganti A.

Institutions

Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy

A0754

Validation of a Multimodal Deep Learning Model for Predicting Biochemical Recurrence in Men Undergoing Radiation Therapy

Authors

Camilloni A.¹, Micoli C.¹, Palsdottir T.¹, Mulliqi N.¹, Everett Palm E.¹, Szolnoky K.¹, Boman S.E.¹, Ji X.¹, Blilie A.¹, Nordström T.¹, Egevad L.², Discacciati A.¹, Kartasalo K.¹, Eklund M.¹

Institutions

¹Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ²Karolinska Institutet, Dept. of Oncology and Pathology, Stockholm, Sweden

A0755

Deep learning-based multimodal biochemical recurrence risk classification score (BRICS) for prostate cancer: An International Multicenter Study

Authors

Chen R.¹, Mao Y.², Deng L.³, Song Z.¹, Tong T.²

Institutions

¹Renji Hospital, Dept. of Urology, Shanghai, China, ²College of Physics and Information Engineering, Fuzhou University, Fuzhou, China, College of Physics and Information Engineering, Fuzhou, China, ³Shanghai Changhai Hospital, The Second Military Medical University, Dept. of Urology, Shanghai, China

A0756

Biochemical Recurrence after Radical Prostatectomy According to Cancer Origin: Peripheral Zone vs Transition Zone. Ten-Year Outcomes Based on Preoperative MRI and Targeted Biopsy-Derived Grade Quantification

Authors

Olivier J.¹, Delobel L.¹, Cailliau E.², Villers A.¹

Institutions

¹CHU de Lille, Dept. of Urology, Lille, France, ²CHU de Lille, Dept. of Statistics, Lille, France

A0757

Influence of Positive Surgical Margin Status and Characteristics on Biochemical Recurrence After Robotic Radical Prostatectomy: Insights from a High-Volume Center

Authors

Piramide F.¹, Sterrantino A.¹, Garino D.¹, Pini F.¹, Rosi F.¹, Ercolani A.¹, Liguori S.¹, De Cillis S.¹, Checcucci E.², Piana A.¹, Volpi G.², Sica M.², Quarà A.¹, Cisero E.¹, Gatti C.¹, Cidda D.¹, Garzena V.¹, Ferrando L.¹, Trapella G.¹, Turcan A.¹, Manfredi M.¹, Fiori C.¹, Amparore D.², Porpiglia F.²

Institutions

¹AOU San Luigi Gonzaga - University of Turin, Dept. of Urology, Orbassano, Italy, ²Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Candiolo, Italy

13:45 - 14:00

Outcomes after BCR

A0758

Incidence and prognostic implications of PSA relapse after radical radiotherapy for prostate cancer. A population-based study

Authors

Zaurito P.¹, Garmo H.², Gedeberg R.², Alhberg M.², Carlsson S.³, Thellenberg C.⁴, Robinson D.⁵, Stattin P.², Westerberg M.²

Institutions

¹IRCCS San Raffaele Scientific Institute - 'Vita-Salute' San Raffaele University, Dept. of Urology, Milan, Italy, ²Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ³Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ⁴Umeå University, Dept. of Diagnostics and Intervention, Umeå, Sweden, ⁵Skåne University Hospital, Dept. of Urology, Malmö, Sweden

A0759

Cancer-Specific Mortality Outcomes in patients with Biochemical Recurrence After Radical Prostatectomy vs Radiation Therapy: Report from a Single Tertiary Referral Center

Authors

Silvani C.¹, Santangelo A.¹, Stephens A.², Msska A.¹, Considine J.¹, Robinson B.¹, Kumar N.¹, Catanzaro M.³, Salonia A.⁴, Briganti A.⁴, Montorsi F.⁴, Nicolai N.³, Montanari E.⁵, Rogers C.¹, Abdollah F.¹

Institutions

¹VUI Center for Outcomes Research Analysis and Evaluation Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy, ⁴IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ⁵Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy

A0760

Late Biochemical Recurrence and Mortality in Patients with 10 years of Recurrence-Free Survival after Radical Prostatectomy

Authors

Werner J.J.¹, Graf L.D.¹, Meissner V.H.¹, Peter C.¹, Kron M.², Schiele S.¹, Gschwend J.E.¹, Herkommer K.¹

Institutions

¹Technical University of Munich, Dept. of Urology, Munich, Germany, ²University of Ulm, Institute of Epidemiology and Medical Biometrics, Ulm, Germany

Targets and strategies for prostate biopsy

Abstract Session 49

Monday 16 March
12:30 - 14:00

Location Blue Area, Victoria 4
Chairs P.K-F. Chiu, Hong Kong (HK)
To be confirmed
J. Olivier, Lille (FR)

12:30 - 13:15

Biopsy strategy: targeted, systematic, peri-lesional biopsies

A0833

Targeted, perilesional, and distant biopsies in prostate cancer: prospective multicentre results from the MIRAGE study

Authors

Peyrottes A.¹, Diamand R.², Uleri A.³, Long-Depaquit T.⁴, Ploussard G.³, Baboudjian M.⁴

Institutions

¹Saint-Louis Hospital, Dept. of Urology, Paris, France, ²Jules-Bordet Institute, Dept. of Urology, Brussels, Belgium, ³La Croix du Sud Hospital, Dept. of Urology, Toulouse, France, ⁴North Hospital, Dept. of Urology, Marseille, France

Study Group

MIRAGE(Marseille, France)

A0834

Optimizing Targeted and Perilesional Biopsy Scheme with Spatial Analysis for Prostate Cancer Detection: Evidence From PERI-PRO RCT

Authors

Deng R.Y., Li D., Wu J., Tian S., Shen Q., Hu S., Shang M., Qiu J., Shang J., Zhou J., Cai L., Liu Y., Gong K.

Institutions

Peking University First Hospital, Dept. of Urology, Beijing, China

A0835

Prostate Biopsies per Lesion: The Real World Stockholm

Authors

Söderbäck H.¹, Sjöström C.², Wassberg K.³, Lindh C.⁴, Elfving S.⁴

Institutions

¹Capio Urokirurgiskt Centrum, Dept. of Urology, Stockholm, Sweden, ²Urologifocus, Dept. of Urology, Stockholm, Sweden, ³UroMedical Stockholm, Dept. of Urology, Stockholm, Sweden, ⁴Inify Laboratories, Dept. of Pathology, Stockholm, Sweden

A0836

Reassessing the Role of Contralateral Sampling in MRI-Fusion Transperineal Prostate Biopsy For Unilateral PI-RADS Lesions

Authors

Wang J., Khanmammadova N., Hanna K., Gao A., Tran K., Ali S., Daneshvar M., Shahait M., Lee D.

Institutions

University of California Irvine, Dept. of Urology, Irvine, United States of America

A0837

Diagnostic Value of Contralateral Systematic Biopsy and MRI Local Staging (rT) in Predicting Bilateral Prostate Cancer in Radical Prostatectomy Specimens

Authors

Rodríguez Cabello M.A., Méndez Rubio S., Garcia-Cano Fernández A.M.A., Moraga Sanz A., Rodríguez Elena L., Vázquez Alba D., Platas Sancho A.

Institutions

Hospital Universitario Sanitas La Moraleja, Dept. of Urology, Madrid, Spain

A0838

Concomitant MRI-detected and MRI-undetected prostate cancer with implications for biopsy strategies and focal therapy planning: An analysis of the PROMIS and PICTURE trials

Authors

Light A.¹, Peters M.², Gopalakrishnan A.¹, Mayor N.¹, Cullen E.¹, Freeman A.³, Emberton M.⁴, Ahmed H.U.¹, Shah T.T.¹

Institutions

¹Imperial College London, Imperial Prostate, London, United Kingdom, ²Radiotherapiegroep, Dept. of Radiotherapy, Deventer, The Netherlands, ³University College London Hospitals NHS Foundation Trust, Dept. of Cellular Pathology, London, United Kingdom, ⁴University College London, Division of Surgery and Interventional Science, London, United Kingdom

A0839

MRI-targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: a multicenter, paired, noninferiority, observational trial

Authors

Cheng Y.¹, Huang H.¹, Wang M.², Zhu L.³, Peng S.⁴, Li D.⁵, Marra G.⁶, Qi R.⁷, Ding X.³, Liu M.², Qiu X.¹, Guo H.¹

Institutions

¹Nanjing Drum Tower Hospital Affiliated Hospital of Medical School Nanjing University, Dept. of Urology, Nanjing, China, ²Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Dept. of Urology, Beijing, China, ³Northern Jiangsu People's Hospital, Dept. of Urology, Yangzhou, China, ⁴Nanjing Drum Tower Hospital Affiliated Hospital of Medical School Nanjing University, Dept. of Pathology, Nanjing, China, ⁵Nanjing Drum Tower Hospital Affiliated Hospital of Medical School Nanjing University, Dept. of Radiology, Nanjing, China, ⁶University of Turin and Città della Salute e della Scienza, Dept. of Urology, Dept. of Surgical Sciences, Turin, Italy, ⁷Nanjing Drum Tower Hospital Affiliated Hospital of Medical School Nanjing University, Medical Statistics and Analysis Center, Nanjing, China

A0840

Effect of ipsilateral-only systematic biopsy in unifocal MRI-visible prostate lesions on the estimation of adverse final pathology by the Gandaglia 2019 nomogram

Authors

Chernysheva D.¹, Avesani G.², Di Bello F.³, Malevich S.⁴, Longo N.³, Jourdan M.⁵, Breda A.¹, Palou Redorta J.¹, Baboudjian M.⁵, Sanguedolce F.¹

Institutions

¹Fundació Puigvert, Dept. of Oncologic Urology, Barcelona, Spain, ²San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ³University of Naples Federico II, Dept. of Urology, Naples, Italy, ⁴St Luca's City Hospital, Dept. of Urology, Saint Petersburg, Russia, ⁵North Academic Hospital, Dept. of Urology, Marseille, France

The role of additional targeted biopsies in detecting clinically significant prostate cancer in patients with multiple lesions: insights from a single-center cohort of over 3,400 prostate biopsies

Authors

Hoeh B.¹, Hallaschek M.¹, Platzek I.², Boehm K.¹, Baunacke M.¹, Borkowetz A.³, Thomas C.¹, Herout R.¹

Institutions

¹University Hospital Carl Gustav Carus, Dept. of Urology, Dresden, Germany,

²University Hospital Carl Gustav Carus, Dept. of Radiology, Dresden, Germany,

³University Medical Centre Rostock, Dept. of Urology, Rostock, Germany

13:15 - 13:30

Factors influencing biopsy yield

A0842

Comparison of prostate cancer yield per MRI target lesion for LAMP versus TRUS prostate biopsy: new insights from the TRANSLATE randomised clinical trial

Authors

Ranasinha N.¹, Lamb A.D.², Marian I.R.³, Leslie T.A.¹, Catto J.W.F.⁴, Rosario D.J.⁴, Yamamoto H.⁵, Eddy B.⁶, Narahari K.⁷, Gray R.H.R.⁸, Good D.W.⁹, Omer A.¹⁰, Landeiro F.¹¹, Liew M.P.C.¹², Tuck S.¹³, Campbell T.¹⁴, Reynard J.M.¹, Lopez J.F.¹⁴, Williams R.¹, Macpherson R.E.¹⁵, Verrill C.¹⁶, Hamdy F.C.¹, Bryant R.J.¹

Institutions

¹University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom,

²Queen Mary University of London, Barts Cancer Institute, London, United Kingdom,

³University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom,

⁴University of Sheffield, Dept. of Urology, Sheffield, United Kingdom,

⁵Maidstone and Tunbridge Wells NHS Trust, Dept. of Urology, Maidstone, United Kingdom,

⁶East Kent Hospitals University NHS Foundation Trust, Dept. of Urology, Canterbury, United Kingdom,

⁷Cardiff and Vale University Health Board, Dept. of Urology, Cardiff, United Kingdom,

⁸Buckinghamshire Healthcare NHS Trust, Dept. of Urology, Oxford, United Kingdom,

⁹Western General Hospital, Dept. of Urology, Edinburgh, United Kingdom,

¹⁰University Hospitals Coventry and Warwickshire NHS Trust, Dept. of Urology, Coventry, United Kingdom,

¹¹University of Oxford, Health Economics Research Centre, Nuffield Department of Population Health, Oxford, United Kingdom,

¹²Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Dept. of Urology, Wigan, United Kingdom,

¹³Oxfordshire Prostate Cancer Support Group, Oxfordshire Prostate Cancer Support Group, Oxford, United Kingdom,

¹⁴Oxford University Hospitals NHS Foundation Trust, Dept. of Urology, Oxford, United Kingdom,

¹⁵Oxford University Hospitals NHS Foundation Trust, Dept. of Radiology, Oxford, United Kingdom,

¹⁶Oxford University Hospitals NHS Foundation Trust, Dept. of Cellular Pathology, Oxford, United Kingdom

Study Group

TRANSLATE Trial Study Group(Oxford, United Kingdom)

13:30 - 13:50

Detection of locally advanced disease

A0845

Evaluation of ProstaScore™ and Magnetic Resonance Imaging for preoperative prediction of Lymph Node Involvement determined by Extended Lymph Node Dissection

Authors

Valeri A.¹, Renand J.¹, Cancel-Tassin G.², Groeneveld C.S.³, Balde T.³, Furet T.¹, Uguen A.⁴, Tissot V.⁵, Le Mener C.M.¹, Fourcade A.¹, Zambon A.¹, Siebert C.¹, Segalen T.¹, Deruelle C.¹, Joulin V.¹, Doucet L.⁴, Fournier G.¹, Roperch J.P.⁶, de Reynies A.³, Cussenot O.²

Institutions

¹University Hospital CHU Brest, Dept. of Urology, Brest, France, ²CeRePP, Dept. of Predictive Onco-Urology, Paris, France, ³INSERM UMR-S 1138, Université Paris Cité, Sorbonne Université, Centre de Recherche des Cordeliers, Paris, France, ⁴University Hospital CHU Brest, Dept. of Pathology, Brest, France, ⁵University Hospital CHU Brest, Dept. of Radiology, Brest, France, ⁶Oncodiag, Dept. of Oncodiag, Evreux, France

A0846

Accuracy of Indocyanine Green Fluorescence in Detecting Lymph Node Metastases in High-Risk Prostate Cancer

Authors

De Carvalho Fazoli A.J., Coelho R.F., Guglielmetti G.B., Barros G.G., Rodrigues G.J., Pontes Junior J., Nahas W.C.

Institutions

University of Sao Paulo, Dept. of Urology, São Paulo, Brazil

A0847

Comparative Analysis of a Machine Learning-Based Model for Predicting Lymph Node Involvement in Prostate Cancer Against Traditional Nomograms

Authors

Demirbilek M.¹, Yilmaz S.E.², Gokcepinar M.E.², Cakmakoglu A.A.³, Baytas I.², Kirli E.A.⁴, Ugur E.², Onal B.L.⁴

Institutions

¹Silvan Dr. Yusuf Azizoglu State Hospital, Dept. of Urology, Diyarbakir, Turkey, ²Bogazici University, Computer Engineering Department, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Dept. of Urology, Istanbul, Turkey

A0848

Effect of ipsilateral-only systematic biopsy on predicted risk of extracapsular extension and seminal vesicle invasion using the Gandaglia nomogram

Authors

Chernysheva D.¹, Di Bello F.², Avesani G.³, Malevich S.⁴, Jourdan M.⁵, Longo N.², Breda A.¹, Palou Redorta J.¹, Baboudjian M.⁵, Sanguedolce F.¹

Institutions

¹Fundació Puigvert, Dept. of Oncological Urology, Barcelona, Spain, ²University of Naples Federico II, Dept. of Urology, Naples, Italy, ³San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ⁴St Luca's City Hospital, Dept. of Urology, Saint Petersburg, Russia, ⁵Aix-Marseille University & Assistance Publique-Hôpitaux de Marseille (AP-HM), Dept. of Urology, Marseille, France

Monday 16 March
12:30 - 14:00

Location Blue Area, Victoria 5
Chairs S. Crabb, Southampton (GB)
To be confirmed
To be confirmed

12:30 - 13:10

Outcomes of metastatic urothelial carcinoma in the real world

A0849

Treatment patterns and survival in local-regional (cN1-3) and distant (cM1a) lymph node positive bladder cancer: Insights from a Dutch nationwide cohort

Authors

Bosveld J.¹, Richters A.², Meijer R.P.¹, Suelmann B.B.M.³

Institutions

¹University Medical Center Utrecht, Dept of. Oncological Urology, Utrecht, The Netherlands, ²The Netherlands Comprehensive Cancer Organisation, Dept of. Research & Development, Utrecht, The Netherlands, ³University Medical Center Utrecht, Dept of. Medical Oncology, Utrecht, The Netherlands

A0851

Treatment outcomes of enfortumab vedotin plus pembrolizumab in lymph node-positive urothelial carcinoma patients fit for cystectomy: Real-world data from an enfortumab registry

Authors

Hassler-Di Fratta M.R.¹, Krauter J.¹, Mayrhofer K.², Franke J.¹, Krallinger C.², Vais D.³, Pallauf M.⁴, Kiesl D.⁵, Pfuner J.⁶, Terbuch A.⁷, Mayr M.⁸, Banner A.⁹, Aufderklamm S.¹⁰, Wiesinger C.¹¹, Mühlmann J.¹², Vallet S.¹³, Stoiber F.¹⁴, Taghizadeh H.¹⁵, Pichler R.¹⁶, Fajkovic H.¹⁷, Shariat S.¹, Niedersuess-Beke D.²

Institutions

¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²Centre for Oncology and Haematology, Vienna Healthcare Group, Ottakring, Dept. of Internal Medicine I, Vienna, Austria, ³State Hospital Klagenfurt, Dept. of Internal Medicine Oncology and Haematology, Klagenfurt, Austria, ⁴Paracelsus Medical University Salzburg, Dept. of Urology, Salzburg, Austria, ⁵Ordensklinikum Linz Elisabethinen, Dept. of Internal Medicine I with Haematology, Linz, Austria, ⁶Klinikum Donaustadt, Dept. of Urology, Vienna, Austria, ⁷Medical University Graz, Division of Clinical Oncology, Dept. of Internal Medicine, Graz, Austria, ⁸Vienna Healthcare Group Ottakring, Dept. of Clinical Pathology, Molecular Pathology and Microbiology, Vienna, Austria, ⁹Vienna Healthcare Group Favoriten, Dept. of Urology, Vienna, Austria, ¹⁰State Hospital Bregenz, Dept. of Urology, Bregenz, Austria, ¹¹Klinikum Wels-Grieskirchen, Dept. of Urology, Wels, Austria, ¹²St. John of God Hospital, Dept. of Internal Medicine, Salzburg, Austria, ¹³University Hospital Krems and Karl Landsteiner University of Health Sciences, Dept. of Internal Medicine II, Krems, Austria, ¹⁴State Hospital Salzkammergut, Dept. of Urology, Vöcklabruck, Austria, ¹⁵University Hospital St. Pölten, Dept. of Oncology, St. Pölten, Austria, ¹⁶Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ¹⁷University Hospital St. Pölten, Dept. of Urology and Andrology, St. Pölten, Austria

Real-world survival improvements in metastatic urothelial carcinoma (mUC) across three key therapeutic eras

Authors

Cigliola A.¹, Maiorano B.A.¹, Tateo V.¹, Mercinelli C.¹, Piacentini M.¹, Bertini A.², Dizman N.³, Pal S.K.⁴, Gupta S.⁵, Grivas P.⁶, Kamat A.⁷, Agarwal N.⁸, Briganti A.², Montorsi F.², Necchi A.¹

Institutions

¹IRCCS San Raffaele Hospital, Dept. of Medical Oncology, Milan, Italy, ²IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ³MD Anderson Cancer Center, Dept. of Hematology & Oncology, Houston, United States of America, ⁴City of Hope Comprehensive Cancer Center, Dept. of Genitourinary Oncology, Duarte, United States of America, ⁵Cleveland Clinic Taussig Cancer Institute, Dept. of Genitourinary Medical Oncology, Cleveland, United States of America, ⁶Fred Hutchinson Cancer Center e University of Washington School of Medicine, Genitourinary Cancers Program, Seattle, United States of America, ⁷MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁸Huntsman Cancer Institute, University of Utah, Dept. of Medical Oncology, Salt Lake City, United States of America

Real-world clinical outcomes of avelumab (A), pembrolizumab (P) or enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC) with squamous differentiation (UCSD): results from the Aron-2 study.

Authors

Mollica V.¹, Massari F.², Giannatempo P.³, Grande E.⁴, Buttner T.⁵, Myint Z.W.⁶, Pichler R.⁷, Molina Cerrillo J.⁸, Kucharz J.⁹, Fiala O.¹⁰, Manneh Kopp R.¹¹, Zgura A.¹², Ansari J.¹³, Zabalza I.O.¹⁴, Monteiro F.S.M.¹⁵, Soares A.¹⁶, Urun Y.¹⁷, Buti S.¹⁸, Santini D.¹⁹, Santoni M.²⁰

Institutions

¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Dept. of Medical Oncology, Bologna, Italy, ²University of Bologna, Dept. of Medical and Surgical Sciences (DIMEC), Bologna, Italy, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, ⁴MD Anderson Cancer Center Madrid, Dept. of Medical Oncology, Madrid, Spain, ⁵University Hospital Bonn, Dept. of Urology, Bonn, Germany, ⁶Markey Cancer Center, University of Kentucky, Division of Medical Oncology, Lexington, United States of America, ⁷Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ⁸Hospital Ramón y Cajal, Dept. of Medical Oncology, Madrid, Spain, ⁹Maria Skłodowska-Curie National Research Institute of Oncology Warsaw, Dept. of Uro-Oncology, Warsaw, Poland, ¹⁰Faculty of Medicine and University Hospital in Pilsen, Charles University, Dept. of Oncology and Radiotherapeutics, Pilsen, Czech Republic, ¹¹Sociedad de Oncología y Hematología del Cesar, Clinical Oncology, Valledupar, Colombia, ¹²Alexandru Trestioreanu Institute of Oncology, Carol Davila University of Medicine and Pharmacy, Dept. of Obstetrics-Radiotherapy, Bucharest, Romania, ¹³Tawam Hospital, Dept. of Medical Oncology, Al Ain, United Arab Emirates, ¹⁴MD Anderson Cancer Center Madrid, Division of Medical Oncology, Madrid, Spain, ¹⁵Hospital Sírio Libanês, Oncology and Hematology Department, Brasilia, Brazil, ¹⁶Hospital Israelita Albert Einstein, Oncology Unit, São Paulo, Brazil, ¹⁷Ankara University Faculty of Medicine, Dept. of Medical Oncology, Ankara, Turkey, ¹⁸University Hospital of Parma, Medical Oncology Unit, Parma, Italy, ¹⁹Policlinico Umberto I, University of Rome, Dept. of Radiological, Oncological and Pathological Sciences, Rome, Italy, ²⁰Macerata Hospital, Medical Oncology Unit, Macerata, Italy

A0855

Efficacy and Safety of a Novel Treatment Scheme of RC48-ADC Plus PD-1 Inhibitors in Metastatic Urothelial Carcinoma: A Multicenter Real-world Study

Authors

Bai J.¹, [Lin J.](#)², Li X.³, Lin B.⁴, Wen Y.², Ye Y.², Chen S.², Chen H.⁵, Qiu Q.², Huang J.², Ye Y.², Liu R.², Kang D.³, Chen R.², Lu Q.², Su Y.², Zhang W.⁵, Wei Y.⁶, Zhu S.², Chen J.⁷

Institutions

¹Shengli Clinical Medical College of Fujian Medical University, Dept. of Urology, Fuzhou, China, ²Fujian Medical University Union Hospital, Dept. of Urology, Fuzhou, China, ³Fujian Medical University Union Hospital, Dept. of Pathology, Fuzhou, China, ⁴Fujian Medical University Union Hospital, Dept. of Pharmacy, Fuzhou, China, ⁵The Second Affiliated Hospital, Fujian University of Traditional Chinese Medicine, Dept. of Urology, Fuzhou, China, ⁶Fuzhou University Affiliated Provincial Hospital, Dept. of Urology, Fuzhou, China, ⁷Fujian Medical University Union Hospital, Dept. of Urology, Fuzhou, China

A0856

Real-world efficacy of Avelumab maintenance therapy in advanced urothelial carcinoma: survival impact of early transition after 2–3 cycles of chemotherapy

Authors

[Ishii N.](#)¹, Sekine Y.², Shinohara M.³, Tanaka T.¹, Fujita N.¹, Okamoto T.¹, Yamamoto H.¹, Kawashima Y.³, Sato S.³, Numakura K.⁴, Habuchi T.², Ohyama C.¹, Hatakeyama S.¹

Institutions

¹Hirosaki University, Dept. of Urology, Aomori, Japan, ²Akita University, Dept. of Urology, Aomori, Japan, ³Ageo Central General Hospital, Dept. of Urology, Saitama, Japan, ⁴Asahikawa Medical University, Dept. of Urology, Hokkaido, Japan

13:10 - 13:25

Improving metastasis detection in urothelial carcinoma

A0857

The comparison of CT and MRI based Node-RADS in predicting lymph node metastasis bladder cancer

Authors

[Yang X.](#), Lyu Q., Cao Q., Bai R.

Institutions

the First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

A0858

A non-invasive preoperative fusion model for predicting lymph node metastasis in bladder cancer: a multicenter study

Authors

[Yang X.](#), Lyu Q., Cao Q., Bai R.

Institutions

The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

A0859

89Zirconium-labelled girentuximab PET in patients with urothelial cancer (ZiPUP) - a phase 1 study of a novel staging modality for urothelial carcinoma

Authors

Hayne D.¹, Gauci R.², Viswambaram P.³, Hoo T.², Keane K.G.¹, McCombie S.P.³, Oakes S.R.⁴, Liow E.⁵, Lim J.¹, Hawks C.³, Lenzo N.⁶, Ferguson T.⁷, Meehan K.¹, Redfern A.D.¹

Institutions

¹University of Western Australia, UWA Medical School, Perth, Australia, ²Fiona Stanley Hospital, Dept. of Nuclear Medicine, Perth, Australia, ³Fiona Stanley Hospital, Dept. of Urology, Perth, Australia, ⁴Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Sydney, Australia, ⁵Monash University, Dept. of Medicine, Melbourne, Australia, ⁶GenesisCare, Dept. of Nuclear Medicine, Perth, Australia, ⁷Fiona Stanley Hospital, Dept. of Medical Oncology, Perth, Australia

Study Group

Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (Sydney, Australia)

13:25 - 13:35

Prognostic factors in metastatic urothelial carcinoma

A0860

Metastatic profile and survival outcomes of metastatic non-muscle invasive bladder cancer in comparison with metastatic muscle invasive bladder cancer: A National Cancer Database analysis

Authors

Raja Iyub M.J., Prabhakar P., Sakthivel D.K., Pon Avudaiappan A., Ozambela Jr M., Eldefrawy A.H., Manoharan M.

Institutions

Miami Cancer Institute, Dept. of Genitourinary Surgical Oncology, Miami, United States of America

Factors associated with inferior outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with first-line enfortumab vedotin plus pembrolizumab (1L EV+P): results from UNITE

Authors

Nizam A.¹, Jindal T.², Cai E.³, Jiang C.Y.⁴, Thomas Z.⁴, Oh E.⁵, Nguyen C.B.⁶, Jang A.⁷, Zhong J.⁸, Reyes K.⁹, Jaime-Casas S.⁶, Bakaloudi D.R.¹⁰, Khaki A.R.¹¹, Govindarajan A.¹, Gupta S.¹, Shah S.A.¹¹, Milowsky M.I.¹², Grivas P.¹⁰, Tripathi A.⁶, Brown J.R.¹³, Tsung I.¹⁴, Campbell M.T.⁴, Alhalabi O.⁴, Koshkin V.S.³

Institutions

¹Cleveland Clinic Taussig Cancer Institute, Dept. of Hematology and Medical Oncology, Cleveland, United States of America, ²Case Western Reserve University School of Medicine, Dept. of Medicine, Cleveland, United States of America, ³University of California San Francisco Helen Diller Family Comprehensive Cancer Center, Dept. of Hematology/Oncology, San Francisco, United States of America, ⁴The University of Texas MD Anderson Cancer Center, Dept. of Genitourinary Medical Oncology, Houston, United States of America, ⁵University of Michigan School of Medicine, Dept. of Medicine, Ann Arbor, United States of America, ⁶City of Hope Comprehensive Cancer Center, Dept. of Medical Oncology & Therapeutics Research, Duarte, United States of America, ⁷Mayo Clinic Comprehensive Cancer Center, Dept. of Oncology, Rochester, United States of America, ⁸Case Western Reserve University, Dept. of Medicine, Cleveland, United States of America, ⁹University of California San Francisco, Dept. of Medicine, San Francisco, United States of America, ¹⁰Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, United States of America, ¹¹Stanford University, Dept. of Medicine, Division of Oncology, Stanford, United States of America, ¹²University of North Carolina School of Medicine, Dept. of Medicine, Division of Oncology, Chapel Hill, United States of America, ¹³Case Western Reserve University/University Hospitals Seidman Cancer Center, Dept. of Medicine, Cleveland, United States of America, ¹⁴University of Michigan Rogel Comprehensive Cancer Center, Dept. of Hematology and Oncology, Ann Arbor, United States of America

13:35 - 13:45

Preventing side effects from new therapies in urothelial carcinoma

A0863

A simple risk score incorporating pan-immune-inflammation value, albumin, and KL-6 effectively stratifies risk of immune-related interstitial lung disease in genitourinary cancer

Authors

Hata S., Abe S., Todaka M., Suzuki S., Fujinami H., Yamanaka N., Shin T.

Institutions

Oita University, Dept. of Urology, Oita, Japan

13:45 - 13:55

New developments in metastatic urothelial cancer

A0864

Noninvasive Evaluation of HER2 Expression AND Heterogeneity in Urothelial Carcinoma on 68Ga-HER2-affibody PET/CT

Authors

Tao Z., Tang Q., Li X.

Institutions

Peking University First Hospital, Dept. of Urology, Beijing, China

Phase 1 Study of B440, an Oral Bifidobacterium-Engineered WT1 Cancer Vaccine, in Patients with Metastatic Urothelial Cancer

Authors

Ueki H.¹, Furukawa J.², Hara T.¹, Goto K.³, Tamura K.⁴, Matsushita Y.⁴, Kakei Y.⁵, Murakami S.⁵, Jimbo N.⁶, Teishima J.¹, Hinata N.³, Miyake H.¹, Shirakawa T.⁷

Institutions

¹Kobe University Graduate School of Medicine, Dept. of Urology, Kobe, Japan, ²Tokushima University Graduate School of Biomedical Sciences, Dept. of Urology, Tokushima, Japan, ³Hiroshima University, Dept. of Urology, Hiroshima, Japan, ⁴Hamamatsu University School of Medicine, Dept. of Urology, Hamamatsu, Japan, ⁵Kobe University Hospital, Clinical and Translational Research Center, Kobe, Japan, ⁶Kobe University Graduate School of Medicine, Dept. of Diagnostic Pathology, Kobe, Japan, ⁷Kobe University Graduate School of Science, Division of Advanced Medical and Pharmaceutical Sciences, Kobe, Japan

Advancements in upper tract urothelial carcinoma: From surgical outcomes to endoscopic management

Abstract Session 45

Monday 16 March
12:30 - 14:00

Location

Blue Area, George 3

Chairs

To be confirmed

M. Rouprêt, Paris (FR)

To be confirmed

12:30 - 12:55

Endoscopic management of upper urinary tract urothelial carcinoma

A0761

A proposal of EAU-YAU trifecta score for upper tract urothelial patients treated with endoscopic kidney sparing approach

Authors

Di Bello F.¹, Andrea G.², Zattoni F.³, Laukhtina E.⁴, D'Andrea D.⁴, Soria F.⁵, Afferi L.⁶, Del Giudice F.⁷, Krajewski W.⁸, Marcq G.⁹, De Lorenzis E.¹⁰, Moschini M.¹¹, Mari A.¹², Subiela J.D.¹³, Dieguez L.², Izquierdo P.², Chung B.I.¹⁴, Pradere B.¹⁵, Avesani G.¹¹, Belarmino A.², Territo A.², Palou J.², Breda A.²

Institutions

¹Università degli studi di Napoli Federico II, Dept. of Neurosciences, Reproductive Sciences and Odontostomatology, Napoli, Italy, ²Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ³University of Padova, Dept. of Urology, Padova, Italy, ⁴Comprehensive Cancer Center, Dept. of Urology, Vienna, Austria, ⁵University of Turin and Città della Salute e della Scienza, Dept. of Urology, Turin, Italy, ⁶Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ⁷Sapienza University of Rome, Dept. of Urology, Rome, Italy, ⁸Wroclaw Medical University, Dept. of Urology, Wroclaw, Poland, ⁹Claude Huriez Hospital, Dept. of Urology, Lille, France, ¹⁰University of Milan, Dept. of Urology, Milan, Italy, ¹¹IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ¹²University of Florence, Dept. of Urology, Florence, Italy, ¹³Universidad de Alcalà, Dept. of Urology, Madrid, Spain, ¹⁴Stanford University School of Medicine, Dept. of Urology, Stanford, United States of America, ¹⁵UROSUD, La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France

Study Group

EAU-YAU Urothelial Working Group and Ureteroscopic Treatment of upper tract Urothelial Carcinoma (UTUC) registry(Barcelona, Spain)

A0762

Perioperative Disitamab Vedotin and Tislelizumab Followed by Nephron-Sparing Surgery in High-Risk Upper Tract Urothelial Carcinoma: A Phase 2 Trial (DISTINCT-I)

Authors

Huang J.¹, Ding Y.¹, Ng C.¹, Xia L.¹, Du C.¹, Chen Q.¹, Hu H.², Xue W.¹

Institutions

¹Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of urology, Shanghai, China, ²The Second Hospital of Tianjin Medical University, Dept. of urology, Tianjin, China

A0763

Conservative treatment of high risk Transitional Cell Carcinoma (TCC) of the Ureter is safe and should be adopted more frequently: results of a retrospective and prospective study

Authors

Brausi M.¹, Peracchia G.², De Luca G.², Diquattro S.¹, Cianci F.¹, Lucariello T.¹, Gallo S.¹, Ferrari G.¹, Morselli S.¹

Institutions

¹Hesperia Hospital, Dept. of Urology, Modena, Italy, ²AUSL modena, Dept. of Urology, Modena, Italy

A0764

Tumor-Related Risk Factors in Imperative Indications for Endoscopic Management of Upper Tract Urothelial Carcinoma

Authors

Yoshida T.¹, Katayama S.², Takazawa R.³, Waseda Y.⁴, Kajikawa K.⁵, Okada S.⁶, Araki M.², Kinoshita H.⁷

Institutions

¹Osaka Saiseikai-Noe Hospital, Dept. of Urology, Osaka, Japan, ²Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Dept. of Urology, Okayama, Japan, ³Tokyo Metropolitan Ohtsuka Hospital, Dept. of Urology, Tokyo, Japan, ⁴Institute of Science Tokyo, Dept. of Urology, Tokyo, Japan, ⁵Aichi Medical University, Dept. of Urology, Aichi, Japan, ⁶Gyotoku General Hospital, Dept. of Urology, Chiba, Japan, ⁷Kansai Medical University, Dept. of Urology and Andrology, Osaka, Japan

A0765

How Accurate Is Ureteroscopic Biopsy in Predicting Grade and Stage of UTUC? An Updated Systematic Review and Meta-Analysis on Behalf of the PACE Group

Authors

Moretto S., Zorzi F., Bravo-Balado A., Chicaud M., Kutchukian S., Quarà A., Madden A., Jannello L.M.I., Altez Fernandes C., Letouche M.L., Pena Lueza J., Popescu R.I., Candela L., Traxer O.

Institutions

Progress and Collaboration in Endourology Group, PACE, Paris, France

12:55 - 13:30

Radical surgery for upper tract urothelial carcinoma

Impact of Surgical Delay on Outcomes in High-Risk Upper Tract Urothelial Carcinoma: Insights from the ROBUUST 3.0 Collaborative

Authors

Lambertini L.¹, Mari A.¹, H. Derweesh I.², Wu Z.³, Singla N.⁴, Djaladat H.⁵, Lee R.⁶, Margulis V.⁷, Antonelli A.⁸, Simone G.⁹, Abdollah F.¹⁰, Yoshida T.¹¹, Shiota M.¹², P. Sundaram C.¹³, L. Gonzalgo M.¹⁴, Perdonà S.¹⁵, Ferro M.¹⁶, Rais-Bahrami S.¹⁷, Porpiglia F.¹⁸, Mehrazin R.¹⁹, Ghodoussipour S.²⁰, Minervini A.¹, Autorino R.²¹

Institutions

¹Unit of Oncologic Minimally Invasive Urology and Andrology Careggi Hospital, Dept. of Experimental and Clinical Medicine University of Florence, Florence, Italy, ²Rush University, Dept. of Urology, Chicago, United States of America, ³Changhai Hospital Naval Medical University, Dept. of Urology, Changhai, China, ⁴Brady Urological Institute, Johns Hopkins University School of Medicine, Dept. of Urology and Oncology, Baltimore, United States of America, ⁵Norris Cancer Center, University of Southern California, Institute of Urology, Los Angeles, United States of America, ⁶Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ⁷UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ⁸Azienda Ospedaliera Universitaria Integrata Verona (AOUI), Unit of Urology, Verona, Italy, ⁹IRCCS Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹⁰Henry Ford Health System, Vattikuti Urology Institute, Detroit, United States of America, ¹¹Kansai Medical University, Dept. of Urology and Andrology, Osaka, Japan, ¹²Graduate School of Medical Sciences, Dept. of Urology, Fukuoka, Japan, ¹³Indiana University, Dept. of Urology, Indianapolis, United States of America, ¹⁴University of Miami Miller School of Medicine, Desai Sethi Urology Institute, Miami, United States of America, ¹⁵IRCCS Fondazione G. Pascale, Istituto Nazionale Tumori Di Napoli, Naples, Italy, ¹⁶University of Milan ASST Santi Paolo e Carlo, Dept. of Health Science, Dept. of Urology, Milan, Italy, ¹⁷University of Alabama at Birmingham Heersink School of Medicine, Dept. of Urology, Birmingham, United States of America, ¹⁸Candiolo Cancer Institute FPO-IRCCS, Dept. of Surgery, Turin, Italy, ¹⁹Icahn School of Medicine at Mount Sinai Hospital, Dept. of Urology, New York, United States of America, ²⁰Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, Section of Urologic Oncology, New Brunswick, United States of America, ²¹Cleveland Clinic, Glickman Urological Institute, Cleveland, United States of America

Anatomical refinement matters: Ureteropelvic junction location confers survival benefit for patients with upper tract urothelial carcinoma after radical nephroureterectomy

Authors

Bao G., Peng K., Zhou L., Li X., Han H.

Institutions

Peking University First Hospital, Dept. of Urology, Beijing, China

A0768

Predicting recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: Development and validation of the novel risk score

Authors

Iwamoto Y.¹, Foss H.², Ishiyama Y.³, Taneda Y.⁴, Kagawa H.⁴, Uchida N.⁴, Koike Y.⁴, Hara S.⁵, Miyajima K.⁴, Iwatani K.⁶, Imai Y.⁴, Tashiro K.¹, Tsuzuki S.⁴, Miki J.⁶, Gupta S.⁷, Boorjian S.A.², Potretzke A.², Urabe F.⁴, Kimura T.⁴

Institutions

¹Atsugi City Hospital, Dept. of Urology, Kanagawa, Japan, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Tokyo Women Medical University, Dept. of Urology, Tokyo, Japan, ⁴The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁵Jikei Katsushika Medical Center, Dept. of Urology, Tokyo, Japan, ⁶Jikei University Kashiwa Hospital, Dept. of Urology, Chiba, Japan, ⁷Mayo Clinic, Dept. of Pathology, Rochester, United States of America

A0769

A preoperative nomogram for predicting postoperative renal function decline after radical nephroureterectomy: Guiding neoadjuvant chemotherapy decisions in upper tract urothelial carcinoma

Authors

Hong P.¹, Yu L.¹, Liu Z.², Xu C.³, Zhang S.¹, Liu Z.², Li X.³, Zhang H.¹

Institutions

¹Peking University Third Hospital, Dept. of Urology, Beijing, China, ²Sun Yat-sen University Cancer Center, Dept. of Urology, Guangzhou, China, ³Peking University First Hospital, Dept. of Urology, Beijing, China

A0770

Open vs Minimally Invasive Radical Nephroureterectomy for Clinical T3–T4 Upper Tract Urothelial Carcinoma: Results from a Large Multicenter International Cohort

Authors

Fertitta G., Bosio A., Polonio L., Dutto D., Livoti S., Rosazza M., Colucci F., Fiameni C., Soria F., Gontero P.

Institutions

AOU Città della Salute e della Scienza - University of Turin School of Medicine, Dept. of Surgical Sciences, Division of Urology, Turin, Italy

A0771

Regional Disparities in Overall and Cancer-Specific Survival after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multi-Institutional Cohort Study across European and Taiwanese Centers

Authors

Rössler N.¹, Miszczyk M.², von Deimling M.¹, Vetterlein M.W.¹, Gontero P.³, Soria F.⁴, Pradere B.⁵, N'Dow J.⁶, Shariat S.F.², Tsai Y.C.⁷, D'andrea D.²

Institutions

¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³Città della Salute e della Scienza, University of Torino School of Medicine, Dept. of Urology, Turin, Italy, ⁴Torino School of Medicine, Division of Urology, Dept. of Surgical Sciences, Turin, Italy, ⁵La Croix du Sud Hospital, Quint Fonsegrives, Dept. of Urology, UROSUD, Quint-Fonsegrives, France, ⁶University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ⁷Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, Division of Urology Dept. of Surgery, New Taipei, Taiwan

A0772

Tailored Cystoscopic Surveillance Intervals Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results from a Multicenter Cohort Study

Authors

Koike Y, Urabe F., Nakata M., Kasuya E., Iwatani K., Atsuta M., Imai Y., Miki J., Kimura T.

Institutions

The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan

13:30 - 14:00

Clinical and molecular correlates of high-risk upper tract urothelial carcinoma

A0773

Synergistic impact of LRRC15+ stroma and CD163+ macrophage infiltration on metastasis in upper tract urothelial carcinoma

Authors

Lo C.H.¹, Hsu S.Y.¹, Sun H.Y.², Jan H.C.¹

Institutions

¹National Cheng Kung University Hospital, Dept. of Urology, Tainan City, Taiwan,

²National Cheng Kung University, Dept. of Physiology, Tainan City, Taiwan

A0774

International Delphi Consensus on UTUC Management: The IMPACT UTUC Project

Authors

Pandolfo S.D.¹, Contieri R.², Catto J.³, Briganti A.⁴, Roupret M.⁵, Pradere B.⁶, Porpiglia F.⁷, Amparore D.⁷, Minervini A.⁸, Bertolo R.⁹, Moschini M.⁴, Mertens L.¹⁰, van Rhijn B.W.G.¹¹, Gallioli A.¹², Formisano L.¹³, Imbimbo C.¹³, Lucarelli G.¹⁴, Ferro M.¹⁵, Gupta S.¹⁶, Mir M.C.¹⁷, Derweesh I.¹⁸, Djaladat H.¹⁹, Bukavina L.²⁰, Autorino R.²⁰

Institutions

¹University of L'Aquila, Dept. of Urology, L'Aquila, Italy, ²Istituto Nazionale Tumori IRCCS, Dept. of Urology, Naples, Italy, ³University of Sheffield, Dept. of Urology, Sheffield, United Kingdom, ⁴Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁵Sorbonne University, Dept. of Urology, Paris, France, ⁶La Croix du Sud Hôpital, Quint Fonsegrives, Dept. of Urology, Quint-Fonsegrives, France, ⁷San Luigi Gonzaga Hospital, University of Turin, Dept. of Urology, Turin, Italy, ⁸University of Florence, Dept. of Urology, Dept. of Experimental and Clinical Medicine, Florence, Italy, ⁹University of Verona, Dept. of Urology, Verona, Italy, ¹⁰Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ¹¹Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ¹²Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ¹³University of Naples, Dept. of Uro-Oncology, Naples, Italy, ¹⁴IRCCS Istituto Tumori Giovanni Paolo II, Dept. of Urology, Bari, Italy, ¹⁵ASST Santi Paolo and Carlo, University of Milan, Dept. of Urology, Milan, Italy, ¹⁶Cleveland Clinic Taussig Cancer Institute, Dept. of Urology, Cleveland, United States of America, ¹⁷Hospital Universitario La Ribera, Dept. of Urology, Valencia, Spain, ¹⁸RUSH University Medical Center, Dept. of Urology, Chicago, United States of America, ¹⁹Keck School of Medicine of the University of Southern California, Dept. of Urology, Los Angeles, United States of America, ²⁰Cleveland Clinic Glickman Urological Institute, Dept. of Urology, Cleveland, United States of America

Study Group

IMPACT UTUC(Cleveland, United States of America)

A0775

Clinical Outcomes of Neoadjuvant Chemotherapy Combined with Adjuvant Nivolumab in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Comparison with Adjuvant Chemotherapy

Authors

Tomisaki I.¹, Nagata Y.¹, Higashijima K.¹, Minato A.¹, Kashiwagi E.¹, Fujimoto N.²

Institutions

¹University of Occupational and Environmental Health, Dept. of Urology, Kitakyushu, Japan, ²Kurate Hospital, Dept. of Urology, Kurate, Japan

A0776

FGFR3 and TERT Mutations Associate with Distinct Clinicopathological Features and Prognosis in Upper Tract and Bladder Urothelial Carcinoma

Authors

Xiong Y., Yu T., Chen N., Zhou Q.

Institutions

West China Hospital of Sichuan University, Dept. of Pathology, Chengdu, China

A0777

The impact of Area Deprivation Index on Adjuvant Chemotherapy utilization in UTUC patients, results from a retrospective analysis.

Authors

Santangelo A.¹, Silvani C.¹, Tylecki A.², Considine J.¹, Msska A.¹, Perry M.¹, Zadeh T.¹, Nazzani S.³, Nicolai N.⁴, Montanari E.⁵, Salonia A.⁶, Montorsi F.⁶, Briganti A.⁶, Rogers C.¹, Abdollah F.¹

Institutions

¹VUI Center for Outcomes Research Analysis and Evaluation Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Unit of Urology, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy, ⁵Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ⁶IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy

A0778

Clinical Link Between Renal Interstitial Fibrosis and Tumor Stroma Activation in Predicting Metastasis of Upper Tract Urothelial Carcinoma

Authors

Lo C.H.¹, Hsu S.Y.¹, Sun H.Y.², Jan H.C.¹

Institutions

¹National Cheng Kung University Hospital, Dept. of Urology, Tainan City, Taiwan, ²National Cheng Kung University, Dept. of Physiology, Tainan City, Taiwan

Monday 16 March
12:30 - 14:00

Location Blue Area, Victoria 2

Chairs G. Kulkarni, Toronto (CA)
K.E.M. Van Kessel, Rotterdam (NL)
E.N. Xylinas, Paris (FR)

12:30 - 12:55

Intravesical therapies for non-muscle invasive bladder cancer

A0815

Treatment of high-grade (HG) non-muscle-invasive urothelial carcinoma (NMIBC): Results from the VERSUS study by d-uo (Germany)

Authors

Doehn C.¹, Eichenauer R.², Klier J.R.³, König F.⁴, Schönfelder R.⁵, Schröder J.⁴, Hempel E.⁶, Johannsen M.⁷

Institutions

¹Urologikum Lübeck, Dept. of Urology, Lübeck, Germany, ²Urologikum MVZ, Dept. of Urology, Hamburg, Germany, ³Urologische Partnerschaft Köln (UPK), Dept. of Urology, Cologne, Germany, ⁴ATURO, Dept. of Urology, Berlin, Germany, ⁵Urologie Schönfelder & Straßer, Dept. of Urology, Hamburg, Germany, ⁶SMGF, Forschungsgesellschaft, Berlin, Germany, ⁷Facharztpraxis Johannsen & Laux, Dept. of Urology, Berlin, Germany

Study Group

Deutsche Uro-Onkologen (d-uo)(Berlin, Germany)

A0816

Reduced vs full dose BCG maintenance in NMIBC patients treated with full dose induction: A matched analysis

Authors

O'Donnell M.A.¹, Lotan Y.², Lajkosz K.³, Kwong J.⁴, Attia S.², Ito W.², McElree I.⁵, Chadee A.⁶, Kulkarni G.S.⁷, Zlotta A.R.⁶

Institutions

¹University of Iowa, Dept. of Urology, Iowa City, United States of America, ²UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ³University Health Network, Dept. of Biostatistics, Toronto, Canada, ⁴University of Toronto, Dept. of Surgery, Toronto, Canada, ⁵Vanderbilt University, Dept. of Urology, Nashville, United States of America, ⁶Mount Sinai Hospital, Dept. of Surgery, Toronto, Canada, ⁷University Health Network, Dept. of Surgery, Toronto, Canada

A0817

Consistent Efficacy of Durable Response in BCG Relapse, Refractory and Unresponsive Disease in a Pre-Determined Subgroup Analysis of ANKTIVA (NAI) plus BCG in BCG-Unresponsive NMIBC CIS With or Without Ta/T1 Papillary Disease

Authors

Chang S.¹, Chamie K.², Huang M.³, Brown B.⁴, Reddy S.⁴, Soon-Shiong P.⁴

Institutions

¹Vanderbilt Ingram Cancer Center, Dept. of Urology, Nashville, United States of America, ²UCLA Medical Center, Dept. of Urology, Los Angeles, United States of America, ³ImmunityBio, Inc., Dept. of BioStatistics, Culver City, United States of America, ⁴ImmunityBio, Inc., Dept. of Urology, Culver City, United States of America

Impact of BCG Failure Pattern on Oncologic Outcomes of Intravesical Gemcitabine and Docetaxel in High-Risk NMIBC: A Multicenter European Study

Authors

Scilipoti P.¹, Longoni M.¹, Zaurito P.¹, Tremolada G.¹, Ślusarczyk A.², Krajewski W.³, Aranda J.³, Hurlle R.⁴, Subiela J.D.⁵, Marcq G.⁶, Simone G.⁷, Pichler R.⁸, Álvarez-Maestro M.⁹, Buisan O.¹⁰, Radziszewski P.², Soria F.¹¹, Pradere B.¹², D'Andrea D.¹³, Shariat S.F.¹³, Montorsi F.¹, Briganti A.¹, Gontero P.¹¹, Xylinas E.¹⁴, Moschini M.¹

Institutions

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Medical University, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ³Wrocław Medical University, Dept. of Urology and Oncologic Urology, Wrocław, Poland, ⁴Humanitas Clinical and Research Institute IRCCS, Dept. of Urology, Rozzano, Italy, ⁵Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Dept. of Urology, Madrid, Spain, ⁶Claude Huriez Hospital, CHU Lille, Dept. of Urology, Lille, France, ⁷IRCCS Regina Elena National Cancer Institute, Uro-Oncology Program, Rome, Italy, ⁸Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ⁹Hospital Universitario La Paz, Dept. of Urology, Madrid, Spain, ¹⁰Hospital Universitari de Bellvitge, Dept. of Urology, Barcelona, Spain, ¹¹San Giovanni Battista Hospital, University of Studies of Torino, Dept. of Urology, Turin, Italy, ¹²La Croix Du Sud Hospital, Dept. of Urology, UROSUD, Quint-Fonsegrives, France, ¹³Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹⁴Bichat-Claude Bernard Hospital, AP-HP, Université de Paris Cité, Dept. of Urology, Paris, France

Periprocedural Prophylactic Antibiotic Use with Gemcitabine Intravesical System (Gem-iDRS) Monotherapy: Analysis of Data from SunRISe-1

Authors

Zainfeld D.¹, Mazarella B.², Kawahara T.³, Pieczonka C.M.⁴, Xylinas E.N.⁵, Somford D.⁶, Sweiti H.⁷, Hapmras S.⁸, Martin J.⁹, Shukla A.¹⁰, Stromberg K.⁸, Decaestecker K.¹¹, Falkowski S.¹², Matulay J.T.¹³, Morris D.S.¹⁴

Institutions

¹Urology San Antonio, Dept. of Urology, San Antonio, United States of America, ²Urology Austin, Dept. of Urology, Austin, United States of America, ³Yokohama City University Medical Center, Dept. of Urology, Yokohama, Japan, ⁴Associated Medical Professionals of New York (an affiliate of US Urology Partners), Dept. of Urology, Syracuse, United States of America, ⁵Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris Cité, Dept. of Urology, Paris, France, ⁶Canisius-Wilhelmina Ziekenhuis, Dept. of Urology, Nijmegen, The Netherlands, ⁷Johnson & Johnson, Dept. of Research and Development, Spring House, United States of America, ⁸Johnson & Johnson, Dept. of Research & Development, Raritan, United States of America, ⁹Johnson & Johnson, Research & Development, High Wycombe, United Kingdom, ¹⁰Johnson & Johnson, Dept. of Research & Development, Lexington, United States of America, ¹¹AZ Maria Middelaes, Dept. of Urology, Ghent, Belgium, ¹²Polyclinique de Limoges - Francois Chenieux, Dept. of Urology, Limoges, France, ¹³Atrium Health, Dept. of Urology, Charlotte, United States of America, ¹⁴Urology Associates P.C, Dept. of Urology, Nashville, United States of America

A0820

How reliable is intraoperative judgment during TURBT? An inter-observer concordance analysis across key surgical parameters

Authors

Scilipoti P.¹, De Angelis M.¹, Longoni M.¹, Zaurito P.¹, Viti A.¹, Cosenza A.¹, Disabato N.¹, Occhi A.¹, Santangelo A.¹, Tremolada G.¹, Tenace N.², Colecchia M.², Burgio G.¹, Villa L.¹, Matloob R.¹, Barletta F.¹, Pozzi E.¹, Quarta L.¹, Bandini M.¹, Rosiello G.¹, Salonia A.¹, Briganti A.¹, Montorsi F.¹, Moschini M.¹

Institutions

¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy

A0821

Transurethral resection of bladder tumor performance between curriculum-trained vs traditionally-trained residents: results from the European TRaining in urology (ENTRY) project

Authors

Diana P.¹, Di Bello F.², Mas L.², Paciotti M.³, Frego N.³, Gallioli A.², Mottrie A.⁴, Palou J.², Buffi N.³, Breda A.²

Institutions

¹Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, ²Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ³IRCCS - Istituto clinico Humanitas, Dept. of Urology, Rozzano, Italy, ⁴ORSI Academy, Dept. of Urology, Melle, Belgium

A0822

Impact of repeat TUR on oncological outcomes in patients with pT1 bladder cancer treated with en bloc TUR: the JET study

Authors

Matsukawa A.¹, Taneda Y.¹, Iwatani K.¹, Kubota R.², Okada Y.³, Hayashida Y.⁴, Miki J.¹, Kimura T.¹, Yanagisawa T.¹

Institutions

¹The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ²Okayama Medical Center, Dept. of Urology, Okayama, Japan, ³Saitama Medical Center, Dept. of Urology, Saitama, Japan, ⁴Ureshino Medical Center, Dept. of Urology, Saga, Japan

A0823

Blue-light-Guided Transurethral Laser Ablation (TULA) for Non-Muscle-Invasive Bladder Cancer: First UK Single-Centre Experience on Recurrence-Free Survival

Authors

Sandhu A., Ceria F., Gad M., Chatterton K., Mensah E., Thurairaja R., Nair R., Khan M.S., Abu Ghanem Y.

Institutions

Department of Urology - Guy's Hospital - Guy's and St Thomas' Foundation Trust, Dept. of Urology, London, United Kingdom

A0824

Nectin4-Targeted Fluorescence Imaging for Enhanced TURBT: From Preclinical Validation to First-in-Human Application

Authors

He Y., Yisen D., Jianfeng W.

Institutions

China-Japan Friendship Hospital, Dept. of Urology, Beijing, China

A0825

Impact of Surgeon Experience on Perioperative and Oncological Outcomes Following En Bloc Resection of Bladder Tumors: The Japan En bloc TUR (JET) Study

Authors

Taneda Y.¹, Iwatani K.², Matsukawa A.¹, Kubota R.³, Okada Y.⁴, Hayashida Y.⁵, Murakami M.¹, Miki J.², Kimura T.¹, Yanagisawa T.¹

Institutions

¹The Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ²Jikei University Kashiwa Hospital, Dept. of Urology, Kashiwa, Japan, ³Okayama Medical Center, Dept. of Urology, Okayama, Japan, ⁴Saitama Medical Center, Dept. of Urology, Saitama, Japan, ⁵Ureshino Medical Center, Dept. of Urology, Saga, Japan

A0826

Prophylactic Ureteral Stenting Prevents Clinically Significant Stricture Formation Following Ureteral Orifice Resection During TURBT: A Risk-Stratified Analysis

Authors

Mahmud H., Roe R., Kleinman N., Laufer M., Zilberman D.E., Dotan Z., Shviro A.

Institutions

Sheba Medical Center, Dept. of Urology, Tel Aviv, Israel

13:30 - 14:00

Clinical outcome of non-muscle invasive bladder cancer patients

A0827

Large-scale external validation of a fully automated AI system for urine cytology

Authors

Kaneko M.¹, Hayakawa K.², Harada Y.², Tsuji K.², Paralkar D.¹, Inoue Y.², Fujihara A.², Ueno K.³, Nakanishi M.³, Konishi E.⁴, Kojima M.⁴, Takamatsu T.⁵, Horiguchi G.⁶, Teramukai S.⁶, Ito-Ihara T.⁷, Aron M.⁸, Abreu A.L.¹, Daneshmand S.¹, Desai M.¹, Gill I.¹, Ukimura O.²

Institutions

¹University of Southern California, USC Institute of Urology, Los Angeles, United States of America, ²Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan, ³KYOCERA Communication Systems Co., Ltd, Corporate R&D Department, Kyoto, Japan, ⁴Kyoto Prefectural University of Medicine, Dept. of Surgical Pathology, Kyoto, Japan, ⁵Kyoto Prefectural University of Medicine, Dept. of Medical Photonics, Kyoto, Japan, ⁶Kyoto Prefectural University of Medicine, Dept. of Biostatistics, Kyoto, Japan, ⁷Kyoto Prefectural University of Medicine, The Clinical and Translational Research Center, Kyoto, Japan, ⁸University of Southern California, Dept. of Pathology, Los Angeles, United States of America

A0829

Disparities in guideline-concordant care and outcomes in non-muscle invasive bladder cancer: The impact of age and socioeconomic marginalization in a universal healthcare system

Authors

Kwong J.¹, Ringa M.², Kassouf W.³, Kim K.⁴, Wettstein M.S.⁵, Breau R.H.⁶, Lodde M.⁷, Fairey A.⁸, Lattouf J.B.⁹, Jeldres C.¹⁰, Rendon R.¹¹, Alimohamed N.¹², Chung P.⁴, Feifer A.², Black P.C.¹³, Kulkarni G.S.⁵, Zlotta A.R.¹⁴

Institutions

¹University of Toronto, Dept. of Surgery, Toronto, Canada, ²Trillium Health Partners, Dept. of Surgery, Mississauga, Canada, ³McGill University Health Centre, Dept. of Urology, Montréal, Canada, ⁴University of Toronto, Temerty Faculty of Medicine, Toronto, Canada, ⁵University Health Network, Dept. of Surgery, Toronto, Canada, ⁶The Ottawa Hospital Research Institute, Dept. of Surgery, Ottawa, Canada, ⁷CHU de Québec-Université Laval, Dept. of Surgery, Quebec City, Canada, ⁸University of Alberta, Dept. of Surgery, Edmonton, Canada, ⁹Centre Hospitalier de l'Université de Montréal, Dept. of Surgery, Montréal, Canada, ¹⁰Université de Sherbrooke, Dept. of Surgery, Sherbrooke, Canada, ¹¹Dalhousie University, Dept. of Urology, Halifax, Canada, ¹²Cumming School of Medicine, Dept. of Oncology, Calgary, Canada, ¹³University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ¹⁴Mount Sinai Hospital, Dept. of Surgery, Toronto, Canada

A0830

Impact of detrusor muscle sampling on clinical outcomes following en bloc resection of non-muscle invasive bladder cancer: the JET study

Authors

Kondo H., Matsukawa A., Taneda Y., Iwatani K., Yanagisawa T., Kubota R., Yohei O., Yasushi O., Miki J., Kimura T.

Institutions

the Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan

A0831

Survival outcomes of BCG only, BCG plus EMDA-MMC, or upfront radical cystectomy in high-risk Non-Muscle Invasive Bladder Cancers (NMIBCs): A multicentre collaborative study from two independent tertiary referral institutions from United Kingdom and Italy

Authors

Carino D.¹, Del Giudice F.¹, Santarelli V.¹, Khan A.², Gad M.², Nair R.², Mensah E.², Crocetto F.³, De Berardinis E.¹, Ibrahim Y.², Challacombe B.², Laszkiewicz J.⁴, Rocco B.⁵, Basile G.⁶, Chung B.I.⁷, Thuraraja R.², O'Brien T.², Khan M.S.², Abu-Ghanem Y.²

Institutions

¹Sapienza University of Rome, Dept. of Maternal Infant and Urological Sciences, Rome, Italy, ²Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, Dept. of Urology, London, United Kingdom, ³University of Naples Federico II, Dept. of Neurosciences, Reproductive Sciences and Odontostomatology, Naples, Italy, ⁴University Center of Excellence in Urology, Wroclaw Medical University, Dept. of Urology, Wroclaw, Poland, ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia, Università Cattolica del Sacro Cuore, Roma, Italia, Dept. of Urology, Rome, Italy, ⁶IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁷Stanford University School of Medicine, Dept. of Urology, Stanford, United States of America

Predicting progression in BCG-naïve high-risk non-muscle invasive bladder cancer using PROGRxN-BCa: An international evaluation study

Authors

Kwong J.¹, Kim K.¹, Ringa M.², Feifer A.², Lajkosz K.³, Wettstein M.S.⁴, Lee T.⁵, Kassouf W.⁶, Black P.C.⁷, St-Laurent M.P.⁷, Breau R.H.⁸, Lodde M.⁹, Fairey A.¹⁰, Lattouf J.B.¹¹, Jeldres C.¹², Rendon R.¹³, Diamand R.¹⁴, Gontero P.¹⁵, Sylvester R.J.¹⁶, van Rhijn B.W.G.¹⁷, Kamat A.M.⁵, Johnson A.E.W.¹⁸, Zlotta A.R.¹⁹, Kulkarni G.S.⁴

Institutions

¹University of Toronto, Dept. of Surgery, Toronto, Canada, ²Trillium Health Partners, Dept. of Surgery, Mississauga, Canada, ³University Health Network, Dept. of Biostatistics, Toronto, Canada, ⁴University Health Network, Dept. of Surgery, Toronto, Canada, ⁵University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ⁶McGill University Health Centre, Dept. of Urology, Montréal, Canada, ⁷University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ⁸The Ottawa Hospital Research Institute, Dept. of Surgery, Ottawa, Canada, ⁹CHU de Québec-Université Laval, Dept. of Surgery, Quebec City, Canada, ¹⁰University of Alberta, Dept. of Surgery, Edmonton, Canada, ¹¹Centre Hospitalier de l'Université de Montréal, Dept. of Surgery, Montréal, Canada, ¹²Université de Sherbrooke, Dept. of Surgery, Sherbrooke, Canada, ¹³Dalhousie University, Dept. of Urology, Halifax, Canada, ¹⁴Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Dept. of Urology, Brussels, Belgium, ¹⁵Città della Salute e della Scienza, University of Torino School of Medicine, Dept. of Urology, Turin, Italy, ¹⁶European Organization for Research and Treatment of Cancer, Dept. of Biostatistics, Brussels, Belgium, ¹⁷Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Surgical Oncology (Urology), Amsterdam, The Netherlands, ¹⁸University of Toronto, Temerty Centre for AI Research and Education in Medicine, Toronto, Canada, ¹⁹Mount Sinai Hospital, Dept. of Surgery, Toronto, Canada

Innovations in urethral stricture management: Techniques and long term outcomes

Abstract Session 47

Monday 16 March
12:30 - 14:00

Location Blue Area, Victoria 1

Chairs To be confirmed
F.E. Martins, Lisbon (PT)
M.W. Vetterlein, Hamburg (DE)

12:30 - 13:15

From primary repair to graft substitution

[A0797](#)

Nationwide patterns and detailed morphology of urethral stricture disease: ten-year analysis of prevalence, treatment approaches, and etiology from a German reconstructive center

Authors

Schulz R.J., Wagner M.C., Roessler N., Klemm J., Dahlem R., Fisch M., Vetterlein M.W.

Institutions

University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

A0798

VeSpAR trial: a randomized controlled trial comparing vessel-sparing anastomotic repair and transecting anastomotic repair in isolated, short, bulbar urethral strictures

Authors

Verla W.¹, Waterloos M.¹, Waterschoot M.², Martins F.³, Giudice C.⁴, Song L.⁵, Suarez O.⁶, Shenfeld O.⁷, Campos F.⁸, Wang J.⁹, François P.¹⁰, Lumen N.²

Institutions

¹AZ Maria Middelaes, Dept. of Urology, Ghent, Belgium, ²Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ³Hospital de Santa María, Dept. of Urology, Lisbon, Portugal, ⁴Hospital Italiano de Buenos Aires, Dept. of Urology, Buenos Aires, Argentina, ⁵Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Dept. of Urology, Shanghai, China, ⁶Hospital San José Tecnológico de Monterrey, Dept. of Urology, Nuevo Leon, Mexico, ⁷Shaare Zedek Medical Center, Dept. of Urology, Jerusalem, Israel, ⁸Hospital Univ. Marqués de Valdecilla, Dept. of Urology, Santander, Spain, ⁹Beijing Jishuitan Hospital, Dept. of Urology, Beijing, China, ¹⁰Centre Hospitalier de Mouscron, Dept. of Urology, Mouscron, Belgium

A0799

Preserving the Urethra! Early Experience with Mucosal-Sparing Augmented Non-Transected Anastomotic Urethroplasty

Authors

Negri F.¹, de Martino F.², Guerrera A.², Fidanza F.L.², Misefari V.², Angelini M.², Longoni M.¹, Corsini C.¹, Doncatto R.¹, Cannoletta D.¹, Folcia A.¹, Raffo M.¹, Briganti A.¹, Salonia A.¹, Montorsi F.¹, Bandini M.¹

Institutions

¹IRCCS Ospedale San Raffaele, Division of Experimental Oncology - Unit of Urology - Urological Research Institute, Milan, Italy, ²Vita-Salute San Raffaele University, Faculty of Medicine and Surgery, Milan, Italy

A0800

Comparative Outcomes of Dorsal Onlay Urethroplasty Using Labia Minora, Buccal Mucosal, and Vaginal Wall Grafts in Female Urethral Stricture

Authors

Singh M., Rathor J.S., Ali Patel A.J.M., Bhirud D., Navariya S.C., Choudhary G.R., Sandhu A.S.

Institutions

AIIMS, Dept. of Urology, Jodhpur, India

A0801

Long-term follow-up in urethroplasty: a methodological approach to minimizing bias and defining success beyond recurrence rates

Authors

Klemm J., Schulz R.J., Wagner M.C., Roessler N., Dahlem R., Fisch M., Vetterlein M.W.

Institutions

University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

A0802

Crafting the Graft: An Umbrella Review of Long-Term Outcomes and Complications for Various Graft Usage in Urethral Reconstruction

Authors

Soeroto A.A., Wahyudi I., Edison E.F., Birowo P.

Institutions

Cipto Mangunkusumo National General Hospital, Dept. of Urology, Central Jakarta, Indonesia

A0803

Long-Term Outcomes of Minced Buccal Mucosal Graft Endo-urethroplasty: A Prospective Study

Authors

Mandal S., Huzaifa M., Nayak P., Tripathy S., Chowdhury P., Yadav M., Rathod V., Dharap S.S., Kumar A., R S., Saharsh A., Das M.K.

Institutions

AllIMS Bhubaneswar, Dept. of Urology and Renal Transplant, Bhubaneswar, India

A0804

From Graft to Growth: Success Rates and Functional Outcomes of Tissue-Engineered Biomaterials in Urethral Surgery

Authors

Silva P., Campos Pinheiro L., Severo L., Gil M., Cunha J.

Institutions

Central Lisbon University Hospital Centre, Dept. of Urology, Lisbon, Portugal

A0805

The New Graft Era in Panurethral Reconstruction: Long-Term Outcomes of Split-Thickness Thigh Skin Urethroplasty

Authors

Bucca B.¹, Dalpiaz O.², Zeder R.³, Alber T.³, Pilhatsch J.³, Bernsteiner A.³, Lo Re M.⁴, Gozzi C.⁵

Institutions

¹University of Rome La Sapienza, Dept. of Urology, Rome, Italy, ²Klinikum Klagenfurt, Dept. of Urology, Klagenfurt, Austria, ³Hochsteiermark Hospital, Dept. of Urology, Leoben, Austria, ⁴University of Florence, Dept. of Urology, Florence, Italy, ⁵City Clinic, Urology Unit, Bolzano, Italy

13:15 - 13:40

Drug-coated balloon: Outcomes and comparative trials

A0806

Optilume Drug-Coated Balloon in Lower Urinary Tract Strictures: Real-World Outcomes Beyond the Hype

Authors

Kovalyonok A.¹, Chertin B.², Mabjeesh N.¹, Shenfeld O.Z.²

Institutions

¹Soroka University Medical Center, Dept. of Urology, Beer Sheva, Israel, ²Shaare Zedek Medical Center, Dept. of Urology, Jerusalem, Israel

A0807

5-Year Outcomes of Optilume for recurrent anterior urethral strictures: Pooled results from the ROBUST I, II and III trials

Authors

Elliott S.P.¹, Virasoro R.², DeLong J.³

Institutions

¹University of Minnesota, Dept. of Urology, Minneapolis, United States of America, ²University of Colorado, Dept. of Urology, Aurora, United States of America, ³Hot Springs Health, Dept. of Urology, Thermopolis, United States of America

Study Group

ROBUST I, II, III Investigators(Portsmouth, United States of America)

A0808

A comparison of Optilume and Urethroplasty: A single-centre experience in Australia

Authors

Dittmer B., Homewood D., Corcoran N., Chee J.

Institutions

Western Health, Dept. of Urology, Melbourne, Australia

A0809

Buccal Mucosa Graft Urethroplasty Versus Optilume™ Drug-Coated Balloon for the Management of Anterior Penile Urethral Strictures

Authors

Seiler L.¹, Karapanos L.², De Giorgi G.L.¹, Mantica G.³, Bodle L.¹, Papagiannakis A.¹, Viktorin P.⁴, Subotic S.⁵, Sauer A.¹, Wyler S.¹, Afferi L.¹

Institutions

¹Kantonsspital Aarau, Dept. of Urology, Aarau, Switzerland, ²Klinikum Leverkusen, Dept. of Urology, Leverkusen, Germany, ³IRCCS Ospedale Policlinico San Martino, Dept. of Urology, Genova, Italy, ⁴Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ⁵Kantonsspital Baselland, Dept. of Urology, Liestal, Switzerland

A0810

Efficacy of Drug-coated Balloon Dilation Versus Endoscopic Standard Treatment in Posterior Urethral Stenosis: A Real-world Comparative Study

Authors

Berg E., Mehmedovic S., Askari D., Hermans J., Hoffmann M., Keller P., Weinhold P., Stief C., Eismann L., Bischoff R.

Institutions

LMU University Hospital, Dept. of Urology, Munich, Germany

13:40 - 14:00

Challenges and solutions in female urethral reconstruction

A0811

Optilume® drug-coated balloon dilation in the treatment of female urethral stricture disease

Authors

Jelisejevas L.A., Tulchiner G., Kink P., Rehder P.

Institutions

Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria

A0812

Clinical Determinants of Urethroplasty Failure in Female Urethral Stricture: Insights From a 91-Patient Cohort

Authors

Huzaifa M., Mandal S., Nayak P., Tripathy S., Das M.K., Saharsh A., Choudhury P., Yadav M., Rathod V., R S., Kumar A., Dharap S.S.

Institutions

All India Institute of Medical Sciences, Dept. of Urology, Bhubaneswar, India

A0813

Outcomes of Female Urethral Stricture Management: Augmentation Urethroplasty versus Incision Urethrotomy – Results from a Randomized Controlled Trial.

Authors

Singh S., Sunny B., Chandra V.

Institutions

All India Institute of Medical Sciences, Dept. of Urology, Patna, India

Female urethroplasty: What did the 100 consecutive cases over nine years teach us?

Authors

Mandal S., R.S., Tripathy S., Nayak P., Das M.K., Muhammed H., Mithilesh Y., Choudhury P., Rathod V., Ambade S., Kumar A., Dharap S.

Institutions

All India Institute of Medical Sciences, Dept. of Urology and Renal Transplant, Bhubaneswar, India

Advances in prostate cancer management: Technology, toxicity, and survivorship

Abstract Session 46

Monday 16 March
12:30 - 14:00

Location Blue Area, George 4

Chairs To be confirmed
To be confirmed
G. Fiard, Grenoble (FR)

From UTUC to bladder tumors: En-bloc resection, cryobiopsy and robotic solutions for complex cases

Video Session 17

Monday 16 March
12:30 - 14:00

Location Blue Area, George 1

Chairs To be confirmed
E. Grobet-Jeandin, Geneva (CH)
F. Soria, Turin (IT)

V117 (□: 7 min.)

Video-based en bloc resection of upper tract urothelial carcinoma using a flexible and navigable suction ureteral access sheath and thulium fiber laser with stereotactic ablative radiotherapy: Feasibility and early outcomes
C. Tan, Beijing (CN)

V118 (□: 8 min.)

Rotatable bi-channel en bloc resection of bladder tumors (RBC-ERBT): Overcoming challenging locations with traction
Q. Yao, Suzhou (CN)

V119 (□: 7 min.)

In vivo endoscopic cryobiopsy of urothelial tumors in the upper urinary tract and bladder: A feasibility pilot study in humans
W. Krajewski, Wrocław (PL)

V120 (□: 8 min.)

Delayed-onset bladder wall necrosis and pelvic abscess following single immediate intravesical Mitomycin C instillation after TURBT: a rare complication and challenges faced during robot assisted cystoprostatectomy
S. Kotwal, Leeds (GB)

V121 (□: 7 min.)

En-bloc transurethral resection of bladder tumor: Difficulties and complications

To be confirmed

V122 (□: 5 min.)

Radical ureterectomy combined with autologous kidney transplantation for the treatment of ureteral tumor using robotic system KD-SR-2000□initial experience

C. Lai, Beijing (CN)

Pioneering imaging techniques for prostate cancer: AI, MRI, and PET

EGPT 53

Monday 16 March

12:30 - 14:00

Location

Orange Area, EGPT 1

Chairs

G. Gandaglia, Milan (IT)

F. Giganti, London (GB)

To be confirmed

12:30 - 12:45

AI for enhancing prostate MRI

P0916

Lightweight machine learning for prostate MRI image quality assessment

Authors

Kaneko M.¹, Alexander C.A.C.², Yang J.², Magoulianitis V.¹, Xue J.², Liu J.², Halteh P.³, Gill K.², Ramacciotti L.S.¹, Cacciamani G.E.¹, Aron M.⁴, Duddalwar V.³, Palmer S.L.³, Kuo C.C.J.², Nikias C.L.², Gill I.S.¹, Abreu A.L.¹

Institutions

¹University of Southern California, USC Institute of Urology, Los Angeles, United States of America, ²University of Southern California, Ming Hsieh Department of Electrical and Computer Engineering, Los Angeles, United States of America, ³University of Southern California, Radiomics Lab, Dept. of Radiology, Keck School of Medicine, Los Angeles, United States of America, ⁴University of Southern California, Dept. of Pathology, Keck School of Medicine, Los Angeles, United States of America

P0917

Artificial Intelligence Incorporating PI-RADS v2.1 reduce ambiguity in PI-RAD 3 lesion and prevent unnecessary prostate biopsies

Authors

Lin K-C.¹, Liu S.W.², Kuo Y.M.³, Tsai Y.S.¹, Ou C.H.¹, Wu K.Y.¹, Yang C.H.³, Hu C.Y.¹

Institutions

¹National Cheng Kung University Hospital, Dept. of Urology, Tainan City, Taiwan, ²Southern Taiwan University of Science and Technology, Dept. of Electronic Engineering, Tainan City, Taiwan, ³National Formosa University, Dept. of Electronic Engineering, Huwei Township, Taiwan

12:45 - 13:05

Image quality and lesion level analysis in prostate MRI

P0919

Real-world interrater agreement of PI-QUAL v2 for prostate MRI quality assessment and its association with diagnostic accuracy

Authors

van den Kroonenberg D.L.¹, Barenstz J.², Hamstra B.J.¹, van den Bosch S.M.¹, Gijsbertsen J.J.¹, Reitsma J.³, Brembilla G.⁴, Caglic I.⁵, Raat H.P.J.⁶, de Rooij M.⁷, Postema A.W.⁸, Giganti F.⁹, Oddens J.R.¹

Institutions

¹Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ²Andros, Dept. of Urology, Arnhem, The Netherlands, ³UMC Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands, ⁴IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy, ⁵Addenbrooke's Hospital and University of Cambridge, Dept. of Radiology, Cambridge, The Netherlands, ⁶Laurentius Hospital, Dept. of Radiology, Roermond, The Netherlands, ⁷Radboud University Medical Center, Dept. of Medical Imaging, Nijmegen, The Netherlands, ⁸Leids Universitair Medisch Centrum, Dept. of Urology, Leiden, The Netherlands, ⁹University College London, Dept. of Surgery and Interventional Science, London, United Kingdom

P0920

The PRIME trial: lesion level and high-grade cancer analysis

Authors

Ng A., Asif A., Kasivisvanathan V.

Institutions

University College London, Dept. of Targeted Intervention, London, United Kingdom

Study Group

PRIME Trial Group(London, United Kingdom)

P0921

HeatMap: a novel apparent diffusion coefficient-based mapping of intralesional heterogeneity in PI-RADS lesions validated against robotic-assisted prostate biopsy histology

Authors

Breit H.C.¹, Alargkof V.², Hehenkamp P.¹, Winkel D.J.¹, Henkel M.¹, Engesser C.², Walter M.³, Seifert H.H.², Wetterauer C.²

Institutions

¹University Hospital Basel, Dept. of Radiology, Basel, Switzerland, ²University Hospital Basel, Dept. of Urology, Basel, Switzerland, ³Hospital of Bozen (SABES-ASDAA), Dept. of Urology, Bozen-Bolzano, Italy

P0922

From uniform risk to size-based stratification: challenging the dogma of mandatory biopsy for all PI-RADS 4 lesions

Authors

Peyrottes A.¹, Diamand R.², Long-Depaquit T.³, Uleri A.⁴, Ploussard G.⁴, Baboudjian M.³

Institutions

¹Saint-Louis Hospital, Dept. of Urology, Paris, France, ²Jules-Bordet Institute, Dept. of Urology, Brussels, Belgium, ³North Hospital, Dept. of Urology, Marseille, France, ⁴La Croix du Sud Hospital, Dept. of Urology, Toulouse, France

Study Group

MIRAGE(Marseille, France)

13:05 - 13:15

Head-to-head: US vs MRI vs PET in prostate cancer detection

P0923

Artificial intelligence-assisted multiparametric ultrasound versus MRI to detect prostate cancer (PCAVISION): a prospective, multicentre, paired, non-inferiority diagnostic study

Authors

van den Kroonenberg D.L.¹, van den Bosch S.M.¹, Jager A.¹, Reitsma J.B.², Postema A.W.³, Brembilla G.⁴, Caglic I.⁵, Raat F.⁶, Barenstz J.⁷, Giganti F.⁸, Rietbergen J.B.W.⁹, Busstra M.⁹, Kil P.J.M.¹⁰, Immerzeel J.J.⁷, Rynja S.¹¹, Mazel J.W.¹¹, Noordzij M.A.¹¹, Bruins Slot A.S.¹², Cools Paulino Pereira L.J.¹², van Melick H.H.E.¹², Mischi M.¹³, Beerlage H.P.¹, Oddens J.R.¹

Institutions

¹Amsterdam UMC, Dept. of Urology, Amsterdam, The Netherlands, ²UMC Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands, ³Leiden Universitair Medisch Centrum, Dept. of Urology, Leiden, The Netherlands, ⁴IRCCS San Raffaele Scientific Institute, Dept. of Radiology, Milan, Italy, ⁵Addenbrooke's Hospital and University of Cambridge, Dept. of Radiology, Cambridge, United Kingdom, ⁶Laurentius Hospital, Dept. of Radiology, Roermond, The Netherlands, ⁷Andros, Dept. of Radiology, Arnhem, The Netherlands, ⁸University College London Hospital NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, ⁹Franciscus Gasthuis, Dept. of Urology, Rotterdam, The Netherlands, ¹⁰Andros, Dept. of Urology, Arnhem, The Netherlands, ¹¹Spaarne Gasthuis, Dept. of Urology, Haarlem, The Netherlands, ¹²St. Antonius Ziekenhuis, Dept. of Urology, Nieuwegein, The Netherlands, ¹³Eindhoven University of Technology, Dept. of Electrical Engineering, Eindhoven, The Netherlands

P0924

PROSPET-BX Trial: Comparison of [68 [68Ga]PSMA PET/CT vs. mpMRI in patients with suspicion of prostate cancer and previously negative biopsy.

Authors

Lopci E.¹, Saita A.², Saitta C.³, Disconzi L.⁴, Colombo P.⁵, Fasulo V.³, Avolio P.P.³, Paciotti M.³, Scapatucci E.⁶, Rodari M.¹, Casale P.², Balzarini L.⁴, Buffi N.³, Lazzeri M.², Lughezzani G.³

Institutions

¹IRCCS Humanitas Research Hospital, Dept. of Nuclear Medicine, Milan, Italy, ²IRCCS Humanitas Research Hospital, Dept. of Urology, Milan, Italy, ³Humanitas University, Dept. of Urology, Milan, Italy, ⁴IRCCS Humanitas Research Hospital, Dept. of Radiology, Milan, Italy, ⁵Humanitas University, Dept. of Pathology, Milan, Italy, ⁶Humanitas PIO X, Dept. of Urology, Milan, Italy

13:15 - 13:40

Improving diagnosis using PSMA PET and SPECT/CT

P0925

Molecular Hallmarks of PSMA PET Visibility in Prostate Cancer Patients: A Secondary Analysis of The Next Generation Trial

Authors

Albers P.¹, Agrawal R.², Felipe Lima J.³, Huang G.¹, Bismar T.³, Boutros P.⁴, Kinnaird A.¹

Institutions

¹University of Alberta, Dept. of Surgery, Edmonton, Canada, ²UCLA, Dept. of Human Genetics, Los Angeles, United States of America, ³University of Calgary, Dept. of Pathology & Laboratory Medicine, Calgary, Canada, ⁴UCLA, Dept. of Urology, Los Angeles, United States of America

Study Group

Next Generation Trial investigators(Edmonton, Canada)

Confirmed prognostic value of PROMISE and PRIMARY at initial PSMA-PET: Preliminary findings from an international, multicentre registry

Authors

Maurer T.¹, Karpinski M.², Hoberück S.³, Fendler W.P.⁴, Civan C.⁴, Bjartell A.⁵, Soeterik T.F.W.⁶, Evangelista L.⁷, Vondrak A.⁸, Rasul S.⁹, Di Giorgio A.¹⁰, Scholtissek H.¹¹, Miksch J.¹², Holzgreve A.¹³, Lanfranchi F.¹⁴, Rahbar K.¹⁵, Hofman M.S.¹⁶, Rauscher I.¹⁷, Köhler D.¹⁸, Umutlu L.¹⁹, Herrmann K.⁴, Hadaschik B.²⁰, Emmett L.²¹

Institutions

¹Universitätsklinikum Hamburg-Eppendorf, Dept. of Urology and Martini-Klinik, Hamburg, Germany, ²University Hospital Essen and University Hospital Münster, Dept. of Nuclear Medicine, DKTK and NCT and Dept. of Nuclear Medicine, Essen, Münster, Germany, ³University Hospital Carl Gustav Carus, TU Dresden, Dept. of Nuclear Medicine, Dresden, Germany, ⁴University Hospital Essen, Dept. of Nuclear Medicine, DKTK and NCT, Essen, Germany, ⁵Skåne University Hospital and Lund University, Dept. of Urology and Dept. of Translational Medicine, Malmö, Sweden, ⁶University Medical Center Utrecht and St Antonius Hospital Nieuwegein/Utrecht, Dept. of Radiation Oncology and Dept. of Urology, Utrecht, The Netherlands, ⁷Humanitas University and IRCCS Humanitas Research Hospital, Dept. of Biomedical Sciences and Nuclear Medicine Unit, Milan, Italy, ⁸IRCCS Humanitas Research Hospital, Nuclear Medicine Unit, Milan, Italy, ⁹Medical University of Vienna, Dept. of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Vienna, Austria, ¹⁰University of Bologna, Nuclear Medicine, Alma Mater Studiorum, Bologna, Italy, ¹¹University of Augsburg, Dept. of Nuclear Medicine, Medical Faculty, Augsburg, Germany, ¹²Ulm University Hospital, Dept. of Nuclear Medicine and Dept. of Radiology, Ulm, Germany, ¹³LMU University Hospital and David Geffen School of Medicine at UCLA, Dept. of Nuclear Medicine and Ahmanson Translational Theranostics Division, Munich and Los Angeles, Germany, ¹⁴University of Genoa, Dept. of Experimental Medicine (DIMES), Genoa, Italy, ¹⁵University Hospital Münster, Dept. of Nuclear Medicine, Münster, Germany, ¹⁶Peter MacCallum Centre and University of Melbourne, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC); Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging and Sir Peter MacCallum Department of Oncology, Melbourne, Australia, ¹⁷TUM University Hospital, Dept. of Nuclear Medicine, School of Medicine and Health, Munich, Germany, ¹⁸Universitätsklinikum Hamburg-Eppendorf (UKE), Dept. of Diagnostic and Interventional Radiology and Nuclear Medicine, Hamburg, Germany, ¹⁹University Hospital Essen, Dept. of Diagnostic and Interventional Radiology and Neuroradiology, Essen, Germany, ²⁰University Hospital Essen, Dept. of Urology, DKTK and NCT, Essen, Germany, ²¹St Vincent's Hospital, Dept. of Theranostics and Nuclear medicine, Sydney, Australia

Study Group

PROMISE REGISTRY STUDY GROUP(Essen, Germany)

P0927

99mTc-MIP-1404 SPECT/CT is promising in local lymph node detection in subjects with newly identified, high risk prostate cancer

Authors

Ettala O.¹, Seppänen M.², Anttinen M.¹, Timonen K.L.³, Raiko J.⁴, Kemppainen J.², Schildt J.⁵, Nummelin L.⁶, Högerman M.¹, Rinta-Kiikka I.⁷, Rinkainen J.⁷, Saukko E.², Kohonen I.⁸, Boström P.¹, Noponen T.², Malaspina S.²

Institutions

¹Turku University Hospital, Dept. of Urology, Turku, Finland, ²Turku University Hospital, Dept. of Nuclear Medicine, Turku, Finland, ³Central Hospital of Central Finland, Dept. of Nuclear Medicine, Jyväskylä, Finland, ⁴Kanta-Häme Central Hospital, Dept. of Nuclear Medicine, Hämeenlinna, Finland, ⁵Helsinki University Hospital, Dept. of Nuclear Medicine, Helsinki, Finland, ⁶Satakunta Central Hospital, Dept. of Nuclear Medicine, Pori, Finland, ⁷Tampere University Hospital, Dept. of Radiology, Tampere, Finland, ⁸Turku University Hospital, Dept. of Radiology, Turku, Finland

P0928

99mTc-PSMA-SPECT/CT vs. PSMA PET for Nodal Metastases Detection in Prostate Cancer Patients Undergoing PSMA-Radioguided Surgery during RARP with ePLND

Authors

Quarta L.¹, Stabile A.¹, Cucchiara V.¹, Barletta F.M.¹, Scuderi S.¹, Leni R.¹, Scilipoti P.¹, Zaurito P.¹, Viti A.¹, Brancaccio M.¹, Dambrosio L.¹, Sollini M.², Samanes Gajate A.M.², Antunovic L.², Ghezzi S.², Pini C.², Lazar A.², Chiti A.², Montorsi F.¹, Briganti A.¹, Gandaglia G.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy

P0929

The Role of SUVmax Ratio at 18F-PSMA-1007 PET for Predicting High Aggressive Pathologic Features and PSA Persistence after Radical Prostatectomy in Prostate Cancer Patients

Authors

Quarta L.¹, Zaurito P.¹, Leni R.¹, Cosenza A.¹, Occhi A.¹, Barletta F.¹, Scuderi S.¹, Cucchiara V.¹, Stabile A.¹, Sollini M.², Gelardi F.², Samanes Gajate A.M.², Antunovic L.², Pini C.², Picchio M.², Chiti A.², Montorsi F.¹, Gandaglia G.¹, Briganti A.¹

Institutions

¹Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy

13:40 - 14:00

MRI and PET post-treatment

The Ablation site IMaging (AIM) multicentre diagnostic accuracy study of MRI after focal therapy for localised prostate cancer

Authors

Light A.¹, Mayor N.¹, Gopalakrishnan A.¹, Cullen E.¹, Carney N.², Zahorska A.², Brewin A.E.², Ewing B.², Alabed Allat O.³, Alnoomani M.³, Fielding B.⁴, Chance T.⁵, Dudderidge T.², Shah A.⁴, Noureldin M.³, Hindley R.³, Tam H.⁶, Lakhani A.⁶, Ahmed H.U.¹, Shah T.T.¹

Institutions

¹Imperial College London, Imperial Prostate, London, United Kingdom, ²University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton General Hospital, Southampton, United Kingdom, ³Hampshire Hospitals NHS Foundation Trust, Dept. of Urology, Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom, ⁴Hampshire Hospitals NHS Foundation Trust, Dept. of Radiology, Basingstoke, United Kingdom, ⁵University Hospital Southampton NHS Foundation Trust, Dept. of Radiology, Southampton, United Kingdom, ⁶Imperial College Healthcare NHS Trust, Dept. of Imaging, London, United Kingdom

The added value of diffusion-weighted imaging and dynamic contrast-enhanced sequences in the diagnosis of localised radiorecurrent prostate cancer: An analysis from the FORECAST trial

Authors

Light A.¹, Kanthabalan A.², Adeleke S.³, Giganti F.², Emara A.⁴, Haroon A.⁵, Latifoltojar A.⁶, Sidhu H.⁶, Freeman A.⁷, Orczyk C.², Nikapota A.⁸, Dudderidge T.⁹, Hindley R.⁴, Viridi J.¹⁰, Arya M.¹¹, Payne H.⁷, Mitra A.¹², Bomanji J.⁵, Winkler M.¹, Horan G.¹³, Moore C.M.², Punwani S.⁶, Ahmed H.U.¹, Shah T.T.¹

Institutions

¹Imperial College London, Imperial Prostate, London, United Kingdom, ²University College London, Division of Surgery and Interventional Science, London, United Kingdom, ³Guy's and St Thomas' NHS Foundation Trust, Dept. of Oncology, London, United Kingdom, ⁴Basingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust, Dept. of Urology, Basingstoke, United Kingdom, ⁵University College London Hospitals NHS Foundation Trust, Institute of Nuclear Medicine, London, United Kingdom, ⁶University College London, Division of Medicine, London, United Kingdom, ⁷University College London Hospitals NHS Foundation Trust, Dept. of Cellular Pathology, London, United Kingdom, ⁸Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Sussex Cancer Centre, Brighton, United Kingdom, ⁹University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton General Hospital, Southampton, United Kingdom, ¹⁰The Princess Alexandra Hospital NHS Trust, Dept. of Urology, Harlow, United Kingdom, ¹¹Imperial College Healthcare NHS Trust, Imperial Urology, Charing Cross Hospital, London, United Kingdom, ¹²University College London Hospitals NHS Foundation Trust, Dept. of Oncology, London, United Kingdom, ¹³The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, Dept. of Oncology, Queen Elizabeth Hospital, King's Lynn, United Kingdom

Study Group

FORECAST Trial Study Group(London, United Kingdom)

P0932

PSMA PET/CT vs Conventional Imaging: Biochemical Recurrence-Free Survival After Radical Prostatectomy

Authors

Mogensen A.W.¹, Torp-Pedersen C.², Noerggard M.³, Jelstrup Petersen L.¹, Busch Oestergren P.⁴, Zacho H.¹

Institutions

¹Aalborg University Hospital, Dept. of Nuclear Medicine, Aalborg, Denmark, ²Nordjaelland Hospital, Dept. of Clinical Medicine, Hilleroed, Denmark, ³Aarhus University Hospital, Dept. of Clinical Epidemiology, Aarhus, Denmark, ⁴Copenhagen University Hospital, Dept. of Urology, Herlev, Denmark

P0933

Superior Detection of Recurrent Prostate Cancer at Low PSA Levels Using [18F]F-PSMA-1007 Compared to [68Ga]Ga-PSMA-11: A Prospective Multicenter Study

Authors

Knudtsen I.S.¹, Druta-Barbatei D.², Abrahamsen B.S.¹, Bogsrud T.V.³, Castillejo M.J.G.⁴, Elschot M.¹, Haugnes H.S.³, Helle S.I.⁵, Hernes E.⁶, Honoré A.⁷, Johansen H.K.², Keil T.M.², Langørgen S.², Ringheim A.⁸, Selnaes K.M.², Tulipan A.J.⁶, Bathen T.F.¹, Tandstad T.⁹

Institutions

¹Norwegian University of Science and Technology, Dept. of Circulation and Medical Imaging, Trondheim, Norway, ²St. Olavs University hospital, Dept. of Radiology and Nuclear Medicine, Trondheim, Norway, ³University Hospital of North-Norway, Dept. of Oncology, Tromsø, Norway, ⁴University Hospital of North-Norway, Dept. of PET and Nuclear Imaging, Tromsø, Norway, ⁵Haukeland University Hospital, Dept. of Oncology, Bergen, Norway, ⁶Oslo University Hospital, Dept. of Radiology and Nuclear Medicine, Oslo, Norway, ⁷Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ⁸Haukeland University Hospital, Dept. of Radiology, Bergen, Norway, ⁹St. Olavs University hospital, The Cancer Clinic, Trondheim, Norway

Pioneering urothelial cancer treatments: Emerging techniques and prognostic markers

EGPT 54

Monday 16 March
12:30 - 14:00

Location

Orange Area, EGPT 2

Chairs

D. D'Andrea, Vienna (AT)
S. Füssel, Dresden (DE)
A. Mattei, Luzern (CH)

12:30 - 12:45

Enhanced drug delivery strategies for muscle-invasive bladder cancer

P0934

Nanosecond pulsed electric fields selectively permeabilize urothelial cancer cell membranes, facilitating targeted intracellular delivery.

Authors

Kielbik A.¹, Hellwich E.H.², Bahlinger V.³, Barcena M.L.¹, Vakhrusheva O.¹, Walz S.¹, Schäffer T.², Fend F.³, Novickij V.⁴, Amend B.¹, Tsaor I.¹

Institutions

¹University Hospital Tübingen, Dept. of Urology, Tübingen, Germany, ²University of Tübingen, Institute for Applied Physics, Tübingen, Germany, ³University Hospital Tübingen, Dept. of Pathology, Tübingen, Germany, ⁴Vilnius Gediminas Technical University, Dept. of Immunology and Bioelectrochemistry, Vilnius, Lithuania

P0935

Unlocking Senolytic-Immunotherapy in Bladder Cancer: A Multi-Omics Roadmap from Senescence Subtyping to Combination Therapy

Authors

Liu T., Yao J., Wang C., Wang C.

Institutions

The First Hospital of China Medical University, Dept. of Urology, Shenyang, China

P0936

Inhibiting α 2,6-Sialylation Boosts Enfortumab Vedotin Response by Stabilizing Nectin-4 and Enhancing Macropinocytic Uptake in Bladder Cancer

Authors

Cheng B.¹, Wu J.², Wu P.¹

Institutions

¹Nanfang hospital Southern Medical University, Dept. of Urology, Guangzhou, China, ²Peking University People's Hospital, Dept. of Urology, Peking, China

12:45 - 13:35

Neoadjuvant therapeutic strategies in muscle-invasive bladder cancer

P0937

Does Modified 5-item Frailty Index predict postoperative complications in radical cystectomy?

Authors

Zein M., Alame N., Aljardali B., Mazloun MA, Balaghi A., Farchoukh W., Soussani A., El Hajj A.

Institutions

American University of Beirut, Medical Center, Dept. of Urology, Beirut, Lebanon

P0938

The Impact of neoadjuvant chemotherapy on Radical cystectomy Outcomes in Bladder Cancer: An ACS-NSQIP Analysis

Authors

Alame N., Balaghi A., Zein M., Mazloun M.A., El Hajj A.

Institutions

American University of Beirut, Medical Center, Dept. of Urology, Beirut, Lebanon

P0939

Does Neoadjuvant chemotherapy and radical cystectomy in muscle invasive bladder cancer obliterate survival differences between genders?

Authors

Sidqi G.¹, Stauch H.¹, Johansson M.², Alamdari F.³, Lidén O.⁴, Hüge Y.⁵, Aljabery F.⁶, Svensson J.⁷, Sherif A.¹

Institutions

¹Umeå University, Dept. of Surgical and Perioperative Sciences, Urology and Andrology, Umeå, Sweden, ²Sundsvall County Hospital, Dept. of Surgery and Urology, Sundsvall, Sweden, ³Västmanland county hospital, Dept. of Urology, Västerås, Sweden, ⁴County Hospital of Hudiksvall, Dept. of Surgery and Urology, Hudiksvall, Sweden, ⁵Linköping University, Dept. of Clinical and Experimental Medicine, Division of Urology, Norrköping, Sweden, ⁶Linköping University, Dept. of Clinical and Experimental Medicine, Division of Urology, Linköping, Sweden, ⁷Umeå University, Dept. of Statistics, Umeå School of Business, Economics and Statistics, Umeå, Sweden

P0940

Reproducibility and predictive value of ADC for assessing response to neoadjuvant immunotherapy in muscle-invasive bladder cancer: An analysis from the phase-Ib NABUCCO trial

Authors

Greidanus J.¹, Bernabei C.², Chupetvloska K.³, Agrotis G.³, Mertens L.S.⁴, van Rhijn B.W.G.⁴, van der Poel H.G.⁴, van der Heijden M.S.⁵, Beets-Tan R.G.H.³, Delli Pizzi A.², Boellaard T.N.³, Trebeschi S.³

Institutions

¹Netherlands Cancer Institute, Dept. of Surgical Oncology Urology, Dept. of Radiology, Amsterdam, The Netherlands, ²Santissima Annunziata Hospital, Dept. of Radiology, Chieti, Italy, ³Netherlands Cancer Institute, Dept. of Radiology, Amsterdam, The Netherlands, ⁴Netherlands Cancer Institute, Dept. of Surgical Oncology (Urology), Amsterdam, The Netherlands, ⁵Netherlands Cancer Institute, Dept. of Medical Oncology, Amsterdam, The Netherlands

P0941

Ultra-early (≤ 21 days) and early (22–28 days) radical cystectomy with orthotopic neobladder after neoadjuvant chemotherapy in muscle invasive bladder cancer

Authors

Jo J., Lee D.H., Ko Y.H., Park S., Kim M.S., Ryu H., Yoon H.S.

Institutions

Ewha Womans University College of Medicine, Dept. of Oncology, Seoul, South Korea

P0942

Real-world data on perioperative systemic therapy for urothelial carcinoma: results from the VERSUS study by d-uo

Authors

Johannsen M.¹, Eichenauer R.², Klier J.³, König F.⁴, Schönfelder R.⁵, Schröder J.⁴, Hempel E.⁶, Doehn C.⁷

Institutions

¹Facharztpraxis Johannsen und Laux, Dept. of Urology, Berlin, Germany, ²Urologikum MVZ, Dept. of Urology, Hamburg, Germany, ³Urologische Partnerschaft Köln (UPK), Dept. of Urology, Cologne, Germany, ⁴ATURO, Dept. of Urology, Berlin, Germany, ⁵Urologie Schönfelder & Straßer, Dept. of Urology, Hamburg, Germany, ⁶SMGF, Forschungsgesellschaft, Berlin, Germany, ⁷Urologikum Lübeck, Dept. of Urology, Lübeck, Germany

Survival after Induction Chemotherapy and Radical Cystectomy in cN+/pN+ M0 Bladder Cancer: Implications for pretreatment patient selection

Authors

von Deimling M.¹, Mari A.², van Ginkel N.³, Furrer M.⁴, Bianchi A.⁵, Longoni M.⁶, Maas M.⁷, Taylor J.⁸, Soria F.⁹, Pichler R.¹⁰, Afferi L.¹¹, Khanna A.¹², Crocetto F.¹³, Tully K.H.¹⁴, del Giudice F.¹⁵, Li R.¹⁶, Spiess P.E.¹⁶, Lotan Y.⁸, Black P.C.¹⁷, Moschini M.⁶, Mertens L.S.³, Fisch M.¹, Pradere B.¹⁸, Shariat S.F.¹⁹

Institutions

¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Careggi Hospital, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Dept. of Experimental and Clinical Medicine, Florence, Italy, ³The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁴Solothurner Spitäler AG, Dept. of Urology, Olten and Solothurn, Switzerland, ⁵University of Verona, Azienda Ospedaliera Universitaria Integrata, Dept. of Urology, Verona, Italy, ⁶Urological Research Institute, Vita-Salute San Raffaele, Dept. of Urology, Milan, Italy, ⁷Eberhard Karls University Tübingen, Dept. of Urology, Tübingen, Germany, ⁸University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, ⁹San Giovanni Battista Hospital, University of Studies of Torino, Dept. of Surgical Sciences, Turin, Italy, ¹⁰Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Dept. of Urology, Innsbruck, Austria, ¹¹Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland, ¹²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ¹³University of Naples Federico II, Dept. of Neurosciences, Reproductive Sciences and Odontostomatology, Napoli, Italy, ¹⁴Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology and Neurourology, Herne, Germany, ¹⁵Sapienza University of Rome, Policlinico Umberto I Hospital, Dept. of Maternal Infant and Urologic Sciences, Rome, Italy, ¹⁶H. Lee Moffitt Cancer Center and Research Institute, Dept. of Genitourinary Oncology, Tampa, United States of America, ¹⁷University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ¹⁸UROSUD, La Croix Du Sud Hospital, Dept. of Urology, Quint-Fonsegrives, France, ¹⁹Comprehensive Cancer Center, Medical University of Vienna, Dept. of Urology, Vienna, Austria

Study Group

CLIPOLY(Vienna, Austria)

Thrombosis and major bleeding in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis

Authors

Halme A.¹, Nordlund N.K.¹, Posa M.², Ruotsalainen J.¹, Ahopelto K.³, Barchuk A.⁴, Hallamies S.⁵, Junkkari H.⁶, Järvinen P.⁵, Järvinen R.⁵, Lavikainen L.I.¹, Mendieta de la Rosa A.⁷, Pourjamal N.¹, Tenhunen O.⁸, Tondroanamag F.¹, Tornberg S.V.⁵, Virtanen S.⁹, Catto W.F.¹⁰, Hussain S.A.¹⁰, Tikkinen K.A.O.⁵

Institutions

¹University of Helsinki, Faculty of Medicine, Helsinki, Finland, ²Päijät-Häme Central Hospital, Dept. of Surgery, Lahti, Finland, ³University of Helsinki and Helsinki University Hospital, Dept. of Transplantation and Liver Surgery, Helsinki, Finland, ⁴Erasmus Medical Center, Dept. of Medical Informatics, Rotterdam, The Netherlands, ⁵University of Helsinki and Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ⁶Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland, ⁷Hispanic Health Professionals Association of New York, New York, United States of America, ⁸University of Oulu and Oulu University Hospital, Medical Research Center Oulu, Oulu, Finland, ⁹FICAN West Cancer Centre, Turku University Hospital, University of Turku, Dept. of Oncology and Radiotherapy, Turku, Finland, ¹⁰The University of Sheffield, Dept. of Oncology and Metabolism, Sheffield, United Kingdom

P0945

MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-Invasive Bladder Cancer: Accuracy and Reproducibility across 3 Prospective Clinical Trials

Authors

Greidanus J.¹, van Dijk - de Haan M.C.², Messina A.³, Calareso G.³, Bruining A.², Westerink B.², Dehghanpour A.⁴, van Dorp J.⁵, Stockem C.F.⁵, Mertens L.S.⁶, van der Poel H.G.⁶, Beets-Tan R.G.H.², van Rhijn B.W.G.⁶, Giannatempo P.⁷, van der Heijden M.S.⁵, Trebeschi S.², Boellaard T.N.²

Institutions

¹Netherlands Cancer Institute, Dept. of Surgical Oncology Urology, Dept. of Radiology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute, Dept. of Radiology, Amsterdam, The Netherlands, ³Fondazione IRCSS istituto Nazionale tumori, Dept. of Radiology, Dept. of Medical oncology, Milan, Italy, ⁴Sapienza University of Rome, Dept. of Radiology, Rome, Italy, ⁵Netherlands Cancer Institute, Dept. of Medical Oncology, Amsterdam, The Netherlands, ⁶Netherlands Cancer Institute, Dept. of Surgical Oncology (Urology), Amsterdam, The Netherlands, ⁷Fondazione IRCSS istituto Nazionale tumori, Dept. of Medical Oncology, Milan, Italy

P0946

Prehabilitation before robot-assisted radical cystectomy is associated with reduced 30-day complications and length of stay: a prospective, single-centre propensity-weighted cohort study

Authors

Alfambra Fernandez H.¹, Ajami Fardoun T.¹, Mercader Barrull C.², Carbonell González E.¹, Muní Sureda M.¹, Martínez Garcia C.¹, Pagès Niubó R.¹, Villalba Lázaro E.¹, Sierra Del Río A.¹, Roldán Chávez F.¹, Izquierdo Reyes L.¹, Vilaseca Cabo A.¹, Musquera Felip M.¹, Dana Muzzio F.³, Tena Blanco B.³, Ribal Caparrós M.J.¹, Alcaraz Asensio A.¹, Martos Calvo R.¹

Institutions

¹Hospital Clínic Barcelona, Dept. of Urology, Barcelona, Spain, ²Hospital Germans Trias i Pujol, Dept. of Urology, Badalona, Spain, ³Hospital Clínic Barcelona, Dept. of Anesthesiology, Barcelona, Spain

13:35 - 14:00

Histopathology of radical cystectomy specimens

P0947

Positive surgical margins in radical cystectomy: Incidence, anatomic patterns, and oncologic impact

Authors

Nocera L., Sciotta M., Donnini I., Zamboni S., Furlan M., Carbotti G., Arrigoni F., Moser G., Matarese S., El Khatteeb H., Al Kurdi A., Suardi N.R.

Institutions

ASST Spedali Civili, Dept. of Urology, Brescia, Italy

P0948

Prognostic significance of tertiary lymphoid structure-like lymphocyte aggregates identified on routine H&E-stained slides of radical cystectomy specimens in bladder cancer

Authors

Sano T.¹, Chisato O.², Yusuke M.¹, Takahiro N.¹, Takashi Y.¹, Junichi I.¹, Hisanori T.¹, Masaaki Y.¹, Hidefumi H.K.¹

Institutions

¹Kansai Medical University, Dept. of Urology and Andrology, Hirakata, Japan, ²Hyogo Medical University, Dept. of Surgical Pathology, Nishinomiya, Japan

P0949

Pattern and predictors of uretero-ileal stenosis after robot assisted radical cystectomy with totally intracorporeal urinary diversion. A single high-volume tertiary referral center experience

Authors

Lipparini F., Lambertini L., Posanzini S., Kucuku N., Zeni G., Carli G., Cadenar A., Valastro F., Di Maida F., Grosso A.A., Saladino M., Oriti R., Vittori G., Mari A., Minervini A.

Institutions

University of Florence Careggi Hospital, Dept. of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, Florence, Italy

P0950

Development of a Transcriptome-Based Model for Predicting Adverse Pathology at Radical Cystectomy

Authors

Viti A.¹, Scilipoti P.¹, Longoni M.¹, de Angelis M.¹, Santangelo A.¹, Zaurito P.¹, Tremolada G.¹, Cosenza A.¹, Occhi A.¹, Galdieri A.¹, Disabato N.¹, Brancaccio M.¹, Burgio G.¹, Maiorano B.², Mercinelli C.², Necchi A.², Tenace N.³, Colecchia M.³, Rosiello G.¹, Salonia A.¹, Montorsi F.¹, Briganti A.¹, Moschini M.¹

Institutions

¹IRCCS Ospedale San Raffaele, Unit of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Oncology, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy

P0951

Oncological survival in patients with pN+ muscle-invasive bladder cancer with or without neoadjuvant or adjuvant oncological treatments

Authors

Rautiola J.¹, Arnold N.¹, Dey L.¹, Björklund J.¹, Mehrazin R.², Eraky A.², Cacciamani G.³, Desai M.³, Miranda G.³, Sfakianos J.², Wiklund P.¹

Institutions

¹Karolinska University Hospital, Dept. of Pelvic Cancer, Stockholm, Sweden, ²Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ³Keck School of Medicine, University of Southern California, Catherine and Joseph Aresty Dept. of Urology, Los Angeles, United States of America

Monday 16 March
12:30 - 14:00

Location Orange Area, EGPT 3
Chairs To be confirmed
H. Langenhuijsen, Nijmegen (NL)
To be confirmed

12:30 - 12:45

Epidemiology and imaging for adrenal gland

P0952

Adrenal incidentalomas in the 4–6 cm range: malignancy risk and surgical outcomes in a nationwide multicentre cohort

Authors

[Chaman Baz A.H.](#)¹, [Viëtor C.](#)², [Schrijvers J.](#)¹, [Koetje J.](#)³, [Kruijff S.](#)³, [Vriens M.R.](#)⁴, [Bouvy N.D.](#)⁵, [Nieveen van Dijkum E.J.](#)⁶, [Timmers H.J.L.M.](#)⁷, [van Ginhoven T.](#)², [Langenhuijsen J.F.](#)¹

Institutions

¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²Erasmus MC, Dept. of Surgery, Rotterdam, The Netherlands, ³UMC Groningen, Dept. of Surgery, Groningen, The Netherlands, ⁴UMC Utrecht, Dept. of Surgery, Utrecht, The Netherlands, ⁵Maastricht UMC+, Dept. of Surgery, Maastricht, The Netherlands, ⁶Amsterdam UMC, Dept. of Surgery, Amsterdam, The Netherlands, ⁷Radboudumc, Dept. of Endocrinology, Nijmegen, The Netherlands

P0953

Comparative performance of CXCR4-directed PET/CT and adrenal venous sampling for subtype classification and outcome prediction in primary aldosteronism

Authors

[Liu X.](#), [Liu S.](#), [Zhu Y.](#), [Dong Q.](#)

Institutions

West China Hospital Sichuan University Chengdu China, Dept. of Urology, Chengdu, China

P0954

The reproducibility of 68Ga-PentixaFor PET/CT scanning for subtyping patients with primary aldosteronism

Authors

[Lamers D.W.A.](#)¹, [Gotthardt M.](#)², [Chaman Baz A.H.](#)¹, [Deinum J.](#)³, [Langenhuijsen J.F.](#)¹

Institutions

¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²Radboudumc, Dept. of Medical Imaging, Nijmegen, The Netherlands, ³Radboudumc, Dept. of Internal Medicine, Nijmegen, The Netherlands

12:45 - 13:15

Pheochromocytoma latest updates

P0955

Impact of Postoperative Hypertension on Coronary Artery Disease and Heart Failure After Resection of Pheochromocytoma or Paraganglioma

Authors

Tu Y.H., Li J.R., Yang C.K.

Institutions

Taichung Veterans General Hospital, Dept. of Urology, Taichung, Taiwan

P0956

Predictive factors and a nomogram for haemodynamic instability during operation in patients with pheochromocytomas and paragangliomas

Authors

Jiang X., Wenqiang Q., Xiang Y., Shi B.

Institutions

Qilu Hospital of Shandong University, Dept. of Urology, Jinan, China

P0958

Phenotypic Characteristics of Patients with FGFR1-Mutant Pheochromocytoma/Paraganglioma: A Multicenter Retrospective Study Based on 1001 Cases

Authors

Li Z.¹, Wang Y.¹, Liu L.², Li M.², Jiang J.³, Chen D.⁴, Dai Y.¹

Institutions

¹The Fifth Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Zhuhai, China, ²Xiangya Hospital of Central South University, Dept. of Urology, Changsha, China, ³Zhongshan Hospital of Fudan University, Dept. of Endocrinology and Metabolism, Shanghai, China, ⁴The First People Hospital Of Yunnan Province, Dept. of Urology, Kunming, China

P0959

Redefining surgical boundaries: outcomes of minimally invasive adrenalectomy in large pheochromocytomas.

Authors

Kong J., Qinghua G., Chun J., Tianxin L.

Institutions

Sun Yat-sen Memorial Hospital, Dept. of Urology, Guangzhou, China

P0960

Comparative Analysis of Laparoscopic Perioperative Hemodynamics in Pseudohypoxic versus Kinase-Signaling Pheochromocytoma/Paraganglioma Patients

Authors

Wang Y.¹, Li Z.¹, Liu L.², Li M.², Jiang J.³, Chen D.⁴, Dai Y.¹

Institutions

¹The Fifth Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Zhuhai, China, ²Xiangya Hospital of Central South University, Dept. of Urology, Changsha, China, ³Zhongshan Hospital of Fudan University, Dept. of Endocrinology and Metabolism, Shanghai, China, ⁴The First People Hospital Of Yunnan Province, Dept. of Urology, Kunming, China

13:15 - 14:00

Clinical and surgical outcomes for adrenal gland

P0961

Comparative Outcomes of Radiotherapy and Interventional Therapy for Adrenal Oligometastases: A Multicenter Retrospective Study

Authors

Yanke Z.¹, Lin X.², Xianda C.¹, Lei Z.³, Shasha H.⁴, Chengqiang M.⁵, Qiuming H.⁶, Peng W.⁷, Xing B.⁸, Qingqun Z.⁹, Kai Y.¹, Hui C.³, Weijun F.², Guo S.¹

Institutions

¹Sun Yat-sen University Cancer Center, Dept. of Urology, Guangzhou, China, ²Sun Yat-sen University Cancer Center, Dept. of Minimally Invasive Interventional Therapy, Guangzhou, China, ³Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Dept. of Urology, Chengdu, China, ⁴Sun Yat-sen University Cancer Center, Dept. of Radiation Oncology, Guangzhou, China, ⁵The First Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Guangzhou, China, ⁶Jiangxi Cancer Hospital, the Second Affiliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer, Dept. of Urology, Nanchang, China, ⁷Southern Medical University Nanfang Hospital, Southern Medical University, Dept. of Urology, Guangzhou, China, ⁸Affiliated Tumor Hospital of Xinjiang Medical University, Dept. of Urology, Urumqi, China, ⁹Guangxi Medical University Cancer Hospital, Dept. of Urology, Nanning, China

P0962

Performance of the ADRENAL and MAP Scores in Predicting Postoperative Complications After Laparoscopic Adrenalectomy

Authors

Başboğa S.¹, Yilmaz A.B.², Karimzada K.³, Ozercan A.Y.⁴, Keten T.³, Guzel O.⁵, Tuncel A.⁵

Institutions

¹Gulhane Training and Research Hospital, Dept. of Urology, Ankara, Turkey, ²Sincan Training and Research Hospital, Dept. of Urology, Ankara, Turkey, ³Bilkent City Hospital, Dept. of Urology, Ankara, Turkey, ⁴Kayseri City Hospital, Dept. of Urology, Kayseri, Turkey, ⁵Güven Hospital, Dept. of Urology, Ankara, Turkey

P0963

From Trial to Practice: No Survival Benefit from Adjuvant Mitotane in Low-Risk Adrenocortical Carcinoma, Insights from a Nationwide Cohort

Authors

Silvani C.¹, Santangelo A.¹, Stephens A.², Saeedi N.¹, Considine J.¹, Zadeh T.¹, Salka B.¹, Catanzaro M.³, Salonia A.⁴, Briganti A.⁴, Montorsi F.⁴, Nicolai N.³, Montanari E.⁵, Rogers C.¹, Abdollah F.¹

Institutions

¹VUI Center for Outcomes Research Analysis and Evaluation Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy, ⁴IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ⁵Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy

P0964

The Impact of Perirenal Fat Thickness (PFT) and Other Factors on Perioperative Outcomes of Transperitoneal Laparoscopic and Robot-Assisted Adrenalectomy

Authors

Fujinami H.¹, Yamanaka N.¹, Hata S.¹, Inoue T.¹, Ando T.², Shin T.¹

Institutions

¹Oita University Hospital, Dept. of Urology, Yufu, Japan, ²Oita University, Dept. of Organ Transplant Promotion Project, Yufu, Japan

P0965

Robotic Approach Is Associated with Lower Positive Margin Rates in Minimally Invasive Adrenalectomy for Adrenocortical Carcinoma: A Nationwide Analysis

Authors

Silvani C.¹, Santangelo A.¹, Perry M.¹, Salka B.¹, Considine J.¹, Niculcea M.¹, Tylecki A.², Catanzaro M.³, Salonia A.⁴, Briganti A.⁴, Montorsi F.⁴, Nicolai N.³, Montanari E.⁵, Rogers C.¹, Abdollah F.¹

Institutions

¹VUI Center for Outcomes Research Analysis and Evaluation Henry Ford Health System, Dept. of Urology, Detroit, United States of America, ²Henry Ford Health System, Dept. of Public Health Sciences, Detroit, United States of America, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Urology, Milan, Italy, ⁴IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University, Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab, Milan, Italy, ⁵Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy

P0966

Retroperitoneal Versus Transperitoneal Laparoscopic Adrenalectomy for Adrenocortical Carcinoma: A Retrospective Comparative Study

Authors

Liu X., Liu S., Zhu Y.

Institutions

West China Hospital Sichuan University Chengdu China, Dept. of Urology, Chengdu, China

P0967

The effects of centralized adrenal care on surgical expertise and patient outcomes

Authors

van de Goor S., Lamers D.W.A., Zhu X., Timmers H.J.L.M., Deinum J., Willems S., d'Ancona F.C.H., Langenhuijsen H.

Institutions

Radboudumc, Dept. of Urology, Nijmegen, The Netherlands

P0968

Impact of the Modified Frailty Index on Postoperative Outcomes after Adrenalectomy

Authors

Chaker K.¹, Marzouki W.¹, Mosbahi B.², Ammar R.², Tebini S.², Ouertani K.¹, Karmous J.¹, Ouanes Y.¹, Bibi M.¹, Ben Chedly W.¹, Ammous A.², Nouira Y.¹

Institutions

¹La Rabta Hospital, Dept. of Urology, Tunis, Tunisia, ²La Rabta Hospital, Dept. of Anesthesiology, Tunis, Tunisia

Authors

Costa Silva A.¹, Vanalia P.², Awanish A.³, Ho J.³, Safwaan A.³, Gulamhusein A.²

Institutions

¹Sao Joao University Hospital, Dept. of Urology, Porto, Portugal, ²The Christie NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom, ³The Christie NHS Foundation Trust, Dept. of Endocrinology, Manchester, United Kingdom

Infections 3: Controversies & novel treatments of urological infections

EGPT 56

Monday 16 March
12:30 - 14:00

Location

Orange Area, EGPT 4

Chairs

G. Bonkat, Basel (CH)

To be confirmed

G. Mantica, Genoa (IT)

12:30 - 12:55

PROCEDURE-RELATED INFECTIONS

P0970

Incidence of Urinary Tract Infection Post Video-Urodynamics: A Prospective Audit of 2627 Patients 2014-2023

Authors

Gill S., Nobrega R., Riley C.

Institutions

Royal National Orthopaedic Hospital, Dept. of Neuro-Urology, London, United Kingdom

P0971

IS URS/RIRS UNDER A MAJOR AMBULATORY SURGERY REGIMEN SAFE IN PATIENTS WITH A POSITIVE PREOPERATIVE URINE CULTURE?

Authors

Fernández Martínez B., Scott Pabon G., Linares Quevedo A., Bueno Bravo C., Rubia Escribano A., Hevia Feliu A., Gómez González B., Moreno Reboiro A., Navarro Pineiro A., de la Morena Gallego J.M.

Institutions

Infanta Sofía University Hospital, Dept. of Urology, Madrid, Spain

P0972

A catheter-induced urinary tract infection microtissue model to study the role of mucoadhesion and microtrauma

Authors

Murray B., Jafari N., Rohn J.

Institutions

University College London, Division of Medicine, London, United Kingdom

P0974

Beyond HbA1c: Dipstick Glycosuria as a Practical Biomarker of Delayed Recovery after Adult Circumcision in Diabetic Men

Authors

Sun S., Chiu Y.C., Chang C.C., Cheng W.M.

Institutions

Taipei City Hospital, Dept. of Urology, Taipei, Taiwan

12:55 - 13:25

CONTROVERSIES

P0975

Schistosoma mansoni Soluble Egg Antigens Suppresses UPEC Invasion in Bladder Cells via Modulating the JAK/STAT Pathway

Authors

Wu C-W.¹, Cheng P.C.², Ho C.H.¹

Institutions

¹Shin Kong Wu Ho-Su Memorial Hospital, Dept. of Urology, Taipei, Taiwan, ²Taipei Medical University, Dept. of Molecular Parasitology and Tropical Diseases, Taipei, Taiwan

P0976

GLP-1 receptor agonists and male genitourinary infections: A 3-year TriNetX comparative cohort study

Authors

Liu P.C.¹, Lin Y.S.², Hsu C.Y.¹, Ou Y.C.¹, Tung M.C.¹

Institutions

¹Tungs' Taichung Metroharbor Hospital, Dept. of Urology, Taichung City, Taiwan, ²National Chung Hsing University, Doctoral Program in Translational Medicine, Taichung City, Taiwan

P0977

AI-Assisted Clinical Decision Intelligence for Emphysematous Pyelonephritis (EPN-CDI).

Authors

Sekar H.¹, Yedulla Reddy R.¹, Sriram S.², Shivakumar G.P.², Meyyappan V.¹, Krishnamoorthy S.¹

Institutions

¹Sri Ramachandra Institute of Higher Education and Research, Dept. of Urology and Renal Transplantation, Chennai, India, ²Amazon Web Services, Dept. of Information and Technology, Seattle, United States of America

P0978

Is it too late to drain? Impact of timing of urinary drainage in acute obstructive uropathy: a retrospective cohort study

Authors

Passarelli F.¹, Ripa F.¹, Ciamarra F.¹, Sorba E.¹, Basadonna L.M.¹, Parolin V.¹, Graps G.¹, Dagnino D.¹, Lucignani G.¹, Zanetti S.P.¹, Turetti M.¹, Longo F.¹, De Lorenzis E.², Albo G.², Montanari E.², Boeri L.¹

Institutions

¹IRCCS Fondazione Ca Granda Policlinico di Milano, Dept. of Urology, Milan, Italy, ²University of Milan, Dept. of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, Milan, Italy

P0979

The UROME Study: Urological Microbes – Epidemiology over 7 years

Authors

Edison E., Pachta T., Okeke N., Ilawole A., Li H., Thomas K.

Institutions

Guy's Hospital, Dept. of Urology, London, United Kingdom

P0980

The Predictive Value of Serum Procalcitonin for Identifying Therapeutic Failure in Urosepsis Caused by Multidrug-Resistant Uropathogens.

Authors

Saldivar Luna A., Perez Soriano A.R., Perez Becerra R., Osornio Sánchez V., Trujillo Ortiz L., Garza Sainz G., Castro Fuentes C.A., Martinez Correa A.A., Delgado Corral A., Santiago González R.M.A., Vieyra Valdez O., Toledo Díaz M.A., Argüelles Morales G., Flores G., Nolasco C., Perez Rojas M.

Institutions

Hospital Regional de Alta Especialidad de Ixtapaluca, Dept. of Urology, Mexico City, Mexico

13:25 - 13:40

INTERSTITIAL CYSTITIS

P0981

Treatment of interstitial cystitis with bladder perfusion of recombinant human collagen type 3

Authors

Xiaokai S., Li Z.

Institutions

Third affiliated hospital of Nanjing medical university, Dept. of Urology, Changzhou, China

P0982

Clustering of Urinary Biomarkers to Identify Interstitial Cystitis Subtypes and Different Clinical Characteristics and Treatment Outcomes

Authors

Tian J.H.¹, Yu W.R.², Lee Y.S.¹, Yang C.C.¹, Huang T.H.¹, Liu M.C.¹, Chang T.L.¹, Jiang Y.H.¹, Jhang J.F.¹, Kuo H.C.¹

Institutions

¹Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Urology, Hualien, Taiwan, ²Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Nursing, Hualien, Taiwan

P0983

Adding Triamcinolone on Platelet-Rich Plasma can Improve Treatment Outcome on Patients with Interstitial Cystitis

Authors

Yu W.R.¹, Jhang J.F.², Lee Y.S.², Yang C.C.², Huang T.H.², Liu M.C.², Chang T.L.², Jiang Y.H.², Kuo H.C.²

Institutions

¹Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Nursing, Hualien, Taiwan, ²Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Dept. of Urology, Hualien, Taiwan

13:40 - 14:00

RECURRENT UTI'S

P0984

Metaphylaxis of recurrent UTI by a combined medical therapy. Metaphylaxis of recurrent UTI by a combined medical therapy. A randomized placebo-controlled trial.

Authors

Moskvina Z.V.¹, Morozov A.O.¹, Boldyreva M.N.², Rossolovskaya K.A.¹, Vinarov A.Z.¹, Spivak L.¹

Institutions

¹Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia, ²Federal Medical and Biological Agency of Russia, State Research Center Institute of Immunology, Moscow, Russia

P0985

Accuracy, readability, and understandability of EAU guidelines bot for urinary infections guidelines.

Authors

Tema G., Santioni M., Pillitteri E., Lombardo R., Romagnoli M., Piccini G.P., Malavasi G., Pacini G., Coppola L., Umbaca M., Pierri E., Lorenti C., Nacchia A., Cicione A., Franco A., Pastore A., Al Salhi Y., Fuschi A., Tubaro A., De Nunzio C.

Institutions

Sapienza, Dept. of Urology, Rome, Italy

P0986

Risk Factors and Microbial Etiology of Healthcare-Associated Urinary Tract Infections in Neurological Patients:Analysis of 1100 Cases

Authors

Lapin I., Kotov S.V., Pulbere S., Zhetikova E., Bolotov A.

Institutions

The Russian National Research Medical University named after N.I. Pirogov, Dept. of Urology and Andrology Named After Academic N.A. Lopatkin, Moscow, Russia

P0987

Bacteriophage therapy in women with chronic recurrent cystitis caused by multidrug-resistant bacteria: a prospective, observational, comparative study

Authors

Krakhotkin D.¹, Iglovikov N.², Blecher G.³, Chernylovskiy V.A.⁴, Greco F.G.⁵, Gayvoronskaya S.A.⁶, Meliegy A.E.⁷

Institutions

¹Central District Hospital, Outpatient Clinic, Kamenolomni, Russia, ²S.M. Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation, Department and Clinic of Urology, Saint Petersburg, Russia, ³The Alfred Hospital, Dept. of Urology, Melbourne, Australia, ⁴Bnai Zion Medical Center, Dept. of Urology, Haifa, Israel, ⁵Centro Salute Uomo, Urology Unit, Bergamo, Italy, ⁶Central District Hospital, Dept. of Bacteriology, Kamenolomni, Russia, ⁷Cairo University, Faculty of Medicine, Dept. of Andrology, Sexology, and STDs, Cairo, Egypt

Monday 16 March
12:30 - 14:00

Location Orange Area, EGPT 5

Chairs To be confirmed
N. Kitrey, Ramat Gan (IL)
M. Waterloos, Ghent (BE)

12:30 - 13:10

Penis and urethra

P0989

FRACT'AFUF : nationwilde multicentric retrospective cohort of penile fracture, epidemiologic & circumtanses features and risk factor for size,multiple cavernosal and urethral fractures

Authors

Boileau A.¹, Mesnard B.², Sabbagh P.³, Clerget A.⁴, Chabenes M.⁵, Reichenbach A.L.⁶, Duffaut L.⁷, Miquel C.⁸, Pattou M.⁹, Gardet J.¹⁰, Chauveau E.¹¹, Bacle C.¹², Galano A.¹³, Delchet O.L.¹⁴, Bourillon A.¹⁵, Lethuillier V.¹⁶, Marthez W.¹⁷, Mardelli C.L.¹⁸, de Brek N.¹⁹, Tissot G.²⁰, Huyghe E.¹, Levy S.¹

Institutions

¹CHU Toulouse, Dept. of Urology, Toulouse, France, ²CHU Nantes, Dept. of Urology, Nantes, France, ³CHU Rouen, Dept. of Urology, Rouen, France, ⁴Bichat, Dept. of Urology, Paris, France, ⁵CHU Grenoble, Dept. of Urology, Grenoble, France, ⁶Hospices Civils Lyon, Dept. of Urology, Lyon, France, ⁷Cochin-Port Royal, Dept. of Urology, Paris, France, ⁸CHU Lille, Dept. of Urology, Lille, France, ⁹HEGP, Dept. of Urology, Paris, France, ¹⁰CHU Amiens, Dept. of Urology, Amiens, France, ¹¹CHU Nancy, Dept. of Urology, Nancy, France, ¹²Foch Hospital, Dept. of Urology, Suresnes, France, ¹³CHU Caen, Dept. of Urology, Caen, France, ¹⁴CHU Reims, Dept. of Urology, Reims, France, ¹⁵CHU Rennes, Dept. of Urology, Rennes, France, ¹⁶CHU Montpellier, Dept. of Urology, Montpellier, France, ¹⁷CHU Tours, Dept. of Urology, Tours, France, ¹⁸Centre Hospitalier Bretagne Atlantique, Dept. of Urology, Vannes, France, ¹⁹CHU Kremlin Bicêtre, Dept. of Urology, Kremlin Bicêtre, France, ²⁰CHU Henri Mondor, Dept. of Urology, Creteil, France

P0991

Penile Fracture Repair: Long-Term Erectile Function, Urinary Symptoms, and Penile Deformity

Authors

Al-Mitwalli A.¹, Shah M.¹, Nasser M.¹, Chua B.¹, Pinni S.², Sangster P.¹, Lee W.G.¹, Ralph D.¹

Institutions

¹University College London Hospitals, Dept. of Andrology, London, United Kingdom, ²AINU, Dept. of Urology, Hyderabad, India

P0992

Penis “En Bloc”: From Reproducible Harvesting to Transplantation - A Cadaveric Study

Authors

Neuville P.¹, Fourel M.¹, Badet L.¹, Ruffion A.¹, Carnicelli D.¹, Chaffanjon P.², Fiard G.L.³, Airolidi S.², Boucher F.¹, Morel-Journal N.¹

Institutions

¹Hospices Civils de Lyon, Dept. of Urology, Lyon, France, ²Laboratory of Anatomy of the French Alps (LADAF), Dept. of Anatomy, Grenoble, France, ³University Hospital Grenoble, Dept. of Urology, Grenoble, France

P0994

Pelvic Fracture and Long-Term Urological Outcomes

Authors

Shah J., Bell D.M.

Institutions

King Edward VII Hospital, Dept. of Urology, London, United Kingdom

P0997

Evaluating functional outcomes of urethroplasty for complete post-traumatic rupture of the posterior urethra

Authors

Chaker K.¹, Chaabouni A.², Ouertani K.², Mosbahi B.³, Bouchaala H.², Marzouki W.¹, Ammar R.³, Ben Chedly W.¹, Ouanes Y.¹, Bibi M.¹, Marrak M.¹, Ammous A.³, Rebai N.², Hadj Slimene M.², Nouira Y.¹

Institutions

¹La Rabta Hospital, Dept. of Urology, Tunis, Tunisia, ²Habib Bourguiba Hospital, Dept. of Urology, Sfax, Tunisia, ³La Rabta Hospital, Dept. of Anesthesiology, Tunis, Tunisia

P0998

Mechanism-Specific Differences in Bladder and Urethral Trauma: A National Analysis of Firearm and Motor Vehicle Injuries

Authors

Packham R.¹, Patel P.C.¹, Moss W.¹, Moreira A.²

Institutions

¹UT Health - San Antonio Long School of Medicine, Dept. of Urology, San Antonio, United States of America, ²UT Health - San Antonio, Dept. of Pediatrics, San Antonio, United States of America

P1001

An Ex-vivo Further Evaluation of the Venting Pressure Threshold of the Transurethral Catheterization Safety Valve (TUCSV) in a Porcine Urethral Model

Authors

Croghan S.M.¹, Budrewicz J.², Rickman B.², Walsh M.T.³, Flood H.D.³, Davis N.F.⁴

Institutions

¹Tallaght University Hospital, Dept. of Urology, Dublin, Ireland, ²CBSET Inc., Dept. of Translation Research, Lexington, United States of America, ³University of Limerick, Bernal Institute, Limerick, Ireland, ⁴Beaumont Hospital, Dept. of Urology, Dublin, Ireland

P1003

Turning the Tide of Scarring: A Supramolecular Hydrogel Delivering BMSCs to Rebuild the Urethra.

Authors

She L., Yin Y., Tang Y., Dai Y.

Institutions

The Fifth Affiliated Hospital of Sun Yat-sen University, Dept. of Urology, Zhuhai, China

The WASHOUT study: early proactive intervention in emergency haematuria reduces length of stay, mortality and readmissions**Authors**

Byrnes K.¹, Bhatt N.², Ippoliti S.³, Varma R.⁴, Jie Chow B.⁵, Mak Q.⁶, Kerdegari N.⁷, Asif A.⁸, Nathan A.⁸, Ng A.⁸, Ireland A.⁹, Joanne Cresswell J.⁹, Qaoud Y.¹⁰, Lavallee L.¹⁰, Phonde A.¹¹, Madhavan K.¹¹, Sarmah P.B.¹², Nichols M.¹³, Green J.¹³, Ahmayda A.¹⁴, MacLennan G.¹⁵, Gallagher K.¹⁶, Khadhour S.¹⁷, Kasivisvanathan V.⁸

Institutions

¹Division of Surgery and Interventional Sciences, University College London, Dept. of Urology, London, United Kingdom, ²St Vincent's University Hospital, Dept. of Urology, Dublin, Ireland, ³Hull University Teaching Hospitals NHS Trust, Dept. of Urology, Hull, United Kingdom, ⁴West Midlands Deanery, Dept. of Urology, Edgbaston, United Kingdom, ⁵Barts and The London School of Medicine and Dentistry,, Dept. of Medicine, London, United Kingdom, ⁶Buckinghamshire Healthcare NHS Trust, Dept. of Urology, Amersham, United Kingdom, ⁷King's College London GKT School of Medical Education, Dept. of Urology, London, United Kingdom, ⁸University College London, Division of Surgery & Interventional Science, London, United Kingdom, ⁹James Cook University Hospital, South Tees NHS Hospitals Foundation Trust, Dept. of Urology, Middlesbrough, United Kingdom, ¹⁰Ottawa Hospital Research Institute, University of Ottawa, Dept. of Urology, Ottawa, Canada, ¹¹All India Institute of Medical Sciences, Dept. of Urology, Bhopal, India, ¹²University Hospital Coventry and Warwickshire, Dept. of Urology, Coventry, United Kingdom, ¹³Whipps Cross University Hospital, Dept. of Urology, London, United Kingdom, ¹⁴Surgical Specialty Center, Dept. of Urology, Benghazi, Libya, ¹⁵University of Aberdeen, Health Services Research Unit, Aberdeen, United Kingdom, ¹⁶Western General Hospital, University of Edinburgh, Dept. of Urology, Edinburgh, United Kingdom, ¹⁷University of Glasgow and Glasgow Royal Infirmary, Dept. of Urology, Glasgow, United Kingdom

Study Group

British Urology Researchers in Surgical Training(London, United Kingdom)

P1006

The WASHOUT study: workup and management of patients with emergency haematuria across the world

Authors

Bhatt N.R.¹, [Byrnes K.](#)², Ippoliti S.³, Varma R.⁴, Jie Chow B.⁵, Mak Q.⁶, Kerdegari N.⁷, Asif A.², Nathan A.², Ng A.², Ireland A.⁸, Cresswell J.⁸, Qaoud Y.⁹, Lavalley L.⁹, Phonde A.¹⁰, Madhavan K.¹⁰, Sarmah P.B.¹¹, Nichols M.¹², Green J.¹², Ahmayda A.¹³, MacLennan G.¹⁴, Gallagher K.¹⁵, Khadhour S.¹⁶, Kasivisvanathan V.²

Institutions

¹St Vincent's University Hospital, Dept. of Urology, Dublin, Ireland, ²University College London Hospital, Division of Surgery & Interventional Science, London, United Kingdom, ³Hull University Teaching Hospitals NHS Trust, Dept. of Urology, Hull, United Kingdom, ⁴West Midlands Deanery, Dept. of Urology, Edgbaston, United Kingdom, ⁵Barts and The London School of Medicine and Dentistry,, Dept. of Medicine, London, United Kingdom, ⁶Buckinghamshire Healthcare NHS Trust, Dept. of Urology, Amersham, United Kingdom, ⁷King's College London GKT School of Medical Education, Dept. of Medicine, London, United Kingdom, ⁸James Cook University Hospital, South Tees NHS Hospitals Foundation Trust, Dept. of Urology, Middlesbrough, United Kingdom, ⁹Ottawa Hospital Research Institute, University of Ottawa, Dept. of Urology, Ottawa, Canada, ¹⁰All India Institute of Medical Sciences, Dept. of Urology, Bhopal, India, ¹¹University Hospital Coventry & Warwickshire, Dept. of Urology, Coventry, United Kingdom, ¹²Whipps Cross University Hospital, Dept. of Urology, London, United Kingdom, ¹³Surgical Specialty Center, Dept. of Urology, Benghazi, Libya, ¹⁴University of Aberdeen, Health Services Research Unit, Aberdeen, United Kingdom, ¹⁵Western General Hospital, University of Edinburgh, Dept. of Urology, Edinburgh, United Kingdom, ¹⁶Glasgow Royal Infirmary and University of Glasgow, Dept. of Urology, Glasgow, United Kingdom

Study Group

British Urology Researchers in Surgical Training(London, United Kingdom)

P1009

Routine cystography after bladder injury: Tradition or necessity?

Authors

[Atallah M.](#), Shafran Y., Gilad A., Assadi A.

Institutions

Rambam Health Care Campus, Dept. of Urology, Haifa, Israel

13:25 - 14:00

Kidney and upper tract

P1010

The Southern Denmark Ureteral Stricture Center: Establishing a Cross-Institutional Collaboration

Authors

[Abdellahi F.](#)¹, Diatchhikine M.¹, Laczko G.², Lildal S.R.², Lund L.¹, Merrild J.³, Scheufen S.³, Tomasevics J.², Zamani R.³, Zoffmann M.¹, Jung H.U.²

Institutions

¹Odense University Hospital, Dept. of Urology, Odense, Denmark, ²Hospital Lillebaelt Vejle, Dept. of Urology, Vejle, Denmark, ³Sydvestjysk Sygehus, Dept. of Urology, Esbjerg, Denmark

P1013

Pre-freezing stimulation mitigates ureteral injury and subsequent obstruction in novel rabbit models for endogenous thermal exposures

Authors

Li B.¹, [Song Q.](#)², Chen J.¹, Chen J.¹, Chen X.¹, Liu L.¹, Chen Z.¹, He Y.¹, Gan Y.¹, Li M.¹, Xu X.¹, Huang J.¹, Cheng K.¹

Institutions

¹Xiangya Hospital Central South University, Dept. of Urology, Changsha, China, ²Changhai Hospital, Dept. of Urology, Shanghai, China

P1015

Changes in renal trauma management over two decades: A single-center study

Authors

[Ferreira A.M.](#), Figueiredo B., Eliseu M., Quaresma V., Jarimba R., Nunes P., Figueiredo A.

Institutions

Unidade Local de Saúde de Coimbra, Dept. of Urology, Coimbra, Portugal

P1017

Lingual mucosal graft ureteroplasty combined with ureteral reimplantation or boari flap ureteroneocystostomy for one-stage repair of long and multifocal ureteral strictures: Technique Description and the Medium-term Outcome

Authors

[Li B.](#)¹, Zhou Y.¹, Chai S.¹, Gao X.¹, Xu Y.², Liang C.¹, Liao Y.³, Xiao X.¹

Institutions

¹Zhongnan Hospital of Wuhan University, Dept. of Urology, Wuhan, China, ²The first affiliated hospital of wannan medical college, Dept. of Urology, Wuhu, China, ³Jingzhou Central Hospital, Dept. of Urology, Jingzhou, China

P1018

Posteriorly Augmented Anastomotic Ureteroplasty with Lingual Mucosal onlay Grafts: 8-Year Multi-institutional Experience in 61 Cases

Authors

[Li B.](#)¹, Zhou Y.¹, Chai S.¹, Gao X.¹, Shen Z.², Han X.³, Liang C.¹, Xiao X.¹

Institutions

¹Zhongnan Hospital of Wuhan University, Dept. of Urology, Wuhan, China, ²Anhui Provincial Hospital, Dept. of Urology, Hefei, China, ³Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China

P1021

Lessons learned from managing ureteric obstruction in a cohort of >800 patients with Retroperitoneal Fibrosis (RPF): a cautionary perspective

Authors

[Fernando A.](#)¹, Viney Z.², D'Cruz D.³, La Rosa A.¹, Simpson S.¹, Azizi E.¹, O'Brien T.¹

Institutions

¹Guy's and St Thomas' Hospital, Dept. of Urology, London, United Kingdom, ²Guy's and St Thomas' Hospital, Dept. of Radiology, London, United Kingdom, ³Guy's and St Thomas' Hospital, Dept. of Rheumatology, London, United Kingdom

Single-port robot-assisted pyeloplasty: multicenter international experience and early outcomes

Authors

Finocchiaro A.¹, Paciotti M.¹, Aljoulani M.¹, Mallia V.¹, Fasulo V.¹, Avolio P.P.¹, De Carne F.¹, Galvagno F.², Casale P.³, Lughezzani G.¹, Lazzeri M.³, Porreca A.⁴, Dagnino F.³, Oderda M.², Ingrassano S.², Sauer R.C.⁵, Gontero P.², Crivellaro S.⁵, Buffi N.M.¹

Institutions

¹Humanitas University, Dept. of Biomedical Sciences, Pieve Emanuele, Italy, ²Città della Salute e della Scienza, University of Torino School of Medicine, Dept. of Urology, Turin, Italy, ³Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy, ⁴Humanitas Gavazzeni, Dept. of Urology, Bergamo, Italy, ⁵University of Illinois Chicago, Dept. of Urology, Chicago, United States of America

Take-Home Messages of EAU26

Special Session

Monday 16 March
14:15 - 16:15

Location Orange Area, eURO Auditorium 2

Chairs
M. Albersen, Leuven (BE)
A. Stenzl, Stuttgart (DE)

14:15 - 14:20

Welcome and introduction

14:20 - 14:30

NMIBC and UTUC

J. Boormans, Rotterdam (NL)

14:30 - 14:40

MIBC and advanced urothelial carcinoma

M. Rouprêt, Paris (FR)

14:40 - 14:50

Paediatric urology

M.S. Silay, Istanbul (TR)

14:50 - 15:00

Prostate cancer 1: imaging, screening and diagnosis

T. Nordström, Stockholm (SE)

15:00 - 15:10

Prostate cancer 2: treatment of localized and advanced disease

D. Tilki, Hamburg (DE)

15:10 - 15:20

Andrology

G.I. Russo, Catania (IT)

15:20 - 15:30

Functional and neuro-urology

B. Peyronnet, Rennes (FR)

15:30 - 15:40

BPH/LUTS

C. De Nunzio, Rome (IT)

15:40 - 15:50

EAU LAB: translational research @EAU

L. Dyrskjød, Aarhus (DK)

15:50 - 16:00

Stones

M. Bultitude, London (GB)

16:00 - 16:10

Renal and rare cancers

M.C. Mir Maresma, Valencia (ES)

16:10 - 16:15

Closing remarks by the chair of the EAU Scientific Congress Committee

M. Albersen, Leuven (BE)